<SEC-DOCUMENT>0000875045-23-000038.txt : 20231108
<SEC-HEADER>0000875045-23-000038.hdr.sgml : 20231108
<ACCEPTANCE-DATETIME>20231108163526
ACCESSION NUMBER:		0000875045-23-000038
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		127
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231108
DATE AS OF CHANGE:		20231108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		231388524

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-20230930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:067ab9af-2745-42fc-8c78-33206b6cc4f8,g:369ca811-9038-4e81-ba44-3ac1f044a248,d:8325bdffeebc49d7b9475241af1c3c2e--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:biib="http://www.biogenidec.com/20230930" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>biib-20230930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0000875045</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-26">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-29">false</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">144,898,112</ix:nonFraction><ix:nonNumeric contextRef="c-451" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1041">4</ix:nonNumeric><ix:nonNumeric contextRef="c-452" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1042">28</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="biib-20230930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>biib:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:SKYCLARYSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OtherClinicalProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>biib:Employee</xbrli:measure></xbrli:unit><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:AcceleratedDepreciationAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:AcceleratedDepreciationAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:AcceleratedDepreciationAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:AcceleratedDepreciationAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:AcceleratedDepreciationAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:AcceleratedDepreciationAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:AcceleratedDepreciationAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:AcceleratedDepreciationAndOtherCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="wholesaler"><xbrli:measure>biib:wholesaler</xbrli:measure></xbrli:unit><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CentersForMedicareAndMedicaidServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB054Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingSaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRate364DayTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityTerminatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRate364DayTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2015-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EquityAwardsOfAcquiredCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EquityAwardsOfAcquiredCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EquityAwardsOfAcquiredCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EquityAwardsOfAcquiredCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MosunetuzumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">biib:CollaborationProfitSharingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">biib:CollaborationProfitSharingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:CollaborativeArrangementProfitLossSharingComponentsAxis">biib:InventoryIdleCapacityChargesAndContractualCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>biib:product</xbrli:measure></xbrli:unit><xbrli:context id="c-743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-746"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-748"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:ERISAClassActionLitigaitonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-753"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:BardoxoloneSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:LenderDisputeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September 30, 2023</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">0-19311</ix:nonNumeric></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><img src="biib-20230930_g1.jpg" alt="biogenlogoa11.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:92px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">BIOGEN INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">33-0112644</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">225 Binney Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-11">MA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">02142</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">679-2000</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:35.463%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, $0.0005 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">BIIB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of November&#160;7, 2023, was <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">144,898,112</ix:nonFraction> shares.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC.</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM&#160;10-Q &#8212; Quarterly Report</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the Quarterly Period Ended September 30, 2023</span><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:14pt;text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;I&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_16">FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_19">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_22">Condensed Consolidated Statements of Income&#160;&#8212; For the Three and </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_22">Nine</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_22"> Months Ended </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_22">September</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_22"> 30, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_22">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_25">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three and </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_25">Ni</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_25">ne</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_25"> Months Ended </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_25">Sept</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_25">ember</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_25"> 30, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_25">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_28">Condensed Consolidated Balance Sheets&#160;&#8212; As of</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_28"> September</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_28"> 30, 2023 and December&#160;31, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_28">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_31">Condensed Consolidated Statements of Cash Flow&#160;&#8212; For the </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_31">Nine</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_31"> Months Ended </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_31">September</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_31"> 30, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_31">10</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_34">Condensed Consolidated Statements of Equity &#8212; For the Three and </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_34">Nine</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_34"> Months Ended </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_34">September</a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_34"> 30, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_34">11</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_37">15</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_115">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_115">51</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_259">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_259">80</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_262">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_262">82</a></span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;II&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_265">OTHER INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_268">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_268">83</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_271">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_271">83</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_274">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_274">98</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_277">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_277">98</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_280">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_280">99</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_286">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_286">100</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; "goal," &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">expectations, plans and prospects relating to product approvals, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivity;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our plans and investments in our portfolio as well as implementation of our corporate strategy;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures, including our Fit for Growth program;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse safety events involving our marketed or pipeline products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the current and potential impacts of geopolitical tensions, acts of war and other large-scale crises, including impacts to our operations, sales and the possible disruptions or delay in our plans to conduct clinical trial activities in areas of geopolitical tension, including regions affected by Russia's invasion of Ukraine and the military conflict in the Middle East;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the direct and indirect impact of the COVID-19 pandemic and other global health outbreaks on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of healthcare reform in the U.S., including the IRA, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:7pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in RTP, North Carolina to be operational;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements involve risks and uncertainties, including those that are described in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report and elsewhere in this report, that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</span></div><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</span></div><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADUHELM&#174;, AVONEX&#174;, BYOOVIZ&#174;, PLEGRIDY&#174;, QALSODY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SKYCLARYS&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and VUMERITY&#174; are registered trademarks of Biogen. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BENEPALI&#8482;, FLIXABI&#8482;, FUMADERM&#8482;, IMRALDI&#8482;  and TOFIDENCE&#8482; are trademarks of Biogen.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACTEMRA&#174;, ENBREL&#174;, EYLEA&#174;, FAMPYRA&#8482;, GAZYVA&#174;, LEQEMBI&#174;, HUMIRA&#174;, LUCENTIS&#174;, LUNSUMIO&#174;, OCREVUS&#174;, REMICADE&#174;, ZURZUVAE&#8482;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other trademarks referenced in this report are the property of their respective owners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">DEFINED TERMS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:27.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022 Form 10-K</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Annual Report on Form 10-K for the year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020 Share Repurchase Program</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Board of Directors authorized program to repurchase up to $5.0 billion of our common stock</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 Binney Street</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 Binney Street, Cambridge, MA</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AI</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Artificial Intelligence</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amyotrophic Lateral Sclerosis</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AOCI</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounting Standards Update</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ATV</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Antibody Transport Vehicle</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BLA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biologics License Application</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Blackstone</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Blackstone Life Sciences</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCPA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California Consumer Privacy Act</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">cGMP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">current Good Manufacturing Practices</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CJEU</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Court of Justice of the European Union</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CLE</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cutaneous Lupus Erythematosus</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CLL</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chronic Lymphocytic Leukemia</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CMS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Centers for Medicare &amp; Medicaid Services</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convergence</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convergence Pharmaceuticals Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CRL</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Complete Response Letter</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CROs</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract Research Organizations</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DEA</span></div></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Drug Enforcement Agency</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denali</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denali Therapeutics Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPN</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetic Painful Neuropathy</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EC</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Commission</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eisai</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eisai Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EMA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Medicines Agency</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ERISA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee Retirement Income Security Act of 1974</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">E.U.</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Union</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Friedreich's Ataxia</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FASB</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial Accounting Standards Board</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FCPA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign Corrupt Practices Act</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Food and Drug Administration</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDIC</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal Deposit Insurance Corporation</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fit for Growth</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost saving program initiated in 2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genentech</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genentech, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global Intangible Low Tax Income</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GloBE</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global Anti-Base Erosion</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GMP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Good Manufacturing Practice</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Humana</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Humana Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process Research and Development</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ionis</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ionis Pharmaceuticals Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IRA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inflation Reduction Act of 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:0.5pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LRRK2</span></td><td colspan="3" style="border-bottom:0.5pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leucine-Rich Repeat Kinase 2</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">DEFINED TERMS (continued)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:27.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MAA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketing Authorization Application</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MDD</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Major Depressive Disorder</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MHRA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicines and Healthcare products Regulatory Agency</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Multiple Sclerosis</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mylan Ireland</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mylan Ireland Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NCD</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">National Coverage Decision</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NDA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Drug Application</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NDS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Drug Submission</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurimmune</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurimmune SubOne AG</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NMPA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">National Medicinal Products Administration</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OECD</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Organization for Economic Co-operation and Development</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Polpharma</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Polpharma Biologics S.A.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PPACA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patient Protection and Affordable Care Act</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PPD</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Postpartum Depression</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PPMS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Primary Progressive MS</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and Development</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reata</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reata Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RMS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Relapsing MS</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RTP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research Triangle Park</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sage Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Samsung Bioepis</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Samsung Bioepis Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Samsung BioLogics</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Samsung BioLogics Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sangamo</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sangamo Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, General and Administrative</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SLE</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Systemic Lupus Erythematosus</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOD1</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Superoxide Dismutase 1</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SVB</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Silicon Valley Bank</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SWISSMEDIC</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Swiss Agency for Therapeutic Products</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TGN</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trigeminal Neuralgia</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transition Toll Tax</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.K.</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. GAAP</span></td><td colspan="3" style="border-bottom:1pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounting Principles Generally Accepted in the U.S.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;I FINANCIAL INFORMATION</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_19"></div><div style="text-align:center"><span><br/></span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_22"></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product, net</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-31">1,805.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-32">1,962.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-33">5,414.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-34">6,083.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-35">420.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-36">416.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-37">1,253.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-38">1,252.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing, royalty and other revenue</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-39">304.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-40">129.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-41">781.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-42">293.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-43">2,530.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-44">2,508.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-45">7,449.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-46">7,629.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost and expense:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-47">659.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-48">469.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-49">1,915.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-50">1,707.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-51">736.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-52">549.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-53">1,891.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-54">1,629.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-55">788.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-56">563.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-57">1,941.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-58">1,770.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-59">60.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-60">56.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-61">164.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-62">190.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration profit sharing/(loss reimbursement)</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-63">50.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-64">45.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-65">164.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="biib:Collaborationprofitlosssharing" scale="6" id="f-66">42.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="6" id="f-67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-68">2.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="6" id="f-69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-70">13.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-71">76.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-72">15.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-73">120.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-74">124.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of building</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="6" id="f-75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="f-76">503.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="6" id="f-77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="f-78">503.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-79">300.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-80">56.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-81">248.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-82">221.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-83">2,671.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-84">1,137.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-85">6,444.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-86">4,641.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) before income tax (benefit) expense and equity in loss of investee, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="f-87">141.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-88">1,371.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-89">1,005.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-90">2,988.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-91">72.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-92">236.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-93">92.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-94">578.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in (income) loss of investee, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" format="ixt:fixed-zero" scale="6" id="f-95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" format="ixt:fixed-zero" scale="6" id="f-96">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" format="ixt:fixed-zero" scale="6" id="f-97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="f-98">2.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-99">68.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-100">1,134.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-101">912.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-102">2,412.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-103">0.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-104">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-105">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-106">84.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-107">68.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-108">1,134.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-109">911.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-110">2,496.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings (loss) per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-111">0.47</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-112">7.86</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-113">6.30</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-114">17.12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings (loss) per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-115">0.47</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-116">7.84</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-117">6.26</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-118">17.07</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings (loss) per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-119">144.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-120">144.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-121">144.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-122">145.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings (loss) per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-123">144.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-124">144.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-125">145.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-126">146.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-127">68.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-128">1,134.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-129">911.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-130">2,496.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on securities available for sale, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="f-131">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="f-132">1.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="f-133">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="f-134">19.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on cash flow hedges, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-135">29.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-136">5.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-137">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-138">79.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="f-139">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="f-140">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="f-141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="f-142">25.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-143">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-144">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-145">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-146">4.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustment</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-147">30.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-148">59.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-149">11.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-150">95.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-151">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-152">53.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-153">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-154">56.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-155">54.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-156">1,081.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-157">917.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-158">2,439.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-159">0.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-160">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-161">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-162">84.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-163">54.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-164">1,081.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-165">918.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-166">2,355.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-167">2,287.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-168">3,419.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="f-169">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-170">1,473.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-171">1,781.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-172">1,705.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-173">428.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-174">431.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-175">2,982.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-176">1,344.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-177">974.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-178">1,417.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-179">8,454.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-180">9,791.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="f-181">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="f-182">705.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-183">3,301.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-184">3,298.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-185">460.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-186">403.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-187">7,344.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-188">1,850.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-189">6,807.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-190">5,749.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-191">1,069.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-192">1,226.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-193">754.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-194">1,529.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-195">28,193.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-196">24,554.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of term loan</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="f-197">500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="6" id="f-198">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="f-199">243.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="f-200">259.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-201">440.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-202">491.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-203">3,838.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-204">2,521.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-205">5,022.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-206">3,272.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable and term loan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-207">6,786.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-208">6,281.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-209">728.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-210">334.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-211">428.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-212">333.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-213">747.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-214">944.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-215">13,713.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-216">11,165.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments, contingencies and guarantees</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-18" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-217"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-19" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-218"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biogen Inc. shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, par value $0.001 per share</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-220">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, par value $0.0005 per share</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-221">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-222">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="f-223">242.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="f-224">73.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-225">159.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-226">164.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-227">17,377.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-228">16,466.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-229">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-230">2,977.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Biogen Inc. shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-231">14,483.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-232">13,397.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" sign="-" name="us-gaap:MinorityInterest" scale="6" id="f-233">4.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:MinorityInterest" scale="6" id="f-234">9.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-235">14,479.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-236">13,388.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-237">28,193.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-238">24,554.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-239">912.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-240">2,412.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-241">354.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-242">398.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Excess and obsolescence charges related to inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="f-243">62.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="f-244">321.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-245">209.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-246">186.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="6" id="f-247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-248">13.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-249">377.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-250">139.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(Gain) loss on strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="f-251">275.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="f-252">160.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(Gain) loss on equity method investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-254">2.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Gain on sale of equity interest in Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" format="ixt:fixed-zero" scale="6" id="f-255">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" format="ixt:num-dot-decimal" scale="6" id="f-256">1,505.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Gain on sale of building</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="6" id="f-257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="f-258">503.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-259">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-260">147.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of effects of business acquired:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-261">76.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-262">109.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-263">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-264">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-265">34.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-266">338.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Accrued expense and other current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="f-267">293.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="f-268">632.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Income tax assets and liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="f-269">114.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="f-270">100.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-271">71.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-272">15.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-273">1,534.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-274">1,559.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">Cash flow from investing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-275">211.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-276">153.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="f-277">7,380.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="f-278">3,104.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-279">5,140.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-280">2,805.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Acquisition of Reata, net of cash acquired</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="f-281">6,335.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0e32e1;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="f-282">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sale of equity interest in Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="f-283">788.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="f-284">990.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sale of building</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="f-286">582.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Acquisitions of intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="f-287">34.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="f-288">1.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sales of strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfOtherInvestments" scale="6" id="f-289">106.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromSaleOfOtherInvestments" format="ixt:fixed-zero" scale="6" id="f-290">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-291">1.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-292">1.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-293">3,448.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-294">1,717.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">Cash flow from financing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="f-295">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-296">750.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Payments related to issuance of stock for share-based compensation arrangements, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-297">48.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-298">5.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Repayment of borrowings and premiums paid</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-299">159.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-300">1,002.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from borrowings, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="f-301">997.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0e32e1;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-302">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net (distribution) contribution to noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="6" id="f-303">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="6" id="f-304">12.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-305">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-306">5.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-307">795.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-308">1,739.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-309">1,118.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-310">1,537.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-311">12.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-312">122.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of the period</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-313">3,419.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-314">2,261.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of the period</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-315">2,287.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-316">3,675.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:19.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.523%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.105%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-319">168.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-320">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-321">170.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-322">172.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-323">17,446.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-324">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-325">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-326">14,466.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-327">6.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-328">14,460.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-329">68.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-330">68.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-331">0.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-332">68.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-333">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-334">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-335">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="f-336">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="f-337">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="f-338">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-339">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-340">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-341">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-343">2.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-344">2.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-345">2.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-346">64.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-347">64.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-348">64.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-349">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-350">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-351">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2023</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-353">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-354">168.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-355">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-356">242.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-357">159.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-358">17,377.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-359">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-360">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-361">14,483.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-362">4.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-363">14,479.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:19.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.523%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.105%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-366">167.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-367">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-368">73.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-369">164.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-370">16,466.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-58" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-371">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-372">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-373">13,397.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-374">9.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-375">13,388.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-376">911.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-377">911.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-378">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-379">912.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-380">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-381">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-382">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="f-383">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="f-384">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="f-385">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-386">38.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-387">38.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-388">38.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="f-389">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-390">86.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-391">86.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-392">86.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-393">217.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-394">217.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-395">217.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-396">0.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-397">0.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-398">0.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2023</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-400">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-401">168.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-402">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-403">242.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-404">159.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-405">17,377.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-406">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-407">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-408">14,483.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-409">4.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-410">14,479.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:19.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.725%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.740%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-67" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-411">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-412">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-413">169.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-414">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-415">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-416">110.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-417">14,959.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-72" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-418">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-419">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-420">11,872.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-421">9.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-422">11,863.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-423">1,134.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-424">1,134.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-425">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-426">1,134.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-427">53.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-428">53.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-429">53.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="f-430">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="f-431">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-80" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-432">1.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-433">250.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-434">250.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-435">250.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-83" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="f-436">1.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="f-437">71.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="f-438">178.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-80" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="f-439">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="f-440">250.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-86" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" format="ixt:fixed-zero" scale="6" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-442">8.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-443">8.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-444">8.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-86" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-446">2.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="f-447">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-448">2.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-449">2.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-450">65.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-451">65.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-452">65.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-453">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-454">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-455">167.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-456">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-457">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-458">163.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-459">15,916.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-93" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-460">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-461">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-462">12,775.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-463">8.7</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-464">12,766.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.783%"><tr><td style="width:1.0%"></td><td style="width:19.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.527%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-96" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-97" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-467">170.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-468">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-469">68.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-470">106.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-471">13,911.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-101" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-472">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-473">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-474">10,896.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-475">63.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-476">10,959.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-477">2,496.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-478">2,496.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-479">84.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-480">2,412.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-481">56.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-482">56.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-483">56.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="f-484">12.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="f-485">12.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-108" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-486">3.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-487">750.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-488">750.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-489">750.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-111" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="f-490">3.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="f-491">257.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="f-492">492.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-108" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="f-493">3.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="f-494">750.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-114" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="f-495">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-496">37.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-497">37.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-498">37.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-114" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="f-499">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-500">43.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="f-501">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-502">43.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-503">43.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-504">194.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-505">194.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-506">194.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-507">1.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-508">1.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-509">1.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-510">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-511">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-512">167.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-513">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-514">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-515">163.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-516">15,916.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-93" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-517">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-518">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-519">12,775.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-520">8.7</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-521">12,766.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_37"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div><span><br/></span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_40"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 1:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Summary of Significant Accounting Policies</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-522" continuedAt="f-522-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Overview</span></div><ix:nonNumeric contextRef="c-1" name="biib:BusinessOverviewPolicyTextBlock" id="f-523" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA and co-developed two treatments to address a defining pathology of Alzheimer's disease. We are focused on advancing our pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs and external collaborations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; QALSODY for the treatment of ALS, which was granted accelerated approval by the FDA during the second quarter of 2023; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease, which was granted traditional approval by the FDA in the third quarter of 2023, and Sage on the commercialization of ZURZUVAE for the treatment of PPD. ZURZUVAE was approved by the FDA in the third quarter of 2023, pending DEA scheduling, which was completed in the fourth quarter of 2023. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma, which was granted accelerated approval by the FDA during the second quarter of 2023; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2023, we completed the acquisition of Reata. As a result of this transaction we acquired SKYCLARYS, the first and only drug approved by the FDA for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. We also have the exclusive rights to commercialize TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, which was approved by the FDA during the third quarter of 2023. We continue to develop the potential biosimilar product SB15, a proposed aflibercept biosimilar referencing EYLEA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our 2022 Form&#160;10-K.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-524" continuedAt="f-524-1" escape="true"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2022 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2022 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, </span></ix:nonNumeric></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-522-1" continuedAt="f-522-2"><ix:continuation id="f-524-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-525">one</ix:nonFraction> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div></ix:continuation><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-526" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="biib:InterestInSubsidiary" scale="-2" id="f-527">100.0</ix:nonFraction>% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-528" continuedAt="f-528-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies disclosed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our audited consolidated financial statements included in our 2022 Form&#160;10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-528-1">Business combinations are recorded using the acquisition method of accounting. The results of operations of the acquired company are included in our results of operations beginning on the acquisition date, and assets acquired and liabilities assumed are recognized on the acquisition date at their respective fair values. Any excess of consideration transferred over the net carrying value of the assets acquired and liabilities assumed as of the acquisition date is recognized as goodwill. Transaction and restructuring costs related to business combinations are expensed as incurred. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. If we determine the assets acquired do not meet the definition of a business, the transaction will be accounted for as an asset acquisition rather than a business combination.</ix:continuation>  </span><span style="color:#3051f2;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-529" continuedAt="f-529-1" escape="true">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-522-2"><ix:continuation id="f-529-1"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022 the FASB issued ASU No. 2022-03, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Fair Value Measurement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (Topic 820): </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for us on January 1, 2024. We elected to early adopt this standard on a prospective basis during the third quarter of 2022. Upon adoption, we recorded an immaterial amount in other (income) expense, net in our condensed consolidated statements of income, as a result of removing the impact of the remaining contractual sale restrictions from the fair value measurement of certain shares in Sage.</span></div></ix:continuation></ix:continuation><div id="i8325bdffeebc49d7b9475241af1c3c2e_43"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 2:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acquisitions</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-530" continuedAt="f-530-1" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reata Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">On September 26, 2023, we completed the acquisition of all of the issued and outstanding shares of Reata, a  biopharmaceutical company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of this transaction we acquired SKYCLARYS, the first and only drug approved by the FDA for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older, as well as other clinical and preclinical pipeline programs. The acquisition of Reata is expected to complement our global portfolio of neuromuscular and rare disease therapies. The addition of SKYCLARYS is anticipated to provide potential operating synergies with SPINRAZA and QALSODY.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Under the terms of this acquisition, we paid Reata shareholders $<ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="1" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="f-531">172.50</ix:nonFraction> in cash for each issued and outstanding Reata share, which totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="f-532">6.6</ix:nonFraction>&#160;billion. In addition, we agreed to pay approximately $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" format="ixt:num-dot-decimal" scale="6" id="f-533">983.9</ix:nonFraction>&#160;million in cash for Reata's outstanding equity awards, inclusive of employer taxes, of which approximately $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" format="ixt:num-dot-decimal" scale="6" id="f-534">590.5</ix:nonFraction>&#160;million was attributable to pre-acquisition services and is therefore reflected as a component of total purchase price paid. Of the $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" format="ixt:num-dot-decimal" scale="6" id="f-535">983.9</ix:nonFraction>&#160;million paid to Reata's equity award holders, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-536">393.4</ix:nonFraction>&#160;million as compensation attributable to the post-acquisition service period, of which $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-537">196.4</ix:nonFraction>&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-538">197.0</ix:nonFraction>&#160;million as a charge to research and development expense within our condensed consolidated statements of income </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and nine months ended September 30, 2023</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest. Approximately $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-539">980.0</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" format="ixt:num-dot-decimal" scale="6" id="f-540">983.9</ix:nonFraction>&#160;million payment to the equity award holders was made in October 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We funded this acquisition through available cash, cash equivalents and marketable securities, supplemented by the issuance of a </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="f-541">1.0</ix:nonFraction> billion</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> term loan under our term loan credit agreement. For additional information on our term loan credit agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We accounted for this acquisition as a business combination using the acquisition method of accounting in accordance with </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASC Topic 805, Business Combinations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, and recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Consideration</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="f-542" continuedAt="f-542-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total consideration transferred for the acquisition of Reata is summarized as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;26, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration paid to Reata shareholders</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-543">6,602.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of Reata equity compensation pre-acquisition services and related taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" scale="6" id="f-544">590.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-545">7,193.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents cash consideration transferred of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="1" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="f-546">172.50</ix:nonFraction></span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> per outstanding Reata ordinary share based on <ix:nonFraction unitRef="shares" contextRef="c-116" decimals="-3" name="biib:BusinessAcquisitionNumberOfCommonStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-547">38.3</ix:nonFraction>&#160;million Reata shares outstanding at closing.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of Reata stock options and stock units issued to Reata equity award holders and the related taxes attributable to pre-acquisition vesting services.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-530-1" continuedAt="f-530-2"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Preliminary Purchase Price Allocation</span></div><ix:continuation id="f-542-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The following table summarizes the preliminary purchase price allocation of the separately identifiable assets acquired and liabilities assumed as of September&#160;26, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;26, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="f-548">267.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="f-549">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="6" id="f-550">1,692.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="6" id="f-551">53.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology for SKYCLARYS (U.S.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-552">3,600.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development (omaveloxolone)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-553">1,900.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="f-554">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other clinical programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="f-555">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" scale="6" id="f-556">122.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" scale="6" id="f-557">98.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="6" id="f-558">159.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent payable to Blackstone</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" scale="6" id="f-559">300.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="f-560">922.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" scale="6" id="f-561">151.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" sign="-" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" scale="6" id="f-562">2.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="f-563">6,136.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-564">1,057.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="f-565">7,193.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> For additional information on the contingent payable to Blackstone, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Other Consolidated Financial Statement Detail</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Total inventory acquired was</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="9" id="f-566">1.7</ix:nonFraction>&#160;billion, which reflects a step-up in the fair value of finished goods and work-in-process inventory for SKYCLARYS. The fair value was determined based on the estimated selling price of the inventory, less the remaining manufacturing and selling costs and a normal profit margin on those manufacturing and selling efforts. This fair value step-up adjustment will be amortized to cost of sales within our condensed consolidated statements of income when the inventory is sold, which is expected to be within approximately <ix:nonNumeric contextRef="c-116" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" format="ixt-sec:duryear" id="f-567">3</ix:nonNumeric> years from the acquisition date.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intang</span><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ible assets:</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Intangible assets are comprised of $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-568">3.6</ix:nonFraction>&#160;billion related to SKYCLARYS commercialization rights in the U.S., $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-569">1.9</ix:nonFraction>&#160;billion of IPR&amp;D related to the omaveloxolone program outside the U.S., $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-570">100.0</ix:nonFraction>&#160;million related to a rare pediatric disease priority voucher which may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party and $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-571">20.0</ix:nonFraction>&#160;million related to other clinical programs. The estimated fair values of the program related intangible assets were determined using a probability adjusted discounted cash flow analysis approach utilizing a discount rate of <ix:nonFraction unitRef="number" contextRef="c-116" decimals="2" name="biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate" scale="-2" id="f-572">17.0</ix:nonFraction>% and the estimated fair value of the priority review voucher was based on recent external purchase and sale transactions of similar vouchers.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The more significant as</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenue, cost of sales, research and development and other operating expense, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. Our valuation of the SKYCLARYS commercialization rights reflects the assumption that, using an economic consumption model, the related $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-573">3.6</ix:nonFraction>&#160;billion intangible asset will be amortized over its expected economic life. Our valuation of the $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-574">1.9</ix:nonFraction>&#160;billion </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D asset related to omaveloxolone, which </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has been submitted to the EMA and is currently under review, reflects the assumption that, if regulatory approval is obtained, sales would commence in certain countries in Europe during 2024.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-530-2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We assumed responsibility for a single-tenant, build-to-suit building of approximately <ix:nonFraction unitRef="sqft" contextRef="c-116" decimals="0" name="biib:OperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="f-575">327,400</ix:nonFraction> square feet of office and laboratory space located in Plano, Texas, with an initial lease term of <ix:nonNumeric contextRef="c-116" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-576">16</ix:nonNumeric> years. We recorded a lease liability of approximately $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-577">151.8</ix:nonFraction>&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately <ix:nonNumeric contextRef="c-116" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-578">15</ix:nonNumeric> years, with a corresponding right-of-use asset of approximately $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="6" id="f-579">122.4</ix:nonFraction>&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. We recognized goodwill of approximately $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="f-580">1.1</ix:nonFraction>&#160;billion, which is not deductible for tax purposes. The goodwill recognized from our acquisition of Reata is primarily the result of the deferred tax consequences from the transaction recorded for financial statement purposes.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-related expenses:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acquisition-related expenses, which were comprised primarily of regulatory, advisory and legal fees, and other transaction costs, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" format="ixt:num-dot-decimal" scale="6" id="f-581"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" format="ixt:num-dot-decimal" scale="6" id="f-582">26.3</ix:nonFraction></ix:nonFraction>&#160;million and are included within selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2023.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Assumptions in the Allocations of Purchase Price</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he results of operations of Reata, along with the estimated fair values of the assets acquired and liabilities assumed in the Reata acquisition, have been included in our condensed consolidated financial statements since the closing of the Reata acquisition on September 26, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our preliminary estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management's analysis related to certain matters, such as finalizing our assessment of intangible assets, inventory, goodwill, leases and income taxes. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. The final determination may result in asset and liability fair values that are different than the preliminary estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the acquisition date, our results of operations include the results of operations of Reata. The Reata operations had an immaterial impact to our results of operations for the three and nine months ended September 30, 2023, given the proximity of the acquisition date to quarter-end. Due to the immateriality of Reata's revenues and expenses, additional pro forma information combining the results of operations of Biogen and Reata have not been included.</span></div></ix:continuation><div id="i8325bdffeebc49d7b9475241af1c3c2e_46"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 3:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dispositions</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-583" continuedAt="f-583-1" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sale of Joint Venture Equity Interest in Samsung Bioepis</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our <ix:nonFraction unitRef="number" contextRef="c-127" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-584">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics in exchange for total consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="f-585">2.3</ix:nonFraction>&#160;billion. Under the terms of this transaction, we received approximately $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-8" name="us-gaap:ProceedsFromDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="f-586">1.0</ix:nonFraction>&#160;billion in cash at closing, with approximately $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-8" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="f-587">1.3</ix:nonFraction>&#160;billion in cash to be deferred over two payments. The first deferred payment of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="f-588">812.5</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was received in April 2023 and the second deferred payment of $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="f-589">437.5</ix:nonFraction>&#160;million is due at the second anniversary of the closing of this transaction in April 2024.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale, the carrying value</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our investment in Samsung Bioepis totaled $<ix:nonFraction unitRef="krw" contextRef="c-133" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-590">581.6</ix:nonFraction>&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022 we recognized a pre-tax gain of approximately $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-8" sign="-" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:num-dot-decimal" scale="9" id="f-591"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-8" sign="-" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:num-dot-decimal" scale="9" id="f-592">1.5</ix:nonFraction></ix:nonFraction>&#160;billion related to this transaction, which was recorded in other (income) expense, net in our condensed consolidated statements of income for the</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> nine months ended September 30, 2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This pre-tax gain included reclassifications from AOCI to net income of approximately $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-593">58.9</ix:nonFraction>&#160;million in cumulative translation losses, partially offset by approximately $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-594">57.0</ix:nonFraction>&#160;million in gains resulting from the termination of our net investment hedge.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We elected the fair value option and measured the payments due to us from Samsung BioLogics at fair value. As of September 30, 2023, the estimated fair value of the remaining second deferred payment using a risk-adjusted </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-583-1"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">discount rate of <ix:nonFraction unitRef="number" contextRef="c-136" decimals="3" name="biib:OtherAssetsMeasurementInput" scale="-2" id="f-595">6.4</ix:nonFraction>% was approximately $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-596">422.3</ix:nonFraction> million. This payment has been classified as a Level 3 measurement and is reflected in other current assets within our condensed consolidated balance sheets as of September 30, 2023.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the nine months ended September 30, 2023, we recognized a gain of approximately $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-597">13.7</ix:nonFraction>&#160;million to reflect the change in fair value related to the first deferred payment due to us, which was received in April 2023. Additionally, for the three and nine months ended September 30, 2023, we recognized gains of approximately $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-598">7.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-599">16.9</ix:nonFraction>&#160;million, respectively, to reflect the changes in fair value related to the second deferred payment due to us. These changes were recorded in other (income) expense, net in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this transaction, we are also eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-600">50.0</ix:nonFraction>&#160;million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize the payments in the period the payments become realizable, which is generally the same period in which the payments are earned.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2022 Form 10-K.</span></div></ix:continuation><div id="i8325bdffeebc49d7b9475241af1c3c2e_49"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 4:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restructuring</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-601" continuedAt="f-601-1" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Fit for Growth Restructuring Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023 we initiated additional cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness. The Fit for Growth program is expected to generate approximately $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-8" name="biib:RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" format="ixt:num-dot-decimal" scale="9" id="f-602">1.0</ix:nonFraction>&#160;billion in gross operating expense savings by 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reduction of approximately <ix:nonFraction unitRef="employee" contextRef="c-142" decimals="INF" name="us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" format="ixt:num-dot-decimal" scale="0" id="f-603">1,000</ix:nonFraction> employees.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-604" continuedAt="f-604-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2023 cost saving initiatives are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-605">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-606">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-607">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-608">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-609">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-610">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-612">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-613">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-615">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-616">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-617">37.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-618">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-619">55.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-620">62.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-621">33.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-622">96.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-623">37.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-624">23.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-625">61.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-626">62.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-627">51.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-628">114.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs associated with items such as asset abandonment and write-offs, facility closure costs, pretax gains and losses resulting from the termination of certain leases, employee non-severance expense, consulting fees and other costs.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reata Integration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the closing of the Reata acquisition, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. We expect to incur restructuring charges of approximately $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-629">30.0</ix:nonFraction>&#160;million in 2023. These amounts are primarily related to severance and are expected to be paid by the end of 2024. For the three and nine months ended September 30, 2023, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-630"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-631">21.0</ix:nonFraction></ix:nonFraction>&#160;million of net pre-tax restructuring charges, primarily consisting of employee severance costs.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022 Cost Saving Initiatives</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, deprioritization of certain research and development programs, the consolidation of certain real estate locations and operating efficiencies across our selling, general and administrative and research and development functions. Charges related to our 2022 cost saving initiatives were substantially incurred during 2022 with remaining payments expected to be made through 2026.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-601-1"><ix:continuation id="f-604-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2022 cost saving initiatives are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:28.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.232%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-635">21.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-636">6.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-637">15.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-641">21.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-642">6.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-643">15.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-645">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-646">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-647">110.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-648">13.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-649">124.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-650">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-651">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-652">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-653">110.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-654">13.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-655">124.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Amounts reflect a gain recorded during the third quarter of 2022 of approximately $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:GainLossOnTerminationOfLease" format="ixt:num-dot-decimal" scale="6" id="f-656">5.3</ix:nonFraction>&#160;million related to the partial termination of a portion of our lease located at 300 Binney Street.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-657" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and spending related to our 2023 and 2022 workforce reductions and Reata Integration are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Workforce Reductions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-658">35.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-659">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-660">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-661">27.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-662">15.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-663">6.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" sign="-" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-664">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:RestructuringReserveTranslationAdjustment" format="ixt:fixed-zero" scale="6" id="f-665">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-666">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-667">21.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-668">17.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-669">60.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-670">13.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-671">29.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-672">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-673">0.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-674">32.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-675">52.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-676">58.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-677">21.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-678">31.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-679">32.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" sign="-" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-680">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-681">1.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-682">59.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-683">40.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_52"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 5:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Revenue</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-684" continuedAt="f-684-1" escape="true"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Revenue</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-685" continuedAt="f-685-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-686">58.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-687">181.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-688">239.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-689">92.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-690">246.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-691">339.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-692">148.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-693">16.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-694">165.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-695">127.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-696">9.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-697">137.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-698">206.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-699">198.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-700">405.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-701">220.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-702">256.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-703">476.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-704">148.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-705">63.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-706">212.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-707">174.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-708">80.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-709">255.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-710">31.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-711">34.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-712">65.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-713">39.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-714">41.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-715">80.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-716">180.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-717">97.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-718">277.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-719">214.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-720">121.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-721">336.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-722">244.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-723">211.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-724">456.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-725">273.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-726">232.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-727">505.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-728">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-729">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-730">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-731">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-732">22.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-733">22.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-734">631.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-735">527.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-736">1,159.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-737">707.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-738">632.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-739">1,340.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-740">150.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-741">297.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-742">448.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-743">140.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-744">290.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-745">431.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: SMA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-746">150.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-747">297.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-748">448.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-749">140.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-750">290.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-751">431.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-752">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-753">112.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-754">112.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-755">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-756">110.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-757">110.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-758">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-759">54.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-760">54.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-761">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-762">57.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-763">57.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-764">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-765">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-766">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-767">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-768">19.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-769">19.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-770">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-771">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-772">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-773">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-774">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-775">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-776">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-777">188.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-778">194.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-779">0.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-780">186.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-781">187.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-782">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-783">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-784">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-785">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-786">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-787">3.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-788">790.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-789">1,014.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-790">1,805.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-791">850.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-792">1,111.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-793">1,962.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in the U.S. during the third quarter of 2022 and commercially available in international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM, ADUHELM and QALSODY, which became commercially available in the U.S. during the second quarter of 2023.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-684-1" continuedAt="f-684-2"><ix:continuation id="f-685-1"><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-794">199.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-795">568.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-796">768.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-797">330.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-798">816.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-799">1,146.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-800">372.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-801">47.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-802">419.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-803">383.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-804">19.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-805">402.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-806">571.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-807">616.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-808">1,188.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-809">713.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-810">836.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-811">1,549.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-812">397.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-813">207.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-814">604.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-815">493.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-816">249.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-817">743.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-818">95.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-819">125.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-820">220.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-821">114.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-822">138.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-823">252.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-824">492.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-825">333.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-826">825.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-827">608.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-828">387.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-829">995.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-830">750.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-831">662.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-832">1,412.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-833">849.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-834">693.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-835">1,542.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-836">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-837">67.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-838">67.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-839">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-840">73.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-841">73.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-842">1,814.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-843">1,678.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-844">3,493.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-845">2,170.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-846">1,990.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-847">4,161.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-848">453.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-849">875.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-850">1,328.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-851">443.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-852">891.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-853">1,334.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: SMA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-854">453.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-358" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-855">875.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-856">1,328.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-857">443.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-858">891.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-362" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-859">1,334.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-860">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-861">331.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-862">331.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-863">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-864">340.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-865">340.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-866">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-867">167.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-868">167.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-869">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-870">172.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-871">172.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-872">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-873">60.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-874">60.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-875">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-876">62.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-877">62.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-878">21.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-879">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-880">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-881">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-882">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-883">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-884">21.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-885">560.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-886">581.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-887">1.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-888">575.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-889">576.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-890">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-891">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-892">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-893">4.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-894">6.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-895">10.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-896">2,293.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-897">3,121.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-898">5,414.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-899">2,619.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-900">3,463.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-901">6,083.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in the U.S. during the third quarter of 2022 and commercially available in international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM, ADUHELM and QALSODY, which became commercially available in the U.S. during the second quarter of 2023.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="c-1" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-902"><ix:nonFraction unitRef="wholesaler" contextRef="c-15" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-903">two</ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="c-403" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-904">26.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-404" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-905">10.5</ix:nonFraction>% of gross product revenue for the three months ended September 30, 2023, and <ix:nonFraction unitRef="number" contextRef="c-405" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-906">27.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-406" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-907">9.1</ix:nonFraction>% of gross product revenue for the nine months ended September 30, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="c-1" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-908"><ix:nonFraction unitRef="wholesaler" contextRef="c-15" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-909">two</ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="c-407" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-910">26.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-408" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-911">10.5</ix:nonFraction>% of gross product revenue for the three months ended September 30, 2022, and <ix:nonFraction unitRef="number" contextRef="c-409" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-912">26.8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-410" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-913">10.7</ix:nonFraction>% of gross product revenue for the nine months ended September 30, 2022.</span></div><ix:nonNumeric contextRef="c-1" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="f-914" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-411" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-915">153.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-916">857.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-917">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-918">1,035.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="f-919">554.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" format="ixt:num-dot-decimal" scale="6" id="f-920">1,983.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="f-921">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" format="ixt:num-dot-decimal" scale="6" id="f-922">2,551.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="f-923">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="f-924">24.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="f-925">19.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="f-926">4.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="f-927">410.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" format="ixt:num-dot-decimal" scale="6" id="f-928">1,362.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="f-929">2.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" format="ixt:num-dot-decimal" scale="6" id="f-930">1,774.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="f-931">137.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="f-932">574.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="f-933">23.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="f-934">735.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-935">160.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-936">879.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-937">32.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-938">1,072.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-684-2"><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="f-939" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-940">131.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-941">143.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-942">940.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-943">891.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-944">1,072.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-945">1,035.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="c-1" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="f-946" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty revenue on sales of OCREVUS</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-424" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-947">319.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-948">281.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-949">928.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-950">825.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="f-951">98.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="f-952">131.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="f-953">315.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="f-954">414.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="f-955">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="f-956">4.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="f-957">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="f-958">13.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-959">420.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-960">416.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-961">1,253.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-962">1,252.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> LUNSUMIO became commercially available in the U.S. during the first quarter of 2023.</span></div></ix:nonNumeric><div style="margin-top:7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in our 2022 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contract Manufacturing, Royalty and Other Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing, royalty and other revenue is summarized in the table below.</span></div><div><ix:nonNumeric contextRef="c-1" name="biib:OtherrevenuesTableTextBlock" id="f-963" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-964">252.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-965">114.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-434" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-966">742.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-435" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-967">242.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-436" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-968">51.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-969">15.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-438" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-970">38.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-439" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-971">50.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-972">304.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-973">129.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-974">781.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-975">293.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Manufacturing Revenue</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing revenue primarily reflects amounts earned under contract manufacturing agreements with our strategic customers. During the first quarter of 2023 we began recognizing contract manufacturing revenue for LEQEMBI, upon accelerated approval of LEQEMBI in the U.S. Prior to accelerated approval, contract manufacturing amounts related to LEQEMBI were recognized in research and development expense within our condensed consolidated income statements.</span></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Other Revenue</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty and other revenue primarily reflects the royalties we receive from net sales on products related to patents that we have out-licensed, as well as royalty revenue on biosimilar products from our license arrangements with Samsung Bioepis and our <ix:nonFraction unitRef="number" contextRef="c-440" decimals="2" name="biib:ShareOfNonControlingInterestRecognized" scale="-2" id="f-976">50.0</ix:nonFraction>% share of LEQEMBI product revenue, net and cost of sales, including royalties, as we are not the principal.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2023 we recorded a reclassification of $<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-977">38.7</ix:nonFraction>&#160;million in LEQEMBI collaboration costs from other revenue to selling, general and administrative expense within our condensed consolidated statements of income. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that this reclassification does not materially impact the current or previously issued condensed consolidated financial statements.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai and our license arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_55"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 6:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Inventory</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-978" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-979" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-980">437.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-981">413.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-982">2,285.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="f-983">751.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-984">316.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-985">200.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-986">3,038.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-987">1,365.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-988">2,982.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-989">1,344.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:InventoryNoncurrent" scale="6" id="f-990">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InventoryNoncurrent" scale="6" id="f-991">21.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-992">3,038.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-993">1,365.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the third quarter of 2023 we recorded approximately $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="9" id="f-994">1.7</ix:nonFraction>&#160;billion of acquired inventory related to SKYCLARYS as a result of our acquisition of Reata in September 2023. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the first quarter of 2022 we wrote-off approximately $<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-995">275.0</ix:nonFraction>&#160;million of inventory related to ADUHELM, as a result of the final NCD, which was recognized in cost of sales within our condensed consolidated statements of income </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">September 30, 2022. We recognized approximately $<ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-996">136.0</ix:nonFraction>&#160;million related to Eisai's <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="f-997">45.0</ix:nonFraction>% share of these charges in collaboration profit sharing/(loss reimbursement) within our condensed consolidated statements of income </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">September 30, 2022. As of September 30, 2023 and December 31, 2022, the carrying value of our ADUHELM inventory was immaterial.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to these condensed consolidated financial statements.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_58"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 7:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Intangible Assets and Goodwill</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-998" continuedAt="f-998-1" escape="true"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="f-999" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1000">11,053.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1001">5,793.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1002">5,260.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1003">7,415.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1004">5,629.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1005">1,786.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1006">1,920.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1007">1,920.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="f-1008">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1009">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1010">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1011">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1012">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1013">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1014">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1015">13,137.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1016">5,793.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1017">7,344.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1018">7,479.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1019">5,629.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1020">1,850.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2023, amortization and impairment of acquired intangible assets totale</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1021">60.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1022">164.0</ix:nonFraction> million, re</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">spectively, compared to $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1023">56.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1024">190.9</ix:nonFraction> million, respectively, in the prior year comparative periods. For the three and nine months ended September 30, 2023 and 2022, we had no impairment charges.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations. In connection with our acquisition of Reata in September 2023 </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we acquired SKYCLARYS, a commercially-approved product in the U.S., with an estimated fair value of approximately </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-998-1" continuedAt="f-998-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-1025">3.6</ix:nonFraction>&#160;billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life and amortize these amounts based upon an economic consumption method. IPR&amp;D balances also include adjustments related to foreign currency exchange rate fluctuations. The carrying value associated with our IPR&amp;D assets as of September 30, 2023, relates to the IPR&amp;D programs we acquired in connection with our acquisition of Reata in September 2023 with an estimated fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-1026">1.9</ix:nonFraction>&#160;billion.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Priority Review Voucher</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we acquired a rare pediatric disease priority review voucher that may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party. We recorded the priority review voucher based on its estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-1027">100.0</ix:nonFraction>&#160;million as an intangible asset. The estimated fair value was based on recent external purchase and sale transactions of similar vouchers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-1028" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 (remaining three months)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="f-1029">75.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="f-1030">325.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="f-1031">430.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="f-1032">440.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="f-1033">435.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="f-1034">445.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-1035" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1036">5,749.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill resulting from Reata acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-1037">1,057.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="f-1038">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1039">6,807.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div></ix:continuation><div style="margin-top:6pt"><ix:continuation id="f-998-2" continuedAt="f-998-3"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="usd" contextRef="c-18" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-1040">no</ix:nonFraction> ac</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-998-3">cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_64"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 8:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Fair Value Measurements</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-1043" continuedAt="f-1043-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-1044" continuedAt="f-1044-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1045">1,920.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1046">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1047">1,920.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1048">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-1049">413.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-1050">413.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1051">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1052">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" scale="6" id="f-1053">422.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1055">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" scale="6" id="f-1056">422.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="f-1057">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1058">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="f-1059">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1060">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="f-1061">39.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1062">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="f-1063">39.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1064">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="f-1065">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-1066">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="f-1067">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-1068">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1069">2,826.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-1070">413.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1071">1,990.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-1072">422.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="f-1073">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1074">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="f-1075">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1076">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1077">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1078">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1079">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1080">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the current payment due from Samsung BioLogics as a result of the sale of our <ix:nonFraction unitRef="number" contextRef="c-460" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-1081">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During the third quarter of 2023 we sold all of our marketable debt securities and used the proceeds to partially fund our acquisition of Reata. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1044-1" continuedAt="f-1044-2"><ix:continuation id="f-1043-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1082">2,847.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1083">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1084">2,847.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1085">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-465" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1086">1,231.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-466" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1087">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-467" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1088">1,231.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-468" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1089">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-469" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1090">810.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1091">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-471" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1092">810.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-472" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1093">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-473" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1094">137.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-474" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1095">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-475" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1096">137.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-476" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1097">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-1098">791.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-1099">791.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1100">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1101">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" scale="6" id="f-1102">798.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1103">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-479" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1104">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" scale="6" id="f-1105">798.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="f-1106">63.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1107">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="f-1108">63.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1109">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="f-1110">32.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1111">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="f-1112">32.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1113">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" scale="6" id="f-1114">405.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1115">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-479" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1116">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" scale="6" id="f-1117">405.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1118">7,117.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-1119">791.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1120">5,122.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1121">1,204.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="f-1122">26.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1123">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="f-1124">26.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1125">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1126">26.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1127">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1128">26.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1129">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our <ix:nonFraction unitRef="number" contextRef="c-460" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-1130">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities represent investments in publicly traded equity securities. Our ability to liquidate our investments in Denali, Sage and Sangamo may be limited by the size of our interest, the volume of market related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Denali, Sangamo and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2022 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="f-1131"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="f-1132">no</ix:nonFraction></ix:nonFraction> material impairments of our assets measured and carried at fair value as of September 30, 2023 and December 31, 2022. In addition, there have been no changes to our valuation techniques as of September 30, 2023 and December 31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2022 Form 10-K. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1044-2"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Level 3 Assets and Liabilities Held at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of assets or liabilities into or out of Level 3 as of September 30, 2023 and December 31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-1133" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Convergence, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair value of our contingent consideration obligations, which were classified as Level 3 measurements:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-481" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-1134">197.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-482" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-1135">209.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-1136">2.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-1137">13.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-1138">195.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-1139">195.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our contingent consideration obligations are recorded in (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022 we discontinued further development efforts related to vixotrigine for the potential treatment of TGN and DPN, resulting in a reduction of our contingent consideration obligations of approximately $<ix:nonFraction unitRef="usd" contextRef="c-484" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" format="ixt:num-dot-decimal" scale="6" id="f-1140">195.4</ix:nonFraction>&#160;million, reducing the fair value of vixotrigine to zero.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, the changes in fair value of our contingent consideration obligations were primarily due to increases in the discount rates used to revalue these obligations and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Instruments Not Carried at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="f-1141" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our senior notes debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-485" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1142">1,689.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-485" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1143">1,746.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1144">1,699.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1145">1,744.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1146">1,196.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1147">1,493.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1148">1,219.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1149">1,492.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1150">972.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1151">1,100.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1152">1,033.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1153">1,100.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1154">909.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1155">1,474.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1156">989.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1157">1,473.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1158">430.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="f-1159">471.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1160">469.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="f-1161">469.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1162">5,198.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1163">6,286.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1164">5,410.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1165">6,281.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The changes in the fair values of our Senior Notes as of September 30, 2023, compared to December 31, 2022, are primarily related to increases in U.S. treasury yields partially offset by a decrease in credit spreads used to value our Senior Notes since December 31, 2022. For additional information related to our Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2022 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we drew</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="f-1166">1.0</ix:nonFraction> billion</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> on term loans under our term loan credit agreement. As of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2023, t</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">he fair value of our term loans outstanding approximate book value based on the current borrowing rates available. For additional information on our term loan credit agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_70"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 9:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Financial Instruments</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-1167" continuedAt="f-1167-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-1168" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-495" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="f-1169">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-496" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-1170">177.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-497" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="f-1171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-498" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-1172">59.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-499" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-1173">1,920.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-500" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-1174">2,581.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-501" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="f-1175">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-502" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-1176">29.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-1177">1,920.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-1178">2,847.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We partially funded our Reata acquisition through available cash, cash equivalents and marketable securities. As of September 30, 2023, we have sold all of our marketable debt securities. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-1179" continuedAt="f-1179-1" escape="true">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</ix:nonNumeric></span></div><ix:continuation id="f-1179-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1180">993.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1181">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1182">579.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1183">413.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1184">993.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1186">579.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1187">413.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-1188">936.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1189">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1190">4.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1191">931.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-1192">305.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-1193">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1194">5.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1195">300.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-1196">547.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-1197">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1198">5.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1199">542.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-507" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-1200">271.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-507" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1201">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-507" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1202">3.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-507" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1203">268.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="6" id="f-1204">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1205">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1206">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1207">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-1208">139.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-1209">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1210">1.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1211">137.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-1212">2,199.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-1213">0.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1214">20.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1215">2,179.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="f-1216">1,133.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1217">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1218">342.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1219">791.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="f-1220">1,133.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1221">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1222">342.7</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1223">791.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1167-1"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-1224" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1225">1,473.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-1226">1,483.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="f-1227">694.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="f-1228">703.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="f-1229">11.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="f-1230">12.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1231">2,179.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-1232">2,199.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities classified as available-for-sale as of December 31, 2022, was approximately <ix:nonNumeric contextRef="c-1" name="biib:AverageMaturityOfMarketableSecurities" format="ixt-sec:durmonth" id="f-1233">8</ix:nonNumeric> months.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="f-1234" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.918%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1235">5,698.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1236">1,643.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1237">7,380.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1238">3,104.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="f-1239">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:fixed-zero" scale="6" id="f-1240">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="f-1241">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:fixed-zero" scale="6" id="f-1242">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="f-1243">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="f-1244">7.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="f-1245">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="f-1246">9.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized losses for the three and nine months ended</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2023, primarily relate to sales of U.S. treasuries and corporate bonds. Realized losses for the three and nine months ended September 30, 2022, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During the third quarter of 2023 we sold all of our marketable debt securities and used the proceeds to partially fund our acquisition of Reata. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, as well as venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, our strategic investment portfolio was comprised of investments totaling $<ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-5" name="biib:StrategicInvestmentPortfolio" format="ixt:num-dot-decimal" scale="6" id="f-1247">465.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="biib:StrategicInvestmentPortfolio" format="ixt:num-dot-decimal" scale="6" id="f-1248">846.0</ix:nonFraction> million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our strategic investment portfolio as of September 30, 2023, was primarily due to the decrease in the fair value of our investments in Denali, Sangamo and Sage common stock. Additionally, we sold a portion of our Sangamo common stock during the third quarter of 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our strategic investments in Denali, Sangamo and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2022 Form 10-K.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_73"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 10:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Derivative Instruments</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="f-1249" continuedAt="f-1249-1" escape="true"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts and foreign currency options in effect as of September 30, 2023 and December 31, 2022, had durations of <ix:nonNumeric contextRef="c-513" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1250">1</ix:nonNumeric> to <ix:nonNumeric contextRef="c-514" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1251">15</ix:nonNumeric> months and <ix:nonNumeric contextRef="c-515" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1252">1</ix:nonNumeric> to <ix:nonNumeric contextRef="c-516" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1253">12</ix:nonNumeric> months, respectively. These contracts have been designated as cash flow hedges and unrealized gains and losses on the portion of these foreign currency forward contracts and foreign currency options that are included in the effectiveness test are reported in AOCI. Realized gains and losses of such contracts and options are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from AOCI and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="f-1254" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-517" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1255">1,006.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1256">1,495.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-519" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1257">43.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1258">162.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1259">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="f-1260">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1261">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1262">57.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts and options</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1263">1,144.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1264">1,715.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock" id="f-1265" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-5" name="biib:UnrealizedGainOnDerivatives" scale="6" id="f-1266">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-5" name="biib:UnrealizedGainOnDerivatives" scale="6" id="f-1267">29.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-5" name="biib:UnrealizedLossOnDerivatives" scale="6" id="f-1268">7.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-5" name="biib:UnrealizedLossOnDerivatives" scale="6" id="f-1269">21.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-5" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="f-1270">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-5" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="f-1271">8.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the net unrealized gains of approximately $<ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-5" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="6" id="f-1272">11.5</ix:nonFraction>&#160;million to be settled over the next <ix:nonNumeric contextRef="c-529" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1273">15</ix:nonNumeric> months, of which approximately $<ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-5" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1274">7.9</ix:nonFraction> million of these net unrealized gains are expected to be settled over the next <ix:nonNumeric contextRef="c-530" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1275">12</ix:nonNumeric> months, with any amounts in AOCI to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2023 and December 31, 2022, credit risk did not materially change the fair value of our foreign currency forward contracts and forward currency options.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1249-1" continuedAt="f-1249-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="f-1276" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1277">1.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1278">77.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1279">2.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1280">6.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-535" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1281">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1282">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1283">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-538" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1284">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-539" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1285">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1286">143.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-541" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1287">1.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-542" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1288">0.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1289">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1290">3.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1291">2.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1292">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Investment Hedges - Hedging Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately <ix:nonFraction unitRef="number" contextRef="c-547" decimals="3" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" scale="-2" id="f-1293">5.0</ix:nonFraction>% to approximately <ix:nonFraction unitRef="number" contextRef="c-460" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-1294">49.9</ix:nonFraction>%. Our investment in the equity of Samsung Bioepis related to this transaction was exposed to the currency fluctuations in the South Korean won.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we entered into foreign currency forward contracts. These contracts were designated as net investment hedges. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our <ix:nonFraction unitRef="number" contextRef="c-127" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-1295">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and closed these foreign currency forward contracts. Upon completing this sale, the cumulative gains on our net investment hedges of $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1296">57.0</ix:nonFraction>&#160;million were reclassified from AOCI and reflected within the total pre-tax gain recognized from the sale, which was recorded in other (income) expense, net in our condensed consolidated statements of income. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-1297" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our net investment hedges in our condensed consolidated financial statements:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:25.192%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.931%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.761%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Recognized in Net Income (Amounts Excluded from Effectiveness Testing)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-548" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="f-1298">20.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-548" decimals="-5" sign="-" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="f-1299">3.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-5" sign="-" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="f-1300">4.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our <ix:nonFraction unitRef="number" contextRef="c-460" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-1301">49.9</ix:nonFraction>% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $<ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1302">1,340.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1303">1,238.8</ix:nonFraction> million as of September 30, 2023 and December 31, 2022, respectively. Net losses of $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1304">22.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1305">28.0</ix:nonFraction> million related to these contracts were recorded as a component of other (income) expense, net for the three </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1249-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and nine months ended September 30, 2023, respectively, compared to net losses of $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1306">36.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1307">85.8</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="f-1308" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1309">20.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1310">37.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1311">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="f-1312">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1313">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-557" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1314">18.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-558" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1315">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-559" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1316">25.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-560" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1317">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1318">7.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8325bdffeebc49d7b9475241af1c3c2e_76"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 11:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Property, Plant and Equipment</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-1319" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1320">2,342.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1321">2,165.7</ix:nonFraction> million as of September 30, 2023 and December 31, 2022, respectively. For the three and nine months ended September 30, 2023, depreciation expense totaled $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-1322">64.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-1323">190.7</ix:nonFraction> million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-1324">64.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-1325">207.7</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are nearing completion of a large-scale biologics manufacturing facility in Solothurn, Switzerland. This facility will include <ix:nonFraction unitRef="sqft" contextRef="c-562" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="f-1326">393,000</ix:nonFraction> square feet related to a large-scale biologics manufacturing facility, <ix:nonFraction unitRef="sqft" contextRef="c-563" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="f-1327">290,000</ix:nonFraction> square feet of warehouse, utilities and support space and <ix:nonFraction unitRef="sqft" contextRef="c-564" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="f-1328">51,000</ix:nonFraction> square feet of administrative space. As of September 30, 2023 and December 31, 2022, we had approximately $<ix:nonFraction unitRef="usd" contextRef="c-565" decimals="-5" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="f-1329">742.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-566" decimals="-5" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="f-1330">711.1</ix:nonFraction> million, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021 a portion of the facility (the first manufacturing suite) received a GMP multi-product license from the SWISSMEDIC and was placed into service. Solothurn has been approved for the manufacture of ADUHELM and LEQEMBI by the FDA. We estimate the second manufacturing suite will be operational by the end of 2023.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">125 Broadway Building Sale</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we completed the sale of our building and land parcel located at 125 Broadway for an aggregate sales price of approximately $<ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1331">603.0</ix:nonFraction>&#160;million, which is inclusive of a $<ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-5" name="biib:GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1332">10.8</ix:nonFraction>&#160;million tenant allowance. This sale resulted in a pre-tax gain on sale of approximately $<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1333"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1334">503.7</ix:nonFraction></ix:nonFraction>&#160;million, net of transaction costs, which is reflected within gain on sale of building in our condensed consolidated statements of income for the three and nine months ended September 30, 2022. This transaction included approximately $<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-1335">79.2</ix:nonFraction>&#160;million of property, plant and equipment, net, which comprised of approximately $<ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-1336">72.6</ix:nonFraction>&#160;million for buildings, approximately $<ix:nonFraction unitRef="usd" contextRef="c-572" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-1337">1.6</ix:nonFraction>&#160;million for land and approximately $<ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-1338">5.0</ix:nonFraction>&#160;million for machinery and equipment.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_79"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 12:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Leases</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-1339" escape="true"><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6100 Legacy Drive Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we assumed responsibility for a single-tenant, build-to-suit building of approximately <ix:nonFraction unitRef="sqft" contextRef="c-116" decimals="0" name="biib:OperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="f-1340">327,400</ix:nonFraction> square feet of office and laboratory space located in Plano, Texas, with an initial lease term of <ix:nonNumeric contextRef="c-116" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1341">16</ix:nonNumeric> years. We recorded a lease liability of approximately $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1342">151.8</ix:nonFraction>&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately <ix:nonNumeric contextRef="c-116" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-1343">15</ix:nonNumeric> years, with a corresponding right-of-use asset of approximately $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="6" id="f-1344">122.4</ix:nonFraction>&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">125 Broadway Building Sale and Leaseback Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of our 125 Broadway building during the third quarter of 2022, we simultaneously leased back the building for a term of approximately <ix:nonNumeric contextRef="c-574" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1345">5.5</ix:nonNumeric> years, which resulted in the recognition of approximately $<ix:nonFraction unitRef="usd" contextRef="c-575" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-1346"><ix:nonFraction unitRef="usd" contextRef="c-575" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-1347">168.2</ix:nonFraction></ix:nonFraction>&#160;million in a new lease liability and right-of-use asset recorded within our condensed consolidated balance sheets as of December 31, 2022. The sale and immediate leaseback of this building qualified for sale and leaseback treatment and is classified as an operating lease. For additional information on the sale of our 125 Broadway building, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11, Property, Plant and Equipment</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">300 Binney Street Lease Modification</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we entered into an agreement to partially terminate a portion of our lease located at 300 Binney Street, as well as to reduce the lease term for the majority of the remaining space. The agreement was driven by our 2022 efforts to reduce costs by consolidating real estate locations. The transaction was treated as a lease modification as of the effective date and resulted in the derecognition of a right-of-use asset of approximately $<ix:nonFraction unitRef="usd" contextRef="c-576" decimals="-5" name="biib:OperatingLeaseRightOfUseAssetDerecognized" format="ixt:num-dot-decimal" scale="6" id="f-1348">47.4</ix:nonFraction>&#160;million and lease liability of approximately $<ix:nonFraction unitRef="usd" contextRef="c-576" decimals="-5" name="biib:OperatingLeaseLiabilityDerecognized" format="ixt:num-dot-decimal" scale="6" id="f-1349">52.7</ix:nonFraction>&#160;million, which resulted in a gain of approximately $<ix:nonFraction unitRef="usd" contextRef="c-576" decimals="-5" name="biib:GainLossOnRestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-1350">5.3</ix:nonFraction>&#160;million, which was recorded within restructuring charges in our condensed consolidated statements of income for the three and nine months ended September 30, 2022.</span></div></ix:nonNumeric><div id="i8325bdffeebc49d7b9475241af1c3c2e_85"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 13:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indebtedness</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Term Loan <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-1351" continuedAt="f-1351-1" escape="true">Credit Agreement</ix:nonNumeric></span></div><ix:continuation id="f-1351-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we entered into a $<ix:nonFraction unitRef="usd" contextRef="c-577" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-1352">1.5</ix:nonFraction>&#160;billion term loan credit agreement. On the closing date of the Reata acquisition we drew $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="f-1353">1.0</ix:nonFraction> billion from the term loan, comprised of a $<ix:nonFraction unitRef="usd" contextRef="c-578" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1354">500.0</ix:nonFraction>&#160;million floating rate 364-day tranche and a $<ix:nonFraction unitRef="usd" contextRef="c-579" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1355">500.0</ix:nonFraction>&#160;million floating rate three-year tranche. The remaining unused commitment of $<ix:nonFraction unitRef="usd" contextRef="c-580" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1356">500.0</ix:nonFraction>&#160;million was terminated. As of September 30, 2023, we had $<ix:nonFraction unitRef="usd" contextRef="c-581" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-1357">1.0</ix:nonFraction>&#160;billion outstanding under the term loan credit agreement, of which $<ix:nonFraction unitRef="usd" contextRef="c-582" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1358">500.0</ix:nonFraction>&#160;million was outstanding under the 364-day tranche and $<ix:nonFraction unitRef="usd" contextRef="c-583" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1359">500.0</ix:nonFraction>&#160;million outstanding under the three-year tranche.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.625% Senior Notes due September 15, 2022</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2015, we issued $<ix:nonFraction unitRef="usd" contextRef="c-584" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1360">1.0</ix:nonFraction>&#160;billion aggregate principal amount of our <ix:nonFraction unitRef="number" contextRef="c-18" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1361"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1362">3.625</ix:nonFraction></ix:nonFraction>% Senior Notes due September 15, 2022, at <ix:nonFraction unitRef="number" contextRef="c-585" decimals="INF" name="biib:DebtInstrumentRedemptionRate" scale="-2" id="f-1363">99.920</ix:nonFraction>% of par. Our <ix:nonFraction unitRef="number" contextRef="c-18" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1364"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1365">3.625</ix:nonFraction></ix:nonFraction>% Senior Notes were senior unsecured obligations. In July 2022 we redeemed our <ix:nonFraction unitRef="number" contextRef="c-18" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1366"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1367">3.625</ix:nonFraction></ix:nonFraction>% Senior Notes prior to their maturity and recognized a net pre-tax charge of approximately $<ix:nonFraction unitRef="usd" contextRef="c-586" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="f-1368">2.4</ix:nonFraction>&#160;million upon the extinguishment of these Senior Notes, which primarily reflects the payment of an early call premium as well as the write-off of remaining unamortized original debt issuance costs and discount balances. These charges were recognized as interest expense in other (income) expense, net in our condensed consolidated statements of income for the three and nine months ended September 30, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_88"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 14:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Equity</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1369" continuedAt="f-1369-1" escape="true"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="c-587" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1370">5.0</ix:nonFraction> billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1371">1.2</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1372">3.6</ix:nonFraction> million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-1373">250.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-1374">750.0</ix:nonFraction> million during the three and nine months ended September 30, 2022, respectively. There were no share repurchases of our common stock during the three and nine months ended September 30, 2023. Approximately $<ix:nonFraction unitRef="usd" contextRef="c-588" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1375">2.1</ix:nonFraction> billion remained available under our 2020 Share Repurchase Program as of September 30, 2023.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-1376" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in AOCI, net of tax by component:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-589" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1377">15.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1378">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1379">1.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1380">163.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1381">164.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-593" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1382">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-594" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1383">18.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1384">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1385">11.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1386">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-593" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1387">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-594" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1388">17.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1391">4.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-593" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1392">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-594" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1393">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1394">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1395">11.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1396">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-597" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1397">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1398">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-599" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1399">0.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-600" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1400">175.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1401">159.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedges, Net of Tax</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-601" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1402">2.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-602" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1403">53.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-603" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1404">25.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-604" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1405">44.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-605" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1406">139.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1407">106.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-606" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1408">26.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-607" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1409">204.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-608" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1410">12.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1411">4.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1412">154.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1413">40.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-606" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1414">7.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-607" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1415">125.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-608" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1416">38.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1417">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1418">58.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1419">97.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-606" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1420">19.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-607" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1421">79.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-608" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1422">25.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1423">4.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1424">95.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1425">56.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1426">21.2</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-612" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1427">132.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-613" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1428">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-614" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1429">40.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-615" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1430">234.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1431">163.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our <ix:nonFraction unitRef="number" contextRef="c-460" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-1432">49.9</ix:nonFraction>% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1369-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="f-1433" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from AOCI:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.398%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1434">15.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1435">8.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1436">17.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-619" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1437">9.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1438">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1439">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1440">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-619" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1441">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="f-1442">1.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1443">77.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1444">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1445">143.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-5" sign="-" name="us-gaap:OperatingExpenses" scale="6" id="f-1446">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-1447">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-5" sign="-" name="us-gaap:OperatingExpenses" scale="6" id="f-1448">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-1449">3.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1450">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="f-1451">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1452">0.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1453">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-1454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1455">7.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1456">2.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1457">14.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-624" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="f-1458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-625" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="f-1459">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-626" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="f-1460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-627" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1461">38.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-628" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="f-1462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-629" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="f-1463">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-630" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="f-1464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-631" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1465">58.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-632" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-1466">12.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-633" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1467">62.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-634" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1468">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-635" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1469">97.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our <ix:nonFraction unitRef="number" contextRef="c-460" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-1470">49.9</ix:nonFraction>% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i8325bdffeebc49d7b9475241af1c3c2e_91"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 15:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per Share</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1471" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1472" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-1473">68.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1474">1,134.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1475">911.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1476">2,496.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1477">144.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1478">144.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1479">144.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1480">145.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-636" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="f-1481">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-637" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1482">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-638" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1483">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-639" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1484">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-640" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="f-1485">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-641" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1486">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-642" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1487">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-643" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1488">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="f-1489">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="f-1490">0.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="f-1491">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="f-1492">0.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1493">144.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1494">144.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1495">145.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1496">146.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income (loss) per diluted share because their effects were anti-dilutive were insignificant.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_94"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 16:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Share-Based Payments</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-1497" escape="true"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-1498" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-644" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1499">217.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-645" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1500">24.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-646" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1501">276.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-647" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1502">72.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-648" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1503">234.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-649" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1504">46.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-650" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1505">333.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-651" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1506">129.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1507">452.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1508">71.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1509">609.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1510">201.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1511">2.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1512">2.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1513">8.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1514">7.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1515">449.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1516">69.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1517">601.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1518">194.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1519">98.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1520">13.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1521">126.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1522">36.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income (loss) attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-652" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1523">350.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-653" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1524">56.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-654" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1525">474.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-655" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1526">158.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> recognized Reata equity-based compensation expense, inclusive of employer taxes, of approximately $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1527">393.4</ix:nonFraction>&#160;million attributable to the post-acquisition service period, of which $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1528">196.4</ix:nonFraction>&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1529">197.0</ix:nonFraction>&#160;million as a charge to research and development expense within our condensed consolidated statements of income</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three and nine months ended September 30, 2023</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">hese amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-1530" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-656" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1531">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1532">4.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-658" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1533">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1534">11.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-660" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1535">53.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-661" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1536">48.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-662" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1537">175.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-663" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1538">150.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-664" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1539">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-665" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1540">10.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-666" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1541">27.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-667" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1542">22.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-668" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1543">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-669" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1544">5.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1545">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-671" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1546">7.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-672" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1547">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-673" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1548">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-674" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1549">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-675" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1550">10.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-676" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1551">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-677" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-1552">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-678" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1553">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-679" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-1554">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata equity awards</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-680" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1555">387.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-681" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-1556">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-682" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1557">387.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-683" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-1558">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1559">452.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1560">71.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1561">609.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1562">201.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1563">2.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1564">2.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1565">8.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1566">7.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1567">449.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1568">69.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1569">601.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1570">194.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> During the fourth quarter of 2022 we granted stock options. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Share-Based Payments</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2022 Form 10-K.</span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the Reata equity-based compensation expense attributable to the post-acquisition service period, associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_97"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 17:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Income Taxes</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1571" continuedAt="f-1571-1" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inflation Reduction Act</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022 the IRA was signed into law in the U.S. The IRA introduced new tax provisions, including a 15.0% corporate alternative minimum tax and a 1.0% excise tax on stock repurchases. The provisions of the IRA are effective for periods after December 31, 2022. The IRA did not result in any material adjustments to our income tax provision or other income tax balances as of September 30, 2023 and December 31, 2022. Preliminary guidance has been issued by the IRS and we expect additional guidance and regulations to be issued in future periods. We will continue to assess its potential impact on our business and results of operations as further information becomes available.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tax Rate</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1572" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1573">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1574">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1575">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1576">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1577">1.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1578">1.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1579">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1580">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1581">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1582">3.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1583">6.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1584">4.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1585">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1586">1.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1587">7.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1588">1.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="f-1589">2.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="f-1590">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="f-1591">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="f-1592">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-1593">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-1594">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-1595">1.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-1596">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis" format="ixt:fixed-zero" scale="-2" id="f-1597">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis" scale="-2" id="f-1598">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis" format="ixt:fixed-zero" scale="-2" id="f-1599">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis" scale="-2" id="f-1600">1.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement agreement</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="biib:EffectiveTaxRateReconciliationLitigationAgreement" format="ixt:fixed-zero" scale="-2" id="f-1601">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationLitigationAgreement" scale="-2" id="f-1602">1.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="biib:EffectiveTaxRateReconciliationLitigationAgreement" format="ixt:fixed-zero" scale="-2" id="f-1603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="biib:EffectiveTaxRateReconciliationLitigationAgreement" scale="-2" id="f-1604">3.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="f-1605">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" format="ixt:fixed-zero" scale="-2" id="f-1606">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" format="ixt:fixed-zero" scale="-2" id="f-1607">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="f-1608">2.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International reorganization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="biib:EffectiveTaxRateReconciliationInternationalReorganization" format="ixt:fixed-zero" scale="-2" id="f-1609">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="biib:EffectiveTaxRateReconciliationInternationalReorganization" format="ixt:fixed-zero" scale="-2" id="f-1610">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="biib:EffectiveTaxRateReconciliationInternationalReorganization" format="ixt:fixed-zero" scale="-2" id="f-1611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationInternationalReorganization" scale="-2" id="f-1612">1.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including permanent items</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1613">7.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1614">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1615">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1616">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1617">51.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1618">17.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1619">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1620">19.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate for the three months ended September 30, 2023, reflects a tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1621">72.9</ix:nonFraction> million recognized as a result of a pretax loss from operations of $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1622">141.2</ix:nonFraction> million recorded during the third quarter of 2023, which was driven, in part, by the impact of the non-cash changes in the value of our equity investments and Reata acquisition-related expenses. For all other periods presented, the effective tax rates reflect tax expense on pretax income from operations in the respective periods.</span></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2023, compared to the same period in 2022, the change in our effective tax rate was driven by the impact of the non-cash changes in the value of our equity investments and Reata acquisition-related expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, compared to the same period in 2022, our effective tax rate, in addition to the items noted above, was also impacted by the combined net unfavorable tax rate impacts in 2022 related to a litigation settlement agreement, the sale of our equity interest in Samsung Bioepis, the impact of a Neurimmune valuation allowance and an international reorganization to align with global tax developments. The change also benefits from the resolution of an uncertain tax matter during the first quarter of 2023 related to tax credits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1571-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal tax examination for years before 2019 or state, local or non-U.S. income tax examinations for years before 2013.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters, withholding taxes and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease by up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="f-1623">460.0</ix:nonFraction>&#160;million, including approximately $<ix:nonFraction unitRef="usd" contextRef="c-684" decimals="-5" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="f-1624">450.0</ix:nonFraction>&#160;million related to the unrecognized</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax benefits related to Neurimmune's tax basis in ADUHELM, as discussed above, in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations. Any changes to our gross unrecognized tax benefits related to Neurimmune's tax basis in ADUHELM would result in a zero net impact to net income attributable to Biogen, Inc., as we have recorded a full valuation allowance against the relevant deferred tax assets.</span></div></ix:continuation><div id="i8325bdffeebc49d7b9475241af1c3c2e_100"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 18:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Other Consolidated Financial Statement Detail</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="f-1625" continuedAt="f-1625-1" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other (Income) Expense, Net</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="f-1626" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of equity interest in Samsung Bioepis</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:fixed-zero" scale="6" id="f-1627">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:fixed-zero" scale="6" id="f-1628">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:fixed-zero" scale="6" id="f-1629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="f-1630">1,505.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="f-1631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="f-1632">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="f-1633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:LitigationSettlementExpense" scale="6" id="f-1634">900.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-1635">95.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-1636">23.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-1637">252.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-1638">39.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1639">63.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1640">59.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1641">175.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1642">191.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains) losses on investments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="f-1643">317.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="f-1644">101.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="f-1645">289.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="f-1646">167.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange (gains) losses, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1647">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1648">11.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1649">30.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1650">39.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1651">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1652">1.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1653">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1654">25.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1655">300.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1656">56.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1657">248.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1658">221.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-127" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-1659">49.9</ix:nonFraction>%</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (gains) losses on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022 we recorded a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="c-685" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="f-1660">900.0</ix:nonFraction>&#160;million, plus settlement fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015. This charge is included within other (income) expense, net in our condensed consolidated statements of income for the nine months ended September 30, 2022.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GainLossOnInvestmentsTextBlock" id="f-1661" continuedAt="f-1661-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-1662">302.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-1663">109.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-1664">273.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-1665">158.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains) losses realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-1666">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-1667">0.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-1668">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:fixed-zero" scale="6" id="f-1669">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-1670">297.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-1671">109.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-1672">268.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-1673">158.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1625-1"><ix:continuation id="f-1661-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the three months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali and Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-686" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1674">295.6</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the three months ended September 30, 2022, primarily reflect an increase in the aggregate fair value of our investments in Sage, Ionis, Sangamo and Denali common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-687" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1675">112.5</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali, Sangamo and Ionis common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-688" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1676">265.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-689" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1677">198.0</ix:nonFraction>&#160;million, partially offset by an increase in the fair value of Ionis and Sage common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-689" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" format="ixt:num-dot-decimal" scale="6" id="f-1678">52.2</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-1679" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata acquisition-related accrued expense</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:SettlementLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1680">1,407.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:SettlementLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="f-1681">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1682">940.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1683">891.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-1684">276.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-1685">395.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="f-1686">298.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="f-1687">277.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="f-1688">202.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="f-1689">209.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="f-1690">712.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="f-1691">746.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1692">3,838.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1693">2,521.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reata Acquisition-Related Accrued Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we accrued approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" format="ixt:num-dot-decimal" scale="6" id="f-1694">983.9</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to Reata's outstanding equity awards, inclusive of employer taxes, of which approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-1695">980.0</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was subsequently paid in October 2023. As of September 30, 2023, this amount was included within accrued expense and other within our condensed consolidated balance sheets. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additionally, we assumed a payable to Blackstone of approximately $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:LossOnContractTermination" format="ixt:num-dot-decimal" scale="6" id="f-1696">300.0</ix:nonFraction>&#160;million related to a one-time contract termination fee to eliminate potential future royalty obligations related to SKYCLARYS, which was triggered as part of the change in control provision under Reata's funding agreement with Blackstone. Payment to Blackstone is expected to be made in November 2023. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:10pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1697">747.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1698">944.2</ix:nonFraction> million as of September 30, 2023 and December 31, 2022, respectively, and included accrued income taxes totaling $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1699">393.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1700">541.7</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i8325bdffeebc49d7b9475241af1c3c2e_103"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-1701" continuedAt="f-1701-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 19:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborative and Other Relationships</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Genentech, Inc. (Roche Group)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO (mosunetuzumab), for the treatment of relapsed or refractory follicular lymphoma, which was granted accelerated approval in the U.S. during the fourth quarter of 2022; COLUMVI (glofitamab), a bispecific antibody for the treatment of non-Hodgkin's lymphoma, which was granted accelerated approval by the FDA during the second quarter of 2023; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1701-1" continuedAt="f-1701-2"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt">U.S.:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt">Canada:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. The level of gross sales of GAZYVA in the U.S. has impacted our percentage of the co-promotion profits for RITUXAN and LUNSUMIO, as summarized in the table below.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCREVUS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from <ix:nonFraction unitRef="number" contextRef="c-690" decimals="INF" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" scale="-2" id="f-1702">13.5</ix:nonFraction>% and increasing up to <ix:nonFraction unitRef="number" contextRef="c-691" decimals="INF" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" scale="-2" id="f-1703">24.0</ix:nonFraction>% if annual net sales exceed $<ix:nonFraction unitRef="usd" contextRef="c-692" decimals="-5" name="biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" format="ixt:num-dot-decimal" scale="6" id="f-1704">900.0</ix:nonFraction>&#160;million. There will be a <ix:nonFraction unitRef="number" contextRef="c-692" decimals="INF" name="biib:Reductioninroyaltyrate" scale="-2" id="f-1705">50.0</ix:nonFraction>% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we receive a gross <ix:nonFraction unitRef="number" contextRef="c-693" decimals="INF" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" scale="-2" id="f-1706">3.0</ix:nonFraction>% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting <ix:nonNumeric contextRef="c-692" name="biib:PeriodOfCollaborationAgreement" format="ixt-sec:duryear" id="f-1707">11</ix:nonNumeric> years from the first commercial sale of OCREVUS on a country-by-country basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third-party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LUNSUMIO (mosunetuzumab)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022 we exercised our option with Genentech to participate in the joint development and commercialization of LUNSUMIO. Under our collaboration with Genentech, we were responsible for <ix:nonFraction unitRef="number" contextRef="c-694" decimals="INF" name="biib:PercentageOfFutureDevelopmentCosts" scale="-2" id="f-1708">30.0</ix:nonFraction>% of development costs for LUNSUMIO prior to FDA approval and will be entitled to a tiered share of co-promotion operating profits and losses in the U.S., as summarized in the table below. In addition, we receive low single-digit royalties on sales of LUNSUMIO outside the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022 LUNSUMIO was granted accelerated approval by the FDA for the treatment of relapsed or refractory follicular lymphoma. Prior to regulatory approval, we record our share of the expense incurred by the collaboration for the development of anti-CD20 products in research and development expense and pre-commercialization costs within selling, general and administrative expense in our condensed consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development and sales and marketing expense related to that product as a reduction of our share of pre-tax profits in revenue from anti-CD20 therapeutic programs.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COLUMVI (glofitamab)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022 we entered into an agreement with Genentech related to the commercialization and sharing of economics for COLUMVI, a bispecific antibody for the treatment of B-cell non-Hodgkin's lymphoma, which was subsequently granted accelerated approval by the FDA in June 2023. Under the terms of this agreement, we will have no payment obligations. Genentech will have sole decision-making rights on the commercialization of COLUMVI within the U.S. and we will receive tiered royalties in the mid-single digit range on net sales of COLUMVI in the U.S. The commercialization of COLUMVI does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1701-2" continuedAt="f-1701-3"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Formulas</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN and LUNSUMIO Profit Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax co-promotion profit-sharing formula for RITUXAN and LUNSUMIO in the U.S. provides for a <ix:nonFraction unitRef="number" contextRef="c-695" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" scale="-2" id="f-1709">30.0</ix:nonFraction>% share on the first $<ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1710"><ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1711">50.0</ix:nonFraction></ix:nonFraction>&#160;million of combined co-promotion operating profits earned each calendar year. <ix:nonNumeric contextRef="c-1" name="biib:CoPromotionProfitSharingFormulaTableTextBlock" id="f-1712" continuedAt="f-1712-1" escape="true">As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $<ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1713"><ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1714">50.0</ix:nonFraction></ix:nonFraction>&#160;million varies upon the following events, as summarized in the table below:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="f-1712-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After LUNSUMIO Approval until the First Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-695" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" scale="-2" id="f-1715">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First Threshold Date until the Second Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-695" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1716">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-695" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" scale="-2" id="f-1717">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">First Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the earlier of (i)&#160;the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $<ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-5" name="biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" format="ixt:num-dot-decimal" scale="6" id="f-1718">500.0</ix:nonFraction>&#160;million or (ii)&#160;the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $<ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-5" name="biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" format="ixt:num-dot-decimal" scale="6" id="f-1719">150.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the later of (i) the first date the gross sales in any calendar year in which U.S. gross sales of LUNSUMIO reach $<ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-5" name="biib:SalesTriggerGrossSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="f-1720">350.0</ix:nonFraction>&#160;million or (ii) January 1 of the calendar year following the calendar year in which the First Threshold Date occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the First Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for RITUXAN and LUNSUMIO was <ix:nonFraction unitRef="number" contextRef="c-696" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1721">35.0</ix:nonFraction>%.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA Profit Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax profit-sharing formula for GAZYVA provides for a <ix:nonFraction unitRef="number" contextRef="c-696" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1722">35.0</ix:nonFraction>% share on the first $<ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1723"><ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1724">50.0</ix:nonFraction></ix:nonFraction>&#160;million of operating profits earned each calendar year. <ix:nonNumeric contextRef="c-1" name="biib:PretaxProfitSharingFormulaTableTextBlock" id="f-1725" continuedAt="f-1725-1" escape="true">Our share of annual co-promotion profits in excess of $<ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1726"><ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1727">50.0</ix:nonFraction></ix:nonFraction>&#160;million varies upon the following events, as summarized in the table below:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="f-1725-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Until Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-696" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" scale="-2" id="f-1728">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-696" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1729">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second GAZYVA Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $<ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-5" name="biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" format="ixt:num-dot-decimal" scale="6" id="f-1730">500.0</ix:nonFraction>&#160;million. The second GAZYVA threshold date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the Second GAZYVA Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for GAZYVA was <ix:nonFraction unitRef="number" contextRef="c-696" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1731">35.0</ix:nonFraction>%.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2023 we accrued a $<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-5" name="biib:AccruedPaymentToTerminationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-1732">31.0</ix:nonFraction>&#160;million payable to Eisai related to the termination of an agreement whereby Eisai co-promoted or distributed our MS products in certain Asia-Pacific markets and settings. This termination fee is included in selling, general and administrative expense in our condensed consolidated statements of income for the nine months ended September 30, 2023.</span></div><div style="margin-top:5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LEQEMBI (lecanemab) Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai to jointly develop and commercialize LEQEMBI (lecanemab), an anti-amyloid antibody for the treatment of Alzheimer's disease (the LEQEMBI Collaboration).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. We and Eisai co-promote LEQEMBI and share profits and losses equally. We currently manufacture LEQEMBI drug substance and drug product and in March 2022 we extended our supply agreement with Eisai related to LEQEMBI from five years to ten years for the manufacture of LEQEMBI drug substance.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1701-3" continuedAt="f-1701-4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 the FDA granted traditional approval of LEQEMBI. Prior to receiving traditional approval, LEQEMBI had been granted accelerated approval by the FDA in January 2023, at which time it became commercially available in the U.S. Additionally, in September 2023 the Japanese Ministry of Health, Labor and Welfare approved LEQEMBI in Japan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of LEQEMBI, we began recognizing our <ix:nonFraction unitRef="number" contextRef="c-440" decimals="2" name="biib:ShareOfNonControlingInterestRecognized" scale="-2" id="f-1733">50.0</ix:nonFraction>% share of LEQEMBI product revenue, net and cost of sales, including royalties, within other revenue in our condensed consolidated income statements, as we are not the principal.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2023 we recorded a reclassification of $<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1734">38.7</ix:nonFraction>&#160;million in LEQEMBI collaboration costs from other revenue to selling, general and administrative expense within our condensed consolidated statements of income. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that this reclassification does not materially impact the current or previously issued condensed consolidated financial statements. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of LEQEMBI development expense will continue to be recorded within research and development expense in our condensed consolidated income statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:</span></div><div><ix:nonNumeric contextRef="c-1" name="biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" id="f-1735" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-698" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="f-1736">88.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-699" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="f-1737">109.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-700" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="f-1738">282.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-701" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="f-1739">264.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-698" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1740">44.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-699" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1741">54.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-700" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1742">141.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-701" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1743">132.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the LEQEMBI Collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-702" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1744">163.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-703" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1745">29.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-704" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1746">191.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-705" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1747">68.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-702" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1748">81.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-703" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1749">14.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-704" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1750">95.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-705" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1751">34.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADUHELM Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LEQEMBI Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (the ADUHELM Collaboration Agreement).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our initial ADUHELM Collaboration Agreement, we would lead the ongoing development of ADUHELM, and we and Eisai would co-promote ADUHELM with a region-based profit split. Beginning in 2019, Eisai was reimbursing us for&#160;<ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="f-1752">45.0</ix:nonFraction>%&#160;of development and sales and marketing expense incurred by the collaboration for the advancement of ADUHELM.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. As of the amendment date, we have sole decision making and commercialization rights worldwide on ADUHELM, and beginning January 1, 2023, Eisai receives only a tiered royalty based on net sales of ADUHELM, and no longer participates in sharing ADUHELM's global profits and losses. Eisai's share of development, commercialization and manufacturing expense was limited to $<ix:nonFraction unitRef="usd" contextRef="c-706" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1753">335.0</ix:nonFraction>&#160;million for the period from January 1, 2022 to December 31, 2022, which was achieved as of December 31, 2022. Once this limit was achieved, we became responsible for all ADUHELM related costs.</span></div><ix:nonNumeric contextRef="c-1" name="biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" id="f-1754" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense and sales and marketing expense related to our initial ADUHELM Collaboration Agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.321%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM Collaboration development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1755">34.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-708" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1756">116.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1757">19.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-708" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1758">63.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-5" sign="-" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1759">8.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1760">127.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM Collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-5" sign="-" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1761">3.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1762">68.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1701-4" continuedAt="f-1701-5"><div style="margin-top:6pt"><span style="color:#6dad46;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM C</span><span style="background-color:#ffffff;color:#6dad46;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">o-promotion Profits and Losses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our initial ADUHELM Collaboration Agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we recognized revenue on sales of ADUHELM in the U.S. to third parties as a component of product revenue in our condensed consolidated statements of income. We also recorded the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs were incurred. Payments made to and received from Eisai for its <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="f-1763">45.0</ix:nonFraction>% share of the co-promotion profits or losses in the U.S. were recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2022,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we recognized net reductions to our operating expense of approximately $<ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-5" name="biib:CollaborativeArrangementProfitLossSharing" format="ixt:num-dot-decimal" scale="6" id="f-1764">3.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-712" decimals="-5" name="biib:CollaborativeArrangementProfitLossSharing" format="ixt:num-dot-decimal" scale="6" id="f-1765">214.0</ix:nonFraction>&#160;million, respectively, to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="c-713" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="f-1766">45.0</ix:nonFraction>% share of net collaboration losses in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, as a result of the final NCD, we recorded approximately $<ix:nonFraction unitRef="usd" contextRef="c-714" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-1767">275.0</ix:nonFraction>&#160;million of charges associated with the write-off of inventory and purchase commitments in excess of forecasted demand related to ADUHELM. Additionally, for the nine months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2022,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we recorded approximately $<ix:nonFraction unitRef="usd" contextRef="c-715" decimals="-5" name="biib:AggregateGrossIdleCapacityCharges" format="ixt:num-dot-decimal" scale="6" id="f-1768">76.0</ix:nonFraction>&#160;million of aggregate gross idle capacity charges related to ADUHELM. These charges were recorded in cost of sales within our consolidated statements of income for the nine months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized approximately $<ix:nonFraction unitRef="usd" contextRef="c-716" decimals="-5" name="biib:CollaborativeArrangementProfitLossSharing" format="ixt:num-dot-decimal" scale="6" id="f-1769">177.0</ix:nonFraction>&#160;million related to Eisai's <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="f-1770">45.0</ix:nonFraction>% share of these charges in collaboration profit sharing/(loss reimbursement) within our condensed consolidated statements of income</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2022.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Eisai related to the agreements discussed ab</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ove were approximately $<ix:nonFraction unitRef="usd" contextRef="c-717" decimals="-5" name="biib:AccountsReceivableFromCollaborator" format="ixt:num-dot-decimal" scale="6" id="f-1771">34.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-718" decimals="-5" name="biib:AccountsReceivableFromCollaborator" format="ixt:num-dot-decimal" scale="6" id="f-1772">88.0</ix:nonFraction>&#160;million as of September 30, 2023 and December 31, 2022, respectively. Amounts payable to Eisai related to the agreements discussed above were $<ix:nonFraction unitRef="usd" contextRef="c-717" decimals="-5" name="biib:AccountsPayableToCollaborator" format="ixt:num-dot-decimal" scale="6" id="f-1773">122.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-718" decimals="-5" name="biib:AccountsPayableToCollaborator" format="ixt:num-dot-decimal" scale="6" id="f-1774">81.2</ix:nonFraction>&#160;million as</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of September 30, 2023 and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2022 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB, effective November 2003, to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of SLE and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, both companies will co-promote dapirolizumab pegol and share profits and losses equally.</span></div><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" id="f-1775" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1776">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1777">18.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1778">46.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1779">51.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1780">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1781">9.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1782">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1783">25.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize ZURZUVAE (zuranolone) for the potential treatment of MDD and PPD and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023 the FDA approved ZURZUVAE for adults with PPD, pending DEA scheduling, which was completed in October 2023. Upon approval, ZURZUVAE became the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms by day 15 for women with PPD. We expect ZURZUVAE for PPD to be commercially available beginning in the fourth quarter of 2023. Additionally, the FDA issued a CRL for the NDA for zuranolone in the treatment of adults with MDD. The CRL stated that the application did not provide substantial </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1701-5" continuedAt="f-1701-6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evidence of effectiveness to support the approval of zuranolone for the treatment of MDD and that an additional study or studies would be needed. We and Sage are reviewing the feedback and evaluating next steps. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties. We will pay Sage a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-5" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" format="ixt:num-dot-decimal" scale="6" id="f-1784">75.0</ix:nonFraction>&#160;million upon the first commercial sale of ZURZUVAE for PPD in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-724" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="f-1785"><ix:nonFraction unitRef="usd" contextRef="c-725" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="f-1786">5.9</ix:nonFraction></ix:nonFraction>&#160;million to reflect Sage's <ix:nonFraction unitRef="number" contextRef="c-18" decimals="2" name="biib:ShareOfNetProfitFromSageTherapeuticsPercent" scale="-2" id="f-1787">50.0</ix:nonFraction>% share of net collaboration expense in the U.S. related to commercialization activities to support ZURZUVAE for PPD, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income.</span></div><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" id="f-1788" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to the Sage collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1789">72.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1790">40.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1791">158.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1792">130.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1793">36.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1794">20.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1795">79.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1796">65.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Sage collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1797">54.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1798">28.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-732" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1799">152.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1800">69.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1801">27.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1802">14.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-732" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1803">76.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1804">34.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of LRRK2 for Parkinson's disease and also entered into a separate agreement to obtain an exclusive option to license two preclinical programs from Denali's Transport Vehicle platform, including its ATV-enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023 we exercised our option with Denali to license the ATV-enabled anti-amyloid beta program. In connection with this exercise, we assumed responsibility for all development and commercial activities and associated expenses related to this program. In addition, we made a one-time option exercise payment to Denali and, should certain milestones be achieved, may pay Denali additional development and commercial milestone payments and royalties based on future net sales. Our agreement with Denali was amended in August 2023, whereby certain milestone criteria were changed, while the total amount of development, regulatory and commercial milestones remains the same. In addition, we agree to waive our option right to the second option program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the LRRK2 collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" id="f-1805" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to the Denali collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1806">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1807">19.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-736" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1808">51.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1809">58.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1810">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1811">11.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-736" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1812">30.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1813">33.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Research and Discovery Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1701-6" continuedAt="f-1701-7"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2023, we recorded </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-738" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:fixed-zero" scale="6" id="f-1814">zero</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-1815">2.8</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-1816">14.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-1817">51.5</ix:nonFraction>&#160;million, respectively,</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the prior year comparative periods.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize <ix:nonFraction unitRef="product" contextRef="c-742" decimals="INF" name="biib:ContingentCommercializedRightsNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="f-1818">two</ix:nonFraction> potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately <ix:nonFraction unitRef="number" contextRef="c-742" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="f-1819">45.0</ix:nonFraction>%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, we may also pay Samsung Bioepis up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-1820">180.0</ix:nonFraction> million in additional development, regulatory and sales-based milestones.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 c</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional <ix:nonNumeric contextRef="c-134" name="biib:CollaborationAgreementTerm" format="ixt-sec:durwordsen" id="f-1821">five years</ix:nonNumeric>, subject to payment of an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="biib:ContractOptionExerciseFee" format="ixt:num-dot-decimal" scale="6" id="f-1822">60.0</ix:nonFraction> million, and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share <ix:nonFraction unitRef="number" contextRef="c-134" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="f-1823">50.0</ix:nonFraction>% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the three and nine months ended September 30, 2023, we recognized net profit-sharing expense of $<ix:nonFraction unitRef="usd" contextRef="c-743" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="f-1824">56.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="f-1825">170.4</ix:nonFraction> million, respectively, to reflect Samsung Bioepis' <ix:nonFraction unitRef="number" contextRef="c-134" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="f-1826">50.0</ix:nonFraction>% sharing of the net collaboration profits, compared to a net profit-sharing expense of $<ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="f-1827">48.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-746" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="f-1828">171.4</ix:nonFraction> million, respectively, in the prior year comparative periods. </span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement with Samsung Bioepis. Under this license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on biosimilar products developed and commercialized by Samsung Bioepis. Royalty revenue under the license agreement is recognized as a component of contract manufacturing, royalty and other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Samsung Bioepis related to the agreements di</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scussed above were $<ix:nonFraction unitRef="usd" contextRef="c-747" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="f-1829">13.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-748" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="f-1830">2.0</ix:nonFraction>&#160;million as of September 30, 2023 and December 31, 2022, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were $<ix:nonFraction unitRef="usd" contextRef="c-747" decimals="-5" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1831">81.6</ix:nonFraction>&#160;million and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-748" decimals="-5" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1832">40.5</ix:nonFraction>&#160;million as of September 30, 2023 and December 31, 2022, respectively.</span></div></ix:continuation><div style="margin-top:6pt"><ix:continuation id="f-1701-7" continuedAt="f-1701-8"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1701-8"> to our consolidated financial statements included in our 2022 Form 10-K.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_106"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 20:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Investments in Variable Interest Entities</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="f-1833" escape="true"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or <ix:nonNumeric contextRef="c-749" name="biib:CollaborationAgreementTerm" format="ixt-sec:duryear" id="f-1834">12</ix:nonNumeric> years from the first commercial sale of a licensed product.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund <ix:nonFraction unitRef="number" contextRef="c-749" decimals="INF" name="biib:ResearchAndDevelopmentCostsPercentage" scale="-2" id="f-1835">100.0</ix:nonFraction>% of the research and development costs incurred in support of the collaboration. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on commercial sales of ADUHELM, range from the high single digits to sub-teens.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an increase in a valuation allowance of approximately $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1836">85.0</ix:nonFraction>&#160;million to reduce the net value of a previously recorded deferred tax asset to zero. This adjustment to our net deferred tax asset is recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" format="ixt:num-dot-decimal" scale="6" id="f-1837">24.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" format="ixt:num-dot-decimal" scale="6" id="f-1838">27.8</ix:nonFraction> million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2022 Form 10-K.</span></div></ix:nonNumeric><div id="i8325bdffeebc49d7b9475241af1c3c2e_109"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 21:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Litigation</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="f-1839" continuedAt="f-1839-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2022 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. If an estimate of the </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1839-1" continuedAt="f-1839-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">possible loss or range of loss can be made at this time, it is included in the potential loss contingency description below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Loss Contingencies</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADUHELM Securities Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are defendants in two actions related to ADUHELM filed in the United States District Court for the District of Massachusetts (the District Court). Both actions allege violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seek declarations of the actions as class actions and monetary relief. In October 2023 the United States Court of Appeals for the First Circuit reversed in part and affirmed in part the dismissal of the shareholder action related to ADUHELM that was filed in November 2020. In March 2023 the District Court dismissed the shareholder action that had been filed in February 2022. In May 2023 the plaintiff filed a motion to alter the judgment and amend the complaint, which is pending.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Actions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and members of the Board of Directors are named as defendants in derivative actions filed by shareholders in February and July 2022, in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C. &#167;78n(a) and 17 C.F.R. &#167;240 14.a-9, and breaches of fiduciary duties and waste of corporate assets, and seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys&#8217; fees and costs payable to the plaintiffs. The District Court has stayed both cases.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) filed a claim for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen commercializes in Europe, infringes the French counterpart of European Patent 3 145 488 (the EP &#8216;488 Patent), which expires in May 2035. In August 2022 Fresenius Kabi filed a claim for damages and injunctive relief against Biogen GmbH in the D&#252;sseldorf Regional Court, alleging infringement of the German counterpart of the EP '488 Patent. A hearing in the D&#252;sseldorf Regional Court has been set for December 2023. No hearing has been set in the French action. The EP '488 Patent is the subject of opposition proceedings in the EPO and a hearing before the EPO's Technical Boards of Appeal is set for June 2024.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation with Former Convergence Shareholders</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015 Biogen acquired Convergence, a U.K. company. In 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, asserted claims of $<ix:nonFraction unitRef="usd" contextRef="c-750" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-1840">200.0</ix:nonFraction> million for alleged breaches of the contract pursuant to which we acquired Convergence. In June 2023 Shareholder Representative Services LLC and 24 former shareholders filed suit against us in the High Court of Justice of England and Wales on one of the previously asserted claims, seeking payment of $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-1841">49.9</ix:nonFraction>&#160;million, interest and costs. No trial date has been set.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ERISA Class Action Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 participants in the Biogen 401(k) Savings Plan filed actions against us in the U.S. District Court for the District of Massachusetts alleging breach of fiduciary duty under ERISA and seeking a declaration of the actions as class actions and monetary and other relief. In August 2023 the court preliminarily approved a settlement under which we agree to pay $<ix:nonFraction unitRef="usd" contextRef="c-751" decimals="-4" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-1842">9.75</ix:nonFraction>&#160;million without any admission of liability. The court has set a hearing for January 2024 to determine whether to grant final approval.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Humana Patient Assistance Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the District Court for the District of Massachusetts dismissed the previously disclosed action filed against us by Humana in September 2020. Humana had alleged damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients and had </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1839-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alleged violations of the federal RICO Act and state laws. In April 2023 Humana filed a motion to alter the judgment and amend the complaint, which is pending.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributor Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022 we terminated our distribution agreement with the distributor of products for Biogen in various countries in the Middle East and northern Africa. The former distributor has asserted breach of contract. No suit has been filed.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023 Genentech, Inc. filed suit against us in the U.S. District Court for the Northern District of California, alleging that it is owed royalties on sales of TYSABRI that occurred after the expiration of a patent licensed by Genentech to Biogen, together with interest and costs. The Company estimates that the royalties claimed total approximately $<ix:nonFraction unitRef="usd" contextRef="c-752" decimals="-5" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="f-1843">88.3</ix:nonFraction>&#160;million. No trial date has been set.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bardoxolone Securities Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 and 2022 putative stockholders of Reata (later acquired by Biogen) filed litigation in the United States District Court for the Eastern District of Texas alleging violations of the federal securities laws by Reata, certain former officers and directors and certain underwriters under 15 U.S.C. &#167;78j(b) and &#167;78t(a), 17 C.F.R. &#167;240.10b-5, and 15 U.S.C. &#167;&#167;77k, 77l(a)(2) and 77o in connection with Reata's asset bardoxolone. Plaintiffs seek declaration of the actions as a class actions and monetary relief. In October 2023 the parties reached a settlement, subject to approval by the court, providing for payment by Reata of $<ix:nonFraction unitRef="usd" contextRef="c-753" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-1844">45.0</ix:nonFraction>&#160;million without any admission of liability. We expect a portion of the payment to be reimbursed under Reata's insurance coverage.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lender Dispute</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of Reata's lenders claims that approximately $<ix:nonFraction unitRef="usd" contextRef="c-754" decimals="-5" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="f-1845">23.3</ix:nonFraction>&#160;million is owing under its loan agreement with Reata.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Investigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received subpoenas from the Securities and Exchange Commission seeking information relating to ADUHELM, including healthcare sites and ADUHELM&#8217;s approval.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TYSABRI Biosimilar Patent Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc., other Sandoz entities and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. &#167;262, seeking a declaratory judgment of patent infringement. The trial has been set for May 2025.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Annulment Proceedings in the General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 Mylan Ireland filed an action in the General Court of the European Union (the General Court) to annul the EMA's decision not to validate its applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. No hearing has been set.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,669,281, 9,090,558 and 10,080,733) pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC. No trial date has been set.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and the accompanying notes beginning on page&#160;7 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and the accompanying notes included in our 2022 Form&#160;10-K. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he results of operations of Reata, along with the estimated fair values of the assets acquired and liabilities assumed in the Reata acquisition, have been included in our condensed consolidated financial statements since the closing of the Reata acquisition on September 26, 2023.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_118"></div><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">EXECUTIVE SUMMARY</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INTRODUCTION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA and co-developed two treatments to address a defining pathology of Alzheimer's disease. We are focused on advancing our pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs and external collaborations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; QALSODY for the treatment of ALS, which was granted accelerated approval by the FDA during the second quarter of 2023; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease, which was granted traditional approval by the FDA in the third quarter of 2023, and Sage on the commercialization of ZURZUVAE for the treatment of PPD. ZURZUVAE was approved by the FDA in the third quarter of 2023, pending DEA scheduling, which was completed in the fourth quarter of 2023. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma, which was granted accelerated approval by the FDA during the second quarter of 2023; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our 2022 Form&#160;10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2023, we completed the acquisition of Reata. As a result of this transaction we acquired SKYCLARYS, the first and only drug approved by the FDA for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. We also have the exclusive rights to commercialize TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, which was approved by the FDA during the third quarter of 2023. We continue to develop the potential biosimilar product SB15, a proposed aflibercept biosimilar referencing EYLEA. In February 2023 we announced that we are exploring strategic options for our biosimilars business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to ensure an uninterrupted supply of medicines to patients around the world. To that end, we continually review our manufacturing capacity, capabilities, processes and facilities. In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland. In the second quarter of 2021 a portion of the facility (the first manufacturing suite) received a GMP multi-product license from the SWISSMEDIC and was placed into service. Solothurn has been approved for the manufacture of ADUHELM and LEQEMBI by the FDA. We estimate the second manufacturing suite will be operational by the end of 2023. We believe that the Solothurn facility will support our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticipated near to mid-term needs for the manufacturing of biologic assets, including the commercial launch of LEQEMBI. The plant represents a significant increase in our overall manufacturing capacity and is not yet being fully utilized, resulting in our recording of excess capacity charges. If we are unable to fully utilize our manufacturing facilities, we will incur additional excess capacity charges which would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BUSINESS ENVIRONMENT</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and revenue streams continue to face increasing competition in many markets from generic versions, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways. Such products are likely to be sold at substantially lower prices than branded products. Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in the markets in which our products are prescribed, for example the IRA has certain provisions related to drug pricing. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products and/or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments, geopolitical events, supply chain disruptions, foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a detailed discussion on our business environment, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in our 2022 Form 10-K. For additional information on our competition and pricing risks that could negatively impact our product sales, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in North America, Brazil and certain E.U. countries and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and we expect that TECFIDERA revenue will continue to decline in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2023 the CJEU decided in favor of Biogen, the EMA and the EC in their appeal of a European General Court decision that had annulled the EMA's refusal to evaluate a generic version of TECFIDERA because of TECFIDERA's </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">regulatory data and marketing protection. The CJEU set aside the General Court's judgment and dismissed the generic's action. On the basis of this favorable decision and the EC determination in May 2023 that TECFIDERA is entitled to an additional year of market protection for its pediatric indication, we believe that TECFIDERA is entitled to regulatory marketing protection in the E.U. until at least February 2, 2025, and are seeking to enforce this protection. As of September 30, 2023, some of the TECFIDERA generics have not yet fully exited some of the E.U. markets and some generic products remain in the channel. We expect removal of generics from the market will take additional time. We are closely monitoring this situation and working to enforce our legal right to market protection. In addition, we will continue to enforce our EP 2 653 873 patent related to TECFIDERA, which expires in 2028.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 21, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BUSINESS UPDATE REGARDING MACROECONOMIC CONDITIONS AND OTHER DISRUPTIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant portions of our business are conducted in Europe, Asia and other international geographies. Factors such as the COVID-19 pandemic and other global health outbreaks, adverse weather events, geopolitical events, inflation, labor or raw material shortages and other supply chain disruptions could result in product shortages or other difficulties and delays or increased costs in manufacturing our products. Additionally, global disputes and interruptions in international relationships, including tariffs, trade protection measures, import or export licensing requirements and the imposition of trade sanctions or similar restrictions by the U.S. or other governments, affect our ability to do business. For example, tensions between the U.S. and China have led to a series of tariffs and sanctions being imposed by the U.S. on imports from China mainland, as well as other business restrictions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CURRENT ECONOMIC CONDITIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic conditions remain vulnerable as markets continue to be impacted in part by elevated inflation, rising interest rates, global supply chain constraints and recent bank failures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023 concerns arose with respect to the financial condition of a number of banking institutions in the U.S., in particular those with exposure to certain types of depositors and large portfolios of investment securities. Additionally, in March 2023 SVB and Signature Bank were closed and taken over by the FDIC, which created significant market disruption and uncertainty with respect to the financial condition of a number of banking institutions in the U.S., in particular those with exposure to certain types of depositors and large portfolios of investment securities. While we do not have any direct exposure to SVB or Signature Bank, we do maintain our cash at financial institutions, often in balances that exceed the current FDIC insurance limits, and will continue to monitor our cash, cash equivalents and investments and take steps to identify any potential impact and minimize any disruptions on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If other banks and financial institutions enter receivership or become insolvent in the future due to financial conditions affecting the banking system and financial markets, our ability to access our cash, cash equivalents and investments, including transferring funds, making payments or receiving funds, may be threatened and could have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">GEOPOLITICAL TENSIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing geopolitical tensions related to Russia's invasion of Ukraine and the recent military conflict in the Middle East have resulted in global business disruptions and economic volatility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example. sanctions and other restrictions have been levied on the government and businesses in Russia. Although we do not have affiliates or employees, in either Russia or Ukraine, we do provide various therapies to patients in Russia through a distributor. In addition, new government sanctions on the export of certain manufacturing materials to Russia may delay or limit our ability to get new products approved. The impact of the conflict on our operations and financial performance remains uncertain and will depend on future developments, including the severity and duration of the conflict between Russia and Ukraine, its impact on regional and global economic conditions and whether the conflict spreads or has effects on countries outside Ukraine and Russia. Revenue generated from sales in these regions represented less than 3.0% of total product revenue for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2023 and the year ended December 31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to monitor the ongoing conflict between Russia and Ukraine as well as the military conflict in the Middle East and assess any potential impacts on our business, supply chain, partners or customers, as well as any factors that could have an adverse effect on our results of operations. Our expected 2023 revenue from the broader Middle East region are estimated to less than 2.0% of total revenue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">COVID-19</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including the economic impact on local, regional, national and international customers and markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the various risks posed by the COVID-19 pandemic and the conflict in Ukraine, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in this report.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INFLATION REDUCTION ACT OF 2022</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022 the IRA was signed into law in the U.S. The IRA introduced new tax provisions, including a 15.0% corporate alternative minimum tax and a 1.0% excise tax on stock repurchases. The provisions of the IRA are effective for periods after December 31, 2022. The IRA did not result in any material adjustments to our income tax provision or other income tax balances as of September 30, 2023 and December 31, 2022. Preliminary guidance has been issued by the IRS and we expect additional guidance and regulations to be issued in future periods. We will continue to assess its potential impact on our business and results of operations as further information becomes available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA also contains substantial drug pricing reforms that may have a significant impact on the pharmaceutical industry in the U.S. This includes allowing CMS to negotiate a maximum fair price for certain high-priced single source Medicare drugs, as well as redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries, potentially resulting in higher contributions from plans and manufacturers. The IRA also establishes drug inflationary rebate requirements to penalize manufacturers from raising the prices of Medicare covered single-source drugs and biologics beyond the inflation-adjusted rate. Further, to incentivize biosimilar development, the IRA provides an 8.0% Medicare Part B add-on payment for qualifying biosimilar products for a five-year period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA's drug pricing controls and Medicare redesign may have an adverse impact on our sales (particularly for our products that are more substantially reliant on Medicare reimbursement), our business and our results of operations. However, the degree of impact from this legislation on our business depends on a number of implementation decisions. We will continue to assess as further information becomes available.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FINANCIAL HIGHLIGHTS</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our net income and diluted earnings per share attributable to Biogen Inc. for the three months ended September 30, 2023, compared to the three months ended September 30, 2022, reflects the following:</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_124"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL REVENUE</span></td></tr></table></div><div><img src="biib-20230930_g2.jpg" alt="6" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increased</span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$21.8 million or 0.9%</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DILUTED EARNINGS (LOSS) PER SHARE</span></td></tr></table></div><div><img src="biib-20230930_g3.jpg" alt="22" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decreased</span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8.31 or 106.0%</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_127"></div></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRODUCT REVENUE</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20230930_g4.jpg" alt="6" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decreased</span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$156.9 million or 8.0%</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">MS revenue decreased $181.3 million, or 13.5%</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">SMA revenue increased $17.1 million, or 4.0%</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.6pt">The decrease in MS product revenue was primarily due to a decrease in TECFIDERA demand as a result of multiple TECFIDERA generic entrants in North America, Brazil and certain E.U. countries, a decrease in Interferon demand due to competition as patients transition to higher efficacy therapies and a decrease in TYSABRI revenue primarily driven by increased competition.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.6pt">The increase in SMA revenue was primarily due to patient growth and an increase in pricing in the U.S. as well as timing of shipments in certain international markets.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_130"></div></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL COST AND EXPENSE</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20230930_g5.jpg" alt="6" style="height:120px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increased</span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1,534.1 million or 134.9%</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">Cost of sales increased $190.1 million, or 40.5%</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">R&amp;D expense increased $187.1 million, or 34.1%</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">SG&amp;A expense increased $224.9 million, or 39.9%</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.6pt">The increase in cost of sales was primarily due to higher cost of sales associated with contract manufacturing revenue driven by increased production, higher idle capacity charges and unfavorable product mix.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.6pt">The increase in research and development expense was primarily due to the recognition of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$197.0&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in equity-based compensation expense related to our acquisition of Reata.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12pt">The increase in selling, general and administrative expense was primarily due to the recognition of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$196.4&#160;million in equity-based compensation expense related to our acquisition of Reata</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12pt">Additionally, total cost and expense in 2022 was reduced by a pre-tax gain of approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$503.7&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> related to the sale of one of our buildings.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_133"></div></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.6pt">We generated $1,534.7 million of net cash flow from operations for the nine months ended September 30, 2023.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.6pt">Cash, cash equivalents and marketable securities totaled approximately $2.3 billion as of September 30, 2023, compared to approximately $5.6 billion as of December 31, 2022. The decrease was primarily due to consideration paid for our acquisition of Reata in September 2023.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.6pt">There were no share repurchases of our common stock during the third quarter of 2023 under our 2020 Share Repurchase Program. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2023.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">RECENT DEVELOPMENTS</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ACQUISITIONS</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">REATA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">On September&#160;26, 2023, we completed the acquisition of all of the issued and outstanding shares of Reata, a  biopharmaceutical company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of this transaction we acquired SKYCLARYS, the first and only drug approved by the FDA for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older, as well as other clinical and preclinical pipeline programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Under the terms of this acquisition, we paid Reata shareholders $<ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="1" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="f-1846">172.50</ix:nonFraction> in cash for each issued and outstanding Reata share, which totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="f-1847">6.6</ix:nonFraction>&#160;billion. In addition, we agreed to pay approximately $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" format="ixt:num-dot-decimal" scale="6" id="f-1848">983.9</ix:nonFraction>&#160;million in cash for Reata's outstanding equity awards, inclusive of employer taxes, of which approximately $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" format="ixt:num-dot-decimal" scale="6" id="f-1849">590.5</ix:nonFraction>&#160;million was attributable to pre-acquisition services and is therefore reflected as a component of total purchase price paid. Of the $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" format="ixt:num-dot-decimal" scale="6" id="f-1850">983.9</ix:nonFraction>&#160;million paid to Reata's equity award holders, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1851">393.4</ix:nonFraction>&#160;million as compensation attributable to the post-acquisition service period, of which $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1852">196.4</ix:nonFraction>&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1853">197.0</ix:nonFraction>&#160;million as a charge to research and development expense within our condensed consolidated statements of income </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and nine months ended September 30, 2023</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest. Approximately $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-1854">980.0</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" format="ixt:num-dot-decimal" scale="6" id="f-1855">983.9</ix:nonFraction>&#160;million payment to the equity award holders was made in October 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DEVELOPMENTS IN KEY COLLABORATIVE RELATIONSHIPS</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">LEQEMBI (lecanemab)</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 the FDA granted traditional approval of LEQEMBI, an anti-amyloid antibody for the treatment of Alzheimer's disease, which was previously granted accelerated approval by the FDA in January 2023. Following the FDA's traditional approval of LEQEMBI, CMS confirmed broader coverage of LEQEMBI.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in March 2023 Eisai announced that the U.S. Veteran's Health Administration will be providing coverage of LEQEMBI to veterans living with early stages of Alzheimer's disease.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rest of World</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key developments related to LEQEMBI (lecanemab) in rest of world markets during 2023 consisted of the following:</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In September 2023 the Japanese Ministry of Health, Labor and Welfare approved LEQEMBI in Japan.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In January 2023 the EMA accepted for review the MAA for lecanemab.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In February 2023 the BLA for lecanemab was granted Priority Review by the NMPA of China.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In May 2023 we and Eisai announced the submission of a MAA for lecanemab to the UK MHRA in Great Britain, which has been designated by the MHRA for the Innovative Licensing and Access Pathway. Additionally, in May 2023 Health Canada accepted for review the NDS for lecanemab.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In June 2023 we and Eisai announced the submission of a MAA for lecanemab to the Ministry of Food and Drug Safety in South Korea.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ZURZUVAE (zuranolone)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023 the FDA approved ZURZUVAE for adults with PPD, pending DEA scheduling, which was completed in October 2023. Upon approval, ZURZUVAE became the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms by day 15 for women with PPD. We expect ZURZUVAE for PPD to be commercially available beginning in the fourth quarter of 2023. Additionally, the FDA issued a CRL for the NDA for zuranolone in the treatment of adults with MDD. The CRL stated that the application did not provide substantial evidence of effectiveness to support the approval of zuranolone for the treatment of MDD and that an additional study or studies would be needed. We and Sage are reviewing the feedback and evaluating next steps. </span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:112%">OTHER KEY DEVELOPMENTS</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FIT FOR GROWTH</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 we announced a new Fit for Growth program which is expected to generate approximately $1.0 billion in gross operating expense savings by 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reduction of approximately 1,000 employees.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">QALSODY (tofersen)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023 the FDA approved QALSODY for the treatment of ALS in adults who have a mutation in the SOD1 gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COLUMVI (glofitamab)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023 the FDA approved COLUMVI for the treatment of adult patients with B-cell non-Hodgkin's lymphoma. This indication is approved under accelerated approval based on response rate and durability of response in the Phase 1/2 study. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the CJEU decided in favor of Biogen, the EMA and the EC in their appeal of a European General Court decision that had annulled the EMA's refusal to evaluate a generic version of TECFIDERA because of TECFIDERA's regulatory data and marketing protection. The CJEU set aside the General Court's judgment and dismissed the generic's action. On the basis of this favorable decision and the EC determination in May 2023 that TECFIDERA is entitled to an additional year of market protection for its pediatric indication, we believe that TECFIDERA is entitled to regulatory marketing protection in the E.U. until at least February 2, 2025, and are seeking to enforce this protection. As of September 30, 2023, some of the TECFIDERA generics have not yet fully exited some of the E.U. markets and some generic products remain in the channel. We expect removal of generics from the market will take additional time. We are closely monitoring this situation and working to enforce our legal right to market protection. In addition, we will continue to enforce our EP 2 653 873 patent related to TECFIDERA, which expires in 2028.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:112%">TOFIDENCE (referencing ACTEMRA)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023 we announced that the FDA approved TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, for the treatment of severe, active and progressive rheumatoid arthritis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:112%">DENALI COLLABORATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023 we and Denali announced plans to terminate the Phase 3 LIGHTHOUSE study for BIIB122, a small molecule inhibitor of LRRK2 in Parkinson's disease. The protocol for the Phase 2b LUMA study for BIIB122 in patients with early-stage Parkinson&#8217;s disease was amended to now include eligible patients with a LRRK2 genetic mutation in addition to continuing to enroll eligible patients with early-stage idiopathic Parkinson&#8217;s disease.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:112%">DISCONTINUED PROGRAMS AND STUDIES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:112%">EMBARK STUDY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023 we discontinued our EMBARK study for aducanumab. In connection with this discontinuation we accrued termination costs of approximately $37.2 million in research and development expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2023</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:112%">BIIB093</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023 we announced that we will be terminating the development of BIIB093 (glibenclamide IV), currently in a Phase 3 study for large hemispheric infarction and a Phase 2 study for brain contusion, due to operational challenges and other strategic considerations. In connection with this termination, we recorded close-out costs of approximately $13.2&#160;million in research and development expense within our condensed consolidated statements of income for the nine months ended September 30, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:112%">BIIB131</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023 we announced that we will be pausing the initiation of a Phase 2b study for BIIB131 (TMS-007) for acute ischemic stroke and will continue to assess whether to initiate this study.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:112%">BIIB132</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023 we announced that we will be discontinuing further development of BIIB132 in spinocerebellar ataxia type 3, as part of our ongoing research and development prioritization initiative.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:13pt"><span style="color:#00587f;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">REVENUE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following revenue discussion should be read in conjunction with </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5, Revenue</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">790.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,014.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,111.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,805.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,962.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(156.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,530.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,508.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,293.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,619.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(326.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,121.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,463.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(342.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,414.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,083.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(669.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,252.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">781.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,449.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,629.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(180.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PRODUCT REVENUE</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="57" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br/>Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br/>Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">631.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">527.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,159.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">632.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,340.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(181.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">790.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,014.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,805.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,111.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,962.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(156.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="57" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br/>Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br/>Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,814.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,678.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,493.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,170.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,990.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,161.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(667.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">453.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,328.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">891.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,334.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">581.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,293.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,121.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,414.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,619.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,463.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,083.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(669.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM, ADUHELM and QALSODY, which became commercially available in the U.S. during the second quarter of 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MULTIPLE SCLEROSIS</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:15pt"><img src="biib-20230930_g6.jpg" alt="6" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global TECFIDERA revenue decreased $99.5 million, from $339.0 million in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> to $239.5 million in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or 29.4%, driven by a decrease in TECFIDERA demand as a result of multiple TECFIDERA generic entrants in North America, Brazil and certain E.U. countries.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global Interferon revenue decreased $58.3 million, from $336.0 million in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> to $277.7 million in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or 17.4%, driven by a decrease in sales volumes as patients transition to higher efficacy therapies.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global VUMERITY revenue increased $27.7 million, from $137.8 million in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 to $165.5 million in 2023, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">or 20.1%, primarily due to an increase in U.S. VUMERITY driven by higher sales volumes and an increase in pricing.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global TYSABRI revenue decreased $49.2 million, from $505.5 million in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 to $456.3 million in 2023,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> or 9.7%, primarily due to a decrease in U.S. TYSABRI revenue driven by increased competition and higher discounts and allowances and a decrease in rest of world TYSABRI revenue driven by unfavorable channel dynamics.</span></div></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.906%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.5pt solid #679acb;padding:0 1pt"></td></tr></table></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_151"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:15pt"><img src="biib-20230930_g7.jpg" alt="4" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global TECFIDERA revenue decreased $378.6 million, from $1,146.8 million in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> to $768.2 million in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or 33.0%, driven by a decrease in TECFIDERA demand as a result of multiple TECFIDERA generic entrants in North America, Brazil and certain E.U. countries.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global Interferon revenue decreased $170.1 million, from $995.8 million in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> to $825.7 million in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or 17.1%, driven by a decrease in sales volumes as patients transition to higher efficacy therapies, as well as pricing pressure and the unfavorable impact of channel dynamics in the U.S.</span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global VUMERITY revenue increased $17.3 million, from $402.6 million in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 to $419.9 million in 2023, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">or 4.3%, primarily due to an increase in rest of world VUMERITY revenue driven by higher sales volumes. The increase was partially offset by a decrease in U.S. VUMERITY revenue driven by unfavorable channel dynamics and a favorable Medicaid-related sales adjustment in the first quarter of 2022 related to VUMERITY. </span></div><div style="margin-top:3pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global TYSABRI revenue decreased $130.3 million, from $1,542.5 million in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 to $1,412.2 million in 2023,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> or 8.4%, primarily due to a decrease in U.S. TYSABRI revenue driven by higher discounts and allowances, increased competition and unfavorable channel dynamics.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_154"></div></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.906%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.25pt dotted #0070c0;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MS revenue includes sales from TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023 we expect total MS revenue will continue to decline as a result of increasing competition for many of our MS products in both the U.S. and rest of world markets. We are also aware of a biosimilar entrant of TYSABRI that was approved in the U.S. in August 2023 and the E.U. in September 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have resolved previously reported manufacturing issues at our VUMERITY contract manufacturer. In addition, we are in the process of securing regulatory approval for a secondary source of supply. We do not anticipate a supply shortage in 2023 and are currently focused on rebuilding adequate inventory.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SPINAL MUSCULAR ATROPHY</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:15pt"><img src="biib-20230930_g8.jpg" alt="6" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-18pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.6pt">U.S. SPINRAZA revenue increased $10.3 million, from $140.2 million in 2022 to $150.5 million in 2023, or 7.3%, primarily due to an increase in sales volumes resulting from patient growth and an increase in pricing.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">Rest of world SPINRAZA revenue increased $6.8 million, from $290.9 million in 2022 to $297.7 million in 2023, or 2.3%, primarily due to timing of shipments in certain international markets.</span></div></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.906%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.25pt dotted #0070c0;padding:0 1pt"></td></tr></table></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_160"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:15pt"><img src="biib-20230930_g9.jpg" alt="4" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-18pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.6pt">U.S. SPINRAZA revenue increased $9.7 million, from $<ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1856">443.3</ix:nonFraction> million in 2022 to $<ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1857">453.0</ix:nonFraction> million in 2023, or 2.2%, primarily due to an increase in sales volumes resulting from patient growth and an increase in pricing.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">Rest of world SPINRAZA revenue decreased $15.8 million, from $<ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1858">891.4</ix:nonFraction> million in 2022 to $<ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1859">875.6</ix:nonFraction> million in 2023, or 1.8%, primarily due to the unfavorable impact of foreign currency exchange and a decrease in pricing, partially offset by sales volume growth in certain Asian markets.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_163"></div></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.906%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.25pt dotted #0070c0;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SMA revenue includes sales from SPINRAZA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite competition from a gene therapy product and an oral product, we anticipate SPINRAZA revenue to be relatively flat in 2023 with the potential to grow thereafter. Moderate growth in the U.S. as well as continued access expansion in emerging markets is expected to offset increased competition and the impact of loading dose dynamics.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BIOSIMILARS</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:15pt"><img src="biib-20230930_g10.jpg" alt="6" style="height:307px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-18pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:11.67pt">For the three months ended September 30, 2023, compared to the same period of 2022, the increase in biosimilar revenue was primarily due to an increase in sales volumes related to the continued launch of BYOOVIZ in the U.S. and rest of world, offset by the unfavorable impact of foreign currency exchange and unfavorable pricing.</span></div><div style="margin-top:6pt"><span><br/></span></div></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.906%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.25pt dotted #0070c0;padding:0 1pt"></td></tr></table></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_169"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:15pt;margin-top:3pt"><img src="biib-20230930_g11.jpg" alt="4" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-bottom:15pt;margin-top:3pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:11.67pt">For the nine months ended September 30, 2023, compared to the same period in 2022, the increase in biosimilar revenue was primarily due to an increase in sales volumes related to the continued launch of BYOOVIZ in the U.S. and rest of world partially offset by the unfavorable impact of foreign currency exchange and unfavorable pricing.</span></div><div style="margin-bottom:15pt;margin-top:3pt"><span><br/></span></div><div><span><br/></span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_172"></div></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.906%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.25pt dotted #0070c0;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilars revenue includes sales from BENEPALI, IMRALDI, FLIXABI and BYOOVIZ. BYOOVIZ launched in the U.S. in June 2022 and became commercially available in July 2022 through major distributors in the U.S. In 2023 BYOOVIZ became commercially available in Canada and certain countries in Europe.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023 we anticipate modest growth in revenue from our biosimilars business driven by the continued launch of BYOOVIZ in the U.S. and rest of world, offset in part by continued price reductions in certain markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently working with our contract manufacturer for IMRALDI to address facility regulatory inspection deficiencies at two filling locations, which could impact supply and have an adverse impact on 2023 IMRALDI sales, if not resolved. Manufacturing of BENEPALI also utilizes one of these facilities and therefore could have an adverse impact on 2023 BENEPALI sales. We are working with our existing secondary supplier for BENEPALI with the aim to secure additional capacity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023 we announced that we are exploring strategic options for our biosimilars business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_2104"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:100%">OTHER PRODUCT REVENUE</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SKYCLARYS (omaveloxolone)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023, we acquired SKYCLARYS, the first and only drug approved by the FDA for the treatment of FA in adults and adolescents aged 16 years and older. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to begin recording revenue from SKYCLARYS in the fourth quarter of 2023 as we continue the launch of SKYCLARYS in the U.S. Additionally, an MAA for omaveloxolone has been submitted to the EMA and is currently under review.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_178"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">REVENUE FROM ANTI-CD20 THERAPEUTIC PROGRAMS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this discussion, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty revenue on sales of OCREVUS</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">928.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">825.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,252.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> LUNSUMIO became commercially available in the U.S. during the first quarter of 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023, compared to the same periods in 2022, the increases in royalty revenue on sales of OCREVUS were primarily due to sales growth of OCREVUS in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023, compared to the same periods in 2022, the decreases in our share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO were primarily due to decreases in sales of RITUXAN in the U.S. resulting from competition from multiple biosimilar products. In April 2023 the pre-tax profit share for RITUXAN, GAZYVA and LUNSUMIO decreased from 37.5% to 35.0%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to regulatory approval, we record our share of the expense incurred by the collaboration for the development of anti-CD20 products in research and development expense and pre-commercialization costs within selling, general and administrative expense in our condensed consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development and sales and marketing expense related to that product as a reduction of our share of pre-tax profits in revenue from anti-CD20 therapeutic programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenue from anti-CD20 therapeutic programs, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_181"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONTRACT MANUFACTURING, ROYALTY AND OTHER REVENUE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing, royalty and other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">742.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">781.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023, compared to the same periods in 2022, the increases in contract manufacturing revenue were primarily driven by higher volumes due to the timing of batch production, which includes batches related to LEQEMBI that we began recognizing in the first quarter of 2023 upon the accelerated approval of LEQEMBI in the U.S.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2023 we recorded a reclassification of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$38.7&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in LEQEMBI collaboration costs from other revenue to selling, general and administrative expense within our condensed consolidated statements of income. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that this reclassification does not materially impact the current or previously issued condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_184"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RESERVES FOR DISCOUNTS AND ALLOWANCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for discounts, contractual adjustments and returns that reduced gross product revenue are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">654.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">687.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,959.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">496.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">845.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">847.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,547.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,472.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both the three and nine months ended September 30, 2023, reserves for discounts and allowances as a percentage of gross product revenue was 31.7%, compared to 31.2% and 29.1%, respectively, in the prior year comparative periods. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONTRACTUAL ADJUSTMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual adjustments primarily relate to Medicaid and managed care rebates in the U.S., pharmacy rebates, co-payment (copay) assistance, Veterans Administration, 340B discounts, specialty pharmacy program fees and other government rebates or applicable allowances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2023, compared to the same period in 2022, the decrease in contractual adjustments was primarily due to lower government rebates in the U.S. as a result of a contract pharmacy change made during the first quarter of 2023 related to our Interferons.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, compared to the same period in 2022, the decrease in contractual adjustments was primarily due to lower government rebates in the U.S. as a result of a contract pharmacy change made during the first quarter of 2023 related to our Interferons, partially offset by higher managed care and Medicaid rebates in the U.S. as well as higher government rebates in rest of world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DISCOUNTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts include trade term discounts and wholesaler incentives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2023, compared to the same period in 2022, the increase in discounts was primarily driven by higher purchase and volume discounts for biosimilars, partially offset by lower purchase discounts in rest of world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, compared to the same period in 2022, the increase in discounts was primarily driven by higher purchase and volume discounts for biosimilars.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RETURNS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenue is recognized, resulting in a reduction to product sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the three and nine months ended September 30, 2023, compared to the same periods in 2022, the increases in returns were primarily driven by higher return rates in the U.S.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our revenue reserves, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5, Revenue,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">COST AND EXPENSE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of total cost and expense is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">659.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">469.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">736.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">788.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit sharing/(loss reimbursement)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">393.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of building</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(503.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">503.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(635.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,671.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,534.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,915.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,707.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,891.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,629.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,941.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,770.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit sharing/(loss reimbursement)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(486.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of building</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(503.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">503.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(221.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">469.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(212.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,444.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,641.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,802.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COST OF SALES, EXCLUDING AMORTIZATION AND IMPAIRMENT OF ACQUIRED INTANGIBLE ASSETS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,355.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,125.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">559.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">582.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">659.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">469.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,915.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,707.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2023, compared to the same period in 2022, product cost of sales increased primarily due to higher cost of sales associated with contract manufacturing revenue driven by increased production and unfavorable product mix.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, compared to the same period in 2022, product cost of sales increased primarily due to higher cost of sales associated with contract manufacturing revenue, in part related to Eisai for LEQEMBI, which we began recognizing in the first quarter of 2023 upon the accelerated approval of LEQEMBI in the U.S. as well as increased production. Cost of sales as a percentage of revenue was adversely affected by LEQEMBI batches due to minimal margins. The increase was partially offset by a write-off of approximately $275.0&#160;million during the first quarter of 2022 of excess inventory and purchase commitments related to ADUHELM.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, for the three and nine months ended September 30, 2023, we recorded approximately $35.0&#160;million and $113.3&#160;million, respectively, of aggregate gross idle capacity charges, compared to approximately $11.0&#160;million and $83.0&#160;million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Reata we recorded a fair value step-up adjustment related to the acquired inventory of SKYCLARYS of approximately $1.7&#160;billion. This fair value step-up adjustment will be amortized to cost of sales within our condensed consolidated statements of income when the inventory is sold, which is expected to be within approximately 3 years from the acquisition date. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RESEARCH AND DEVELOPMENT</span></div><div><img src="biib-20230930_g12.jpg" alt="29" style="height:766px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div><span><br/></span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">Research and development expense, as a percentage of total revenue, was 29.1% and 21.9% for the three months ended September 30, 2023 and 2022, respectively. For the three months ended September 30, 2023, compared to the same period in 2022, the increase in research and development was primarily due to approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:700;line-height:120%">$197.0&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%"> of equity-based compensation expense incurred as a result of our acquisition of Reata in September 2023, an increase in spending in the development of litifilimab for the treatment of CLE and SLE, an increase in spending in ADUHELM primarily due to the change in our cost sharing arrangement with Eisai, as well as close out costs incurred during the third quarter of 2023 of approximately $37.2&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">EARLY STAGE PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">Q3 2023 vs. Q3 2022</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">The increase in early stage programs was driven by an increase in costs associated with:</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%;padding-left:12.36pt">development of litifilimab for the treatment of CLE; and</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%;padding-left:12.36pt">development of BIIB121 for the treatment of Angelman syndrome.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">LATE STAGE PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">Q3 2023 vs. Q3 2022</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">The decrease in late stage programs was driven by a decrease in costs associated with:</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%;padding-left:12.36pt">advancement of LEQEMBI from late stage to marketed upon the accelerated approval of LEQEMBI in the U.S.;</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%;padding-left:12.36pt">advancement of LUNSUMIO from late stage to marketed upon the accelerated approval of LUNSUMIO in the U.S.;</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%;padding-left:12.36pt">advancement of ZURZUVAE from late stage to marketed upon the approval of ZURZUVAE for PPD in the U.S.; and</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%;padding-left:12.36pt">discontinuation of BIIB093 for large hemispheric infarction.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%;padding-left:12.36pt">development of litifilimab for the treatment of SLE.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">MARKETED PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">Q3 2023 vs. Q3 2022</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">The increase in marketed programs was driven by an increase in costs associated with:</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%;padding-left:12.36pt">advancement of LEQEMBI from late stage to marketed upon the accelerated approval of LEQEMBI in the U.S.;</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%;padding-left:12.36pt">advancement of ZURZUVAE from late stage to marketed upon the approval of ZURZUVAE for PPD in the U.S.;</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%;padding-left:12.36pt">increased spend in ADUHELM primarily due to the change in our cost sharing arrangement with Eisai; and</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%;padding-left:12.36pt">close out costs related to the discontinuation of our EMBARK study.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">OTHER RESEARCH AND DEVELOPMENT COSTS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">Q3 2023 vs. Q3 2022</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">The increase in other research and development costs was driven by an increase in costs associated with:</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%;padding-left:12.36pt">acquisition of Reata in September 2023.</span></div></div></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20230930_g13.jpg" alt="4" style="height:864px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div><span><br/></span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">Research and development expense, as a percentage of total revenue, was 25.4% and 21.4% for the nine months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023, compared to the same period in 2022, the increase in research and development was primarily due to approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1860">197.0</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%"> of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">equity-based compensation expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%"> incurred as a result of our acquisition of Reata in September 2023, an increase in spending in the development of LEQEMBI for the treatment of Alzheimer's disease, litifilimab for the treatment of CLE and SLE, and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, as well as close out costs incurred during 2023 of approximately $57.7&#160;million.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">EARLY STAGE PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">YTD 2023 vs. YTD 2022</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The increase in early stage programs was driven by an increase in costs associated with:</span></div><div style="margin-top:2pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">development of litifilimab for the treatment of CLE;</span></div><div style="margin-top:2pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">development of BIIB121 for the treatment of Angelman syndrome;</span></div><div style="margin-top:2pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">development of BIIB115 for the treatment of SMA;</span></div><div style="margin-top:2pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">development of BIIB091 for the treatment of MS; and</span></div><div style="margin-top:2pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">development of BIIB080 for the treatment of Alzheimer's disease.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The increase was partially offset by a decrease in costs associated with:</span></div><div style="margin-top:2pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">discontinuation of BIIB104 for the treatment of cognitive impairment associated with schizophrenia; and</span></div><div style="margin-top:2pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">discontinuation of BIIB078 for the treatment of Alzheimer's disease.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">LATE STAGE PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">YTD 2023 vs. YTD 2022</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease in late stage programs was driven by a decrease in costs associated with:</span></div><div style="margin-top:2pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">advancement of LEQEMBI from late stage to marketed upon the accelerated approval of LEQEMBI in the U.S.;</span></div><div style="margin-top:2pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">advancement of LUNSUMIO from late stage to marketed upon the accelerated approval of LUNSUMIO in the U.S; and</span></div><div style="margin-top:2pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">advancement of ZURZUVAE from late stage to marketed upon the approval of ZURZUVAE for PPD in the U.S.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="margin-top:2pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">development of litifilimab for the treatment of SLE into late stage; and</span></div><div style="margin-top:2pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">development of TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">MARKETED PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">YTD 2023 vs. YTD 2022</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The increase in marketed programs was driven by an increase in costs associated with:</span></div><div style="margin-top:2pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">advancement of LEQEMBI from late stage to marketed upon the accelerated approval of LEQEMBI in the U.S.;</span></div><div style="margin-top:2pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">advancement of ZURZUVAE from late stage to marketed upon the approval of ZURZUVAE for PPD in the U.S.; and</span></div><div style="margin-top:2pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:12.42pt">increased spend in ADUHELM primarily due to change in our cost sharing arrangement with Eisai.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_202"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Marketed products:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Late stage programs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are programs in Phase 3 development or in registration stage.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Early stage programs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are programs in Phase 1 or Phase 2 development.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Research and discovery:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represents costs incurred to support our discovery research and translational science efforts. </span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Development stage:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Other research and development costs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding upfront payments, we expect our core research and development expense to modestly increase in 2023, as we continue to invest in our pipeline. We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_205"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SELLING, GENERAL AND ADMINISTRATIVE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2023, compared to the same periods in 2022, selling, general and administrative expense increased by approximately 39.9% and 9.6%, respectively, primarily due to the recognition of approximately $196.4&#160;million in compensation expense related to our acquisition of Reata. This amount was associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest. Additionally, we incurred transaction and integration-related expenses of approximately $29.6&#160;million related to the acquisition. The increases were partially offset by the impact of cost-reduction measures realized during 2023.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2023 we recorded a reclassification of</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $38.7&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in LEQEMBI collaboration costs from other revenue to selling, general and administrative expense within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2023, selling, general and administrative expense also includes a $31.0&#160;million obligation to Eisai related to the termination of the co-promotion agreement for our MS products in Japan during the first quarter of 2023 and accelerated depreciation recognized during the second quarter of 2023 of approximately $11.5&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the Reata acquisition-related costs, we expect selling, general and administrative costs to continue to decline in 2023 due to the implementation of our cost saving initiatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, to our condensed consolidated financial statements included in this report. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_208"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AMORTIZATION AND IMPAIRMENT OF ACQUIRED INTANGIBLE ASSETS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant amortizable intangible assets are related to TYSABRI, AVONEX, SPINRAZA, VUMERITY and SKYCLARYS, which was obtained as part of our acquisition of Reata in September 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, compared to the same period in 2022, the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease i</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n amortization and impairment of acquired intangible assets was primarily due to lower rates of amortization for acquired intangible assets in the current year. For the three and nine months ended September 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had no impairment charges.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the amortization and impairment of our acquired intangible assets, please read </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Intangible Assets and Goodwill</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_211"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COLLABORATION PROFIT SHARING/(LOSS REIMBURSEMENT)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration profit sharing/(loss reimbursement) primarily includes Samsung Bioepis' 50.0% share of the profit or loss related to our biosimilars 2013 commercial agreement with Samsung Bioepis and Eisai's 45.0% share of income and expense in the U.S. related to the ADUHELM Collaboration Agreement. Beginning January 1, 2023, Eisai receives only a tiered royalty based on net sales of ADUHELM, and will no longer share global profits and losses. In the third quarter of 2023 we began recognizing collaboration profit sharing/(loss reimbursement) related to Sage's 50.0% share of income and expense in the U.S. related to ZURZUVAE.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023, we recognized net profit-sharing expense of $56.4 million and $170.4 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of $48.7 million and $171.4 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three and nine months ended September 30, 2023, we recorded $5.9&#160;million to reflect Sage's 50.0% share of net collaboration expense in the U.S. related to commercialization activities to support ZURZUVAE for PPD.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> three and nine months ended September 30, 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we recognized net reductions to our operating expense of approximately $3.4 million and $214.0 million, respectively,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to reflect Eisai's 45.0% </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">share of net collaboration losses in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration and license arrangements with Samsung Bioepis, Sage and Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_220"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RESTRUCTURING CHARGES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023 COST SAVING INITIATIVES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023 we initiated additional cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness. The Fit for Growth program is expected to generate approximately $1.0&#160;billion in gross operating expense savings by 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reduction of approximately 1,000 employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2023 cost saving initiatives are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs associated with items such as asset abandonment and write-offs, facility closure costs, pretax gains and losses resulting from the termination of certain leases, employee non-severance expense, consulting fees and other costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">REATA INTEGRATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the closing of the Reata acquisition, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. We expect to incur restructuring charges of approximately $30.0&#160;million in 2023. These amounts are primarily related to severance and are expected to be paid by the end of 2024. For the three and nine months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2023</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized approximately $21.0&#160;million of net pre-tax restructuring charges, primarily consisting of employee severance costs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022 COST SAVING INITIATIVES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are being achieved through a number of initiatives, including reductions to our workforce, the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial elimination of our commercial ADUHELM infrastructure, deprioritization of certain research and development programs, the consolidation of certain real estate locations and operating efficiencies across our selling, general and administrative and research and development functions. Charges related to our 2022 cost saving initiatives were substantially incurred during 2022 with remaining payments expected to be made through 2026.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2022 cost saving initiatives are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Amounts reflect a gain recorded during the third quarter of 2022 of approximately $5.3&#160;million related to the partial termination of a portion of our lease located at 300 Binney Street.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our cost saving initiatives, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4, Restructuring,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_223"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">GAIN ON SALE OF BUILDING</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we completed the sale of our building and land parcel located at 125 Broadway for an aggregate sales price of approximately $603.0&#160;million, which is inclusive of a $10.8&#160;million tenant allowance. This sale resulted in a pre-tax gain on sale of approximately $503.7&#160;million, net of transaction costs, which is reflected within gain on sale of building in our condensed consolidated statements of income for the three and nine months ended September 30, 2022. Simultaneously, with the close of this transaction we leased back the building for a term of approximately 5.5 years, which resulted in the recognition of approximately $168.2&#160;million in a new lease liability and right-of-use asset recorded within our condensed consolidated balance sheets as of December 31, 2022. The sale and immediate leaseback of this building qualified for sale and leaseback treatment and is classified as an operating lease.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our building, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11, Property, Plant and Equipment</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our 300 Binney Street lease modification, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements included in this report.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_226"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTHER (INCOME) EXPENSE, NET</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2023, compared to the same period in 2022, the change in other (income) expense, net primarily reflects net losses on our holdings in equity securities of approximately $302.0 million partially offset by higher interest income driven by higher interest rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, compared to the same period in 2022, the change in other (income) expense, net primarily reflects a pre-tax gain recorded during the second quarter of 2022 of approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.5&#160;billion related to the sale of our 49.9% equity interest in Samsung Bioepis, partially offset by a pre-tax charge recorded during the second quarter of 2022 of approximately $900.0 million, plus settlement fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NET (GAINS) LOSSES IN EQUITY SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2023, net unrealized and realized losses on our holdings in equity securities were approximately $297.6 million and $4.4 million, respectively, compared to net unrealized and realized gains of approximately $109.3 million and $0.5 million, respectively, in the prior year comparative period. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The net unrealized losses recognized during the three months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali and Sangamo common stock of approximately $295.6&#160;million.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The net unrealized gains recognized during the three months ended September 30, 2022, primarily reflect an increase in the aggregate fair value of our investments in Sage, Ionis, Sangamo and Denali common stock of approximately $112.5&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, net unrealized and realized losses on our holdings in equity securities were approximately $268.3 million and $5.3 million, respectively, compared to net unrealized losses and realized (gains) losses of $158.1 million and zero, respectively, in the prior year comparative period.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The net unrealized losses recognized during the nine months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali, Sangamo and Ionis common stock of approximately $265.0&#160;million.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The net unrealized losses recognized during the nine months ended September 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $198.0&#160;million, partially offset by an increase in the fair value of Ionis and Sage common stock of approximately $52.2&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_229"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INCOME TAX PROVISION</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income tax (benefit) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,371.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,005.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,988.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(72.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expense, the levels of certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate for the three months ended September 30, 2023, reflects a tax benefit of $72.9 million recognized as a result of a pretax loss from operations of $141.2 million recorded during the third quarter of 2023, which was driven, in part, by the impact of the non-cash changes in the value of our equity investments and Reata acquisition-related expenses. For all other periods presented, the effective tax rates reflect tax expense on pretax income from operations in the respective periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2023, compared to the same period in 2022, the change in our effective tax rate was driven by the impact of the non-cash changes in the value of our equity investments and Reata acquisition-related expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, compared to the same period in 2022, our effective tax rate, in addition to the items noted above, was also impacted by the combined net unfavorable tax rate impacts in 2022 related to a litigation settlement agreement, the sale of our equity interest in Samsung Bioepis, the impact of a Neurimmune valuation allowance and an international reorganization to align with global tax developments. The change also benefits from the resolution of an uncertain tax matter during the first quarter of 2023 related to tax credits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:112%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:112%">, to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our income taxes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 17, Income Taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to our condensed consolidated financial statements included in this report.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_235"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NONCONTROLLING INTERESTS, NET OF TAX</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of our variable interest entity, Neurimmune, as we determined that we are the primary beneficiary.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, compared to the same period in 2022, the change in net income (loss) attributable to noncontrolling interests, net of tax, was primarily due to an increase in a valuation allowance of approximately $85.0&#160;million recorded in the first quarter of 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the valuation allowance and our collaboration agreement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_238"></div><div style="margin-top:9pt"><span style="color:#00587f;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,287.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,419.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,131.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,473.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">705.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(705.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,288.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,598.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,310.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of term loan</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes payable and term loan</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,786.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,281.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,286.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,281.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,005.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Working capital:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,454.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,791.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,337.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,022.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,272.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,749.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total working capital</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,431.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,518.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,086.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_241"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">OVERVIEW</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have historically financed and expect to continue to fund our operating and capital expenditures primarily through cash flow earned through our operations, as well as our existing cash resources. We believe generic competition for TECFIDERA in the U.S. and other key markets, continued decline in the Interferon product class and investments in the development and launch of potential new products will continue to reduce our cash flow from operations in 2023 and will have a significant adverse impact on our future cash flow from operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:115%">September&#160;26, 2023</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we completed the acquisition of all of the issued and outstanding shares of Reata for </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$6.6&#160;billion</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$983.9&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for outstanding equity awards. This transaction was funded with cash on hand and the issuance of a $1.0 billion term loan. As of September 30, 2023, approximately $1.3&#160;billion associated with the Reata transaction is accrued and will be paid by November 2023. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:115%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:115%">, to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> included in this report.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:115%">LIQUIDITY</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:115%">WORKING CAPITAL</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital is defined as current assets less current liabilities. Our working capital was $3.4 billion and $6.5 billion as of September 30, 2023 and December 31, 2022, respectively. The change in working capital reflects a decrease in total current assets of approximately $1,337.1 million and an increase in total current liabilities of approximately $1,749.5 million. The changes in current assets and current liabilities were primarily driven by the following:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CURRENT ASSETS</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10pt">$2,604.9 million decrease in cash, cash equivalents and current marketable securities primarily due to consideration paid for </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our acquisition of Reata</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10pt">$443.5 million decrease in other current assets primarily due to the receipt of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$812.5&#160;million from Samsung BioLogics related to the sale of Samsung Bioepis, partially offset by </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the second deferred payment of $437.5&#160;million being due within one year</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10pt">$1,638.0 million increase in inventory due to the acquired inventory resulting from our acquisition of Reata.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CURRENT LIABILITIES</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10pt">$51.4 million decrease in accounts payable primarily due to timing of payments;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10pt">$500.0 million increase in current portion of debt due to the short-term portion of the outstanding term loan related to</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> our acquisition of Reata</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">; and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10pt">$1,317.0 million increase in accrued expense and other primarily reflecting accrued costs related to our acquisition of Reata.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, we had cash, cash equivalents and marketable securities totaling approximately $2.3 billion compared to approximately $5.6 billion as of December 31, 2022. The decrease in the balance was primarily due to the use of cash, cash equivalents and marketable securities to fund our acquisition of Reata. In connection with our acquisition of Reata we accrued approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$983.9&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to Reata's outstanding equity awards, inclusive of employer taxes, of which approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$980.0&#160;million </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was subsequently paid in October 2023. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additionally, we assumed a payable to Blackstone of approximately $300.0&#160;million related to a one-time contract termination fee to eliminate potential future royalty obligations related to SKYCLARYS, which was triggered as part of the change in control provision under Reata's funding agreement with Blackstone. Payment to Blackstone is expected to be made in November 2023. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. We have experienced no significant limitations in our liquidity resulting from uncertainties in the banking sector.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our significant common stock investments in our strategic investment portfolio:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.003%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denali</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">274.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sangamo</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ionis</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During the third quarter of 2023 we sold a portion of our Sangamo common stock.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During the second quarter of 2023 we sold our remaining shares of Ionis common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the contractual holding period restrictions on our investments in Denali, Sage and Sangamo have expired, our ability to liquidate these investments may be limited by the size of our interest, the volume of market related activity, our concentrated level of ownership and other potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_244"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CASH FLOW</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,534.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,559.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,448.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,717.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(300.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">795.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,739.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">OPERATING ACTIVITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow is derived by adjusting our net income for:</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.4pt">non-cash operating items such as depreciation and amortization, impairment charges, unrealized (gain) loss on strategic investments and share-based compensation;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.4pt">changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.4pt">(gains) losses on the disposal of assets, deferred income taxes, changes in the fair value of contingent payments associated with our acquisitions of businesses and acquired IPR&amp;D.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, compared to the same period in 2022, net cash flow provided by operating activities was relatively flat. Net cash flow from operations in 2023 was primarily driven by net income of $912.6 million, lower inventory purchases and the timing of payments. Net cash flow from operations in 2022 was primarily driven by net income of $2.4 billion adjusted for a </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pre-tax gain of approximately $1.5&#160;billion related to the sale of our equity interest in Samsung Bioepis and a pre-tax gain of approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$503.7&#160;million related to the sale of one of our buildings as well as timing of payments.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">INVESTING ACTIVITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, compared to the same period in 2022, the change in net cash flow provided by (used in) investing activities was primarily due to a $6.3&#160;billion payment made in 2023 for our acquisition of Reata, net of cash acquired, partially offset by higher net sales of marketable securities in the current period. Additionally, we received $582.6 million in 2022 related to the sale of one of our buildings.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FINANCING ACTIVITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, compared to the same period in 2022, the change in net cash flow provided by (used in) financing activities was primarily due to the issuance of term loans totaling $1.0 billion under our $1.5&#160;billion term loan credit agreement which were used to partially fund our acquisition of Reata, compared to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">debt repayments of approximately $1.0 billion and share repurchases of $750.0 million during the same period in 2022. Additionally, we repaid Reata's outstanding debt obligation of $159.9 million during the third quarter of 2023.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_247"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">CAPITAL RESOURCES</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DEBT AND CREDIT FACILITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LONG-TERM DEBT AND TERM LOAN CREDIT AGREEMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term obligations primarily consist of long-term debt related to our Senior Notes with final maturity dates ranging between 2025 and 2051. As of September 30, 2023, our outstanding balance related to long-term debt was $6,786.4 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we entered into a $1.5&#160;billion term loan credit agreement. On the closing date of the Reata acquisition we drew $1.0 billion from the term loan, comprised of a $500.0&#160;million floating rate 364-day tranche and a $500.0&#160;million floating rate three-year tranche. The remaining unused commitment of $500.0&#160;million was terminated. As of September 30, 2023, we had $1.0&#160;billion outstanding under the term loan credit agreement, of which $500.0&#160;million was outstanding under the 364-day tranche and $500.0&#160;million outstanding under the three-year tranche.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:700;line-height:120%">REVOLVING CREDIT FACILITY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of September 30, 2023 and December 31, 2022, we had no outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a summary of the fair and carrying values of our outstanding borrowings as of September 30, 2023 and December 31, 2022, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Senior Notes and credit facility please read, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2022 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SHARE REPURCHASE PROGRAMS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 1.2 million and 3.6 million shares of our common stock at a cost of approximately $250.0 million and $750.0 million during the three and nine months ended September 30, 2022, respectively. There were no share repurchases of our common stock during the three and nine months ended September 30, 2023. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2023.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CAPITAL EXPENDITURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the fourth quarter of 2021 we began construction of a new gene therapy manufacturing facility in RTP, North Carolina to support our gene therapy pipeline across multiple therapeutic areas. The new manufacturing facility will be approximately 197,000 square feet with an estimated total investment of approximately $195.0&#160;million. As we continue to advance our research and development prioritization efforts, which includes refocusing our investment in gene therapy, we are evaluating several alternative uses for this facility.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_250"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONTRACTUAL OBLIGATIONS AND OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONTRACTUAL OBLIGATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments and contingent payments, as described below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of our collaboration and licensing arrangements include royalty payment obligations. For additional information on our royalty payments please read, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2022 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we assumed additional contractual obligations related to operating lease commitments and royalty payments. Reata entered into agreements to pay royalties on future sales of SKYCLARYS, which will cumulatively range in the low to mid single digits</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additionally, as of September 30, 2023, our contractual obligations include a liability assumed from Reata of approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$300.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">related to a one-time contract termination fee to eliminate potential future royalty obligations related to SKYCLARYS, w</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">hich was triggered as part of the change in control provision under Reata's funding agreement with Blackston</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e. Additionally, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">we</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> This lease was expected to be Reata&#8217;s future headquarters. Total net present value of rental expense is approximately $151.8&#160;million over </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the next 15 years.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aside from our new commitments related to Reata, there have been no material changes in our contractual obligations since December 31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONTINGENT DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our development plans as of September 30, 2023, we could trigger potential future milestone payments to third parties of up to approximately $6.0 billion, including approximately $1.2 billion in development milestones, approximately $500.0 million in regulatory milestones and approximately $4.3 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of September 30, 2023, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain clinical and commercial milestones are met, we may pay up to approximately $91.7&#160;million in milestones in 2023 under our current agreements. This includes milestones totaling $75.0&#160;million due to Sage </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upon the first commercial sale of ZURZUVAE for PPD in the U.S.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTHER FUNDING COMMITMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expense of approximately $34.3 million in our condensed consolidated balance sheets for expenditures incurred by CROs as of September 30, 2023. We have approximately $777.0 million in cancellable future commitments based on existing CRO contracts as of September 30, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TAX RELATED OBLIGATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of September 30, 2023, we have approximately $163.7 million of liabilities associated with uncertain tax positions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, we have accrued income tax liabilities of approximately $419.5&#160;million and $558.0&#160;million, respectively, under the Transition Toll Tax. Of the amounts accrued as of September 30, 2023, approximately $185.4&#160;million is expected to be paid within one year. The Transition Toll Tax is being paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_253"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of new accounting standards please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_256"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BUSINESS COMBINATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are recorded using the acquisition method of accounting. The results of operations of the acquired company are included in our results of operations beginning on the acquisition date, and assets acquired and liabilities assumed are recognized on the acquisition date at their respective fair values. Any excess of consideration transferred over the net carrying value of the assets acquired and liabilities assumed as of the acquisition date is recognized as goodwill. Transaction and restructuring costs related to business combinations are expensed as incurred. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. If we determine the assets acquired do not meet the definition of a business, the transaction will be accounted for as an asset acquisition rather than a business combination.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for business combinations, as discussed above, there have been no material changes to our critical accounting estimates since our 2022 Form&#160;10-K. For a discussion of our other critical accounting estimates, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part&#160;II,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2022 Form&#160;10-K. </span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_259"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain risks that may affect our results of operations, cash flow and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements and equity price exposure as well as changes in economic conditions in the markets in which we operate as a result of the COVID-19 pandemic, the conflict in Ukraine and the military conflict in the Middle East. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, foreign currency options, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.  </span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FOREIGN CURRENCY EXCHANGE RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. As a result, our consolidated financial position, results of operations and cash flow can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar and Swiss franc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expense, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue and expense will increase when reported in U.S. dollars.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flow and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100.0%, which indicated that Argentina's economy is highly inflationary. This categorization did not have a material impact on our results of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations or financial position as of September 30, 2023, and is not expected to have a material impact on our results of operations or financial position in the future.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REVENUE AND OPERATING EXPENSE HEDGING PROGRAM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenue and operating expense. We use foreign currency forward contracts and foreign currency options to manage foreign currency risk, with the majority of our forward contracts and options used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next 15 months. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to mitigate the impact of foreign currency exchange rate changes on revenue and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BALANCE SHEET RISK MANAGEMENT HEDGING PROGRAM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of September 30, 2023 and December 31, 2022, a hypothetical adverse 10.0% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $230.9 million and $293.7 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INTEREST RATE RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of December 31, 2022, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $11.7 million to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We partially funded our Reata acquisition through available cash, cash equivalents and marketable securities. As of September 30, 2023, we have sold all of our marketable debt securities. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CREDIT RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We operate in certain countries where weakness in economic conditions, including the effects of the COVID-19 pandemic, the conflict in Ukraine and the military conflict in the Middle East, can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our allowance for doubtful accounts was adequate as of September 30, 2023 and December 31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EQUITY PRICE RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies. While we are holding such securities, we are subject to equity price risk, and this may increase the volatility of our income in future periods due to changes in the fair value of equity investments. We may sell such equity securities based on our business considerations, which may include limiting our price risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the fair value of these equity securities are impacted by the volatility of the stock market and changes in general economic conditions, among other factors. The potential change in fair value for equity price sensitive instruments has been assessed on a hypothetical 10.0% adverse movement. As of September 30, 2023 and December 31, 2022, a hypothetical adverse 10.0% movement would result in a hypothetical decrease in fair value of approximately $41.4&#160;million and $79.1&#160;million, respectively.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_262"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM 4. &#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DISCLOSURE CONTROLS AND PROCEDURES AND INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of September 30, 2023. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms; and </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2023, we completed our acquisition of Reata. The Reata acquisition was accounted for as a business combination using the acquisition method of accounting. The results of operations of the acquired Reata business have been included in our results of operations since September 26, 2023, and we are currently in the process of evaluating and integrating Reata's historical internal controls over financial reporting with ours.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the evaluation and integration of internal controls resulting from the Reata acquisition, as discussed above, there were no changes in our internal control over financial reporting during the quarter ended September 30, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_265"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;II OTHER INFORMATION</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_268"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of legal proceedings as of September 30, 2023, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 21, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_271"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on revenue from our products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs. A significant portion of our revenue is concentrated on sales of our products in increasingly competitive markets. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenue and results of operations or could cause a decline in our stock price: </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction, greater acceptance or more favorable reimbursement of competing products, including new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">safety or efficacy issues;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements; increased competition, including from generic or biosimilar versions of our products; or changes in, or implementation of, reimbursement policies and practices of payors and other third-parties;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse legal, administrative, geopolitical events, regulatory or legislative developments; or</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to maintain a positive reputation among patients, healthcare providers and others, which may be impacted by our pricing and reimbursement decisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LEQEMBI and SKYCLARYS are in the early stages of commercial launch in the U.S. In addition to risks associated with new product launches and the other factors described in these Risk Factors, Biogen&#8217;s and Eisai&#8217;s ability to successfully commercialize LEQEMBI and our ability to successfully commercialize SKYCLARYS may be adversely affected due to:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">Eisai&#8217;s ability to obtain and maintain adequate reimbursement for LEQEMBI;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">the effectiveness of Eisai's and Biogen&#8217;s commercial strategy for marketing LEQEMBI;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">requirements such as participation in a registry and the use of imaging or other diagnostics;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">the approval of other new products for the same or similar indications;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">Eisai&#8217;s and Biogen&#8217;s ability to maintain a positive reputation among patients, healthcare providers and others in the Alzheimer&#8217;s disease community, which may be impacted by pricing and reimbursement decisions relating to LEQEMBI, which are made by Eisai;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">Biogen's ability to obtain and maintain adequate reimbursement for SKYCLARYS; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12pt">the effectiveness of Biogen's commercial strategy for marketing SKYCLARYS.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our long-term success depends upon the successful development of new products and additional indications for our existing products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success will depend upon the successful development of new products from our research and development activities or our licenses or acquisitions from third-parties, as well as additional indications for our existing products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product development is very expensive and involves a high degree of uncertainty and risk and may not be successful. Only a small number of research and development programs result in the commercialization of a product. It is difficult to predict the success and the time and cost of product development of novel approaches for the treatment of diseases. The development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the antisense oligonucleotide platform and gene therapy, may present additional challenges and risks, including obtaining approval from regulatory authorities that have limited experience </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">with the development of such therapies. For example, we are currently seeking approval of SKYCLARYS in Europe and any delays or challenges regarding its approval in Europe may adversely impact our ability to realize the anticipated benefits from the Reata acquisition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trial data are subject to differing interpretations and even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, limit the scope of the approval or deny approval altogether. Furthermore, the approval of a product candidate by one regulatory agency does not mean that other regulatory agencies will also approve such product candidate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical work or early-stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce or delay the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we could successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or we prefer to pursue other opportunities in our pipeline. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of new products or products with additional indications may not meet investor expectations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing, research and development and other resources and other technological or competitive advantages. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products continue to face increasing competition from the introduction of new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways. Some of these products are likely to be sold at substantially lower prices than our branded products. The introduction of such products as well as other lower-priced competing products has reduced, and may in the future, significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. For instance, demand and price for TECFIDERA declined significantly as a result of multiple TECFIDERA generic entrants entering the U.S. market in 2020. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete, maintain and grow our business may also be adversely affected due to a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction of other products, including products that may be more efficacious, safer, less expensive or more convenient alternatives to our products, including our own products and products of our collaborators;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the off-label use by physicians of therapies indicated for other conditions to treat patients; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patient dynamics, including the size of the patient population and our ability to identify, attract and maintain new and current patients to our therapies;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the reluctance of physicians to prescribe, and patients to use, our products without additional data on the efficacy and safety of such products;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">damage to physician and patient confidence in any of our products, generic or biosimilars of our products or any other product from the same class as one of our products, or to our sales and reputation as a result of label changes, pricing and reimbursement decisions or adverse experiences or events that may occur with patients treated with our products or generic or biosimilars of our products;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inability to obtain appropriate pricing and adequate reimbursement for our products compared to our competitors in key international markets; or</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain patent, data or market exclusivity for our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives and external opportunities, which may include the acquisition and in-licensing of products, technologies, companies, the entry into strategic alliances and collaborations or our Fit for Growth program. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. We have made, and may continue to make, significant operating and capital expenditures for potential new products prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may fail to initiate or complete transactions for many reasons, including failure to obtain regulatory or other approvals as well as disputes or litigation. Furthermore, we may not be able to achieve the full strategic and financial benefits expected to result from transactions, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations. For example, we recently acquired Reata and are in the process of integrating Reata into our Company. The ultimate success of our acquisition of Reata and our ability to realize the anticipated benefits from the acquisition, including the SKYCLARYS product and anticipated synergies, depends on, among other things, how effective we are in integrating the Biogen and Reata operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face risks associated with our Fit for Growth program that may impair our ability to achieve anticipated savings and operational efficiencies or that may otherwise harm our business. These risks include delays in implementation of cost optimization actions, loss of workforce capabilities, higher than anticipated separation expenses, litigation and the failure to meet financial and operational targets. In addition, the calculation of the anticipated cost savings and other benefits resulting from our Fit for Growth program are subject to many estimates and assumptions. These estimates and assumptions are subject to significant business, economic, competitive and other uncertainties and contingencies, many of which are beyond our control. if these estimates and assumptions are incorrect or if we experience delays or unforeseen events, our business and financial results could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product, diagnosis of the condition it treats and the cost to administer it may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and reimbursement for our products may be adversely affected by a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">pressure by employers on private health insurance plans to reduce costs;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">consolidation and increasing assertiveness of payors seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to receive reimbursement for our products or our ability to receive comparable reimbursement to that of competing products; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to set the price for our products varies significantly from country to country and, as a result, so can the price of our products. Governments may use a variety of cost-containment measures to control the cost of products, including price cuts, mandatory rebates, value-based pricing and reference pricing (i.e., referencing prices in other countries and using those reference prices to set a price). Drug prices are under significant scrutiny in the markets in which our products are prescribed; for example the IRA has certain provisions related to drug pricing. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. Certain countries set prices by reference to the prices in other countries where our products are marketed. Our inability to obtain and maintain adequate prices in a particular country may not only limit the revenue from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenue. Additionally, and in part due to the impact of the COVID-19 pandemic, in certain jurisdictions governmental health agencies may adjust, retroactively and/or prospectively, reimbursement rates for our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products marketed by our competitors could cause our revenue to decrease due to potential price reductions and lower sales volumes. Additionally, the introduction of generic or biosimilar versions of our products, follow-on products, prodrugs or products approved under abbreviated regulatory pathways may significantly reduce the price that we are able to charge for our products and the volume of products we sell.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients, including more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on relationships with collaborators and other third-parties for revenue, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of collaborative and other third-party relationships for revenue and the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource certain aspects of our regulatory affairs and clinical development relating to our products and product candidates to third-parties. Reliance on third-parties subjects us to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">we may be unable to control the resources our collaborators or third-parties devote to our programs, products or product candidates;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">disputes may arise under an agreement, including with respect to the achievement and payment of milestones, payment of development or commercial costs, ownership of rights to technology developed, and the underlying agreement may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators or third-parties fail to perform; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the interests of our collaborators or third-parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenue, or may adopt tax strategies that could have an adverse effect on our business, results of operations or financial condition; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">third-party relationships require the parties to cooperate, and failure to do so effectively could adversely affect product sales or the clinical development or regulatory approvals of product candidates under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any failure on the part of our collaborators or third-parties to comply with applicable laws, including tax laws, regulatory requirements and/or applicable contractual obligations or to fulfill any responsibilities they may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenue as well as involve us in possible legal proceedings; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any improper conduct or actions on the part of our collaborators or third-parties could subject us to civil or criminal investigations and monetary and injunctive penalties, impact the accuracy and timing of our financial reporting and/or adversely impact our ability to conduct business, our operating results and our reputation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, revenue from products could decline and/or we may not realize the anticipated benefits of these arrangements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations may be adversely affected by current and potential future healthcare reforms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs (including those contained in the IRA) and increasing pressure from social sources could significantly influence the manner in which our products are prescribed, purchased and reimbursed. For example, provisions of the PPACA have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is increasing public attention on the costs of prescription drugs and we expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. For example, two committees of the U.S. House of Representatives previously investigated the approval and price of ADUHELM. In addition, there have been (including elements of the IRA), and are expected to continue to be, legislative proposals to address prescription drug pricing. Some of these proposals could have significant effects on our business, including an executive order issued in September 2020 to test a &#8220;most favored nation&#8221; model for Part B and Part D drugs that tie reimbursement rates to international drug pricing metrics. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant economic pressure on state budgets, including as a result of the COVID-19 pandemic, that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expense may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenue and may continue to adversely affect our revenue and results of operations in the future.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful in such activities, our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture and commercialization of biosimilar products require specialized expertise and are very costly and subject to complex regulation. Our success in commercializing biosimilars is subject to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Reliance on Third-Parties.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are dependent, in part, on the efforts of collaboration partners and other third-parties over whom we have limited or no control in the development and manufacturing of biosimilars products. If these third-parties fail to perform successfully, our biosimilar product development or commercialization of biosimilar products could be delayed, revenue from biosimilar products could decline and/or we may not realize the anticipated benefits of these arrangements;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Regulatory Compliance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Ability to Provide Adequate Supply.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Manufacturing biosimilars is complex. If we encounter any manufacturing or supply chain difficulties we may be unable to meet demand. We are dependent on a third-party for the manufacture of our biosimilar products and such third-party may not perform its obligations in a timely and cost-effective manner or in compliance with applicable regulations and may be unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Intellectual Property and Regulatory Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Failure to Gain Market and Patient Acceptance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Competitive Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products face significant competition, including from innovator products and biosimilar products offered by other companies that may receive greater acceptance or more favorable reimbursement. Local tendering processes may restrict biosimilar products from being marketed and sold in some jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success in this business area. The decision to explore strategic options related to our biosimilars business could adversely effect our operations related to our biosimilars business.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success, including our long-term viability and growth, depends, in part, on our ability to obtain and defend patent and other intellectual property rights, including certain regulatory forms of exclusivity, that are important to the commercialization of our products and product candidates. Patent protection and/or regulatory exclusivity in the U.S. and other important markets remains uncertain and depends, in part, upon decisions of the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to obtain, defend or preserve patent and other intellectual property rights, including certain regulatory forms of exclusivity, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business, which could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price. In addition, settlements of such proceedings often result in reducing the period of exclusivity and other protections, resulting in a reduction in revenue from affected products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many markets, including the U.S., manufacturers may be allowed to rely on the safety and efficacy data of the innovator's product and do not need to conduct clinical trials before marketing a competing version of a product after there is no longer patent or regulatory exclusivity. In such cases, manufacturers often charge significantly lower prices and a major portion of the company's revenue may be reduced in a short period of time. In addition, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturers of generics and biosimilars may choose to launch or attempt to launch their products before the expiration of our patent or other intellectual property protections.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third-parties. Legal proceedings, administrative challenges or other types of proceedings are and may in the future be necessary to determine the validity, scope or non-infringement of certain patent rights claimed by third-parties to be pertinent to the manufacture, use or sale of our products.&#160;Legal proceedings may also be necessary to determine the rights, obligations and payments claimed during and after the expiration of intellectual property license agreements we have entered with third parties. Such proceedings are unpredictable and are often protracted and expensive. Negative outcomes of such proceedings could hinder or prevent us from manufacturing and marketing our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. A failure to obtain necessary licenses for an infringed product or technology could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain could reduce our profits from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Development, Clinical Testing and Regulation of Our Products and Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. Even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies, disagree with our trial design or endpoints or not approve adequate reimbursement. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated, including limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements, requiring confirmatory trials and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expense, have an adverse effect on our business, financial condition and results of operations and/or cause our stock price to decline or experience periods of volatility.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors, including protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or denied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third-parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third-parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials and if such CRO does not adequately perform, many of our trials may be affected, including adversely affecting our expenses associated with such trials. We may need to replace our CROs, which may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or products from the same class as one of our products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and/or the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in adverse impacts on our results of operations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales to decline or our stock price to experience periods of volatility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restrictions on use or safety warnings that may be required to be included in the label of our products may significantly reduce expected revenue for those products and require significant expense and management time.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon technology systems and data to operate our business. The COVID-19 pandemic has caused us to modify our business practices in ways that heighten this dependence, including changing the requirement that most of our office-based employees in the U.S. and our other key markets work from the office, with a number of our employees now working in hybrid or full-remote positions. As a result, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies, including Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS). Breakdowns, invasions, corruptions, destructions and/or breaches of our technology systems or those of our business partners, including our cloud technologies, and/or unauthorized access to our data and information could subject us to liability, negatively impact our business operations, and/or require replacement of technology and/or ransom payments. Our technology systems, including our cloud technologies, continue to increase in multitude and complexity, increasing our vulnerability when breakdowns, malicious intrusions and random attacks occur.&#160;Data privacy or security breaches also pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, patients, customers or other business partners, may be exposed to unauthorized persons or to the public.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect, when they impact vendors, customers or companies, including vendors, suppliers and other companies in our supply chain. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with careless or malicious intent. Geopolitical instability, including that related to Russia's invasion of Ukraine or the conflict in the Middle East, may increase cyber-attacks. Cyber-attacks include deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyber-attacks also include manufacturing, hardware or software supply chain attacks, which could cause a delay in the manufacturing of products or products produced for contract manufacturing or lead to a data privacy or security breach. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies heightens these and other operational risks, and any failure by cloud or other technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Regulations continue to change as regulators worldwide consider new rules. For example, the SEC has adopted additional disclosure rules regarding cyber security risk management, strategy, governance and incident reporting by public companies. These new regulations or other regulations being considered in Europe and around the world may impact the manner in which we operate.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators are imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the E.U.&#8217;s General Data Protection Regulation established regulations regarding the handling of personal data, and provides an enforcement authority and imposes large penalties for noncompliance. New U.S. data privacy and security laws, such as the CCPA, and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with the CCPA may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Failure to comply with these current and future laws, policies, industry standards or legal obligations or any security </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incident resulting in the unauthorized access to, or acquisition, release or transfer of personal information may result in governmental enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenue.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:12pt">Risks of Reliance on Third-Parties and Single Source Providers.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third-parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third-parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:12pt">Global Bulk Supply Risks. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We rely on our manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor or raw material shortages, geopolitical instability, public health epidemics, natural disasters, power failures, cyber-attacks and many other factors.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risks Relating to Compliance with current GMP (cGMP).</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and other regulatory authorities to confirm compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or operations or those of third-parties to receive regulatory approval or pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk of Product Loss.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Furthermore, factors such as the COVID-19 pandemic and other global health outbreaks, weather events, labor or raw material shortages and other supply chain disruptions could result in difficulties and delays in manufacturing our products, which could have an adverse impact on our results in operations or result in product shortages. We may also have to take inventory write-offs and incur other charges and expense for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management, personnel and other organizational changes may disrupt our operations, and we may have difficulty retaining personnel or attracting and retaining qualified replacements on a timely basis for the management and other personnel who may leave the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in management, other personnel and our overall retention rate may disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. New </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new opportunities or reduce or change emphasis on our existing programs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is dependent upon our ability to attract and retain qualified management and other personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract or retain them. We may face difficulty in attracting and retaining talent for a number of reasons, including management changes, integration related to the Reata acquisition, the underperformance or discontinuation of one or more marketed, pre-clinical or clinical programs, recruitment by competitors or changes in the overall labor market. In addition, changes in our organizational structure or in our flexible working arrangements could impact employees' productivity and morale as well as our ability to attract, retain and motivate employees. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight in the U.S.&#160;and in foreign jurisdictions, and are subject to change and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our business practices. The FDA and comparable foreign agencies directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting, product risk management and our compliance with good practice quality guidelines and regulations. Our interactions with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies are facing heightened scrutiny of their relationships with health care providers and have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. The U.S. government has challenged some of our donations to third-party charities that provide patient assistance. If we, or our vendors or donation recipients, are found to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the FDA and foreign regulatory approval processes or perspectives that may delay or prevent the approval of new products and result in lost market opportunity; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of governmental regulation may be punishable by criminal and civil sanctions, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. We could also be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we submitted to the government. In addition, legal proceedings and investigations are inherently unpredictable, and large judgments or settlements sometimes occur. While we believe that we have appropriate compliance controls, policies and procedures in place to comply with the laws or regulations of the jurisdictions in which we operate, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate such laws or regulations. Whether or not we have complied with the law, an investigation or litigation related to alleged unlawful conduct could increase our expense, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasing our presence in international markets, subjecting us to many risks that could adversely affect our business and revenue. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents or distributors and unfamiliar operations and arrangements previously utilized by companies we collaborate with or acquire in emerging markets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, such as the COVID-19 pandemic, on the global economy and the delivery of healthcare treatments;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">less favorable intellectual property or other applicable laws; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to obtain necessary foreign regulatory approvals of products in a timely manner; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on our ability to obtain and maintain product pricing, reimbursement or receive price increases, including those resulting from governmental or regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increased cost of goods due to factors such as inflation and supply chain disruptions;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">additional complexity in manufacturing internationally;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">delays in clinical trials relating to geopolitical instability related to Russia's invasion of Ukraine and the military conflict in the Middle East;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">fluctuations in foreign currency exchange rates that may adversely impact our revenue, net income and value of certain of our investments; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of governmental controls; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">diverse data privacy and protection requirements;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">compliance with complex import and export control laws;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in tax laws; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of tariffs or embargoes and other trade restrictions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, our international operations are subject to regulation under U.S. law. For example, the U.S. FCPA prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results. In addition, while we believe that we have appropriate compliance controls, policies and procedures in place to comply with the FCPA, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate the FCPA and we might be held responsible. If our employees, agents, distributors, collaborators or third-party providers are found to have engaged in such practices, we could suffer severe penalties and may be subject to other liabilities, which could negatively affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are building a large-scale biologics manufacturing facility and a gene therapy manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity will be required or this investment will be recouped.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity may continue to occur and would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Solothurn facility was approved by the FDA for ADUHELM and LEQEMBI, there can be no assurance that the regulatory authorities will approve the Solothurn facility for the manufacturing of other products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, we are building a new gene therapy manufacturing facility in RTP, North Carolina with no assurance that this investment will be fully utilized. If we are unable to fully utilize this gene therapy manufacturing facility, charges from excess capacity may occur and would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic and other global health outbreaks may, directly or indirectly, adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business has and could continue to be adversely affected, directly or indirectly, by the COVID-19 pandemic and other global health outbreaks.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in flexible working arrangements could impact employee retention, employees' productivity and morale, strain our technology resources and introduce operational risks. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our moving increasingly towards a remote working environment, which may be less secure and more susceptible to hacking attacks.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays and disruptions experienced by our collaborators or other third-parties due to the COVID-19 pandemic and other global health outbreaks could adversely impact the ability of such parties to fulfill their obligations, which could affect product sales or the clinical development or regulatory approvals of product candidates under joint control.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and federal healthcare reform measures have been adopted in the past, and may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures and have a financial impact on our business that we cannot predict.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While it is not possible at this time to estimate the entirety of the impact that the COVID-19 pandemic and other global health outbreaks may have on our business, the broad global health outbreaks on our business activities may materially and adversely affect our business, supply chain and distribution systems, results of operations and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third-parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms and artificial intelligence based software presents new risks and challenges.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear and create uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on social media. We may also encounter criticism on social media regarding our company, management, product candidates or products. The immediacy of social media precludes us from having real-time control over postings made regarding us via social media, whether matters of fact or opinion. Our reputation could be damaged by negative publicity or if adverse information concerning us is posted on social media platforms or similar mediums, which we may not be able to reverse. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business. Additionally, the use of artificial intelligence (AI) based software is increasingly being used in the biopharmaceutical industry. Use of AI based software may lead to the release of confidential proprietary information which may impact our ability to realize the benefit of our intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Holding Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results are subject to significant fluctuations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenue, expense and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as the timing of charges and expense that we may take. We have recorded, or may be required to record, charges that include:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">impairments with respect to investments, fixed assets and long-lived assets, including IPR&amp;D and other intangible assets; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inventory write-downs for failed quality specifications, recurring charges for excess or obsolete inventory and charges for inventory write-downs relating to product suspensions, expirations or recalls; </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent consideration or our equity investments;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">bad debt expense and increased bad debt reserves;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">payments in connection with acquisitions, divestitures and other business development activities and under license and collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">failure to meet certain contractual commitments; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments in properties may not be fully realized.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. We may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate a property, we may incur significant cost, including facility closing costs, employee separation and retention expense, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investment portfolio is subject to market, interest and credit risk that may reduce its value.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a portfolio of marketable securities for investment of our cash as well as investments in equity securities of certain biotechnology companies. Changes in the value of our investment portfolio could adversely affect our earnings. The value of our investments may decline due to, among other things, increases in interest rates, downgrades of the bonds and other securities in our portfolio, negative company-specific news, biotechnology market sentiment, instability in the global financial markets that reduces the liquidity of securities in our portfolio, declines in the value of collateral underlying the securities in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time our Board of Directors authorizes share repurchase programs. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our applicable agreements. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. Additionally, the recently enacted IRA includes an excise tax on share repurchases, which will increase the cost of share repurchases. A reduction in repurchases under, or the completion of, our share repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to access the capital and credit markets on terms that are favorable to us.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets are experiencing, and have in the past experienced, extreme volatility and disruption, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our ability to access capital markets and incur additional debt in the future;</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development, research and development and mergers and acquisitions;&#160;and</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a disadvantage compared to our competitors that have less debt.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our collaboration agreements contain change in control provisions that may discourage a third-party from attempting to acquire us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates, including withholding taxes, in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate may be different than experienced in the past or our current expectations due to many factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, interpretations by tax authorities or other bodies with jurisdiction, the result of tax cases, changes in accounting for income taxes and changes in tax laws and regulations either prospectively or retrospectively and the effects of the integration of Reata. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enactment of some or all of the recommendations set forth or that may be forthcoming in the OECD&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; by tax authorities and economic blocs in the countries in which we operate, could unfavorably impact our effective tax rate. These initiatives focus on common international principles for the entitlement to taxation of global corporate profits and minimum global tax rates. Many countries have or are in the process of enacting legislation intended to implement the OECD GloBE Model Rules effective starting on January 1, 2024. The impact on the Company will depend on the exact nature of each country's GloBE legislation, guidance and regulations thereon and their application by tax authorities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business. Additionally, regulators are considering new environmental disclosure rules. For example, the SEC has proposed amendments to its disclosure rules regarding climate-related disclosure requirements. These proposed regulations may impact the manner in which we operate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_274"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our common stock repurchase activity under our 2020 Share Repurchase Program during the third quarter of 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price<br/>Paid&#160;per&#160;Share<br/>($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>as&#160;Part&#160;of&#160;Publicly<br/>Announced Programs<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value<br/>of Shares That May Yet Be Purchased Under<br/>Our Programs<br/>($ in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,050.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">August 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,050.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,050.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There were no share repurchases during the third quarter of 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 1.2 million and 3.6 million shares of our common stock at a cost of approximately $250.0 million and $750.0 million during the three and nine months ended September 30, 2022, respectively. There were no share repurchases of our common stock during the three and nine months ended September 30, 2023. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2023.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_277"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TRADING ARRANGEMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no trading arrangements for the purchase or sale of our securities entered into or terminated by our Directors or Officers during the third quarter of 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_280"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</span></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_283"></div><div style="-sec-extract:summary;margin-top:14pt;text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">EXHIBIT&#160;INDEX&#160;</span></div><div style="margin-top:19pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agreement and Plan of Merger, dated as of July 28, 2023, by and among Biogen Inc., River Acquisition, Inc. and Reata Pharmaceuticals, Inc. filed as Exhibit 2.1 to our Current Report on Form 8-K on July 31, 2023.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth Amended and Restated Bylaws of Biogen Inc. as filed as Exhibit 3.1 to our Current Report on Form 8-K on July 31, 2023.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement, dated as of August 28, 2023 among Biogen Inc., JPMorgan Chase Bank N.A., as administrative agent and the other lenders party thereto filed as Exhibit 10.1 to our Current Report on Form 8-K on September 1, 2023.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2023930xex311.htm">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2023930xex312.htm">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2023930xex321.htm">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended September 30, 2023, formatted in iXBRL (Inline Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flow, (v) the Condensed Consolidated Statements of Equity and (vi)&#160;Notes to Condensed Consolidated Financial Statements.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104++</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, formatted in Inline XBRL.</span></div></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">*&#160;&#160;&#160;&#160;The schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Biogen agrees to furnish supplementally a copy of such schedules and exhibits, or any section thereof, to the SEC upon request.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Filed herewith </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Furnished herewith</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i8325bdffeebc49d7b9475241af1c3c2e_286"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8325bdffeebc49d7b9475241af1c3c2e_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;padding-left:297pt;text-indent:-13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.590%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BIOGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November&#160;8, 2023 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>biib-2023930xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8d7bc1aefb9a4bcb8db7adb2809d7a83_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher A. Viehbacher, certify that&#58;</font></div><div style="margin-top:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;8, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher A. Viehbacher</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher A. Viehbacher</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>biib-2023930xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib220a607bd974dceb59ba41b23da184e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael R. McDonnell, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;8, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>biib-2023930xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i23637c5f1e4d41c5b702da159581a172_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;8, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher A. Viehbacher</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher A. Viehbacher</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal executive officer&#93;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;8, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal financial officer&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>biib-20230930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:067ab9af-2745-42fc-8c78-33206b6cc4f8,g:369ca811-9038-4e81-ba44-3ac1f044a248-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:biib="http://www.biogenidec.com/20230930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20230930">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited">
        <link:definition>0000002 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1">
        <link:definition>0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>0000004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquityStatement" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement">
        <link:definition>0000006 - Statement - Condensed Consolidated Statement of Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000007 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>0000008 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Dispositions" roleURI="http://www.biogenidec.com/role/Dispositions">
        <link:definition>0000009 - Disclosure - Dispositions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiatives" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives">
        <link:definition>0000010 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.biogenidec.com/role/Revenues">
        <link:definition>0000011 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>0000012 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill">
        <link:definition>0000013 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>0000014 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>0000015 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>0000016 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment">
        <link:definition>0000017 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.biogenidec.com/role/Leases">
        <link:definition>0000018 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Indebtedness" roleURI="http://www.biogenidec.com/role/Indebtedness">
        <link:definition>0000019 - Disclosure - Indebtedness</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>0000020 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.biogenidec.com/role/EarningsperShare">
        <link:definition>0000021 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedPayments" roleURI="http://www.biogenidec.com/role/SharebasedPayments">
        <link:definition>0000022 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>0000023 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>0000024 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships">
        <link:definition>0000025 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities">
        <link:definition>0000026 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>0000027 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.biogenidec.com/role/AcquisitionsTables">
        <link:definition>9954472 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables">
        <link:definition>9954473 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>9954474 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>9954475 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>9954476 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>9954477 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>9954478 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>9954479 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>9954480 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.biogenidec.com/role/EarningsperShareTables">
        <link:definition>9954481 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>9954482 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>9954483 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>9954484 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables">
        <link:definition>9954485 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9954486 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDetailsTextual" roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual">
        <link:definition>9954487 - Disclosure - Acquisitions (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsPurchasePriceConsiderationDetails" roleURI="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails">
        <link:definition>9954488 - Disclosure - Acquisitions - Purchase Price Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsPreliminatyPurchasePriceAllocationDetails" roleURI="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails">
        <link:definition>9954489 - Disclosure - Acquisitions Preliminaty Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DispositionsDetailsTextual" roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual">
        <link:definition>9954490 - Disclosure - Dispositions (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails">
        <link:definition>9954491 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails">
        <link:definition>9954492 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails">
        <link:definition>9954493 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails">
        <link:definition>9954494 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyproductDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails">
        <link:definition>9954495 - Disclosure - Revenues - Revenues by product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails1" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1">
        <link:definition>9954496 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails2" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2">
        <link:definition>9954497 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails">
        <link:definition>9954498 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesOtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails">
        <link:definition>9954499 - Disclosure - Revenues - Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails">
        <link:definition>9954500 - Disclosure - Revenues - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryComponentsofInventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails">
        <link:definition>9954501 - Disclosure - Inventory - Components of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNarrativeDetails" roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails">
        <link:definition>9954502 - Disclosure - Inventory - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails">
        <link:definition>9954503 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1">
        <link:definition>9954504 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>9954505 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>9954506 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
        <link:definition>9954507 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>9954508 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>9954509 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>9954510 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>9954511 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>9954512 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>9954513 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>9954514 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>9954515 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>9954516 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails">
        <link:definition>9954517 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetailsTextual" roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual">
        <link:definition>9954518 - Disclosure - Leases (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessDetails">
        <link:definition>9954519 - Disclosure - Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchasesDetails" roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails">
        <link:definition>9954520 - Disclosure - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>9954521 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>9954522 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareDetails" roleURI="http://www.biogenidec.com/role/EarningsperShareDetails">
        <link:definition>9954523 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>9954524 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>9954525 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>9954526 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>9954527 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>9954528 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>9954529 - Disclosure - Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsOCREVUSDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails">
        <link:definition>9954530 - Disclosure - Collaborative and Other Relationships - OCREVUS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsProfitSharingDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails">
        <link:definition>9954531 - Disclosure - Collaborative and Other Relationships - Profit Sharing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsEisaiDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails">
        <link:definition>9954532 - Disclosure - Collaborative and Other Relationships - Eisai (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails">
        <link:definition>9954533 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails">
        <link:definition>9954534 - Disclosure - Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails">
        <link:definition>9954535 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails">
        <link:definition>9954536 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails">
        <link:definition>9954537 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails">
        <link:definition>9954538 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails">
        <link:definition>9954539 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Sangamo Therapeutics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsOtherArrangementsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails">
        <link:definition>9954540 - Disclosure - Collaborative and Other Relationships - Other Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSamsungBioepisDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails">
        <link:definition>9954541 - Disclosure - Collaborative and Other Relationships - Samsung Bioepis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails">
        <link:definition>9954542 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>9954543 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="biib_BYOOVIZMember" abstract="true" name="BYOOVIZMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_TheCreditFacilityTerminatedMember" abstract="true" name="TheCreditFacilityTerminatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" abstract="false" name="EffectiveTaxRateReconciliationSaleOfSamsungBioepis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationInternationalReorganization" abstract="false" name="EffectiveTaxRateReconciliationInternationalReorganization" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_OtherAssetsMeasurementInput" abstract="false" name="OtherAssetsMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="biib_A3.15SeniorNotesdueMay12050Member" abstract="true" name="A3.15SeniorNotesdueMay12050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" abstract="false" name="FairValueIndefiniteLivedIntangibleAssetsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" abstract="false" name="RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IonisSangamoDenaliAndSageMember" abstract="true" name="IonisSangamoDenaliAndSageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_IMRALDIMember" abstract="true" name="IMRALDIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_WarehouseUtilitiesAndSupportSpaceMember" abstract="true" name="WarehouseUtilitiesAndSupportSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesNonCurrentMember" abstract="true" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ShareOfNetProfitFromSageTherapeuticsAmount" abstract="false" name="ShareOfNetProfitFromSageTherapeuticsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BIIB054Member" abstract="true" name="BIIB054Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_FacilityTypeDomain" abstract="true" name="FacilityTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_OtherAssetsCurrentFairValueDisclosure" abstract="false" name="OtherAssetsCurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SamsungBiosimilarAgreementMember" abstract="true" name="SamsungBiosimilarAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_SKYCLARYSMember" abstract="true" name="SKYCLARYSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_A125BroadwayBuildingSaleMember" abstract="true" name="A125BroadwayBuildingSaleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_OperatingLeaseRightOfUseAssetDerecognized" abstract="false" name="OperatingLeaseRightOfUseAssetDerecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PriorityReviewVoucherMember" abstract="true" name="PriorityReviewVoucherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PeriodOfCollaborationAgreement" abstract="false" name="PeriodOfCollaborationAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_PayablesToDivestitureOfInterestInJointVenture" abstract="false" name="PayablesToDivestitureOfInterestInJointVenture" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ERISAClassActionLitigaitonMember" abstract="true" name="ERISAClassActionLitigaitonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TysabriProductMember" abstract="true" name="TysabriProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_VUMERITYMember" abstract="true" name="VUMERITYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_MarketStockUnitsMember" abstract="true" name="MarketStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FacilityLocationAxis" abstract="true" name="FacilityLocationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" abstract="false" name="BusinessAcquisitionNumberOfCommonStockSharesAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="biib_OperatingLeaseLiabilityDerecognized" abstract="false" name="OperatingLeaseLiabilityDerecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ReserveforCashDiscountsMember" abstract="true" name="ReserveforCashDiscountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_MSProductRevenuesMember" abstract="true" name="MSProductRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_NoncontrollingInterestCapitalContribution" abstract="false" name="NoncontrollingInterestCapitalContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" abstract="false" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_UnrealizedLossOnDerivatives" abstract="false" name="UnrealizedLossOnDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" abstract="false" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_SalesTriggerGrossSalesThreshold" abstract="false" name="SalesTriggerGrossSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InterferonMember" abstract="true" name="InterferonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_SpinalMuscularAtrophyMember" abstract="true" name="SpinalMuscularAtrophyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" abstract="true" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_ContractOptionExerciseFee" abstract="false" name="ContractOptionExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SolothurnSwitzerlandMember" abstract="true" name="SolothurnSwitzerlandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_GovernmentSecuritiesNonCurrentMember" abstract="true" name="GovernmentSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_StrategicInvestmentsMember" abstract="true" name="StrategicInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" abstract="false" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FacilityTypeAxis" abstract="true" name="FacilityTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_PretaxProfitSharingFormulaTableTextBlock" abstract="false" name="PretaxProfitSharingFormulaTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_NumberOfSquareFeet" abstract="false" name="NumberOfSquareFeet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" abstract="false" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" abstract="false" name="ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_StrategicInvestmentPortfolio" abstract="false" name="StrategicInvestmentPortfolio" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" abstract="true" name="ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_PercentageOfFutureDevelopmentCosts" abstract="false" name="PercentageOfFutureDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_AccountsPayableToCollaborator" abstract="false" name="AccountsPayableToCollaborator" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A2.25SeniorNotesdueMay12030Member" abstract="true" name="A2.25SeniorNotesdueMay12030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ExpenseIncurredByCollaboration" abstract="false" name="ExpenseIncurredByCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" abstract="false" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" abstract="false" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_RoyaltiesClaimed" abstract="false" name="RoyaltiesClaimed" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CollaborativeArrangementProfitLossSharingComponentsDomain" abstract="true" name="CollaborativeArrangementProfitLossSharingComponentsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_InvestmentsInVariableInterestEntitiesAbstract" abstract="true" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_ContingentCommercializedRightsNumberOfProducts" abstract="false" name="ContingentCommercializedRightsNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_BiosimilarsMember" abstract="true" name="BiosimilarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_AverageMaturityOfMarketableSecurities" abstract="false" name="AverageMaturityOfMarketableSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_OutLicensedPatentsMember" abstract="true" name="OutLicensedPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BENEPALIMember" abstract="true" name="BENEPALIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" abstract="false" name="GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" abstract="true" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_AccruedPaymentToTerminationAgreement" abstract="false" name="AccruedPaymentToTerminationAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SPINRAZAMember" abstract="true" name="SPINRAZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" abstract="false" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_OtherrevenuesAbstract" abstract="true" name="OtherrevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" abstract="false" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember" abstract="true" name="InventoryIdleCapacityChargesAndContractualCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_Collaborationprofitlosssharing" abstract="false" name="Collaborationprofitlosssharing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_TheCreditFacilityMember" abstract="true" name="TheCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_Reductioninroyaltyrate" abstract="false" name="Reductioninroyaltyrate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" abstract="false" name="EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_BusinessOverviewPolicyTextBlock" abstract="false" name="BusinessOverviewPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_GovernmentSecuritiesCurrentMember" abstract="true" name="GovernmentSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ContractualAdjustmentsMember" abstract="true" name="ContractualAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_Expensereflectedwithinstatementsofincome" abstract="false" name="Expensereflectedwithinstatementsofincome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationLitigationAgreement" abstract="false" name="EffectiveTaxRateReconciliationLitigationAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" abstract="true" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_EquityMethodInvestmentsExpectedProfitShare" abstract="false" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" abstract="false" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AccountsReceivableFromCollaborator" abstract="false" name="AccountsReceivableFromCollaborator" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AcceleratedDepreciationAndOtherCostsMember" abstract="true" name="AcceleratedDepreciationAndOtherCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" abstract="false" name="BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" abstract="false" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationGILTItax" abstract="false" name="EffectiveTaxRateReconciliationGILTItax" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_NeurimmuneMember" abstract="true" name="NeurimmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesDomain" abstract="true" name="FutureContingentMilestoneTypesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" abstract="false" name="Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CashflowsoperatingexpensesMember" abstract="true" name="CashflowsoperatingexpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" abstract="false" name="CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CollaborativeArrangementProfitLossSharing" abstract="false" name="CollaborativeArrangementProfitLossSharing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A2022CostSavingInitiativesMember" abstract="true" name="A2022CostSavingInitiativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinStockMember" abstract="true" name="PerformanceStockUnitsSettledinStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ResearchAndDevelopmentAssetDomain" abstract="true" name="ResearchAndDevelopmentAssetDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_RituxanMember" abstract="true" name="RituxanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OtherClinicalProgramsMember" abstract="true" name="OtherClinicalProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TECFIDERAMember" abstract="true" name="TECFIDERAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" abstract="false" name="Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ReataPharmaceuticalsIncMember" abstract="true" name="ReataPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PaymentDueAtSecondAnniversaryMember" abstract="true" name="PaymentDueAtSecondAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_FacilityLocationDomain" abstract="true" name="FacilityLocationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_AggregateGrossIdleCapacityCharges" abstract="false" name="AggregateGrossIdleCapacityCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CollaborationProfitSharingMember" abstract="true" name="CollaborationProfitSharingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" abstract="false" name="AmortizationAndImpairmentOfAcquiredIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DistributorOneMember" abstract="true" name="DistributorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_CashflowsrevenueMember" abstract="true" name="CashflowsrevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_PaymentDueAtFirstAnniversaryMember" abstract="true" name="PaymentDueAtFirstAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ShorttermderivativeMember" abstract="true" name="ShorttermderivativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesAxis" abstract="true" name="FutureContingentMilestoneTypesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_RocheGroupGenentechMember" abstract="true" name="RocheGroupGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" abstract="true" name="TheCreditFacilityFloatingRateThreeYearTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" abstract="false" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_E2609andBAN2401Member" abstract="true" name="E2609andBAN2401Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" abstract="false" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" abstract="false" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" abstract="false" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ResearchanddevelopmentassetAxis" abstract="true" name="ResearchanddevelopmentassetAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_DerivativeMaturityAxis" abstract="true" name="DerivativeMaturityAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" abstract="false" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FumarateMember" abstract="true" name="FumarateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_Expenseincurredbythecollaboration" abstract="false" name="Expenseincurredbythecollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PLEGRIDYMember" abstract="true" name="PLEGRIDYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_FAMPYRAMember" abstract="true" name="FAMPYRAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BiologicsManufacturingMember" abstract="true" name="BiologicsManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_LEQEMBICollaborationMember" abstract="true" name="LEQEMBICollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_A2023CostSavingInitiativesMember" abstract="true" name="A2023CostSavingInitiativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DebtInstrumentRedemptionRate" abstract="false" name="DebtInstrumentRedemptionRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_Collaborationexpensesaccrual" abstract="false" name="Collaborationexpensesaccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A3250SeniorNotesDueFebruary152051Member" abstract="true" name="A3250SeniorNotesDueFebruary152051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_AVONEXMember" abstract="true" name="AVONEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_NumberOfWholesalers" abstract="false" name="NumberOfWholesalers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_ShareOfNonControlingInterestRecognized" abstract="false" name="ShareOfNonControlingInterestRecognized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_CoPromotionProfitSharingFormulaTableTextBlock" abstract="false" name="CoPromotionProfitSharingFormulaTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" abstract="false" name="IncomeLossFromEquityMethodInvestmentsNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OperatingLeaseArea" abstract="false" name="OperatingLeaseArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="biib_DerivativeMaturityDomain" abstract="true" name="DerivativeMaturityDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_AdditionalMilestonePayment" abstract="false" name="AdditionalMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A2020ShareRepurchaseProgramMember" abstract="true" name="A2020ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" abstract="false" name="DerivativeInstrumentsUnrealizedGainLossTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_MosunetuzumabMember" abstract="true" name="MosunetuzumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_CollaborativeArrangementProfitLossSharingComponentsAxis" abstract="true" name="CollaborativeArrangementProfitLossSharingComponentsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_DivestituresAbstract" abstract="true" name="DivestituresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_FUMADERMAndADUHELMMember" abstract="true" name="FUMADERMAndADUHELMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ResearchAndDevelopmentCostsPercentage" abstract="false" name="ResearchAndDevelopmentCostsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_SageTherapeuticsIncMember" abstract="true" name="SageTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_UCBPharmaS.A.Member" abstract="true" name="UCBPharmaS.A.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_WorkforceReductionMember" abstract="true" name="WorkforceReductionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ShareOfCoPromotionProfits" abstract="false" name="ShareOfCoPromotionProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_GAZYVAMember" abstract="true" name="GAZYVAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OtherresearchanddiscoveryMember" abstract="true" name="OtherresearchanddiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" abstract="false" name="EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="biib_OtherrevenuesTableTextBlock" abstract="false" name="OtherrevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_LenderDisputeMember" abstract="true" name="LenderDisputeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" abstract="false" name="FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_TheCreditFacilityFloatingRate364DayTrancheMember" abstract="true" name="TheCreditFacilityFloatingRate364DayTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" abstract="false" name="PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CollaborationAgreementTerm" abstract="false" name="CollaborationAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BasicAndDilutedEarningsPerShareAbstract" abstract="true" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_DenaliTherapeuticsIncMember" abstract="true" name="DenaliTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinCashMember" abstract="true" name="PerformanceStockUnitsSettledinCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_GenentechMember" abstract="true" name="GenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TimeVestedRestrictedStockUnitsMember" abstract="true" name="TimeVestedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" abstract="false" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EquityAwardsOfAcquiredCompanyMember" abstract="true" name="EquityAwardsOfAcquiredCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FLIXABIMember" abstract="true" name="FLIXABIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_OCREVUSMember" abstract="true" name="OCREVUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" abstract="false" name="PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_DistributorTwoMember" abstract="true" name="DistributorTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_BardoxoloneSecuritiesMember" abstract="true" name="BardoxoloneSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_InventoryNetCurrentAndNoncurrent" abstract="false" name="InventoryNetCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_RoyaltyAttributedToOCREVUSMember" abstract="true" name="RoyaltyAttributedToOCREVUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_UnrealizedGainOnDerivatives" abstract="false" name="UnrealizedGainOnDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AdministrativeSpaceMember" abstract="true" name="AdministrativeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" abstract="false" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CentersForMedicareAndMedicaidServiceMember" abstract="true" name="CentersForMedicareAndMedicaidServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_Revenuesfromanticd20therapeuticprogramsMember" abstract="true" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ADUHELMMember" abstract="true" name="ADUHELMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" abstract="false" name="ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InterestInSubsidiary" abstract="false" name="InterestInSubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="biib_EquitySecuritiesCurrentMember" abstract="true" name="EquitySecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesNonCurrentMember" abstract="true" name="EquitySecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ContractManufacturingAndOtherRevenueMember" abstract="true" name="ContractManufacturingAndOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="biib_ShareOfNetProfitFromSageTherapeuticsPercent" abstract="false" name="ShareOfNetProfitFromSageTherapeuticsPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_A2023And2022CostSavingInitiativesMember" abstract="true" name="A2023And2022CostSavingInitiativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" abstract="false" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="biib_GainLossOnRestructuringCharges" abstract="false" name="GainLossOnRestructuringCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesCurrentMember" abstract="true" name="CorporateDebtSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>biib-20230930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:067ab9af-2745-42fc-8c78-33206b6cc4f8,g:369ca811-9038-4e81-ba44-3ac1f044a248-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20230930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dab37e44-a726-42dd-8625-de05b13b5646" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9cd0d47a-0ecb-43c7-9b5f-97540c5c059e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_dab37e44-a726-42dd-8625-de05b13b5646" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9cd0d47a-0ecb-43c7-9b5f-97540c5c059e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cc11159a-0ab6-472f-a140-d9c0673dbfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_dab37e44-a726-42dd-8625-de05b13b5646" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cc11159a-0ab6-472f-a140-d9c0673dbfa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_41252d9c-b4f4-4a4e-8d52-0755cedde228" xlink:href="biib-20230930.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_dab37e44-a726-42dd-8625-de05b13b5646" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_41252d9c-b4f4-4a4e-8d52-0755cedde228" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f2133644-0f3f-48e5-9573-4f87e6463c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4f6565c6-71e7-4176-b51c-cb8689e512a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f2133644-0f3f-48e5-9573-4f87e6463c1e" xlink:to="loc_us-gaap_Revenues_4f6565c6-71e7-4176-b51c-cb8689e512a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8c597f04-f00e-4525-9e78-df8e778bfda8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f2133644-0f3f-48e5-9573-4f87e6463c1e" xlink:to="loc_us-gaap_CostsAndExpenses_8c597f04-f00e-4525-9e78-df8e778bfda8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0dad8bb4-a731-4cb8-b3fb-7c56f238bc12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d0f8e2be-97f4-444c-8c0a-5c0af708f416" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0dad8bb4-a731-4cb8-b3fb-7c56f238bc12" xlink:to="loc_us-gaap_ProfitLoss_d0f8e2be-97f4-444c-8c0a-5c0af708f416" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4f2da177-4b5c-4a9f-ac27-4eacf7f7b58a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0dad8bb4-a731-4cb8-b3fb-7c56f238bc12" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4f2da177-4b5c-4a9f-ac27-4eacf7f7b58a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3c630acd-7e3f-423a-9f7a-7f7750b1621c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_92bb7c26-7619-4bfb-a0ea-c6e89a07df38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3c630acd-7e3f-423a-9f7a-7f7750b1621c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_92bb7c26-7619-4bfb-a0ea-c6e89a07df38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_9f019e5d-60d4-493b-a09e-37daf528324d" xlink:href="biib-20230930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3c630acd-7e3f-423a-9f7a-7f7750b1621c" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_9f019e5d-60d4-493b-a09e-37daf528324d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_439e1443-dfe3-48aa-944b-38e6e135fa1c" xlink:href="biib-20230930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3c630acd-7e3f-423a-9f7a-7f7750b1621c" xlink:to="loc_biib_Collaborationprofitlosssharing_439e1443-dfe3-48aa-944b-38e6e135fa1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9d59ce71-a3e3-4471-a8df-5a04687d3958" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3c630acd-7e3f-423a-9f7a-7f7750b1621c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9d59ce71-a3e3-4471-a8df-5a04687d3958" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_30d309a6-9e45-4189-af4f-5f2c550e72ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3c630acd-7e3f-423a-9f7a-7f7750b1621c" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_30d309a6-9e45-4189-af4f-5f2c550e72ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a2874582-8af8-4e74-aad0-d7705f0d0a40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3c630acd-7e3f-423a-9f7a-7f7750b1621c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a2874582-8af8-4e74-aad0-d7705f0d0a40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_16b56539-1afd-47f6-b347-9a5631a15fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3c630acd-7e3f-423a-9f7a-7f7750b1621c" xlink:to="loc_us-gaap_RestructuringCharges_16b56539-1afd-47f6-b347-9a5631a15fc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_972b1336-9728-4e05-972d-e63d106f11b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3c630acd-7e3f-423a-9f7a-7f7750b1621c" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_972b1336-9728-4e05-972d-e63d106f11b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_82ace880-a629-4b63-9377-5184d60f1c95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3c630acd-7e3f-423a-9f7a-7f7750b1621c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_82ace880-a629-4b63-9377-5184d60f1c95" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20230930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_09cea506-e0ab-4516-a01f-5c2735866755" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_77a04fdb-b35a-4ffb-8b8f-6d8caf79f40e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_09cea506-e0ab-4516-a01f-5c2735866755" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_77a04fdb-b35a-4ffb-8b8f-6d8caf79f40e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_20f26d55-edd9-4b88-8bb4-6d9a8ca6ab95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_09cea506-e0ab-4516-a01f-5c2735866755" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_20f26d55-edd9-4b88-8bb4-6d9a8ca6ab95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7e31af1b-d973-45b2-b44b-c8a14799586c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6251de30-4b0d-48bd-8452-28164b250916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7e31af1b-d973-45b2-b44b-c8a14799586c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6251de30-4b0d-48bd-8452-28164b250916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ad3340a1-c03f-4c92-b872-a49bfec34aac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7e31af1b-d973-45b2-b44b-c8a14799586c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ad3340a1-c03f-4c92-b872-a49bfec34aac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_e6cf1fa6-e694-48f0-ae6d-45b74e8072b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7e31af1b-d973-45b2-b44b-c8a14799586c" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_e6cf1fa6-e694-48f0-ae6d-45b74e8072b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_aff46267-8ab8-481c-a186-c4d9704deff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7e31af1b-d973-45b2-b44b-c8a14799586c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_aff46267-8ab8-481c-a186-c4d9704deff4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_94c4643b-899c-45d4-86b7-6911ba676ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7e31af1b-d973-45b2-b44b-c8a14799586c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_94c4643b-899c-45d4-86b7-6911ba676ad9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20230930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_40ab582a-ee5d-42e4-9989-c1cdefd7d0da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4bc01dd0-bd04-4221-9ed6-caf14d1135ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_40ab582a-ee5d-42e4-9989-c1cdefd7d0da" xlink:to="loc_us-gaap_NetIncomeLoss_4bc01dd0-bd04-4221-9ed6-caf14d1135ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2e3e271b-ecbc-4c6d-b9a2-206b68d6d200" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_40ab582a-ee5d-42e4-9989-c1cdefd7d0da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2e3e271b-ecbc-4c6d-b9a2-206b68d6d200" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20230930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8316609f-90d7-463a-bb4c-707a801c1981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4ff7e5b6-a0b7-4c10-8bc8-95c364d5a1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8316609f-90d7-463a-bb4c-707a801c1981" xlink:to="loc_us-gaap_LiabilitiesCurrent_4ff7e5b6-a0b7-4c10-8bc8-95c364d5a1f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e6421836-950d-4166-ae1c-2b76d0d96c08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8316609f-90d7-463a-bb4c-707a801c1981" xlink:to="loc_us-gaap_LongTermDebt_e6421836-950d-4166-ae1c-2b76d0d96c08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f5bd19fa-2622-4a0c-89ea-50b953fdb4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8316609f-90d7-463a-bb4c-707a801c1981" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f5bd19fa-2622-4a0c-89ea-50b953fdb4ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6e5dec7b-b96d-4bba-b029-8dc01397bae9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8316609f-90d7-463a-bb4c-707a801c1981" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6e5dec7b-b96d-4bba-b029-8dc01397bae9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7ac7dc60-b8d6-42d4-a633-02fef622a197" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8316609f-90d7-463a-bb4c-707a801c1981" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7ac7dc60-b8d6-42d4-a633-02fef622a197" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9e50afec-595f-4d90-b720-bd7c510ab63b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e1954488-f2b6-492d-8083-9b3bba1ab711" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9e50afec-595f-4d90-b720-bd7c510ab63b" xlink:to="loc_us-gaap_PreferredStockValue_e1954488-f2b6-492d-8083-9b3bba1ab711" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b97b25eb-b4b6-43f7-81e1-bf60a42359ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9e50afec-595f-4d90-b720-bd7c510ab63b" xlink:to="loc_us-gaap_CommonStockValue_b97b25eb-b4b6-43f7-81e1-bf60a42359ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_84885d8b-4158-44b8-9a75-f45b053deb66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9e50afec-595f-4d90-b720-bd7c510ab63b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_84885d8b-4158-44b8-9a75-f45b053deb66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8bd5e163-f0e3-41e0-a6ed-cd4d4c09152f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9e50afec-595f-4d90-b720-bd7c510ab63b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8bd5e163-f0e3-41e0-a6ed-cd4d4c09152f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e3b335cc-4965-4a7b-8640-afbccc7908fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9e50afec-595f-4d90-b720-bd7c510ab63b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e3b335cc-4965-4a7b-8640-afbccc7908fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_a2f409fa-19cf-48cf-b77c-92b2096ef99a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9e50afec-595f-4d90-b720-bd7c510ab63b" xlink:to="loc_us-gaap_TreasuryStockValue_a2f409fa-19cf-48cf-b77c-92b2096ef99a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_548f0e26-1c25-45bd-93d7-d736548a5d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2618ec93-a0a4-4102-8b60-dab234565c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_548f0e26-1c25-45bd-93d7-d736548a5d1b" xlink:to="loc_us-gaap_AssetsCurrent_2618ec93-a0a4-4102-8b60-dab234565c2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_1469f094-838e-4ddd-bfa0-7b423deea3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_548f0e26-1c25-45bd-93d7-d736548a5d1b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_1469f094-838e-4ddd-bfa0-7b423deea3cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8aa5c409-982f-4e80-9720-4a6b1bc54edf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_548f0e26-1c25-45bd-93d7-d736548a5d1b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8aa5c409-982f-4e80-9720-4a6b1bc54edf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7cc752c8-34ad-4907-9ad7-6dc383c521d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_548f0e26-1c25-45bd-93d7-d736548a5d1b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7cc752c8-34ad-4907-9ad7-6dc383c521d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_43a83a87-2052-4db7-ae32-8bb524d47c18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_548f0e26-1c25-45bd-93d7-d736548a5d1b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_43a83a87-2052-4db7-ae32-8bb524d47c18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0dac1bc3-4498-4fc0-aa5a-46f9a0d42520" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_548f0e26-1c25-45bd-93d7-d736548a5d1b" xlink:to="loc_us-gaap_Goodwill_0dac1bc3-4498-4fc0-aa5a-46f9a0d42520" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_6835c158-3277-436c-af1f-107f9d54edae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_548f0e26-1c25-45bd-93d7-d736548a5d1b" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_6835c158-3277-436c-af1f-107f9d54edae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_70cd691f-4365-4a29-9415-2c14d18e9c64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_548f0e26-1c25-45bd-93d7-d736548a5d1b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_70cd691f-4365-4a29-9415-2c14d18e9c64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_69674a50-8565-47b4-ac8b-4c00215e1a81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ba83d0f-b181-487d-9ff0-f487cfbcb51e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_69674a50-8565-47b4-ac8b-4c00215e1a81" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ba83d0f-b181-487d-9ff0-f487cfbcb51e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_16799e31-9909-4284-a978-7380bf47a0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_69674a50-8565-47b4-ac8b-4c00215e1a81" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_16799e31-9909-4284-a978-7380bf47a0a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_060ae956-28b0-4431-8cae-3461ecbd1003" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_69674a50-8565-47b4-ac8b-4c00215e1a81" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_060ae956-28b0-4431-8cae-3461ecbd1003" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4bf64a0a-c45c-4227-91fc-4c2b1c3bf185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_69674a50-8565-47b4-ac8b-4c00215e1a81" xlink:to="loc_us-gaap_InventoryNet_4bf64a0a-c45c-4227-91fc-4c2b1c3bf185" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_fda53403-9374-4098-a018-9227147c1edf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_69674a50-8565-47b4-ac8b-4c00215e1a81" xlink:to="loc_us-gaap_OtherAssetsCurrent_fda53403-9374-4098-a018-9227147c1edf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63c7bbf0-cd5b-4564-8c06-af1668b52793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_623ba686-f150-4b09-828c-8cd322f7c516" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63c7bbf0-cd5b-4564-8c06-af1668b52793" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_623ba686-f150-4b09-828c-8cd322f7c516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0c524aae-167d-44c0-985d-d6a56958cb87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63c7bbf0-cd5b-4564-8c06-af1668b52793" xlink:to="loc_us-gaap_Liabilities_0c524aae-167d-44c0-985d-d6a56958cb87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7367dcd4-f8f6-4cd4-ad1a-5995ce1166cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63c7bbf0-cd5b-4564-8c06-af1668b52793" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7367dcd4-f8f6-4cd4-ad1a-5995ce1166cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb213498-7dbb-4ef4-84e5-753c505d7343" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c1cc571d-5b2b-41df-b8fa-2408507291c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb213498-7dbb-4ef4-84e5-753c505d7343" xlink:to="loc_us-gaap_StockholdersEquity_c1cc571d-5b2b-41df-b8fa-2408507291c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_137d93cc-125e-414b-9afa-0e3121b96247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb213498-7dbb-4ef4-84e5-753c505d7343" xlink:to="loc_us-gaap_MinorityInterest_137d93cc-125e-414b-9afa-0e3121b96247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_513a3c19-a98b-4ff7-9e24-89c66a18bf57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_17cf3049-ba65-4ee1-b628-c9e7bb25b4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_513a3c19-a98b-4ff7-9e24-89c66a18bf57" xlink:to="loc_us-gaap_NotesPayableCurrent_17cf3049-ba65-4ee1-b628-c9e7bb25b4f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1db9a19d-bbc2-4475-8cfc-0fb6ea944762" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_513a3c19-a98b-4ff7-9e24-89c66a18bf57" xlink:to="loc_us-gaap_AccountsPayableCurrent_1db9a19d-bbc2-4475-8cfc-0fb6ea944762" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_e580f893-9b52-49b3-9c87-ce00b4415983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_513a3c19-a98b-4ff7-9e24-89c66a18bf57" xlink:to="loc_us-gaap_TaxesPayableCurrent_e580f893-9b52-49b3-9c87-ce00b4415983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ab147bac-e94e-4d05-9e6d-19bf327f2489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_513a3c19-a98b-4ff7-9e24-89c66a18bf57" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ab147bac-e94e-4d05-9e6d-19bf327f2489" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20230930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_857def4f-100c-4ba3-a20f-4a6becc1672c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_857def4f-100c-4ba3-a20f-4a6becc1672c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a6dc6ab2-e5c0-49f4-b2b7-f3df18fc4fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:to="loc_us-gaap_ShareBasedCompensation_a6dc6ab2-e5c0-49f4-b2b7-f3df18fc4fb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_098cf693-8250-4a24-9989-81cf35fb467e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_098cf693-8250-4a24-9989-81cf35fb467e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_874f0cde-4752-4d38-98a2-a7d988b35c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_874f0cde-4752-4d38-98a2-a7d988b35c1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3681fb50-416e-416d-a87c-12905470286a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3681fb50-416e-416d-a87c-12905470286a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_56dfc466-85c7-4953-8b77-221df20ddb39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_56dfc466-85c7-4953-8b77-221df20ddb39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0cf702da-b4a5-487f-81a2-21cd3ffeab0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0cf702da-b4a5-487f-81a2-21cd3ffeab0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_e313390a-5a34-4f72-a98e-b8dcd3a61ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:to="loc_us-gaap_InventoryWriteDown_e313390a-5a34-4f72-a98e-b8dcd3a61ff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_42d140ef-8c3e-4dc8-a118-74028e87eeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_42d140ef-8c3e-4dc8-a118-74028e87eeb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f7201c7b-8600-4185-9bd0-e1dff720e662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f7201c7b-8600-4185-9bd0-e1dff720e662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_feef1d66-4652-44e1-bb75-41350cacbaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:to="loc_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_feef1d66-4652-44e1-bb75-41350cacbaf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_044a581b-6235-4b72-8840-65e08931a947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_044a581b-6235-4b72-8840-65e08931a947" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_f6c92486-22c0-4d41-a8eb-609d68dd5b52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_f6c92486-22c0-4d41-a8eb-609d68dd5b52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_36bd45d6-08d1-4a43-a44e-c2e0f4785d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:to="loc_us-gaap_ProfitLoss_36bd45d6-08d1-4a43-a44e-c2e0f4785d8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8de4254e-2804-471d-a9a9-0971f1d617a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8de4254e-2804-471d-a9a9-0971f1d617a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_37f08d6b-6181-40dd-92d8-74388616d571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e4aa733-6cb4-4fd3-9d97-9e2d4144a149" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_37f08d6b-6181-40dd-92d8-74388616d571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c91a4f5-33c7-4049-bb22-07bc3752e55b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f56f485f-d135-4f1a-a7d8-ff6cb5f4be9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c91a4f5-33c7-4049-bb22-07bc3752e55b" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f56f485f-d135-4f1a-a7d8-ff6cb5f4be9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_68717c59-218c-4851-8166-f0fa541f8f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c91a4f5-33c7-4049-bb22-07bc3752e55b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_68717c59-218c-4851-8166-f0fa541f8f0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a490ddb5-a65c-4122-9f2d-f0f5255ea3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c91a4f5-33c7-4049-bb22-07bc3752e55b" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a490ddb5-a65c-4122-9f2d-f0f5255ea3d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_b0cc685c-ea79-4d33-aed7-991bc5f5c3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c91a4f5-33c7-4049-bb22-07bc3752e55b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_b0cc685c-ea79-4d33-aed7-991bc5f5c3d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7e939536-dea9-41f8-96d9-b635c00974e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c91a4f5-33c7-4049-bb22-07bc3752e55b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7e939536-dea9-41f8-96d9-b635c00974e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_87f756b5-08b5-43c3-9753-23d43f1d7071" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c91a4f5-33c7-4049-bb22-07bc3752e55b" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_87f756b5-08b5-43c3-9753-23d43f1d7071" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18ce4a86-318a-49e6-8f73-022b7f8c7abe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_dc757ffa-b0c1-442f-8d79-2d4a8be33718" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18ce4a86-318a-49e6-8f73-022b7f8c7abe" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_dc757ffa-b0c1-442f-8d79-2d4a8be33718" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_7376d4d0-766e-47de-bca9-3eb64e20fbdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18ce4a86-318a-49e6-8f73-022b7f8c7abe" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_7376d4d0-766e-47de-bca9-3eb64e20fbdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6227e65d-9ffb-42b8-a401-303dde31ac6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18ce4a86-318a-49e6-8f73-022b7f8c7abe" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6227e65d-9ffb-42b8-a401-303dde31ac6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8c7a719c-156d-4ddf-923e-5fb735e73f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18ce4a86-318a-49e6-8f73-022b7f8c7abe" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8c7a719c-156d-4ddf-923e-5fb735e73f5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_12786160-8ed4-4222-8d39-5270faf0ffe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18ce4a86-318a-49e6-8f73-022b7f8c7abe" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_12786160-8ed4-4222-8d39-5270faf0ffe6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_14fee342-4c3c-4a6d-af27-faa49c8af58f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18ce4a86-318a-49e6-8f73-022b7f8c7abe" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_14fee342-4c3c-4a6d-af27-faa49c8af58f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b7764738-0672-4331-a209-0fb07bff71ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18ce4a86-318a-49e6-8f73-022b7f8c7abe" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b7764738-0672-4331-a209-0fb07bff71ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_16eaef49-5a89-4c52-9eeb-37a1edbc01b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_18ce4a86-318a-49e6-8f73-022b7f8c7abe" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_16eaef49-5a89-4c52-9eeb-37a1edbc01b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_428bc43d-12de-4207-94a1-4dc71e22c24a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0f8a55b8-41b7-4ca5-8dcc-20b09db65032" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_428bc43d-12de-4207-94a1-4dc71e22c24a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0f8a55b8-41b7-4ca5-8dcc-20b09db65032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5a9e544-813d-4e42-b7ba-a3df6348406b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_428bc43d-12de-4207-94a1-4dc71e22c24a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5a9e544-813d-4e42-b7ba-a3df6348406b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bd2c53ab-2f45-4ea8-94be-a86521556d07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_428bc43d-12de-4207-94a1-4dc71e22c24a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bd2c53ab-2f45-4ea8-94be-a86521556d07" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#AcquisitionsPreliminatyPurchasePriceAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_69f0c5b0-d7e7-495c-a6a3-1104a860722d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7bcb572f-c74b-4eb5-ba31-c0a074f92218" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_69f0c5b0-d7e7-495c-a6a3-1104a860722d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7bcb572f-c74b-4eb5-ba31-c0a074f92218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3c906cb5-483e-4870-8dea-146fa781ae17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_69f0c5b0-d7e7-495c-a6a3-1104a860722d" xlink:to="loc_us-gaap_Goodwill_3c906cb5-483e-4870-8dea-146fa781ae17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9a383f22-eb84-4240-bd74-a34881c510b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_94232d55-8b63-4cf4-bd2e-9a91669240a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9a383f22-eb84-4240-bd74-a34881c510b1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_94232d55-8b63-4cf4-bd2e-9a91669240a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_19cef5e8-71cb-4908-8d92-325273c8dcb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9a383f22-eb84-4240-bd74-a34881c510b1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_19cef5e8-71cb-4908-8d92-325273c8dcb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_1b5115cb-1a11-4da5-b7c6-84b5cefff0b7" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9a383f22-eb84-4240-bd74-a34881c510b1" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_1b5115cb-1a11-4da5-b7c6-84b5cefff0b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_b581c67d-52af-4acd-925c-aac40d3dd5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9a383f22-eb84-4240-bd74-a34881c510b1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_b581c67d-52af-4acd-925c-aac40d3dd5d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_3cf88950-e74d-4ddf-a49a-9a7a36160196" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9a383f22-eb84-4240-bd74-a34881c510b1" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_3cf88950-e74d-4ddf-a49a-9a7a36160196" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_951d057c-d694-4d4d-86b6-307e09c20eee" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9a383f22-eb84-4240-bd74-a34881c510b1" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_951d057c-d694-4d4d-86b6-307e09c20eee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_a356ce7e-e7db-4e3b-8ffa-eb0eeedb8031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9a383f22-eb84-4240-bd74-a34881c510b1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_a356ce7e-e7db-4e3b-8ffa-eb0eeedb8031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_13d4969c-a707-414b-8bbb-677a5101b292" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9a383f22-eb84-4240-bd74-a34881c510b1" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_13d4969c-a707-414b-8bbb-677a5101b292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b7354e2f-019b-4a20-8a5a-d9bfa12efd07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9a383f22-eb84-4240-bd74-a34881c510b1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b7354e2f-019b-4a20-8a5a-d9bfa12efd07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_27e5d174-1b8c-4a69-bab2-76b59384ffcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9a383f22-eb84-4240-bd74-a34881c510b1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_27e5d174-1b8c-4a69-bab2-76b59384ffcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_22b629b1-fd58-4368-aba2-1c4baffb6b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9a383f22-eb84-4240-bd74-a34881c510b1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_22b629b1-fd58-4368-aba2-1c4baffb6b4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_28a9c6e8-116d-4dc2-947e-3e48629845a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9a383f22-eb84-4240-bd74-a34881c510b1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_28a9c6e8-116d-4dc2-947e-3e48629845a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6829d6c3-8bc9-4de0-91d1-dbe398a2802b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_64bd7961-7908-4392-acb6-21a1dc982baa" xlink:href="biib-20230930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_6829d6c3-8bc9-4de0-91d1-dbe398a2802b" xlink:to="loc_biib_ShareOfCoPromotionProfits_64bd7961-7908-4392-acb6-21a1dc982baa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#InventoryComponentsofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent_4a44af7e-1a6e-4414-b1f4-4c3b0ca99d32" xlink:href="biib-20230930.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_78221688-8336-4b3e-adfb-d64255795767" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent_4a44af7e-1a6e-4414-b1f4-4c3b0ca99d32" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_78221688-8336-4b3e-adfb-d64255795767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b2402311-c834-4159-8eb0-040d4fa33d02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent_4a44af7e-1a6e-4414-b1f4-4c3b0ca99d32" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b2402311-c834-4159-8eb0-040d4fa33d02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_17136b85-286a-409c-9239-fb407535cc18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent_4a44af7e-1a6e-4414-b1f4-4c3b0ca99d32" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_17136b85-286a-409c-9239-fb407535cc18" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0624d109-b1d8-48ae-8f09-3713e4e6e75c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fc73e0df-f58c-4c9d-a2df-071691f3de1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0624d109-b1d8-48ae-8f09-3713e4e6e75c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fc73e0df-f58c-4c9d-a2df-071691f3de1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1c8246f0-f070-472e-9b01-355bf94c8327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0624d109-b1d8-48ae-8f09-3713e4e6e75c" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1c8246f0-f070-472e-9b01-355bf94c8327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e1ded026-57fc-4447-b29a-64435283b632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9659e090-c66c-4add-93d6-62ca33bf06b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e1ded026-57fc-4447-b29a-64435283b632" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9659e090-c66c-4add-93d6-62ca33bf06b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0de01d37-6f25-46cc-a9a2-edc9c66f300c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e1ded026-57fc-4447-b29a-64435283b632" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0de01d37-6f25-46cc-a9a2-edc9c66f300c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_000bd0f7-1e16-4490-8623-cf0bf93d3451" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e8e9ca29-e075-4621-bab5-ccae2a9094c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_000bd0f7-1e16-4490-8623-cf0bf93d3451" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e8e9ca29-e075-4621-bab5-ccae2a9094c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_45420978-4545-4b90-8872-afd58ca7816a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_000bd0f7-1e16-4490-8623-cf0bf93d3451" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_45420978-4545-4b90-8872-afd58ca7816a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20230930.xsd#FinancialInstrumentsDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_8be4e40e-df1d-4aee-91bb-b9093fcc9205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_7a9041a8-1304-443d-b472-446454c244f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_8be4e40e-df1d-4aee-91bb-b9093fcc9205" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_7a9041a8-1304-443d-b472-446454c244f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_dc0a1523-c8ab-4b3e-bc33-0bad5f3fe52f" xlink:href="biib-20230930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_8be4e40e-df1d-4aee-91bb-b9093fcc9205" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_dc0a1523-c8ab-4b3e-bc33-0bad5f3fe52f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_944c3473-52b6-412f-b780-d311b8d48c54" xlink:href="biib-20230930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_8be4e40e-df1d-4aee-91bb-b9093fcc9205" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_944c3473-52b6-412f-b780-d311b8d48c54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_49fe9389-8e45-482f-be90-718ce3d43d73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_837944bb-cf1c-43de-b27c-350f463449fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_49fe9389-8e45-482f-be90-718ce3d43d73" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_837944bb-cf1c-43de-b27c-350f463449fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a6c112c8-4b71-4c67-9d77-26ce8a4b3315" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_49fe9389-8e45-482f-be90-718ce3d43d73" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a6c112c8-4b71-4c67-9d77-26ce8a4b3315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_557ffff0-fd66-4b64-96eb-dcf547840e19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_49fe9389-8e45-482f-be90-718ce3d43d73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_557ffff0-fd66-4b64-96eb-dcf547840e19" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#EarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d5aee85a-fbd2-4bc5-b549-cc56cf6565b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4acdcaa5-0bc2-4e10-bb19-7e34473efcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d5aee85a-fbd2-4bc5-b549-cc56cf6565b1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4acdcaa5-0bc2-4e10-bb19-7e34473efcf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4dbeda22-db80-47df-83c6-d76481016612" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d5aee85a-fbd2-4bc5-b549-cc56cf6565b1" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4dbeda22-db80-47df-83c6-d76481016612" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_748875fd-1d07-4934-81d4-2b719e6170a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_df6e839b-aa54-4f38-9d02-f33264725168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_748875fd-1d07-4934-81d4-2b719e6170a7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_df6e839b-aa54-4f38-9d02-f33264725168" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#ShareBasedPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e9612786-3cdb-40fa-a837-b0282152710f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a02e3fcd-c7e7-4c79-b30f-dcf0d0df4045" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e9612786-3cdb-40fa-a837-b0282152710f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a02e3fcd-c7e7-4c79-b30f-dcf0d0df4045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_26b48640-acf5-42ea-b4bc-650d089e383a" xlink:href="biib-20230930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e9612786-3cdb-40fa-a837-b0282152710f" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_26b48640-acf5-42ea-b4bc-650d089e383a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0311e094-228e-4a96-9461-1b83385a6a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c3380c6f-bbd5-4108-8b4d-92eea8e6da7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0311e094-228e-4a96-9461-1b83385a6a8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c3380c6f-bbd5-4108-8b4d-92eea8e6da7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_99adcca1-e8dc-422b-aaed-ff76463800ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0311e094-228e-4a96-9461-1b83385a6a8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_99adcca1-e8dc-422b-aaed-ff76463800ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_db6260b5-58ba-41e2-9b6f-da7ef75aebc1" xlink:href="biib-20230930.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0311e094-228e-4a96-9461-1b83385a6a8c" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_db6260b5-58ba-41e2-9b6f-da7ef75aebc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement_6a8cf2d5-b4a6-46f4-9de0-2aad85580fb0" xlink:href="biib-20230930.xsd#biib_EffectiveTaxRateReconciliationLitigationAgreement"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0311e094-228e-4a96-9461-1b83385a6a8c" xlink:to="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement_6a8cf2d5-b4a6-46f4-9de0-2aad85580fb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7933a660-89f7-4816-8da9-80f8e4318a18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0311e094-228e-4a96-9461-1b83385a6a8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7933a660-89f7-4816-8da9-80f8e4318a18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_d1d84da7-72f3-4404-bf1e-e5119da3fb62" xlink:href="biib-20230930.xsd#biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0311e094-228e-4a96-9461-1b83385a6a8c" xlink:to="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_d1d84da7-72f3-4404-bf1e-e5119da3fb62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization_794a76be-7600-402c-9261-168f6563d4af" xlink:href="biib-20230930.xsd#biib_EffectiveTaxRateReconciliationInternationalReorganization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0311e094-228e-4a96-9461-1b83385a6a8c" xlink:to="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization_794a76be-7600-402c-9261-168f6563d4af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0c855eee-9235-4327-8908-89d595715c27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0311e094-228e-4a96-9461-1b83385a6a8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0c855eee-9235-4327-8908-89d595715c27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_40fe2b6d-9f2e-4fe7-99c7-b95a58776757" xlink:href="biib-20230930.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0311e094-228e-4a96-9461-1b83385a6a8c" xlink:to="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_40fe2b6d-9f2e-4fe7-99c7-b95a58776757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_7d9cae5d-28ad-43a9-aa9d-1da953cc0c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0311e094-228e-4a96-9461-1b83385a6a8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_7d9cae5d-28ad-43a9-aa9d-1da953cc0c1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_883971a1-2160-4935-9fed-b9d380eaa5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0311e094-228e-4a96-9461-1b83385a6a8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_883971a1-2160-4935-9fed-b9d380eaa5c4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_07ac5559-ecb0-4469-a263-7973e96e7541" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a3274430-5eda-4dd2-ab67-cf0f5999df13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_07ac5559-ecb0-4469-a263-7973e96e7541" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a3274430-5eda-4dd2-ab67-cf0f5999df13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1d1e90a4-a2b6-46d6-95f4-f70010e9d511" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_07ac5559-ecb0-4469-a263-7973e96e7541" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1d1e90a4-a2b6-46d6-95f4-f70010e9d511" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>biib-20230930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:067ab9af-2745-42fc-8c78-33206b6cc4f8,g:369ca811-9038-4e81-ba44-3ac1f044a248-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20230930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d8eac713-2f32-4665-8393-3411fd2a130d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_Revenues_d8eac713-2f32-4665-8393-3411fd2a130d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_188e2814-8b21-4c4c-b911-1776bc497d76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_188e2814-8b21-4c4c-b911-1776bc497d76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ef1f3e2b-3c49-44ad-909f-9f3d455815db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ef1f3e2b-3c49-44ad-909f-9f3d455815db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_39cd8c19-4cb1-4dc5-98e1-b5601ebcb39e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_39cd8c19-4cb1-4dc5-98e1-b5601ebcb39e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_eb3e87c0-bfed-4f83-9dc3-833ae69450d3" xlink:href="biib-20230930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_eb3e87c0-bfed-4f83-9dc3-833ae69450d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_13a1a35a-4ad5-4314-a087-521b2414943a" xlink:href="biib-20230930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_biib_Collaborationprofitlosssharing_13a1a35a-4ad5-4314-a087-521b2414943a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9889acc9-7692-43d1-9734-23557cac33ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9889acc9-7692-43d1-9734-23557cac33ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_81b45f09-6ffa-46e0-b7d4-68925d891e40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_us-gaap_RestructuringCharges_81b45f09-6ffa-46e0-b7d4-68925d891e40" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_682db4ac-9c85-41af-9b67-dbbec6222a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_682db4ac-9c85-41af-9b67-dbbec6222a7a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_f5e597c5-f66a-4caa-8e33-f5d15834ad6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_f5e597c5-f66a-4caa-8e33-f5d15834ad6f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ba4415bd-a2d5-4a7e-a80c-8a24d6d95502" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_us-gaap_CostsAndExpenses_ba4415bd-a2d5-4a7e-a80c-8a24d6d95502" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0284ffcd-f43e-45b1-8609-a0d7563efc03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0284ffcd-f43e-45b1-8609-a0d7563efc03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_85c3de70-4da9-4aef-aacd-ecfee7eaa4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_85c3de70-4da9-4aef-aacd-ecfee7eaa4e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_e4ce85d2-36a0-48d8-95ad-54f4c92cf1f4" xlink:href="biib-20230930.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_e4ce85d2-36a0-48d8-95ad-54f4c92cf1f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d380b116-5bb0-46fd-842a-c7a7c37f7601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_ProfitLoss_d380b116-5bb0-46fd-842a-c7a7c37f7601" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ac71e9f4-e729-423d-9ca0-6623062f41cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ac71e9f4-e729-423d-9ca0-6623062f41cd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_051792a5-69ad-4476-becf-4d61e0759a08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_NetIncomeLoss_051792a5-69ad-4476-becf-4d61e0759a08" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2f255eb0-bf8f-4d71-a30e-1ccef55688bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_EarningsPerShareAbstract_2f255eb0-bf8f-4d71-a30e-1ccef55688bb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_acbfac87-2582-49d6-a869-2a0ec16534b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2f255eb0-bf8f-4d71-a30e-1ccef55688bb" xlink:to="loc_us-gaap_EarningsPerShareBasic_acbfac87-2582-49d6-a869-2a0ec16534b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4c87f40b-8bf4-4ca4-8a09-ca9e5e628b54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2f255eb0-bf8f-4d71-a30e-1ccef55688bb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4c87f40b-8bf4-4ca4-8a09-ca9e5e628b54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_08e031e4-a5ba-40de-9b1f-d117be85dfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_08e031e4-a5ba-40de-9b1f-d117be85dfcc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_217598bf-caf1-4941-a040-2e7497d307d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_08e031e4-a5ba-40de-9b1f-d117be85dfcc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_217598bf-caf1-4941-a040-2e7497d307d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_768fa1ad-c68d-4585-ac60-61555f74effd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_08e031e4-a5ba-40de-9b1f-d117be85dfcc" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_768fa1ad-c68d-4585-ac60-61555f74effd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6f14283c-887e-4e25-a4bc-822927471a22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_StatementTable_6f14283c-887e-4e25-a4bc-822927471a22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_85828fe6-8e54-4ffc-8e4b-b8aa4fd74f24" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6f14283c-887e-4e25-a4bc-822927471a22" xlink:to="loc_srt_ProductOrServiceAxis_85828fe6-8e54-4ffc-8e4b-b8aa4fd74f24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_85828fe6-8e54-4ffc-8e4b-b8aa4fd74f24_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_85828fe6-8e54-4ffc-8e4b-b8aa4fd74f24" xlink:to="loc_srt_ProductsAndServicesDomain_85828fe6-8e54-4ffc-8e4b-b8aa4fd74f24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_db2596e9-ff08-4c66-8c62-680b8f6c3ed9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_85828fe6-8e54-4ffc-8e4b-b8aa4fd74f24" xlink:to="loc_srt_ProductsAndServicesDomain_db2596e9-ff08-4c66-8c62-680b8f6c3ed9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d6572867-32eb-40fe-97fe-10d5a66f941d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_db2596e9-ff08-4c66-8c62-680b8f6c3ed9" xlink:to="loc_us-gaap_ProductMember_d6572867-32eb-40fe-97fe-10d5a66f941d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_d50ffd47-a83e-4640-9dab-e5dfaaafc2a9" xlink:href="biib-20230930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_db2596e9-ff08-4c66-8c62-680b8f6c3ed9" xlink:to="loc_biib_LEQEMBICollaborationMember_d50ffd47-a83e-4640-9dab-e5dfaaafc2a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_e475a869-1f4a-48a3-b4c5-f877a5ab6c26" xlink:href="biib-20230930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_db2596e9-ff08-4c66-8c62-680b8f6c3ed9" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_e475a869-1f4a-48a3-b4c5-f877a5ab6c26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_5827d867-2dbf-4ac0-a39a-852e59354f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_db2596e9-ff08-4c66-8c62-680b8f6c3ed9" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_5827d867-2dbf-4ac0-a39a-852e59354f75" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20230930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_63b6c6ca-002f-41c7-957f-021a12c39f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63b6c6ca-002f-41c7-957f-021a12c39f3e" xlink:to="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7b2c9bc7-60ea-468e-94c7-566d15b7fb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7b2c9bc7-60ea-468e-94c7-566d15b7fb0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f06f526-32b4-492c-83dd-fd41ae303746" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b2c9bc7-60ea-468e-94c7-566d15b7fb0d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f06f526-32b4-492c-83dd-fd41ae303746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2b689dd7-789b-4a65-8e0f-6622ac134673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b2c9bc7-60ea-468e-94c7-566d15b7fb0d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2b689dd7-789b-4a65-8e0f-6622ac134673" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e6459512-155c-4998-a3cd-1d0bacbbbe75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b2c9bc7-60ea-468e-94c7-566d15b7fb0d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e6459512-155c-4998-a3cd-1d0bacbbbe75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_008c6f97-0519-44bf-ac8f-7d9cdf24e2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b2c9bc7-60ea-468e-94c7-566d15b7fb0d" xlink:to="loc_us-gaap_InventoryNet_008c6f97-0519-44bf-ac8f-7d9cdf24e2f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a8d66ee9-01d8-4149-9875-7a6e6a2a32c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b2c9bc7-60ea-468e-94c7-566d15b7fb0d" xlink:to="loc_us-gaap_OtherAssetsCurrent_a8d66ee9-01d8-4149-9875-7a6e6a2a32c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_27079327-5b40-4a6d-aa58-27cd21b792d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b2c9bc7-60ea-468e-94c7-566d15b7fb0d" xlink:to="loc_us-gaap_AssetsCurrent_27079327-5b40-4a6d-aa58-27cd21b792d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_92810b03-e8df-432f-b09c-d1a99bcd26e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_92810b03-e8df-432f-b09c-d1a99bcd26e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8fd2c613-73d3-4159-a6c8-5eea66c7ecac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8fd2c613-73d3-4159-a6c8-5eea66c7ecac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3d8549b9-2885-4ded-9b5a-255a857f3d44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3d8549b9-2885-4ded-9b5a-255a857f3d44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f12d5d2f-4008-4457-9639-3c16b92b0adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f12d5d2f-4008-4457-9639-3c16b92b0adf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_afd83321-d692-4f0b-b46b-958bb180c79f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_Goodwill_afd83321-d692-4f0b-b46b-958bb180c79f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_7e580701-00cc-43c5-b79e-26f80fe834f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_7e580701-00cc-43c5-b79e-26f80fe834f0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0bb0e2dc-2e96-4f82-8dbf-3daf89b5047e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0bb0e2dc-2e96-4f82-8dbf-3daf89b5047e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4497c724-1554-4912-984a-ec3243d36b28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_Assets_4497c724-1554-4912-984a-ec3243d36b28" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63b6c6ca-002f-41c7-957f-021a12c39f3e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_334c162a-579d-41ec-8ba6-4aa9bb4fa338" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_334c162a-579d-41ec-8ba6-4aa9bb4fa338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_6428e495-d30b-4071-8438-8cc1b742c509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_334c162a-579d-41ec-8ba6-4aa9bb4fa338" xlink:to="loc_us-gaap_NotesPayableCurrent_6428e495-d30b-4071-8438-8cc1b742c509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_683e6aa6-addf-4c81-ac6f-503de6ab56c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_334c162a-579d-41ec-8ba6-4aa9bb4fa338" xlink:to="loc_us-gaap_TaxesPayableCurrent_683e6aa6-addf-4c81-ac6f-503de6ab56c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2659ef2d-30ce-48e0-a64e-7435f0286c21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_334c162a-579d-41ec-8ba6-4aa9bb4fa338" xlink:to="loc_us-gaap_AccountsPayableCurrent_2659ef2d-30ce-48e0-a64e-7435f0286c21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_52452b3c-8d71-41a4-ab7e-a6338929e2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_334c162a-579d-41ec-8ba6-4aa9bb4fa338" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_52452b3c-8d71-41a4-ab7e-a6338929e2ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3e6c0ab6-ab8c-4a44-a598-cb2582d15f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_334c162a-579d-41ec-8ba6-4aa9bb4fa338" xlink:to="loc_us-gaap_LiabilitiesCurrent_3e6c0ab6-ab8c-4a44-a598-cb2582d15f0c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d0b12039-0610-4f92-b964-2455da895d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_LongTermDebt_d0b12039-0610-4f92-b964-2455da895d86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d9337476-a7e5-4f7f-ac91-d73e72f24e80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d9337476-a7e5-4f7f-ac91-d73e72f24e80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dbf8a93a-6ea1-4263-ac07-37b147ac00cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dbf8a93a-6ea1-4263-ac07-37b147ac00cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b680e0c9-36a7-439a-9757-c6d37bf91e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b680e0c9-36a7-439a-9757-c6d37bf91e7a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_06596b75-350f-46af-9cf5-da25a6a2e0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_Liabilities_06596b75-350f-46af-9cf5-da25a6a2e0bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e4588c0b-1ddd-4565-98cc-d1d794199bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e4588c0b-1ddd-4565-98cc-d1d794199bb7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb358b7c-daef-4993-98e5-d3ffa6a3a002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb358b7c-daef-4993-98e5-d3ffa6a3a002" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb358b7c-daef-4993-98e5-d3ffa6a3a002" xlink:to="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ff808dc5-9793-409f-9457-969ba91ae9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:to="loc_us-gaap_PreferredStockValue_ff808dc5-9793-409f-9457-969ba91ae9ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7998e5c0-9cac-438f-a601-ed285b35bb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:to="loc_us-gaap_CommonStockValue_7998e5c0-9cac-438f-a601-ed285b35bb8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8f2d9796-ec32-4ac9-b2e9-96cbacd3a9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8f2d9796-ec32-4ac9-b2e9-96cbacd3a9f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_24a7307d-6423-43a9-8ea3-7fcf8d02322d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_24a7307d-6423-43a9-8ea3-7fcf8d02322d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ae88eb11-6440-4da4-bc80-f74e92cb66e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ae88eb11-6440-4da4-bc80-f74e92cb66e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_4e105f54-b0d7-4f85-8495-76bc3183871f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:to="loc_us-gaap_TreasuryStockValue_4e105f54-b0d7-4f85-8495-76bc3183871f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e58fa292-7eef-4689-a613-929ee4d75d21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:to="loc_us-gaap_StockholdersEquity_e58fa292-7eef-4689-a613-929ee4d75d21" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a4cd69b6-2ec0-43a7-8e5d-19a0ec35beae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb358b7c-daef-4993-98e5-d3ffa6a3a002" xlink:to="loc_us-gaap_MinorityInterest_a4cd69b6-2ec0-43a7-8e5d-19a0ec35beae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8c5ac855-2209-4313-9980-f448da4b533f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb358b7c-daef-4993-98e5-d3ffa6a3a002" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8c5ac855-2209-4313-9980-f448da4b533f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_377db8a9-85a3-46fd-9f8c-3f17e1e842cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_377db8a9-85a3-46fd-9f8c-3f17e1e842cf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4485b864-a600-4a79-a01d-1c43bdcd1dad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_63b6c6ca-002f-41c7-957f-021a12c39f3e" xlink:to="loc_us-gaap_StatementTable_4485b864-a600-4a79-a01d-1c43bdcd1dad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8cc17705-a142-44a9-84dc-77bbfd2d6523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4485b864-a600-4a79-a01d-1c43bdcd1dad" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8cc17705-a142-44a9-84dc-77bbfd2d6523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8cc17705-a142-44a9-84dc-77bbfd2d6523_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8cc17705-a142-44a9-84dc-77bbfd2d6523" xlink:to="loc_us-gaap_RelatedPartyDomain_8cc17705-a142-44a9-84dc-77bbfd2d6523_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_58815559-f91a-4906-aae8-cddcdea8bcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8cc17705-a142-44a9-84dc-77bbfd2d6523" xlink:to="loc_us-gaap_RelatedPartyDomain_58815559-f91a-4906-aae8-cddcdea8bcbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_6ffacbbc-a563-4e7d-a5dd-59c883c1a584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_58815559-f91a-4906-aae8-cddcdea8bcbb" xlink:to="loc_us-gaap_NonrelatedPartyMember_6ffacbbc-a563-4e7d-a5dd-59c883c1a584" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_2b04959e-d88d-48b9-a0b2-7c06fc6eae5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_58815559-f91a-4906-aae8-cddcdea8bcbb" xlink:to="loc_us-gaap_RelatedPartyMember_2b04959e-d88d-48b9-a0b2-7c06fc6eae5b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20230930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bdc13fc4-b5bc-4335-94be-2a5b6dbc4a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bdc13fc4-b5bc-4335-94be-2a5b6dbc4a6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c59be703-238f-4507-9a33-b989fb817af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bdc13fc4-b5bc-4335-94be-2a5b6dbc4a6e" xlink:to="loc_us-gaap_ProfitLoss_c59be703-238f-4507-9a33-b989fb817af7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bdc13fc4-b5bc-4335-94be-2a5b6dbc4a6e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9be70362-c346-4485-a14a-822bb98839c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9be70362-c346-4485-a14a-822bb98839c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_364388e7-3be5-4ac4-8a0e-2df10abf13c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_InventoryWriteDown_364388e7-3be5-4ac4-8a0e-2df10abf13c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_71afa0ce-72ea-4f7e-a91f-56ce71566e72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_ShareBasedCompensation_71afa0ce-72ea-4f7e-a91f-56ce71566e72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e798fd3f-d696-4dc4-96a4-051b86f92743" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e798fd3f-d696-4dc4-96a4-051b86f92743" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f14e7fa6-0fa6-44f9-8f3d-5fe26b5c1640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f14e7fa6-0fa6-44f9-8f3d-5fe26b5c1640" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_c1d9d066-0295-4a88-a36d-d01b85f764ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_c1d9d066-0295-4a88-a36d-d01b85f764ee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c85626cd-4966-4a32-94e7-a65e66da6a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c85626cd-4966-4a32-94e7-a65e66da6a4b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_e08f5ba1-0abc-4924-bfe3-aec69b9fd7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_e08f5ba1-0abc-4924-bfe3-aec69b9fd7a1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_66296515-72dc-45a4-b378-1978fc37031f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_66296515-72dc-45a4-b378-1978fc37031f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_a3264350-20d3-49a2-a632-9eb0e94487a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_a3264350-20d3-49a2-a632-9eb0e94487a9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c375779a-55d8-4a8e-ab60-dbc5c68c813e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c375779a-55d8-4a8e-ab60-dbc5c68c813e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dc7ce171-6ffb-4bac-aef0-e0f8b246c212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c375779a-55d8-4a8e-ab60-dbc5c68c813e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dc7ce171-6ffb-4bac-aef0-e0f8b246c212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_594d9cb5-c217-41e4-940b-4445a3aa6eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c375779a-55d8-4a8e-ab60-dbc5c68c813e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_594d9cb5-c217-41e4-940b-4445a3aa6eaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_eea98527-4b8e-4571-83bd-02393ff641e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c375779a-55d8-4a8e-ab60-dbc5c68c813e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_eea98527-4b8e-4571-83bd-02393ff641e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_c5d557d6-76ab-4089-aca9-aa4b6593390d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c375779a-55d8-4a8e-ab60-dbc5c68c813e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_c5d557d6-76ab-4089-aca9-aa4b6593390d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_7b89150f-c28a-44b3-9d4c-0b25bb4dcef0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c375779a-55d8-4a8e-ab60-dbc5c68c813e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_7b89150f-c28a-44b3-9d4c-0b25bb4dcef0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bef81465-e4e3-43d6-adad-94e4fbd3ab2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bef81465-e4e3-43d6-adad-94e4fbd3ab2f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_57dfe379-cf59-4308-b9d2-88311f5b1e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_57dfe379-cf59-4308-b9d2-88311f5b1e6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_b7e9ea2f-44c9-4655-b93a-44550a66ae47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_b7e9ea2f-44c9-4655-b93a-44550a66ae47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b3385eba-3012-4146-ac4f-273792c6f4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b3385eba-3012-4146-ac4f-273792c6f4d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f3e73f11-cf8c-46f0-a96e-72793a4624fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f3e73f11-cf8c-46f0-a96e-72793a4624fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_51de111f-001e-45e1-a601-8693707cb752" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_51de111f-001e-45e1-a601-8693707cb752" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1a2abac1-755d-46ba-9208-0284febf7a19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1a2abac1-755d-46ba-9208-0284febf7a19" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_92c63748-9d13-4b13-9737-237d01b7d7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_92c63748-9d13-4b13-9737-237d01b7d7c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_05320392-4c74-4ba4-a851-af6d87f8fe09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_05320392-4c74-4ba4-a851-af6d87f8fe09" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5d8f75d8-1f93-4533-9c8f-352b3c814d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5d8f75d8-1f93-4533-9c8f-352b3c814d1c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e6c92a02-a578-4b3b-9dc9-6b4dbb7ccf70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e6c92a02-a578-4b3b-9dc9-6b4dbb7ccf70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_10ac1948-4f7c-42a2-8de9-2ecae1726fec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_10ac1948-4f7c-42a2-8de9-2ecae1726fec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_008b3e48-2e0e-4d33-b041-bd313f730e59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_008b3e48-2e0e-4d33-b041-bd313f730e59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_db0b810f-c1f7-434b-9164-02f2cfb1e989" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_db0b810f-c1f7-434b-9164-02f2cfb1e989" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_ed5d81be-c69f-4f6a-880f-4992f08bfd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_ed5d81be-c69f-4f6a-880f-4992f08bfd4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d2658763-99b3-4e87-b720-ce385af70f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d2658763-99b3-4e87-b720-ce385af70f1a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d9699de-4ce3-4b90-8c80-1abe28209c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d9699de-4ce3-4b90-8c80-1abe28209c9a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_30f3ed03-d2ff-4720-924b-f80e4c85b211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_30f3ed03-d2ff-4720-924b-f80e4c85b211" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8bceae88-bcaf-4b14-bd9f-66ed2838da99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8bceae88-bcaf-4b14-bd9f-66ed2838da99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8803defa-9d63-48d4-b8c5-8716ae628b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8803defa-9d63-48d4-b8c5-8716ae628b6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fe7649e9-dbb2-4d86-aa20-94c3b0c002ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a8b8c1e9-a11e-416e-8aba-a164431c4345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:to="loc_us-gaap_StatementTable_a8b8c1e9-a11e-416e-8aba-a164431c4345" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64c4a6f6-cf3a-4a00-8f41-964e0bb57135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a8b8c1e9-a11e-416e-8aba-a164431c4345" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64c4a6f6-cf3a-4a00-8f41-964e0bb57135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_64c4a6f6-cf3a-4a00-8f41-964e0bb57135_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64c4a6f6-cf3a-4a00-8f41-964e0bb57135" xlink:to="loc_us-gaap_RelatedPartyDomain_64c4a6f6-cf3a-4a00-8f41-964e0bb57135_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ec9fc289-3534-439e-9502-1381ad7596d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64c4a6f6-cf3a-4a00-8f41-964e0bb57135" xlink:to="loc_us-gaap_RelatedPartyDomain_ec9fc289-3534-439e-9502-1381ad7596d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_e04ceb80-3fac-4efa-b77c-24a622b345ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ec9fc289-3534-439e-9502-1381ad7596d8" xlink:to="loc_us-gaap_NonrelatedPartyMember_e04ceb80-3fac-4efa-b77c-24a622b345ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_c235257c-1e01-412c-bc05-b537114abca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ec9fc289-3534-439e-9502-1381ad7596d8" xlink:to="loc_us-gaap_RelatedPartyMember_c235257c-1e01-412c-bc05-b537114abca2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20230930.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e8795dc2-18a3-4e90-a44d-7dc268916b63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e8795dc2-18a3-4e90-a44d-7dc268916b63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f722ac2e-f351-4fdd-9455-969bcb2f11d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f722ac2e-f351-4fdd-9455-969bcb2f11d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_57ba1bd1-87e5-4b2b-a315-c305cd81f847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_TreasuryStockCommonShares_57ba1bd1-87e5-4b2b-a315-c305cd81f847" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dadb14c1-0ac7-48e5-a55d-c03f10d6cf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_ProfitLoss_dadb14c1-0ac7-48e5-a55d-c03f10d6cf2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6d29d6a9-aa0b-4ac8-b147-decf80b11281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6d29d6a9-aa0b-4ac8-b147-decf80b11281" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution_cbe0c427-b5ef-47a6-a8ca-b30a0a64b8bb" xlink:href="biib-20230930.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_biib_NoncontrollingInterestCapitalContribution_cbe0c427-b5ef-47a6-a8ca-b30a0a64b8bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_6e18bc3e-d7bd-4059-9a6a-2c449879e461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_6e18bc3e-d7bd-4059-9a6a-2c449879e461" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_345c42ca-e1d1-4f7d-b749-c7a7ade6de70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_345c42ca-e1d1-4f7d-b749-c7a7ade6de70" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_db99c6d8-9555-4ebb-80d3-75d4009fbdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_db99c6d8-9555-4ebb-80d3-75d4009fbdd4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_dd87cd23-aa38-4b70-a705-bb222487d89d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_dd87cd23-aa38-4b70-a705-bb222487d89d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0b529862-b927-4540-ba40-7e038260d7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0b529862-b927-4540-ba40-7e038260d7c2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_25c6adf7-8970-401a-bff3-ea51aa11db3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_25c6adf7-8970-401a-bff3-ea51aa11db3e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3e97db7-99a1-41f1-8323-40b9693eba77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3e97db7-99a1-41f1-8323-40b9693eba77" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_da2e728d-d720-4b01-8d8d-79af75a09359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_da2e728d-d720-4b01-8d8d-79af75a09359" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_97341052-663e-4d43-b514-a9b88622e7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_97341052-663e-4d43-b514-a9b88622e7e6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_bf9261b4-bd55-444b-a0d6-8bb946131a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_StockholdersEquityOther_bf9261b4-bd55-444b-a0d6-8bb946131a7e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e9442f2-fd07-4c6f-a101-1a4e34bab155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_841887c4-7a6c-4e7b-9907-5ccc8c2cb1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_b1e7b6ba-3130-4d96-b58f-23de1c60f581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_48cca863-b893-45cb-adef-20a2b6e1087b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_StatementTable_48cca863-b893-45cb-adef-20a2b6e1087b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_63ab1dc0-4cd8-47f0-9093-d2c472751a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_48cca863-b893-45cb-adef-20a2b6e1087b" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_63ab1dc0-4cd8-47f0-9093-d2c472751a07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_63ab1dc0-4cd8-47f0-9093-d2c472751a07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_63ab1dc0-4cd8-47f0-9093-d2c472751a07" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_63ab1dc0-4cd8-47f0-9093-d2c472751a07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_672c247d-5ece-41c6-a275-c2ad9d88f2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_63ab1dc0-4cd8-47f0-9093-d2c472751a07" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_672c247d-5ece-41c6-a275-c2ad9d88f2ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_84e4f00e-3195-4693-9cf1-2231dfc4cb9a" xlink:href="biib-20230930.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_672c247d-5ece-41c6-a275-c2ad9d88f2ee" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_84e4f00e-3195-4693-9cf1-2231dfc4cb9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_12780393-bb81-44b9-a235-01e3538b8a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_48cca863-b893-45cb-adef-20a2b6e1087b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_12780393-bb81-44b9-a235-01e3538b8a9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_12780393-bb81-44b9-a235-01e3538b8a9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_12780393-bb81-44b9-a235-01e3538b8a9e" xlink:to="loc_us-gaap_EquityComponentDomain_12780393-bb81-44b9-a235-01e3538b8a9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_12780393-bb81-44b9-a235-01e3538b8a9e" xlink:to="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_e7560486-a00b-4f24-9145-7629d7af96aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:to="loc_us-gaap_PreferredStockMember_e7560486-a00b-4f24-9145-7629d7af96aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_838fa61c-bafa-47b5-ae9a-936184e26e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:to="loc_us-gaap_CommonStockMember_838fa61c-bafa-47b5-ae9a-936184e26e9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8635cb97-b767-49b6-92db-ea00738cf03b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8635cb97-b767-49b6-92db-ea00738cf03b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a1fd09e7-4081-4a38-ae5c-bc909d55e2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a1fd09e7-4081-4a38-ae5c-bc909d55e2b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_381c6fe9-b41e-4859-8457-36590410ea8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:to="loc_us-gaap_RetainedEarningsMember_381c6fe9-b41e-4859-8457-36590410ea8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_129407f7-b641-4049-b85e-687c0448b90c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:to="loc_us-gaap_TreasuryStockCommonMember_129407f7-b641-4049-b85e-687c0448b90c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_c8bb9165-e09e-4934-927c-b5f4ea27f3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:to="loc_us-gaap_ParentMember_c8bb9165-e09e-4934-927c-b5f4ea27f3a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_22e4331d-71e4-4f0b-8a6c-50c186f5b518" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:to="loc_us-gaap_NoncontrollingInterestMember_22e4331d-71e4-4f0b-8a6c-50c186f5b518" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="simple" xlink:href="biib-20230930.xsd#AcquisitionsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_7077a59f-9985-4fa6-9885-3f76ef955b76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_7077a59f-9985-4fa6-9885-3f76ef955b76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2d0a1771-1d71-4606-969f-bbf64471af4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2d0a1771-1d71-4606-969f-bbf64471af4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_cc6aaa05-7419-4f19-b5f0-c95859e181f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_cc6aaa05-7419-4f19-b5f0-c95859e181f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_fd4aa74c-ed17-4043-8fe6-041aea3596eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_fd4aa74c-ed17-4043-8fe6-041aea3596eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_aae9644c-dbcc-49ff-8954-6e7911d8ba91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_aae9644c-dbcc-49ff-8954-6e7911d8ba91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b28610ef-599d-4803-ab4f-2dccf02b7c11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b28610ef-599d-4803-ab4f-2dccf02b7c11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_670c941b-6c76-438e-9cdb-616b4192220e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_OperatingExpenses_670c941b-6c76-438e-9cdb-616b4192220e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_efbf169f-0c95-4916-b435-f5ddd10727a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_efbf169f-0c95-4916-b435-f5ddd10727a9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9270604e-5cf6-48c8-805c-6376493250bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9270604e-5cf6-48c8-805c-6376493250bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f7e0a052-9e74-4768-bd9a-b2b39287bfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f7e0a052-9e74-4768-bd9a-b2b39287bfc8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_4164a710-5497-41a4-a082-d225b8442418" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_4164a710-5497-41a4-a082-d225b8442418" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_934693da-962f-469a-8685-c6ea57cbebd8" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_934693da-962f-469a-8685-c6ea57cbebd8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ac757c28-f114-4edb-8d56-b91eac01425e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ac757c28-f114-4edb-8d56-b91eac01425e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_38095bc6-7e44-41e7-9432-c5434dc08fc1" xlink:href="biib-20230930.xsd#biib_OperatingLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_biib_OperatingLeaseArea_38095bc6-7e44-41e7-9432-c5434dc08fc1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5c15d924-3b2d-49d5-8b4a-0732a9c1fd16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5c15d924-3b2d-49d5-8b4a-0732a9c1fd16" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_8bce8b3c-51fb-406b-8d52-344b92de9c17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_8bce8b3c-51fb-406b-8d52-344b92de9c17" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_14a6a25d-c23e-454f-8399-6da7795f5dad" xlink:href="biib-20230930.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_14a6a25d-c23e-454f-8399-6da7795f5dad" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_6e25fcdd-cf27-46ce-a3e3-6aa2cc7a32cf" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_6e25fcdd-cf27-46ce-a3e3-6aa2cc7a32cf" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_43fb2d88-3ae0-45fd-a741-8db98f733f22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_Goodwill_43fb2d88-3ae0-45fd-a741-8db98f733f22" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_5d15f448-4d92-4f7f-af46-774f6e42b31e" xlink:href="biib-20230930.xsd#biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_5d15f448-4d92-4f7f-af46-774f6e42b31e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_a0125937-9a17-46ea-89fc-ecfe927720a7" xlink:href="biib-20230930.xsd#biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_a0125937-9a17-46ea-89fc-ecfe927720a7" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26b0dbd9-6d0b-4b24-aadc-8cf4114e06fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26b0dbd9-6d0b-4b24-aadc-8cf4114e06fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_90881ebb-b087-4cc0-9e6f-5f90b8d6a1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26b0dbd9-6d0b-4b24-aadc-8cf4114e06fc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_90881ebb-b087-4cc0-9e6f-5f90b8d6a1a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90881ebb-b087-4cc0-9e6f-5f90b8d6a1a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_90881ebb-b087-4cc0-9e6f-5f90b8d6a1a4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90881ebb-b087-4cc0-9e6f-5f90b8d6a1a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2f62006-b719-4f63-9c23-2c5f47095f35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_90881ebb-b087-4cc0-9e6f-5f90b8d6a1a4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2f62006-b719-4f63-9c23-2c5f47095f35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_86718d36-69bb-4ed6-bee7-ab7453bf0c53" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2f62006-b719-4f63-9c23-2c5f47095f35" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_86718d36-69bb-4ed6-bee7-ab7453bf0c53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b5e2a326-3c44-4acd-b344-c17c8a0b143f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26b0dbd9-6d0b-4b24-aadc-8cf4114e06fc" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b5e2a326-3c44-4acd-b344-c17c8a0b143f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b5e2a326-3c44-4acd-b344-c17c8a0b143f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b5e2a326-3c44-4acd-b344-c17c8a0b143f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b5e2a326-3c44-4acd-b344-c17c8a0b143f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7d36ee84-b52f-4bb3-929a-b004b6682973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b5e2a326-3c44-4acd-b344-c17c8a0b143f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7d36ee84-b52f-4bb3-929a-b004b6682973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4afbaef1-4dfa-4ea8-9d11-1df4ccff5e68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7d36ee84-b52f-4bb3-929a-b004b6682973" xlink:to="loc_us-gaap_SubsequentEventMember_4afbaef1-4dfa-4ea8-9d11-1df4ccff5e68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_210f687c-2b7a-49dc-83b3-43867af8cd01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26b0dbd9-6d0b-4b24-aadc-8cf4114e06fc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_210f687c-2b7a-49dc-83b3-43867af8cd01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_210f687c-2b7a-49dc-83b3-43867af8cd01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_210f687c-2b7a-49dc-83b3-43867af8cd01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_210f687c-2b7a-49dc-83b3-43867af8cd01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ee4546d1-f003-4ef0-b2fb-1a9c7672362b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_210f687c-2b7a-49dc-83b3-43867af8cd01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ee4546d1-f003-4ef0-b2fb-1a9c7672362b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_7e625a12-099a-4833-98fe-91a0ef36b51b" xlink:href="biib-20230930.xsd#biib_SKYCLARYSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ee4546d1-f003-4ef0-b2fb-1a9c7672362b" xlink:to="loc_biib_SKYCLARYSMember_7e625a12-099a-4833-98fe-91a0ef36b51b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_4239c6d7-6db9-4830-9d09-7bd5b13dbfe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ee4546d1-f003-4ef0-b2fb-1a9c7672362b" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_4239c6d7-6db9-4830-9d09-7bd5b13dbfe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_ed290d25-6bc1-40d9-9072-a22d21e45979" xlink:href="biib-20230930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ee4546d1-f003-4ef0-b2fb-1a9c7672362b" xlink:to="loc_biib_PriorityReviewVoucherMember_ed290d25-6bc1-40d9-9072-a22d21e45979" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember_bf8b4533-8377-42e4-b645-b0cb17b9708d" xlink:href="biib-20230930.xsd#biib_OtherClinicalProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ee4546d1-f003-4ef0-b2fb-1a9c7672362b" xlink:to="loc_biib_OtherClinicalProgramsMember_bf8b4533-8377-42e4-b645-b0cb17b9708d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fcf2a748-41fa-42d3-97bb-f493cce81a04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26b0dbd9-6d0b-4b24-aadc-8cf4114e06fc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fcf2a748-41fa-42d3-97bb-f493cce81a04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fcf2a748-41fa-42d3-97bb-f493cce81a04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fcf2a748-41fa-42d3-97bb-f493cce81a04" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fcf2a748-41fa-42d3-97bb-f493cce81a04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d6f475dc-a82e-47b9-80e0-045acfe0e80e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fcf2a748-41fa-42d3-97bb-f493cce81a04" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d6f475dc-a82e-47b9-80e0-045acfe0e80e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bb547114-f6cc-4707-9ebf-8a2068329b29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d6f475dc-a82e-47b9-80e0-045acfe0e80e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bb547114-f6cc-4707-9ebf-8a2068329b29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d3d7f712-d909-4fb9-bf9d-78c68e94cb7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26b0dbd9-6d0b-4b24-aadc-8cf4114e06fc" xlink:to="loc_srt_StatementScenarioAxis_d3d7f712-d909-4fb9-bf9d-78c68e94cb7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d3d7f712-d909-4fb9-bf9d-78c68e94cb7c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_d3d7f712-d909-4fb9-bf9d-78c68e94cb7c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d3d7f712-d909-4fb9-bf9d-78c68e94cb7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_17825170-c7f4-4d7a-be91-15ccce7fab7d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_d3d7f712-d909-4fb9-bf9d-78c68e94cb7c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_17825170-c7f4-4d7a-be91-15ccce7fab7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b211017e-67bc-4c8f-82e0-74e6f93cf73b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_17825170-c7f4-4d7a-be91-15ccce7fab7d" xlink:to="loc_srt_ScenarioForecastMember_b211017e-67bc-4c8f-82e0-74e6f93cf73b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#AcquisitionsPurchasePriceConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_11788c9f-1ffa-481c-b710-d4ef62d1a930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_dc0e38c1-50a3-4f6f-a8b8-a7ab629855b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11788c9f-1ffa-481c-b710-d4ef62d1a930" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_dc0e38c1-50a3-4f6f-a8b8-a7ab629855b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_a3bb4d29-3ae9-480b-a344-e7ebfb22e49f" xlink:href="biib-20230930.xsd#biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11788c9f-1ffa-481c-b710-d4ef62d1a930" xlink:to="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_a3bb4d29-3ae9-480b-a344-e7ebfb22e49f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c0f06f88-b4c9-4c2e-9868-f963520c1612" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11788c9f-1ffa-481c-b710-d4ef62d1a930" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c0f06f88-b4c9-4c2e-9868-f963520c1612" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_0e12fdba-91ae-4b71-a020-ff0b8b54d92e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11788c9f-1ffa-481c-b710-d4ef62d1a930" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_0e12fdba-91ae-4b71-a020-ff0b8b54d92e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_08688132-8a7c-4f8f-a8d8-f181c682eae5" xlink:href="biib-20230930.xsd#biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11788c9f-1ffa-481c-b710-d4ef62d1a930" xlink:to="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_08688132-8a7c-4f8f-a8d8-f181c682eae5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_42fb94ae-8c3d-4555-afd1-9629c56cea28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11788c9f-1ffa-481c-b710-d4ef62d1a930" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_42fb94ae-8c3d-4555-afd1-9629c56cea28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d7606cb1-9771-42c7-a0e1-750429d16093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_42fb94ae-8c3d-4555-afd1-9629c56cea28" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d7606cb1-9771-42c7-a0e1-750429d16093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d7606cb1-9771-42c7-a0e1-750429d16093_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d7606cb1-9771-42c7-a0e1-750429d16093" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d7606cb1-9771-42c7-a0e1-750429d16093_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c003e96c-c203-4331-a928-37b2db8cc856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d7606cb1-9771-42c7-a0e1-750429d16093" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c003e96c-c203-4331-a928-37b2db8cc856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_0f6e3210-c58e-4edc-a9cf-17984b1b29d9" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c003e96c-c203-4331-a928-37b2db8cc856" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_0f6e3210-c58e-4edc-a9cf-17984b1b29d9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#AcquisitionsPreliminatyPurchasePriceAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_efc44947-092f-418e-9093-94f9b7013477" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_efc44947-092f-418e-9093-94f9b7013477" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_e9e1dd43-0817-4b27-bba3-5a8d87323bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_e9e1dd43-0817-4b27-bba3-5a8d87323bcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_724d4d1b-42f5-4c4a-857b-d47ad28fec4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_724d4d1b-42f5-4c4a-857b-d47ad28fec4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_bf361bbe-81c0-45c2-9530-e1c5bcd4d213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_bf361bbe-81c0-45c2-9530-e1c5bcd4d213" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f2944015-2c78-466b-a4f2-e8407a17c711" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f2944015-2c78-466b-a4f2-e8407a17c711" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_1da8e17b-32c3-4808-ab9b-d001192986cf" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_1da8e17b-32c3-4808-ab9b-d001192986cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_94150c20-1c9f-4573-b545-d3e8f3c9c77e" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_94150c20-1c9f-4573-b545-d3e8f3c9c77e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_9d08ecf9-5ae6-4671-acce-0002a0d602b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_9d08ecf9-5ae6-4671-acce-0002a0d602b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_926f7123-9270-4328-bddd-8db27a1f0b50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_926f7123-9270-4328-bddd-8db27a1f0b50" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_eaf698e4-56f4-4403-9d73-d7d1a8dd5027" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_eaf698e4-56f4-4403-9d73-d7d1a8dd5027" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_a25ad5d8-c5f0-4dfe-9687-390357ab48fe" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_a25ad5d8-c5f0-4dfe-9687-390357ab48fe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_1dcfa8ad-0650-474e-9a85-06db384a87f7" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_1dcfa8ad-0650-474e-9a85-06db384a87f7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_3919c905-5707-422f-be29-5a0d286a86f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_3919c905-5707-422f-be29-5a0d286a86f5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6d45c9e6-fe09-4221-9c7b-0aa4c0bbf806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_Goodwill_6d45c9e6-fe09-4221-9c7b-0aa4c0bbf806" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0a1bb4f5-2067-4efb-9a8e-5e7ad3edd0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0a1bb4f5-2067-4efb-9a8e-5e7ad3edd0a9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e90bc187-5439-4e3e-ac29-9455ffe622b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e90bc187-5439-4e3e-ac29-9455ffe622b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6236b239-cf2e-4b88-bf80-9e538eca149c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e90bc187-5439-4e3e-ac29-9455ffe622b8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6236b239-cf2e-4b88-bf80-9e538eca149c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6236b239-cf2e-4b88-bf80-9e538eca149c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6236b239-cf2e-4b88-bf80-9e538eca149c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6236b239-cf2e-4b88-bf80-9e538eca149c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c7c5c43-a1e2-4a95-b482-f89707ca05f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6236b239-cf2e-4b88-bf80-9e538eca149c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c7c5c43-a1e2-4a95-b482-f89707ca05f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_25b835f8-bf02-4961-8e17-5a3dc7b1c094" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c7c5c43-a1e2-4a95-b482-f89707ca05f2" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_25b835f8-bf02-4961-8e17-5a3dc7b1c094" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a28e6e79-58de-40cb-8432-38bff50f858f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e90bc187-5439-4e3e-ac29-9455ffe622b8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a28e6e79-58de-40cb-8432-38bff50f858f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a28e6e79-58de-40cb-8432-38bff50f858f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a28e6e79-58de-40cb-8432-38bff50f858f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a28e6e79-58de-40cb-8432-38bff50f858f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_495badcc-925a-406e-8cc0-c4fa45c69457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a28e6e79-58de-40cb-8432-38bff50f858f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_495badcc-925a-406e-8cc0-c4fa45c69457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_24862fe6-5548-4602-88b7-e9c58bb949b2" xlink:href="biib-20230930.xsd#biib_SKYCLARYSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_495badcc-925a-406e-8cc0-c4fa45c69457" xlink:to="loc_biib_SKYCLARYSMember_24862fe6-5548-4602-88b7-e9c58bb949b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_57cd6264-76b9-41f1-844b-c2d656431458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_495badcc-925a-406e-8cc0-c4fa45c69457" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_57cd6264-76b9-41f1-844b-c2d656431458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_d0c97d0b-27d5-40f2-84ba-9885dd7003bc" xlink:href="biib-20230930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_495badcc-925a-406e-8cc0-c4fa45c69457" xlink:to="loc_biib_PriorityReviewVoucherMember_d0c97d0b-27d5-40f2-84ba-9885dd7003bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember_41bf9c8c-be4e-4b54-9a8a-c572d6dd2aa6" xlink:href="biib-20230930.xsd#biib_OtherClinicalProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_495badcc-925a-406e-8cc0-c4fa45c69457" xlink:to="loc_biib_OtherClinicalProgramsMember_41bf9c8c-be4e-4b54-9a8a-c572d6dd2aa6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="simple" xlink:href="biib-20230930.xsd#DispositionsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_448d2d49-359b-4f75-bd8f-76ff20e41303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_448d2d49-359b-4f75-bd8f-76ff20e41303" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_d38e59cf-590b-45c5-9e6d-848e9ac168ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_d38e59cf-590b-45c5-9e6d-848e9ac168ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_8a7f48d3-bf60-4769-ab03-fe21279791cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_8a7f48d3-bf60-4769-ab03-fe21279791cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_51b1af82-0f9e-415a-91ae-3bec357fe9e4" xlink:href="biib-20230930.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_51b1af82-0f9e-415a-91ae-3bec357fe9e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_580bc8fb-4fe0-42d8-a8e1-5b1fc1bbd000" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_EquityMethodInvestments_580bc8fb-4fe0-42d8-a8e1-5b1fc1bbd000" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_ed5f7cc2-c353-4efa-adca-2b032a7ca8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_ed5f7cc2-c353-4efa-adca-2b032a7ca8cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_b60975ba-fe57-4b56-8b13-124443f9a1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_b60975ba-fe57-4b56-8b13-124443f9a1ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_034e419b-267e-42fd-94bf-956869c668c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_034e419b-267e-42fd-94bf-956869c668c1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsMeasurementInput_12405fa9-1a16-46f8-aceb-3f00b8c155a2" xlink:href="biib-20230930.xsd#biib_OtherAssetsMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_biib_OtherAssetsMeasurementInput_12405fa9-1a16-46f8-aceb-3f00b8c155a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure_7c20132b-f293-4517-aa85-a0cc4d8c9ef0" xlink:href="biib-20230930.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_biib_OtherAssetsCurrentFairValueDisclosure_7c20132b-f293-4517-aa85-a0cc4d8c9ef0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_3d0f2e16-cac1-4b99-8f6d-3e908d888813" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_3d0f2e16-cac1-4b99-8f6d-3e908d888813" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_677e5cdf-1d9f-4b95-8e36-af3d2ceafdd1" xlink:href="biib-20230930.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_biib_AdditionalMilestonePayment_677e5cdf-1d9f-4b95-8e36-af3d2ceafdd1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_67f31c82-a06d-4854-b3b6-98106389e18c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_67f31c82-a06d-4854-b3b6-98106389e18c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bd991708-8a0a-40fb-9737-28e8c28c5033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_67f31c82-a06d-4854-b3b6-98106389e18c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bd991708-8a0a-40fb-9737-28e8c28c5033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd991708-8a0a-40fb-9737-28e8c28c5033_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bd991708-8a0a-40fb-9737-28e8c28c5033" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd991708-8a0a-40fb-9737-28e8c28c5033_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf718d4c-4685-415e-a53b-338514452346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bd991708-8a0a-40fb-9737-28e8c28c5033" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf718d4c-4685-415e-a53b-338514452346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_6730dc70-cf88-4cce-b206-d2ff016a6876" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf718d4c-4685-415e-a53b-338514452346" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_6730dc70-cf88-4cce-b206-d2ff016a6876" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cb5934f0-2800-4b94-94ac-139ba4398470" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_67f31c82-a06d-4854-b3b6-98106389e18c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cb5934f0-2800-4b94-94ac-139ba4398470" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_cb5934f0-2800-4b94-94ac-139ba4398470_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cb5934f0-2800-4b94-94ac-139ba4398470" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_cb5934f0-2800-4b94-94ac-139ba4398470_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f3793f0f-0f37-4dfc-aa1e-3954ae6afa26" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cb5934f0-2800-4b94-94ac-139ba4398470" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f3793f0f-0f37-4dfc-aa1e-3954ae6afa26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_90d94c9a-7e94-4fc4-b480-b1a22e7c62b3" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3793f0f-0f37-4dfc-aa1e-3954ae6afa26" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_90d94c9a-7e94-4fc4-b480-b1a22e7c62b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_8394abb8-aa89-41c4-82dc-2a8331c3ce1f" xlink:href="biib-20230930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_67f31c82-a06d-4854-b3b6-98106389e18c" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_8394abb8-aa89-41c4-82dc-2a8331c3ce1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_8394abb8-aa89-41c4-82dc-2a8331c3ce1f_default" xlink:href="biib-20230930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_8394abb8-aa89-41c4-82dc-2a8331c3ce1f" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_8394abb8-aa89-41c4-82dc-2a8331c3ce1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_763562ed-bc45-4a1a-8866-5d1cd23eed7e" xlink:href="biib-20230930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_8394abb8-aa89-41c4-82dc-2a8331c3ce1f" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_763562ed-bc45-4a1a-8866-5d1cd23eed7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_7f35da22-e5ff-4a53-ae28-b0991f5fbdbb" xlink:href="biib-20230930.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_763562ed-bc45-4a1a-8866-5d1cd23eed7e" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_7f35da22-e5ff-4a53-ae28-b0991f5fbdbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_7e06fd21-56ff-43ae-bee3-993441cf5f8b" xlink:href="biib-20230930.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_763562ed-bc45-4a1a-8866-5d1cd23eed7e" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_7e06fd21-56ff-43ae-bee3-993441cf5f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_02edbeb0-5bbe-48fe-b1ad-e1f83aced445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_67f31c82-a06d-4854-b3b6-98106389e18c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_02edbeb0-5bbe-48fe-b1ad-e1f83aced445" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_02edbeb0-5bbe-48fe-b1ad-e1f83aced445_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_02edbeb0-5bbe-48fe-b1ad-e1f83aced445" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_02edbeb0-5bbe-48fe-b1ad-e1f83aced445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_5708e350-a63a-4779-a467-6794e5f5e591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_02edbeb0-5bbe-48fe-b1ad-e1f83aced445" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_5708e350-a63a-4779-a467-6794e5f5e591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_67011821-2b8e-433c-a161-f484840e1ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_5708e350-a63a-4779-a467-6794e5f5e591" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_67011821-2b8e-433c-a161-f484840e1ad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_073b4775-bd50-4065-a2ef-6de6501a0e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_67f31c82-a06d-4854-b3b6-98106389e18c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_073b4775-bd50-4065-a2ef-6de6501a0e3b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_073b4775-bd50-4065-a2ef-6de6501a0e3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_073b4775-bd50-4065-a2ef-6de6501a0e3b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_073b4775-bd50-4065-a2ef-6de6501a0e3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_31dea1db-007f-4981-b227-108b298ec736" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_073b4775-bd50-4065-a2ef-6de6501a0e3b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_31dea1db-007f-4981-b227-108b298ec736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_bc86100a-4665-4567-a3e9-7384e5f22b20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_31dea1db-007f-4981-b227-108b298ec736" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_bc86100a-4665-4567-a3e9-7384e5f22b20" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_07f4c0e1-e2f4-4562-8bef-535b2bafe045" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_4127d317-073c-4de2-b2f9-ae0bf57eb954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_07f4c0e1-e2f4-4562-8bef-535b2bafe045" xlink:to="loc_us-gaap_SeveranceCosts1_4127d317-073c-4de2-b2f9-ae0bf57eb954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_23671b59-b823-463e-8300-a6c50d8988e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_07f4c0e1-e2f4-4562-8bef-535b2bafe045" xlink:to="loc_us-gaap_OtherRestructuringCosts_23671b59-b823-463e-8300-a6c50d8988e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1666c08f-2286-4527-98ce-f9f56811b3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_07f4c0e1-e2f4-4562-8bef-535b2bafe045" xlink:to="loc_us-gaap_RestructuringCharges_1666c08f-2286-4527-98ce-f9f56811b3ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_17c35980-0ad8-4a44-90ed-3c03e18269e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_07f4c0e1-e2f4-4562-8bef-535b2bafe045" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_17c35980-0ad8-4a44-90ed-3c03e18269e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_67ba0f6e-da5a-4c00-8f23-6fa3e6d53d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_17c35980-0ad8-4a44-90ed-3c03e18269e3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_67ba0f6e-da5a-4c00-8f23-6fa3e6d53d1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_67ba0f6e-da5a-4c00-8f23-6fa3e6d53d1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_67ba0f6e-da5a-4c00-8f23-6fa3e6d53d1c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_67ba0f6e-da5a-4c00-8f23-6fa3e6d53d1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a00fd739-27c1-4d58-af9c-35f7342ade0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_67ba0f6e-da5a-4c00-8f23-6fa3e6d53d1c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a00fd739-27c1-4d58-af9c-35f7342ade0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b23c82bd-6d4f-4dce-a419-13aef4a4bd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a00fd739-27c1-4d58-af9c-35f7342ade0d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b23c82bd-6d4f-4dce-a419-13aef4a4bd8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_adfecbdb-2404-46fe-9e3c-6d6fe9a07316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a00fd739-27c1-4d58-af9c-35f7342ade0d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_adfecbdb-2404-46fe-9e3c-6d6fe9a07316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_5739c4b0-30d0-4905-86b2-e01a1010e892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a00fd739-27c1-4d58-af9c-35f7342ade0d" xlink:to="loc_us-gaap_RestructuringChargesMember_5739c4b0-30d0-4905-86b2-e01a1010e892" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_549724ac-559e-4c94-aad5-11fe5548683e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_17c35980-0ad8-4a44-90ed-3c03e18269e3" xlink:to="loc_us-gaap_RestructuringPlanAxis_549724ac-559e-4c94-aad5-11fe5548683e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_549724ac-559e-4c94-aad5-11fe5548683e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_549724ac-559e-4c94-aad5-11fe5548683e" xlink:to="loc_us-gaap_RestructuringPlanDomain_549724ac-559e-4c94-aad5-11fe5548683e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_14c97242-b58a-41d7-84b5-8a9a820223cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_549724ac-559e-4c94-aad5-11fe5548683e" xlink:to="loc_us-gaap_RestructuringPlanDomain_14c97242-b58a-41d7-84b5-8a9a820223cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_748aa332-dfa4-4124-ad57-768e469b096a" xlink:href="biib-20230930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_14c97242-b58a-41d7-84b5-8a9a820223cd" xlink:to="loc_biib_A2023CostSavingInitiativesMember_748aa332-dfa4-4124-ad57-768e469b096a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_d4f9b07c-e4f8-4c9a-a6c7-9daffbe0f0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_9a366b35-95a4-4da7-bea3-5c59f4b921b7" xlink:href="biib-20230930.xsd#biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d4f9b07c-e4f8-4c9a-a6c7-9daffbe0f0a4" xlink:to="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_9a366b35-95a4-4da7-bea3-5c59f4b921b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_e4cb4b07-e8fb-4466-9293-44e283e909a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d4f9b07c-e4f8-4c9a-a6c7-9daffbe0f0a4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_e4cb4b07-e8fb-4466-9293-44e283e909a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_cb13ff42-629a-46dd-b403-88512cc8a05d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d4f9b07c-e4f8-4c9a-a6c7-9daffbe0f0a4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_cb13ff42-629a-46dd-b403-88512cc8a05d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_7dbb4bee-ca0c-47a0-8132-9d3e85b542f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d4f9b07c-e4f8-4c9a-a6c7-9daffbe0f0a4" xlink:to="loc_us-gaap_SeveranceCosts1_7dbb4bee-ca0c-47a0-8132-9d3e85b542f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_efc1bdf9-b0df-452f-bda5-bd007b7046c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d4f9b07c-e4f8-4c9a-a6c7-9daffbe0f0a4" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_efc1bdf9-b0df-452f-bda5-bd007b7046c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_3b9631a1-852c-4bd4-a7b8-76ed7824bb74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_efc1bdf9-b0df-452f-bda5-bd007b7046c9" xlink:to="loc_us-gaap_RestructuringPlanAxis_3b9631a1-852c-4bd4-a7b8-76ed7824bb74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_3b9631a1-852c-4bd4-a7b8-76ed7824bb74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_3b9631a1-852c-4bd4-a7b8-76ed7824bb74" xlink:to="loc_us-gaap_RestructuringPlanDomain_3b9631a1-852c-4bd4-a7b8-76ed7824bb74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_67f918fa-cb31-4daa-bc35-7999537eec61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_3b9631a1-852c-4bd4-a7b8-76ed7824bb74" xlink:to="loc_us-gaap_RestructuringPlanDomain_67f918fa-cb31-4daa-bc35-7999537eec61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2022CostSavingInitiativesMember_81428f56-145b-4fb9-97a6-fb708db7efae" xlink:href="biib-20230930.xsd#biib_A2022CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_67f918fa-cb31-4daa-bc35-7999537eec61" xlink:to="loc_biib_A2022CostSavingInitiativesMember_81428f56-145b-4fb9-97a6-fb708db7efae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_e2eaff57-db85-401b-b773-0331758e0d5b" xlink:href="biib-20230930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_67f918fa-cb31-4daa-bc35-7999537eec61" xlink:to="loc_biib_A2023CostSavingInitiativesMember_e2eaff57-db85-401b-b773-0331758e0d5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_004a1fdb-7498-4afe-9c0b-74dcf629f92c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_efc1bdf9-b0df-452f-bda5-bd007b7046c9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_004a1fdb-7498-4afe-9c0b-74dcf629f92c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_004a1fdb-7498-4afe-9c0b-74dcf629f92c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_004a1fdb-7498-4afe-9c0b-74dcf629f92c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_004a1fdb-7498-4afe-9c0b-74dcf629f92c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_566fec7d-d76f-4701-8dde-021f44c47df7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_004a1fdb-7498-4afe-9c0b-74dcf629f92c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_566fec7d-d76f-4701-8dde-021f44c47df7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_629d4607-9dd7-40b8-9712-93884eedc228" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_566fec7d-d76f-4701-8dde-021f44c47df7" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_629d4607-9dd7-40b8-9712-93884eedc228" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c0a658b8-bfd6-41fe-8038-edec258686a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_efc1bdf9-b0df-452f-bda5-bd007b7046c9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c0a658b8-bfd6-41fe-8038-edec258686a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c0a658b8-bfd6-41fe-8038-edec258686a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c0a658b8-bfd6-41fe-8038-edec258686a1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c0a658b8-bfd6-41fe-8038-edec258686a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_80f34bcf-1cc4-46a3-ac59-8001f76d7a77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c0a658b8-bfd6-41fe-8038-edec258686a1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_80f34bcf-1cc4-46a3-ac59-8001f76d7a77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_8aec9956-fa05-4689-bc3a-f4c038f1e332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80f34bcf-1cc4-46a3-ac59-8001f76d7a77" xlink:to="loc_us-gaap_RestructuringChargesMember_8aec9956-fa05-4689-bc3a-f4c038f1e332" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_dc9ac4fa-db3c-47e4-b7c7-f904cdb6435c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_845823a0-6514-4f31-8183-16a153cb1d69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dc9ac4fa-db3c-47e4-b7c7-f904cdb6435c" xlink:to="loc_us-gaap_RestructuringCharges_845823a0-6514-4f31-8183-16a153cb1d69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_1decd585-a05e-4ad0-a611-52efea47e109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dc9ac4fa-db3c-47e4-b7c7-f904cdb6435c" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_1decd585-a05e-4ad0-a611-52efea47e109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d14b1381-0bb2-481b-81d3-4fb02f4cbae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dc9ac4fa-db3c-47e4-b7c7-f904cdb6435c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d14b1381-0bb2-481b-81d3-4fb02f4cbae6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_acecf880-3b9e-413f-9b43-1e8aeec714c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d14b1381-0bb2-481b-81d3-4fb02f4cbae6" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_acecf880-3b9e-413f-9b43-1e8aeec714c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_acecf880-3b9e-413f-9b43-1e8aeec714c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_acecf880-3b9e-413f-9b43-1e8aeec714c0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_acecf880-3b9e-413f-9b43-1e8aeec714c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2057bcee-d288-4f52-af86-b2c55fe30dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_acecf880-3b9e-413f-9b43-1e8aeec714c0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2057bcee-d288-4f52-af86-b2c55fe30dc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_b85f7019-c103-42db-aa8a-f4255ef34357" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2057bcee-d288-4f52-af86-b2c55fe30dc7" xlink:to="loc_us-gaap_EmployeeSeveranceMember_b85f7019-c103-42db-aa8a-f4255ef34357" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcceleratedDepreciationAndOtherCostsMember_63094d82-9e07-4584-8d2a-88c47b371046" xlink:href="biib-20230930.xsd#biib_AcceleratedDepreciationAndOtherCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2057bcee-d288-4f52-af86-b2c55fe30dc7" xlink:to="loc_biib_AcceleratedDepreciationAndOtherCostsMember_63094d82-9e07-4584-8d2a-88c47b371046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WorkforceReductionMember_32715952-517a-41d7-92de-48b78611b735" xlink:href="biib-20230930.xsd#biib_WorkforceReductionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2057bcee-d288-4f52-af86-b2c55fe30dc7" xlink:to="loc_biib_WorkforceReductionMember_32715952-517a-41d7-92de-48b78611b735" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_66ee4eed-69cf-4bf0-aa44-8cb4165599b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d14b1381-0bb2-481b-81d3-4fb02f4cbae6" xlink:to="loc_us-gaap_RestructuringPlanAxis_66ee4eed-69cf-4bf0-aa44-8cb4165599b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_66ee4eed-69cf-4bf0-aa44-8cb4165599b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_66ee4eed-69cf-4bf0-aa44-8cb4165599b6" xlink:to="loc_us-gaap_RestructuringPlanDomain_66ee4eed-69cf-4bf0-aa44-8cb4165599b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b606dd72-fbf4-4e43-bd9c-fb30a28f31c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_66ee4eed-69cf-4bf0-aa44-8cb4165599b6" xlink:to="loc_us-gaap_RestructuringPlanDomain_b606dd72-fbf4-4e43-bd9c-fb30a28f31c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2022CostSavingInitiativesMember_9e8a42c2-c0d9-4ebc-a01b-db2cbfffa402" xlink:href="biib-20230930.xsd#biib_A2022CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_b606dd72-fbf4-4e43-bd9c-fb30a28f31c8" xlink:to="loc_biib_A2022CostSavingInitiativesMember_9e8a42c2-c0d9-4ebc-a01b-db2cbfffa402" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_06c55010-492c-49ff-a3d8-4de93b74d226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d14b1381-0bb2-481b-81d3-4fb02f4cbae6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_06c55010-492c-49ff-a3d8-4de93b74d226" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_06c55010-492c-49ff-a3d8-4de93b74d226_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_06c55010-492c-49ff-a3d8-4de93b74d226" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_06c55010-492c-49ff-a3d8-4de93b74d226_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e6fd84a3-2df7-4ae0-877f-5997268c8813" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_06c55010-492c-49ff-a3d8-4de93b74d226" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e6fd84a3-2df7-4ae0-877f-5997268c8813" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_0d62b999-e997-4238-b382-bf84fc7f0c39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e6fd84a3-2df7-4ae0-877f-5997268c8813" xlink:to="loc_us-gaap_RestructuringChargesMember_0d62b999-e997-4238-b382-bf84fc7f0c39" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8e22b590-11dd-4e18-a226-8e9e5688eaea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_83c18e23-3f28-4d55-aa20-cecd7e1d038d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e22b590-11dd-4e18-a226-8e9e5688eaea" xlink:to="loc_us-gaap_RestructuringReserve_83c18e23-3f28-4d55-aa20-cecd7e1d038d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a2d51055-f629-44d0-bf20-02734b3fa3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e22b590-11dd-4e18-a226-8e9e5688eaea" xlink:to="loc_us-gaap_RestructuringCharges_a2d51055-f629-44d0-bf20-02734b3fa3f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_f48fb3dd-c59d-4522-9b0e-971ebc042060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e22b590-11dd-4e18-a226-8e9e5688eaea" xlink:to="loc_us-gaap_PaymentsForRestructuring_f48fb3dd-c59d-4522-9b0e-971ebc042060" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAdjustment_1510873e-d937-4b86-8af7-8c2dd7865dab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveTranslationAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e22b590-11dd-4e18-a226-8e9e5688eaea" xlink:to="loc_us-gaap_RestructuringReserveTranslationAdjustment_1510873e-d937-4b86-8af7-8c2dd7865dab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_9d874123-ae57-4e36-89b2-77c05dde0970" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5e4bc230-37c6-442a-b9a7-2c062b598e70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e22b590-11dd-4e18-a226-8e9e5688eaea" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5e4bc230-37c6-442a-b9a7-2c062b598e70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_09200e85-3766-4359-a0b1-269f30c21eca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5e4bc230-37c6-442a-b9a7-2c062b598e70" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_09200e85-3766-4359-a0b1-269f30c21eca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_09200e85-3766-4359-a0b1-269f30c21eca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_09200e85-3766-4359-a0b1-269f30c21eca" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_09200e85-3766-4359-a0b1-269f30c21eca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7295e9e6-6a10-49cc-8dd8-b38b41cfcc57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_09200e85-3766-4359-a0b1-269f30c21eca" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7295e9e6-6a10-49cc-8dd8-b38b41cfcc57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_15121aae-b1e4-4987-b824-27fbe44ebcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7295e9e6-6a10-49cc-8dd8-b38b41cfcc57" xlink:to="loc_us-gaap_EmployeeSeveranceMember_15121aae-b1e4-4987-b824-27fbe44ebcb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_e3987a6e-6c21-44c5-aa9d-2122f1ea6d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5e4bc230-37c6-442a-b9a7-2c062b598e70" xlink:to="loc_us-gaap_RestructuringPlanAxis_e3987a6e-6c21-44c5-aa9d-2122f1ea6d9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e3987a6e-6c21-44c5-aa9d-2122f1ea6d9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_e3987a6e-6c21-44c5-aa9d-2122f1ea6d9d" xlink:to="loc_us-gaap_RestructuringPlanDomain_e3987a6e-6c21-44c5-aa9d-2122f1ea6d9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e575c769-92b2-4bdd-b67b-42cdcb7f2229" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_e3987a6e-6c21-44c5-aa9d-2122f1ea6d9d" xlink:to="loc_us-gaap_RestructuringPlanDomain_e575c769-92b2-4bdd-b67b-42cdcb7f2229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2022CostSavingInitiativesMember_4132272d-950a-4dd0-b6a4-88308d0297ea" xlink:href="biib-20230930.xsd#biib_A2022CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_e575c769-92b2-4bdd-b67b-42cdcb7f2229" xlink:to="loc_biib_A2022CostSavingInitiativesMember_4132272d-950a-4dd0-b6a4-88308d0297ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_e14fec06-894a-48fe-97de-576c91250e18" xlink:href="biib-20230930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_e575c769-92b2-4bdd-b67b-42cdcb7f2229" xlink:to="loc_biib_A2023CostSavingInitiativesMember_e14fec06-894a-48fe-97de-576c91250e18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023And2022CostSavingInitiativesMember_34823e33-b456-49ec-9f27-14c2fe7f81e3" xlink:href="biib-20230930.xsd#biib_A2023And2022CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_e575c769-92b2-4bdd-b67b-42cdcb7f2229" xlink:to="loc_biib_A2023And2022CostSavingInitiativesMember_34823e33-b456-49ec-9f27-14c2fe7f81e3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RevenuesRevenuesbyproductDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e973195d-bdd8-4e62-9439-b225245cb9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9d7df7bb-a2b6-4b0c-b4b0-f8fd3655f581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e973195d-bdd8-4e62-9439-b225245cb9e2" xlink:to="loc_us-gaap_Revenues_9d7df7bb-a2b6-4b0c-b4b0-f8fd3655f581" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_da7f9fde-cb2e-44a2-a3ed-803d26f849bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e973195d-bdd8-4e62-9439-b225245cb9e2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_da7f9fde-cb2e-44a2-a3ed-803d26f849bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ea5263bd-7e01-4cd6-b045-d38c321143ea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_da7f9fde-cb2e-44a2-a3ed-803d26f849bc" xlink:to="loc_srt_ProductOrServiceAxis_ea5263bd-7e01-4cd6-b045-d38c321143ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea5263bd-7e01-4cd6-b045-d38c321143ea_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ea5263bd-7e01-4cd6-b045-d38c321143ea" xlink:to="loc_srt_ProductsAndServicesDomain_ea5263bd-7e01-4cd6-b045-d38c321143ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ea5263bd-7e01-4cd6-b045-d38c321143ea" xlink:to="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_02b5a037-25c4-4622-8eed-b43913a24c9f" xlink:href="biib-20230930.xsd#biib_MSProductRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:to="loc_biib_MSProductRevenuesMember_02b5a037-25c4-4622-8eed-b43913a24c9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_768f8b80-1417-4554-b565-a9f59a6f6bd1" xlink:href="biib-20230930.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MSProductRevenuesMember_02b5a037-25c4-4622-8eed-b43913a24c9f" xlink:to="loc_biib_FumarateMember_768f8b80-1417-4554-b565-a9f59a6f6bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_859918b3-1fcd-4681-b4a1-946ef8a05cad" xlink:href="biib-20230930.xsd#biib_TECFIDERAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FumarateMember_768f8b80-1417-4554-b565-a9f59a6f6bd1" xlink:to="loc_biib_TECFIDERAMember_859918b3-1fcd-4681-b4a1-946ef8a05cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember_f122db2c-605c-43e7-a217-ed5ca1cf6c7e" xlink:href="biib-20230930.xsd#biib_VUMERITYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FumarateMember_768f8b80-1417-4554-b565-a9f59a6f6bd1" xlink:to="loc_biib_VUMERITYMember_f122db2c-605c-43e7-a217-ed5ca1cf6c7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_97da49e2-2f83-4c1e-9fe9-8348e8b00889" xlink:href="biib-20230930.xsd#biib_InterferonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MSProductRevenuesMember_02b5a037-25c4-4622-8eed-b43913a24c9f" xlink:to="loc_biib_InterferonMember_97da49e2-2f83-4c1e-9fe9-8348e8b00889" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember_64726bef-9137-40a3-a8b9-3e9680d614ee" xlink:href="biib-20230930.xsd#biib_AVONEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InterferonMember_97da49e2-2f83-4c1e-9fe9-8348e8b00889" xlink:to="loc_biib_AVONEXMember_64726bef-9137-40a3-a8b9-3e9680d614ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember_c1ad8f4d-2615-4d26-a2f8-ee6542f79059" xlink:href="biib-20230930.xsd#biib_PLEGRIDYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InterferonMember_97da49e2-2f83-4c1e-9fe9-8348e8b00889" xlink:to="loc_biib_PLEGRIDYMember_c1ad8f4d-2615-4d26-a2f8-ee6542f79059" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_b4895430-9f6d-49c6-8814-92b6c769ab7a" xlink:href="biib-20230930.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:to="loc_biib_TysabriProductMember_b4895430-9f6d-49c6-8814-92b6c769ab7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_df1c7dc1-84bf-49da-b0eb-b7682ba756be" xlink:href="biib-20230930.xsd#biib_FAMPYRAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:to="loc_biib_FAMPYRAMember_df1c7dc1-84bf-49da-b0eb-b7682ba756be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_6ee341bf-7cb4-4405-98e0-2c8582aaf2ce" xlink:href="biib-20230930.xsd#biib_SPINRAZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:to="loc_biib_SPINRAZAMember_6ee341bf-7cb4-4405-98e0-2c8582aaf2ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_ada52e27-615d-4842-8299-68825c18aada" xlink:href="biib-20230930.xsd#biib_BiosimilarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:to="loc_biib_BiosimilarsMember_ada52e27-615d-4842-8299-68825c18aada" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_baf126ea-2ab1-4eab-82ef-227ed9896356" xlink:href="biib-20230930.xsd#biib_BENEPALIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_ada52e27-615d-4842-8299-68825c18aada" xlink:to="loc_biib_BENEPALIMember_baf126ea-2ab1-4eab-82ef-227ed9896356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_8fbeea85-811b-4851-b56c-e65ed668c9cf" xlink:href="biib-20230930.xsd#biib_IMRALDIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_ada52e27-615d-4842-8299-68825c18aada" xlink:to="loc_biib_IMRALDIMember_8fbeea85-811b-4851-b56c-e65ed668c9cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_59dc9ada-6723-4db2-8eb3-e69e52e7c23a" xlink:href="biib-20230930.xsd#biib_FLIXABIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_ada52e27-615d-4842-8299-68825c18aada" xlink:to="loc_biib_FLIXABIMember_59dc9ada-6723-4db2-8eb3-e69e52e7c23a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember_953f4cc3-8cc5-4ad7-aba0-86db6459594d" xlink:href="biib-20230930.xsd#biib_BYOOVIZMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_ada52e27-615d-4842-8299-68825c18aada" xlink:to="loc_biib_BYOOVIZMember_953f4cc3-8cc5-4ad7-aba0-86db6459594d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4ced39b8-7770-4f86-9b05-df78512c23c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:to="loc_us-gaap_ProductMember_4ced39b8-7770-4f86-9b05-df78512c23c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMAndADUHELMMember_37fcd51f-5f4f-43a8-b4e1-2be7f5dac806" xlink:href="biib-20230930.xsd#biib_FUMADERMAndADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:to="loc_biib_FUMADERMAndADUHELMMember_37fcd51f-5f4f-43a8-b4e1-2be7f5dac806" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SpinalMuscularAtrophyMember_d220c5fe-e8f4-4c0c-b7e0-482db8038fb4" xlink:href="biib-20230930.xsd#biib_SpinalMuscularAtrophyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:to="loc_biib_SpinalMuscularAtrophyMember_d220c5fe-e8f4-4c0c-b7e0-482db8038fb4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_06adf991-0dd8-42fe-906c-5747c657cd9e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_da7f9fde-cb2e-44a2-a3ed-803d26f849bc" xlink:to="loc_srt_StatementGeographicalAxis_06adf991-0dd8-42fe-906c-5747c657cd9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_06adf991-0dd8-42fe-906c-5747c657cd9e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_06adf991-0dd8-42fe-906c-5747c657cd9e" xlink:to="loc_srt_SegmentGeographicalDomain_06adf991-0dd8-42fe-906c-5747c657cd9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4ecb72ba-b58b-4375-829d-5c0cc835ad95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_06adf991-0dd8-42fe-906c-5747c657cd9e" xlink:to="loc_srt_SegmentGeographicalDomain_4ecb72ba-b58b-4375-829d-5c0cc835ad95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6d2458f8-a065-47a6-93c2-c97d29cdebc9" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4ecb72ba-b58b-4375-829d-5c0cc835ad95" xlink:to="loc_country_US_6d2458f8-a065-47a6-93c2-c97d29cdebc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_2b9a5df1-a323-4899-8de4-f2cab1f49f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4ecb72ba-b58b-4375-829d-5c0cc835ad95" xlink:to="loc_us-gaap_NonUsMember_2b9a5df1-a323-4899-8de4-f2cab1f49f5d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20230930.xsd#RevenuesReservesforDiscountsandAllowancesDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_709dd2d0-0dcd-4d9e-9e46-eef68255b2a5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_75e9fcb2-4939-4a16-8b3d-b63697e2ee26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_709dd2d0-0dcd-4d9e-9e46-eef68255b2a5" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_75e9fcb2-4939-4a16-8b3d-b63697e2ee26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_b042d92b-b1e1-4506-9b03-ece9451fb77e" xlink:href="biib-20230930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_709dd2d0-0dcd-4d9e-9e46-eef68255b2a5" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_b042d92b-b1e1-4506-9b03-ece9451fb77e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_704479dd-9b70-4a3e-9573-1161679d1784" xlink:href="biib-20230930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_709dd2d0-0dcd-4d9e-9e46-eef68255b2a5" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_704479dd-9b70-4a3e-9573-1161679d1784" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_7c8e9f78-a164-4704-9789-f41c598fcf59" xlink:href="biib-20230930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_709dd2d0-0dcd-4d9e-9e46-eef68255b2a5" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_7c8e9f78-a164-4704-9789-f41c598fcf59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_82276e06-4641-4a35-bbcc-517245f1c8fa" xlink:href="biib-20230930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_709dd2d0-0dcd-4d9e-9e46-eef68255b2a5" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_82276e06-4641-4a35-bbcc-517245f1c8fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_79242d00-ae16-4a44-9a7c-b0289efc1f62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_fc49983d-f4b7-4cb5-b443-19a1266c0db9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_709dd2d0-0dcd-4d9e-9e46-eef68255b2a5" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_fc49983d-f4b7-4cb5-b443-19a1266c0db9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_65d580dc-b7bd-4a19-9eb5-87261791cafe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_fc49983d-f4b7-4cb5-b443-19a1266c0db9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_65d580dc-b7bd-4a19-9eb5-87261791cafe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_65d580dc-b7bd-4a19-9eb5-87261791cafe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_65d580dc-b7bd-4a19-9eb5-87261791cafe" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_65d580dc-b7bd-4a19-9eb5-87261791cafe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_71bc0bd8-2c8b-4c7b-a30d-0446cea34792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_65d580dc-b7bd-4a19-9eb5-87261791cafe" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_71bc0bd8-2c8b-4c7b-a30d-0446cea34792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_f6429fdf-1f2b-4226-b2f2-b73ee2cac37a" xlink:href="biib-20230930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_71bc0bd8-2c8b-4c7b-a30d-0446cea34792" xlink:to="loc_biib_ReserveforCashDiscountsMember_f6429fdf-1f2b-4226-b2f2-b73ee2cac37a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_4f685e1f-ee4b-4e6d-9ed3-97f49911db12" xlink:href="biib-20230930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_71bc0bd8-2c8b-4c7b-a30d-0446cea34792" xlink:to="loc_biib_ContractualAdjustmentsMember_4f685e1f-ee4b-4e6d-9ed3-97f49911db12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_21a6dce1-309a-416b-a900-2d10ccb27b12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_71bc0bd8-2c8b-4c7b-a30d-0446cea34792" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_21a6dce1-309a-416b-a900-2d10ccb27b12" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20230930.xsd#RevenuesReservesforDiscountsandAllowancesDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_02a2a73a-58b5-4400-807a-cddeb09a8f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_bac3e25e-c1bb-42df-a469-f7a8edb6a89b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_02a2a73a-58b5-4400-807a-cddeb09a8f75" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_bac3e25e-c1bb-42df-a469-f7a8edb6a89b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_947d0bfb-f548-4708-804d-463b9279908e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_02a2a73a-58b5-4400-807a-cddeb09a8f75" xlink:to="loc_us-gaap_StatementTable_947d0bfb-f548-4708-804d-463b9279908e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ec40e539-7267-4e30-a037-7e6a183a1b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_947d0bfb-f548-4708-804d-463b9279908e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ec40e539-7267-4e30-a037-7e6a183a1b8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ec40e539-7267-4e30-a037-7e6a183a1b8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ec40e539-7267-4e30-a037-7e6a183a1b8f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ec40e539-7267-4e30-a037-7e6a183a1b8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_07e82d0c-9d02-4ded-b8e5-4b8f0f5b393e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ec40e539-7267-4e30-a037-7e6a183a1b8f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_07e82d0c-9d02-4ded-b8e5-4b8f0f5b393e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_324faf03-b198-40fd-8651-cc64989d4173" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_07e82d0c-9d02-4ded-b8e5-4b8f0f5b393e" xlink:to="loc_us-gaap_AccountsReceivableMember_324faf03-b198-40fd-8651-cc64989d4173" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_6df91ece-d004-4e8d-9b2e-7e5649b05fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_07e82d0c-9d02-4ded-b8e5-4b8f0f5b393e" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_6df91ece-d004-4e8d-9b2e-7e5649b05fe7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d23970ec-a2bc-4b1f-bc7c-3762db55f2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_a866e88b-93b3-4047-89ff-cc961c30001b" xlink:href="biib-20230930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d23970ec-a2bc-4b1f-bc7c-3762db55f2b4" xlink:to="loc_biib_ShareOfCoPromotionProfits_a866e88b-93b3-4047-89ff-cc961c30001b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_498a5c95-9e36-49a2-bc93-6ee2c5799c67" xlink:href="biib-20230930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d23970ec-a2bc-4b1f-bc7c-3762db55f2b4" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_498a5c95-9e36-49a2-bc93-6ee2c5799c67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d62804ee-e70e-4308-9275-76e2e7e5f4df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d23970ec-a2bc-4b1f-bc7c-3762db55f2b4" xlink:to="loc_us-gaap_Revenues_d62804ee-e70e-4308-9275-76e2e7e5f4df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e2fa1290-d5f9-427a-b322-43b1f77548cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d23970ec-a2bc-4b1f-bc7c-3762db55f2b4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e2fa1290-d5f9-427a-b322-43b1f77548cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bbecce26-5c3d-4ebc-b5b5-52cd8044630e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e2fa1290-d5f9-427a-b322-43b1f77548cd" xlink:to="loc_srt_ProductOrServiceAxis_bbecce26-5c3d-4ebc-b5b5-52cd8044630e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bbecce26-5c3d-4ebc-b5b5-52cd8044630e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bbecce26-5c3d-4ebc-b5b5-52cd8044630e" xlink:to="loc_srt_ProductsAndServicesDomain_bbecce26-5c3d-4ebc-b5b5-52cd8044630e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8288b6f1-5f1a-4f6a-a4a2-6ffe86a22173" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bbecce26-5c3d-4ebc-b5b5-52cd8044630e" xlink:to="loc_srt_ProductsAndServicesDomain_8288b6f1-5f1a-4f6a-a4a2-6ffe86a22173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_066c0bf8-7261-40bc-9c55-6bb4328fa894" xlink:href="biib-20230930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8288b6f1-5f1a-4f6a-a4a2-6ffe86a22173" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_066c0bf8-7261-40bc-9c55-6bb4328fa894" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltyAttributedToOCREVUSMember_9e6ccf5f-e20c-4dfd-9666-fd0686a89500" xlink:href="biib-20230930.xsd#biib_RoyaltyAttributedToOCREVUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8288b6f1-5f1a-4f6a-a4a2-6ffe86a22173" xlink:to="loc_biib_RoyaltyAttributedToOCREVUSMember_9e6ccf5f-e20c-4dfd-9666-fd0686a89500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_830d6573-adfc-4fd1-87df-dbc95dfb7224" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e2fa1290-d5f9-427a-b322-43b1f77548cd" xlink:to="loc_srt_MajorCustomersAxis_830d6573-adfc-4fd1-87df-dbc95dfb7224" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_830d6573-adfc-4fd1-87df-dbc95dfb7224_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_830d6573-adfc-4fd1-87df-dbc95dfb7224" xlink:to="loc_srt_NameOfMajorCustomerDomain_830d6573-adfc-4fd1-87df-dbc95dfb7224_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6c1b535e-a98e-4d03-973e-b57781fa8512" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_830d6573-adfc-4fd1-87df-dbc95dfb7224" xlink:to="loc_srt_NameOfMajorCustomerDomain_6c1b535e-a98e-4d03-973e-b57781fa8512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_59c0a007-424a-4c4c-a4a6-b0e3e51d858e" xlink:href="biib-20230930.xsd#biib_RocheGroupGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_6c1b535e-a98e-4d03-973e-b57781fa8512" xlink:to="loc_biib_RocheGroupGenentechMember_59c0a007-424a-4c4c-a4a6-b0e3e51d858e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RevenuesOtherRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a3a3c8a4-a41a-4fbb-8e4a-90517bc6090c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_735ed473-6fb9-4bdc-a167-89196c801f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a3a3c8a4-a41a-4fbb-8e4a-90517bc6090c" xlink:to="loc_us-gaap_Revenues_735ed473-6fb9-4bdc-a167-89196c801f3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_87e91217-a533-40c2-94e4-0c5b85c0f1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a3a3c8a4-a41a-4fbb-8e4a-90517bc6090c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_87e91217-a533-40c2-94e4-0c5b85c0f1e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_37e1653b-d5d9-48b8-a391-3e67ad5bec56" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_87e91217-a533-40c2-94e4-0c5b85c0f1e8" xlink:to="loc_srt_ProductOrServiceAxis_37e1653b-d5d9-48b8-a391-3e67ad5bec56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_37e1653b-d5d9-48b8-a391-3e67ad5bec56_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_37e1653b-d5d9-48b8-a391-3e67ad5bec56" xlink:to="loc_srt_ProductsAndServicesDomain_37e1653b-d5d9-48b8-a391-3e67ad5bec56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2d04f173-abfd-4e03-80a6-f1b23bded7dc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_37e1653b-d5d9-48b8-a391-3e67ad5bec56" xlink:to="loc_srt_ProductsAndServicesDomain_2d04f173-abfd-4e03-80a6-f1b23bded7dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingAndOtherRevenueMember_6e8dd9bb-bac5-44c2-bcd8-4ab58f08d671" xlink:href="biib-20230930.xsd#biib_ContractManufacturingAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2d04f173-abfd-4e03-80a6-f1b23bded7dc" xlink:to="loc_biib_ContractManufacturingAndOtherRevenueMember_6e8dd9bb-bac5-44c2-bcd8-4ab58f08d671" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_b3cf47bc-f031-4e5d-bf1d-e430578bfd39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2d04f173-abfd-4e03-80a6-f1b23bded7dc" xlink:to="loc_us-gaap_RoyaltyMember_b3cf47bc-f031-4e5d-bf1d-e430578bfd39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_ec6763cb-1826-481a-9f76-90f716c63497" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2d04f173-abfd-4e03-80a6-f1b23bded7dc" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_ec6763cb-1826-481a-9f76-90f716c63497" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_22ea322a-cfa9-4f48-916f-cd11ff875094" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_bb470a6d-5005-433c-ac51-9bdb86038565" xlink:href="biib-20230930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22ea322a-cfa9-4f48-916f-cd11ff875094" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_bb470a6d-5005-433c-ac51-9bdb86038565" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_d6cbf20a-2ab1-44d2-8ae8-3de3232db52e" xlink:href="biib-20230930.xsd#biib_NumberOfWholesalers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22ea322a-cfa9-4f48-916f-cd11ff875094" xlink:to="loc_biib_NumberOfWholesalers_d6cbf20a-2ab1-44d2-8ae8-3de3232db52e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fe27f079-899c-493e-a37f-b52f86f76116" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22ea322a-cfa9-4f48-916f-cd11ff875094" xlink:to="loc_us-gaap_Revenues_fe27f079-899c-493e-a37f-b52f86f76116" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized_4a2b7c86-5fd0-43f4-9702-3431898533ca" xlink:href="biib-20230930.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22ea322a-cfa9-4f48-916f-cd11ff875094" xlink:to="loc_biib_ShareOfNonControlingInterestRecognized_4a2b7c86-5fd0-43f4-9702-3431898533ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_23946e84-cd7c-4dd4-9637-757a36d4d726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22ea322a-cfa9-4f48-916f-cd11ff875094" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_23946e84-cd7c-4dd4-9637-757a36d4d726" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0bed294d-14d1-44aa-8d08-42d68b3e76c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22ea322a-cfa9-4f48-916f-cd11ff875094" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0bed294d-14d1-44aa-8d08-42d68b3e76c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d559597e-0eb8-44e6-9778-e9fb230aa1a9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0bed294d-14d1-44aa-8d08-42d68b3e76c3" xlink:to="loc_srt_ProductOrServiceAxis_d559597e-0eb8-44e6-9778-e9fb230aa1a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d559597e-0eb8-44e6-9778-e9fb230aa1a9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d559597e-0eb8-44e6-9778-e9fb230aa1a9" xlink:to="loc_srt_ProductsAndServicesDomain_d559597e-0eb8-44e6-9778-e9fb230aa1a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5831f1e9-ad62-46a3-8f5c-a1a3210a8d1f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d559597e-0eb8-44e6-9778-e9fb230aa1a9" xlink:to="loc_srt_ProductsAndServicesDomain_5831f1e9-ad62-46a3-8f5c-a1a3210a8d1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_4a2791f4-f5de-451b-a9bf-2b3bb34acad2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5831f1e9-ad62-46a3-8f5c-a1a3210a8d1f" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_4a2791f4-f5de-451b-a9bf-2b3bb34acad2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_892dba95-c0f7-4416-9129-9e89ffb487e3" xlink:href="biib-20230930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5831f1e9-ad62-46a3-8f5c-a1a3210a8d1f" xlink:to="loc_biib_LEQEMBICollaborationMember_892dba95-c0f7-4416-9129-9e89ffb487e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_65295922-9234-4ab2-9124-928aaae79c2a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0bed294d-14d1-44aa-8d08-42d68b3e76c3" xlink:to="loc_srt_MajorCustomersAxis_65295922-9234-4ab2-9124-928aaae79c2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_65295922-9234-4ab2-9124-928aaae79c2a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_65295922-9234-4ab2-9124-928aaae79c2a" xlink:to="loc_srt_NameOfMajorCustomerDomain_65295922-9234-4ab2-9124-928aaae79c2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_390d9d92-1090-487a-96bd-401b41aefc09" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_65295922-9234-4ab2-9124-928aaae79c2a" xlink:to="loc_srt_NameOfMajorCustomerDomain_390d9d92-1090-487a-96bd-401b41aefc09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_ff93ecd8-4695-4f79-a046-afe717a6bb72" xlink:href="biib-20230930.xsd#biib_DistributorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_390d9d92-1090-487a-96bd-401b41aefc09" xlink:to="loc_biib_DistributorOneMember_ff93ecd8-4695-4f79-a046-afe717a6bb72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_bbe3ab84-a876-4b06-bf9a-26160bb60b44" xlink:href="biib-20230930.xsd#biib_DistributorTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_390d9d92-1090-487a-96bd-401b41aefc09" xlink:to="loc_biib_DistributorTwoMember_bbe3ab84-a876-4b06-bf9a-26160bb60b44" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#InventoryNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_72dc2d38-0433-414f-a6e0-91daf8b15faa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_3a13a1b8-6631-4562-8f2a-945aba4cdda6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_72dc2d38-0433-414f-a6e0-91daf8b15faa" xlink:to="loc_us-gaap_InventoryWriteDown_3a13a1b8-6631-4562-8f2a-945aba4cdda6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c4abf015-261c-44ed-a965-efb6e68c2e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_72dc2d38-0433-414f-a6e0-91daf8b15faa" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c4abf015-261c-44ed-a965-efb6e68c2e5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5091933d-22ba-4629-9a0b-8ab567d07127" xlink:href="biib-20230930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_72dc2d38-0433-414f-a6e0-91daf8b15faa" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5091933d-22ba-4629-9a0b-8ab567d07127" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent_91b143cf-e690-4bb4-b3f1-e3b213d4320c" xlink:href="biib-20230930.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_72dc2d38-0433-414f-a6e0-91daf8b15faa" xlink:to="loc_biib_InventoryNetCurrentAndNoncurrent_91b143cf-e690-4bb4-b3f1-e3b213d4320c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_6a487729-a0ce-4f11-9409-2e18fbd9d86c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_72dc2d38-0433-414f-a6e0-91daf8b15faa" xlink:to="loc_us-gaap_InventoryCurrentTable_6a487729-a0ce-4f11-9409-2e18fbd9d86c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_077d6036-0562-4eab-861e-c68a9186ce41" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_6a487729-a0ce-4f11-9409-2e18fbd9d86c" xlink:to="loc_srt_ProductOrServiceAxis_077d6036-0562-4eab-861e-c68a9186ce41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_077d6036-0562-4eab-861e-c68a9186ce41_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_077d6036-0562-4eab-861e-c68a9186ce41" xlink:to="loc_srt_ProductsAndServicesDomain_077d6036-0562-4eab-861e-c68a9186ce41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_09106211-ad1b-41de-8fc1-ec4b8583e6d1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_077d6036-0562-4eab-861e-c68a9186ce41" xlink:to="loc_srt_ProductsAndServicesDomain_09106211-ad1b-41de-8fc1-ec4b8583e6d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_a1c363f9-768f-47a6-8590-ca2e2a5896d6" xlink:href="biib-20230930.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_09106211-ad1b-41de-8fc1-ec4b8583e6d1" xlink:to="loc_biib_ADUHELMMember_a1c363f9-768f-47a6-8590-ca2e2a5896d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2a25c751-e32c-43da-ac12-6d9ee5efdc47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_6a487729-a0ce-4f11-9409-2e18fbd9d86c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2a25c751-e32c-43da-ac12-6d9ee5efdc47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a25c751-e32c-43da-ac12-6d9ee5efdc47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2a25c751-e32c-43da-ac12-6d9ee5efdc47" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a25c751-e32c-43da-ac12-6d9ee5efdc47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8970c816-45e8-4a60-a146-9d1548d5a8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2a25c751-e32c-43da-ac12-6d9ee5efdc47" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8970c816-45e8-4a60-a146-9d1548d5a8fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_197d1f5c-f13a-4543-aa35-f934885f9967" xlink:href="biib-20230930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8970c816-45e8-4a60-a146-9d1548d5a8fa" xlink:to="loc_biib_EisaiMember_197d1f5c-f13a-4543-aa35-f934885f9967" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_313e7fa9-df55-4ae8-bad7-03c29154d290" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_6a487729-a0ce-4f11-9409-2e18fbd9d86c" xlink:to="loc_srt_CounterpartyNameAxis_313e7fa9-df55-4ae8-bad7-03c29154d290" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_313e7fa9-df55-4ae8-bad7-03c29154d290_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_313e7fa9-df55-4ae8-bad7-03c29154d290" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_313e7fa9-df55-4ae8-bad7-03c29154d290_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bec504c6-b478-4c04-936f-798f84450aa2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_313e7fa9-df55-4ae8-bad7-03c29154d290" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bec504c6-b478-4c04-936f-798f84450aa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CentersForMedicareAndMedicaidServiceMember_9525f04e-e6b0-4a4e-bc4c-db960d53c23c" xlink:href="biib-20230930.xsd#biib_CentersForMedicareAndMedicaidServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bec504c6-b478-4c04-936f-798f84450aa2" xlink:to="loc_biib_CentersForMedicareAndMedicaidServiceMember_9525f04e-e6b0-4a4e-bc4c-db960d53c23c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e776c40b-7c16-42b6-9dc4-d6b19de1ac09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e776c40b-7c16-42b6-9dc4-d6b19de1ac09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3bf84b3b-9e28-40a7-acec-c7d92666866b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3bf84b3b-9e28-40a7-acec-c7d92666866b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_14980f8c-09b7-42ef-8103-220b0882db47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_14980f8c-09b7-42ef-8103-220b0882db47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2805588f-bfd9-4a46-bd41-d2ba05553687" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2805588f-bfd9-4a46-bd41-d2ba05553687" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ad514145-1664-4b81-b99b-4066abcd7986" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ad514145-1664-4b81-b99b-4066abcd7986" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d19b94a5-4103-4d20-b23f-5fc1de4c1d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d19b94a5-4103-4d20-b23f-5fc1de4c1d1b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ee066a37-1b11-42f9-87eb-829a61f1c03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ee066a37-1b11-42f9-87eb-829a61f1c03c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_d2bd755b-edd7-43be-9f0d-93723cb0522b" xlink:href="biib-20230930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_d2bd755b-edd7-43be-9f0d-93723cb0522b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e11c209b-1779-4d59-bddb-ea0ce1f67653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_823509ba-df85-4905-b289-ec278ba46daf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_823509ba-df85-4905-b289-ec278ba46daf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a6d13eb7-d0f0-4a0d-a7b4-4d3008d33e61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a6d13eb7-d0f0-4a0d-a7b4-4d3008d33e61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8e7058f6-3881-45b1-8d65-4beb09be7a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8e7058f6-3881-45b1-8d65-4beb09be7a07" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_341c138a-72d6-4e0a-815f-dc1d595e281e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_341c138a-72d6-4e0a-815f-dc1d595e281e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9e3c6666-1307-4153-9c2b-3a5aeea7744f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9e3c6666-1307-4153-9c2b-3a5aeea7744f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2c9f929d-284f-4554-a5f9-4015a7764eca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2c9f929d-284f-4554-a5f9-4015a7764eca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_56c23cfe-efd4-40e8-afac-1e0591e01362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_56c23cfe-efd4-40e8-afac-1e0591e01362" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bccdc891-45a5-4afe-b2e3-bcfd590ebd2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bccdc891-45a5-4afe-b2e3-bcfd590ebd2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4a368725-f0b1-4a45-9bd9-fcc2bfeafb22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bccdc891-45a5-4afe-b2e3-bcfd590ebd2f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4a368725-f0b1-4a45-9bd9-fcc2bfeafb22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4a368725-f0b1-4a45-9bd9-fcc2bfeafb22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4a368725-f0b1-4a45-9bd9-fcc2bfeafb22" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4a368725-f0b1-4a45-9bd9-fcc2bfeafb22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc93211c-548d-4d73-b047-5f638b8a2f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4a368725-f0b1-4a45-9bd9-fcc2bfeafb22" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc93211c-548d-4d73-b047-5f638b8a2f1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_5ba3b23a-9fd0-46c7-984f-565946ae2d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc93211c-548d-4d73-b047-5f638b8a2f1a" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_5ba3b23a-9fd0-46c7-984f-565946ae2d8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9bc7c12c-745e-4d3f-ac82-0674c06a2740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc93211c-548d-4d73-b047-5f638b8a2f1a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9bc7c12c-745e-4d3f-ac82-0674c06a2740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_e1b17908-c64d-4286-8afc-f6f3873d7080" xlink:href="biib-20230930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc93211c-548d-4d73-b047-5f638b8a2f1a" xlink:to="loc_biib_PriorityReviewVoucherMember_e1b17908-c64d-4286-8afc-f6f3873d7080" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6f87ec68-74e5-4cd5-9d83-0484299174ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bccdc891-45a5-4afe-b2e3-bcfd590ebd2f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6f87ec68-74e5-4cd5-9d83-0484299174ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6f87ec68-74e5-4cd5-9d83-0484299174ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6f87ec68-74e5-4cd5-9d83-0484299174ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6f87ec68-74e5-4cd5-9d83-0484299174ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdf5b423-6645-450b-b5e6-d03468799855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6f87ec68-74e5-4cd5-9d83-0484299174ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdf5b423-6645-450b-b5e6-d03468799855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember_a04340a7-f9c2-4427-801a-7e6840d9db99" xlink:href="biib-20230930.xsd#biib_OutLicensedPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdf5b423-6645-450b-b5e6-d03468799855" xlink:to="loc_biib_OutLicensedPatentsMember_a04340a7-f9c2-4427-801a-7e6840d9db99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_fb91012c-7da0-4a8b-900e-fc78d310798b" xlink:href="biib-20230930.xsd#biib_SKYCLARYSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdf5b423-6645-450b-b5e6-d03468799855" xlink:to="loc_biib_SKYCLARYSMember_fb91012c-7da0-4a8b-900e-fc78d310798b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ea6c47a0-9de3-4b32-93b7-a1cdefd22482" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bccdc891-45a5-4afe-b2e3-bcfd590ebd2f" xlink:to="loc_srt_RangeAxis_ea6c47a0-9de3-4b32-93b7-a1cdefd22482" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ea6c47a0-9de3-4b32-93b7-a1cdefd22482_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ea6c47a0-9de3-4b32-93b7-a1cdefd22482" xlink:to="loc_srt_RangeMember_ea6c47a0-9de3-4b32-93b7-a1cdefd22482_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5486b424-6003-470c-9b0c-07854ad4c9d4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ea6c47a0-9de3-4b32-93b7-a1cdefd22482" xlink:to="loc_srt_RangeMember_5486b424-6003-470c-9b0c-07854ad4c9d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ede6a8a7-a12b-446a-9334-346587044b20" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5486b424-6003-470c-9b0c-07854ad4c9d4" xlink:to="loc_srt_MinimumMember_ede6a8a7-a12b-446a-9334-346587044b20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e8340873-e70d-4026-bfc5-d8a1ea245ad2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5486b424-6003-470c-9b0c-07854ad4c9d4" xlink:to="loc_srt_MaximumMember_e8340873-e70d-4026-bfc5-d8a1ea245ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ca26def8-6083-4db5-9f51-66829e914340" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bccdc891-45a5-4afe-b2e3-bcfd590ebd2f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ca26def8-6083-4db5-9f51-66829e914340" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ca26def8-6083-4db5-9f51-66829e914340_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ca26def8-6083-4db5-9f51-66829e914340" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ca26def8-6083-4db5-9f51-66829e914340_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0ed486aa-a169-4fc3-a35b-87ce1fb07536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ca26def8-6083-4db5-9f51-66829e914340" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0ed486aa-a169-4fc3-a35b-87ce1fb07536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_d2253b7e-fa75-4fbf-95e0-49e79b71f3cc" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0ed486aa-a169-4fc3-a35b-87ce1fb07536" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_d2253b7e-fa75-4fbf-95e0-49e79b71f3cc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e9dbf74d-3ea8-4ea4-bdc2-599c3591f4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_44e660af-abc7-4b04-b3fc-8e339126552f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e9dbf74d-3ea8-4ea4-bdc2-599c3591f4e8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_44e660af-abc7-4b04-b3fc-8e339126552f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_44e660af-abc7-4b04-b3fc-8e339126552f" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c7e39eb8-90d4-442f-beee-a6d7866fb246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c7e39eb8-90d4-442f-beee-a6d7866fb246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_578f8517-bf3c-42e6-a9a8-277cd786ea05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_578f8517-bf3c-42e6-a9a8-277cd786ea05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_ffed7695-828e-4547-9454-a1fcdef56ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_ffed7695-828e-4547-9454-a1fcdef56ab8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure_00816f86-2675-458d-8e7f-c1ad7c5e8bcd" xlink:href="biib-20230930.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_biib_OtherAssetsCurrentFairValueDisclosure_00816f86-2675-458d-8e7f-c1ad7c5e8bcd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_34e5ceff-b374-4d28-996b-dd30179580f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_34e5ceff-b374-4d28-996b-dd30179580f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_2df9476d-46c6-4a28-9efc-7eafc3dbac5e" xlink:href="biib-20230930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_2df9476d-46c6-4a28-9efc-7eafc3dbac5e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_93d1f98b-ad89-4b77-89d9-70c1f0c34511" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_93d1f98b-ad89-4b77-89d9-70c1f0c34511" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_c57027e2-6761-404c-83b3-aa31f02f4ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_us-gaap_DerivativeAssets_c57027e2-6761-404c-83b3-aa31f02f4ab2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3299e9e1-45e5-41a6-a011-3d34ca31bbad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3299e9e1-45e5-41a6-a011-3d34ca31bbad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a06b2d9-1add-4d53-8de9-4dbc56480c62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_44e660af-abc7-4b04-b3fc-8e339126552f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a06b2d9-1add-4d53-8de9-4dbc56480c62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1d25e5cb-e4ae-4b37-830c-03956e822baa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a06b2d9-1add-4d53-8de9-4dbc56480c62" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1d25e5cb-e4ae-4b37-830c-03956e822baa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_127ed584-fd13-4ef4-958d-1c90d9ff0129" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a06b2d9-1add-4d53-8de9-4dbc56480c62" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_127ed584-fd13-4ef4-958d-1c90d9ff0129" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_20505c03-eab3-4d6b-83e2-9ce39a3a8704" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a06b2d9-1add-4d53-8de9-4dbc56480c62" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_20505c03-eab3-4d6b-83e2-9ce39a3a8704" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f494a12a-ca29-4d76-abeb-7f0311ac5f97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a06b2d9-1add-4d53-8de9-4dbc56480c62" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f494a12a-ca29-4d76-abeb-7f0311ac5f97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f745d356-379c-4d73-ade8-187455821ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e9dbf74d-3ea8-4ea4-bdc2-599c3591f4e8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f745d356-379c-4d73-ade8-187455821ad3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e1aa458e-e3b2-4a23-951b-22c4580af92e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f745d356-379c-4d73-ade8-187455821ad3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e1aa458e-e3b2-4a23-951b-22c4580af92e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e1aa458e-e3b2-4a23-951b-22c4580af92e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e1aa458e-e3b2-4a23-951b-22c4580af92e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e1aa458e-e3b2-4a23-951b-22c4580af92e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_faedeca0-f925-4cae-b57b-ed6b800ac9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e1aa458e-e3b2-4a23-951b-22c4580af92e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_faedeca0-f925-4cae-b57b-ed6b800ac9eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5f258d6e-5b59-4f80-b7ff-ef43ee7fc1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_faedeca0-f925-4cae-b57b-ed6b800ac9eb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5f258d6e-5b59-4f80-b7ff-ef43ee7fc1b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_91350d80-80df-46d7-800a-0a73713f80c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_faedeca0-f925-4cae-b57b-ed6b800ac9eb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_91350d80-80df-46d7-800a-0a73713f80c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7934bfac-6ae7-4ada-8518-e98e4785a7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_faedeca0-f925-4cae-b57b-ed6b800ac9eb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7934bfac-6ae7-4ada-8518-e98e4785a7ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b64d3891-81b4-41f4-beef-0c5f51e8de7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f745d356-379c-4d73-ade8-187455821ad3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b64d3891-81b4-41f4-beef-0c5f51e8de7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b64d3891-81b4-41f4-beef-0c5f51e8de7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b64d3891-81b4-41f4-beef-0c5f51e8de7f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b64d3891-81b4-41f4-beef-0c5f51e8de7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3f5cdb94-3eee-4a5a-84b7-48dc518fe114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b64d3891-81b4-41f4-beef-0c5f51e8de7f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3f5cdb94-3eee-4a5a-84b7-48dc518fe114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_849915f3-ba66-4203-984c-184b0ae3db05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3f5cdb94-3eee-4a5a-84b7-48dc518fe114" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_849915f3-ba66-4203-984c-184b0ae3db05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2a4a88dc-21b5-497d-b3d5-0aabd1fa7cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f745d356-379c-4d73-ade8-187455821ad3" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2a4a88dc-21b5-497d-b3d5-0aabd1fa7cd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2a4a88dc-21b5-497d-b3d5-0aabd1fa7cd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2a4a88dc-21b5-497d-b3d5-0aabd1fa7cd4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2a4a88dc-21b5-497d-b3d5-0aabd1fa7cd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bdd74b4b-d9df-45aa-b3e2-b65b9d79469d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2a4a88dc-21b5-497d-b3d5-0aabd1fa7cd4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bdd74b4b-d9df-45aa-b3e2-b65b9d79469d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d4d0034d-96db-4ff2-a278-7afd55a59e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bdd74b4b-d9df-45aa-b3e2-b65b9d79469d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d4d0034d-96db-4ff2-a278-7afd55a59e1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_aecd1cbc-4d5c-4ffe-905f-ca99812c6bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bdd74b4b-d9df-45aa-b3e2-b65b9d79469d" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_aecd1cbc-4d5c-4ffe-905f-ca99812c6bd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_2ef47873-b9c8-4ba9-abed-3f463ca25308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bdd74b4b-d9df-45aa-b3e2-b65b9d79469d" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_2ef47873-b9c8-4ba9-abed-3f463ca25308" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5181bec5-9be4-43f1-9967-2313a5902918" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f745d356-379c-4d73-ade8-187455821ad3" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5181bec5-9be4-43f1-9967-2313a5902918" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5181bec5-9be4-43f1-9967-2313a5902918_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5181bec5-9be4-43f1-9967-2313a5902918" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5181bec5-9be4-43f1-9967-2313a5902918_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_679b2c9a-d30a-493e-8b05-9bf8a3c514b4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5181bec5-9be4-43f1-9967-2313a5902918" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_679b2c9a-d30a-493e-8b05-9bf8a3c514b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_47515f9b-3bf5-474c-8a7b-5f9d2a537762" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_679b2c9a-d30a-493e-8b05-9bf8a3c514b4" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_47515f9b-3bf5-474c-8a7b-5f9d2a537762" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20230930.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4c5b3703-645f-44dc-84d9-b57c63c02719" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a9204dfb-d1aa-4ee1-ac33-3908f5732517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c5b3703-645f-44dc-84d9-b57c63c02719" xlink:to="loc_us-gaap_AssetImpairmentCharges_a9204dfb-d1aa-4ee1-ac33-3908f5732517" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1047a54b-3a6e-42df-86c7-d0ed911e4ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c5b3703-645f-44dc-84d9-b57c63c02719" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1047a54b-3a6e-42df-86c7-d0ed911e4ddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2ba4867f-88d4-4f77-b67e-71b87946fa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c5b3703-645f-44dc-84d9-b57c63c02719" xlink:to="loc_us-gaap_DebtInstrumentTable_2ba4867f-88d4-4f77-b67e-71b87946fa0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1e7a10b6-53f7-478d-8c1c-f67569bc42c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2ba4867f-88d4-4f77-b67e-71b87946fa0d" xlink:to="loc_us-gaap_CreditFacilityAxis_1e7a10b6-53f7-478d-8c1c-f67569bc42c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1e7a10b6-53f7-478d-8c1c-f67569bc42c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1e7a10b6-53f7-478d-8c1c-f67569bc42c3" xlink:to="loc_us-gaap_CreditFacilityDomain_1e7a10b6-53f7-478d-8c1c-f67569bc42c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c865efc7-cd02-4f24-9e60-ae45118b4395" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1e7a10b6-53f7-478d-8c1c-f67569bc42c3" xlink:to="loc_us-gaap_CreditFacilityDomain_c865efc7-cd02-4f24-9e60-ae45118b4395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_4a692cd1-5f9c-4987-876b-3e0d3da4ba6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c865efc7-cd02-4f24-9e60-ae45118b4395" xlink:to="loc_us-gaap_SecuredDebtMember_4a692cd1-5f9c-4987-876b-3e0d3da4ba6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_69f37148-a756-4cde-8b42-6a51d5d9e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2ba4867f-88d4-4f77-b67e-71b87946fa0d" xlink:to="loc_us-gaap_DebtInstrumentAxis_69f37148-a756-4cde-8b42-6a51d5d9e89f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_69f37148-a756-4cde-8b42-6a51d5d9e89f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_69f37148-a756-4cde-8b42-6a51d5d9e89f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_69f37148-a756-4cde-8b42-6a51d5d9e89f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2c4d2fcc-8bd4-435a-9868-c0823b7bac15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_69f37148-a756-4cde-8b42-6a51d5d9e89f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2c4d2fcc-8bd4-435a-9868-c0823b7bac15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_2a654cd3-456f-4fe0-82b8-ab4d1d458091" xlink:href="biib-20230930.xsd#biib_TheCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c4d2fcc-8bd4-435a-9868-c0823b7bac15" xlink:to="loc_biib_TheCreditFacilityMember_2a654cd3-456f-4fe0-82b8-ab4d1d458091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a728d77d-4217-4b8f-9838-c0aa99299929" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2ba4867f-88d4-4f77-b67e-71b87946fa0d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a728d77d-4217-4b8f-9838-c0aa99299929" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a728d77d-4217-4b8f-9838-c0aa99299929_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a728d77d-4217-4b8f-9838-c0aa99299929" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a728d77d-4217-4b8f-9838-c0aa99299929_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4b2cbd68-17a8-4fc0-880d-b757f22f9e94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a728d77d-4217-4b8f-9838-c0aa99299929" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4b2cbd68-17a8-4fc0-880d-b757f22f9e94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_97a72f6a-5dbb-4fd8-ab2b-3ef4a45abbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4b2cbd68-17a8-4fc0-880d-b757f22f9e94" xlink:to="loc_us-gaap_LineOfCreditMember_97a72f6a-5dbb-4fd8-ab2b-3ef4a45abbe3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f89f9c1-36ca-42dd-b6f3-386c2fc8fcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_528fbdd1-4b40-426f-8fad-6aed45e2b021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f89f9c1-36ca-42dd-b6f3-386c2fc8fcd1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_528fbdd1-4b40-426f-8fad-6aed45e2b021" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a69c6926-a619-4f5d-8037-f410456bccc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f89f9c1-36ca-42dd-b6f3-386c2fc8fcd1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a69c6926-a619-4f5d-8037-f410456bccc0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a0f53205-df4f-48c8-8219-6a0d3ccefede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a69c6926-a619-4f5d-8037-f410456bccc0" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a0f53205-df4f-48c8-8219-6a0d3ccefede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a0f53205-df4f-48c8-8219-6a0d3ccefede_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a0f53205-df4f-48c8-8219-6a0d3ccefede" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a0f53205-df4f-48c8-8219-6a0d3ccefede_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9a7e5e42-ef3f-42a2-a4e6-d5205d4d37de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a0f53205-df4f-48c8-8219-6a0d3ccefede" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9a7e5e42-ef3f-42a2-a4e6-d5205d4d37de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_dd1ef4a4-8f7b-411c-b414-e5529e46eaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9a7e5e42-ef3f-42a2-a4e6-d5205d4d37de" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_dd1ef4a4-8f7b-411c-b414-e5529e46eaf4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20230930.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7cb6574d-b305-4628-b422-35aacd61df7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_3c61264e-dfe5-408b-8044-ad2f3143afa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7cb6574d-b305-4628-b422-35aacd61df7e" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_3c61264e-dfe5-408b-8044-ad2f3143afa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_408f8db1-8f00-4c29-afbd-e6223ee10c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7cb6574d-b305-4628-b422-35aacd61df7e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_408f8db1-8f00-4c29-afbd-e6223ee10c7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_93d09f6f-6380-41f0-af46-ace0a7473389" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7cb6574d-b305-4628-b422-35aacd61df7e" xlink:to="loc_us-gaap_NotesPayable_93d09f6f-6380-41f0-af46-ace0a7473389" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6ca91225-ee3c-4280-9d89-ef5a0d559197" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7cb6574d-b305-4628-b422-35aacd61df7e" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6ca91225-ee3c-4280-9d89-ef5a0d559197" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bc2507d0-b78c-46b4-895f-b7f5ad81f1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7cb6574d-b305-4628-b422-35aacd61df7e" xlink:to="loc_us-gaap_DebtInstrumentTable_bc2507d0-b78c-46b4-895f-b7f5ad81f1e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_eade1eff-8b85-44f5-afbe-664757bc110c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bc2507d0-b78c-46b4-895f-b7f5ad81f1e7" xlink:to="loc_us-gaap_DebtInstrumentAxis_eade1eff-8b85-44f5-afbe-664757bc110c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_eade1eff-8b85-44f5-afbe-664757bc110c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_eade1eff-8b85-44f5-afbe-664757bc110c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_eade1eff-8b85-44f5-afbe-664757bc110c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f4b08c87-d263-49c6-b580-7d3d993e86d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_eade1eff-8b85-44f5-afbe-664757bc110c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f4b08c87-d263-49c6-b580-7d3d993e86d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_3547a83f-8498-4283-a905-13c0241ec239" xlink:href="biib-20230930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f4b08c87-d263-49c6-b580-7d3d993e86d8" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_3547a83f-8498-4283-a905-13c0241ec239" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_9a5c55eb-669a-4e31-82d1-9d3c5c59fb75" xlink:href="biib-20230930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f4b08c87-d263-49c6-b580-7d3d993e86d8" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_9a5c55eb-669a-4e31-82d1-9d3c5c59fb75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1f8bbda1-0008-404a-9dc6-629004da32da" xlink:href="biib-20230930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f4b08c87-d263-49c6-b580-7d3d993e86d8" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1f8bbda1-0008-404a-9dc6-629004da32da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_9ab4b359-a0ac-432e-98f8-1fd1f9b00562" xlink:href="biib-20230930.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f4b08c87-d263-49c6-b580-7d3d993e86d8" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_9ab4b359-a0ac-432e-98f8-1fd1f9b00562" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_46c0fc30-2b48-4e81-91f5-e0e67a9caf4a" xlink:href="biib-20230930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f4b08c87-d263-49c6-b580-7d3d993e86d8" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_46c0fc30-2b48-4e81-91f5-e0e67a9caf4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_3b2d3dca-40b9-4617-b384-121c5c109ac0" xlink:href="biib-20230930.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bc2507d0-b78c-46b4-895f-b7f5ad81f1e7" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_3b2d3dca-40b9-4617-b384-121c5c109ac0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentAssetDomain_3b2d3dca-40b9-4617-b384-121c5c109ac0_default" xlink:href="biib-20230930.xsd#biib_ResearchAndDevelopmentAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_3b2d3dca-40b9-4617-b384-121c5c109ac0" xlink:to="loc_biib_ResearchAndDevelopmentAssetDomain_3b2d3dca-40b9-4617-b384-121c5c109ac0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentAssetDomain_730342c0-dae0-4f37-8d3f-69329e7a96c9" xlink:href="biib-20230930.xsd#biib_ResearchAndDevelopmentAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_3b2d3dca-40b9-4617-b384-121c5c109ac0" xlink:to="loc_biib_ResearchAndDevelopmentAssetDomain_730342c0-dae0-4f37-8d3f-69329e7a96c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB054Member_5c9bee20-5b00-4765-9ec4-2344b27cf803" xlink:href="biib-20230930.xsd#biib_BIIB054Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_730342c0-dae0-4f37-8d3f-69329e7a96c9" xlink:to="loc_biib_BIIB054Member_5c9bee20-5b00-4765-9ec4-2344b27cf803" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20230930.xsd#FairValueMeasurementsDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_07ca5c0e-186c-48c3-904c-dc6992e94383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e4f89d4b-c7db-4ee3-a78f-dd41dcc2da19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_07ca5c0e-186c-48c3-904c-dc6992e94383" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e4f89d4b-c7db-4ee3-a78f-dd41dcc2da19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_82f9dc7f-98a2-459d-ac5c-93adf918647a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_07ca5c0e-186c-48c3-904c-dc6992e94383" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_82f9dc7f-98a2-459d-ac5c-93adf918647a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_95831208-0579-4e92-9361-09fcf4b0d794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1a94e71c-9eb3-49b5-b343-064e61693fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_07ca5c0e-186c-48c3-904c-dc6992e94383" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1a94e71c-9eb3-49b5-b343-064e61693fb1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_098e2e33-9918-4710-b578-45eead50d365" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1a94e71c-9eb3-49b5-b343-064e61693fb1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_098e2e33-9918-4710-b578-45eead50d365" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_098e2e33-9918-4710-b578-45eead50d365_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_098e2e33-9918-4710-b578-45eead50d365" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_098e2e33-9918-4710-b578-45eead50d365_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5357c4d9-16ef-4911-9bb6-f2e3d0d94a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_098e2e33-9918-4710-b578-45eead50d365" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5357c4d9-16ef-4911-9bb6-f2e3d0d94a3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_58716b1f-d067-4b4b-91fc-9dba6111143e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5357c4d9-16ef-4911-9bb6-f2e3d0d94a3f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_58716b1f-d067-4b4b-91fc-9dba6111143e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_e4130185-4c71-4ac3-b520-7c228f7a063a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_1a81619d-39cc-478c-ac93-c5fcaa1cdd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_e4130185-4c71-4ac3-b520-7c228f7a063a" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_1a81619d-39cc-478c-ac93-c5fcaa1cdd6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_c576b3de-b07c-48a1-b60f-3d42e31f8346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_1a81619d-39cc-478c-ac93-c5fcaa1cdd6c" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_c576b3de-b07c-48a1-b60f-3d42e31f8346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ea03d437-aef1-4ae1-ae23-2af49b4b53d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_e4130185-4c71-4ac3-b520-7c228f7a063a" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ea03d437-aef1-4ae1-ae23-2af49b4b53d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_efbaa399-6e25-449c-bb4e-64e4d560c60d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ea03d437-aef1-4ae1-ae23-2af49b4b53d9" xlink:to="loc_us-gaap_InvestmentTypeAxis_efbaa399-6e25-449c-bb4e-64e4d560c60d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_efbaa399-6e25-449c-bb4e-64e4d560c60d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_efbaa399-6e25-449c-bb4e-64e4d560c60d" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_efbaa399-6e25-449c-bb4e-64e4d560c60d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1e0cf289-ab56-4052-8dc1-5a41141ef52d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_efbaa399-6e25-449c-bb4e-64e4d560c60d" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1e0cf289-ab56-4052-8dc1-5a41141ef52d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b2f7bce1-aaf0-47d7-a1d3-6a3c5df94e82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1e0cf289-ab56-4052-8dc1-5a41141ef52d" xlink:to="loc_us-gaap_CommercialPaperMember_b2f7bce1-aaf0-47d7-a1d3-6a3c5df94e82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_ddaa7e62-f97b-4f82-9731-9bb68b146039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1e0cf289-ab56-4052-8dc1-5a41141ef52d" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_ddaa7e62-f97b-4f82-9731-9bb68b146039" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c3599485-f960-4a4a-86f5-fb74d21755fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1e0cf289-ab56-4052-8dc1-5a41141ef52d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c3599485-f960-4a4a-86f5-fb74d21755fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_2241ac30-25db-4380-b697-e05e7dd5d001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1e0cf289-ab56-4052-8dc1-5a41141ef52d" xlink:to="loc_us-gaap_CertificatesOfDepositMember_2241ac30-25db-4380-b697-e05e7dd5d001" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_779aac2f-554e-4740-af34-c592b80541b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1e0cf289-ab56-4052-8dc1-5a41141ef52d" xlink:to="loc_us-gaap_DebtSecuritiesMember_779aac2f-554e-4740-af34-c592b80541b9" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20230930.xsd#FinancialInstrumentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_01277945-9a7d-476a-aeeb-73ff1f27eb73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_21c34235-fbad-4820-a2ba-fbc99376883e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_01277945-9a7d-476a-aeeb-73ff1f27eb73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_21c34235-fbad-4820-a2ba-fbc99376883e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5c91efc2-3a35-4c50-a24a-a06b4b071254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_21c34235-fbad-4820-a2ba-fbc99376883e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5c91efc2-3a35-4c50-a24a-a06b4b071254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b3e5f4e9-da87-4fb0-8fea-5e216e30c9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_21c34235-fbad-4820-a2ba-fbc99376883e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b3e5f4e9-da87-4fb0-8fea-5e216e30c9e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fe368f4a-fb3c-452a-8725-89003168e9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_21c34235-fbad-4820-a2ba-fbc99376883e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fe368f4a-fb3c-452a-8725-89003168e9cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_69bfb3ed-9e92-4c2f-ad9b-030f02a2578f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_21c34235-fbad-4820-a2ba-fbc99376883e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_69bfb3ed-9e92-4c2f-ad9b-030f02a2578f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_a4aea19a-ddcf-47ba-81e3-18d9146f44f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_01277945-9a7d-476a-aeeb-73ff1f27eb73" xlink:to="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_a4aea19a-ddcf-47ba-81e3-18d9146f44f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_ef3684d8-421f-427a-950b-925d502d349d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_a4aea19a-ddcf-47ba-81e3-18d9146f44f4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_ef3684d8-421f-427a-950b-925d502d349d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_c2015764-e8ef-4f92-9f09-c595320b9a21" xlink:href="biib-20230930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_a4aea19a-ddcf-47ba-81e3-18d9146f44f4" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_c2015764-e8ef-4f92-9f09-c595320b9a21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_6ba023ff-d373-4528-8fc8-aa6c52edf03c" xlink:href="biib-20230930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_a4aea19a-ddcf-47ba-81e3-18d9146f44f4" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_6ba023ff-d373-4528-8fc8-aa6c52edf03c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_be1d6b39-8f41-458d-ad54-0e7275110ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_a4aea19a-ddcf-47ba-81e3-18d9146f44f4" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_be1d6b39-8f41-458d-ad54-0e7275110ad0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c685393e-73fc-4612-a875-1e383389c20a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_01277945-9a7d-476a-aeeb-73ff1f27eb73" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c685393e-73fc-4612-a875-1e383389c20a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_00ef5742-e891-46a5-9f38-673e4d27c96c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c685393e-73fc-4612-a875-1e383389c20a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_00ef5742-e891-46a5-9f38-673e4d27c96c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00ef5742-e891-46a5-9f38-673e4d27c96c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_00ef5742-e891-46a5-9f38-673e4d27c96c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00ef5742-e891-46a5-9f38-673e4d27c96c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_00ef5742-e891-46a5-9f38-673e4d27c96c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_773b8c9a-e97d-4ae1-b810-845672bc4e46" xlink:href="biib-20230930.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_773b8c9a-e97d-4ae1-b810-845672bc4e46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_44a1751f-80eb-4da8-8161-ff0c0012a1bd" xlink:href="biib-20230930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_44a1751f-80eb-4da8-8161-ff0c0012a1bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_2d080cc4-691e-4f49-bc07-961cfa04cb74" xlink:href="biib-20230930.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_2d080cc4-691e-4f49-bc07-961cfa04cb74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_2dc93954-32c1-4d32-8556-2c256024a827" xlink:href="biib-20230930.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_2dc93954-32c1-4d32-8556-2c256024a827" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_66cb6aca-0e78-4ff9-a786-13c853217396" xlink:href="biib-20230930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_66cb6aca-0e78-4ff9-a786-13c853217396" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_3a9744c7-1f57-4596-9b8e-3189b5366891" xlink:href="biib-20230930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_3a9744c7-1f57-4596-9b8e-3189b5366891" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_624afc20-c3b6-4cfc-981e-76f514a1b222" xlink:href="biib-20230930.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:to="loc_biib_EquitySecuritiesCurrentMember_624afc20-c3b6-4cfc-981e-76f514a1b222" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_73085b8c-876e-48b2-a71c-7d5210946d2d" xlink:href="biib-20230930.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_73085b8c-876e-48b2-a71c-7d5210946d2d" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20230930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d47fa2c9-69f2-4c7c-8bd8-507780f59086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_dfcb5da8-1ce8-46ed-8be2-98f38c1edfcc" xlink:href="biib-20230930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d47fa2c9-69f2-4c7c-8bd8-507780f59086" xlink:to="loc_biib_StrategicInvestmentPortfolio_dfcb5da8-1ce8-46ed-8be2-98f38c1edfcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6ed157d5-5c02-412d-a895-b805d5e16291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d47fa2c9-69f2-4c7c-8bd8-507780f59086" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6ed157d5-5c02-412d-a895-b805d5e16291" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4ccd82a3-146b-41fb-bbfc-c1875df77eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6ed157d5-5c02-412d-a895-b805d5e16291" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4ccd82a3-146b-41fb-bbfc-c1875df77eac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4ccd82a3-146b-41fb-bbfc-c1875df77eac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4ccd82a3-146b-41fb-bbfc-c1875df77eac" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4ccd82a3-146b-41fb-bbfc-c1875df77eac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c8dfc7b4-1790-49bf-a5e5-1283b9f809ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4ccd82a3-146b-41fb-bbfc-c1875df77eac" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c8dfc7b4-1790-49bf-a5e5-1283b9f809ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_ba79897b-6b04-44a4-b7a4-66d0bf5f0276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c8dfc7b4-1790-49bf-a5e5-1283b9f809ee" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_ba79897b-6b04-44a4-b7a4-66d0bf5f0276" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d15fa5ef-16d3-4e9c-ac5d-5d56fd768e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6ed157d5-5c02-412d-a895-b805d5e16291" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d15fa5ef-16d3-4e9c-ac5d-5d56fd768e0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d15fa5ef-16d3-4e9c-ac5d-5d56fd768e0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d15fa5ef-16d3-4e9c-ac5d-5d56fd768e0a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d15fa5ef-16d3-4e9c-ac5d-5d56fd768e0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c460c4e-9871-4080-9aa2-0db426a09349" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d15fa5ef-16d3-4e9c-ac5d-5d56fd768e0a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c460c4e-9871-4080-9aa2-0db426a09349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_fa759b04-ab4e-407a-8651-a57a865fe865" xlink:href="biib-20230930.xsd#biib_StrategicInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c460c4e-9871-4080-9aa2-0db426a09349" xlink:to="loc_biib_StrategicInvestmentsMember_fa759b04-ab4e-407a-8651-a57a865fe865" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#DerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_8a3133f7-7a75-4fb9-8123-d44f56499e57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_8a3133f7-7a75-4fb9-8123-d44f56499e57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_6d8f80e7-4d84-464a-bd3d-9e4b9466f144" xlink:href="biib-20230930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_6d8f80e7-4d84-464a-bd3d-9e4b9466f144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_26ca59a6-d7fa-461e-be07-f3357fc9f06b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_26ca59a6-d7fa-461e-be07-f3357fc9f06b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_94d0e32e-f9f2-4318-bae3-565c2540c6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_DerivativeNotionalAmount_94d0e32e-f9f2-4318-bae3-565c2540c6a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7bca0575-833b-4365-8fd6-6a9fc2899b36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7bca0575-833b-4365-8fd6-6a9fc2899b36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_ffe8e1eb-40bd-46dc-904c-9b8bf9417281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_ffe8e1eb-40bd-46dc-904c-9b8bf9417281" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1741ac37-c3a1-4469-b3da-171fe401ec5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1741ac37-c3a1-4469-b3da-171fe401ec5e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3c02f00d-12f0-4d22-a1b8-d72febc0a156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3c02f00d-12f0-4d22-a1b8-d72febc0a156" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_b4364a47-589b-4b4a-96fd-e59128276ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_b4364a47-589b-4b4a-96fd-e59128276ca4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_66ef650b-64d7-43a7-936c-3829daff4874" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_66ef650b-64d7-43a7-936c-3829daff4874" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_054861b3-ead3-4304-bec6-18f865b95aab" xlink:href="biib-20230930.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_054861b3-ead3-4304-bec6-18f865b95aab" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_ad1c65fb-8498-4ba2-bce2-d8a7ff526665" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_ad1c65fb-8498-4ba2-bce2-d8a7ff526665" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives_d8595808-3df7-401c-a991-1371ab28ce78" xlink:href="biib-20230930.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_biib_UnrealizedGainOnDerivatives_d8595808-3df7-401c-a991-1371ab28ce78" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives_5c660348-960e-46e9-912e-a34d9f7e4361" xlink:href="biib-20230930.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_biib_UnrealizedLossOnDerivatives_5c660348-960e-46e9-912e-a34d9f7e4361" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_917100eb-b932-4c89-b866-89ebbe3a260c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_917100eb-b932-4c89-b866-89ebbe3a260c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_20ff4dc0-1c00-4b60-8907-335db075798a" xlink:href="biib-20230930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_20ff4dc0-1c00-4b60-8907-335db075798a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_058f9e22-c17f-4d21-b778-b3e4e238b3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_058f9e22-c17f-4d21-b778-b3e4e238b3f8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_bdf98bc3-04b8-4422-97d6-0ad566152f06" xlink:href="biib-20230930.xsd#biib_DerivativeMaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_biib_DerivativeMaturityAxis_bdf98bc3-04b8-4422-97d6-0ad566152f06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_bdf98bc3-04b8-4422-97d6-0ad566152f06_default" xlink:href="biib-20230930.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DerivativeMaturityAxis_bdf98bc3-04b8-4422-97d6-0ad566152f06" xlink:to="loc_biib_DerivativeMaturityDomain_bdf98bc3-04b8-4422-97d6-0ad566152f06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_8f461b45-7bc1-4321-bf5a-fc1f2ecba3d8" xlink:href="biib-20230930.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DerivativeMaturityAxis_bdf98bc3-04b8-4422-97d6-0ad566152f06" xlink:to="loc_biib_DerivativeMaturityDomain_8f461b45-7bc1-4321-bf5a-fc1f2ecba3d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_f435547d-75cc-4f3c-889a-2a34538edb15" xlink:href="biib-20230930.xsd#biib_ShorttermderivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeMaturityDomain_8f461b45-7bc1-4321-bf5a-fc1f2ecba3d8" xlink:to="loc_biib_ShorttermderivativeMember_f435547d-75cc-4f3c-889a-2a34538edb15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_81213972-8791-4ca9-8fb6-2fef6b5b7ccc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_81213972-8791-4ca9-8fb6-2fef6b5b7ccc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_81213972-8791-4ca9-8fb6-2fef6b5b7ccc_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_81213972-8791-4ca9-8fb6-2fef6b5b7ccc" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_81213972-8791-4ca9-8fb6-2fef6b5b7ccc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_bd967844-e381-4db2-bcb7-d6b92a7e53ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_81213972-8791-4ca9-8fb6-2fef6b5b7ccc" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_bd967844-e381-4db2-bcb7-d6b92a7e53ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_eee7f7f5-c762-4f73-a2a1-58f7f95105af" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bd967844-e381-4db2-bcb7-d6b92a7e53ce" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_eee7f7f5-c762-4f73-a2a1-58f7f95105af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_27c17d71-8034-443f-adef-e0a6a768172f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_srt_CurrencyAxis_27c17d71-8034-443f-adef-e0a6a768172f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_27c17d71-8034-443f-adef-e0a6a768172f_default" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_27c17d71-8034-443f-adef-e0a6a768172f" xlink:to="loc_currency_AllCurrenciesDomain_27c17d71-8034-443f-adef-e0a6a768172f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_44a42d60-330d-4bf3-933c-1f2f189ba47e" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_27c17d71-8034-443f-adef-e0a6a768172f" xlink:to="loc_currency_AllCurrenciesDomain_44a42d60-330d-4bf3-933c-1f2f189ba47e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_660d269d-697e-4b16-94fa-8042a526f63d" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_44a42d60-330d-4bf3-933c-1f2f189ba47e" xlink:to="loc_currency_EUR_660d269d-697e-4b16-94fa-8042a526f63d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_6c809c96-f0fa-4c56-a038-6725a1094117" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_44a42d60-330d-4bf3-933c-1f2f189ba47e" xlink:to="loc_currency_CHF_6c809c96-f0fa-4c56-a038-6725a1094117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_dcf432ee-232c-4b31-856d-1d37551a16a2" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_JPY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_44a42d60-330d-4bf3-933c-1f2f189ba47e" xlink:to="loc_currency_JPY_dcf432ee-232c-4b31-856d-1d37551a16a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_04245929-1e60-4268-970d-7955127d7af2" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_44a42d60-330d-4bf3-933c-1f2f189ba47e" xlink:to="loc_currency_CAD_04245929-1e60-4268-970d-7955127d7af2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_811d30ed-0f8e-402a-b905-b7eb35772e13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_811d30ed-0f8e-402a-b905-b7eb35772e13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_811d30ed-0f8e-402a-b905-b7eb35772e13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_811d30ed-0f8e-402a-b905-b7eb35772e13" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_811d30ed-0f8e-402a-b905-b7eb35772e13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d2c37601-3f6e-43fc-bf3f-d14d753e1059" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_811d30ed-0f8e-402a-b905-b7eb35772e13" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d2c37601-3f6e-43fc-bf3f-d14d753e1059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_335ece78-9f32-40ff-b647-c7560a8dc5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2c37601-3f6e-43fc-bf3f-d14d753e1059" xlink:to="loc_us-gaap_SalesMember_335ece78-9f32-40ff-b647-c7560a8dc5d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_cc499dcb-ec6a-4348-b7b3-1cae57412f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2c37601-3f6e-43fc-bf3f-d14d753e1059" xlink:to="loc_us-gaap_OperatingExpenseMember_cc499dcb-ec6a-4348-b7b3-1cae57412f9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_b65a888d-c2ad-46e4-8f87-d1101325b118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2c37601-3f6e-43fc-bf3f-d14d753e1059" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_b65a888d-c2ad-46e4-8f87-d1101325b118" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_db6b8fee-d1a1-41b8-bf97-0e4358028653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_db6b8fee-d1a1-41b8-bf97-0e4358028653" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_db6b8fee-d1a1-41b8-bf97-0e4358028653_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_db6b8fee-d1a1-41b8-bf97-0e4358028653" xlink:to="loc_us-gaap_HedgingRelationshipDomain_db6b8fee-d1a1-41b8-bf97-0e4358028653_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7d37deb5-5f6f-4fdb-a917-2232760787e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_db6b8fee-d1a1-41b8-bf97-0e4358028653" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7d37deb5-5f6f-4fdb-a917-2232760787e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_301077bd-ca32-414c-a98e-152dfcba20c5" xlink:href="biib-20230930.xsd#biib_CashflowsrevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7d37deb5-5f6f-4fdb-a917-2232760787e7" xlink:to="loc_biib_CashflowsrevenueMember_301077bd-ca32-414c-a98e-152dfcba20c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_606810da-478e-4c8a-93be-d988a8c09843" xlink:href="biib-20230930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7d37deb5-5f6f-4fdb-a917-2232760787e7" xlink:to="loc_biib_CashflowsoperatingexpensesMember_606810da-478e-4c8a-93be-d988a8c09843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_fbab272e-b356-4691-89d1-07f8f2ef28c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7d37deb5-5f6f-4fdb-a917-2232760787e7" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_fbab272e-b356-4691-89d1-07f8f2ef28c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b8ef5400-88ed-4f29-b547-fcd9cd85b932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b8ef5400-88ed-4f29-b547-fcd9cd85b932" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b8ef5400-88ed-4f29-b547-fcd9cd85b932_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b8ef5400-88ed-4f29-b547-fcd9cd85b932" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b8ef5400-88ed-4f29-b547-fcd9cd85b932_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ec9a2ea7-a9e6-4a6b-9974-5d228e1a5b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b8ef5400-88ed-4f29-b547-fcd9cd85b932" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ec9a2ea7-a9e6-4a6b-9974-5d228e1a5b4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_fec7a06f-48bc-4ce6-8702-0f8bac612e27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ec9a2ea7-a9e6-4a6b-9974-5d228e1a5b4f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_fec7a06f-48bc-4ce6-8702-0f8bac612e27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_7286aaf1-eedf-40b8-bc7b-1c1403c4a3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ec9a2ea7-a9e6-4a6b-9974-5d228e1a5b4f" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_7286aaf1-eedf-40b8-bc7b-1c1403c4a3fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c7e7014a-16d4-4e4b-acae-1ce37af95cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c7e7014a-16d4-4e4b-acae-1ce37af95cfb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c7e7014a-16d4-4e4b-acae-1ce37af95cfb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c7e7014a-16d4-4e4b-acae-1ce37af95cfb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c7e7014a-16d4-4e4b-acae-1ce37af95cfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2ae9d23a-043d-499a-9519-66d69edaa224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c7e7014a-16d4-4e4b-acae-1ce37af95cfb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2ae9d23a-043d-499a-9519-66d69edaa224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_67edace0-2833-45c3-8543-5a2ebfef983d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2ae9d23a-043d-499a-9519-66d69edaa224" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_67edace0-2833-45c3-8543-5a2ebfef983d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_9940c5ae-a2c7-4c8c-9adf-53f71a47f866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2ae9d23a-043d-499a-9519-66d69edaa224" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_9940c5ae-a2c7-4c8c-9adf-53f71a47f866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_ce44deb6-ab98-4bf3-9d3c-f6d052437043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2ae9d23a-043d-499a-9519-66d69edaa224" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_ce44deb6-ab98-4bf3-9d3c-f6d052437043" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_001006a0-4def-4da4-bf57-a8d530b96abf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_us-gaap_HedgingDesignationAxis_001006a0-4def-4da4-bf57-a8d530b96abf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_001006a0-4def-4da4-bf57-a8d530b96abf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_001006a0-4def-4da4-bf57-a8d530b96abf" xlink:to="loc_us-gaap_HedgingDesignationDomain_001006a0-4def-4da4-bf57-a8d530b96abf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a1deca99-5738-4c1f-bf58-08030594884d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_001006a0-4def-4da4-bf57-a8d530b96abf" xlink:to="loc_us-gaap_HedgingDesignationDomain_a1deca99-5738-4c1f-bf58-08030594884d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_127a4058-e9fc-479a-bc7a-7a9d0572cc03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_a1deca99-5738-4c1f-bf58-08030594884d" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_127a4058-e9fc-479a-bc7a-7a9d0572cc03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_2a7cfb40-5c6e-4751-8885-97901b359f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_a1deca99-5738-4c1f-bf58-08030594884d" xlink:to="loc_us-gaap_NondesignatedMember_2a7cfb40-5c6e-4751-8885-97901b359f2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9fc2ebe1-2185-4a61-9a85-af13ed437612" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_srt_RangeAxis_9fc2ebe1-2185-4a61-9a85-af13ed437612" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9fc2ebe1-2185-4a61-9a85-af13ed437612_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9fc2ebe1-2185-4a61-9a85-af13ed437612" xlink:to="loc_srt_RangeMember_9fc2ebe1-2185-4a61-9a85-af13ed437612_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d82b3a5-6b3c-499c-a335-908faf278c23" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9fc2ebe1-2185-4a61-9a85-af13ed437612" xlink:to="loc_srt_RangeMember_6d82b3a5-6b3c-499c-a335-908faf278c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3966527c-2634-451a-83bb-6e611471829c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6d82b3a5-6b3c-499c-a335-908faf278c23" xlink:to="loc_srt_MinimumMember_3966527c-2634-451a-83bb-6e611471829c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f38499b8-962e-4ada-a304-c4789ed932c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6d82b3a5-6b3c-499c-a335-908faf278c23" xlink:to="loc_srt_MaximumMember_f38499b8-962e-4ada-a304-c4789ed932c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_071d13c9-f905-4926-9251-34448e28ead8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_us-gaap_TypeOfArrangementAxis_071d13c9-f905-4926-9251-34448e28ead8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_071d13c9-f905-4926-9251-34448e28ead8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_071d13c9-f905-4926-9251-34448e28ead8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_071d13c9-f905-4926-9251-34448e28ead8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8598fd4e-6082-46a9-95af-12b64d2f8c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_071d13c9-f905-4926-9251-34448e28ead8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8598fd4e-6082-46a9-95af-12b64d2f8c96" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#PropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3ad569d6-161a-4f0c-b7aa-0db8199fd3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3ad569d6-161a-4f0c-b7aa-0db8199fd3dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a93554e0-553c-47db-87be-d3ce4760c759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_Depreciation_a93554e0-553c-47db-87be-d3ce4760c759" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_f9da24e5-0336-4b07-b387-73a79ce1e458" xlink:href="biib-20230930.xsd#biib_NumberOfSquareFeet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_biib_NumberOfSquareFeet_f9da24e5-0336-4b07-b387-73a79ce1e458" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_dddc96b8-e89f-4f7e-bf2a-477fbc31942b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_ConstructionInProgressGross_dddc96b8-e89f-4f7e-bf2a-477fbc31942b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_414bdd1e-e487-4513-bbfa-c60386e258ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_414bdd1e-e487-4513-bbfa-c60386e258ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_d9f054d3-5f22-4de8-9426-b3a49d9391f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_d9f054d3-5f22-4de8-9426-b3a49d9391f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_0874f502-66b8-4b94-b1c4-54f0d402debc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_0874f502-66b8-4b94-b1c4-54f0d402debc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_9fb29597-3bfc-44a2-8bcf-3661255f519c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_9fb29597-3bfc-44a2-8bcf-3661255f519c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance_757b3399-13ac-48b5-8842-16ed22b13d65" xlink:href="biib-20230930.xsd#biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance_757b3399-13ac-48b5-8842-16ed22b13d65" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ff4e412e-bfb2-4b16-a5cc-a399702da6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ff4e412e-bfb2-4b16-a5cc-a399702da6ab" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7f87c200-9a2b-4309-884c-4d228ade8cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7f87c200-9a2b-4309-884c-4d228ade8cf1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9026b9-b478-4119-9b4c-2228dfed929f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9026b9-b478-4119-9b4c-2228dfed929f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_579342f4-e748-4dac-8c9f-106216248aa7" xlink:href="biib-20230930.xsd#biib_FacilityLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9026b9-b478-4119-9b4c-2228dfed929f" xlink:to="loc_biib_FacilityLocationAxis_579342f4-e748-4dac-8c9f-106216248aa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_579342f4-e748-4dac-8c9f-106216248aa7_default" xlink:href="biib-20230930.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_579342f4-e748-4dac-8c9f-106216248aa7" xlink:to="loc_biib_FacilityLocationDomain_579342f4-e748-4dac-8c9f-106216248aa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_3b8f1779-1d72-4dc1-a788-55d24d4c802d" xlink:href="biib-20230930.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_579342f4-e748-4dac-8c9f-106216248aa7" xlink:to="loc_biib_FacilityLocationDomain_3b8f1779-1d72-4dc1-a788-55d24d4c802d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_eefd9265-95d9-4ded-93b1-afc432587b3c" xlink:href="biib-20230930.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_3b8f1779-1d72-4dc1-a788-55d24d4c802d" xlink:to="loc_biib_SolothurnSwitzerlandMember_eefd9265-95d9-4ded-93b1-afc432587b3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_1a251349-b840-42b4-aac3-d385f9620032" xlink:href="biib-20230930.xsd#biib_FacilityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9026b9-b478-4119-9b4c-2228dfed929f" xlink:to="loc_biib_FacilityTypeAxis_1a251349-b840-42b4-aac3-d385f9620032" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_1a251349-b840-42b4-aac3-d385f9620032_default" xlink:href="biib-20230930.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityTypeAxis_1a251349-b840-42b4-aac3-d385f9620032" xlink:to="loc_biib_FacilityTypeDomain_1a251349-b840-42b4-aac3-d385f9620032_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_dc671c01-16d7-446c-a4b4-ab6de2db9dad" xlink:href="biib-20230930.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityTypeAxis_1a251349-b840-42b4-aac3-d385f9620032" xlink:to="loc_biib_FacilityTypeDomain_dc671c01-16d7-446c-a4b4-ab6de2db9dad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_27c6e7c5-4187-459f-b00b-d3764597964a" xlink:href="biib-20230930.xsd#biib_BiologicsManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_dc671c01-16d7-446c-a4b4-ab6de2db9dad" xlink:to="loc_biib_BiologicsManufacturingMember_27c6e7c5-4187-459f-b00b-d3764597964a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_0c718a99-fea1-4b5a-bf41-0004e1aeac22" xlink:href="biib-20230930.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_dc671c01-16d7-446c-a4b4-ab6de2db9dad" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_0c718a99-fea1-4b5a-bf41-0004e1aeac22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_8cd9143a-5382-4371-9958-03a41a7ecb56" xlink:href="biib-20230930.xsd#biib_AdministrativeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_dc671c01-16d7-446c-a4b4-ab6de2db9dad" xlink:to="loc_biib_AdministrativeSpaceMember_8cd9143a-5382-4371-9958-03a41a7ecb56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_96201eb9-1c80-4241-95db-639039639043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9026b9-b478-4119-9b4c-2228dfed929f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_96201eb9-1c80-4241-95db-639039639043" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_96201eb9-1c80-4241-95db-639039639043_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_96201eb9-1c80-4241-95db-639039639043" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_96201eb9-1c80-4241-95db-639039639043_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_23f5ce00-8632-4b25-bcc6-15ed22827f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_96201eb9-1c80-4241-95db-639039639043" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_23f5ce00-8632-4b25-bcc6-15ed22827f7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A125BroadwayBuildingSaleMember_4308a4e8-305a-42bb-b50f-1b5f02ac2f6a" xlink:href="biib-20230930.xsd#biib_A125BroadwayBuildingSaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_23f5ce00-8632-4b25-bcc6-15ed22827f7b" xlink:to="loc_biib_A125BroadwayBuildingSaleMember_4308a4e8-305a-42bb-b50f-1b5f02ac2f6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4b4b2eb5-673f-4339-9386-2c73335543c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9026b9-b478-4119-9b4c-2228dfed929f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4b4b2eb5-673f-4339-9386-2c73335543c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b4b2eb5-673f-4339-9386-2c73335543c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4b4b2eb5-673f-4339-9386-2c73335543c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b4b2eb5-673f-4339-9386-2c73335543c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b932c77a-d0cf-48fa-8b2a-0cf82e2fad16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4b4b2eb5-673f-4339-9386-2c73335543c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b932c77a-d0cf-48fa-8b2a-0cf82e2fad16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_ff250b5b-a6e9-45a8-b9ab-5d37359d5caf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b932c77a-d0cf-48fa-8b2a-0cf82e2fad16" xlink:to="loc_us-gaap_BuildingMember_ff250b5b-a6e9-45a8-b9ab-5d37359d5caf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_1b77fcbd-65af-4195-9149-1ff5296ae3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b932c77a-d0cf-48fa-8b2a-0cf82e2fad16" xlink:to="loc_us-gaap_LandMember_1b77fcbd-65af-4195-9149-1ff5296ae3fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_e81b6746-fdf5-43e8-94b2-14897fa48514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b932c77a-d0cf-48fa-8b2a-0cf82e2fad16" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_e81b6746-fdf5-43e8-94b2-14897fa48514" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="simple" xlink:href="biib-20230930.xsd#LeasesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_52e708fe-3d91-45cd-a7ca-ec8a4664cb09" xlink:href="biib-20230930.xsd#biib_OperatingLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_biib_OperatingLeaseArea_52e708fe-3d91-45cd-a7ca-ec8a4664cb09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1290c016-a91e-48d0-b94f-acb1f09e52ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1290c016-a91e-48d0-b94f-acb1f09e52ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_48e35310-e958-4743-8324-f516be407e90" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_48e35310-e958-4743-8324-f516be407e90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_57e69a99-4da5-480d-b407-5655e55d8455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_57e69a99-4da5-480d-b407-5655e55d8455" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_ce3625ce-7cea-4972-a6d9-d21ab4763736" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_ce3625ce-7cea-4972-a6d9-d21ab4763736" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e006f15b-fb3e-4287-b73a-de5c9703a193" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e006f15b-fb3e-4287-b73a-de5c9703a193" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_89469490-945a-4b29-ae85-71c6a186419b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_us-gaap_OperatingLeaseLiability_89469490-945a-4b29-ae85-71c6a186419b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseRightOfUseAssetDerecognized_6528983d-477d-48bb-95f9-440e9b2a0423" xlink:href="biib-20230930.xsd#biib_OperatingLeaseRightOfUseAssetDerecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_biib_OperatingLeaseRightOfUseAssetDerecognized_6528983d-477d-48bb-95f9-440e9b2a0423" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseLiabilityDerecognized_618c228d-f47f-46af-811f-bed33b84a704" xlink:href="biib-20230930.xsd#biib_OperatingLeaseLiabilityDerecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_biib_OperatingLeaseLiabilityDerecognized_618c228d-f47f-46af-811f-bed33b84a704" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GainLossOnRestructuringCharges_41d77cfc-eaa4-4346-a228-65a8c1d337f9" xlink:href="biib-20230930.xsd#biib_GainLossOnRestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_biib_GainLossOnRestructuringCharges_41d77cfc-eaa4-4346-a228-65a8c1d337f9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_901fa31a-760c-4369-8a65-675f60ad07a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_901fa31a-760c-4369-8a65-675f60ad07a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6c338913-1d33-497f-a30d-337c3b822028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_901fa31a-760c-4369-8a65-675f60ad07a4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6c338913-1d33-497f-a30d-337c3b822028" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c338913-1d33-497f-a30d-337c3b822028_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6c338913-1d33-497f-a30d-337c3b822028" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c338913-1d33-497f-a30d-337c3b822028_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_538a2301-79a1-4686-afc6-6a7d3a8fef9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6c338913-1d33-497f-a30d-337c3b822028" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_538a2301-79a1-4686-afc6-6a7d3a8fef9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_fc4c0f5e-2952-4cc4-bbcc-1413f0f6ba1a" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_538a2301-79a1-4686-afc6-6a7d3a8fef9d" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_fc4c0f5e-2952-4cc4-bbcc-1413f0f6ba1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3a8b8770-a44e-4a7a-af5b-1f2ce063ac1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_901fa31a-760c-4369-8a65-675f60ad07a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3a8b8770-a44e-4a7a-af5b-1f2ce063ac1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a8b8770-a44e-4a7a-af5b-1f2ce063ac1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3a8b8770-a44e-4a7a-af5b-1f2ce063ac1f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a8b8770-a44e-4a7a-af5b-1f2ce063ac1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72846db2-3634-4cd1-8865-9b714fd5b4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3a8b8770-a44e-4a7a-af5b-1f2ce063ac1f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72846db2-3634-4cd1-8865-9b714fd5b4fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_4bcde39e-0499-4fd3-88c5-d4c573bd87e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72846db2-3634-4cd1-8865-9b714fd5b4fe" xlink:to="loc_us-gaap_BuildingMember_4bcde39e-0499-4fd3-88c5-d4c573bd87e2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#IndebtednessDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_937f69b5-c72b-4abe-ba3f-709817c569e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_cc419967-0777-46c4-b883-feb499e89ace" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_937f69b5-c72b-4abe-ba3f-709817c569e8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_cc419967-0777-46c4-b883-feb499e89ace" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionRate_b16e3205-0848-40bc-bc6d-a224bff829cc" xlink:href="biib-20230930.xsd#biib_DebtInstrumentRedemptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_937f69b5-c72b-4abe-ba3f-709817c569e8" xlink:to="loc_biib_DebtInstrumentRedemptionRate_b16e3205-0848-40bc-bc6d-a224bff829cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cc23418a-5f01-4252-9fd8-3f4f0e2e4c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_937f69b5-c72b-4abe-ba3f-709817c569e8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cc23418a-5f01-4252-9fd8-3f4f0e2e4c4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_6094c85f-8bcf-4990-beb4-107ff6d6c787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_937f69b5-c72b-4abe-ba3f-709817c569e8" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_6094c85f-8bcf-4990-beb4-107ff6d6c787" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_718fe174-f9ae-4acc-8862-71ff96b71c83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_937f69b5-c72b-4abe-ba3f-709817c569e8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_718fe174-f9ae-4acc-8862-71ff96b71c83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3212e150-9ed9-4c8c-8bd8-2abadccfa2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_937f69b5-c72b-4abe-ba3f-709817c569e8" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3212e150-9ed9-4c8c-8bd8-2abadccfa2c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ad6dadab-ff9b-41e8-b129-651793f49ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_937f69b5-c72b-4abe-ba3f-709817c569e8" xlink:to="loc_us-gaap_DebtInstrumentTable_ad6dadab-ff9b-41e8-b129-651793f49ef3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_63cacc3c-f1a7-44a4-8bfc-be7f16e8e840" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ad6dadab-ff9b-41e8-b129-651793f49ef3" xlink:to="loc_us-gaap_DebtInstrumentAxis_63cacc3c-f1a7-44a4-8bfc-be7f16e8e840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_63cacc3c-f1a7-44a4-8bfc-be7f16e8e840_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_63cacc3c-f1a7-44a4-8bfc-be7f16e8e840" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_63cacc3c-f1a7-44a4-8bfc-be7f16e8e840_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_55ea5fe0-5837-4879-bf8d-58b4af7694c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_63cacc3c-f1a7-44a4-8bfc-be7f16e8e840" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_55ea5fe0-5837-4879-bf8d-58b4af7694c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_8aee700f-e7c6-48d3-9c34-13a4491e0faa" xlink:href="biib-20230930.xsd#biib_TheCreditFacilityFloatingRate364DayTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_55ea5fe0-5837-4879-bf8d-58b4af7694c4" xlink:to="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_8aee700f-e7c6-48d3-9c34-13a4491e0faa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_56c7ea78-5bb0-40fb-ac3d-a48714f788dd" xlink:href="biib-20230930.xsd#biib_TheCreditFacilityFloatingRateThreeYearTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_55ea5fe0-5837-4879-bf8d-58b4af7694c4" xlink:to="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_56c7ea78-5bb0-40fb-ac3d-a48714f788dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityTerminatedMember_7b216031-c282-4762-83ae-86d2da6186eb" xlink:href="biib-20230930.xsd#biib_TheCreditFacilityTerminatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_55ea5fe0-5837-4879-bf8d-58b4af7694c4" xlink:to="loc_biib_TheCreditFacilityTerminatedMember_7b216031-c282-4762-83ae-86d2da6186eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_ad6c2ce6-9508-491d-84dd-bfb359c24f29" xlink:href="biib-20230930.xsd#biib_TheCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_55ea5fe0-5837-4879-bf8d-58b4af7694c4" xlink:to="loc_biib_TheCreditFacilityMember_ad6c2ce6-9508-491d-84dd-bfb359c24f29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_17fa091a-3b76-47b4-a70a-0571588d2d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ad6dadab-ff9b-41e8-b129-651793f49ef3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_17fa091a-3b76-47b4-a70a-0571588d2d59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_17fa091a-3b76-47b4-a70a-0571588d2d59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_17fa091a-3b76-47b4-a70a-0571588d2d59" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_17fa091a-3b76-47b4-a70a-0571588d2d59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7f52b7a7-b1d0-4790-986f-a13a40a92f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_17fa091a-3b76-47b4-a70a-0571588d2d59" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7f52b7a7-b1d0-4790-986f-a13a40a92f6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5c8b9f57-2690-4bb8-85b0-19ce5b53c37b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7f52b7a7-b1d0-4790-986f-a13a40a92f6a" xlink:to="loc_us-gaap_LineOfCreditMember_5c8b9f57-2690-4bb8-85b0-19ce5b53c37b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9c15ae09-c7d3-4adf-8284-af138cc99628" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ad6dadab-ff9b-41e8-b129-651793f49ef3" xlink:to="loc_us-gaap_CreditFacilityAxis_9c15ae09-c7d3-4adf-8284-af138cc99628" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9c15ae09-c7d3-4adf-8284-af138cc99628_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_9c15ae09-c7d3-4adf-8284-af138cc99628" xlink:to="loc_us-gaap_CreditFacilityDomain_9c15ae09-c7d3-4adf-8284-af138cc99628_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0254c92c-b3ba-424f-8f53-65e953120297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_9c15ae09-c7d3-4adf-8284-af138cc99628" xlink:to="loc_us-gaap_CreditFacilityDomain_0254c92c-b3ba-424f-8f53-65e953120297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_1c1221f4-67d3-4de6-aed2-4678ddf34c41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0254c92c-b3ba-424f-8f53-65e953120297" xlink:to="loc_us-gaap_SecuredDebtMember_1c1221f4-67d3-4de6-aed2-4678ddf34c41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ebfc370f-5c00-4a37-8a4d-52c7c4e09b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ad6dadab-ff9b-41e8-b129-651793f49ef3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ebfc370f-5c00-4a37-8a4d-52c7c4e09b7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ebfc370f-5c00-4a37-8a4d-52c7c4e09b7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ebfc370f-5c00-4a37-8a4d-52c7c4e09b7e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ebfc370f-5c00-4a37-8a4d-52c7c4e09b7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d985d3a1-3ecb-4593-88eb-943f72a155a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ebfc370f-5c00-4a37-8a4d-52c7c4e09b7e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d985d3a1-3ecb-4593-88eb-943f72a155a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_aa2e558f-82d2-4890-8aa4-c9584e8e4c8e" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d985d3a1-3ecb-4593-88eb-943f72a155a0" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_aa2e558f-82d2-4890-8aa4-c9584e8e4c8e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#ShareRepurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b550047e-8d37-47a3-b342-6a92fbd9892e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_f03b6f20-c9e2-4d08-8a1a-01f6b3a806a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b550047e-8d37-47a3-b342-6a92fbd9892e" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_f03b6f20-c9e2-4d08-8a1a-01f6b3a806a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_22190842-7b02-4e5a-911a-0eaabeaf3028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b550047e-8d37-47a3-b342-6a92fbd9892e" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_22190842-7b02-4e5a-911a-0eaabeaf3028" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_170c6e45-7d96-460d-8997-6ac5e609a542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b550047e-8d37-47a3-b342-6a92fbd9892e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_170c6e45-7d96-460d-8997-6ac5e609a542" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_63ee33af-eab3-4a1b-a6a1-65ea167dac0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b550047e-8d37-47a3-b342-6a92fbd9892e" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_63ee33af-eab3-4a1b-a6a1-65ea167dac0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f0d23541-790b-4849-ae7c-af5c8b1f5afb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b550047e-8d37-47a3-b342-6a92fbd9892e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f0d23541-790b-4849-ae7c-af5c8b1f5afb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_3d892e44-3a0e-4732-b649-0472bca23524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f0d23541-790b-4849-ae7c-af5c8b1f5afb" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_3d892e44-3a0e-4732-b649-0472bca23524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_3d892e44-3a0e-4732-b649-0472bca23524_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_3d892e44-3a0e-4732-b649-0472bca23524" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_3d892e44-3a0e-4732-b649-0472bca23524_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_510e7f29-e6d3-4630-a1b0-122934ffd9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_3d892e44-3a0e-4732-b649-0472bca23524" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_510e7f29-e6d3-4630-a1b0-122934ffd9dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_0f3e406c-f304-4841-b3a9-12594a2872c4" xlink:href="biib-20230930.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_510e7f29-e6d3-4630-a1b0-122934ffd9dc" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_0f3e406c-f304-4841-b3a9-12594a2872c4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b18bb230-58ed-423d-b468-9f5596f2f13f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b82bb91-d5e6-49e7-a5de-4d4504c4246e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b18bb230-58ed-423d-b468-9f5596f2f13f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b82bb91-d5e6-49e7-a5de-4d4504c4246e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ee275015-d5f4-4b9b-8687-37ef6b9666a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_bd145d32-1429-4cbe-a19c-74d8428174bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b18bb230-58ed-423d-b468-9f5596f2f13f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_bd145d32-1429-4cbe-a19c-74d8428174bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7b102feb-3655-43e1-9639-5cef3b394cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b18bb230-58ed-423d-b468-9f5596f2f13f" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7b102feb-3655-43e1-9639-5cef3b394cd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2532f3d4-e8dd-4957-b6e4-67cb05c068bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b18bb230-58ed-423d-b468-9f5596f2f13f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2532f3d4-e8dd-4957-b6e4-67cb05c068bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ba2b6ded-9e35-4f90-833e-f29d62636969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_abf152ab-8e98-49db-b6a8-6da3a5ef0876" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b18bb230-58ed-423d-b468-9f5596f2f13f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_abf152ab-8e98-49db-b6a8-6da3a5ef0876" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3600f90b-5874-4aae-9b40-66b7efa10a08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b18bb230-58ed-423d-b468-9f5596f2f13f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3600f90b-5874-4aae-9b40-66b7efa10a08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d702a827-cfd7-4dc2-bf6d-d9628f99b237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3600f90b-5874-4aae-9b40-66b7efa10a08" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d702a827-cfd7-4dc2-bf6d-d9628f99b237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d702a827-cfd7-4dc2-bf6d-d9628f99b237_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d702a827-cfd7-4dc2-bf6d-d9628f99b237" xlink:to="loc_us-gaap_EquityComponentDomain_d702a827-cfd7-4dc2-bf6d-d9628f99b237_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e5c73d32-05be-40d8-9bcb-766140aaff6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d702a827-cfd7-4dc2-bf6d-d9628f99b237" xlink:to="loc_us-gaap_EquityComponentDomain_e5c73d32-05be-40d8-9bcb-766140aaff6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_26586ff1-0167-4a26-8e18-55b4d71f3c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e5c73d32-05be-40d8-9bcb-766140aaff6e" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_26586ff1-0167-4a26-8e18-55b4d71f3c9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9157f1e2-6f40-4d3e-9afe-52535168ed56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e5c73d32-05be-40d8-9bcb-766140aaff6e" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9157f1e2-6f40-4d3e-9afe-52535168ed56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_bb648e4c-6846-49ef-b23b-7baf8ed2b057" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e5c73d32-05be-40d8-9bcb-766140aaff6e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_bb648e4c-6846-49ef-b23b-7baf8ed2b057" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_1653f06c-8fd1-41d6-bd28-0138dab03a85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e5c73d32-05be-40d8-9bcb-766140aaff6e" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_1653f06c-8fd1-41d6-bd28-0138dab03a85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7c1a472d-691f-4d2c-b40b-c43a6a61fc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e5c73d32-05be-40d8-9bcb-766140aaff6e" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7c1a472d-691f-4d2c-b40b-c43a6a61fc7f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b2f160bc-f76a-4ef7-8478-adda51a8cbad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1cf006c9-51bb-41d8-8bd5-430d3427928e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b2f160bc-f76a-4ef7-8478-adda51a8cbad" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1cf006c9-51bb-41d8-8bd5-430d3427928e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2d8371bf-cc2e-48f8-a84d-663efd8b6b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b2f160bc-f76a-4ef7-8478-adda51a8cbad" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2d8371bf-cc2e-48f8-a84d-663efd8b6b2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fc96df3f-d048-4402-9bfe-058f274ce4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b2f160bc-f76a-4ef7-8478-adda51a8cbad" xlink:to="loc_us-gaap_Revenues_fc96df3f-d048-4402-9bfe-058f274ce4c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6d9c78db-0f09-4a5e-8712-6fd49f0a1416" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b2f160bc-f76a-4ef7-8478-adda51a8cbad" xlink:to="loc_us-gaap_OperatingExpenses_6d9c78db-0f09-4a5e-8712-6fd49f0a1416" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6558e6f4-d266-433a-80a0-91bdff898139" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b2f160bc-f76a-4ef7-8478-adda51a8cbad" xlink:to="loc_us-gaap_NetIncomeLoss_6558e6f4-d266-433a-80a0-91bdff898139" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_6e048844-0f43-41da-b73d-caa220f7f8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b2f160bc-f76a-4ef7-8478-adda51a8cbad" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_6e048844-0f43-41da-b73d-caa220f7f8b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b75c8865-544f-412b-b87f-87b938ef499c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b2f160bc-f76a-4ef7-8478-adda51a8cbad" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b75c8865-544f-412b-b87f-87b938ef499c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a1c54b86-36a7-4a8d-bd29-70003328485d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b75c8865-544f-412b-b87f-87b938ef499c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a1c54b86-36a7-4a8d-bd29-70003328485d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a1c54b86-36a7-4a8d-bd29-70003328485d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a1c54b86-36a7-4a8d-bd29-70003328485d" xlink:to="loc_us-gaap_EquityComponentDomain_a1c54b86-36a7-4a8d-bd29-70003328485d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5f640077-51cd-43a3-8161-0bfe09801678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a1c54b86-36a7-4a8d-bd29-70003328485d" xlink:to="loc_us-gaap_EquityComponentDomain_5f640077-51cd-43a3-8161-0bfe09801678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_7c003900-9c5b-401e-9c6a-3155cf691c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5f640077-51cd-43a3-8161-0bfe09801678" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_7c003900-9c5b-401e-9c6a-3155cf691c8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_34e2debc-43f5-4db2-aebf-dd11bffaf1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5f640077-51cd-43a3-8161-0bfe09801678" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_34e2debc-43f5-4db2-aebf-dd11bffaf1c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_c8c1c0d5-14f0-4102-ab31-5e6f72076093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5f640077-51cd-43a3-8161-0bfe09801678" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_c8c1c0d5-14f0-4102-ab31-5e6f72076093" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_8f3d6af6-c5a8-498a-b960-3b51466c4475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5f640077-51cd-43a3-8161-0bfe09801678" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_8f3d6af6-c5a8-498a-b960-3b51466c4475" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_35c8fc89-b268-4810-8590-31c03cff56d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b75c8865-544f-412b-b87f-87b938ef499c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_35c8fc89-b268-4810-8590-31c03cff56d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_35c8fc89-b268-4810-8590-31c03cff56d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_35c8fc89-b268-4810-8590-31c03cff56d6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_35c8fc89-b268-4810-8590-31c03cff56d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_76dd2d12-f884-4ae0-b34c-acd3eb746362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_35c8fc89-b268-4810-8590-31c03cff56d6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_76dd2d12-f884-4ae0-b34c-acd3eb746362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_44f904e7-55e0-4b1c-8f12-948e6cd69d22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_76dd2d12-f884-4ae0-b34c-acd3eb746362" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_44f904e7-55e0-4b1c-8f12-948e6cd69d22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_26d82635-a917-4c29-9d8c-a34695682100" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b75c8865-544f-412b-b87f-87b938ef499c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_26d82635-a917-4c29-9d8c-a34695682100" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_26d82635-a917-4c29-9d8c-a34695682100_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_26d82635-a917-4c29-9d8c-a34695682100" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_26d82635-a917-4c29-9d8c-a34695682100_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_52b51d50-5875-45f7-a57f-0bfdd50c23d9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_26d82635-a917-4c29-9d8c-a34695682100" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_52b51d50-5875-45f7-a57f-0bfdd50c23d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_4c462db2-cec3-4b13-9902-8e046823cb24" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52b51d50-5875-45f7-a57f-0bfdd50c23d9" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_4c462db2-cec3-4b13-9902-8e046823cb24" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#EarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_836d0087-4127-4b48-b768-244217ec5c25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1228b794-e0e0-4160-89ac-f8a252a3dd90" xlink:href="biib-20230930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_836d0087-4127-4b48-b768-244217ec5c25" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1228b794-e0e0-4160-89ac-f8a252a3dd90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_0bd00b35-c3a5-4d53-b478-99edb07c449b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1228b794-e0e0-4160-89ac-f8a252a3dd90" xlink:to="loc_us-gaap_NetIncomeLossAbstract_0bd00b35-c3a5-4d53-b478-99edb07c449b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_596cd850-9aea-4f53-8d36-f0f04a43f7df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_0bd00b35-c3a5-4d53-b478-99edb07c449b" xlink:to="loc_us-gaap_NetIncomeLoss_596cd850-9aea-4f53-8d36-f0f04a43f7df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4caac43f-beca-4d62-9dfe-79c459199a44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1228b794-e0e0-4160-89ac-f8a252a3dd90" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4caac43f-beca-4d62-9dfe-79c459199a44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8e412c48-d9fb-414a-aba2-43764b8141ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4caac43f-beca-4d62-9dfe-79c459199a44" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8e412c48-d9fb-414a-aba2-43764b8141ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_70f1092c-cc03-408c-8c57-f9821ca63016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4caac43f-beca-4d62-9dfe-79c459199a44" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_70f1092c-cc03-408c-8c57-f9821ca63016" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_aef7947f-65c5-4851-9abc-736b11345630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_70f1092c-cc03-408c-8c57-f9821ca63016" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_aef7947f-65c5-4851-9abc-736b11345630" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1b4ac2b3-8060-435e-b651-e74068c1835b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_70f1092c-cc03-408c-8c57-f9821ca63016" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1b4ac2b3-8060-435e-b651-e74068c1835b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d3e96a09-8131-46c0-a387-56c7bd0433f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4caac43f-beca-4d62-9dfe-79c459199a44" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d3e96a09-8131-46c0-a387-56c7bd0433f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc97a85d-9691-4726-8eb0-e0641f2fc7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_836d0087-4127-4b48-b768-244217ec5c25" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc97a85d-9691-4726-8eb0-e0641f2fc7b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_db5ea084-a684-4d6f-befd-a4a380d76460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc97a85d-9691-4726-8eb0-e0641f2fc7b0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_db5ea084-a684-4d6f-befd-a4a380d76460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_db5ea084-a684-4d6f-befd-a4a380d76460_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_db5ea084-a684-4d6f-befd-a4a380d76460" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_db5ea084-a684-4d6f-befd-a4a380d76460_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfcabece-9540-4071-9c60-ccae89e696c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_db5ea084-a684-4d6f-befd-a4a380d76460" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfcabece-9540-4071-9c60-ccae89e696c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_5f51fc9a-aa31-4300-8353-14828a16eead" xlink:href="biib-20230930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfcabece-9540-4071-9c60-ccae89e696c5" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_5f51fc9a-aa31-4300-8353-14828a16eead" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_18a74cf6-d9ee-4e16-b8ad-2dfc9a6e2192" xlink:href="biib-20230930.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfcabece-9540-4071-9c60-ccae89e696c5" xlink:to="loc_biib_MarketStockUnitsMember_18a74cf6-d9ee-4e16-b8ad-2dfc9a6e2192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_e91dedb5-a0d5-43ba-bfee-a0f51bb54c7c" xlink:href="biib-20230930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfcabece-9540-4071-9c60-ccae89e696c5" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_e91dedb5-a0d5-43ba-bfee-a0f51bb54c7c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#ShareBasedPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23ce317a-995b-4746-a462-2dcc7f1f956d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6a5d84f6-2af3-4cc8-8c47-a4c899a99454" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23ce317a-995b-4746-a462-2dcc7f1f956d" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6a5d84f6-2af3-4cc8-8c47-a4c899a99454" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d995834f-b2af-4944-961e-f381a66bcb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6a5d84f6-2af3-4cc8-8c47-a4c899a99454" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d995834f-b2af-4944-961e-f381a66bcb3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5c0e9fc8-b758-4362-819f-0c3d662ca9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6a5d84f6-2af3-4cc8-8c47-a4c899a99454" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5c0e9fc8-b758-4362-819f-0c3d662ca9ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_086db288-8128-48d4-a96c-bb32706b8cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6a5d84f6-2af3-4cc8-8c47-a4c899a99454" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_086db288-8128-48d4-a96c-bb32706b8cab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_cc71ac23-0b7e-4a53-a71f-e3ac7e5ccc91" xlink:href="biib-20230930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6a5d84f6-2af3-4cc8-8c47-a4c899a99454" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_cc71ac23-0b7e-4a53-a71f-e3ac7e5ccc91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_414319ba-0ac3-4aee-add7-f79d1ece8c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6a5d84f6-2af3-4cc8-8c47-a4c899a99454" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_414319ba-0ac3-4aee-add7-f79d1ece8c4b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b5633707-aa4c-4f01-b005-ef74a15a6696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23ce317a-995b-4746-a462-2dcc7f1f956d" xlink:to="loc_us-gaap_OperatingExpenses_b5633707-aa4c-4f01-b005-ef74a15a6696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8303d18e-9edf-4e8b-9fcd-74edec9463b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23ce317a-995b-4746-a462-2dcc7f1f956d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8303d18e-9edf-4e8b-9fcd-74edec9463b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_805486a9-b9c4-4798-abd5-cfbce1f71b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23ce317a-995b-4746-a462-2dcc7f1f956d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_805486a9-b9c4-4798-abd5-cfbce1f71b6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b234df1f-9791-4ef8-9ca3-65a4aac00a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23ce317a-995b-4746-a462-2dcc7f1f956d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b234df1f-9791-4ef8-9ca3-65a4aac00a9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0e38116f-4fa5-4c50-ab6d-0d70162ec8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b234df1f-9791-4ef8-9ca3-65a4aac00a9e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0e38116f-4fa5-4c50-ab6d-0d70162ec8b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0e38116f-4fa5-4c50-ab6d-0d70162ec8b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0e38116f-4fa5-4c50-ab6d-0d70162ec8b7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0e38116f-4fa5-4c50-ab6d-0d70162ec8b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6c7b448e-e45c-4521-8ef9-dd5f981cf6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0e38116f-4fa5-4c50-ab6d-0d70162ec8b7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6c7b448e-e45c-4521-8ef9-dd5f981cf6ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d56fc863-4089-4658-8d94-175b410575f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c7b448e-e45c-4521-8ef9-dd5f981cf6ff" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d56fc863-4089-4658-8d94-175b410575f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a20f1ea8-660f-4636-9914-72d2d7337031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c7b448e-e45c-4521-8ef9-dd5f981cf6ff" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a20f1ea8-660f-4636-9914-72d2d7337031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_ecbd7652-4b99-410e-8f25-9f73d63515f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c7b448e-e45c-4521-8ef9-dd5f981cf6ff" xlink:to="loc_us-gaap_ParentMember_ecbd7652-4b99-410e-8f25-9f73d63515f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_35732d97-355b-4792-808c-b35fa0acaf91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b234df1f-9791-4ef8-9ca3-65a4aac00a9e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_35732d97-355b-4792-808c-b35fa0acaf91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_35732d97-355b-4792-808c-b35fa0acaf91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_35732d97-355b-4792-808c-b35fa0acaf91" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_35732d97-355b-4792-808c-b35fa0acaf91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46d2891d-21bd-4797-8af7-3bfa1179d1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_35732d97-355b-4792-808c-b35fa0acaf91" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46d2891d-21bd-4797-8af7-3bfa1179d1ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_137bad06-1a80-4f7c-b776-37befadb6032" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46d2891d-21bd-4797-8af7-3bfa1179d1ea" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_137bad06-1a80-4f7c-b776-37befadb6032" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20230930.xsd#ShareBasedPaymentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_646a8aa7-8826-4551-8178-8c1d884b2155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_7bda1ebd-0a28-48c5-9069-9866822ef420" xlink:href="biib-20230930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_646a8aa7-8826-4551-8178-8c1d884b2155" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_7bda1ebd-0a28-48c5-9069-9866822ef420" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c4c9f5e8-5da9-4ad2-ad7b-b6b95d1e48e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_7bda1ebd-0a28-48c5-9069-9866822ef420" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c4c9f5e8-5da9-4ad2-ad7b-b6b95d1e48e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a43f8887-7ecf-440e-ab9d-92a6df0ca79b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_7bda1ebd-0a28-48c5-9069-9866822ef420" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a43f8887-7ecf-440e-ab9d-92a6df0ca79b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_fe668a51-db04-4628-a3f9-6a1ec322b63d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_7bda1ebd-0a28-48c5-9069-9866822ef420" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_fe668a51-db04-4628-a3f9-6a1ec322b63d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_7a7e4c74-45e3-4a28-b563-4023c7e9ebea" xlink:href="biib-20230930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_7bda1ebd-0a28-48c5-9069-9866822ef420" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_7a7e4c74-45e3-4a28-b563-4023c7e9ebea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_8a18ab71-ab29-4b57-8e00-fb2df6270569" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_646a8aa7-8826-4551-8178-8c1d884b2155" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_8a18ab71-ab29-4b57-8e00-fb2df6270569" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e640247e-34dd-4ce9-8710-ee23a7c7a0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_646a8aa7-8826-4551-8178-8c1d884b2155" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e640247e-34dd-4ce9-8710-ee23a7c7a0d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_698cabc6-bbf3-4a6e-9fe9-745c20344753" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e640247e-34dd-4ce9-8710-ee23a7c7a0d0" xlink:to="loc_us-gaap_AwardTypeAxis_698cabc6-bbf3-4a6e-9fe9-745c20344753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_698cabc6-bbf3-4a6e-9fe9-745c20344753_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_698cabc6-bbf3-4a6e-9fe9-745c20344753" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_698cabc6-bbf3-4a6e-9fe9-745c20344753_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_698cabc6-bbf3-4a6e-9fe9-745c20344753" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_aedac6df-44e2-43da-848c-c411030588c5" xlink:href="biib-20230930.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:to="loc_biib_MarketStockUnitsMember_aedac6df-44e2-43da-848c-c411030588c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_af498cfb-5ea2-4a68-9f7b-5ba54e1bdefa" xlink:href="biib-20230930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_af498cfb-5ea2-4a68-9f7b-5ba54e1bdefa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_22706b65-5945-4d13-b836-2f99f245fb81" xlink:href="biib-20230930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_22706b65-5945-4d13-b836-2f99f245fb81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_243ac61d-1940-4403-af4f-7e80dc4068f8" xlink:href="biib-20230930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_243ac61d-1940-4403-af4f-7e80dc4068f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_9107b5fb-5737-4551-bf54-a93be20590a9" xlink:href="biib-20230930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_9107b5fb-5737-4551-bf54-a93be20590a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e00b8460-3a72-468b-ae2b-94a4cb0d6c10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e00b8460-3a72-468b-ae2b-94a4cb0d6c10" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityAwardsOfAcquiredCompanyMember_8af9e306-e2fb-429c-9c15-d954972c4eed" xlink:href="biib-20230930.xsd#biib_EquityAwardsOfAcquiredCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:to="loc_biib_EquityAwardsOfAcquiredCompanyMember_8af9e306-e2fb-429c-9c15-d954972c4eed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1d4eae56-4d18-4be1-9ed1-3a994eef130f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e640247e-34dd-4ce9-8710-ee23a7c7a0d0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1d4eae56-4d18-4be1-9ed1-3a994eef130f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1d4eae56-4d18-4be1-9ed1-3a994eef130f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1d4eae56-4d18-4be1-9ed1-3a994eef130f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1d4eae56-4d18-4be1-9ed1-3a994eef130f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10a3af3e-f281-487e-9301-dc66158ed067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1d4eae56-4d18-4be1-9ed1-3a994eef130f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10a3af3e-f281-487e-9301-dc66158ed067" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_cd89e34f-c354-4544-9dee-d058d4b78e65" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10a3af3e-f281-487e-9301-dc66158ed067" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_cd89e34f-c354-4544-9dee-d058d4b78e65" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20230930.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_25217c06-3030-4c17-bcb0-9e9c682c4ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_aab72881-ad2d-459a-8f64-0119476736e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25217c06-3030-4c17-bcb0-9e9c682c4ce1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_aab72881-ad2d-459a-8f64-0119476736e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_7d9ccc60-c2e0-4e4f-8a01-4f6fa2bcf0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25217c06-3030-4c17-bcb0-9e9c682c4ce1" xlink:to="loc_us-gaap_EquityMethodInvestments_7d9ccc60-c2e0-4e4f-8a01-4f6fa2bcf0ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_cca2d7e9-6c00-43ca-b11e-685eccd0f643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25217c06-3030-4c17-bcb0-9e9c682c4ce1" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_cca2d7e9-6c00-43ca-b11e-685eccd0f643" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_01a02dc6-4e54-4524-aaed-39e9fe2eb36a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25217c06-3030-4c17-bcb0-9e9c682c4ce1" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_01a02dc6-4e54-4524-aaed-39e9fe2eb36a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_17695cf0-b352-4c55-a7ae-69fc997b87a6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_01a02dc6-4e54-4524-aaed-39e9fe2eb36a" xlink:to="loc_srt_StatementScenarioAxis_17695cf0-b352-4c55-a7ae-69fc997b87a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_17695cf0-b352-4c55-a7ae-69fc997b87a6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_17695cf0-b352-4c55-a7ae-69fc997b87a6" xlink:to="loc_srt_ScenarioUnspecifiedDomain_17695cf0-b352-4c55-a7ae-69fc997b87a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_09cc6f15-791c-4f8e-a7e8-40e142a4abeb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_17695cf0-b352-4c55-a7ae-69fc997b87a6" xlink:to="loc_srt_ScenarioUnspecifiedDomain_09cc6f15-791c-4f8e-a7e8-40e142a4abeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a9df2c12-b906-4c3c-92fa-22fcb6644c51" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_09cc6f15-791c-4f8e-a7e8-40e142a4abeb" xlink:to="loc_srt_ScenarioForecastMember_a9df2c12-b906-4c3c-92fa-22fcb6644c51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_efc8b9df-00bd-4a74-934c-170b65890a5f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_01a02dc6-4e54-4524-aaed-39e9fe2eb36a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_efc8b9df-00bd-4a74-934c-170b65890a5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_efc8b9df-00bd-4a74-934c-170b65890a5f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_efc8b9df-00bd-4a74-934c-170b65890a5f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_efc8b9df-00bd-4a74-934c-170b65890a5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_802c388a-0c73-4199-8b5d-040c72c7e941" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_efc8b9df-00bd-4a74-934c-170b65890a5f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_802c388a-0c73-4199-8b5d-040c72c7e941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_17529daa-0df8-47b8-b113-ad95c2787ad3" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_802c388a-0c73-4199-8b5d-040c72c7e941" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_17529daa-0df8-47b8-b113-ad95c2787ad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4aeb574e-18fe-48aa-9534-3115134d8b6d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_01a02dc6-4e54-4524-aaed-39e9fe2eb36a" xlink:to="loc_srt_ProductOrServiceAxis_4aeb574e-18fe-48aa-9534-3115134d8b6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4aeb574e-18fe-48aa-9534-3115134d8b6d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4aeb574e-18fe-48aa-9534-3115134d8b6d" xlink:to="loc_srt_ProductsAndServicesDomain_4aeb574e-18fe-48aa-9534-3115134d8b6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_37642972-c032-48e3-ad6c-ebb5ce876d72" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4aeb574e-18fe-48aa-9534-3115134d8b6d" xlink:to="loc_srt_ProductsAndServicesDomain_37642972-c032-48e3-ad6c-ebb5ce876d72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_48f779e2-4c2d-4f4b-b424-07da5ef902ca" xlink:href="biib-20230930.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37642972-c032-48e3-ad6c-ebb5ce876d72" xlink:to="loc_biib_ADUHELMMember_48f779e2-4c2d-4f4b-b424-07da5ef902ca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b6342ebe-cbae-4847-885e-7cb22098ca40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b6342ebe-cbae-4847-885e-7cb22098ca40" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_390d3ebd-eb1b-4021-922c-c37e2c74a29e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_390d3ebd-eb1b-4021-922c-c37e2c74a29e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_6e67d2a0-38a2-4d12-b82b-c486168988ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_LitigationSettlementExpense_6e67d2a0-38a2-4d12-b82b-c486168988ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_989a2139-90d3-4a0e-b440-7a54d3b67b49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_989a2139-90d3-4a0e-b440-7a54d3b67b49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9ea8c263-954c-448b-9ddb-5687f95c6864" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_InterestExpense_9ea8c263-954c-448b-9ddb-5687f95c6864" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_e438e9e1-0f1b-4c40-ae84-465ba1a182ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_e438e9e1-0f1b-4c40-ae84-465ba1a182ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8df7d98e-ef3a-4c50-b264-4a495aba6d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8df7d98e-ef3a-4c50-b264-4a495aba6d50" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_737ae87d-a7e6-4b56-a447-6df7627b8b31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_737ae87d-a7e6-4b56-a447-6df7627b8b31" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_d606325f-d1ad-4996-8761-398eeb38d2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_d606325f-d1ad-4996-8761-398eeb38d2d4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_44a24d88-407c-4afa-9143-bc59474dce5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_44a24d88-407c-4afa-9143-bc59474dce5e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_5c1a0023-0555-4d11-8c53-6da3424eaa21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b6342ebe-cbae-4847-885e-7cb22098ca40" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_5c1a0023-0555-4d11-8c53-6da3424eaa21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_c824403d-173e-40b3-95e2-bb5b4487f06f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_5c1a0023-0555-4d11-8c53-6da3424eaa21" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_c824403d-173e-40b3-95e2-bb5b4487f06f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_e10237d2-7224-41e9-9f0e-687f26a1a840" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_5c1a0023-0555-4d11-8c53-6da3424eaa21" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_e10237d2-7224-41e9-9f0e-687f26a1a840" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_25ccf128-5c62-468c-924d-ab28886e5295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_5c1a0023-0555-4d11-8c53-6da3424eaa21" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_25ccf128-5c62-468c-924d-ab28886e5295" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b6342ebe-cbae-4847-885e-7cb22098ca40" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent_a9eced45-9c20-49f2-a66c-1a27262086d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:to="loc_us-gaap_SettlementLiabilitiesCurrent_a9eced45-9c20-49f2-a66c-1a27262086d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_08302578-8670-4f5b-8ade-a4093dd24139" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_08302578-8670-4f5b-8ade-a4093dd24139" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7a3799f6-5b6d-4d0e-9a6b-625e93379693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7a3799f6-5b6d-4d0e-9a6b-625e93379693" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_c15b2e44-0d2b-4446-a91d-0a352146263f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_c15b2e44-0d2b-4446-a91d-0a352146263f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_4e509e9b-a735-4dc1-bd15-f91eb4a49724" xlink:href="biib-20230930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:to="loc_biib_Collaborationexpensesaccrual_4e509e9b-a735-4dc1-bd15-f91eb4a49724" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_59f0a7f1-d883-4d2f-90c9-fe53c50a45c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_59f0a7f1-d883-4d2f-90c9-fe53c50a45c9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_bcf20e53-2068-419f-b6cc-e1583a6a08ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_bcf20e53-2068-419f-b6cc-e1583a6a08ca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_200b5a04-998f-43b9-ae74-92815a01e408" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b6342ebe-cbae-4847-885e-7cb22098ca40" xlink:to="loc_us-gaap_StatementTable_200b5a04-998f-43b9-ae74-92815a01e408" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d4906e1c-3097-448d-90d5-d40561f4c996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_200b5a04-998f-43b9-ae74-92815a01e408" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d4906e1c-3097-448d-90d5-d40561f4c996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d4906e1c-3097-448d-90d5-d40561f4c996_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d4906e1c-3097-448d-90d5-d40561f4c996" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d4906e1c-3097-448d-90d5-d40561f4c996_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9b2b2fb7-1679-4023-9714-28792ed624b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d4906e1c-3097-448d-90d5-d40561f4c996" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9b2b2fb7-1679-4023-9714-28792ed624b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_4dfc5984-4a62-475a-84dc-4fb617e7ca9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9b2b2fb7-1679-4023-9714-28792ed624b1" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_4dfc5984-4a62-475a-84dc-4fb617e7ca9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1bfa0aac-8b27-4c50-abd7-abacb762e2e8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_200b5a04-998f-43b9-ae74-92815a01e408" xlink:to="loc_dei_LegalEntityAxis_1bfa0aac-8b27-4c50-abd7-abacb762e2e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1bfa0aac-8b27-4c50-abd7-abacb762e2e8_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1bfa0aac-8b27-4c50-abd7-abacb762e2e8" xlink:to="loc_dei_EntityDomain_1bfa0aac-8b27-4c50-abd7-abacb762e2e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_976677be-90bf-49b9-a947-ae26b373f704" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1bfa0aac-8b27-4c50-abd7-abacb762e2e8" xlink:to="loc_dei_EntityDomain_976677be-90bf-49b9-a947-ae26b373f704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_78e09f4f-ab0b-4006-9448-56b46fd4e9df" xlink:href="biib-20230930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_976677be-90bf-49b9-a947-ae26b373f704" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_78e09f4f-ab0b-4006-9448-56b46fd4e9df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f3ed7fd5-8b19-414a-877d-17dbf33e0edf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_200b5a04-998f-43b9-ae74-92815a01e408" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f3ed7fd5-8b19-414a-877d-17dbf33e0edf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f3ed7fd5-8b19-414a-877d-17dbf33e0edf_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f3ed7fd5-8b19-414a-877d-17dbf33e0edf" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f3ed7fd5-8b19-414a-877d-17dbf33e0edf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8dbca22c-1962-49c8-9f07-50d2784dc46e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f3ed7fd5-8b19-414a-877d-17dbf33e0edf" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8dbca22c-1962-49c8-9f07-50d2784dc46e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_865e04d4-1b9f-407d-be40-94e55cfac9a3" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8dbca22c-1962-49c8-9f07-50d2784dc46e" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_865e04d4-1b9f-407d-be40-94e55cfac9a3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20230930.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_0ff6617e-11c5-4349-b8dc-ffd02105fb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_LitigationSettlementExpense_0ff6617e-11c5-4349-b8dc-ffd02105fb9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1392e7e2-ea4b-484f-adea-14af2ff3fa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1392e7e2-ea4b-484f-adea-14af2ff3fa9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_aa4da42c-f7ce-4310-ad37-4868f509e9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_aa4da42c-f7ce-4310-ad37-4868f509e9b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f4aa40e5-45fb-4066-a210-b165e46e8fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f4aa40e5-45fb-4066-a210-b165e46e8fbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_bcb9a7f7-9ebb-4db6-8dd0-89cbe3280467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_LossOnContractTermination_bcb9a7f7-9ebb-4db6-8dd0-89cbe3280467" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0b562a04-6baf-4bd5-a007-eadcbe2c89d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0b562a04-6baf-4bd5-a007-eadcbe2c89d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_290fddf6-3614-482c-8bd2-b19ba1632e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_290fddf6-3614-482c-8bd2-b19ba1632e0c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_be4c1337-1428-48cf-a23a-9ac38039df75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_be4c1337-1428-48cf-a23a-9ac38039df75" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_00fc6546-4e9f-4bfa-8123-9be9dbfef3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_StatementTable_00fc6546-4e9f-4bfa-8123-9be9dbfef3f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cde9dd4d-2985-4b01-8d15-a2ad90a23d7e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_00fc6546-4e9f-4bfa-8123-9be9dbfef3f1" xlink:to="loc_dei_LegalEntityAxis_cde9dd4d-2985-4b01-8d15-a2ad90a23d7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cde9dd4d-2985-4b01-8d15-a2ad90a23d7e_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_cde9dd4d-2985-4b01-8d15-a2ad90a23d7e" xlink:to="loc_dei_EntityDomain_cde9dd4d-2985-4b01-8d15-a2ad90a23d7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d0b5e144-fc17-4fd5-a6ac-11ecb1051b1e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_cde9dd4d-2985-4b01-8d15-a2ad90a23d7e" xlink:to="loc_dei_EntityDomain_d0b5e144-fc17-4fd5-a6ac-11ecb1051b1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_ca2bdc2c-3c9f-4d2c-a215-622ab5c0fa98" xlink:href="biib-20230930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d0b5e144-fc17-4fd5-a6ac-11ecb1051b1e" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_ca2bdc2c-3c9f-4d2c-a215-622ab5c0fa98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b5b2f492-ef0d-4a62-9aaf-32428e309328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_00fc6546-4e9f-4bfa-8123-9be9dbfef3f1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b5b2f492-ef0d-4a62-9aaf-32428e309328" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5b2f492-ef0d-4a62-9aaf-32428e309328_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b5b2f492-ef0d-4a62-9aaf-32428e309328" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5b2f492-ef0d-4a62-9aaf-32428e309328_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92b11582-02d5-41e5-86e9-4061dc0bea35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b5b2f492-ef0d-4a62-9aaf-32428e309328" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92b11582-02d5-41e5-86e9-4061dc0bea35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_fc5e29ad-549f-4348-b728-28c0021ed14c" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92b11582-02d5-41e5-86e9-4061dc0bea35" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_fc5e29ad-549f-4348-b728-28c0021ed14c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_28b2aaa0-e1e8-44ab-809f-33d88c0b2dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_00fc6546-4e9f-4bfa-8123-9be9dbfef3f1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_28b2aaa0-e1e8-44ab-809f-33d88c0b2dbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_28b2aaa0-e1e8-44ab-809f-33d88c0b2dbf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_28b2aaa0-e1e8-44ab-809f-33d88c0b2dbf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_28b2aaa0-e1e8-44ab-809f-33d88c0b2dbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3aeae0c0-0429-4a2b-be1e-2f233b925eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_28b2aaa0-e1e8-44ab-809f-33d88c0b2dbf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3aeae0c0-0429-4a2b-be1e-2f233b925eb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_32e56f75-a6bd-47c1-b3b9-64546baae8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3aeae0c0-0429-4a2b-be1e-2f233b925eb5" xlink:to="loc_us-gaap_SubsequentEventMember_32e56f75-a6bd-47c1-b3b9-64546baae8ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsOCREVUSDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_015ad1bd-f95e-4ce4-94d3-0a67f3259d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_1e934677-30a8-4411-a41c-106be062f20f" xlink:href="biib-20230930.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_015ad1bd-f95e-4ce4-94d3-0a67f3259d50" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_1e934677-30a8-4411-a41c-106be062f20f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_94460fff-7cd0-478c-bded-2dc54e6bd929" xlink:href="biib-20230930.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_015ad1bd-f95e-4ce4-94d3-0a67f3259d50" xlink:to="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_94460fff-7cd0-478c-bded-2dc54e6bd929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyrate_d3a2f46f-0e5f-424c-99b4-27a8ce891c4d" xlink:href="biib-20230930.xsd#biib_Reductioninroyaltyrate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_015ad1bd-f95e-4ce4-94d3-0a67f3259d50" xlink:to="loc_biib_Reductioninroyaltyrate_d3a2f46f-0e5f-424c-99b4-27a8ce891c4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PeriodOfCollaborationAgreement_58513aca-76c2-40f1-a495-fa96aa4b467c" xlink:href="biib-20230930.xsd#biib_PeriodOfCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_015ad1bd-f95e-4ce4-94d3-0a67f3259d50" xlink:to="loc_biib_PeriodOfCollaborationAgreement_58513aca-76c2-40f1-a495-fa96aa4b467c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfFutureDevelopmentCosts_fada1a7b-cadf-46c0-a3e8-23cc22130ae9" xlink:href="biib-20230930.xsd#biib_PercentageOfFutureDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_015ad1bd-f95e-4ce4-94d3-0a67f3259d50" xlink:to="loc_biib_PercentageOfFutureDevelopmentCosts_fada1a7b-cadf-46c0-a3e8-23cc22130ae9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0205c080-57e0-48d5-8192-a11a991454c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_015ad1bd-f95e-4ce4-94d3-0a67f3259d50" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0205c080-57e0-48d5-8192-a11a991454c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6b205cfa-3944-4147-9859-73913c98bb4b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0205c080-57e0-48d5-8192-a11a991454c7" xlink:to="loc_srt_ProductOrServiceAxis_6b205cfa-3944-4147-9859-73913c98bb4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6b205cfa-3944-4147-9859-73913c98bb4b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6b205cfa-3944-4147-9859-73913c98bb4b" xlink:to="loc_srt_ProductsAndServicesDomain_6b205cfa-3944-4147-9859-73913c98bb4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_38484b8d-f7f7-468c-bb26-949445728cdb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6b205cfa-3944-4147-9859-73913c98bb4b" xlink:to="loc_srt_ProductsAndServicesDomain_38484b8d-f7f7-468c-bb26-949445728cdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OCREVUSMember_89b1ebaa-fe9d-48fd-b46b-2b520bcc532b" xlink:href="biib-20230930.xsd#biib_OCREVUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_38484b8d-f7f7-468c-bb26-949445728cdb" xlink:to="loc_biib_OCREVUSMember_89b1ebaa-fe9d-48fd-b46b-2b520bcc532b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MosunetuzumabMember_be6d739c-cca2-47e4-abdb-ed61a27d87f8" xlink:href="biib-20230930.xsd#biib_MosunetuzumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_38484b8d-f7f7-468c-bb26-949445728cdb" xlink:to="loc_biib_MosunetuzumabMember_be6d739c-cca2-47e4-abdb-ed61a27d87f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_500003ed-da01-4b95-a96c-aa6ace51a560" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0205c080-57e0-48d5-8192-a11a991454c7" xlink:to="loc_srt_RangeAxis_500003ed-da01-4b95-a96c-aa6ace51a560" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_500003ed-da01-4b95-a96c-aa6ace51a560_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_500003ed-da01-4b95-a96c-aa6ace51a560" xlink:to="loc_srt_RangeMember_500003ed-da01-4b95-a96c-aa6ace51a560_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c2f6549-ed4e-4350-b955-e7eb743dcc23" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_500003ed-da01-4b95-a96c-aa6ace51a560" xlink:to="loc_srt_RangeMember_1c2f6549-ed4e-4350-b955-e7eb743dcc23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ed59b9f6-3c58-4f97-b419-99d29c735e2c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1c2f6549-ed4e-4350-b955-e7eb743dcc23" xlink:to="loc_srt_MinimumMember_ed59b9f6-3c58-4f97-b419-99d29c735e2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0fa4b63c-7f44-4321-8578-2e0d01c4b3a5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1c2f6549-ed4e-4350-b955-e7eb743dcc23" xlink:to="loc_srt_MaximumMember_0fa4b63c-7f44-4321-8578-2e0d01c4b3a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3a405396-5556-418f-9012-fdb0398e8938" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0205c080-57e0-48d5-8192-a11a991454c7" xlink:to="loc_srt_StatementGeographicalAxis_3a405396-5556-418f-9012-fdb0398e8938" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3a405396-5556-418f-9012-fdb0398e8938_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3a405396-5556-418f-9012-fdb0398e8938" xlink:to="loc_srt_SegmentGeographicalDomain_3a405396-5556-418f-9012-fdb0398e8938_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3efdf33b-7a7d-462b-99b3-473099e39233" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3a405396-5556-418f-9012-fdb0398e8938" xlink:to="loc_srt_SegmentGeographicalDomain_3efdf33b-7a7d-462b-99b3-473099e39233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_9f8ea436-3437-4706-b335-59b263bf0fef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3efdf33b-7a7d-462b-99b3-473099e39233" xlink:to="loc_us-gaap_ForeignCountryMember_9f8ea436-3437-4706-b335-59b263bf0fef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsProfitSharingDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_8311f127-d992-479a-a1d7-a38181b338aa" xlink:href="biib-20230930.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_8311f127-d992-479a-a1d7-a38181b338aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_53335da0-0d56-442f-b4cc-dcf2a979599b" xlink:href="biib-20230930.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_53335da0-0d56-442f-b4cc-dcf2a979599b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_faba79d4-10af-43fa-8b6d-3811622d0348" xlink:href="biib-20230930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_faba79d4-10af-43fa-8b6d-3811622d0348" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_268f7963-2338-4130-b9b3-28974dafceb7" xlink:href="biib-20230930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_268f7963-2338-4130-b9b3-28974dafceb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_3001ce41-861b-4b40-92cb-6de139e6deb1" xlink:href="biib-20230930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_3001ce41-861b-4b40-92cb-6de139e6deb1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_d05efb46-49e7-4fbc-8163-68e316ac0ca0" xlink:href="biib-20230930.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_d05efb46-49e7-4fbc-8163-68e316ac0ca0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_3420b301-4800-49d9-bbc1-549627374d39" xlink:href="biib-20230930.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_3420b301-4800-49d9-bbc1-549627374d39" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_5dbb7036-5fe5-4753-b455-0dbbf94d5105" xlink:href="biib-20230930.xsd#biib_SalesTriggerGrossSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_5dbb7036-5fe5-4753-b455-0dbbf94d5105" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9a2f91fb-b2d4-418f-b628-8efb551236dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9a2f91fb-b2d4-418f-b628-8efb551236dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6ef2c7eb-647d-4109-b4d3-60922532037e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9a2f91fb-b2d4-418f-b628-8efb551236dd" xlink:to="loc_srt_ProductOrServiceAxis_6ef2c7eb-647d-4109-b4d3-60922532037e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ef2c7eb-647d-4109-b4d3-60922532037e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6ef2c7eb-647d-4109-b4d3-60922532037e" xlink:to="loc_srt_ProductsAndServicesDomain_6ef2c7eb-647d-4109-b4d3-60922532037e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_45ba4de8-293f-4c41-96fd-49b9d1eafa67" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6ef2c7eb-647d-4109-b4d3-60922532037e" xlink:to="loc_srt_ProductsAndServicesDomain_45ba4de8-293f-4c41-96fd-49b9d1eafa67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember_f847dde9-d555-4a7f-bcd3-55373f50725b" xlink:href="biib-20230930.xsd#biib_RituxanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_45ba4de8-293f-4c41-96fd-49b9d1eafa67" xlink:to="loc_biib_RituxanMember_f847dde9-d555-4a7f-bcd3-55373f50725b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember_e1cff975-50a8-4ca8-a333-c1d058a669bd" xlink:href="biib-20230930.xsd#biib_GAZYVAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_45ba4de8-293f-4c41-96fd-49b9d1eafa67" xlink:to="loc_biib_GAZYVAMember_e1cff975-50a8-4ca8-a333-c1d058a669bd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsEisaiDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_555c7169-fc59-4423-a3ca-7c8425a922f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedPaymentToTerminationAgreement_2f8720f9-1c6b-4755-b115-0f5e0876c07f" xlink:href="biib-20230930.xsd#biib_AccruedPaymentToTerminationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_555c7169-fc59-4423-a3ca-7c8425a922f6" xlink:to="loc_biib_AccruedPaymentToTerminationAgreement_2f8720f9-1c6b-4755-b115-0f5e0876c07f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df765277-2e6e-4835-b0ea-89e6e80baa86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_555c7169-fc59-4423-a3ca-7c8425a922f6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df765277-2e6e-4835-b0ea-89e6e80baa86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_56b79743-33aa-462e-a5db-7db6ba25d283" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df765277-2e6e-4835-b0ea-89e6e80baa86" xlink:to="loc_srt_ProductOrServiceAxis_56b79743-33aa-462e-a5db-7db6ba25d283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_56b79743-33aa-462e-a5db-7db6ba25d283_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_56b79743-33aa-462e-a5db-7db6ba25d283" xlink:to="loc_srt_ProductsAndServicesDomain_56b79743-33aa-462e-a5db-7db6ba25d283_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ec29d090-9d53-40d0-9942-3fc06d33b953" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_56b79743-33aa-462e-a5db-7db6ba25d283" xlink:to="loc_srt_ProductsAndServicesDomain_ec29d090-9d53-40d0-9942-3fc06d33b953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_dce3015d-9c09-4a21-82cd-58107edfb356" xlink:href="biib-20230930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ec29d090-9d53-40d0-9942-3fc06d33b953" xlink:to="loc_biib_LEQEMBICollaborationMember_dce3015d-9c09-4a21-82cd-58107edfb356" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e87b6fa3-cf76-404a-af8a-ff7ae8eeeb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_3dc9a53e-813d-4f91-ad9c-4e2ce8b306a9" xlink:href="biib-20230930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e87b6fa3-cf76-404a-af8a-ff7ae8eeeb7f" xlink:to="loc_biib_ExpenseIncurredByCollaboration_3dc9a53e-813d-4f91-ad9c-4e2ce8b306a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_b5aa8a7d-830b-4b79-9d7a-bd3e9e83430b" xlink:href="biib-20230930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e87b6fa3-cf76-404a-af8a-ff7ae8eeeb7f" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_b5aa8a7d-830b-4b79-9d7a-bd3e9e83430b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_142d4f9c-a3fe-4512-a3d7-77e78dace559" xlink:href="biib-20230930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e87b6fa3-cf76-404a-af8a-ff7ae8eeeb7f" xlink:to="loc_biib_Expenseincurredbythecollaboration_142d4f9c-a3fe-4512-a3d7-77e78dace559" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc2d3a73-abee-4138-b0fa-a1fff6cb4a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e87b6fa3-cf76-404a-af8a-ff7ae8eeeb7f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc2d3a73-abee-4138-b0fa-a1fff6cb4a8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_24f9a182-47b4-4708-913c-ef71e84ba9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc2d3a73-abee-4138-b0fa-a1fff6cb4a8c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_24f9a182-47b4-4708-913c-ef71e84ba9ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_24f9a182-47b4-4708-913c-ef71e84ba9ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24f9a182-47b4-4708-913c-ef71e84ba9ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_24f9a182-47b4-4708-913c-ef71e84ba9ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ab5ebedb-b6bf-4ccb-9af1-24dc2b4e73b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24f9a182-47b4-4708-913c-ef71e84ba9ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ab5ebedb-b6bf-4ccb-9af1-24dc2b4e73b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3a3e3cbd-fa1d-4eff-a007-6bba3e6c4647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ab5ebedb-b6bf-4ccb-9af1-24dc2b4e73b5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3a3e3cbd-fa1d-4eff-a007-6bba3e6c4647" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0f325f25-01da-4ec8-bae3-df46e78ed90e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc2d3a73-abee-4138-b0fa-a1fff6cb4a8c" xlink:to="loc_srt_ProductOrServiceAxis_0f325f25-01da-4ec8-bae3-df46e78ed90e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0f325f25-01da-4ec8-bae3-df46e78ed90e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0f325f25-01da-4ec8-bae3-df46e78ed90e" xlink:to="loc_srt_ProductsAndServicesDomain_0f325f25-01da-4ec8-bae3-df46e78ed90e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7d39f3b9-b819-4e80-8c3d-0adbd93c5871" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0f325f25-01da-4ec8-bae3-df46e78ed90e" xlink:to="loc_srt_ProductsAndServicesDomain_7d39f3b9-b819-4e80-8c3d-0adbd93c5871" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_b236477a-b615-47b5-843f-afe6a0ffd132" xlink:href="biib-20230930.xsd#biib_E2609andBAN2401Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7d39f3b9-b819-4e80-8c3d-0adbd93c5871" xlink:to="loc_biib_E2609andBAN2401Member_b236477a-b615-47b5-843f-afe6a0ffd132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_9f34a82d-979c-4c13-8a90-49648a158634" xlink:href="biib-20230930.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7d39f3b9-b819-4e80-8c3d-0adbd93c5871" xlink:to="loc_biib_ADUHELMMember_9f34a82d-979c-4c13-8a90-49648a158634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_24f7a4fa-1a90-458a-8c6c-3ea88dffbde1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc2d3a73-abee-4138-b0fa-a1fff6cb4a8c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_24f7a4fa-1a90-458a-8c6c-3ea88dffbde1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24f7a4fa-1a90-458a-8c6c-3ea88dffbde1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_24f7a4fa-1a90-458a-8c6c-3ea88dffbde1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24f7a4fa-1a90-458a-8c6c-3ea88dffbde1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55ea068a-f480-4c46-aca8-b9c691afc39f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_24f7a4fa-1a90-458a-8c6c-3ea88dffbde1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55ea068a-f480-4c46-aca8-b9c691afc39f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_546ce065-8175-4e60-b13e-c6a44691f411" xlink:href="biib-20230930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55ea068a-f480-4c46-aca8-b9c691afc39f" xlink:to="loc_biib_EisaiMember_546ce065-8175-4e60-b13e-c6a44691f411" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_693a87dc-5148-484d-bd03-cb12d8c7050f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5c48f7b5-2d10-433f-86b5-9e7eae4b3501" xlink:href="biib-20230930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_693a87dc-5148-484d-bd03-cb12d8c7050f" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5c48f7b5-2d10-433f-86b5-9e7eae4b3501" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_438e4778-9441-475d-bcc1-9384ace94f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_693a87dc-5148-484d-bd03-cb12d8c7050f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_438e4778-9441-475d-bcc1-9384ace94f88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementProfitLossSharing_f4255da1-7b42-4090-9470-d9b2b9251a78" xlink:href="biib-20230930.xsd#biib_CollaborativeArrangementProfitLossSharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_693a87dc-5148-484d-bd03-cb12d8c7050f" xlink:to="loc_biib_CollaborativeArrangementProfitLossSharing_f4255da1-7b42-4090-9470-d9b2b9251a78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_b72ca646-6e52-4d25-bdee-4de9d4a83381" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_693a87dc-5148-484d-bd03-cb12d8c7050f" xlink:to="loc_us-gaap_InventoryWriteDown_b72ca646-6e52-4d25-bdee-4de9d4a83381" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsReceivableFromCollaborator_fce8e7aa-16bf-45f8-bb3f-159fd114895a" xlink:href="biib-20230930.xsd#biib_AccountsReceivableFromCollaborator"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_693a87dc-5148-484d-bd03-cb12d8c7050f" xlink:to="loc_biib_AccountsReceivableFromCollaborator_fce8e7aa-16bf-45f8-bb3f-159fd114895a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsPayableToCollaborator_bbd8031e-6bab-41d0-95bf-ae7fda4a11e7" xlink:href="biib-20230930.xsd#biib_AccountsPayableToCollaborator"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_693a87dc-5148-484d-bd03-cb12d8c7050f" xlink:to="loc_biib_AccountsPayableToCollaborator_bbd8031e-6bab-41d0-95bf-ae7fda4a11e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_693a87dc-5148-484d-bd03-cb12d8c7050f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6ad2cc68-1cae-460c-84df-b884d03a0e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6ad2cc68-1cae-460c-84df-b884d03a0e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ad2cc68-1cae-460c-84df-b884d03a0e16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6ad2cc68-1cae-460c-84df-b884d03a0e16" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ad2cc68-1cae-460c-84df-b884d03a0e16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e244704b-fb8d-4cc8-9fdf-d9ff0ef1a389" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6ad2cc68-1cae-460c-84df-b884d03a0e16" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e244704b-fb8d-4cc8-9fdf-d9ff0ef1a389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_dac71ce3-53f8-49fe-b0e5-f23217bbfb5f" xlink:href="biib-20230930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e244704b-fb8d-4cc8-9fdf-d9ff0ef1a389" xlink:to="loc_biib_EisaiMember_dac71ce3-53f8-49fe-b0e5-f23217bbfb5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d7957da6-f65f-4460-b85e-71673bf81dac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:to="loc_srt_ProductOrServiceAxis_d7957da6-f65f-4460-b85e-71673bf81dac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7957da6-f65f-4460-b85e-71673bf81dac_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d7957da6-f65f-4460-b85e-71673bf81dac" xlink:to="loc_srt_ProductsAndServicesDomain_d7957da6-f65f-4460-b85e-71673bf81dac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fedeb990-4925-43ec-9729-838358f8c977" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d7957da6-f65f-4460-b85e-71673bf81dac" xlink:to="loc_srt_ProductsAndServicesDomain_fedeb990-4925-43ec-9729-838358f8c977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_3eb1e1a0-029a-4e82-9e72-8e7444ea9d02" xlink:href="biib-20230930.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fedeb990-4925-43ec-9729-838358f8c977" xlink:to="loc_biib_ADUHELMMember_3eb1e1a0-029a-4e82-9e72-8e7444ea9d02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f1a13f72-3ce9-40c0-a805-8e2d23b6c2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f1a13f72-3ce9-40c0-a805-8e2d23b6c2c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f1a13f72-3ce9-40c0-a805-8e2d23b6c2c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f1a13f72-3ce9-40c0-a805-8e2d23b6c2c0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f1a13f72-3ce9-40c0-a805-8e2d23b6c2c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_870c65ac-b97f-4c3a-8d32-4f43e0c9a6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f1a13f72-3ce9-40c0-a805-8e2d23b6c2c0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_870c65ac-b97f-4c3a-8d32-4f43e0c9a6e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationProfitSharingMember_f85e3b92-af04-4e69-b849-91d55e9ce4d0" xlink:href="biib-20230930.xsd#biib_CollaborationProfitSharingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_870c65ac-b97f-4c3a-8d32-4f43e0c9a6e0" xlink:to="loc_biib_CollaborationProfitSharingMember_f85e3b92-af04-4e69-b849-91d55e9ce4d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementProfitLossSharingComponentsAxis_a3d003f8-ed70-4be8-9e9e-5053a759f91e" xlink:href="biib-20230930.xsd#biib_CollaborativeArrangementProfitLossSharingComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:to="loc_biib_CollaborativeArrangementProfitLossSharingComponentsAxis_a3d003f8-ed70-4be8-9e9e-5053a759f91e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementProfitLossSharingComponentsDomain_a3d003f8-ed70-4be8-9e9e-5053a759f91e_default" xlink:href="biib-20230930.xsd#biib_CollaborativeArrangementProfitLossSharingComponentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CollaborativeArrangementProfitLossSharingComponentsAxis_a3d003f8-ed70-4be8-9e9e-5053a759f91e" xlink:to="loc_biib_CollaborativeArrangementProfitLossSharingComponentsDomain_a3d003f8-ed70-4be8-9e9e-5053a759f91e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementProfitLossSharingComponentsDomain_2f9b402e-2765-4a94-912b-76334fd8a67d" xlink:href="biib-20230930.xsd#biib_CollaborativeArrangementProfitLossSharingComponentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CollaborativeArrangementProfitLossSharingComponentsAxis_a3d003f8-ed70-4be8-9e9e-5053a759f91e" xlink:to="loc_biib_CollaborativeArrangementProfitLossSharingComponentsDomain_2f9b402e-2765-4a94-912b-76334fd8a67d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember_60dd902b-a465-4beb-9a77-eaf75f943188" xlink:href="biib-20230930.xsd#biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborativeArrangementProfitLossSharingComponentsDomain_2f9b402e-2765-4a94-912b-76334fd8a67d" xlink:to="loc_biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember_60dd902b-a465-4beb-9a77-eaf75f943188" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5b52023d-9f7b-452e-b705-e8df4663b158" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:to="loc_srt_RangeAxis_5b52023d-9f7b-452e-b705-e8df4663b158" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5b52023d-9f7b-452e-b705-e8df4663b158_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5b52023d-9f7b-452e-b705-e8df4663b158" xlink:to="loc_srt_RangeMember_5b52023d-9f7b-452e-b705-e8df4663b158_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c9913b4e-8044-49de-a1ad-6241ef51a298" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5b52023d-9f7b-452e-b705-e8df4663b158" xlink:to="loc_srt_RangeMember_c9913b4e-8044-49de-a1ad-6241ef51a298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d6f6e40c-aef1-4f41-9033-8746a5becb7b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c9913b4e-8044-49de-a1ad-6241ef51a298" xlink:to="loc_srt_MaximumMember_d6f6e40c-aef1-4f41-9033-8746a5becb7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d27aa372-23cf-4cf8-b77d-749c4dc80443" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:to="loc_srt_StatementScenarioAxis_d27aa372-23cf-4cf8-b77d-749c4dc80443" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d27aa372-23cf-4cf8-b77d-749c4dc80443_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_d27aa372-23cf-4cf8-b77d-749c4dc80443" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d27aa372-23cf-4cf8-b77d-749c4dc80443_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_52a98a92-79b0-4d97-aa9c-0cb4c3868c46" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_d27aa372-23cf-4cf8-b77d-749c4dc80443" xlink:to="loc_srt_ScenarioUnspecifiedDomain_52a98a92-79b0-4d97-aa9c-0cb4c3868c46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_053906fd-6a08-48a6-92e8-eb841d928492" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_52a98a92-79b0-4d97-aa9c-0cb4c3868c46" xlink:to="loc_srt_ScenarioForecastMember_053906fd-6a08-48a6-92e8-eb841d928492" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ddd6d0e5-4d74-4d18-92e6-d81ee3807709" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_677bf2fa-b1d8-4562-aae3-302cc85866c3" xlink:href="biib-20230930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ddd6d0e5-4d74-4d18-92e6-d81ee3807709" xlink:to="loc_biib_Expenseincurredbythecollaboration_677bf2fa-b1d8-4562-aae3-302cc85866c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_08d78731-129b-4ead-a4a5-1fbe207304fe" xlink:href="biib-20230930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ddd6d0e5-4d74-4d18-92e6-d81ee3807709" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_08d78731-129b-4ead-a4a5-1fbe207304fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized_ee6146c4-1137-43d6-8a85-0af836bfcf9d" xlink:href="biib-20230930.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ddd6d0e5-4d74-4d18-92e6-d81ee3807709" xlink:to="loc_biib_ShareOfNonControlingInterestRecognized_ee6146c4-1137-43d6-8a85-0af836bfcf9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AggregateGrossIdleCapacityCharges_66671657-3101-47d7-bfc7-6b2b15a0fe86" xlink:href="biib-20230930.xsd#biib_AggregateGrossIdleCapacityCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ddd6d0e5-4d74-4d18-92e6-d81ee3807709" xlink:to="loc_biib_AggregateGrossIdleCapacityCharges_66671657-3101-47d7-bfc7-6b2b15a0fe86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f265bac3-0e9a-4bb7-bab8-c718d4a8e8be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ddd6d0e5-4d74-4d18-92e6-d81ee3807709" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f265bac3-0e9a-4bb7-bab8-c718d4a8e8be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57e45f0b-0fde-43ef-a4ff-c64aeff1d205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ddd6d0e5-4d74-4d18-92e6-d81ee3807709" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57e45f0b-0fde-43ef-a4ff-c64aeff1d205" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fb90bc64-9906-4044-b521-b62f0af07e01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57e45f0b-0fde-43ef-a4ff-c64aeff1d205" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fb90bc64-9906-4044-b521-b62f0af07e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fb90bc64-9906-4044-b521-b62f0af07e01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fb90bc64-9906-4044-b521-b62f0af07e01" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fb90bc64-9906-4044-b521-b62f0af07e01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ad19f59c-ced4-4fe6-9409-79d454338e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fb90bc64-9906-4044-b521-b62f0af07e01" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ad19f59c-ced4-4fe6-9409-79d454338e8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_df42c52a-45e6-4050-bdf3-f8fe5f768bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad19f59c-ced4-4fe6-9409-79d454338e8b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_df42c52a-45e6-4050-bdf3-f8fe5f768bbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bdc2fe90-9d76-4df5-b05a-474a4fa8a6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad19f59c-ced4-4fe6-9409-79d454338e8b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bdc2fe90-9d76-4df5-b05a-474a4fa8a6b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4ea29251-f7e3-44b1-bca6-2a7a3eb8c305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57e45f0b-0fde-43ef-a4ff-c64aeff1d205" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4ea29251-f7e3-44b1-bca6-2a7a3eb8c305" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4ea29251-f7e3-44b1-bca6-2a7a3eb8c305_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4ea29251-f7e3-44b1-bca6-2a7a3eb8c305" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4ea29251-f7e3-44b1-bca6-2a7a3eb8c305_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_424491dd-2898-4f09-99ff-5fe63cc9478b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4ea29251-f7e3-44b1-bca6-2a7a3eb8c305" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_424491dd-2898-4f09-99ff-5fe63cc9478b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_e8a02153-64d9-4dc3-bd59-a14db7fde293" xlink:href="biib-20230930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_424491dd-2898-4f09-99ff-5fe63cc9478b" xlink:to="loc_biib_EisaiMember_e8a02153-64d9-4dc3-bd59-a14db7fde293" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c64ad3de-aae9-4bf2-8964-767dffba6af7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57e45f0b-0fde-43ef-a4ff-c64aeff1d205" xlink:to="loc_srt_ProductOrServiceAxis_c64ad3de-aae9-4bf2-8964-767dffba6af7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c64ad3de-aae9-4bf2-8964-767dffba6af7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c64ad3de-aae9-4bf2-8964-767dffba6af7" xlink:to="loc_srt_ProductsAndServicesDomain_c64ad3de-aae9-4bf2-8964-767dffba6af7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_18a956ca-0d2b-4459-9322-6c9936ee77aa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c64ad3de-aae9-4bf2-8964-767dffba6af7" xlink:to="loc_srt_ProductsAndServicesDomain_18a956ca-0d2b-4459-9322-6c9936ee77aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_a1e25ee1-c875-4d48-ad24-69d6e6ee2201" xlink:href="biib-20230930.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_18a956ca-0d2b-4459-9322-6c9936ee77aa" xlink:to="loc_biib_ADUHELMMember_a1e25ee1-c875-4d48-ad24-69d6e6ee2201" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_a019c998-221b-46ab-9ef6-5ddc7c4f1d4a" xlink:href="biib-20230930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_18a956ca-0d2b-4459-9322-6c9936ee77aa" xlink:to="loc_biib_LEQEMBICollaborationMember_a019c998-221b-46ab-9ef6-5ddc7c4f1d4a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dccbab8a-b940-4c5d-92f8-4e70903e5bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_111615c5-91f3-4540-b9f5-f942d64bbae9" xlink:href="biib-20230930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dccbab8a-b940-4c5d-92f8-4e70903e5bf3" xlink:to="loc_biib_Expenseincurredbythecollaboration_111615c5-91f3-4540-b9f5-f942d64bbae9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_dfc12e5d-c61e-448e-94ab-862db4ccfa57" xlink:href="biib-20230930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dccbab8a-b940-4c5d-92f8-4e70903e5bf3" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_dfc12e5d-c61e-448e-94ab-862db4ccfa57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa3c8df6-3f0a-4864-adbd-9688559ea25b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dccbab8a-b940-4c5d-92f8-4e70903e5bf3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa3c8df6-3f0a-4864-adbd-9688559ea25b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5541c622-bc77-4ee1-a818-1fcc9d4cea74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa3c8df6-3f0a-4864-adbd-9688559ea25b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5541c622-bc77-4ee1-a818-1fcc9d4cea74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5541c622-bc77-4ee1-a818-1fcc9d4cea74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5541c622-bc77-4ee1-a818-1fcc9d4cea74" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5541c622-bc77-4ee1-a818-1fcc9d4cea74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_03175bb1-8520-4181-b7b2-f062dcab8a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5541c622-bc77-4ee1-a818-1fcc9d4cea74" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_03175bb1-8520-4181-b7b2-f062dcab8a0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_528999fb-64c1-46d5-abc1-4e9edebd2014" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_03175bb1-8520-4181-b7b2-f062dcab8a0c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_528999fb-64c1-46d5-abc1-4e9edebd2014" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f4d1a425-9563-4625-9f1d-57dffa34787c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa3c8df6-3f0a-4864-adbd-9688559ea25b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f4d1a425-9563-4625-9f1d-57dffa34787c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f4d1a425-9563-4625-9f1d-57dffa34787c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f4d1a425-9563-4625-9f1d-57dffa34787c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f4d1a425-9563-4625-9f1d-57dffa34787c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ee1e255-c9a1-4043-9914-4e87af3127e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f4d1a425-9563-4625-9f1d-57dffa34787c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ee1e255-c9a1-4043-9914-4e87af3127e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_d5c3759e-3627-49e9-ad57-ef8c0600bf39" xlink:href="biib-20230930.xsd#biib_UCBPharmaS.A.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ee1e255-c9a1-4043-9914-4e87af3127e0" xlink:to="loc_biib_UCBPharmaS.A.Member_d5c3759e-3627-49e9-ad57-ef8c0600bf39" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06a03a03-ce7c-4ce4-910e-4808b2980cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_c9ea1199-e85e-4c05-aa27-13beac1849e4" xlink:href="biib-20230930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06a03a03-ce7c-4ce4-910e-4808b2980cd5" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_c9ea1199-e85e-4c05-aa27-13beac1849e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_47df9d56-42cb-4e5e-8b70-b6b947a9716c" xlink:href="biib-20230930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06a03a03-ce7c-4ce4-910e-4808b2980cd5" xlink:to="loc_biib_Expenseincurredbythecollaboration_47df9d56-42cb-4e5e-8b70-b6b947a9716c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_a730cd96-c361-46d6-ac10-761d4f56a021" xlink:href="biib-20230930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06a03a03-ce7c-4ce4-910e-4808b2980cd5" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_a730cd96-c361-46d6-ac10-761d4f56a021" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNetProfitFromSageTherapeuticsAmount_59985daf-6190-4832-ae93-e12f06c9b6e2" xlink:href="biib-20230930.xsd#biib_ShareOfNetProfitFromSageTherapeuticsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06a03a03-ce7c-4ce4-910e-4808b2980cd5" xlink:to="loc_biib_ShareOfNetProfitFromSageTherapeuticsAmount_59985daf-6190-4832-ae93-e12f06c9b6e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent_ab0eb600-fea1-408a-b3d2-01958278c807" xlink:href="biib-20230930.xsd#biib_ShareOfNetProfitFromSageTherapeuticsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06a03a03-ce7c-4ce4-910e-4808b2980cd5" xlink:to="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent_ab0eb600-fea1-408a-b3d2-01958278c807" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_47f74d28-e070-4c7e-9bcf-78ba1cf3c32c" xlink:href="biib-20230930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06a03a03-ce7c-4ce4-910e-4808b2980cd5" xlink:to="loc_biib_Collaborationprofitlosssharing_47f74d28-e070-4c7e-9bcf-78ba1cf3c32c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_015fb201-07c8-429c-8270-4c56103d77a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06a03a03-ce7c-4ce4-910e-4808b2980cd5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_015fb201-07c8-429c-8270-4c56103d77a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4a7e5064-1d47-4010-a8dc-0a4e9ef04972" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_015fb201-07c8-429c-8270-4c56103d77a7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4a7e5064-1d47-4010-a8dc-0a4e9ef04972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4a7e5064-1d47-4010-a8dc-0a4e9ef04972_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4a7e5064-1d47-4010-a8dc-0a4e9ef04972" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4a7e5064-1d47-4010-a8dc-0a4e9ef04972_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_45dc50c0-39d4-46f4-bfcd-f48ebae46cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4a7e5064-1d47-4010-a8dc-0a4e9ef04972" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_45dc50c0-39d4-46f4-bfcd-f48ebae46cdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17ae0901-85d0-438c-b125-0dad8c6ac0de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_45dc50c0-39d4-46f4-bfcd-f48ebae46cdc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17ae0901-85d0-438c-b125-0dad8c6ac0de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b1136b76-857c-40c7-ba47-265d67f42306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_45dc50c0-39d4-46f4-bfcd-f48ebae46cdc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b1136b76-857c-40c7-ba47-265d67f42306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d8e60717-4e31-41e5-828d-a87f89f2935f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_015fb201-07c8-429c-8270-4c56103d77a7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d8e60717-4e31-41e5-828d-a87f89f2935f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8e60717-4e31-41e5-828d-a87f89f2935f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d8e60717-4e31-41e5-828d-a87f89f2935f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8e60717-4e31-41e5-828d-a87f89f2935f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bd4ab-5d6c-4e95-9369-89fdc8554ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d8e60717-4e31-41e5-828d-a87f89f2935f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bd4ab-5d6c-4e95-9369-89fdc8554ab5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_150ac8d3-279c-4aed-bd59-0874a8209c67" xlink:href="biib-20230930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bd4ab-5d6c-4e95-9369-89fdc8554ab5" xlink:to="loc_biib_SageTherapeuticsIncMember_150ac8d3-279c-4aed-bd59-0874a8209c67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2a739370-32a6-491c-8b98-e1de2acc9a40" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_015fb201-07c8-429c-8270-4c56103d77a7" xlink:to="loc_srt_StatementScenarioAxis_2a739370-32a6-491c-8b98-e1de2acc9a40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2a739370-32a6-491c-8b98-e1de2acc9a40_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_2a739370-32a6-491c-8b98-e1de2acc9a40" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2a739370-32a6-491c-8b98-e1de2acc9a40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7175401d-a399-4125-b953-2ebb6626fe32" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_2a739370-32a6-491c-8b98-e1de2acc9a40" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7175401d-a399-4125-b953-2ebb6626fe32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_105ec211-b41f-4538-bca3-3aac09555045" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7175401d-a399-4125-b953-2ebb6626fe32" xlink:to="loc_srt_ScenarioForecastMember_105ec211-b41f-4538-bca3-3aac09555045" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d6213c1f-da56-446b-be4b-5bb990bbbda1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_44c59a8e-1f1c-42fb-a11b-dde482b7b491" xlink:href="biib-20230930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d6213c1f-da56-446b-be4b-5bb990bbbda1" xlink:to="loc_biib_Expenseincurredbythecollaboration_44c59a8e-1f1c-42fb-a11b-dde482b7b491" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_05ddcaae-b2af-4859-98aa-c61c06305863" xlink:href="biib-20230930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d6213c1f-da56-446b-be4b-5bb990bbbda1" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_05ddcaae-b2af-4859-98aa-c61c06305863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924621a4-835e-4385-9559-8489bb2ca498" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d6213c1f-da56-446b-be4b-5bb990bbbda1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924621a4-835e-4385-9559-8489bb2ca498" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_18ea499c-af3b-4501-8c23-bf26cd669cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924621a4-835e-4385-9559-8489bb2ca498" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_18ea499c-af3b-4501-8c23-bf26cd669cc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_18ea499c-af3b-4501-8c23-bf26cd669cc6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18ea499c-af3b-4501-8c23-bf26cd669cc6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_18ea499c-af3b-4501-8c23-bf26cd669cc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_86e54af6-2abb-4f60-91ad-36a4fa9725eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18ea499c-af3b-4501-8c23-bf26cd669cc6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_86e54af6-2abb-4f60-91ad-36a4fa9725eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8a595491-5ed6-4a57-806a-1b5a2f02e3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_86e54af6-2abb-4f60-91ad-36a4fa9725eb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8a595491-5ed6-4a57-806a-1b5a2f02e3ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e9b7781c-628c-4afe-beef-924e67a709e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924621a4-835e-4385-9559-8489bb2ca498" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e9b7781c-628c-4afe-beef-924e67a709e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e9b7781c-628c-4afe-beef-924e67a709e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e9b7781c-628c-4afe-beef-924e67a709e7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e9b7781c-628c-4afe-beef-924e67a709e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10c4afe9-f5c8-40b4-9a51-41a1993242fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e9b7781c-628c-4afe-beef-924e67a709e7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10c4afe9-f5c8-40b4-9a51-41a1993242fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_45403bf9-bf1f-409e-8cf5-aa819584a1d9" xlink:href="biib-20230930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10c4afe9-f5c8-40b4-9a51-41a1993242fb" xlink:to="loc_biib_DenaliTherapeuticsIncMember_45403bf9-bf1f-409e-8cf5-aa819584a1d9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_74de10e3-273d-44b6-a11d-715f7e1cc4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_a8104668-15e4-484c-8c9b-17ed7ceb3b01" xlink:href="biib-20230930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_74de10e3-273d-44b6-a11d-715f7e1cc4a0" xlink:to="loc_biib_Expenseincurredbythecollaboration_a8104668-15e4-484c-8c9b-17ed7ceb3b01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_f6647de5-37ef-420a-96a8-43d6dc4add68" xlink:href="biib-20230930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_74de10e3-273d-44b6-a11d-715f7e1cc4a0" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_f6647de5-37ef-420a-96a8-43d6dc4add68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b106ae-9cf5-4c8b-ae38-667db481ed7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_74de10e3-273d-44b6-a11d-715f7e1cc4a0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b106ae-9cf5-4c8b-ae38-667db481ed7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ce85f6ea-0be9-4a77-a8ba-dbb8e2129aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b106ae-9cf5-4c8b-ae38-667db481ed7f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ce85f6ea-0be9-4a77-a8ba-dbb8e2129aec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ce85f6ea-0be9-4a77-a8ba-dbb8e2129aec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ce85f6ea-0be9-4a77-a8ba-dbb8e2129aec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ce85f6ea-0be9-4a77-a8ba-dbb8e2129aec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3a39aa18-12e9-41d8-b465-769d5885bed4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ce85f6ea-0be9-4a77-a8ba-dbb8e2129aec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3a39aa18-12e9-41d8-b465-769d5885bed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_630559d5-7cd3-4ec7-a97e-3a35defb7c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3a39aa18-12e9-41d8-b465-769d5885bed4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_630559d5-7cd3-4ec7-a97e-3a35defb7c4f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsOtherArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_38dbbf4a-d3ca-4338-b8a9-6006c548d5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e4a56898-028d-407e-aab7-b637a4f1421d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_38dbbf4a-d3ca-4338-b8a9-6006c548d5ee" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e4a56898-028d-407e-aab7-b637a4f1421d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_febe79fb-99af-4ae2-9e01-f81e0a231d32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_38dbbf4a-d3ca-4338-b8a9-6006c548d5ee" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_febe79fb-99af-4ae2-9e01-f81e0a231d32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ac080e64-ca58-47de-8a18-37b7c912cfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_febe79fb-99af-4ae2-9e01-f81e0a231d32" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ac080e64-ca58-47de-8a18-37b7c912cfe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ac080e64-ca58-47de-8a18-37b7c912cfe2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ac080e64-ca58-47de-8a18-37b7c912cfe2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ac080e64-ca58-47de-8a18-37b7c912cfe2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_abdde5d7-bff7-4b95-ac3c-09583533bf52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ac080e64-ca58-47de-8a18-37b7c912cfe2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_abdde5d7-bff7-4b95-ac3c-09583533bf52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_bd707da4-e83d-4262-9341-6bbd710e179e" xlink:href="biib-20230930.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_abdde5d7-bff7-4b95-ac3c-09583533bf52" xlink:to="loc_biib_OtherresearchanddiscoveryMember_bd707da4-e83d-4262-9341-6bbd710e179e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsSamsungBioepisDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts_0ce9e0dd-047f-483b-820e-8d761c1040f1" xlink:href="biib-20230930.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_biib_ContingentCommercializedRightsNumberOfProducts_0ce9e0dd-047f-483b-820e-8d761c1040f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_75453842-db3c-4f6d-a5c5-82a89a798a16" xlink:href="biib-20230930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_75453842-db3c-4f6d-a5c5-82a89a798a16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_b5743c7d-330d-4fe2-bfa0-338821566836" xlink:href="biib-20230930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_b5743c7d-330d-4fe2-bfa0-338821566836" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_c4035502-02aa-42ac-bcb5-2fd84ef41324" xlink:href="biib-20230930.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_biib_CollaborationAgreementTerm_c4035502-02aa-42ac-bcb5-2fd84ef41324" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_4bc12a05-afd9-4ca1-9c39-73faabaf09dd" xlink:href="biib-20230930.xsd#biib_ContractOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_biib_ContractOptionExerciseFee_4bc12a05-afd9-4ca1-9c39-73faabaf09dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_1797ac72-bf91-423a-9152-ef856276d5db" xlink:href="biib-20230930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_biib_Collaborationprofitlosssharing_1797ac72-bf91-423a-9152-ef856276d5db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_f960e02b-f4fc-4ca3-82ce-53a8e1151de7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_us-gaap_AccountsReceivableNet_f960e02b-f4fc-4ca3-82ce-53a8e1151de7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_51568609-a69b-4733-9ade-788597207518" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_51568609-a69b-4733-9ade-788597207518" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cab56b4-773d-4573-8c0b-e6b43c6f0bde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cab56b4-773d-4573-8c0b-e6b43c6f0bde" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fe9db320-cdad-455a-b20b-9b124b60f172" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cab56b4-773d-4573-8c0b-e6b43c6f0bde" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fe9db320-cdad-455a-b20b-9b124b60f172" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fe9db320-cdad-455a-b20b-9b124b60f172_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fe9db320-cdad-455a-b20b-9b124b60f172" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fe9db320-cdad-455a-b20b-9b124b60f172_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_865ebb38-f0fd-4597-b281-152b843959c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fe9db320-cdad-455a-b20b-9b124b60f172" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_865ebb38-f0fd-4597-b281-152b843959c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_44f81ebf-3a7c-46df-b525-910840154799" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_865ebb38-f0fd-4597-b281-152b843959c3" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_44f81ebf-3a7c-46df-b525-910840154799" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fbb51951-c980-4928-9a9e-125f540dedd2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cab56b4-773d-4573-8c0b-e6b43c6f0bde" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fbb51951-c980-4928-9a9e-125f540dedd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_fbb51951-c980-4928-9a9e-125f540dedd2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fbb51951-c980-4928-9a9e-125f540dedd2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_fbb51951-c980-4928-9a9e-125f540dedd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ae72da93-34b0-494f-8854-e8733ab9b153" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fbb51951-c980-4928-9a9e-125f540dedd2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ae72da93-34b0-494f-8854-e8733ab9b153" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_efdacc6b-32ea-4e06-af82-727a5ab4d35c" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ae72da93-34b0-494f-8854-e8733ab9b153" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_efdacc6b-32ea-4e06-af82-727a5ab4d35c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_77297844-388e-4aeb-afd9-dce9a10ec682" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cab56b4-773d-4573-8c0b-e6b43c6f0bde" xlink:to="loc_srt_CounterpartyNameAxis_77297844-388e-4aeb-afd9-dce9a10ec682" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77297844-388e-4aeb-afd9-dce9a10ec682_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_77297844-388e-4aeb-afd9-dce9a10ec682" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77297844-388e-4aeb-afd9-dce9a10ec682_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a31cbdfa-94e7-47c3-982c-ba913376f235" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_77297844-388e-4aeb-afd9-dce9a10ec682" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a31cbdfa-94e7-47c3-982c-ba913376f235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f13df057-8db2-4f31-ab89-43e5cc305f84" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cab56b4-773d-4573-8c0b-e6b43c6f0bde" xlink:to="loc_srt_ProductOrServiceAxis_f13df057-8db2-4f31-ab89-43e5cc305f84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f13df057-8db2-4f31-ab89-43e5cc305f84_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f13df057-8db2-4f31-ab89-43e5cc305f84" xlink:to="loc_srt_ProductsAndServicesDomain_f13df057-8db2-4f31-ab89-43e5cc305f84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a0ecd5c4-cf5b-4366-82b6-f891061ded17" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f13df057-8db2-4f31-ab89-43e5cc305f84" xlink:to="loc_srt_ProductsAndServicesDomain_a0ecd5c4-cf5b-4366-82b6-f891061ded17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_aca986e1-fe67-4779-9058-93efaf2ba689" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cab56b4-773d-4573-8c0b-e6b43c6f0bde" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_aca986e1-fe67-4779-9058-93efaf2ba689" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_aca986e1-fe67-4779-9058-93efaf2ba689_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_aca986e1-fe67-4779-9058-93efaf2ba689" xlink:to="loc_us-gaap_RelatedPartyDomain_aca986e1-fe67-4779-9058-93efaf2ba689_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1af6b50a-bc56-4187-8036-206da63c67e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_aca986e1-fe67-4779-9058-93efaf2ba689" xlink:to="loc_us-gaap_RelatedPartyDomain_1af6b50a-bc56-4187-8036-206da63c67e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_6b571cfd-d4eb-42f5-b30b-5757c701615e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1af6b50a-bc56-4187-8036-206da63c67e4" xlink:to="loc_us-gaap_RelatedPartyMember_6b571cfd-d4eb-42f5-b30b-5757c701615e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_7759660f-381d-4971-8822-4cab355d22c0" xlink:href="biib-20230930.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_biib_CollaborationAgreementTerm_7759660f-381d-4971-8822-4cab355d22c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_fcd1416a-a464-4cfc-919d-04f5a4f7e309" xlink:href="biib-20230930.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_fcd1416a-a464-4cfc-919d-04f5a4f7e309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_2d01b9df-45ac-478f-a12f-02236aabe518" xlink:href="biib-20230930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_2d01b9df-45ac-478f-a12f-02236aabe518" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_97f6ed74-9fc5-4c32-be9c-a9b503ff9be0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_97f6ed74-9fc5-4c32-be9c-a9b503ff9be0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5a1f4aa4-0165-4607-b0aa-3d3a5a573434" xlink:href="biib-20230930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5a1f4aa4-0165-4607-b0aa-3d3a5a573434" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_3db55448-7d12-48ac-9c25-55520236607b" xlink:href="biib-20230930.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_biib_AdditionalMilestonePayment_3db55448-7d12-48ac-9c25-55520236607b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7961f598-da7f-44c7-97c9-2d37e347f0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7961f598-da7f-44c7-97c9-2d37e347f0b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0f8e3d5d-aab8-413a-a0b4-f9b3bef899ba" xlink:href="biib-20230930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0f8e3d5d-aab8-413a-a0b4-f9b3bef899ba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6c6ae470-6e4f-4a4d-8007-93710b5005c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6c6ae470-6e4f-4a4d-8007-93710b5005c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_483f81a2-9951-4a4b-87f6-994a552cb20b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6c6ae470-6e4f-4a4d-8007-93710b5005c1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_483f81a2-9951-4a4b-87f6-994a552cb20b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_483f81a2-9951-4a4b-87f6-994a552cb20b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_483f81a2-9951-4a4b-87f6-994a552cb20b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_483f81a2-9951-4a4b-87f6-994a552cb20b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35c74246-6a95-4b10-966c-80904e290613" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_483f81a2-9951-4a4b-87f6-994a552cb20b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35c74246-6a95-4b10-966c-80904e290613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_537186c7-10b3-4dd9-a535-386e1d56c708" xlink:href="biib-20230930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35c74246-6a95-4b10-966c-80904e290613" xlink:to="loc_biib_EisaiMember_537186c7-10b3-4dd9-a535-386e1d56c708" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_5605d367-a270-474d-b88d-90028572b728" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6c6ae470-6e4f-4a4d-8007-93710b5005c1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_5605d367-a270-474d-b88d-90028572b728" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_5605d367-a270-474d-b88d-90028572b728_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_5605d367-a270-474d-b88d-90028572b728" xlink:to="loc_srt_ConsolidatedEntitiesDomain_5605d367-a270-474d-b88d-90028572b728_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_5693027c-8cd3-4d80-8491-9517a9827ee7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_5605d367-a270-474d-b88d-90028572b728" xlink:to="loc_srt_ConsolidatedEntitiesDomain_5693027c-8cd3-4d80-8491-9517a9827ee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_ba916a74-2ff2-4dae-ad51-a4587736609d" xlink:href="biib-20230930.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_5693027c-8cd3-4d80-8491-9517a9827ee7" xlink:to="loc_biib_NeurimmuneMember_ba916a74-2ff2-4dae-ad51-a4587736609d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2a5a0778-4cdf-413a-b18d-e01813ad6085" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6c6ae470-6e4f-4a4d-8007-93710b5005c1" xlink:to="loc_srt_ProductOrServiceAxis_2a5a0778-4cdf-413a-b18d-e01813ad6085" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2a5a0778-4cdf-413a-b18d-e01813ad6085_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2a5a0778-4cdf-413a-b18d-e01813ad6085" xlink:to="loc_srt_ProductsAndServicesDomain_2a5a0778-4cdf-413a-b18d-e01813ad6085_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6f96de30-a3cf-47fe-81fb-525807008dae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2a5a0778-4cdf-413a-b18d-e01813ad6085" xlink:to="loc_srt_ProductsAndServicesDomain_6f96de30-a3cf-47fe-81fb-525807008dae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_921c1d50-5685-4689-a5f8-97d71d38f5ef" xlink:href="biib-20230930.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6f96de30-a3cf-47fe-81fb-525807008dae" xlink:to="loc_biib_ADUHELMMember_921c1d50-5685-4689-a5f8-97d71d38f5ef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#LitigationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_3fa7afe9-b5b9-4bd7-b1a2-189844ec7d46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_6d9c6eaf-b271-45d8-9795-78971691630b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3fa7afe9-b5b9-4bd7-b1a2-189844ec7d46" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_6d9c6eaf-b271-45d8-9795-78971691630b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a953e8c2-87ae-467c-b3e5-32070ec75198" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3fa7afe9-b5b9-4bd7-b1a2-189844ec7d46" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a953e8c2-87ae-467c-b3e5-32070ec75198" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltiesClaimed_aa5b3bfe-a3f4-462a-a426-d4898a912962" xlink:href="biib-20230930.xsd#biib_RoyaltiesClaimed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3fa7afe9-b5b9-4bd7-b1a2-189844ec7d46" xlink:to="loc_biib_RoyaltiesClaimed_aa5b3bfe-a3f4-462a-a426-d4898a912962" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_55a7e331-dc73-4c27-a902-6fb264299ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3fa7afe9-b5b9-4bd7-b1a2-189844ec7d46" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_55a7e331-dc73-4c27-a902-6fb264299ff9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_dad07ff6-b492-414d-b10d-716979ff4df2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_3fa7afe9-b5b9-4bd7-b1a2-189844ec7d46" xlink:to="loc_us-gaap_LossContingenciesTable_dad07ff6-b492-414d-b10d-716979ff4df2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8171e590-38b0-4e84-a30e-0637163d2424" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_dad07ff6-b492-414d-b10d-716979ff4df2" xlink:to="loc_dei_LegalEntityAxis_8171e590-38b0-4e84-a30e-0637163d2424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8171e590-38b0-4e84-a30e-0637163d2424_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8171e590-38b0-4e84-a30e-0637163d2424" xlink:to="loc_dei_EntityDomain_8171e590-38b0-4e84-a30e-0637163d2424_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_aeb88782-1106-4e61-a474-740dff4bff12" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8171e590-38b0-4e84-a30e-0637163d2424" xlink:to="loc_dei_EntityDomain_aeb88782-1106-4e61-a474-740dff4bff12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ERISAClassActionLitigaitonMember_14c36a6e-74de-4054-93a4-2c9873c746d7" xlink:href="biib-20230930.xsd#biib_ERISAClassActionLitigaitonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_aeb88782-1106-4e61-a474-740dff4bff12" xlink:to="loc_biib_ERISAClassActionLitigaitonMember_14c36a6e-74de-4054-93a4-2c9873c746d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GenentechMember_eb18610a-bb02-4ee6-9198-44b60cb48fa1" xlink:href="biib-20230930.xsd#biib_GenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_aeb88782-1106-4e61-a474-740dff4bff12" xlink:to="loc_biib_GenentechMember_eb18610a-bb02-4ee6-9198-44b60cb48fa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BardoxoloneSecuritiesMember_67243fea-e141-4ad3-9145-e71ce3308a63" xlink:href="biib-20230930.xsd#biib_BardoxoloneSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_aeb88782-1106-4e61-a474-740dff4bff12" xlink:to="loc_biib_BardoxoloneSecuritiesMember_67243fea-e141-4ad3-9145-e71ce3308a63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LenderDisputeMember_5fdbd168-c01c-4a2e-8492-04da5fa48c9b" xlink:href="biib-20230930.xsd#biib_LenderDisputeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_aeb88782-1106-4e61-a474-740dff4bff12" xlink:to="loc_biib_LenderDisputeMember_5fdbd168-c01c-4a2e-8492-04da5fa48c9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b2c7ca44-9e87-44e9-b8cd-c3ada10adc2a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_dad07ff6-b492-414d-b10d-716979ff4df2" xlink:to="loc_srt_LitigationCaseAxis_b2c7ca44-9e87-44e9-b8cd-c3ada10adc2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b2c7ca44-9e87-44e9-b8cd-c3ada10adc2a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_b2c7ca44-9e87-44e9-b8cd-c3ada10adc2a" xlink:to="loc_srt_LitigationCaseTypeDomain_b2c7ca44-9e87-44e9-b8cd-c3ada10adc2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ce1a7196-1278-4103-85ce-38966c3f1524" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_b2c7ca44-9e87-44e9-b8cd-c3ada10adc2a" xlink:to="loc_srt_LitigationCaseTypeDomain_ce1a7196-1278-4103-85ce-38966c3f1524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ERISAClassActionLitigaitonMember_1bc3e7b1-23c8-471b-b6d4-748896ef5962" xlink:href="biib-20230930.xsd#biib_ERISAClassActionLitigaitonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ce1a7196-1278-4103-85ce-38966c3f1524" xlink:to="loc_biib_ERISAClassActionLitigaitonMember_1bc3e7b1-23c8-471b-b6d4-748896ef5962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GenentechMember_2cf535e2-2615-4220-ace6-d8694f0f97ae" xlink:href="biib-20230930.xsd#biib_GenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ce1a7196-1278-4103-85ce-38966c3f1524" xlink:to="loc_biib_GenentechMember_2cf535e2-2615-4220-ace6-d8694f0f97ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LenderDisputeMember_a5568496-fa70-4ff4-827b-93dd1756d0bf" xlink:href="biib-20230930.xsd#biib_LenderDisputeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ce1a7196-1278-4103-85ce-38966c3f1524" xlink:to="loc_biib_LenderDisputeMember_a5568496-fa70-4ff4-827b-93dd1756d0bf" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>biib-20230930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:067ab9af-2745-42fc-8c78-33206b6cc4f8,g:369ca811-9038-4e81-ba44-3ac1f044a248-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_db8bcafb-834e-40e6-9b3d-c97410313c28_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_ab6d86ba-1a01-442b-9cb6-df97181c301a_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:href="biib-20230930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_3f4fb5f4-38df-4bc9-8faa-2af14228b03d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ed91c791-c538-4a24-86b5-8aff450662b2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ed1ad82e-ed59-41b2-90e5-3d6df0ca4508_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense asset acquired</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64e55ef3-6f8e-4cea-89af-5ae9ae25fa8b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_3c586be7-44eb-4b2c-8921-9f4929d07afc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on derivative used in net investment hedge</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eea1eb6d-834e-4458-ba0d-986a4b24ba7b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_42d7e1a5-2942-4ec4-ae7c-b3caa46208e0_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_a4c2e6eb-5184-4f96-8b23-b168c87ff990_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total transaction value</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_84cc8e4c-0dd1-49c7-ae5e-6cce1f84a939_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_c5590bc0-33ba-475d-b6e4-76f1fdd1da94_terseLabel_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc [Member]</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember" xlink:href="biib-20230930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenaliTherapeuticsIncMember" xlink:to="lab_biib_DenaliTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_e761d9ae-7973-4198-b43b-0ea7dfd3cb98_terseLabel_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty percentage to be received</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_label_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Royalties Percentage To Be Received On Sale Of Product</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_documentation_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future royalties percentage to be received on sale of product.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:href="biib-20230930.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:to="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_d0b69e26-b99d-4438-9d23-43f15731ccd2_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveTranslationAdjustment_aeef5700-b001-4891-a425-4c2b5a75a7fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveTranslationAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency and other adjustments</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveTranslationAdjustment_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveTranslationAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveTranslationAdjustment" xlink:to="lab_us-gaap_RestructuringReserveTranslationAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SPINRAZAMember_52b75075-7167-40c0-ab20-b6547c6f2804_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_label_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember" xlink:href="biib-20230930.xsd#biib_SPINRAZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember" xlink:to="lab_biib_SPINRAZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dfc645ff-3dc3-49a5-b167-6c9e8a3de61b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6b87307b-047b-4436-8aaf-e807709743e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_0a658b87-4b35-4d44-84be-1021d153e4dc_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_d6612d7b-dd51-4472-bf52-dca2d47d90a4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess and obsolescence charges related to inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_693b42dd-2fc0-4bba-aa70-f021e561835d_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CentersForMedicareAndMedicaidServiceMember_006e61bc-71b0-4a74-bd09-2fb3064ad400_terseLabel_en-US" xlink:label="lab_biib_CentersForMedicareAndMedicaidServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centers for Medicare and Medicaid Service</link:label>
    <link:label id="lab_biib_CentersForMedicareAndMedicaidServiceMember_label_en-US" xlink:label="lab_biib_CentersForMedicareAndMedicaidServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centers for Medicare and Medicaid Service [Member]</link:label>
    <link:label id="lab_biib_CentersForMedicareAndMedicaidServiceMember_documentation_en-US" xlink:label="lab_biib_CentersForMedicareAndMedicaidServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centers for Medicare and Medicaid Service</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CentersForMedicareAndMedicaidServiceMember" xlink:href="biib-20230930.xsd#biib_CentersForMedicareAndMedicaidServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CentersForMedicareAndMedicaidServiceMember" xlink:to="lab_biib_CentersForMedicareAndMedicaidServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_9534d1fb-4857-4929-a547-73968cc9a4df_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CAD_ac3f8420-6f40-409b-a2af-a710cb4af8f4_verboseLabel_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_label_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD" xlink:to="lab_currency_CAD" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_207e19b4-a32a-462e-8a0e-1ca3150624bf_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_340b6dad-02ee-42bc-81b2-2b7f2f99d4bd_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_0762c60d-ded4-441e-ab04-84f252585a3b_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_70f69d2a-ec3c-4faf-be29-621e87e083bf_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_edbce40d-a72e-4154-b599-ea1716684c86_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7108b0e3-8a13-4fa2-9e10-4be7968b3a55_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings (loss) per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_72d6845c-5068-4a43-9af2-d100bb13f4d7_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_083af5d2-ed70-4e3a-93fe-8c6dba87a41c_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1b914845-d7ce-47f0-8a97-999142da415c_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization_40b44631-633e-4d84-b1a3-a669cd9703b6_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International reorganization</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, International Reorganization</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, International Reorganization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:href="biib-20230930.xsd#biib_EffectiveTaxRateReconciliationInternationalReorganization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:to="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_bf9d571b-bc15-434d-9841-dd82d73860ed_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of debt, amount</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_21c286f2-b29f-4f9b-a73e-66bd90d1a2f2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ERISAClassActionLitigaitonMember_6fa61eb6-5cc3-4b78-b3d1-fffa22fae8d8_terseLabel_en-US" xlink:label="lab_biib_ERISAClassActionLitigaitonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERISA Class Action Litigaiton</link:label>
    <link:label id="lab_biib_ERISAClassActionLitigaitonMember_label_en-US" xlink:label="lab_biib_ERISAClassActionLitigaitonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERISA Class Action Litigaiton [Member]</link:label>
    <link:label id="lab_biib_ERISAClassActionLitigaitonMember_documentation_en-US" xlink:label="lab_biib_ERISAClassActionLitigaitonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERISA Class Action Litigaiton</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ERISAClassActionLitigaitonMember" xlink:href="biib-20230930.xsd#biib_ERISAClassActionLitigaitonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ERISAClassActionLitigaitonMember" xlink:to="lab_biib_ERISAClassActionLitigaitonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_b5cc9ceb-4432-4b45-aeea-78107b3ab333_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_823dc541-6cde-4e99-8002-55b465f59ed3_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_66d6ad0c-6e06-4203-9f80-b6cb410d65f7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_90e24fb2-9071-41ee-83bc-3125636970b2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0a442632-4de2-4a07-9c55-4d579019014a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e5624f2a-28b6-42b4-93dd-e3224e5ad901_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_48c8a701-c6ad-402a-a728-dd33e2ec9a3d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OutLicensedPatentsMember_56c29114-9694-4a78-8a73-05ca9fa7923a_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Completed technology</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember" xlink:href="biib-20230930.xsd#biib_OutLicensedPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember" xlink:to="lab_biib_OutLicensedPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorTwoMember_0ab1c9ea-43b7-4e2b-a10a-d75c09990272_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_label_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember" xlink:href="biib-20230930.xsd#biib_DistributorTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember" xlink:to="lab_biib_DistributorTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_1e12c940-af24-4365-9a58-59f7e3bda09a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_50753048-3265-42a1-ad81-1871137b4b64_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:href="biib-20230930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_84e696dc-5384-4480-8374-57e7a2138ec6_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e578e214-642b-40bb-9007-5f0127c93bfb_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_c900bbf3-2447-4f79-98f3-cbb5d901225b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_281e9222-cb6b-49ae-9851-e0d409bdffbb_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_ef92d887-fdd3-4bc5-8bae-418c94f74f4c_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MarketStockUnitsMember_eda7b194-d7e0-4897-b71f-8e35715b5987_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember" xlink:href="biib-20230930.xsd#biib_MarketStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember" xlink:to="lab_biib_MarketStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_feec8599-6c92-42bc-ba38-28dcdee400dd_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_11efe5df-04b6-4d0c-802d-de6f7c10dd01_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_48346cbb-b7a7-44d0-b821-4717239ee6ea_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_c3d3368a-d9c0-4970-ae79-58c4e9cc8ed7_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_a8918476-072c-4271-9a2a-dc1ec574e396_terseLabel_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_label_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_documentation_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts" xlink:href="biib-20230930.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContingentCommercializedRightsNumberOfProducts" xlink:to="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_06acb33f-2123-4583-a544-fe33e68d7745_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_7057915d-5e33-4cb3-865a-33a83e1c7f76_negatedTerseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Samsung Bioepis</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Sale Of Samsung Bioepis</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Sale Of Samsung Bioepis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:href="biib-20230930.xsd#biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:to="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_44114bd8-f093-4097-be54-91fd6a803be8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of post-combination equity compensation</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_97693542-4eaf-4033-876c-8b9262d68fe9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d2e6f602-3fa1-4ee8-87dc-79623ec95f6a_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IMRALDIMember_720e79c4-0755-4fc4-8221-e7a4e1d9a5c9_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_label_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_documentation_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember" xlink:href="biib-20230930.xsd#biib_IMRALDIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember" xlink:to="lab_biib_IMRALDIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_d67f1af6-8b26-4446-bbe8-8eaa3f70913b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expense and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_364c34fc-6787-44b8-8f3c-89c2e5cd4c28_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_d3ba917a-c4c8-4ff4-b734-9eb046ff2162_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_37dfa0a0-84a3-49fc-b90d-c97bd99d6ef8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_c3a468cf-0fcb-41fc-a2cd-9787c97ee653_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_702c3d89-415a-4a89-808e-fe1233d80108_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_f9113da1-e733-4437-b439-bb33e2b5d8ed_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:href="biib-20230930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_801da2eb-9254-414a-8b7f-deb7a69a940f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_b2a2d1e0-7680-4db8-9eda-c89626292d9e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_75824a11-1f32-4887-9140-fbbcf70e4bbe_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9d869ece-68ea-4bdd-8734-6b864cf9bc14_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_c3355865-1c91-4ddf-95a1-6f482e8a5567_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_9237edcc-3b9e-4434-a16a-768a1e0413b1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_37597472-630b-49bc-8d7d-648582981486_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_cc51f2ce-2b31-4551-8422-4db1dec55639_terseLabel_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:href="biib-20230930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7005d913-df8e-4cfc-ae80-a19a6c642c38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_85fa18fd-3b8a-4c2e-a0ed-79c095ca8b69_terseLabel_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_label_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_documentation_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember" xlink:href="biib-20230930.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherresearchanddiscoveryMember" xlink:to="lab_biib_OtherresearchanddiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_aad4ebae-147d-4c56-aeac-66198095f5c5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_8cb753a8-fe1f-41da-85b3-0bc10802073d_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_db413e37-ed24-4e2b-9431-2b84c3083bdb_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_def6d1aa-8a7a-4fc4-9395-fd999aac4298_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FumarateMember_284d170f-b260-47bc-8624-da3dc63f15a3_terseLabel_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate</link:label>
    <link:label id="lab_biib_FumarateMember_label_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:label id="lab_biib_FumarateMember_documentation_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember" xlink:href="biib-20230930.xsd#biib_FumarateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumarateMember" xlink:to="lab_biib_FumarateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_b1cdda13-e166-420f-8d76-619bcbeabc87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OperatingLeaseLiabilityDerecognized_4aa48c93-a5f5-47c9-9f14-2ed88fa06c96_terseLabel_en-US" xlink:label="lab_biib_OperatingLeaseLiabilityDerecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities derecognized</link:label>
    <link:label id="lab_biib_OperatingLeaseLiabilityDerecognized_label_en-US" xlink:label="lab_biib_OperatingLeaseLiabilityDerecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Derecognized</link:label>
    <link:label id="lab_biib_OperatingLeaseLiabilityDerecognized_documentation_en-US" xlink:label="lab_biib_OperatingLeaseLiabilityDerecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Derecognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseLiabilityDerecognized" xlink:href="biib-20230930.xsd#biib_OperatingLeaseLiabilityDerecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingLeaseLiabilityDerecognized" xlink:to="lab_biib_OperatingLeaseLiabilityDerecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_1008c71c-a1b3-4f96-a9b2-755a41b3eb12_terseLabel_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.150% Senior Notes due May 1, 2050</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_label_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_documentation_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:href="biib-20230930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:to="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_a1dcd7ad-e749-4145-97ab-dea629d0ed97_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity interest in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_885c9978-2804-4a59-a2a5-e0cd5b0faf2d_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_5620c623-7421-4afa-a9e6-9afea3a1c679_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_6e9a1e9c-2a98-4e9a-937e-c0e9cd611be2_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BYOOVIZMember_ccc47852-224c-4bfa-aa0a-9d0ad0db61fd_terseLabel_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BYOOVIZ</link:label>
    <link:label id="lab_biib_BYOOVIZMember_label_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BYOOVIZ [Member]</link:label>
    <link:label id="lab_biib_BYOOVIZMember_documentation_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BYOOVIZ</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember" xlink:href="biib-20230930.xsd#biib_BYOOVIZMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BYOOVIZMember" xlink:to="lab_biib_BYOOVIZMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborativeArrangementProfitLossSharingComponentsDomain_27af49c6-72a2-4f15-90d6-ac938ccbe598_terseLabel_en-US" xlink:label="lab_biib_CollaborativeArrangementProfitLossSharingComponentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit (Loss) Sharing Components [Domain]</link:label>
    <link:label id="lab_biib_CollaborativeArrangementProfitLossSharingComponentsDomain_label_en-US" xlink:label="lab_biib_CollaborativeArrangementProfitLossSharingComponentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit (Loss) Sharing Components [Domain]</link:label>
    <link:label id="lab_biib_CollaborativeArrangementProfitLossSharingComponentsDomain_documentation_en-US" xlink:label="lab_biib_CollaborativeArrangementProfitLossSharingComponentsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit (Loss) Sharing Components</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementProfitLossSharingComponentsDomain" xlink:href="biib-20230930.xsd#biib_CollaborativeArrangementProfitLossSharingComponentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborativeArrangementProfitLossSharingComponentsDomain" xlink:to="lab_biib_CollaborativeArrangementProfitLossSharingComponentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_834cebdb-a07b-4a4d-85ef-f5777f88791b_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:href="biib-20230930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a2236749-07c5-4512-8f66-479078451edf_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d366f605-c3e5-4787-b88a-b0b2401682c5_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_1df5b0a9-2657-407d-904e-059858b1e849_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_9acbbf6b-b345-468d-bad1-fa4e57e31e6c_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_250fbb15-aa3a-4664-bfbf-0942ba2c62de_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5983e790-23af-45e9-b222-ac6b09e256e7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_2544dcef-629d-4170-bd10-641214625689_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d281703-3d05-4bc1-be2e-847717a69761_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_d4c4003f-b0bf-4a26-9ae1-3084260e6e5c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_be17c0cc-de27-4071-ae2c-a919a130f21c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_fd141b39-dd44-4198-b9c7-af7b40f48019_terseLabel_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_label_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage [Member]</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_documentation_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember" xlink:href="biib-20230930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisSangamoDenaliAndSageMember" xlink:to="lab_biib_IonisSangamoDenaliAndSageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fa9a9135-227b-4ae7-b993-e5f363bef4af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_a3427f0b-0ccc-4467-8a51-39bd1777050f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_d70839af-960b-41c9-9908-0c88c84a85a3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchAndDevelopmentAssetDomain_5e7ec7a0-60f9-47be-beeb-36cb0393bc5f_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentAssetDomain_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentAssetDomain_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentAssetDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentAssetDomain" xlink:href="biib-20230930.xsd#biib_ResearchAndDevelopmentAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain" xlink:to="lab_biib_ResearchAndDevelopmentAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_a3272256-9202-4bff-9260-911a9e2eb6e5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_55726159-9a11-4e4f-af53-e812470f8ecb_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PriorityReviewVoucherMember_441c4db9-3880-4c80-bdc8-f1e224762da9_terseLabel_en-US" xlink:label="lab_biib_PriorityReviewVoucherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Priority review voucher</link:label>
    <link:label id="lab_biib_PriorityReviewVoucherMember_label_en-US" xlink:label="lab_biib_PriorityReviewVoucherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Priority Review Voucher [Member]</link:label>
    <link:label id="lab_biib_PriorityReviewVoucherMember_documentation_en-US" xlink:label="lab_biib_PriorityReviewVoucherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Priority Review Voucher</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember" xlink:href="biib-20230930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PriorityReviewVoucherMember" xlink:to="lab_biib_PriorityReviewVoucherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_66be1ca2-e18e-491f-8688-f3a5c34deda2_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborativeArrangementProfitLossSharingComponentsAxis_55ce667a-b8cd-4fe6-b869-ad3120438e24_terseLabel_en-US" xlink:label="lab_biib_CollaborativeArrangementProfitLossSharingComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit (Loss) Sharing Components [Axis]</link:label>
    <link:label id="lab_biib_CollaborativeArrangementProfitLossSharingComponentsAxis_label_en-US" xlink:label="lab_biib_CollaborativeArrangementProfitLossSharingComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit (Loss) Sharing Components [Axis]</link:label>
    <link:label id="lab_biib_CollaborativeArrangementProfitLossSharingComponentsAxis_documentation_en-US" xlink:label="lab_biib_CollaborativeArrangementProfitLossSharingComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit (Loss) Sharing Components</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementProfitLossSharingComponentsAxis" xlink:href="biib-20230930.xsd#biib_CollaborativeArrangementProfitLossSharingComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborativeArrangementProfitLossSharingComponentsAxis" xlink:to="lab_biib_CollaborativeArrangementProfitLossSharingComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_f3e97240-9809-4df0-ada0-b2ab0ab0ae84_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_467cb371-e39e-43db-818d-9650d8da6ef5_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_ce743571-6bba-424c-9687-ac64505d6ccb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationDomain_9ae5aec2-42ae-47cf-b983-30af60746a14_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_label_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain" xlink:href="biib-20230930.xsd#biib_FacilityLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain" xlink:to="lab_biib_FacilityLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_d9259c21-a604-43ec-a13f-15e0ffd190e8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_666ac3f6-a293-4f88-89f3-03701ea9720e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_02a9f2c8-22fa-4537-aa95-a4923894bed0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_d995747d-598f-47d5-a287-bba15e300bb3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_2fac0ec3-423e-4265-af9d-201fe3d6b83d_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_4ab94003-7bb9-477f-ba87-44ecb12493cf_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GainLossOnRestructuringCharges_24a3e387-7902-4dce-83ab-ddbba8a2583d_terseLabel_en-US" xlink:label="lab_biib_GainLossOnRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain due to lease termination</link:label>
    <link:label id="lab_biib_GainLossOnRestructuringCharges_label_en-US" xlink:label="lab_biib_GainLossOnRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Restructuring Charges</link:label>
    <link:label id="lab_biib_GainLossOnRestructuringCharges_documentation_en-US" xlink:label="lab_biib_GainLossOnRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GainLossOnRestructuringCharges" xlink:href="biib-20230930.xsd#biib_GainLossOnRestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GainLossOnRestructuringCharges" xlink:to="lab_biib_GainLossOnRestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_134c7c4f-21e9-4297-8e2f-2c4eee1bf300_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a889dc2e-58a5-4c83-aa8a-2221ab7df09e_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f282978c-26a2-4ba1-9b8d-d8528d687a10_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, January 1, 2018</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_89022c83-d2e4-4128-adfa-d9cbc6e95154_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CHF_f46c5293-e130-4407-8524-c8124157b4e6_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_031733c8-2a82-4b45-b166-e9959ae5a467_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_22585d1a-c7e8-4f29-bbda-6d758758c132_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2fe907dd-eb4a-4bd6-b15b-fb7b07a94317_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_b761456b-e1d0-4482-94d8-c4a2cba3fbd3_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_c352087d-9fee-4ce8-b699-1125f1c7fdf5_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_510da9b7-b8f2-4097-b872-61077ae9bef5_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost and expense</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_82dc5b38-52b4-4b2c-a02e-a87edf609b0c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1350ede4-a821-4e21-a18f-1a3033038095_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_17f56a1b-8d2a-45d4-8f2e-efec467750f3_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3b3a45b3-e3fa-44c3-ae8e-0d37739cd588_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_99285ee0-0020-419b-af12-f47973ab3ae0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill resulting from Reata acquisition</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_08617613-5e2a-4dbb-aa89-db9714003b66_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeDomain_584b1cfe-581f-427c-8c64-22e65a7f3bac_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_label_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_documentation_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain" xlink:href="biib-20230930.xsd#biib_FacilityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeDomain" xlink:to="lab_biib_FacilityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_6499ed8e-2128-4bdb-8d13-8b59db64bf1a_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember" xlink:to="lab_us-gaap_RepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BENEPALIMember_085789b0-4e1b-465f-970c-bf443f849af0_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_label_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_documentation_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember" xlink:href="biib-20230930.xsd#biib_BENEPALIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember" xlink:to="lab_biib_BENEPALIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_b9d946d8-36be-4089-af3c-d1d5e667cc97_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_352a2dee-5fc2-4237-9975-ee8a61f0a2f6_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, value, acquired, cost method</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6322a31a-4530-4716-ad90-b8deaee2b363_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TheCreditFacilityMember_80b40112-cba7-40e3-8fab-2a650b22d558_terseLabel_en-US" xlink:label="lab_biib_TheCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Credit Facility</link:label>
    <link:label id="lab_biib_TheCreditFacilityMember_label_en-US" xlink:label="lab_biib_TheCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Credit Facility [Member]</link:label>
    <link:label id="lab_biib_TheCreditFacilityMember_documentation_en-US" xlink:label="lab_biib_TheCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember" xlink:href="biib-20230930.xsd#biib_TheCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TheCreditFacilityMember" xlink:to="lab_biib_TheCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_c1684f92-6223-474f-b319-3ecdce3d7b5f_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_33d4e203-cfd0-43a9-ac99-270a04b152fa_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_565cbd7e-062c-4d77-8888-49922f14ffa4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity interest in Samsung Bioepis(1)</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance_68b70c1f-a617-4e5a-ad51-543504bb7e23_terseLabel_en-US" xlink:label="lab_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Tenant Allowance</link:label>
    <link:label id="lab_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance_label_en-US" xlink:label="lab_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Tenant Allowance</link:label>
    <link:label id="lab_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance_documentation_en-US" xlink:label="lab_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Tenant Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" xlink:href="biib-20230930.xsd#biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" xlink:to="lab_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7ba81ad2-5fd5-4e87-9bda-b13f70ebfe7e_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_7a0991f0-1fed-4043-b44e-189f9d79d78a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1370c9c3-d972-4e0f-93ac-69221ddcf955_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_af6a8baf-f0fb-488c-8f28-ba360539755e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_5a62ea76-d282-404f-87df-316e911e516a_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="biib-20230930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_c51c6095-c80f-48cf-bb03-a2a4e295078a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_17a636ae-b372-4cff-8374-db7e429fd7f4_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:href="biib-20230930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_8a4f7bda-bf59-43a0-b197-2acf654e4aef_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_f39ad47e-b8e2-4104-8a99-1a0286a36795_totalLabel_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_844a5dac-69fc-4be5-b391-958c0edec549_terseLabel_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_label_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net Current and Noncurrent</link:label>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_documentation_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent" xlink:href="biib-20230930.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent" xlink:to="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_7b1d6261-ac02-4b63-a9cb-1892e59d22ac_terseLabel_en-US" xlink:label="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares acquired</link:label>
    <link:label id="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_label_en-US" xlink:label="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Number of Common Stock Shares Acquired</link:label>
    <link:label id="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_documentation_en-US" xlink:label="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Number of Common Stock Shares Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:href="biib-20230930.xsd#biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:to="lab_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_72e766bb-867b-4694-b0fc-8e149b7db162_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity interest in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" xlink:to="lab_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_fd429f3f-4f13-48b3-b9d3-4e2bcdf133bd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_5368cff4-ed78-460c-9f7b-e70956809020_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_88b3d99a-92a4-4d3d-8fed-6415af31225a_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractOptionExerciseFee_8bb62dda-82ef-4e75-bac2-c9448f5b1e96_terseLabel_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_label_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_documentation_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee" xlink:href="biib-20230930.xsd#biib_ContractOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractOptionExerciseFee" xlink:to="lab_biib_ContractOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_573f836b-8a52-45f1-a706-a5081199caf8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_2e53ed5a-b77e-4df1-81f4-06987fa4ad1a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_3a7944f4-c553-4eb9-8404-8292aa7999e1_terseLabel_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables to divestiture of interest in joint venture</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_label_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_documentation_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:href="biib-20230930.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:to="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_d9bfd733-1d60-41a4-aa72-cbc0a8d0e648_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of gross sales to be achieved in any twelve consecutive months under option one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:href="biib-20230930.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:to="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_21006786-0189-43db-b705-91adfc9f7752_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_67ed9a08-1553-4c1e-baeb-9bb88be85323_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0bd9b775-7560-43e0-9392-8db042b32e13_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7903a80f-b223-4c73-90e7-ab1d3c470560_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_5151c8bd-85df-4fdd-b034-796a7b6872e0_terseLabel_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss)</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_label_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss) [Table Text Block]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_documentation_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:href="biib-20230930.xsd#biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:to="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_cb63ef97-3ac9-4213-9952-f7b4e6ca8b3f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_288d8ba1-260b-4a4e-80ee-c7acba60c751_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_649d3ea6-aee4-405a-8c45-d561d0bab679_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_77ff90bc-5909-4f47-9a14-db39c108e7dd_terseLabel_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At First Anniversary</link:label>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_label_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At First Anniversary [Member]</link:label>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_documentation_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At First Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember" xlink:href="biib-20230930.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentDueAtFirstAnniversaryMember" xlink:to="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_e3cf67bc-6700-4d4d-91f9-8dd5e9350723_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_e22619ea-28f4-4737-ab8d-1fd0460abb1a_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdministrativeSpaceMember_1e792e56-be14-4cc4-b6b3-5675f1eb4894_terseLabel_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_label_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space [Member]</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_documentation_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember" xlink:href="biib-20230930.xsd#biib_AdministrativeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdministrativeSpaceMember" xlink:to="lab_biib_AdministrativeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_f46877db-7103-48c5-aad8-3ec4a873b2d1_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c6190179-678a-4c4a-8eae-e29ef08db0d2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_87eb2ab9-47fe-4f91-8725-a1e8ff121422_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_e1b67637-d0ef-477d-bece-c69aae302671_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity related to the UCB collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to the UCB Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to the UCB Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:href="biib-20230930.xsd#biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_3e352eb8-9e81-4435-8f1a-d19b77138aef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_48542e6e-7c93-40f0-9cf1-c7fb3a9d9a66_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_6736097c-7333-47f7-b7a5-7dd2ddf963d1_terseLabel_en-US" xlink:label="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross, Outstanding Equity Awards</link:label>
    <link:label id="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_label_en-US" xlink:label="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross, Outstanding Equity Awards</link:label>
    <link:label id="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_documentation_en-US" xlink:label="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross, Outstanding Equity Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:href="biib-20230930.xsd#biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:to="lab_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterferonMember_79e65e3b-0e51-4b1c-8367-15f17ef76693_terseLabel_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_label_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_documentation_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember" xlink:href="biib-20230930.xsd#biib_InterferonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember" xlink:to="lab_biib_InterferonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FUMADERMAndADUHELMMember_c7cb6b66-2334-460f-838c-71cc30fa1e55_terseLabel_en-US" xlink:label="lab_biib_FUMADERMAndADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM And ADUHELM</link:label>
    <link:label id="lab_biib_FUMADERMAndADUHELMMember_label_en-US" xlink:label="lab_biib_FUMADERMAndADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM And ADUHELM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMAndADUHELMMember_documentation_en-US" xlink:label="lab_biib_FUMADERMAndADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM And ADUHELM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMAndADUHELMMember" xlink:href="biib-20230930.xsd#biib_FUMADERMAndADUHELMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMAndADUHELMMember" xlink:to="lab_biib_FUMADERMAndADUHELMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_36e64907-4de1-4d64-a263-3aba0edef99a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_b048caf5-cc4e-4a51-9263-b6017f80a6d2_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs, percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:href="biib-20230930.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:to="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShorttermderivativeMember_171b7e9b-dd5b-4dc0-a5b3-a30c32056b27_terseLabel_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_label_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_documentation_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember" xlink:href="biib-20230930.xsd#biib_ShorttermderivativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShorttermderivativeMember" xlink:to="lab_biib_ShorttermderivativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1f105dcc-efe7-4e64-9ca1-503545df7d03_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_4f6c9f83-23f3-4a01-8574-5093f3e8a0e6_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_15f8fca0-e1aa-4436-abde-4d36d77cf90f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f1ee7a74-45b4-40d3-a793-4bbd02be9591_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6213a4c2-8b20-4778-a831-2e58a4344069_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b6b817dc-ce2a-40dd-8af2-46e9e9db8c36_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9cd9e351-66ac-4b17-a1c5-1ae76a32b770_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_65cce75a-1ad4-4cfd-a903-af296aeac5e7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1c5c3a9c-0a49-4bdf-8367-f6fc69978319_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_cdefbfc2-100d-4a37-8e94-cdd0d948f2c5_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on interest rate swap</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_70f89483-83d1-4dfa-8466-97c9409ac647_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_72d4c3a6-63a6-411d-9466-8a0f8dcb92de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_a754433c-75a7-4b08-981a-e81c0cd2f8cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_34662790-cc98-485a-980d-16c13919a398_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_04e24a8d-9c99-40b1-8a2c-1a407d9f23b6_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_ccd884cf-0227-45c8-9def-e9e2dae24276_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterestInSubsidiary_66cd52f5-95f2-46e3-a2b2-4c44cfe9864b_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_label_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary" xlink:href="biib-20230930.xsd#biib_InterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary" xlink:to="lab_biib_InterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_afc177f9-c41d-4ff1-8fd1-8ff7ba7016e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NeurimmuneMember_76f7a161-b3a1-46e8-a41d-ae9d19f96cb2_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_label_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember" xlink:href="biib-20230930.xsd#biib_NeurimmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember" xlink:to="lab_biib_NeurimmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_E2609andBAN2401Member_385b9feb-25c9-40b2-8c6a-314da034e14f_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member" xlink:href="biib-20230930.xsd#biib_E2609andBAN2401Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member" xlink:to="lab_biib_E2609andBAN2401Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_641bd023-a946-4d5e-8765-a99a9e0cf5d7_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_344377ad-ac65-44b7-a131-592aaf43ca4c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_7a982391-b6fc-4824-8c64-eae52df1f05e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2488217a-572d-4a86-ba8a-194c194ddbf3_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_2cb68e23-c557-4c12-96b4-d244f27a3ac7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_12841e2b-a98a-433e-8432-6aa56c507119_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborationProfitSharingMember_6bf37453-dba0-40ce-b055-880b03513ee9_terseLabel_en-US" xlink:label="lab_biib_CollaborationProfitSharingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit sharing</link:label>
    <link:label id="lab_biib_CollaborationProfitSharingMember_label_en-US" xlink:label="lab_biib_CollaborationProfitSharingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Profit Sharing [Member]</link:label>
    <link:label id="lab_biib_CollaborationProfitSharingMember_documentation_en-US" xlink:label="lab_biib_CollaborationProfitSharingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Profit Sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationProfitSharingMember" xlink:href="biib-20230930.xsd#biib_CollaborationProfitSharingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationProfitSharingMember" xlink:to="lab_biib_CollaborationProfitSharingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_721362b8-71ac-46a1-ade4-2dd8b2fa16f3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationexpensesaccrual_ebd30016-1646-409c-8150-5e20f9434ef7_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual" xlink:href="biib-20230930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual" xlink:to="lab_biib_Collaborationexpensesaccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_05db1777-b798-4aa5-b94e-68eaf6820f62_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_3baf8dbe-3386-47be-a4b5-6a369b478674_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_4b412740-8543-4a57-8ddf-a48448b779b1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative translation loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_c8c06876-6348-42d9-99ff-2182b954a9ee_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock" xlink:href="biib-20230930.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock" xlink:to="lab_biib_OtherrevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_581e2de1-2e91-4bca-934f-021c7f3b35f9_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember" xlink:href="biib-20230930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember" xlink:to="lab_biib_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_07e82b04-e5ae-4bfe-a856-ccb1b30bf1f5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_ecbc89fd-38d7-4812-8048-0c16b2e76be9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6fe95ddb-363f-427b-8a5b-42bc6f651e0d_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:href="biib-20230930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_9673248f-b574-4a97-824a-d2308b322c26_terseLabel_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_label_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_documentation_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:href="biib-20230930.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:to="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_fdefa415-06bb-4fff-935b-bbe3d9afe408_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_e6355cc5-7c2f-41bf-843b-f5f1af9355cc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6b9f0169-28b9-418c-91c5-b91360969a70_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_70a49bf0-5c29-4f8f-97ac-3e6ff566cfc1_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement_d2604278-3e16-43fc-a594-a3102834642f_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement agreement</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Litigation Agreement</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Litigation Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:href="biib-20230930.xsd#biib_EffectiveTaxRateReconciliationLitigationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:to="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_c142ffe2-8e55-484b-8e76-6c473b030fb0_negatedTerseLabel_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in (income) loss of investee, net of tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_label_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_documentation_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:href="biib-20230930.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:to="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccountsPayableToCollaborator_32a22d49-911a-49cd-a976-aaf001b6b9a2_terseLabel_en-US" xlink:label="lab_biib_AccountsPayableToCollaborator" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts payable</link:label>
    <link:label id="lab_biib_AccountsPayableToCollaborator_label_en-US" xlink:label="lab_biib_AccountsPayableToCollaborator" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, To Collaborator</link:label>
    <link:label id="lab_biib_AccountsPayableToCollaborator_documentation_en-US" xlink:label="lab_biib_AccountsPayableToCollaborator" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, To Collaborator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsPayableToCollaborator" xlink:href="biib-20230930.xsd#biib_AccountsPayableToCollaborator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccountsPayableToCollaborator" xlink:to="lab_biib_AccountsPayableToCollaborator" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_dfb70a04-0538-43ae-b57f-c60903636263_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_492e065f-0ca2-4f89-ac36-45468635adc7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b2d39fb4-dbaa-4bde-81eb-26f6a983565e_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UCBPharmaS.A.Member_317e198b-778e-466c-8182-8fa701277011_terseLabel_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A.</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_label_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_documentation_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member" xlink:href="biib-20230930.xsd#biib_UCBPharmaS.A.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UCBPharmaS.A.Member" xlink:to="lab_biib_UCBPharmaS.A.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_18eab530-de36-44f8-97e6-473e1dc90945_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_daa2cd7f-666b-4339-8d96-7df7d9e769b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherAssetsCurrentFairValueDisclosure_44c205c7-82b4-4f61-be36-e55dca6ff6e5_terseLabel_en-US" xlink:label="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets, receivable</link:label>
    <link:label id="lab_biib_OtherAssetsCurrentFairValueDisclosure_label_en-US" xlink:label="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current, Fair Value Disclosure,</link:label>
    <link:label id="lab_biib_OtherAssetsCurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current, Fair Value Disclosure,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure" xlink:href="biib-20230930.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherAssetsCurrentFairValueDisclosure" xlink:to="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_db26a7ef-9014-40eb-8595-ac505505fe00_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_2854145b-24d6-4b51-9fb5-67e21236115d_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ba1b0fcc-f01a-4b16-ac07-163bbae61286_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_d94b6a06-f335-4f26-9ad2-405682e1010c_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9b05d5c-8f14-416a-96b1-d2674058fa73_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_794d4ff1-d72e-48f5-b681-012b888989a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_f819611d-bcab-44e9-a689-4d21c0a248ad_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_b67086b6-2122-4b00-80fb-c6a851145033_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_f11da7e6-f845-469e-b1c0-6ce12ef8728e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_f86a10b3-1c6f-4dd2-b69b-83247392547f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_144cf576-2b35-4c8e-891e-0ab5dd6aef21_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_4e6a19c8-d1dc-43ad-823d-23d93391dcab_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_45a2960d-5fc9-4c22-b376-dbdd3941f66e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2ca30c01-6e74-4664-9270-f717352992ca_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, unrecognized tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_15dceeec-5ffa-48ac-bd43-49310af15642_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_978174c1-b7dd-4392-b670-c593c44971f1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_13ad4a05-dcfc-430d-bc19-760ee79184d6_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After Second GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:href="biib-20230930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7ef12ab3-d6a4-4b40-984a-56a680479f09_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_962c9b92-6c96-4190-877f-ffd5f1000aa2_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_399f1296-b8d6-4338-a1a8-35724658e70d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2023And2022CostSavingInitiativesMember_90877bd0-1855-4902-a51e-0885e505d3d6_terseLabel_en-US" xlink:label="lab_biib_A2023And2022CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 and 2022 Cost Saving Initiatives</link:label>
    <link:label id="lab_biib_A2023And2022CostSavingInitiativesMember_label_en-US" xlink:label="lab_biib_A2023And2022CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 and 2022 Cost Saving Initiatives [Member]</link:label>
    <link:label id="lab_biib_A2023And2022CostSavingInitiativesMember_documentation_en-US" xlink:label="lab_biib_A2023And2022CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 and 2022 Cost Saving Initiatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023And2022CostSavingInitiativesMember" xlink:href="biib-20230930.xsd#biib_A2023And2022CostSavingInitiativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2023And2022CostSavingInitiativesMember" xlink:to="lab_biib_A2023And2022CostSavingInitiativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4a78d054-5c09-4b67-9d31-ac2cbb3f4513_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity related to Aducanumab collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:href="biib-20230930.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f2bdf5d0-5d30-44f8-b25c-fa97345503c7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6de4e235-7078-47e9-a7cc-f9c650cf8afa_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_42b3b869-5ce2-45fd-a43a-9d0b1c62fbfe_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5ad6038a-ddda-4694-a8fa-9d800220e8c0_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_b23028e9-1cc1-4ae1-8bdd-b972555c5212_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_ae32f11d-817d-4013-8738-7d04eaa5c84e_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember" xlink:href="biib-20230930.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember" xlink:to="lab_biib_SolothurnSwitzerlandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_7d945fdf-1138-4ac9-bc08-0b5400347c1d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent payable to Blackstone(1)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_0e48422a-7b1d-4437-90b4-dc5bc0fb0c87_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeAxis_f957f310-0c3d-4249-82dc-8ae0e999092c_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_label_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_documentation_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis" xlink:href="biib-20230930.xsd#biib_FacilityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeAxis" xlink:to="lab_biib_FacilityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AcceleratedDepreciationAndOtherCostsMember_c8413730-a4a9-422c-9777-88eee84d78d5_terseLabel_en-US" xlink:label="lab_biib_AcceleratedDepreciationAndOtherCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation and Other Costs</link:label>
    <link:label id="lab_biib_AcceleratedDepreciationAndOtherCostsMember_label_en-US" xlink:label="lab_biib_AcceleratedDepreciationAndOtherCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation And Other Costs [Member]</link:label>
    <link:label id="lab_biib_AcceleratedDepreciationAndOtherCostsMember_documentation_en-US" xlink:label="lab_biib_AcceleratedDepreciationAndOtherCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation And Other Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcceleratedDepreciationAndOtherCostsMember" xlink:href="biib-20230930.xsd#biib_AcceleratedDepreciationAndOtherCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcceleratedDepreciationAndOtherCostsMember" xlink:to="lab_biib_AcceleratedDepreciationAndOtherCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5bfaf4fe-ee69-40ed-9e26-83ff708487a7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_99dbe97b-bf16-42bd-bee9-0eee9333337e_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:href="biib-20230930.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_99deb62b-96d2-4880-99d1-6c22fcfd1358_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_89425962-2b75-45ee-9995-5fffbf86fc22_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_2dd95e6e-bf15-4db1-96ab-5579b3d6a46e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f62e3029-d255-4a52-8c4e-a210ce9d1d4f_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_952fd9c8-0a17-40eb-91a7-2297a53ad5a8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_44aaa0b9-7efe-40e1-ac9c-0cca903c665b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_7074e800-4352-4d53-aa33-f3bff6f184df_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_444f0e58-b0c8-48dd-b87f-413194d169be_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty and other revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_9bfc8187-f3f2-41e9-98bf-96128ad366f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationprofitlosssharing_64317ed1-0589-4f67-94f2-a3720afec826_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit sharing/(loss reimbursement)</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing" xlink:href="biib-20230930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing" xlink:to="lab_biib_Collaborationprofitlosssharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_5011753f-d9df-41d5-bd98-868f14139079_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GAZYVAMember_a1b675a1-50a0-44e7-83c8-bdba38bb8a0b_terseLabel_en-US" xlink:label="lab_biib_GAZYVAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GAZYVA</link:label>
    <link:label id="lab_biib_GAZYVAMember_label_en-US" xlink:label="lab_biib_GAZYVAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:label id="lab_biib_GAZYVAMember_documentation_en-US" xlink:label="lab_biib_GAZYVAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember" xlink:href="biib-20230930.xsd#biib_GAZYVAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GAZYVAMember" xlink:to="lab_biib_GAZYVAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_0cc43a89-34d1-4d81-8f11-3c5e97e16fa4_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c3ed6261-25c8-42ef-abd4-3cdcaefa259c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa0e204c-f799-4712-8c17-854f62544100_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05e707e9-d173-4c42-bcc6-5d443d53791b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_29f7503b-90fe-4134-b17a-1a0b46f67eee_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b6bfe395-3040-4cd4-b0c6-9f2f8e46114a_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_19c90611-8c71-4823-b7e3-130078cdac48_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e6e2f184-bfef-4ab3-af51-232b2f7d301b_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_b24b2961-8810-4e21-ae89-c3e0f5ef2a91_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:href="biib-20230930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_10a4c412-14be-4a3b-a825-cacdd515f116_terseLabel_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At Second Anniversary</link:label>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_label_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At Second Anniversary [Member]</link:label>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_documentation_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At Second Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember" xlink:href="biib-20230930.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentDueAtSecondAnniversaryMember" xlink:to="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_730a705d-13cd-4e0e-8ff9-834a8eb224d8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f9c458fc-f0ea-47b7-b614-c77c080ba4e7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_84564c8c-057f-4a72-8c9a-62ee6614ff24_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_15a8f2e8-bdb6-48af-bb0f-cb0173dc6728_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3c0b6f73-5745-4a6c-9f19-09843147dd65_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1b3deb29-047c-45c5-b494-638e858ffd96_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange (gains) losses, net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_44fdd91b-88fc-4e60-9626-7d0bfdf05d42_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f3007987-acdc-44b5-a01d-ca6bc84d36e8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_378da819-0b72-49a6-912e-888656dbcf15_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_94b6b5cc-aba9-44ac-a6d6-db4e6319af67_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_7d4d1813-d4cc-43a2-85fa-2f246fd13618_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsrevenueMember_02d6e811-5901-49b4-a5b1-9df3d36baa3c_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember" xlink:href="biib-20230930.xsd#biib_CashflowsrevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember" xlink:to="lab_biib_CashflowsrevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_34f29317-8cbf-441e-b777-5474e3f38c3e_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome" xlink:href="biib-20230930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_ba9bfb22-eb7e-40e6-9dfb-3293a7dc9f39_terseLabel_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_label_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_documentation_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:href="biib-20230930.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9cd5eba5-ab0c-4810-a9e3-bfe5a27c1c4f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d82a126d-90c3-4486-88c7-ab8cadd55b26_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_271d2c5d-303a-4242-b77b-31a1ddbae4eb_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_865377bc-474a-4281-988e-9471c972b9fc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_26ffd701-108c-4105-86c2-200d84bea54a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a6423a08-758b-4214-a39a-52edc3210aa0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings (loss) per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_cdd3db1f-3fd0-4ea5-94fa-35c255067ef9_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_dcdcc595-2235-4a4d-84fa-b6fe0229701f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_1dc9cd5a-b6c8-4aa2-ab46-1c41875a76d7_terseLabel_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember" xlink:href="biib-20230930.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2020ShareRepurchaseProgramMember" xlink:to="lab_biib_A2020ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_004630ca-5329-403f-a59b-744fa6afb37b_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on sale</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_61dca558-2497-4f73-b956-4dad6b05cfd3_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:href="biib-20230930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_85ac3834-2f82-410c-9eb8-b09ad13a9761_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_ee8ecb52-fb58-4fc1-a0a6-06c67c0e212a_negatedTerseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SpinalMuscularAtrophyMember_d7b75d33-68b3-4459-aaf4-c48f913371b3_terseLabel_en-US" xlink:label="lab_biib_SpinalMuscularAtrophyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spinal Muscular Atrophy</link:label>
    <link:label id="lab_biib_SpinalMuscularAtrophyMember_label_en-US" xlink:label="lab_biib_SpinalMuscularAtrophyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spinal Muscular Atrophy [Member]</link:label>
    <link:label id="lab_biib_SpinalMuscularAtrophyMember_documentation_en-US" xlink:label="lab_biib_SpinalMuscularAtrophyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spinal Muscular Atrophy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SpinalMuscularAtrophyMember" xlink:href="biib-20230930.xsd#biib_SpinalMuscularAtrophyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SpinalMuscularAtrophyMember" xlink:to="lab_biib_SpinalMuscularAtrophyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_f60c12e0-1c7f-4bcc-8371-36312623d32c_terseLabel_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax profit sharing formula</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_label_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_documentation_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:href="biib-20230930.xsd#biib_PretaxProfitSharingFormulaTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:to="lab_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4c935f46-2bd0-4c59-a337-d0834b84f37c_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:href="biib-20230930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_a39f5571-22b8-4d93-a4a3-d102dc15cc5a_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RituxanMember_1f1ccea4-dd14-4e7a-b920-f99e6e303a1d_terseLabel_en-US" xlink:label="lab_biib_RituxanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RITUXAN</link:label>
    <link:label id="lab_biib_RituxanMember_label_en-US" xlink:label="lab_biib_RituxanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RITUXAN [Member]</link:label>
    <link:label id="lab_biib_RituxanMember_documentation_en-US" xlink:label="lab_biib_RituxanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RITUXAN.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember" xlink:href="biib-20230930.xsd#biib_RituxanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RituxanMember" xlink:to="lab_biib_RituxanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_4d84f250-1b0c-4375-9d65-aba5491329cd_terseLabel_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_label_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space [Member]</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_documentation_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:href="biib-20230930.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:to="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0cb3b903-66a9-4083-9e72-13725f788b98_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_c7805130-b66f-4e03-83f8-a8027fb43850_terseLabel_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051</link:label>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_label_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051 [Member]</link:label>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_documentation_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member" xlink:href="biib-20230930.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3250SeniorNotesDueFebruary152051Member" xlink:to="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_33ccfc57-6d9b-45af-aef7-5d4b98dc7593_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_450f7bda-84fa-4c96-b959-cbda5bc04534_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains recognized on the decrease in fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fff6c558-7b93-4cfa-b670-ff77fd2e6363_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_5615bd9b-43f5-4d59-b506-80e66f47146f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_dc814555-9b4e-42af-9ea7-06f5a521111c_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:href="biib-20230930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_06581f67-7cc9-42bc-9044-8041d9083572_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_1d32ed64-d32c-4f61-9590-fffe3318725b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_8b8d831c-18d6-4d17-92fd-37c738eeee47_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1a49a005-dc68-4904-a0ea-05285fbebdff_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_710f2b3f-08d2-40b2-9a63-b19da582336d_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:href="biib-20230930.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_f1878ea7-334a-4bb3-8141-d6da5360c5ac_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Until Second GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:href="biib-20230930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_ab7c5003-cf63-44b9-9e16-c5409e1b8aa5_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_label_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnTerminationOfLease" xlink:to="lab_us-gaap_GainLossOnTerminationOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_35b8b694-39dc-4182-a575-b02478d87803_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock" xlink:href="biib-20230930.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_5305f638-111b-40ca-b09e-aff440b2f697_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2b6223c9-b1bf-42cf-8dac-717be927c929_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_cd592a12-3a1b-4af3-a5e6-907f7432928d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_a48b7a30-3a3f-40a3-a6af-1b42db20e797_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_2d009102-7731-430c-913b-6cc59df9cc39_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ea0838ff-d52d-4248-8980-f5476215d7f6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ADUHELMMember_0ccbb945-0693-44b6-853e-dd33cbbc609f_terseLabel_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM</link:label>
    <link:label id="lab_biib_ADUHELMMember_label_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM [Member]</link:label>
    <link:label id="lab_biib_ADUHELMMember_documentation_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember" xlink:href="biib-20230930.xsd#biib_ADUHELMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ADUHELMMember" xlink:to="lab_biib_ADUHELMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_0f05a6ea-7f0f-4001-a96b-176142584b36_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:href="biib-20230930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_0c81a07f-f554-442e-875c-ae23835d31dc_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration" xlink:href="biib-20230930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration" xlink:to="lab_biib_ExpenseIncurredByCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_d4ac3e8a-d38f-4b00-98e7-6db6c4aa9935_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:to="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_febbf071-189c-4a1b-996f-49c5a665f79a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a7672c7c-1768-4da6-a565-acc68c3afa1c_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (gains) losses recognized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_229a0b4f-e1c3-48d6-a8f4-7df5e19b1e49_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains recognized on the increase in fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_fa6adcff-ac4b-4856-82c8-54f736406ea2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales price</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_e532eabf-0f24-4e85-9f8a-778e1ab16658_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_8168be9a-2526-4213-b26a-da85c76a4ebb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8ed4899e-625f-4d76-b631-72aae2de31cc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_5a25c1b0-880a-4e92-a986-4a802b512faf_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RoyaltiesClaimed_0c38cd82-a180-46a3-b85b-fcb45203cf9b_terseLabel_en-US" xlink:label="lab_biib_RoyaltiesClaimed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Claimed</link:label>
    <link:label id="lab_biib_RoyaltiesClaimed_label_en-US" xlink:label="lab_biib_RoyaltiesClaimed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Claimed</link:label>
    <link:label id="lab_biib_RoyaltiesClaimed_documentation_en-US" xlink:label="lab_biib_RoyaltiesClaimed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Claimed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltiesClaimed" xlink:href="biib-20230930.xsd#biib_RoyaltiesClaimed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltiesClaimed" xlink:to="lab_biib_RoyaltiesClaimed" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_04638995-2d86-4c0a-9a04-a6c58284835e_terseLabel_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_label_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_documentation_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PeriodOfCollaborationAgreement" xlink:href="biib-20230930.xsd#biib_PeriodOfCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PeriodOfCollaborationAgreement" xlink:to="lab_biib_PeriodOfCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_81a197f9-7120-462b-a12f-830fafdfdb79_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b8e513af-95ab-43e4-9a42-2bef46242597_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_3482bc06-4598-4328-be55-45047f4c08b6_terseLabel_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales trigger gross sales threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_label_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Trigger Gross Sales Threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_documentation_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales trigger gross sales threshold.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold" xlink:href="biib-20230930.xsd#biib_SalesTriggerGrossSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SalesTriggerGrossSalesThreshold" xlink:to="lab_biib_SalesTriggerGrossSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6e40a718-7750-4866-a0bf-73175e7814df_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of building</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9bec15d5-65ea-4794-b3d3-a49d8230da65_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of building</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_cb105228-b109-4993-8e00-50e51d8b03fc_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_83b29378-8f29-45df-8106-8c57b103ef9a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_012e8f73-73b4-4820-b4f5-e09b1fbef1f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_85ea458a-bc76-4291-a321-85d404c9ed90_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_147bb7e9-c97e-4fbf-8189-bc2d49a28d06_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FLIXABIMember_f872ba24-839a-4bc4-9555-a5f6758770b2_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_label_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_documentation_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember" xlink:href="biib-20230930.xsd#biib_FLIXABIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember" xlink:to="lab_biib_FLIXABIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_31a76485-ac7f-44fc-b14f-94c8ac75c124_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_430d6b7a-f811-4179-ac62-fea82917cdac_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_1b885970-e1f4-4f4f-9e11-79f13e60ed29_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d82a7f20-04e3-4220-8b53-a2012af676e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_394b037a-d919-4aeb-949c-e4fb72acac7c_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_fbee45c6-1edc-489e-a190-5a7d4e44ace6_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_caf2d7de-46b5-40d7-a3e6-9dcf43ee6c4c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_b18daace-f948-4563-a831-3837f6462ca9_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AggregateGrossIdleCapacityCharges_a757568d-1b53-493f-84db-9f85247d3b8b_terseLabel_en-US" xlink:label="lab_biib_AggregateGrossIdleCapacityCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate gross idle capacity charges</link:label>
    <link:label id="lab_biib_AggregateGrossIdleCapacityCharges_label_en-US" xlink:label="lab_biib_AggregateGrossIdleCapacityCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Gross Idle Capacity Charges</link:label>
    <link:label id="lab_biib_AggregateGrossIdleCapacityCharges_documentation_en-US" xlink:label="lab_biib_AggregateGrossIdleCapacityCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Gross Idle Capacity Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AggregateGrossIdleCapacityCharges" xlink:href="biib-20230930.xsd#biib_AggregateGrossIdleCapacityCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AggregateGrossIdleCapacityCharges" xlink:to="lab_biib_AggregateGrossIdleCapacityCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_483fef4b-93d2-4a28-b7c1-9dd74674f35c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Reata, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_abab88c0-4f98-466c-b670-dcbf6ee5c3e9_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_2a30da2d-82e7-44c6-b305-9f57483b86f7_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_972f9ce7-eb49-4f99-bed4-1ede8b6bc779_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_b37e89d6-d0e6-4c74-b7ea-d76fb1374d76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_77f3a2bb-433d-45c4-99d2-01f59256cb3e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1f2b1d05-c799-4f1a-aea5-86b22a11844b_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:href="biib-20230930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_269cba01-bb08-42e2-acd6-5f784e45da86_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brazil tax assessment, including interest and penalties</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8e331d3d-72fa-4af3-a403-4e9cd72eee0e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity interest in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_9d3d40bf-8ddd-40b1-9277-7cb3a74c587d_terseLabel_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_label_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_documentation_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:href="biib-20230930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:to="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MSProductRevenuesMember_8a25e00f-ce54-4507-8ff4-b3676662fbf6_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember" xlink:href="biib-20230930.xsd#biib_MSProductRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember" xlink:to="lab_biib_MSProductRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_66d532d1-72ef-4143-83ba-9a4b64d85928_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_23fedd95-426a-41fb-8a39-e3b00e70314b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractManufacturingAndOtherRevenueMember_5cb1e582-a2d2-458d-8cdb-40349bb99f7e_terseLabel_en-US" xlink:label="lab_biib_ContractManufacturingAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract manufacturing revenue</link:label>
    <link:label id="lab_biib_ContractManufacturingAndOtherRevenueMember_label_en-US" xlink:label="lab_biib_ContractManufacturingAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract manufacturing and other revenue [Member]</link:label>
    <link:label id="lab_biib_ContractManufacturingAndOtherRevenueMember_documentation_en-US" xlink:label="lab_biib_ContractManufacturingAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingAndOtherRevenueMember" xlink:href="biib-20230930.xsd#biib_ContractManufacturingAndOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractManufacturingAndOtherRevenueMember" xlink:to="lab_biib_ContractManufacturingAndOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7421bde3-1ec5-4320-89d5-99439366a112_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_6d5f5089-af83-436d-aa76-c63020b975fd_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net (gains) losses realized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_9e63c81b-6837-4a3f-ae25-72ba282b0294_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) realized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_fe115426-6844-427b-a37a-4fefa81c83a8_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_a0892714-a3d8-479b-b5fc-2202aafa896c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_27389c98-f1fd-4dfd-9c68-3b2efa64868e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_4789fb48-9ec3-4a13-a93c-ec73127be8e7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5362b9e9-0dc4-494e-ac82-651f1585d03d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_af633cde-e523-47dc-906a-3c82cbf213b9_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_8a886cae-f63c-4559-b00c-51edf569d580_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_c7decbbf-ed0f-4739-9b1a-369d5a766cb5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_f5faab4c-5c04-45a3-9f8a-008f9545ba61_terseLabel_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Credit Facility Floating Rate Three-Year Tranche</link:label>
    <link:label id="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_label_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Credit Facility Floating Rate Three-Year Tranche [Member]</link:label>
    <link:label id="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_documentation_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Credit Facility Floating Rate Three-Year Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:href="biib-20230930.xsd#biib_TheCreditFacilityFloatingRateThreeYearTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:to="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ade58675-034f-43e9-b9ef-bbb5b60a123a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_1efa42e8-65a9-4201-8cbb-f1695ba8a962_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_d535f59a-f531-41c9-bce5-e6d5829512d6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_642adb51-0012-4b0a-bd59-c145b6195faf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EisaiMember_d943797a-fe2a-4591-a949-df31b24bf475_terseLabel_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_label_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_documentation_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember" xlink:href="biib-20230930.xsd#biib_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember" xlink:to="lab_biib_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_5f73b7af-0442-45d1-9353-65c152ab5982_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-promotion operating profit threshold for Rituxan in US and Canada to determine share of co promotion operating profit prior to amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_label_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_documentation_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:href="biib-20230930.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:to="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_0308e144-e0b9-4b74-a40f-e9a2ab35e8b3_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_21afbb04-1fc1-4533-a3a9-bc74e6721f99_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorOneMember_178e0fe6-6d78-4166-be4d-e4e5a8e55a7d_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_label_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_documentation_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember" xlink:href="biib-20230930.xsd#biib_DistributorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember" xlink:to="lab_biib_DistributorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_e4111860-642e-4e56-b819-dcb667ca944c_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and (Liabilities) Assumed, Assets,Other Assets And Liabilities, Net</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and (Liabilities) Assumed, Assets,Other Assets And Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_7bf0f217-5432-4bc7-a4f4-e9c1feb14345_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_6ddf27da-ddb0-40ad-a8cb-abea03c809c9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in net income, excluded component</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_67b3cb2b-84c2-480d-a078-42d8b61e0a12_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_9c7b97af-5bc2-4a5e-9a70-e54b86d07017_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gains) losses on investments, net</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_c4a7972b-7886-494e-aff7-038ea47a506d_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_d9aa187f-d829-4c30-9983-4ce0a8fa6da6_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Sage Therapeutics</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Sage Therapeutics [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Sage Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:href="biib-20230930.xsd#biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_25129470-79fa-4fc1-b4c4-3053bbf07e38_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangements and non-collaborative arrangement transactions</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_7a4e4251-504b-4900-8b4b-57afd2989d0f_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember" xlink:href="biib-20230930.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesNonCurrentMember" xlink:to="lab_biib_EquitySecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_eb693bc2-7699-4ff2-a940-ef2e4f1d9dbd_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_cd3c9536-f93b-4831-b86c-67ede1ce0a30_terseLabel_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge, excluded component</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_label_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_documentation_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:href="biib-20230930.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:to="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_9de19e45-d6f3-4c64-b8df-2797ce1b131b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5c1df17f-2537-4fc6-9218-55599600ba55_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReataPharmaceuticalsIncMember_4b168200-68db-4c95-aa6f-0efab5e17343_terseLabel_en-US" xlink:label="lab_biib_ReataPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reata Pharmaceuticals, Inc</link:label>
    <link:label id="lab_biib_ReataPharmaceuticalsIncMember_label_en-US" xlink:label="lab_biib_ReataPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reata Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_biib_ReataPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_biib_ReataPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reata Pharmaceuticals, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReataPharmaceuticalsIncMember" xlink:to="lab_biib_ReataPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_4c26cc7a-907b-4a25-8a9f-de51cfb9d3d2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation and Other Costs</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringCosts" xlink:to="lab_us-gaap_OtherRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_c8302662-2cf7-469c-ab19-c9d80aa956a1_verboseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_9930cad7-ba53-426e-99ff-65e0a2f5d4ab_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration" xlink:href="biib-20230930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration" xlink:to="lab_biib_Expenseincurredbythecollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_e9c24127-83e9-4f24-803a-0142afbb6b4a_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_acd5a206-c707-41a8-9079-1e1ecbf29587_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7f15d279-aff4-4aca-9f3d-f25fe26b6e40_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ccba9b87-e7c9-49bf-858f-4d666ab1da71_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2bf7a3f7-f0b6-404c-8c82-0a7cd4726e82_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration impairment</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_7eb9fe5f-cd88-4459-ade7-fa9ef4611335_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_5fd744be-9c7d-4209-a9c4-6f95e094ba59_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f74acf91-1440-49eb-b01b-b8cab44b29b6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TheCreditFacilityTerminatedMember_ee18e76a-9fb1-4caf-b08a-90c671943931_terseLabel_en-US" xlink:label="lab_biib_TheCreditFacilityTerminatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Credit Facility, Terminated</link:label>
    <link:label id="lab_biib_TheCreditFacilityTerminatedMember_label_en-US" xlink:label="lab_biib_TheCreditFacilityTerminatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Credit Facility, Terminated [Member]</link:label>
    <link:label id="lab_biib_TheCreditFacilityTerminatedMember_documentation_en-US" xlink:label="lab_biib_TheCreditFacilityTerminatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Credit Facility, Terminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityTerminatedMember" xlink:href="biib-20230930.xsd#biib_TheCreditFacilityTerminatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TheCreditFacilityTerminatedMember" xlink:to="lab_biib_TheCreditFacilityTerminatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_0bf6a798-38db-47af-8d85-7bc531827210_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_257b28af-29df-40bb-8705-7949c3c7e4f3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_593e3eec-822e-4705-9b37-932ef42f41db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_fa3efd6f-6d5a-4cc8-8c9f-370afae5cacc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3724a01f-e5e5-4911-bb7f-52e9d0436c25_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_5950277d-559d-4ab5-9c6a-66e0005ad878_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:href="biib-20230930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62081ca8-fa8f-4f1a-a208-0c19197eb6b9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e4a62627-5177-46e2-8421-dcbee200c17e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_597c3512-f02f-4186-b062-3be7b8844bfa_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_61e6213a-9f45-4f7f-b3d2-5a35aac3ad8e_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3a3c817e-a663-4b57-9e69-979316787053_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_7dfffadf-b94c-4677-8f2e-0c4c6ec965df_negatedTerseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expense and other</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued expense And Other</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued expense And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0346c40f-4524-4ad9-a57b-0264a1adadc7_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, contingencies and guarantees</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_5578f31d-3f88-4702-899d-0d8dafa86371_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TysabriProductMember_b0b26cd1-0ffa-41b9-ba34-e10563ddec73_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_label_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_documentation_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember" xlink:href="biib-20230930.xsd#biib_TysabriProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember" xlink:to="lab_biib_TysabriProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_4262dd74-62d9-4cd9-877e-916218aeb58b_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2022CostSavingInitiativesMember_c006f0bd-4de7-47dc-83c2-0177d28267ad_terseLabel_en-US" xlink:label="lab_biib_A2022CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Cost Saving Initiative</link:label>
    <link:label id="lab_biib_A2022CostSavingInitiativesMember_label_en-US" xlink:label="lab_biib_A2022CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Cost Saving Initiatives [Member]</link:label>
    <link:label id="lab_biib_A2022CostSavingInitiativesMember_documentation_en-US" xlink:label="lab_biib_A2022CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Cost Saving Initiatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2022CostSavingInitiativesMember" xlink:href="biib-20230930.xsd#biib_A2022CostSavingInitiativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2022CostSavingInitiativesMember" xlink:to="lab_biib_A2022CostSavingInitiativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettlementLiabilitiesCurrent_b4538a7b-229e-4333-bdbd-9a34048d66b6_terseLabel_en-US" xlink:label="lab_us-gaap_SettlementLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reata acquisition-related accrued expense</link:label>
    <link:label id="lab_us-gaap_SettlementLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_SettlementLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettlementLiabilitiesCurrent" xlink:to="lab_us-gaap_SettlementLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_531d2599-8c86-405e-af7f-1bd9d58497ff_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_5d6a7eaa-94a2-4b46-a325-9c939f875111_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_fd9e7362-0147-4836-87bc-325fe79a1881_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits" xlink:href="biib-20230930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits" xlink:to="lab_biib_ShareOfCoPromotionProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_23dc3c6f-c345-4c02-a578-a6569065dc04_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6451cdec-bdf2-4488-9bbb-3ebb9c227080_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_228ec565-24bc-4934-88d5-0565df28a920_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c76762d7-5593-4cce-a1b2-56f0daa0fcd3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2ca7a0ce-a79d-4e79-8257-965897baedba_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_a11cae73-a0c7-4db4-9b20-85fa6e3d409a_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_ebf311bd-8570-4493-98eb-43176ecbe65b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_1e451f6a-2f77-417b-a5a8-6ada614d32a9_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_b5c0aef6-a686-41a3-b4aa-92c6f40d3f6a_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_3b084e5b-3bd0-43f5-8ce0-ecaf41262019_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6c601ff9-9abb-4739-8d07-27ed9f8b27a1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractualAdjustmentsMember_9c647599-1f6d-4424-a170-193e09b11a5c_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember" xlink:href="biib-20230930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember" xlink:to="lab_biib_ContractualAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_2a9286a1-fe62-4a58-9137-ea2c653d8cc0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_6f43a897-abed-4632-808c-61be7e0c75fe_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ffc2a5b5-1167-47f5-bf57-eb095cf90ef6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5cd1e194-58f7-427a-a008-88136acedf4c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_ce1797f8-9b5d-4dc8-8195-a7b3fc8586f3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_3b40753e-7e69-4760-b3c6-c2050aa1f2b4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_100a676e-dcca-4346-a9e4-737e88834445_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stake in entity</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:href="biib-20230930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_f87b1388-ab76-44ef-86ca-e6ec426638c0_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_643b11c7-5468-4b83-82ca-225eecda1b05_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_882cd98e-8a64-490c-91cd-c9390bf0832a_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_a245e3fe-e1ba-492f-804b-5ccf8b95465b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e48c8ca6-31ec-4cfc-8bf1-2e7383b9a65a_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5a702d62-ea17-46b3-988b-77e918dc280c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under award plan, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_896b5496-6bed-47d9-8ff3-ae96d6ea59fb_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:href="biib-20230930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_384ca29f-fabf-4f9d-b7cc-c1b109671de4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SKYCLARYSMember_d5526015-22c3-47bf-a9fa-44a50fa26975_terseLabel_en-US" xlink:label="lab_biib_SKYCLARYSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Completed technology for SKYCLARYS (U.S.)</link:label>
    <link:label id="lab_biib_SKYCLARYSMember_label_en-US" xlink:label="lab_biib_SKYCLARYSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SKYCLARYS [Member]</link:label>
    <link:label id="lab_biib_SKYCLARYSMember_documentation_en-US" xlink:label="lab_biib_SKYCLARYSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SKYCLARYS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember" xlink:href="biib-20230930.xsd#biib_SKYCLARYSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SKYCLARYSMember" xlink:to="lab_biib_SKYCLARYSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_9898f9da-296c-4f2f-8359-868887f2f232_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_375bb929-2a7e-4017-85a7-8dfb4143b387_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on foreign currency derivative instruments not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Reductioninroyaltyrate_0c44a824-81f1-4a8f-8a9a-a8069ecfa2d1_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyrate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_label_en-US" xlink:label="lab_biib_Reductioninroyaltyrate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyrate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyrate" xlink:href="biib-20230930.xsd#biib_Reductioninroyaltyrate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyrate" xlink:to="lab_biib_Reductioninroyaltyrate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_14437c31-0e29-4883-ab38-539060a91249_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune tax impacts</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:href="biib-20230930.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:to="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_449d7eac-fd01-49fb-bb2a-7256a40bc55b_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_975c7f88-aced-48fd-8cad-23cfd63d0c49_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:href="biib-20230930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_ca3217aa-9987-4f60-aae5-a0773add1b59_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_68d68b97-9c04-47f1-a133-efe71572113d_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_ccc0e9f2-5765-4369-bd63-ea48beddeede_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_1b1a04f1-e15b-4ef6-9b76-e928c2ca416e_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LenderDisputeMember_df203b8a-a917-4d4b-a7ff-193e275e7c2d_terseLabel_en-US" xlink:label="lab_biib_LenderDisputeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Dispute</link:label>
    <link:label id="lab_biib_LenderDisputeMember_label_en-US" xlink:label="lab_biib_LenderDisputeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Dispute [Member]</link:label>
    <link:label id="lab_biib_LenderDisputeMember_documentation_en-US" xlink:label="lab_biib_LenderDisputeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Dispute</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LenderDisputeMember" xlink:href="biib-20230930.xsd#biib_LenderDisputeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LenderDisputeMember" xlink:to="lab_biib_LenderDisputeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_02224d7b-6f75-4ca3-8e2a-2be705a4f06d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_74bd5b14-2528-4335-be34-0c930dfe011d_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_be8c9889-d3c0-4cfa-b4e3-8f0832a91ba9_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fc33800a-5e31-4ee2-9598-c5f2d1d3333b_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_407da3fa-8e49-4af0-822d-3ed711cef74e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_f492637c-5a50-4986-b840-f2d9142597bc_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_4d1d0021-e992-4713-94bd-ee3dba9a568b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_2bf1efa1-3545-4541-85c5-eff48a8bf7c1_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:href="biib-20230930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_4f586d2a-7b5e-4768-be55-52c82f71fccf_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_d52f4e86-1774-4db6-add4-2a623aeb7cb1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_35cc9f55-aafd-4f65-97dc-32ce6e477c30_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e54a35d2-d03a-4bed-abf0-68e4725dc4b1_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_d85d4063-556e-4a67-86e7-4b1974ed7159_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1e99bbf6-7f55-47ac-b84d-60a16b23ce59_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:href="biib-20230930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d4433878-d3fb-448c-a3b4-4867cf69e56c_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_f5cdcbbe-eb13-4fc6-823c-866c7537d480_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_68c60345-4a88-4966-a3d4-64e18d8d2faa_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_10796f0c-d466-4564-ace5-e28fea644399_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember" xlink:href="biib-20230930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember" xlink:to="lab_biib_ReserveforCashDiscountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfWholesalers_e9ac4e6e-bb86-44ec-ba19-8ac0529617ad_terseLabel_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_label_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_documentation_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers" xlink:href="biib-20230930.xsd#biib_NumberOfWholesalers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfWholesalers" xlink:to="lab_biib_NumberOfWholesalers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_df640eef-84a7-41c0-b459-ddd7855658fe_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4582168-47b7-41ee-8e13-eb1a84fec30c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_b829f68a-24c4-4c7e-8254-5e0b9d8082b4_terseLabel_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Indefinite Lived Intangible Assets Discount Rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_label_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Indefinite Lived Intangible Assets Discount Rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_documentation_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Indefinite Lived Intangible Assets Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:href="biib-20230930.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:to="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1a0f2f69-5f62-4e04-8e5f-ded8b8ae9a74_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_1ae5afad-1714-46a6-bd15-f459d94d8099_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected profit share percentage</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:href="biib-20230930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_cc4d6d4b-f7f0-4ddb-9c81-d99e0787abde_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccruedPaymentToTerminationAgreement_e6b789f2-a245-45db-a13e-46a8541fdb98_terseLabel_en-US" xlink:label="lab_biib_AccruedPaymentToTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable Due To Termination Agreement</link:label>
    <link:label id="lab_biib_AccruedPaymentToTerminationAgreement_label_en-US" xlink:label="lab_biib_AccruedPaymentToTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payment To Termination Agreement</link:label>
    <link:label id="lab_biib_AccruedPaymentToTerminationAgreement_documentation_en-US" xlink:label="lab_biib_AccruedPaymentToTerminationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payment To Termination Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedPaymentToTerminationAgreement" xlink:href="biib-20230930.xsd#biib_AccruedPaymentToTerminationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccruedPaymentToTerminationAgreement" xlink:to="lab_biib_AccruedPaymentToTerminationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_f5b3f79d-852c-46bf-9d38-c04f15953c77_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_f6470928-78aa-4ada-8390-701b0335242a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2023 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_9416af2a-f857-4007-8de3-5dfe94ec434d_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_6110a090-d2f7-4f3e-84b3-e1e282afa095_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_e2ff8824-0dda-4db3-920f-b26e7bc1b6a1_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:href="biib-20230930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_16145f04-0446-4fd7-b956-1bf166364881_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c86c7efc-488c-4fea-b7ee-ea009ae94f8b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_e42f2934-70b8-41c1-992e-ac5e29f13c35_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_44f65d84-5968-46cf-b907-f8bc54c9e3d8_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DivestituresAbstract_ba453018-ebdd-4ed9-9a2b-9facbb182188_terseLabel_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_label_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_documentation_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract" xlink:href="biib-20230930.xsd#biib_DivestituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DivestituresAbstract" xlink:to="lab_biib_DivestituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_5ca86058-75b1-4bcb-a4f2-f1554b717773_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rates</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_59551708-7523-45d5-ac10-086284fca813_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on securities available for sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_820f30d1-4c4f-45e2-bf2d-7252c2a93b72_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_1b167bad-b8cd-42c1-9e64-1e21733dbaec_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amount Sold</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amount Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_eafbdad1-3cd9-441c-9d23-9d29444a302b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_76d2ea08-702c-4405-9ffb-d7b2fad2ff65_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of co promotion operating profits first fifty million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Co Promotion Operating Profits First Fifty Million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of co promotion operating profits first fifty million.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:href="biib-20230930.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_26dbd2eb-178e-4744-90db-b7a00a117cff_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_19d114a6-e0f9-4d4b-b84e-07b635ab06e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2cb63118-9ec6-4607-b7c4-3ea93a05831b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b850bf6-84d4-481b-a4f8-cb81905360bc_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa76595b-606d-462d-9b85-41d8caf84eb9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_fb0a07fb-514c-4222-a927-a2eda6e6d8d7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiologicsManufacturingMember_d14e35d6-681c-4e02-b7f7-b5e54ca0331b_terseLabel_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_label_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing [Member]</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_documentation_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember" xlink:href="biib-20230930.xsd#biib_BiologicsManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiologicsManufacturingMember" xlink:to="lab_biib_BiologicsManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_04069bcc-7f52-43ed-b636-b6bb25814515_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_123904b3-64f8-4479-9856-c7a1c893c0f0_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_3a19f454-f47a-4fed-8a0f-65648fc1cb8a_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable and term loan</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_34e32735-b54c-4609-84d0-26725a844960_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-promotion profit sharing formula</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_label_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co Promotion Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_documentation_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-promotion profit sharing formula.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:href="biib-20230930.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:to="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_8d2dc8ea-749e-4a8d-a208-041bb2277a17_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_b0f86115-40ca-44a3-8c83-432fa290ba55_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_fc712f34-e5e2-44d6-bab6-abb6a166a52b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_38623fd5-9ee4-43b9-bac9-f1a6bef836c8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_0eff3dd5-b88b-4104-b628-2ecd4322354d_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OperatingLeaseArea_eef26e6d-f231-4825-830b-818adc7e5c1e_terseLabel_en-US" xlink:label="lab_biib_OperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Area</link:label>
    <link:label id="lab_biib_OperatingLeaseArea_label_en-US" xlink:label="lab_biib_OperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Area</link:label>
    <link:label id="lab_biib_OperatingLeaseArea_documentation_en-US" xlink:label="lab_biib_OperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea" xlink:href="biib-20230930.xsd#biib_OperatingLeaseArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingLeaseArea" xlink:to="lab_biib_OperatingLeaseArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_fdab9204-8858-4519-a52c-ffba34859121_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_105d5f86-e367-4dd7-b2b6-ff9a634a0acf_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_e1fa4c26-58c5-4504-8be1-ffc8adda042d_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:href="biib-20230930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2fbba2a2-3357-4ada-be03-ad141b37de48_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_bb414e2f-d1b4-4bda-b91b-799662c400cb_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember_69718f06-f6aa-4b19-85c6-47c096437f5c_terseLabel_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Floating Rate 364-Day Tranche</link:label>
    <link:label id="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember_label_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Credit Facility Floating Rate 364-Day Tranche [Member]</link:label>
    <link:label id="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember_documentation_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Floating Rate 364-Day Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:href="biib-20230930.xsd#biib_TheCreditFacilityFloatingRate364DayTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:to="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_3b00876f-682a-4630-b7a7-050c72c320f5_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentsMember_0a588e60-b01b-4384-acc6-71706dc4a460_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember" xlink:href="biib-20230930.xsd#biib_StrategicInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember" xlink:to="lab_biib_StrategicInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_16b5581d-d127-49e8-ab72-78aa50aaaa0f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_6a0c3a79-24cb-4cd4-935a-e9fc431c7c77_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_85a779ce-8160-494d-9db2-017416c93785_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_85d242fb-0eed-4922-b684-a4c33599c871_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_7738b3ce-e49a-4589-aef8-8a5760031ef5_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain" xlink:href="biib-20230930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_071f99e5-8b4a-4775-aaa4-acffb0e8a847_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2937917d-807d-42ea-b4ce-6f0fc4b49266_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_552ad161-f6a1-4014-9abb-a4ad42baf42d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TECFIDERAMember_7e18993e-9e56-4fdb-8cb7-9e8fb7940612_terseLabel_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TECFIDERAMember_label_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TECFIDERAMember_documentation_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember" xlink:href="biib-20230930.xsd#biib_TECFIDERAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TECFIDERAMember" xlink:to="lab_biib_TECFIDERAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_904733f4-012c-4225-8e0b-70d77dbd096e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_2f0e528f-7c8d-451b-aa86-a8ac7ba6d514_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_16c89a5b-8347-49ed-99be-bc4e554672d6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_6f92fd5e-bdbe-40e6-b329-dfa7d7e7f62b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfFutureDevelopmentCosts_bb5ef0e4-77e8-4799-acd2-dacd6512c21a_terseLabel_en-US" xlink:label="lab_biib_PercentageOfFutureDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs</link:label>
    <link:label id="lab_biib_PercentageOfFutureDevelopmentCosts_label_en-US" xlink:label="lab_biib_PercentageOfFutureDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Future Development Costs</link:label>
    <link:label id="lab_biib_PercentageOfFutureDevelopmentCosts_documentation_en-US" xlink:label="lab_biib_PercentageOfFutureDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Future Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfFutureDevelopmentCosts" xlink:href="biib-20230930.xsd#biib_PercentageOfFutureDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfFutureDevelopmentCosts" xlink:to="lab_biib_PercentageOfFutureDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OCREVUSMember_5b367112-d7c2-483c-8b26-5b3cff351c26_terseLabel_en-US" xlink:label="lab_biib_OCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCREVUS</link:label>
    <link:label id="lab_biib_OCREVUSMember_label_en-US" xlink:label="lab_biib_OCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCREVUS [Member]</link:label>
    <link:label id="lab_biib_OCREVUSMember_documentation_en-US" xlink:label="lab_biib_OCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCREVUS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OCREVUSMember" xlink:href="biib-20230930.xsd#biib_OCREVUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OCREVUSMember" xlink:to="lab_biib_OCREVUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_c81ab8c6-165d-4549-b98c-77d3fe174ee1_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_a0902bf1-2c13-43ce-bca2-567f57393798_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_37338ac6-c374-4d4b-b7b1-14a0f3e93e2e_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_e3e6ad9a-3bec-4252-8c48-595bedcbbcc7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_156e4362-e4eb-4284-8647-58f3c2031600_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (distribution) contribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments to) Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_bcc7254b-1f28-4bb4-be9a-a98b8967348e_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_afbcd627-a3b6-4ebe-8ea4-4915ffa2e8ee_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dispositions</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityAxis_e17c760c-0fe1-4b77-81a9-5b4126d04ea5_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_label_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis" xlink:href="biib-20230930.xsd#biib_DerivativeMaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityAxis" xlink:to="lab_biib_DerivativeMaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_11a33a2f-4a5d-4316-8009-a8a624c3ac82_negatedTerseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="biib-20230930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_25e92a34-ea0d-43d4-b5d9-41d54ad15059_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c47fd50b-5b90-405e-ab49-28fca0107c45_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_aa3c66be-e145-48af-91c7-34e2ebe094ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_JPY_2c26380c-f606-456c-842c-53a5ff4a34a9_terseLabel_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_label_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_JPY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY" xlink:to="lab_currency_JPY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_035b5ad9-d346-4d3b-8252-c04188fb43c0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_ab2461dd-3bd7-48df-aabc-fe4d425bfc67_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_f00208aa-ecf9-4730-975c-82f60288c69b_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfSquareFeet_9e5c8a88-8035-45ba-8c90-3781faf2b1a6_terseLabel_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of square feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_label_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_documentation_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet" xlink:href="biib-20230930.xsd#biib_NumberOfSquareFeet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSquareFeet" xlink:to="lab_biib_NumberOfSquareFeet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca3bfaba-1c69-468b-a4be-13c991f94416_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_b1eabdfd-6172-4846-9d4b-38dad719256d_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:href="biib-20230930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_d378d511-ef07-4bba-8421-90a4f3a89759_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d6729d4f-eb55-40b7-b631-4b3c5009f806_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_1eadb2c2-1b17-42cb-bf3e-25c8511bdead_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:href="biib-20230930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_750fa2f8-4864-4bde-9f98-2ea95e164a44_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember" xlink:to="lab_biib_SamsungBiosimilarAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_38716fca-6e43-48a0-a5dc-68502304ed4b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_94b98f1c-ff95-4b35-af91-bd63e7a21076_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_17fcb9b8-f040-46fc-9d35-83db62ed3523_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_986f1ee0-9fa4-44d7-8e5e-fdd1f939b0a1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherAssetsMeasurementInput_f4062d2c-a70d-470a-b2ca-4216d4099b2b_terseLabel_en-US" xlink:label="lab_biib_OtherAssetsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-adjusted discount rates</link:label>
    <link:label id="lab_biib_OtherAssetsMeasurementInput_label_en-US" xlink:label="lab_biib_OtherAssetsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Measurement Input</link:label>
    <link:label id="lab_biib_OtherAssetsMeasurementInput_documentation_en-US" xlink:label="lab_biib_OtherAssetsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsMeasurementInput" xlink:href="biib-20230930.xsd#biib_OtherAssetsMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherAssetsMeasurementInput" xlink:to="lab_biib_OtherAssetsMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b656613-f862-48d1-a105-acbf3c49a0a1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_3860ca29-f7b8-43b6-a63f-c14eb5f07891_terseLabel_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_label_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_documentation_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives" xlink:href="biib-20230930.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainOnDerivatives" xlink:to="lab_biib_UnrealizedGainOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_66db706c-31d6-418b-b69f-cc5e95bc2bb5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_006b37d7-02df-4aee-92f4-678d65a6b119_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_09dbde52-d58e-48d1-88d6-9cf21ec09bf8_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_91649104-4b40-439f-91f5-dc40efb90d28_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GenentechMember_bacb0327-d0c6-4569-8f68-9693f2537f8c_terseLabel_en-US" xlink:label="lab_biib_GenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_GenentechMember_label_en-US" xlink:label="lab_biib_GenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech [Member]</link:label>
    <link:label id="lab_biib_GenentechMember_documentation_en-US" xlink:label="lab_biib_GenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GenentechMember" xlink:href="biib-20230930.xsd#biib_GenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GenentechMember" xlink:to="lab_biib_GenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_21842151-84f6-4ce8-99f8-2ca2e2d66212_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_60b90c7e-190d-49a5-ad85-ac2f9945dac5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_a7496e5d-cfb0-4be2-94f4-0f0b0699d4d0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b36055da-b1db-4810-90fe-51a621a07a90_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_f914629d-115b-489a-8540-e54e5d7dbf11_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f99889a7-569c-4685-809f-c8e91a1fb3a5_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_63b51dd9-65d7-43a6-9c94-43a538224c32_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_38e5a905-be44-443b-bb8a-24e8663065f0_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0d871b0d-839f-44a8-bcea-ab0e38aec5d2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_c6610bad-d80f-40ec-baa7-13f829bae846_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement agreement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b73cccb6-2303-4675-9a0f-05fad117f5e1_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_779b0878-b312-4c7c-b0e2-a57c45dad863_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_70e0b83a-60ce-49a1-a5c3-9752e07fd7be_terseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:href="biib-20230930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6d2d5e29-5eef-4629-aa4a-cd4fa6e79305_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_69e0964c-8429-472c-984e-fa38817654b6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration expected to be received for sale of Denmark Manufacturing Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_57e9b086-73da-4d94-aa41-884199c455b5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ea87d13a-d61f-49ca-a8c9-028ec9f13e0e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_ba6055a9-5fed-4509-9f30-2e392b5cabc8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c029c366-f2bf-415d-8e40-6b6afe57911f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_46ac5f84-69dd-46cc-bfb5-554d71164699_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_7560e334-f61a-4350-ba7a-b0e8f5fe6d3a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded status of postretirement benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_d3ff9ac3-ab08-47fa-bf78-257add566b22_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d143ee4f-ccfe-4209-af78-195a93cb84ca_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_b0ddb478-5f35-4fb5-addb-ace69914b042_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_7f77be04-96f1-4094-a976-f8277705904b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a2b9065e-1c2d-4c55-aef4-dc897c232313_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityAwardsOfAcquiredCompanyMember_87f7734c-6f75-4008-a3e8-d56562d5c8d4_terseLabel_en-US" xlink:label="lab_biib_EquityAwardsOfAcquiredCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Awards Of Acquired Company</link:label>
    <link:label id="lab_biib_EquityAwardsOfAcquiredCompanyMember_label_en-US" xlink:label="lab_biib_EquityAwardsOfAcquiredCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Awards Of Acquired Company [Member]</link:label>
    <link:label id="lab_biib_EquityAwardsOfAcquiredCompanyMember_documentation_en-US" xlink:label="lab_biib_EquityAwardsOfAcquiredCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Awards Of Acquired Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityAwardsOfAcquiredCompanyMember" xlink:href="biib-20230930.xsd#biib_EquityAwardsOfAcquiredCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityAwardsOfAcquiredCompanyMember" xlink:to="lab_biib_EquityAwardsOfAcquiredCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_36d3c756-0b42-4060-8169-ebc8584fd996_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d54d508d-b798-45cb-b84c-54c5021b5e40_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityDomain_799dd6ed-6419-49a9-9c53-db00bf0819f8_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_label_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain" xlink:href="biib-20230930.xsd#biib_DerivativeMaturityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityDomain" xlink:to="lab_biib_DerivativeMaturityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_81e1a77b-b028-4e1b-8126-c64f1b43e75a_terseLabel_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contribution from noncontrolling interest</link:label>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_label_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Capital Contribution</link:label>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_documentation_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Capital Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution" xlink:href="biib-20230930.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NoncontrollingInterestCapitalContribution" xlink:to="lab_biib_NoncontrollingInterestCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_0a419fdf-7b35-4da1-83f7-dc2fb9b9baac_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis" xlink:href="biib-20230930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f51f1e27-e637-4eb0-a251-fbdb778bf3f4_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9a643d56-3e2c-423c-b19c-18f2c0a1fc63_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_f363be8d-8886-4f1a-b370-dc49d71d0213_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_46f11093-4e51-47a0-8507-58977be1f041_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, GILTI, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_52036009-263e-4716-97b7-f4f35de95261_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_a23f5bc2-7ea0-4781-89de-e40cdd974542_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_fb3ffd6b-6e59-4519-8711-4615f879c563_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_562c902f-c8b1-49f8-b582-9c9c708779de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f98a59b3-fa24-4ea9-a4e0-74babaf80a37_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_cf54abd9-6ac4-44dc-a845-526dd86d953d_terseLabel_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Senior Notes due May 1, 2030</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_label_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_documentation_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:href="biib-20230930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:to="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfNetProfitFromSageTherapeuticsAmount_7c829956-490e-47d8-b49c-f7b1daec3a4f_terseLabel_en-US" xlink:label="lab_biib_ShareOfNetProfitFromSageTherapeuticsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of net profit from sage therapeutics</link:label>
    <link:label id="lab_biib_ShareOfNetProfitFromSageTherapeuticsAmount_label_en-US" xlink:label="lab_biib_ShareOfNetProfitFromSageTherapeuticsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Net Profit From Sage Therapeutics, Amount</link:label>
    <link:label id="lab_biib_ShareOfNetProfitFromSageTherapeuticsAmount_documentation_en-US" xlink:label="lab_biib_ShareOfNetProfitFromSageTherapeuticsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Net Profit From Sage Therapeutics, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNetProfitFromSageTherapeuticsAmount" xlink:href="biib-20230930.xsd#biib_ShareOfNetProfitFromSageTherapeuticsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfNetProfitFromSageTherapeuticsAmount" xlink:to="lab_biib_ShareOfNetProfitFromSageTherapeuticsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_0fd681c8-90b2-46eb-9933-64ce91c8ecc8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5d96490f-5392-4f4d-8c3d-7bc557e4e38c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_30a151aa-38ea-4817-bf19-fdf8e1fb82f4_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b0620fe3-ce03-4c29-aa39-524c955e806a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_4c4fc948-9ed5-40d9-accc-cfdf6e65a351_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">125 Broadway Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_2291e68f-f976-40b8-81cf-01f689d42953_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RoyaltyAttributedToOCREVUSMember_4f26f414-fe71-4ffe-89e2-ee4e0b26ac3e_terseLabel_en-US" xlink:label="lab_biib_RoyaltyAttributedToOCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Attributed To OCREVUS</link:label>
    <link:label id="lab_biib_RoyaltyAttributedToOCREVUSMember_label_en-US" xlink:label="lab_biib_RoyaltyAttributedToOCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Attributed To OCREVUS [Member]</link:label>
    <link:label id="lab_biib_RoyaltyAttributedToOCREVUSMember_documentation_en-US" xlink:label="lab_biib_RoyaltyAttributedToOCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Attributed To OCREVUS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltyAttributedToOCREVUSMember" xlink:href="biib-20230930.xsd#biib_RoyaltyAttributedToOCREVUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyAttributedToOCREVUSMember" xlink:to="lab_biib_RoyaltyAttributedToOCREVUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiosimilarsMember_90dfb940-031d-4b78-92b9-9a3da782dec4_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_label_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember" xlink:href="biib-20230930.xsd#biib_BiosimilarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember" xlink:to="lab_biib_BiosimilarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cc0d5844-b8c4-4d38-a314-24de711ee35e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_aa37ab6a-cee3-48e8-b606-dd123896596c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_47ffb43a-12a4-43f6-ac4f-a821df654a88_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_4514895a-59aa-4f24-ae61-f288c6ccd4ac_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a70d8c39-fd28-4663-a2fd-10b0f9e9712f_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_ddeebd86-8d28-4180-9bab-88b5095c836a_negatedTerseLabel_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_label_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_documentation_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives" xlink:href="biib-20230930.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedLossOnDerivatives" xlink:to="lab_biib_UnrealizedLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_6ba4d1f6-a4db-4522-bb7e-ae532df16515_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_a75f7d8a-79fe-40de-9287-4c45b3a5727f_verboseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_395978af-59a5-43c8-bc92-fc89dee45df2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_514a6eab-492d-42d0-9992-938b4f839fa7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3bb02ef4-04c1-4263-b9a0-5bb2ab762874_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent_9523524f-7695-47fe-b785-3381b146c339_terseLabel_en-US" xlink:label="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of net profit from sage therapeutics, Percent</link:label>
    <link:label id="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent_label_en-US" xlink:label="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Net Profit From Sage Therapeutics, Percent</link:label>
    <link:label id="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent_documentation_en-US" xlink:label="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Net Profit From Sage Therapeutics, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:href="biib-20230930.xsd#biib_ShareOfNetProfitFromSageTherapeuticsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:to="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherClinicalProgramsMember_1aa3d6be-cd77-4548-b43b-f46ce9df512b_terseLabel_en-US" xlink:label="lab_biib_OtherClinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other clinical programs</link:label>
    <link:label id="lab_biib_OtherClinicalProgramsMember_label_en-US" xlink:label="lab_biib_OtherClinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Clinical Programs [Member]</link:label>
    <link:label id="lab_biib_OtherClinicalProgramsMember_documentation_en-US" xlink:label="lab_biib_OtherClinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Clinical Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember" xlink:href="biib-20230930.xsd#biib_OtherClinicalProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherClinicalProgramsMember" xlink:to="lab_biib_OtherClinicalProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_7edf4406-6ee9-469e-8e76-fdf55f9adf15_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:href="biib-20230930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c34cdcb4-8fef-496b-8a9e-8b6182be0842_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_050404b8-1a6e-4d60-a2da-537b5759e468_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_9b175d4c-22ad-4c2b-835e-5cc3a05e11d5_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember" xlink:href="biib-20230930.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_b3d1d721-c1cf-45fa-9129-cd53e0466014_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:href="biib-20230930.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_03e50778-4800-4a34-b0e6-4bd405cca630_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborationAgreementTerm_b8e76de8-399d-4343-a681-da352aa1eeb0_terseLabel_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_biib_CollaborationAgreementTerm_label_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:label id="lab_biib_CollaborationAgreementTerm_documentation_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm" xlink:href="biib-20230930.xsd#biib_CollaborationAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationAgreementTerm" xlink:to="lab_biib_CollaborationAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_3ad81a1d-ce9b-4305-9d9c-4a3d77d082ae_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_67e92319-6eeb-4f12-9e86-f93321e8f144_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Business Transformation and Other Cost Saving Initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RocheGroupGenentechMember_b8318257-2ffd-4186-ada7-b5767863c805_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember" xlink:href="biib-20230930.xsd#biib_RocheGroupGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember" xlink:to="lab_biib_RocheGroupGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A125BroadwayBuildingSaleMember_f352a58f-acd9-4c6b-9632-6a69bfc7260b_terseLabel_en-US" xlink:label="lab_biib_A125BroadwayBuildingSaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">125 Broadway Building Sale</link:label>
    <link:label id="lab_biib_A125BroadwayBuildingSaleMember_label_en-US" xlink:label="lab_biib_A125BroadwayBuildingSaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">125 Broadway Building Sale [Member]</link:label>
    <link:label id="lab_biib_A125BroadwayBuildingSaleMember_documentation_en-US" xlink:label="lab_biib_A125BroadwayBuildingSaleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">125 Broadway Building Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A125BroadwayBuildingSaleMember" xlink:href="biib-20230930.xsd#biib_A125BroadwayBuildingSaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A125BroadwayBuildingSaleMember" xlink:to="lab_biib_A125BroadwayBuildingSaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_d5d17178-9209-4977-af7a-8ec3d6cb84dd_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_daba2d68-54e5-4591-8795-eb5822ecc3ba_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:href="biib-20230930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_05896d7b-f8da-4d0b-808f-b2fb2edd833a_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_39c28bc8-dd20-4d6c-af08-db3ab7aa4c9b_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment to third party</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:href="biib-20230930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_c6a50bac-9a3e-44b1-8a02-75b9e78389ca_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_9f09b2da-9c08-49ee-a5de-4270acec3fed_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e9b878d0-a95a-4713-91c7-a3d15ad892f2_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_e18e4ae6-e4fd-48d9-9a54-0737a7208a02_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_38cc0c90-8d1c-4572-aafc-e3da336f8409_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WorkforceReductionMember_43e710bf-a57d-4245-8fa6-b2f94cbed8d3_terseLabel_en-US" xlink:label="lab_biib_WorkforceReductionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Reduction</link:label>
    <link:label id="lab_biib_WorkforceReductionMember_label_en-US" xlink:label="lab_biib_WorkforceReductionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Reduction [Member]</link:label>
    <link:label id="lab_biib_WorkforceReductionMember_documentation_en-US" xlink:label="lab_biib_WorkforceReductionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WorkforceReductionMember" xlink:href="biib-20230930.xsd#biib_WorkforceReductionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WorkforceReductionMember" xlink:to="lab_biib_WorkforceReductionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cd0b9bf3-30d7-47e3-b737-7de42f90a566_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_03ac4a48-868f-4b9a-8902-ce16fc3bddfc_terseLabel_en-US" xlink:label="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected operating expense reduction</link:label>
    <link:label id="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_label_en-US" xlink:label="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Activities, Expected Operating Expense Reduction</link:label>
    <link:label id="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_documentation_en-US" xlink:label="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Activities, Expected Operating Expense Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:href="biib-20230930.xsd#biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:to="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesAbstract_de561eea-d7d6-4606-9fd3-f35becaf05d1_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract" xlink:href="biib-20230930.xsd#biib_OtherrevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract" xlink:to="lab_biib_OtherrevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_47102a18-caa0-4b6f-b13f-439f41975902_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_2168845f-9787-45c5-b6ce-4f970248d25c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_d80f5e93-4b50-4bef-b56b-eabd049d25c4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_202ed4c4-ea68-4ddd-a5e7-cdcc560ee1a5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_3f1c1047-9b3f-4260-9de3-2e8d9dc1dbbc_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_230b340c-8175-4037-80ea-e9024f272ec6_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_f1d84a2b-539f-48e6-ae26-131074082548_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected number of positions eliminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_4704ce7b-6e7d-42df-a78f-dfaca67011c7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_01a1f83f-65fe-44d7-a681-07685ec0a422_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_37dc7a8c-21e5-496f-a7ca-8080686ddf9d_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AVONEXMember_92b1cdee-1974-44dd-844c-1c64c0d607b9_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_label_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_documentation_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember" xlink:href="biib-20230930.xsd#biib_AVONEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember" xlink:to="lab_biib_AVONEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LEQEMBICollaborationMember_2c10ca3a-dc12-47e3-9c0f-cd131bcd3e68_terseLabel_en-US" xlink:label="lab_biib_LEQEMBICollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEQEMBI Collaboration</link:label>
    <link:label id="lab_biib_LEQEMBICollaborationMember_label_en-US" xlink:label="lab_biib_LEQEMBICollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEQEMBI Collaboration [Member]</link:label>
    <link:label id="lab_biib_LEQEMBICollaborationMember_documentation_en-US" xlink:label="lab_biib_LEQEMBICollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEQEMBI Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember" xlink:href="biib-20230930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LEQEMBICollaborationMember" xlink:to="lab_biib_LEQEMBICollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_VUMERITYMember_9eb61521-85ab-4478-8d08-838f170e93fa_terseLabel_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VUMERITY</link:label>
    <link:label id="lab_biib_VUMERITYMember_label_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VUMERITY [Member]</link:label>
    <link:label id="lab_biib_VUMERITYMember_documentation_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VUMERITY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember" xlink:href="biib-20230930.xsd#biib_VUMERITYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_VUMERITYMember" xlink:to="lab_biib_VUMERITYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_8b8d63c4-78dc-4783-a62f-9dd99975afb4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborativeArrangementProfitLossSharing_99d65de8-e635-42f3-901b-d1f774d2e34e_terseLabel_en-US" xlink:label="lab_biib_CollaborativeArrangementProfitLossSharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized net reductions to operating expense</link:label>
    <link:label id="lab_biib_CollaborativeArrangementProfitLossSharing_label_en-US" xlink:label="lab_biib_CollaborativeArrangementProfitLossSharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit (Loss) Sharing</link:label>
    <link:label id="lab_biib_CollaborativeArrangementProfitLossSharing_documentation_en-US" xlink:label="lab_biib_CollaborativeArrangementProfitLossSharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit (Loss) Sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementProfitLossSharing" xlink:href="biib-20230930.xsd#biib_CollaborativeArrangementProfitLossSharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborativeArrangementProfitLossSharing" xlink:to="lab_biib_CollaborativeArrangementProfitLossSharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_6fca36d3-15da-45fe-9f95-2ee8b75fdac2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_76f9a452-9ae3-4214-b7c5-fd9994f67046_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PLEGRIDYMember_aa7147ef-ca6e-4c39-8b33-6bdea23d2a5e_terseLabel_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLEGRIDY</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_label_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLEGRIDY [Member]</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_documentation_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLEGRIDY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember" xlink:href="biib-20230930.xsd#biib_PLEGRIDYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PLEGRIDYMember" xlink:to="lab_biib_PLEGRIDYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_10d2e736-691e-44b7-a575-0d6bd550b71d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_771d1b9b-1bd5-44a7-89f1-41de77e53927_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_300cc724-4458-486d-b226-624410e2e53b_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_9757201e-9463-4e4f-9adf-fa490a88afcd_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_172000ab-f0bd-46cb-be44-3ad2d7ec852e_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract manufacturing, royalty and other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_f4053a28-48f3-490e-abd8-fe7718b18353_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:href="biib-20230930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_c3338e05-501d-491a-9a6b-803f470ae4a9_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_c8bd1de4-dd01-4148-b770-0d60755b5300_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_02582a09-1dfd-46ba-89c9-64d0e8643dfa_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4cfe9913-41fc-4274-8fda-401ad0de4cf4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_44f7c3e8-708e-49ad-8590-bcffbe9addfa_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a572656e-a0d7-4800-b9ef-4b0fd84529f0_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_30acfe78-f8ce-4cd2-b846-fa320a0cccbf_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_35d45fe0-25f8-47b5-85f4-3ee024afdc16_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_f2e47195-3a91-492b-8660-2d475131eca5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1de0f220-5663-4b91-a2bf-ff2e4694f90c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2023CostSavingInitiativesMember_ab727e50-5397-409c-af19-aa77afd8be1a_terseLabel_en-US" xlink:label="lab_biib_A2023CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Cost Saving Initiatives</link:label>
    <link:label id="lab_biib_A2023CostSavingInitiativesMember_label_en-US" xlink:label="lab_biib_A2023CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Cost Saving Initiatives [Member]</link:label>
    <link:label id="lab_biib_A2023CostSavingInitiativesMember_documentation_en-US" xlink:label="lab_biib_A2023CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Cost Saving Initiatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember" xlink:href="biib-20230930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2023CostSavingInitiativesMember" xlink:to="lab_biib_A2023CostSavingInitiativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccountsReceivableFromCollaborator_ede8c98e-159e-4a3c-9924-1dd4946f16cb_terseLabel_en-US" xlink:label="lab_biib_AccountsReceivableFromCollaborator" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts receivable</link:label>
    <link:label id="lab_biib_AccountsReceivableFromCollaborator_label_en-US" xlink:label="lab_biib_AccountsReceivableFromCollaborator" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, From Collaborator</link:label>
    <link:label id="lab_biib_AccountsReceivableFromCollaborator_documentation_en-US" xlink:label="lab_biib_AccountsReceivableFromCollaborator" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, From Collaborator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsReceivableFromCollaborator" xlink:href="biib-20230930.xsd#biib_AccountsReceivableFromCollaborator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccountsReceivableFromCollaborator" xlink:to="lab_biib_AccountsReceivableFromCollaborator" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_66730bf4-1a0d-4669-a213-6c5b53a3ffbe_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Recognized Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_460023f8-697d-4e1d-80a3-e74c432601f9_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_cfc9cdde-e5ba-4fde-86b7-0cd48103d2c9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_ea76eed1-4157-4728-be66-290049a06182_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:href="biib-20230930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_1ffa2184-d73e-442f-91ca-d9baa753f39e_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_844e979c-53c7-4e57-8ec2-19e6b7739536_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_eefd1920-bfb0-48ed-b6cd-9d06c49bdb17_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_5e4e633e-7511-4418-97df-e1f1e3261396_verboseLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="biib-20230930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_02816ca2-f4dd-41e9-af63-1b4fd0a97f90_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_e32dd028-8dd4-43b5-8f9b-97dc41b7cecd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_0fcf2138-ac7b-47eb-b326-808c76d5bbf0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Step acquisition, equity interest in acquiree, fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_985293cf-94e5-4db9-8c37-d1f03bf446bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_5d1bf541-c9dd-45df-a72b-2c3969b5d9b1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_506cde14-8826-4de2-845e-9894e31a31fc_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_403df45a-c286-41f7-bc54-7399096e3831_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_da6bc111-1c51-4989-8d39-ef5c69f96d9d_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount remaining under 2019 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_d54973eb-c1d9-421f-9f83-1dcc0f01b34a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_2eb787ca-c76b-4a4e-8577-3064c9c61ed6_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember" xlink:href="biib-20230930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember" xlink:to="lab_biib_CashflowsoperatingexpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_513a0871-e00f-4051-9814-dd900744cbca_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fc790a5f-08b3-4861-afba-e3d8e5323143_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_abda20aa-af1f-4e04-b256-4c328b3f72f9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_652b9a4c-c77e-4f65-b644-139ac665e37a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_37c629c3-9684-45ea-be18-4b8a0929220d_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains) losses recognized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OperatingLeaseRightOfUseAssetDerecognized_d89cc507-860b-45a6-b293-7a1074a8710f_terseLabel_en-US" xlink:label="lab_biib_OperatingLeaseRightOfUseAssetDerecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets derecognized</link:label>
    <link:label id="lab_biib_OperatingLeaseRightOfUseAssetDerecognized_label_en-US" xlink:label="lab_biib_OperatingLeaseRightOfUseAssetDerecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Derecognized</link:label>
    <link:label id="lab_biib_OperatingLeaseRightOfUseAssetDerecognized_documentation_en-US" xlink:label="lab_biib_OperatingLeaseRightOfUseAssetDerecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Derecognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseRightOfUseAssetDerecognized" xlink:href="biib-20230930.xsd#biib_OperatingLeaseRightOfUseAssetDerecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingLeaseRightOfUseAssetDerecognized" xlink:to="lab_biib_OperatingLeaseRightOfUseAssetDerecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_37a581b4-ab36-4bb5-8513-0b4ba65ea478_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsFairValueDisclosure_506d23a2-851c-4ec0-ba01-ee4d50918b5e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, receivable</link:label>
    <link:label id="lab_us-gaap_OtherAssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_OtherAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsFairValueDisclosure" xlink:to="lab_us-gaap_OtherAssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d5b5eb1-1e65-4551-a763-9a4b2ad4ca6c_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_bfee69c5-e0ec-4627-8fc3-ad7507fc5492_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_466b80b5-908b-4c7a-903c-e689e5a73d48_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of term loan</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_7a140094-bd3a-431e-a8bd-72462c5c5941_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities" xlink:href="biib-20230930.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_4d9c146c-f918-495b-a9e9-45ebea527033_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember" xlink:href="biib-20230930.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesCurrentMember" xlink:to="lab_biib_EquitySecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BardoxoloneSecuritiesMember_7df5835a-e066-478a-b14d-de0651fddc0f_terseLabel_en-US" xlink:label="lab_biib_BardoxoloneSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bardoxolone Securities</link:label>
    <link:label id="lab_biib_BardoxoloneSecuritiesMember_label_en-US" xlink:label="lab_biib_BardoxoloneSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bardoxolone Securities [Member]</link:label>
    <link:label id="lab_biib_BardoxoloneSecuritiesMember_documentation_en-US" xlink:label="lab_biib_BardoxoloneSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bardoxolone Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BardoxoloneSecuritiesMember" xlink:href="biib-20230930.xsd#biib_BardoxoloneSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BardoxoloneSecuritiesMember" xlink:to="lab_biib_BardoxoloneSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_9a075842-2d53-4e22-9bf4-2e0a6288c77a_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_667fb6ea-af92-49df-9ef7-2cb52ba8b0d5_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_3aed5bfa-4a17-4c11-bc5b-cf5b65c1b3e0_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:href="biib-20230930.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfNonControlingInterestRecognized_0afe84a2-9d13-441d-b09d-1dcc1915b27d_terseLabel_en-US" xlink:label="lab_biib_ShareOfNonControlingInterestRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of non-controling interest recognized</link:label>
    <link:label id="lab_biib_ShareOfNonControlingInterestRecognized_label_en-US" xlink:label="lab_biib_ShareOfNonControlingInterestRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Non-Controling Interest Recognized</link:label>
    <link:label id="lab_biib_ShareOfNonControlingInterestRecognized_documentation_en-US" xlink:label="lab_biib_ShareOfNonControlingInterestRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Non-Controling Interest Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized" xlink:href="biib-20230930.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfNonControlingInterestRecognized" xlink:to="lab_biib_ShareOfNonControlingInterestRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_8a89cdff-9464-4418-9fe7-6cca285d5bc1_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_551eb564-a668-4b1e-8368-ed1882e2308f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdditionalMilestonePayment_ce72e260-dcf1-4508-b58a-5f1a03daceee_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment" xlink:href="biib-20230930.xsd#biib_AdditionalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment" xlink:to="lab_biib_AdditionalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d4689316-ccb0-490d-b017-17b7579f2714_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d8cd10f1-9b3c-4010-b842-e05c1b6a11cd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_6a14b3a7-cf66-4094-9a88-d628e7bb5366_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</link:label>
    <link:label id="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_label_en-US" xlink:label="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</link:label>
    <link:label id="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_documentation_en-US" xlink:label="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:href="biib-20230930.xsd#biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:to="lab_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_80b99cd9-ff25-44a4-8f6c-69dcf89db08e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4e46b651-890a-4930-a793-9cca0817fc87_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_44f8e386-5a62-4e37-9769-d9d8f8113b35_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b74ff524-2160-4949-9a38-f353ad534d04_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_ff5036c3-f97a-4198-a4b7-c58113111320_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_0175ea30-ea99-4943-a146-7a85c5631da9_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_df15ef64-e6b4-4b2d-8dd1-7152988bebae_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c50fbd47-1603-4e40-a257-84bcda93441e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2356312b-b354-4c68-b582-d3281a44c4f2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_151dd44e-b392-4ad8-961a-c97af33ffe5d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of interest in joint venture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Interest in Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_5e24c923-0232-4f70-8156-4532248d3d05_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of borrowings and premiums paid</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_cb078c4b-32a7-4037-bf0d-aaa2545e9ebd_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_772488fb-a708-4df8-8280-4c3c634be05d_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_04769c1a-21df-41a6-af6d-0c850576367f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_79523b32-ba3b-4f62-908f-bb82a7cb1a76_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_98774827-e02e-440c-91d4-1dd1896b735c_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_8e4534ef-8cbf-414b-83da-80dc8666ad12_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_8b28cf98-446b-4dc4-841f-bfb9ff54d18a_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio" xlink:href="biib-20230930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio" xlink:to="lab_biib_StrategicInvestmentPortfolio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_7be7c254-e79f-46f5-9e95-af1a6b8244a1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_973d1858-0326-4628-b918-0c69d2e65dd5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9ef21374-eb01-4a84-9e48-fe22e4d39384_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fd8b0add-d30c-4078-8125-b7a1c73a38c8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_a3619ddb-cc2d-458a-9423-7225f14c2dc3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember_deac6674-2e67-4381-a27d-934260fa1308_terseLabel_en-US" xlink:label="lab_biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Idle Capacity Charges And Contractual Commitments</link:label>
    <link:label id="lab_biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember_label_en-US" xlink:label="lab_biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Idle Capacity Charges And Contractual Commitments [Member]</link:label>
    <link:label id="lab_biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember_documentation_en-US" xlink:label="lab_biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Idle Capacity Charges And Contractual Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember" xlink:href="biib-20230930.xsd#biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember" xlink:to="lab_biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_66ae7eba-0460-4df1-909a-3332bd79f987_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationAxis_267d7e82-6b34-44ef-be68-00dddf897d5f_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_label_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis" xlink:href="biib-20230930.xsd#biib_FacilityLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis" xlink:to="lab_biib_FacilityLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB054Member_62e9523d-c205-4d5a-9eef-0d65b1261961_terseLabel_en-US" xlink:label="lab_biib_BIIB054Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB054</link:label>
    <link:label id="lab_biib_BIIB054Member_label_en-US" xlink:label="lab_biib_BIIB054Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB054 [Member]</link:label>
    <link:label id="lab_biib_BIIB054Member_documentation_en-US" xlink:label="lab_biib_BIIB054Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB054</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB054Member" xlink:href="biib-20230930.xsd#biib_BIIB054Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB054Member" xlink:to="lab_biib_BIIB054Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_b0e4c736-bb28-477c-a0c9-0776362b1015_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_cea99eed-92f5-407e-8ffa-30c32d991ff8_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_dc1af381-be59-4620-8cdd-9cf797590016_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_eb02a992-1bbc-4070-bc7f-406efde32b21_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_510a2142-4efb-4b74-b0b5-98adb49a2678_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_28b31861-dea1-48d1-998b-51ffc2724f09_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_69af3a7a-debc-433c-9bd5-e0082bbe306d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of strategic investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SageTherapeuticsIncMember_d69b64ab-7707-4d1c-aa19-74f7d27eb579_terseLabel_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember" xlink:href="biib-20230930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SageTherapeuticsIncMember" xlink:to="lab_biib_SageTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_fba5e60e-0d9f-40fb-a6e7-f5b9a359fe30_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ed1c99f4-8691-4bdb-bc13-183503750f4d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings (loss) per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb8cc25e-3f01-4553-83ce-a9490248fb44_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_d5155b7c-ff66-451a-b1e4-311ee7b62793_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:href="biib-20230930.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:to="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_c737ae00-d5c7-44b1-b20f-7ac5789bc819_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis" xlink:href="biib-20230930.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetAxis" xlink:to="lab_biib_ResearchanddevelopmentassetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_3dc2d549-44a8-460d-9e7d-ef3a0b29050a_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5287f140-a11d-4b8e-b6b8-e25a1c3f0ed7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_30ae422a-17f9-4e95-ae12-07df4eec5a77_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_fda71341-c6cd-455d-a82b-3310fcfc01eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_f934508c-6aad-4664-bf89-a9d789baa4fe_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FAMPYRAMember_de21cad3-0b12-401e-b9a3-aea8a144bef9_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_label_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember" xlink:href="biib-20230930.xsd#biib_FAMPYRAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember" xlink:to="lab_biib_FAMPYRAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossOnContractTermination_921d7719-d671-40db-9165-bdc7e2946259_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on research and development contracts terminated with Eisai</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossOnContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination" xlink:to="lab_us-gaap_LossOnContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_fd029659-9860-4121-bf72-c0bf2ae9ec1d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b6986c5-3eb5-4340-8db9-b3dafb01edf8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7c291a1e-750e-4994-8935-8936b89d3bb7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income tax (benefit) expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_e2fa0ce7-9466-43f1-a90a-2a1b98eaf4f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_a26a94ef-30f8-4385-ac31-fa576cb8a708_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MosunetuzumabMember_0a059f79-0db5-4e03-a9fe-488d6f4ad03a_terseLabel_en-US" xlink:label="lab_biib_MosunetuzumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mosunetuzumab</link:label>
    <link:label id="lab_biib_MosunetuzumabMember_label_en-US" xlink:label="lab_biib_MosunetuzumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mosunetuzumab [Member]</link:label>
    <link:label id="lab_biib_MosunetuzumabMember_documentation_en-US" xlink:label="lab_biib_MosunetuzumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mosunetuzumab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MosunetuzumabMember" xlink:href="biib-20230930.xsd#biib_MosunetuzumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MosunetuzumabMember" xlink:to="lab_biib_MosunetuzumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_06d4ff2d-dfcd-47e5-a00d-7f284ba454c4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_8f92f68f-0e12-4752-8336-fb3991608ce1_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4e755a6a-3841-4770-8be4-d14b171ac823_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings (loss) per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_705b6c24-e7a1-4d10-9fb0-51e392dd457c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_30c036c6-d427-4458-9dfb-24dbb8979540_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:href="biib-20230930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_d5a70290-3d3b-4e48-adbb-bf93e1961621_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:href="biib-20230930.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_db05182c-a1ee-438b-af25-03a2aedfc64c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DebtInstrumentRedemptionRate_b75327df-57cc-4de0-8645-87d4a9e926af_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption rate</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionRate_label_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Rate</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionRate_documentation_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionRate" xlink:href="biib-20230930.xsd#biib_DebtInstrumentRedemptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentRedemptionRate" xlink:to="lab_biib_DebtInstrumentRedemptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_aba6e11a-dbb6-421d-bd1d-a12bc9a45138_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0f642312-944f-45c9-aab9-1bf7f9ba056e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_cd2aed08-bb51-499e-89bf-1b3b687ddecb_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_cf4a43db-5df5-471a-87f0-c8bb0995251b_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:href="biib-20230930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>biib-20230930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:067ab9af-2745-42fc-8c78-33206b6cc4f8,g:369ca811-9038-4e81-ba44-3ac1f044a248-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20230930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e0f288b9-c06f-4642-acf0-46da67404289" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_DocumentType_e0f288b9-c06f-4642-acf0-46da67404289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b9ed19a8-66fb-4be7-b7a1-c646dac0c612" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_DocumentQuarterlyReport_b9ed19a8-66fb-4be7-b7a1-c646dac0c612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_271bfe31-1fb2-4805-974b-62ba3e95c621" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_DocumentPeriodEndDate_271bfe31-1fb2-4805-974b-62ba3e95c621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ff320d33-194a-4191-b9d6-4270cd2e1afe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_DocumentTransitionReport_ff320d33-194a-4191-b9d6-4270cd2e1afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b644d3b5-6da9-434e-82e9-00cd8a024fd2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_EntityFileNumber_b644d3b5-6da9-434e-82e9-00cd8a024fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e26e6afe-821c-4b46-9cb1-403c5f6dd161" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_EntityRegistrantName_e26e6afe-821c-4b46-9cb1-403c5f6dd161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0e53c214-9ae5-4e6f-9af6-1850c2262fe6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_EntityCentralIndexKey_0e53c214-9ae5-4e6f-9af6-1850c2262fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4d71cc39-1e55-45d2-92c0-90480e15ddad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_CurrentFiscalYearEndDate_4d71cc39-1e55-45d2-92c0-90480e15ddad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_6d8b575e-2092-4a1e-80c9-a9ea2e16e9c8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_DocumentFiscalYearFocus_6d8b575e-2092-4a1e-80c9-a9ea2e16e9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6e8320bd-3d97-4828-822c-e0428a824566" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6e8320bd-3d97-4828-822c-e0428a824566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f754d87a-56f3-4ef2-a314-a31aaec6d554" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_AmendmentFlag_f754d87a-56f3-4ef2-a314-a31aaec6d554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1b60575e-b3bc-4554-a1d0-b67338534a4d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1b60575e-b3bc-4554-a1d0-b67338534a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_09b69ed7-684d-413b-af60-be7e07fefd13" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_EntityTaxIdentificationNumber_09b69ed7-684d-413b-af60-be7e07fefd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_708fa643-aca5-490b-b245-e04127610d28" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_EntityAddressAddressLine1_708fa643-aca5-490b-b245-e04127610d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_53b7d006-9b58-4970-9af3-5ffefdcb1c4a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_EntityAddressCityOrTown_53b7d006-9b58-4970-9af3-5ffefdcb1c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_57546172-9cc6-43d0-9a95-6cc1cde8848a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_EntityAddressStateOrProvince_57546172-9cc6-43d0-9a95-6cc1cde8848a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9113aa45-e41f-4aab-b427-9ef4fd4d9b51" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_EntityAddressPostalZipCode_9113aa45-e41f-4aab-b427-9ef4fd4d9b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f71a9a29-7e81-4890-9dd5-0131606f7e2d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_CityAreaCode_f71a9a29-7e81-4890-9dd5-0131606f7e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5dd37a5a-bb47-40f0-8c81-0398635b23d6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_LocalPhoneNumber_5dd37a5a-bb47-40f0-8c81-0398635b23d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_73ad1afe-27bd-4ad5-b654-d056bff6ba31" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_Security12bTitle_73ad1afe-27bd-4ad5-b654-d056bff6ba31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8a194457-9658-4194-8258-493b9500d1d9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_TradingSymbol_8a194457-9658-4194-8258-493b9500d1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9c116a43-b4c2-4ea3-baf0-d332c887d7f6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_SecurityExchangeName_9c116a43-b4c2-4ea3-baf0-d332c887d7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_542b5ae3-c83c-4758-afa0-28f2fdd9aa3a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_EntityCurrentReportingStatus_542b5ae3-c83c-4758-afa0-28f2fdd9aa3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1578b805-1fa8-4407-b78f-9596baecec00" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_EntityInteractiveDataCurrent_1578b805-1fa8-4407-b78f-9596baecec00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2e3851ab-bd6f-40c6-be92-ff5f7fb4ce23" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_EntityFilerCategory_2e3851ab-bd6f-40c6-be92-ff5f7fb4ce23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_12e97849-9435-488c-92f8-72c676c70741" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_EntitySmallBusiness_12e97849-9435-488c-92f8-72c676c70741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ef7874e3-74ef-409c-996a-1fd5c0623a51" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_EntityEmergingGrowthCompany_ef7874e3-74ef-409c-996a-1fd5c0623a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b908289e-dc06-4a9f-b790-99132efdfc1f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_EntityShellCompany_b908289e-dc06-4a9f-b790-99132efdfc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_54ccb599-c4a3-4aca-aa53-d5f3fb3ce38a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f0273945-f283-40ef-a692-1dddf6bcc14e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_54ccb599-c4a3-4aca-aa53-d5f3fb3ce38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20230930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_efb662b4-1672-4a4d-b74d-177515542851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6f14283c-887e-4e25-a4bc-822927471a22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_efb662b4-1672-4a4d-b74d-177515542851" xlink:to="loc_us-gaap_StatementTable_6f14283c-887e-4e25-a4bc-822927471a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_85828fe6-8e54-4ffc-8e4b-b8aa4fd74f24" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6f14283c-887e-4e25-a4bc-822927471a22" xlink:to="loc_srt_ProductOrServiceAxis_85828fe6-8e54-4ffc-8e4b-b8aa4fd74f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_db2596e9-ff08-4c66-8c62-680b8f6c3ed9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_85828fe6-8e54-4ffc-8e4b-b8aa4fd74f24" xlink:to="loc_srt_ProductsAndServicesDomain_db2596e9-ff08-4c66-8c62-680b8f6c3ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d6572867-32eb-40fe-97fe-10d5a66f941d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_db2596e9-ff08-4c66-8c62-680b8f6c3ed9" xlink:to="loc_us-gaap_ProductMember_d6572867-32eb-40fe-97fe-10d5a66f941d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_d50ffd47-a83e-4640-9dab-e5dfaaafc2a9" xlink:href="biib-20230930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_db2596e9-ff08-4c66-8c62-680b8f6c3ed9" xlink:to="loc_biib_LEQEMBICollaborationMember_d50ffd47-a83e-4640-9dab-e5dfaaafc2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_e475a869-1f4a-48a3-b4c5-f877a5ab6c26" xlink:href="biib-20230930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_db2596e9-ff08-4c66-8c62-680b8f6c3ed9" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_e475a869-1f4a-48a3-b4c5-f877a5ab6c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_5827d867-2dbf-4ac0-a39a-852e59354f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_db2596e9-ff08-4c66-8c62-680b8f6c3ed9" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_5827d867-2dbf-4ac0-a39a-852e59354f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6f14283c-887e-4e25-a4bc-822927471a22" xlink:to="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d8eac713-2f32-4665-8393-3411fd2a130d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_Revenues_d8eac713-2f32-4665-8393-3411fd2a130d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_188e2814-8b21-4c4c-b911-1776bc497d76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_188e2814-8b21-4c4c-b911-1776bc497d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ef1f3e2b-3c49-44ad-909f-9f3d455815db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ef1f3e2b-3c49-44ad-909f-9f3d455815db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_39cd8c19-4cb1-4dc5-98e1-b5601ebcb39e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_39cd8c19-4cb1-4dc5-98e1-b5601ebcb39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_eb3e87c0-bfed-4f83-9dc3-833ae69450d3" xlink:href="biib-20230930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_eb3e87c0-bfed-4f83-9dc3-833ae69450d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_13a1a35a-4ad5-4314-a087-521b2414943a" xlink:href="biib-20230930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_biib_Collaborationprofitlosssharing_13a1a35a-4ad5-4314-a087-521b2414943a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9889acc9-7692-43d1-9734-23557cac33ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9889acc9-7692-43d1-9734-23557cac33ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_81b45f09-6ffa-46e0-b7d4-68925d891e40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_us-gaap_RestructuringCharges_81b45f09-6ffa-46e0-b7d4-68925d891e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_682db4ac-9c85-41af-9b67-dbbec6222a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_682db4ac-9c85-41af-9b67-dbbec6222a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_f5e597c5-f66a-4caa-8e33-f5d15834ad6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_f5e597c5-f66a-4caa-8e33-f5d15834ad6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ba4415bd-a2d5-4a7e-a80c-8a24d6d95502" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_45bddd4b-0ad2-426c-bae2-d1226750bdff" xlink:to="loc_us-gaap_CostsAndExpenses_ba4415bd-a2d5-4a7e-a80c-8a24d6d95502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0284ffcd-f43e-45b1-8609-a0d7563efc03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0284ffcd-f43e-45b1-8609-a0d7563efc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_85c3de70-4da9-4aef-aacd-ecfee7eaa4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_85c3de70-4da9-4aef-aacd-ecfee7eaa4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_e4ce85d2-36a0-48d8-95ad-54f4c92cf1f4" xlink:href="biib-20230930.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_e4ce85d2-36a0-48d8-95ad-54f4c92cf1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d380b116-5bb0-46fd-842a-c7a7c37f7601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_ProfitLoss_d380b116-5bb0-46fd-842a-c7a7c37f7601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ac71e9f4-e729-423d-9ca0-6623062f41cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ac71e9f4-e729-423d-9ca0-6623062f41cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_051792a5-69ad-4476-becf-4d61e0759a08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_NetIncomeLoss_051792a5-69ad-4476-becf-4d61e0759a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2f255eb0-bf8f-4d71-a30e-1ccef55688bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_EarningsPerShareAbstract_2f255eb0-bf8f-4d71-a30e-1ccef55688bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_acbfac87-2582-49d6-a869-2a0ec16534b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2f255eb0-bf8f-4d71-a30e-1ccef55688bb" xlink:to="loc_us-gaap_EarningsPerShareBasic_acbfac87-2582-49d6-a869-2a0ec16534b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4c87f40b-8bf4-4ca4-8a09-ca9e5e628b54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2f255eb0-bf8f-4d71-a30e-1ccef55688bb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4c87f40b-8bf4-4ca4-8a09-ca9e5e628b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_08e031e4-a5ba-40de-9b1f-d117be85dfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbbb83dc-4123-4ea1-87b9-ae86d7e81636" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_08e031e4-a5ba-40de-9b1f-d117be85dfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_217598bf-caf1-4941-a040-2e7497d307d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_08e031e4-a5ba-40de-9b1f-d117be85dfcc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_217598bf-caf1-4941-a040-2e7497d307d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_768fa1ad-c68d-4585-ac60-61555f74effd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_08e031e4-a5ba-40de-9b1f-d117be85dfcc" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_768fa1ad-c68d-4585-ac60-61555f74effd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20230930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_de5979f3-0ada-494c-b84f-8d991fabd138" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d7d093cf-9582-4a88-bbd8-7714d02b87e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_de5979f3-0ada-494c-b84f-8d991fabd138" xlink:to="loc_us-gaap_NetIncomeLoss_d7d093cf-9582-4a88-bbd8-7714d02b87e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_81f3be1c-3f36-4d63-aee2-a21dc79e990c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_de5979f3-0ada-494c-b84f-8d991fabd138" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_81f3be1c-3f36-4d63-aee2-a21dc79e990c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9ba5c3f3-1968-4626-8d63-1eb93bb5e9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_81f3be1c-3f36-4d63-aee2-a21dc79e990c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9ba5c3f3-1968-4626-8d63-1eb93bb5e9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_34e82136-702b-4c85-9009-afddf6502de7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_81f3be1c-3f36-4d63-aee2-a21dc79e990c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_34e82136-702b-4c85-9009-afddf6502de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_13237dc8-a0e6-4091-ae99-0040aa0fca82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_81f3be1c-3f36-4d63-aee2-a21dc79e990c" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_13237dc8-a0e6-4091-ae99-0040aa0fca82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_8b1a20dd-31c8-4deb-8eb4-d69e7deae16d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_81f3be1c-3f36-4d63-aee2-a21dc79e990c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_8b1a20dd-31c8-4deb-8eb4-d69e7deae16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7aa88da2-6afe-47d1-974c-09a00141b84e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_81f3be1c-3f36-4d63-aee2-a21dc79e990c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7aa88da2-6afe-47d1-974c-09a00141b84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6cafdf6a-8270-425b-a9c3-2525ef0821b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_81f3be1c-3f36-4d63-aee2-a21dc79e990c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6cafdf6a-8270-425b-a9c3-2525ef0821b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e9ee1bea-4a87-4539-b4bf-dc020f3104b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_81f3be1c-3f36-4d63-aee2-a21dc79e990c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e9ee1bea-4a87-4539-b4bf-dc020f3104b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_12aef200-6f78-46ed-92e6-111a40da64ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_81f3be1c-3f36-4d63-aee2-a21dc79e990c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_12aef200-6f78-46ed-92e6-111a40da64ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_608e5af8-db5f-4542-bf1f-78aad32fdd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_81f3be1c-3f36-4d63-aee2-a21dc79e990c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_608e5af8-db5f-4542-bf1f-78aad32fdd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20230930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20230930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4a39f61c-0eee-4db1-a39b-24fd8a76937e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4485b864-a600-4a79-a01d-1c43bdcd1dad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4a39f61c-0eee-4db1-a39b-24fd8a76937e" xlink:to="loc_us-gaap_StatementTable_4485b864-a600-4a79-a01d-1c43bdcd1dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8cc17705-a142-44a9-84dc-77bbfd2d6523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4485b864-a600-4a79-a01d-1c43bdcd1dad" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8cc17705-a142-44a9-84dc-77bbfd2d6523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_58815559-f91a-4906-aae8-cddcdea8bcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8cc17705-a142-44a9-84dc-77bbfd2d6523" xlink:to="loc_us-gaap_RelatedPartyDomain_58815559-f91a-4906-aae8-cddcdea8bcbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_6ffacbbc-a563-4e7d-a5dd-59c883c1a584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_58815559-f91a-4906-aae8-cddcdea8bcbb" xlink:to="loc_us-gaap_NonrelatedPartyMember_6ffacbbc-a563-4e7d-a5dd-59c883c1a584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_2b04959e-d88d-48b9-a0b2-7c06fc6eae5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_58815559-f91a-4906-aae8-cddcdea8bcbb" xlink:to="loc_us-gaap_RelatedPartyMember_2b04959e-d88d-48b9-a0b2-7c06fc6eae5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_63b6c6ca-002f-41c7-957f-021a12c39f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4485b864-a600-4a79-a01d-1c43bdcd1dad" xlink:to="loc_us-gaap_StatementLineItems_63b6c6ca-002f-41c7-957f-021a12c39f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63b6c6ca-002f-41c7-957f-021a12c39f3e" xlink:to="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7b2c9bc7-60ea-468e-94c7-566d15b7fb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7b2c9bc7-60ea-468e-94c7-566d15b7fb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f06f526-32b4-492c-83dd-fd41ae303746" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b2c9bc7-60ea-468e-94c7-566d15b7fb0d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f06f526-32b4-492c-83dd-fd41ae303746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2b689dd7-789b-4a65-8e0f-6622ac134673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b2c9bc7-60ea-468e-94c7-566d15b7fb0d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2b689dd7-789b-4a65-8e0f-6622ac134673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e6459512-155c-4998-a3cd-1d0bacbbbe75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b2c9bc7-60ea-468e-94c7-566d15b7fb0d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e6459512-155c-4998-a3cd-1d0bacbbbe75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_008c6f97-0519-44bf-ac8f-7d9cdf24e2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b2c9bc7-60ea-468e-94c7-566d15b7fb0d" xlink:to="loc_us-gaap_InventoryNet_008c6f97-0519-44bf-ac8f-7d9cdf24e2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a8d66ee9-01d8-4149-9875-7a6e6a2a32c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b2c9bc7-60ea-468e-94c7-566d15b7fb0d" xlink:to="loc_us-gaap_OtherAssetsCurrent_a8d66ee9-01d8-4149-9875-7a6e6a2a32c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_27079327-5b40-4a6d-aa58-27cd21b792d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b2c9bc7-60ea-468e-94c7-566d15b7fb0d" xlink:to="loc_us-gaap_AssetsCurrent_27079327-5b40-4a6d-aa58-27cd21b792d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_92810b03-e8df-432f-b09c-d1a99bcd26e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_92810b03-e8df-432f-b09c-d1a99bcd26e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8fd2c613-73d3-4159-a6c8-5eea66c7ecac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8fd2c613-73d3-4159-a6c8-5eea66c7ecac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3d8549b9-2885-4ded-9b5a-255a857f3d44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3d8549b9-2885-4ded-9b5a-255a857f3d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f12d5d2f-4008-4457-9639-3c16b92b0adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f12d5d2f-4008-4457-9639-3c16b92b0adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_afd83321-d692-4f0b-b46b-958bb180c79f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_Goodwill_afd83321-d692-4f0b-b46b-958bb180c79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_7e580701-00cc-43c5-b79e-26f80fe834f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_7e580701-00cc-43c5-b79e-26f80fe834f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0bb0e2dc-2e96-4f82-8dbf-3daf89b5047e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0bb0e2dc-2e96-4f82-8dbf-3daf89b5047e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4497c724-1554-4912-984a-ec3243d36b28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1cef2f63-f06e-4db7-be7a-743e7e727396" xlink:to="loc_us-gaap_Assets_4497c724-1554-4912-984a-ec3243d36b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63b6c6ca-002f-41c7-957f-021a12c39f3e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_334c162a-579d-41ec-8ba6-4aa9bb4fa338" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_334c162a-579d-41ec-8ba6-4aa9bb4fa338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_6428e495-d30b-4071-8438-8cc1b742c509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_334c162a-579d-41ec-8ba6-4aa9bb4fa338" xlink:to="loc_us-gaap_NotesPayableCurrent_6428e495-d30b-4071-8438-8cc1b742c509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_683e6aa6-addf-4c81-ac6f-503de6ab56c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_334c162a-579d-41ec-8ba6-4aa9bb4fa338" xlink:to="loc_us-gaap_TaxesPayableCurrent_683e6aa6-addf-4c81-ac6f-503de6ab56c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2659ef2d-30ce-48e0-a64e-7435f0286c21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_334c162a-579d-41ec-8ba6-4aa9bb4fa338" xlink:to="loc_us-gaap_AccountsPayableCurrent_2659ef2d-30ce-48e0-a64e-7435f0286c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_52452b3c-8d71-41a4-ab7e-a6338929e2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_334c162a-579d-41ec-8ba6-4aa9bb4fa338" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_52452b3c-8d71-41a4-ab7e-a6338929e2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3e6c0ab6-ab8c-4a44-a598-cb2582d15f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_334c162a-579d-41ec-8ba6-4aa9bb4fa338" xlink:to="loc_us-gaap_LiabilitiesCurrent_3e6c0ab6-ab8c-4a44-a598-cb2582d15f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d0b12039-0610-4f92-b964-2455da895d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_LongTermDebt_d0b12039-0610-4f92-b964-2455da895d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d9337476-a7e5-4f7f-ac91-d73e72f24e80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d9337476-a7e5-4f7f-ac91-d73e72f24e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dbf8a93a-6ea1-4263-ac07-37b147ac00cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dbf8a93a-6ea1-4263-ac07-37b147ac00cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b680e0c9-36a7-439a-9757-c6d37bf91e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b680e0c9-36a7-439a-9757-c6d37bf91e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_06596b75-350f-46af-9cf5-da25a6a2e0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_Liabilities_06596b75-350f-46af-9cf5-da25a6a2e0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e4588c0b-1ddd-4565-98cc-d1d794199bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e4588c0b-1ddd-4565-98cc-d1d794199bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb358b7c-daef-4993-98e5-d3ffa6a3a002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb358b7c-daef-4993-98e5-d3ffa6a3a002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb358b7c-daef-4993-98e5-d3ffa6a3a002" xlink:to="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ff808dc5-9793-409f-9457-969ba91ae9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:to="loc_us-gaap_PreferredStockValue_ff808dc5-9793-409f-9457-969ba91ae9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7998e5c0-9cac-438f-a601-ed285b35bb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:to="loc_us-gaap_CommonStockValue_7998e5c0-9cac-438f-a601-ed285b35bb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8f2d9796-ec32-4ac9-b2e9-96cbacd3a9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8f2d9796-ec32-4ac9-b2e9-96cbacd3a9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_24a7307d-6423-43a9-8ea3-7fcf8d02322d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_24a7307d-6423-43a9-8ea3-7fcf8d02322d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ae88eb11-6440-4da4-bc80-f74e92cb66e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ae88eb11-6440-4da4-bc80-f74e92cb66e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_4e105f54-b0d7-4f85-8495-76bc3183871f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:to="loc_us-gaap_TreasuryStockValue_4e105f54-b0d7-4f85-8495-76bc3183871f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e58fa292-7eef-4689-a613-929ee4d75d21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80c94a6f-cfe8-4d10-8fd7-8086dcfd3233" xlink:to="loc_us-gaap_StockholdersEquity_e58fa292-7eef-4689-a613-929ee4d75d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a4cd69b6-2ec0-43a7-8e5d-19a0ec35beae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb358b7c-daef-4993-98e5-d3ffa6a3a002" xlink:to="loc_us-gaap_MinorityInterest_a4cd69b6-2ec0-43a7-8e5d-19a0ec35beae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8c5ac855-2209-4313-9980-f448da4b533f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb358b7c-daef-4993-98e5-d3ffa6a3a002" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8c5ac855-2209-4313-9980-f448da4b533f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_377db8a9-85a3-46fd-9f8c-3f17e1e842cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10b9e2d4-a587-4477-b749-655e161b503c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_377db8a9-85a3-46fd-9f8c-3f17e1e842cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20230930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4777effd-255e-4788-98fc-481e92eafe1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a8b8c1e9-a11e-416e-8aba-a164431c4345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4777effd-255e-4788-98fc-481e92eafe1a" xlink:to="loc_us-gaap_StatementTable_a8b8c1e9-a11e-416e-8aba-a164431c4345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64c4a6f6-cf3a-4a00-8f41-964e0bb57135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a8b8c1e9-a11e-416e-8aba-a164431c4345" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64c4a6f6-cf3a-4a00-8f41-964e0bb57135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ec9fc289-3534-439e-9502-1381ad7596d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64c4a6f6-cf3a-4a00-8f41-964e0bb57135" xlink:to="loc_us-gaap_RelatedPartyDomain_ec9fc289-3534-439e-9502-1381ad7596d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_e04ceb80-3fac-4efa-b77c-24a622b345ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ec9fc289-3534-439e-9502-1381ad7596d8" xlink:to="loc_us-gaap_NonrelatedPartyMember_e04ceb80-3fac-4efa-b77c-24a622b345ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_c235257c-1e01-412c-bc05-b537114abca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ec9fc289-3534-439e-9502-1381ad7596d8" xlink:to="loc_us-gaap_RelatedPartyMember_c235257c-1e01-412c-bc05-b537114abca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a8b8c1e9-a11e-416e-8aba-a164431c4345" xlink:to="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bdc13fc4-b5bc-4335-94be-2a5b6dbc4a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bdc13fc4-b5bc-4335-94be-2a5b6dbc4a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c59be703-238f-4507-9a33-b989fb817af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bdc13fc4-b5bc-4335-94be-2a5b6dbc4a6e" xlink:to="loc_us-gaap_ProfitLoss_c59be703-238f-4507-9a33-b989fb817af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bdc13fc4-b5bc-4335-94be-2a5b6dbc4a6e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9be70362-c346-4485-a14a-822bb98839c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9be70362-c346-4485-a14a-822bb98839c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_364388e7-3be5-4ac4-8a0e-2df10abf13c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_InventoryWriteDown_364388e7-3be5-4ac4-8a0e-2df10abf13c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_71afa0ce-72ea-4f7e-a91f-56ce71566e72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_ShareBasedCompensation_71afa0ce-72ea-4f7e-a91f-56ce71566e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e798fd3f-d696-4dc4-96a4-051b86f92743" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e798fd3f-d696-4dc4-96a4-051b86f92743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f14e7fa6-0fa6-44f9-8f3d-5fe26b5c1640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f14e7fa6-0fa6-44f9-8f3d-5fe26b5c1640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_c1d9d066-0295-4a88-a36d-d01b85f764ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_c1d9d066-0295-4a88-a36d-d01b85f764ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c85626cd-4966-4a32-94e7-a65e66da6a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c85626cd-4966-4a32-94e7-a65e66da6a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_e08f5ba1-0abc-4924-bfe3-aec69b9fd7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_e08f5ba1-0abc-4924-bfe3-aec69b9fd7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_66296515-72dc-45a4-b378-1978fc37031f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_66296515-72dc-45a4-b378-1978fc37031f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_a3264350-20d3-49a2-a632-9eb0e94487a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_a3264350-20d3-49a2-a632-9eb0e94487a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c375779a-55d8-4a8e-ab60-dbc5c68c813e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c375779a-55d8-4a8e-ab60-dbc5c68c813e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dc7ce171-6ffb-4bac-aef0-e0f8b246c212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c375779a-55d8-4a8e-ab60-dbc5c68c813e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dc7ce171-6ffb-4bac-aef0-e0f8b246c212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_594d9cb5-c217-41e4-940b-4445a3aa6eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c375779a-55d8-4a8e-ab60-dbc5c68c813e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_594d9cb5-c217-41e4-940b-4445a3aa6eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_eea98527-4b8e-4571-83bd-02393ff641e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c375779a-55d8-4a8e-ab60-dbc5c68c813e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_eea98527-4b8e-4571-83bd-02393ff641e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_c5d557d6-76ab-4089-aca9-aa4b6593390d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c375779a-55d8-4a8e-ab60-dbc5c68c813e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_c5d557d6-76ab-4089-aca9-aa4b6593390d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_7b89150f-c28a-44b3-9d4c-0b25bb4dcef0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c375779a-55d8-4a8e-ab60-dbc5c68c813e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_7b89150f-c28a-44b3-9d4c-0b25bb4dcef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bef81465-e4e3-43d6-adad-94e4fbd3ab2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9203c740-6f64-4f69-a145-3a1721acf075" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bef81465-e4e3-43d6-adad-94e4fbd3ab2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_57dfe379-cf59-4308-b9d2-88311f5b1e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_57dfe379-cf59-4308-b9d2-88311f5b1e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_b7e9ea2f-44c9-4655-b93a-44550a66ae47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_b7e9ea2f-44c9-4655-b93a-44550a66ae47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b3385eba-3012-4146-ac4f-273792c6f4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b3385eba-3012-4146-ac4f-273792c6f4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f3e73f11-cf8c-46f0-a96e-72793a4624fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f3e73f11-cf8c-46f0-a96e-72793a4624fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_51de111f-001e-45e1-a601-8693707cb752" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_51de111f-001e-45e1-a601-8693707cb752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1a2abac1-755d-46ba-9208-0284febf7a19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1a2abac1-755d-46ba-9208-0284febf7a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_92c63748-9d13-4b13-9737-237d01b7d7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_92c63748-9d13-4b13-9737-237d01b7d7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_05320392-4c74-4ba4-a851-af6d87f8fe09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_05320392-4c74-4ba4-a851-af6d87f8fe09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5d8f75d8-1f93-4533-9c8f-352b3c814d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55792222-29d0-4313-a50a-e4649d65c6b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5d8f75d8-1f93-4533-9c8f-352b3c814d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e6c92a02-a578-4b3b-9dc9-6b4dbb7ccf70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e6c92a02-a578-4b3b-9dc9-6b4dbb7ccf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_10ac1948-4f7c-42a2-8de9-2ecae1726fec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_10ac1948-4f7c-42a2-8de9-2ecae1726fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_008b3e48-2e0e-4d33-b041-bd313f730e59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_008b3e48-2e0e-4d33-b041-bd313f730e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_db0b810f-c1f7-434b-9164-02f2cfb1e989" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_db0b810f-c1f7-434b-9164-02f2cfb1e989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_ed5d81be-c69f-4f6a-880f-4992f08bfd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_ed5d81be-c69f-4f6a-880f-4992f08bfd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d2658763-99b3-4e87-b720-ce385af70f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d2658763-99b3-4e87-b720-ce385af70f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d9699de-4ce3-4b90-8c80-1abe28209c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69806d9b-31fb-4311-a40f-c8ff209ce7a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d9699de-4ce3-4b90-8c80-1abe28209c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_30f3ed03-d2ff-4720-924b-f80e4c85b211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_30f3ed03-d2ff-4720-924b-f80e4c85b211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8bceae88-bcaf-4b14-bd9f-66ed2838da99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8bceae88-bcaf-4b14-bd9f-66ed2838da99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8803defa-9d63-48d4-b8c5-8716ae628b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8803defa-9d63-48d4-b8c5-8716ae628b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fe7649e9-dbb2-4d86-aa20-94c3b0c002ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_849fcdc3-673a-4c44-a04f-39689a1fff9d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fe7649e9-dbb2-4d86-aa20-94c3b0c002ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20230930.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0e0a7ef0-b7fd-4e80-97b5-aa6bbddf4e20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_48cca863-b893-45cb-adef-20a2b6e1087b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0e0a7ef0-b7fd-4e80-97b5-aa6bbddf4e20" xlink:to="loc_us-gaap_StatementTable_48cca863-b893-45cb-adef-20a2b6e1087b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_63ab1dc0-4cd8-47f0-9093-d2c472751a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_48cca863-b893-45cb-adef-20a2b6e1087b" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_63ab1dc0-4cd8-47f0-9093-d2c472751a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_672c247d-5ece-41c6-a275-c2ad9d88f2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_63ab1dc0-4cd8-47f0-9093-d2c472751a07" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_672c247d-5ece-41c6-a275-c2ad9d88f2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_84e4f00e-3195-4693-9cf1-2231dfc4cb9a" xlink:href="biib-20230930.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_672c247d-5ece-41c6-a275-c2ad9d88f2ee" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_84e4f00e-3195-4693-9cf1-2231dfc4cb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_12780393-bb81-44b9-a235-01e3538b8a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_48cca863-b893-45cb-adef-20a2b6e1087b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_12780393-bb81-44b9-a235-01e3538b8a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_12780393-bb81-44b9-a235-01e3538b8a9e" xlink:to="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_e7560486-a00b-4f24-9145-7629d7af96aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:to="loc_us-gaap_PreferredStockMember_e7560486-a00b-4f24-9145-7629d7af96aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_838fa61c-bafa-47b5-ae9a-936184e26e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:to="loc_us-gaap_CommonStockMember_838fa61c-bafa-47b5-ae9a-936184e26e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8635cb97-b767-49b6-92db-ea00738cf03b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8635cb97-b767-49b6-92db-ea00738cf03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a1fd09e7-4081-4a38-ae5c-bc909d55e2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a1fd09e7-4081-4a38-ae5c-bc909d55e2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_381c6fe9-b41e-4859-8457-36590410ea8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:to="loc_us-gaap_RetainedEarningsMember_381c6fe9-b41e-4859-8457-36590410ea8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_129407f7-b641-4049-b85e-687c0448b90c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:to="loc_us-gaap_TreasuryStockCommonMember_129407f7-b641-4049-b85e-687c0448b90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_c8bb9165-e09e-4934-927c-b5f4ea27f3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:to="loc_us-gaap_ParentMember_c8bb9165-e09e-4934-927c-b5f4ea27f3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_22e4331d-71e4-4f0b-8a6c-50c186f5b518" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_54df57a8-05a8-4290-9246-dbcb548a4651" xlink:to="loc_us-gaap_NoncontrollingInterestMember_22e4331d-71e4-4f0b-8a6c-50c186f5b518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_48cca863-b893-45cb-adef-20a2b6e1087b" xlink:to="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e8795dc2-18a3-4e90-a44d-7dc268916b63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e8795dc2-18a3-4e90-a44d-7dc268916b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f722ac2e-f351-4fdd-9455-969bcb2f11d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f722ac2e-f351-4fdd-9455-969bcb2f11d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_57ba1bd1-87e5-4b2b-a315-c305cd81f847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_TreasuryStockCommonShares_57ba1bd1-87e5-4b2b-a315-c305cd81f847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dadb14c1-0ac7-48e5-a55d-c03f10d6cf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_ProfitLoss_dadb14c1-0ac7-48e5-a55d-c03f10d6cf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6d29d6a9-aa0b-4ac8-b147-decf80b11281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6d29d6a9-aa0b-4ac8-b147-decf80b11281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution_cbe0c427-b5ef-47a6-a8ca-b30a0a64b8bb" xlink:href="biib-20230930.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_biib_NoncontrollingInterestCapitalContribution_cbe0c427-b5ef-47a6-a8ca-b30a0a64b8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_6e18bc3e-d7bd-4059-9a6a-2c449879e461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_6e18bc3e-d7bd-4059-9a6a-2c449879e461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_345c42ca-e1d1-4f7d-b749-c7a7ade6de70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_345c42ca-e1d1-4f7d-b749-c7a7ade6de70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_db99c6d8-9555-4ebb-80d3-75d4009fbdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_db99c6d8-9555-4ebb-80d3-75d4009fbdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_dd87cd23-aa38-4b70-a705-bb222487d89d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_dd87cd23-aa38-4b70-a705-bb222487d89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0b529862-b927-4540-ba40-7e038260d7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0b529862-b927-4540-ba40-7e038260d7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_25c6adf7-8970-401a-bff3-ea51aa11db3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_25c6adf7-8970-401a-bff3-ea51aa11db3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3e97db7-99a1-41f1-8323-40b9693eba77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3e97db7-99a1-41f1-8323-40b9693eba77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_da2e728d-d720-4b01-8d8d-79af75a09359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_da2e728d-d720-4b01-8d8d-79af75a09359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_97341052-663e-4d43-b514-a9b88622e7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_97341052-663e-4d43-b514-a9b88622e7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_bf9261b4-bd55-444b-a0d6-8bb946131a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_StockholdersEquityOther_bf9261b4-bd55-444b-a0d6-8bb946131a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e9442f2-fd07-4c6f-a101-1a4e34bab155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e9442f2-fd07-4c6f-a101-1a4e34bab155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_841887c4-7a6c-4e7b-9907-5ccc8c2cb1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_841887c4-7a6c-4e7b-9907-5ccc8c2cb1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_b1e7b6ba-3130-4d96-b58f-23de1c60f581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b5757f64-305f-4ff0-8959-32419662678c" xlink:to="loc_us-gaap_TreasuryStockCommonShares_b1e7b6ba-3130-4d96-b58f-23de1c60f581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20230930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e046eacc-8201-4323-9117-c11131692f53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9e54c43e-d878-4680-b47f-809e01ce4d88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e046eacc-8201-4323-9117-c11131692f53" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9e54c43e-d878-4680-b47f-809e01ce4d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:type="simple" xlink:href="biib-20230930.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_758b7fb8-27b9-43b7-8179-b10acd95dbdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_d258fdca-9f96-47ae-a16c-f95fa420bd34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_758b7fb8-27b9-43b7-8179-b10acd95dbdc" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_d258fdca-9f96-47ae-a16c-f95fa420bd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Dispositions" xlink:type="simple" xlink:href="biib-20230930.xsd#Dispositions"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Dispositions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract_c239229b-91c4-4e5b-82d1-498bf6213ca5" xlink:href="biib-20230930.xsd#biib_DivestituresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_6a0e89e7-f169-44ea-81a3-b5c9510f7152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_c239229b-91c4-4e5b-82d1-498bf6213ca5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_6a0e89e7-f169-44ea-81a3-b5c9510f7152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives" xlink:type="simple" xlink:href="biib-20230930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiatives"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_df84d512-cc9b-48e6-9693-420509dff393" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_20af560b-ccc7-4fdf-88c6-2ec2bc63cc04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_df84d512-cc9b-48e6-9693-420509dff393" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_20af560b-ccc7-4fdf-88c6-2ec2bc63cc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_32acd15b-c5da-4515-941d-f7739380b708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_df84d512-cc9b-48e6-9693-420509dff393" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_32acd15b-c5da-4515-941d-f7739380b708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20230930.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f7ec0b97-d856-4d10-9e36-3d70dbd38e02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_ec69a751-f786-4358-bcb2-0637feefe3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f7ec0b97-d856-4d10-9e36-3d70dbd38e02" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_ec69a751-f786-4358-bcb2-0637feefe3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20230930.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_acd300a4-3e85-4eb4-ab04-c85bbf347dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_ccb59144-06fa-4682-a537-20db66fd073d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_acd300a4-3e85-4eb4-ab04-c85bbf347dd5" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_ccb59144-06fa-4682-a537-20db66fd073d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20230930.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b4f06adc-538b-4b5f-bc68-53a7628b968b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8255d181-1f5c-44d2-bd13-8a0e69d596ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b4f06adc-538b-4b5f-bc68-53a7628b968b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8255d181-1f5c-44d2-bd13-8a0e69d596ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20230930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e7f0d4f9-1da6-4e5a-9737-dc95520c4cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_8f3397e8-1b36-47c2-82ca-82986a280623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e7f0d4f9-1da6-4e5a-9737-dc95520c4cbc" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_8f3397e8-1b36-47c2-82ca-82986a280623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20230930.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f0923a0d-b33c-4de7-a0dd-69a5f86a12b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_5fe65b7f-255a-4e74-a686-23ffa35c4f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f0923a0d-b33c-4de7-a0dd-69a5f86a12b2" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_5fe65b7f-255a-4e74-a686-23ffa35c4f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20230930.xsd#DerivativeInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_77bcc77a-a442-451d-8155-954d23e71f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_d7928b51-5727-4a14-bab9-99891699a543" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_77bcc77a-a442-451d-8155-954d23e71f5c" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_d7928b51-5727-4a14-bab9-99891699a543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20230930.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c0e5e1bf-38d5-4c9e-8f81-98ea2fc8eee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_33ac25cb-8c00-4aab-8e63-8795841724b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c0e5e1bf-38d5-4c9e-8f81-98ea2fc8eee4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_33ac25cb-8c00-4aab-8e63-8795841724b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Leases" xlink:type="simple" xlink:href="biib-20230930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5b18369d-6748-4120-9d67-c62f7f59d544" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_2a757009-3faa-4de1-b273-42ddb3142ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5b18369d-6748-4120-9d67-c62f7f59d544" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_2a757009-3faa-4de1-b273-42ddb3142ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:type="simple" xlink:href="biib-20230930.xsd#Indebtedness"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0c9991b7-fe41-48c4-a198-de3a795cf0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_81c8479d-de4d-41fd-b740-3adcaf83f7be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0c9991b7-fe41-48c4-a198-de3a795cf0cb" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_81c8479d-de4d-41fd-b740-3adcaf83f7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20230930.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a299f2dc-0f45-454b-ae4d-adb86ada7079" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_914510c7-0052-4714-8c53-f2413846a0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a299f2dc-0f45-454b-ae4d-adb86ada7079" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_914510c7-0052-4714-8c53-f2413846a0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20230930.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f110d0bd-2e26-4213-b51e-57436993bcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1159cfcc-406f-48ff-b4c5-8cbc5c3dc907" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f110d0bd-2e26-4213-b51e-57436993bcd2" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1159cfcc-406f-48ff-b4c5-8cbc5c3dc907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="simple" xlink:href="biib-20230930.xsd#SharebasedPayments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a38f439-9e07-4264-8999-0a0c79acfeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2f8b00ca-113f-4a72-8c89-e41881a7a349" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a38f439-9e07-4264-8999-0a0c79acfeeb" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2f8b00ca-113f-4a72-8c89-e41881a7a349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20230930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_22574f19-f68d-4e61-a46f-b70eb6a0fe0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_b2572196-21fa-46a9-a66e-ebdc02502c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_22574f19-f68d-4e61-a46f-b70eb6a0fe0d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_b2572196-21fa-46a9-a66e-ebdc02502c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20230930.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_141bc818-bdf0-4fe3-81f5-c008cdee6ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_956b7138-b63e-4c1d-a499-0dd0ada6297e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_141bc818-bdf0-4fe3-81f5-c008cdee6ed4" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_956b7138-b63e-4c1d-a499-0dd0ada6297e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationships"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7b64b8b9-1d5d-4d03-ba75-3408b70c0b98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d00d9a8d-8a26-427f-ad71-248eb235e27a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7b64b8b9-1d5d-4d03-ba75-3408b70c0b98" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d00d9a8d-8a26-427f-ad71-248eb235e27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20230930.xsd#InvestmentsinVariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_5dc09e8c-d4a9-470a-8962-4eab9985ef3f" xlink:href="biib-20230930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_222e4024-bce6-42a5-ad92-05c8454bd5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_5dc09e8c-d4a9-470a-8962-4eab9985ef3f" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_222e4024-bce6-42a5-ad92-05c8454bd5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20230930.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_8d866f8d-01c5-4010-abfa-52ce76cce28e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_6566b13c-aa46-43f0-925f-5f8c4e60a3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_8d866f8d-01c5-4010-abfa-52ce76cce28e" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_6566b13c-aa46-43f0-925f-5f8c4e60a3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20230930.xsd#SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a2d1a5f6-4aa3-4a52-bcc6-48802fa0038a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_82e80667-1c68-4f0e-8979-34ebdf888695" xlink:href="biib-20230930.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a2d1a5f6-4aa3-4a52-bcc6-48802fa0038a" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_82e80667-1c68-4f0e-8979-34ebdf888695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c225ea80-8afc-4103-a4c6-6cdfbb061947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a2d1a5f6-4aa3-4a52-bcc6-48802fa0038a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c225ea80-8afc-4103-a4c6-6cdfbb061947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_97648f1e-442b-4c4f-90f6-d817085a6274" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a2d1a5f6-4aa3-4a52-bcc6-48802fa0038a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_97648f1e-442b-4c4f-90f6-d817085a6274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_e04d5707-9433-4302-b870-81c9457c054a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a2d1a5f6-4aa3-4a52-bcc6-48802fa0038a" xlink:to="loc_us-gaap_UseOfEstimates_e04d5707-9433-4302-b870-81c9457c054a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8a7bc2aa-abaa-4174-a8eb-ef0cd9fa2285" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a2d1a5f6-4aa3-4a52-bcc6-48802fa0038a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8a7bc2aa-abaa-4174-a8eb-ef0cd9fa2285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="biib-20230930.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5d0045c4-4571-4f81-87d4-75700374198a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_ac633b02-ca12-43a9-a00d-e372a3846a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5d0045c4-4571-4f81-87d4-75700374198a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_ac633b02-ca12-43a9-a00d-e372a3846a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" xlink:type="simple" xlink:href="biib-20230930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5c04e1ff-e6e7-4510-a277-becca0fe63c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_3daf53d6-ebce-412a-8d99-9fc62bb7696f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5c04e1ff-e6e7-4510-a277-becca0fe63c5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_3daf53d6-ebce-412a-8d99-9fc62bb7696f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_0b67dc96-8a76-4856-ac62-929a47a3062b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5c04e1ff-e6e7-4510-a277-becca0fe63c5" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_0b67dc96-8a76-4856-ac62-929a47a3062b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20230930.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6cf6e63-9e9b-4816-aa1c-b2bfe08d2e11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_75b7503f-12bd-4a3c-a22f-fa85726bf55e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6cf6e63-9e9b-4816-aa1c-b2bfe08d2e11" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_75b7503f-12bd-4a3c-a22f-fa85726bf55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_4bb30236-8a76-4245-81a4-354c841b2b24" xlink:href="biib-20230930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6cf6e63-9e9b-4816-aa1c-b2bfe08d2e11" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_4bb30236-8a76-4245-81a4-354c841b2b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_ecbe5078-eaf3-4db3-a3f8-17520742d134" xlink:href="biib-20230930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6cf6e63-9e9b-4816-aa1c-b2bfe08d2e11" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_ecbe5078-eaf3-4db3-a3f8-17520742d134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_d79c96ea-87a6-4cbf-82af-417b67d20a77" xlink:href="biib-20230930.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6cf6e63-9e9b-4816-aa1c-b2bfe08d2e11" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_d79c96ea-87a6-4cbf-82af-417b67d20a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock_5b22aa64-a772-4f72-a32e-ba0e0fe4549b" xlink:href="biib-20230930.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6cf6e63-9e9b-4816-aa1c-b2bfe08d2e11" xlink:to="loc_biib_OtherrevenuesTableTextBlock_5b22aa64-a772-4f72-a32e-ba0e0fe4549b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20230930.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8aa02d48-3a00-46ad-9859-40d4965983c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ea1367ee-c039-449a-a345-2af7b602a2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8aa02d48-3a00-46ad-9859-40d4965983c5" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ea1367ee-c039-449a-a345-2af7b602a2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20230930.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_45bd4ff7-5148-4985-ba8a-1a7fc68f8d19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_3a5dc5a1-7d20-4aa3-8e64-55a737550452" xlink:href="biib-20230930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_45bd4ff7-5148-4985-ba8a-1a7fc68f8d19" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_3a5dc5a1-7d20-4aa3-8e64-55a737550452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_76b174d5-357b-4c1e-a3f4-1affd4371022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_45bd4ff7-5148-4985-ba8a-1a7fc68f8d19" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_76b174d5-357b-4c1e-a3f4-1affd4371022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_c3a5f8a2-2db6-4f12-b041-d9fb7721ef34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_45bd4ff7-5148-4985-ba8a-1a7fc68f8d19" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_c3a5f8a2-2db6-4f12-b041-d9fb7721ef34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20230930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7be990cc-6a44-44f2-aa78-ad7fd9a81c17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e4f11310-367e-4ebe-82c3-683e141dab1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7be990cc-6a44-44f2-aa78-ad7fd9a81c17" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e4f11310-367e-4ebe-82c3-683e141dab1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8bc7339f-6395-4fcb-87f6-eb4f1d089474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7be990cc-6a44-44f2-aa78-ad7fd9a81c17" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8bc7339f-6395-4fcb-87f6-eb4f1d089474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_875db938-2e66-4602-a010-219ad1f46324" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7be990cc-6a44-44f2-aa78-ad7fd9a81c17" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_875db938-2e66-4602-a010-219ad1f46324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20230930.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_78040c24-4a98-4ee3-8a07-8d7bb64bdbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_dd9935e1-7f24-45d6-827f-a2428860f9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_78040c24-4a98-4ee3-8a07-8d7bb64bdbc9" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_dd9935e1-7f24-45d6-827f-a2428860f9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_45dce97c-1d99-4a3d-bef1-41660d1441c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_78040c24-4a98-4ee3-8a07-8d7bb64bdbc9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_45dce97c-1d99-4a3d-bef1-41660d1441c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e7800145-391c-434d-93b1-1f266f0ad9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_78040c24-4a98-4ee3-8a07-8d7bb64bdbc9" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e7800145-391c-434d-93b1-1f266f0ad9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_6d79d188-ad89-40d3-89a5-6e4bb2e73365" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_78040c24-4a98-4ee3-8a07-8d7bb64bdbc9" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_6d79d188-ad89-40d3-89a5-6e4bb2e73365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20230930.xsd#DerivativeInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d5f25dfe-9d9a-47c1-ae3d-a8bd6c35215d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_474f0da6-2cd5-444a-bb72-a440ddc6e84b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d5f25dfe-9d9a-47c1-ae3d-a8bd6c35215d" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_474f0da6-2cd5-444a-bb72-a440ddc6e84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_f0ede1f4-8eff-4466-b0a7-6773148f4bad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d5f25dfe-9d9a-47c1-ae3d-a8bd6c35215d" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_f0ede1f4-8eff-4466-b0a7-6773148f4bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8d4a0236-454e-430c-a031-db34b628c02f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d5f25dfe-9d9a-47c1-ae3d-a8bd6c35215d" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8d4a0236-454e-430c-a031-db34b628c02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_e5165908-a3ec-45f7-9af3-57777e63b960" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d5f25dfe-9d9a-47c1-ae3d-a8bd6c35215d" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_e5165908-a3ec-45f7-9af3-57777e63b960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_9eb79a6b-1e09-438b-9377-0c2185a27f28" xlink:href="biib-20230930.xsd#biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d5f25dfe-9d9a-47c1-ae3d-a8bd6c35215d" xlink:to="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_9eb79a6b-1e09-438b-9377-0c2185a27f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="biib-20230930.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_95e2e9e3-91d7-4145-84af-5d1a2b97b518" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_174b96ed-c43c-4320-b339-297e6489954e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_95e2e9e3-91d7-4145-84af-5d1a2b97b518" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_174b96ed-c43c-4320-b339-297e6489954e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_d4eae65a-57c7-4231-b8b4-7efeb4bb5101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_95e2e9e3-91d7-4145-84af-5d1a2b97b518" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_d4eae65a-57c7-4231-b8b4-7efeb4bb5101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20230930.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_700e8a05-87f7-4931-98dc-af5f02ab26be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_51c287dc-852b-494d-9259-e33ec31c4e90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_700e8a05-87f7-4931-98dc-af5f02ab26be" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_51c287dc-852b-494d-9259-e33ec31c4e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20230930.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54ba9518-7baf-43f3-8e4c-746b1a99d238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f027cbb1-9095-474f-8f14-a2d6d510e2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54ba9518-7baf-43f3-8e4c-746b1a99d238" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f027cbb1-9095-474f-8f14-a2d6d510e2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_69794dba-165e-4a1d-bc29-38bcded55819" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54ba9518-7baf-43f3-8e4c-746b1a99d238" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_69794dba-165e-4a1d-bc29-38bcded55819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20230930.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ade2eb77-3735-4684-af11-63d407753bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1360bdcd-41cd-4570-bdee-0cc8dff436f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ade2eb77-3735-4684-af11-63d407753bd1" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1360bdcd-41cd-4570-bdee-0cc8dff436f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20230930.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c9f1772-86ab-467d-b897-19b884bc3568" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3a04a364-d203-4acd-8187-8cc8ebbe1d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c9f1772-86ab-467d-b897-19b884bc3568" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3a04a364-d203-4acd-8187-8cc8ebbe1d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_b40ca8f0-1392-432a-be8d-5d4b79ff67b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c9f1772-86ab-467d-b897-19b884bc3568" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_b40ca8f0-1392-432a-be8d-5d4b79ff67b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6da4eff7-e3c9-475a-a7ca-4abb8dbef975" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c9f1772-86ab-467d-b897-19b884bc3568" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6da4eff7-e3c9-475a-a7ca-4abb8dbef975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c86c35a8-cf97-4316-bceb-3f4eb5a035d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_12bf7531-1aee-4d51-944e-53c962c4af32" xlink:href="biib-20230930.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c86c35a8-cf97-4316-bceb-3f4eb5a035d7" xlink:to="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_12bf7531-1aee-4d51-944e-53c962c4af32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock_38aa345e-c206-4e54-aca0-386f86bb52ce" xlink:href="biib-20230930.xsd#biib_PretaxProfitSharingFormulaTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c86c35a8-cf97-4316-bceb-3f4eb5a035d7" xlink:to="loc_biib_PretaxProfitSharingFormulaTableTextBlock_38aa345e-c206-4e54-aca0-386f86bb52ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_a53b98d2-6204-4383-bf5e-9424dbb191c1" xlink:href="biib-20230930.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c86c35a8-cf97-4316-bceb-3f4eb5a035d7" xlink:to="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_a53b98d2-6204-4383-bf5e-9424dbb191c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_f6d4ec36-f985-4b26-9f1d-b8ad56041f28" xlink:href="biib-20230930.xsd#biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c86c35a8-cf97-4316-bceb-3f4eb5a035d7" xlink:to="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_f6d4ec36-f985-4b26-9f1d-b8ad56041f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_4eb55bb1-ad57-4eaf-b71b-421541dde7c8" xlink:href="biib-20230930.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c86c35a8-cf97-4316-bceb-3f4eb5a035d7" xlink:to="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_4eb55bb1-ad57-4eaf-b71b-421541dde7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_be0634e3-3202-4840-b5f7-83f41f8efc19" xlink:href="biib-20230930.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c86c35a8-cf97-4316-bceb-3f4eb5a035d7" xlink:to="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_be0634e3-3202-4840-b5f7-83f41f8efc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_69857228-8fe8-4586-a5b2-eddc66e69282" xlink:href="biib-20230930.xsd#biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c86c35a8-cf97-4316-bceb-3f4eb5a035d7" xlink:to="loc_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_69857228-8fe8-4586-a5b2-eddc66e69282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f1057503-6fea-4fc2-bcc6-4eb6d1b59596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_d31c0dcf-753f-4714-83f9-298c2aa8a038" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f1057503-6fea-4fc2-bcc6-4eb6d1b59596" xlink:to="loc_us-gaap_NumberOfReportableSegments_d31c0dcf-753f-4714-83f9-298c2aa8a038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary_d9acaed2-1a3f-4e4a-9c75-7c24bc2e9a7e" xlink:href="biib-20230930.xsd#biib_InterestInSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f1057503-6fea-4fc2-bcc6-4eb6d1b59596" xlink:to="loc_biib_InterestInSubsidiary_d9acaed2-1a3f-4e4a-9c75-7c24bc2e9a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="simple" xlink:href="biib-20230930.xsd#AcquisitionsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_a1c51cad-3520-457b-a781-04c736d532ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26b0dbd9-6d0b-4b24-aadc-8cf4114e06fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a1c51cad-3520-457b-a781-04c736d532ba" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26b0dbd9-6d0b-4b24-aadc-8cf4114e06fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_90881ebb-b087-4cc0-9e6f-5f90b8d6a1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26b0dbd9-6d0b-4b24-aadc-8cf4114e06fc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_90881ebb-b087-4cc0-9e6f-5f90b8d6a1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2f62006-b719-4f63-9c23-2c5f47095f35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_90881ebb-b087-4cc0-9e6f-5f90b8d6a1a4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2f62006-b719-4f63-9c23-2c5f47095f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_86718d36-69bb-4ed6-bee7-ab7453bf0c53" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2f62006-b719-4f63-9c23-2c5f47095f35" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_86718d36-69bb-4ed6-bee7-ab7453bf0c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b5e2a326-3c44-4acd-b344-c17c8a0b143f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26b0dbd9-6d0b-4b24-aadc-8cf4114e06fc" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b5e2a326-3c44-4acd-b344-c17c8a0b143f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7d36ee84-b52f-4bb3-929a-b004b6682973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b5e2a326-3c44-4acd-b344-c17c8a0b143f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7d36ee84-b52f-4bb3-929a-b004b6682973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4afbaef1-4dfa-4ea8-9d11-1df4ccff5e68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7d36ee84-b52f-4bb3-929a-b004b6682973" xlink:to="loc_us-gaap_SubsequentEventMember_4afbaef1-4dfa-4ea8-9d11-1df4ccff5e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_210f687c-2b7a-49dc-83b3-43867af8cd01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26b0dbd9-6d0b-4b24-aadc-8cf4114e06fc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_210f687c-2b7a-49dc-83b3-43867af8cd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ee4546d1-f003-4ef0-b2fb-1a9c7672362b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_210f687c-2b7a-49dc-83b3-43867af8cd01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ee4546d1-f003-4ef0-b2fb-1a9c7672362b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_7e625a12-099a-4833-98fe-91a0ef36b51b" xlink:href="biib-20230930.xsd#biib_SKYCLARYSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ee4546d1-f003-4ef0-b2fb-1a9c7672362b" xlink:to="loc_biib_SKYCLARYSMember_7e625a12-099a-4833-98fe-91a0ef36b51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_4239c6d7-6db9-4830-9d09-7bd5b13dbfe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ee4546d1-f003-4ef0-b2fb-1a9c7672362b" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_4239c6d7-6db9-4830-9d09-7bd5b13dbfe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_ed290d25-6bc1-40d9-9072-a22d21e45979" xlink:href="biib-20230930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ee4546d1-f003-4ef0-b2fb-1a9c7672362b" xlink:to="loc_biib_PriorityReviewVoucherMember_ed290d25-6bc1-40d9-9072-a22d21e45979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember_bf8b4533-8377-42e4-b645-b0cb17b9708d" xlink:href="biib-20230930.xsd#biib_OtherClinicalProgramsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ee4546d1-f003-4ef0-b2fb-1a9c7672362b" xlink:to="loc_biib_OtherClinicalProgramsMember_bf8b4533-8377-42e4-b645-b0cb17b9708d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fcf2a748-41fa-42d3-97bb-f493cce81a04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26b0dbd9-6d0b-4b24-aadc-8cf4114e06fc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fcf2a748-41fa-42d3-97bb-f493cce81a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d6f475dc-a82e-47b9-80e0-045acfe0e80e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fcf2a748-41fa-42d3-97bb-f493cce81a04" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d6f475dc-a82e-47b9-80e0-045acfe0e80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bb547114-f6cc-4707-9ebf-8a2068329b29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d6f475dc-a82e-47b9-80e0-045acfe0e80e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bb547114-f6cc-4707-9ebf-8a2068329b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d3d7f712-d909-4fb9-bf9d-78c68e94cb7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26b0dbd9-6d0b-4b24-aadc-8cf4114e06fc" xlink:to="loc_srt_StatementScenarioAxis_d3d7f712-d909-4fb9-bf9d-78c68e94cb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_17825170-c7f4-4d7a-be91-15ccce7fab7d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_d3d7f712-d909-4fb9-bf9d-78c68e94cb7c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_17825170-c7f4-4d7a-be91-15ccce7fab7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b211017e-67bc-4c8f-82e0-74e6f93cf73b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_17825170-c7f4-4d7a-be91-15ccce7fab7d" xlink:to="loc_srt_ScenarioForecastMember_b211017e-67bc-4c8f-82e0-74e6f93cf73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_26b0dbd9-6d0b-4b24-aadc-8cf4114e06fc" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_7077a59f-9985-4fa6-9885-3f76ef955b76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_7077a59f-9985-4fa6-9885-3f76ef955b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2d0a1771-1d71-4606-969f-bbf64471af4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2d0a1771-1d71-4606-969f-bbf64471af4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_cc6aaa05-7419-4f19-b5f0-c95859e181f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_cc6aaa05-7419-4f19-b5f0-c95859e181f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_fd4aa74c-ed17-4043-8fe6-041aea3596eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_fd4aa74c-ed17-4043-8fe6-041aea3596eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_aae9644c-dbcc-49ff-8954-6e7911d8ba91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_aae9644c-dbcc-49ff-8954-6e7911d8ba91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b28610ef-599d-4803-ab4f-2dccf02b7c11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b28610ef-599d-4803-ab4f-2dccf02b7c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_670c941b-6c76-438e-9cdb-616b4192220e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_OperatingExpenses_670c941b-6c76-438e-9cdb-616b4192220e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_efbf169f-0c95-4916-b435-f5ddd10727a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_efbf169f-0c95-4916-b435-f5ddd10727a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9270604e-5cf6-48c8-805c-6376493250bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9270604e-5cf6-48c8-805c-6376493250bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f7e0a052-9e74-4768-bd9a-b2b39287bfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f7e0a052-9e74-4768-bd9a-b2b39287bfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_4164a710-5497-41a4-a082-d225b8442418" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_4164a710-5497-41a4-a082-d225b8442418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_934693da-962f-469a-8685-c6ea57cbebd8" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_934693da-962f-469a-8685-c6ea57cbebd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ac757c28-f114-4edb-8d56-b91eac01425e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ac757c28-f114-4edb-8d56-b91eac01425e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_38095bc6-7e44-41e7-9432-c5434dc08fc1" xlink:href="biib-20230930.xsd#biib_OperatingLeaseArea"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_biib_OperatingLeaseArea_38095bc6-7e44-41e7-9432-c5434dc08fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5c15d924-3b2d-49d5-8b4a-0732a9c1fd16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5c15d924-3b2d-49d5-8b4a-0732a9c1fd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_8bce8b3c-51fb-406b-8d52-344b92de9c17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_8bce8b3c-51fb-406b-8d52-344b92de9c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_14a6a25d-c23e-454f-8399-6da7795f5dad" xlink:href="biib-20230930.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_14a6a25d-c23e-454f-8399-6da7795f5dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_6e25fcdd-cf27-46ce-a3e3-6aa2cc7a32cf" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod_6e25fcdd-cf27-46ce-a3e3-6aa2cc7a32cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_43fb2d88-3ae0-45fd-a741-8db98f733f22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_us-gaap_Goodwill_43fb2d88-3ae0-45fd-a741-8db98f733f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_5d15f448-4d92-4f7f-af46-774f6e42b31e" xlink:href="biib-20230930.xsd#biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards_5d15f448-4d92-4f7f-af46-774f6e42b31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_a0125937-9a17-46ea-89fc-ecfe927720a7" xlink:href="biib-20230930.xsd#biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_41e7a874-5ead-4112-a220-a9bd031dc28c" xlink:to="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_a0125937-9a17-46ea-89fc-ecfe927720a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#AcquisitionsPurchasePriceConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_ba1749bf-a080-47fd-a705-296e7d554176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_42fb94ae-8c3d-4555-afd1-9629c56cea28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_ba1749bf-a080-47fd-a705-296e7d554176" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_42fb94ae-8c3d-4555-afd1-9629c56cea28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d7606cb1-9771-42c7-a0e1-750429d16093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_42fb94ae-8c3d-4555-afd1-9629c56cea28" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d7606cb1-9771-42c7-a0e1-750429d16093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c003e96c-c203-4331-a928-37b2db8cc856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d7606cb1-9771-42c7-a0e1-750429d16093" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c003e96c-c203-4331-a928-37b2db8cc856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_0f6e3210-c58e-4edc-a9cf-17984b1b29d9" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c003e96c-c203-4331-a928-37b2db8cc856" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_0f6e3210-c58e-4edc-a9cf-17984b1b29d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_11788c9f-1ffa-481c-b710-d4ef62d1a930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_42fb94ae-8c3d-4555-afd1-9629c56cea28" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_11788c9f-1ffa-481c-b710-d4ef62d1a930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_dc0e38c1-50a3-4f6f-a8b8-a7ab629855b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11788c9f-1ffa-481c-b710-d4ef62d1a930" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_dc0e38c1-50a3-4f6f-a8b8-a7ab629855b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_a3bb4d29-3ae9-480b-a344-e7ebfb22e49f" xlink:href="biib-20230930.xsd#biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11788c9f-1ffa-481c-b710-d4ef62d1a930" xlink:to="loc_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices_a3bb4d29-3ae9-480b-a344-e7ebfb22e49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c0f06f88-b4c9-4c2e-9868-f963520c1612" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11788c9f-1ffa-481c-b710-d4ef62d1a930" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c0f06f88-b4c9-4c2e-9868-f963520c1612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_0e12fdba-91ae-4b71-a020-ff0b8b54d92e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11788c9f-1ffa-481c-b710-d4ef62d1a930" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_0e12fdba-91ae-4b71-a020-ff0b8b54d92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_08688132-8a7c-4f8f-a8d8-f181c682eae5" xlink:href="biib-20230930.xsd#biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_11788c9f-1ffa-481c-b710-d4ef62d1a930" xlink:to="loc_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired_08688132-8a7c-4f8f-a8d8-f181c682eae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#AcquisitionsPreliminatyPurchasePriceAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a4c02b39-fac8-4b44-aca1-dddb91a94e29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e90bc187-5439-4e3e-ac29-9455ffe622b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a4c02b39-fac8-4b44-aca1-dddb91a94e29" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e90bc187-5439-4e3e-ac29-9455ffe622b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6236b239-cf2e-4b88-bf80-9e538eca149c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e90bc187-5439-4e3e-ac29-9455ffe622b8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6236b239-cf2e-4b88-bf80-9e538eca149c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c7c5c43-a1e2-4a95-b482-f89707ca05f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6236b239-cf2e-4b88-bf80-9e538eca149c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c7c5c43-a1e2-4a95-b482-f89707ca05f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_25b835f8-bf02-4961-8e17-5a3dc7b1c094" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c7c5c43-a1e2-4a95-b482-f89707ca05f2" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_25b835f8-bf02-4961-8e17-5a3dc7b1c094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a28e6e79-58de-40cb-8432-38bff50f858f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e90bc187-5439-4e3e-ac29-9455ffe622b8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a28e6e79-58de-40cb-8432-38bff50f858f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_495badcc-925a-406e-8cc0-c4fa45c69457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a28e6e79-58de-40cb-8432-38bff50f858f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_495badcc-925a-406e-8cc0-c4fa45c69457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_24862fe6-5548-4602-88b7-e9c58bb949b2" xlink:href="biib-20230930.xsd#biib_SKYCLARYSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_495badcc-925a-406e-8cc0-c4fa45c69457" xlink:to="loc_biib_SKYCLARYSMember_24862fe6-5548-4602-88b7-e9c58bb949b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_57cd6264-76b9-41f1-844b-c2d656431458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_495badcc-925a-406e-8cc0-c4fa45c69457" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_57cd6264-76b9-41f1-844b-c2d656431458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_d0c97d0b-27d5-40f2-84ba-9885dd7003bc" xlink:href="biib-20230930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_495badcc-925a-406e-8cc0-c4fa45c69457" xlink:to="loc_biib_PriorityReviewVoucherMember_d0c97d0b-27d5-40f2-84ba-9885dd7003bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember_41bf9c8c-be4e-4b54-9a8a-c572d6dd2aa6" xlink:href="biib-20230930.xsd#biib_OtherClinicalProgramsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_495badcc-925a-406e-8cc0-c4fa45c69457" xlink:to="loc_biib_OtherClinicalProgramsMember_41bf9c8c-be4e-4b54-9a8a-c572d6dd2aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e90bc187-5439-4e3e-ac29-9455ffe622b8" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_efc44947-092f-418e-9093-94f9b7013477" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_efc44947-092f-418e-9093-94f9b7013477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_e9e1dd43-0817-4b27-bba3-5a8d87323bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_e9e1dd43-0817-4b27-bba3-5a8d87323bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_724d4d1b-42f5-4c4a-857b-d47ad28fec4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_724d4d1b-42f5-4c4a-857b-d47ad28fec4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_bf361bbe-81c0-45c2-9530-e1c5bcd4d213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_bf361bbe-81c0-45c2-9530-e1c5bcd4d213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f2944015-2c78-466b-a4f2-e8407a17c711" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f2944015-2c78-466b-a4f2-e8407a17c711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_1da8e17b-32c3-4808-ab9b-d001192986cf" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_1da8e17b-32c3-4808-ab9b-d001192986cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_94150c20-1c9f-4573-b545-d3e8f3c9c77e" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther_94150c20-1c9f-4573-b545-d3e8f3c9c77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_9d08ecf9-5ae6-4671-acce-0002a0d602b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_9d08ecf9-5ae6-4671-acce-0002a0d602b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_926f7123-9270-4328-bddd-8db27a1f0b50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_926f7123-9270-4328-bddd-8db27a1f0b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_eaf698e4-56f4-4403-9d73-d7d1a8dd5027" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_eaf698e4-56f4-4403-9d73-d7d1a8dd5027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_a25ad5d8-c5f0-4dfe-9687-390357ab48fe" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_a25ad5d8-c5f0-4dfe-9687-390357ab48fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_1dcfa8ad-0650-474e-9a85-06db384a87f7" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet_1dcfa8ad-0650-474e-9a85-06db384a87f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_3919c905-5707-422f-be29-5a0d286a86f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_3919c905-5707-422f-be29-5a0d286a86f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6d45c9e6-fe09-4221-9c7b-0aa4c0bbf806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_Goodwill_6d45c9e6-fe09-4221-9c7b-0aa4c0bbf806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0a1bb4f5-2067-4efb-9a8e-5e7ad3edd0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ac5db28e-56fa-473f-be20-3ce722a9026f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0a1bb4f5-2067-4efb-9a8e-5e7ad3edd0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="simple" xlink:href="biib-20230930.xsd#DispositionsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract_08ace58e-29d2-4ba1-9f60-e511e4d9ac8d" xlink:href="biib-20230930.xsd#biib_DivestituresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_67f31c82-a06d-4854-b3b6-98106389e18c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_08ace58e-29d2-4ba1-9f60-e511e4d9ac8d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_67f31c82-a06d-4854-b3b6-98106389e18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bd991708-8a0a-40fb-9737-28e8c28c5033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_67f31c82-a06d-4854-b3b6-98106389e18c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bd991708-8a0a-40fb-9737-28e8c28c5033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf718d4c-4685-415e-a53b-338514452346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bd991708-8a0a-40fb-9737-28e8c28c5033" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf718d4c-4685-415e-a53b-338514452346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_6730dc70-cf88-4cce-b206-d2ff016a6876" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf718d4c-4685-415e-a53b-338514452346" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_6730dc70-cf88-4cce-b206-d2ff016a6876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cb5934f0-2800-4b94-94ac-139ba4398470" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_67f31c82-a06d-4854-b3b6-98106389e18c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cb5934f0-2800-4b94-94ac-139ba4398470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f3793f0f-0f37-4dfc-aa1e-3954ae6afa26" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cb5934f0-2800-4b94-94ac-139ba4398470" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f3793f0f-0f37-4dfc-aa1e-3954ae6afa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_90d94c9a-7e94-4fc4-b480-b1a22e7c62b3" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f3793f0f-0f37-4dfc-aa1e-3954ae6afa26" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_90d94c9a-7e94-4fc4-b480-b1a22e7c62b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_8394abb8-aa89-41c4-82dc-2a8331c3ce1f" xlink:href="biib-20230930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_67f31c82-a06d-4854-b3b6-98106389e18c" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_8394abb8-aa89-41c4-82dc-2a8331c3ce1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_763562ed-bc45-4a1a-8866-5d1cd23eed7e" xlink:href="biib-20230930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_8394abb8-aa89-41c4-82dc-2a8331c3ce1f" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_763562ed-bc45-4a1a-8866-5d1cd23eed7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_7f35da22-e5ff-4a53-ae28-b0991f5fbdbb" xlink:href="biib-20230930.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_763562ed-bc45-4a1a-8866-5d1cd23eed7e" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_7f35da22-e5ff-4a53-ae28-b0991f5fbdbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_7e06fd21-56ff-43ae-bee3-993441cf5f8b" xlink:href="biib-20230930.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_763562ed-bc45-4a1a-8866-5d1cd23eed7e" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_7e06fd21-56ff-43ae-bee3-993441cf5f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_02edbeb0-5bbe-48fe-b1ad-e1f83aced445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_67f31c82-a06d-4854-b3b6-98106389e18c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_02edbeb0-5bbe-48fe-b1ad-e1f83aced445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_5708e350-a63a-4779-a467-6794e5f5e591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_02edbeb0-5bbe-48fe-b1ad-e1f83aced445" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_5708e350-a63a-4779-a467-6794e5f5e591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_67011821-2b8e-433c-a161-f484840e1ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_5708e350-a63a-4779-a467-6794e5f5e591" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_67011821-2b8e-433c-a161-f484840e1ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_073b4775-bd50-4065-a2ef-6de6501a0e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_67f31c82-a06d-4854-b3b6-98106389e18c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_073b4775-bd50-4065-a2ef-6de6501a0e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_31dea1db-007f-4981-b227-108b298ec736" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_073b4775-bd50-4065-a2ef-6de6501a0e3b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_31dea1db-007f-4981-b227-108b298ec736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_bc86100a-4665-4567-a3e9-7384e5f22b20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_31dea1db-007f-4981-b227-108b298ec736" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_bc86100a-4665-4567-a3e9-7384e5f22b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_67f31c82-a06d-4854-b3b6-98106389e18c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_448d2d49-359b-4f75-bd8f-76ff20e41303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_448d2d49-359b-4f75-bd8f-76ff20e41303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_d38e59cf-590b-45c5-9e6d-848e9ac168ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_d38e59cf-590b-45c5-9e6d-848e9ac168ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_8a7f48d3-bf60-4769-ab03-fe21279791cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_8a7f48d3-bf60-4769-ab03-fe21279791cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_51b1af82-0f9e-415a-91ae-3bec357fe9e4" xlink:href="biib-20230930.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_51b1af82-0f9e-415a-91ae-3bec357fe9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_580bc8fb-4fe0-42d8-a8e1-5b1fc1bbd000" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_EquityMethodInvestments_580bc8fb-4fe0-42d8-a8e1-5b1fc1bbd000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_ed5f7cc2-c353-4efa-adca-2b032a7ca8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_ed5f7cc2-c353-4efa-adca-2b032a7ca8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_b60975ba-fe57-4b56-8b13-124443f9a1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_b60975ba-fe57-4b56-8b13-124443f9a1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_034e419b-267e-42fd-94bf-956869c668c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_034e419b-267e-42fd-94bf-956869c668c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsMeasurementInput_12405fa9-1a16-46f8-aceb-3f00b8c155a2" xlink:href="biib-20230930.xsd#biib_OtherAssetsMeasurementInput"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_biib_OtherAssetsMeasurementInput_12405fa9-1a16-46f8-aceb-3f00b8c155a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure_7c20132b-f293-4517-aa85-a0cc4d8c9ef0" xlink:href="biib-20230930.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_biib_OtherAssetsCurrentFairValueDisclosure_7c20132b-f293-4517-aa85-a0cc4d8c9ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_3d0f2e16-cac1-4b99-8f6d-3e908d888813" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_3d0f2e16-cac1-4b99-8f6d-3e908d888813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_677e5cdf-1d9f-4b95-8e36-af3d2ceafdd1" xlink:href="biib-20230930.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_43f05bfa-fc76-4784-b29e-7d70f5328d2e" xlink:to="loc_biib_AdditionalMilestonePayment_677e5cdf-1d9f-4b95-8e36-af3d2ceafdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5c475e68-284a-41fe-a16a-d5ab8c2f504e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_17c35980-0ad8-4a44-90ed-3c03e18269e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5c475e68-284a-41fe-a16a-d5ab8c2f504e" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_17c35980-0ad8-4a44-90ed-3c03e18269e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_67ba0f6e-da5a-4c00-8f23-6fa3e6d53d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_17c35980-0ad8-4a44-90ed-3c03e18269e3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_67ba0f6e-da5a-4c00-8f23-6fa3e6d53d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a00fd739-27c1-4d58-af9c-35f7342ade0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_67ba0f6e-da5a-4c00-8f23-6fa3e6d53d1c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a00fd739-27c1-4d58-af9c-35f7342ade0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b23c82bd-6d4f-4dce-a419-13aef4a4bd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a00fd739-27c1-4d58-af9c-35f7342ade0d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b23c82bd-6d4f-4dce-a419-13aef4a4bd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_adfecbdb-2404-46fe-9e3c-6d6fe9a07316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a00fd739-27c1-4d58-af9c-35f7342ade0d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_adfecbdb-2404-46fe-9e3c-6d6fe9a07316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_5739c4b0-30d0-4905-86b2-e01a1010e892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a00fd739-27c1-4d58-af9c-35f7342ade0d" xlink:to="loc_us-gaap_RestructuringChargesMember_5739c4b0-30d0-4905-86b2-e01a1010e892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_549724ac-559e-4c94-aad5-11fe5548683e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_17c35980-0ad8-4a44-90ed-3c03e18269e3" xlink:to="loc_us-gaap_RestructuringPlanAxis_549724ac-559e-4c94-aad5-11fe5548683e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_14c97242-b58a-41d7-84b5-8a9a820223cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_549724ac-559e-4c94-aad5-11fe5548683e" xlink:to="loc_us-gaap_RestructuringPlanDomain_14c97242-b58a-41d7-84b5-8a9a820223cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_748aa332-dfa4-4124-ad57-768e469b096a" xlink:href="biib-20230930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_14c97242-b58a-41d7-84b5-8a9a820223cd" xlink:to="loc_biib_A2023CostSavingInitiativesMember_748aa332-dfa4-4124-ad57-768e469b096a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_07f4c0e1-e2f4-4562-8bef-535b2bafe045" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_17c35980-0ad8-4a44-90ed-3c03e18269e3" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_07f4c0e1-e2f4-4562-8bef-535b2bafe045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_4127d317-073c-4de2-b2f9-ae0bf57eb954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_07f4c0e1-e2f4-4562-8bef-535b2bafe045" xlink:to="loc_us-gaap_SeveranceCosts1_4127d317-073c-4de2-b2f9-ae0bf57eb954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_23671b59-b823-463e-8300-a6c50d8988e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_07f4c0e1-e2f4-4562-8bef-535b2bafe045" xlink:to="loc_us-gaap_OtherRestructuringCosts_23671b59-b823-463e-8300-a6c50d8988e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1666c08f-2286-4527-98ce-f9f56811b3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_07f4c0e1-e2f4-4562-8bef-535b2bafe045" xlink:to="loc_us-gaap_RestructuringCharges_1666c08f-2286-4527-98ce-f9f56811b3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_38f9246e-2ae7-4c73-9b52-9ad43ee33cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5c475e68-284a-41fe-a16a-d5ab8c2f504e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_38f9246e-2ae7-4c73-9b52-9ad43ee33cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4219ff63-8f42-420e-bc5e-28ae0c254c77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_efc1bdf9-b0df-452f-bda5-bd007b7046c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4219ff63-8f42-420e-bc5e-28ae0c254c77" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_efc1bdf9-b0df-452f-bda5-bd007b7046c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_3b9631a1-852c-4bd4-a7b8-76ed7824bb74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_efc1bdf9-b0df-452f-bda5-bd007b7046c9" xlink:to="loc_us-gaap_RestructuringPlanAxis_3b9631a1-852c-4bd4-a7b8-76ed7824bb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_67f918fa-cb31-4daa-bc35-7999537eec61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_3b9631a1-852c-4bd4-a7b8-76ed7824bb74" xlink:to="loc_us-gaap_RestructuringPlanDomain_67f918fa-cb31-4daa-bc35-7999537eec61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2022CostSavingInitiativesMember_81428f56-145b-4fb9-97a6-fb708db7efae" xlink:href="biib-20230930.xsd#biib_A2022CostSavingInitiativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_67f918fa-cb31-4daa-bc35-7999537eec61" xlink:to="loc_biib_A2022CostSavingInitiativesMember_81428f56-145b-4fb9-97a6-fb708db7efae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_e2eaff57-db85-401b-b773-0331758e0d5b" xlink:href="biib-20230930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_67f918fa-cb31-4daa-bc35-7999537eec61" xlink:to="loc_biib_A2023CostSavingInitiativesMember_e2eaff57-db85-401b-b773-0331758e0d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_004a1fdb-7498-4afe-9c0b-74dcf629f92c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_efc1bdf9-b0df-452f-bda5-bd007b7046c9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_004a1fdb-7498-4afe-9c0b-74dcf629f92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_566fec7d-d76f-4701-8dde-021f44c47df7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_004a1fdb-7498-4afe-9c0b-74dcf629f92c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_566fec7d-d76f-4701-8dde-021f44c47df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_629d4607-9dd7-40b8-9712-93884eedc228" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_566fec7d-d76f-4701-8dde-021f44c47df7" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_629d4607-9dd7-40b8-9712-93884eedc228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c0a658b8-bfd6-41fe-8038-edec258686a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_efc1bdf9-b0df-452f-bda5-bd007b7046c9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c0a658b8-bfd6-41fe-8038-edec258686a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_80f34bcf-1cc4-46a3-ac59-8001f76d7a77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c0a658b8-bfd6-41fe-8038-edec258686a1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_80f34bcf-1cc4-46a3-ac59-8001f76d7a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_8aec9956-fa05-4689-bc3a-f4c038f1e332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80f34bcf-1cc4-46a3-ac59-8001f76d7a77" xlink:to="loc_us-gaap_RestructuringChargesMember_8aec9956-fa05-4689-bc3a-f4c038f1e332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_d4f9b07c-e4f8-4c9a-a6c7-9daffbe0f0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_efc1bdf9-b0df-452f-bda5-bd007b7046c9" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_d4f9b07c-e4f8-4c9a-a6c7-9daffbe0f0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_9a366b35-95a4-4da7-bea3-5c59f4b921b7" xlink:href="biib-20230930.xsd#biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d4f9b07c-e4f8-4c9a-a6c7-9daffbe0f0a4" xlink:to="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_9a366b35-95a4-4da7-bea3-5c59f4b921b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_e4cb4b07-e8fb-4466-9293-44e283e909a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d4f9b07c-e4f8-4c9a-a6c7-9daffbe0f0a4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_e4cb4b07-e8fb-4466-9293-44e283e909a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_cb13ff42-629a-46dd-b403-88512cc8a05d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d4f9b07c-e4f8-4c9a-a6c7-9daffbe0f0a4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_cb13ff42-629a-46dd-b403-88512cc8a05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_7dbb4bee-ca0c-47a0-8132-9d3e85b542f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d4f9b07c-e4f8-4c9a-a6c7-9daffbe0f0a4" xlink:to="loc_us-gaap_SeveranceCosts1_7dbb4bee-ca0c-47a0-8132-9d3e85b542f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e829d837-f64e-43cd-b57d-83bb1d74cfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d14b1381-0bb2-481b-81d3-4fb02f4cbae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e829d837-f64e-43cd-b57d-83bb1d74cfa2" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d14b1381-0bb2-481b-81d3-4fb02f4cbae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_acecf880-3b9e-413f-9b43-1e8aeec714c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d14b1381-0bb2-481b-81d3-4fb02f4cbae6" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_acecf880-3b9e-413f-9b43-1e8aeec714c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2057bcee-d288-4f52-af86-b2c55fe30dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_acecf880-3b9e-413f-9b43-1e8aeec714c0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2057bcee-d288-4f52-af86-b2c55fe30dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_b85f7019-c103-42db-aa8a-f4255ef34357" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2057bcee-d288-4f52-af86-b2c55fe30dc7" xlink:to="loc_us-gaap_EmployeeSeveranceMember_b85f7019-c103-42db-aa8a-f4255ef34357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcceleratedDepreciationAndOtherCostsMember_63094d82-9e07-4584-8d2a-88c47b371046" xlink:href="biib-20230930.xsd#biib_AcceleratedDepreciationAndOtherCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2057bcee-d288-4f52-af86-b2c55fe30dc7" xlink:to="loc_biib_AcceleratedDepreciationAndOtherCostsMember_63094d82-9e07-4584-8d2a-88c47b371046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WorkforceReductionMember_32715952-517a-41d7-92de-48b78611b735" xlink:href="biib-20230930.xsd#biib_WorkforceReductionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2057bcee-d288-4f52-af86-b2c55fe30dc7" xlink:to="loc_biib_WorkforceReductionMember_32715952-517a-41d7-92de-48b78611b735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_66ee4eed-69cf-4bf0-aa44-8cb4165599b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d14b1381-0bb2-481b-81d3-4fb02f4cbae6" xlink:to="loc_us-gaap_RestructuringPlanAxis_66ee4eed-69cf-4bf0-aa44-8cb4165599b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b606dd72-fbf4-4e43-bd9c-fb30a28f31c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_66ee4eed-69cf-4bf0-aa44-8cb4165599b6" xlink:to="loc_us-gaap_RestructuringPlanDomain_b606dd72-fbf4-4e43-bd9c-fb30a28f31c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2022CostSavingInitiativesMember_9e8a42c2-c0d9-4ebc-a01b-db2cbfffa402" xlink:href="biib-20230930.xsd#biib_A2022CostSavingInitiativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_b606dd72-fbf4-4e43-bd9c-fb30a28f31c8" xlink:to="loc_biib_A2022CostSavingInitiativesMember_9e8a42c2-c0d9-4ebc-a01b-db2cbfffa402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_06c55010-492c-49ff-a3d8-4de93b74d226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d14b1381-0bb2-481b-81d3-4fb02f4cbae6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_06c55010-492c-49ff-a3d8-4de93b74d226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e6fd84a3-2df7-4ae0-877f-5997268c8813" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_06c55010-492c-49ff-a3d8-4de93b74d226" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e6fd84a3-2df7-4ae0-877f-5997268c8813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_0d62b999-e997-4238-b382-bf84fc7f0c39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e6fd84a3-2df7-4ae0-877f-5997268c8813" xlink:to="loc_us-gaap_RestructuringChargesMember_0d62b999-e997-4238-b382-bf84fc7f0c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_dc9ac4fa-db3c-47e4-b7c7-f904cdb6435c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d14b1381-0bb2-481b-81d3-4fb02f4cbae6" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_dc9ac4fa-db3c-47e4-b7c7-f904cdb6435c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_845823a0-6514-4f31-8183-16a153cb1d69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dc9ac4fa-db3c-47e4-b7c7-f904cdb6435c" xlink:to="loc_us-gaap_RestructuringCharges_845823a0-6514-4f31-8183-16a153cb1d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_1decd585-a05e-4ad0-a611-52efea47e109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dc9ac4fa-db3c-47e4-b7c7-f904cdb6435c" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_1decd585-a05e-4ad0-a611-52efea47e109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_dc2f47d8-29d2-4d8e-9b3f-71a73a2be9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5e4bc230-37c6-442a-b9a7-2c062b598e70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_dc2f47d8-29d2-4d8e-9b3f-71a73a2be9ae" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5e4bc230-37c6-442a-b9a7-2c062b598e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_09200e85-3766-4359-a0b1-269f30c21eca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5e4bc230-37c6-442a-b9a7-2c062b598e70" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_09200e85-3766-4359-a0b1-269f30c21eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7295e9e6-6a10-49cc-8dd8-b38b41cfcc57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_09200e85-3766-4359-a0b1-269f30c21eca" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7295e9e6-6a10-49cc-8dd8-b38b41cfcc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_15121aae-b1e4-4987-b824-27fbe44ebcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_7295e9e6-6a10-49cc-8dd8-b38b41cfcc57" xlink:to="loc_us-gaap_EmployeeSeveranceMember_15121aae-b1e4-4987-b824-27fbe44ebcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_e3987a6e-6c21-44c5-aa9d-2122f1ea6d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5e4bc230-37c6-442a-b9a7-2c062b598e70" xlink:to="loc_us-gaap_RestructuringPlanAxis_e3987a6e-6c21-44c5-aa9d-2122f1ea6d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e575c769-92b2-4bdd-b67b-42cdcb7f2229" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_e3987a6e-6c21-44c5-aa9d-2122f1ea6d9d" xlink:to="loc_us-gaap_RestructuringPlanDomain_e575c769-92b2-4bdd-b67b-42cdcb7f2229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2022CostSavingInitiativesMember_4132272d-950a-4dd0-b6a4-88308d0297ea" xlink:href="biib-20230930.xsd#biib_A2022CostSavingInitiativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_e575c769-92b2-4bdd-b67b-42cdcb7f2229" xlink:to="loc_biib_A2022CostSavingInitiativesMember_4132272d-950a-4dd0-b6a4-88308d0297ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_e14fec06-894a-48fe-97de-576c91250e18" xlink:href="biib-20230930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_e575c769-92b2-4bdd-b67b-42cdcb7f2229" xlink:to="loc_biib_A2023CostSavingInitiativesMember_e14fec06-894a-48fe-97de-576c91250e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023And2022CostSavingInitiativesMember_34823e33-b456-49ec-9f27-14c2fe7f81e3" xlink:href="biib-20230930.xsd#biib_A2023And2022CostSavingInitiativesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_e575c769-92b2-4bdd-b67b-42cdcb7f2229" xlink:to="loc_biib_A2023And2022CostSavingInitiativesMember_34823e33-b456-49ec-9f27-14c2fe7f81e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8e22b590-11dd-4e18-a226-8e9e5688eaea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5e4bc230-37c6-442a-b9a7-2c062b598e70" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_8e22b590-11dd-4e18-a226-8e9e5688eaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_83c18e23-3f28-4d55-aa20-cecd7e1d038d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e22b590-11dd-4e18-a226-8e9e5688eaea" xlink:to="loc_us-gaap_RestructuringReserve_83c18e23-3f28-4d55-aa20-cecd7e1d038d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a2d51055-f629-44d0-bf20-02734b3fa3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e22b590-11dd-4e18-a226-8e9e5688eaea" xlink:to="loc_us-gaap_RestructuringCharges_a2d51055-f629-44d0-bf20-02734b3fa3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_f48fb3dd-c59d-4522-9b0e-971ebc042060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e22b590-11dd-4e18-a226-8e9e5688eaea" xlink:to="loc_us-gaap_PaymentsForRestructuring_f48fb3dd-c59d-4522-9b0e-971ebc042060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAdjustment_1510873e-d937-4b86-8af7-8c2dd7865dab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveTranslationAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e22b590-11dd-4e18-a226-8e9e5688eaea" xlink:to="loc_us-gaap_RestructuringReserveTranslationAdjustment_1510873e-d937-4b86-8af7-8c2dd7865dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_9d874123-ae57-4e36-89b2-77c05dde0970" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8e22b590-11dd-4e18-a226-8e9e5688eaea" xlink:to="loc_us-gaap_RestructuringReserve_9d874123-ae57-4e36-89b2-77c05dde0970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RevenuesRevenuesbyproductDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_407f78f5-80a1-4d04-9f76-c7c7ad408cca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_da7f9fde-cb2e-44a2-a3ed-803d26f849bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_407f78f5-80a1-4d04-9f76-c7c7ad408cca" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_da7f9fde-cb2e-44a2-a3ed-803d26f849bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ea5263bd-7e01-4cd6-b045-d38c321143ea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_da7f9fde-cb2e-44a2-a3ed-803d26f849bc" xlink:to="loc_srt_ProductOrServiceAxis_ea5263bd-7e01-4cd6-b045-d38c321143ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ea5263bd-7e01-4cd6-b045-d38c321143ea" xlink:to="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_02b5a037-25c4-4622-8eed-b43913a24c9f" xlink:href="biib-20230930.xsd#biib_MSProductRevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:to="loc_biib_MSProductRevenuesMember_02b5a037-25c4-4622-8eed-b43913a24c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_768f8b80-1417-4554-b565-a9f59a6f6bd1" xlink:href="biib-20230930.xsd#biib_FumarateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MSProductRevenuesMember_02b5a037-25c4-4622-8eed-b43913a24c9f" xlink:to="loc_biib_FumarateMember_768f8b80-1417-4554-b565-a9f59a6f6bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_859918b3-1fcd-4681-b4a1-946ef8a05cad" xlink:href="biib-20230930.xsd#biib_TECFIDERAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FumarateMember_768f8b80-1417-4554-b565-a9f59a6f6bd1" xlink:to="loc_biib_TECFIDERAMember_859918b3-1fcd-4681-b4a1-946ef8a05cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember_f122db2c-605c-43e7-a217-ed5ca1cf6c7e" xlink:href="biib-20230930.xsd#biib_VUMERITYMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FumarateMember_768f8b80-1417-4554-b565-a9f59a6f6bd1" xlink:to="loc_biib_VUMERITYMember_f122db2c-605c-43e7-a217-ed5ca1cf6c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_97da49e2-2f83-4c1e-9fe9-8348e8b00889" xlink:href="biib-20230930.xsd#biib_InterferonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MSProductRevenuesMember_02b5a037-25c4-4622-8eed-b43913a24c9f" xlink:to="loc_biib_InterferonMember_97da49e2-2f83-4c1e-9fe9-8348e8b00889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember_64726bef-9137-40a3-a8b9-3e9680d614ee" xlink:href="biib-20230930.xsd#biib_AVONEXMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InterferonMember_97da49e2-2f83-4c1e-9fe9-8348e8b00889" xlink:to="loc_biib_AVONEXMember_64726bef-9137-40a3-a8b9-3e9680d614ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember_c1ad8f4d-2615-4d26-a2f8-ee6542f79059" xlink:href="biib-20230930.xsd#biib_PLEGRIDYMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InterferonMember_97da49e2-2f83-4c1e-9fe9-8348e8b00889" xlink:to="loc_biib_PLEGRIDYMember_c1ad8f4d-2615-4d26-a2f8-ee6542f79059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_b4895430-9f6d-49c6-8814-92b6c769ab7a" xlink:href="biib-20230930.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:to="loc_biib_TysabriProductMember_b4895430-9f6d-49c6-8814-92b6c769ab7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_df1c7dc1-84bf-49da-b0eb-b7682ba756be" xlink:href="biib-20230930.xsd#biib_FAMPYRAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:to="loc_biib_FAMPYRAMember_df1c7dc1-84bf-49da-b0eb-b7682ba756be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_6ee341bf-7cb4-4405-98e0-2c8582aaf2ce" xlink:href="biib-20230930.xsd#biib_SPINRAZAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:to="loc_biib_SPINRAZAMember_6ee341bf-7cb4-4405-98e0-2c8582aaf2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_ada52e27-615d-4842-8299-68825c18aada" xlink:href="biib-20230930.xsd#biib_BiosimilarsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:to="loc_biib_BiosimilarsMember_ada52e27-615d-4842-8299-68825c18aada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_baf126ea-2ab1-4eab-82ef-227ed9896356" xlink:href="biib-20230930.xsd#biib_BENEPALIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_ada52e27-615d-4842-8299-68825c18aada" xlink:to="loc_biib_BENEPALIMember_baf126ea-2ab1-4eab-82ef-227ed9896356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_8fbeea85-811b-4851-b56c-e65ed668c9cf" xlink:href="biib-20230930.xsd#biib_IMRALDIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_ada52e27-615d-4842-8299-68825c18aada" xlink:to="loc_biib_IMRALDIMember_8fbeea85-811b-4851-b56c-e65ed668c9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_59dc9ada-6723-4db2-8eb3-e69e52e7c23a" xlink:href="biib-20230930.xsd#biib_FLIXABIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_ada52e27-615d-4842-8299-68825c18aada" xlink:to="loc_biib_FLIXABIMember_59dc9ada-6723-4db2-8eb3-e69e52e7c23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember_953f4cc3-8cc5-4ad7-aba0-86db6459594d" xlink:href="biib-20230930.xsd#biib_BYOOVIZMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_ada52e27-615d-4842-8299-68825c18aada" xlink:to="loc_biib_BYOOVIZMember_953f4cc3-8cc5-4ad7-aba0-86db6459594d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4ced39b8-7770-4f86-9b05-df78512c23c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:to="loc_us-gaap_ProductMember_4ced39b8-7770-4f86-9b05-df78512c23c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMAndADUHELMMember_37fcd51f-5f4f-43a8-b4e1-2be7f5dac806" xlink:href="biib-20230930.xsd#biib_FUMADERMAndADUHELMMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:to="loc_biib_FUMADERMAndADUHELMMember_37fcd51f-5f4f-43a8-b4e1-2be7f5dac806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SpinalMuscularAtrophyMember_d220c5fe-e8f4-4c0c-b7e0-482db8038fb4" xlink:href="biib-20230930.xsd#biib_SpinalMuscularAtrophyMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7e7a410-c936-4be3-8c6e-cc1afd1e3b14" xlink:to="loc_biib_SpinalMuscularAtrophyMember_d220c5fe-e8f4-4c0c-b7e0-482db8038fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_06adf991-0dd8-42fe-906c-5747c657cd9e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_da7f9fde-cb2e-44a2-a3ed-803d26f849bc" xlink:to="loc_srt_StatementGeographicalAxis_06adf991-0dd8-42fe-906c-5747c657cd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4ecb72ba-b58b-4375-829d-5c0cc835ad95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_06adf991-0dd8-42fe-906c-5747c657cd9e" xlink:to="loc_srt_SegmentGeographicalDomain_4ecb72ba-b58b-4375-829d-5c0cc835ad95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6d2458f8-a065-47a6-93c2-c97d29cdebc9" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4ecb72ba-b58b-4375-829d-5c0cc835ad95" xlink:to="loc_country_US_6d2458f8-a065-47a6-93c2-c97d29cdebc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_2b9a5df1-a323-4899-8de4-f2cab1f49f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4ecb72ba-b58b-4375-829d-5c0cc835ad95" xlink:to="loc_us-gaap_NonUsMember_2b9a5df1-a323-4899-8de4-f2cab1f49f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e973195d-bdd8-4e62-9439-b225245cb9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_da7f9fde-cb2e-44a2-a3ed-803d26f849bc" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e973195d-bdd8-4e62-9439-b225245cb9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9d7df7bb-a2b6-4b0c-b4b0-f8fd3655f581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e973195d-bdd8-4e62-9439-b225245cb9e2" xlink:to="loc_us-gaap_Revenues_9d7df7bb-a2b6-4b0c-b4b0-f8fd3655f581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20230930.xsd#RevenuesReservesforDiscountsandAllowancesDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_4ac4b4bd-3798-461d-8efa-d08483021b54" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_fc49983d-f4b7-4cb5-b443-19a1266c0db9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_4ac4b4bd-3798-461d-8efa-d08483021b54" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_fc49983d-f4b7-4cb5-b443-19a1266c0db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_65d580dc-b7bd-4a19-9eb5-87261791cafe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_fc49983d-f4b7-4cb5-b443-19a1266c0db9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_65d580dc-b7bd-4a19-9eb5-87261791cafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_71bc0bd8-2c8b-4c7b-a30d-0446cea34792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_65d580dc-b7bd-4a19-9eb5-87261791cafe" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_71bc0bd8-2c8b-4c7b-a30d-0446cea34792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_f6429fdf-1f2b-4226-b2f2-b73ee2cac37a" xlink:href="biib-20230930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_71bc0bd8-2c8b-4c7b-a30d-0446cea34792" xlink:to="loc_biib_ReserveforCashDiscountsMember_f6429fdf-1f2b-4226-b2f2-b73ee2cac37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_4f685e1f-ee4b-4e6d-9ed3-97f49911db12" xlink:href="biib-20230930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_71bc0bd8-2c8b-4c7b-a30d-0446cea34792" xlink:to="loc_biib_ContractualAdjustmentsMember_4f685e1f-ee4b-4e6d-9ed3-97f49911db12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_21a6dce1-309a-416b-a900-2d10ccb27b12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_71bc0bd8-2c8b-4c7b-a30d-0446cea34792" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_21a6dce1-309a-416b-a900-2d10ccb27b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_709dd2d0-0dcd-4d9e-9e46-eef68255b2a5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_fc49983d-f4b7-4cb5-b443-19a1266c0db9" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_709dd2d0-0dcd-4d9e-9e46-eef68255b2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_75e9fcb2-4939-4a16-8b3d-b63697e2ee26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_709dd2d0-0dcd-4d9e-9e46-eef68255b2a5" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_75e9fcb2-4939-4a16-8b3d-b63697e2ee26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_b042d92b-b1e1-4506-9b03-ece9451fb77e" xlink:href="biib-20230930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_709dd2d0-0dcd-4d9e-9e46-eef68255b2a5" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_b042d92b-b1e1-4506-9b03-ece9451fb77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_704479dd-9b70-4a3e-9573-1161679d1784" xlink:href="biib-20230930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_709dd2d0-0dcd-4d9e-9e46-eef68255b2a5" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_704479dd-9b70-4a3e-9573-1161679d1784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_7c8e9f78-a164-4704-9789-f41c598fcf59" xlink:href="biib-20230930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_709dd2d0-0dcd-4d9e-9e46-eef68255b2a5" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_7c8e9f78-a164-4704-9789-f41c598fcf59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_82276e06-4641-4a35-bbcc-517245f1c8fa" xlink:href="biib-20230930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_709dd2d0-0dcd-4d9e-9e46-eef68255b2a5" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_82276e06-4641-4a35-bbcc-517245f1c8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_79242d00-ae16-4a44-9a7c-b0289efc1f62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_709dd2d0-0dcd-4d9e-9e46-eef68255b2a5" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_79242d00-ae16-4a44-9a7c-b0289efc1f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20230930.xsd#RevenuesReservesforDiscountsandAllowancesDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_f3e54d18-7faa-4d64-b854-5b056bf04501" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_947d0bfb-f548-4708-804d-463b9279908e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_f3e54d18-7faa-4d64-b854-5b056bf04501" xlink:to="loc_us-gaap_StatementTable_947d0bfb-f548-4708-804d-463b9279908e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ec40e539-7267-4e30-a037-7e6a183a1b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_947d0bfb-f548-4708-804d-463b9279908e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ec40e539-7267-4e30-a037-7e6a183a1b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_07e82d0c-9d02-4ded-b8e5-4b8f0f5b393e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ec40e539-7267-4e30-a037-7e6a183a1b8f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_07e82d0c-9d02-4ded-b8e5-4b8f0f5b393e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_324faf03-b198-40fd-8651-cc64989d4173" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_07e82d0c-9d02-4ded-b8e5-4b8f0f5b393e" xlink:to="loc_us-gaap_AccountsReceivableMember_324faf03-b198-40fd-8651-cc64989d4173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_6df91ece-d004-4e8d-9b2e-7e5649b05fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_07e82d0c-9d02-4ded-b8e5-4b8f0f5b393e" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_6df91ece-d004-4e8d-9b2e-7e5649b05fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_02a2a73a-58b5-4400-807a-cddeb09a8f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_947d0bfb-f548-4708-804d-463b9279908e" xlink:to="loc_us-gaap_StatementLineItems_02a2a73a-58b5-4400-807a-cddeb09a8f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_bac3e25e-c1bb-42df-a469-f7a8edb6a89b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_02a2a73a-58b5-4400-807a-cddeb09a8f75" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_bac3e25e-c1bb-42df-a469-f7a8edb6a89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4ab0276b-b59e-4060-bce1-c1a17e4dd6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e2fa1290-d5f9-427a-b322-43b1f77548cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4ab0276b-b59e-4060-bce1-c1a17e4dd6dc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e2fa1290-d5f9-427a-b322-43b1f77548cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bbecce26-5c3d-4ebc-b5b5-52cd8044630e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e2fa1290-d5f9-427a-b322-43b1f77548cd" xlink:to="loc_srt_ProductOrServiceAxis_bbecce26-5c3d-4ebc-b5b5-52cd8044630e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8288b6f1-5f1a-4f6a-a4a2-6ffe86a22173" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bbecce26-5c3d-4ebc-b5b5-52cd8044630e" xlink:to="loc_srt_ProductsAndServicesDomain_8288b6f1-5f1a-4f6a-a4a2-6ffe86a22173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_066c0bf8-7261-40bc-9c55-6bb4328fa894" xlink:href="biib-20230930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8288b6f1-5f1a-4f6a-a4a2-6ffe86a22173" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_066c0bf8-7261-40bc-9c55-6bb4328fa894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltyAttributedToOCREVUSMember_9e6ccf5f-e20c-4dfd-9666-fd0686a89500" xlink:href="biib-20230930.xsd#biib_RoyaltyAttributedToOCREVUSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8288b6f1-5f1a-4f6a-a4a2-6ffe86a22173" xlink:to="loc_biib_RoyaltyAttributedToOCREVUSMember_9e6ccf5f-e20c-4dfd-9666-fd0686a89500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_830d6573-adfc-4fd1-87df-dbc95dfb7224" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e2fa1290-d5f9-427a-b322-43b1f77548cd" xlink:to="loc_srt_MajorCustomersAxis_830d6573-adfc-4fd1-87df-dbc95dfb7224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6c1b535e-a98e-4d03-973e-b57781fa8512" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_830d6573-adfc-4fd1-87df-dbc95dfb7224" xlink:to="loc_srt_NameOfMajorCustomerDomain_6c1b535e-a98e-4d03-973e-b57781fa8512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_59c0a007-424a-4c4c-a4a6-b0e3e51d858e" xlink:href="biib-20230930.xsd#biib_RocheGroupGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_6c1b535e-a98e-4d03-973e-b57781fa8512" xlink:to="loc_biib_RocheGroupGenentechMember_59c0a007-424a-4c4c-a4a6-b0e3e51d858e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d23970ec-a2bc-4b1f-bc7c-3762db55f2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e2fa1290-d5f9-427a-b322-43b1f77548cd" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_d23970ec-a2bc-4b1f-bc7c-3762db55f2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_a866e88b-93b3-4047-89ff-cc961c30001b" xlink:href="biib-20230930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d23970ec-a2bc-4b1f-bc7c-3762db55f2b4" xlink:to="loc_biib_ShareOfCoPromotionProfits_a866e88b-93b3-4047-89ff-cc961c30001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_498a5c95-9e36-49a2-bc93-6ee2c5799c67" xlink:href="biib-20230930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d23970ec-a2bc-4b1f-bc7c-3762db55f2b4" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_498a5c95-9e36-49a2-bc93-6ee2c5799c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d62804ee-e70e-4308-9275-76e2e7e5f4df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d23970ec-a2bc-4b1f-bc7c-3762db55f2b4" xlink:to="loc_us-gaap_Revenues_d62804ee-e70e-4308-9275-76e2e7e5f4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RevenuesOtherRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract_6cdc81a0-14af-46d6-a68f-2b576ec3ecac" xlink:href="biib-20230930.xsd#biib_OtherrevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_87e91217-a533-40c2-94e4-0c5b85c0f1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_6cdc81a0-14af-46d6-a68f-2b576ec3ecac" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_87e91217-a533-40c2-94e4-0c5b85c0f1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_37e1653b-d5d9-48b8-a391-3e67ad5bec56" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_87e91217-a533-40c2-94e4-0c5b85c0f1e8" xlink:to="loc_srt_ProductOrServiceAxis_37e1653b-d5d9-48b8-a391-3e67ad5bec56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2d04f173-abfd-4e03-80a6-f1b23bded7dc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_37e1653b-d5d9-48b8-a391-3e67ad5bec56" xlink:to="loc_srt_ProductsAndServicesDomain_2d04f173-abfd-4e03-80a6-f1b23bded7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingAndOtherRevenueMember_6e8dd9bb-bac5-44c2-bcd8-4ab58f08d671" xlink:href="biib-20230930.xsd#biib_ContractManufacturingAndOtherRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2d04f173-abfd-4e03-80a6-f1b23bded7dc" xlink:to="loc_biib_ContractManufacturingAndOtherRevenueMember_6e8dd9bb-bac5-44c2-bcd8-4ab58f08d671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_b3cf47bc-f031-4e5d-bf1d-e430578bfd39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2d04f173-abfd-4e03-80a6-f1b23bded7dc" xlink:to="loc_us-gaap_RoyaltyMember_b3cf47bc-f031-4e5d-bf1d-e430578bfd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_ec6763cb-1826-481a-9f76-90f716c63497" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2d04f173-abfd-4e03-80a6-f1b23bded7dc" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_ec6763cb-1826-481a-9f76-90f716c63497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a3a3c8a4-a41a-4fbb-8e4a-90517bc6090c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_87e91217-a533-40c2-94e4-0c5b85c0f1e8" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a3a3c8a4-a41a-4fbb-8e4a-90517bc6090c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_735ed473-6fb9-4bdc-a167-89196c801f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a3a3c8a4-a41a-4fbb-8e4a-90517bc6090c" xlink:to="loc_us-gaap_Revenues_735ed473-6fb9-4bdc-a167-89196c801f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2e234385-474e-4f86-b764-992276a052ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0bed294d-14d1-44aa-8d08-42d68b3e76c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2e234385-474e-4f86-b764-992276a052ef" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0bed294d-14d1-44aa-8d08-42d68b3e76c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d559597e-0eb8-44e6-9778-e9fb230aa1a9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0bed294d-14d1-44aa-8d08-42d68b3e76c3" xlink:to="loc_srt_ProductOrServiceAxis_d559597e-0eb8-44e6-9778-e9fb230aa1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5831f1e9-ad62-46a3-8f5c-a1a3210a8d1f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d559597e-0eb8-44e6-9778-e9fb230aa1a9" xlink:to="loc_srt_ProductsAndServicesDomain_5831f1e9-ad62-46a3-8f5c-a1a3210a8d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_4a2791f4-f5de-451b-a9bf-2b3bb34acad2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5831f1e9-ad62-46a3-8f5c-a1a3210a8d1f" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_4a2791f4-f5de-451b-a9bf-2b3bb34acad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_892dba95-c0f7-4416-9129-9e89ffb487e3" xlink:href="biib-20230930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5831f1e9-ad62-46a3-8f5c-a1a3210a8d1f" xlink:to="loc_biib_LEQEMBICollaborationMember_892dba95-c0f7-4416-9129-9e89ffb487e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_65295922-9234-4ab2-9124-928aaae79c2a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0bed294d-14d1-44aa-8d08-42d68b3e76c3" xlink:to="loc_srt_MajorCustomersAxis_65295922-9234-4ab2-9124-928aaae79c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_390d9d92-1090-487a-96bd-401b41aefc09" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_65295922-9234-4ab2-9124-928aaae79c2a" xlink:to="loc_srt_NameOfMajorCustomerDomain_390d9d92-1090-487a-96bd-401b41aefc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_ff93ecd8-4695-4f79-a046-afe717a6bb72" xlink:href="biib-20230930.xsd#biib_DistributorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_390d9d92-1090-487a-96bd-401b41aefc09" xlink:to="loc_biib_DistributorOneMember_ff93ecd8-4695-4f79-a046-afe717a6bb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_bbe3ab84-a876-4b06-bf9a-26160bb60b44" xlink:href="biib-20230930.xsd#biib_DistributorTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_390d9d92-1090-487a-96bd-401b41aefc09" xlink:to="loc_biib_DistributorTwoMember_bbe3ab84-a876-4b06-bf9a-26160bb60b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_22ea322a-cfa9-4f48-916f-cd11ff875094" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0bed294d-14d1-44aa-8d08-42d68b3e76c3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_22ea322a-cfa9-4f48-916f-cd11ff875094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_bb470a6d-5005-433c-ac51-9bdb86038565" xlink:href="biib-20230930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22ea322a-cfa9-4f48-916f-cd11ff875094" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_bb470a6d-5005-433c-ac51-9bdb86038565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_d6cbf20a-2ab1-44d2-8ae8-3de3232db52e" xlink:href="biib-20230930.xsd#biib_NumberOfWholesalers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22ea322a-cfa9-4f48-916f-cd11ff875094" xlink:to="loc_biib_NumberOfWholesalers_d6cbf20a-2ab1-44d2-8ae8-3de3232db52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fe27f079-899c-493e-a37f-b52f86f76116" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22ea322a-cfa9-4f48-916f-cd11ff875094" xlink:to="loc_us-gaap_Revenues_fe27f079-899c-493e-a37f-b52f86f76116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized_4a2b7c86-5fd0-43f4-9702-3431898533ca" xlink:href="biib-20230930.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22ea322a-cfa9-4f48-916f-cd11ff875094" xlink:to="loc_biib_ShareOfNonControlingInterestRecognized_4a2b7c86-5fd0-43f4-9702-3431898533ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_23946e84-cd7c-4dd4-9637-757a36d4d726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22ea322a-cfa9-4f48-916f-cd11ff875094" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_23946e84-cd7c-4dd4-9637-757a36d4d726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#InventoryComponentsofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_55ea2ff7-517d-4258-b71e-434b98eed4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_6df4ef30-f771-4b3f-bc82-fe61e0fe1ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_55ea2ff7-517d-4258-b71e-434b98eed4cb" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_6df4ef30-f771-4b3f-bc82-fe61e0fe1ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_079a3c3f-14c9-451b-b7d4-425437a24a97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_55ea2ff7-517d-4258-b71e-434b98eed4cb" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_079a3c3f-14c9-451b-b7d4-425437a24a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_a41d837d-d512-406b-af9b-6a680cbfd575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_55ea2ff7-517d-4258-b71e-434b98eed4cb" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_a41d837d-d512-406b-af9b-6a680cbfd575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent_6724fbcc-15be-45e0-9559-c38423c280ee" xlink:href="biib-20230930.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_55ea2ff7-517d-4258-b71e-434b98eed4cb" xlink:to="loc_biib_InventoryNetCurrentAndNoncurrent_6724fbcc-15be-45e0-9559-c38423c280ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d4f29138-40ff-40ed-a41a-7ca680102f71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_55ea2ff7-517d-4258-b71e-434b98eed4cb" xlink:to="loc_us-gaap_InventoryNet_d4f29138-40ff-40ed-a41a-7ca680102f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_22b22a3e-ed4f-4b42-af05-bb367d7fed2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_55ea2ff7-517d-4258-b71e-434b98eed4cb" xlink:to="loc_us-gaap_InventoryNoncurrent_22b22a3e-ed4f-4b42-af05-bb367d7fed2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#InventoryNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0d45101f-ad32-4173-a026-dee51ab506e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_6a487729-a0ce-4f11-9409-2e18fbd9d86c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0d45101f-ad32-4173-a026-dee51ab506e8" xlink:to="loc_us-gaap_InventoryCurrentTable_6a487729-a0ce-4f11-9409-2e18fbd9d86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_077d6036-0562-4eab-861e-c68a9186ce41" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_6a487729-a0ce-4f11-9409-2e18fbd9d86c" xlink:to="loc_srt_ProductOrServiceAxis_077d6036-0562-4eab-861e-c68a9186ce41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_09106211-ad1b-41de-8fc1-ec4b8583e6d1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_077d6036-0562-4eab-861e-c68a9186ce41" xlink:to="loc_srt_ProductsAndServicesDomain_09106211-ad1b-41de-8fc1-ec4b8583e6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_a1c363f9-768f-47a6-8590-ca2e2a5896d6" xlink:href="biib-20230930.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_09106211-ad1b-41de-8fc1-ec4b8583e6d1" xlink:to="loc_biib_ADUHELMMember_a1c363f9-768f-47a6-8590-ca2e2a5896d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2a25c751-e32c-43da-ac12-6d9ee5efdc47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_6a487729-a0ce-4f11-9409-2e18fbd9d86c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2a25c751-e32c-43da-ac12-6d9ee5efdc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8970c816-45e8-4a60-a146-9d1548d5a8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2a25c751-e32c-43da-ac12-6d9ee5efdc47" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8970c816-45e8-4a60-a146-9d1548d5a8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_197d1f5c-f13a-4543-aa35-f934885f9967" xlink:href="biib-20230930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8970c816-45e8-4a60-a146-9d1548d5a8fa" xlink:to="loc_biib_EisaiMember_197d1f5c-f13a-4543-aa35-f934885f9967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_313e7fa9-df55-4ae8-bad7-03c29154d290" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_6a487729-a0ce-4f11-9409-2e18fbd9d86c" xlink:to="loc_srt_CounterpartyNameAxis_313e7fa9-df55-4ae8-bad7-03c29154d290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bec504c6-b478-4c04-936f-798f84450aa2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_313e7fa9-df55-4ae8-bad7-03c29154d290" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bec504c6-b478-4c04-936f-798f84450aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CentersForMedicareAndMedicaidServiceMember_9525f04e-e6b0-4a4e-bc4c-db960d53c23c" xlink:href="biib-20230930.xsd#biib_CentersForMedicareAndMedicaidServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bec504c6-b478-4c04-936f-798f84450aa2" xlink:to="loc_biib_CentersForMedicareAndMedicaidServiceMember_9525f04e-e6b0-4a4e-bc4c-db960d53c23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_72dc2d38-0433-414f-a6e0-91daf8b15faa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_6a487729-a0ce-4f11-9409-2e18fbd9d86c" xlink:to="loc_us-gaap_InventoryLineItems_72dc2d38-0433-414f-a6e0-91daf8b15faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_3a13a1b8-6631-4562-8f2a-945aba4cdda6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_72dc2d38-0433-414f-a6e0-91daf8b15faa" xlink:to="loc_us-gaap_InventoryWriteDown_3a13a1b8-6631-4562-8f2a-945aba4cdda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c4abf015-261c-44ed-a965-efb6e68c2e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_72dc2d38-0433-414f-a6e0-91daf8b15faa" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c4abf015-261c-44ed-a965-efb6e68c2e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5091933d-22ba-4629-9a0b-8ab567d07127" xlink:href="biib-20230930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_72dc2d38-0433-414f-a6e0-91daf8b15faa" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5091933d-22ba-4629-9a0b-8ab567d07127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent_91b143cf-e690-4bb4-b3f1-e3b213d4320c" xlink:href="biib-20230930.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_72dc2d38-0433-414f-a6e0-91daf8b15faa" xlink:to="loc_biib_InventoryNetCurrentAndNoncurrent_91b143cf-e690-4bb4-b3f1-e3b213d4320c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1400045d-7a15-4bc2-bdf1-58d67931a948" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bccdc891-45a5-4afe-b2e3-bcfd590ebd2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1400045d-7a15-4bc2-bdf1-58d67931a948" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bccdc891-45a5-4afe-b2e3-bcfd590ebd2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4a368725-f0b1-4a45-9bd9-fcc2bfeafb22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bccdc891-45a5-4afe-b2e3-bcfd590ebd2f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4a368725-f0b1-4a45-9bd9-fcc2bfeafb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc93211c-548d-4d73-b047-5f638b8a2f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4a368725-f0b1-4a45-9bd9-fcc2bfeafb22" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc93211c-548d-4d73-b047-5f638b8a2f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_5ba3b23a-9fd0-46c7-984f-565946ae2d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc93211c-548d-4d73-b047-5f638b8a2f1a" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_5ba3b23a-9fd0-46c7-984f-565946ae2d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9bc7c12c-745e-4d3f-ac82-0674c06a2740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc93211c-548d-4d73-b047-5f638b8a2f1a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9bc7c12c-745e-4d3f-ac82-0674c06a2740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_e1b17908-c64d-4286-8afc-f6f3873d7080" xlink:href="biib-20230930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dc93211c-548d-4d73-b047-5f638b8a2f1a" xlink:to="loc_biib_PriorityReviewVoucherMember_e1b17908-c64d-4286-8afc-f6f3873d7080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6f87ec68-74e5-4cd5-9d83-0484299174ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bccdc891-45a5-4afe-b2e3-bcfd590ebd2f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6f87ec68-74e5-4cd5-9d83-0484299174ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdf5b423-6645-450b-b5e6-d03468799855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6f87ec68-74e5-4cd5-9d83-0484299174ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdf5b423-6645-450b-b5e6-d03468799855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember_a04340a7-f9c2-4427-801a-7e6840d9db99" xlink:href="biib-20230930.xsd#biib_OutLicensedPatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdf5b423-6645-450b-b5e6-d03468799855" xlink:to="loc_biib_OutLicensedPatentsMember_a04340a7-f9c2-4427-801a-7e6840d9db99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_fb91012c-7da0-4a8b-900e-fc78d310798b" xlink:href="biib-20230930.xsd#biib_SKYCLARYSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdf5b423-6645-450b-b5e6-d03468799855" xlink:to="loc_biib_SKYCLARYSMember_fb91012c-7da0-4a8b-900e-fc78d310798b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ea6c47a0-9de3-4b32-93b7-a1cdefd22482" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bccdc891-45a5-4afe-b2e3-bcfd590ebd2f" xlink:to="loc_srt_RangeAxis_ea6c47a0-9de3-4b32-93b7-a1cdefd22482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5486b424-6003-470c-9b0c-07854ad4c9d4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ea6c47a0-9de3-4b32-93b7-a1cdefd22482" xlink:to="loc_srt_RangeMember_5486b424-6003-470c-9b0c-07854ad4c9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ede6a8a7-a12b-446a-9334-346587044b20" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5486b424-6003-470c-9b0c-07854ad4c9d4" xlink:to="loc_srt_MinimumMember_ede6a8a7-a12b-446a-9334-346587044b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e8340873-e70d-4026-bfc5-d8a1ea245ad2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5486b424-6003-470c-9b0c-07854ad4c9d4" xlink:to="loc_srt_MaximumMember_e8340873-e70d-4026-bfc5-d8a1ea245ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ca26def8-6083-4db5-9f51-66829e914340" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bccdc891-45a5-4afe-b2e3-bcfd590ebd2f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ca26def8-6083-4db5-9f51-66829e914340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0ed486aa-a169-4fc3-a35b-87ce1fb07536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ca26def8-6083-4db5-9f51-66829e914340" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0ed486aa-a169-4fc3-a35b-87ce1fb07536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_d2253b7e-fa75-4fbf-95e0-49e79b71f3cc" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0ed486aa-a169-4fc3-a35b-87ce1fb07536" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_d2253b7e-fa75-4fbf-95e0-49e79b71f3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bccdc891-45a5-4afe-b2e3-bcfd590ebd2f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e776c40b-7c16-42b6-9dc4-d6b19de1ac09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e776c40b-7c16-42b6-9dc4-d6b19de1ac09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3bf84b3b-9e28-40a7-acec-c7d92666866b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3bf84b3b-9e28-40a7-acec-c7d92666866b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_14980f8c-09b7-42ef-8103-220b0882db47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_14980f8c-09b7-42ef-8103-220b0882db47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2805588f-bfd9-4a46-bd41-d2ba05553687" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2805588f-bfd9-4a46-bd41-d2ba05553687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ad514145-1664-4b81-b99b-4066abcd7986" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ad514145-1664-4b81-b99b-4066abcd7986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d19b94a5-4103-4d20-b23f-5fc1de4c1d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d19b94a5-4103-4d20-b23f-5fc1de4c1d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ee066a37-1b11-42f9-87eb-829a61f1c03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_63a510b6-13cf-44ab-b2a5-4347bf146505" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ee066a37-1b11-42f9-87eb-829a61f1c03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_d2bd755b-edd7-43be-9f0d-93723cb0522b" xlink:href="biib-20230930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_d2bd755b-edd7-43be-9f0d-93723cb0522b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e11c209b-1779-4d59-bddb-ea0ce1f67653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e11c209b-1779-4d59-bddb-ea0ce1f67653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_823509ba-df85-4905-b289-ec278ba46daf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_823509ba-df85-4905-b289-ec278ba46daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a6d13eb7-d0f0-4a0d-a7b4-4d3008d33e61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a6d13eb7-d0f0-4a0d-a7b4-4d3008d33e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8e7058f6-3881-45b1-8d65-4beb09be7a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8e7058f6-3881-45b1-8d65-4beb09be7a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_341c138a-72d6-4e0a-815f-dc1d595e281e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_341c138a-72d6-4e0a-815f-dc1d595e281e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9e3c6666-1307-4153-9c2b-3a5aeea7744f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9e3c6666-1307-4153-9c2b-3a5aeea7744f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2c9f929d-284f-4554-a5f9-4015a7764eca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2c9f929d-284f-4554-a5f9-4015a7764eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_56c23cfe-efd4-40e8-afac-1e0591e01362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e397289-ab04-4630-bec0-56091306c211" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_56c23cfe-efd4-40e8-afac-1e0591e01362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="simple" xlink:href="biib-20230930.xsd#IntangibleAssetsandGoodwillDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9a60be77-ac53-4003-b9aa-0f7ac3a8c50b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_a62a4ef0-dece-4a20-9d7b-f3478af05c87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9a60be77-ac53-4003-b9aa-0f7ac3a8c50b" xlink:to="loc_us-gaap_GoodwillRollForward_a62a4ef0-dece-4a20-9d7b-f3478af05c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_886cdfb8-cb90-48ea-8d65-bc0725fd6352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a62a4ef0-dece-4a20-9d7b-f3478af05c87" xlink:to="loc_us-gaap_Goodwill_886cdfb8-cb90-48ea-8d65-bc0725fd6352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_2526ce77-7ee5-44dd-90e2-d2e819c70bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a62a4ef0-dece-4a20-9d7b-f3478af05c87" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_2526ce77-7ee5-44dd-90e2-d2e819c70bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_140b270d-614e-4910-9aed-96b4223b3947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a62a4ef0-dece-4a20-9d7b-f3478af05c87" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_140b270d-614e-4910-9aed-96b4223b3947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ae54e4e9-12fa-4631-b687-8de016379f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a62a4ef0-dece-4a20-9d7b-f3478af05c87" xlink:to="loc_us-gaap_Goodwill_ae54e4e9-12fa-4631-b687-8de016379f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_439af6f5-453c-46a9-b778-5e083fa34d44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9a60be77-ac53-4003-b9aa-0f7ac3a8c50b" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_439af6f5-453c-46a9-b778-5e083fa34d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_56115aef-206f-4fa7-8c5a-6507c5c62114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f745d356-379c-4d73-ade8-187455821ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_56115aef-206f-4fa7-8c5a-6507c5c62114" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f745d356-379c-4d73-ade8-187455821ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e1aa458e-e3b2-4a23-951b-22c4580af92e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f745d356-379c-4d73-ade8-187455821ad3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e1aa458e-e3b2-4a23-951b-22c4580af92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_faedeca0-f925-4cae-b57b-ed6b800ac9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e1aa458e-e3b2-4a23-951b-22c4580af92e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_faedeca0-f925-4cae-b57b-ed6b800ac9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5f258d6e-5b59-4f80-b7ff-ef43ee7fc1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_faedeca0-f925-4cae-b57b-ed6b800ac9eb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5f258d6e-5b59-4f80-b7ff-ef43ee7fc1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_91350d80-80df-46d7-800a-0a73713f80c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_faedeca0-f925-4cae-b57b-ed6b800ac9eb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_91350d80-80df-46d7-800a-0a73713f80c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7934bfac-6ae7-4ada-8518-e98e4785a7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_faedeca0-f925-4cae-b57b-ed6b800ac9eb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7934bfac-6ae7-4ada-8518-e98e4785a7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b64d3891-81b4-41f4-beef-0c5f51e8de7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f745d356-379c-4d73-ade8-187455821ad3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b64d3891-81b4-41f4-beef-0c5f51e8de7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3f5cdb94-3eee-4a5a-84b7-48dc518fe114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b64d3891-81b4-41f4-beef-0c5f51e8de7f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3f5cdb94-3eee-4a5a-84b7-48dc518fe114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_849915f3-ba66-4203-984c-184b0ae3db05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3f5cdb94-3eee-4a5a-84b7-48dc518fe114" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_849915f3-ba66-4203-984c-184b0ae3db05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2a4a88dc-21b5-497d-b3d5-0aabd1fa7cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f745d356-379c-4d73-ade8-187455821ad3" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2a4a88dc-21b5-497d-b3d5-0aabd1fa7cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bdd74b4b-d9df-45aa-b3e2-b65b9d79469d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2a4a88dc-21b5-497d-b3d5-0aabd1fa7cd4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bdd74b4b-d9df-45aa-b3e2-b65b9d79469d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d4d0034d-96db-4ff2-a278-7afd55a59e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bdd74b4b-d9df-45aa-b3e2-b65b9d79469d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d4d0034d-96db-4ff2-a278-7afd55a59e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_aecd1cbc-4d5c-4ffe-905f-ca99812c6bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bdd74b4b-d9df-45aa-b3e2-b65b9d79469d" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_aecd1cbc-4d5c-4ffe-905f-ca99812c6bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_2ef47873-b9c8-4ba9-abed-3f463ca25308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_bdd74b4b-d9df-45aa-b3e2-b65b9d79469d" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_2ef47873-b9c8-4ba9-abed-3f463ca25308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5181bec5-9be4-43f1-9967-2313a5902918" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f745d356-379c-4d73-ade8-187455821ad3" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5181bec5-9be4-43f1-9967-2313a5902918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_679b2c9a-d30a-493e-8b05-9bf8a3c514b4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5181bec5-9be4-43f1-9967-2313a5902918" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_679b2c9a-d30a-493e-8b05-9bf8a3c514b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_47515f9b-3bf5-474c-8a7b-5f9d2a537762" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_679b2c9a-d30a-493e-8b05-9bf8a3c514b4" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_47515f9b-3bf5-474c-8a7b-5f9d2a537762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e9dbf74d-3ea8-4ea4-bdc2-599c3591f4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f745d356-379c-4d73-ade8-187455821ad3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e9dbf74d-3ea8-4ea4-bdc2-599c3591f4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_44e660af-abc7-4b04-b3fc-8e339126552f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e9dbf74d-3ea8-4ea4-bdc2-599c3591f4e8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_44e660af-abc7-4b04-b3fc-8e339126552f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_44e660af-abc7-4b04-b3fc-8e339126552f" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c7e39eb8-90d4-442f-beee-a6d7866fb246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c7e39eb8-90d4-442f-beee-a6d7866fb246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_578f8517-bf3c-42e6-a9a8-277cd786ea05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_578f8517-bf3c-42e6-a9a8-277cd786ea05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_ffed7695-828e-4547-9454-a1fcdef56ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_ffed7695-828e-4547-9454-a1fcdef56ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure_00816f86-2675-458d-8e7f-c1ad7c5e8bcd" xlink:href="biib-20230930.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_biib_OtherAssetsCurrentFairValueDisclosure_00816f86-2675-458d-8e7f-c1ad7c5e8bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_34e5ceff-b374-4d28-996b-dd30179580f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_34e5ceff-b374-4d28-996b-dd30179580f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_2df9476d-46c6-4a28-9efc-7eafc3dbac5e" xlink:href="biib-20230930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_2df9476d-46c6-4a28-9efc-7eafc3dbac5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_93d1f98b-ad89-4b77-89d9-70c1f0c34511" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_93d1f98b-ad89-4b77-89d9-70c1f0c34511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_c57027e2-6761-404c-83b3-aa31f02f4ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_us-gaap_DerivativeAssets_c57027e2-6761-404c-83b3-aa31f02f4ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3299e9e1-45e5-41a6-a011-3d34ca31bbad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ecfaff60-7e5b-4261-86fe-c5156517bda9" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3299e9e1-45e5-41a6-a011-3d34ca31bbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a06b2d9-1add-4d53-8de9-4dbc56480c62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_44e660af-abc7-4b04-b3fc-8e339126552f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a06b2d9-1add-4d53-8de9-4dbc56480c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1d25e5cb-e4ae-4b37-830c-03956e822baa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a06b2d9-1add-4d53-8de9-4dbc56480c62" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_1d25e5cb-e4ae-4b37-830c-03956e822baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_127ed584-fd13-4ef4-958d-1c90d9ff0129" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a06b2d9-1add-4d53-8de9-4dbc56480c62" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_127ed584-fd13-4ef4-958d-1c90d9ff0129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_20505c03-eab3-4d6b-83e2-9ce39a3a8704" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a06b2d9-1add-4d53-8de9-4dbc56480c62" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_20505c03-eab3-4d6b-83e2-9ce39a3a8704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f494a12a-ca29-4d76-abeb-7f0311ac5f97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a06b2d9-1add-4d53-8de9-4dbc56480c62" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_f494a12a-ca29-4d76-abeb-7f0311ac5f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20230930.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c25d06d6-0cd9-4cef-ab1c-0b9bbea8dd09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2ba4867f-88d4-4f77-b67e-71b87946fa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c25d06d6-0cd9-4cef-ab1c-0b9bbea8dd09" xlink:to="loc_us-gaap_DebtInstrumentTable_2ba4867f-88d4-4f77-b67e-71b87946fa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1e7a10b6-53f7-478d-8c1c-f67569bc42c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2ba4867f-88d4-4f77-b67e-71b87946fa0d" xlink:to="loc_us-gaap_CreditFacilityAxis_1e7a10b6-53f7-478d-8c1c-f67569bc42c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c865efc7-cd02-4f24-9e60-ae45118b4395" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1e7a10b6-53f7-478d-8c1c-f67569bc42c3" xlink:to="loc_us-gaap_CreditFacilityDomain_c865efc7-cd02-4f24-9e60-ae45118b4395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_4a692cd1-5f9c-4987-876b-3e0d3da4ba6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c865efc7-cd02-4f24-9e60-ae45118b4395" xlink:to="loc_us-gaap_SecuredDebtMember_4a692cd1-5f9c-4987-876b-3e0d3da4ba6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_69f37148-a756-4cde-8b42-6a51d5d9e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2ba4867f-88d4-4f77-b67e-71b87946fa0d" xlink:to="loc_us-gaap_DebtInstrumentAxis_69f37148-a756-4cde-8b42-6a51d5d9e89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2c4d2fcc-8bd4-435a-9868-c0823b7bac15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_69f37148-a756-4cde-8b42-6a51d5d9e89f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2c4d2fcc-8bd4-435a-9868-c0823b7bac15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_2a654cd3-456f-4fe0-82b8-ab4d1d458091" xlink:href="biib-20230930.xsd#biib_TheCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2c4d2fcc-8bd4-435a-9868-c0823b7bac15" xlink:to="loc_biib_TheCreditFacilityMember_2a654cd3-456f-4fe0-82b8-ab4d1d458091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a728d77d-4217-4b8f-9838-c0aa99299929" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2ba4867f-88d4-4f77-b67e-71b87946fa0d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a728d77d-4217-4b8f-9838-c0aa99299929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4b2cbd68-17a8-4fc0-880d-b757f22f9e94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a728d77d-4217-4b8f-9838-c0aa99299929" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4b2cbd68-17a8-4fc0-880d-b757f22f9e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_97a72f6a-5dbb-4fd8-ab2b-3ef4a45abbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4b2cbd68-17a8-4fc0-880d-b757f22f9e94" xlink:to="loc_us-gaap_LineOfCreditMember_97a72f6a-5dbb-4fd8-ab2b-3ef4a45abbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4c5b3703-645f-44dc-84d9-b57c63c02719" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2ba4867f-88d4-4f77-b67e-71b87946fa0d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4c5b3703-645f-44dc-84d9-b57c63c02719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a9204dfb-d1aa-4ee1-ac33-3908f5732517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c5b3703-645f-44dc-84d9-b57c63c02719" xlink:to="loc_us-gaap_AssetImpairmentCharges_a9204dfb-d1aa-4ee1-ac33-3908f5732517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1047a54b-3a6e-42df-86c7-d0ed911e4ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c5b3703-645f-44dc-84d9-b57c63c02719" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1047a54b-3a6e-42df-86c7-d0ed911e4ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1ac97db2-ff54-4fbb-a206-a0e96f95dc00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a69c6926-a619-4f5d-8037-f410456bccc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ac97db2-ff54-4fbb-a206-a0e96f95dc00" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a69c6926-a619-4f5d-8037-f410456bccc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a0f53205-df4f-48c8-8219-6a0d3ccefede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a69c6926-a619-4f5d-8037-f410456bccc0" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a0f53205-df4f-48c8-8219-6a0d3ccefede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9a7e5e42-ef3f-42a2-a4e6-d5205d4d37de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a0f53205-df4f-48c8-8219-6a0d3ccefede" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9a7e5e42-ef3f-42a2-a4e6-d5205d4d37de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_dd1ef4a4-8f7b-411c-b414-e5529e46eaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9a7e5e42-ef3f-42a2-a4e6-d5205d4d37de" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_dd1ef4a4-8f7b-411c-b414-e5529e46eaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f89f9c1-36ca-42dd-b6f3-386c2fc8fcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a69c6926-a619-4f5d-8037-f410456bccc0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f89f9c1-36ca-42dd-b6f3-386c2fc8fcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_528fbdd1-4b40-426f-8fad-6aed45e2b021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f89f9c1-36ca-42dd-b6f3-386c2fc8fcd1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_528fbdd1-4b40-426f-8fad-6aed45e2b021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20230930.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c6e83557-d4aa-4c16-9ddb-d533247f12c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bc2507d0-b78c-46b4-895f-b7f5ad81f1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c6e83557-d4aa-4c16-9ddb-d533247f12c1" xlink:to="loc_us-gaap_DebtInstrumentTable_bc2507d0-b78c-46b4-895f-b7f5ad81f1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_eade1eff-8b85-44f5-afbe-664757bc110c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bc2507d0-b78c-46b4-895f-b7f5ad81f1e7" xlink:to="loc_us-gaap_DebtInstrumentAxis_eade1eff-8b85-44f5-afbe-664757bc110c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f4b08c87-d263-49c6-b580-7d3d993e86d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_eade1eff-8b85-44f5-afbe-664757bc110c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f4b08c87-d263-49c6-b580-7d3d993e86d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_3547a83f-8498-4283-a905-13c0241ec239" xlink:href="biib-20230930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f4b08c87-d263-49c6-b580-7d3d993e86d8" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_3547a83f-8498-4283-a905-13c0241ec239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_9a5c55eb-669a-4e31-82d1-9d3c5c59fb75" xlink:href="biib-20230930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f4b08c87-d263-49c6-b580-7d3d993e86d8" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_9a5c55eb-669a-4e31-82d1-9d3c5c59fb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1f8bbda1-0008-404a-9dc6-629004da32da" xlink:href="biib-20230930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f4b08c87-d263-49c6-b580-7d3d993e86d8" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1f8bbda1-0008-404a-9dc6-629004da32da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_9ab4b359-a0ac-432e-98f8-1fd1f9b00562" xlink:href="biib-20230930.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f4b08c87-d263-49c6-b580-7d3d993e86d8" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_9ab4b359-a0ac-432e-98f8-1fd1f9b00562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_46c0fc30-2b48-4e81-91f5-e0e67a9caf4a" xlink:href="biib-20230930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f4b08c87-d263-49c6-b580-7d3d993e86d8" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_46c0fc30-2b48-4e81-91f5-e0e67a9caf4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_3b2d3dca-40b9-4617-b384-121c5c109ac0" xlink:href="biib-20230930.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bc2507d0-b78c-46b4-895f-b7f5ad81f1e7" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_3b2d3dca-40b9-4617-b384-121c5c109ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentAssetDomain_730342c0-dae0-4f37-8d3f-69329e7a96c9" xlink:href="biib-20230930.xsd#biib_ResearchAndDevelopmentAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_3b2d3dca-40b9-4617-b384-121c5c109ac0" xlink:to="loc_biib_ResearchAndDevelopmentAssetDomain_730342c0-dae0-4f37-8d3f-69329e7a96c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB054Member_5c9bee20-5b00-4765-9ec4-2344b27cf803" xlink:href="biib-20230930.xsd#biib_BIIB054Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_730342c0-dae0-4f37-8d3f-69329e7a96c9" xlink:to="loc_biib_BIIB054Member_5c9bee20-5b00-4765-9ec4-2344b27cf803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7cb6574d-b305-4628-b422-35aacd61df7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bc2507d0-b78c-46b4-895f-b7f5ad81f1e7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7cb6574d-b305-4628-b422-35aacd61df7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_3c61264e-dfe5-408b-8044-ad2f3143afa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7cb6574d-b305-4628-b422-35aacd61df7e" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_3c61264e-dfe5-408b-8044-ad2f3143afa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_408f8db1-8f00-4c29-afbd-e6223ee10c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7cb6574d-b305-4628-b422-35aacd61df7e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_408f8db1-8f00-4c29-afbd-e6223ee10c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_93d09f6f-6380-41f0-af46-ace0a7473389" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7cb6574d-b305-4628-b422-35aacd61df7e" xlink:to="loc_us-gaap_NotesPayable_93d09f6f-6380-41f0-af46-ace0a7473389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6ca91225-ee3c-4280-9d89-ef5a0d559197" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7cb6574d-b305-4628-b422-35aacd61df7e" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6ca91225-ee3c-4280-9d89-ef5a0d559197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20230930.xsd#FairValueMeasurementsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f194a3d8-5a51-4eaf-ab3c-d86df5de51f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1a94e71c-9eb3-49b5-b343-064e61693fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f194a3d8-5a51-4eaf-ab3c-d86df5de51f1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1a94e71c-9eb3-49b5-b343-064e61693fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_098e2e33-9918-4710-b578-45eead50d365" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1a94e71c-9eb3-49b5-b343-064e61693fb1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_098e2e33-9918-4710-b578-45eead50d365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5357c4d9-16ef-4911-9bb6-f2e3d0d94a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_098e2e33-9918-4710-b578-45eead50d365" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5357c4d9-16ef-4911-9bb6-f2e3d0d94a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_58716b1f-d067-4b4b-91fc-9dba6111143e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5357c4d9-16ef-4911-9bb6-f2e3d0d94a3f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_58716b1f-d067-4b4b-91fc-9dba6111143e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_07ca5c0e-186c-48c3-904c-dc6992e94383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1a94e71c-9eb3-49b5-b343-064e61693fb1" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_07ca5c0e-186c-48c3-904c-dc6992e94383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e4f89d4b-c7db-4ee3-a78f-dd41dcc2da19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_07ca5c0e-186c-48c3-904c-dc6992e94383" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e4f89d4b-c7db-4ee3-a78f-dd41dcc2da19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_82f9dc7f-98a2-459d-ac5c-93adf918647a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_07ca5c0e-186c-48c3-904c-dc6992e94383" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_82f9dc7f-98a2-459d-ac5c-93adf918647a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_95831208-0579-4e92-9361-09fcf4b0d794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_07ca5c0e-186c-48c3-904c-dc6992e94383" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_95831208-0579-4e92-9361-09fcf4b0d794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ecb8985d-f3df-4dd9-a97f-86d28b95a4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ea03d437-aef1-4ae1-ae23-2af49b4b53d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ecb8985d-f3df-4dd9-a97f-86d28b95a4e6" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ea03d437-aef1-4ae1-ae23-2af49b4b53d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_efbaa399-6e25-449c-bb4e-64e4d560c60d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ea03d437-aef1-4ae1-ae23-2af49b4b53d9" xlink:to="loc_us-gaap_InvestmentTypeAxis_efbaa399-6e25-449c-bb4e-64e4d560c60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1e0cf289-ab56-4052-8dc1-5a41141ef52d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_efbaa399-6e25-449c-bb4e-64e4d560c60d" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1e0cf289-ab56-4052-8dc1-5a41141ef52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b2f7bce1-aaf0-47d7-a1d3-6a3c5df94e82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1e0cf289-ab56-4052-8dc1-5a41141ef52d" xlink:to="loc_us-gaap_CommercialPaperMember_b2f7bce1-aaf0-47d7-a1d3-6a3c5df94e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_ddaa7e62-f97b-4f82-9731-9bb68b146039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1e0cf289-ab56-4052-8dc1-5a41141ef52d" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_ddaa7e62-f97b-4f82-9731-9bb68b146039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c3599485-f960-4a4a-86f5-fb74d21755fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1e0cf289-ab56-4052-8dc1-5a41141ef52d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c3599485-f960-4a4a-86f5-fb74d21755fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_2241ac30-25db-4380-b697-e05e7dd5d001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1e0cf289-ab56-4052-8dc1-5a41141ef52d" xlink:to="loc_us-gaap_CertificatesOfDepositMember_2241ac30-25db-4380-b697-e05e7dd5d001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_779aac2f-554e-4740-af34-c592b80541b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1e0cf289-ab56-4052-8dc1-5a41141ef52d" xlink:to="loc_us-gaap_DebtSecuritiesMember_779aac2f-554e-4740-af34-c592b80541b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_e4130185-4c71-4ac3-b520-7c228f7a063a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ea03d437-aef1-4ae1-ae23-2af49b4b53d9" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_e4130185-4c71-4ac3-b520-7c228f7a063a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_1a81619d-39cc-478c-ac93-c5fcaa1cdd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_e4130185-4c71-4ac3-b520-7c228f7a063a" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_1a81619d-39cc-478c-ac93-c5fcaa1cdd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_c576b3de-b07c-48a1-b60f-3d42e31f8346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_1a81619d-39cc-478c-ac93-c5fcaa1cdd6c" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_c576b3de-b07c-48a1-b60f-3d42e31f8346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20230930.xsd#FinancialInstrumentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1bded30f-741b-4452-a39f-dc12bee6b715" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c685393e-73fc-4612-a875-1e383389c20a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1bded30f-741b-4452-a39f-dc12bee6b715" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c685393e-73fc-4612-a875-1e383389c20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_00ef5742-e891-46a5-9f38-673e4d27c96c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c685393e-73fc-4612-a875-1e383389c20a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_00ef5742-e891-46a5-9f38-673e4d27c96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_00ef5742-e891-46a5-9f38-673e4d27c96c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_773b8c9a-e97d-4ae1-b810-845672bc4e46" xlink:href="biib-20230930.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_773b8c9a-e97d-4ae1-b810-845672bc4e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_44a1751f-80eb-4da8-8161-ff0c0012a1bd" xlink:href="biib-20230930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_44a1751f-80eb-4da8-8161-ff0c0012a1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_2d080cc4-691e-4f49-bc07-961cfa04cb74" xlink:href="biib-20230930.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_2d080cc4-691e-4f49-bc07-961cfa04cb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_2dc93954-32c1-4d32-8556-2c256024a827" xlink:href="biib-20230930.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_2dc93954-32c1-4d32-8556-2c256024a827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_66cb6aca-0e78-4ff9-a786-13c853217396" xlink:href="biib-20230930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_66cb6aca-0e78-4ff9-a786-13c853217396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_3a9744c7-1f57-4596-9b8e-3189b5366891" xlink:href="biib-20230930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_3a9744c7-1f57-4596-9b8e-3189b5366891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_624afc20-c3b6-4cfc-981e-76f514a1b222" xlink:href="biib-20230930.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:to="loc_biib_EquitySecuritiesCurrentMember_624afc20-c3b6-4cfc-981e-76f514a1b222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_73085b8c-876e-48b2-a71c-7d5210946d2d" xlink:href="biib-20230930.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_858c2172-f556-4fe7-bb9c-bc45bdf43524" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_73085b8c-876e-48b2-a71c-7d5210946d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_01277945-9a7d-476a-aeeb-73ff1f27eb73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c685393e-73fc-4612-a875-1e383389c20a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_01277945-9a7d-476a-aeeb-73ff1f27eb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_21c34235-fbad-4820-a2ba-fbc99376883e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_01277945-9a7d-476a-aeeb-73ff1f27eb73" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_21c34235-fbad-4820-a2ba-fbc99376883e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5c91efc2-3a35-4c50-a24a-a06b4b071254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_21c34235-fbad-4820-a2ba-fbc99376883e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5c91efc2-3a35-4c50-a24a-a06b4b071254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b3e5f4e9-da87-4fb0-8fea-5e216e30c9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_21c34235-fbad-4820-a2ba-fbc99376883e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b3e5f4e9-da87-4fb0-8fea-5e216e30c9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fe368f4a-fb3c-452a-8725-89003168e9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_21c34235-fbad-4820-a2ba-fbc99376883e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fe368f4a-fb3c-452a-8725-89003168e9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_69bfb3ed-9e92-4c2f-ad9b-030f02a2578f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_21c34235-fbad-4820-a2ba-fbc99376883e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_69bfb3ed-9e92-4c2f-ad9b-030f02a2578f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_a4aea19a-ddcf-47ba-81e3-18d9146f44f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_01277945-9a7d-476a-aeeb-73ff1f27eb73" xlink:to="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_a4aea19a-ddcf-47ba-81e3-18d9146f44f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_ef3684d8-421f-427a-950b-925d502d349d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_a4aea19a-ddcf-47ba-81e3-18d9146f44f4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_ef3684d8-421f-427a-950b-925d502d349d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_c2015764-e8ef-4f92-9f09-c595320b9a21" xlink:href="biib-20230930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_a4aea19a-ddcf-47ba-81e3-18d9146f44f4" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_c2015764-e8ef-4f92-9f09-c595320b9a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_6ba023ff-d373-4528-8fc8-aa6c52edf03c" xlink:href="biib-20230930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_a4aea19a-ddcf-47ba-81e3-18d9146f44f4" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_6ba023ff-d373-4528-8fc8-aa6c52edf03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_be1d6b39-8f41-458d-ad54-0e7275110ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_a4aea19a-ddcf-47ba-81e3-18d9146f44f4" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_be1d6b39-8f41-458d-ad54-0e7275110ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20230930.xsd#FinancialInstrumentsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_64edcdbc-dd23-4898-9fca-c1d4b3d39ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8f29742a-433d-4b1a-a1ff-d46a3a88f4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_64edcdbc-dd23-4898-9fca-c1d4b3d39ae6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8f29742a-433d-4b1a-a1ff-d46a3a88f4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c942a316-cd20-4463-bc85-7d2f0292052c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8f29742a-433d-4b1a-a1ff-d46a3a88f4f8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c942a316-cd20-4463-bc85-7d2f0292052c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_58f583ab-700a-402a-b5ef-09ad3b795caa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8f29742a-433d-4b1a-a1ff-d46a3a88f4f8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_58f583ab-700a-402a-b5ef-09ad3b795caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c1ffd299-c33f-4cba-a08d-81d27dc4ff7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8f29742a-433d-4b1a-a1ff-d46a3a88f4f8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c1ffd299-c33f-4cba-a08d-81d27dc4ff7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d130627c-738b-484c-aa9e-d41f329915c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8f29742a-433d-4b1a-a1ff-d46a3a88f4f8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d130627c-738b-484c-aa9e-d41f329915c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_202242a8-3758-4dc1-8fb0-b502a1da9838" xlink:href="biib-20230930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8f29742a-433d-4b1a-a1ff-d46a3a88f4f8" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_202242a8-3758-4dc1-8fb0-b502a1da9838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_8ba76cb1-3ffa-439d-ae42-dd1ab755df11" xlink:href="biib-20230930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8f29742a-433d-4b1a-a1ff-d46a3a88f4f8" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_8ba76cb1-3ffa-439d-ae42-dd1ab755df11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b73215a6-743f-44da-9383-c63e8b5f8f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8f29742a-433d-4b1a-a1ff-d46a3a88f4f8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b73215a6-743f-44da-9383-c63e8b5f8f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0ec7ee6d-5329-4b43-9d6e-bc7c686e2a42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_8f29742a-433d-4b1a-a1ff-d46a3a88f4f8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0ec7ee6d-5329-4b43-9d6e-bc7c686e2a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="simple" xlink:href="biib-20230930.xsd#FinancialInstrumentsDetails3"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bfbaa7bd-2d3e-49a2-8506-35eaa4cb77b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2e75904f-2341-4099-acaf-341ddaeafcec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bfbaa7bd-2d3e-49a2-8506-35eaa4cb77b6" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2e75904f-2341-4099-acaf-341ddaeafcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_cf0bc41e-6ecf-44ae-830e-4b0a27e9a262" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bfbaa7bd-2d3e-49a2-8506-35eaa4cb77b6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_cf0bc41e-6ecf-44ae-830e-4b0a27e9a262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_af129418-4bc0-4ffe-9ba9-c17cfe4d9456" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bfbaa7bd-2d3e-49a2-8506-35eaa4cb77b6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_af129418-4bc0-4ffe-9ba9-c17cfe4d9456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="simple" xlink:href="biib-20230930.xsd#FinancialInstrumentsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0f37d0b9-2575-4ac9-b41c-e9c5c0d2c470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_5a1b4bf2-aeb0-43f9-940b-c396d98e19dd" xlink:href="biib-20230930.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0f37d0b9-2575-4ac9-b41c-e9c5c0d2c470" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_5a1b4bf2-aeb0-43f9-940b-c396d98e19dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20230930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f9d85c5a-aca6-4601-a59d-e97462e10ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6ed157d5-5c02-412d-a895-b805d5e16291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f9d85c5a-aca6-4601-a59d-e97462e10ed0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6ed157d5-5c02-412d-a895-b805d5e16291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4ccd82a3-146b-41fb-bbfc-c1875df77eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6ed157d5-5c02-412d-a895-b805d5e16291" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4ccd82a3-146b-41fb-bbfc-c1875df77eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c8dfc7b4-1790-49bf-a5e5-1283b9f809ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4ccd82a3-146b-41fb-bbfc-c1875df77eac" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c8dfc7b4-1790-49bf-a5e5-1283b9f809ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_ba79897b-6b04-44a4-b7a4-66d0bf5f0276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c8dfc7b4-1790-49bf-a5e5-1283b9f809ee" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_ba79897b-6b04-44a4-b7a4-66d0bf5f0276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d15fa5ef-16d3-4e9c-ac5d-5d56fd768e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6ed157d5-5c02-412d-a895-b805d5e16291" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d15fa5ef-16d3-4e9c-ac5d-5d56fd768e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c460c4e-9871-4080-9aa2-0db426a09349" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d15fa5ef-16d3-4e9c-ac5d-5d56fd768e0a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c460c4e-9871-4080-9aa2-0db426a09349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_fa759b04-ab4e-407a-8651-a57a865fe865" xlink:href="biib-20230930.xsd#biib_StrategicInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1c460c4e-9871-4080-9aa2-0db426a09349" xlink:to="loc_biib_StrategicInvestmentsMember_fa759b04-ab4e-407a-8651-a57a865fe865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d47fa2c9-69f2-4c7c-8bd8-507780f59086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6ed157d5-5c02-412d-a895-b805d5e16291" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_d47fa2c9-69f2-4c7c-8bd8-507780f59086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_dfcb5da8-1ce8-46ed-8be2-98f38c1edfcc" xlink:href="biib-20230930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d47fa2c9-69f2-4c7c-8bd8-507780f59086" xlink:to="loc_biib_StrategicInvestmentPortfolio_dfcb5da8-1ce8-46ed-8be2-98f38c1edfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#DerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fdd7afd6-8985-4ecf-801c-288a60a76c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fdd7afd6-8985-4ecf-801c-288a60a76c05" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_bdf98bc3-04b8-4422-97d6-0ad566152f06" xlink:href="biib-20230930.xsd#biib_DerivativeMaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_biib_DerivativeMaturityAxis_bdf98bc3-04b8-4422-97d6-0ad566152f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_8f461b45-7bc1-4321-bf5a-fc1f2ecba3d8" xlink:href="biib-20230930.xsd#biib_DerivativeMaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityAxis_bdf98bc3-04b8-4422-97d6-0ad566152f06" xlink:to="loc_biib_DerivativeMaturityDomain_8f461b45-7bc1-4321-bf5a-fc1f2ecba3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_f435547d-75cc-4f3c-889a-2a34538edb15" xlink:href="biib-20230930.xsd#biib_ShorttermderivativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityDomain_8f461b45-7bc1-4321-bf5a-fc1f2ecba3d8" xlink:to="loc_biib_ShorttermderivativeMember_f435547d-75cc-4f3c-889a-2a34538edb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_81213972-8791-4ca9-8fb6-2fef6b5b7ccc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_81213972-8791-4ca9-8fb6-2fef6b5b7ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_bd967844-e381-4db2-bcb7-d6b92a7e53ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_81213972-8791-4ca9-8fb6-2fef6b5b7ccc" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_bd967844-e381-4db2-bcb7-d6b92a7e53ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_eee7f7f5-c762-4f73-a2a1-58f7f95105af" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bd967844-e381-4db2-bcb7-d6b92a7e53ce" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_eee7f7f5-c762-4f73-a2a1-58f7f95105af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_27c17d71-8034-443f-adef-e0a6a768172f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_srt_CurrencyAxis_27c17d71-8034-443f-adef-e0a6a768172f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_44a42d60-330d-4bf3-933c-1f2f189ba47e" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_27c17d71-8034-443f-adef-e0a6a768172f" xlink:to="loc_currency_AllCurrenciesDomain_44a42d60-330d-4bf3-933c-1f2f189ba47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_660d269d-697e-4b16-94fa-8042a526f63d" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_44a42d60-330d-4bf3-933c-1f2f189ba47e" xlink:to="loc_currency_EUR_660d269d-697e-4b16-94fa-8042a526f63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_6c809c96-f0fa-4c56-a038-6725a1094117" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CHF"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_44a42d60-330d-4bf3-933c-1f2f189ba47e" xlink:to="loc_currency_CHF_6c809c96-f0fa-4c56-a038-6725a1094117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_dcf432ee-232c-4b31-856d-1d37551a16a2" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_JPY"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_44a42d60-330d-4bf3-933c-1f2f189ba47e" xlink:to="loc_currency_JPY_dcf432ee-232c-4b31-856d-1d37551a16a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_04245929-1e60-4268-970d-7955127d7af2" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_44a42d60-330d-4bf3-933c-1f2f189ba47e" xlink:to="loc_currency_CAD_04245929-1e60-4268-970d-7955127d7af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_811d30ed-0f8e-402a-b905-b7eb35772e13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_811d30ed-0f8e-402a-b905-b7eb35772e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d2c37601-3f6e-43fc-bf3f-d14d753e1059" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_811d30ed-0f8e-402a-b905-b7eb35772e13" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d2c37601-3f6e-43fc-bf3f-d14d753e1059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_335ece78-9f32-40ff-b647-c7560a8dc5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2c37601-3f6e-43fc-bf3f-d14d753e1059" xlink:to="loc_us-gaap_SalesMember_335ece78-9f32-40ff-b647-c7560a8dc5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_cc499dcb-ec6a-4348-b7b3-1cae57412f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2c37601-3f6e-43fc-bf3f-d14d753e1059" xlink:to="loc_us-gaap_OperatingExpenseMember_cc499dcb-ec6a-4348-b7b3-1cae57412f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_b65a888d-c2ad-46e4-8f87-d1101325b118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2c37601-3f6e-43fc-bf3f-d14d753e1059" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_b65a888d-c2ad-46e4-8f87-d1101325b118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_db6b8fee-d1a1-41b8-bf97-0e4358028653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_db6b8fee-d1a1-41b8-bf97-0e4358028653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7d37deb5-5f6f-4fdb-a917-2232760787e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_db6b8fee-d1a1-41b8-bf97-0e4358028653" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7d37deb5-5f6f-4fdb-a917-2232760787e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_301077bd-ca32-414c-a98e-152dfcba20c5" xlink:href="biib-20230930.xsd#biib_CashflowsrevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7d37deb5-5f6f-4fdb-a917-2232760787e7" xlink:to="loc_biib_CashflowsrevenueMember_301077bd-ca32-414c-a98e-152dfcba20c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_606810da-478e-4c8a-93be-d988a8c09843" xlink:href="biib-20230930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7d37deb5-5f6f-4fdb-a917-2232760787e7" xlink:to="loc_biib_CashflowsoperatingexpensesMember_606810da-478e-4c8a-93be-d988a8c09843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_fbab272e-b356-4691-89d1-07f8f2ef28c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7d37deb5-5f6f-4fdb-a917-2232760787e7" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_fbab272e-b356-4691-89d1-07f8f2ef28c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b8ef5400-88ed-4f29-b547-fcd9cd85b932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b8ef5400-88ed-4f29-b547-fcd9cd85b932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ec9a2ea7-a9e6-4a6b-9974-5d228e1a5b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b8ef5400-88ed-4f29-b547-fcd9cd85b932" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ec9a2ea7-a9e6-4a6b-9974-5d228e1a5b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_fec7a06f-48bc-4ce6-8702-0f8bac612e27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ec9a2ea7-a9e6-4a6b-9974-5d228e1a5b4f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_fec7a06f-48bc-4ce6-8702-0f8bac612e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_7286aaf1-eedf-40b8-bc7b-1c1403c4a3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ec9a2ea7-a9e6-4a6b-9974-5d228e1a5b4f" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_7286aaf1-eedf-40b8-bc7b-1c1403c4a3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c7e7014a-16d4-4e4b-acae-1ce37af95cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c7e7014a-16d4-4e4b-acae-1ce37af95cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2ae9d23a-043d-499a-9519-66d69edaa224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c7e7014a-16d4-4e4b-acae-1ce37af95cfb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2ae9d23a-043d-499a-9519-66d69edaa224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_67edace0-2833-45c3-8543-5a2ebfef983d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2ae9d23a-043d-499a-9519-66d69edaa224" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_67edace0-2833-45c3-8543-5a2ebfef983d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_9940c5ae-a2c7-4c8c-9adf-53f71a47f866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2ae9d23a-043d-499a-9519-66d69edaa224" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_9940c5ae-a2c7-4c8c-9adf-53f71a47f866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_ce44deb6-ab98-4bf3-9d3c-f6d052437043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2ae9d23a-043d-499a-9519-66d69edaa224" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_ce44deb6-ab98-4bf3-9d3c-f6d052437043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_001006a0-4def-4da4-bf57-a8d530b96abf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_us-gaap_HedgingDesignationAxis_001006a0-4def-4da4-bf57-a8d530b96abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a1deca99-5738-4c1f-bf58-08030594884d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_001006a0-4def-4da4-bf57-a8d530b96abf" xlink:to="loc_us-gaap_HedgingDesignationDomain_a1deca99-5738-4c1f-bf58-08030594884d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_127a4058-e9fc-479a-bc7a-7a9d0572cc03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_a1deca99-5738-4c1f-bf58-08030594884d" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_127a4058-e9fc-479a-bc7a-7a9d0572cc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_2a7cfb40-5c6e-4751-8885-97901b359f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_a1deca99-5738-4c1f-bf58-08030594884d" xlink:to="loc_us-gaap_NondesignatedMember_2a7cfb40-5c6e-4751-8885-97901b359f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9fc2ebe1-2185-4a61-9a85-af13ed437612" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_srt_RangeAxis_9fc2ebe1-2185-4a61-9a85-af13ed437612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d82b3a5-6b3c-499c-a335-908faf278c23" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9fc2ebe1-2185-4a61-9a85-af13ed437612" xlink:to="loc_srt_RangeMember_6d82b3a5-6b3c-499c-a335-908faf278c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3966527c-2634-451a-83bb-6e611471829c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6d82b3a5-6b3c-499c-a335-908faf278c23" xlink:to="loc_srt_MinimumMember_3966527c-2634-451a-83bb-6e611471829c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f38499b8-962e-4ada-a304-c4789ed932c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6d82b3a5-6b3c-499c-a335-908faf278c23" xlink:to="loc_srt_MaximumMember_f38499b8-962e-4ada-a304-c4789ed932c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_071d13c9-f905-4926-9251-34448e28ead8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_us-gaap_TypeOfArrangementAxis_071d13c9-f905-4926-9251-34448e28ead8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8598fd4e-6082-46a9-95af-12b64d2f8c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_071d13c9-f905-4926-9251-34448e28ead8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8598fd4e-6082-46a9-95af-12b64d2f8c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_15ed180d-9dac-4f42-aa2c-84186dcd3b72" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_8a3133f7-7a75-4fb9-8123-d44f56499e57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_8a3133f7-7a75-4fb9-8123-d44f56499e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_6d8f80e7-4d84-464a-bd3d-9e4b9466f144" xlink:href="biib-20230930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_6d8f80e7-4d84-464a-bd3d-9e4b9466f144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_26ca59a6-d7fa-461e-be07-f3357fc9f06b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_26ca59a6-d7fa-461e-be07-f3357fc9f06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_94d0e32e-f9f2-4318-bae3-565c2540c6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_DerivativeNotionalAmount_94d0e32e-f9f2-4318-bae3-565c2540c6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7bca0575-833b-4365-8fd6-6a9fc2899b36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7bca0575-833b-4365-8fd6-6a9fc2899b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_ffe8e1eb-40bd-46dc-904c-9b8bf9417281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_ffe8e1eb-40bd-46dc-904c-9b8bf9417281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1741ac37-c3a1-4469-b3da-171fe401ec5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1741ac37-c3a1-4469-b3da-171fe401ec5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3c02f00d-12f0-4d22-a1b8-d72febc0a156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3c02f00d-12f0-4d22-a1b8-d72febc0a156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_b4364a47-589b-4b4a-96fd-e59128276ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_b4364a47-589b-4b4a-96fd-e59128276ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_66ef650b-64d7-43a7-936c-3829daff4874" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_66ef650b-64d7-43a7-936c-3829daff4874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_054861b3-ead3-4304-bec6-18f865b95aab" xlink:href="biib-20230930.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_054861b3-ead3-4304-bec6-18f865b95aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_ad1c65fb-8498-4ba2-bce2-d8a7ff526665" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_ad1c65fb-8498-4ba2-bce2-d8a7ff526665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives_d8595808-3df7-401c-a991-1371ab28ce78" xlink:href="biib-20230930.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_biib_UnrealizedGainOnDerivatives_d8595808-3df7-401c-a991-1371ab28ce78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives_5c660348-960e-46e9-912e-a34d9f7e4361" xlink:href="biib-20230930.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_biib_UnrealizedLossOnDerivatives_5c660348-960e-46e9-912e-a34d9f7e4361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_917100eb-b932-4c89-b866-89ebbe3a260c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_917100eb-b932-4c89-b866-89ebbe3a260c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_20ff4dc0-1c00-4b60-8907-335db075798a" xlink:href="biib-20230930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_20ff4dc0-1c00-4b60-8907-335db075798a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_058f9e22-c17f-4d21-b778-b3e4e238b3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48225a4b-b28f-463f-a495-40e066b65db5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_058f9e22-c17f-4d21-b778-b3e4e238b3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#PropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8f590a7b-1410-403b-99c5-e64606ffb7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9026b9-b478-4119-9b4c-2228dfed929f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8f590a7b-1410-403b-99c5-e64606ffb7b0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9026b9-b478-4119-9b4c-2228dfed929f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_579342f4-e748-4dac-8c9f-106216248aa7" xlink:href="biib-20230930.xsd#biib_FacilityLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9026b9-b478-4119-9b4c-2228dfed929f" xlink:to="loc_biib_FacilityLocationAxis_579342f4-e748-4dac-8c9f-106216248aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_3b8f1779-1d72-4dc1-a788-55d24d4c802d" xlink:href="biib-20230930.xsd#biib_FacilityLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_579342f4-e748-4dac-8c9f-106216248aa7" xlink:to="loc_biib_FacilityLocationDomain_3b8f1779-1d72-4dc1-a788-55d24d4c802d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_eefd9265-95d9-4ded-93b1-afc432587b3c" xlink:href="biib-20230930.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_3b8f1779-1d72-4dc1-a788-55d24d4c802d" xlink:to="loc_biib_SolothurnSwitzerlandMember_eefd9265-95d9-4ded-93b1-afc432587b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_1a251349-b840-42b4-aac3-d385f9620032" xlink:href="biib-20230930.xsd#biib_FacilityTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9026b9-b478-4119-9b4c-2228dfed929f" xlink:to="loc_biib_FacilityTypeAxis_1a251349-b840-42b4-aac3-d385f9620032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_dc671c01-16d7-446c-a4b4-ab6de2db9dad" xlink:href="biib-20230930.xsd#biib_FacilityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeAxis_1a251349-b840-42b4-aac3-d385f9620032" xlink:to="loc_biib_FacilityTypeDomain_dc671c01-16d7-446c-a4b4-ab6de2db9dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_27c6e7c5-4187-459f-b00b-d3764597964a" xlink:href="biib-20230930.xsd#biib_BiologicsManufacturingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_dc671c01-16d7-446c-a4b4-ab6de2db9dad" xlink:to="loc_biib_BiologicsManufacturingMember_27c6e7c5-4187-459f-b00b-d3764597964a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_0c718a99-fea1-4b5a-bf41-0004e1aeac22" xlink:href="biib-20230930.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_dc671c01-16d7-446c-a4b4-ab6de2db9dad" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_0c718a99-fea1-4b5a-bf41-0004e1aeac22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_8cd9143a-5382-4371-9958-03a41a7ecb56" xlink:href="biib-20230930.xsd#biib_AdministrativeSpaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_dc671c01-16d7-446c-a4b4-ab6de2db9dad" xlink:to="loc_biib_AdministrativeSpaceMember_8cd9143a-5382-4371-9958-03a41a7ecb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_96201eb9-1c80-4241-95db-639039639043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9026b9-b478-4119-9b4c-2228dfed929f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_96201eb9-1c80-4241-95db-639039639043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_23f5ce00-8632-4b25-bcc6-15ed22827f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_96201eb9-1c80-4241-95db-639039639043" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_23f5ce00-8632-4b25-bcc6-15ed22827f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A125BroadwayBuildingSaleMember_4308a4e8-305a-42bb-b50f-1b5f02ac2f6a" xlink:href="biib-20230930.xsd#biib_A125BroadwayBuildingSaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_23f5ce00-8632-4b25-bcc6-15ed22827f7b" xlink:to="loc_biib_A125BroadwayBuildingSaleMember_4308a4e8-305a-42bb-b50f-1b5f02ac2f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4b4b2eb5-673f-4339-9386-2c73335543c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9026b9-b478-4119-9b4c-2228dfed929f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4b4b2eb5-673f-4339-9386-2c73335543c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b932c77a-d0cf-48fa-8b2a-0cf82e2fad16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4b4b2eb5-673f-4339-9386-2c73335543c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b932c77a-d0cf-48fa-8b2a-0cf82e2fad16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_ff250b5b-a6e9-45a8-b9ab-5d37359d5caf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b932c77a-d0cf-48fa-8b2a-0cf82e2fad16" xlink:to="loc_us-gaap_BuildingMember_ff250b5b-a6e9-45a8-b9ab-5d37359d5caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_1b77fcbd-65af-4195-9149-1ff5296ae3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b932c77a-d0cf-48fa-8b2a-0cf82e2fad16" xlink:to="loc_us-gaap_LandMember_1b77fcbd-65af-4195-9149-1ff5296ae3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_e81b6746-fdf5-43e8-94b2-14897fa48514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b932c77a-d0cf-48fa-8b2a-0cf82e2fad16" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_e81b6746-fdf5-43e8-94b2-14897fa48514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9026b9-b478-4119-9b4c-2228dfed929f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3ad569d6-161a-4f0c-b7aa-0db8199fd3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3ad569d6-161a-4f0c-b7aa-0db8199fd3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a93554e0-553c-47db-87be-d3ce4760c759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_Depreciation_a93554e0-553c-47db-87be-d3ce4760c759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_f9da24e5-0336-4b07-b387-73a79ce1e458" xlink:href="biib-20230930.xsd#biib_NumberOfSquareFeet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_biib_NumberOfSquareFeet_f9da24e5-0336-4b07-b387-73a79ce1e458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_dddc96b8-e89f-4f7e-bf2a-477fbc31942b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_ConstructionInProgressGross_dddc96b8-e89f-4f7e-bf2a-477fbc31942b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_414bdd1e-e487-4513-bbfa-c60386e258ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_414bdd1e-e487-4513-bbfa-c60386e258ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_d9f054d3-5f22-4de8-9426-b3a49d9391f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_d9f054d3-5f22-4de8-9426-b3a49d9391f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_0874f502-66b8-4b94-b1c4-54f0d402debc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_0874f502-66b8-4b94-b1c4-54f0d402debc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_9fb29597-3bfc-44a2-8bcf-3661255f519c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_9fb29597-3bfc-44a2-8bcf-3661255f519c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance_757b3399-13ac-48b5-8842-16ed22b13d65" xlink:href="biib-20230930.xsd#biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance_757b3399-13ac-48b5-8842-16ed22b13d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ff4e412e-bfb2-4b16-a5cc-a399702da6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ff4e412e-bfb2-4b16-a5cc-a399702da6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7f87c200-9a2b-4309-884c-4d228ade8cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9f965a99-bf44-4dab-bcba-1809556df0b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7f87c200-9a2b-4309-884c-4d228ade8cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="simple" xlink:href="biib-20230930.xsd#LeasesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d58aa75e-9090-450c-a07f-2d3fe2ced101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_901fa31a-760c-4369-8a65-675f60ad07a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d58aa75e-9090-450c-a07f-2d3fe2ced101" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_901fa31a-760c-4369-8a65-675f60ad07a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6c338913-1d33-497f-a30d-337c3b822028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_901fa31a-760c-4369-8a65-675f60ad07a4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6c338913-1d33-497f-a30d-337c3b822028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_538a2301-79a1-4686-afc6-6a7d3a8fef9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6c338913-1d33-497f-a30d-337c3b822028" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_538a2301-79a1-4686-afc6-6a7d3a8fef9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_fc4c0f5e-2952-4cc4-bbcc-1413f0f6ba1a" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_538a2301-79a1-4686-afc6-6a7d3a8fef9d" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_fc4c0f5e-2952-4cc4-bbcc-1413f0f6ba1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3a8b8770-a44e-4a7a-af5b-1f2ce063ac1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_901fa31a-760c-4369-8a65-675f60ad07a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3a8b8770-a44e-4a7a-af5b-1f2ce063ac1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72846db2-3634-4cd1-8865-9b714fd5b4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3a8b8770-a44e-4a7a-af5b-1f2ce063ac1f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72846db2-3634-4cd1-8865-9b714fd5b4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_4bcde39e-0499-4fd3-88c5-d4c573bd87e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72846db2-3634-4cd1-8865-9b714fd5b4fe" xlink:to="loc_us-gaap_BuildingMember_4bcde39e-0499-4fd3-88c5-d4c573bd87e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_901fa31a-760c-4369-8a65-675f60ad07a4" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_52e708fe-3d91-45cd-a7ca-ec8a4664cb09" xlink:href="biib-20230930.xsd#biib_OperatingLeaseArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_biib_OperatingLeaseArea_52e708fe-3d91-45cd-a7ca-ec8a4664cb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1290c016-a91e-48d0-b94f-acb1f09e52ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1290c016-a91e-48d0-b94f-acb1f09e52ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_48e35310-e958-4743-8324-f516be407e90" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_48e35310-e958-4743-8324-f516be407e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_57e69a99-4da5-480d-b407-5655e55d8455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_57e69a99-4da5-480d-b407-5655e55d8455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_ce3625ce-7cea-4972-a6d9-d21ab4763736" xlink:href="biib-20230930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_ce3625ce-7cea-4972-a6d9-d21ab4763736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e006f15b-fb3e-4287-b73a-de5c9703a193" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e006f15b-fb3e-4287-b73a-de5c9703a193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_89469490-945a-4b29-ae85-71c6a186419b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_us-gaap_OperatingLeaseLiability_89469490-945a-4b29-ae85-71c6a186419b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseRightOfUseAssetDerecognized_6528983d-477d-48bb-95f9-440e9b2a0423" xlink:href="biib-20230930.xsd#biib_OperatingLeaseRightOfUseAssetDerecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_biib_OperatingLeaseRightOfUseAssetDerecognized_6528983d-477d-48bb-95f9-440e9b2a0423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseLiabilityDerecognized_618c228d-f47f-46af-811f-bed33b84a704" xlink:href="biib-20230930.xsd#biib_OperatingLeaseLiabilityDerecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_biib_OperatingLeaseLiabilityDerecognized_618c228d-f47f-46af-811f-bed33b84a704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GainLossOnRestructuringCharges_41d77cfc-eaa4-4346-a228-65a8c1d337f9" xlink:href="biib-20230930.xsd#biib_GainLossOnRestructuringCharges"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_5aadf5c3-0417-4000-b7a8-9936181b1b94" xlink:to="loc_biib_GainLossOnRestructuringCharges_41d77cfc-eaa4-4346-a228-65a8c1d337f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#IndebtednessDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3e1bc0f8-e188-4357-a1c6-5725d24f28bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ad6dadab-ff9b-41e8-b129-651793f49ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3e1bc0f8-e188-4357-a1c6-5725d24f28bb" xlink:to="loc_us-gaap_DebtInstrumentTable_ad6dadab-ff9b-41e8-b129-651793f49ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_63cacc3c-f1a7-44a4-8bfc-be7f16e8e840" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad6dadab-ff9b-41e8-b129-651793f49ef3" xlink:to="loc_us-gaap_DebtInstrumentAxis_63cacc3c-f1a7-44a4-8bfc-be7f16e8e840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_55ea5fe0-5837-4879-bf8d-58b4af7694c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_63cacc3c-f1a7-44a4-8bfc-be7f16e8e840" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_55ea5fe0-5837-4879-bf8d-58b4af7694c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_8aee700f-e7c6-48d3-9c34-13a4491e0faa" xlink:href="biib-20230930.xsd#biib_TheCreditFacilityFloatingRate364DayTrancheMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_55ea5fe0-5837-4879-bf8d-58b4af7694c4" xlink:to="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_8aee700f-e7c6-48d3-9c34-13a4491e0faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_56c7ea78-5bb0-40fb-ac3d-a48714f788dd" xlink:href="biib-20230930.xsd#biib_TheCreditFacilityFloatingRateThreeYearTrancheMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_55ea5fe0-5837-4879-bf8d-58b4af7694c4" xlink:to="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_56c7ea78-5bb0-40fb-ac3d-a48714f788dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityTerminatedMember_7b216031-c282-4762-83ae-86d2da6186eb" xlink:href="biib-20230930.xsd#biib_TheCreditFacilityTerminatedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_55ea5fe0-5837-4879-bf8d-58b4af7694c4" xlink:to="loc_biib_TheCreditFacilityTerminatedMember_7b216031-c282-4762-83ae-86d2da6186eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_ad6c2ce6-9508-491d-84dd-bfb359c24f29" xlink:href="biib-20230930.xsd#biib_TheCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_55ea5fe0-5837-4879-bf8d-58b4af7694c4" xlink:to="loc_biib_TheCreditFacilityMember_ad6c2ce6-9508-491d-84dd-bfb359c24f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_17fa091a-3b76-47b4-a70a-0571588d2d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad6dadab-ff9b-41e8-b129-651793f49ef3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_17fa091a-3b76-47b4-a70a-0571588d2d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7f52b7a7-b1d0-4790-986f-a13a40a92f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_17fa091a-3b76-47b4-a70a-0571588d2d59" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7f52b7a7-b1d0-4790-986f-a13a40a92f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5c8b9f57-2690-4bb8-85b0-19ce5b53c37b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7f52b7a7-b1d0-4790-986f-a13a40a92f6a" xlink:to="loc_us-gaap_LineOfCreditMember_5c8b9f57-2690-4bb8-85b0-19ce5b53c37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9c15ae09-c7d3-4adf-8284-af138cc99628" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad6dadab-ff9b-41e8-b129-651793f49ef3" xlink:to="loc_us-gaap_CreditFacilityAxis_9c15ae09-c7d3-4adf-8284-af138cc99628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0254c92c-b3ba-424f-8f53-65e953120297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_9c15ae09-c7d3-4adf-8284-af138cc99628" xlink:to="loc_us-gaap_CreditFacilityDomain_0254c92c-b3ba-424f-8f53-65e953120297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_1c1221f4-67d3-4de6-aed2-4678ddf34c41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0254c92c-b3ba-424f-8f53-65e953120297" xlink:to="loc_us-gaap_SecuredDebtMember_1c1221f4-67d3-4de6-aed2-4678ddf34c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ebfc370f-5c00-4a37-8a4d-52c7c4e09b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad6dadab-ff9b-41e8-b129-651793f49ef3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ebfc370f-5c00-4a37-8a4d-52c7c4e09b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d985d3a1-3ecb-4593-88eb-943f72a155a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ebfc370f-5c00-4a37-8a4d-52c7c4e09b7e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d985d3a1-3ecb-4593-88eb-943f72a155a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_aa2e558f-82d2-4890-8aa4-c9584e8e4c8e" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d985d3a1-3ecb-4593-88eb-943f72a155a0" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_aa2e558f-82d2-4890-8aa4-c9584e8e4c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_937f69b5-c72b-4abe-ba3f-709817c569e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad6dadab-ff9b-41e8-b129-651793f49ef3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_937f69b5-c72b-4abe-ba3f-709817c569e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_cc419967-0777-46c4-b883-feb499e89ace" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_937f69b5-c72b-4abe-ba3f-709817c569e8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_cc419967-0777-46c4-b883-feb499e89ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionRate_b16e3205-0848-40bc-bc6d-a224bff829cc" xlink:href="biib-20230930.xsd#biib_DebtInstrumentRedemptionRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_937f69b5-c72b-4abe-ba3f-709817c569e8" xlink:to="loc_biib_DebtInstrumentRedemptionRate_b16e3205-0848-40bc-bc6d-a224bff829cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cc23418a-5f01-4252-9fd8-3f4f0e2e4c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_937f69b5-c72b-4abe-ba3f-709817c569e8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cc23418a-5f01-4252-9fd8-3f4f0e2e4c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_6094c85f-8bcf-4990-beb4-107ff6d6c787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_937f69b5-c72b-4abe-ba3f-709817c569e8" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_6094c85f-8bcf-4990-beb4-107ff6d6c787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_718fe174-f9ae-4acc-8862-71ff96b71c83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_937f69b5-c72b-4abe-ba3f-709817c569e8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_718fe174-f9ae-4acc-8862-71ff96b71c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3212e150-9ed9-4c8c-8bd8-2abadccfa2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_937f69b5-c72b-4abe-ba3f-709817c569e8" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3212e150-9ed9-4c8c-8bd8-2abadccfa2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#ShareRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f6d3faea-0446-4b70-b133-e80f9d8b5295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f0d23541-790b-4849-ae7c-af5c8b1f5afb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6d3faea-0446-4b70-b133-e80f9d8b5295" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f0d23541-790b-4849-ae7c-af5c8b1f5afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_3d892e44-3a0e-4732-b649-0472bca23524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f0d23541-790b-4849-ae7c-af5c8b1f5afb" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_3d892e44-3a0e-4732-b649-0472bca23524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_510e7f29-e6d3-4630-a1b0-122934ffd9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_3d892e44-3a0e-4732-b649-0472bca23524" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_510e7f29-e6d3-4630-a1b0-122934ffd9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_0f3e406c-f304-4841-b3a9-12594a2872c4" xlink:href="biib-20230930.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_510e7f29-e6d3-4630-a1b0-122934ffd9dc" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_0f3e406c-f304-4841-b3a9-12594a2872c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b550047e-8d37-47a3-b342-6a92fbd9892e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f0d23541-790b-4849-ae7c-af5c8b1f5afb" xlink:to="loc_us-gaap_ClassOfStockLineItems_b550047e-8d37-47a3-b342-6a92fbd9892e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_f03b6f20-c9e2-4d08-8a1a-01f6b3a806a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b550047e-8d37-47a3-b342-6a92fbd9892e" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_f03b6f20-c9e2-4d08-8a1a-01f6b3a806a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_22190842-7b02-4e5a-911a-0eaabeaf3028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b550047e-8d37-47a3-b342-6a92fbd9892e" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_22190842-7b02-4e5a-911a-0eaabeaf3028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_170c6e45-7d96-460d-8997-6ac5e609a542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b550047e-8d37-47a3-b342-6a92fbd9892e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_170c6e45-7d96-460d-8997-6ac5e609a542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_63ee33af-eab3-4a1b-a6a1-65ea167dac0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b550047e-8d37-47a3-b342-6a92fbd9892e" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_63ee33af-eab3-4a1b-a6a1-65ea167dac0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2cca02e5-4acd-42b9-b0fc-a7f37b4941fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3600f90b-5874-4aae-9b40-66b7efa10a08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2cca02e5-4acd-42b9-b0fc-a7f37b4941fd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3600f90b-5874-4aae-9b40-66b7efa10a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d702a827-cfd7-4dc2-bf6d-d9628f99b237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3600f90b-5874-4aae-9b40-66b7efa10a08" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d702a827-cfd7-4dc2-bf6d-d9628f99b237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e5c73d32-05be-40d8-9bcb-766140aaff6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d702a827-cfd7-4dc2-bf6d-d9628f99b237" xlink:to="loc_us-gaap_EquityComponentDomain_e5c73d32-05be-40d8-9bcb-766140aaff6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_26586ff1-0167-4a26-8e18-55b4d71f3c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e5c73d32-05be-40d8-9bcb-766140aaff6e" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_26586ff1-0167-4a26-8e18-55b4d71f3c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9157f1e2-6f40-4d3e-9afe-52535168ed56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e5c73d32-05be-40d8-9bcb-766140aaff6e" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9157f1e2-6f40-4d3e-9afe-52535168ed56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_bb648e4c-6846-49ef-b23b-7baf8ed2b057" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e5c73d32-05be-40d8-9bcb-766140aaff6e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_bb648e4c-6846-49ef-b23b-7baf8ed2b057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_1653f06c-8fd1-41d6-bd28-0138dab03a85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e5c73d32-05be-40d8-9bcb-766140aaff6e" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_1653f06c-8fd1-41d6-bd28-0138dab03a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7c1a472d-691f-4d2c-b40b-c43a6a61fc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e5c73d32-05be-40d8-9bcb-766140aaff6e" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7c1a472d-691f-4d2c-b40b-c43a6a61fc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b18bb230-58ed-423d-b468-9f5596f2f13f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3600f90b-5874-4aae-9b40-66b7efa10a08" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b18bb230-58ed-423d-b468-9f5596f2f13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b82bb91-d5e6-49e7-a5de-4d4504c4246e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b18bb230-58ed-423d-b468-9f5596f2f13f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b82bb91-d5e6-49e7-a5de-4d4504c4246e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ee275015-d5f4-4b9b-8687-37ef6b9666a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b18bb230-58ed-423d-b468-9f5596f2f13f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ee275015-d5f4-4b9b-8687-37ef6b9666a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_bd145d32-1429-4cbe-a19c-74d8428174bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b18bb230-58ed-423d-b468-9f5596f2f13f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_bd145d32-1429-4cbe-a19c-74d8428174bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7b102feb-3655-43e1-9639-5cef3b394cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b18bb230-58ed-423d-b468-9f5596f2f13f" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7b102feb-3655-43e1-9639-5cef3b394cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2532f3d4-e8dd-4957-b6e4-67cb05c068bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b18bb230-58ed-423d-b468-9f5596f2f13f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2532f3d4-e8dd-4957-b6e4-67cb05c068bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ba2b6ded-9e35-4f90-833e-f29d62636969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b18bb230-58ed-423d-b468-9f5596f2f13f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ba2b6ded-9e35-4f90-833e-f29d62636969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_abf152ab-8e98-49db-b6a8-6da3a5ef0876" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b18bb230-58ed-423d-b468-9f5596f2f13f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_abf152ab-8e98-49db-b6a8-6da3a5ef0876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_342d6120-bd40-42e3-8346-464719f9db59" xlink:href="biib-20230930.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b75c8865-544f-412b-b87f-87b938ef499c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_342d6120-bd40-42e3-8346-464719f9db59" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b75c8865-544f-412b-b87f-87b938ef499c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a1c54b86-36a7-4a8d-bd29-70003328485d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b75c8865-544f-412b-b87f-87b938ef499c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a1c54b86-36a7-4a8d-bd29-70003328485d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5f640077-51cd-43a3-8161-0bfe09801678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a1c54b86-36a7-4a8d-bd29-70003328485d" xlink:to="loc_us-gaap_EquityComponentDomain_5f640077-51cd-43a3-8161-0bfe09801678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_7c003900-9c5b-401e-9c6a-3155cf691c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5f640077-51cd-43a3-8161-0bfe09801678" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_7c003900-9c5b-401e-9c6a-3155cf691c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_34e2debc-43f5-4db2-aebf-dd11bffaf1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5f640077-51cd-43a3-8161-0bfe09801678" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_34e2debc-43f5-4db2-aebf-dd11bffaf1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_c8c1c0d5-14f0-4102-ab31-5e6f72076093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5f640077-51cd-43a3-8161-0bfe09801678" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_c8c1c0d5-14f0-4102-ab31-5e6f72076093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_8f3d6af6-c5a8-498a-b960-3b51466c4475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5f640077-51cd-43a3-8161-0bfe09801678" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_8f3d6af6-c5a8-498a-b960-3b51466c4475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_35c8fc89-b268-4810-8590-31c03cff56d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b75c8865-544f-412b-b87f-87b938ef499c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_35c8fc89-b268-4810-8590-31c03cff56d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_76dd2d12-f884-4ae0-b34c-acd3eb746362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_35c8fc89-b268-4810-8590-31c03cff56d6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_76dd2d12-f884-4ae0-b34c-acd3eb746362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_44f904e7-55e0-4b1c-8f12-948e6cd69d22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_76dd2d12-f884-4ae0-b34c-acd3eb746362" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_44f904e7-55e0-4b1c-8f12-948e6cd69d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_26d82635-a917-4c29-9d8c-a34695682100" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b75c8865-544f-412b-b87f-87b938ef499c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_26d82635-a917-4c29-9d8c-a34695682100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_52b51d50-5875-45f7-a57f-0bfdd50c23d9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_26d82635-a917-4c29-9d8c-a34695682100" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_52b51d50-5875-45f7-a57f-0bfdd50c23d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_4c462db2-cec3-4b13-9902-8e046823cb24" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_52b51d50-5875-45f7-a57f-0bfdd50c23d9" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_4c462db2-cec3-4b13-9902-8e046823cb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b2f160bc-f76a-4ef7-8478-adda51a8cbad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b75c8865-544f-412b-b87f-87b938ef499c" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b2f160bc-f76a-4ef7-8478-adda51a8cbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1cf006c9-51bb-41d8-8bd5-430d3427928e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b2f160bc-f76a-4ef7-8478-adda51a8cbad" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1cf006c9-51bb-41d8-8bd5-430d3427928e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2d8371bf-cc2e-48f8-a84d-663efd8b6b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b2f160bc-f76a-4ef7-8478-adda51a8cbad" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2d8371bf-cc2e-48f8-a84d-663efd8b6b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fc96df3f-d048-4402-9bfe-058f274ce4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b2f160bc-f76a-4ef7-8478-adda51a8cbad" xlink:to="loc_us-gaap_Revenues_fc96df3f-d048-4402-9bfe-058f274ce4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6d9c78db-0f09-4a5e-8712-6fd49f0a1416" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b2f160bc-f76a-4ef7-8478-adda51a8cbad" xlink:to="loc_us-gaap_OperatingExpenses_6d9c78db-0f09-4a5e-8712-6fd49f0a1416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6558e6f4-d266-433a-80a0-91bdff898139" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b2f160bc-f76a-4ef7-8478-adda51a8cbad" xlink:to="loc_us-gaap_NetIncomeLoss_6558e6f4-d266-433a-80a0-91bdff898139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_6e048844-0f43-41da-b73d-caa220f7f8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_b2f160bc-f76a-4ef7-8478-adda51a8cbad" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_6e048844-0f43-41da-b73d-caa220f7f8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#EarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a955c747-7580-41b8-980b-831519c25643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc97a85d-9691-4726-8eb0-e0641f2fc7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a955c747-7580-41b8-980b-831519c25643" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc97a85d-9691-4726-8eb0-e0641f2fc7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_db5ea084-a684-4d6f-befd-a4a380d76460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc97a85d-9691-4726-8eb0-e0641f2fc7b0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_db5ea084-a684-4d6f-befd-a4a380d76460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfcabece-9540-4071-9c60-ccae89e696c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_db5ea084-a684-4d6f-befd-a4a380d76460" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfcabece-9540-4071-9c60-ccae89e696c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_5f51fc9a-aa31-4300-8353-14828a16eead" xlink:href="biib-20230930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfcabece-9540-4071-9c60-ccae89e696c5" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_5f51fc9a-aa31-4300-8353-14828a16eead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_18a74cf6-d9ee-4e16-b8ad-2dfc9a6e2192" xlink:href="biib-20230930.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfcabece-9540-4071-9c60-ccae89e696c5" xlink:to="loc_biib_MarketStockUnitsMember_18a74cf6-d9ee-4e16-b8ad-2dfc9a6e2192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_e91dedb5-a0d5-43ba-bfee-a0f51bb54c7c" xlink:href="biib-20230930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfcabece-9540-4071-9c60-ccae89e696c5" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_e91dedb5-a0d5-43ba-bfee-a0f51bb54c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_836d0087-4127-4b48-b768-244217ec5c25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cc97a85d-9691-4726-8eb0-e0641f2fc7b0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_836d0087-4127-4b48-b768-244217ec5c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1228b794-e0e0-4160-89ac-f8a252a3dd90" xlink:href="biib-20230930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_836d0087-4127-4b48-b768-244217ec5c25" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1228b794-e0e0-4160-89ac-f8a252a3dd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_0bd00b35-c3a5-4d53-b478-99edb07c449b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1228b794-e0e0-4160-89ac-f8a252a3dd90" xlink:to="loc_us-gaap_NetIncomeLossAbstract_0bd00b35-c3a5-4d53-b478-99edb07c449b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_596cd850-9aea-4f53-8d36-f0f04a43f7df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_0bd00b35-c3a5-4d53-b478-99edb07c449b" xlink:to="loc_us-gaap_NetIncomeLoss_596cd850-9aea-4f53-8d36-f0f04a43f7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4caac43f-beca-4d62-9dfe-79c459199a44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1228b794-e0e0-4160-89ac-f8a252a3dd90" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4caac43f-beca-4d62-9dfe-79c459199a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8e412c48-d9fb-414a-aba2-43764b8141ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4caac43f-beca-4d62-9dfe-79c459199a44" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8e412c48-d9fb-414a-aba2-43764b8141ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_70f1092c-cc03-408c-8c57-f9821ca63016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4caac43f-beca-4d62-9dfe-79c459199a44" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_70f1092c-cc03-408c-8c57-f9821ca63016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_aef7947f-65c5-4851-9abc-736b11345630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_70f1092c-cc03-408c-8c57-f9821ca63016" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_aef7947f-65c5-4851-9abc-736b11345630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1b4ac2b3-8060-435e-b651-e74068c1835b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_70f1092c-cc03-408c-8c57-f9821ca63016" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1b4ac2b3-8060-435e-b651-e74068c1835b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d3e96a09-8131-46c0-a387-56c7bd0433f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4caac43f-beca-4d62-9dfe-79c459199a44" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d3e96a09-8131-46c0-a387-56c7bd0433f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#ShareBasedPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_de98bd93-a05a-4ad9-9939-f5ce322e40cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b234df1f-9791-4ef8-9ca3-65a4aac00a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_de98bd93-a05a-4ad9-9939-f5ce322e40cb" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b234df1f-9791-4ef8-9ca3-65a4aac00a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0e38116f-4fa5-4c50-ab6d-0d70162ec8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b234df1f-9791-4ef8-9ca3-65a4aac00a9e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0e38116f-4fa5-4c50-ab6d-0d70162ec8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6c7b448e-e45c-4521-8ef9-dd5f981cf6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0e38116f-4fa5-4c50-ab6d-0d70162ec8b7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6c7b448e-e45c-4521-8ef9-dd5f981cf6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d56fc863-4089-4658-8d94-175b410575f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c7b448e-e45c-4521-8ef9-dd5f981cf6ff" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d56fc863-4089-4658-8d94-175b410575f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a20f1ea8-660f-4636-9914-72d2d7337031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c7b448e-e45c-4521-8ef9-dd5f981cf6ff" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a20f1ea8-660f-4636-9914-72d2d7337031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_ecbd7652-4b99-410e-8f25-9f73d63515f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c7b448e-e45c-4521-8ef9-dd5f981cf6ff" xlink:to="loc_us-gaap_ParentMember_ecbd7652-4b99-410e-8f25-9f73d63515f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_35732d97-355b-4792-808c-b35fa0acaf91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b234df1f-9791-4ef8-9ca3-65a4aac00a9e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_35732d97-355b-4792-808c-b35fa0acaf91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46d2891d-21bd-4797-8af7-3bfa1179d1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_35732d97-355b-4792-808c-b35fa0acaf91" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46d2891d-21bd-4797-8af7-3bfa1179d1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_137bad06-1a80-4f7c-b776-37befadb6032" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46d2891d-21bd-4797-8af7-3bfa1179d1ea" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_137bad06-1a80-4f7c-b776-37befadb6032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23ce317a-995b-4746-a462-2dcc7f1f956d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b234df1f-9791-4ef8-9ca3-65a4aac00a9e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23ce317a-995b-4746-a462-2dcc7f1f956d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6a5d84f6-2af3-4cc8-8c47-a4c899a99454" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23ce317a-995b-4746-a462-2dcc7f1f956d" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6a5d84f6-2af3-4cc8-8c47-a4c899a99454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d995834f-b2af-4944-961e-f381a66bcb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6a5d84f6-2af3-4cc8-8c47-a4c899a99454" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d995834f-b2af-4944-961e-f381a66bcb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5c0e9fc8-b758-4362-819f-0c3d662ca9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6a5d84f6-2af3-4cc8-8c47-a4c899a99454" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5c0e9fc8-b758-4362-819f-0c3d662ca9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_086db288-8128-48d4-a96c-bb32706b8cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6a5d84f6-2af3-4cc8-8c47-a4c899a99454" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_086db288-8128-48d4-a96c-bb32706b8cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_cc71ac23-0b7e-4a53-a71f-e3ac7e5ccc91" xlink:href="biib-20230930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6a5d84f6-2af3-4cc8-8c47-a4c899a99454" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_cc71ac23-0b7e-4a53-a71f-e3ac7e5ccc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_414319ba-0ac3-4aee-add7-f79d1ece8c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6a5d84f6-2af3-4cc8-8c47-a4c899a99454" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_414319ba-0ac3-4aee-add7-f79d1ece8c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b5633707-aa4c-4f01-b005-ef74a15a6696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23ce317a-995b-4746-a462-2dcc7f1f956d" xlink:to="loc_us-gaap_OperatingExpenses_b5633707-aa4c-4f01-b005-ef74a15a6696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8303d18e-9edf-4e8b-9fcd-74edec9463b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23ce317a-995b-4746-a462-2dcc7f1f956d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8303d18e-9edf-4e8b-9fcd-74edec9463b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_805486a9-b9c4-4798-abd5-cfbce1f71b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_23ce317a-995b-4746-a462-2dcc7f1f956d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_805486a9-b9c4-4798-abd5-cfbce1f71b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20230930.xsd#ShareBasedPaymentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5eaa053-89cd-475f-a501-86e76323c1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e640247e-34dd-4ce9-8710-ee23a7c7a0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5eaa053-89cd-475f-a501-86e76323c1cc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e640247e-34dd-4ce9-8710-ee23a7c7a0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_698cabc6-bbf3-4a6e-9fe9-745c20344753" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e640247e-34dd-4ce9-8710-ee23a7c7a0d0" xlink:to="loc_us-gaap_AwardTypeAxis_698cabc6-bbf3-4a6e-9fe9-745c20344753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_698cabc6-bbf3-4a6e-9fe9-745c20344753" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_aedac6df-44e2-43da-848c-c411030588c5" xlink:href="biib-20230930.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:to="loc_biib_MarketStockUnitsMember_aedac6df-44e2-43da-848c-c411030588c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_af498cfb-5ea2-4a68-9f7b-5ba54e1bdefa" xlink:href="biib-20230930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_af498cfb-5ea2-4a68-9f7b-5ba54e1bdefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_22706b65-5945-4d13-b836-2f99f245fb81" xlink:href="biib-20230930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_22706b65-5945-4d13-b836-2f99f245fb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_243ac61d-1940-4403-af4f-7e80dc4068f8" xlink:href="biib-20230930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_243ac61d-1940-4403-af4f-7e80dc4068f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_9107b5fb-5737-4551-bf54-a93be20590a9" xlink:href="biib-20230930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_9107b5fb-5737-4551-bf54-a93be20590a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e00b8460-3a72-468b-ae2b-94a4cb0d6c10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e00b8460-3a72-468b-ae2b-94a4cb0d6c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityAwardsOfAcquiredCompanyMember_8af9e306-e2fb-429c-9c15-d954972c4eed" xlink:href="biib-20230930.xsd#biib_EquityAwardsOfAcquiredCompanyMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee666a0e-f83b-4c77-9e69-c8daba32f483" xlink:to="loc_biib_EquityAwardsOfAcquiredCompanyMember_8af9e306-e2fb-429c-9c15-d954972c4eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1d4eae56-4d18-4be1-9ed1-3a994eef130f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e640247e-34dd-4ce9-8710-ee23a7c7a0d0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1d4eae56-4d18-4be1-9ed1-3a994eef130f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10a3af3e-f281-487e-9301-dc66158ed067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1d4eae56-4d18-4be1-9ed1-3a994eef130f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10a3af3e-f281-487e-9301-dc66158ed067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_cd89e34f-c354-4544-9dee-d058d4b78e65" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10a3af3e-f281-487e-9301-dc66158ed067" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_cd89e34f-c354-4544-9dee-d058d4b78e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_646a8aa7-8826-4551-8178-8c1d884b2155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e640247e-34dd-4ce9-8710-ee23a7c7a0d0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_646a8aa7-8826-4551-8178-8c1d884b2155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_7bda1ebd-0a28-48c5-9069-9866822ef420" xlink:href="biib-20230930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_646a8aa7-8826-4551-8178-8c1d884b2155" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_7bda1ebd-0a28-48c5-9069-9866822ef420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c4c9f5e8-5da9-4ad2-ad7b-b6b95d1e48e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_7bda1ebd-0a28-48c5-9069-9866822ef420" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c4c9f5e8-5da9-4ad2-ad7b-b6b95d1e48e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a43f8887-7ecf-440e-ab9d-92a6df0ca79b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_7bda1ebd-0a28-48c5-9069-9866822ef420" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a43f8887-7ecf-440e-ab9d-92a6df0ca79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_fe668a51-db04-4628-a3f9-6a1ec322b63d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_7bda1ebd-0a28-48c5-9069-9866822ef420" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_fe668a51-db04-4628-a3f9-6a1ec322b63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_7a7e4c74-45e3-4a28-b563-4023c7e9ebea" xlink:href="biib-20230930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_7bda1ebd-0a28-48c5-9069-9866822ef420" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_7a7e4c74-45e3-4a28-b563-4023c7e9ebea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_8a18ab71-ab29-4b57-8e00-fb2df6270569" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_646a8aa7-8826-4551-8178-8c1d884b2155" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_8a18ab71-ab29-4b57-8e00-fb2df6270569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20230930.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2d78d767-1e26-4ebd-a7c4-6e89e14228b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_01a02dc6-4e54-4524-aaed-39e9fe2eb36a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d78d767-1e26-4ebd-a7c4-6e89e14228b1" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_01a02dc6-4e54-4524-aaed-39e9fe2eb36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_17695cf0-b352-4c55-a7ae-69fc997b87a6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_01a02dc6-4e54-4524-aaed-39e9fe2eb36a" xlink:to="loc_srt_StatementScenarioAxis_17695cf0-b352-4c55-a7ae-69fc997b87a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_09cc6f15-791c-4f8e-a7e8-40e142a4abeb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_17695cf0-b352-4c55-a7ae-69fc997b87a6" xlink:to="loc_srt_ScenarioUnspecifiedDomain_09cc6f15-791c-4f8e-a7e8-40e142a4abeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a9df2c12-b906-4c3c-92fa-22fcb6644c51" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_09cc6f15-791c-4f8e-a7e8-40e142a4abeb" xlink:to="loc_srt_ScenarioForecastMember_a9df2c12-b906-4c3c-92fa-22fcb6644c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_efc8b9df-00bd-4a74-934c-170b65890a5f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_01a02dc6-4e54-4524-aaed-39e9fe2eb36a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_efc8b9df-00bd-4a74-934c-170b65890a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_802c388a-0c73-4199-8b5d-040c72c7e941" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_efc8b9df-00bd-4a74-934c-170b65890a5f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_802c388a-0c73-4199-8b5d-040c72c7e941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_17529daa-0df8-47b8-b113-ad95c2787ad3" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_802c388a-0c73-4199-8b5d-040c72c7e941" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_17529daa-0df8-47b8-b113-ad95c2787ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4aeb574e-18fe-48aa-9534-3115134d8b6d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_01a02dc6-4e54-4524-aaed-39e9fe2eb36a" xlink:to="loc_srt_ProductOrServiceAxis_4aeb574e-18fe-48aa-9534-3115134d8b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_37642972-c032-48e3-ad6c-ebb5ce876d72" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4aeb574e-18fe-48aa-9534-3115134d8b6d" xlink:to="loc_srt_ProductsAndServicesDomain_37642972-c032-48e3-ad6c-ebb5ce876d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_48f779e2-4c2d-4f4b-b424-07da5ef902ca" xlink:href="biib-20230930.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37642972-c032-48e3-ad6c-ebb5ce876d72" xlink:to="loc_biib_ADUHELMMember_48f779e2-4c2d-4f4b-b424-07da5ef902ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_25217c06-3030-4c17-bcb0-9e9c682c4ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_01a02dc6-4e54-4524-aaed-39e9fe2eb36a" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_25217c06-3030-4c17-bcb0-9e9c682c4ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_aab72881-ad2d-459a-8f64-0119476736e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25217c06-3030-4c17-bcb0-9e9c682c4ce1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_aab72881-ad2d-459a-8f64-0119476736e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_7d9ccc60-c2e0-4e4f-8a01-4f6fa2bcf0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25217c06-3030-4c17-bcb0-9e9c682c4ce1" xlink:to="loc_us-gaap_EquityMethodInvestments_7d9ccc60-c2e0-4e4f-8a01-4f6fa2bcf0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_cca2d7e9-6c00-43ca-b11e-685eccd0f643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_25217c06-3030-4c17-bcb0-9e9c682c4ce1" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_cca2d7e9-6c00-43ca-b11e-685eccd0f643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2dfc360f-639c-4bc1-b239-f6f736b06393" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f8aab2cf-2a5f-4d57-8858-b446453a54aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2dfc360f-639c-4bc1-b239-f6f736b06393" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f8aab2cf-2a5f-4d57-8858-b446453a54aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4b3cd718-9b7f-4542-93a4-3bd91bd1495a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f8aab2cf-2a5f-4d57-8858-b446453a54aa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4b3cd718-9b7f-4542-93a4-3bd91bd1495a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_95c12d93-9d2d-4115-b2bb-d823d650ea39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f8aab2cf-2a5f-4d57-8858-b446453a54aa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_95c12d93-9d2d-4115-b2bb-d823d650ea39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_b2d6da96-396d-4b7f-bae0-bc26cb325ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f8aab2cf-2a5f-4d57-8858-b446453a54aa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_b2d6da96-396d-4b7f-bae0-bc26cb325ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_3a43202a-0652-429d-8e68-2fb4a5b94c36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f8aab2cf-2a5f-4d57-8858-b446453a54aa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_3a43202a-0652-429d-8e68-2fb4a5b94c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_9eb74b48-f28f-446a-91ec-a766d871f9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f8aab2cf-2a5f-4d57-8858-b446453a54aa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_9eb74b48-f28f-446a-91ec-a766d871f9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_2031cb67-205b-4646-97a5-c0ce290413ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f8aab2cf-2a5f-4d57-8858-b446453a54aa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_2031cb67-205b-4646-97a5-c0ce290413ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_d710e615-d442-40b1-b281-8d6ef984e8c4" xlink:href="biib-20230930.xsd#biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f8aab2cf-2a5f-4d57-8858-b446453a54aa" xlink:to="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_d710e615-d442-40b1-b281-8d6ef984e8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement_7dd84428-955a-4884-9f90-abdd7fb97740" xlink:href="biib-20230930.xsd#biib_EffectiveTaxRateReconciliationLitigationAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f8aab2cf-2a5f-4d57-8858-b446453a54aa" xlink:to="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement_7dd84428-955a-4884-9f90-abdd7fb97740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_14ec6478-55e7-4f9d-b36b-d95f1f8927a7" xlink:href="biib-20230930.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f8aab2cf-2a5f-4d57-8858-b446453a54aa" xlink:to="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_14ec6478-55e7-4f9d-b36b-d95f1f8927a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization_77109d18-73de-42bb-9897-f3f9d633b8e5" xlink:href="biib-20230930.xsd#biib_EffectiveTaxRateReconciliationInternationalReorganization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f8aab2cf-2a5f-4d57-8858-b446453a54aa" xlink:to="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization_77109d18-73de-42bb-9897-f3f9d633b8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d41ec792-a6d7-4aec-9eac-a6cdc3a344d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f8aab2cf-2a5f-4d57-8858-b446453a54aa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d41ec792-a6d7-4aec-9eac-a6cdc3a344d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c338c2e2-d984-437c-83fd-734c105c95d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_f8aab2cf-2a5f-4d57-8858-b446453a54aa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c338c2e2-d984-437c-83fd-734c105c95d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4ee934c3-adbf-4455-bc53-18bc2d141b09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_200b5a04-998f-43b9-ae74-92815a01e408" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4ee934c3-adbf-4455-bc53-18bc2d141b09" xlink:to="loc_us-gaap_StatementTable_200b5a04-998f-43b9-ae74-92815a01e408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d4906e1c-3097-448d-90d5-d40561f4c996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_200b5a04-998f-43b9-ae74-92815a01e408" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d4906e1c-3097-448d-90d5-d40561f4c996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9b2b2fb7-1679-4023-9714-28792ed624b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d4906e1c-3097-448d-90d5-d40561f4c996" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9b2b2fb7-1679-4023-9714-28792ed624b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_4dfc5984-4a62-475a-84dc-4fb617e7ca9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9b2b2fb7-1679-4023-9714-28792ed624b1" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_4dfc5984-4a62-475a-84dc-4fb617e7ca9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1bfa0aac-8b27-4c50-abd7-abacb762e2e8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_200b5a04-998f-43b9-ae74-92815a01e408" xlink:to="loc_dei_LegalEntityAxis_1bfa0aac-8b27-4c50-abd7-abacb762e2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_976677be-90bf-49b9-a947-ae26b373f704" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1bfa0aac-8b27-4c50-abd7-abacb762e2e8" xlink:to="loc_dei_EntityDomain_976677be-90bf-49b9-a947-ae26b373f704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_78e09f4f-ab0b-4006-9448-56b46fd4e9df" xlink:href="biib-20230930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_976677be-90bf-49b9-a947-ae26b373f704" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_78e09f4f-ab0b-4006-9448-56b46fd4e9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f3ed7fd5-8b19-414a-877d-17dbf33e0edf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_200b5a04-998f-43b9-ae74-92815a01e408" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f3ed7fd5-8b19-414a-877d-17dbf33e0edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8dbca22c-1962-49c8-9f07-50d2784dc46e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f3ed7fd5-8b19-414a-877d-17dbf33e0edf" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8dbca22c-1962-49c8-9f07-50d2784dc46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_865e04d4-1b9f-407d-be40-94e55cfac9a3" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8dbca22c-1962-49c8-9f07-50d2784dc46e" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_865e04d4-1b9f-407d-be40-94e55cfac9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b6342ebe-cbae-4847-885e-7cb22098ca40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_200b5a04-998f-43b9-ae74-92815a01e408" xlink:to="loc_us-gaap_StatementLineItems_b6342ebe-cbae-4847-885e-7cb22098ca40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b6342ebe-cbae-4847-885e-7cb22098ca40" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_390d3ebd-eb1b-4021-922c-c37e2c74a29e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_390d3ebd-eb1b-4021-922c-c37e2c74a29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_6e67d2a0-38a2-4d12-b82b-c486168988ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_LitigationSettlementExpense_6e67d2a0-38a2-4d12-b82b-c486168988ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_989a2139-90d3-4a0e-b440-7a54d3b67b49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_989a2139-90d3-4a0e-b440-7a54d3b67b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9ea8c263-954c-448b-9ddb-5687f95c6864" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_InterestExpense_9ea8c263-954c-448b-9ddb-5687f95c6864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_e438e9e1-0f1b-4c40-ae84-465ba1a182ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_e438e9e1-0f1b-4c40-ae84-465ba1a182ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8df7d98e-ef3a-4c50-b264-4a495aba6d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8df7d98e-ef3a-4c50-b264-4a495aba6d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_737ae87d-a7e6-4b56-a447-6df7627b8b31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_737ae87d-a7e6-4b56-a447-6df7627b8b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_d606325f-d1ad-4996-8761-398eeb38d2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_d606325f-d1ad-4996-8761-398eeb38d2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_44a24d88-407c-4afa-9143-bc59474dce5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_86d77a2c-335e-4d62-ac47-364efacfabb2" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_44a24d88-407c-4afa-9143-bc59474dce5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_5c1a0023-0555-4d11-8c53-6da3424eaa21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b6342ebe-cbae-4847-885e-7cb22098ca40" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_5c1a0023-0555-4d11-8c53-6da3424eaa21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_c824403d-173e-40b3-95e2-bb5b4487f06f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_5c1a0023-0555-4d11-8c53-6da3424eaa21" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_c824403d-173e-40b3-95e2-bb5b4487f06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_e10237d2-7224-41e9-9f0e-687f26a1a840" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_5c1a0023-0555-4d11-8c53-6da3424eaa21" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_e10237d2-7224-41e9-9f0e-687f26a1a840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_25ccf128-5c62-468c-924d-ab28886e5295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_5c1a0023-0555-4d11-8c53-6da3424eaa21" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_25ccf128-5c62-468c-924d-ab28886e5295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b6342ebe-cbae-4847-885e-7cb22098ca40" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent_a9eced45-9c20-49f2-a66c-1a27262086d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:to="loc_us-gaap_SettlementLiabilitiesCurrent_a9eced45-9c20-49f2-a66c-1a27262086d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_08302578-8670-4f5b-8ade-a4093dd24139" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_08302578-8670-4f5b-8ade-a4093dd24139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7a3799f6-5b6d-4d0e-9a6b-625e93379693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7a3799f6-5b6d-4d0e-9a6b-625e93379693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_c15b2e44-0d2b-4446-a91d-0a352146263f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_c15b2e44-0d2b-4446-a91d-0a352146263f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_4e509e9b-a735-4dc1-bd15-f91eb4a49724" xlink:href="biib-20230930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:to="loc_biib_Collaborationexpensesaccrual_4e509e9b-a735-4dc1-bd15-f91eb4a49724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_59f0a7f1-d883-4d2f-90c9-fe53c50a45c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_59f0a7f1-d883-4d2f-90c9-fe53c50a45c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_bcf20e53-2068-419f-b6cc-e1583a6a08ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_7327d132-6262-4284-a44a-3f22cb549a3d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_bcf20e53-2068-419f-b6cc-e1583a6a08ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20230930.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1c269e9d-336f-44ab-b051-eb5bf927e1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_00fc6546-4e9f-4bfa-8123-9be9dbfef3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1c269e9d-336f-44ab-b051-eb5bf927e1a9" xlink:to="loc_us-gaap_StatementTable_00fc6546-4e9f-4bfa-8123-9be9dbfef3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cde9dd4d-2985-4b01-8d15-a2ad90a23d7e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_00fc6546-4e9f-4bfa-8123-9be9dbfef3f1" xlink:to="loc_dei_LegalEntityAxis_cde9dd4d-2985-4b01-8d15-a2ad90a23d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d0b5e144-fc17-4fd5-a6ac-11ecb1051b1e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_cde9dd4d-2985-4b01-8d15-a2ad90a23d7e" xlink:to="loc_dei_EntityDomain_d0b5e144-fc17-4fd5-a6ac-11ecb1051b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_ca2bdc2c-3c9f-4d2c-a215-622ab5c0fa98" xlink:href="biib-20230930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d0b5e144-fc17-4fd5-a6ac-11ecb1051b1e" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_ca2bdc2c-3c9f-4d2c-a215-622ab5c0fa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b5b2f492-ef0d-4a62-9aaf-32428e309328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_00fc6546-4e9f-4bfa-8123-9be9dbfef3f1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b5b2f492-ef0d-4a62-9aaf-32428e309328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92b11582-02d5-41e5-86e9-4061dc0bea35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b5b2f492-ef0d-4a62-9aaf-32428e309328" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92b11582-02d5-41e5-86e9-4061dc0bea35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_fc5e29ad-549f-4348-b728-28c0021ed14c" xlink:href="biib-20230930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92b11582-02d5-41e5-86e9-4061dc0bea35" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_fc5e29ad-549f-4348-b728-28c0021ed14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_28b2aaa0-e1e8-44ab-809f-33d88c0b2dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_00fc6546-4e9f-4bfa-8123-9be9dbfef3f1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_28b2aaa0-e1e8-44ab-809f-33d88c0b2dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3aeae0c0-0429-4a2b-be1e-2f233b925eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_28b2aaa0-e1e8-44ab-809f-33d88c0b2dbf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3aeae0c0-0429-4a2b-be1e-2f233b925eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_32e56f75-a6bd-47c1-b3b9-64546baae8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3aeae0c0-0429-4a2b-be1e-2f233b925eb5" xlink:to="loc_us-gaap_SubsequentEventMember_32e56f75-a6bd-47c1-b3b9-64546baae8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_00fc6546-4e9f-4bfa-8123-9be9dbfef3f1" xlink:to="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_0ff6617e-11c5-4349-b8dc-ffd02105fb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_LitigationSettlementExpense_0ff6617e-11c5-4349-b8dc-ffd02105fb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1392e7e2-ea4b-484f-adea-14af2ff3fa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1392e7e2-ea4b-484f-adea-14af2ff3fa9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_aa4da42c-f7ce-4310-ad37-4868f509e9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_aa4da42c-f7ce-4310-ad37-4868f509e9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f4aa40e5-45fb-4066-a210-b165e46e8fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f4aa40e5-45fb-4066-a210-b165e46e8fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_bcb9a7f7-9ebb-4db6-8dd0-89cbe3280467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_LossOnContractTermination_bcb9a7f7-9ebb-4db6-8dd0-89cbe3280467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0b562a04-6baf-4bd5-a007-eadcbe2c89d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0b562a04-6baf-4bd5-a007-eadcbe2c89d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_290fddf6-3614-482c-8bd2-b19ba1632e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_290fddf6-3614-482c-8bd2-b19ba1632e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_be4c1337-1428-48cf-a23a-9ac38039df75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c926e4a4-3d77-4aa4-8444-2245ca2877a6" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_be4c1337-1428-48cf-a23a-9ac38039df75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsOCREVUSDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_213e389f-b16a-44c7-ad47-bdfbc471de3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0205c080-57e0-48d5-8192-a11a991454c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_213e389f-b16a-44c7-ad47-bdfbc471de3d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0205c080-57e0-48d5-8192-a11a991454c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6b205cfa-3944-4147-9859-73913c98bb4b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0205c080-57e0-48d5-8192-a11a991454c7" xlink:to="loc_srt_ProductOrServiceAxis_6b205cfa-3944-4147-9859-73913c98bb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_38484b8d-f7f7-468c-bb26-949445728cdb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6b205cfa-3944-4147-9859-73913c98bb4b" xlink:to="loc_srt_ProductsAndServicesDomain_38484b8d-f7f7-468c-bb26-949445728cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OCREVUSMember_89b1ebaa-fe9d-48fd-b46b-2b520bcc532b" xlink:href="biib-20230930.xsd#biib_OCREVUSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_38484b8d-f7f7-468c-bb26-949445728cdb" xlink:to="loc_biib_OCREVUSMember_89b1ebaa-fe9d-48fd-b46b-2b520bcc532b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MosunetuzumabMember_be6d739c-cca2-47e4-abdb-ed61a27d87f8" xlink:href="biib-20230930.xsd#biib_MosunetuzumabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_38484b8d-f7f7-468c-bb26-949445728cdb" xlink:to="loc_biib_MosunetuzumabMember_be6d739c-cca2-47e4-abdb-ed61a27d87f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_500003ed-da01-4b95-a96c-aa6ace51a560" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0205c080-57e0-48d5-8192-a11a991454c7" xlink:to="loc_srt_RangeAxis_500003ed-da01-4b95-a96c-aa6ace51a560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c2f6549-ed4e-4350-b955-e7eb743dcc23" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_500003ed-da01-4b95-a96c-aa6ace51a560" xlink:to="loc_srt_RangeMember_1c2f6549-ed4e-4350-b955-e7eb743dcc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ed59b9f6-3c58-4f97-b419-99d29c735e2c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1c2f6549-ed4e-4350-b955-e7eb743dcc23" xlink:to="loc_srt_MinimumMember_ed59b9f6-3c58-4f97-b419-99d29c735e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0fa4b63c-7f44-4321-8578-2e0d01c4b3a5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1c2f6549-ed4e-4350-b955-e7eb743dcc23" xlink:to="loc_srt_MaximumMember_0fa4b63c-7f44-4321-8578-2e0d01c4b3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3a405396-5556-418f-9012-fdb0398e8938" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0205c080-57e0-48d5-8192-a11a991454c7" xlink:to="loc_srt_StatementGeographicalAxis_3a405396-5556-418f-9012-fdb0398e8938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3efdf33b-7a7d-462b-99b3-473099e39233" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3a405396-5556-418f-9012-fdb0398e8938" xlink:to="loc_srt_SegmentGeographicalDomain_3efdf33b-7a7d-462b-99b3-473099e39233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_9f8ea436-3437-4706-b335-59b263bf0fef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3efdf33b-7a7d-462b-99b3-473099e39233" xlink:to="loc_us-gaap_ForeignCountryMember_9f8ea436-3437-4706-b335-59b263bf0fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_015ad1bd-f95e-4ce4-94d3-0a67f3259d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0205c080-57e0-48d5-8192-a11a991454c7" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_015ad1bd-f95e-4ce4-94d3-0a67f3259d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_1e934677-30a8-4411-a41c-106be062f20f" xlink:href="biib-20230930.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_015ad1bd-f95e-4ce4-94d3-0a67f3259d50" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_1e934677-30a8-4411-a41c-106be062f20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_94460fff-7cd0-478c-bded-2dc54e6bd929" xlink:href="biib-20230930.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_015ad1bd-f95e-4ce4-94d3-0a67f3259d50" xlink:to="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_94460fff-7cd0-478c-bded-2dc54e6bd929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyrate_d3a2f46f-0e5f-424c-99b4-27a8ce891c4d" xlink:href="biib-20230930.xsd#biib_Reductioninroyaltyrate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_015ad1bd-f95e-4ce4-94d3-0a67f3259d50" xlink:to="loc_biib_Reductioninroyaltyrate_d3a2f46f-0e5f-424c-99b4-27a8ce891c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PeriodOfCollaborationAgreement_58513aca-76c2-40f1-a495-fa96aa4b467c" xlink:href="biib-20230930.xsd#biib_PeriodOfCollaborationAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_015ad1bd-f95e-4ce4-94d3-0a67f3259d50" xlink:to="loc_biib_PeriodOfCollaborationAgreement_58513aca-76c2-40f1-a495-fa96aa4b467c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfFutureDevelopmentCosts_fada1a7b-cadf-46c0-a3e8-23cc22130ae9" xlink:href="biib-20230930.xsd#biib_PercentageOfFutureDevelopmentCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_015ad1bd-f95e-4ce4-94d3-0a67f3259d50" xlink:to="loc_biib_PercentageOfFutureDevelopmentCosts_fada1a7b-cadf-46c0-a3e8-23cc22130ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsProfitSharingDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0285dad6-5b37-4da9-aa41-dd1f9f0271b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9a2f91fb-b2d4-418f-b628-8efb551236dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0285dad6-5b37-4da9-aa41-dd1f9f0271b1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9a2f91fb-b2d4-418f-b628-8efb551236dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6ef2c7eb-647d-4109-b4d3-60922532037e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9a2f91fb-b2d4-418f-b628-8efb551236dd" xlink:to="loc_srt_ProductOrServiceAxis_6ef2c7eb-647d-4109-b4d3-60922532037e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_45ba4de8-293f-4c41-96fd-49b9d1eafa67" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6ef2c7eb-647d-4109-b4d3-60922532037e" xlink:to="loc_srt_ProductsAndServicesDomain_45ba4de8-293f-4c41-96fd-49b9d1eafa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember_f847dde9-d555-4a7f-bcd3-55373f50725b" xlink:href="biib-20230930.xsd#biib_RituxanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_45ba4de8-293f-4c41-96fd-49b9d1eafa67" xlink:to="loc_biib_RituxanMember_f847dde9-d555-4a7f-bcd3-55373f50725b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember_e1cff975-50a8-4ca8-a333-c1d058a669bd" xlink:href="biib-20230930.xsd#biib_GAZYVAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_45ba4de8-293f-4c41-96fd-49b9d1eafa67" xlink:to="loc_biib_GAZYVAMember_e1cff975-50a8-4ca8-a333-c1d058a669bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9a2f91fb-b2d4-418f-b628-8efb551236dd" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_8311f127-d992-479a-a1d7-a38181b338aa" xlink:href="biib-20230930.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_8311f127-d992-479a-a1d7-a38181b338aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_53335da0-0d56-442f-b4cc-dcf2a979599b" xlink:href="biib-20230930.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_53335da0-0d56-442f-b4cc-dcf2a979599b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_faba79d4-10af-43fa-8b6d-3811622d0348" xlink:href="biib-20230930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_faba79d4-10af-43fa-8b6d-3811622d0348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_268f7963-2338-4130-b9b3-28974dafceb7" xlink:href="biib-20230930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_268f7963-2338-4130-b9b3-28974dafceb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_3001ce41-861b-4b40-92cb-6de139e6deb1" xlink:href="biib-20230930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_3001ce41-861b-4b40-92cb-6de139e6deb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_d05efb46-49e7-4fbc-8163-68e316ac0ca0" xlink:href="biib-20230930.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_d05efb46-49e7-4fbc-8163-68e316ac0ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_3420b301-4800-49d9-bbc1-549627374d39" xlink:href="biib-20230930.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_3420b301-4800-49d9-bbc1-549627374d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_5dbb7036-5fe5-4753-b455-0dbbf94d5105" xlink:href="biib-20230930.xsd#biib_SalesTriggerGrossSalesThreshold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2a925271-961a-4202-bd40-a9e1fb4d7fd9" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_5dbb7036-5fe5-4753-b455-0dbbf94d5105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsEisaiDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_410d11a9-dbf7-4891-a2e1-1cda9e5061cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df765277-2e6e-4835-b0ea-89e6e80baa86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_410d11a9-dbf7-4891-a2e1-1cda9e5061cb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df765277-2e6e-4835-b0ea-89e6e80baa86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_56b79743-33aa-462e-a5db-7db6ba25d283" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df765277-2e6e-4835-b0ea-89e6e80baa86" xlink:to="loc_srt_ProductOrServiceAxis_56b79743-33aa-462e-a5db-7db6ba25d283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ec29d090-9d53-40d0-9942-3fc06d33b953" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_56b79743-33aa-462e-a5db-7db6ba25d283" xlink:to="loc_srt_ProductsAndServicesDomain_ec29d090-9d53-40d0-9942-3fc06d33b953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_dce3015d-9c09-4a21-82cd-58107edfb356" xlink:href="biib-20230930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ec29d090-9d53-40d0-9942-3fc06d33b953" xlink:to="loc_biib_LEQEMBICollaborationMember_dce3015d-9c09-4a21-82cd-58107edfb356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_555c7169-fc59-4423-a3ca-7c8425a922f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_df765277-2e6e-4835-b0ea-89e6e80baa86" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_555c7169-fc59-4423-a3ca-7c8425a922f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedPaymentToTerminationAgreement_2f8720f9-1c6b-4755-b115-0f5e0876c07f" xlink:href="biib-20230930.xsd#biib_AccruedPaymentToTerminationAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_555c7169-fc59-4423-a3ca-7c8425a922f6" xlink:to="loc_biib_AccruedPaymentToTerminationAgreement_2f8720f9-1c6b-4755-b115-0f5e0876c07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7a296348-8139-410d-a1a0-ba60aebe3b55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc2d3a73-abee-4138-b0fa-a1fff6cb4a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7a296348-8139-410d-a1a0-ba60aebe3b55" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc2d3a73-abee-4138-b0fa-a1fff6cb4a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_24f9a182-47b4-4708-913c-ef71e84ba9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc2d3a73-abee-4138-b0fa-a1fff6cb4a8c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_24f9a182-47b4-4708-913c-ef71e84ba9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ab5ebedb-b6bf-4ccb-9af1-24dc2b4e73b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24f9a182-47b4-4708-913c-ef71e84ba9ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ab5ebedb-b6bf-4ccb-9af1-24dc2b4e73b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3a3e3cbd-fa1d-4eff-a007-6bba3e6c4647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ab5ebedb-b6bf-4ccb-9af1-24dc2b4e73b5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3a3e3cbd-fa1d-4eff-a007-6bba3e6c4647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0f325f25-01da-4ec8-bae3-df46e78ed90e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc2d3a73-abee-4138-b0fa-a1fff6cb4a8c" xlink:to="loc_srt_ProductOrServiceAxis_0f325f25-01da-4ec8-bae3-df46e78ed90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7d39f3b9-b819-4e80-8c3d-0adbd93c5871" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0f325f25-01da-4ec8-bae3-df46e78ed90e" xlink:to="loc_srt_ProductsAndServicesDomain_7d39f3b9-b819-4e80-8c3d-0adbd93c5871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_b236477a-b615-47b5-843f-afe6a0ffd132" xlink:href="biib-20230930.xsd#biib_E2609andBAN2401Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7d39f3b9-b819-4e80-8c3d-0adbd93c5871" xlink:to="loc_biib_E2609andBAN2401Member_b236477a-b615-47b5-843f-afe6a0ffd132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_9f34a82d-979c-4c13-8a90-49648a158634" xlink:href="biib-20230930.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7d39f3b9-b819-4e80-8c3d-0adbd93c5871" xlink:to="loc_biib_ADUHELMMember_9f34a82d-979c-4c13-8a90-49648a158634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_24f7a4fa-1a90-458a-8c6c-3ea88dffbde1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc2d3a73-abee-4138-b0fa-a1fff6cb4a8c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_24f7a4fa-1a90-458a-8c6c-3ea88dffbde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55ea068a-f480-4c46-aca8-b9c691afc39f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_24f7a4fa-1a90-458a-8c6c-3ea88dffbde1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55ea068a-f480-4c46-aca8-b9c691afc39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_546ce065-8175-4e60-b13e-c6a44691f411" xlink:href="biib-20230930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_55ea068a-f480-4c46-aca8-b9c691afc39f" xlink:to="loc_biib_EisaiMember_546ce065-8175-4e60-b13e-c6a44691f411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e87b6fa3-cf76-404a-af8a-ff7ae8eeeb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc2d3a73-abee-4138-b0fa-a1fff6cb4a8c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e87b6fa3-cf76-404a-af8a-ff7ae8eeeb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_3dc9a53e-813d-4f91-ad9c-4e2ce8b306a9" xlink:href="biib-20230930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e87b6fa3-cf76-404a-af8a-ff7ae8eeeb7f" xlink:to="loc_biib_ExpenseIncurredByCollaboration_3dc9a53e-813d-4f91-ad9c-4e2ce8b306a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_b5aa8a7d-830b-4b79-9d7a-bd3e9e83430b" xlink:href="biib-20230930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e87b6fa3-cf76-404a-af8a-ff7ae8eeeb7f" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_b5aa8a7d-830b-4b79-9d7a-bd3e9e83430b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_142d4f9c-a3fe-4512-a3d7-77e78dace559" xlink:href="biib-20230930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e87b6fa3-cf76-404a-af8a-ff7ae8eeeb7f" xlink:to="loc_biib_Expenseincurredbythecollaboration_142d4f9c-a3fe-4512-a3d7-77e78dace559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8f1d220d-90ed-4c2c-93b2-c147c40e5e66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8f1d220d-90ed-4c2c-93b2-c147c40e5e66" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6ad2cc68-1cae-460c-84df-b884d03a0e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6ad2cc68-1cae-460c-84df-b884d03a0e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e244704b-fb8d-4cc8-9fdf-d9ff0ef1a389" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6ad2cc68-1cae-460c-84df-b884d03a0e16" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e244704b-fb8d-4cc8-9fdf-d9ff0ef1a389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_dac71ce3-53f8-49fe-b0e5-f23217bbfb5f" xlink:href="biib-20230930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e244704b-fb8d-4cc8-9fdf-d9ff0ef1a389" xlink:to="loc_biib_EisaiMember_dac71ce3-53f8-49fe-b0e5-f23217bbfb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d7957da6-f65f-4460-b85e-71673bf81dac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:to="loc_srt_ProductOrServiceAxis_d7957da6-f65f-4460-b85e-71673bf81dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fedeb990-4925-43ec-9729-838358f8c977" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d7957da6-f65f-4460-b85e-71673bf81dac" xlink:to="loc_srt_ProductsAndServicesDomain_fedeb990-4925-43ec-9729-838358f8c977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_3eb1e1a0-029a-4e82-9e72-8e7444ea9d02" xlink:href="biib-20230930.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fedeb990-4925-43ec-9729-838358f8c977" xlink:to="loc_biib_ADUHELMMember_3eb1e1a0-029a-4e82-9e72-8e7444ea9d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f1a13f72-3ce9-40c0-a805-8e2d23b6c2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f1a13f72-3ce9-40c0-a805-8e2d23b6c2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_870c65ac-b97f-4c3a-8d32-4f43e0c9a6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f1a13f72-3ce9-40c0-a805-8e2d23b6c2c0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_870c65ac-b97f-4c3a-8d32-4f43e0c9a6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationProfitSharingMember_f85e3b92-af04-4e69-b849-91d55e9ce4d0" xlink:href="biib-20230930.xsd#biib_CollaborationProfitSharingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_870c65ac-b97f-4c3a-8d32-4f43e0c9a6e0" xlink:to="loc_biib_CollaborationProfitSharingMember_f85e3b92-af04-4e69-b849-91d55e9ce4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementProfitLossSharingComponentsAxis_a3d003f8-ed70-4be8-9e9e-5053a759f91e" xlink:href="biib-20230930.xsd#biib_CollaborativeArrangementProfitLossSharingComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:to="loc_biib_CollaborativeArrangementProfitLossSharingComponentsAxis_a3d003f8-ed70-4be8-9e9e-5053a759f91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementProfitLossSharingComponentsDomain_2f9b402e-2765-4a94-912b-76334fd8a67d" xlink:href="biib-20230930.xsd#biib_CollaborativeArrangementProfitLossSharingComponentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborativeArrangementProfitLossSharingComponentsAxis_a3d003f8-ed70-4be8-9e9e-5053a759f91e" xlink:to="loc_biib_CollaborativeArrangementProfitLossSharingComponentsDomain_2f9b402e-2765-4a94-912b-76334fd8a67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember_60dd902b-a465-4beb-9a77-eaf75f943188" xlink:href="biib-20230930.xsd#biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborativeArrangementProfitLossSharingComponentsDomain_2f9b402e-2765-4a94-912b-76334fd8a67d" xlink:to="loc_biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember_60dd902b-a465-4beb-9a77-eaf75f943188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5b52023d-9f7b-452e-b705-e8df4663b158" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:to="loc_srt_RangeAxis_5b52023d-9f7b-452e-b705-e8df4663b158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c9913b4e-8044-49de-a1ad-6241ef51a298" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5b52023d-9f7b-452e-b705-e8df4663b158" xlink:to="loc_srt_RangeMember_c9913b4e-8044-49de-a1ad-6241ef51a298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d6f6e40c-aef1-4f41-9033-8746a5becb7b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c9913b4e-8044-49de-a1ad-6241ef51a298" xlink:to="loc_srt_MaximumMember_d6f6e40c-aef1-4f41-9033-8746a5becb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d27aa372-23cf-4cf8-b77d-749c4dc80443" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:to="loc_srt_StatementScenarioAxis_d27aa372-23cf-4cf8-b77d-749c4dc80443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_52a98a92-79b0-4d97-aa9c-0cb4c3868c46" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_d27aa372-23cf-4cf8-b77d-749c4dc80443" xlink:to="loc_srt_ScenarioUnspecifiedDomain_52a98a92-79b0-4d97-aa9c-0cb4c3868c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_053906fd-6a08-48a6-92e8-eb841d928492" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_52a98a92-79b0-4d97-aa9c-0cb4c3868c46" xlink:to="loc_srt_ScenarioForecastMember_053906fd-6a08-48a6-92e8-eb841d928492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_693a87dc-5148-484d-bd03-cb12d8c7050f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43b20fa3-33d4-413a-b1b1-43231ba2d243" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_693a87dc-5148-484d-bd03-cb12d8c7050f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5c48f7b5-2d10-433f-86b5-9e7eae4b3501" xlink:href="biib-20230930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_693a87dc-5148-484d-bd03-cb12d8c7050f" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5c48f7b5-2d10-433f-86b5-9e7eae4b3501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_438e4778-9441-475d-bcc1-9384ace94f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_693a87dc-5148-484d-bd03-cb12d8c7050f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_438e4778-9441-475d-bcc1-9384ace94f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementProfitLossSharing_f4255da1-7b42-4090-9470-d9b2b9251a78" xlink:href="biib-20230930.xsd#biib_CollaborativeArrangementProfitLossSharing"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_693a87dc-5148-484d-bd03-cb12d8c7050f" xlink:to="loc_biib_CollaborativeArrangementProfitLossSharing_f4255da1-7b42-4090-9470-d9b2b9251a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_b72ca646-6e52-4d25-bdee-4de9d4a83381" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_693a87dc-5148-484d-bd03-cb12d8c7050f" xlink:to="loc_us-gaap_InventoryWriteDown_b72ca646-6e52-4d25-bdee-4de9d4a83381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsReceivableFromCollaborator_fce8e7aa-16bf-45f8-bb3f-159fd114895a" xlink:href="biib-20230930.xsd#biib_AccountsReceivableFromCollaborator"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_693a87dc-5148-484d-bd03-cb12d8c7050f" xlink:to="loc_biib_AccountsReceivableFromCollaborator_fce8e7aa-16bf-45f8-bb3f-159fd114895a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsPayableToCollaborator_bbd8031e-6bab-41d0-95bf-ae7fda4a11e7" xlink:href="biib-20230930.xsd#biib_AccountsPayableToCollaborator"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_693a87dc-5148-484d-bd03-cb12d8c7050f" xlink:to="loc_biib_AccountsPayableToCollaborator_bbd8031e-6bab-41d0-95bf-ae7fda4a11e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_567a539e-db30-414e-a730-85ca60cdbb78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57e45f0b-0fde-43ef-a4ff-c64aeff1d205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_567a539e-db30-414e-a730-85ca60cdbb78" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57e45f0b-0fde-43ef-a4ff-c64aeff1d205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fb90bc64-9906-4044-b521-b62f0af07e01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57e45f0b-0fde-43ef-a4ff-c64aeff1d205" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fb90bc64-9906-4044-b521-b62f0af07e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ad19f59c-ced4-4fe6-9409-79d454338e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fb90bc64-9906-4044-b521-b62f0af07e01" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ad19f59c-ced4-4fe6-9409-79d454338e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_df42c52a-45e6-4050-bdf3-f8fe5f768bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad19f59c-ced4-4fe6-9409-79d454338e8b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_df42c52a-45e6-4050-bdf3-f8fe5f768bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bdc2fe90-9d76-4df5-b05a-474a4fa8a6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad19f59c-ced4-4fe6-9409-79d454338e8b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bdc2fe90-9d76-4df5-b05a-474a4fa8a6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4ea29251-f7e3-44b1-bca6-2a7a3eb8c305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57e45f0b-0fde-43ef-a4ff-c64aeff1d205" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4ea29251-f7e3-44b1-bca6-2a7a3eb8c305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_424491dd-2898-4f09-99ff-5fe63cc9478b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4ea29251-f7e3-44b1-bca6-2a7a3eb8c305" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_424491dd-2898-4f09-99ff-5fe63cc9478b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_e8a02153-64d9-4dc3-bd59-a14db7fde293" xlink:href="biib-20230930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_424491dd-2898-4f09-99ff-5fe63cc9478b" xlink:to="loc_biib_EisaiMember_e8a02153-64d9-4dc3-bd59-a14db7fde293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c64ad3de-aae9-4bf2-8964-767dffba6af7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57e45f0b-0fde-43ef-a4ff-c64aeff1d205" xlink:to="loc_srt_ProductOrServiceAxis_c64ad3de-aae9-4bf2-8964-767dffba6af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_18a956ca-0d2b-4459-9322-6c9936ee77aa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c64ad3de-aae9-4bf2-8964-767dffba6af7" xlink:to="loc_srt_ProductsAndServicesDomain_18a956ca-0d2b-4459-9322-6c9936ee77aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_a1e25ee1-c875-4d48-ad24-69d6e6ee2201" xlink:href="biib-20230930.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_18a956ca-0d2b-4459-9322-6c9936ee77aa" xlink:to="loc_biib_ADUHELMMember_a1e25ee1-c875-4d48-ad24-69d6e6ee2201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_a019c998-221b-46ab-9ef6-5ddc7c4f1d4a" xlink:href="biib-20230930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_18a956ca-0d2b-4459-9322-6c9936ee77aa" xlink:to="loc_biib_LEQEMBICollaborationMember_a019c998-221b-46ab-9ef6-5ddc7c4f1d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ddd6d0e5-4d74-4d18-92e6-d81ee3807709" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_57e45f0b-0fde-43ef-a4ff-c64aeff1d205" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ddd6d0e5-4d74-4d18-92e6-d81ee3807709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_677bf2fa-b1d8-4562-aae3-302cc85866c3" xlink:href="biib-20230930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ddd6d0e5-4d74-4d18-92e6-d81ee3807709" xlink:to="loc_biib_Expenseincurredbythecollaboration_677bf2fa-b1d8-4562-aae3-302cc85866c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_08d78731-129b-4ead-a4a5-1fbe207304fe" xlink:href="biib-20230930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ddd6d0e5-4d74-4d18-92e6-d81ee3807709" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_08d78731-129b-4ead-a4a5-1fbe207304fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized_ee6146c4-1137-43d6-8a85-0af836bfcf9d" xlink:href="biib-20230930.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ddd6d0e5-4d74-4d18-92e6-d81ee3807709" xlink:to="loc_biib_ShareOfNonControlingInterestRecognized_ee6146c4-1137-43d6-8a85-0af836bfcf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AggregateGrossIdleCapacityCharges_66671657-3101-47d7-bfc7-6b2b15a0fe86" xlink:href="biib-20230930.xsd#biib_AggregateGrossIdleCapacityCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ddd6d0e5-4d74-4d18-92e6-d81ee3807709" xlink:to="loc_biib_AggregateGrossIdleCapacityCharges_66671657-3101-47d7-bfc7-6b2b15a0fe86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f265bac3-0e9a-4bb7-bab8-c718d4a8e8be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ddd6d0e5-4d74-4d18-92e6-d81ee3807709" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f265bac3-0e9a-4bb7-bab8-c718d4a8e8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0c744224-baba-42ca-b234-ae5a4deddfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa3c8df6-3f0a-4864-adbd-9688559ea25b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0c744224-baba-42ca-b234-ae5a4deddfa4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa3c8df6-3f0a-4864-adbd-9688559ea25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5541c622-bc77-4ee1-a818-1fcc9d4cea74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa3c8df6-3f0a-4864-adbd-9688559ea25b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5541c622-bc77-4ee1-a818-1fcc9d4cea74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_03175bb1-8520-4181-b7b2-f062dcab8a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5541c622-bc77-4ee1-a818-1fcc9d4cea74" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_03175bb1-8520-4181-b7b2-f062dcab8a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_528999fb-64c1-46d5-abc1-4e9edebd2014" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_03175bb1-8520-4181-b7b2-f062dcab8a0c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_528999fb-64c1-46d5-abc1-4e9edebd2014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f4d1a425-9563-4625-9f1d-57dffa34787c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa3c8df6-3f0a-4864-adbd-9688559ea25b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f4d1a425-9563-4625-9f1d-57dffa34787c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ee1e255-c9a1-4043-9914-4e87af3127e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f4d1a425-9563-4625-9f1d-57dffa34787c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ee1e255-c9a1-4043-9914-4e87af3127e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_d5c3759e-3627-49e9-ad57-ef8c0600bf39" xlink:href="biib-20230930.xsd#biib_UCBPharmaS.A.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ee1e255-c9a1-4043-9914-4e87af3127e0" xlink:to="loc_biib_UCBPharmaS.A.Member_d5c3759e-3627-49e9-ad57-ef8c0600bf39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dccbab8a-b940-4c5d-92f8-4e70903e5bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa3c8df6-3f0a-4864-adbd-9688559ea25b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dccbab8a-b940-4c5d-92f8-4e70903e5bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_111615c5-91f3-4540-b9f5-f942d64bbae9" xlink:href="biib-20230930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dccbab8a-b940-4c5d-92f8-4e70903e5bf3" xlink:to="loc_biib_Expenseincurredbythecollaboration_111615c5-91f3-4540-b9f5-f942d64bbae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_dfc12e5d-c61e-448e-94ab-862db4ccfa57" xlink:href="biib-20230930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dccbab8a-b940-4c5d-92f8-4e70903e5bf3" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_dfc12e5d-c61e-448e-94ab-862db4ccfa57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bbba74cf-f60f-49c1-94d6-84ccb0303ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_015fb201-07c8-429c-8270-4c56103d77a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bbba74cf-f60f-49c1-94d6-84ccb0303ff8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_015fb201-07c8-429c-8270-4c56103d77a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4a7e5064-1d47-4010-a8dc-0a4e9ef04972" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_015fb201-07c8-429c-8270-4c56103d77a7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4a7e5064-1d47-4010-a8dc-0a4e9ef04972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_45dc50c0-39d4-46f4-bfcd-f48ebae46cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4a7e5064-1d47-4010-a8dc-0a4e9ef04972" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_45dc50c0-39d4-46f4-bfcd-f48ebae46cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17ae0901-85d0-438c-b125-0dad8c6ac0de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_45dc50c0-39d4-46f4-bfcd-f48ebae46cdc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_17ae0901-85d0-438c-b125-0dad8c6ac0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b1136b76-857c-40c7-ba47-265d67f42306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_45dc50c0-39d4-46f4-bfcd-f48ebae46cdc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b1136b76-857c-40c7-ba47-265d67f42306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d8e60717-4e31-41e5-828d-a87f89f2935f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_015fb201-07c8-429c-8270-4c56103d77a7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d8e60717-4e31-41e5-828d-a87f89f2935f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bd4ab-5d6c-4e95-9369-89fdc8554ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d8e60717-4e31-41e5-828d-a87f89f2935f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bd4ab-5d6c-4e95-9369-89fdc8554ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_150ac8d3-279c-4aed-bd59-0874a8209c67" xlink:href="biib-20230930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_705bd4ab-5d6c-4e95-9369-89fdc8554ab5" xlink:to="loc_biib_SageTherapeuticsIncMember_150ac8d3-279c-4aed-bd59-0874a8209c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2a739370-32a6-491c-8b98-e1de2acc9a40" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_015fb201-07c8-429c-8270-4c56103d77a7" xlink:to="loc_srt_StatementScenarioAxis_2a739370-32a6-491c-8b98-e1de2acc9a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7175401d-a399-4125-b953-2ebb6626fe32" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_2a739370-32a6-491c-8b98-e1de2acc9a40" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7175401d-a399-4125-b953-2ebb6626fe32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_105ec211-b41f-4538-bca3-3aac09555045" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7175401d-a399-4125-b953-2ebb6626fe32" xlink:to="loc_srt_ScenarioForecastMember_105ec211-b41f-4538-bca3-3aac09555045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06a03a03-ce7c-4ce4-910e-4808b2980cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_015fb201-07c8-429c-8270-4c56103d77a7" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06a03a03-ce7c-4ce4-910e-4808b2980cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_c9ea1199-e85e-4c05-aa27-13beac1849e4" xlink:href="biib-20230930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06a03a03-ce7c-4ce4-910e-4808b2980cd5" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_c9ea1199-e85e-4c05-aa27-13beac1849e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_47df9d56-42cb-4e5e-8b70-b6b947a9716c" xlink:href="biib-20230930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06a03a03-ce7c-4ce4-910e-4808b2980cd5" xlink:to="loc_biib_Expenseincurredbythecollaboration_47df9d56-42cb-4e5e-8b70-b6b947a9716c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_a730cd96-c361-46d6-ac10-761d4f56a021" xlink:href="biib-20230930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06a03a03-ce7c-4ce4-910e-4808b2980cd5" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_a730cd96-c361-46d6-ac10-761d4f56a021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNetProfitFromSageTherapeuticsAmount_59985daf-6190-4832-ae93-e12f06c9b6e2" xlink:href="biib-20230930.xsd#biib_ShareOfNetProfitFromSageTherapeuticsAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06a03a03-ce7c-4ce4-910e-4808b2980cd5" xlink:to="loc_biib_ShareOfNetProfitFromSageTherapeuticsAmount_59985daf-6190-4832-ae93-e12f06c9b6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent_ab0eb600-fea1-408a-b3d2-01958278c807" xlink:href="biib-20230930.xsd#biib_ShareOfNetProfitFromSageTherapeuticsPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06a03a03-ce7c-4ce4-910e-4808b2980cd5" xlink:to="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent_ab0eb600-fea1-408a-b3d2-01958278c807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_47f74d28-e070-4c7e-9bcf-78ba1cf3c32c" xlink:href="biib-20230930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06a03a03-ce7c-4ce4-910e-4808b2980cd5" xlink:to="loc_biib_Collaborationprofitlosssharing_47f74d28-e070-4c7e-9bcf-78ba1cf3c32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b577885e-171d-449f-a560-d1eeb5f2c763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924621a4-835e-4385-9559-8489bb2ca498" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b577885e-171d-449f-a560-d1eeb5f2c763" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924621a4-835e-4385-9559-8489bb2ca498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_18ea499c-af3b-4501-8c23-bf26cd669cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924621a4-835e-4385-9559-8489bb2ca498" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_18ea499c-af3b-4501-8c23-bf26cd669cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_86e54af6-2abb-4f60-91ad-36a4fa9725eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18ea499c-af3b-4501-8c23-bf26cd669cc6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_86e54af6-2abb-4f60-91ad-36a4fa9725eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8a595491-5ed6-4a57-806a-1b5a2f02e3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_86e54af6-2abb-4f60-91ad-36a4fa9725eb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8a595491-5ed6-4a57-806a-1b5a2f02e3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e9b7781c-628c-4afe-beef-924e67a709e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924621a4-835e-4385-9559-8489bb2ca498" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e9b7781c-628c-4afe-beef-924e67a709e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10c4afe9-f5c8-40b4-9a51-41a1993242fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e9b7781c-628c-4afe-beef-924e67a709e7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10c4afe9-f5c8-40b4-9a51-41a1993242fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_45403bf9-bf1f-409e-8cf5-aa819584a1d9" xlink:href="biib-20230930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10c4afe9-f5c8-40b4-9a51-41a1993242fb" xlink:to="loc_biib_DenaliTherapeuticsIncMember_45403bf9-bf1f-409e-8cf5-aa819584a1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d6213c1f-da56-446b-be4b-5bb990bbbda1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_924621a4-835e-4385-9559-8489bb2ca498" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d6213c1f-da56-446b-be4b-5bb990bbbda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_44c59a8e-1f1c-42fb-a11b-dde482b7b491" xlink:href="biib-20230930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d6213c1f-da56-446b-be4b-5bb990bbbda1" xlink:to="loc_biib_Expenseincurredbythecollaboration_44c59a8e-1f1c-42fb-a11b-dde482b7b491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_05ddcaae-b2af-4859-98aa-c61c06305863" xlink:href="biib-20230930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d6213c1f-da56-446b-be4b-5bb990bbbda1" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_05ddcaae-b2af-4859-98aa-c61c06305863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aca7c66f-d142-4a64-8360-d93c55a7b4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b106ae-9cf5-4c8b-ae38-667db481ed7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aca7c66f-d142-4a64-8360-d93c55a7b4cd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b106ae-9cf5-4c8b-ae38-667db481ed7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ce85f6ea-0be9-4a77-a8ba-dbb8e2129aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b106ae-9cf5-4c8b-ae38-667db481ed7f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ce85f6ea-0be9-4a77-a8ba-dbb8e2129aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3a39aa18-12e9-41d8-b465-769d5885bed4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ce85f6ea-0be9-4a77-a8ba-dbb8e2129aec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3a39aa18-12e9-41d8-b465-769d5885bed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_630559d5-7cd3-4ec7-a97e-3a35defb7c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3a39aa18-12e9-41d8-b465-769d5885bed4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_630559d5-7cd3-4ec7-a97e-3a35defb7c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_74de10e3-273d-44b6-a11d-715f7e1cc4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b106ae-9cf5-4c8b-ae38-667db481ed7f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_74de10e3-273d-44b6-a11d-715f7e1cc4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_a8104668-15e4-484c-8c9b-17ed7ceb3b01" xlink:href="biib-20230930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_74de10e3-273d-44b6-a11d-715f7e1cc4a0" xlink:to="loc_biib_Expenseincurredbythecollaboration_a8104668-15e4-484c-8c9b-17ed7ceb3b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_f6647de5-37ef-420a-96a8-43d6dc4add68" xlink:href="biib-20230930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_74de10e3-273d-44b6-a11d-715f7e1cc4a0" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_f6647de5-37ef-420a-96a8-43d6dc4add68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsOtherArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_813914f8-6cab-4085-bb7f-88c2e80d667b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_febe79fb-99af-4ae2-9e01-f81e0a231d32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_813914f8-6cab-4085-bb7f-88c2e80d667b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_febe79fb-99af-4ae2-9e01-f81e0a231d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ac080e64-ca58-47de-8a18-37b7c912cfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_febe79fb-99af-4ae2-9e01-f81e0a231d32" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ac080e64-ca58-47de-8a18-37b7c912cfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_abdde5d7-bff7-4b95-ac3c-09583533bf52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ac080e64-ca58-47de-8a18-37b7c912cfe2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_abdde5d7-bff7-4b95-ac3c-09583533bf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_bd707da4-e83d-4262-9341-6bbd710e179e" xlink:href="biib-20230930.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_abdde5d7-bff7-4b95-ac3c-09583533bf52" xlink:to="loc_biib_OtherresearchanddiscoveryMember_bd707da4-e83d-4262-9341-6bbd710e179e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_38dbbf4a-d3ca-4338-b8a9-6006c548d5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_febe79fb-99af-4ae2-9e01-f81e0a231d32" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_38dbbf4a-d3ca-4338-b8a9-6006c548d5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e4a56898-028d-407e-aab7-b637a4f1421d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_38dbbf4a-d3ca-4338-b8a9-6006c548d5ee" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e4a56898-028d-407e-aab7-b637a4f1421d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#CollaborativeandOtherRelationshipsSamsungBioepisDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_177c9c24-f76b-4952-9f14-4df498a373fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cab56b4-773d-4573-8c0b-e6b43c6f0bde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_177c9c24-f76b-4952-9f14-4df498a373fb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cab56b4-773d-4573-8c0b-e6b43c6f0bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fe9db320-cdad-455a-b20b-9b124b60f172" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cab56b4-773d-4573-8c0b-e6b43c6f0bde" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fe9db320-cdad-455a-b20b-9b124b60f172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_865ebb38-f0fd-4597-b281-152b843959c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fe9db320-cdad-455a-b20b-9b124b60f172" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_865ebb38-f0fd-4597-b281-152b843959c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_44f81ebf-3a7c-46df-b525-910840154799" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_865ebb38-f0fd-4597-b281-152b843959c3" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_44f81ebf-3a7c-46df-b525-910840154799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fbb51951-c980-4928-9a9e-125f540dedd2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cab56b4-773d-4573-8c0b-e6b43c6f0bde" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fbb51951-c980-4928-9a9e-125f540dedd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ae72da93-34b0-494f-8854-e8733ab9b153" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fbb51951-c980-4928-9a9e-125f540dedd2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ae72da93-34b0-494f-8854-e8733ab9b153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_efdacc6b-32ea-4e06-af82-727a5ab4d35c" xlink:href="biib-20230930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ae72da93-34b0-494f-8854-e8733ab9b153" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_efdacc6b-32ea-4e06-af82-727a5ab4d35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_77297844-388e-4aeb-afd9-dce9a10ec682" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cab56b4-773d-4573-8c0b-e6b43c6f0bde" xlink:to="loc_srt_CounterpartyNameAxis_77297844-388e-4aeb-afd9-dce9a10ec682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a31cbdfa-94e7-47c3-982c-ba913376f235" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_77297844-388e-4aeb-afd9-dce9a10ec682" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a31cbdfa-94e7-47c3-982c-ba913376f235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f13df057-8db2-4f31-ab89-43e5cc305f84" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cab56b4-773d-4573-8c0b-e6b43c6f0bde" xlink:to="loc_srt_ProductOrServiceAxis_f13df057-8db2-4f31-ab89-43e5cc305f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a0ecd5c4-cf5b-4366-82b6-f891061ded17" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f13df057-8db2-4f31-ab89-43e5cc305f84" xlink:to="loc_srt_ProductsAndServicesDomain_a0ecd5c4-cf5b-4366-82b6-f891061ded17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_aca986e1-fe67-4779-9058-93efaf2ba689" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cab56b4-773d-4573-8c0b-e6b43c6f0bde" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_aca986e1-fe67-4779-9058-93efaf2ba689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1af6b50a-bc56-4187-8036-206da63c67e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_aca986e1-fe67-4779-9058-93efaf2ba689" xlink:to="loc_us-gaap_RelatedPartyDomain_1af6b50a-bc56-4187-8036-206da63c67e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_6b571cfd-d4eb-42f5-b30b-5757c701615e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1af6b50a-bc56-4187-8036-206da63c67e4" xlink:to="loc_us-gaap_RelatedPartyMember_6b571cfd-d4eb-42f5-b30b-5757c701615e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8cab56b4-773d-4573-8c0b-e6b43c6f0bde" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts_0ce9e0dd-047f-483b-820e-8d761c1040f1" xlink:href="biib-20230930.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_biib_ContingentCommercializedRightsNumberOfProducts_0ce9e0dd-047f-483b-820e-8d761c1040f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_75453842-db3c-4f6d-a5c5-82a89a798a16" xlink:href="biib-20230930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_75453842-db3c-4f6d-a5c5-82a89a798a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_b5743c7d-330d-4fe2-bfa0-338821566836" xlink:href="biib-20230930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_b5743c7d-330d-4fe2-bfa0-338821566836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_c4035502-02aa-42ac-bcb5-2fd84ef41324" xlink:href="biib-20230930.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_biib_CollaborationAgreementTerm_c4035502-02aa-42ac-bcb5-2fd84ef41324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_4bc12a05-afd9-4ca1-9c39-73faabaf09dd" xlink:href="biib-20230930.xsd#biib_ContractOptionExerciseFee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_biib_ContractOptionExerciseFee_4bc12a05-afd9-4ca1-9c39-73faabaf09dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_1797ac72-bf91-423a-9152-ef856276d5db" xlink:href="biib-20230930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_biib_Collaborationprofitlosssharing_1797ac72-bf91-423a-9152-ef856276d5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_f960e02b-f4fc-4ca3-82ce-53a8e1151de7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_us-gaap_AccountsReceivableNet_f960e02b-f4fc-4ca3-82ce-53a8e1151de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_51568609-a69b-4733-9ade-788597207518" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b30836b-28e0-4f21-8e69-e4686404300d" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_51568609-a69b-4733-9ade-788597207518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_4fc3300c-6619-43f6-8a19-6a462d0a5f4f" xlink:href="biib-20230930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6c6ae470-6e4f-4a4d-8007-93710b5005c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_4fc3300c-6619-43f6-8a19-6a462d0a5f4f" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6c6ae470-6e4f-4a4d-8007-93710b5005c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_483f81a2-9951-4a4b-87f6-994a552cb20b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6c6ae470-6e4f-4a4d-8007-93710b5005c1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_483f81a2-9951-4a4b-87f6-994a552cb20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35c74246-6a95-4b10-966c-80904e290613" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_483f81a2-9951-4a4b-87f6-994a552cb20b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35c74246-6a95-4b10-966c-80904e290613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_537186c7-10b3-4dd9-a535-386e1d56c708" xlink:href="biib-20230930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35c74246-6a95-4b10-966c-80904e290613" xlink:to="loc_biib_EisaiMember_537186c7-10b3-4dd9-a535-386e1d56c708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_5605d367-a270-474d-b88d-90028572b728" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6c6ae470-6e4f-4a4d-8007-93710b5005c1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_5605d367-a270-474d-b88d-90028572b728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_5693027c-8cd3-4d80-8491-9517a9827ee7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_5605d367-a270-474d-b88d-90028572b728" xlink:to="loc_srt_ConsolidatedEntitiesDomain_5693027c-8cd3-4d80-8491-9517a9827ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_ba916a74-2ff2-4dae-ad51-a4587736609d" xlink:href="biib-20230930.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_5693027c-8cd3-4d80-8491-9517a9827ee7" xlink:to="loc_biib_NeurimmuneMember_ba916a74-2ff2-4dae-ad51-a4587736609d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2a5a0778-4cdf-413a-b18d-e01813ad6085" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6c6ae470-6e4f-4a4d-8007-93710b5005c1" xlink:to="loc_srt_ProductOrServiceAxis_2a5a0778-4cdf-413a-b18d-e01813ad6085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6f96de30-a3cf-47fe-81fb-525807008dae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2a5a0778-4cdf-413a-b18d-e01813ad6085" xlink:to="loc_srt_ProductsAndServicesDomain_6f96de30-a3cf-47fe-81fb-525807008dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_921c1d50-5685-4689-a5f8-97d71d38f5ef" xlink:href="biib-20230930.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6f96de30-a3cf-47fe-81fb-525807008dae" xlink:to="loc_biib_ADUHELMMember_921c1d50-5685-4689-a5f8-97d71d38f5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6c6ae470-6e4f-4a4d-8007-93710b5005c1" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_7759660f-381d-4971-8822-4cab355d22c0" xlink:href="biib-20230930.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_biib_CollaborationAgreementTerm_7759660f-381d-4971-8822-4cab355d22c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_fcd1416a-a464-4cfc-919d-04f5a4f7e309" xlink:href="biib-20230930.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_fcd1416a-a464-4cfc-919d-04f5a4f7e309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_2d01b9df-45ac-478f-a12f-02236aabe518" xlink:href="biib-20230930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_2d01b9df-45ac-478f-a12f-02236aabe518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_97f6ed74-9fc5-4c32-be9c-a9b503ff9be0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_97f6ed74-9fc5-4c32-be9c-a9b503ff9be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5a1f4aa4-0165-4607-b0aa-3d3a5a573434" xlink:href="biib-20230930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5a1f4aa4-0165-4607-b0aa-3d3a5a573434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_3db55448-7d12-48ac-9c25-55520236607b" xlink:href="biib-20230930.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_biib_AdditionalMilestonePayment_3db55448-7d12-48ac-9c25-55520236607b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7961f598-da7f-44c7-97c9-2d37e347f0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7961f598-da7f-44c7-97c9-2d37e347f0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0f8e3d5d-aab8-413a-a0b4-f9b3bef899ba" xlink:href="biib-20230930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_8655caaf-5283-403d-8441-984674639eb6" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0f8e3d5d-aab8-413a-a0b4-f9b3bef899ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20230930.xsd#LitigationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_7f1bc71d-2b78-480b-8b95-0cebe4280070" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_dad07ff6-b492-414d-b10d-716979ff4df2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_7f1bc71d-2b78-480b-8b95-0cebe4280070" xlink:to="loc_us-gaap_LossContingenciesTable_dad07ff6-b492-414d-b10d-716979ff4df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8171e590-38b0-4e84-a30e-0637163d2424" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_dad07ff6-b492-414d-b10d-716979ff4df2" xlink:to="loc_dei_LegalEntityAxis_8171e590-38b0-4e84-a30e-0637163d2424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_aeb88782-1106-4e61-a474-740dff4bff12" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_8171e590-38b0-4e84-a30e-0637163d2424" xlink:to="loc_dei_EntityDomain_aeb88782-1106-4e61-a474-740dff4bff12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ERISAClassActionLitigaitonMember_14c36a6e-74de-4054-93a4-2c9873c746d7" xlink:href="biib-20230930.xsd#biib_ERISAClassActionLitigaitonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_aeb88782-1106-4e61-a474-740dff4bff12" xlink:to="loc_biib_ERISAClassActionLitigaitonMember_14c36a6e-74de-4054-93a4-2c9873c746d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GenentechMember_eb18610a-bb02-4ee6-9198-44b60cb48fa1" xlink:href="biib-20230930.xsd#biib_GenentechMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_aeb88782-1106-4e61-a474-740dff4bff12" xlink:to="loc_biib_GenentechMember_eb18610a-bb02-4ee6-9198-44b60cb48fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BardoxoloneSecuritiesMember_67243fea-e141-4ad3-9145-e71ce3308a63" xlink:href="biib-20230930.xsd#biib_BardoxoloneSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_aeb88782-1106-4e61-a474-740dff4bff12" xlink:to="loc_biib_BardoxoloneSecuritiesMember_67243fea-e141-4ad3-9145-e71ce3308a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LenderDisputeMember_5fdbd168-c01c-4a2e-8492-04da5fa48c9b" xlink:href="biib-20230930.xsd#biib_LenderDisputeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_aeb88782-1106-4e61-a474-740dff4bff12" xlink:to="loc_biib_LenderDisputeMember_5fdbd168-c01c-4a2e-8492-04da5fa48c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b2c7ca44-9e87-44e9-b8cd-c3ada10adc2a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_dad07ff6-b492-414d-b10d-716979ff4df2" xlink:to="loc_srt_LitigationCaseAxis_b2c7ca44-9e87-44e9-b8cd-c3ada10adc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ce1a7196-1278-4103-85ce-38966c3f1524" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_b2c7ca44-9e87-44e9-b8cd-c3ada10adc2a" xlink:to="loc_srt_LitigationCaseTypeDomain_ce1a7196-1278-4103-85ce-38966c3f1524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ERISAClassActionLitigaitonMember_1bc3e7b1-23c8-471b-b6d4-748896ef5962" xlink:href="biib-20230930.xsd#biib_ERISAClassActionLitigaitonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ce1a7196-1278-4103-85ce-38966c3f1524" xlink:to="loc_biib_ERISAClassActionLitigaitonMember_1bc3e7b1-23c8-471b-b6d4-748896ef5962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GenentechMember_2cf535e2-2615-4220-ace6-d8694f0f97ae" xlink:href="biib-20230930.xsd#biib_GenentechMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ce1a7196-1278-4103-85ce-38966c3f1524" xlink:to="loc_biib_GenentechMember_2cf535e2-2615-4220-ace6-d8694f0f97ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LenderDisputeMember_a5568496-fa70-4ff4-827b-93dd1756d0bf" xlink:href="biib-20230930.xsd#biib_LenderDisputeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ce1a7196-1278-4103-85ce-38966c3f1524" xlink:to="loc_biib_LenderDisputeMember_a5568496-fa70-4ff4-827b-93dd1756d0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_3fa7afe9-b5b9-4bd7-b1a2-189844ec7d46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_dad07ff6-b492-414d-b10d-716979ff4df2" xlink:to="loc_us-gaap_LossContingenciesLineItems_3fa7afe9-b5b9-4bd7-b1a2-189844ec7d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_6d9c6eaf-b271-45d8-9795-78971691630b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3fa7afe9-b5b9-4bd7-b1a2-189844ec7d46" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_6d9c6eaf-b271-45d8-9795-78971691630b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a953e8c2-87ae-467c-b3e5-32070ec75198" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3fa7afe9-b5b9-4bd7-b1a2-189844ec7d46" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a953e8c2-87ae-467c-b3e5-32070ec75198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltiesClaimed_aa5b3bfe-a3f4-462a-a426-d4898a912962" xlink:href="biib-20230930.xsd#biib_RoyaltiesClaimed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3fa7afe9-b5b9-4bd7-b1a2-189844ec7d46" xlink:to="loc_biib_RoyaltiesClaimed_aa5b3bfe-a3f4-462a-a426-d4898a912962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_55a7e331-dc73-4c27-a902-6fb264299ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3fa7afe9-b5b9-4bd7-b1a2-189844ec7d46" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_55a7e331-dc73-4c27-a902-6fb264299ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>biib-20230930_g1.jpg
<TEXT>
begin 644 biib-20230930_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
MGP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8 ^P$! 0<!#0$3
M 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@%U 7P!@P&+ 9(!F@&A :D!
ML0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B8"+P(X D$"2P)4 ET"9P)Q
M GH"A *. I@"H@*L K8"P0++ M4"X +K O4#  ,+ Q8#(0,M S@#0P-/ UH#
M9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M!#L$2 15!&,$<01^
M!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%2058!6<%=P6&!98%I@6U!<4%
MU07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/
M!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)
M$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS
M"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-
M)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z
M#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2
M)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P
M%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8
M&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC
M&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?
M$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=
M(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G
M&"=))WHGJR?<* TH/RAQ**(HU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K-BMI
M*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP
M-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43
M-4TUAS7"-?TV-S9R-JXVZ3<D-V WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z
M=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B
M0"- 9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%
MWD8B1F=&JT;P1S5'>T? 2 5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB
M3"I,<DRZ30)-2DV33=Q.)4YN3K=/ $])3Y-/W5 G4'%0NU$&45!1FU'F4C%2
M?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:
M66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8 5@
M5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG/6>3
M9^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO
M>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV^'=6
M=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_
MY8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(!(AI
MB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D :0;I#6D3^1
MJ)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5
MFT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:D
MQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZA
MKQ:OB[  L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y
M2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7 <,#LP6?!X\)?PMO#6,/4
MQ%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/
M-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IV
MVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WF
MEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.] [\SP6/#E\7+Q__*,
M\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_
M;?___]L 0P " 0$" 0$" @(" @(" @,% P,# P,&! 0#!0<&!P<'!@<'" D+
M"0@("@@'!PH-"@H+# P,# <)#@\-# X+# P,_]L 0P$" @(# P,& P,&# @'
M" P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,_\  $0@!(@-H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M5AT8'D&OVK@O.98W!>RJN\Z=D_-='^C]+]3VJ=^6S)****^R- HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH _+_ ,0V3>&_'&L:>PVM8WT]N1C&TI(R
M]/PK7TC4]H7FM/\ :_\ #A\%?M+^)H=NV*^G6_C./O\ G*'8_P#?9<?A7&Z;
MJ6%ZU^N4VJU"%1=4G]Z/RVHG2K2IOHVON.\MM9PGWJ;=ZU\GWJYB+5L+UIES
MJ^5ZUE[#4T]MH6M8U7<#S7)ZU?[MU6M1U/.>:YS5;[.:[Z%*QQUJAFZM<Y)K
MGK^7)K1U&YR36-=RY->M2B>;4D59WYK$\:^+[;P1H$U]<'.T;8HP?FE?LH_S
MP,T[Q?XQLO"%EYUU)\[#]W$OWY3[#^O2O#O&?B2\\=ZQ]JNOEC3(AA!^6%?0
M>I/<]_R ,17Y%9;BHT7-W>QSM]<W'B#6+B^NFWW%U(9'/N?3V'3Z"M+3;'&.
M*DM=,P>E:]AIO/2O*C!WNST92Z$NEVG2NDTJVZ53TVQZ?+70:9:=*[:<3EJ2
M.Z^ 6@MJ_P 3M(4)N6&;[0W^R$&[/Y@?B:^K*\S_ &<OA<W@_1&U2]C,=_J"
M (C##0Q=0#[MP3]!7IE?QOXQ<24,USSV>%?-"C'DNMG*[<FO*^GG:ZT9]]P_
M@Y4,->>\G?Y=/\QR#FK4"5! N:NVR5^5P1[T2Y:1UJV472J5G'6M8Q?=XKMI
MQ-8FA80]*]&^ MCY_P 1K!L?+"LCG_OA@/U(K@M/ASBO6_V;M)\S7[V[(^6W
M@$?T+-_@IKZGAVA[3,*,5_,G]VOZ&_2Y[)1117[D2>8_M=?M,6/[(OP,U/QU
MJ6EWFKVFFS00M:VTBQR/YLJQ@@MQP6R?I7Q[_P 1#G@W_HG?B;_P.@_PKV+_
M (+6?\H]O%7_ %^Z?_Z5Q5^(-?K7 W">6YEE\L1BX-R4VMVM$HOH_,_+.-.*
M,PR['QH86:47%/9/5MKJO(_5S_B(<\&_]$[\3?\ @=!_A1_Q$.>#?^B=^)O_
M  .@_P *_*.BOLO^(=Y'_P ^W_X%+_,^1_U^SK_GXO\ P&/^1^KG_$0YX-_Z
M)WXF_P# Z#_"C_B(<\&_]$[\3?\ @=!_A7Y1T4?\0[R/_GV__ I?YA_K]G7_
M #\7_@,?\C]7/^(ASP;_ -$[\3?^!T'^%'_$0YX-_P"B=^)O_ Z#_"ORCHH_
MXAWD?_/M_P#@4O\ ,/\ 7[.O^?B_\!C_ )'ZN?\ $0YX-_Z)WXF_\#H/\*U-
M-_X.$OAE*8OMG@OQW!NQYODK:2[/IF9=WXXK\CZ*4O#K)'M3:_[>?^8X^(&<
MK>:?_;J_R/VD\(_\%T?@1XD=5O+GQ9X?#8R;_2#(%^OV=Y>GMFO</A5^W-\(
M/C9/%#X:^(GA>^N[@[8K26[%K=2'T6&;9(?P6OYZZ*\S%>%V6S7[BI.+^37W
M63_$]+#>)680?[Z$9+YI_?=K\#^FRBOP1_95_P""E?Q5_9/U&UCTK7KC7/#L
M) DT+5I&N+,IW$>3NA/)(,9 SC(8<']?/V)_V]O!?[;O@R2ZT&9M-\0:>BMJ
MFB7+#[39D\;U/22(G@.H[@$*>*_-^(N"\=E2]K+WZ?\ ,NG^)=/Q7G<_0LAX
MPP6:/V4?<J?ROKZ/K^#\CW*BBBOCSZP*X/\ ::^.]G^S+\"_$'CJ^L+G4[/P
M]#'+):P.$DE#2I'@%N!@N#SZ5WE?._\ P5A_Y1Z_$O\ Z\K?_P!*X*[\JP\*
M^-HT:GPRG%/T;29PYI7G1P=6M3^*,9->J3:/G?\ XB'/!O\ T3OQ-_X'0?X4
M?\1#G@W_ *)WXF_\#H/\*_*.BOWW_B'>1_\ /M_^!2_S/PS_ %^SK_GXO_ 8
M_P"1^KG_ !$.>#?^B=^)O_ Z#_"OM3]F7X[V?[37P+\/^.K&PN=,L_$,,DL=
MK.X>2(+*\>"5X.2A/'K7\Y]?O)_P2>_Y1Z_#3_KRN/\ TKGKXGCSA;+LLP4*
MV#@U)S2=VWI9OJ_(^RX)XFS#,<9.CBY)Q46UHEK=+HO,^B****_*3]/"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X[_ ."H7@-K35O#?BN)
M/W<T;:7<,.S*3)%^8,O_ 'R/P^6[2_P.M?I)^U1\*6^,OP,UW1X8]]^L7VJQ
MXR?/C^90/][!3Z.:_,&&]:-MK95AP0>U?IG"^)5?!^S>\';Y/5?JOD?GO$F'
M='%^T6TE?Y[/_/YG4)J>T=:CGU3*GFL-=1XZTR74>.M?0^QU/!]H7;[4<CK6
M+?WF<TV[O\*>?S-<UKWC&&S#+&&GD]ONC\?\*Z:=.QSSJ%S4+M45F9E55Y))
MQBN \8_%*.U5X=-433=#*P_=K]/7^7UJOXCU*\UUCYTA\O/$:\*/\?QK"FTG
MVK24FE9$1BKZG,:G'<:O>-<74CS3/U9SD_Y]JACT?GI73G2?:E32*YO9ZW-_
M::6,.VTK!Z5IV6F;>U:<&D\]*],^!'[+7BKX]:H(]$T]ELD<+/J%P#':P>N6
MQ\Q_V5!;V[UEB*]##4G6Q$E&*W;=D53C.K)0IJ[?1'G>C:-)=W$<,,3RS2L$
M1$7<SL3@  =23VKZN^$'[".N^%O#=OXH\262^<O[V/3/O2VR]1)*O3/?;G*\
M9YR!]%?LY?L9^%_V>;>.\5!K'B+;A]1G0?NB1@B%.0@Z\\L<\G' ]8EEK\+X
MV\1I8RC/+\I;A"2LY[2?^'LGWW?D?;93PRJ=JV+UET71>O=_AZGRO0!DUZ_\
M1_@S#K,DEYI2QV]TQ+/#]V.4^W]T_I].M>476GS:9>/#<120S1G#(XPPK^9L
M5@ZE"5I;='T/HY4W'<6 5?M8ZJP)6E:1U%-#B7+**MBPBZ50LHNE;-A%TKT*
M43:)I:?#TKW_ .!&@?V1X*6X9<27\AE_X"/E7^1/XUXOX+\.R>)-<M;*'[UP
MX4G'W1U)_ 9/X5],65G'I]G#;PKMBA01HOH ,"OTC@? .566*EM%67J]_N7Y
MFCV):***_3"3Y1_X+6?\H]O%7_7[I_\ Z5Q5^(-?M]_P6L_Y1[>*O^OW3_\
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M8?#Z;PYXRTF.^MV!:VND 6[T^3_GI#)@E&X&>H8<,""17X/?M9?LSZU^R/\
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M#^IV>L:/J"E[:\M)1+#. Q4E6'!PP(^H-<>,CCE!?6E/EO\ :YK7^?4ZL)+
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MDAAC2&*,;51!A5'L*DK]3R;):6 IZ:S>[_1=E^9E*5PHHHKVR0HHHH ^4?\
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ML3#@BUC/$I!_Y:/\G'"N"&K\U?BC\8O%7QM\32:QXN\0:MXBU*0G]_?7+2E
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M,<7SN?QZ#]:]8HKUL)P=@Z;O6;F_N7W+7\2>=F/X9\#:9X23_0[95DQ@RO\
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MQ]@,U^D?_!/#_@BI>IK&G^-/C):10V]NXN+/PLQ$C3,.5:\(RH4<'R@23T?
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M^?X*RZ'\RYSFM7,<7+%5>NR[+HOE^=V%%%?6W_!);]@:+]L#XMW&M>)+=Y/
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MP_:XT_\ 8Q_9YU3Q9.L5SJTQ^PZ+9N3B[O'!*9QSL0!G;I\J$9!(KV:OQ/\
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M_P#E^!_-'XM\(ZKX!\2WNC:WI]YI.K:;*8;JTNXC%- XZJRMR#_C6?7[;_\
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M=O'%OXB\&ZY?:'JEN1EX'_=SK_<EC.5D0_W7!'Y U^;Y]X<X;%MUL+-QJ/\
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M#V(!K^<WXI?#V^^$OQ+\0>%]2&-0\.ZC/IMQQ@,\4C(2/8[<CV(K^DZOP_\
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MFOY)S'"_5L75P_\ )*4?N;1_4V7XGZQA:>(_FBG]Z3/P;_X*O_\ *0GXE_\
M7[;_ /I)!7SO7T1_P5?_ .4A/Q+_ .OVW_\ 22"OG>OZBR'_ )%F'_Z]P_\
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M4E_:6(U?\2?_ *4S^GLDIQ>78?3[$/\ TE&7_P (3HO_ $"-+_\  5/\*/\
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M^(F1QQ>7O%P7OTM?6/5?+?Y/N?>< YU+"X]863]RKIZ2Z/Y[?-=C];J^=_\
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M['Q__/B?_@,O\CPNBO=/^'9WQZ_Z)?XG_P"_2?\ Q5'_  [.^/7_ $2_Q/\
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M M]_Z M?M57\^^)G_(W7^"/YL_=O#C_D4O\ QR_)!1117YZ??!1110 4444
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MMG.8I+AWCQ[!2 /85Q-?UU@5-8:FJGQ<JOZVU/Y5QKB\1-PVYG;TOH%>S?\
M!.OQC-X%_;G^%=] TBO-XBM=..WKMNG^S-^!64Y]L]>E>,UZ!^R38R:G^U7\
M,K:$A9;CQ9I42$G #&\B Y^IK/,X*>$JPELXR3^YE9;-PQ=*<=U*+_%']%E?
M._\ P5A_Y1Z_$O\ Z\K?_P!*X*^B*^=_^"L/_*/7XE_]>5O_ .E<%?R_D/\
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M.':H5Z_=Q7W)O_VY&5XV\:Z3\.?".I:]KE];Z9H^DV[W5Y=3MB."-1DD_P"
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M4>OPT_Z\KC_TKGK\R\4_^1;2_P"OB_\ 29'Z-X9_\C&I_@?_ *5$^B*^ O\
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M'Y?C'A]YM@'2I_Q(OFCZ]5\U^-CZ3A//EE>.52I\$M)>G1_)_A<_H2HKSO\
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M\!?:W_ :_G-UG1[KP]K%UI]["]O>6,SV\\3_ 'HI$8JRGW!!'X5_3)7XO_\
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MA/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]6Y#_ ,BS#_\
M7N'_ *2C^8,[_P"1C7_QS_\ 2F%?='_!OQ_R>7XF_P"Q+NO_ $NL*^%Z^Z/^
M#?C_ )/+\3?]B7=?^EUA7G\8_P#(EQ'^']4=W"?_ ".,/_B/V$HHHK^83^D@
MHHHH *_"[_@L;_RD>^(W_<,_]-=I7[HU^%W_  6-_P"4CWQ&_P"X9_Z:[2OT
MKPM_Y&M3_KV__2H'YWXF?\BNG_U\7_I,SYDHHHK]Z/P\^PO^"&O_ "?KI_\
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MU6V$5W=IS;Z;&<%K>WSR>0-TAY; P%'!^KJ_ >.>+EF4_J>$?[J+U?\ ,_\
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MU=;+JG<^KZ***^=/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.>'4;@KIFFPV:G\(U%1B/%7"I?N:$F_-I?ES%4/#'$M_OJ\4O)-_G8_$O\
M9Y_X),?&K]H*YMY1X7F\):/*P+ZCX@#62A3SE82/.?(Y!";3Q\PSFOTH_8N_
MX)%_#O\ 92N+76]27_A-O&5N1(FI7\(6WLG'>W@R54CC#N68$9!7.*^L**^$
MSKCK,\QBZ5_9P?2/7U>[_!/L?;9/P3EV DJMN>:ZRZ>BV7XOS"BBBOC3ZX*X
M7]I'X\Z/^S+\$?$/C?7&W66AVQE6%6P]U,2%BA7_ &G<JN>@SD\ UW5?G/\
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M47!RW<_-%?TV5^)G_!9[]F;2/V>?VL5O/#]K#8:-XTL!JRVD*;(K6XWM',J
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MBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$QY\/-37=-/\C\UQ6#KX>7)B(.+\TU^8VBBBNHY0HHHH **** "BO0O@_\
MLE_$SX^3QKX0\#^(M;BF/RW45FR6@_WIWQ$OXL*^U_V9_P#@@)KFLW5MJ'Q6
M\0V^C67#MI&BN+B[?I\KSL/+C/7.P29'0CMX>:<29;EZ;Q-5)]D[R^Y:_H>U
MEO#V88YI8:DVN[TC][T_4^%?@=\!?%G[1WC^U\,^#='NM8U2Z(RL:_N[9,X,
MDKGY8XQW9B!T')(!_:O_ ()W_P#!.O0?V&_!4TTDL6L^-]:A1=4U3;\D0X/V
M>#/*Q!N23AG(!.,*J^M? ?\ 9R\%?LS>#5T'P1X?LM#L,AIC$"TUVX_CEE8E
MY&Y/+$X' P,"NXK\3XJXXKYHGAL.G"CVZR]>R\E\V^G[%PQP71RUK$5VIU>_
M2/IY^?X+J4445\&?<!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>biib-20230930_g10.jpg
<TEXT>
begin 644 biib-20230930_g10.jpg
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M$F&;P=ILABU+4TL;@R6<HE6)H9;<1^?'(KNH,;(&&X$C!S7C'PXU+P=\%O\
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M/%=#^TSHND^&O^"/7A'3]"T^*UBLM)\"/:I"@'EN=2TLEQ_M$LQ)ZDL2>IH
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MXS^'?VRM/^ GQ:^(_P /?BG+JW@F\OK7QQX2T-++5-*A@FB_<WJ1R2(D$K2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHKYLT']KC]I[XX76O>*/V6?V;?#VM>#_#^NW>
ME0ZKXJ\;-IUSKTUK(8YS:11VTJQ()%95>9UW8R0O(H ^DZSO#GA'PGX.M[FT
M\(^&-.TJ*\O9;R[BTVRC@6>YD.Z29P@ :1SRSGECU)KG/@)\9K7XY_"ZS^(S
M^#M7\-W#RSVVJ:%K]L8KG3[J"1HIHF_A<!U.)%^5EP1C.!O>%O'O@;QREQ)X
M*\9Z3K"VLGEW3:7J,5P(7_NOY;':>#P?2@"I\1?A%\)_C!ID.B_%KX8>'?%-
MG;R^;;VGB/18+Z*)\8W*LR,%..X&:FN?AK\.KSP1_P *RN_ &B2^&_LZP?\
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M36OB+X4TO6?%VE_N-6O[?58S;Z@)KM,2N9DE?)+<'&W;M&/2+CX5?#7X$_\
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MM#U2?XL:,-8.LG2H;6!38W;7DK27$+-.3$(WE96#<*I()^W* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BL[5O%
MOAC0M9TKP[K.O6MK?:Y<20:/:3S!9+R2.)YG2-3RQ6.-W('15)[5HT %%%%
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M#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\
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MM'_#UW]@3_HO7_EK:K_\BT?4L9_S[E]S_P @_M# ?\_8_P#@2_S/HBBOG?\
MX>N_L"?]%Z_\M;5?_D6N]^!'[8/[.G[3.IZAH_P1^(G]MW.E0)-?Q_V1>6WE
M([%5.;B) V2#P,FIGA<33CS2@TO-,N&,P=6:C"I%M]$TV>ET445@=(4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?!G_  7=_P"2
M:?#_ /[#MY_Z)2OO.O@S_@N[_P DT^'_ /V';S_T2E>AE7_(PA\_R9Y6=_\
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M7P>UM=6NM%23]H)NY5>UE<$!MHD3C*HOW:@\<_'7X>_&7X^Z+XL^)G@F]LO
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M % ?^5?_ +F',>1T5ZY11_Q&O_J _P#*O_W,.8\CHKURBC_B-?\ U ?^5?\
M[F',>1T5ZY11_P 1K_Z@/_*O_P!S#F/(Z*]<HH_XC7_U ?\ E7_[F',>1U[9
M_P $Y?\ D]WX=?\ 8=/_ *)DK/KUG]A;_D[?P+_V&/\ VD]:T/&#Z_6CAOJ-
MO:-1O[6]N9VO;V:O:^UT=."E_ME/_$OS1^M=%%%?4GZJ%%%% !1110 4444
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MGG7_  @GBO\ Z!7_ )'C_P#BJ/\ A!/%?_0*_P#(\?\ \57HM%'_ !&/B?\
MY\T?_ 9__+ YF>=?\()XK_Z!7_D>/_XJC_A!/%?_ $"O_(\?_P 57HM%'_$8
M^)_^?-'_ ,!G_P#+ YF>=?\ "">*_P#H%?\ D>/_ .*K[I_X(;>']7T7XD>/
M9-3M/*$FB680^8K9/G/Z$U\MU]E?\$<_^1_\:_\ 8'M?_1KUZ.4^)N?9YF%/
M UZ=)0G=-Q4D]$WI>;73L>MDC;S6EZO\F??5%%%?=GZ2%%%% !1110 4444
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M/G:BBBOQ0^!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[*_P"".?\
MR/\ XU_[ ]K_ .C7KXUK[*_X(Y_\C_XU_P"P/:_^C7KZ3A#_ )*3#^K_ /26
M>KD?_(UI>K_)GWU1117] 'Z6%%%% !1110 4444 %%%% !1110 4444 %%%1
M7BW3VKI8RJDI7]V[KD ^XH EHK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8KXU_X+&?\B!X*_[#%U_Z*2OK+[%XW_Z#=E_X
M#'_&OC__ (*[P:]#X$\&G6+^"93J]SL$46W!\I:^:XP_Y)O$>B_]*1Y.>?\
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MK0TV/48K4)JEQ'++N.7B3:,=N* +%%%% !1110 4444 %%%% !1110 4444
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MU+_L#V/_ **KX;Q!_P"1%'_''\I'SO$W_(N7^)?DSYVHHHK\4/@0HHHH **
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M /26>KD?_(UI>K_)GWU1117] 'Z6%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7QK_P6,_Y$#P5_V&+K_P!%)7V57YJ_\')7_)(O
MAC_V,E__ .D\==&%X6_UUQ$<E]M[+VVG/R\W+;WOAYHW^&WQ+>Y\QQGF']E<
M,XC%<O-RI:7M>\HK>S[]CYEHKXGHKW/^)2O^IS_Y;?\ W<_GC_B(_P#U"_\
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M_P")?_%S_H6_^5L/_P#+0_URX;_Y_P#_ )+/_P"1/;**\3_X;$_ZIU_Y5_\
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M\CB#_D0XO_KU4_\ 2&>SPY_R4.#_ .OM/_TM']#-%%%?Q4?W&%%%% !1110
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MO$G_ )(C&>D?_2XGY&T445_6Y_'@4444 %%%% !1110 4444 %%%% !1110
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M_"#Z1_S\WO\ X%M6AING0:5:BTMWD90Q.97+'GW-6** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K\U?\ @Y*_Y)%\,?\ L9+_ /\ 2>.OTJK\U?\
M@Y*_Y)%\,?\ L9+_ /\ 2>.OM?#O_DL\)ZR_](D?#>)/_)$8STC_ .EQ/R-H
MHHK^MS^/ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^@_\ @E-_RD.^
M%7_8R'_T1+7SY7T'_P $IO\ E(=\*O\ L9#_ .B):\CB#_D0XO\ Z]5/_2&>
MSPY_R4.#_P"OM/\ ]+1_0S1117\5']QA1110 4444 %%%% !1110 4444 %%
M%% !7X7?\%Y/^4AVM?\ 8MZ7_P"B*_=&OPN_X+R?\I#M:_[%O2__ $17ZGX0
M_P#)52_Z]2_]*@?D_C)_R24?^OL?_29GQI1117],G\MA1110 4444 %%%% !
M1110 4444 %%%% !1110 5^E?_!MK_R5WXG?]BW8?^E$E?FI7Z5_\&VO_)7?
MB=_V+=A_Z425\5XB_P#)&8OTC_Z7$^X\-O\ DM\'ZR_](D?KC1117\D']B!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^:O_!R5
M_P DB^&/_8R7_P#Z3QU^E5?FK_P<E?\ )(OAC_V,E_\ ^D\=?:^'?_)9X3UE
M_P"D2/AO$G_DB,9Z1_\ 2XGY&T445_6Y_'@4444 %%%% !1110 4444 %%%%
M !1110 4444 %?0?_!*;_E(=\*O^QD/_ *(EKY\KZ#_X)3?\I#OA5_V,A_\
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M#'_L9+__ -)XZ^U\._\ DL\)ZR_](D?#>)/_ "1&,](_^EQ/R-HHHK^MS^/
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YJ_\ !R5_R2+X8_\
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M,5]7?M*?&;X@?'G_ ()I>$?B%\2-72YOI?C9JL%O!;VZ06UE;1Z7:K%;6\*
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M^OM/_P!+1_0[16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U?Q4?W&;%%8_\
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ME%8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U?R0?V(;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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MOS4K]*_^#;7_ )*[\3O^Q;L/_2B2OBO$7_DC,7Z1_P#2XGW'AM_R6^#]9?\
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M %%%% !1110 4444 %%%,N;F"S@:ZNI0D:#+NW0"@!]%9O\ PF/AC_H-0?\
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M#_Y(/]4^*?\ H K?^"I__(GS717TI_PZ$_X*&_\ 1 X/_"TT;_Y,H_X="?\
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M_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5
M&E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I5^%W_!>3_E(=K7_ &+>E_\
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M  Z$_P""AO\ T0.#_P +31O_ ),H_P!:>&/^@ZC_ .#8?_)!_JGQ3_T 5O\
MP5/_ .1/FNBOI3_AT)_P4-_Z('!_X6FC?_)E'_#H3_@H;_T0.#_PM-&_^3*/
M]:>&/^@ZC_X-A_\ )!_JGQ3_ - %;_P5/_Y$^:Z*^E/^'0G_  4-_P"B!P?^
M%IHW_P F4?\ #H3_ (*&_P#1 X/_  M-&_\ DRC_ %IX8_Z#J/\ X-A_\D'^
MJ?%/_0!6_P#!4_\ Y$^:Z*^E/^'0G_!0W_H@<'_A::-_\F4?\.A/^"AO_1 X
M/_"TT;_Y,H_UIX8_Z#J/_@V'_P D'^J?%/\ T 5O_!4__D3YKHKZ4_X="?\
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M'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZK^7S^JS2HK-_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZH TJ*S?^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/
M^^JN6-_9ZE +JQN%EC)(#KTS0!-1110 4444 %%%% !2.B2*4D0,IZAAD&EH
MH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C
M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
MA_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^S
MM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQ
MA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_
ML[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_O
MT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/
M_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_
M[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[
M3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*
MFHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
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M%5+C5KM?^6/FQ*J1P]=N&/0,X!]34444 %%%% !1110 4444 %%%% !1110
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M ()_^+_B?^U!-^U1X2_:P\2^$];718])TJWL=#L;I--M H\Q(3<H^PR/O=F
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** .5^.GQ,_X4M\$O&/QC_L3^TO^$2\*ZAK
M/]G?:?)^U?9;:2?RO,VMLW;-N[:V,YP<8K\V_P#B)=_ZLJ_\R/\ _>ZOOO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Y9^W1_P F2_&+_LE?B'_TVW%?S;5_3+^TQ<>&+3]G#X@W?C;P
MO_;FC1>"-6?5]%^W/;?VA:BSE,MOYT?SQ>8FY-Z_,N[(Y%?C_P#\+!_X)E?]
M(O/_ #-FM?\ Q-?KOAOQ7@^'L#7IUJ4YN4D_<Y.UM>:<?PN?C7B?PIB^(<=A
MZE&M3@HQ:]_GN[N^G+"7XV/AJOOO_@W0_P"3VO%/_9*[[_TY:963_P +!_X)
ME?\ 2+S_ ,S9K7_Q-?4O_!(_Q3^Q]K?[2&MVG[/W[&O_  KO65\$7+W.M?\
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M_%#_ +)WK?\ Z035^$=?4Y!_!GZGQ?%'\>GZ/\PK[,_X(;_\G9>(?^R=W?\
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MC7"?M1?$7QK_ ,$ZOV@M0^.'@WP]<:_X/^,<?]GOX?\ M82.P\9)$WV*8%V
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M[6GP^T3]@76WO=(^*"ZE<Z+\;]0M-R-IFCV!C%S>12 #YK]'ABB8#&;B4CA
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MW_@G?IGC36M3F\ 6.F^(OA+JUY?R2ZA;Q31&\M[$SD[V$5Q;^2K,2QCE()(
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MK_\ )5%%:TZ]>DK0DUZ-HQJX;#UVG4@I6[I/\P_X=1?L"?\ 1!?_ "Z=5_\
MDJNS^!O[$O[,7[-OBVX\<_!;X9?V+JMWISV%Q=?VU>W.^W:2.1DVSS.HRT2'
M(&?EQG!.2BJEBL5./+*;:]61#!8.G)2C3BFNJ2_R/5:***P.D**** "BBB@
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$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>biib-20230930_g11.jpg
<TEXT>
begin 644 biib-20230930_g11.jpg
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M>G\%SZGH]G<+JFG0021W44$EU@*8[G>[1H<MY@8C"Y'J?["&A> TU[XI^.O
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M 'TG6=XG\(^$_&^E_P!A^,_#&G:O9>?'-]CU2RCN(O,C8.C[) 1N5@&!QD$
MCFN<^ GQFM?CG\+K/XC/X.U?PW</+/;:IH6OVQBN=/NH)&BFB;^%P'4XD7Y6
M7!&,X&]X6\>^!O'*7$G@KQGI.L+:R>7=-I>HQ7 A?^Z_EL=IX/!]* -:N2A^
M 7P)MOB"WQ9M_@KX2C\5/(7?Q,GARU&H,Q&"QN!'YA)'?=6IK?Q'^'GAJ)9_
M$?CS1M/1[PVB/>ZI#$&N!UA!9AEQD?+UYZ5Q_P ??VI/AC^SKJ'A'2_&^H1F
MX\7^*[/1+6)+V%&M?M"RD7<HD=2+=?)8,XSR0* .Z/A7PP?$X\;GPY8?VT+
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MT8](N/A5\-?@3_P4H^&=C\&/ FD^%K7Q)\,]?M=<L= L([2"\2TELGMS)'$
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M'P%\0;JV\3^)=.N)I8_$MY<*L[:C(TSNZW#A@)8R[!"H (&%7LO'/[!_P?\
M%7C?5?B'X3\6^.O NIZ_<?:/$3_#[QI=Z3%JLV,>=/#$WEM*1UD"JYZDD\UW
M?P1^ _PL_9V\$CP!\)?#(TVP>[DN[MY+B2>XO;J0@R7$\TK-)-*Q R[L3@ <
M    \?\ VZ]0\!:U\0?A=\+-0^"!^)/BW5-5U"_\*>#]2UE;/1F^S6P\^\U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$>6]'Q%\$/J4>J-IUI;VQDAU(7)W3VZB3:FV61ED+X7GI]TT %%%% !1110
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M;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
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MQ?\ !+X;?$'1)/#/CWPW!K>FRL&ET_5XUN8'(Z$QR J<?2NLHH X/X??LR_
MSX20SVWPJ^&ND>&8[D@W,?A[3H;)92.FX0JN[\:QM3_8@_9*UO4KC6=9_9Z\
M'W=Y=SO-=W=UX:M))9I78LSNS1DLQ))))R2<FO5:* //=/\ V5/V>])\&7GP
MYTKX3:%;>'M1G$VH:#;Z3 EE=2C9AY( FQV_=Q\L"?D7T%:7B3X#?"KQEX9'
M@KQ?X1M-5T9515TG4K=)[8!1A1Y3J4P!P..*["B@#@_A]^S-\#/A+!/:_"KX
M:Z1X9BN2#<Q^'M.ALEE(Z%A"J[OQKI/^$'TC_GYO?_ MJV** ,?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P#
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M='N+B0$O<W,S1J);F0*3@<(J[5& 2:]C5<[)._S(>(H1IWE)6>VJ^\Q/V;/
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MY8(KZY *I+.\TLLDA4$A5+[5R2%SS7'_ /"">*_^@5_Y'C_^*H_X03Q7_P!
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MH_XC7_U ?^5?_N8<QY'17KE%'_$:_P#J _\ *O\ ]S#F/(Z*]<HH_P"(U_\
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MK\MW9WNXV=MM[)WWM;+#2HT)<TWJUHUK;76^JUM^?<H_MA?\G2^/O^QIN_\
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MM)OEU:7I:[OVO&7PZI**7??7;Y)Z:O\ X)]):M\)].O/V6-&^$L/QO\ AO\
MVQ9>-;O4YT/C>U\L6\EM%&I#;N3N0\5SW@;6]*^('[/>H_LKZK\2M&T+4](\
M8'5]'O-3OQ'INIIY30R0&X'R(0?WB.WRMN(R.#7AU%5+-(>T4HT[+EY&KO6-
MK>5GI>_?I;0;QD>9-1Z<KUW5CV?QS<>&/A#^S=<_ \_$#1_$FNZ]XH@U6ZC\
M/WHN[/2X8(7C'[]?D>:0O@A"0%3D\@503Q+X:T#]BQ_"VEZY9G7/$/Q $VJV
M4=POGBQMK7$.],Y"&61V!(QD5Y/16$LQDYMQBDN3D2[)[Z]6[N_KI961F\4^
M9V5ER\J\E_5_O.H^$WP^T?XD^))]"UOXB:1X9BATZ:Y6_P!:F"12.F,0@DCY
MVSP/:O0_AMXHTCXJ?LTS_LU:E\0M-\.:EIWBD:WHTVN7?V>ROXVA,<EN\Q^6
M)U;]XI?"G<1D'!KQ2BL\-C%AE90O=-2U?O)VT\K6NK==[K0FC75+:.Z:?FG_
M )?\.>S^.KCPS\(OV;I_@;_PG^C^)-=USQ3!JUTGA^]%W9Z7##"\:_OU^1YI
M"_(0D!4Y/(%>,445GBL3]9E&RLHI)+LEY]7=M_E9:$UJOM9+2R2LEY!1117,
M8A7K/["W_)V_@7_L,?\ M)Z\FKUG]A;_ ).W\"_]AC_VD]>AE'_(VP_^.'_I
M2.G!?[Y3_P 4?S1^M=%%%?TH?JX4444 %%%% !1110 4444 %%%% !1110 5
M^8G_  5'_P"3M]2_[ ]C_P"BJ_3NOS$_X*C_ /)V^I?]@>Q_]%5\-X@_\B*/
M^./Y2/G>)O\ D7+_ !+\F?.U%%%?BA\"%%%% !1110 4444 %%%% !1110 4
M444 %%%% !7V5_P1S_Y'_P :_P#8'M?_ $:]?&M?97_!'/\ Y'_QK_V![7_T
M:]?2<(?\E)A_5_\ I+/5R/\ Y&M+U?Y,^^J***_H _2PHHHH **** "BBB@
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M#V/_ **K].Z_,3_@J/\ \G;ZE_V!['_T57PWB#_R(H_XX_E(^=XF_P"1<O\
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M=."_WRG_ (H_FC]6O^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A7]*'ZN4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9
MVG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN
M?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_O
MJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@
M_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\
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M?-<8?\DWB/1?^E(\G//^155]%^:/@6BBBOP _-0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *]9_86_Y.W\"_P#88_\ :3UY-7K/["W_ "=OX%_[#'_M
M)Z]#*/\ D;8?_'#_ -*1TX+_ 'RG_BC^:/UKHHHK^E#]7"BBB@ HHHH ****
M "BBB@ HHHH **** "OS$_X*C_\ )V^I?]@>Q_\ 15?IW7YB?\%1_P#D[?4O
M^P/8_P#HJOAO$'_D11_QQ_*1\[Q-_P BY?XE^3/G:BBBOQ0^!"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K[*_X(Y_\C_XU_P"P/:_^C7KXUK[*_P""
M.?\ R/\ XU_[ ]K_ .C7KZ3A#_DI,/ZO_P!)9ZN1_P#(UI>K_)GWU1117] '
MZ6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7P[_
M ,%O/'WA+P%\.? EUXLU;[(EQK=VL+>1))N(A0D?(IQ^-?<5?FK_ ,')7_)(
MOAC_ -C)?_\ I/'7IY-PU@.,<SIY/C92C2K-J3@TI*R<E9R4ENENGH?*<<8^
MMEG"N)Q-))RBHVOMK**Z-=^Y\7_\-%?!O_H<?_*?<?\ QNC_ (:*^#?_ $./
M_E/N/_C=?+M%?H?_ !*QX??]!6*_\#I?_*#^:/\ B(.=?\^Z?W2_^3/J+_AH
MKX-_]#C_ .4^X_\ C='_  T5\&_^AQ_\I]Q_\;KY=HH_XE8\/O\ H*Q7_@=+
M_P"4!_Q$'.O^?=/[I?\ R9]1?\-%?!O_ *''_P I]Q_\;H_X:*^#?_0X_P#E
M/N/_ (W7R[11_P 2L>'W_05BO_ Z7_R@/^(@YU_S[I_=+_Y,^HO^&BO@W_T.
M/_E/N/\ XW1_PT5\&_\ H<?_ "GW'_QNOEVBC_B5CP^_Z"L5_P"!TO\ Y0'_
M !$'.O\ GW3^Z7_R9]1?\-%?!O\ Z''_ ,I]Q_\ &Z/^&BO@W_T./_E/N/\
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M27\Q_0S1117YB?U<%%%% !1110 4444 %%%% !1110 4444 %?A=_P %Y/\
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M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\U?\
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MIK4?VL?CYJ?Q2EL5M=-BB33_  ]:&WBCDBL(2PB,OE*JM,Y9I'(&-\C!<*%
M\GHHKVL)A:&"PT,/15H0227DCP\7BJ^.Q4\16=YS;;?FPHHHKH.<*_2O_@VU
M_P"2N_$[_L6[#_THDK\U*_2O_@VU_P"2N_$[_L6[#_THDKXKQ%_Y(S%^D?\
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M_@E-_P I#OA5_P!C(?\ T1+7D<0?\B'%_P#7JI_Z0SV>'/\ DH<'_P!?:?\
MZ6C^AFBBBOXJ/[C"BBB@ HHHH **** "BBB@ HHHH **** "OPN_X+R?\I#M
M:_[%O2__ $17[HU^%W_!>3_E(=K7_8MZ7_Z(K]3\(?\ DJI?]>I?^E0/R?QD
M_P"22C_U]C_Z3,^-****_ID_EL**** )X]2U&+3Y-(BU"=;2:5)9K592(W=
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MY_R4.#_Z^T__ $M']#-%%%?Q4?W&%%%% !1110 4444 %%%% !1110 4444
M%?A=_P %Y/\ E(=K7_8MZ7_Z(K]T:_"[_@O)_P I#M:_[%O2_P#T17ZGX0_\
ME5+_ *]2_P#2H'Y/XR?\DE'_ *^Q_P#29GQI1117],G\MA1110 4444 %%%%
M !1110 4444 %%%% !1110 5^E?_  ;:_P#)7?B=_P!BW8?^E$E?FI7Z5_\
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M]QX;?\EO@_67_I$C]<:***_D@_L0**** "BBB@ HHHH **** "BBB@ HHHH
M***BO)Y+:U>>&V:9E7*Q)U;V% $M%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[
M_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\
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M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8K\+O^"\G_*0[6O^Q;TO_P!$
M5^W/_"2ZO_T*%[_WTM?A]_P72NY[[_@H)K-Q<6,ELQ\.Z8/*E(R/W'7BOU/P
MA_Y*J7_7J7_I4#\G\9/^22C_ -?8_P#I,SX\HHHK^F3^6PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *_2O_ (-M?^2N_$[_ +%NP_\ 2B2OS4K](/\
M@W+U&ZT_XL_$Q[72IKHMX=L05B(^7]_)SS7Q7B+_ ,D9B_2/_I<3[CPV_P"2
MWP?K+_TB1^OE%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+7\D']B&Q16/
M_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'
M_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM:&FWD]]:B>XL)+9BQ'E2D9^
MO% %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\U?\ @Y*_Y)%\,?\
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ME_\ ^D\=?:^'?_)9X3UE_P"D2/AO$G_DB,9Z1_\ 2XGY&T445_6Y_'@4444
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MQ;TO_P!$5^Z-?A=_P7D_Y2':U_V+>E_^B*_4_"'_ )*J7_7J7_I4#\G\9/\
MDDH_]?8_^DS/C2BBBOZ9/Y;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K]*_P#@VU_Y*[\3O^Q;L/\ THDK\U*_2O\ X-M?^2N_$[_L6[#_ -*)*^*\
M1?\ DC,7Z1_]+B?<>&W_ "6^#]9?^D2/UQHHHK^2#^Q HHHH **** "BBB@
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MDH_]?8_^DS/C2BBBOZ9/Y;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK]*_^#;7_DKOQ._[%NP_]*)*_-2OTK_X-M?^2N_$[_L6[#_THDKXKQ%_Y(S%
M^D?_ $N)]QX;?\EO@_67_I$C]<:***_D@_L0**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "OS5_X.2O\ DD7PQ_[&2_\ _2>.OTJK
M\U?^#DK_ ))%\,?^QDO_ /TGCK[7P[_Y+/">LO\ TB1\-XD_\D1C/2/_ *7$
M_(VBBBOZW/X\"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ#_X)3?\
M*0[X5?\ 8R'_ -$2U\^5]!_\$IO^4AWPJ_[&0_\ HB6O(X@_Y$.+_P"O53_T
MAGL\.?\ )0X/_K[3_P#2T?T,T445_%1_<84444 %%%% !1110 4444 %%%%
M!1110 5^%W_!>3_E(=K7_8MZ7_Z(K]T:_"[_ (+R?\I#M:_[%O2__1%?J?A#
M_P E5+_KU+_TJ!^3^,G_ "24?^OL?_29GQI1117],G\MA1110 4444 %%%%
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M+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\
MP+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8H
MH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A
M!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$
M'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^
M;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GY
MO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "
MVK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+
M:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'
M_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!]
M(_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'T
MC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W
M_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;
MW_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MB
MB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C
M_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:M#3=.@TJU%I;O(RAB<RN6//
MN:L44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<K\8O
MC;\+OV?_  =_PL'XP^+(]#T07D5K)J<]O*\44DIVIYAC5O+4MQO;"@D D$C/
M55A_$SX<>#?B_P##_6/A?\0M%BU'1-=L)+/4K.4<21N,'!ZJPX*L.58 C! H
M UVOK);(ZDUY$+<1>:;@R#8$QG=NZ8QSGIBO#/$/_!3;]A?PIX>TGQ7XA_:!
ML+73==^T?V->OI=Z8[T02>5*T9$)WJKY7</E)! )P:^8=#A_:EU:23_@C)J6
MI7X_L^;S-0^)JR*'D^'ORB-5YS]J<L++H5 !'(!>OT \">!_"GPS\&:7\/?
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MV\5PV&J^,+Z2S\-V<D,C-?3HH=T4JI"D*0<L0*^;OV']%TWX,_MT_M$?LW>
M+5;/P=9SZ%XBTG1K<;8-+N[ZT+721J.$5V"L%  4( !@5[M\7?V=O"_QA^)W
MPZ^)^NZC+#<_#G7;G4["".,,MRTUK)!L8D_* S))D9YC [YH Q/BE^WI^Q_\
M%O&L_P ._B9\>=%TW6;0(;^Q_>S&RWXV^>T2,L&<@XD*\$'H<UV?C3XX_!WX
M=_#/_A<OC7XF:+IWA5K>.>+7Y[]/LLT<@!C,;@D2;P1M"Y+9&,UX_P#$"?\
M9G_X)U?!;Q/>7FFW.MWGCWQ%?7B>'[H+>:GXNU>];FT1 FZ8,6"8*D(AY]\/
M]DO]@VVTC]E?X+^"_P!I%+F;6_AQJ=QX@M]$BNU>SMKV>6>6*&56#"7[,L^U
M<-A64D$C% 'K_P $/VN?V;_VC]1OM&^"WQ:TW6[_ $V(2WNFHLD%U%&< 2&&
M94D*9(&\+MR0,\BO1Z^1-&U_2?VN/^"DOA?XM_ RS2?PI\'-%U?3/%?CJV7%
MOKM]>1"./2X9!_Q\);G,Q8$HK,>FY2WUW0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7-A9B%7BDE>)3^^(" D<\$?8EO!%:P);0+M2- J+G. !@4^B@ HHHH ****
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M:=XT^&FJQ6>H7'CC0]-EEEM4F!M[F]CBF7:X(!*,1GJ.HKVV@ HHHH ****
M"O'/$_[?O[)'@WQ+J/A#Q)\6?LVHZ5?36=_;_P!@W[^5/$Y1TW) 5;#*1D$@
MXX)KV.OQT_:=_P"3E/B'_P!CSJW_ *62U\EQ;GV,R'#TJF'C%N3:?,F^GDT>
M+G695\MI0E22=W;6_P"C1^C7_#R+]B[_ *+-_P"6[J/_ ,CU>\,?M^_LD>,O
M$NG>$/#?Q9^TZCJM]#9V%O\ V#?IYL\KA$3<\ 5<LP&20!GDBOR>KN?V8O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\43>.(/#&G)K5Q9K:7&L)91BZEMU8LL+2@;VC#$D*3@$DXH T:*** "BBB@
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MUMLW;,;L'&<X/2BBK]M4[D*A23V/M6BBBLC8X;Q3^S#^S5XYU^Y\5^-?V>?
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M'& J@DD\#J2:T*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>biib-20230930_g12.jpg
<TEXT>
begin 644 biib-20230930_g12.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!GP?^(7@;Q;H]Y%\6O\ A<MA)?>(+0W,2ZA:ZM.D"2ZJM[ TJLLSMF21&7!
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M)+JWP?OO'R^*AJ2^1'#;:G;6)MO*V<EC<B3S-^ $(VG.1^4FH_"7X4_MC_\
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M?'$'BJ?2)GL7U6VB\-&:XMB8FWQ0W(B:&1%<$Q32)NYS7(WGA+P1_P $S/\
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M(M+^(_@.WN/&&E7#1WWC&.;7K#S3J<P;.I>8Y^U@S;RLD2NFT B@#];J***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO"_VJ
M?^"C7[+7['_C/1_A7\3O$6O:MXV\06#W^B^ O OA'4/$&MW5FC%'NOLEA#+)
M' &#+YL@1"58 DJ0 #W2O*])_9!^%^C?MG:Q^W3::EK1\8ZY\/+3P9>6CW<9
MT]=/M[R2[1UC\O>)C)*P+&0J5P-H/-1_LG?MN?LV_ML>&]6\0?L^^/)=0G\.
MZ@+#Q1H&K:3<Z9JVAW97<(+RQNXXY[=B =I= K[6*E@":]8H \H_;"_8T^#G
M[;GPRL_AM\7&UFPET;7;;7/"OBCPOJK6&K^'=6MRWD7]C<J"89D#. 2&4AV#
M*P.*Y;]F/_@G7\,?V<OB[J?[17B'XN_$3XJ?$?4M#71%\=_%37H+Z^L-*$GF
M_8;1+6WM[>VA:4"1Q'"K2, 79L5] 5F^,O&/A7X>>$-5^('CKQ#9Z1H>A:;/
MJ&LZMJ$ZQ6]E:0QM)-/*[<(B(K,S'@!2: .%_8__ &4_AM^Q-^S]I'[-OPCU
M'5[O0-%O]4O+2?7;J.:Z:2_U&YU"8,\<<:D":ZD"X480*"206-G]J[]F#X5_
MMF_L]^)OV9_C5:WTOAOQ3:QQ7KZ7>&WNK>2*:.X@N()0#LEBGBBE1B" T:Y!
M&0>T\*^*/#OCCPQIOC7P?K5OJ6DZQ80WNEZC9RAX;JVE0212HPX961E8$=01
M5^@#YY\'?\$[/"6D?$+X3_%OXE?M'?%'XB>*/@WJFNWOA77?&VJ::\\_]JZ<
M-/GAN?LEA;K)&D0+1[51P[%G:3.*[:X_9)^%MY^U_-^VK>7&J3>*KCX7_P#"
M!3:?+/$VG/I7]H&_+&(Q[S,96*EB^TIQLSS7J%% 'Q7%_P $+OV9;;0;GX/V
M/Q^^-MM\&KO4GNY_@%;^/U3PF8WF\Y[-8Q;_ &U+-I"6-JMV(CDC;@D5]G:;
MINGZ/IT&D:180VMI:PK#:VUO$$CAC4!515& J@   < "N-\"?M&_"#XD_&OQ
MY^SUX.\3O=>+?AFFE-XSTUK":-;$:E;O<6>)701R[XHW;]VS;<8;!(%=Q0!Y
M7^T#^R#\+_VDOB9\+/BKX^U+6H-2^$/C!_$GA>/2[N..&:[:UDMBMPKQN7CV
M2L=JE#G!W8XJQ\6OV4_AM\9?C_\ "C]I#Q7J.KQ:]\'-1UB\\*P6-U&EK-)J
M6G2:?.+E&C9I (96*!&3#X)+#Y:],HH \OO_ -DGX9:C^UX?VU)]2UD>+3\+
MI? 1M5NH_L/]F2:@M^9/+\O?Y_FJ 'W[=O&S/-8_P8_8)_9X^#7[$&G?\$]A
MH=WXG^&MCX6G\/3Z?XJG2>:_L9C(9$F>)(@6/F-AD5".",$ UZSXI\4^&O _
MAG4/&GC/Q!9:3H^DV4MYJFJ:E<K!;V=O$A>2:61R%1%52S,2  "37RIX=_X+
MC?\ !//Q!KVBP3>.?&&D>&_$VIQZ=X8^(_B/X8ZWIOA;5KJ1ML<<&K7-HEL0
MQR%D9UC;&0Q!&0"/X=?\$9_@=X1UOP@GQ!_:3^-WQ*\)?#W5;?4O WPV^(WC
MJ*^T+1[JV.;.011VL4UW]FX\D7<TZQ[5P.*ZK]H#_@F)\+_C-\>KS]I_X=?'
MOXJ_![QYK6CP:7XL\0?"3Q+;V)\1VL *VZWT%W:W,$SPJS+',(UF13M#X"@>
M@_M4_MF_L_?L:>&M)\0?''Q5>0W/B+4O[.\+>'="T6ZU75]=O-I;[/96-G')
M/<.%&6V(508+%00:I?LI?MT_LZ?ME?\ "0:9\'?$.K0>(/"%U%;^+_!GBSPW
M>:+KFAR2J7B%U87T44T:R*"4DVE'VL%8E6  -;]E+]D[X-_L9_"=?A#\%=,O
MDLYM4N=5UK5M:U*2^U+6]3N7WW.H7MU*2]Q<RM@L['H%50JJJB3XF_LP?#SX
MK_'_ .&7[2'B6_U6/7OA/)K+^&H+.YC6UF.IV8M+C[0C1LSXC&4VLF&Y.X<5
MZ-7#_M%_M)? W]DKX2:G\=/VB_B/8>%?"ND!!>:I?[VR[L%CBCCC5I)I78A4
MBC5G<G"J30!Q_P +/V!OV=/@[^V3\2OV[?!7A^ZB\?\ Q5TG3-.\3W,LR&W2
M*RC"*8$" QM*$A,I+,'-O&0%.[=R&C_\$G?V2K']D#Q3^Q'KMAK^M^#/%GBW
M4/$UU-J6K!-0L=4N[XWWVBUN+>.(P/#<8>)@-R[0&+@D&;]GG_@J[^QU^T?\
M7;+X!:#K?BSPKXUU>REO?#GAKXD^ -4\-W.NVL:[GFL1J%O$MT%4%BL9+A06
M*A02-C]IC_@I!^S)^RS\1K/X,>,+GQ9XE\;W>DG5CX+^''@74O$FJ6NFABAO
MKB#3X)6MH-P(#R[=Q5MN[:V ##^ 7_!,3X9_!SXV:1^T7\1_V@/BQ\8_&?A?
M2;C3?!>M?%WQ1;Z@?#=O<*$N39Q6MK;1+-,BJDEPZ/.Z#:9,$@^C_LU?LG_#
M3]E?3O'>F?#C4=8N(_B'\2M:\<:X=7NHY3'J6J2B6X2'9&FV$,!L5MS =6:I
M_@K^UU^S9^T+\ U_:@^$OQ?TC4? BVES<7GB&>4VD6GK;[OM*W:W 1[1X=K>
M8DRHT>T[@*\*\(_\%RO^"=7B_P 2Z-IJ?$;Q3I6@>)=333O"_P 0_$?PXUG3
M?"^LW;MM2*WU:YM4M6W,"%=G5&Q\K'(R ;3_ /!)+]FN/]ACP#^P5I/C#QSI
MN@_"[5[+5_ 'C#3M;@B\0:+J=I<27%O?13_9_),JM-*OS0,A1R"IZUV/PM_8
M1\%_#OX^^&OVG_$/QC\>>-?'/AKX:7W@===\77UB[ZAI]UJ<6HO+<):6D"&=
M9(8XU:-8T$:X*%OFK2_:M_;K_9J_8QBT*S^-WC"^&M^*KB2#PGX0\-:!>:QK
M>N2QJ&D%K8644L\H0%=S[=B;EW,-PS4_9-_X*!_LQ_MH:GXA\*?!SQ3JUMXH
M\(M$OBSP1XO\,WNAZWH_F@F)I[*^BBE".!Q(JLAZ;L\4 5M:_P""=_[-7B[Q
M[\<?&_Q T*^\10_M"Z#H^C_$30-7NE:QDM--M)[6!;=8T22%BEP[,_F,P=49
M"A6O,M"_X(U_"8W?AK1_BU^UM\?/B7X+\(:S9ZIH'PV^('CRWN]%BN+-UDLS
M,(K.*ZO$A=$9([F>5<HNX-BOL"B@ KX=T#_@A?\ #OP'JOB*Z^$'_!0K]J?P
M-I_B;Q5J/B&^\/\ @[XH6MEI\5]>W#3SM'$+ [078]23@#)/6ON*B@#Y[\%_
M\$Y_AWX;\4?!?Q[XP^.7Q/\ ''B'X&:AX@O/"WB'QQXEAOKW4'U>UEM+A;^7
M[.IF6.&8K$$\O9L3)<#![2\_9)^%NH?M?_\ #:U[<ZI+XJ/POD\!/I\D\3:<
M^EOJ"W[,T1CWF8RJ%W;]NPD;,\UL?$O]HWX0?"'XF^ ?@_X_\3O9>(/B=JUW
MIO@NR6PFE%]<VUI)>3(7C0I#M@B=LR%0<8!)(%=NS*BEW8  9))Z4 ?$&O?\
M$$OV5O$'PLU[]G"[^/'QJC^$&KPWZZ=\&X?'$(\.Z#)<^8PDLXS:F?$$TAN(
M(9YIH(YE1_*)1<>I_'O_ ()D?!/XXS^ /%FC_$CX@?#WQQ\,]"&B>%?B3\.O
M$$5AK2:8419+*=I8);>Z@<QHYCFA=0X+($+-GC-9_P""Z_\ P3?T76+QI/B=
MXFNO"FFZLVEZE\4=-^'.LW/A&TO!)Y9B?68K5K3 <A3(',0)Y<#)'O'[0/[7
M/[.O[+_P8C_: ^,_Q/LM.\*W4MM#I5_9I)>OJT]S_P >T%E#;+)+>2RYS''"
MKLPR0, D '#_  0_X)J?LU_!WX=_$3P)XC3Q!\1KOXO0F#XJ>*_B7K']I:MX
MJA^SM;)!<RJD:)#'"[QQPPI%'&&;8JDDGR.^_P""$?[.GB?P)H_PK^)O[3GQ
MW\8^%O"5_IMW\/\ P[XH\=V]Q:>$WL;N&X@^QJMFID(CA^RA[HW$B6\LL<;H
M7+5[3^R__P %%/V:/VLO'>K?"'P)?^)_#_CG1--34M2\!_$/P7J/AW6DL'?8
MEZEIJ$,3S6Y;"^;'N52RABI90>9^/G_!7#]B_P#9\^+&K_!#6M>\7^*?$_AF
M".?QEIOPX^'FK>(_^$:AD7>DFH2:?;RI:Y7YMC-YFWG;@@D ^F:*\Q\*?MH?
MLJ>-_P!F+_AL[PQ\>?#MS\+5TB74Y?&QOA'90V\1*R&0N T;HRLC1L!(K@H5
M#?+7D7PB_P""S_[!OQA^(_ASX:6'B_Q=X<N/&]TMMX U;QY\-]9T'3/%4K#*
M1V%Y?6T4,[N,;$W!I-P"!B<4 ?5=%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %?"G[5?[,_P#P4&^ O[?VK_\ !1?]@'P%X#^)R>,?
MA[8>&/'?PT\:Z\^D7P^PSRRV\^F7^QHHPXE*O'* NY0WSEAY?W77R9\=_P!B
M[]L+P?\ M0Z[^U__ ,$]_P!I#PSX>U;QMIUC:?$+X=_%+0;K5/#NL2V<9BMK
M^!K6>*XL+E83Y;>63'* C.NY26 /&OAC_P %1?@]X:\6_M!_%;X]_P#!/_7?
M@G^TI\._@?/XN\7>%]>N+>[?Q5X>TQ)V@DM-2M?W5["EPQ@\S:-IE4 L$8)\
MXZ/^VS^U%/\ LBZ5^V3X*_:6_:I\5?M"WVCV?B8?#B#]G7Q ? &HM+LG?P_!
M NB^6+;R&,"7ZW)D9P)Q,0V*^V?@W_P3&^)OQ%^,OQ!_:A_X*3_%GPUX^\9_
M$#X4W'PT7PYX$\/S:7H&@^%[B1I;NT@%Q--<7$L\C;FGE8,!\H&W&.:^'O[
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MWE@+&/$RNJJ5Y]!_X=D?M=?%C]C#P?\ LT_'[X_^!-*\7_!#5_#FJ? 3XF>
M/#=WYUG?Z- T$-UJ=G=S-'-YL1V2P1.J$2R<\*!ZG\#O@1_P4A\2_'?P_P#&
M#]L_]J7P7!HGA&PNHM/^'OP:T*_L-/UZ[GB\LW>JRWUQ+)*L0W-%;(%17(<N
MVW! /D3P+>?MT_M/_LC?M*?M.W?_  4'^(/A#5O@Y\4_B-;?##2_"L.GI9/'
MHU[=2VZZHLUK(]]%A$MA!N1%AB#8:1V86?B5\8_VV/!?[%GP-_X+ WO[87BC
M^W?&VO>!K[Q'\)+6WLQX/.@>(+JSA.G16Q@\];B.&\C?[8\[R&59" J,D<?U
M1\!?^"??C#X0?LA_'7]FW4OB%IEY??%OQIX\UO3M2@M9%BL(]?EG>&.13RS1
M"8!BO!P<5C_%3_@FOXW^(/\ P2S^%'_!/VS^)>E6^L?#S3O %M>^();24VUV
M?#T^GRS%$'SJ)19,$STWC/0T >&?#_\ 9^^+'[1?_!:']LSPEX=_:9\7_#3P
MG:Z7\.)M=G^'D]O:ZSJ=V=$N!;1K=SPS>1;QJ)W=40/([0C>$1T?A?B!_P %
M5_VNOV5OV-?C+\#?%?Q!E\4_%SX>?M'Z=\(O!GQ+F\)_;KFZLM66&YL=5N-/
MM(\7E]#:/./)AC(FEBA^1R[*WU)XL_81_;&^&/[:'Q8_;F_8]^/W@JUUKXJ?
MV+8ZQX'^(?AZZNM'FL=-TV&WMI_-M)HIX;N.<W; C?&\5QM90P#C$B_X(R6?
MBS]C/QO\&_BK\?;JY^+?Q"^)R_$W5_BYHVBK#_9?BZ&:&6RN+*TD=MMI:K;P
MP) \A+1"3YD:3*@'C7PP_:>^*7P8_:;^#>G_ +/'QA_:U^,&B>,O&EOX:^+F
MA?&CX(:Y:VEE:744BQZ_;7L^C6D>G?9[H1"6$.8FAF/R+Y6\=[^QO_PV1^V'
M^V_\=+[Q_P#M@>+= ^&?P/\ VBKJQ\,^%?"_V2&37F6RT^?^SM0FD@=CIT*$
M8ACVO*U],6D'EQBO7_A3^S__ ,%0?&GQ<\'>*_VPOVN? MGX6\#73WA\-_!C
MPW?Z:_C&Z\EXHVU6:[N9=ENF\R&TA78\F"SX15KM?V+OV1O$?[+OCKXZ^+=>
M\7V6JQ_%OXS7GC73H;.!T:P@FL+&U%O(6^\X:T9MR\8<>AH ]:^)GPQ^'?QG
M\ ZK\*_BUX)TSQ'X;UVS:UUC0]9LTN+6\A;JDD;@AAP#ST(!ZBOS<_X+B^.?
MVMO$G[+/C3]FSXB?L10>%/V;)K^SM?&_QF\)^);37]0T7PU;7<,IO(/#XCMW
MB*B%,LLDWV=,OY;[./OS]J_]G_\ X:D_9[\3_ >/XI^*?!$VOV2QV?BSP9JT
MEEJ.F3I(DL4T<B$%@'1=\9.V1"\;?*QKY4^,/[%O_!7[]JKX.ZK^R!^T7^V=
M\&K+X=>)-..D>,/&?@;X:ZA;^*=;TMALN(1%<7TEC9R7$>Z-W1'5-[%$Z+0!
ME_#[6_"OQ=_X.!=$O8=6CUCP[X0_8NM-8^%T\DIFC=-4USRKG4X&;DO)!#;P
MF0<E.#]ZM7]I2#_A7/\ P7__ &9/%G@>!8K[XD_"'QSX>\=&W&#/ING+9W]D
MTH'4+=2N%8\C>0.M>@?M!?\ !.3Q#!XI^%'QY_84^(>D?#_XC_!GPFWA+P\/
M$NERZAH^O>&6CB0Z-J,<4L<QC5H(I8IHWWQR*3AMW&A^R]^Q9\<-/_:@U?\
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M1Y"+\L<,;/@,SEAX>W_!.'_@K3:_MH>(/VT-4^/_ .SGX\\1&]N(?AU-\3/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKOPQXUT*WU;1IKF'RY1#*@;9(F3LD4Y1ER<,I&3C- ':T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %<S\9?B98_!OX7:W\4-3TR:]M]%LC<RVL#A7D (& 3P#S73
M5Y1^W/\ \FC^/?\ L O_ .AK0!V>@7OB[Q)H5EXBL]3M88;^TCN8HI+?+(KJ
M&"D@\D XJY]B\;_]!NR_\!C_ (U%\+O^29^'?^P%:?\ HE*W: ,?[%XW_P"@
MW9?^ Q_QH^Q>-_\ H-V7_@,?\:V** ,?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7
M_@,?\:V** ,?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\:V** ,?[%XW_P"@
MW9?^ Q_QH^Q>-_\ H-V7_@,?\:V** ,?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7
M_@,?\:V** /&/VT= ^$VN_LI>/O#'[7OQ!T'1OAGK/AJYTOQEJ>JW'V.&"SN
ME^SL3,2/*;,BA&'(<KCG%?EU=ZM_P4/_ ."4/[1'[1/QI^'_ .TSX:^-'@SX
M3?"SX>WGC>T^)>CI9ZUJWAL/K:6D%G?6>V)KRWC2X_>S1G[1YR[AN4;OV7\=
M>!?!GQ/\&:K\.OB+X6L-<T'7-/EL=8T?5+59[:]MI5*2121N"KHRD@@C!!KX
M;^$__!OC^QE\/OVG/$_Q/\0:5K>O_#Z>Q\-_\(7\,]:\=ZU>Z9IEWIDEZY-Q
M;7%TT5Y;HUQ";:WF$D<!$VU1YAH ]T_;E_:WUK]D/]@OQ_\ MGRWEK+'X8\#
MRZOI5C>V3(9[N2,+9P2#.5WW$L,;=QN/I69_P3Q_9R\2_L9_L1^'-!^(?C6Q
MC\07.FS>*_BIXFUH!)+W7KT&\U2]NIG('$KNNYB-L42+P$&/1/VT_P!D'X7_
M +=_[.>M?LO?&;4]:M?#6OWFG7&HOH%U%#<L;*^M[Z) TL<B[3+;1A@5.5W
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M]JUJ\0;]XB6Y!(]C6I110 4444 %%%% !1110 4444 %>4?MS_\ )H_CW_L
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MT?\ "U_'_P#T'_\ R5B_^)H ]FHKQG_A:_C_ /Z#_P#Y*Q?_ !-'_"U_'_\
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>4?MS_\
M)H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\ HE*W
M:POA=_R3/P[_ -@*T_\ 1*5NT %>">)/^1BO_P#K]E_]#->]UX)XD_Y&*_\
M^OV7_P!#- %*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KV+X0_\B):_]=)?_0S7CM>Q?"'_ )$2U_ZZ2_\
MH9H Z:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *\H_;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH [
MKX7?\DS\._\ 8"M/_1*5NUA?"[_DF?AW_L!6G_HE*W: "O!/$G_(Q7__ %^R
M_P#H9KWNO!/$G_(Q7_\ U^R_^AF@"E1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5[%\(?^1$M?\ KI+_ .AF
MO':]B^$/_(B6O_727_T,T =-1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\
M)H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;
MM !7@GB3_D8K_P#Z_9?_ $,U[W7@GB3_ )&*_P#^OV7_ -#- %*BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+
MO^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %>">)/\ D8K_ /Z_9?\
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MQ[_V 7_]#6@#NOA=_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5Y1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L
M O\ ^AK0!W7PN_Y)GX=_[ 5I_P"B4K=K"^%W_),_#O\ V K3_P!$I6[0 5X)
MXD_Y&*__ .OV7_T,U[W7@GB3_D8K_P#Z_9?_ $,T 4J*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O8OA#_R(
MEK_UTE_]#->.U[%\(?\ D1+7_KI+_P"AF@#IJ*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T
M-:]7KRC]N?\ Y-'\>_\ 8!?_ -#6@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29
M^'?^P%:?^B4K=H *\$\2?\C%?_\ 7[+_ .AFO>Z\$\2?\C%?_P#7[+_Z&: *
M5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7L7PA_Y$2U_P"NDO\ Z&:\=KV+X0_\B):_]=)?_0S0!TU%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1
M^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\ DF?AW_L!
M6G_HE*W:POA=_P DS\._]@*T_P#1*5NT %>">)/^1BO_ /K]E_\ 0S7O=>">
M)/\ D8K_ /Z_9?\ T,T 4J*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O8OA#_P B):_]=)?_ $,UX[7L7PA_
MY$2U_P"NDO\ Z&: .FHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%
M_P#T-: .Z^%W_),_#O\ V K3_P!$I6[6%\+O^29^'?\ L!6G_HE*W: "O!/$
MG_(Q7_\ U^R_^AFO>Z\$\2?\C%?_ /7[+_Z&: *5%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7L7PA_Y$2U_
MZZ2_^AFO':]B^$/_ "(EK_UTE_\ 0S0!TU%%% !1110 4444 %%%% !1110
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M -$I6[6%\+O^29^'?^P%:?\ HE*W: "O!/$G_(Q7_P#U^R_^AFO>Z\$\2?\
M(Q7_ /U^R_\ H9H I4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %>Q?"'_D1+7_KI+_Z&:\=KV+X0_P#(B6O_
M %TE_P#0S0!TU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\
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M[%\(?^1$M?\ KI+_ .AF@#IJ*** "BBB@ HHHH **** "BBB@ HHHH ****
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MX]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4K=K"^%W_ "3/P[_V K3_ -$I6[0
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MTD1[:TB"*8(2LK?+ECPI!!%>S44 ?*;?\$H/";^%?^%6-^VS^T0? )M_LA\
MGXBP_8C8XV_8OM7V3^T/L^S]WL^U9V?+G%?2?P\^'W@KX3^!-'^&/PW\-6NC
M:!H&FPV&C:591[8K6VB0)'&H] H YR3U))K9HH **** "BBB@ HHHH ****
M"O8OA#_R(EK_ -=)?_0S7CM>Q?"'_D1+7_KI+_Z&: .FHHHH **** "BBB@
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MBB@ HHHH **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\
MDT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!6G_HE*W:
M "O!/$G_ ",5_P#]?LO_ *&:][KP3Q)_R,5__P!?LO\ Z&: *5%%% !1110
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M%!/CC9>*[/P-=_&JTCUG4+&>\L=,?3+$33V\+1)+*J>3DJC31!CV,B^M:/\
MPVK^TS_T4O\ \HUE_P#&:_$WP3J?P@\9_M%>#M,_;&^.OCGP#\5Y/"/B6'QE
MKOB+Q7J&C/I.N-?V'V#^SW:1+06OE"X,4<689%4>8&8+C]#_ (F>%OVF+[X6
M>'/ /P:^*>C1:Q.L%KXF\?ZSIHDGCMEA(DO+6UC_ '3W4CA2JN1$NYC@@!2
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M* "BBB@ HHHH **** "O8OA#_P B):_]=)?_ $,UX[7L7PA_Y$2U_P"NDO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBB@ HHHH **** "BBB@ HHHH *Z_X)_\CB__ %Y/_P"A+7(5U_P3_P"1Q?\
MZ\G_ /0EH ]9HHHH **** "BBB@ HHHH **** "BBB@ KRC]N?\ Y-'\>_\
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M (T?8O&__0;LO_ 8_P"- &Q1679VGBU+I'OM6M7B#?O$2W()'L:U* "BBB@
MHHHH **** "BBB@ KRC]N?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?
M_P!#6@#NOA=_R3/P[_V K3_T2E;M87PN_P"29^'?^P%:?^B4K=H *\$\2?\
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MH **** "BBB@ HHHH *Z_P""?_(XO_UY/_Z$M<A77_!/_D<7_P"O)_\ T):
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M_P"1Q?\ Z\G_ /0EH ]9HHHH **** "BBB@ HHHH **** "BBB@ KRC]N?\
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MVD:Y;+9:WI5M>0I/',D5U LBK+&X>-P&! 97564]05!'(JS10 4444 %%%%
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]B^$/\
MR(EK_P!=)?\ T,UX[7L7PA_Y$2U_ZZ2_^AF@#IJ*** "BBB@ KS?X\_\?>F?
M]<Y?YK7I%>;_ !Y_X^],_P"N<O\ -: //Z*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NO^"?_(XO_P!>3_\
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MX\6_ACP_<?V9;ZQ9_#*WU3P]IA5MBVT>IMH\MND"9"IY<OD1J H*JH _8O\
M9?\ #NI^%_@%X8TK5OVA;[XKR-IYN8OB)J L_-UR">1IH9\V2);LGE2(J-&H
M5D13R220#O:\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX
M7?\ ),_#O_8"M/\ T2E;M87PN_Y)GX=_[ 5I_P"B4K=H *\$\2?\C%?_ /7[
M+_Z&:][K\S_BQ_R5+Q+_ -C!>?\ H]Z^&XWXT_U-P]&K[#VOM&U;FY;62?\
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M_P"N<O\ -:](KS?X\_\ 'WIG_7.7^:T >?T444 %%%% !1110 4444 %%%%
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M"6@#UFBBB@ HHHH **** "BBB@ KY!_X*'^&/$.N?%+1;C2/^"(GAG]IZ--
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M_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3/P[_ -@*T_\
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M/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M
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MG?WL[+_AH#XN?]#;_P"2%O\ _&Z/^&@/BY_T-O\ Y(6__P ;KC:*/];.*?\
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MN*L'1K8RK*$II-.I-IKLTW9G1A*]>6)BG-M7[L^W****_K8^F"BBB@ HHHH
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M_P#H58G_ ,$5?_D3YO\ M'+_ /G]#_P)?YD-%3?8+O\ YY?^/"C[!=_\\O\
MQX4?Z@\=_P#0JQ/_ ((J_P#R(?VCE_\ S^A_X$O\R&BIOL%W_P \O_'A1]@N
M_P#GE_X\*/\ 4'CO_H58G_P15_\ D0_M'+_^?T/_  )?YD-%3?8+O_GE_P"/
M"C[!=_\ /+_QX4?Z@\=_]"K$_P#@BK_\B']HY?\ \_H?^!+_ #(:*F^P7?\
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M=3_P/_TJ)ZO1117YR?L(4444 %?)O_!2O_D.>$O^O2\_]"BKZRKY-_X*5_\
M(<\)?]>EY_Z%%7YYXJ?\D/B?6G_Z<B<.8_[G+Y?FCYAHHHK^1CYD**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]T_
MX)[?\EYF_P"Q?N/_ $9%7A=>Z?\ !/;_ )+S-_V+]Q_Z,BKZO@7_ )+# _\
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M %%%% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[
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M?^C(J^KX%_Y+# _]?(G3@_\ >H>I]N4445_:)]6%%%% !1110 4444 %%%%
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>Z?\$]O^2\S?\
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M\+_@AJOB?XD_"K4/&/AAFAM?$^E6&EI>^7ITT@CGN9;=N9H8D8NZJK-M!.W
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MIK>A3=*DH62MV_X.OKYG+BZJKXB51-N_>U_PT271+9!1116QSA1110 4444
M%%%% !7W#^Q1_P F\Z3_ -?5U_Z/>OAZON']BC_DWG2?^OJZ_P#1[U\SQ9_R
M+(_XE^3/M^ ?^1U/_ __ $J)ZO1117YR?L(4444 %?)O_!2O_D.>$O\ KTO/
M_0HJ^LJ^3?\ @I7_ ,ASPE_UZ7G_ *%%7YYXJ?\ )#XGUI_^G(G#F/\ N<OE
M^:/F&BBBOY&/F0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KW3_@GM_R7F;_L7[C_ -&15X77NG_!/;_DO,W_ &+]
MQ_Z,BKZO@7_DL,#_ -?(G3@_]ZAZGVY1117]HGU84444 %%%% !1110 4444
M %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M '=?
M"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T2E;M !7YR_%+_DIOB/\ [#UY
M_P"CGK]&J_.7XI?\E-\1_P#8>O/_ $<]?8\'_P >KZ+\V?G7B'_NU#UE^2,&
MBBBONS\L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "ON']BC_ )-YTG_KZNO_ $>]?#U?</[%'_)O.D_]?5U_Z/>O
MF>+/^19'_$OR9]OP#_R.I_X'_P"E1/5Z***_.3]A"BBB@ KY:_X*+?\ (9\*
M_P#7K=_^A15]2U\M?\%%O^0SX5_Z];O_ -"BKW>&_P#D<4_^WO\ TEGR_&7_
M "3M;_MW_P!*1\V4445^GGX>%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %>V?L$_\EPF_[ -Q_P"C(J\3KVS]@G_D
MN$W_ & ;C_T9%7FYS_R*ZW^%GM<.?\CW#_XD?9E%%%?DI^_!1110 4444 %%
M%% !1110 4444 %>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\ )H_CW_L O_Z&
MM '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;M !7YR_%+_DI
MOB/_ +#UY_Z.>OT:K\Y?BE_R4WQ'_P!AZ\_]'/7V/!_\>KZ+\V?G7B'_ +M0
M]9?DC!HHHK[L_+ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K[A_8H_Y-YTG_ *^KK_T>]?#U?</[%'_)O.D_]?5U
M_P"CWKYGBS_D61_Q+\F?;\ _\CJ?^!_^E1/5Z***_.3]A"BBB@ KY:_X*+?\
MAGPK_P!>MW_Z%%7U+7RU_P %%O\ D,^%?^O6[_\ 0HJ]WAO_ )'%/_M[_P!)
M9\OQE_R3M;_MW_TI'S91117Z>?AX4444 %%%% !1110 4444 %%%% !1110
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MQA\'O#O[-NL?LP>#KG7=%T?7DG?5];T_6&.KW5U.P>:]DNY0[/<NP!,C \8
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M15YN<_\ (KK?X6>UPY_R/</_ (D?9E%%%?DI^_!1110 4444 %%%% !1110
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M_P#D<4_^WO\ TEGR_&7_ "3M;_MW_P!*1\V4445^GGX>%%%% !1110 4444
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M$B!0 J"@PQ S7UC112KUZN(JNI4=VP"BBBL@"BBB@ HHHH **** "O9?@_\
M\B':_P#727_T,UXU7LOP?_Y$.U_ZZ2_^AFOI>%?^1E+_  O\T!T]%%%?H8!1
M110 5\M?\%%O^0SX5_Z];O\ ]"BKZEKY:_X*+?\ (9\*_P#7K=_^A15[O#?_
M ".*?_;W_I+/E^,O^2=K?]N_^E(^;****_3S\/"BBB@ HHHH **** "BBB@
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M_P"(I?\ 4)_Y4_\ M#]X**_!^BC_ (EW_P"IG_Y1_P#NH?\ $4O^H3_RI_\
M:'[P45^#]%'_ !+O_P!3/_RC_P#=0_XBE_U"?^5/_M#]X**_!^BC_B7?_J9_
M^4?_ +J'_$4O^H3_ ,J?_:'[P45^#]%'_$N__4S_ /*/_P!U#_B*7_4)_P"5
M/_M#]X**_!^BC_B7?_J9_P#E'_[J'_$4O^H3_P J?_:'[P45^#]%'_$N_P#U
M,_\ RC_]U#_B*7_4)_Y4_P#M#]X**_!^BC_B7?\ ZF?_ )1_^ZA_Q%+_ *A/
M_*G_ -H?O!17X/T4?\2[_P#4S_\ */\ ]U#_ (BE_P!0G_E3_P"T/W@HK\'Z
M*/\ B7?_ *F?_E'_ .ZA_P 12_ZA/_*G_P!H?O!17X/T4?\ $N__ %,__*/_
M -U#_B*7_4)_Y4_^T/W@HK\'Z*/^)=_^IG_Y1_\ NH?\12_ZA/\ RI_]H?O!
M7LOP?_Y$.U_ZZ2_^AFOYNJ_;[_@BG_RCV\*?]A35?_2Z:O/S/PH_U(PZS#ZY
M[;F?)R^SY-[N]^>7\NUNNY]!PUQI_K#CY8;V'):+E?FYMFE:W*N_<^KJ***\
M$^Z"BBB@ KP?]LGX6?\ "Q=2T"?^W?L?V6"X7'V7S-VXQ_[2XZ5[Q7FOQ]_X
M^],_ZYR_S6N+,<RQN4826*PD^6I&UG9/=I/1IK9]CEQN"PV889T,1'F@[75V
MMG=:II[GS/\ \,Q_]3O_ .4W_P"V4?\ #,?_ %.__E-_^V5ZM17S/_$1.,?^
M@K_R2G_\@>'_ *G<.?\ /C_R:?\ \D>4_P##,?\ U.__ )3?_ME'_#,?_4[_
M /E-_P#ME>K44?\ $1.,?^@K_P DI_\ R ?ZG<.?\^/_ ":?_P D>4_\,Q_]
M3O\ ^4W_ .V4?\,Q_P#4[_\ E-_^V5ZM11_Q$3C'_H*_\DI__(!_J=PY_P ^
M/_)I_P#R1Y3_ ,,Q_P#4[_\ E-_^V4?\,Q_]3O\ ^4W_ .V5ZM11_P 1$XQ_
MZ"O_ "2G_P#(!_J=PY_SX_\ )I__ "1Y3_PS'_U._P#Y3?\ [91_PS'_ -3O
M_P"4W_[97JU%'_$1.,?^@K_R2G_\@'^IW#G_ #X_\FG_ /)'E/\ PS'_ -3O
M_P"4W_[91_PS'_U._P#Y3?\ [97JU%'_ !$3C'_H*_\ )*?_ ,@'^IW#G_/C
M_P FG_\ )'E/_#,?_4[_ /E-_P#ME'_#,?\ U.__ )3?_ME>K44?\1$XQ_Z"
MO_)*?_R ?ZG<.?\ /C_R:?\ \D>4_P##,?\ U.__ )3?_ME'_#,?_4[_ /E-
M_P#ME>K44?\ $1.,?^@K_P DI_\ R ?ZG<.?\^/_ ":?_P D>4_\,Q_]3O\
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M?S9^6^)_^Z8;_%+\D<+1117[6?CH4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5^WW_!%/_E'MX4_["FJ_^ETU?B#7
M[??\$4_^4>WA3_L*:K_Z735^<^*'_).P_P"OD?\ TF9^@^&W_(_G_P!>Y?\
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M^/O3/^N<O\UKTJO-?C[_ ,?>F?\ 7.7^:UX?$?\ R**GR_\ 2D!Y[1117YF
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M#X;?\C^?_7N7_I43ZNHHHK\!/W,**** "O-?C[_Q]Z9_USE_FM>E5YK\??\
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M1110 4444 %%%% !1110 5V/P0_Y')_^O%__ $):XZNQ^"'_ ".3_P#7B_\
MZ$M>CE'_ ",Z/^) >MT445^K@%%%% !1110 4444 %%%% !1110 5Y1^W/\
M\FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z
M)2MVL+X7?\DS\._]@*T_]$I6[0 5_.;^U#_R<Q\1/^QZU?\ ]+9:_HRK^<W]
MJ'_DYCXB?]CUJ_\ Z6RU^L^%/^^8K_#'\V?EOB?_ +IAO\4OR1PM%%%?M9^.
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7[??\$4_P#E'MX4_P"PIJO_ *735^(-?M]_P13_ .4>WA3_ +"FJ_\
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MUKTJO-?C[_Q]Z9_USE_FM>'Q'_R**GR_]*0'GM%%%?F8!1110 4444 %%%%
M!117YP?\%#OVJ?VJ/BK\6/&_P$^ 7Q?T#X<:5\*/B?\ #;2M1G?2YKW6M:O-
M8U339([@!;F!8=/B%PBM'AS<F*:(O&K9'1A<-+%5.5.W=OIJE^;0'Z/T5XU\
M-_BA^T?\+OV?_%/C7]LCP-8:AKO@^>]:&;X86,UT?%%A$BO!<VU@SO+#<RY,
M9M2[_O%RK[6&/&/V/?VP_P!L+XR?\%#O&GP7_:#^'MCX&\-1?"73?%'A7P*7
MBN-2TY+C4)[=7U"X0$?:G2(LT,;-'$&1,LZNQ<<+4E&<DU:/GOZ=]_EU ^S*
M*\]_:D_:,\)?LK_!75?B_P"*K"XU&6W:*TT+P_I_-WKFJ7#B*STZV7^*:>9D
MC7C R6.%5B/!O^"67[07[7'Q?G^-O@_]KWQ)H^K^)_A_\1UTB&V\/Z=%;6UF
MKZ=;736<3* 94CDG>-99"68*&)YJ88:I.A*KT7X^GI=7]0/KNBOBKQMX-_X*
MR/\ !KQ)^TUX[_;6\)_"[6=)TZ_UBV^%]GX&T_4M T^VMU>2.VOM2G/VJ9FC
MC'FW$+PJA=BJ$* ?H+]B#]H+7?VK/V1/AU^T=XG\'_V#J/C+PI::G>Z2N[9!
M+(@+&/=\QB8_.A.249<D]:JKAG3I\ZDFKV=KZ/[E?U5T!ZG17RC^UY^TA\=?
M$/[4&E_L4_LS_%+0OAY-8^"7\:?%#XH:]I<-\OA[2#<&VM;>V@G98&N9Y4E)
M:8[(XHBVUB0*WOV,+[]KNV\?:SH_Q)_:1\'_ !P^&%SHZ77ACXGZ/:V-CJ4&
MHB79-IUQ;V!-M.GED2+/&(R#E64Y!4>%E&C[1R2TO;6]ONM\KWMT ^D****Y
M@"BBB@ HHHH **** "NQ^"'_ ".3_P#7B_\ Z$M<=78_!#_D<G_Z\7_]"6O1
MRC_D9T?\2 ];HHHK]7 **** "BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_V
M 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3/P[_ -@*T_\ 1*5NUA?"
M[_DF?AW_ + 5I_Z)2MV@ K^<W]J'_DYCXB?]CUJ__I;+7]&5?SF_M0_\G,?$
M3_L>M7_]+9:_6?"G_?,5_AC^;/RWQ/\ ]TPW^*7Y(X6BBBOVL_'0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]OO
M^"*?_*/;PI_V%-5_]+IJ_$&OV^_X(I_\H]O"G_84U7_TNFK\Y\4/^2=A_P!?
M(_\ I,S]!\-O^1_/_KW+_P!*B?5U%%%?@)^YA1110 5YK\??^/O3/^N<O\UK
MTJO-?C[_ ,?>F?\ 7.7^:UX?$?\ R**GR_\ 2D!Y[1117YF 4444 %%%% !1
M110 5^5W_!8WQW_P3Q^*WC*[\$?M)_#Z/X??%CPC\2/!]EH_BW7YSI-YK?AB
M;6=/-WJ%A?PR!9[:*"2[W!G+VS1/(5C89'ZHUQ/QY_9[^%O[27A&R\$?%G0!
M?V&G^(=-UJU0$!ENK&\BNX>2#\ADA0.O1T+*>":[,#B(8;$*<K_)V?\ P?0#
MYJ_X)._%;5IOAE\4[K4_CKKOC/X-^&?'[VGPD^)GQ!U M=:EI(M8#<!KN<(;
MJVANVFABN6SO"D!B% '.^!/CM\$(?^"WGQ"\4R_&3PHNF3?LZ:#;PZBWB&V$
M#S+K%ZS1B3?M+@$$J#D @U]L>+/ O@CQ[X3NO 7CGP=I6M:%?0""]T75M/BN
M;2XB!!"/#(I1UR!P01P*\T_X=Z_L"?\ 1COP?_\ #::5_P#(]:K%8>4ZDI)K
MF5M+>6O37371 >)_M.?#[]N/QU^V_P"$OCS\/?V?O!/Q*^&G@/03<_#_ $C4
M?BD=&7^W;J/;-K$RC3[I9WC@9H+<<",22R [I!M\Q_X)>?%G]J33_P!IC]JC
M5?''[+6EV^EGXJW>H^+FT#Q\=1O=.OXM%M6CL+.V-C$-0\P)&!*9(,-)C8=N
M3^B6DZ3I6@:5:Z%H6F6]E8V5ND%G9VD*QQ01(H5(T10 JJH "@    52\.^!
M/!'A#4=5U?PGX-TK2[O7;[[;KEUIVG102:C<[%3SYV109I-JJN]\MA0,X J5
MC8^PE3<%LDGKT=^]O/;<#X4^.NC_ /!'/_@I;\$9OVL/BW\;AH)F\/QB^N=0
M^)4^G77AV2WW.+>[TAKIK/[5#)N#12V\N]E 'F*5)]$_8#_;9N-!_P""8GPH
M_:*_;Z\;6'A34=?C&FQZMJE@+%=1W74\6G2^1&NV)[BUBAE"J OSY  ( ]R\
M4_L9?L?>.?'I^*OC7]E'X:ZQXH,PF/B35/ NGW%^9!T?[1)"9-P]=V:ZWQ]\
M+OAG\5M$A\,_%'X=Z%XDTVWNX[NWT_7](AO((IX\^7*L<RLJNN3M8#(R<&G4
MQ-"=)4GS.-[ZM7BM=(^O7T6@'P)^TQ\#O@/IG_!::S\:_MK7.FM\,OB-\*;.
M/PO9^+'1=!U+Q/I=W(%L[L2_N99$MKF2>&&;Y'>0L%:2),='^SOH?P%\+_\
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MP^(_^114^7_I2 \]HHHK\S **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *['X(?\CD_P#UXO\ ^A+7'5V/P0_Y')_^
MO%__ $):]'*/^1G1_P 2 ];HHHK]7 **** "BBB@ HHHH **** "BBB@ KRC
M]N?_ )-'\>_]@%__ $-:]7KRC]N?_DT?Q[_V 7_]#6@#NOA=_P DS\._]@*T
M_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ K^<W]J'_ ).8^(G_ &/6K_\ I;+7
M]&5?SF_M0_\ )S'Q$_['K5__ $MEK]9\*?\ ?,5_AC^;/RWQ/_W3#?XI?DCA
M:***_:S\="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "OV^_X(I_\ */;PI_V%-5_]+IJ_$&OV^_X(I_\ */;PI_V%
M-5_]+IJ_.?%#_DG8?]?(_P#I,S]!\-O^1_/_ *]R_P#2HGU=1117X"?N8444
M4 %>:_'W_C[TS_KG+_-:]*KS7X^_\?>F?]<Y?YK7A\1_\BBI\O\ TI >>T44
M5^9@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %=C\$/\ D<G_ .O%_P#T):XZNQ^"'_(Y/_UXO_Z$M>CE'_(SH_XD
M!ZW1117ZN 4444 %%%% !1110 4444 %%%% !7E'[<__ ":/X]_[ +_^AK7J
M]>4?MS_\FC^/?^P"_P#Z&M '=?"[_DF?AW_L!6G_ *)2MVL+X7?\DS\._P#8
M"M/_ $2E;M !7\YO[4/_ "<Q\1/^QZU?_P!+9:_HRK^<W]J'_DYCXB?]CUJ_
M_I;+7ZSX4_[YBO\ #'\V?EOB?_NF&_Q2_)'"T445^UGXZ%%%% !1110 4444
M %%>D?LD_ VP_:._: T+X1:MJUU96E^MU<7DFGPK)<O%;6LMR\4"-PTSK"40
M'(W."00,5[9^TC8?L3WOP5\!VME\.?$_@;5[GX;WE_X9U(:C%?\ VJ>+6-0A
M6TU&-;>)G>0Q-_I"D>7N1"C+&"?+Q6:TL-C(890E*3M>WV4^:S>MW?E>R>WI
M?TL-EE3$82>(YU%*]K]6N6Z[+XENUOZV^2Z*]O\ A[+^R/\ ";X):1X_^)'@
MU?B9XS\1W]TI\*?\)#<:?9^'[2!@BO<FVVS2S3$ED57"!!D\C!W/C/\ L^?
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M\C.C_B0'K=%%%?JX!1110 4444 %%%% !1110 4444 %>4?MS_\ )H_CW_L
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M_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\ ),_#O_8"M/\
MT2E;M87PN_Y)GX=_[ 5I_P"B4K=H *_G-_:A_P"3F/B)_P!CUJ__ *6RU_1E
M7\YO[4/_ "<Q\1/^QZU?_P!+9:_6?"G_ 'S%?X8_FS\M\3_]TPW^*7Y(X6BB
MBOVL_'0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K]OO^"*?_ "CV\*?]A35?_2Z:OQ!K]OO^"*?_ "CV\*?]A35?
M_2Z:OSGQ0_Y)V'_7R/\ Z3,_0?#;_D?S_P"O<O\ TJ)]74445^ G[F%%%% !
M7FOQ]_X^],_ZYR_S6O2J\U^/O_'WIG_7.7^:UX?$?_(HJ?+_ -*0'GM%%%?F
M8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWA17P?\ \/L_^K9O_+S_ /N.C_A]G_U;-_Y>?_W'1_Q!_P 1?^@'_P JT?\
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M?"G_ 'S%?X8_FS\M\3_]TPW^*7Y(X6BBBOVL_'0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]OO^"*?_ "CV\*?]
MA35?_2Z:OQ!K]OO^"*?_ "CV\*?]A35?_2Z:OSGQ0_Y)V'_7R/\ Z3,_0?#;
M_D?S_P"O<O\ TJ)]74445^ G[F%%%% !7Y;?\'$__(Y_"S_L%ZM_Z,M:_4FO
MRV_X.)_^1S^%G_8+U;_T9:U]IX??\E90])_^D2/C^//^27K^L/\ TN)^;E%%
M%?T@?SV%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ_\ Z6RU_1E7\YO[4/\ R<Q\1/\ L>M7_P#2V6OUGPI_WS%?X8_FS\M\3_\
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MVM?.\6_\DUB_\#/?X6_Y*+"_XT?LO1117\NG]*A1110 4444 %%%% !1110
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MBB@ I55F8*H)). !WI*GTNRU'4M3M].T>VEFN[B=([6&!2TDDC, JJ!R6)(
M [TF[*XTKNQ]46'_  3D\)Z3\*=;M/B;^T7X5\/?$6Q\2Z-IITF\ENS9Z5->
M6]W*MC>SQV[1I</Y*G<K-'%Y;J[ LM>4_"']DOQ)\0O%/C2P\;>,--\)Z'\.
M8'F\;>(;P-=Q60$_D+'$EON-S))+\J!#M;&=W3/U!)\6OA5\;/@?X\L/VU/@
M%K7A[Q-_PLOPYI/C75_!5T;>_N]3%IJ<45Y+9W"O$LB+'*)$CVB4R[@ 5&>=
M^ GPRC_8B\<?'#6OBYXEM->^&WA.^3PEXH\.)I(N'\7/<.[6T*J9%%HR"/S3
M,7)B(*J')(KX:EFN94Z%>-6;]K>/*K1:=_9I^S:NG?F]U23M>+E]H^TJY7E]
M2M0E3@O96E=W::MSM>T3LU;E]YQ:VDH_9/#_ !?^S%\-]0^%6O\ Q;_9Y^/H
M\:6GA$V[^*-,U+PO+I-[:6\\HACN8T:69)HO-95;#AUW*2H!R+6A?LM_!CP]
MX.T#Q%^T1^U58^#]0\3Z<FHZ5H>C^&)M;GM[.0D1S7;12QI;[L$B,&20+@E0
M>*]C/B/]G?\ :%_9,^(O@/\ 8T\!7/PLU30](/B7QSX?U*X;4_\ A)-)M)T(
M1-0D;S(A"[QOY.Q5=MO+'+#Y\^$VI_!GX.:[=:3^U5^S%XB\1SRFTN+.T_X2
M>;1)+:!D+DM']G=IEE1XV4[D^49!(;(]+#8K'XBA4BY34X2^&U/VO+:.]_W>
M[;NK^[97YKH\_$8; T*U.2C!QG'XKU/9WN^W[S9)6=M;NW+8R_VD/V??$_[-
M?Q*;X?\ B+6+#58;G3K;4]$UO2I"UMJ=A<)O@N8]P# ,N001P5(Y&";G[._[
M.5[\=/\ A(/$NM>-]/\ "?A#PA81WGBOQ7JD,DL5DDC^7#&D48+S3ROE4C7&
MXJ>1CGT+_@I/IVI:A\4?"?Q8MO$BWOAOQIX!T[4?!EA_9HLVT73%#0Q:<8@[
M@>5Y9 8,P?=NR237BGP[\.?$SXAZY%\*?ACI^K:G>^(+B.)=#TLNWVUU)9-R
M*<,%Y;<W"@%L@ FO0PN(Q&+R:%5U%&;2YI6VL_>T>B:L]U9/HUH<&)H8?"YO
M.DJ;E%-VC?>Z]W5:M.ZV=VNJ>IZ9\0?V3_!?_"G-6^._[.OQYM_'N@^&;NV@
M\66MSX>ETG4-*^T/L@F:"1Y%DA=QLWJY(8@%1SCQ.OH_XB:UX'_9(_9Z\3?L
MN>%_%=EXE\>>.KFR_P"%BZGI,XET_0[:TE\Z+3()1Q<3F7#32+\B[?+!8@L/
MG"M,JJXBM2G*I)RCS>Y)I)RC9:M))?%S6=E>-GUN\\SI4*56$8149<OOQ3;2
ME=Z)MM_#:ZN[2NO)%%%%>H>:%%%% !1110 4444 %?:O_!!;_D^"[_[$6_\
M_1]K7Q57VK_P06_Y/@N_^Q%O_P#T?:U\[Q;_ ,DUB_\  SW^%O\ DHL+_C1^
MR]%%%?RZ?TJ%%%% !1110 4444 %%%% !1110 5Y1^W/_P FC^/?^P"__H:U
MZO7E'[<__)H_CW_L O\ ^AK0!W7PN_Y)GX=_[ 5I_P"B4K=K"^%W_),_#O\
MV K3_P!$I6[0 5_.;^U#_P G,?$3_L>M7_\ 2V6OZ,J_G-_:A_Y.8^(G_8]:
MO_Z6RU^L^%/^^8K_  Q_-GY;XG_[IAO\4OR1PM%%%?M9^.A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7[??\$4_^
M4>WA3_L*:K_Z735^(-?M]_P13_Y1[>%/^PIJO_I=-7YSXH?\D[#_ *^1_P#2
M9GZ#X;?\C^?_ %[E_P"E1/JZBBBOP$_<PHHHH *_+;_@XG_Y'/X6?]@O5O\
MT9:U^I-?EM_P<3_\CG\+/^P7JW_HRUK[3P^_Y*RAZ3_](D?'\>?\DO7]8?\
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M*/VY_P#DT?Q[_P!@%_\ T-: .Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX=_[
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M#_TN)^;E%%%?T@?SV%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$^KJ***_ 3]S"BBB@ K\MO\ @XG_ .1S^%G_ &"]6_\ 1EK7ZDU^6W_!Q/\
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M#_Z+QHG_ 'U)_P#$5WDOPK^&$\K3S_#C07=V+.[Z/ 2Q/4D[>33?^%3?"O\
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M7_T33P__ .":#_XBOJ?^(I<0?\^J7_@,_P#Y,^:_XAID7_/RK]\?_D#^?/\
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M_P#$4?\ $4N(/^?5+_P&?_R8?\0TR+_GY5^^/_R!_/G_ ,,O_&/_ *!>B?\
MA8:7_P#)-'_#+_QC_P"@7HG_ (6&E_\ R37]!G_"IOA7_P!$T\/_ /@F@_\
MB*/^%3?"O_HFGA__ ,$T'_Q%'_$4N(/^?5+_ ,!G_P#)A_Q#3(O^?E7[X_\
MR!_/G_PR_P#&/_H%Z)_X6&E__)-'_#+_ ,8_^@7HG_A8:7_\DU_09_PJ;X5_
M]$T\/_\ @F@_^(H_X5-\*_\ HFGA_P#\$T'_ ,11_P 12X@_Y]4O_ 9__)A_
MQ#3(O^?E7[X__('\^?\ PR_\8_\ H%Z)_P"%AI?_ ,DT?\,O_&/_ *!>B?\
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M_GY5^^/_ ,@?SY_\,O\ QC_Z!>B?^%AI?_R37ZG_ /!+[X_?!3]G;]CCP_\
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M_P *F^%?_1-/#_\ X)H/_B*/^%3?"O\ Z)IX?_\ !-!_\11_Q%+B#_GU2_\
M 9__ "8?\0TR+_GY5^^/_P @?SY_\,O_ !C_ .@7HG_A8:7_ /)-'_#+_P 8
M_P#H%Z)_X6&E_P#R37]!G_"IOA7_ -$T\/\ _@F@_P#B*/\ A4WPK_Z)IX?_
M /!-!_\ $4?\12X@_P"?5+_P&?\ \F'_ !#3(O\ GY5^^/\ \@?SY_\ #+_Q
MC_Z!>B?^%AI?_P DT?\ #+_QC_Z!>B?^%AI?_P DU_09_P *F^%?_1-/#_\
MX)H/_B*/^%3?"O\ Z)IX?_\ !-!_\11_Q%+B#_GU2_\  9__ "8?\0TR+_GY
M5^^/_P @?SY_\,O_ !C_ .@7HG_A8:7_ /)-'_#+_P 8_P#H%Z)_X6&E_P#R
M37]!G_"IOA7_ -$T\/\ _@F@_P#B*/\ A4WPK_Z)IX?_ /!-!_\ $4?\12X@
M_P"?5+_P&?\ \F'_ !#3(O\ GY5^^/\ \@?SY_\ #+_QC_Z!>B?^%AI?_P D
MTQ?V9_B^T[6PTK2-RJ"2?%FFA?P;[1@_0&OZ#_\ A4WPK_Z)IX?_ /!-!_\
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M^*6\._$?P!KUU#<S:1?>6LL;17,!,=U;RQN'CF7 < _*!@FU_P %&/VT8O\
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M)&:^DOV@(/C;^T+X6N/#O["W[:G@WP-X@\,^))+#Q;J,W@VW\6""9( S:?-
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M\//V^O%WA^ZD^(?PRT#4='\-W<<R"W:WO%96,R%"SO$)+@1$,H7[3*2&)4J
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MI_CSXT^'5MH_]G>%_!WB3QM9R6?AU%3RX)+?R[%'N)((_EA-ZUT(L*R@.JL
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\:0'QW!X1C\43>'?(E\Q=(DNGM$NM^WR]IGC=-N[=E<[<8- '74444 %%%%
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M_!9OA5;7E]'\._'7C6/53XG\'Z=>7$LY@-E#$UKJ<ELTSB&1YX%;:F]-HVT
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M%XGTGQ)X6BDT+PGJMAI\5GX86*\O!)':R6]O'/*)2RLQN))2#&NTJ"0?3/\
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M:?XOTUYFTC4\&?3[F&>2VN;9R.&,=Q#+'N &X(&P,X'D'_!+'X6?$CX:>/\
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M'WDW^C:3XI.JZ1J2MXG#)?V-SY4#O&RNT9\V&*5'BD4J5"NZ_LT_\%'?AQ\
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MW1/ ][K7BCP=<GP%;6.GF&TFUIM9BDCAN(&L83,D4,GGM,P3RS@Y /<_BO\
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M6?@[X*T_1/$=QITBV=[<6\^J&>"*<C9(\8DB+J"2N]<]17S3\:OV7?B9>_\
M!="/]F7PG';2?!WXOW&@?''XD6*R_P#'MJ/ADRV8@\D<&*\OQH4TC-]]K5\
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M/_RLWO\ \>JWH7[(?[._AK7+/Q'HGP]\B]T^[CN;2;^UKMO+EC8,C8:4@X8
MX((/>HO^&R/V;_\ HHW_ )2+S_XS5K1/VK_@#XCUJT\/:-X]\Z\O[J.WM(?[
M*NEWRNP55RT0 R2!DD"N:/ F4TI*:RN":UO["*M;K?ETL<4<PR!R2C6I7Z>]
M#_,]$HHHKT3V HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "O%OV8?V%OA1^RYXU\3_%/2?&GC?QIXQ\
M6PV]KJOC'XC^*I=7U%+"W:1[?3X9) %@M8WFE<1HHW-(6<NV"/::* "BBB@
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M<ZQK6C?"_4/%WA:/Q7J7AC3YI[O3HY_#>FYO8XX(I#F.8QS.Y1D4(SR?('-
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MG73[$>*+19/#BN]@WF69<EC,<W)*_+, <5@_M._M_P#C;0OVY/BO\%_VM?\
M@IUXI_9)M_#VKVUO\#K"W^'-A/HGB73VLXI#JUUJ%_87$=[FX:1'MUFMUC6/
M;DMO90#]6Z*\_P#V5/%/CGQO^SAX+\6?$OXB^#?%^O7_ (?MYM4\4_#V<RZ)
MJ\I7_CZLV).8I!AQ@D#<0"0!7H% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biib-20230930_g13.jpg
<TEXT>
begin 644 biib-20230930_g13.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"CQK^QE_P3,\%? [QCX'\=:1)??$.W^,%B]WXCTEIUCU'3M5=($EU4W<+/\
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M@'@_3?A-X<@M=*TKXAZ-X-NX?B F@VQ40V"S?:38Q3B%%M_MHB+;!O\ *WT
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MEK](_'_@?PY\3O FM_#;QC;33:1XATBYTS58;:\EMI)+:>)HI526%EDB8H[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+<)<:BMD+81Q>7EU/D2;B/NX'K0!^I5?"'_!</P%^VA\0?V4OC-<^!_C;8>
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M]%+_ /*->_\ QF@#U.BO+/\ AM7]F;_HI?\ Y1KW_P",T?\ #:O[,W_12_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.H"]C8W$:SSNMN(KB1]Q=F&21M_2+XE?!_X2?&?PQ_PA/QA^%WASQ9HV\/\
MV1XET2WO[7< 0&\J=&3(!(SCO57X2? +X$_ '2I]!^!/P5\)>"K&ZD$ES9>$
MO#EKIL4SC.&9+>- QY/)'>@"/_A0/PD_Z%/_ ,G[C_XY1_PH'X2?]"G_ .3]
MQ_\ '*[&B@#CO^% _"3_ *%/_P G[C_XY1_PH'X2?]"G_P"3]Q_\<KL:* ..
M_P"% _"3_H4__)^X_P#CE'_"@?A)_P!"G_Y/W'_QRNQHH X[_A0/PD_Z%/\
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MK0!W7PN_Y)GX=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 5X)XD_P"1BO\
M_K]E_P#0S7O=>">)/^1BO_\ K]E_]#- %*BBB@ HHHH **** "BBB@ HHHH
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M7_KI+_Z&:\=KU#X9>%]/U/P?;WEQ/<JS/("([AE'#D=!0!W%%8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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M #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_
M (%M1_P@^D?\_-[_ .!;4 ;%%9=GX2TVQNDNX;BZ+1ME0]RQ'XBM2@ HHHH
M**** "BBB@ HHHH *\H_;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7
M_P#0UH [KX7?\DS\._\ 8"M/_1*5NUA?"[_DF?AW_L!6G_HE*W: "O!/$G_(
MQ7__ %^R_P#H9KWNO!/$G_(Q7_\ U^R_^AF@"E1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5[%\(?^1$M?\
MKI+_ .AFO':]B^$/_(B6O_727_T,T =-1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %>4?MS_P#)H_CW_L O_P"AK7J]
M>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"
MM/\ T2E;M !7@GB3_D8K_P#Z_9?_ $,U[W7@GB3_ )&*_P#^OV7_ -#- %*B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KV+X0_\ (B6O_727_P!#->.U[%\(?^1$M?\ KI+_ .AF@#IJ***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR
MC]N?_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3/P[_ -@*
MT_\ 1*5NUA?"[_DF?AW_ + 5I_Z)2MV@ KP3Q)_R,5__ -?LO_H9KWNO!/$G
M_(Q7_P#U^R_^AF@"E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5[%\(?^1$M?^NDO_H9KQVO8OA#_P B):_]
M=)?_ $,T =-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\
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M%% !7L7PA_Y$2U_ZZ2_^AFO':]B^$/\ R(EK_P!=)?\ T,T =-1110 4444
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M ."FO['/P=_;"\?_  2TR.YOHX?$VC:3K-O'>C0M9B6XLWN+:1U^\A:Y6*<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>Q?"'_D1+7_ *Z2_P#H9KQVO8OA#_R(EK_UTE_]#- '34444 %%%% !117S
MW^V[\<?BE\(-5\/6WP[\4?V<E];W+72_8H)MY5HPO^M1L8W'ICK0!]"45\#?
M\-J_M,_]%+_\HUE_\9H_X;5_:9_Z*7_Y1K+_ .,T ??-%? W_#:O[3/_ $4O
M_P HUE_\9H_X;5_:9_Z*7_Y1K+_XS0!]\T5\#?\ #:O[3/\ T4O_ ,HUE_\
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M[#4M1%A8S/9SSF:X,;R"-4A1VSLC=LXQ\O7I7;5\_?MK>#_V@-?^)'P;\4_
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M_;:/^&3?^I^_\I7_ -MH \=HKV+_ (9-_P"I^_\ *5_]MH_X9-_ZG[_RE?\
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M =-1110 4444 %>;_'G_ (^],_ZYR_S6O2*\W^//_'WIG_7.7^:T >?T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %=?\$_\ D<7_ .O)_P#T):Y"NO\ @G_R.+_]>3_^A+0!ZS1110 4444
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MJ,5N-8A6W%S->R74N4M[.*!DD>8AL"1 %;=Q7'BCX5WO_!+K_A,#=6@\%2?
M;[49=R^0--.B[C[;?*KXD_X)SZ5XT\%_M-?L3#XS)+$FJ_L=ZG8>$DO,@B^2
MXM+EHU#='&FF'*]0J^U 'VA\ /VX_&?B[]H"3]DW]J;]G>;X5_$.YT%]<\,V
M<7BB+6M+\1:?&XCG>SO8XH2TT+,OF0/$CJK*XW*21[IXW\46O@?P7J_C6^A,
MD&CZ7<7LT8;:66*-I",]LA>M?)'[>4,NJ?\ !3K]C#3_  NV==M/$7C&]N#'
MRT.DC10ETSX^ZC,T"#/!8J.37TW^T+HNF^)O@)XV\,:QXULO#=KJGA/4;*?Q
M#J3JMOIJS6TD?VF0LR#8F[<<LHPO4=: /FOX5_M]?\%!OC/\,/#GQ@\ _P#!
M*.6YT+Q7H-GK&BW,WQPTB%Y;2YA2:%V1X0R$HZDJP!&<$9KZ^TV>\N=.M[G4
M;$6UQ)"C3VPE#^4Y +)N'#8.1GOBO@[4?^"='Q-^ O[%Z^/_  K_ ,%*_BRG
MC?X??#Q;K0=>L/%(@\*HFGV.8(?[%"M:267EQ(K&0/*RY=I2QKZI_8K^..O?
MM,?LB_#3]H/Q3H2:9J?C/P1INL:A8PJ1'%//;)(_E[B3Y99B5R2=I7- 'IU%
M%% !1110 4444 %%%% !7L7PA_Y$2U_ZZ2_^AFO':]B^$/\ R(EK_P!=)?\
MT,T =-1110 4444 %>;_ !Y_X^],_P"N<O\ -:](KS?X\_\ 'WIG_7.7^:T
M>?T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!$D#E#TR5H XBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KK_@G_ ,CB_P#UY/\ ^A+7(5U/PBU&QTSQ4USJ
M%RL49M'7<YXSE>* /7Z*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BJ%MXH
M\/WDZVMKJL3R.<(BGDFK] !1110 4444 %%%% !1110 5Y1^W/\ \FC^/?\
ML O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!VOPPL+%OAKX>9K*(DZ':$DQCG
M]RE;G]G:?_SXP_\ ?H5D?"[_ ))GX=_[ 5I_Z)2MV@"'^SM/_P"?&'_OT*\)
M\1JJ^(;]5  %Y* !V^<U[Y7@GB3_ )&*_P#^OV7_ -#- %*BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KU[X
M36=I-X'MI);6-F,DF69 3]\UY#7L7PA_Y$2U_P"NDO\ Z&: .@_L[3_^?&'_
M +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L
M[3_^?&'_ +]"O.OCI;P076FB"!$S'+G8H&>5KTNO-_CS_P ?>F?]<Y?YK0!Y
M_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5UOP8ABG\7NDT2N/L;G#+D?>6N2KK_ ()_\CB__7D__H2T >I_
MV=I__/C#_P!^A1_9VG_\^,/_ 'Z%344 1)8V4;!X[.)6'0K& 14M%% !1110
M 4444 %%%% !1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"_
M_H:T =U\+O\ DF?AW_L!6G_HE*W:POA=_P DS\._]@*T_P#1*5NT %>">)/^
M1BO_ /K]E_\ 0S7O=>">)/\ D8K_ /Z_9?\ T,T 4J*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O8OA#_P B
M):_]=)?_ $,UX[7L7PA_Y$2U_P"NDO\ Z&: .FHHHH **** "O-_CS_Q]Z9_
MUSE_FM>D5YO\>?\ C[TS_KG+_-: //Z*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "NO\ @G_R.+_]>3_^A+7(
M5U_P3_Y'%_\ KR?_ -"6@#UFBBB@ HHHH **** "BBB@ HHHH **** "O*/V
MY_\ DT?Q[_V 7_\ 0UKU>O*/VY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V K3_
M -$I6[6%\+O^29^'?^P%:?\ HE*W: "O!/$G_(Q7_P#U^R_^AFO>Z\$\2?\
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MBBB@ KV+X0_\B):_]=)?_0S7CM>Q?"'_ )$2U_ZZ2_\ H9H Z:BBB@ HHHH
M*\W^//\ Q]Z9_P!<Y?YK7I%>;_'G_C[TS_KG+_-: //Z*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NO^"?\
MR.+_ /7D_P#Z$M<A77_!/_D<7_Z\G_\ 0EH ]9HHHH **** "BBB@ HHHH *
M*** "BBB@ KRC]N?_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA
M=_R3/P[_ -@*T_\ 1*5NUA?"[_DF?AW_ + 5I_Z)2MV@ KP3Q)_R,5__ -?L
MO_H9KWNO!/$G_(Q7_P#U^R_^AF@"E1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5[%\(?^1$M?^NDO_H9KQVO
M8OA#_P B):_]=)?_ $,T =-1110 4444 %>;_'G_ (^],_ZYR_S6O2*\W^//
M_'WIG_7.7^:T >?T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %=?\$_\ D<7_ .O)_P#T):Y"NO\ @G_R.+_]
M>3_^A+0!ZS1110 4444 %%%% !1110 4444 %%%% !7E'[<__)H_CW_L O\
M^AK7J]>4?MS_ /)H_CW_ + +_P#H:T =U\+O^29^'?\ L!6G_HE*W:POA=_R
M3/P[_P!@*T_]$I6[0 5X)XD_Y&*__P"OV7_T,U[W7@GB3_D8K_\ Z_9?_0S0
M!2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *]B^$/_(B6O\ UTE_]#->.U[%\(?^1$M?^NDO_H9H Z:BBB@
MHHHH *\W^//_ !]Z9_USE_FM>D5YO\>?^/O3/^N<O\UH \_HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z_X
M)_\ (XO_ ->3_P#H2UR%=?\ !/\ Y'%_^O)__0EH ]9HHHH **** "BBB@ H
MHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\ 8!?_
M -#6@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K=H *\$\2?\C%
M?_\ 7[+_ .AFO>Z\$\2?\C%?_P#7[+_Z&: *5%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7L7PA_Y$2U_P"N
MDO\ Z&:\=KV+X0_\B):_]=)?_0S0!TU%%% !1110 5YO\>?^/O3/^N<O\UKT
MBO-_CS_Q]Z9_USE_FM 'G]%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !77_!/_D<7_P"O)_\ T):Y"NO^"?\
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MH_#1KGPM\2/ 6HSW.G^)_#T-XGGV?^D(DT$T$\D3F)P^0VY6"@;@#[ HHHH
M**** "BBB@ HHHH *Z_X)_\ (XO_ ->3_P#H2UR%=?\ !/\ Y'%_^O)__0EH
M ]9HHHH **** "BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7
MKRC]N?\ Y-'\>_\ 8!?_ -#6@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^
MP%:?^B4K=H *\$\2?\C%?_\ 7[+_ .AFO>Z\$\2?\C%?_P#7[+_Z&: *5%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_(Q7_\ U^R_^AFO>Z\$\2?\C%?_ /7[+_Z&: *5%%% !1110 4444 %%%%
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M_P#K]E_]#- %*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEKD*Z_X)_P#(XO\ ]>3_ /H2T >LT444 %%%% !1110 4444 %%%% !1110
M5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!TGPU\1:K%
M\.= B3PI=N%T2U =67##R5YK;_X275_^A0O?^^EJ+X7?\DS\._\ 8"M/_1*5
MNT 8_P#PDNK_ /0H7O\ WTM>-:](TNN7LKQ%"UW(2C=5.X\5[[7@GB3_ )&*
M_P#^OV7_ -#- %*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KU#X9:WJ%EX/M[>W\.W-PH>3$L;+@_.?6O+Z
M]B^$/_(B6O\ UTE_]#- %[_A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?
M_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V** ,?\ X275_P#H4+W_ +Z6N$^,
M>HW>HW-@UUI,UIL23:)B#NY7IBO4Z\W^//\ Q]Z9_P!<Y?YK0!Y_1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5T_PGO;BP\4-/;:?)<M]D<>7$1G&5YYKF*Z_P""?_(XO_UY/_Z$M 'H/_"2
MZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 9=GKVI7-TD$WAFZA5FPTKLN%]S6
MI110 4444 %%%% !1110 4444 %>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\
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M^"?_ ".+_P#7D_\ Z$M<A77_  3_ .1Q?_KR?_T): /6:*** "BBB@ HHHH
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=?\ !/\
MY'%_^O)__0EKD*Z_X)_\CB__ %Y/_P"A+0!ZS1110 4444 %%%% !1110 44
M44 %%%% !7E'[<__ ":/X]_[ +_^AK7J]>4?MS_\FC^/?^P"_P#Z&M '=?"[
M_DF?AW_L!6G_ *)2MVL+X7?\DS\._P#8"M/_ $2E;M !7YG_ !8_Y*EXE_[&
M"\_]'O7Z85^9_P 6/^2I>)?^Q@O/_1[U^&^-_P#R+\'_ (I_DCQ\W^"'JSGZ
M***_G4\,**** "BBB@ HHHH ***SM$\7>%_$FHZKI&@:_:WEUH=\MGK%O;S!
MGL[@PQS"*0#[K&*6-\'^%U/>J4923:6V_ET"S-&BBBI **** "BBB@ HHHH
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M;?I'_7W=_P#H]Z_6_!C_ )*NI_UYE_Z7 ]/*O]Y?I^J/7J***_J$^A"BBB@
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M8]1V)\JFYCM$G.T!<RG: ,4 ?1M>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\
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M'_$4>!?^@O\ \IU?_D _M'!_S?@_\CV2BO&_^&M?^J?_ /E5_P#M5'_#6O\
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M ,JO_P!JH_XBCP+_ -!?_E.K_P#(!_:.#_F_!_Y'LE%>-_\ #6O_ %3_ /\
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M91_S]_\ )9?Y%.BKG]D_]/'_ (Y_]>C^R?\ IX_\<_\ KT?\0,\4_P#H7_\
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M6R/5RC*:V<8KV,)**5FY.]DG*,5HDV_>DEHNNME=FE*DZLK+^NA]OT5XK?\
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M+ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%%% !1110 4444 %>Z?\$]O^2\S?]B_<?^C(J\+KW3_@GM_R7F;_ +%^X_\
M1D5?5\"_\EA@?^OD3IP?^]0]3[<HHHK^T3ZL**** "BBB@ HHHH **** "BB
MB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\ 8!?_ -#6@#NOA=_R
M3/P[_P!@*T_]$I6[7&?#7P;I4_PYT"=[F[!?1+5B%NF R85K;_X0?2/^?F]_
M\"VH V*_.7XI?\E-\1_]AZ\_]'/7Z!?\(/I'_/S>_P#@6U?GU\2XE@^(_B"!
M"2$UN[4%CDX$SU]CP?\ QZOHOS9^=>(?^[4/67Y(Q****^[/RP**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^X?V*
M/^3>=)_Z^KK_ -'O7P]7V?\ L<^%]/U/X":7>7$]RK-<W0(CN&4<3..@KYGB
MS_D61_Q+\F?;\ _\CJ?^!_\ I43VFBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?
M_ MJ_.3]A-BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8KY-_X*5_\
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M.84G5,$@  XKZ)T71=(\.:-:>'O#^F065A86T=M96=K$$B@A10J1HHX554
M#@ 59HHI8>C1;<(V_K;T\M@KXO$XE)59-V_/OYM]6]0HHHK8YPHHHH ****
M"BBB@ K[A_8H_P"3>=)_Z^KK_P!'O7P]7W#^Q1_R;SI/_7U=?^CWKYGBS_D6
M1_Q+\F?;\ _\CJ?^!_\ I43U>BBBOSD_80HHHH *^3?^"E?_ "'/"7_7I>?^
MA15]95\F_P#!2O\ Y#GA+_KTO/\ T**OSSQ4_P"2'Q/K3_\ 3D3AS'_<Y?+\
MT?,-%%%?R,?,A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%?=GY8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]@M/^>7_ (\:/L%I_P \O_'C4U%'^H/ G_0JPW_@BE_\B']HYA_S^G_X$_\
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MZ_1JOSE^*7_)3?$?_8>O/_1SU]CP?_'J^B_-GYUXA_[M0]9?DC!HHHK[L_+
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K[A_8H_Y-YTG_KZNO_1[U\/5]P_L4?\ )O.D_P#7U=?^CWKYGBS_ )%D
M?\2_)GV_ /\ R.I_X'_Z5$]7HHHK\Y/V$**** "OEK_@HM_R&?"O_7K=_P#H
M45?4M?+7_!1;_D,^%?\ KUN__0HJ]WAO_D<4_P#M[_TEGR_&7_).UO\ MW_T
MI'S91117Z>?AX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5[9^P3_ ,EPF_[ -Q_Z,BKQ.O;/V"?^2X3?]@&X_P#1
MD5>;G/\ R*ZW^%GM<.?\CW#_ .)'V91117Y*?OP4444 %%%% !1110 4444
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M %%%% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[
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MX4C\4/\ H6/_ "=@_P#BZ^@:*/\ B+/$?_/JE_X#/_Y8'_$/\F_Y^5/OC_\
M('S]_P *1^*'_0L?^3L'_P 71_PI'XH?]"Q_Y.P?_%U] T4?\19XC_Y]4O\
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M\!\3?\C'J'_7]+_Z&:]^KP'Q-_R,>H?]?TO_ *&:^/XN_@TO5_H!1HHHKX<
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KV7X/_\ (AVO_727_P!#->-5[+\'_P#D0[7_ *Z2_P#H9KZ7A7_D92_P
MO\T!T]%%%?H8!1110 5\M?\ !1;_ )#/A7_KUN__ $**OJ6OEK_@HM_R&?"O
M_7K=_P#H45>[PW_R.*?_ &]_Z2SY?C+_ ))VM_V[_P"E(^;****_3S\/"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\SWDZ1Q0K<)FS=6$VR202(\Q ZJ6$G5HRJW22[];6O\ FMP/O^BOF'XNP_\
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MN/\ T9%7FYS_ ,BNM_A9[7#G_(]P_P#B1]F4445^2G[\%%%% !1110 4444
M%%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\ Z&M
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M ,71_P *1^%__0L?^3L__P 775T4?ZR\1_\ 095_\&3_ ,P_L7)O^@:G_P"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ'_R**GR_P#2D!Y[1117YF 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5V/P0_P"1R?\ Z\7_ /0EKCJ['X(?\CD_
M_7B__H2UZ.4?\C.C_B0'K=%%%?JX!1110 4444 %%%% !1110 4444 %>4?M
MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\
MHE*W:POA=_R3/P[_ -@*T_\ 1*5NT %> ^)O^1CU#_K^E_\ 0S7OU> ^)O\
MD8]0_P"OZ7_T,U\?Q=_!I>K_ $ HT445\. 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5[+\'_P#D0[7_ *Z2_P#H
M9KQJO9?@_P#\B':_]=)?_0S7TO"O_(RE_A?YH#IZ***_0P"BBB@ KS7X^_\
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M_P#J9_\ E'_[J'_$4O\ J$_\J?\ VA^\%%?@_11_Q+O_ -3/_P H_P#W4/\
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M^%/^^8K_  Q_-GY;XG_[IAO\4OR1PM%%%?M9^.A1110 4444 %%%% !1110
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MO^1_/_KW+_TJ)]74445^ G[F%%%% !7FOQ]_X^],_P"N<O\ -:]*KS7X^_\
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MCTBBBI<Y."C?1:_?:_Y( HHHJ0"BBB@ HHHH **** "NQ^"'_(Y/_P!>+_\
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M?^B4K=H *_G-_:A_Y.8^(G_8]:O_ .ELM?T95_.;^U#_ ,G,?$3_ +'K5_\
MTMEK]9\*?]\Q7^&/YL_+?$__ '3#?XI?DCA:***_:S\="BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OV^_P""*?\
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M^],_ZYR_S6O#XC_Y%%3Y?^E(#SVBBBOS, HHHH **** "BBB@ HHHH ****
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M@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX?\ \$T__D0_M_/?^@NK_P"#)?YGO'_#S3]M[_HMG_EMZ;_\C4?\/-/VWO\
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M^@NK_P"#)?YGO'_#S3]M[_HMG_EMZ;_\C5]6?\$=?VROVDOCS^UI<^!_BO\
M$?\ M72U\(7ETMK_ &/9P8E26W"MNAA1N S<9QSTK\VZ^U?^""W_ "?!=_\
M8BW_ /Z/M:\/B7A3A;!Y#B:]# 483C%M2C2@FGW34;I^A[G#>=9Q7S[#TZN)
MJ2BY*Z<Y-/U39^R]%%%?SX?T$%%%% !1110 4444 %%%% !1110 5Y1^W/\
M\FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z
M)2MVL+X7?\DS\._]@*T_]$I6[0 5_.;^U#_R<Q\1/^QZU?\ ]+9:_HRK^<W]
MJ'_DYCXB?]CUJ_\ Z6RU^L^%/^^8K_#'\V?EOB?_ +IAO\4OR1PM%%%?M9^.
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7[??\$4_P#E'MX4_P"PIJO_ *735^(-?M]_P13_ .4>WA3_ +"FJ_\
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MP%:?^B4K=H *_G-_:A_Y.8^(G_8]:O\ ^ELM?T95_.;^U#_R<Q\1/^QZU?\
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M444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\
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M^=XM_P"2:Q?^!GO\+?\ )187_&C]EZ***_ET_I4**** "BBB@ HHHH ****
M"BBB@ KRC]N?_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3
M/P[_ -@*T_\ 1*5NUA?"[_DF?AW_ + 5I_Z)2MV@ K^<W]J'_DYCXB?]CUJ_
M_I;+7]&5?SF_M0_\G,?$3_L>M7_]+9:_6?"G_?,5_AC^;/RWQ/\ ]TPW^*7Y
M(X6BBBOVL_'0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3/P[_ -@*T_\
M1*5NUA?"[_DF?AW_ + 5I_Z)2MV@ K^<W]J'_DYCXB?]CUJ__I;+7]&5?SF_
MM0_\G,?$3_L>M7_]+9:_6?"G_?,5_AC^;/RWQ/\ ]TPW^*7Y(X6BBBOVL_'0
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K]OO^"*?_*/;PI_V%-5_]+IJ_$&OV^_X(I_\H]O"G_84U7_TNFK\Y\4/
M^2=A_P!?(_\ I,S]!\-O^1_/_KW+_P!*B?5U%%%?@)^YA1110 5^6W_!Q/\
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MM?.\6_\ )-8O_ SW^%O^2BPO^-'[+T445_+I_2H4444 %%%% !1110 4444
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M^-'[+T445_+I_2H4444 %%%% !1110 4444 %%%% !7E'[<__)H_CW_L O\
M^AK7J]>4?MS_ /)H_CW_ + +_P#H:T =U\+O^29^'?\ L!6G_HE*W:POA=_R
M3/P[_P!@*T_]$I6[0 5_.;^U#_R<Q\1/^QZU?_TMEK^C*OYS?VH?^3F/B)_V
M/6K_ /I;+7ZSX4_[YBO\,?S9^6^)_P#NF&_Q2_)'"T445^UGXZ%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?M]_P
M13_Y1[>%/^PIJO\ Z735^(-?M]_P13_Y1[>%/^PIJO\ Z735^<^*'_).P_Z^
M1_\ 29GZ#X;?\C^?_7N7_I43ZNHHHK\!/W,**** "ORV_P"#B?\ Y'/X6?\
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M%?X8_FS\M\3_ /=,-_BE^2.%HHHK]K/QT**** "BBB@ HHHH **** "BBB@
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M[Q;_ ,DUB_\  SW^%O\ DHL+_C1^R]%%%?RZ?TJ%%%% !1110 4444 %%%%
M!1110 5Y1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L O\ ^AK0!W7PN_Y)
MGX=_[ 5I_P"B4K=K"^%W_),_#O\ V K3_P!$I6[0 5_.;^U#_P G,?$3_L>M
M7_\ 2V6OZ,J_G-_:A_Y.8^(G_8]:O_Z6RU^L^%/^^8K_  Q_-GY;XG_[IAO\
M4OR1PM%%%?M9^.A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7[??\$4_^4>WA3_L*:K_Z735^(-?M]_P13_Y1[>%/
M^PIJO_I=-7YSXH?\D[#_ *^1_P#29GZ#X;?\C^?_ %[E_P"E1/JZBBBOP$_<
MPHHHH *_+;_@XG_Y'/X6?]@O5O\ T9:U^I-?EM_P<3_\CG\+/^P7JW_HRUK[
M3P^_Y*RAZ3_](D?'\>?\DO7]8?\ I<3\W****_I _GL**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^U?^""W_ "?!
M=_\ 8BW_ /Z/M:^*J^U?^""W_)\%W_V(M_\ ^C[6OG>+?^2:Q?\ @9[_  M_
MR46%_P :/V7HHHK^73^E0HHHH **** "BBB@ HHHH **** "O*/VY_\ DT?Q
M[_V 7_\ 0UKU>L3XD?#[PY\5? NI_#OQ=%*^FZM;&"\6"4HY0D'AAT/% #?A
M=_R3/P[_ -@*T_\ 1*5NUX''\+?V]-(C72?#/QX\$P:;:@0Z?!-X;=WC@7Y8
MU9OXB% !/<T[_A7W_!0__HX+P)_X2[T >]5_.;^U#_R<Q\1/^QZU?_TMEK]N
M/^%??\%#_P#HX+P)_P"$N]?.7BC_ ((K7GC3Q-J/C'Q+)X$N=2U:_FO-0N=V
ML)YL\KEY'VI=!5RS$X  &> !7V_!/$N!X;Q%:>)C*2FDERI/9O>[1\9QEP[C
M>(:%&&&E%.#;?,VMTMK)GY-45^J__#C&P_Y]O G_ '_UO_Y+H_X<8V'_ #[>
M!/\ O_K?_P EU^B?\12X?_Y]5?\ P&'_ ,F? _\ $-,]_P"?E+[Y?_('Y445
M^J__  XQL/\ GV\"?]_];_\ DNC_ (<8V'_/MX$_[_ZW_P#)='_$4N'_ /GU
M5_\  8?_ "8?\0TSW_GY2^^7_P @?E117ZK_ /#C&P_Y]O G_?\ UO\ ^2Z/
M^'&-A_S[>!/^_P#K?_R71_Q%+A__ )]5?_ 8?_)A_P 0TSW_ )^4OOE_\@?E
M117ZK_\ #C&P_P"?;P)_W_UO_P"2Z/\ AQC8?\^W@3_O_K?_ ,ET?\12X?\
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M_P"Q%O\ _P!'VM?07_#C&P_Y]O G_?\ UO\ ^2Z[7X"_\$N?BG^S%XX?XD?
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M+1/&F@SZ==S>,-4NHX+@ ,T,DY9'X/0CD5Z_10 4444 %%%% !1110 4444
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M,K]BKQ8OQ'^//B3X5:C>^*_AE^U5XMTKP1JD_C?62--L]+U%!80^3]L\J81
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAG/\'['4(;N_N/'$>H'3QHUO=#;%,'F <3X4>5ERN5V5M>"OV\/VF_AM\?\
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M1XCM=/U/XG>%)]!U'Q)K>MI;V\D$%A=!;@6L%O;[S/(B!I'"H& +4 <M\/\
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MJM?'7@S2/&]EI&J:?#K.EV]]#8:WILME>VRS1K((KBWE"R03*&VO$X#(P*L
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M1]0@G"^67\A8X;F-&9HI8B6P7 H ^N;#_@I=^T[\*_C]\-O W[;7[#MO\-/
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M"S'P'^+FB> =6NO#&B?!WQK8ZOXAAL)&L;*ZN+C2V@@FG"E(WD$4A52<L$;
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M@ HHHH **** "BBB@ HHHH *X#XA_LT?"CXH?'3X=_M&>+M+NI?%'PM_M?\
MX1"YBO7CB@_M*U6UN_,C!VR[HD &[[IY%=_10 4444 %%%% !1110 4444 %
M<!^TY^S1\*/VO/@U?_ ;XV:7=7OAS4M0TZ]NK>SO7MY&FL;Z"^MR)$(( GMH
MB1W (/!KOZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O"/%_\ R-NJ?]A&?_T8U>[UX1XO_P"1MU3_ +",_P#Z,:@#.K1\(?\
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M*)86B9+8RL)"D>"SJ#H_LZ?\%&?V6?VGOB%)\(O 6O>)='\6C23JUGX8\>^
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M%NEZ.NL?V!XH\':IH=S?:4T@C74;1-1MX3=6I<A?.BW+EES@,I/,_$/_ (+
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M/X7\1?#70+_3/#M]:7OA_3KW1H)8-,N;0@VLUO&RE89(2 8W0 QX&TC%;]%
M&1J7P_\  6L>,M,^(NK^"-(NO$.BVUQ;Z-KMSIL3WEA#/L\^.&=E+Q))Y:;U
M4@-L7.<"N/\ %W['/[(GQ ^*EM\=/'G[*_PXUOQO9O&]IXQU?P/87.JP-'@1
ME+N2$S*5P-I#<8XKT>B@#(U3X?\ @+7/&&D_$/6O!&D7FOZ#!<PZ'KEUIL4E
MYIT=P$%PD$S*7A641QAPA <(N[.!1!\/_ 5KXYN/B?;>"-(C\2WFF1Z==^(H
M]-B%]/9QNTD=L]P%\QHE=W=8RVT,[$#)-:]% '#^ OV9?V;OA5\1-<^+WPO_
M &?/ _AOQ9XGW?\ "2>*- \)V=GJ.K;G$C?:;F&-99\N QWLV6&>M;WQ#^&_
MP[^+O@Z^^'?Q7\!:+XG\/ZG&(]2T+Q#I<-[9W: @A989E9)!D X8'D"MJB@#
ME_A'\$?@Q^S_ .$$^'OP&^$7A?P3H$<[S)H?A'0+;3;-9&QN<0VZ(@8X&3C)
MP*PO '['_P"R5\*/B/??&/X6_LN?#KPUXOU,R'4O%6@>";"SU*[\PY?S;F&)
M99-V>=S'/>O1:* .!^-G[*7[+G[2IL6_:-_9L\ ^/SIF?[-/C;P=8ZK]DR<G
MROM43^7G_9Q6_;?"GX767PY/P=L_AMH$7A$Z<VGGPM%H\"Z;]D8%6M_LP7RO
M*()!3;M()&*WZ* /---_8O\ V.]'^#\_[/6D?LG_  TM? %U>-=W7@:V\":>
MFCS7#8W3-9+"(&<X&6*9.!S6Y\&_V??@)^SIX=E\(?L^?!'PAX$TF>;SI]+\
M&^&K72[>23&-[1VT:*6QQDC-=?10 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %?FS\=?^2W>,?^QJU'_P!*
M9*_2:OS9^.O_ "6[QC_V-6H_^E,E?B'C=_R*\)_CE_Z2>1F_\./J<K75? K_
M )+=X._[&K3O_2F.N5KJO@5_R6[P=_V-6G?^E,=?@64_\C7#_P".'_I2/%I?
MQ8^J/TFHHHK^[#[$**** /!_^"D'[;7_  [Z_9=O?VCX_A3/XUG@\0:3I%IX
M=MM82P:YGO[V*TC_ '[HZH TH)RN,#J.M>+?$3_@JY^U#^RU8V/Q+_;P_P""
M8?B+X;?#!M5M+#7_ (BZ)\3M(\10^'VN9T@AN+RVM]DR6WFR(KRH&V;AP20I
MS?\ @Y%76W_X)B7R>&9K2/4C\4/!8T^2_C9X%G_M^R\LR*A5F3=C< 02,X(/
M->)?\%"-"_X*+?%KXG_!7]@G_@IC\8?A+I_P*^//C?\ L;Q+K?P9\%:E975W
MJ%H$O['0[F?4K^X%NE]) 462%2^Z%E/RL: /U8U35]*T2R;4M:U.WM+=" ]Q
M=3+&BDG RS$ 9/%3JRNH=&!!&00>"*_*CXTZ+XZ_;#_X+-?&SX8_$S]B;1/C
MUX.^!G@SPG9^!O 7C#Q?:6.C:=)JUE+=W6JFQNX98;R=W4VPF*GREM]O5AC<
M\%?L2_MX3?L"?M4_L<> ]1T7X.Z=XBU:"3X%:$?B1_:0\)VUS%;R7^B/=P /
M9VLLB2K$BC]U'J!VC"@4 ?IEINN:+K#SQ:1K%K=-:RF*Y6VN%<PO_=;:3M/L
M>:6^UG2-,GM[;4M5MK>2[E\NUCGG5&F?^Z@)^8^PYK\G_P!FVU_9[_9*_;%^
M##?'K_@C_P"*/V1O%VJZV?"7A?QM\,_$^G:EX4\57UW;.D6EZM/8,&N/.93)
M#]IB,HEC5BZ[7-<Q^S-\+/%?_!0'X@_M#?'S]HW_ ()F^&_V@=4F^-_B7P=I
M>K>-?B):6K^$-)TR<6UOI-A;3PNVG/&H\YIX3'+)).7+9P: /V/=TB0R2.%5
M1EF8X 'K5;1]<T3Q#9_VAH&L6M];[ROGV=PLJ;AU&Y21D>E?EAXOT;Q-X6_8
M'_9T_8]_X*$^"/&'QG^)FJ_$/5-/\$?"3P=X_M)[;Q]:Z>+N6V37[^79%<6=
MG8F%[@NV'EMXVD27YA4_[(O@[Q)^S=_P6P\$^ M _8>\#_LYZ;\0?@9X@F\1
M>!OASXUAU"PUHV5]8M:7T]I;6=K!;7$1DGC655=G621=^%.0#]3)]1T^VO(-
M/N;^&.XN=WV:!Y0'EVC+;5/+8')QTIEMK.D7M_<:59ZK;2W5IM^U6T4ZM)#N
M&5WJ#E<CIGK7XG_LL?"#1/V>?^")/Q8_X*H>$]/N=7^-7AO3OB'8_#CQ/=S2
M22>"M/&NZI:-'81Y\N$"26[O'?:6=YF#$JJJ/L#X;?\ !*;]@OX!^!O@-\>O
MA/XXTKX7^/-#U[0KJ3XKKJ*)J7Q"ENT476F:A//*IU#^TC(WR,7<.RF%00!0
M!]'?LL_MH^&_VEM;^+VD2^%QX;3X3_&&]\ 37-]JB2+JD]O:65P+E/E3RP_V
MP((R6.4ZG.![77Y>_L'?\$]/V5?VR/CU^V=XD_:M^%MA\0+"W_:DU_2M%\/>
M)5,]CI#/I6EM<7EM%D"*[E62%#<#]ZBVT81DRV[Z _X(&>-/&7CO_@DI\(]5
M\>>*K_6M0L8=:TA=2U.X,L\EM8:Y?V-LKN>6*V]O$F3SA10!]=ZGJFF:+9/J
M6L:C!:6T0S+<7,RQH@SCEF( I]I=VE_:QWMC=1S0RH'BFA<,KJ>A!'!'O7Y\
M_P#!0K3?@7\=O^"A>@_!F#]B[6/VFOB%X8^&:ZG<?#?Q7XEL++P)X4L+B]=$
MU6[2]CD2349W0PJ!%._DQ9"(/F;Y6TJW\2?#;]D+_@J1^S.WP<T;X8^'O"'@
M>RU+2/A9X7\5G6-)\-7.I>&IIKM;2;R(%C29HHIVA2)%C>1E P* /VL74]-;
M46T==1@-VL(E:U$R^8(R<;RN<[<\9Z4E_JVEZ4(CJFI6]MY\RPP?:)E3S)#T
M1<GECV YK\G_ -J']B?X"_LA?L2_ #]MCX4^&'M_C;I_Q(^'5QJWQ8>[E.M:
MVVI7]E:ZA#=S[LS6TT-Q+']E/[E(]J(BJJ@>H?"7]GCX$?\ !1O_ (*@?M57
M?[;?PRTGX@6_PAU3P]X0^'7@_P 6VPNK'P]IUQI,=]/>P6[_ "+<7<\C/]HV
M^8$A158!: /K3]D#]KW3OVM;SXLVFG>!I]$/PK^,FK^ +AIK\3_VC)80VLIN
MUPB^6K_:@!&=Q&P_,<\>P7=Y::?:R7U_=1P00H7EFF<*B*.223P /6O@S_@@
M9X'T+X9>$/VIOASX7UN^U#3=!_;)\8:?87.IZE)>7'DPVFE1HDD\C,\SHJA"
M[L78IEB3DT__ (*(>&O#G[4G_!43]G#]A/X[V7]H_"G4O"GBGQGKGA&[D(L/
M%FJ:>+6*SM;M 0+B*W$\MSY+91FVEU8*!0!]%+^V7I-S^WDW[#6E^!Y+NY;X
M*CXAV_B:'4T,,T1U0Z>MHL>SJ2/,\W?C!QM[UVO[/_Q$^)?Q*^"NB?$3XW?!
M6Y^&OB2_M9)=9\%ZAKEOJ$FD,LCJ$>YM_P!U+E%5\KP ^#R#7PK^SU^S+\#O
MV4_^#@GQ#\/OV>_#,'ASP]??L=#4D\):;*5L-)FD\4['%I;YV6D,AB$AAC"Q
M^8TCA=TC$^&_L\?LQ_';]J/_ (-Y_P!D?PU\$O"^A^-8O#VO6VN^+?A!XB\3
MG1[3XAZ5;W&I>9I+W."OWVCG\N4&%O(RX.T @'[$Z5J^DZ[8IJ>B:G;WEM)G
MR[BUG61&P<'#*2#S2+K.D/JK:$NJVQODA$K68G7S1'G&\IG.W/&<8K\K_P!F
M3XS_  1_9)^+/Q;T_P %_P#!.7QW^RU\8[OX$:QXBT?X5?;;&Y\%^*VTF-I?
MM=D-.=K62^B9HXW95C)BDY#$DU?_ &5_^":O[&/CK_@F%\(_VW/&GQ2L? WQ
MDUW0?#OQ"UO]J#4M31=:@UV]:WNK@7%[/*BRV\CS/8FUE;R2CA-F[% 'Z@ZG
MK&DZ);K=ZSJEM:1-(L:RW4ZQJ7/106(&3V%6:_.'X._LZ_!#_@I-_P %,?VK
M+O\ ;H^&FF?$&T^$>NZ'X/\ AUX)\60_:M/\/:;/I27<U[#:O^[%Q=RRES<E
M3(%B54957%?,U[I?Q!^&W['GQ2^*/PZO-6\0V_\ P3Y_;+OKWX93W-Y)=77_
M  AENEK_ &KH!N)"7DB@LKZZ0EF)"6\:9 04 ?MO5:#6=(N=2FT:VU6VDO+=
M5:XM4G4R1*W0LH.5![9ZU^67[<G[3OC#QA?_ +57_!1W]G'6_M]C^SU\ X?!
M/PIUZQ'G11ZWK45MJNKZI 2,![>TET89P<&.0-QD'B+W]@'XZ>&_V4/!/CK]
MD+_@G-X/\!_&/P^VBZ_H7[0]Y\:K%]5UB],UO+=2ZI=^0)M0AOT::.2":1HS
M]I 51A10!^P^H:CI^DV<FHZK?PVUO$,RSW$H1$&<9+' %35^9WB7]C#X-_MK
M_P#!=7XU>$OVD]$?Q'X*T#X/^!=5G\"7=PZZ?J>IB;5H[6YNDC9?/%NCW6R)
M\QEKC>5+1H1YA%XX\3?LX?!_X\_\$+?!.KRZ9XGU_P"-MKX5^#)@.&M/!?C)
MIM1FGA_B9=/M4UT,ZC"-;Q#C(R ?L!169X)\&^&OASX,TCX>^"])BL-'T'2[
M?3M)L81A+:V@C6**-?9450/85IT %%%% !1110 4444 %%%% !1110 4444
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M<FT'2O$GQ9\06UZ^DZ;,Z//;VMO:6MM;1>:T<?F2>49'"!2^"0> \,?\$/\
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M=5US5+J[F>>YCMDED*VMM;230I*Y7S6U"7;E8P:^[** "BBB@ HHHH ****
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MSF\L733Q%1IR7VY=_4_1&BBBOR8_?0HHHH X/]I/]IKX%_L@?"'4/CS^T?\
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M4?"GQ?>\\?:CH5C87#R2V&CLICMK>/R(TCW81"K#"@-OYS!X%_X**_M4ZO\
M\$SKOP'K/CNU/[4UI\:9/@9+K(T6U$?_  E+:EY*ZN+41B QII;?VGM\OR2(
MF&TI0!^D5%164$MK9Q6T]Y)<O'$JO<3!0\I P68(%4$]3@ <\ #BOQM^%?\
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MWB70[T 7NC:_I<5Y:7 !R \,RLCX(SR#7+?![]DG]E/]GG4;C6/@!^S)\/?
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MF1@K>([ $94@X()!]0:^X)9%AC:5PQ"J20JECQZ <GZ"@!U%?#?Q#_X*/?\
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MPP"&._8LTB?OA<&..8F5(RH; V@?8]%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?SP?MK_P#)Y?Q;_P"RG:]_Z<9Z_H?K\\/C9_P0
M3_X7#\9?%WQ<_P"&K?[._P"$I\3W^K_V?_P@OG?9?M-Q)-Y7F?;EW[=^W=M7
M.,X&<5^@>'^=Y7DF,K5,;4Y%**2TD];_ -U,^$X[R;,LYPE&&#I\[C)MZQ6E
MO[S1^45>F_L4?\GE_"3_ +*=H/\ Z<8*^Z?^(<W_ *O%_P#,>_\ WPKI_@G_
M ,$$_P#A3WQE\(_%S_AJW^T?^$6\3V&K_P!G_P#""^3]J^S7$<WE>9]N;9NV
M;=VUL9S@XQ7Z5C>.^%*N#J0AB+MQ:7N5-VO\)^>8/@GB>EBZ<Y8>R4DW[\-D
M_P#$?H?1117\ZG[\%%%% 'QY_P %N?\ DU7P/_V<7\-__4HL*^-?VG_"/Q%^
M$_[?/Q2_X(X>"M#U!?!G[:GCC1?'&E:A8J1%I&ER&0^.$+] \T.F_*G&/MX[
MMFOUX\8>!/ _Q#TV'1?'_@W2M<L[:_M[ZWM-8TZ*YBBNH)%E@G59%(62.15=
M' W*RA@00#2:AX#\#ZOXOTWX@ZKX,TFZU_1K:XMM'URXTZ)[RQAGV>?'#,5+
MQ))Y4>]5(#^6N<[1@ _*OQE\8M+_ &6/VA?^"KGQAMO@;I'CJR\)>&_AQ+'X
M'U33EGTZ]C7PDL8CN(,$-:H#OD7'^JC?!'4<+_P4Q\8_%;3?V,_AGJGQ4_X*
MJ^'OB-?>*_B'X'O](^&_PW\":):Z/'"FMV$IN8)85FOH;.W.R-;AIU5G:"-L
M&81G]AM.^%GPQTCQ%XA\8:3\.=!M=6\7+ OBS5+?2(4N=:$$/D0B[D50UR(X
MOW:>86VI\HP.*X?PG^PC^P_X"TK6-"\"_L:_"G1;'Q%-!+X@L])^'FF6T6IR
M0SK<0O<)' !,R3(DJEP2KHK#! - 'S9^SIX)\+:G_P %_P#]I3Q_?Z)!-K&C
M_!;P)9Z9?R(#);PW+ZBTZ*>V\VT.?]P5\7W/[,/[6GQYU+]LGXH?#G7].UKP
M3\(?VPK_ ,:V/P8^P>:/B-K%A!HUU=V&I%@0]LMC @MH$!WW<^^3(AB%?M%I
MWP^\!:1XSU+XC:3X(TBU\0ZS:V]MK&O6^FQ)>WT,&_R(IIU4/*D?F/L5B0N]
ML 9-'A3X?^ _ D^K7/@?P3I&C2:_JTFJZ[)I6FQ6[:C?R(B/=3F-1YTS+'&I
MD?+$1J"<** /RW_:Q^-6C_'/_@I?^R5^V=X%_:OM?AO\+_'_ ,$-<M?AE\1-
M4T*RO;.T\074MO/+92_;3Y%I=3V8\H;B)"]O)",G<*]O_8R\%_#CQ%_P4X^(
MWQ0L_P!O>\^,GQ"T7X.6/AGQC;:)X-LK/1K*WDU&2ZLA/=V(,#WZ%;D")F\P
M0SDD!0,?6^I_LP_LU:U\)G^ FL_L\^!KOP+)-)+)X+N?"5G)I+2/*TSN;-HS
M"6:5WD)VY+LS'DDUI?"3X)_!GX ^$4^'_P "/A'X8\%:#',TL>B>$M M]-LU
MD;&YQ#;HB!C@9.,G H _&.>2\^(7_!H]X-\#> /$B75QX5M-*N/B3HFE*EW?
M6>DV/B</J0EM 2Q\E$\V2-P 4B8-P>?HSXVV'PM^._B']GO0_B3_ ,%CK?Q^
M-4^+V@>(/A3H/P_^'VC3W=]J%FS3Q3 Z>&E@LUB$J3SD+%''(PD(!Q7W]X'_
M &8/V:?ACX_U[XK_  V_9X\#>'O%/BI77Q/XET/PE9VFH:P&?>PNKB*)9+@%
MP&/F,V2,]:I?"?\ 8^_9)^ OBR^\>_ S]EOX<^"]=U1&34]:\)^"+#3KN[5F
MW,)9K>)'D!;DAB<GF@#XX_X)M_''X._LW_M'?ML^#_VI_B;X>\'^-8OVAM0\
M5WEUXKU:&R>Y\(W.FV7]D7*R3,OF6T<44T?RDK&00<%L5N_\&Z^J>%];_8'U
M[6O!&EO8Z+>?'+QS/I%E)9-;-;VKZW<-%&8F ,15"HV$ KC! Q7UG\4OV5_V
M8?CEXKTCQY\:_P!G#P%XPUSP^0=!UKQ3X/LM0N]-P^\?9YIXG>'#?-\A'//6
MNH\(^!/!'P_L;G3/ 7@W2M$MKW4KC4+RWTC3HK9)[NXD,L]PZQJ TLDC,[N<
ML[,222<T ?!7_!13XE_!/X2_\%LOV,?&/QVUG2]*TQ?"GQ M=-UK6BJ6MAJ$
M\6EPP.\K_+"79S KL0"\Z*#EQ7E'[37BGPA\8_\ @I/^UO\ $O\ 9\\0V&M^
M%?#?_!/K4_#WQ*UC0;A)[,^)9+F\N+*WEDC)1[E+%9<\DJC!3C&!]N?M$?L)
MZ5^T3^VA\+?VD?&EUH>I>%_ W@KQ5X?U[P9KFC+=Q:TFKK9 ;A)F,QI]D;<C
MJP;>.F*]1^'G[-O[.WPC^&UY\&OA1\!/!?ACP?J*SKJ'A3P]X6M++3;I9DV3
M"2UAC6)PZ_*V5.X<'(H _,K]J+X7Z=X0_P"#:'X _P#")^#F;P1X?T7X8^*O
MBGI&G6AD^W:()["_U>:6-03*&ED:ZF.#D+(YX!KU?_@J3\9?@U^TW\3?V./A
MY^RQ\4/#GC#QW<_M+>'/%NB-X2U:&]EM/#-E#<RZM?NT#-LM#;,(VR0LAD51
MDCC] M'\(^%/#OA2U\!^'_#&GV.AV.GI86.C6=E'%:6]HD8C2W2%0$2)4 0(
M %"@ #%<=\&_V2OV5/V==7U'Q!^S[^S+\/O E_K QJU]X-\&6.ES7HW;L3/;
M1(TGS<_,3SS0!\5_\$O?V@/@9^S/KW[8OA#]JSXI>'/!OC'1OVF_%/B7Q4?%
M>J0VDUQH-XD$VEWZB5@SVK6:JD>,@>65 R>?DWX ^(O"'@O_ ()"_L7?%Z_@
M'ASP7X3_ &^)=3UJ[U* VD.@Z:^N^)K5)+D. +:-)+F"-B^T(6P<8K]BOB)^
MRO\ LP_%[Q]I'Q5^+/[.'@+Q1XH\/[?[!\2>(O!]E>W^F[6WK]GN)HFDAPWS
M#8PP>>M:;_ OX)2?#B_^#DGP=\*MX0U1KAM3\*MX>MCIMV;B5IIS+;;/*D,D
MKO(^Y3O=F9LDDT ?#7QM_:#^%?QK_P""\/[.O@;X*_$/2]=O_"_PF^(']J:C
MI%TEW:6=S=0Z8T4#2QED\Y5B61XL[U2:%F $J$^8_P#!/']IC]A7X%_\$"Y_
MA-^VI-IM[<^$[?Q#X8^,WPLFGBD\0:GK\NJ7:W&GBT:6.6:\NI)5:+YE)\U&
M#J%++^D?PY_9=_9F^#T.BV_PC_9V\"^%H_#8O!X=C\.>$;*Q&EB[\L77V80Q
M+Y'G>5%YFS'F>4F[.T8KZM^R3^RGKWQBM_VB-<_9E^'M[\0+5T:U\=7?@NQD
MUB%D&U"EZT1G4J. 0_ X% 'R5<^)? WPR_X+S>!M2\47,'A'2-2_8FO-/T*#
MQ%>);$2P^)+*9K/<[E6FBAPS*&8@*6R0":\VU[PY_P (Y^UE\?\ XA?\$X/^
M"MOA+X4>(7\;&Z^,7P>^-'@JVGT]M;BLH$-_%)<R6UY;6DT"Q-Y\7FPRX9D8
MJJA?T)^-G[,O[-W[2VGV&D_M&_L^>!_B!:Z5.T^EVWC;PG9ZK'9RL &>);J-
MQ&Q  )7!.!6;\8/V-OV0?VA?$EIXR^/O[*GPV\<:O81B.QU7QAX&T_4[FV0'
M(6.6YA=D /. 1S0!YC_P2!_:0U+]K#_@GIX ^->K?"3PWX*GO$U"R;1O!=J8
M=$D^R7]Q:_:].0@%;2?R?.C!Y"R]6^^WTO4&EZ7IFAZ9;Z+HNG06=G:0)#:6
MEK"L<4,:@*J(J@!5    & !BIZ "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biib-20230930_g2.jpg
<TEXT>
begin 644 biib-20230930_g2.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBOGO]OG_ (*>?LA?\$X_"-GKW[17Q4TFSU74[RQBTOPG
M'JD"ZI>03WL5K)=QV[N&:" 2-+))C 2%P,MA2 ?0E%<A\,?C_P# WXU?"N'X
MY?"3XO\ AOQ)X-N+:2XC\4:-K,-Q8>7'GS6:9&*+LVMO!(*%2&P0:\)\!?\
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M-_9RMLG6WN8E8^4Y\R,QLK$]*^8_^"W_ ,3OC9XL_99\0?L;_$K]@C4_A=\
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M>O\ Q)U+4/V?M-\6:TVH:E8>#7C@%K%+*\LLBQ^>MVT44KM+'$Z*QX"CQ/\
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M[$GB*!8#]K2QD&IWMK+,D+%GA<K,JG=L&"1] _'']JG]J?PW\&?@Y^U+\/\
M]AC6O%&A:K%!J7Q5^'?V3=XT\+075B'C:RM9&C6>YMIG,=Q!_K67(1<[BOC/
MQ-\3?%?_ (*E_M7_   7X9?LI?%'X?> ?@O\2U\>^+_B!\6/!<_AN>YGM[*Y
MM[;2=/L[O;=7'G/<DS2%$B1(A\SL0M 'Z#T444 %%%% !1110 4444 %%%%
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M5^6/_$2[_P!65?\ F1__ +W4?\1+O_5E7_F1_P#[W4?\0SXW_P"@3_RI2_\
MDP_XBCP+_P!!?_E.K_\ ('ZG45^6/_$2[_U95_YD?_[W4?\ $2[_ -65?^9'
M_P#O=1_Q#/C?_H$_\J4O_DP_XBCP+_T%_P#E.K_\@?J=17Y8_P#$2[_U95_Y
MD?\ ^]U'_$2[_P!65?\ F1__ +W4?\0SXW_Z!/\ RI2_^3#_ (BCP+_T%_\
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M^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\
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MS+_P]T_8A_Z*=/\ ^"'4/_D>C_A[I^Q#_P!%.G_\$.H?_(]'U+&?\^Y?<_\
M(/[0P'_/V/\ X$O\SZ:HKR+X%_MJ_!7]I6YU*T^"6IW.N2:0D3ZBJ6$\'DK(
M6"']_&F[.QNF>G->B_\ "2ZO_P!"A>_]]+6$X3IRY9JS\SIIU*=6'-!IKNM4
M;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM26;%%8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T
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M7_I<S^FO!7_DFJ__ %^?_I$ HHHK\C/V(**** "BBB@ HHHH **** "BBB@
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M_KQTS_TAAKYIK[[ _P"YT_\ "OR/S#,O^1A5_P 3_,****ZCB"BBB@ HHHH
M**** "BBB@ HHHH **** /T#_P""#/\ R,?Q,_Z\=*_]#NJ_1VOSB_X(,_\
M(Q_$S_KQTK_T.ZK]':^*SC_D83^7Y(_0\@_Y%</G^;"BBBO,/9"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _,+_@Y4_P"1
M4^$7_81UK_T79U^4%?J__P '*G_(J?"+_L(ZU_Z+LZ_*"OZN\,?^2*PWK/\
M].2/Y%\4_P#DN<5Z4_\ TW ****^^/ST**** "BBB@ HHHH **** "BBB@ H
MHHH ^EO^"/?_ "DB^%__ &$;W_TW75?T#5_/S_P1[_Y21?"__L(WO_INNJ_H
M&K^;_&3_ )*.A_UZ7_I<S^FO!7_DFJ__ %^?_I$ HHHK\C/V(**** "BBB@
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MBBO,/9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_I$ HHHK\C/V(**** "BBB@ HHHH **** "BBB@ HHHH **** /QU_X*Y?\
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MJRB@#Y3_ .'/7[,/_10?BG_X<2[H_P"'/7[,/_10?BG_ .'$NZ^K** /E/\
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M:[7?:WNOQO'9V\[QGY9)+9&:6(D91G+#DT?\%\-.L_ASX;_9Y_:^\&6J6WQ
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M1%(C\K2.RQQ*WS  'Z%45!IMK+8Z=;V,]Y)<O# B/<2_?E( !9L=SU/UJ>@
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M#PY#<S:GXAOH!%)J=_=74MW=7'E@D1*T\\A6,%MB;5W,1N)10![77YM?'/\
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<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>biib-20230930_g3.jpg
<TEXT>
begin 644 biib-20230930_g3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@
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M3X7.J:KIUQ<>8FGR1-)'<A9,#S(@\4A23 W)M; SBO%_^")\&H_'/X+>+/\
M@I=\0+23_A*_VC?%MWK=L+H?O-+\,6<\MEH>F+V$<=K$9^/O27DK'EJ^H=5^
M ?PTN?V?;S]F/PWHB^'/"-QX1E\-6FG^'8TMAINGO;-;!+8;2D92,X3Y2 0.
M#TJ/]FKX!>!_V5OV??!G[-GPTGOI?#_@7PU9Z)H\VJ3))<R6]M$L2/*R(BM(
M0N6*JH))( Z4 6/V@?BOX(^ _P !O&WQQ^)EK-/X;\&^$=2USQ!!;VPFDDLK
M2UDGG58R0'8QQL I."3BOR,_9T_X)S_\%C->_87GUG]AW]L+3OA+\)?'T:>(
M_A[^SKJE^-1N]*T"_7[4=.C\2_9OM&G/,DN0D*.(3)_K@WF.WZ>^$/V'OA9X
M6_:'^+'[1&H>*_%7B";XQZ78Z=XH\'^)-62[T&VMK:U%KY=I9F(>4)8\^:&9
MPY8\ '%>0:7_ ,$;_!?@WPY_PK'X1?MY_M,>"/A]&IAL?AUX:^)< T[3[3H+
M.UN+BREU"V@5?E5([I=B\*0* /DOQ3_P43^&/B?_ ():? #]G;]G/X0^._@U
MX/\ B<M[X2\;W_AGPIJWB&7X=Z#H\[V6KP0S:;;7$L][<R1-;6]QL)/VA[B0
MHR59_9C_ &V_V&_#_P#P71L=$^"%MXKTGP:_[*?AOX?^#-,7X/\ B6S^S72>
M([@06[03Z>LMM;+&\0^US*EN.09<JV/T_P#@#\ _A%^R[\'- ^ /P'\%6WAW
MPEX8L?LFC:1:L[+"FYG9F=RSR.[L[O(Y+N[LS$EB:YZR_9(^&-A^V?J'[=4.
MI:R?&.I?#6V\#W%HUU'_ &>--@OY;Y'6/R]XF\V9@6\PKM &T'D@'J-%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45^:_\ P45_;]_:
MV^!'[67B#X9_"KXL_P!E:)8VMB]K9?V#83[&DM8I'.^:!W.68GECC/'%>'_\
M/7?V^_\ HO7_ ):VE?\ R+7KTLEQ5:E&<91LU?=_Y'@U^(<%0K2IRC*\6ULN
MGS/V8HK\9_\ AZ[^WW_T7K_RUM*_^1:/^'KO[??_ $7K_P M;2O_ )%K3^P<
M9_-'[W_D9?ZSX#^67W+_ .2/V8HK\9_^'KO[??\ T7K_ ,M;2O\ Y%H_X>N_
MM]_]%Z_\M;2O_D6C^P<9_-'[W_D'^L^ _EE]R_\ DC]F**_&?_AZ[^WW_P!%
MZ_\ +6TK_P"1:/\ AZ[^WW_T7K_RUM*_^1:/[!QG\T?O?^0?ZSX#^67W+_Y(
M_9BBOQG_ .'KO[??_1>O_+6TK_Y%H_X>N_M]_P#1>O\ RUM*_P#D6C^P<9_-
M'[W_ )!_K/@/Y9?<O_DC]F**_&?_ (>N_M]_]%Z_\M;2O_D6C_AZ[^WW_P!%
MZ_\ +6TK_P"1:/[!QG\T?O?^0?ZSX#^67W+_ .2/V8HK\9_^'KO[??\ T7K_
M ,M;2O\ Y%H_X>N_M]_]%Z_\M;2O_D6C^P<9_-'[W_D'^L^ _EE]R_\ DC]F
M**_&?_AZ[^WW_P!%Z_\ +6TK_P"1:/\ AZ[^WW_T7K_RUM*_^1:/[!QG\T?O
M?^0?ZSX#^67W+_Y(_9BBOBG_ ())_M;_ +0G[3FM^.;3XX?$#^VX]'M=/?35
M_LJTMO):1K@.?]'B3=G8OWLXQQC)K[6KR\3AYX6LZ4]UV/:P>*IXW#JM!-)]
M]]';S"BBBL#I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\=?^"N7_)]OBO_ *\=
M,_\ 2&&OFFOI;_@KE_R?;XK_ .O'3/\ TAAKYIK[[ _[G3_PK\C\PS+_ )&%
M7_$_S"BBBNHX@HHHH **** "BBB@ HHHH **** "BBB@#] _^"#/_(Q_$S_K
MQTK_ -#NJ_1VOSB_X(,_\C'\3/\ KQTK_P!#NJ_1VOBLX_Y&$_E^2/T/(/\
MD5P^?YL****\P]D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /QU_X*Y?\GV^*_\
MKQTS_P!(8:^::^EO^"N7_)]OBO\ Z\=,_P#2&&OFFOOL#_N=/_"OR/S#,O\
MD85?\3_,****ZCB"BBB@ HHHH **** "BBB@ HHHH **** /T#_X(,_\C'\3
M/^O'2O\ T.ZK]':_.+_@@S_R,?Q,_P"O'2O_ $.ZK]':^*SC_D83^7Y(_0\@
M_P"17#Y_FPHHHKS#V0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG6BC_B(7#'_0BH_^2?\ RD/^(<<4_P#0_K?^3_\ RX_F*_X7;\9_^BN>)_\
MP?7'_P 71_PNWXS_ /17/$__ (/KC_XNOZ=:*/\ B(7#'_0BH_\ DG_RD/\
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M+[W_ )A_9^ _Y]1_\!7^1\E_\.7/V-/7Q;_X/5_^-4?\.7/V-/7Q;_X/5_\
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M1^=O' [5VU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!^8O_!<?]M3]IN+3_C5^R%^S?\ $G0?AY'X$_9S?X@>)?$E[!<2Z[K4
M4]S<VR6>D"*XA%JL?V9C->DRLC31JL8.6/V'^S[XR_:\^$7@_P"(#_\ !0/6
MO!%_I'@F/[?HGQ0\(V<FG1:WI26S37$MUIKS3M93P&-@VV5XY P*!=I!^%?^
M#C?XH_L!^+_A%\4?@9^U[\#XM$^(_ASX63:O\"?B-XGLA;P:]=RH_G6>EW\+
MY,T,BQB2SF93)YBL(G7#'D-$UKQ/XK_8O_;Z^"?['/[1?C3XO_L_:#\%)U^'
M'B_Q1KLVL&WUA]+OVU;1]-U.4;]0M4@2WZ,ZQ/*$5B6)(!]1^/O^"BG[1WPK
M_P"":G@[]J2X\-:9J7Q3_:"\:Z7I?P3\&:K (++2Y?$%Q_Q);.[:+#R"WL<7
M-PQ.YY4F4&-2NS+^./Q._P""A/\ P2X;P/\ M'?M)_MF6OQN^%NK^,M,\-_%
M73=0^'6FZ%-X7349UMH-6TZ6Q"LT$5S)$DD%R9G:.3Y9-W(Q?^"F5HE[_P $
M]_V6/VT/A]HUQJ7A+X'_ !-\ ?$GQ#;:3;-.X\,16K075Q%&@)?R8+Q9^!\J
M1.QX!(L_\%L?C3\$_P!M3]BG0/V%_P!G#XL^'?&GC#]H;QMX:T[PG;>%=9AO
MWBT^#5;34[S5F$#,4M8+:TD=YCA5+*,Y(% 'Z)5\6_\ !7O]NGXV_ +X;ZS\
M&/V+=0L(_BQ;_#O6O'FKZQJ%@EW;>$_#6DVTL\U[/$X*O+=31+8VT;##/++)
MRMNX/TQ>_M+? VS_ &@8_P!E%OB5I?\ PLFX\+'Q';>#FE87<FEB9H?M6-N!
M'YJLF<YR.E?F#\3OA_\ \%6_@7^QA^UG\2?C]^Q!\.-?\5?%KP5XGOOB%\1K
M7X\NKZ=HZ:5=0V=C9:>=&8FWL+0L(X#< S2-*[.K3': ?<_PVO?VJ_VN?^";
M/PG\=_#']I:U^'7Q'\9?#KPSKVK^-F\#6NL1F:XT^"XNE6QE>*)?,>1L$$!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ;7EO(H>.:*1"5D1E((9200<BM*OD7_@A#X;^$W@K_@D_P#!_P $?!CXS?\
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M&FVLMCIUO8SWDER\,"(]Q+]^4@ %FQW/4_6IZ "BBB@ HHHH **** "BBB@
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M^SA\1O"?A?7)9?@CX&\>:YK\.G>%8%D<0W\EE;6317&J-&5+7$KR^4Q;R?+
M7!10!]!>*-'_ ."QOC+]DCQWX<L]?^ 'A#XRWTD$'@#7="N=7O='L;=G07$]
MR+JUW_:%C\TQ 1R1[]F\%=P/@/['G[%W_!8/]BKPIJ.G?#;P'^RCJ_B3Q)=B
M^\<_$+Q3XR\57NO>*;['-S?7;66Z0\G;&NV*,$B-%!-%% 'Z-Z<=0.GP'5EA
M%UY*_:1;$F,28&[:6YVYSC/.*FHHH **** "BBB@ HHHH **** "BBB@ HHH
,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biib-20230930_g4.jpg
<TEXT>
begin 644 biib-20230930_g4.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@
MR )8 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBHKR>2VM7GAMFF95
MRL2=6]A0!+16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\
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M6=U(6&U5BF<L2 ,DB@#ZYHK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z
M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
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ML-ZS_P#3DC^1?%/_ )+G%>E/_P!-P"BBBOOC\]"BBB@ HHHH **** "BBB@
MHHHH **** /I;_@CW_RDB^%__81O?_3==5_0-7\_/_!'O_E)%\+_ /L(WO\
MZ;KJOZ!J_F_QD_Y*.A_UZ7_I<S^FO!7_ ))JO_U^?_I$ HHHK\C/V(**** "
MBBB@ HHHH **** "BBB@ HHHH **** /QU_X*Y?\GV^*_P#KQTS_ -(8:^::
M^EO^"N7_ "?;XK_Z\=,_](8:^::^^P/^YT_\*_(_,,R_Y&%7_$_S"BBBNHX@
MHHHH **** "BBB@ HHHH **** "BBB@#] _^"#/_ ",?Q,_Z\=*_]#NJ_1VO
MSB_X(,_\C'\3/^O'2O\ T.ZK]':^*SC_ )&$_E^2/T/(/^17#Y_FPHHHKS#V
M0HHHH **** "BBB@ HHHH **** "BBB@ KGOBOIOQ)U?X=:MIOP?\1Z?I'B:
M:U*Z-J6JVAGM[>;(^:2,<L,9X]ZZ&B@#Y3_X5)_P5]_Z.X^%G_A"R4?\*D_X
M*^_]'<?"S_PA9*^K** /E/\ X5)_P5]_Z.X^%G_A"R4?\*D_X*^_]'<?"S_P
MA9*^K** /E/_ (5)_P %??\ H[CX6?\ A"R4?\*D_P""OO\ T=Q\+/\ PA9*
M^K** /E/_A4G_!7W_H[CX6?^$+)1_P *D_X*^_\ 1W'PL_\ "%DKZLHH ^!/
MVE?^";'[=?[7]II%C^T5\<?A9XBBT&2:325_X1W4;3R&F""0YM9HRV1&GWLX
MQQC)KR?_ (A^/B3_ -#%\+/^_&O?_)E?JG17K87/L\P-!4<-BJD(+:,9RBE?
M5V2:6KU/(Q7#^0XZNZ^)PE*<WO*5.$F[*RNVF]%IZ'Y6?\0_'Q)_Z&+X6?\
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M5^FE%'UW&?\ /R7WO_,/[/P'_/J/_@*_R/S+_P"'(_[07_0_?"S_ ,%VL_\
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M$5Y+\5/C#K__  7)^+GP\^ 7P0^ 7C[PK\*_A%\9K#Q)\<?%GQ*\/G19EO\
M246ZM_#<%E,WVA[B5YX))F9$6&+80S%P#^F%>$:E_P $W?V5KO\ :N_X;0TK
MP]XBT7QS<7MO>:U)X>\:ZG8:=K=S!$(89KZP@G6UNW2,*NZ2,DA5W;L"@#S_
M ,=?M]?M'_LT_'+QO\//VH/V'OB)XG\&2ZDMS\+?'7P,\!WOB6&^TQH$W6FI
MVUN\MQ:WL<PD!?RU@D5EV[=I+\7_ ,$D_@=\4])_:8_:3_:_O/V>M8^#7PW^
M,'B#0Y_ 7PP\06D5E?B6RLI(;[6;FPB9DL);R5T)C.)&\K=(,[6/W710 5\,
M_P#!6S]M[]L_X*^+/#G[-'[(7[,GQ1N_^$JTP7GBKXV>#OAA=>)X/"EFTDL1
MAL[2$;+G4SY18+.Z11+)&["7?M7[FHH ^'?^"7_C3X$_#:TO?V>/V?\ ]C3]
MHSPEK>NI=:WXF^)OQR^&%_:OXDU;:-]YJ>I3L&N+B1CP@V@#*QA%  K6/_!2
M;XQZ5\+K[X+_ +?7_!*_XR:SX_B6XL->T;X9?"BX\3>$O$B[F6.6SOM\D"V\
MT>PE+QXWC+,KCY<U]UT4 ?)O_!$[]F/XX?LD_P#!/SPY\)?C]HJZ%K,FN:OJ
MUEX+CU,7B>$]/O+Z6XM=(68$K)Y$<@!VDJ&9E!(4$_65%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YXW][\3_
M /@DA^W)\=?C[KG[/'CKQ[\"OCG<V7BV77?AGH+:O?\ @[7K:T\B_2^LHV\Y
MK6=$6=;F-66(J4< ?,)_V2M%^-?_  4"_;8U'_@KOIWPQG\%^";#X)'PG^SC
MIGCI56YU[[=*+Z7Q#=P6\C-;6TG[F&*/?YDD):3"$KG] [RSM-1M)=/U"UCG
M@GC:.>"9 R2(PP58'@@@D$'K7B'[)?\ P3I_9A_8@UW5]6_9QTGQ-H]GJML+
M>/P[>^.=4O\ 2=+A\PRF.RLKJXDALU+G.(E7 PHPHQ0!\^WG_!2+XE:U\"KK
MX(_MP?\ !(WXV:_\1I-,?3?%7@WPA\*)==\):_=;60O::IODLULIB P^TRJ\
M2OM<,5W-ZM_P1I_9G^.7['__  38^&/[/G[1MRH\6Z'I]V]]IJ:C]L71X9[V
MXN+?35GRWFBV@EB@R&9?W6$)0*:^GZ* "ORM_;F_:Z_:;_:>_:4\4_LH_$G]
MD+]J+P?^SQX9U*;3=?O?A;\)]1O=6^*)CD:.2)-0AVII^CR;?O0,T]U$V-\*
MN5'ZI44 ?'_AG]MO0/@U^P/XC\>?LI_\$SOC=:V_PQM+32?"'P;G^%]QHFH:
MF79(XEL[=E9FMD+[IIE5RBK(VUV&#\J?LQ_M":Q>_&*R_;<_X*$?L1_M8_$+
MXS6T$J>%]+TO]G;5$\,_#NWF&)+71K:1LM,RX674)@9Y0H \M,J?UKHH ATZ
M\&HZ?!J"VTT(GA600W,922/< =K*?NL,X([&IJ** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biib-20230930_g5.jpg
<TEXT>
begin 644 biib-20230930_g5.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***9<W,%G UU=2A(T&7=N@% #Z*S?^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH X
M+]I7]LO]FS]D"TTB^_:*^)'_  CL6O231Z2W]CWEWY[0A#(,6L,A7 D3[V,Y
MXS@UY/\ \/K/^"97_1RW_EFZU_\ (=?+_P#P<B:UI6K>%?A(NFWR3%-0UG?L
M/3*6>*_*JOVW@[PVR/B'AZCC\34J*<^:ZBXI:2<5:\&]EW/POC3Q.S[ASB.M
ME^&I4G"'+9RC-OWH1D[VFEN^VQ^^O_#ZS_@F5_T<M_Y9NM?_ "'1_P /K/\
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M ,AU^!5%'_$'.&/^?U;_ ,"A_P#*P_XC5Q3_ ,^:/_@,_P#Y8?OK_P /K/\
M@F5_T<M_Y9NM?_(='_#ZS_@F5_T<M_Y9NM?_ "'7X%44?\0<X8_Y_5O_  *'
M_P K#_B-7%/_ #YH_P#@,_\ Y8?OK_P^L_X)E?\ 1RW_ )9NM?\ R'1_P^L_
MX)E?]'+?^6;K7_R'7X%44?\ $'.&/^?U;_P*'_RL/^(U<4_\^:/_ (#/_P"6
M'[Z_\/K/^"97_1RW_EFZU_\ (='_  ^L_P""97_1RW_EFZU_\AU^!5%'_$'.
M&/\ G]6_\"A_\K#_ (C5Q3_SYH_^ S_^6']#?P>_X*F?L(?'SXDZ7\(OA+\=
M?[6\1:U(\>FZ?_PC&J0><R1M(P\R:V1%PB,?F8=,=<"OH&OY]?\ @D-=VUC_
M ,%&OAC=W<PCC34;W<[=!_Q+[D5^_'_"8^&/^@U!_P!]5^2<?<,X#A7-J>%P
MDI2C*"D^9IN[E)=(QTT70_8?#SBG,.+<HJ8K&1C&4:CBN1-*RC%]92=[M]32
MHK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J^&/O32HK-_X3'PQ_T&H/\ OJC_
M (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'P
MQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_O
MJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X
M3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?
M#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^
M^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_
M (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'P
MQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_O
MJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X
M3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?
M#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^
M^J -*BLW_A,?#'_0:@_[ZJY8W]GJ4 NK&X66,D@.O3- $U%%% !1110 4444
M %(Z)(I21 RGJ&&0:6B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/
M_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:
MB@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@#\OO^#D^VM[?PI\(_(@1,ZAK
M6=B@9_=V=?E)7ZO_ /!RI_R*GPB_[".M?^B[.OR@K^KO#'_DBL-ZS_\ 3DC^
M1?%/_DN<5Z4__3< HHHK[X_/0HHHH **** "BBB@ HHHH **** "BBB@#Z5_
MX(_1QR_\%(/AA'*@93J-[E6&0?\ B775?T _V=I__/C#_P!^A7\__P#P1[_Y
M21?"_P#["-[_ .FZZK^@:OYO\9/^2CH?]>E_Z7,_IKP5_P"2:K_]?G_Z1 A_
ML[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHK\C/V(A_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C
M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
MA_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^S
MM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQ
MA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_
ML[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_O
MT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/
M_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_
M[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"I(XHH5V0QJB^BK@4ZB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /S"_X.5/^14^$7_81UK_T
M79U^4%?J_P#\'*G_ "*GPB_[".M?^B[.OR@K^KO#'_DBL-ZS_P#3DC^1?%/_
M )+G%>E/_P!-P"BBBOOC\]"BBB@ HHHH **** "BBB@ HHHH **** /I;_@C
MW_RDB^%__81O?_3==5_0-7\_/_!'O_E)%\+_ /L(WO\ Z;KJOZ!J_F_QD_Y*
M.A_UZ7_I<S^FO!7_ ))JO_U^?_I$ HHHK\C/V(**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /S"_X.5/^14^$7_81UK_T79U^4%?J_P#\'*G_ "*GPB_[".M?^B[.
MOR@K^KO#'_DBL-ZS_P#3DC^1?%/_ )+G%>E/_P!-P"BBBOOC\]"BBB@ HHHH
M **** "BBB@ HHHH **** /I;_@CW_RDB^%__81O?_3==5_0-7\_/_!'O_E)
M%\+_ /L(WO\ Z;KJOZ!J_F_QD_Y*.A_UZ7_I<S^FO!7_ ))JO_U^?_I$ HHH
MK\C/V(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY7^-?_  6<
M_P""=OP _:LT+]D7XD_M,>$+'7]3AU#^VK^7Q):)9^&[FV-L([34)&D MIIS
M.VQ&QCR'W[?EW?5%?B(W@[]HG_@F%^T3\&/V;_VDOV$Y/C)X$\.>%?BMY&O?
M"U[;5=2\=:/J=YI%Q>7M_I%R(G-W AA6=?,D\_SAY9(C.0#]MK:]L[VSCU&S
MNXI;>6(213Q2!D=",A@PX((YSTQ7$?L_?M/? ']JKPWJ_C+]G7XI:7XOTC0O
M$EWH&IZIH[L]O'J%ML\Z%9" LH7S$.]"R,&!5C7C.C_L]_LD?\% OV"_A7X+
M^!'Q$\2Z3\";BQTZ]T[1/!>MW&G+KVA16LL*:)>2$_:$M,N@FA#I(3;"-F W
M@^8_\$$?"WAKP-\.OVF_!7@S0+/2M'T?]M/XB6.DZ7IULL-O9VT5W!'%#%&@
M"HB(JJJ@    =* /O"N#\9?M/_ #X??'7P=^S)XP^*FEV7C_ ,?P7L_A'PHT
MC->:A#:0//<2A%!\N-8XY#O?:K%&526!%=Y7Y=^/OV)OA?\ LA?\%A?V(M5T
M'Q!X@\6>,_&.N?$N[\<_$7QIJ9O=9UZ9/"Q$2RRD 1P0JS)#;1*D42DA5RS,
MP!^AO[0G[27P(_90^&5W\9/VC?BGI'A#PU9RI#+JNL7.Q7F?(2&-1EYI6P=L
M4:L[8.%.*\__ &8O^"F7[#_[8GCJ^^%OP!^.<6H^*=.L?MMSX7UK0=0T74C:
M[MIN([74K>"::$,0#)&K(,C)Y&>T^/?P6^&WQ!.B?%OQ/\$;7QUXI^&<UWKO
MP]TV>X2-TU7[+)&GDM,ZP),X8QI)+\L;.'RI7</S]UKXR?%/X_?\%FOV;?$O
M[;/[,.I_LV2^"-.\3+\,UUS5;76IOB!JFH:>()=,_M#3&DL[1(80TX@DF:29
M\!5'< ^F?B[_ ,%O/^"6WP'^)VN?!OXL?M86&D>)?#>HR6&MZ8WAO59C:W"'
M#QEXK5D8@\95B/>O6OV3/VT_V8OVY_A_?_%/]E/XJV_B_0-+UJ32;_4;;3[J
MV6*]CCCE>';<Q1L2$FC)(!'S8SD$#S__ (*H?M1_$#]F;]F6WTKX%/;_ /"T
MOBCXMTWP!\*Q=)NBAUO4Y#$EW(.?DMH5GNFR"I^SX;@FO4/V5?V;/ /[(WP$
M\._ 'X<FXGLM#M#]LU6^<O=ZO?2,9;O4+J0DF2XN)WDFD<GEY&[8% 'H5>7_
M  __ &T?V7?BI^T;XM_9)^'7QCTS6/B)X$LH[OQ;X:LDE:338G,8!>39Y1;,
MJ HKEE)PP!! XK_@HA^U=XR_9]^'VA?"G]G^QM=5^-/Q:U<^'/A-HMTN^*.\
M*%[G5;E0"?L5A!ONIFQ@A$CX,JU\M?L._LR^#?V0_P#@M[J_P+\&ZC=:E_9W
M[&FDW&M>(-2;=>Z]JEQXKU">]U*Z?)+SW%Q)),YR<%]HPJ@  _2JBBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH _,+_@Y4_Y%3X1?]A'6O_1=G7Y05^K_ /P<J?\ (J?"+_L(ZU_Z+LZ_
M*"OZN\,?^2*PWK/_ -.2/Y%\4_\ DN<5Z4__ $W ****^^/ST**** "BBB@
MHHHH **** "BBB@ HHHH ^EO^"/?_*2+X7_]A&]_]-UU7] U?S\_\$>_^4D7
MPO\ ^PC>_P#INNJ_H&K^;_&3_DHZ'_7I?^ES/Z:\%?\ DFJ__7Y_^D0"BBBO
MR,_8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (=0L8-3L)]-NF
ME$5Q"T4AAG>)PK @[70AD.#PRD$'D$&OS#\7_P#!-O\ X*H?#']K+X/>"O@-
M^W/#JO@;POX.\:Z7X9^)'CCX=G5];\%V-ZVD[;.ZG^VQQZG<,L"BVGE1-HMI
M1*LGRX_4*B@#YL\*_LT?'_\ 8@_9 ^'7[+?_  3GT?P%K$?@RS6PO+CXNZY?
MVPN8</))<A["VE+7$MP[2,I54&]MN, 5XS_P3V_91_X*R_L?^+_&6F^,K#]G
M;4O"_P 3?CMK7Q!\7W&F>*=>:_T]-6NHY;JWLT?3TCE:-5(C\QE#'&X@<U]\
MT4 ?.7P0\9_MD>)/V^_C]X<\8>(M"O?@_P"'--\.V_PVMH=-:&XM-6FT]9K^
MVN)O+!F*DPS$J754O85!W+(B?/7QL_95_P""TOQL_:Q^"7[6&J:+^R]8ZA\$
MI_$4NEZ3;^,?$;0ZD=7TW[!()6.F;D\M?G7;U/!XK]$J* /E?XP?!#_@I=\2
M/!_PV^-7@7XZ^"/!'Q>\$7NHMXA\#6=]J=]X#\6V=R6C2VN\I#=+)'$L4L=P
M(R8I3*-DBD$<4W[%O[?O[7G[2_PJ^,7_  4'\3_"3P[X2^#'B=O%'ACP/\(K
MK4]1EUC7! \-O<WE]J$%L8HH!([+#%$=Y8[W(QC[=HH ^<?VL/V.OB'^T1^V
MM^S1\>;#Q#HL?@OX,^(/$>M>*=%U"6475_>76DFSTV2V58V1C#+)([%W3 (V
M[CQ7KO[0>F_'#6/@AXITO]FGQ#H>D_$"?1)T\(:EXFA>33[:_*GRI+A45V:,
M-C< I..U=C10!\\^+/\ @GM\#?VNOA7\/9?^"E/P'^'OQ/\ B)X9\*V]KK.K
MOI!DLEU%XHC?/9K(JLD$DZ%E!4':%R!C%>$?#/\ X(&?L@_"K_@I>O[6_@_]
MFOX8Z;\/M)^'FEV_A/PS8Z;(MWI?BRTU:2[_ +72/R_+0^3Y"+()"^Z/&T
MG[]HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#\PO^#E3_D5/A%_V$=:_]%V=?E!7ZO\ _!RI_P B
MI\(O^PCK7_HNSK\H*_J[PQ_Y(K#>L_\ TY(_D7Q3_P"2YQ7I3_\ 3< HHHK[
MX_/0HHHH **** "BBB@ HHHH **** "BBB@#Z6_X(]_\I(OA?_V$;W_TW75?
MT#5_/S_P1[_Y21?"_P#["-[_ .FZZK^@:OYO\9/^2CH?]>E_Z7,_IKP5_P"2
M:K_]?G_Z1 ****_(S]B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XZ_
M:Y_X*S?\,K_';5?@I_PH'^W?[,@MI/[3_P"$J^R^;YT"2X\O[+)MQOQ]XYQG
MCI7FG_#^W_JU+_R^O_N&O!?^"N7_ "?;XK_Z\=,_](8:^::^OPN5X&IAH3E#
M5I/=]O4^$QN<YE1QE2$*EDI-+2/?T/T0_P"']O\ U:E_Y?7_ -PT?\/[?^K4
MO_+Z_P#N&OSOHK?^R,N_D_%_YG+_ &]FO_/S\(_Y'Z(?\/[?^K4O_+Z_^X:/
M^']O_5J7_E]?_<-?G?11_9&7?R?B_P#,/[>S7_GY^$?\C]$/^']O_5J7_E]?
M_<-'_#^W_JU+_P OK_[AK\[Z*/[(R[^3\7_F']O9K_S\_"/^1^B'_#^W_JU+
M_P OK_[AH_X?V_\ 5J7_ )?7_P!PU^=]%']D9=_)^+_S#^WLU_Y^?A'_ "/T
M0_X?V_\ 5J7_ )?7_P!PT?\ #^W_ *M2_P#+Z_\ N&OSOHH_LC+OY/Q?^8?V
M]FO_ #\_"/\ D?HA_P /[?\ JU+_ ,OK_P"X:/\ A_;_ -6I?^7U_P#<-?G?
M11_9&7?R?B_\P_M[-?\ GY^$?\C]$/\ A_;_ -6I?^7U_P#<-'_#^W_JU+_R
M^O\ [AK\[Z*/[(R[^3\7_F']O9K_ ,_/PC_D?LC^P9_P4#_X;<U+Q-I__"I/
M^$8_X1V"TDW_ -O?;?M'G&48QY$6S'E>^=W;'/T?7YQ?\$&?^1C^)G_7CI7_
M *'=5^CM?+YE1IX?&2A35DK?DC[/*,16Q6 C4JN\G?\ -]@HHHKA/2"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _,+_@Y4
M_P"14^$7_81UK_T79U^4%?J__P '*G_(J?"+_L(ZU_Z+LZ_*"OZN\,?^2*PW
MK/\ ].2/Y%\4_P#DN<5Z4_\ TW ****^^/ST**** "BBB@ HHHH **** "BB
MB@ HHHH ^EO^"/?_ "DB^%__ &$;W_TW75?T#5_/S_P1[_Y21?"__L(WO_IN
MNJ_H&K^;_&3_ )*.A_UZ7_I<S^FO!7_DFJ__ %^?_I$ HHHK\C/V(**** "B
MBB@ HHHH **** "BBB@ HHHH **** /QU_X*Y?\ )]OBO_KQTS_TAAKYIKZ6
M_P""N7_)]OBO_KQTS_TAAKYIK[[ _P"YT_\ "OR/S#,O^1A5_P 3_,****ZC
MB"BBB@ HHHH **** "BBB@ HHHH **** /T#_P""#/\ R,?Q,_Z\=*_]#NJ_
M1VOSB_X(,_\ (Q_$S_KQTK_T.ZK]':^*SC_D83^7Y(_0\@_Y%</G^;"BBBO,
M/9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M _,+_@Y4_P"14^$7_81UK_T79U^4%?J__P '*G_(J?"+_L(ZU_Z+LZ_*"OZN
M\,?^2*PWK/\ ].2/Y%\4_P#DN<5Z4_\ TW ****^^/ST**** "BBB@ HHHH
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MG_!7W_H[CX6?^$+)1_PJ3_@K[_T=Q\+/_"%DH ^(?^"N7_)]OBO_ *\=,_\
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MH+_H?OA9_P""[6?_ )*H_P"'(_[07_0_?"S_ ,%VL_\ R51_;V#_ )9?<O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN'9@2#[-_P %&O@C\=/AS^V%\%_^"H'[.OPDU+XA3_#33M7\,_$KP%X?:/\
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M8YA("_EK!(K+MV[27XO_ ())_ [XIZ3^TQ^TG^U_>?L]:Q\&OAO\8/$&AS^
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M\1K;3W-Q'9Q:':V4ACL$B,1@A2$*"T1+_*<#WG_@E_XT^!/PVM+W]GC]G_\
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M$\*R"&YC*21[@#M93]UAG!'8U-0 4444 %%%% !1110 4444 %%%% !1110
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M#M[XYU2_TG2X?,,ICLK*ZN)(;-2YSB)5P,*,*,5[G10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biib-20230930_g6.jpg
<TEXT>
begin 644 biib-20230930_g6.jpg
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M&R^_9Y_9^^ FJ_$CQ/H.G07WBU;36;;3K/18IP6@CEN+@[6GD4;UB R5^;(
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M5/#MA<ZEI(F&EZA<6B//9B50LOE2$;H]Z@!MI&X  YJ_2,RHI=V  &22> *
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MGU/[JMG2_@U\(-#T6W\-Z+\*?#5GIUKJ::E:V%KH5O'##>IC;<HBH%688&)
M-PP,&NDKA?C_ /M!>#/V<?#&D^+/&^F:G=6VL^)[#0K5-*AC=UN;R7RHG822
M(!&&Y8@D@=%/2@#J]<\+^&?$YLCXE\.V&HG3K^.]T\WUHDWV6Z3(2>/>#LD7
M<V'7##)P>:SO'WPE^%7Q5AMK;XH?#/P]XDCLI#)9QZ_HL%XL#G&603(VT\#D
M8Z5T%>*_&7]N/P!\+OB@WP.\'_#?QG\1/&=O9)>:IX>\!:.ET^E6[\QR74LL
MD<4&\<JI;<<J< ,I(!ZSH_A#PGX>O[K5?#_A?3K&ZOHX8[VYL[*.*2X2%-D*
MNR@%PBG:H.=HX&!6*OP(^!Z^.?\ A9Z_!KPH/$IE\P^(1X=MOMV_^]Y^SS,^
M^[-<Q^SA^UU\+_VF)]:T#PUINNZ!XE\,S1Q^)/!OBW2S9:III<9C:2(E@R,!
ME71F4^O(KD_&'_!07P9IGC/7_"'PL^!7Q)^)*>$KMK3Q3J_@/0(;FST^Z0 R
M6HDEGB,\Z @M'$'*YP>>* /;O%'A3PMXWT*X\+^-/#6GZOIEVH6ZT[5+-+B"
M9<YP\<@*L,@'D=JS?#?PA^$W@V+3(/"'PO\ #NE)HIF.C)INB00"P,P"S>2$
M0>5O  ;;C< ,YK'^&_[2GP5^*OP13]HGPEXYM3X2%C-=W>J79, LDA#>>LZO
M@Q-'M8,K=,=P03XTW_!4WX:+X>/Q/_X9R^,!^'@._P#X6,/!0_LS[/G_ (_-
MOF_:/LV.?,\KIVH ^GZ*\^^)O[4GP-^$OP1B_:'\5^.;=O"MY;6\NE7U@IN&
MU,S@&".V1 6F>3(VJ!TR3@ D>:Z/_P %(_ %IXGT30_C-\!/BA\,['Q+>I9Z
M%XA\>>&8[;3Y[B3_ %<$DL4TAMY'[+*%[Y(P: /HNBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQUG_ &L/'/["ES^U9X^F\!Z5H-AXGMM=FUOS/$B+<;HCIRZBREU@,BF3> )
M(U0, [D^UZQ\"?B!=_M_^'/VAXE@E\-Z7\*[S0+NYEN%$[7DE]',O[L 9!12
M2PP >,4[P9\#/'NB?M[>-OVA+^WM1X<UWP!I>D6$JW(,QN8)Y7D#)U5<.,'O
M0!\[ZGXJ^).B_LT_MB?LP^/?B7J_C"T^&OA^X3P[KWB*<3:BUE?:.]RL$\V
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MQ)L_ /@?P!I>L_!Z&VCDUO0[;QS_ &)>>(IR,M!<SB*1UM1P#%&%,@)R_3:
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MC^S7'\.K?]GGP-8?"'Q(=8\+6GA+3[;P]JC,2UU9Q6Z1Q.V0"&*J-P(!#9!
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MS$(H +')./4]Z=3+=IGMT>YB"2% 9$5MP5L<C/?ZT^@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#"\/_  S\!>%?&GB#XB^'O"]K::WXJ:U;Q%J42D27
MYMHO)@,ASSLC^48[5NT44 %%%% !1110 4444 %%%% !1110 4444 %07NF:
M;J30/J.GP3FVG$UL9H@YBD (#KD?*P!(R.>3ZU/10 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !45Y
M/);6KSPVS3,JY6).K>PJ6B@#'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB
M@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\
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MXB5_U"_^3_\ VAA_K9_TY_\ )O\ [4_<2BOP[HH_XB5_U"_^3_\ V@?ZV?\
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M_MK?"SX;V^H>,OA_XS_MC6/ R78B343;//97L-N[DA7)0R1;B< XRS8!Q?\
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M2+'P_>_\*[_X2#^W9KE-O]K_ &3R/*$9SGR9-V?,]L8[YKPC_A\U_P!6W_\
MEX?_ ''7@X[B?(\NQ,L/B*O+-6NN63W5UJHM;,\W$9OE^%JNE5G:2\GZ]$?<
M5%?#O_#YK_JV_P#\O#_[CH_X?-?]6W_^7A_]QUR?ZZ\,_P#/_P#\EG_\B8_V
M_E/_ #\_"7^1]Q45\._\/FO^K;__ "\/_N.C_A\U_P!6W_\ EX?_ ''1_KKP
MS_S_ /\ R6?_ ,B']OY3_P _/PE_D?<5%?#O_#YK_JV__P O#_[CH_X?-?\
M5M__ )>'_P!QT?ZZ\,_\_P#_ ,EG_P#(A_;^4_\ /S\)?Y'W%17P[_P^:_ZM
MO_\ +P_^XZ/^'S7_ %;?_P"7A_\ <='^NO#/_/\ _P#)9_\ R(?V_E/_ #\_
M"7^1]Q45\._\/FO^K;__ "\/_N.C_A\U_P!6W_\ EX?_ ''1_KKPS_S_ /\
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M_P C&M_B?YA7HOP)^#6L?%FUU2?X=^.X;/QEI+0S:)X?:86\VIH2PD:WG9U
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M "-JGR_])0445K>!/ _B;XE>,-.\!^#=-:\U/5+E8+.W5@NYCW)/"@ $DG@
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MWG@G_DFJ/_;W_I<C]&X?_P"153^?YL****^K/:"BBB@ HHHH **** "BBB@
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MG&#UZTWX3_&/0OAU\'OB-X$N-+NY-5\8Z?8VFG7D&WR[>..=I)Q(20<.NT#
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M_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U?5GM&Q16/_P@^D?\_-[_ .!;4?\
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MH!]*%%%% !1110 4444 %%%% !1110 4444 %%%% 'Y;_P#!3/\ Y/%\2?\
M7I8?^D<5>!U[Y_P4S_Y/%\2?]>EA_P"D<5>!U_.6?_\ (\Q/_7R?_I3/RS,O
M^1C6_P 3_,****\@X@HHHH **** "BBB@ HHHH **** "BBB@#[7_P""-?\
MR'?'_P#UZ:;_ .A7-?=M?"7_  1K_P"0[X__ .O33?\ T*YK[MK]YX)_Y)JC
M_P!O?^ER/T;A_P#Y%5/Y_FPHHHKZL]H**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#XH_P""RG_("\ ?]?>I?^@VU?"5?=O_
M  64_P"0%X _Z^]2_P#0;:OA*OP;C;_DI:W_ &[_ .D1/SCB#_D;5/E_Z2@H
MHHKY0\8**** "BBB@ HHHH **** "BBB@ HHHH ]F_X)[_\ )XO@G_K[N?\
MTCGK]7J_*'_@GO\ \GB^"?\ K[N?_2.>OU>K]D\.O^1/5_Z^/_TF)]WPM_N,
M_P#$_P D%%%%?H!]*%%%% !1110 4444 %%%% !1110 4444 %%%% 'Y;_\
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M /DL/_D3VS_AL3_JG7_E7_\ M-'_  V)_P!4Z_\ *O\ _::\3HH_XE_\(_\
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MD_XE_P#"/_H6_P#E;$?_ "T^'_URXD_Y_P#_ )+#_P"1/;/^&Q/^J=?^5?\
M^TT?\-B?]4Z_\J__ -IKQ.BC_B7_ ,(_^A;_ .5L1_\ +0_URXD_Y_\ _DL/
M_D3VS_AL3_JG7_E7_P#M-'_#8G_5.O\ RK__ &FO$Z*/^)?_  C_ .A;_P"5
ML1_\M#_7+B3_ )__ /DL/_D3VS_AL3_JG7_E7_\ M-'_  V)_P!4Z_\ *O\
M_::\3HH_XE_\(_\ H6_^5L1_\M#_ %RXD_Y__P#DL/\ Y$]L_P"&Q/\ JG7_
M )5__M-'_#8G_5.O_*O_ /::\3HH_P")?_"/_H6_^5L1_P#+0_URXD_Y_P#_
M )+#_P"1/;/^&Q/^J=?^5?\ ^TT?\-B?]4Z_\J__ -IKQ.BC_B7_ ,(_^A;_
M .5L1_\ +0_URXD_Y_\ _DL/_D3VS_AL3_JG7_E7_P#M-'_#8G_5.O\ RK__
M &FO$Z*/^)?_  C_ .A;_P"5L1_\M#_7+B3_ )__ /DL/_D3[J_X)<_M,?\
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MFGQA^T1?ZS<:7XBT7P]H'AC3UOO%/BSQ+>-!8:5;LXC0NRJSN[N0B1HK,[<
M<$CSJO9OV3?VD_ _P:T;QK\*/C1\-KKQ1X!^(>G6EKXELM+U#[)?6TMK/Y]M
M=6\I5EWQN6.QAM?."<#!]',YXVG@92PBO/3M>UUS6NTG)1NXINS=D]#S,JA@
M:F/A'%NU/6^]KV?+=I-J+E92:5U&[6IZ3^V?_P $\-%^%MWXA\8_LZ?$[0/$
M^A^%-!T6]\3:!;WTXU;2XKJQM7-\T4\:>;;22S!PT98QK,BN%VMCSKX.? ;]
MD?QQ\/[/Q+\5OV\=/\$:Y.\HNO#<WPYU;4'ME61E0F>W0QMO4!\*3@-@\@U]
M*?M__LJ_!CXW>-?''Q(_9[^,VIMXP\%_#C0M;\2?#_Q%I02230X='L MU!=1
MGRY'C@,#RQE1\Y;:0 H/R5^R!\ +[]J/]I;P?\"+.9X8]?U=8]0N(A\T%G&I
MEN91VRL,<C#/&0*^8R?'U,7P[[:MBYQ=.*E.7)%32Y%)J7/&49)ZR4E%75M6
MTV_JLYR^GA.)?8T,'"2J2<81YY.#?M'%./).,HM:1<')V=]$FDNX_:9_8X^$
M/P/^!7AOXX_#S]K"S\;P>*]5EM=%TU?!E[I4MQ!"&$]VHNB&:))-D>[;M9G(
M5B48"SHG[$OPM\&> O#7BW]K7]JJS^&NH>,M-34_#?AR#PC=:S>'3Y"1%=W0
MA=!:QR8)0?.[*,[>"!RG[8'QQT7]H+]I.^UW2(EL/!>D30Z'X-TVVR(M.T*U
M/E6Z1CME 96Z_/(Q[UZ-_P %GOM,/_!17QOIGEB.QLK+1H-'AC_U<=H-*M"B
MQ]MN2QXXR36^'J9O.>&P=:O*,ZD:E24K4^9*+@E#X.2Z]HN9\FO*[6OISXBG
MDT(8K&T:$90IRITHQO4Y&Y*;E4^/GL_9OE7/IS*][:^9?&G]E/5_V>?CIHOP
MK^+/CS3+7P_KJV5]IWCW2X9;VPN=&N6&W4H4C'F2HJ;R8U&XE"HSP3Z=X*_8
ME_8L^(_B[3? 7@;_ (*666J:QK%['::9I]I\'->:2XF=@JHHV=R>IX'4X%3_
M +7CQZG_ ,$V_P!E?7=;8G6!;^++..1_OR6,6IHL(/\ LH,*OL3BJ7[+MJ?V
M;OV.?'W[;"IY?B;6-2'@+X;W6,/8W%Q TNHWT?=76US$D@^ZTK<UE4QF88C*
M8UE7E"JIRI)15.TYQJ2IJ3YX3:3Y>9V>D;Z:&U/!9;A\XE1>'C.BX1K-R=3F
MA"5*-1Q7)4@FUS<L>9:RMKJ>)?M#_"_PY\%?C5XB^%'A/XDV?B^RT&_^R+XB
MT^U,,-W(JKYNQ2S<))OCW!B&V;@<$5N?LP?LM^*?VF==UG[+XHTOPUX;\+:4
M=3\7^+M==EL])M =H9@@+22.WRI$HW.<XP 2/,*^DOV&OB3\([WX2_%O]D/X
MP_$&'P;:_%/3M*?1_%]Y"SVMCJ&G737$,5SL!9892Y5GP0FW/?->YF=3'8+*
M+TI.51<B<N6[MS14YJ*5FU'FDHI6NK6Z'@Y72P&.SGEJQ4:<N=J/-97Y9.$'
M)NZ3ERP<F[V=[]2'7OV'_A?XR\ ^(?&?[(O[6&G?$V\\(Z8^I^(O#<_A.[T7
M4$L$QYMU;1SLXN8X\Y?!5E7G;D@'YSK]$O\ @EW^SG\*_P!GO]L'2[GX@_M&
M>!/&FIZMHVJ6>GZ)\.];.J6\5I]BFDNKR^N BQ0PB&-D6+)D>25<A0AK\[GV
M;SY>=N?ESUQ7%DF8U,3C:^&=252,%"49RBHM\_.FM(Q32<-&HK>VMKG;GN6T
M\-@</BE3C2G-U(RA&3DER<C3]Z4FFU/5.3VOI>PE%%%?2GS!^GO_  ;5_P#(
MV_%W_L':+_Z,O*_5^OR@_P"#:O\ Y&WXN_\ 8.T7_P!&7E?J_7\H^)W_ "6N
M)](?^FXG]=>%G_)#87UJ?^G)A1117P)^A!1110 4444 %%%% !1110 4444
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M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
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M3_DHZ'_7I?\ I<S^FO!7_DFJ_P#U^?\ Z1 ****_(S]B"BBB@ HHHH ****
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M[_Y21?"__L(WO_INNJ_H&K^;_&3_ )*.A_UZ7_I<S^FO!7_DFJ__ %^?_I$
MHHHK\C/V(**** "BBB@ HHHH **** "BBB@ HHHH **** /P;_X+C?\ *2/Q
MI_V#M(_]-UO7R/7UQ_P7&_Y21^-/^P=I'_INMZ^1Z_LSA+_DE\#_ ->J?_I*
M/XFXP_Y*O'?]?JG_ *6PHHHKZ ^<"BBB@ HHHH **** "BBB@ HHHH ****
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MPQ_T'4?_  ;#_P"2#_5/BG_H K?^"I__ ")YG17IG_#('QY_Z .B?^%II/\
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M#_Z+QHG_ 'U)_P#$4?\ #=W[(?\ T7C1/^^I/_B*^)/NCUJBO)?^&[OV0_\
MHO&B?]]2?_$4?\-W?LA_]%XT3_OJ3_XB@#UJBO)?^&[OV0_^B\:)_P!]2?\
MQ%'_  W=^R'_ -%XT3_OJ3_XB@#UJBO)?^&[OV0_^B\:)_WU)_\ $5WOP[^)
MG@/XL^'%\7?#GQ-;:MIK3/$MY:D["Z_>7D Y&10!NT444 %%%% !1110 5#J
M&G:?JUE)INJV,-S;S+MEM[B(.CCT*G((^M344 <__P *F^%?_1-/#_\ X)H/
M_B*/^%3?"O\ Z)IX?_\ !-!_\17044 <_P#\*F^%?_1-/#__ ()H/_B*/^%3
M?"O_ *)IX?\ _!-!_P#$5T%% '/_ /"IOA7_ -$T\/\ _@F@_P#B*/\ A4WP
MK_Z)IX?_ /!-!_\ $5T%% '/_P#"IOA7_P!$T\/_ /@F@_\ B*/^%3?"O_HF
MGA__ ,$T'_Q%=!10!S__  J;X5_]$T\/_P#@F@_^(H_X5-\*_P#HFGA__P $
MT'_Q%=!10!S_ /PJ;X5_]$T\/_\ @F@_^(H_X5-\*_\ HFGA_P#\$T'_ ,17
M044 <_\ \*F^%?\ T33P_P#^":#_ .(H_P"%3?"O_HFGA_\ \$T'_P 17044
M <__ ,*F^%?_ $33P_\ ^":#_P"(H_X5-\*_^B:>'_\ P30?_$5T%% '/_\
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M%=!10!S_ /PJ;X5_]$T\/_\ @F@_^(H_X5-\*_\ HFGA_P#\$T'_ ,17044
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M0!S_ /PJ;X5_]$T\/_\ @F@_^(H_X5-\*_\ HFGA_P#\$T'_ ,17044 <_\
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M%% !6/\ $'Q_X/\ A7X'U7XC_$#78=,T71+&2\U._N"=L,*+EC@<D]@H!))
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2\>_ ?7O$]G=>-/B''X9\:QZIXJO=0CU^WN+69_.N5N97!F62,.KJ%P2>,8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biib-20230930_g7.jpg
<TEXT>
begin 644 biib-20230930_g7.jpg
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M!'C?PA^V!XO_ ."<WAW1[D>#_P!H#QCIGC%;J#Y8['3@7EUZ/<.C2M9J@48
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M&8==IGC?P7\,?^"L'CN;XC^+M,T&/7/A%HSZ/+K%_';)>".\G201M(0&*MU
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MQ U^#2]$T6RDN]3U"Y)V00H,LQ !)/8  DD@ $D"OGM?^"H7@2VT"+XD:_\
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MYJE[\(?V?OBK\1/#FB7<EMJ7C'P5X52XTTR1G$H@>2:-[K80=QB1A@9!8$4
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MW\-W9WEND]I=6\@>.:)U#*ZL.&4@@@CJ#5B@ KEO&'P-^"?Q#U?_ (2#Q_\
M![PMKE_Y2Q?;M8\/VUS-L&<+OD0MM&3@9P,FNIHH Y3PK\!O@;X%U)]9\$?!
MGPIHUY) T#W6E>';:WD:)L;D+1H"5.!D=#BMO2?"7A30/#B>#M"\,Z?9:1%
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M"%O/KL31ZY-!X:M4?448Y99R(\S GDA\@FNM@@@M8$MK:%(XXT"QQHH"JH&
M !T %</\-_VE/@K\5?@BG[1/A+QS:GPD+&:[N]4NR8!9)"&\]9U?!B:/:P96
MZ8[@@GQIO^"IOPT7P\?B?_PSE\8#\/ =_P#PL8>"A_9GV?/_ !^;?-^T?9L<
M^9Y73M0!]/T5Y]\3?VI/@;\)?@C%^T/XK\<V[>%;RVMY=*OK!3<-J9G ,$=L
MB M,\F1M4#IDG !(\UT?_@I'X M/$^B:'\9O@)\4/AG8^);U+/0O$/CSPS';
M:?/<2?ZN"26*:0V\C]EE"]\D8- 'T71110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&4MH?\$K9&\1:7\;OB1K2[]<UGX]Z_%J<KC]Y'';^3'!;D]=L:$A1V#&NT^
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MC/3$MM&\-Z??.^GZ+96L;&TTX7#*K2%Y2'FE"A2Q^4 #GQ/X5?"+_@H=X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZSUCQ]X\\1P>'_!6G:B["V6YD!9[FXV_-Y$,:L[XY/RC(SD<)?> _P#@IO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/XJ^(WQ4^)7Q$3PY>)=^'='^(7C*34;#3KA/]7,D&Q!(Z_PM+O(Z]>:^@:*
M/-?C5^S;_P +H\06NO\ _"_/B5X3^RV8M_L7@KQ3]@MYOG9O,=/+;=)\V-V>
MB@=JX?X%?\$[/ ?[.KZ-9?#7]H#XLP:/HE^;JV\-3^,5;3I6:4RNDD"PJ&1W
M9BPR,[CZU]!44 >9^%_V4?A?X1_:B\2_M<Z5<:J?%7BK0X=)U..:[4V@@B$
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M=_@+XYTB:[^"&LSZ^FK:QXQ\27M[K#:CJD\\;F20D0K&"L86.- %1511CJ2
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M117U9[04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW)"A(*NO9E*GISP*/BM\=_&7Q:LM/T'4;#2M'T32=YTSP]X>L!:V5N[_ 'Y
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MH **** "BBB@ HHHH **** "BBB@#\M_^"F?_)XOB3_KTL/_ $CBKP.O?/\
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M\_S84445]6>T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!\4?\ !93_ ) 7@#_K[U+_ -!MJ^$J^[?^"RG_ " O '_7WJ7_
M *#;5\)5^#<;?\E+6_[=_P#2(GYQQ!_R-JGR_P#24%%%%?*'C!1110 4444
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M %%%% !1110 4444 ?%'_!93_D!> /\ K[U+_P!!MJ^$J^[?^"RG_("\ ?\
M7WJ7_H-M7PE7X-QM_P E+6_[=_\ 2(GYQQ!_R-JGR_\ 24%%%%?*'C!1110
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M^)6/$'_H*PO_ ('5_P#E ?\ $0<E_P"?=3[H_P#R9]145\N_\-%?&3_H<?\
MRGV__P ;H_X:*^,G_0X_^4^W_P#C='_$K'B#_P!!6%_\#J__ "@/^(@Y+_S[
MJ?='_P"3/J*BOEW_ (:*^,G_ $./_E/M_P#XW1_PT5\9/^AQ_P#*?;__ !NC
M_B5CQ!_Z"L+_ .!U?_E ?\1!R7_GW4^Z/_R9]145\N_\-%?&3_H<?_*?;_\
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M\3HH_P")?_"/_H6_^5L1_P#+0_URXD_Y_P#_ )+#_P"1/;/^&Q/^J=?^5?\
M^TT?\-B?]4Z_\J__ -IKQ.BC_B7_ ,(_^A;_ .5L1_\ +0_URXD_Y_\ _DL/
M_D3VS_AL3_JG7_E7_P#M-'_#8G_5.O\ RK__ &FO$Z*/^)?_  C_ .A;_P"5
ML1_\M#_7+B3_ )__ /DL/_D3VS_AL3_JG7_E7_\ M-'_  V)_P!4Z_\ *O\
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M-/\ L':1_P"FZWKY'K^S.$O^27P/_7JG_P"DH_B;C#_DJ\=_U^J?^EL^[/\
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M+ROU?K^4?$[_ )+7$^D/_3<3^NO"S_DAL+ZU/_3DPHHHKX$_0@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S"_X.5/^14^
M$7_81UK_ -%V=?E!7ZO_ /!RI_R*GPB_[".M?^B[.OR@K^KO#'_DBL-ZS_\
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M^(OA-XLUBR_9/^+WQ#\,^%KRXC>VA?Q ]E=S[4 W7 LW6-F#%P".BD>]>K>
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MNMZ^1Z_LSA+_ ))? _\ 7JG_ .DH_B;C#_DJ\=_U^J?^EL****^@/G HHHH
M**** "BBB@ HHHH **** "BBB@#]/?\ @VK_ .1M^+O_ &#M%_\ 1EY7ZOU^
M4'_!M7_R-OQ=_P"P=HO_ *,O*_5^OY1\3O\ DM<3Z0_]-Q/ZZ\+/^2&POK4_
M].3"BBBO@3]""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** /I;_ ((]_P#*2+X7_P#81O?_ $W75?T#5_/S_P $>_\ E)%\+_\
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M]_\ *2+X7_\ 81O?_3==5_0-7\_/_!'O_E)%\+_^PC>_^FZZK^@:OYO\9/\
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MPW=^R'_T7C1/^^I/_B* /6J*\E_X;N_9#_Z+QHG_ 'U)_P#$4?\ #=W[(?\
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M2#_5/BG_ * *W_@J?_R)YG17IG_#('QY_P"@#HG_ (6FD_\ R51_PR!\>?\
MH Z)_P"%II/_ ,E4?ZT\,?\ 0=1_\&P_^2#_ %3XI_Z *W_@J?\ \B>9T5Z9
M_P ,@?'G_H Z)_X6FD__ "51_P ,@?'G_H Z)_X6FD__ "51_K3PQ_T'4?\
MP;#_ .2#_5/BG_H K?\ @J?_ ,B>9T5Z9_PR!\>?^@#HG_A::3_\E4?\,@?'
MG_H Z)_X6FD__)5'^M/#'_0=1_\ !L/_ )(/]4^*?^@"M_X*G_\ (GF=%>F?
M\,@?'G_H Z)_X6FD_P#R51_PR!\>?^@#HG_A::3_ /)5'^M/#'_0=1_\&P_^
M2#_5/BG_ * *W_@J?_R)YG17IG_#('QY_P"@#HG_ (6FD_\ R51_PR!\>?\
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M_DJC_AD#X\_] '1/_"TTG_Y*KW?]:>&/^@ZC_P"#8?\ R1X'^J?%/_0!6_\
M!4__ )$\SHKTS_AD#X\_] '1/_"TTG_Y*H_X9 ^//_0!T3_PM-)_^2J/]:>&
M/^@ZC_X-A_\ )!_JGQ3_ - %;_P5/_Y$\SHKTS_AD#X\_P#0!T3_ ,+32?\
MY*H_X9 ^//\ T =$_P#"TTG_ .2J/]:>&/\ H.H_^#8?_)!_JGQ3_P! %;_P
M5/\ ^1/,Z*],_P"&0/CS_P! '1/_  M-)_\ DJC_ (9 ^//_ $ =$_\ "TTG
M_P"2J/\ 6GAC_H.H_P#@V'_R0?ZI\4_] %;_ ,%3_P#D3S.BO3/^&0/CS_T
M=$_\+32?_DJC_AD#X\_] '1/_"TTG_Y*H_UIX8_Z#J/_ (-A_P#)!_JGQ3_T
M 5O_  5/_P"1/,Z*],_X9 ^//_0!T3_PM-)_^2J/^&0/CS_T =$_\+32?_DJ
MC_6GAC_H.H_^#8?_ "0?ZI\4_P#0!6_\%3_^1/,Z*],_X9 ^//\ T =$_P#"
MTTG_ .2J/^&0/CS_ - '1/\ PM-)_P#DJC_6GAC_ *#J/_@V'_R0?ZI\4_\
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M  30?_$5T%% '/\ _"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\
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M/#__ ()H/_B*/^%3?"O_ *)IX?\ _!-!_P#$5T%% '/_ /"IOA7_ -$T\/\
M_@F@_P#B*/\ A4WPK_Z)IX?_ /!-!_\ $5T%% '/_P#"IOA7_P!$T\/_ /@F
M@_\ B*/^%3?"O_HFGA__ ,$T'_Q%=!10!S__  J;X5_]$T\/_P#@F@_^(H_X
M5-\*_P#HFGA__P $T'_Q%=!10!S_ /PJ;X5_]$T\/_\ @F@_^(H_X5-\*_\
MHFGA_P#\$T'_ ,17044 <_\ \*F^%?\ T33P_P#^":#_ .(H_P"%3?"O_HFG
MA_\ \$T'_P 17044 <__ ,*F^%?_ $33P_\ ^":#_P"(H_X5-\*_^B:>'_\
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M]F^WG_IV- &S\8/VXOC)\(-)^&&AZE^Q[?W/CSXEW^HVEOX'3QO8*]C):_.
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M/[2]W?7OA_1_"SW<'B_3]<M3%>:+>6N//M)HUS^]!*X5<EMZ@<G%/^,/QM^
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M+.O>)==T^]C^('Q-OO$NFI8E]UM;SJ@6.7>H^<;3G;D>]>S44 ?*_C3]F?\
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M$%WI4[)O0Y0E98I%!:.53M< D8Z5T/[/OQU\$?M+?![1?CA\-UO1HFO1RR6
MU&W$4VV.:2%MR!F ^:-L<],?2O"/@U\9O#O[:B^/_P!E?]JW]G.X\#^.O#\=
MI>>*/#UOK;^7J,'!M[N&\M&C=T!1 1N( *C<X+ >?_\ !,7X1?#'X?\ _!,B
MT^.&C^+I/ ^NZ]X,U-=<\<SW\]Q'IT<=W=!;I;>:4P(8PH8;57)7G.3D ^Z:
MXOXG_'GP-\)/&7@OP+XK6]-]X\UQ]*T/[+;AT$ZPM*3(2PV+M4\C//:OSQ^+
MZ_L[:1^S%J_Q<^ ?P?\ VA[[Q9H^A-J6C?':XBU.!+NZB42?;Y9+N[7?;R$$
MMB%E",=J\"O2_P!KOX*?"KXX_%;]F#XH^//"\\^J?$/6K:/Q.\&MWD*SQ'2&
ME"(L<RK#AOXHPK'N30!][T5\+?M=^+-/MOVJO 7["L?A/XAWWPR\-_#;_A(-
M;\,?#U;NYO=747!LK6WN94E$YM8_+W,?,^=W4,2<$;7[+DOB;X=_M@Z?X6^
MWP,^+/AKX3^)/#=T/$.D^.=)O$L-'U6']Y!<VSW$DAB\Y \3H&"EMAQG& #[
M/HK\SO$?_"J?!/C/QU+_ ,%,_A;\98O%$_BO4)M$^*6BRZI+H]CI9?-F;&2R
MFV6XC3#;#$2#]_)R@^\_V6]=T#Q)^SWX3U?PO\9Y?B'8/I");>,[A0)=45"4
M\R4 #$@*E7##?N5MWS9H [ZBBB@ HHHH *^'?^"S7_--_P#N,?\ MC7W%7P[
M_P %FO\ FF__ '&/_;&OEN-?^29K_P#;O_I<3Q\__P"134^7_I2/AVBBBOP0
M_-S[B_X(R_\ -2/^X/\ ^WU?<5?#O_!&7_FI'_<'_P#;ZON*OWO@K_DF:'_;
MW_I<C](R#_D4T_G_ .E,\O\ VR_VF+']C_\ 9R\0?M#:EX1EUV'06M ^EP7@
M@:;S[N&V&'*L%P90W0YVX[YKR_Q-^W#^UE\,M!NO'GQ?_P"":OBK2_#.EPM<
M:SJ>B^/M'U6>UMU&7E%M#('D"J"QP1@ DD"JO_!;'_E&C\1?^NNC_P#IWLZX
MC]K#]K?]O7PK\-[7P3X^_9:\(^ ++Q_J\/A./QM=^/O[5MM'EOE:(3RPP6RL
M %W8<G8&"[@0<'ZD]@^Q_AS\0?"7Q8\!:/\ $SP%JZ7^BZ]IT5]IEVBD>;#(
MH920>5.#@J<$$$'!%;5?!G[45MJ7[+_A']GC_@G?X,U/QM>>'=8@O5\87?@6
MTD.LZK9:?;I++;P")@\:SRRL9-C!DC4C<1G-GX;PW?PI_:=^'M]^R+^S9\9_
M"WA;5]1ETOXE:)XHT>__ +)>UDCQ!?@W,THBGAE"DNN-R%@>IR ?=5<O\:_B
M[X2^ GPHU[XR>.Q='1_#NGM>:@+&$23&-<9V*2 3STR*^'?C];>%/#?[4?Q#
MUO\ X*$_ _XK>*?#%W?0-\-O$WA1M1GT31],$"AHREC/&;>X\P%F9E9V()&!
M@M;^/GA#]GSXS?\ !)+Q/XS\'_&[6?BEIWA#3M2F\*>(]8U&YBO;!BZXM+I0
MT;3/$C*N+A22NTXP5H ^\_#VN67B;0+'Q)IH<6^H6<5S )5PVR1 ZY'.#@BK
ME>9?LC_!3X;?!'X):/I'PTT.>QM]5L+74;])]4N;HR7+VT2LX-Q(Y0$*ORJ0
MHQP!DUYE_P %"/&GC75?&OP?_93\(^,=2\.VWQ5\7SVWB36M&N3!=KI=G )Y
M[:&4<Q/-N5=Z\@ CD$B@#Z:KPSXL_M:_$71/V@V_9M^ /[/G_"=ZYIWAV+6O
M$MQ=^*XM)MM,MYI&CA0.\4IFE<HQV * N#NZX\@^-/PF\+?\$]/C/\'/B5^S
M?>ZUI.B>-OB38^"?&?A.X\07=]9ZDE\D@BN]ES+(4GA:(MO4@MG!R"V[(^$/
M['OP#3_@J-\1M(7P_K7D>'O"GA_6M*7_ (335=T=Z\\SL[M]JW3)N1?W4A:,
M#("@$@@'W317/_%GP)'\4/A=XC^&\FHS68U[0[K3Q>V\C));M-$R"5&7!5E+
M!@1R"!7YZ?$K]H+X^_%[]A#X2?#+X9^(;NR^)&A+JVH>+F6=VN ?"<,@EBEV
MD$M<7 L^IPQEYSR* /TKHKY,O_VC+7XS_M!^'OBUX-NKF?PK\./@9<^.[^SM
M+E@EQ?:K#BSMI@."RVT%TP!'!D!QGIRG[,/[&GAO]L#]EO2OVEOCC\0O%=W\
M3_'5E-J]GXPT[Q5>VK>'GD=S;16,$4JQ11PJ$^0J=QW9XP  ?;U>;?M!_M%6
M7P#UOX>Z+>>%9=3/C_Q[:>&(9([L1?8GGCE<3L"IW@>5C:,9W=>*^+?%7[0_
MQX_:*_8(_9H\:V?CR;1O&^O_ !RT_P -ZAX@MA@-,JZI9&[9%PLOW$G*$;"X
MQC Q7HG[2'[.GP[_ &93^SQX$^',NL3PWO[2FEZCJ=_KVM3W]W?7CV4Z23R2
M3,<,PB3*H%3()"@DY /M>O-OAM^T79?$7]HSXE_L]0^%9;6;X;P:))/JC78=
M;[^T;:6=0J;08]@CVG).[.>*\&T?X?Z!^W5^VK\6]$^.E_JFH>#OA3-IFB^%
M_"-KK-S9VINY[8SW-].+>1&EEW?)&2<*O;.#2_L%?#QOA3^WK^TSX!B\5:IK
M%KI]MX+73KK6KUKFZCMFL+MXX'F?+RB)6$:NY9RJ+N8G)(!]@T444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^6/_!R[
M_P T5_[F3_W%U^6-?U.45^L\,^*'^KN24LO^J<_)S>][3EOS2E+;D=K7MN?D
M'%'A3_K+GM;,OKGL_:<ON^SYK<L8QWYU>]K[+>Q_+'7ZG?\ !M%_S6K_ +EO
M_P!RE?J=11Q-XH?ZQ9)5R_ZIR<_+[WM.:W+*,MN17O:VX<+^%/\ JUGM',OK
MGM/9\WN^SY;\T91WYW:U[[/:P5Q'[2/P)\*_M-? SQ+\"/&EQ-!IWB333;27
M-N 9+>0,KQ3*#P2DB(X!X.W!ZUV]%?DQ^OGR0WP _P""IGB#X;M^SQXL_:'^
M%</AF?3O[*O/'.G:!?MXAFL2GEL?)=Q;).R9!<'@G(^8;J[WXP_L9_\ "0_#
MKX(_"WX3ZG::=I/PC^(OA_6@FIN[/<6&FPS1&-2BG=,PD4Y; )W$D5[U10!Y
M'^U!^SUXF^.GBSX5>(/#VMV%G%X"^)%KXCU)+TONN((H9HS''M4_.3("-V!@
M'FCX7_L]>)O O[77Q4_:&U'6[";3/'FEZ#:Z=90E_/MVL8)8Y#)E0N&,@*[2
M> <XKURB@#YC^ 7[('QJ^%?A3Q-^ROXUOO!6O?!C7)=;$$J/=PZZEMJ#RR&W
M=-A@.UIG'F!@2,$ $8K*\)_LW_\ !1[X<_"R']F+P/\ M!_#U?"%A8C2M%\>
MW>DWO_"2:?IH79&JP(PMGGCCPB2;U^Z"1GD?6-% '@'Q\_8^\;>*;#X9^/\
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MLH@2XNKB=YI3'$I(BC#.55 3A5&<G)KU&B@ HHHH **** "OAW_@LU_S3?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biib-20230930_g8.jpg
<TEXT>
begin 644 biib-20230930_g8.jpg
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M&R^_9Y_9^^ FJ_$CQ/H.G07WBU;36;;3K/18IP6@CEN+@[6GD4;UB R5^;(
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M5/#MA<ZEI(F&EZA<6B//9B50LOE2$;H]Z@!MI&X  YJ_2,RHI=V  &22> *
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MGU/[JMG2_@U\(-#T6W\-Z+\*?#5GIUKJ::E:V%KH5O'##>IC;<HBH%688&)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQUG_ &L/'/["ES^U9X^F\!Z5H-AXGMM=FUOS/$B+<;HCIRZBREU@,BF3> )
M(U0, [D^UZQ\"?B!=_M_^'/VAXE@E\-Z7\*[S0+NYEN%$[7DE]',O[L 9!12
M2PP >,4[P9\#/'NB?M[>-OVA+^WM1X<UWP!I>D6$JW(,QN8)Y7D#)U5<.,'O
M0!\[ZGXJ^).B_LT_MB?LP^/?B7J_C"T^&OA^X3P[KWB*<3:BUE?:.]RL$\V
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MQ)L_ /@?P!I>L_!Z&VCDUO0[;QS_ &)>>(IR,M!<SB*1UM1P#%&%,@)R_3:
M1Z+KEI^VS_P4+\&_&;X01?:/ 'P/L-9M;KQK$N+?7M6OX%MWL[5_^6\4"#>T
MBY7<2!D,I;0_X)6R-XBTOXW?$C6EWZYK/Q[U^+4Y7'[R..W\F."W)Z[8T)"C
ML&-=I\ O$G[6VA:OH7PV\0_L7>"_ _@FSA:W:X\/_$)+D:="L;&-8K5+.,,"
MX5<!AC<6YQ@\U<_"#]IG]E'XW^-?B1^R]\-=&\?>$/B1J@UG6_!M]XD72+K2
M=9*!)[J":2-XY8IPJLZ-A@P&W@8(!BZ/HMA8?\%@O'?@"UM"='\>?L_6NI^*
M(()&0374.H&QC9BA!#?9V900=V#D$5ZWXW\??LY?\$]?V>;#3W@31?#FB0"P
M\+^'+%GGO-0G))CM+9&8R7$SNW<DY8L[ 9:N7^ /P'^./A7Q)\1/VL?BY8Z'
M<_%+QGIB6VC>&]/OG?3]%LK6-C::<+AE5I"\I#S2A0I8_* !SXG\*OA%_P %
M#O#_ ,6;G]H?XZ?LJ^$?B)X^9Y$T?5]1^**6UGX?M6/%OIUF+.1;88X:0L\K
M\DO\S @'KO[ 7[,.J^%/V7=6T']H[X>:6]W\0O&.H^+-9\&:E:1W5KIGVN5)
M(K-HW4H3&L<;$8^5R1U7-<1_P40^+_[7<_P@\<_#-OV2I-.^'VH07.G:Y\2;
M'Q#;:O/9Z,P*37JZ4GE2D^46;'F?NQECG;7K7BCP]^UY\?OV=M4TN^DM/@Y\
M0(-72?P_/HGB'^UK:5(?+D07#B&,^5*WF1O&%)"@-\V=AXCQ[XH_X*=_%/X>
MZE\%U_9A\ ^&]0UG39=.O_'S_$,W6GP)*ACDGALA;"<MM9BB.Q .W=N&10![
MC^S7'\.K?]GGP-8?"'Q(=8\+6GA+3[;P]JC,2UU9Q6Z1Q.V0"&*J-P(!#9!
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MS$(H +')./4]Z=3+=IGMT>YB"2% 9$5MP5L<C/?ZT^@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#"\/_  S\!>%?&GB#XB^'O"]K::WXJ:U;Q%J42D27
MYMHO)@,ASSLC^48[5NT44 %%%% !1110 4444 %%%% !1110 4444 %07NF:
M;J30/J.GP3FVG$UL9H@YBD (#KD?*P!(R.>3ZU/10 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !45Y
M/);6KSPVS3,JY6).K>PJ6B@#'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB
M@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\
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M?%WB7P)\*]877-5\'W2VWB2ULF)^Q2L\B!68@*QW12#Y2>4-8_QB_;T_9X^
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M%"]_[Z6MBB@#'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\
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MI.#P<&OM"TN[34+2*_L+J.>">-9(9H7#)(A&0RD<$$$$$=: )**** "BBB@
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MPPH%2- ,!5 X     Z5)10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'Q1_P %E/\ D!> /^OO4O\
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M_P#2Y'Z-P_\ \BJG\_S84445]6>T%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!\4?\ !93_ ) 7@#_K[U+_ -!MJ^$J^[?^
M"RG_ " O '_7WJ7_ *#;5\)5^#<;?\E+6_[=_P#2(GYQQ!_R-JGR_P#24%=+
M\(M5^&>D>/;*Y^,'AFZU7P\XDBU"WL;AHIXPZ%5FC((!9&(<*QVMMP>M<U17
MR]*HZ51323L[ZJZ^:>Z/(A)PFI+IW/KZPTO]G7X5_#?X7?$23]H:YO='\+^+
M=8U/24T[P[<1WNK2!K)S:X;"PE2BJ[,VTB3Y2><>=_ SPC\$_CM\3?%GQ@^-
MWC_0-"MWU>>_LO"NHZO]B74)IY'E$33!6:.!20K,B,QSQBO"I+^^FM(M/FO)
M7MX&9H8&D)2,MC<57H"<#..N!Z5%7M5,ZA4K4VZ$>2-O=]ZS:BHW=V]%;1;=
M[ZG?+'QE.+]FN56TULVDEU;VMHOON?1GQ[\#>)_BDK:YKW[4WP=&FZ)92#0O
M"F@>(ITM[*%5R(+:'[,!O; &2<L<9.,8Y#X%^%M%U;PFVL?#W]I1/ ?CBWO7
M2Y@U?69-,M;NS(4HT-U&.'#;@R.>>",8Y\BHKGJ9E3J8OV[IZO?WI7\FG>Z:
MZ=.EK&4L5&=;VCAKUU?Y]+'NWQ:\;^'?AO\ !34?@]IWQ4A\;>*_&&L6]_XU
M\0V-W)<VT<%L";>U2>0 W#;V+LXX'W>>M9?[.?B_PIX%^"_Q>UB^U^SM=>U#
MPQ;:1HMI-,%FNHKFXVW(C'5MJ(I;'0=:\=HJ7FE7ZTJRBERQ<8K71-25[O5N
M\G*_\WEH#QD_;*HELFDNUT_QN[^H 9.":[/X[_#?P3\*_'7_  BW@#XLV/C.
MP^QQS?VSI]NL4>]BV8]JR2#*X'\7?I7&45PQG35*47&[=K/6ZM>ZMMKINNFG
M4YE**@TUKIKV_34]B^,WB_PHO[+GPI^&OA37[2YN+;^U-2\16]M,&>*ZEG41
M"4#[K",$#/:O':**TQ6)EBJJFU:RC&WE&*C^E_4JM5=:?,U;1+[DE^@4445S
M&1[-_P $]_\ D\7P3_U]W/\ Z1SU^KU?E#_P3W_Y/%\$_P#7W<_^D<]?J]7[
M)X=?\B>K_P!?'_Z3$^[X6_W&?^)_D@HHHK] /I0HHHH **** "BBB@ HHHH
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M.^/_ /KTTW_T*YK[MKX2_P""-?\ R'?'_P#UZ:;_ .A7-?=M?O/!/_)-4?\
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MHHHKY0\8**** "BBB@ HHHH **** "BBB@ HHHH ]F_X)[_\GB^"?^ONY_\
M2.>OU>K\H?\ @GO_ ,GB^"?^ONY_](YZ_5ZOV3PZ_P"1/5_Z^/\ ])B?=\+?
M[C/_ !/\D%%%%?H!]*%%%% !1110 4444 %%%% !1110 4444 %%%% 'Y;_\
M%,_^3Q?$G_7I8?\ I'%7@=>^?\%,_P#D\7Q)_P!>EA_Z1Q5X'7\Y9_\ \CS$
M_P#7R?\ Z4S\LS+_ )&-;_$_S"BBBO(.(**** "BBB@ HHHH **** "BBB@
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M%KIWF>='NS\UQC'ZU]P_8O&__0;LO_ 8_P"-?O/!/_)-4?\ M[_TN1^C</\
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M1Q5X'7\Y9_\ \CS$_P#7R?\ Z4S\LS+_ )&-;_$_S"BBBO(.(**** "BBB@
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M3\XX@_Y&U3Y?^DH****^4/&"BBB@ HHHH **** "BBB@ HHHH **** /9O\
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MW_T./_E/N/\ XW1_PT5\&_\ H<?_ "GW'_QNOEVBC_B5CP^_Z"L5_P"!TO\
MY0'_ !$'.O\ GW3^Z7_R9]1?\-%?!O\ Z''_ ,I]Q_\ &Z/^&BO@W_T./_E/
MN/\ XW7R[11_Q*QX??\ 05BO_ Z7_P H#_B(.=?\^Z?W2_\ DSZB_P"&BO@W
M_P!#C_Y3[C_XW1_PT5\&_P#H<?\ RGW'_P ;KY=HH_XE8\/O^@K%?^!TO_E
M?\1!SK_GW3^Z7_R9]1?\-%?!O_H<?_*?<?\ QNC_ (:*^#?_ $./_E/N/_C=
M?+M%'_$K'A]_T%8K_P #I?\ R@/^(@YU_P ^Z?W2_P#DSZB_X:*^#?\ T./_
M )3[C_XW1_PT5\&_^AQ_\I]Q_P#&Z^7:*/\ B5CP^_Z"L5_X'2_^4!_Q$'.O
M^?=/[I?_ "9^BG_!-CXV?#'Q1^VYX#T'0O$WGW=Q>W0AB^Q3+N(LIR>60 <
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M3^NO"S_DAL+ZU/\ TY,****^!/T(**** "BBB@ HHHH **** "BBB@ HHHH
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MOU_*/B=_R6N)](?^FXG]=>%G_)#87UJ?^G)A1117P)^A!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?F%_P<J?\BI\(O^PC
MK7_HNSK\H*_5_P#X.5/^14^$7_81UK_T79U^4%?U=X8_\D5AO6?_ *<D?R+X
MI_\ )<XKTI_^FX!1117WQ^>A1110 4444 %%%% !1110 4444 %%%% 'TM_P
M1[_Y21?"_P#["-[_ .FZZK^@:OY^?^"/?_*2+X7_ /81O?\ TW75?T#5_-_C
M)_R4=#_KTO\ TN9_37@K_P DU7_Z_/\ ](@%%%%?D9^Q!1110 4444 %%%%
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M)W_):XGTA_Z;B?UUX6?\D-A?6I_Z<F%%%%? GZ$%%%% !1110 4444 %%%%
M!1110 4444 %%%9WB[Q=X;\!^&[SQAXPU>*PTRPB\V\O)\[(DR!DXR>I% &C
M17DO_#=W[(?_ $7C1/\ OJ3_ .(H_P"&[OV0_P#HO&B?]]2?_$4 >M45Y+_P
MW=^R'_T7C1/^^I/_ (BC_AN[]D/_ *+QHG_?4G_Q% 'K5%>2_P##=W[(?_1>
M-$_[ZD_^(H_X;N_9#_Z+QHG_ 'U)_P#$4 >M45Y+_P -W?LA_P#1>-$_[ZD_
M^(H_X;N_9#_Z+QHG_?4G_P 10!\.?\'*G_(J?"+_ +".M?\ HNSK\H*_5/\
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MX9 ^//\ T =$_P#"TTG_ .2J/]:>&/\ H.H_^#8?_)!_JGQ3_P! %;_P5/\
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M%_\ V$;W_P!-UU7] U?A!_P3<^$/C3X!_MM> _B[\6GT32?#NBWMU)J6H?\
M"4Z?/Y*O93QJ?+AG=VR[J/E4]<],FOV%_P"&[OV0_P#HO&B?]]2?_$5^ >*^
M88#,<^HU,)5C4BJ23<9*2OSS=KIO75:']$>$679AEO#U:GC*,J<G5;2G%Q;7
M)!7LTG:Z>OD>M45Y+_PW=^R'_P!%XT3_ +ZD_P#B*/\ AN[]D/\ Z+QHG_?4
MG_Q%?EY^JGK5%>2_\-W?LA_]%XT3_OJ3_P"(H_X;N_9#_P"B\:)_WU)_\10!
MZU17DO\ PW=^R'_T7C1/^^I/_B*/^&[OV0_^B\:)_P!]2?\ Q% 'K5%>2_\
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M]]2?_$5\2?='K5%>2_\ #=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU)_\
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M%?\ T33P_P#^":#_ .(KH** .?\ ^%3?"O\ Z)IX?_\ !-!_\11_PJ;X5_\
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MT'_Q%'_"IOA7_P!$T\/_ /@F@_\ B*Z"B@#G_P#A4WPK_P"B:>'_ /P30?\
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M,ES=R22")+6.+@F<S'RMAQM<'<0%)'J5M:VUG:QV5G;I%#%&$BBC4!44# 4
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M@[2M):^D$EZVF:?% ;AQG#/L4;SR>3GJ: /G/P=\'O\ @IC\#_"MO\(OA?\
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MN\3?L0^.? OB'P=XL\37/B"[\!>/8)X9;*]N"#<"UN8.JLRC D*JH &"068
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MYTF\2PT?58?WD%S;/<22&+SD#Q.@8*6V'&<8 /L^BOS.\1_\*I\$^,_'4O\
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M+*QDV,&2-2-Q&<V?AO#=_"G]IWX>WW[(O[-GQG\+>%M7U&72_B5HGBC1[_\
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M\7M'Q%I+:?H_@+P$UTFC0;G#/=SO<$/=7!QM4E55%S@$G(]HHH ^;--^%?\
MP4A^%)U'P5\-/C+\._&GAR>]N)M'U?XF0:B=8T^*5V<02M;$I>+'NVJ6,9(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>biib-20230930_g9.jpg
<TEXT>
begin 644 biib-20230930_g9.jpg
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M!'C?PA^V!XO_ ."<WAW1[D>#_P!H#QCIGC%;J#Y8['3@7EUZ/<.C2M9J@48
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M&8==IGC?P7\,?^"L'CN;XC^+M,T&/7/A%HSZ/+K%_';)>".\G201M(0&*MU
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MQ U^#2]$T6RDN]3U"Y)V00H,LQ !)/8  DD@ $D"OGM?^"H7@2VT"+XD:_\
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MYJE[\(?V?OBK\1/#FB7<EMJ7C'P5X52XTTR1G$H@>2:-[K80=QB1A@9!8$4
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MW\-W9WEND]I=6\@>.:)U#*ZL.&4@@@CJ#5B@ KEO&'P-^"?Q#U?_ (2#Q_\
M![PMKE_Y2Q?;M8\/VUS-L&<+OD0MM&3@9P,FNIHH Y3PK\!O@;X%U)]9\$?!
MGPIHUY) T#W6E>';:WD:)L;D+1H"5.!D=#BMO2?"7A30/#B>#M"\,Z?9:1%
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M"%O/KL31ZY-!X:M4?448Y99R(\S GDA\@FNM@@@M8$MK:%(XXT"QQHH"JH&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&4MH?\$K9&\1:7\;OB1K2[]<UGX]Z_%J<KC]Y'';^3'!;D]=L:$A1V#&NT^
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MC/3$MM&\-Z??.^GZ+96L;&TTX7#*K2%Y2'FE"A2Q^4 #GQ/X5?"+_@H=X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\
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MGXBM_!G@;P]XSTRT\,^&M!O?-O/$(;4H8A?7\XP(X=A+QVR<[F#2'**#]]T
M8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UG_ !I\)_$#QW\*M<\'?"WX
MC#PCK^I6+0:;XD.G?:S8,Q ,BQ%TRVW<%.[Y6(;!VX/Q1^UA^S)^P-\ ?@9X
M@UKP=\5;NV^,^CZ?(?#?B*R\?W-SXIU+7E7,*-$LY>5Y9MJO&(]JJ[$!,9 !
M]S_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+7CWB+X/?'3]I/]E_X=^%_B=\6M
M2\#:A<:9IEW\58-&A\B\U("U5KJQ6X1U-F&E)WL@8X!0$ G/S?\ '#X;?LQ?
M ?XD?#2^_P"";?BB"'XF7WCNPMK_ ,/>#O%DVI1:KH[$_:VU*+SI5$*H 3/)
M@@\[B0"H!]X_\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+7(?M2_M 6O[.OPLD\
M4V6C-K'B+5+R+2?!GAR)L2:QJTYVV]LOHN<N[?PQH[=J^:_^"?/P\\:_"?\
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M@_$KP-K/P[\4P/+IFNZ7<:?J$<;[6:&:-HWVGL=K'!['FI/!GA/1O 7A#2_
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M[IW_ ,CT?\/(OVT?^BS?^6[IW_R/1_Q$7)/^?=3[H_\ R8?ZT9?_ "R^Y?\
MR1^J=%?GS^QS^W!^U%\5?VE/"_@#Q[\3_M^D:C<3K>6G]BV47F!;:5P-T<*L
M/F53P1TK]!J^FR7.\+GN&E7P\9))\OO))WLGT;[GK8#,*.8TG4III)VUMY/H
MWW"BBBO8.X**** "BBB@ HHHH **** "BBB@ HHHH **** "BORW_P""F?\
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M117U9[04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M--_]"N:^[:_>>"?^2:H_]O?^ER/T;A__ )%5/Y_FPHHHKZL]H**** "BBB@
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M/\D%%%%?H!]*%%%% !1110 4444 %%%% !1110 4444 %%%% 'Y;_P#!3/\
MY/%\2?\ 7I8?^D<5>!U[Y_P4S_Y/%\2?]>EA_P"D<5>!U_.6?_\ (\Q/_7R?
M_I3/RS,O^1C6_P 3_,****\@X@HHHH **** "BBB@ HHHH **** "BBB@#[7
M_P""-?\ R'?'_P#UZ:;_ .A7-?=M?"7_  1K_P"0[X__ .O33?\ T*YK[MK]
MYX)_Y)JC_P!O?^ER/T;A_P#Y%5/Y_FPHHHKZL]H**** "BBB@ HHHH ****
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MBB@ HHHH **** "BBB@#[7_X(U_\AWQ__P!>FF_^A7-?=M?"7_!&O_D.^/\
M_KTTW_T*YK[MK]YX)_Y)JC_V]_Z7(_1N'_\ D54_G^;"BBBOJSV@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /BC_@LI_R
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M5X'7\Y9__P CS$_]?)_^E,_+,R_Y&-;_ !/\PHHHKR#B"BBB@ HHHH ****
M"BBB@ HHHH **** /M?_ ((U_P#(=\?_ /7IIO\ Z%<U]VU\)?\ !&O_ )#O
MC_\ Z]--_P#0KFONVOWG@G_DFJ/_ &]_Z7(_1N'_ /D54_G^;"BBBOJSV@HH
MHH **** "BBB@ HHHH **** "BBB@ HHJ*\GDMK5YX;9IF5<K$G5O84 2T5C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
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MT%8K_P #I?\ R@^,_P"(@YU_S[I_=+_Y,^HO^&BO@W_T./\ Y3[C_P"-T?\
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M^)OB#P]XM\6:N=<T;7_].UBWN/[/8J]I>8-S(JQ/YUL1)CS$&&W@5\3?LO\
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M6]OB:BKMZ))N\GT5WT/+RO+YYICHX:#LW=[7?NQ<FDEJY-*T4MW9=3YT\<>
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MH04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P EKB?2'_IN)_77A9_R0V%]:G_IR84445\"?H04444 %%%% !1110 4444
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M,Z*],_X9 ^//_0!T3_PM-)_^2J/^&0/CS_T =$_\+32?_DJC_6GAC_H.H_\
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MI/\ \E5[O^M/#'_0=1_\&P_^2/ _U3XI_P"@"M_X*G_\B>9T5Z9_PR!\>?\
MH Z)_P"%II/_ ,E4?\,@?'G_ * .B?\ A::3_P#)5'^M/#'_ $'4?_!L/_D@
M_P!4^*?^@"M_X*G_ /(GF=%>F?\ #('QY_Z .B?^%II/_P E4?\ #('QY_Z
M.B?^%II/_P E4?ZT\,?]!U'_ ,&P_P#D@_U3XI_Z *W_ (*G_P#(GF=%>F?\
M,@?'G_H Z)_X6FD__)5'_#('QY_Z .B?^%II/_R51_K3PQ_T'4?_  ;#_P"2
M#_5/BG_H K?^"I__ ")YG17IG_#('QY_Z .B?^%II/\ \E4?\,@?'G_H Z)_
MX6FD_P#R51_K3PQ_T'4?_!L/_D@_U3XI_P"@"M_X*G_\B>9T5Z9_PR!\>?\
MH Z)_P"%II/_ ,E4?\,@?'G_ * .B?\ A::3_P#)5'^M/#'_ $'4?_!L/_D@
M_P!4^*?^@"M_X*G_ /(GF=%>F?\ #('QY_Z .B?^%II/_P E4?\ #('QY_Z
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M$T\/_P#@F@_^(KH** .?_P"%3?"O_HFGA_\ \$T'_P 11_PJ;X5_]$T\/_\
M@F@_^(KH** .?_X5-\*_^B:>'_\ P30?_$4?\*F^%?\ T33P_P#^":#_ .(K
MH** .?\ ^%3?"O\ Z)IX?_\ !-!_\11_PJ;X5_\ 1-/#_P#X)H/_ (BN@HH
MY_\ X5-\*_\ HFGA_P#\$T'_ ,11_P *F^%?_1-/#_\ X)H/_B*Z"B@#G_\
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M** .?_X5-\*_^B:>'_\ P30?_$4?\*F^%?\ T33P_P#^":#_ .(KH** .?\
M^%3?"O\ Z)IX?_\ !-!_\11_PJ;X5_\ 1-/#_P#X)H/_ (BN@HH Y_\ X5-\
M*_\ HFGA_P#\$T'_ ,11_P *F^%?_1-/#_\ X)H/_B*Z"B@#G_\ A4WPK_Z)
MIX?_ /!-!_\ $4?\*F^%?_1-/#__ ()H/_B*Z"B@#G_^%3?"O_HFGA__ ,$T
M'_Q%'_"IOA7_ -$T\/\ _@F@_P#B*Z"B@#G_ /A4WPK_ .B:>'__  30?_$4
M?\*F^%?_ $33P_\ ^":#_P"(KH** .?_ .%3?"O_ *)IX?\ _!-!_P#$4?\
M"IOA7_T33P__ .":#_XBN@HH Y__ (5-\*_^B:>'_P#P30?_ !%'_"IOA7_T
M33P__P"":#_XBN@HH Y__A4WPK_Z)IX?_P#!-!_\11_PJ;X5_P#1-/#_ /X)
MH/\ XBN@HH Y_P#X5-\*_P#HFGA__P $T'_Q%'_"IOA7_P!$T\/_ /@F@_\
MB*Z"B@#G_P#A4WPK_P"B:>'_ /P30?\ Q%'_  J;X5_]$T\/_P#@F@_^(KH*
M* .?_P"%3?"O_HFGA_\ \$T'_P 11_PJ;X5_]$T\/_\ @F@_^(KH** .?_X5
M-\*_^B:>'_\ P30?_$4?\*F^%?\ T33P_P#^":#_ .(KH** .?\ ^%3?"O\
MZ)IX?_\ !-!_\16MH^AZ)X>LAIV@:/:V-N&+""SMUB0$]3M4 9JU10 4444
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MM\//B-X?T^/4;SPOJM[%=QW5@[A!=VEU#\EQ$'(1B I#$#&<X[?Q//\  O\
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MXNV^L+",ZC=KOBEMO()C^R/&A\H Y^5CT() /JVBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH JZW<ZI9Z-=W>AZ8E[>Q6LCV
M=E)<>2MQ*%)2,R8;8&; W8.,YP<8KS7]D+]JCPW^UM\*Y?'NE^'+G0-5TS5[
MG2?$WA?4)0]SH]_ Y5X)2 ,G&U@<#AL<$$#U2O@/]N+X9?%WX&_M9V3?LR>+
M;70;7]I]%\*^+5D##^S=0C*;M6@5<?OC:/,HQCYRS'+," #W2T_;2^,/Q(T?
M6O%W[,G[(]]\0=!TWQ;<:)I^JQ>-;'35U);==L]Y$+H*K0"?="C*S%RC-\H%
M<;\,/^"B/[5?QBU7Q)HWP]_X)PZK?S^$/$4NA^)%_P"%I:1%]COH@#)%F3:)
M,!A\R;E/8FOIOX5_#/P?\&?AQHGPI^'^EK9:-X?TV*QTZW'41QJ "Q_B8G+,
MW5F))Y-?.?\ P32_Y*-^TM_V<%J__HN*@#8^(G[<GQFT_P#:6\5_LU_ K]CJ
M_P#B!?>#]/L+S5K^#QQ8:8JI=Q"2/"W87/\ $ORL?NY.,BNA^!?[;5A\1_BL
M_P"SU\8_@]X@^&7Q!^P-?6/AWQ%+!/#JMLN=\EG=P,T=QLP=RC! !(!"MMX;
M]G[_ )2P?M!_]BAX5_\ 29JA_P""F:6^G_$_]FGQ+X?POBF+X]:79V#1\2'3
M9TD6_7/7RRJPA_:@#ZQKRKX+_M06OQA^/?Q5^!:>"+C39/A=>Z9;SZI-=ATU
M'[9!),&5-@\O:$&<EL[@>*]5KGM"^%/@#PWXK\3^-M(\.0QZEXREMY/$EPS,
MXO3!;K;Q;E8E0!$H7  !YSDDT >"6'[?'Q@^+4^I^(OV2/V,M7^(G@W2K^:S
M/B^X\7V>CQ:G)"Q64V$4ZLUT@8%0Y**Q! .17=_"_P#;@^!_Q(_9RUG]I>[O
MKWP_H_A9[N#Q?I^N6IBO-%O+7'GVDT:Y_>@E<*N2V]0.3BG_ !A^-OP#_86^
M%6G:#I_AN&V,SO:>"?A]X4L!]KU6Z9BPMK.VC'0N_+ !$W9)&0#QW[&W[(U]
MH_P&\86?[5?@W1M3UGXM^,;WQ7XS\+7,"75E92W+H\=GA@5D\H1H=W.),X)V
MJQ ,6X_X*"?M"67@8_'F^_X)Z^+H_AHMK]O?6_\ A*K$ZPFG8W?:VTK[X79\
MY7S=P7D\<U]'_#GXA>$/BSX"T?XF> =834-%UW3HKW3+R,$"6&10RD@\J<'!
M4X((((!%>)_MI_M+CP_I-U^RG\!M&'BGXL>,-(EL])\.V1!CT>WF0QMJ-^X^
M6VMXU?<-^#(=JJ""2/2/V6O@=;?LU_L\>$/@5;:K]N/AK1(K2>]VX$\W+2R
M'[JM(SD#L"!VH [ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "O,_VQ_@EK_[1_P"S%XS^!WA;
M5K.QU#Q+I!M+6[U OY,3%U;+[ 6Q\IZ UZ910!B_#?PS=^"_AWH'@Z_N(Y9]
M)T6ULII8<['>*%4++D X)4D9KS/6/V;?%6H_M[Z/^UE%KNGKHNG?#*?PU+IK
M%_M37#WIN!(/EV;-O'WLY[5[-10!\]_MK?LU?'KXR?$CX5_%W]GOQ)X0L=:^
M&^K:A>I#XRBNGM;@W$"0@%;;#G #'[R\XY/(KD_&/[(G[9W[5UQ8^#_VTOC=
MX(M_A_;W\-WJ_@SX9Z+=PC7C$X>.&YN+N1I$AWJ&94^]@="%9?K"B@!EM;6]
MG;QVEI D442!(HHU"JB@8  '  ':GT44 ?''[2'['G[<WQC_ &G%^+L'C3X3
M>(?".@SK)X(\%>.[34Y;+3I0J_Z7+;VIC2>YSOP\K2!0WRA<#'LGP5L/V]Y?
M%TL'[3.K?"&;PU)I\J;/ EEJT%_YY*A#ON9F0)C?G W9VX(KV.B@#Y>\(? ?
M_@H3^SGILWPV^ 'Q?^'GC#PC'=SS:'-\58M2.K:;'*[2>0\]JS"\568X=]CX
M.,@  =S^R'^RMKGP N_&7Q*^)OQ 3Q5X_P#B-J\6H>+M:MK+[-;#R4,=O:V\
M66*PPHS*I8ECGG' 'M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %>,_M-?LV>*OC?\ %[X/_$3P_KNGVEK\.O&,FL:I
M!>%_,N8FA\L)%M4C=GGYB![U[-10 5XS^R9^S;XJ_9_\5?%G7O$NNZ?>Q_$#
MXFWWB734L2^ZVMYU0+'+O4?.-ISMR/>O9J* /E?QI^S/^VQX-_;"\=_M+?LS
M^+?A8MGXWTG2K*XL?'5IJ4TL(LX0F5%HR 98L>6;C' YK:^$/['WQGUWX]Z;
M^U!^V=\7M)\6>(_#=G/;>"O#OAG27M-'T$SC;-<()6:2:9U^7>_W1_>PFSZ.
MHH *KZLNJ-I5RNB/ MZ;=Q9M<@F,2[3L+@<E=V,XYQ5BB@#X<^%7['?_  4Q
M^&7Q1UCXYZIXY^!/B_QOK!,;^*_%^GZU<75E:GI9VJQ/%%:P#)^2)%+9.XMQ
M7N=WX=_X*$>(OV=_%7AW6/'WPOT;XD7DL<?A36_#6G7XT^R@+1>:\J71E=I@
MGG;" 5#&/*G!KW"B@#XK_9X_94_X*2_LS>'[O2OA]J?[/-UJ.K7)N?$7BC7+
M#Q!=:KK5R<DS75P9P9&R3@ !%R=JKDU]:_"]/B@G@+35^-$^@2^*!"W]KOX7
MBG2P,F]L>2L[-(%V[<[B3G/;%;]% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'Y8_P#!R[_S17_N9/\ W%U^6-?J=_P<
MN_\ -%?^YD_]Q=?EC7]8^&?_ "1&$_[B?^G9G\A>*/\ R76+_P"X?_IJ 5^I
MW_!M%_S6K_N6_P#W*5^6-?J=_P &T7_-:O\ N6__ '*4>)G_ "1&+_[A_P#I
MV >%W_)=83_N)_Z:F?J=7F7[8W[25C^R'^SAXC_:(U'PG+KD/AX6F_2H+L0-
M/Y]Y#;#$A5@N#,&Z'.W'?->FU\M_\%I03_P3.^)>!_#H_P#Z>+&OY./Z]/I/
M7O$":'X3O?%3VID6STZ2[,(?!8)&7VY[9QC-<W^SC\9;7]H?X%>%?C?9:!)I
M<7BC1XK^/3I;@2M;AQG87"J&QZX%:'Q 8?\ "G];;/'_  C5R<_]N[5\&>)9
M_'G_  [9_8_T'X=>-[WPYJ>M_$OPKIJ:M9/AX%GMKY"^T_+(%R'","I*+D&@
M#]&*Y+PSX]\<:U\6_$_@+6/A->Z9H>BVUG)H_BR:^C>#67FC+2QQQ ;HS$WR
MDL3DG(KY>^+7P*\(?L4_M"?!+Q[\!]>\3V=UXT^(<?AGQK'JGBJ]U"/7[>XM
M9G\ZY6YE<&99(PZNH7!)XQ@#?\%^$='^-7[=_P"TG\'OB7)?ZCX;F\.^#<Z4
MNK7$"1_N)Y28VAD1HB71"2A&[&#D<4 >]_ #X\^!OVD_AK!\5OARMZ-*N;^[
MM(O[0MQ%*9+:XDMY#M#-QOC;'/(P>.E=I7Y\?L#Z%\//V7/^";WB[]LCP;X3
ME?Q=I>D^*46:?5;N6&9;?4+CR(V@:4Q*-T,.YU4.0IR3DYYCP9X5\-^-/V<K
M7XC:Q\(/VD]5^-&M>'EU:#XHV.EZCF/598?-B-OY=P(?L:NRHL8C"-$.@)R
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M  5&^(VD+X?UKR/#WA3P_K6E+_PFFJ[H[UYYG9W;[5NF3<B_NI"T8&0% )!
M/NFBN?\ BSX$C^*'PN\1_#>349K,:]H=UIXO;>1DDMVFB9!*C+@JRE@P(Y!
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MO!:Z==:U>M<W4=LUA=O' \SY>41*PC5W+.51=S$Y) /L&BBB@ HHHH ****
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M5^XE%?!?\0U_ZBO_ "3_ .W/F_\ 5/\ Z??^2_\ VQ\._P#!&7_FI'_<'_\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283167456656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 07, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,898,112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283166022272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,530.3<span></span>
</td>
<td class="nump">$ 2,508.5<span></span>
</td>
<td class="nump">$ 7,449.3<span></span>
</td>
<td class="nump">$ 7,629.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">659.6<span></span>
</td>
<td class="nump">469.5<span></span>
</td>
<td class="nump">1,915.1<span></span>
</td>
<td class="nump">1,707.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">736.3<span></span>
</td>
<td class="nump">549.2<span></span>
</td>
<td class="nump">1,891.1<span></span>
</td>
<td class="nump">1,629.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">788.2<span></span>
</td>
<td class="nump">563.3<span></span>
</td>
<td class="nump">1,941.2<span></span>
</td>
<td class="nump">1,770.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">60.9<span></span>
</td>
<td class="nump">56.5<span></span>
</td>
<td class="nump">164.0<span></span>
</td>
<td class="nump">190.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="nump">50.5<span></span>
</td>
<td class="nump">45.3<span></span>
</td>
<td class="nump">164.5<span></span>
</td>
<td class="num">(42.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(13.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">76.0<span></span>
</td>
<td class="nump">15.4<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
<td class="nump">124.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of building</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">503.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">503.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense, net</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="num">(56.0)<span></span>
</td>
<td class="nump">248.2<span></span>
</td>
<td class="num">(221.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expense</a></td>
<td class="nump">2,671.5<span></span>
</td>
<td class="nump">1,137.4<span></span>
</td>
<td class="nump">6,444.1<span></span>
</td>
<td class="nump">4,641.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income tax (benefit) expense and equity in loss of investee, net of tax</a></td>
<td class="num">(141.2)<span></span>
</td>
<td class="nump">1,371.1<span></span>
</td>
<td class="nump">1,005.2<span></span>
</td>
<td class="nump">2,988.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(72.9)<span></span>
</td>
<td class="nump">236.2<span></span>
</td>
<td class="nump">92.6<span></span>
</td>
<td class="nump">578.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax', window );">Equity in (income) loss of investee, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(68.3)<span></span>
</td>
<td class="nump">1,134.9<span></span>
</td>
<td class="nump">912.6<span></span>
</td>
<td class="nump">2,412.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="num">(84.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Biogen Inc.</a></td>
<td class="num">$ (68.1)<span></span>
</td>
<td class="nump">$ 1,134.7<span></span>
</td>
<td class="nump">$ 911.4<span></span>
</td>
<td class="nump">$ 2,496.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings (loss) per share attributable to Biogen Inc.</a></td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="nump">$ 7.86<span></span>
</td>
<td class="nump">$ 6.30<span></span>
</td>
<td class="nump">$ 17.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings (loss) per share attributable to Biogen Inc.</a></td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="nump">$ 7.84<span></span>
</td>
<td class="nump">$ 6.26<span></span>
</td>
<td class="nump">$ 17.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings (loss) per share attributable to Biogen Inc.</a></td>
<td class="nump">144,800<span></span>
</td>
<td class="nump">144,400<span></span>
</td>
<td class="nump">144,700<span></span>
</td>
<td class="nump">145,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings (loss) per share attributable to Biogen Inc.</a></td>
<td class="nump">144,800<span></span>
</td>
<td class="nump">144,800<span></span>
</td>
<td class="nump">145,500<span></span>
</td>
<td class="nump">146,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 1,805.2<span></span>
</td>
<td class="nump">$ 1,962.1<span></span>
</td>
<td class="nump">$ 5,414.3<span></span>
</td>
<td class="nump">$ 6,083.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember', window );">LEQEMBI Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">420.9<span></span>
</td>
<td class="nump">416.9<span></span>
</td>
<td class="nump">1,253.8<span></span>
</td>
<td class="nump">1,252.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Contract manufacturing, royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 304.2<span></span>
</td>
<td class="nump">$ 129.5<span></span>
</td>
<td class="nump">$ 781.2<span></span>
</td>
<td class="nump">$ 293.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Method Investments, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeLossFromEquityMethodInvestmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165872224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Biogen Inc.</a></td>
<td class="num">$ (68.1)<span></span>
</td>
<td class="nump">$ 1,134.7<span></span>
</td>
<td class="nump">$ 911.4<span></span>
</td>
<td class="nump">$ 2,496.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="nump">14.5<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
<td class="num">(19.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="nump">29.6<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">79.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(25.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(30.5)<span></span>
</td>
<td class="num">(59.6)<span></span>
</td>
<td class="num">(11.8)<span></span>
</td>
<td class="num">(95.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">13.5<span></span>
</td>
<td class="num">(53.2)<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="num">(56.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Biogen Inc.</a></td>
<td class="num">(54.6)<span></span>
</td>
<td class="nump">1,081.5<span></span>
</td>
<td class="nump">917.0<span></span>
</td>
<td class="nump">2,439.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="num">(84.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">$ (54.8)<span></span>
</td>
<td class="nump">$ 1,081.7<span></span>
</td>
<td class="nump">$ 918.2<span></span>
</td>
<td class="nump">$ 2,355.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283161574896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,287.9<span></span>
</td>
<td class="nump">$ 3,419.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1,473.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">2,982.4<span></span>
</td>
<td class="nump">1,344.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">974.1<span></span>
</td>
<td class="nump">1,417.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,454.1<span></span>
</td>
<td class="nump">9,791.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">705.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,301.6<span></span>
</td>
<td class="nump">3,298.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">460.9<span></span>
</td>
<td class="nump">403.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">7,344.6<span></span>
</td>
<td class="nump">1,850.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">6,807.5<span></span>
</td>
<td class="nump">5,749.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">1,069.8<span></span>
</td>
<td class="nump">1,226.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">754.6<span></span>
</td>
<td class="nump">1,529.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">28,193.2<span></span>
</td>
<td class="nump">24,554.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of term loan</a></td>
<td class="nump">500.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">243.8<span></span>
</td>
<td class="nump">259.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">440.1<span></span>
</td>
<td class="nump">491.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expense and other</a></td>
<td class="nump">3,838.4<span></span>
</td>
<td class="nump">2,521.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,022.3<span></span>
</td>
<td class="nump">3,272.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable and term loan</a></td>
<td class="nump">6,786.4<span></span>
</td>
<td class="nump">6,281.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">728.1<span></span>
</td>
<td class="nump">334.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">428.8<span></span>
</td>
<td class="nump">333.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">747.9<span></span>
</td>
<td class="nump">944.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,713.5<span></span>
</td>
<td class="nump">11,165.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments, contingencies and guarantees</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">242.2<span></span>
</td>
<td class="nump">73.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(159.3)<span></span>
</td>
<td class="num">(164.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">17,377.9<span></span>
</td>
<td class="nump">16,466.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">14,483.8<span></span>
</td>
<td class="nump">13,397.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="num">(9.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">14,479.7<span></span>
</td>
<td class="nump">13,388.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">28,193.2<span></span>
</td>
<td class="nump">24,554.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,781.4<span></span>
</td>
<td class="nump">1,705.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 428.3<span></span>
</td>
<td class="nump">$ 431.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283159816624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 912.6<span></span>
</td>
<td class="nump">$ 2,412.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">354.7<span></span>
</td>
<td class="nump">398.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="nump">62.1<span></span>
</td>
<td class="nump">321.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">209.3<span></span>
</td>
<td class="nump">186.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(13.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(377.7)<span></span>
</td>
<td class="num">(139.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">(Gain) loss on strategic investments</a></td>
<td class="nump">275.7<span></span>
</td>
<td class="nump">160.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee', window );">Gain on sale of equity interest in Samsung Bioepis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1,505.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of building</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(503.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">98.6<span></span>
</td>
<td class="nump">147.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(34.9)<span></span>
</td>
<td class="num">(338.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expense and other current liabilities</a></td>
<td class="nump">293.9<span></span>
</td>
<td class="nump">632.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="num">(114.8)<span></span>
</td>
<td class="num">(100.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(71.4)<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flow provided by (used in) operating activities</a></td>
<td class="nump">1,534.7<span></span>
</td>
<td class="nump">1,559.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(211.8)<span></span>
</td>
<td class="num">(153.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">7,380.8<span></span>
</td>
<td class="nump">3,104.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(5,140.7)<span></span>
</td>
<td class="num">(2,805.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of Reata, net of cash acquired</a></td>
<td class="num">(6,335.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity interest in Samsung Bioepis</a></td>
<td class="nump">788.1<span></span>
</td>
<td class="nump">990.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(34.4)<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherInvestments', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">106.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flow provided by (used in) investing activities</a></td>
<td class="num">(3,448.7)<span></span>
</td>
<td class="nump">1,717.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">750.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(48.0)<span></span>
</td>
<td class="num">(5.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of borrowings and premiums paid</a></td>
<td class="nump">159.9<span></span>
</td>
<td class="nump">1,002.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from borrowings, net</a></td>
<td class="nump">997.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Net (distribution) contribution to noncontrolling interest</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flow provided by (used in) financing activities</a></td>
<td class="nump">795.4<span></span>
</td>
<td class="num">(1,739.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(1,118.6)<span></span>
</td>
<td class="nump">1,537.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(12.8)<span></span>
</td>
<td class="num">(122.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">3,419.3<span></span>
</td>
<td class="nump">2,261.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">2,287.9<span></span>
</td>
<td class="nump">3,675.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(76.5)<span></span>
</td>
<td class="num">(109.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="num">$ (3.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(g))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479567/321-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283161021600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity Statement - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
<th class="th"><div>2020 Share Repurchase Program</div></th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Parent</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">170,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 10,959.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 68.2<span></span>
</td>
<td class="num">$ (106.7)<span></span>
</td>
<td class="nump">$ 13,911.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 10,896.2<span></span>
</td>
<td class="nump">$ 63.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,412.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,496.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,496.5<span></span>
</td>
<td class="num">(84.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(56.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">$ 12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost (in shares)</a></td>
<td class="num">(3,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</a></td>
<td class="num">$ (750.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (750.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (750.0)<span></span>
</td>
<td class="num">$ (750.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (257.9)<span></span>
</td>
<td class="num">$ (492.1)<span></span>
</td>
<td class="nump">$ 750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(43.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">194.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">12,766.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(163.6)<span></span>
</td>
<td class="nump">15,916.1<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">12,775.5<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">167,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="nump">11,863.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(110.4)<span></span>
</td>
<td class="nump">14,959.9<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">11,872.5<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, shares at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,134.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,134.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,134.7<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(53.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost (in shares)</a></td>
<td class="num">(1,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</a></td>
<td class="num">$ (250.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (250.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (250.0)<span></span>
</td>
<td class="num">$ (250.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (71.5)<span></span>
</td>
<td class="num">$ (178.5)<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">65.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">12,766.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(163.6)<span></span>
</td>
<td class="nump">15,916.1<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">12,775.5<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">167,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">167,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">13,388.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">73.3<span></span>
</td>
<td class="num">(164.9)<span></span>
</td>
<td class="nump">16,466.5<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">13,397.9<span></span>
</td>
<td class="num">(9.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">912.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">911.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">911.4<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(86.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">217.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">14,479.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">242.2<span></span>
</td>
<td class="num">(159.3)<span></span>
</td>
<td class="nump">17,377.9<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">14,483.8<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">168,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">168,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2023</a></td>
<td class="nump">14,460.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">170.7<span></span>
</td>
<td class="num">(172.8)<span></span>
</td>
<td class="nump">17,446.0<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">14,466.9<span></span>
</td>
<td class="num">(6.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="num">(68.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68.1)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(2.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">64.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 14,479.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 242.2<span></span>
</td>
<td class="num">$ (159.3)<span></span>
</td>
<td class="nump">$ 17,377.9<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 14,483.8<span></span>
</td>
<td class="num">$ (4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">168,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NoncontrollingInterestCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NoncontrollingInterestCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171019056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA and co-developed two treatments to address a defining pathology of Alzheimer's disease. We are focused on advancing our pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs and external collaborations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; QALSODY for the treatment of ALS, which was granted accelerated approval by the FDA during the second quarter of 2023; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease, which was granted traditional approval by the FDA in the third quarter of 2023, and Sage on the commercialization of ZURZUVAE for the treatment of PPD. ZURZUVAE was approved by the FDA in the third quarter of 2023, pending DEA scheduling, which was completed in the fourth quarter of 2023. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma, which was granted accelerated approval by the FDA during the second quarter of 2023; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2023, we completed the acquisition of Reata. As a result of this transaction we acquired SKYCLARYS, the first and only drug approved by the FDA for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. We also have the exclusive rights to commercialize TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, which was approved by the FDA during the third quarter of 2023. We continue to develop the potential biosimilar product SB15, a proposed aflibercept biosimilar referencing EYLEA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our 2022 Form&#160;10-K.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2022 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2022 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies disclosed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our audited consolidated financial statements included in our 2022 Form&#160;10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are recorded using the acquisition method of accounting. The results of operations of the acquired company are included in our results of operations beginning on the acquisition date, and assets acquired and liabilities assumed are recognized on the acquisition date at their respective fair values. Any excess of consideration transferred over the net carrying value of the assets acquired and liabilities assumed as of the acquisition date is recognized as goodwill. Transaction and restructuring costs related to business combinations are expensed as incurred. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. If we determine the assets acquired do not meet the definition of a business, the transaction will be accounted for as an asset acquisition rather than a business combination.  </span><span style="color:#3051f2;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022 the FASB issued ASU No. 2022-03, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Fair Value Measurement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (Topic 820): </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for us on January 1, 2024. We elected to early adopt this standard on a prospective basis during the third quarter of 2022. Upon adoption, we recorded an immaterial amount in other (income) expense, net in our condensed consolidated statements of income, as a result of removing the impact of the remaining contractual sale restrictions from the fair value measurement of certain shares in Sage.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171265184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reata Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">On September 26, 2023, we completed the acquisition of all of the issued and outstanding shares of Reata, a  biopharmaceutical company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of this transaction we acquired SKYCLARYS, the first and only drug approved by the FDA for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older, as well as other clinical and preclinical pipeline programs. The acquisition of Reata is expected to complement our global portfolio of neuromuscular and rare disease therapies. The addition of SKYCLARYS is anticipated to provide potential operating synergies with SPINRAZA and QALSODY.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Under the terms of this acquisition, we paid Reata shareholders $172.50 in cash for each issued and outstanding Reata share, which totaled approximately $6.6&#160;billion. In addition, we agreed to pay approximately $983.9&#160;million in cash for Reata's outstanding equity awards, inclusive of employer taxes, of which approximately $590.5&#160;million was attributable to pre-acquisition services and is therefore reflected as a component of total purchase price paid. Of the $983.9&#160;million paid to Reata's equity award holders, we recognized approximately $393.4&#160;million as compensation attributable to the post-acquisition service period, of which $196.4&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $197.0&#160;million as a charge to research and development expense within our condensed consolidated statements of income </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and nine months ended September 30, 2023</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest. Approximately $980.0&#160;million of the $983.9&#160;million payment to the equity award holders was made in October 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We funded this acquisition through available cash, cash equivalents and marketable securities, supplemented by the issuance of a </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.0 billion</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> term loan under our term loan credit agreement. For additional information on our term loan credit agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We accounted for this acquisition as a business combination using the acquisition method of accounting in accordance with </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASC Topic 805, Business Combinations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, and recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Consideration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total consideration transferred for the acquisition of Reata is summarized as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;26, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration paid to Reata shareholders</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,602.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of Reata equity compensation pre-acquisition services and related taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">590.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,193.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents cash consideration transferred of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$172.50</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> per outstanding Reata ordinary share based on 38.3&#160;million Reata shares outstanding at closing.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of Reata stock options and stock units issued to Reata equity award holders and the related taxes attributable to pre-acquisition vesting services.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Preliminary Purchase Price Allocation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The following table summarizes the preliminary purchase price allocation of the separately identifiable assets acquired and liabilities assumed as of September&#160;26, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;26, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,692.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology for SKYCLARYS (U.S.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,600.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development (omaveloxolone)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,900.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other clinical programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(98.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent payable to Blackstone</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(300.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(922.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(151.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,136.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,057.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,193.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> For additional information on the contingent payable to Blackstone, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Other Consolidated Financial Statement Detail</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Total inventory acquired was</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $1.7&#160;billion, which reflects a step-up in the fair value of finished goods and work-in-process inventory for SKYCLARYS. The fair value was determined based on the estimated selling price of the inventory, less the remaining manufacturing and selling costs and a normal profit margin on those manufacturing and selling efforts. This fair value step-up adjustment will be amortized to cost of sales within our condensed consolidated statements of income when the inventory is sold, which is expected to be within approximately 3 years from the acquisition date.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intang</span><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ible assets:</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Intangible assets are comprised of $3.6&#160;billion related to SKYCLARYS commercialization rights in the U.S., $1.9&#160;billion of IPR&amp;D related to the omaveloxolone program outside the U.S., $100.0&#160;million related to a rare pediatric disease priority voucher which may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party and $20.0&#160;million related to other clinical programs. The estimated fair values of the program related intangible assets were determined using a probability adjusted discounted cash flow analysis approach utilizing a discount rate of 17.0% and the estimated fair value of the priority review voucher was based on recent external purchase and sale transactions of similar vouchers.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The more significant as</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenue, cost of sales, research and development and other operating expense, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. Our valuation of the SKYCLARYS commercialization rights reflects the assumption that, using an economic consumption model, the related $3.6&#160;billion intangible asset will be amortized over its expected economic life. Our valuation of the $1.9&#160;billion </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D asset related to omaveloxolone, which </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has been submitted to the EMA and is currently under review, reflects the assumption that, if regulatory approval is obtained, sales would commence in certain countries in Europe during 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We recorded a lease liability of approximately $151.8&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately 15 years, with a corresponding right-of-use asset of approximately $122.4&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. We recognized goodwill of approximately $1.1&#160;billion, which is not deductible for tax purposes. The goodwill recognized from our acquisition of Reata is primarily the result of the deferred tax consequences from the transaction recorded for financial statement purposes.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-related expenses:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acquisition-related expenses, which were comprised primarily of regulatory, advisory and legal fees, and other transaction costs, totaled approximately $26.3&#160;million and are included within selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2023.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Assumptions in the Allocations of Purchase Price</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he results of operations of Reata, along with the estimated fair values of the assets acquired and liabilities assumed in the Reata acquisition, have been included in our condensed consolidated financial statements since the closing of the Reata acquisition on September 26, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our preliminary estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management's analysis related to certain matters, such as finalizing our assessment of intangible assets, inventory, goodwill, leases and income taxes. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. The final determination may result in asset and liability fair values that are different than the preliminary estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the acquisition date, our results of operations include the results of operations of Reata. The Reata operations had an immaterial impact to our results of operations for the three and nine months ended September 30, 2023, given the proximity of the acquisition date to quarter-end. Due to the immateriality of Reata's revenues and expenses, additional pro forma information combining the results of operations of Biogen and Reata have not been included.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283168468144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dispositions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DivestituresAbstract', window );"><strong>Divestitures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Dispositions</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sale of Joint Venture Equity Interest in Samsung Bioepis</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in exchange for total consideration of approximately $2.3&#160;billion. Under the terms of this transaction, we received approximately $1.0&#160;billion in cash at closing, with approximately $1.3&#160;billion in cash to be deferred over two payments. The first deferred payment of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$812.5&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was received in April 2023 and the second deferred payment of $437.5&#160;million is due at the second anniversary of the closing of this transaction in April 2024.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale, the carrying value</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our investment in Samsung Bioepis totaled $581.6&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022 we recognized a pre-tax gain of approximately $1.5&#160;billion related to this transaction, which was recorded in other (income) expense, net in our condensed consolidated statements of income for the</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> nine months ended September 30, 2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This pre-tax gain included reclassifications from AOCI to net income of approximately $58.9&#160;million in cumulative translation losses, partially offset by approximately $57.0&#160;million in gains resulting from the termination of our net investment hedge.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We elected the fair value option and measured the payments due to us from Samsung BioLogics at fair value. As of September 30, 2023, the estimated fair value of the remaining second deferred payment using a risk-adjusted </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">discount rate of 6.4% was approximately $422.3 million. This payment has been classified as a Level 3 measurement and is reflected in other current assets within our condensed consolidated balance sheets as of September 30, 2023.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the nine months ended September 30, 2023, we recognized a gain of approximately $13.7&#160;million to reflect the change in fair value related to the first deferred payment due to us, which was received in April 2023. Additionally, for the three and nine months ended September 30, 2023, we recognized gains of approximately $7.1&#160;million and $16.9&#160;million, respectively, to reflect the changes in fair value related to the second deferred payment due to us. These changes were recorded in other (income) expense, net in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this transaction, we are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize the payments in the period the payments become realizable, which is generally the same period in which the payments are earned.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2022 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DivestituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DivestituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165900944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring, Business Transformation and Other Cost Saving Initiatives</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Fit for Growth Restructuring Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023 we initiated additional cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness. The Fit for Growth program is expected to generate approximately $1.0&#160;billion in gross operating expense savings by 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reduction of approximately 1,000 employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2023 cost saving initiatives are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs associated with items such as asset abandonment and write-offs, facility closure costs, pretax gains and losses resulting from the termination of certain leases, employee non-severance expense, consulting fees and other costs.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reata Integration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the closing of the Reata acquisition, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. We expect to incur restructuring charges of approximately $30.0&#160;million in 2023. These amounts are primarily related to severance and are expected to be paid by the end of 2024. For the three and nine months ended September 30, 2023, we recognized approximately $21.0&#160;million of net pre-tax restructuring charges, primarily consisting of employee severance costs.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022 Cost Saving Initiatives</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, deprioritization of certain research and development programs, the consolidation of certain real estate locations and operating efficiencies across our selling, general and administrative and research and development functions. Charges related to our 2022 cost saving initiatives were substantially incurred during 2022 with remaining payments expected to be made through 2026.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2022 cost saving initiatives are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:28.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.232%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Amounts reflect a gain recorded during the third quarter of 2022 of approximately $5.3&#160;million related to the partial termination of a portion of our lease located at 300 Binney Street.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and spending related to our 2023 and 2022 workforce reductions and Reata Integration are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Workforce Reductions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets Disclosure [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,053.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,793.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,260.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,415.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,629.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,786.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,920.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,920.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,137.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,793.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,344.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,479.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,629.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,850.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2023, amortization and impairment of acquired intangible assets totale</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $60.9 million and $164.0 million, re</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">spectively, compared to $56.5 million and $190.9 million, respectively, in the prior year comparative periods. For the three and nine months ended September 30, 2023 and 2022, we had no impairment charges.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations. In connection with our acquisition of Reata in September 2023 </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we acquired SKYCLARYS, a commercially-approved product in the U.S., with an estimated fair value of approximately </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.6&#160;billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life and amortize these amounts based upon an economic consumption method. IPR&amp;D balances also include adjustments related to foreign currency exchange rate fluctuations. The carrying value associated with our IPR&amp;D assets as of September 30, 2023, relates to the IPR&amp;D programs we acquired in connection with our acquisition of Reata in September 2023 with an estimated fair value of approximately $1.9&#160;billion.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Priority Review Voucher</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we acquired a rare pediatric disease priority review voucher that may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party. We recorded the priority review voucher based on its estimated fair value of $100.0&#160;million as an intangible asset. The estimated fair value was based on recent external purchase and sale transactions of similar vouchers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 (remaining three months)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,749.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill resulting from Reata acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,057.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,807.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> no ac</span>cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171229552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">339.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">336.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">631.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">527.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,159.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">632.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,340.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: SMA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">790.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,014.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,805.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,111.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,962.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in the U.S. during the third quarter of 2022 and commercially available in international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM, ADUHELM and QALSODY, which became commercially available in the U.S. during the second quarter of 2023.</span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">568.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">768.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">816.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,146.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">419.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">383.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">571.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">616.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,188.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">713.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">836.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,549.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">604.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">743.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">492.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">825.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">608.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">995.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">662.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,412.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">849.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,814.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,678.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,493.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,170.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,990.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,161.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">453.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,328.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">891.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,334.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: SMA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">453.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,328.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">891.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,334.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">581.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,293.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,121.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,414.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,619.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,463.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,083.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in the U.S. during the third quarter of 2022 and commercially available in international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM, ADUHELM and QALSODY, which became commercially available in the U.S. during the second quarter of 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 26.9% and 10.5% of gross product revenue for the three months ended September 30, 2023, and 27.1% and 9.1% of gross product revenue for the nine months ended September 30, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 26.9% and 10.5% of gross product revenue for the three months ended September 30, 2022, and 26.8% and 10.7% of gross product revenue for the nine months ended September 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">857.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,035.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,983.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,551.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(410.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,362.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,774.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(574.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(735.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">879.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">940.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">891.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,035.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty revenue on sales of OCREVUS</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">928.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">825.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,252.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> LUNSUMIO became commercially available in the U.S. during the first quarter of 2023.</span></div><div style="margin-top:7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in our 2022 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contract Manufacturing, Royalty and Other Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing, royalty and other revenue is summarized in the table below.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">742.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">781.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Manufacturing Revenue</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing revenue primarily reflects amounts earned under contract manufacturing agreements with our strategic customers. During the first quarter of 2023 we began recognizing contract manufacturing revenue for LEQEMBI, upon accelerated approval of LEQEMBI in the U.S. Prior to accelerated approval, contract manufacturing amounts related to LEQEMBI were recognized in research and development expense within our condensed consolidated income statements.</span></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Other Revenue</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty and other revenue primarily reflects the royalties we receive from net sales on products related to patents that we have out-licensed, as well as royalty revenue on biosimilar products from our license arrangements with Samsung Bioepis and our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, as we are not the principal.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2023 we recorded a reclassification of $38.7&#160;million in LEQEMBI collaboration costs from other revenue to selling, general and administrative expense within our condensed consolidated statements of income. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that this reclassification does not materially impact the current or previously issued condensed consolidated financial statements.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai and our license arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283168029888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,285.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">751.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,038.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,365.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,982.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,344.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,038.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,365.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the third quarter of 2023 we recorded approximately $1.7&#160;billion of acquired inventory related to SKYCLARYS as a result of our acquisition of Reata in September 2023. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the first quarter of 2022 we wrote-off approximately $275.0&#160;million of inventory related to ADUHELM, as a result of the final NCD, which was recognized in cost of sales within our condensed consolidated statements of income </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">September 30, 2022. We recognized approximately $136.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit sharing/(loss reimbursement) within our condensed consolidated statements of income </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">September 30, 2022. As of September 30, 2023 and December 31, 2022, the carrying value of our ADUHELM inventory was immaterial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283172778128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,053.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,793.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,260.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,415.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,629.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,786.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,920.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,920.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,137.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,793.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,344.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,479.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,629.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,850.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2023, amortization and impairment of acquired intangible assets totale</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $60.9 million and $164.0 million, re</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">spectively, compared to $56.5 million and $190.9 million, respectively, in the prior year comparative periods. For the three and nine months ended September 30, 2023 and 2022, we had no impairment charges.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations. In connection with our acquisition of Reata in September 2023 </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we acquired SKYCLARYS, a commercially-approved product in the U.S., with an estimated fair value of approximately </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.6&#160;billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life and amortize these amounts based upon an economic consumption method. IPR&amp;D balances also include adjustments related to foreign currency exchange rate fluctuations. The carrying value associated with our IPR&amp;D assets as of September 30, 2023, relates to the IPR&amp;D programs we acquired in connection with our acquisition of Reata in September 2023 with an estimated fair value of approximately $1.9&#160;billion.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Priority Review Voucher</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we acquired a rare pediatric disease priority review voucher that may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party. We recorded the priority review voucher based on its estimated fair value of $100.0&#160;million as an intangible asset. The estimated fair value was based on recent external purchase and sale transactions of similar vouchers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 (remaining three months)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,749.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill resulting from Reata acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,057.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,807.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> no ac</span>cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171314992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,920.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,920.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">422.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">422.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,826.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,990.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">422.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the current payment due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During the third quarter of 2023 we sold all of our marketable debt securities and used the proceeds to partially fund our acquisition of Reata. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,847.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,847.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,231.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,231.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">810.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">810.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,117.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,122.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,204.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities represent investments in publicly traded equity securities. Our ability to liquidate our investments in Denali, Sage and Sangamo may be limited by the size of our interest, the volume of market related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Denali, Sangamo and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2022 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material impairments of our assets measured and carried at fair value as of September 30, 2023 and December 31, 2022. In addition, there have been no changes to our valuation techniques as of September 30, 2023 and December 31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2022 Form 10-K. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Level 3 Assets and Liabilities Held at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of assets or liabilities into or out of Level 3 as of September 30, 2023 and December 31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Convergence, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair value of our contingent consideration obligations, which were classified as Level 3 measurements:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our contingent consideration obligations are recorded in (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022 we discontinued further development efforts related to vixotrigine for the potential treatment of TGN and DPN, resulting in a reduction of our contingent consideration obligations of approximately $195.4&#160;million, reducing the fair value of vixotrigine to zero.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, the changes in fair value of our contingent consideration obligations were primarily due to increases in the discount rates used to revalue these obligations and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Instruments Not Carried at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our senior notes debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,689.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,746.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,699.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,744.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,196.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,493.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,219.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">972.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,033.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">909.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,474.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">989.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">469.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">469.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,198.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,286.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,410.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,281.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The changes in the fair values of our Senior Notes as of September 30, 2023, compared to December 31, 2022, are primarily related to increases in U.S. treasury yields partially offset by a decrease in credit spreads used to value our Senior Notes since December 31, 2022. For additional information related to our Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2022 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we drew</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.0 billion</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> on term loans under our term loan credit agreement. As of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2023, t</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">he fair value of our term loans outstanding approximate book value based on the current borrowing rates available. For additional information on our term loan credit agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171465184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,920.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,581.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,920.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,847.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We partially funded our Reata acquisition through available cash, cash equivalents and marketable securities. As of September 30, 2023, we have sold all of our marketable debt securities. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">993.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(579.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">993.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(579.7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">936.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">931.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">547.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">542.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,199.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,179.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(342.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(342.7)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,483.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">694.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,179.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,199.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities classified as available-for-sale as of December 31, 2022, was approximately 8 months.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.918%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,698.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,643.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,380.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,104.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized losses for the three and nine months ended</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2023, primarily relate to sales of U.S. treasuries and corporate bonds. Realized losses for the three and nine months ended September 30, 2022, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During the third quarter of 2023 we sold all of our marketable debt securities and used the proceeds to partially fund our acquisition of Reata. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, as well as venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, our strategic investment portfolio was comprised of investments totaling $465.5 million and $846.0 million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our strategic investment portfolio as of September 30, 2023, was primarily due to the decrease in the fair value of our investments in Denali, Sangamo and Sage common stock. Additionally, we sold a portion of our Sangamo common stock during the third quarter of 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our strategic investments in Denali, Sangamo and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2022 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171093904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts and foreign currency options in effect as of September 30, 2023 and December 31, 2022, had durations of 1 to 15 months and 1 to 12 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains and losses on the portion of these foreign currency forward contracts and foreign currency options that are included in the effectiveness test are reported in AOCI. Realized gains and losses of such contracts and options are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from AOCI and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,006.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,495.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts and options</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,144.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,715.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the net unrealized gains of approximately $11.5&#160;million to be settled over the next 15 months, of which approximately $7.9 million of these net unrealized gains are expected to be settled over the next 12 months, with any amounts in AOCI to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2023 and December 31, 2022, credit risk did not materially change the fair value of our foreign currency forward contracts and forward currency options.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Investment Hedges - Hedging Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. Our investment in the equity of Samsung Bioepis related to this transaction was exposed to the currency fluctuations in the South Korean won.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we entered into foreign currency forward contracts. These contracts were designated as net investment hedges. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and closed these foreign currency forward contracts. Upon completing this sale, the cumulative gains on our net investment hedges of $57.0&#160;million were reclassified from AOCI and reflected within the total pre-tax gain recognized from the sale, which was recorded in other (income) expense, net in our condensed consolidated statements of income. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our net investment hedges in our condensed consolidated financial statements:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:25.192%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.931%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.761%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Recognized in Net Income (Amounts Excluded from Effectiveness Testing)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $1,340.8 million and $1,238.8 million as of September 30, 2023 and December 31, 2022, respectively. Net losses of $22.6 million and $28.0 million related to these contracts were recorded as a component of other (income) expense, net for the three </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and nine months ended September 30, 2023, respectively, compared to net losses of $36.5 million and $85.8 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//815/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171035824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $2,342.7 million and $2,165.7 million as of September 30, 2023 and December 31, 2022, respectively. For the three and nine months ended September 30, 2023, depreciation expense totaled $64.1 million and $190.7 million, respectively, compared to $64.2 million and $207.7 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are nearing completion of a large-scale biologics manufacturing facility in Solothurn, Switzerland. This facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of September 30, 2023 and December 31, 2022, we had approximately $742.0 million and $711.1 million, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021 a portion of the facility (the first manufacturing suite) received a GMP multi-product license from the SWISSMEDIC and was placed into service. Solothurn has been approved for the manufacture of ADUHELM and LEQEMBI by the FDA. We estimate the second manufacturing suite will be operational by the end of 2023.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">125 Broadway Building Sale</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we completed the sale of our building and land parcel located at 125 Broadway for an aggregate sales price of approximately $603.0&#160;million, which is inclusive of a $10.8&#160;million tenant allowance. This sale resulted in a pre-tax gain on sale of approximately $503.7&#160;million, net of transaction costs, which is reflected within gain on sale of building in our condensed consolidated statements of income for the three and nine months ended September 30, 2022. This transaction included approximately $79.2&#160;million of property, plant and equipment, net, which comprised of approximately $72.6&#160;million for buildings, approximately $1.6&#160;million for land and approximately $5.0&#160;million for machinery and equipment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283172778128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6100 Legacy Drive Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We recorded a lease liability of approximately $151.8&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately 15 years, with a corresponding right-of-use asset of approximately $122.4&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">125 Broadway Building Sale and Leaseback Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of our 125 Broadway building during the third quarter of 2022, we simultaneously leased back the building for a term of approximately 5.5 years, which resulted in the recognition of approximately $168.2&#160;million in a new lease liability and right-of-use asset recorded within our condensed consolidated balance sheets as of December 31, 2022. The sale and immediate leaseback of this building qualified for sale and leaseback treatment and is classified as an operating lease. For additional information on the sale of our 125 Broadway building, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11, Property, Plant and Equipment</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">300 Binney Street Lease Modification</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we entered into an agreement to partially terminate a portion of our lease located at 300 Binney Street, as well as to reduce the lease term for the majority of the remaining space. The agreement was driven by our 2022 efforts to reduce costs by consolidating real estate locations. The transaction was treated as a lease modification as of the effective date and resulted in the derecognition of a right-of-use asset of approximately $47.4&#160;million and lease liability of approximately $52.7&#160;million, which resulted in a gain of approximately $5.3&#160;million, which was recorded within restructuring charges in our condensed consolidated statements of income for the three and nine months ended September 30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283168029888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text">Credit Agreement<div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we entered into a $1.5&#160;billion term loan credit agreement. On the closing date of the Reata acquisition we drew $1.0 billion from the term loan, comprised of a $500.0&#160;million floating rate 364-day tranche and a $500.0&#160;million floating rate three-year tranche. The remaining unused commitment of $500.0&#160;million was terminated. As of September 30, 2023, we had $1.0&#160;billion outstanding under the term loan credit agreement, of which $500.0&#160;million was outstanding under the 364-day tranche and $500.0&#160;million outstanding under the three-year tranche.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.625% Senior Notes due September 15, 2022</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2015, we issued $1.0&#160;billion aggregate principal amount of our 3.625% Senior Notes due September 15, 2022, at 99.920% of par. Our 3.625% Senior Notes were senior unsecured obligations. In July 2022 we redeemed our 3.625% Senior Notes prior to their maturity and recognized a net pre-tax charge of approximately $2.4&#160;million upon the extinguishment of these Senior Notes, which primarily reflects the payment of an early call premium as well as the write-off of remaining unamortized original debt issuance costs and discount balances. These charges were recognized as interest expense in other (income) expense, net in our condensed consolidated statements of income for the three and nine months ended September 30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283172778128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 1.2 million and 3.6 million shares of our common stock at a cost of approximately $250.0 million and $750.0 million during the three and nine months ended September 30, 2022, respectively. There were no share repurchases of our common stock during the three and nine months ended September 30, 2023. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2023.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in AOCI, net of tax by component:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedges, Net of Tax</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(154.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(125.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(234.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from AOCI:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.398%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171181264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,134.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,496.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income (loss) per diluted share because their effects were anti-dilutive were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171203696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(98.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(126.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income (loss) attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> recognized Reata equity-based compensation expense, inclusive of employer taxes, of approximately $393.4&#160;million attributable to the post-acquisition service period, of which $196.4&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $197.0&#160;million as a charge to research and development expense within our condensed consolidated statements of income</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three and nine months ended September 30, 2023</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">hese amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata equity awards</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> During the fourth quarter of 2022 we granted stock options. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Share-Based Payments</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2022 Form 10-K.</span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the Reata equity-based compensation expense attributable to the post-acquisition service period, associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171093904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inflation Reduction Act</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022 the IRA was signed into law in the U.S. The IRA introduced new tax provisions, including a 15.0% corporate alternative minimum tax and a 1.0% excise tax on stock repurchases. The provisions of the IRA are effective for periods after December 31, 2022. The IRA did not result in any material adjustments to our income tax provision or other income tax balances as of September 30, 2023 and December 31, 2022. Preliminary guidance has been issued by the IRS and we expect additional guidance and regulations to be issued in future periods. We will continue to assess its potential impact on our business and results of operations as further information becomes available.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tax Rate</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement agreement</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International reorganization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including permanent items</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate for the three months ended September 30, 2023, reflects a tax benefit of $72.9 million recognized as a result of a pretax loss from operations of $141.2 million recorded during the third quarter of 2023, which was driven, in part, by the impact of the non-cash changes in the value of our equity investments and Reata acquisition-related expenses. For all other periods presented, the effective tax rates reflect tax expense on pretax income from operations in the respective periods.</span></div><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2023, compared to the same period in 2022, the change in our effective tax rate was driven by the impact of the non-cash changes in the value of our equity investments and Reata acquisition-related expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2023, compared to the same period in 2022, our effective tax rate, in addition to the items noted above, was also impacted by the combined net unfavorable tax rate impacts in 2022 related to a litigation settlement agreement, the sale of our equity interest in Samsung Bioepis, the impact of a Neurimmune valuation allowance and an international reorganization to align with global tax developments. The change also benefits from the resolution of an uncertain tax matter during the first quarter of 2023 related to tax credits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal tax examination for years before 2019 or state, local or non-U.S. income tax examinations for years before 2013.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters, withholding taxes and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease by up to approximately $460.0&#160;million, including approximately $450.0&#160;million related to the unrecognized</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax benefits related to Neurimmune's tax basis in ADUHELM, as discussed above, in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations. Any changes to our gross unrecognized tax benefits related to Neurimmune's tax basis in ADUHELM would result in a zero net impact to net income attributable to Biogen, Inc., as we have recorded a full valuation allowance against the relevant deferred tax assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171283360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other (Income) Expense, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of equity interest in Samsung Bioepis</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,505.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(252.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains) losses on investments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(101.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">289.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange (gains) losses, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.0)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(221.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">49.9%</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (gains) losses on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus settlement fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015. This charge is included within other (income) expense, net in our condensed consolidated statements of income for the nine months ended September 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains) losses realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the three months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali and Sangamo common stock of approximately $295.6&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the three months ended September 30, 2022, primarily reflect an increase in the aggregate fair value of our investments in Sage, Ionis, Sangamo and Denali common stock of approximately $112.5&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali, Sangamo and Ionis common stock of approximately $265.0&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $198.0&#160;million, partially offset by an increase in the fair value of Ionis and Sage common stock of approximately $52.2&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata acquisition-related accrued expense</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,407.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">940.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">891.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">712.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">746.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,838.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,521.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reata Acquisition-Related Accrued Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we accrued approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$983.9&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to Reata's outstanding equity awards, inclusive of employer taxes, of which approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$980.0&#160;million </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was subsequently paid in October 2023. As of September 30, 2023, this amount was included within accrued expense and other within our condensed consolidated balance sheets. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additionally, we assumed a payable to Blackstone of approximately $300.0&#160;million related to a one-time contract termination fee to eliminate potential future royalty obligations related to SKYCLARYS, which was triggered as part of the change in control provision under Reata's funding agreement with Blackstone. Payment to Blackstone is expected to be made in November 2023. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:10pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $747.9 million and $944.2 million as of September 30, 2023 and December 31, 2022, respectively, and included accrued income taxes totaling $393.8 million and $541.7 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171121856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 19:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborative and Other Relationships</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Genentech, Inc. (Roche Group)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO (mosunetuzumab), for the treatment of relapsed or refractory follicular lymphoma, which was granted accelerated approval in the U.S. during the fourth quarter of 2022; COLUMVI (glofitamab), a bispecific antibody for the treatment of non-Hodgkin's lymphoma, which was granted accelerated approval by the FDA during the second quarter of 2023; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt">U.S.:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt">Canada:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. The level of gross sales of GAZYVA in the U.S. has impacted our percentage of the co-promotion profits for RITUXAN and LUNSUMIO, as summarized in the table below.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCREVUS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24.0% if annual net sales exceed $900.0&#160;million. There will be a 50.0% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we receive a gross 3.0% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third-party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LUNSUMIO (mosunetuzumab)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022 we exercised our option with Genentech to participate in the joint development and commercialization of LUNSUMIO. Under our collaboration with Genentech, we were responsible for 30.0% of development costs for LUNSUMIO prior to FDA approval and will be entitled to a tiered share of co-promotion operating profits and losses in the U.S., as summarized in the table below. In addition, we receive low single-digit royalties on sales of LUNSUMIO outside the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022 LUNSUMIO was granted accelerated approval by the FDA for the treatment of relapsed or refractory follicular lymphoma. Prior to regulatory approval, we record our share of the expense incurred by the collaboration for the development of anti-CD20 products in research and development expense and pre-commercialization costs within selling, general and administrative expense in our condensed consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development and sales and marketing expense related to that product as a reduction of our share of pre-tax profits in revenue from anti-CD20 therapeutic programs.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COLUMVI (glofitamab)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022 we entered into an agreement with Genentech related to the commercialization and sharing of economics for COLUMVI, a bispecific antibody for the treatment of B-cell non-Hodgkin's lymphoma, which was subsequently granted accelerated approval by the FDA in June 2023. Under the terms of this agreement, we will have no payment obligations. Genentech will have sole decision-making rights on the commercialization of COLUMVI within the U.S. and we will receive tiered royalties in the mid-single digit range on net sales of COLUMVI in the U.S. The commercialization of COLUMVI does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Formulas</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN and LUNSUMIO Profit Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax co-promotion profit-sharing formula for RITUXAN and LUNSUMIO in the U.S. provides for a 30.0% share on the first $50.0&#160;million of combined co-promotion operating profits earned each calendar year. As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After LUNSUMIO Approval until the First Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First Threshold Date until the Second Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">First Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the earlier of (i)&#160;the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0&#160;million or (ii)&#160;the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $150.0&#160;million.</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the later of (i) the first date the gross sales in any calendar year in which U.S. gross sales of LUNSUMIO reach $350.0&#160;million or (ii) January 1 of the calendar year following the calendar year in which the First Threshold Date occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the First Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for RITUXAN and LUNSUMIO was 35.0%.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA Profit Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax profit-sharing formula for GAZYVA provides for a 35.0% share on the first $50.0&#160;million of operating profits earned each calendar year. Our share of annual co-promotion profits in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Until Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second GAZYVA Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0&#160;million. The second GAZYVA threshold date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the Second GAZYVA Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for GAZYVA was 35.0%.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2023 we accrued a $31.0&#160;million payable to Eisai related to the termination of an agreement whereby Eisai co-promoted or distributed our MS products in certain Asia-Pacific markets and settings. This termination fee is included in selling, general and administrative expense in our condensed consolidated statements of income for the nine months ended September 30, 2023.</span></div><div style="margin-top:5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LEQEMBI (lecanemab) Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai to jointly develop and commercialize LEQEMBI (lecanemab), an anti-amyloid antibody for the treatment of Alzheimer's disease (the LEQEMBI Collaboration).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. We and Eisai co-promote LEQEMBI and share profits and losses equally. We currently manufacture LEQEMBI drug substance and drug product and in March 2022 we extended our supply agreement with Eisai related to LEQEMBI from five years to ten years for the manufacture of LEQEMBI drug substance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 the FDA granted traditional approval of LEQEMBI. Prior to receiving traditional approval, LEQEMBI had been granted accelerated approval by the FDA in January 2023, at which time it became commercially available in the U.S. Additionally, in September 2023 the Japanese Ministry of Health, Labor and Welfare approved LEQEMBI in Japan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of LEQEMBI, we began recognizing our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, within other revenue in our condensed consolidated income statements, as we are not the principal.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2023 we recorded a reclassification of $38.7&#160;million in LEQEMBI collaboration costs from other revenue to selling, general and administrative expense within our condensed consolidated statements of income. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that this reclassification does not materially impact the current or previously issued condensed consolidated financial statements. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of LEQEMBI development expense will continue to be recorded within research and development expense in our condensed consolidated income statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the LEQEMBI Collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADUHELM Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LEQEMBI Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (the ADUHELM Collaboration Agreement).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our initial ADUHELM Collaboration Agreement, we would lead the ongoing development of ADUHELM, and we and Eisai would co-promote ADUHELM with a region-based profit split. Beginning in 2019, Eisai was reimbursing us for&#160;45.0%&#160;of development and sales and marketing expense incurred by the collaboration for the advancement of ADUHELM.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. As of the amendment date, we have sole decision making and commercialization rights worldwide on ADUHELM, and beginning January 1, 2023, Eisai receives only a tiered royalty based on net sales of ADUHELM, and no longer participates in sharing ADUHELM's global profits and losses. Eisai's share of development, commercialization and manufacturing expense was limited to $335.0&#160;million for the period from January 1, 2022 to December 31, 2022, which was achieved as of December 31, 2022. Once this limit was achieved, we became responsible for all ADUHELM related costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense and sales and marketing expense related to our initial ADUHELM Collaboration Agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.321%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM Collaboration development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM Collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#6dad46;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM C</span><span style="background-color:#ffffff;color:#6dad46;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">o-promotion Profits and Losses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our initial ADUHELM Collaboration Agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we recognized revenue on sales of ADUHELM in the U.S. to third parties as a component of product revenue in our condensed consolidated statements of income. We also recorded the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs were incurred. Payments made to and received from Eisai for its 45.0% share of the co-promotion profits or losses in the U.S. were recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2022,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we recognized net reductions to our operating expense of approximately $3.4&#160;million and $214.0&#160;million, respectively, to reflect Eisai's 45.0% share of net collaboration losses in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, as a result of the final NCD, we recorded approximately $275.0&#160;million of charges associated with the write-off of inventory and purchase commitments in excess of forecasted demand related to ADUHELM. Additionally, for the nine months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2022,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we recorded approximately $76.0&#160;million of aggregate gross idle capacity charges related to ADUHELM. These charges were recorded in cost of sales within our consolidated statements of income for the nine months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized approximately $177.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit sharing/(loss reimbursement) within our condensed consolidated statements of income</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2022.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Eisai related to the agreements discussed ab</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ove were approximately $34.3&#160;million and $88.0&#160;million as of September 30, 2023 and December 31, 2022, respectively. Amounts payable to Eisai related to the agreements discussed above were $122.6&#160;million and $81.2&#160;million as</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of September 30, 2023 and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2022 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB, effective November 2003, to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of SLE and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, both companies will co-promote dapirolizumab pegol and share profits and losses equally.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize ZURZUVAE (zuranolone) for the potential treatment of MDD and PPD and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023 the FDA approved ZURZUVAE for adults with PPD, pending DEA scheduling, which was completed in October 2023. Upon approval, ZURZUVAE became the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms by day 15 for women with PPD. We expect ZURZUVAE for PPD to be commercially available beginning in the fourth quarter of 2023. Additionally, the FDA issued a CRL for the NDA for zuranolone in the treatment of adults with MDD. The CRL stated that the application did not provide substantial </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evidence of effectiveness to support the approval of zuranolone for the treatment of MDD and that an additional study or studies would be needed. We and Sage are reviewing the feedback and evaluating next steps. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties. We will pay Sage a milestone payment of $75.0&#160;million upon the first commercial sale of ZURZUVAE for PPD in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023, we recorded $5.9&#160;million to reflect Sage's 50.0% share of net collaboration expense in the U.S. related to commercialization activities to support ZURZUVAE for PPD, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to the Sage collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Sage collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of LRRK2 for Parkinson's disease and also entered into a separate agreement to obtain an exclusive option to license two preclinical programs from Denali's Transport Vehicle platform, including its ATV-enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023 we exercised our option with Denali to license the ATV-enabled anti-amyloid beta program. In connection with this exercise, we assumed responsibility for all development and commercial activities and associated expenses related to this program. In addition, we made a one-time option exercise payment to Denali and, should certain milestones be achieved, may pay Denali additional development and commercial milestone payments and royalties based on future net sales. Our agreement with Denali was amended in August 2023, whereby certain milestone criteria were changed, while the total amount of development, regulatory and commercial milestones remains the same. In addition, we agree to waive our option right to the second option program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the LRRK2 collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to the Denali collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Research and Discovery Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2023, we recorded </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">zero</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$14.0&#160;million and $51.5&#160;million, respectively,</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the prior year comparative periods.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately 45.0%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, we may also pay Samsung Bioepis up to approximately $180.0 million in additional development, regulatory and sales-based milestones.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 c</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the three and nine months ended September 30, 2023, we recognized net profit-sharing expense of $56.4&#160;million and $170.4 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of $48.7 million and $171.4 million, respectively, in the prior year comparative periods. </span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement with Samsung Bioepis. Under this license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on biosimilar products developed and commercialized by Samsung Bioepis. Royalty revenue under the license agreement is recognized as a component of contract manufacturing, royalty and other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Samsung Bioepis related to the agreements di</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scussed above were $13.0&#160;million and $2.0&#160;million as of September 30, 2023 and December 31, 2022, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were $81.6&#160;million and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$40.5&#160;million as of September 30, 2023 and December 31, 2022, respectively.</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span> to our consolidated financial statements included in our 2022 Form 10-K.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171185968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on commercial sales of ADUHELM, range from the high single digits to sub-teens.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an increase in a valuation allowance of approximately $85.0&#160;million to reduce the net value of a previously recorded deferred tax asset to zero. This adjustment to our net deferred tax asset is recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023 and December 31, 2022, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $24.4 million and $27.8 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2022 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171001008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2022 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. If an estimate of the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">possible loss or range of loss can be made at this time, it is included in the potential loss contingency description below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Loss Contingencies</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADUHELM Securities Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are defendants in two actions related to ADUHELM filed in the United States District Court for the District of Massachusetts (the District Court). Both actions allege violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seek declarations of the actions as class actions and monetary relief. In October 2023 the United States Court of Appeals for the First Circuit reversed in part and affirmed in part the dismissal of the shareholder action related to ADUHELM that was filed in November 2020. In March 2023 the District Court dismissed the shareholder action that had been filed in February 2022. In May 2023 the plaintiff filed a motion to alter the judgment and amend the complaint, which is pending.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Actions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and members of the Board of Directors are named as defendants in derivative actions filed by shareholders in February and July 2022, in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C. &#167;78n(a) and 17 C.F.R. &#167;240 14.a-9, and breaches of fiduciary duties and waste of corporate assets, and seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys&#8217; fees and costs payable to the plaintiffs. The District Court has stayed both cases.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) filed a claim for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen commercializes in Europe, infringes the French counterpart of European Patent 3 145 488 (the EP &#8216;488 Patent), which expires in May 2035. In August 2022 Fresenius Kabi filed a claim for damages and injunctive relief against Biogen GmbH in the D&#252;sseldorf Regional Court, alleging infringement of the German counterpart of the EP '488 Patent. A hearing in the D&#252;sseldorf Regional Court has been set for December 2023. No hearing has been set in the French action. The EP '488 Patent is the subject of opposition proceedings in the EPO and a hearing before the EPO's Technical Boards of Appeal is set for June 2024.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation with Former Convergence Shareholders</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015 Biogen acquired Convergence, a U.K. company. In 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, asserted claims of $200.0 million for alleged breaches of the contract pursuant to which we acquired Convergence. In June 2023 Shareholder Representative Services LLC and 24 former shareholders filed suit against us in the High Court of Justice of England and Wales on one of the previously asserted claims, seeking payment of $49.9&#160;million, interest and costs. No trial date has been set.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ERISA Class Action Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 participants in the Biogen 401(k) Savings Plan filed actions against us in the U.S. District Court for the District of Massachusetts alleging breach of fiduciary duty under ERISA and seeking a declaration of the actions as class actions and monetary and other relief. In August 2023 the court preliminarily approved a settlement under which we agree to pay $9.75&#160;million without any admission of liability. The court has set a hearing for January 2024 to determine whether to grant final approval.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Humana Patient Assistance Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the District Court for the District of Massachusetts dismissed the previously disclosed action filed against us by Humana in September 2020. Humana had alleged damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients and had </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alleged violations of the federal RICO Act and state laws. In April 2023 Humana filed a motion to alter the judgment and amend the complaint, which is pending.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributor Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022 we terminated our distribution agreement with the distributor of products for Biogen in various countries in the Middle East and northern Africa. The former distributor has asserted breach of contract. No suit has been filed.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023 Genentech, Inc. filed suit against us in the U.S. District Court for the Northern District of California, alleging that it is owed royalties on sales of TYSABRI that occurred after the expiration of a patent licensed by Genentech to Biogen, together with interest and costs. The Company estimates that the royalties claimed total approximately $88.3&#160;million. No trial date has been set.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bardoxolone Securities Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 and 2022 putative stockholders of Reata (later acquired by Biogen) filed litigation in the United States District Court for the Eastern District of Texas alleging violations of the federal securities laws by Reata, certain former officers and directors and certain underwriters under 15 U.S.C. &#167;78j(b) and &#167;78t(a), 17 C.F.R. &#167;240.10b-5, and 15 U.S.C. &#167;&#167;77k, 77l(a)(2) and 77o in connection with Reata's asset bardoxolone. Plaintiffs seek declaration of the actions as a class actions and monetary relief. In October 2023 the parties reached a settlement, subject to approval by the court, providing for payment by Reata of $45.0&#160;million without any admission of liability. We expect a portion of the payment to be reimbursed under Reata's insurance coverage.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lender Dispute</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of Reata's lenders claims that approximately $23.3&#160;million is owing under its loan agreement with Reata.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Investigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received subpoenas from the Securities and Exchange Commission seeking information relating to ADUHELM, including healthcare sites and ADUHELM&#8217;s approval.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TYSABRI Biosimilar Patent Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc., other Sandoz entities and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. &#167;262, seeking a declaratory judgment of patent infringement. The trial has been set for May 2025.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Annulment Proceedings in the General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 Mylan Ireland filed an action in the General Court of the European Union (the General Court) to annul the EMA's decision not to validate its applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. No hearing has been set.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,669,281, 9,090,558 and 10,080,733) pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC. No trial date has been set.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283167424432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA and co-developed two treatments to address a defining pathology of Alzheimer's disease. We are focused on advancing our pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs and external collaborations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; QALSODY for the treatment of ALS, which was granted accelerated approval by the FDA during the second quarter of 2023; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease, which was granted traditional approval by the FDA in the third quarter of 2023, and Sage on the commercialization of ZURZUVAE for the treatment of PPD. ZURZUVAE was approved by the FDA in the third quarter of 2023, pending DEA scheduling, which was completed in the fourth quarter of 2023. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma, which was granted accelerated approval by the FDA during the second quarter of 2023; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2023, we completed the acquisition of Reata. As a result of this transaction we acquired SKYCLARYS, the first and only drug approved by the FDA for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. We also have the exclusive rights to commercialize TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, which was approved by the FDA during the third quarter of 2023. We continue to develop the potential biosimilar product SB15, a proposed aflibercept biosimilar referencing EYLEA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our 2022 Form&#160;10-K.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2022 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2022 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, </span><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies disclosed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our audited consolidated financial statements included in our 2022 Form&#160;10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div>Business combinations are recorded using the acquisition method of accounting. The results of operations of the acquired company are included in our results of operations beginning on the acquisition date, and assets acquired and liabilities assumed are recognized on the acquisition date at their respective fair values. Any excess of consideration transferred over the net carrying value of the assets acquired and liabilities assumed as of the acquisition date is recognized as goodwill. Transaction and restructuring costs related to business combinations are expensed as incurred. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. If we determine the assets acquired do not meet the definition of a business, the transaction will be accounted for as an asset acquisition rather than a business combination.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.<div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022 the FASB issued ASU No. 2022-03, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Fair Value Measurement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (Topic 820): </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for us on January 1, 2024. We elected to early adopt this standard on a prospective basis during the third quarter of 2022. Upon adoption, we recorded an immaterial amount in other (income) expense, net in our condensed consolidated statements of income, as a result of removing the impact of the remaining contractual sale restrictions from the fair value measurement of certain shares in Sage.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171068176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total consideration transferred for the acquisition of Reata is summarized as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;26, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration paid to Reata shareholders</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,602.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of Reata equity compensation pre-acquisition services and related taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">590.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,193.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents cash consideration transferred of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$172.50</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> per outstanding Reata ordinary share based on 38.3&#160;million Reata shares outstanding at closing.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of Reata stock options and stock units issued to Reata equity award holders and the related taxes attributable to pre-acquisition vesting services.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The following table summarizes the preliminary purchase price allocation of the separately identifiable assets acquired and liabilities assumed as of September&#160;26, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;26, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,692.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology for SKYCLARYS (U.S.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,600.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development (omaveloxolone)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,900.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other clinical programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(98.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent payable to Blackstone</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(300.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(922.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(151.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,136.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,057.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,193.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> For additional information on the contingent payable to Blackstone, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Other Consolidated Financial Statement Detail</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283167458608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Restructuring and Related Costs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2023 cost saving initiatives are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2022 cost saving initiatives are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:28.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.232%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Amounts reflect a gain recorded during the third quarter of 2022 of approximately $5.3&#160;million related to the partial termination of a portion of our lease located at 300 Binney Street.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and spending related to our 2023 and 2022 workforce reductions and Reata Integration are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Workforce Reductions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283164823760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">339.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">336.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">631.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">527.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,159.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">632.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,340.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: SMA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">790.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,014.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,805.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,111.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,962.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in the U.S. during the third quarter of 2022 and commercially available in international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM, ADUHELM and QALSODY, which became commercially available in the U.S. during the second quarter of 2023.</span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">568.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">768.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">816.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,146.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">419.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">383.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">571.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">616.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,188.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">713.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">836.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,549.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">604.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">743.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">492.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">825.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">608.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">995.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">662.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,412.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">849.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,814.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,678.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,493.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,170.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,990.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,161.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">453.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,328.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">891.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,334.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: SMA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">453.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,328.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">891.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,334.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">581.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,293.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,121.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,414.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,619.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,463.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,083.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> BYOOVIZ became commercially available in the U.S. during the third quarter of 2022 and commercially available in international markets in 2023.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM, ADUHELM and QALSODY, which became commercially available in the U.S. during the second quarter of 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">857.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,035.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,983.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,551.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(410.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,362.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,774.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(574.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(735.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">879.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">940.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">891.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,035.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty revenue on sales of OCREVUS</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">928.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">825.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,253.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,252.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> LUNSUMIO became commercially available in the U.S. during the first quarter of 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">742.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">781.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171181264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,285.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">751.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,038.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,365.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,982.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,344.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,038.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,365.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171267728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,053.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,793.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,260.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,415.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,629.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,786.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,920.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,920.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,137.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,793.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,344.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,479.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,629.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,850.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 (remaining three months)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,749.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill resulting from Reata acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,057.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,807.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283172327360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,920.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,920.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">422.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">422.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,826.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,990.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">422.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the current payment due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During the third quarter of 2023 we sold all of our marketable debt securities and used the proceeds to partially fund our acquisition of Reata. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,847.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,847.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,231.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,231.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">810.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">810.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,117.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,122.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,204.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our senior notes debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,689.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,746.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,699.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,744.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,196.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,493.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,219.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">972.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,033.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">909.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,474.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">989.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">469.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">469.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,198.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,286.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,410.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,281.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Convergence, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair value of our contingent consideration obligations, which were classified as Level 3 measurements:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283164729872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,920.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,581.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,920.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,847.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">993.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(579.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">993.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(579.7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">936.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">931.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">547.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">542.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,199.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,179.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(342.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(342.7)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,483.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">694.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,179.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,199.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.918%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,698.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,643.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,380.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,104.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283167815952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,006.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,495.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts and options</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,144.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,715.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our net investment hedges in our condensed consolidated financial statements:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:25.192%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.931%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.761%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Recognized in Net Income (Amounts Excluded from Effectiveness Testing)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock', window );">Derivative Instruments, Unrealized Gain (Loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments, Unrealized Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283167413232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in AOCI, net of tax by component:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedges, Net of Tax</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(154.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(125.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(234.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from AOCI:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.398%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165993360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,134.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,496.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283159987664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(98.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(126.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income (loss) attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> recognized Reata equity-based compensation expense, inclusive of employer taxes, of approximately $393.4&#160;million attributable to the post-acquisition service period, of which $196.4&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $197.0&#160;million as a charge to research and development expense within our condensed consolidated statements of income</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three and nine months ended September 30, 2023</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">hese amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata equity awards</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> During the fourth quarter of 2022 we granted stock options. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Share-Based Payments</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2022 Form 10-K.</span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the Reata equity-based compensation expense attributable to the post-acquisition service period, associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171070176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement agreement</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International reorganization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including permanent items</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate for the three months ended September 30, 2023, reflects a tax benefit of $72.9 million recognized as a result of a pretax loss from operations of $141.2 million recorded during the third quarter of 2023, which was driven, in part, by the impact of the non-cash changes in the value of our equity investments and Reata acquisition-related expenses. For all other periods presented, the effective tax rates reflect tax expense on pretax income from operations in the respective periods.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283160057152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of equity interest in Samsung Bioepis</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,505.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(252.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains) losses on investments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(101.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">289.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange (gains) losses, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.0)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(221.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">49.9%</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments in equity securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains) losses realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109.3)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the three months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali and Sangamo common stock of approximately $295.6&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the three months ended September 30, 2022, primarily reflect an increase in the aggregate fair value of our investments in Sage, Ionis, Sangamo and Denali common stock of approximately $112.5&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali, Sangamo and Ionis common stock of approximately $265.0&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $198.0&#160;million, partially offset by an increase in the fair value of Ionis and Sage common stock of approximately $52.2&#160;million.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata acquisition-related accrued expense</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,407.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">940.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">891.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">712.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">746.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,838.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,521.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283159927712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaTableTextBlock', window );">Co-promotion profit sharing formula</a></td>
<td class="text">As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After LUNSUMIO Approval until the First Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First Threshold Date until the Second Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PretaxProfitSharingFormulaTableTextBlock', window );">Pretax profit sharing formula</a></td>
<td class="text">Our share of annual co-promotion profits in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Until Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock', window );">Summary of activity related to Aducanumab collaboration</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense and sales and marketing expense related to our initial ADUHELM Collaboration Agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.321%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM Collaboration development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM Collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock', window );">Summary of activity related to the UCB collaboration</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock', window );">Summary of Activity Related to Denali Therapeutics Collaboration</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to the Denali collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock', window );">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the LEQEMBI Collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock', window );">Summary of Activity Related to Sage Therapeutics</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to the Sage collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Sage collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PretaxProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pretax Profit Sharing Formula [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PretaxProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to Denali Therapeutics Collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to Sage Therapeutics</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to the UCB Collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165861408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283160497024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details Textual)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 788.2<span></span>
</td>
<td class="nump">$ 563.3<span></span>
</td>
<td class="nump">$ 1,941.2<span></span>
</td>
<td class="nump">$ 1,770.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,807.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,807.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,749.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards', window );">Payments to Acquire Businesses, Gross, Outstanding Equity Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 983.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Price per share | $ / shares</a></td>
<td class="nump">$ 172.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 7,193.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="nump">6,602.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">196.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="nump">197.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">393.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">1,692.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">151.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">$ 122.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OperatingLeaseArea', window );">Operating Lease Area | ft&#178;</a></td>
<td class="nump">327,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, Operating Lease, Remaining Lease Term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate', window );">Fair Value Indefinite Lived Intangible Assets Discount Rate</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 1,057.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices', window );">Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</a></td>
<td class="nump">590.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed', window );">Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Completed technology for SKYCLARYS (U.S.)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">3,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Priority review voucher</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Other clinical programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 980.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Indefinite Lived Intangible Assets Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Businesses, Gross, Outstanding Equity Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OtherClinicalProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OtherClinicalProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283160270416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Purchase Price Consideration (Details) - Reata Pharmaceuticals, Inc<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="nump">$ 6,602.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices', window );">Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</a></td>
<td class="nump">590.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 7,193.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Price per share | $ / shares</a></td>
<td class="nump">$ 172.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired', window );">Number of common stock shares acquired | shares</a></td>
<td class="nump">38,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Number of Common Stock Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283160872736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions Preliminaty Purchase Price Allocation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 6,807.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,749.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,692.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther', window );">Accrued expense and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Debt payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(159.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Contingent payable to Blackstone(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(922.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(151.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,136.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,057.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total assets acquired and liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,193.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Completed technology for SKYCLARYS (U.S.)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Priority review voucher</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Other clinical programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and (Liabilities) Assumed, Assets,Other Assets And Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued expense And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OtherClinicalProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OtherClinicalProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165720672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dispositions (Details Textual)<br> &#8361; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Equity Method Investment, Amount Sold</a></td>
<td class="nump">$ 2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 422.3<span></span>
</td>
<td class="nump">$ 422.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 798.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At First Anniversary | Discount rates | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsMeasurementInput', window );">Risk-adjusted discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.064<span></span>
</td>
<td class="nump">0.064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture', window );">Proceeds from divestiture of interest in joint venture</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis | &#8361;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 581.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on sale of equity interest in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Cumulative translation loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Gain on derivative used in net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="nump">812.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="nump">$ 437.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="nump">$ 16.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherAssetsCurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Assets, Current, Fair Value Disclosure,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherAssetsCurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherAssetsMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Assets, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherAssetsMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PayablesToDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payables To Divestiture Of Interest In Joint Venture</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PayablesToDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283160861712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 76.0<span></span>
</td>
<td class="nump">$ 15.4<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="nump">$ 124.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember', window );">2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">37.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">23.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">61.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | 2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | 2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges | 2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">37.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">17.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165923792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>Employee</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.0<span></span>
</td>
<td class="nump">$ 21.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember', window );">2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction', window );">Expected operating expense reduction</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated', window );">Expected number of positions eliminated | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.7<span></span>
</td>
<td class="nump">$ 62.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember', window );">2023 Cost Saving Initiatives | Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.7<span></span>
</td>
<td class="nump">$ 62.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Activities, Expected Operating Expense Reduction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected number of positions to be eliminated as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283160112448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 76.0<span></span>
</td>
<td class="nump">$ 15.4<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="nump">$ 124.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance Costs | 2022 Cost Saving Initiative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">110.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance Costs | 2022 Cost Saving Initiative | Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">110.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=biib_AcceleratedDepreciationAndOtherCostsMember', window );">Accelerated Depreciation and Other Costs | 2022 Cost Saving Initiative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=biib_AcceleratedDepreciationAndOtherCostsMember', window );">Accelerated Depreciation and Other Costs | 2022 Cost Saving Initiative | Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain (Loss) on Termination of Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=biib_WorkforceReductionMember', window );">Workforce Reduction | 2022 Cost Saving Initiative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">15.4<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">124.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=biib_WorkforceReductionMember', window );">Workforce Reduction | 2022 Cost Saving Initiative | Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 15.4<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 124.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479092/842-20-40-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2022CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2022CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=biib_AcceleratedDepreciationAndOtherCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=biib_AcceleratedDepreciationAndOtherCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=biib_WorkforceReductionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=biib_WorkforceReductionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165810464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">$ 76.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="nump">$ 124.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember', window );">2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">61.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance Costs | 2022 Cost Saving Initiative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">110.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance Costs | 2023 and 2022 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning</a></td>
<td class="nump">32.3<span></span>
</td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="nump">$ 35.9<span></span>
</td>
<td class="nump">52.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">35.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">58.7<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="nump">60.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payment</a></td>
<td class="num">(31.8)<span></span>
</td>
<td class="num">(13.4)<span></span>
</td>
<td class="num">(15.6)<span></span>
</td>
<td class="num">(32.3)<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="num">(29.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveTranslationAdjustment', window );">Foreign currency and other adjustments</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending</a></td>
<td class="nump">$ 59.3<span></span>
</td>
<td class="nump">$ 32.3<span></span>
</td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="nump">$ 21.5<span></span>
</td>
<td class="nump">$ 52.2<span></span>
</td>
<td class="nump">$ 59.3<span></span>
</td>
<td class="nump">$ 40.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2022CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2022CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2023And2022CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2023And2022CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283159159920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 2,530.3<span></span>
</td>
<td class="nump">$ 2,508.5<span></span>
</td>
<td class="nump">$ 7,449.3<span></span>
</td>
<td class="nump">$ 7,629.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,159.0<span></span>
</td>
<td class="nump">1,340.3<span></span>
</td>
<td class="nump">3,493.5<span></span>
</td>
<td class="nump">4,161.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">631.8<span></span>
</td>
<td class="nump">707.9<span></span>
</td>
<td class="nump">1,814.6<span></span>
</td>
<td class="nump">2,170.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">527.2<span></span>
</td>
<td class="nump">632.4<span></span>
</td>
<td class="nump">1,678.9<span></span>
</td>
<td class="nump">1,990.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">405.0<span></span>
</td>
<td class="nump">476.8<span></span>
</td>
<td class="nump">1,188.1<span></span>
</td>
<td class="nump">1,549.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">206.9<span></span>
</td>
<td class="nump">220.4<span></span>
</td>
<td class="nump">571.9<span></span>
</td>
<td class="nump">713.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">198.1<span></span>
</td>
<td class="nump">256.4<span></span>
</td>
<td class="nump">616.2<span></span>
</td>
<td class="nump">836.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">239.5<span></span>
</td>
<td class="nump">339.0<span></span>
</td>
<td class="nump">768.2<span></span>
</td>
<td class="nump">1,146.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">58.1<span></span>
</td>
<td class="nump">92.5<span></span>
</td>
<td class="nump">199.3<span></span>
</td>
<td class="nump">330.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">181.4<span></span>
</td>
<td class="nump">246.5<span></span>
</td>
<td class="nump">568.9<span></span>
</td>
<td class="nump">816.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">165.5<span></span>
</td>
<td class="nump">137.8<span></span>
</td>
<td class="nump">419.9<span></span>
</td>
<td class="nump">402.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">148.8<span></span>
</td>
<td class="nump">127.9<span></span>
</td>
<td class="nump">372.6<span></span>
</td>
<td class="nump">383.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">16.7<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
<td class="nump">47.3<span></span>
</td>
<td class="nump">19.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">277.7<span></span>
</td>
<td class="nump">336.0<span></span>
</td>
<td class="nump">825.7<span></span>
</td>
<td class="nump">995.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">180.1<span></span>
</td>
<td class="nump">214.5<span></span>
</td>
<td class="nump">492.6<span></span>
</td>
<td class="nump">608.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">97.6<span></span>
</td>
<td class="nump">121.5<span></span>
</td>
<td class="nump">333.1<span></span>
</td>
<td class="nump">387.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">212.2<span></span>
</td>
<td class="nump">255.1<span></span>
</td>
<td class="nump">604.9<span></span>
</td>
<td class="nump">743.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">148.7<span></span>
</td>
<td class="nump">174.8<span></span>
</td>
<td class="nump">397.2<span></span>
</td>
<td class="nump">493.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">63.5<span></span>
</td>
<td class="nump">80.3<span></span>
</td>
<td class="nump">207.7<span></span>
</td>
<td class="nump">249.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">65.5<span></span>
</td>
<td class="nump">80.9<span></span>
</td>
<td class="nump">220.8<span></span>
</td>
<td class="nump">252.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">31.4<span></span>
</td>
<td class="nump">39.7<span></span>
</td>
<td class="nump">95.4<span></span>
</td>
<td class="nump">114.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">34.1<span></span>
</td>
<td class="nump">41.2<span></span>
</td>
<td class="nump">125.4<span></span>
</td>
<td class="nump">138.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">456.3<span></span>
</td>
<td class="nump">505.5<span></span>
</td>
<td class="nump">1,412.2<span></span>
</td>
<td class="nump">1,542.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">244.8<span></span>
</td>
<td class="nump">273.0<span></span>
</td>
<td class="nump">750.1<span></span>
</td>
<td class="nump">849.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">211.5<span></span>
</td>
<td class="nump">232.5<span></span>
</td>
<td class="nump">662.1<span></span>
</td>
<td class="nump">693.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">67.5<span></span>
</td>
<td class="nump">73.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">67.5<span></span>
</td>
<td class="nump">73.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">448.2<span></span>
</td>
<td class="nump">431.1<span></span>
</td>
<td class="nump">1,328.6<span></span>
</td>
<td class="nump">1,334.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">150.5<span></span>
</td>
<td class="nump">140.2<span></span>
</td>
<td class="nump">453.0<span></span>
</td>
<td class="nump">443.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">297.7<span></span>
</td>
<td class="nump">290.9<span></span>
</td>
<td class="nump">875.6<span></span>
</td>
<td class="nump">891.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">194.3<span></span>
</td>
<td class="nump">187.6<span></span>
</td>
<td class="nump">581.8<span></span>
</td>
<td class="nump">576.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">21.3<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">188.2<span></span>
</td>
<td class="nump">186.9<span></span>
</td>
<td class="nump">560.5<span></span>
</td>
<td class="nump">575.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">112.8<span></span>
</td>
<td class="nump">110.2<span></span>
</td>
<td class="nump">331.0<span></span>
</td>
<td class="nump">340.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">112.8<span></span>
</td>
<td class="nump">110.2<span></span>
</td>
<td class="nump">331.0<span></span>
</td>
<td class="nump">340.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">54.4<span></span>
</td>
<td class="nump">57.7<span></span>
</td>
<td class="nump">167.6<span></span>
</td>
<td class="nump">172.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">54.4<span></span>
</td>
<td class="nump">57.7<span></span>
</td>
<td class="nump">167.6<span></span>
</td>
<td class="nump">172.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
<td class="nump">60.7<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
<td class="nump">60.7<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">21.3<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,805.2<span></span>
</td>
<td class="nump">1,962.1<span></span>
</td>
<td class="nump">5,414.3<span></span>
</td>
<td class="nump">6,083.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">790.9<span></span>
</td>
<td class="nump">850.4<span></span>
</td>
<td class="nump">2,293.3<span></span>
</td>
<td class="nump">2,619.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,014.3<span></span>
</td>
<td class="nump">1,111.7<span></span>
</td>
<td class="nump">3,121.0<span></span>
</td>
<td class="nump">3,463.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember', window );">FUMADERM And ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember', window );">FUMADERM And ADUHELM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember', window );">FUMADERM And ADUHELM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SpinalMuscularAtrophyMember', window );">Spinal Muscular Atrophy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">448.2<span></span>
</td>
<td class="nump">431.1<span></span>
</td>
<td class="nump">1,328.6<span></span>
</td>
<td class="nump">1,334.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SpinalMuscularAtrophyMember', window );">Spinal Muscular Atrophy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">150.5<span></span>
</td>
<td class="nump">140.2<span></span>
</td>
<td class="nump">453.0<span></span>
</td>
<td class="nump">443.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SpinalMuscularAtrophyMember', window );">Spinal Muscular Atrophy | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 297.7<span></span>
</td>
<td class="nump">$ 290.9<span></span>
</td>
<td class="nump">$ 875.6<span></span>
</td>
<td class="nump">$ 891.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FumarateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FumarateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TECFIDERAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_VUMERITYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_VUMERITYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_PLEGRIDYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BYOOVIZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SpinalMuscularAtrophyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SpinalMuscularAtrophyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165155952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 1,035.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">2,551.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(4.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,774.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(735.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,072.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">153.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">554.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(410.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(137.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">160.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">857.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">1,983.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(24.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,362.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(574.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">879.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">23.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">14.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">19.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(2.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(23.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 32.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C(1)))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C(2)))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283164601376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues- Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,072.3<span></span>
</td>
<td class="nump">$ 1,035.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">131.4<span></span>
</td>
<td class="nump">143.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 940.9<span></span>
</td>
<td class="nump">$ 891.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165027312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 2,530.3<span></span>
</td>
<td class="nump">$ 2,508.5<span></span>
</td>
<td class="nump">$ 7,449.3<span></span>
</td>
<td class="nump">$ 7,629.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="nump">98.9<span></span>
</td>
<td class="nump">131.1<span></span>
</td>
<td class="nump">315.0<span></span>
</td>
<td class="nump">414.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">13.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">420.9<span></span>
</td>
<td class="nump">416.9<span></span>
</td>
<td class="nump">1,253.8<span></span>
</td>
<td class="nump">1,252.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RoyaltyAttributedToOCREVUSMember', window );">Royalty Attributed To OCREVUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 319.1<span></span>
</td>
<td class="nump">$ 281.1<span></span>
</td>
<td class="nump">$ 928.2<span></span>
</td>
<td class="nump">$ 825.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RoyaltyAttributedToOCREVUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RoyaltyAttributedToOCREVUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165926720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,530.3<span></span>
</td>
<td class="nump">$ 2,508.5<span></span>
</td>
<td class="nump">$ 7,449.3<span></span>
</td>
<td class="nump">$ 7,629.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ContractManufacturingAndOtherRevenueMember', window );">Contract manufacturing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">252.9<span></span>
</td>
<td class="nump">114.2<span></span>
</td>
<td class="nump">742.9<span></span>
</td>
<td class="nump">242.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">51.3<span></span>
</td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">38.3<span></span>
</td>
<td class="nump">50.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Contract manufacturing, royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 304.2<span></span>
</td>
<td class="nump">$ 129.5<span></span>
</td>
<td class="nump">$ 781.2<span></span>
</td>
<td class="nump">$ 293.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ContractManufacturingAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ContractManufacturingAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283158996640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfWholesalers', window );">Number of wholesalers | wholesaler</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 2,530.3<span></span>
</td>
<td class="nump">$ 2,508.5<span></span>
</td>
<td class="nump">$ 7,449.3<span></span>
</td>
<td class="nump">$ 7,629.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 788.2<span></span>
</td>
<td class="nump">$ 563.3<span></span>
</td>
<td class="nump">$ 1,941.2<span></span>
</td>
<td class="nump">$ 1,770.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">26.90%<span></span>
</td>
<td class="nump">26.90%<span></span>
</td>
<td class="nump">27.10%<span></span>
</td>
<td class="nump">26.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">9.10%<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Contract manufacturing, royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 304.2<span></span>
</td>
<td class="nump">$ 129.5<span></span>
</td>
<td class="nump">$ 781.2<span></span>
</td>
<td class="nump">$ 293.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember', window );">LEQEMBI Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfNonControlingInterestRecognized', window );">Share of non-controling interest recognized</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfWholesalers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Wholesalers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfWholesalers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfNonControlingInterestRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Of Non-Controling Interest Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfNonControlingInterestRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283159094752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Components of Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 437.1<span></span>
</td>
<td class="nump">$ 413.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">2,285.1<span></span>
</td>
<td class="nump">751.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">316.1<span></span>
</td>
<td class="nump">200.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InventoryNetCurrentAndNoncurrent', window );">Inventory</a></td>
<td class="nump">3,038.3<span></span>
</td>
<td class="nump">1,365.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, current</a></td>
<td class="nump">2,982.4<span></span>
</td>
<td class="nump">1,344.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, noncurrent</a></td>
<td class="nump">$ 55.9<span></span>
</td>
<td class="nump">$ 21.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryNetCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory, Net Current and Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryNetCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283158102240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.1<span></span>
</td>
<td class="nump">$ 321.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InventoryNetCurrentAndNoncurrent', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,038.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,365.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="nump">$ 275.0<span></span>
</td>
<td class="nump">$ 275.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | Eisai | Centers for Medicare and Medicaid Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryNetCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory, Net Current and Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryNetCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=biib_CentersForMedicareAndMedicaidServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=biib_CentersForMedicareAndMedicaidServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283157989776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">$ 13,137.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,137.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,479.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,793.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,793.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,629.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">7,344.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,344.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">60.9<span></span>
</td>
<td class="nump">$ 56.5<span></span>
</td>
<td class="nump">164.0<span></span>
</td>
<td class="nump">$ 190.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2023 (remaining three months)</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2024</a></td>
<td class="nump">325.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2025</a></td>
<td class="nump">430.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2026</a></td>
<td class="nump">440.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2027</a></td>
<td class="nump">435.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2028</a></td>
<td class="nump">445.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Completed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">11,053.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,053.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,415.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">5,260.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,260.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,786.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (5,793.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,793.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,629.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Completed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Completed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">28 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">28 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember', window );">Completed technology for SKYCLARYS (U.S.) | Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">1,920.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,920.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">1,920.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,920.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember', window );">Priority review voucher</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_SKYCLARYSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171462736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">$ 5,749,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill resulting from Reata acquisition</a></td>
<td class="nump">1,057,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">6,807,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283161284672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,179.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative contracts</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 1,920.4<span></span>
</td>
<td class="nump">2,847.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">413.6<span></span>
</td>
<td class="nump">791.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">27.8<span></span>
</td>
<td class="nump">63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">39.0<span></span>
</td>
<td class="nump">32.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">2,826.5<span></span>
</td>
<td class="nump">7,117.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195.4<span></span>
</td>
<td class="nump">$ 197.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="nump">422.3<span></span>
</td>
<td class="nump">798.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,231.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">413.6<span></span>
</td>
<td class="nump">791.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">413.6<span></span>
</td>
<td class="nump">791.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,920.4<span></span>
</td>
<td class="nump">2,847.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">27.8<span></span>
</td>
<td class="nump">63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">39.0<span></span>
</td>
<td class="nump">32.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative contracts</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">1,990.6<span></span>
</td>
<td class="nump">5,122.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,231.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">422.3<span></span>
</td>
<td class="nump">1,204.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="nump">$ 422.3<span></span>
</td>
<td class="nump">798.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherAssetsCurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Assets, Current, Fair Value Disclosure,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherAssetsCurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283172653136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165665488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">$ 6,286.4<span></span>
</td>
<td class="nump">$ 6,281.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="nump">5,198.5<span></span>
</td>
<td class="nump">5,410.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB054Member', window );">BIIB054</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Reduction in contingent consideration</a></td>
<td class="nump">195.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,689.6<span></span>
</td>
<td class="nump">1,699.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">1,746.2<span></span>
</td>
<td class="nump">1,744.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">972.7<span></span>
</td>
<td class="nump">1,033.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">1,100.5<span></span>
</td>
<td class="nump">1,100.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,196.2<span></span>
</td>
<td class="nump">1,219.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">1,493.6<span></span>
</td>
<td class="nump">1,492.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">430.8<span></span>
</td>
<td class="nump">469.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">471.9<span></span>
</td>
<td class="nump">469.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">909.2<span></span>
</td>
<td class="nump">989.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">$ 1,474.2<span></span>
</td>
<td class="nump">$ 1,473.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB054Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB054Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283160049328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 13.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283167676272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 1,920.4<span></span>
</td>
<td class="nump">$ 2,847.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">177.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">1,920.4<span></span>
</td>
<td class="nump">2,581.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 29.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283159101936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,199.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,179.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">$ 993.3<span></span>
</td>
<td class="nump">1,133.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(579.7)<span></span>
</td>
<td class="num">(342.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">413.6<span></span>
</td>
<td class="nump">791.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">936.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">931.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember', window );">Equity Securities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,133.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(342.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 791.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember', window );">Equity Securities, Non-Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">993.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(579.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">$ 413.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283168326864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">$ 1,483.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">1,473.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, amortized cost</a></td>
<td class="nump">703.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, estimated fair value</a></td>
<td class="nump">694.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">12.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">11.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,179.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 2,199.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283172370704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 5,698.6<span></span>
</td>
<td class="nump">$ 1,643.2<span></span>
</td>
<td class="nump">$ 7,380.8<span></span>
</td>
<td class="nump">$ 3,104.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses</a></td>
<td class="nump">$ 16.3<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="nump">$ 18.4<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283172862256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">8 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171078272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 465.5<span></span>
</td>
<td class="nump">$ 846.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283161572064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (loss) on foreign currency derivative instruments not designated as hedging instruments</a></td>
<td class="num">$ (22.6)<span></span>
</td>
<td class="num">$ (36.5)<span></span>
</td>
<td class="num">$ (28.0)<span></span>
</td>
<td class="num">$ (85.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges, net of tax</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(25.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">$ 1,340.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,340.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,238.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">20.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">32.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">1,144.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,144.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,715.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UnrealizedGainOnDerivatives', window );">Unrealized Gain on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
<td class="nump">29.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UnrealizedLossOnDerivatives', window );">Unrealized Loss on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
<td class="num">(21.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized Gain (Loss) on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease', window );">Gains (losses) on net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="nump">77.7<span></span>
</td>
<td class="nump">18.3<span></span>
</td>
<td class="nump">143.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">1,006.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,006.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">43.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="nump">$ 78.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember', window );">Short-term derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gain on Derivatives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized Loss on Derivatives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480238/815-25-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283161522080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,342.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,342.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,165.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.1<span></span>
</td>
<td class="nump">$ 64.2<span></span>
</td>
<td class="nump">190.7<span></span>
</td>
<td class="nump">$ 207.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">582.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">503.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">503.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,301.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,298.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_A125BroadwayBuildingSaleMember', window );">125 Broadway Building Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sales price</a></td>
<td class="nump">$ 603.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance', window );">Gain (Loss) on Disposition of Property Plant Equipment, Tenant Allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">79.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_A125BroadwayBuildingSaleMember', window );">125 Broadway Building Sale | 125 Broadway Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_A125BroadwayBuildingSaleMember', window );">125 Broadway Building Sale | Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_A125BroadwayBuildingSaleMember', window );">125 Broadway Building Sale | Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember', window );">Biologics Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember', window );">Warehouse, Utilities and Support Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember', window );">Administrative Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 742.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 742.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 711.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Disposition of Property Plant Equipment, Tenant Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSquareFeet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Square Feet</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSquareFeet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_A125BroadwayBuildingSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_A125BroadwayBuildingSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_BiologicsManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_AdministrativeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165039712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 460.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OperatingLeaseRightOfUseAssetDerecognized', window );">Right-of-use assets derecognized</a></td>
<td class="nump">$ 47.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OperatingLeaseLiabilityDerecognized', window );">Lease liabilities derecognized</a></td>
<td class="nump">52.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_GainLossOnRestructuringCharges', window );">Gain due to lease termination</a></td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">125 Broadway Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OperatingLeaseArea', window );">Operating Lease Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, Operating Lease, Remaining Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GainLossOnRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Restructuring Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GainLossOnRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingLeaseLiabilityDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liability, Derecognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingLeaseLiabilityDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingLeaseRightOfUseAssetDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset, Derecognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingLeaseRightOfUseAssetDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283166820960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Sep. 15, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DebtInstrumentRedemptionRate', window );">Redemption rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember', window );">Credit Facility Floating Rate 364-Day Tranche | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember', window );">The Credit Facility Floating Rate Three-Year Tranche | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityTerminatedMember', window );">The Credit Facility, Terminated | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember', window );">The Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember', window );">The Credit Facility | Line of Credit | Secured Debt | Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentRedemptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentRedemptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityTerminatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityTerminatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283172135552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchases (Details) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost (in shares)</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock, value, acquired, cost method</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember', window );">2020 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount remaining under 2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock, value, acquired, cost method</a></td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="nump">$ 750,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283161476704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (164.9)<span></span>
</td>
<td class="num">$ (106.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">$ (159.3)<span></span>
</td>
<td class="num">$ (163.6)<span></span>
</td>
<td class="num">(159.3)<span></span>
</td>
<td class="num">(163.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">40.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
<td class="num">(97.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">13.5<span></span>
</td>
<td class="num">(53.2)<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="num">(56.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(159.3)<span></span>
</td>
<td class="num">(163.6)<span></span>
</td>
<td class="num">(159.3)<span></span>
</td>
<td class="num">(163.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">13.5<span></span>
</td>
<td class="num">(53.2)<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="num">(56.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.7)<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(21.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(21.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="num">(26.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.4<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
<td class="num">(19.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(21.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(21.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
<td class="nump">53.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">132.8<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">132.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.9<span></span>
</td>
<td class="nump">204.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.8)<span></span>
</td>
<td class="num">(125.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">79.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">132.8<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">132.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(44.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(40.6)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(40.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(40.6)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(40.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163.2)<span></span>
</td>
<td class="num">(139.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(175.0)<span></span>
</td>
<td class="num">(234.6)<span></span>
</td>
<td class="num">(175.0)<span></span>
</td>
<td class="num">(234.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.8)<span></span>
</td>
<td class="num">(154.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">58.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.8)<span></span>
</td>
<td class="num">(95.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (175.0)<span></span>
</td>
<td class="num">$ (234.6)<span></span>
</td>
<td class="num">$ (175.0)<span></span>
</td>
<td class="num">$ (234.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283158120848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="num">$ (300.0)<span></span>
</td>
<td class="nump">$ 56.0<span></span>
</td>
<td class="num">$ (248.2)<span></span>
</td>
<td class="nump">$ 221.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(72.9)<span></span>
</td>
<td class="nump">236.2<span></span>
</td>
<td class="nump">92.6<span></span>
</td>
<td class="nump">578.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,530.3<span></span>
</td>
<td class="nump">2,508.5<span></span>
</td>
<td class="nump">7,449.3<span></span>
</td>
<td class="nump">7,629.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Biogen Inc.</a></td>
<td class="num">$ (68.1)<span></span>
</td>
<td class="nump">1,134.7<span></span>
</td>
<td class="nump">$ 911.4<span></span>
</td>
<td class="nump">2,496.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Biogen Inc.</a></td>
<td class="num">$ (12.6)<span></span>
</td>
<td class="nump">62.8<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="nump">97.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="num">(15.2)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
<td class="num">(9.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="nump">77.7<span></span>
</td>
<td class="nump">18.3<span></span>
</td>
<td class="nump">143.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Currency translation adjustments | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (58.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165472752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Biogen Inc.</a></td>
<td class="num">$ (68.1)<span></span>
</td>
<td class="nump">$ 1,134.7<span></span>
</td>
<td class="nump">$ 911.4<span></span>
</td>
<td class="nump">$ 2,496.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">144,800<span></span>
</td>
<td class="nump">144,400<span></span>
</td>
<td class="nump">144,700<span></span>
</td>
<td class="nump">145,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">144,800<span></span>
</td>
<td class="nump">144,800<span></span>
</td>
<td class="nump">145,500<span></span>
</td>
<td class="nump">146,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165490160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (64.8)<span></span>
</td>
<td class="num">$ (65.7)<span></span>
</td>
<td class="num">$ (217.8)<span></span>
</td>
<td class="num">$ (194.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">452.0<span></span>
</td>
<td class="nump">71.0<span></span>
</td>
<td class="nump">609.7<span></span>
</td>
<td class="nump">201.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="num">(7.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449.4<span></span>
</td>
<td class="nump">69.0<span></span>
</td>
<td class="nump">601.2<span></span>
</td>
<td class="nump">194.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98.5)<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
<td class="num">(126.5)<span></span>
</td>
<td class="num">(36.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">788.2<span></span>
</td>
<td class="nump">563.3<span></span>
</td>
<td class="nump">1,941.2<span></span>
</td>
<td class="nump">1,770.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">$ 393.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, General and Administrative Expense</a></td>
<td class="nump">196.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="nump">$ 197.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217.1<span></span>
</td>
<td class="nump">24.5<span></span>
</td>
<td class="nump">276.3<span></span>
</td>
<td class="nump">72.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234.9<span></span>
</td>
<td class="nump">46.5<span></span>
</td>
<td class="nump">333.4<span></span>
</td>
<td class="nump">129.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350.9<span></span>
</td>
<td class="nump">$ 56.0<span></span>
</td>
<td class="nump">$ 474.7<span></span>
</td>
<td class="nump">$ 158.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283158342144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (64.8)<span></span>
</td>
<td class="num">$ (65.7)<span></span>
</td>
<td class="num">$ (217.8)<span></span>
</td>
<td class="num">$ (194.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">452.0<span></span>
</td>
<td class="nump">71.0<span></span>
</td>
<td class="nump">609.7<span></span>
</td>
<td class="nump">201.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="num">(7.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">449.4<span></span>
</td>
<td class="nump">69.0<span></span>
</td>
<td class="nump">601.2<span></span>
</td>
<td class="nump">194.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">53.4<span></span>
</td>
<td class="nump">48.7<span></span>
</td>
<td class="nump">175.0<span></span>
</td>
<td class="nump">150.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">27.1<span></span>
</td>
<td class="nump">22.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EquityAwardsOfAcquiredCompanyMember', window );">Equity Awards Of Acquired Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 387.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 387.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EquityAwardsOfAcquiredCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EquityAwardsOfAcquiredCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283160950928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, unrecognized tax benefit</a></td>
<td class="nump">$ 85.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="nump">460.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283159867440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="num">(3.40%)<span></span>
</td>
<td class="num">(6.10%)<span></span>
</td>
<td class="num">(4.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="nump">24.60%<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(7.70%)<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="num">(2.30%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent', window );">GILTI</a></td>
<td class="nump">14.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis', window );">Sale of Samsung Bioepis</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationLitigationAgreement', window );">Litigation settlement agreement</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts', window );">Neurimmune tax impacts</a></td>
<td class="num">(0.001)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationInternationalReorganization', window );">International reorganization</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(7.70%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">51.60%<span></span>
</td>
<td class="nump">17.20%<span></span>
</td>
<td class="nump">9.20%<span></span>
</td>
<td class="nump">19.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationInternationalReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, International Reorganization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationInternationalReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationLitigationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Litigation Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationLitigationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Sale Of Samsung Bioepis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165071664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on sale of equity interest in Samsung Bioepis(1)</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (1,505.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement agreement</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(95.9)<span></span>
</td>
<td class="num">(23.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(252.7)<span></span>
</td>
<td class="num">(39.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">63.8<span></span>
</td>
<td class="nump">59.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175.4<span></span>
</td>
<td class="nump">191.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">(Gains) losses on investments, net</a></td>
<td class="nump">317.3<span></span>
</td>
<td class="num">(101.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289.6<span></span>
</td>
<td class="nump">167.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (gains) losses, net</a></td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.8<span></span>
</td>
<td class="nump">39.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="num">(56.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248.2<span></span>
</td>
<td class="num">(221.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net (gains) losses recognized on equity securities</a></td>
<td class="nump">302.0<span></span>
</td>
<td class="num">(109.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273.6<span></span>
</td>
<td class="nump">158.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net (gains) losses realized on equity securities</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains) losses recognized on equity securities</a></td>
<td class="nump">297.6<span></span>
</td>
<td class="num">(109.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268.3<span></span>
</td>
<td class="nump">158.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Reata acquisition-related accrued expense</a></td>
<td class="nump">1,407.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,407.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">1,072.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,072.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,035.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Collaboration expense</a></td>
<td class="nump">276.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">202.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expense</a></td>
<td class="nump">298.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">712.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">746.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expense and other</a></td>
<td class="nump">$ 3,838.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,838.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,521.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains) losses recognized on equity securities</a></td>
<td class="nump">$ 295.6<span></span>
</td>
<td class="nump">$ 112.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265.0<span></span>
</td>
<td class="nump">$ 198.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 940.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 940.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 891.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283156165472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297.6<span></span>
</td>
<td class="num">(109.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268.3<span></span>
</td>
<td class="nump">158.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Net gains (losses) realized during the period on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">747.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">747.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 944.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 541.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on research and development contracts terminated with Eisai</a></td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="nump">$ 6,602.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 980.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295.6<span></span>
</td>
<td class="nump">$ 112.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265.0<span></span>
</td>
<td class="nump">198.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Net gains recognized on the decrease in fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 275<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482094/912-275-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165047136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - OCREVUS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage', window );">Royalty operating profit threshold for highest royalty rate percentage</a></td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Reductioninroyaltyrate', window );">Reduction in royalty rate</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PeriodOfCollaborationAgreement', window );">Collaboration agreement term</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Royalty percentage to be received</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Royalty percentage to be received</a></td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Royalty percentage to be received</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MosunetuzumabMember', window );">Mosunetuzumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfFutureDevelopmentCosts', window );">Percentage of future development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future royalties percentage to be received on sale of product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfFutureDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Future Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfFutureDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PeriodOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period Of Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PeriodOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyrate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyrate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty operating profit threshold for highest royalty rate percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OCREVUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OCREVUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MosunetuzumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MosunetuzumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283160463280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Profit Sharing (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion', window );">Percentage of co promotion operating profits first fifty million</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">Until Second GAZYVA Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second GAZYVA Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour', window );">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_GAZYVAMember', window );">GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment', window );">Co-promotion operating profit threshold for Rituxan in US and Canada to determine share of co promotion operating profit prior to amendment</a></td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">Until Second GAZYVA Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second GAZYVA Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</a></td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</a></td>
<td class="nump">150.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SalesTriggerGrossSalesThreshold', window );">Sales trigger gross sales threshold</a></td>
<td class="nump">$ 350.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits first fifty million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SalesTriggerGrossSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales trigger gross sales threshold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SalesTriggerGrossSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales to be achieved in any twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283171186784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Eisai (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember', window );">LEQEMBI Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AccruedPaymentToTerminationAgreement', window );">Payable Due To Termination Agreement</a></td>
<td class="nump">$ 31.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccruedPaymentToTerminationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Payment To Termination Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccruedPaymentToTerminationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283158117920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details) - Eisai - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member', window );">E2609 and BAN2401</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</a></td>
<td class="nump">$ 88.5<span></span>
</td>
<td class="nump">$ 109.3<span></span>
</td>
<td class="nump">$ 282.6<span></span>
</td>
<td class="nump">$ 264.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">44.3<span></span>
</td>
<td class="nump">54.7<span></span>
</td>
<td class="nump">141.3<span></span>
</td>
<td class="nump">132.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | E2609 and BAN2401</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">81.7<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="nump">95.5<span></span>
</td>
<td class="nump">34.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">$ 163.4<span></span>
</td>
<td class="nump">29.0<span></span>
</td>
<td class="nump">$ 191.0<span></span>
</td>
<td class="nump">68.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283160878592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.1<span></span>
</td>
<td class="nump">$ 321.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275.0<span></span>
</td>
<td class="nump">$ 275.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AccountsReceivableFromCollaborator', window );">Amounts receivable</a></td>
<td class="nump">$ 34.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AccountsPayableToCollaborator', window );">Amounts payable</a></td>
<td class="nump">122.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | Collaboration profit sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CollaborativeArrangementProfitLossSharing', window );">Recognized net reductions to operating expense</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM | Inventory, Idle Capacity Charges And Contractual Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CollaborativeArrangementProfitLossSharing', window );">Recognized net reductions to operating expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccountsPayableToCollaborator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, To Collaborator</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccountsPayableToCollaborator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccountsReceivableFromCollaborator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, From Collaborator</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccountsReceivableFromCollaborator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborativeArrangementProfitLossSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Profit (Loss) Sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborativeArrangementProfitLossSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=biib_CollaborationProfitSharingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=biib_CollaborationProfitSharingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborativeArrangementProfitLossSharingComponentsAxis=biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborativeArrangementProfitLossSharingComponentsAxis=biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283156153200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 788.2<span></span>
</td>
<td class="nump">$ 563.3<span></span>
</td>
<td class="nump">$ 1,941.2<span></span>
</td>
<td class="nump">$ 1,770.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AggregateGrossIdleCapacityCharges', window );">Aggregate gross idle capacity charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember', window );">LEQEMBI Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfNonControlingInterestRecognized', window );">Share of non-controling interest recognized</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AggregateGrossIdleCapacityCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Gross Idle Capacity Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AggregateGrossIdleCapacityCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfNonControlingInterestRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Of Non-Controling Interest Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfNonControlingInterestRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165003216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details) - Research and development - UCB Pharma S.A. - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">$ 13.6<span></span>
</td>
<td class="nump">$ 18.3<span></span>
</td>
<td class="nump">$ 46.2<span></span>
</td>
<td class="nump">$ 51.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="nump">$ 23.1<span></span>
</td>
<td class="nump">$ 25.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283165753120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfNetProfitFromSageTherapeuticsPercent', window );">Share of net profit from sage therapeutics, Percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="nump">$ 50.5<span></span>
</td>
<td class="nump">$ 45.3<span></span>
</td>
<td class="nump">$ 164.5<span></span>
</td>
<td class="num">$ (42.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Sage Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">72.0<span></span>
</td>
<td class="nump">40.9<span></span>
</td>
<td class="nump">158.9<span></span>
</td>
<td class="nump">130.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">36.0<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
<td class="nump">79.5<span></span>
</td>
<td class="nump">65.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Sage Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">54.0<span></span>
</td>
<td class="nump">28.5<span></span>
</td>
<td class="nump">152.3<span></span>
</td>
<td class="nump">69.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">$ 27.0<span></span>
</td>
<td class="nump">$ 14.2<span></span>
</td>
<td class="nump">$ 76.1<span></span>
</td>
<td class="nump">$ 34.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfNetProfitFromSageTherapeuticsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Of Net Profit From Sage Therapeutics, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfNetProfitFromSageTherapeuticsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283172200016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details) - Research and development - Denali Therapeutics - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">$ 12.6<span></span>
</td>
<td class="nump">$ 19.9<span></span>
</td>
<td class="nump">$ 51.3<span></span>
</td>
<td class="nump">$ 58.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="nump">$ 11.4<span></span>
</td>
<td class="nump">$ 30.8<span></span>
</td>
<td class="nump">$ 33.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283164601376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Other Arrangements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 736.3<span></span>
</td>
<td class="nump">$ 549.2<span></span>
</td>
<td class="nump">$ 1,891.1<span></span>
</td>
<td class="nump">$ 1,629.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember', window );">Other research and discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 51.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283157435376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Samsung Bioepis (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>product</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.5<span></span>
</td>
<td class="nump">$ 45.3<span></span>
</td>
<td class="nump">$ 164.5<span></span>
</td>
<td class="num">$ (42.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.4<span></span>
</td>
<td class="nump">$ 48.7<span></span>
</td>
<td class="nump">$ 170.4<span></span>
</td>
<td class="nump">$ 171.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ContingentCommercializedRightsNumberOfProducts', window );">Contingent Commercialized Rights, Number Of Products | product</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Expected profit share percentage</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ContractOptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContingentCommercializedRightsNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Commercialized Rights, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContingentCommercializedRightsNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContractOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContractOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481058/954-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283160477200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, unrecognized tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ResearchAndDevelopmentCostsPercentage', window );">Research and development costs, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Costs, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140283160344304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,900<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=biib_ERISAClassActionLitigaitonMember', window );">ERISA Class Action Litigaiton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation Settlement, Amount Awarded to Other Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=biib_GenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Brazil tax assessment, including interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=biib_LenderDisputeMember', window );">Lender Dispute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Brazil tax assessment, including interest and penalties</a></td>
<td class="nump">$ 23,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_BardoxoloneSecuritiesMember', window );">Bardoxolone Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation Settlement, Amount Awarded to Other Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=biib_ERISAClassActionLitigaitonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=biib_ERISAClassActionLitigaitonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=biib_GenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=biib_GenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=biib_LenderDisputeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=biib_LenderDisputeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_BardoxoloneSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_BardoxoloneSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>biib-20230930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20230930"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:currency="http://xbrl.sec.gov/currency/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20230930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OtherClinicalProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:AcceleratedDepreciationAndOtherCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:AcceleratedDepreciationAndOtherCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:AcceleratedDepreciationAndOtherCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:AcceleratedDepreciationAndOtherCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:AcceleratedDepreciationAndOtherCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:AcceleratedDepreciationAndOtherCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:AcceleratedDepreciationAndOtherCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:AcceleratedDepreciationAndOtherCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SpinalMuscularAtrophyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CentersForMedicareAndMedicaidServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB054Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingSaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingSaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingSaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRate364DayTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityTerminatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRate364DayTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2015-09-15</instant>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EquityAwardsOfAcquiredCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EquityAwardsOfAcquiredCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EquityAwardsOfAcquiredCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EquityAwardsOfAcquiredCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MosunetuzumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">biib:CollaborationProfitSharingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">biib:CollaborationProfitSharingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:CollaborativeArrangementProfitLossSharingComponentsAxis">biib:InventoryIdleCapacityChargesAndContractualCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-746">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-748">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:ERISAClassActionLitigaitonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c-752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:BardoxoloneSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:LenderDisputeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="employee">
        <measure>biib:Employee</measure>
    </unit>
    <unit id="wholesaler">
        <measure>biib:wholesaler</measure>
    </unit>
    <unit id="product">
        <measure>biib:product</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0000875045</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-30" unitRef="shares">144898112</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-451" id="f-1041">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-452" id="f-1042">P28Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">144898112</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues contextRef="c-3" decimals="-5" id="f-31" unitRef="usd">1805200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-4" decimals="-5" id="f-32" unitRef="usd">1962100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-5" id="f-33" unitRef="usd">5414300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-5" id="f-34" unitRef="usd">6083300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="-5" id="f-35" unitRef="usd">420900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-5" id="f-36" unitRef="usd">416900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-9" decimals="-5" id="f-37" unitRef="usd">1253800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-10" decimals="-5" id="f-38" unitRef="usd">1252600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-11" decimals="-5" id="f-39" unitRef="usd">304200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-12" decimals="-5" id="f-40" unitRef="usd">129500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-13" decimals="-5" id="f-41" unitRef="usd">781200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-14" decimals="-5" id="f-42" unitRef="usd">293500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-15" decimals="-5" id="f-43" unitRef="usd">2530300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-16" decimals="-5" id="f-44" unitRef="usd">2508500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-5" id="f-45" unitRef="usd">7449300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-17" decimals="-5" id="f-46" unitRef="usd">7629400000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-15" decimals="-5" id="f-47" unitRef="usd">659600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-16" decimals="-5" id="f-48" unitRef="usd">469500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-5" id="f-49" unitRef="usd">1915100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-17" decimals="-5" id="f-50" unitRef="usd">1707400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-15" decimals="-5" id="f-51" unitRef="usd">736300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-16" decimals="-5" id="f-52" unitRef="usd">549200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-5" id="f-53" unitRef="usd">1891100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-17" decimals="-5" id="f-54" unitRef="usd">1629500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-15" decimals="-5" id="f-55" unitRef="usd">788200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-16" decimals="-5" id="f-56" unitRef="usd">563300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-5" id="f-57" unitRef="usd">1941200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-17" decimals="-5" id="f-58" unitRef="usd">1770800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-15" decimals="-5" id="f-59" unitRef="usd">60900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-16" decimals="-5" id="f-60" unitRef="usd">56500000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-1" decimals="-5" id="f-61" unitRef="usd">164000000.0</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-17" decimals="-5" id="f-62" unitRef="usd">190900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:Collaborationprofitlosssharing contextRef="c-15" decimals="-5" id="f-63" unitRef="usd">50500000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-16" decimals="-5" id="f-64" unitRef="usd">45300000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-1" decimals="-5" id="f-65" unitRef="usd">164500000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-17" decimals="-5" id="f-66" unitRef="usd">-42600000</biib:Collaborationprofitlosssharing>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-15" decimals="-5" id="f-67" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-16" decimals="-5" id="f-68" unitRef="usd">2100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-5" id="f-69" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-17" decimals="-5" id="f-70" unitRef="usd">13700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:RestructuringCharges contextRef="c-15" decimals="-5" id="f-71" unitRef="usd">76000000.0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-16" decimals="-5" id="f-72" unitRef="usd">15400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-5" id="f-73" unitRef="usd">120000000.0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-17" decimals="-5" id="f-74" unitRef="usd">124100000</us-gaap:RestructuringCharges>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-15" decimals="-5" id="f-75" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-16" decimals="-5" id="f-76" unitRef="usd">503700000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-5" id="f-77" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-17" decimals="-5" id="f-78" unitRef="usd">503700000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-15" decimals="-5" id="f-79" unitRef="usd">-300000000.0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-16" decimals="-5" id="f-80" unitRef="usd">56000000.0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-5" id="f-81" unitRef="usd">-248200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-17" decimals="-5" id="f-82" unitRef="usd">221300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses contextRef="c-15" decimals="-5" id="f-83" unitRef="usd">2671500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-16" decimals="-5" id="f-84" unitRef="usd">1137400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-5" id="f-85" unitRef="usd">6444100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-17" decimals="-5" id="f-86" unitRef="usd">4641400000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-15" decimals="-5" id="f-87" unitRef="usd">-141200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-16" decimals="-5" id="f-88" unitRef="usd">1371100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-5" id="f-89" unitRef="usd">1005200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-17" decimals="-5" id="f-90" unitRef="usd">2988000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-5" id="f-91" unitRef="usd">-72900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-5" id="f-92" unitRef="usd">236200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-93" unitRef="usd">92600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-17" decimals="-5" id="f-94" unitRef="usd">578500000</us-gaap:IncomeTaxExpenseBenefit>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax contextRef="c-15" decimals="-5" id="f-95" unitRef="usd">0</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax contextRef="c-16" decimals="-5" id="f-96" unitRef="usd">0</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax contextRef="c-1" decimals="-5" id="f-97" unitRef="usd">0</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax contextRef="c-17" decimals="-5" id="f-98" unitRef="usd">2600000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-5" id="f-99" unitRef="usd">-68300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-5" id="f-100" unitRef="usd">1134900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-5" id="f-101" unitRef="usd">912600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-5" id="f-102" unitRef="usd">2412100000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-15" decimals="-5" id="f-103" unitRef="usd">-200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-16" decimals="-5" id="f-104" unitRef="usd">200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-105" unitRef="usd">1200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-17" decimals="-5" id="f-106" unitRef="usd">-84400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-5" id="f-107" unitRef="usd">-68100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-5" id="f-108" unitRef="usd">1134700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-109" unitRef="usd">911400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-5" id="f-110" unitRef="usd">2496500000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-111"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-16"
      decimals="2"
      id="f-112"
      unitRef="usdPerShare">7.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-113"
      unitRef="usdPerShare">6.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-17"
      decimals="2"
      id="f-114"
      unitRef="usdPerShare">17.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-115"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-16"
      decimals="2"
      id="f-116"
      unitRef="usdPerShare">7.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-117"
      unitRef="usdPerShare">6.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-17"
      decimals="2"
      id="f-118"
      unitRef="usdPerShare">17.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="-5" id="f-119" unitRef="shares">144800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-16" decimals="-5" id="f-120" unitRef="shares">144400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-121" unitRef="shares">144700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-17" decimals="-5" id="f-122" unitRef="shares">145800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="-5" id="f-123" unitRef="shares">144800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-16" decimals="-5" id="f-124" unitRef="shares">144800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-125" unitRef="shares">145500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-17" decimals="-5" id="f-126" unitRef="shares">146200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-5" id="f-127" unitRef="usd">-68100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-5" id="f-128" unitRef="usd">1134700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-129" unitRef="usd">911400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-5" id="f-130" unitRef="usd">2496500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-15" decimals="-5" id="f-131" unitRef="usd">14500000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-16" decimals="-5" id="f-132" unitRef="usd">-1000000.0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-5" id="f-133" unitRef="usd">15700000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-17" decimals="-5" id="f-134" unitRef="usd">-19000000.0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-15" decimals="-5" id="f-135" unitRef="usd">29600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-16" decimals="-5" id="f-136" unitRef="usd">5900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-1" decimals="-5" id="f-137" unitRef="usd">1100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-17" decimals="-5" id="f-138" unitRef="usd">79000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease contextRef="c-15" decimals="-5" id="f-139" unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease contextRef="c-16" decimals="-5" id="f-140" unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease contextRef="c-1" decimals="-5" id="f-141" unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease contextRef="c-17" decimals="-5" id="f-142" unitRef="usd">-25500000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-15" decimals="-5" id="f-143" unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-16" decimals="-5" id="f-144" unitRef="usd">-1500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-1" decimals="-5" id="f-145" unitRef="usd">-600000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-17" decimals="-5" id="f-146" unitRef="usd">-4200000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-15" decimals="-5" id="f-147" unitRef="usd">-30500000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-16" decimals="-5" id="f-148" unitRef="usd">-59600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-5" id="f-149" unitRef="usd">-11800000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-17" decimals="-5" id="f-150" unitRef="usd">-95600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-5" id="f-151" unitRef="usd">13500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-16" decimals="-5" id="f-152" unitRef="usd">-53200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-153" unitRef="usd">5600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-17" decimals="-5" id="f-154" unitRef="usd">-56900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-15" decimals="-5" id="f-155" unitRef="usd">-54600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-16" decimals="-5" id="f-156" unitRef="usd">1081500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-5" id="f-157" unitRef="usd">917000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-17" decimals="-5" id="f-158" unitRef="usd">2439600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-15" decimals="-5" id="f-159" unitRef="usd">-200000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-16" decimals="-5" id="f-160" unitRef="usd">200000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-161" unitRef="usd">1200000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-17" decimals="-5" id="f-162" unitRef="usd">-84400000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-5" id="f-163" unitRef="usd">-54800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-5" id="f-164" unitRef="usd">1081700000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-165" unitRef="usd">918200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-5" id="f-166" unitRef="usd">2355200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-5" id="f-167" unitRef="usd">2287900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-19" decimals="-5" id="f-168" unitRef="usd">3419300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-18" decimals="-5" id="f-169" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-19" decimals="-5" id="f-170" unitRef="usd">1473500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-20" decimals="-5" id="f-171" unitRef="usd">1781400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-21" decimals="-5" id="f-172" unitRef="usd">1705000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-22" decimals="-5" id="f-173" unitRef="usd">428300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-23" decimals="-5" id="f-174" unitRef="usd">431400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-18" decimals="-5" id="f-175" unitRef="usd">2982400000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-19" decimals="-5" id="f-176" unitRef="usd">1344400000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="c-18" decimals="-5" id="f-177" unitRef="usd">974100000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-19" decimals="-5" id="f-178" unitRef="usd">1417600000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-18" decimals="-5" id="f-179" unitRef="usd">8454100000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-19" decimals="-5" id="f-180" unitRef="usd">9791200000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-18" decimals="-5" id="f-181" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-19" decimals="-5" id="f-182" unitRef="usd">705700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-18" decimals="-5" id="f-183" unitRef="usd">3301600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-19" decimals="-5" id="f-184" unitRef="usd">3298600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-18" decimals="-5" id="f-185" unitRef="usd">460900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-19" decimals="-5" id="f-186" unitRef="usd">403900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-18" decimals="-5" id="f-187" unitRef="usd">7344600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-19" decimals="-5" id="f-188" unitRef="usd">1850100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-18" decimals="-5" id="f-189" unitRef="usd">6807500000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-19" decimals="-5" id="f-190" unitRef="usd">5749000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-18" decimals="-5" id="f-191" unitRef="usd">1069800000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-19" decimals="-5" id="f-192" unitRef="usd">1226400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-18" decimals="-5" id="f-193" unitRef="usd">754600000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-19" decimals="-5" id="f-194" unitRef="usd">1529200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-18" decimals="-5" id="f-195" unitRef="usd">28193200000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-19" decimals="-5" id="f-196" unitRef="usd">24554100000</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent contextRef="c-18" decimals="-5" id="f-197" unitRef="usd">500000000.0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-19" decimals="-5" id="f-198" unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-18" decimals="-5" id="f-199" unitRef="usd">243800000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-19" decimals="-5" id="f-200" unitRef="usd">259900000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-18" decimals="-5" id="f-201" unitRef="usd">440100000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-19" decimals="-5" id="f-202" unitRef="usd">491500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-203" unitRef="usd">3838400000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-204" unitRef="usd">2521400000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-205" unitRef="usd">5022300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-206" unitRef="usd">3272800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt contextRef="c-18" decimals="-5" id="f-207" unitRef="usd">6786400000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-19" decimals="-5" id="f-208" unitRef="usd">6281000000</us-gaap:LongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-18" decimals="-5" id="f-209" unitRef="usd">728100000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-19" decimals="-5" id="f-210" unitRef="usd">334700000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-18" decimals="-5" id="f-211" unitRef="usd">428800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-19" decimals="-5" id="f-212" unitRef="usd">333000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-18" decimals="-5" id="f-213" unitRef="usd">747900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-19" decimals="-5" id="f-214" unitRef="usd">944200000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-18" decimals="-5" id="f-215" unitRef="usd">13713500000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-19" decimals="-5" id="f-216" unitRef="usd">11165700000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-18" id="f-217" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-19" id="f-218" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-18" decimals="-5" id="f-219" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-19" decimals="-5" id="f-220" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue contextRef="c-18" decimals="-5" id="f-221" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-19" decimals="-5" id="f-222" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-18" decimals="-5" id="f-223" unitRef="usd">242200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-19" decimals="-5" id="f-224" unitRef="usd">73300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-18" decimals="-5" id="f-225" unitRef="usd">-159300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-19" decimals="-5" id="f-226" unitRef="usd">-164900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-18" decimals="-5" id="f-227" unitRef="usd">17377900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-19" decimals="-5" id="f-228" unitRef="usd">16466500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue contextRef="c-18" decimals="-5" id="f-229" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c-19" decimals="-5" id="f-230" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-5" id="f-231" unitRef="usd">14483800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-5" id="f-232" unitRef="usd">13397900000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-18" decimals="-5" id="f-233" unitRef="usd">-4100000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-19" decimals="-5" id="f-234" unitRef="usd">-9500000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-5" id="f-235" unitRef="usd">14479700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-5" id="f-236" unitRef="usd">13388400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-18" decimals="-5" id="f-237" unitRef="usd">28193200000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-19" decimals="-5" id="f-238" unitRef="usd">24554100000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-5" id="f-239" unitRef="usd">912600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-5" id="f-240" unitRef="usd">2412100000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-241" unitRef="usd">354700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-17" decimals="-5" id="f-242" unitRef="usd">398600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InventoryWriteDown contextRef="c-1" decimals="-5" id="f-243" unitRef="usd">62100000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-17" decimals="-5" id="f-244" unitRef="usd">321600000</us-gaap:InventoryWriteDown>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-5" id="f-245" unitRef="usd">209300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-17" decimals="-5" id="f-246" unitRef="usd">186900000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-5" id="f-247" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-17" decimals="-5" id="f-248" unitRef="usd">13700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-249" unitRef="usd">-377700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-17" decimals="-5" id="f-250" unitRef="usd">-139800000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi contextRef="c-1" decimals="-5" id="f-251" unitRef="usd">-275700000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi contextRef="c-17" decimals="-5" id="f-252" unitRef="usd">-160300000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-5" id="f-253" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-17" decimals="-5" id="f-254" unitRef="usd">2600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee contextRef="c-1" decimals="-5" id="f-255" unitRef="usd">0</us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee>
    <us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee contextRef="c-17" decimals="-5" id="f-256" unitRef="usd">1505400000</us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-5" id="f-257" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-17" decimals="-5" id="f-258" unitRef="usd">503700000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-5" id="f-259" unitRef="usd">-98600000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-17" decimals="-5" id="f-260" unitRef="usd">-147800000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-24" decimals="-5" id="f-261" unitRef="usd">76500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-25" decimals="-5" id="f-262" unitRef="usd">109500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-26" decimals="-5" id="f-263" unitRef="usd">-3100000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-27" decimals="-5" id="f-264" unitRef="usd">3000000.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-5" id="f-265" unitRef="usd">34900000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-17" decimals="-5" id="f-266" unitRef="usd">338300000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-5" id="f-267" unitRef="usd">293900000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-17" decimals="-5" id="f-268" unitRef="usd">632300000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-1" decimals="-5" id="f-269" unitRef="usd">-114800000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-17" decimals="-5" id="f-270" unitRef="usd">-100200000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-1" decimals="-5" id="f-271" unitRef="usd">71400000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-17" decimals="-5" id="f-272" unitRef="usd">-15900000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-273" unitRef="usd">1534700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-17" decimals="-5" id="f-274" unitRef="usd">1559300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-275" unitRef="usd">211800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-17" decimals="-5" id="f-276" unitRef="usd">153900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-1" decimals="-5" id="f-277" unitRef="usd">7380800000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-17" decimals="-5" id="f-278" unitRef="usd">3104700000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-5" id="f-279" unitRef="usd">5140700000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-17" decimals="-5" id="f-280" unitRef="usd">2805900000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-5" id="f-281" unitRef="usd">6335600000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-17" decimals="-5" id="f-282" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c-1" decimals="-5" id="f-283" unitRef="usd">788100000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c-17" decimals="-5" id="f-284" unitRef="usd">990300000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-285" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-17" decimals="-5" id="f-286" unitRef="usd">582600000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-5" id="f-287" unitRef="usd">34400000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-17" decimals="-5" id="f-288" unitRef="usd">1900000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfOtherInvestments contextRef="c-1" decimals="-5" id="f-289" unitRef="usd">106200000</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:ProceedsFromSaleOfOtherInvestments contextRef="c-17" decimals="-5" id="f-290" unitRef="usd">0</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-1" decimals="-5" id="f-291" unitRef="usd">1300000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-17" decimals="-5" id="f-292" unitRef="usd">-1800000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-5" id="f-293" unitRef="usd">-3448700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-17" decimals="-5" id="f-294" unitRef="usd">1717700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-5" id="f-295" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-17" decimals="-5" id="f-296" unitRef="usd">750000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-5" id="f-297" unitRef="usd">48000000.0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-17" decimals="-5" id="f-298" unitRef="usd">5800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-5" id="f-299" unitRef="usd">159900000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-17" decimals="-5" id="f-300" unitRef="usd">1002200000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-5" id="f-301" unitRef="usd">997200000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-17" decimals="-5" id="f-302" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="c-1" decimals="-5" id="f-303" unitRef="usd">4200000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="c-17" decimals="-5" id="f-304" unitRef="usd">12200000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-1" decimals="-5" id="f-305" unitRef="usd">1900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-17" decimals="-5" id="f-306" unitRef="usd">5900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-5" id="f-307" unitRef="usd">795400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-17" decimals="-5" id="f-308" unitRef="usd">-1739900000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-1" decimals="-5" id="f-309" unitRef="usd">-1118600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-17" decimals="-5" id="f-310" unitRef="usd">1537100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-5" id="f-311" unitRef="usd">-12800000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-17" decimals="-5" id="f-312" unitRef="usd">-122900000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-19" decimals="-5" id="f-313" unitRef="usd">3419300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-28" decimals="-5" id="f-314" unitRef="usd">2261400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-5" id="f-315" unitRef="usd">2287900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="-5" id="f-316" unitRef="usd">3675600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-30" decimals="-5" id="f-317" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-5" id="f-318" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-31" decimals="-5" id="f-319" unitRef="shares">168600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-5" id="f-320" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-5" id="f-321" unitRef="usd">170700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-5" id="f-322" unitRef="usd">-172800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-5" id="f-323" unitRef="usd">17446000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-35" decimals="-5" id="f-324" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-5" id="f-325" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-36" decimals="-5" id="f-326" unitRef="usd">14466900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-37" decimals="-5" id="f-327" unitRef="usd">-6400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-38" decimals="-5" id="f-328" unitRef="usd">14460500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-39" decimals="-5" id="f-329" unitRef="usd">-68100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-40" decimals="-5" id="f-330" unitRef="usd">-68100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-41" decimals="-5" id="f-331" unitRef="usd">-200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-5" id="f-332" unitRef="usd">-68300000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-42" decimals="-5" id="f-333" unitRef="usd">13500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-40" decimals="-5" id="f-334" unitRef="usd">13500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-15" decimals="-5" id="f-335" unitRef="usd">13500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution contextRef="c-41" decimals="-5" id="f-336" unitRef="usd">2500000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution contextRef="c-15" decimals="-5" id="f-337" unitRef="usd">2500000</biib:NoncontrollingInterestCapitalContribution>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="c-43" decimals="-5" id="f-338" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-44" decimals="-5" id="f-339" unitRef="usd">9300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-40" decimals="-5" id="f-340" unitRef="usd">9300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-15" decimals="-5" id="f-341" unitRef="usd">9300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-43" decimals="-5" id="f-342" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-44" decimals="-5" id="f-343" unitRef="usd">-2700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-40" decimals="-5" id="f-344" unitRef="usd">-2700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-15" decimals="-5" id="f-345" unitRef="usd">-2700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-44" decimals="-5" id="f-346" unitRef="usd">-64800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-40" decimals="-5" id="f-347" unitRef="usd">-64800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-15" decimals="-5" id="f-348" unitRef="usd">-64800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther contextRef="c-44" decimals="-5" id="f-349" unitRef="usd">-100000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-40" decimals="-5" id="f-350" unitRef="usd">-100000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-15" decimals="-5" id="f-351" unitRef="usd">-100000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-45" decimals="-5" id="f-352" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-5" id="f-353" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-46" decimals="-5" id="f-354" unitRef="shares">168700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-5" id="f-355" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-5" id="f-356" unitRef="usd">242200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-5" id="f-357" unitRef="usd">-159300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-5" id="f-358" unitRef="usd">17377900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-50" decimals="-5" id="f-359" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-5" id="f-360" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-51" decimals="-5" id="f-361" unitRef="usd">14483800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-52" decimals="-5" id="f-362" unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-5" id="f-363" unitRef="usd">14479700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-53" decimals="-5" id="f-364" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-53" decimals="-5" id="f-365" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-54" decimals="-5" id="f-366" unitRef="shares">167900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-54" decimals="-5" id="f-367" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-55" decimals="-5" id="f-368" unitRef="usd">73300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-5" id="f-369" unitRef="usd">-164900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-5" id="f-370" unitRef="usd">16466500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-58" decimals="-5" id="f-371" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-5" id="f-372" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-5" id="f-373" unitRef="usd">13397900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-5" id="f-374" unitRef="usd">-9500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-5" id="f-375" unitRef="usd">13388400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-61" decimals="-5" id="f-376" unitRef="usd">911400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-62" decimals="-5" id="f-377" unitRef="usd">911400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-63" decimals="-5" id="f-378" unitRef="usd">1200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-5" id="f-379" unitRef="usd">912600000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-64" decimals="-5" id="f-380" unitRef="usd">5600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-62" decimals="-5" id="f-381" unitRef="usd">5600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-5" id="f-382" unitRef="usd">5600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution contextRef="c-63" decimals="-5" id="f-383" unitRef="usd">4200000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution contextRef="c-1" decimals="-5" id="f-384" unitRef="usd">4200000</biib:NoncontrollingInterestCapitalContribution>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="c-65" decimals="-5" id="f-385" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-66" decimals="-5" id="f-386" unitRef="usd">38700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-62" decimals="-5" id="f-387" unitRef="usd">38700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-1" decimals="-5" id="f-388" unitRef="usd">38700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-65" decimals="-5" id="f-389" unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-66" decimals="-5" id="f-390" unitRef="usd">-86700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-62" decimals="-5" id="f-391" unitRef="usd">-86700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-5" id="f-392" unitRef="usd">-86700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-66" decimals="-5" id="f-393" unitRef="usd">-217800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-62" decimals="-5" id="f-394" unitRef="usd">-217800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-5" id="f-395" unitRef="usd">-217800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther contextRef="c-66" decimals="-5" id="f-396" unitRef="usd">900000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-62" decimals="-5" id="f-397" unitRef="usd">900000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-1" decimals="-5" id="f-398" unitRef="usd">900000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-45" decimals="-5" id="f-399" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-5" id="f-400" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-46" decimals="-5" id="f-401" unitRef="shares">168700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-5" id="f-402" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-5" id="f-403" unitRef="usd">242200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-5" id="f-404" unitRef="usd">-159300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-5" id="f-405" unitRef="usd">17377900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-50" decimals="-5" id="f-406" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-5" id="f-407" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-51" decimals="-5" id="f-408" unitRef="usd">14483800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-52" decimals="-5" id="f-409" unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-5" id="f-410" unitRef="usd">14479700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-67" decimals="-5" id="f-411" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-67" decimals="-5" id="f-412" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-68" decimals="-5" id="f-413" unitRef="shares">169000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-68" decimals="-5" id="f-414" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-69" decimals="-5" id="f-415" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-70" decimals="-5" id="f-416" unitRef="usd">-110400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-71" decimals="-5" id="f-417" unitRef="usd">14959900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-72" decimals="-5" id="f-418" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-72" decimals="-5" id="f-419" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-73" decimals="-5" id="f-420" unitRef="usd">11872500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-74" decimals="-5" id="f-421" unitRef="usd">-9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-75" decimals="-5" id="f-422" unitRef="usd">11863400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-76" decimals="-5" id="f-423" unitRef="usd">1134700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-77" decimals="-5" id="f-424" unitRef="usd">1134700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-78" decimals="-5" id="f-425" unitRef="usd">200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-5" id="f-426" unitRef="usd">1134900000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-79" decimals="-5" id="f-427" unitRef="usd">-53200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-77" decimals="-5" id="f-428" unitRef="usd">-53200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-16" decimals="-5" id="f-429" unitRef="usd">-53200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution contextRef="c-78" decimals="-5" id="f-430" unitRef="usd">200000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution contextRef="c-16" decimals="-5" id="f-431" unitRef="usd">200000</biib:NoncontrollingInterestCapitalContribution>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-80" decimals="-5" id="f-432" unitRef="shares">1200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-80" decimals="-5" id="f-433" unitRef="usd">250000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-81" decimals="-5" id="f-434" unitRef="usd">250000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-82" decimals="-5" id="f-435" unitRef="usd">250000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="c-83" decimals="-5" id="f-436" unitRef="shares">1200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-84" decimals="-5" id="f-437" unitRef="usd">71500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-85" decimals="-5" id="f-438" unitRef="usd">178500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="c-80" decimals="-5" id="f-439" unitRef="shares">1200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-80" decimals="-5" id="f-440" unitRef="usd">-250000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="c-86" decimals="-5" id="f-441" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-87" decimals="-5" id="f-442" unitRef="usd">8600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-77" decimals="-5" id="f-443" unitRef="usd">8600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-16" decimals="-5" id="f-444" unitRef="usd">8600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-86" decimals="-5" id="f-445" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-87" decimals="-5" id="f-446" unitRef="usd">-2800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-76" decimals="-5" id="f-447" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-77" decimals="-5" id="f-448" unitRef="usd">-2800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-16" decimals="-5" id="f-449" unitRef="usd">-2800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-87" decimals="-5" id="f-450" unitRef="usd">-65700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-77" decimals="-5" id="f-451" unitRef="usd">-65700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-16" decimals="-5" id="f-452" unitRef="usd">-65700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-88" decimals="-5" id="f-453" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-88" decimals="-5" id="f-454" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-89" decimals="-5" id="f-455" unitRef="shares">167800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-89" decimals="-5" id="f-456" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-90" decimals="-5" id="f-457" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-91" decimals="-5" id="f-458" unitRef="usd">-163600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-92" decimals="-5" id="f-459" unitRef="usd">15916100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-93" decimals="-5" id="f-460" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-93" decimals="-5" id="f-461" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-94" decimals="-5" id="f-462" unitRef="usd">12775500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-95" decimals="-5" id="f-463" unitRef="usd">-8700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-5" id="f-464" unitRef="usd">12766800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-96" decimals="-5" id="f-465" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-96" decimals="-5" id="f-466" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-97" decimals="-5" id="f-467" unitRef="shares">170800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-97" decimals="-5" id="f-468" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-98" decimals="-5" id="f-469" unitRef="usd">68200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-99" decimals="-5" id="f-470" unitRef="usd">-106700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-100" decimals="-5" id="f-471" unitRef="usd">13911700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-101"
      decimals="-5"
      id="f-472"
      unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-101" decimals="-5" id="f-473" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-102" decimals="-5" id="f-474" unitRef="usd">10896200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-103" decimals="-5" id="f-475" unitRef="usd">63500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-5" id="f-476" unitRef="usd">10959700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-104" decimals="-5" id="f-477" unitRef="usd">2496500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-105" decimals="-5" id="f-478" unitRef="usd">2496500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-106" decimals="-5" id="f-479" unitRef="usd">-84400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-5" id="f-480" unitRef="usd">2412100000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-107" decimals="-5" id="f-481" unitRef="usd">-56900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-105" decimals="-5" id="f-482" unitRef="usd">-56900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-17" decimals="-5" id="f-483" unitRef="usd">-56900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution contextRef="c-106" decimals="-5" id="f-484" unitRef="usd">12200000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution contextRef="c-17" decimals="-5" id="f-485" unitRef="usd">12200000</biib:NoncontrollingInterestCapitalContribution>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-108"
      decimals="-5"
      id="f-486"
      unitRef="shares">3600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-108" decimals="-5" id="f-487" unitRef="usd">750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-109" decimals="-5" id="f-488" unitRef="usd">750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-110" decimals="-5" id="f-489" unitRef="usd">750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="c-111"
      decimals="-5"
      id="f-490"
      unitRef="shares">3600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-112" decimals="-5" id="f-491" unitRef="usd">257900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-113" decimals="-5" id="f-492" unitRef="usd">492100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="c-108"
      decimals="-5"
      id="f-493"
      unitRef="shares">3600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-108" decimals="-5" id="f-494" unitRef="usd">-750000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="c-114"
      decimals="-5"
      id="f-495"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-115" decimals="-5" id="f-496" unitRef="usd">37500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-105" decimals="-5" id="f-497" unitRef="usd">37500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-17" decimals="-5" id="f-498" unitRef="usd">37500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-114"
      decimals="-5"
      id="f-499"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-115" decimals="-5" id="f-500" unitRef="usd">-43200000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-104" decimals="-5" id="f-501" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-105" decimals="-5" id="f-502" unitRef="usd">-43200000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-17" decimals="-5" id="f-503" unitRef="usd">-43200000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-115" decimals="-5" id="f-504" unitRef="usd">-194100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-105" decimals="-5" id="f-505" unitRef="usd">-194100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-17" decimals="-5" id="f-506" unitRef="usd">-194100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther contextRef="c-115" decimals="-5" id="f-507" unitRef="usd">-1300000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-105" decimals="-5" id="f-508" unitRef="usd">-1300000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-17" decimals="-5" id="f-509" unitRef="usd">-1300000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-88" decimals="-5" id="f-510" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-88" decimals="-5" id="f-511" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-89" decimals="-5" id="f-512" unitRef="shares">167800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-89" decimals="-5" id="f-513" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-90" decimals="-5" id="f-514" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-91" decimals="-5" id="f-515" unitRef="usd">-163600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-92" decimals="-5" id="f-516" unitRef="usd">15916100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-93" decimals="-5" id="f-517" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-93" decimals="-5" id="f-518" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-94" decimals="-5" id="f-519" unitRef="usd">12775500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-95" decimals="-5" id="f-520" unitRef="usd">-8700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-5" id="f-521" unitRef="usd">12766800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-522">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA and co-developed two treatments to address a defining pathology of Alzheimer's disease. We are focused on advancing our pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs and external collaborations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; QALSODY for the treatment of ALS, which was granted accelerated approval by the FDA during the second quarter of 2023; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease, which was granted traditional approval by the FDA in the third quarter of 2023, and Sage on the commercialization of ZURZUVAE for the treatment of PPD. ZURZUVAE was approved by the FDA in the third quarter of 2023, pending DEA scheduling, which was completed in the fourth quarter of 2023. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma, which was granted accelerated approval by the FDA during the second quarter of 2023; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 26, 2023, we completed the acquisition of Reata. As a result of this transaction we acquired SKYCLARYS, the first and only drug approved by the FDA for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We commercialize biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. We also have the exclusive rights to commercialize TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, which was approved by the FDA during the third quarter of 2023. We continue to develop the potential biosimilar product SB15, a proposed aflibercept biosimilar referencing EYLEA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our audited consolidated financial statements included in our 2022 Form&#160;10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2022 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2022 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our significant accounting policies disclosed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our audited consolidated financial statements included in our 2022 Form&#160;10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are recorded using the acquisition method of accounting. The results of operations of the acquired company are included in our results of operations beginning on the acquisition date, and assets acquired and liabilities assumed are recognized on the acquisition date at their respective fair values. Any excess of consideration transferred over the net carrying value of the assets acquired and liabilities assumed as of the acquisition date is recognized as goodwill. Transaction and restructuring costs related to business combinations are expensed as incurred. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. If we determine the assets acquired do not meet the definition of a business, the transaction will be accounted for as an asset acquisition rather than a business combination.  &lt;/span&gt;&lt;span style="color:#3051f2;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2022 the FASB issued ASU No. 2022-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (Topic 820): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for us on January 1, 2024. We elected to early adopt this standard on a prospective basis during the third quarter of 2022. Upon adoption, we recorded an immaterial amount in other (income) expense, net in our condensed consolidated statements of income, as a result of removing the impact of the remaining contractual sale restrictions from the fair value measurement of certain shares in Sage.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock contextRef="c-1" id="f-523">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA and co-developed two treatments to address a defining pathology of Alzheimer's disease. We are focused on advancing our pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs and external collaborations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; QALSODY for the treatment of ALS, which was granted accelerated approval by the FDA during the second quarter of 2023; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease, which was granted traditional approval by the FDA in the third quarter of 2023, and Sage on the commercialization of ZURZUVAE for the treatment of PPD. ZURZUVAE was approved by the FDA in the third quarter of 2023, pending DEA scheduling, which was completed in the fourth quarter of 2023. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma, which was granted accelerated approval by the FDA during the second quarter of 2023; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 26, 2023, we completed the acquisition of Reata. As a result of this transaction we acquired SKYCLARYS, the first and only drug approved by the FDA for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older. For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We commercialize biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. We also have the exclusive rights to commercialize TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, which was approved by the FDA during the third quarter of 2023. We continue to develop the potential biosimilar product SB15, a proposed aflibercept biosimilar referencing EYLEA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our audited consolidated financial statements included in our 2022 Form&#160;10-K.&lt;/span&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-524">&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2022 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2022 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, &lt;/span&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-525"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-526">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary contextRef="c-1" decimals="INF" id="f-527" unitRef="number">1.000</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-528">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our significant accounting policies disclosed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our audited consolidated financial statements included in our 2022 Form&#160;10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;Business combinations are recorded using the acquisition method of accounting. The results of operations of the acquired company are included in our results of operations beginning on the acquisition date, and assets acquired and liabilities assumed are recognized on the acquisition date at their respective fair values. Any excess of consideration transferred over the net carrying value of the assets acquired and liabilities assumed as of the acquisition date is recognized as goodwill. Transaction and restructuring costs related to business combinations are expensed as incurred. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. If we determine the assets acquired do not meet the definition of a business, the transaction will be accounted for as an asset acquisition rather than a business combination.</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-529">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2022 the FASB issued ASU No. 2022-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (Topic 820): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for us on January 1, 2024. We elected to early adopt this standard on a prospective basis during the third quarter of 2022. Upon adoption, we recorded an immaterial amount in other (income) expense, net in our condensed consolidated statements of income, as a result of removing the impact of the remaining contractual sale restrictions from the fair value measurement of certain shares in Sage.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-530">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Reata Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;On September 26, 2023, we completed the acquisition of all of the issued and outstanding shares of Reata, a  biopharmaceutical company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of this transaction we acquired SKYCLARYS, the first and only drug approved by the FDA for the treatment of Friedreich's Ataxia in adults and adolescents aged 16 years and older, as well as other clinical and preclinical pipeline programs. The acquisition of Reata is expected to complement our global portfolio of neuromuscular and rare disease therapies. The addition of SKYCLARYS is anticipated to provide potential operating synergies with SPINRAZA and QALSODY.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Under the terms of this acquisition, we paid Reata shareholders $172.50 in cash for each issued and outstanding Reata share, which totaled approximately $6.6&#160;billion. In addition, we agreed to pay approximately $983.9&#160;million in cash for Reata's outstanding equity awards, inclusive of employer taxes, of which approximately $590.5&#160;million was attributable to pre-acquisition services and is therefore reflected as a component of total purchase price paid. Of the $983.9&#160;million paid to Reata's equity award holders, we recognized approximately $393.4&#160;million as compensation attributable to the post-acquisition service period, of which $196.4&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $197.0&#160;million as a charge to research and development expense within our condensed consolidated statements of income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three and nine months ended September 30, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest. Approximately $980.0&#160;million of the $983.9&#160;million payment to the equity award holders was made in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;We funded this acquisition through available cash, cash equivalents and marketable securities, supplemented by the issuance of a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.0 billion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; term loan under our term loan credit agreement. For additional information on our term loan credit agreement, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Note 13, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;We accounted for this acquisition as a business combination using the acquisition method of accounting in accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASC Topic 805, Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, and recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Price Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total consideration transferred for the acquisition of Reata is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September&#160;26, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash consideration paid to Reata shareholders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,602.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of Reata equity compensation pre-acquisition services and related taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;590.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents cash consideration transferred of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;$172.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; per outstanding Reata ordinary share based on 38.3&#160;million Reata shares outstanding at closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of Reata stock options and stock units issued to Reata equity award holders and the related taxes attributable to pre-acquisition vesting services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preliminary Purchase Price Allocation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;The following table summarizes the preliminary purchase price allocation of the separately identifiable assets acquired and liabilities assumed as of September&#160;26, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September&#160;26, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,692.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology for SKYCLARYS (U.S.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,600.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development (omaveloxolone)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,900.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Priority review voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other clinical programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(98.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(159.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent payable to Blackstone&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(300.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(922.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(151.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,136.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,057.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; For additional information on the contingent payable to Blackstone, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Other Consolidated Financial Statement Detail&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Total inventory acquired was&lt;/span&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approximately $1.7&#160;billion, which reflects a step-up in the fair value of finished goods and work-in-process inventory for SKYCLARYS. The fair value was determined based on the estimated selling price of the inventory, less the remaining manufacturing and selling costs and a normal profit margin on those manufacturing and selling efforts. This fair value step-up adjustment will be amortized to cost of sales within our condensed consolidated statements of income when the inventory is sold, which is expected to be within approximately 3 years from the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intang&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ible assets:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Intangible assets are comprised of $3.6&#160;billion related to SKYCLARYS commercialization rights in the U.S., $1.9&#160;billion of IPR&amp;amp;D related to the omaveloxolone program outside the U.S., $100.0&#160;million related to a rare pediatric disease priority voucher which may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party and $20.0&#160;million related to other clinical programs. The estimated fair values of the program related intangible assets were determined using a probability adjusted discounted cash flow analysis approach utilizing a discount rate of 17.0% and the estimated fair value of the priority review voucher was based on recent external purchase and sale transactions of similar vouchers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The more significant as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenue, cost of sales, research and development and other operating expense, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. Our valuation of the SKYCLARYS commercialization rights reflects the assumption that, using an economic consumption model, the related $3.6&#160;billion intangible asset will be amortized over its expected economic life. Our valuation of the $1.9&#160;billion &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D asset related to omaveloxolone, which &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;has been submitted to the EMA and is currently under review, reflects the assumption that, if regulatory approval is obtained, sales would commence in certain countries in Europe during 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We recorded a lease liability of approximately $151.8&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately 15 years, with a corresponding right-of-use asset of approximately $122.4&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. We recognized goodwill of approximately $1.1&#160;billion, which is not deductible for tax purposes. The goodwill recognized from our acquisition of Reata is primarily the result of the deferred tax consequences from the transaction recorded for financial statement purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition-related expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acquisition-related expenses, which were comprised primarily of regulatory, advisory and legal fees, and other transaction costs, totaled approximately $26.3&#160;million and are included within selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assumptions in the Allocations of Purchase Price&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he results of operations of Reata, along with the estimated fair values of the assets acquired and liabilities assumed in the Reata acquisition, have been included in our condensed consolidated financial statements since the closing of the Reata acquisition on September 26, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our preliminary estimate of the fair value of the specifically identifiable assets acquired and liabilities assumed as of the date of acquisition is subject to the finalization of management's analysis related to certain matters, such as finalizing our assessment of intangible assets, inventory, goodwill, leases and income taxes. The final determination of these fair values will be completed as additional information becomes available but no later than one year from the acquisition date. The final determination may result in asset and liability fair values that are different than the preliminary estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the acquisition date, our results of operations include the results of operations of Reata. The Reata operations had an immaterial impact to our results of operations for the three and nine months ended September 30, 2023, given the proximity of the acquisition date to quarter-end. Due to the immateriality of Reata's revenues and expenses, additional pro forma information combining the results of operations of Biogen and Reata have not been included.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c-116"
      decimals="1"
      id="f-531"
      unitRef="usdPerShare">172.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-117" decimals="-8" id="f-532" unitRef="usd">6600000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards contextRef="c-118" decimals="-5" id="f-533" unitRef="usd">983900000</biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards>
    <biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices contextRef="c-117" decimals="-5" id="f-534" unitRef="usd">590500000</biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices>
    <biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards contextRef="c-118" decimals="-5" id="f-535" unitRef="usd">983900000</biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards>
    <us-gaap:OperatingExpenses contextRef="c-117" decimals="-5" id="f-536" unitRef="usd">393400000</us-gaap:OperatingExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-117" decimals="-5" id="f-537" unitRef="usd">196400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-117" decimals="-5" id="f-538" unitRef="usd">197000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-119" decimals="-5" id="f-539" unitRef="usd">980000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards contextRef="c-118" decimals="-5" id="f-540" unitRef="usd">983900000</biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-120" decimals="-8" id="f-541" unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c-1" id="f-542">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total consideration transferred for the acquisition of Reata is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September&#160;26, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash consideration paid to Reata shareholders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,602.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of Reata equity compensation pre-acquisition services and related taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;590.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents cash consideration transferred of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;$172.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; per outstanding Reata ordinary share based on 38.3&#160;million Reata shares outstanding at closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of Reata stock options and stock units issued to Reata equity award holders and the related taxes attributable to pre-acquisition vesting services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;The following table summarizes the preliminary purchase price allocation of the separately identifiable assets acquired and liabilities assumed as of September&#160;26, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September&#160;26, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,692.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology for SKYCLARYS (U.S.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,600.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development (omaveloxolone)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,900.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Priority review voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other clinical programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(98.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(159.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent payable to Blackstone&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(300.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(922.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(151.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,136.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,057.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; For additional information on the contingent payable to Blackstone, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Other Consolidated Financial Statement Detail&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-117" decimals="-5" id="f-543" unitRef="usd">6602900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices contextRef="c-117" decimals="-5" id="f-544" unitRef="usd">590500000</biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-117" decimals="-5" id="f-545" unitRef="usd">7193400000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c-116"
      decimals="1"
      id="f-546"
      unitRef="usdPerShare">172.50</us-gaap:BusinessAcquisitionSharePrice>
    <biib:BusinessAcquisitionNumberOfCommonStockSharesAcquired
      contextRef="c-116"
      decimals="-3"
      id="f-547"
      unitRef="shares">38300000</biib:BusinessAcquisitionNumberOfCommonStockSharesAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-116" decimals="-5" id="f-548" unitRef="usd">267300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c-116" decimals="-5" id="f-549" unitRef="usd">15900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-116" decimals="-5" id="f-550" unitRef="usd">1692000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="c-116" decimals="-5" id="f-551" unitRef="usd">53600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-121" decimals="-5" id="f-552" unitRef="usd">3600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-122" decimals="-5" id="f-553" unitRef="usd">1900000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-123" decimals="-5" id="f-554" unitRef="usd">100000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-124" decimals="-5" id="f-555" unitRef="usd">20000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets contextRef="c-116" decimals="-5" id="f-556" unitRef="usd">122400000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther contextRef="c-116" decimals="-5" id="f-557" unitRef="usd">98900000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt contextRef="c-116" decimals="-5" id="f-558" unitRef="usd">159900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability contextRef="c-116" decimals="-5" id="f-559" unitRef="usd">300000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-116" decimals="-5" id="f-560" unitRef="usd">922500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities contextRef="c-116" decimals="-5" id="f-561" unitRef="usd">151800000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet contextRef="c-116" decimals="-5" id="f-562" unitRef="usd">-2000000.0</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-116" decimals="-5" id="f-563" unitRef="usd">6136100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill contextRef="c-116" decimals="-5" id="f-564" unitRef="usd">1057300000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-116" decimals="-5" id="f-565" unitRef="usd">7193400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-116" decimals="-8" id="f-566" unitRef="usd">1700000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod contextRef="c-116" id="f-567">P3Y</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-121" decimals="-8" id="f-568" unitRef="usd">3600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-122" decimals="-8" id="f-569" unitRef="usd">1900000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-123" decimals="-5" id="f-570" unitRef="usd">100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-124" decimals="-5" id="f-571" unitRef="usd">20000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate contextRef="c-116" decimals="2" id="f-572" unitRef="number">0.170</biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-121" decimals="-8" id="f-573" unitRef="usd">3600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-122" decimals="-8" id="f-574" unitRef="usd">1900000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <biib:OperatingLeaseArea contextRef="c-116" decimals="0" id="f-575" unitRef="sqft">327400</biib:OperatingLeaseArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-116" id="f-576">P16Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities contextRef="c-116" decimals="-5" id="f-577" unitRef="usd">151800000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-116" id="f-578">P15Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets contextRef="c-116" decimals="-5" id="f-579" unitRef="usd">122400000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets>
    <us-gaap:Goodwill contextRef="c-116" decimals="-8" id="f-580" unitRef="usd">1100000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed contextRef="c-125" decimals="-5" id="f-581" unitRef="usd">26300000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed contextRef="c-126" decimals="-5" id="f-582" unitRef="usd">26300000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-583">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Sale of Joint Venture Equity Interest in Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in exchange for total consideration of approximately $2.3&#160;billion. Under the terms of this transaction, we received approximately $1.0&#160;billion in cash at closing, with approximately $1.3&#160;billion in cash to be deferred over two payments. The first deferred payment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$812.5&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was received in April 2023 and the second deferred payment of $437.5&#160;million is due at the second anniversary of the closing of this transaction in April 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the sale, the carrying value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of our investment in Samsung Bioepis totaled $581.6&#160;million. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2022 we recognized a pre-tax gain of approximately $1.5&#160;billion related to this transaction, which was recorded in other (income) expense, net in our condensed consolidated statements of income for the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; nine months ended September 30, 2022. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This pre-tax gain included reclassifications from AOCI to net income of approximately $58.9&#160;million in cumulative translation losses, partially offset by approximately $57.0&#160;million in gains resulting from the termination of our net investment hedge.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We elected the fair value option and measured the payments due to us from Samsung BioLogics at fair value. As of September 30, 2023, the estimated fair value of the remaining second deferred payment using a risk-adjusted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;discount rate of 6.4% was approximately $422.3 million. This payment has been classified as a Level 3 measurement and is reflected in other current assets within our condensed consolidated balance sheets as of September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For the nine months ended September 30, 2023, we recognized a gain of approximately $13.7&#160;million to reflect the change in fair value related to the first deferred payment due to us, which was received in April 2023. Additionally, for the three and nine months ended September 30, 2023, we recognized gains of approximately $7.1&#160;million and $16.9&#160;million, respectively, to reflect the changes in fair value related to the second deferred payment due to us. These changes were recorded in other (income) expense, net in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of this transaction, we are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize the payments in the period the payments become realizable, which is generally the same period in which the payments are earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2022 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-127" decimals="3" id="f-584" unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-128" decimals="-5" id="f-585" unitRef="usd">2300000000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:ProceedsFromDivestitureOfInterestInJointVenture contextRef="c-129" decimals="-8" id="f-586" unitRef="usd">1000000000</us-gaap:ProceedsFromDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture contextRef="c-130" decimals="-8" id="f-587" unitRef="usd">1300000000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture contextRef="c-131" decimals="-5" id="f-588" unitRef="usd">812500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture contextRef="c-132" decimals="-5" id="f-589" unitRef="usd">437500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <us-gaap:EquityMethodInvestments contextRef="c-133" decimals="-5" id="f-590" unitRef="krw">581600000</us-gaap:EquityMethodInvestments>
    <us-gaap:GainLossOnSaleOfInvestments contextRef="c-134" decimals="-8" id="f-591" unitRef="usd">-1500000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments contextRef="c-135" decimals="-8" id="f-592" unitRef="usd">-1500000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax contextRef="c-134" decimals="-5" id="f-593" unitRef="usd">-58900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-134" decimals="-5" id="f-594" unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <biib:OtherAssetsMeasurementInput contextRef="c-136" decimals="3" id="f-595" unitRef="number">0.064</biib:OtherAssetsMeasurementInput>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-137" decimals="-5" id="f-596" unitRef="usd">422300000</biib:OtherAssetsCurrentFairValueDisclosure>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-138" decimals="-5" id="f-597" unitRef="usd">13700000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-139" decimals="-5" id="f-598" unitRef="usd">7100000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-140" decimals="-5" id="f-599" unitRef="usd">16900000</us-gaap:GainLossOnDispositionOfAssets1>
    <biib:AdditionalMilestonePayment contextRef="c-129" decimals="-5" id="f-600" unitRef="usd">50000000</biib:AdditionalMilestonePayment>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-601">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2023 Fit for Growth Restructuring Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023 we initiated additional cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness. The Fit for Growth program is expected to generate approximately $1.0&#160;billion in gross operating expense savings by 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reduction of approximately 1,000 employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total charges incurred from our 2023 cost saving initiatives are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.018%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Costs:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; includes costs associated with items such as asset abandonment and write-offs, facility closure costs, pretax gains and losses resulting from the termination of certain leases, employee non-severance expense, consulting fees and other costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Reata Integration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the closing of the Reata acquisition, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. We expect to incur restructuring charges of approximately $30.0&#160;million in 2023. These amounts are primarily related to severance and are expected to be paid by the end of 2024. For the three and nine months ended September 30, 2023, we recognized approximately $21.0&#160;million of net pre-tax restructuring charges, primarily consisting of employee severance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2022 Cost Saving Initiatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, deprioritization of certain research and development programs, the consolidation of certain real estate locations and operating efficiencies across our selling, general and administrative and research and development functions. Charges related to our 2022 cost saving initiatives were substantially incurred during 2022 with remaining payments expected to be made through 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total charges incurred from our 2022 cost saving initiatives are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.232%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.158%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Amounts reflect a gain recorded during the third quarter of 2022 of approximately $5.3&#160;million related to the partial termination of a portion of our lease located at 300 Binney Street.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges and spending related to our 2023 and 2022 workforce reductions and Reata Integration are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Workforce Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <biib:RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction contextRef="c-141" decimals="-8" id="f-602" unitRef="usd">1000000000</biib:RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction>
    <us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
      contextRef="c-142"
      decimals="INF"
      id="f-603"
      unitRef="employee">1000</us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-604">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total charges incurred from our 2023 cost saving initiatives are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.018%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total charges incurred from our 2022 cost saving initiatives are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.232%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.158%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Amounts reflect a gain recorded during the third quarter of 2022 of approximately $5.3&#160;million related to the partial termination of a portion of our lease located at 300 Binney Street.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1 contextRef="c-143" decimals="-5" id="f-605" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-143" decimals="-5" id="f-606" unitRef="usd">5900000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-143" decimals="-5" id="f-607" unitRef="usd">5900000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-144" decimals="-5" id="f-608" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-144" decimals="-5" id="f-609" unitRef="usd">17400000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-144" decimals="-5" id="f-610" unitRef="usd">17400000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-145" decimals="-5" id="f-611" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-145" decimals="-5" id="f-612" unitRef="usd">200000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-145" decimals="-5" id="f-613" unitRef="usd">200000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-146" decimals="-5" id="f-614" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-146" decimals="-5" id="f-615" unitRef="usd">700000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-146" decimals="-5" id="f-616" unitRef="usd">700000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-147" decimals="-5" id="f-617" unitRef="usd">37700000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-147" decimals="-5" id="f-618" unitRef="usd">17300000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-147" decimals="-5" id="f-619" unitRef="usd">55000000.0</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-148" decimals="-5" id="f-620" unitRef="usd">62600000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-148" decimals="-5" id="f-621" unitRef="usd">33800000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-148" decimals="-5" id="f-622" unitRef="usd">96400000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-149" decimals="-5" id="f-623" unitRef="usd">37700000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-149" decimals="-5" id="f-624" unitRef="usd">23400000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-149" decimals="-5" id="f-625" unitRef="usd">61100000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-142" decimals="-5" id="f-626" unitRef="usd">62600000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-142" decimals="-5" id="f-627" unitRef="usd">51900000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-142" decimals="-5" id="f-628" unitRef="usd">114500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-150" decimals="-5" id="f-629" unitRef="usd">30000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:SeveranceCosts1 contextRef="c-151" decimals="-5" id="f-630" unitRef="usd">21000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-152" decimals="-5" id="f-631" unitRef="usd">21000000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringCharges contextRef="c-153" decimals="-5" id="f-632" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-154" decimals="-5" id="f-633" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-155" decimals="-5" id="f-634" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-156" decimals="-5" id="f-635" unitRef="usd">21600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-157" decimals="-5" id="f-636" unitRef="usd">-6200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-158" decimals="-5" id="f-637" unitRef="usd">15400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-159" decimals="-5" id="f-638" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-160" decimals="-5" id="f-639" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-161" decimals="-5" id="f-640" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-162" decimals="-5" id="f-641" unitRef="usd">21600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-163" decimals="-5" id="f-642" unitRef="usd">-6200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-164" decimals="-5" id="f-643" unitRef="usd">15400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-165" decimals="-5" id="f-644" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-166" decimals="-5" id="f-645" unitRef="usd">2600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-167" decimals="-5" id="f-646" unitRef="usd">2600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-168" decimals="-5" id="f-647" unitRef="usd">110200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-169" decimals="-5" id="f-648" unitRef="usd">13900000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-170" decimals="-5" id="f-649" unitRef="usd">124100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-171" decimals="-5" id="f-650" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-172" decimals="-5" id="f-651" unitRef="usd">2600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-173" decimals="-5" id="f-652" unitRef="usd">2600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-174" decimals="-5" id="f-653" unitRef="usd">110200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-175" decimals="-5" id="f-654" unitRef="usd">13900000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-176" decimals="-5" id="f-655" unitRef="usd">124100000</us-gaap:RestructuringCharges>
    <us-gaap:GainLossOnTerminationOfLease contextRef="c-157" decimals="-5" id="f-656" unitRef="usd">5300000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-657">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges and spending related to our 2023 and 2022 workforce reductions and Reata Integration are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Workforce Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-177" decimals="-5" id="f-658" unitRef="usd">35900000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-178" decimals="-5" id="f-659" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-179" decimals="-5" id="f-660" unitRef="usd">7100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-180" decimals="-5" id="f-661" unitRef="usd">27700000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-179" decimals="-5" id="f-662" unitRef="usd">15600000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-180" decimals="-5" id="f-663" unitRef="usd">6200000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-179" decimals="-5" id="f-664" unitRef="usd">-600000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-180" decimals="-5" id="f-665" unitRef="usd">0</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserve contextRef="c-181" decimals="-5" id="f-666" unitRef="usd">28000000.0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-182" decimals="-5" id="f-667" unitRef="usd">21500000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-183" decimals="-5" id="f-668" unitRef="usd">17800000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-184" decimals="-5" id="f-669" unitRef="usd">60900000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-183" decimals="-5" id="f-670" unitRef="usd">13400000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-184" decimals="-5" id="f-671" unitRef="usd">29700000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-183" decimals="-5" id="f-672" unitRef="usd">100000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-184" decimals="-5" id="f-673" unitRef="usd">500000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserve contextRef="c-185" decimals="-5" id="f-674" unitRef="usd">32300000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-186" decimals="-5" id="f-675" unitRef="usd">52200000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-187" decimals="-5" id="f-676" unitRef="usd">58700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-188" decimals="-5" id="f-677" unitRef="usd">21600000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-187" decimals="-5" id="f-678" unitRef="usd">31800000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-188" decimals="-5" id="f-679" unitRef="usd">32300000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-187" decimals="-5" id="f-680" unitRef="usd">-100000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-188" decimals="-5" id="f-681" unitRef="usd">1300000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserve contextRef="c-189" decimals="-5" id="f-682" unitRef="usd">59300000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-190" decimals="-5" id="f-683" unitRef="usd">40200000</us-gaap:RestructuringReserve>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-684">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;246.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;339.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;256.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;336.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;631.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;527.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,159.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;707.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;632.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,340.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;290.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: SMA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;290.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;188.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;790.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,014.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,805.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;850.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,111.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,962.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; BYOOVIZ became commercially available in the U.S. during the third quarter of 2022 and commercially available in international markets in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes FUMADERM, ADUHELM and QALSODY, which became commercially available in the U.S. during the second quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;568.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;768.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;816.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,146.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;372.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;419.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;383.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;571.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;616.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,188.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;713.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;836.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,549.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;397.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;604.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;493.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;249.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;743.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;492.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;825.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;608.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;995.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;750.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;662.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,412.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;849.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;693.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,542.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,814.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,678.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,493.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,990.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,161.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;453.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;875.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,328.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;443.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;891.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,334.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: SMA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;453.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;875.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,328.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;443.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;891.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,334.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;331.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;331.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;560.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;581.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;575.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;576.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,293.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,414.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,619.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,463.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,083.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; BYOOVIZ became commercially available in the U.S. during the third quarter of 2022 and commercially available in international markets in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes FUMADERM, ADUHELM and QALSODY, which became commercially available in the U.S. during the second quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 26.9% and 10.5% of gross product revenue for the three months ended September 30, 2023, and 27.1% and 9.1% of gross product revenue for the nine months ended September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 26.9% and 10.5% of gross product revenue for the three months ended September 30, 2022, and 26.8% and 10.7% of gross product revenue for the nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;857.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,035.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;554.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,983.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,551.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(410.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,362.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,774.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(574.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(735.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;879.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;940.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;891.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,035.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Revenue from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty revenue on sales of OCREVUS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;928.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;825.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;315.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;414.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;420.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,253.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,252.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; LUNSUMIO became commercially available in the U.S. during the first quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to our consolidated financial statements included in our 2022 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Contract Manufacturing, Royalty and Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract manufacturing, royalty and other revenue is summarized in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;742.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total contract manufacturing, royalty and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;781.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Manufacturing Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract manufacturing revenue primarily reflects amounts earned under contract manufacturing agreements with our strategic customers. During the first quarter of 2023 we began recognizing contract manufacturing revenue for LEQEMBI, upon accelerated approval of LEQEMBI in the U.S. Prior to accelerated approval, contract manufacturing amounts related to LEQEMBI were recognized in research and development expense within our condensed consolidated income statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty and other revenue primarily reflects the royalties we receive from net sales on products related to patents that we have out-licensed, as well as royalty revenue on biosimilar products from our license arrangements with Samsung Bioepis and our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, as we are not the principal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2023 we recorded a reclassification of $38.7&#160;million in LEQEMBI collaboration costs from other revenue to selling, general and administrative expense within our condensed consolidated statements of income. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that this reclassification does not materially impact the current or previously issued condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Eisai and our license arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-685">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;246.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;339.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;256.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;336.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;631.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;527.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,159.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;707.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;632.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,340.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;290.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: SMA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;290.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;188.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;790.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,014.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,805.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;850.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,111.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,962.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; BYOOVIZ became commercially available in the U.S. during the third quarter of 2022 and commercially available in international markets in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes FUMADERM, ADUHELM and QALSODY, which became commercially available in the U.S. during the second quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;568.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;768.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;816.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,146.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;372.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;419.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;383.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;571.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;616.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,188.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;713.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;836.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,549.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;397.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;604.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;493.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;249.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;743.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;492.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;825.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;608.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;995.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;750.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;662.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,412.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;849.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;693.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,542.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,814.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,678.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,493.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,990.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,161.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;453.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;875.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,328.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;443.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;891.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,334.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: SMA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;453.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;875.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,328.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;443.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;891.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,334.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;331.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;331.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;560.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;581.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;575.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;576.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,293.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,414.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,619.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,463.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,083.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; BYOOVIZ became commercially available in the U.S. during the third quarter of 2022 and commercially available in international markets in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes FUMADERM, ADUHELM and QALSODY, which became commercially available in the U.S. during the second quarter of 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues contextRef="c-191" decimals="-5" id="f-686" unitRef="usd">58100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-192" decimals="-5" id="f-687" unitRef="usd">181400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-193" decimals="-5" id="f-688" unitRef="usd">239500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-194" decimals="-5" id="f-689" unitRef="usd">92500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-195" decimals="-5" id="f-690" unitRef="usd">246500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-196" decimals="-5" id="f-691" unitRef="usd">339000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-197" decimals="-5" id="f-692" unitRef="usd">148800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-198" decimals="-5" id="f-693" unitRef="usd">16700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-199" decimals="-5" id="f-694" unitRef="usd">165500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-200" decimals="-5" id="f-695" unitRef="usd">127900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-201" decimals="-5" id="f-696" unitRef="usd">9900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-202" decimals="-5" id="f-697" unitRef="usd">137800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-203" decimals="-5" id="f-698" unitRef="usd">206900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-204" decimals="-5" id="f-699" unitRef="usd">198100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-205" decimals="-5" id="f-700" unitRef="usd">405000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-206" decimals="-5" id="f-701" unitRef="usd">220400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-207" decimals="-5" id="f-702" unitRef="usd">256400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-208" decimals="-5" id="f-703" unitRef="usd">476800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-209" decimals="-5" id="f-704" unitRef="usd">148700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-210" decimals="-5" id="f-705" unitRef="usd">63500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-211" decimals="-5" id="f-706" unitRef="usd">212200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-212" decimals="-5" id="f-707" unitRef="usd">174800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-213" decimals="-5" id="f-708" unitRef="usd">80300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-214" decimals="-5" id="f-709" unitRef="usd">255100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-215" decimals="-5" id="f-710" unitRef="usd">31400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-216" decimals="-5" id="f-711" unitRef="usd">34100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-217" decimals="-5" id="f-712" unitRef="usd">65500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-218" decimals="-5" id="f-713" unitRef="usd">39700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-219" decimals="-5" id="f-714" unitRef="usd">41200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-220" decimals="-5" id="f-715" unitRef="usd">80900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-221" decimals="-5" id="f-716" unitRef="usd">180100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-222" decimals="-5" id="f-717" unitRef="usd">97600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-223" decimals="-5" id="f-718" unitRef="usd">277700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-224" decimals="-5" id="f-719" unitRef="usd">214500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-225" decimals="-5" id="f-720" unitRef="usd">121500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-226" decimals="-5" id="f-721" unitRef="usd">336000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-227" decimals="-5" id="f-722" unitRef="usd">244800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-228" decimals="-5" id="f-723" unitRef="usd">211500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-229" decimals="-5" id="f-724" unitRef="usd">456300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-230" decimals="-5" id="f-725" unitRef="usd">273000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-231" decimals="-5" id="f-726" unitRef="usd">232500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-232" decimals="-5" id="f-727" unitRef="usd">505500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-233" decimals="-5" id="f-728" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-234" decimals="-5" id="f-729" unitRef="usd">20000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-235" decimals="-5" id="f-730" unitRef="usd">20000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-236" decimals="-5" id="f-731" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-237" decimals="-5" id="f-732" unitRef="usd">22000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-238" decimals="-5" id="f-733" unitRef="usd">22000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-239" decimals="-5" id="f-734" unitRef="usd">631800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-240" decimals="-5" id="f-735" unitRef="usd">527200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-241" decimals="-5" id="f-736" unitRef="usd">1159000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-242" decimals="-5" id="f-737" unitRef="usd">707900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-243" decimals="-5" id="f-738" unitRef="usd">632400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-244" decimals="-5" id="f-739" unitRef="usd">1340300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-245" decimals="-5" id="f-740" unitRef="usd">150500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-246" decimals="-5" id="f-741" unitRef="usd">297700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-247" decimals="-5" id="f-742" unitRef="usd">448200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-248" decimals="-5" id="f-743" unitRef="usd">140200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-249" decimals="-5" id="f-744" unitRef="usd">290900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-250" decimals="-5" id="f-745" unitRef="usd">431100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-251" decimals="-5" id="f-746" unitRef="usd">150500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-252" decimals="-5" id="f-747" unitRef="usd">297700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-253" decimals="-5" id="f-748" unitRef="usd">448200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-254" decimals="-5" id="f-749" unitRef="usd">140200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-255" decimals="-5" id="f-750" unitRef="usd">290900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-256" decimals="-5" id="f-751" unitRef="usd">431100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-257" decimals="-5" id="f-752" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-258" decimals="-5" id="f-753" unitRef="usd">112800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-259" decimals="-5" id="f-754" unitRef="usd">112800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-260" decimals="-5" id="f-755" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-261" decimals="-5" id="f-756" unitRef="usd">110200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-262" decimals="-5" id="f-757" unitRef="usd">110200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-263" decimals="-5" id="f-758" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-264" decimals="-5" id="f-759" unitRef="usd">54400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-265" decimals="-5" id="f-760" unitRef="usd">54400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-266" decimals="-5" id="f-761" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-267" decimals="-5" id="f-762" unitRef="usd">57700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-268" decimals="-5" id="f-763" unitRef="usd">57700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-269" decimals="-5" id="f-764" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-270" decimals="-5" id="f-765" unitRef="usd">20200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-271" decimals="-5" id="f-766" unitRef="usd">20200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-272" decimals="-5" id="f-767" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-273" decimals="-5" id="f-768" unitRef="usd">19000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-274" decimals="-5" id="f-769" unitRef="usd">19000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-275" decimals="-5" id="f-770" unitRef="usd">6100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-276" decimals="-5" id="f-771" unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-277" decimals="-5" id="f-772" unitRef="usd">6900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-278" decimals="-5" id="f-773" unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-279" decimals="-5" id="f-774" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-280" decimals="-5" id="f-775" unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-281" decimals="-5" id="f-776" unitRef="usd">6100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-282" decimals="-5" id="f-777" unitRef="usd">188200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-283" decimals="-5" id="f-778" unitRef="usd">194300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-284" decimals="-5" id="f-779" unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-285" decimals="-5" id="f-780" unitRef="usd">186900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-286" decimals="-5" id="f-781" unitRef="usd">187600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-287" decimals="-5" id="f-782" unitRef="usd">2500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-288" decimals="-5" id="f-783" unitRef="usd">1200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-289" decimals="-5" id="f-784" unitRef="usd">3700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-290" decimals="-5" id="f-785" unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-291" decimals="-5" id="f-786" unitRef="usd">1500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-292" decimals="-5" id="f-787" unitRef="usd">3100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-293" decimals="-5" id="f-788" unitRef="usd">790900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-294" decimals="-5" id="f-789" unitRef="usd">1014300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-3" decimals="-5" id="f-790" unitRef="usd">1805200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-295" decimals="-5" id="f-791" unitRef="usd">850400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-296" decimals="-5" id="f-792" unitRef="usd">1111700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-4" decimals="-5" id="f-793" unitRef="usd">1962100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-297" decimals="-5" id="f-794" unitRef="usd">199300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-298" decimals="-5" id="f-795" unitRef="usd">568900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-299" decimals="-5" id="f-796" unitRef="usd">768200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-300" decimals="-5" id="f-797" unitRef="usd">330300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-301" decimals="-5" id="f-798" unitRef="usd">816500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-302" decimals="-5" id="f-799" unitRef="usd">1146800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-303" decimals="-5" id="f-800" unitRef="usd">372600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-304" decimals="-5" id="f-801" unitRef="usd">47300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-305" decimals="-5" id="f-802" unitRef="usd">419900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-306" decimals="-5" id="f-803" unitRef="usd">383000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-307" decimals="-5" id="f-804" unitRef="usd">19600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-308" decimals="-5" id="f-805" unitRef="usd">402600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-309" decimals="-5" id="f-806" unitRef="usd">571900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-310" decimals="-5" id="f-807" unitRef="usd">616200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-311" decimals="-5" id="f-808" unitRef="usd">1188100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-312" decimals="-5" id="f-809" unitRef="usd">713300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-313" decimals="-5" id="f-810" unitRef="usd">836100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-314" decimals="-5" id="f-811" unitRef="usd">1549400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-315" decimals="-5" id="f-812" unitRef="usd">397200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-316" decimals="-5" id="f-813" unitRef="usd">207700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-317" decimals="-5" id="f-814" unitRef="usd">604900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-318" decimals="-5" id="f-815" unitRef="usd">493800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-319" decimals="-5" id="f-816" unitRef="usd">249600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-320" decimals="-5" id="f-817" unitRef="usd">743400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-321" decimals="-5" id="f-818" unitRef="usd">95400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-322" decimals="-5" id="f-819" unitRef="usd">125400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-323" decimals="-5" id="f-820" unitRef="usd">220800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-324" decimals="-5" id="f-821" unitRef="usd">114200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-325" decimals="-5" id="f-822" unitRef="usd">138200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-326" decimals="-5" id="f-823" unitRef="usd">252400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-327" decimals="-5" id="f-824" unitRef="usd">492600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-328" decimals="-5" id="f-825" unitRef="usd">333100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-329" decimals="-5" id="f-826" unitRef="usd">825700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-330" decimals="-5" id="f-827" unitRef="usd">608000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-331" decimals="-5" id="f-828" unitRef="usd">387800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-332" decimals="-5" id="f-829" unitRef="usd">995800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-333" decimals="-5" id="f-830" unitRef="usd">750100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-334" decimals="-5" id="f-831" unitRef="usd">662100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-335" decimals="-5" id="f-832" unitRef="usd">1412200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-336" decimals="-5" id="f-833" unitRef="usd">849400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-337" decimals="-5" id="f-834" unitRef="usd">693100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-338" decimals="-5" id="f-835" unitRef="usd">1542500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-339" decimals="-5" id="f-836" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-340" decimals="-5" id="f-837" unitRef="usd">67500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-341" decimals="-5" id="f-838" unitRef="usd">67500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-342" decimals="-5" id="f-839" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-343" decimals="-5" id="f-840" unitRef="usd">73700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-344" decimals="-5" id="f-841" unitRef="usd">73700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-345" decimals="-5" id="f-842" unitRef="usd">1814600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-346" decimals="-5" id="f-843" unitRef="usd">1678900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-347" decimals="-5" id="f-844" unitRef="usd">3493500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-348" decimals="-5" id="f-845" unitRef="usd">2170700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-349" decimals="-5" id="f-846" unitRef="usd">1990700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-350" decimals="-5" id="f-847" unitRef="usd">4161400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-351" decimals="-5" id="f-848" unitRef="usd">453000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-352" decimals="-5" id="f-849" unitRef="usd">875600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-353" decimals="-5" id="f-850" unitRef="usd">1328600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-354" decimals="-5" id="f-851" unitRef="usd">443300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-355" decimals="-5" id="f-852" unitRef="usd">891400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-356" decimals="-5" id="f-853" unitRef="usd">1334700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-357" decimals="-5" id="f-854" unitRef="usd">453000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-358" decimals="-5" id="f-855" unitRef="usd">875600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-359" decimals="-5" id="f-856" unitRef="usd">1328600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-360" decimals="-5" id="f-857" unitRef="usd">443300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-361" decimals="-5" id="f-858" unitRef="usd">891400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-362" decimals="-5" id="f-859" unitRef="usd">1334700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-363" decimals="-5" id="f-860" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-364" decimals="-5" id="f-861" unitRef="usd">331000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-365" decimals="-5" id="f-862" unitRef="usd">331000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-366" decimals="-5" id="f-863" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-367" decimals="-5" id="f-864" unitRef="usd">340700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-368" decimals="-5" id="f-865" unitRef="usd">340700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-369" decimals="-5" id="f-866" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-370" decimals="-5" id="f-867" unitRef="usd">167600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-371" decimals="-5" id="f-868" unitRef="usd">167600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-372" decimals="-5" id="f-869" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-373" decimals="-5" id="f-870" unitRef="usd">172400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-374" decimals="-5" id="f-871" unitRef="usd">172400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-375" decimals="-5" id="f-872" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-376" decimals="-5" id="f-873" unitRef="usd">60700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-377" decimals="-5" id="f-874" unitRef="usd">60700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-378" decimals="-5" id="f-875" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-379" decimals="-5" id="f-876" unitRef="usd">62000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-380" decimals="-5" id="f-877" unitRef="usd">62000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-381" decimals="-5" id="f-878" unitRef="usd">21300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-382" decimals="-5" id="f-879" unitRef="usd">1200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-383" decimals="-5" id="f-880" unitRef="usd">22500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-384" decimals="-5" id="f-881" unitRef="usd">1200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-385" decimals="-5" id="f-882" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-386" decimals="-5" id="f-883" unitRef="usd">1200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-387" decimals="-5" id="f-884" unitRef="usd">21300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-388" decimals="-5" id="f-885" unitRef="usd">560500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-389" decimals="-5" id="f-886" unitRef="usd">581800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-390" decimals="-5" id="f-887" unitRef="usd">1200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-391" decimals="-5" id="f-888" unitRef="usd">575100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-392" decimals="-5" id="f-889" unitRef="usd">576300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-393" decimals="-5" id="f-890" unitRef="usd">4400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-394" decimals="-5" id="f-891" unitRef="usd">6000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-395" decimals="-5" id="f-892" unitRef="usd">10400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-396" decimals="-5" id="f-893" unitRef="usd">4500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-397" decimals="-5" id="f-894" unitRef="usd">6400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-398" decimals="-5" id="f-895" unitRef="usd">10900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-399" decimals="-5" id="f-896" unitRef="usd">2293300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-400" decimals="-5" id="f-897" unitRef="usd">3121000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-5" id="f-898" unitRef="usd">5414300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-401" decimals="-5" id="f-899" unitRef="usd">2619700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-402" decimals="-5" id="f-900" unitRef="usd">3463600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-5" id="f-901" unitRef="usd">6083300000</us-gaap:Revenues>
    <biib:NumberOfWholesalers
      contextRef="c-1"
      decimals="INF"
      id="f-902"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-15"
      decimals="INF"
      id="f-903"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-403"
      decimals="INF"
      id="f-904"
      unitRef="number">0.269</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-404"
      decimals="INF"
      id="f-905"
      unitRef="number">0.105</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-405"
      decimals="INF"
      id="f-906"
      unitRef="number">0.271</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-406"
      decimals="INF"
      id="f-907"
      unitRef="number">0.091</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:NumberOfWholesalers
      contextRef="c-1"
      decimals="INF"
      id="f-908"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-15"
      decimals="INF"
      id="f-909"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="c-407" decimals="3" id="f-910" unitRef="number">0.269</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="c-408" decimals="3" id="f-911" unitRef="number">0.105</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="c-409" decimals="3" id="f-912" unitRef="number">0.268</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="c-410" decimals="3" id="f-913" unitRef="number">0.107</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock contextRef="c-1" id="f-914">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;857.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,035.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;554.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,983.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,551.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(410.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,362.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,774.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(574.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(735.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;879.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-411" decimals="-5" id="f-915" unitRef="usd">153800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-412" decimals="-5" id="f-916" unitRef="usd">857700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-413" decimals="-5" id="f-917" unitRef="usd">23500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-19" decimals="-5" id="f-918" unitRef="usd">1035000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="c-414" decimals="-5" id="f-919" unitRef="usd">554100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="c-415" decimals="-5" id="f-920" unitRef="usd">1983600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="c-416" decimals="-5" id="f-921" unitRef="usd">14200000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="c-1" decimals="-5" id="f-922" unitRef="usd">2551900000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="c-414" decimals="-5" id="f-923" unitRef="usd">-200000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="c-415" decimals="-5" id="f-924" unitRef="usd">24500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="c-416" decimals="-5" id="f-925" unitRef="usd">-19900000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="c-1" decimals="-5" id="f-926" unitRef="usd">4400000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="c-414" decimals="-5" id="f-927" unitRef="usd">410400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="c-415" decimals="-5" id="f-928" unitRef="usd">1362300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="c-416" decimals="-5" id="f-929" unitRef="usd">2000000.0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="c-1" decimals="-5" id="f-930" unitRef="usd">1774700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="c-414" decimals="-5" id="f-931" unitRef="usd">137500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="c-415" decimals="-5" id="f-932" unitRef="usd">574800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="c-416" decimals="-5" id="f-933" unitRef="usd">23200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="c-1" decimals="-5" id="f-934" unitRef="usd">735500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-417" decimals="-5" id="f-935" unitRef="usd">160200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-418" decimals="-5" id="f-936" unitRef="usd">879700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-419" decimals="-5" id="f-937" unitRef="usd">32400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-18" decimals="-5" id="f-938" unitRef="usd">1072300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock contextRef="c-1" id="f-939">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;940.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;891.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,035.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-420" decimals="-5" id="f-940" unitRef="usd">131400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-421" decimals="-5" id="f-941" unitRef="usd">143400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-422" decimals="-5" id="f-942" unitRef="usd">940900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-423" decimals="-5" id="f-943" unitRef="usd">891600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-18" decimals="-5" id="f-944" unitRef="usd">1072300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-19" decimals="-5" id="f-945" unitRef="usd">1035000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock contextRef="c-1" id="f-946">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty revenue on sales of OCREVUS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;928.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;825.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;315.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;414.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;420.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,253.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,252.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; LUNSUMIO became commercially available in the U.S. during the first quarter of 2023.&lt;/span&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <us-gaap:Revenues contextRef="c-424" decimals="-5" id="f-947" unitRef="usd">319100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-425" decimals="-5" id="f-948" unitRef="usd">281100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-426" decimals="-5" id="f-949" unitRef="usd">928200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-427" decimals="-5" id="f-950" unitRef="usd">825200000</us-gaap:Revenues>
    <biib:ShareOfCoPromotionProfits contextRef="c-428" decimals="-5" id="f-951" unitRef="usd">98900000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits contextRef="c-429" decimals="-5" id="f-952" unitRef="usd">131100000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits contextRef="c-430" decimals="-5" id="f-953" unitRef="usd">315000000.0</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits contextRef="c-431" decimals="-5" id="f-954" unitRef="usd">414200000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="c-428" decimals="-5" id="f-955" unitRef="usd">2900000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="c-429" decimals="-5" id="f-956" unitRef="usd">4700000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="c-430" decimals="-5" id="f-957" unitRef="usd">10600000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="c-431" decimals="-5" id="f-958" unitRef="usd">13200000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues contextRef="c-7" decimals="-5" id="f-959" unitRef="usd">420900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-5" id="f-960" unitRef="usd">416900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-9" decimals="-5" id="f-961" unitRef="usd">1253800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-10" decimals="-5" id="f-962" unitRef="usd">1252600000</us-gaap:Revenues>
    <biib:OtherrevenuesTableTextBlock contextRef="c-1" id="f-963">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;742.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total contract manufacturing, royalty and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;781.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues contextRef="c-432" decimals="-5" id="f-964" unitRef="usd">252900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-433" decimals="-5" id="f-965" unitRef="usd">114200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-434" decimals="-5" id="f-966" unitRef="usd">742900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-435" decimals="-5" id="f-967" unitRef="usd">242900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-436" decimals="-5" id="f-968" unitRef="usd">51300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-437" decimals="-5" id="f-969" unitRef="usd">15300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-438" decimals="-5" id="f-970" unitRef="usd">38300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-439" decimals="-5" id="f-971" unitRef="usd">50600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-11" decimals="-5" id="f-972" unitRef="usd">304200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-12" decimals="-5" id="f-973" unitRef="usd">129500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-13" decimals="-5" id="f-974" unitRef="usd">781200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-14" decimals="-5" id="f-975" unitRef="usd">293500000</us-gaap:Revenues>
    <biib:ShareOfNonControlingInterestRecognized contextRef="c-440" decimals="2" id="f-976" unitRef="number">0.500</biib:ShareOfNonControlingInterestRecognized>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-441" decimals="-5" id="f-977" unitRef="usd">38700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-978">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;437.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,285.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;751.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;316.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,038.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,365.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,982.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,344.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,038.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,365.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the third quarter of 2023 we recorded approximately $1.7&#160;billion of acquired inventory related to SKYCLARYS as a result of our acquisition of Reata in September 2023. For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the first quarter of 2022 we wrote-off approximately $275.0&#160;million of inventory related to ADUHELM, as a result of the final NCD, which was recognized in cost of sales within our condensed consolidated statements of income &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; months ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;September 30, 2022. We recognized approximately $136.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit sharing/(loss reimbursement) within our condensed consolidated statements of income &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; months ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;September 30, 2022. As of September 30, 2023 and December 31, 2022, the carrying value of our ADUHELM inventory was immaterial.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-979">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;437.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,285.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;751.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;316.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,038.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,365.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,982.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,344.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,038.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,365.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-18" decimals="-5" id="f-980" unitRef="usd">437100000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-19" decimals="-5" id="f-981" unitRef="usd">413200000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-18" decimals="-5" id="f-982" unitRef="usd">2285100000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-19" decimals="-5" id="f-983" unitRef="usd">751900000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-18" decimals="-5" id="f-984" unitRef="usd">316100000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-19" decimals="-5" id="f-985" unitRef="usd">200400000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:InventoryNetCurrentAndNoncurrent contextRef="c-18" decimals="-5" id="f-986" unitRef="usd">3038300000</biib:InventoryNetCurrentAndNoncurrent>
    <biib:InventoryNetCurrentAndNoncurrent contextRef="c-19" decimals="-5" id="f-987" unitRef="usd">1365500000</biib:InventoryNetCurrentAndNoncurrent>
    <us-gaap:InventoryNet contextRef="c-18" decimals="-5" id="f-988" unitRef="usd">2982400000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-19" decimals="-5" id="f-989" unitRef="usd">1344400000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent contextRef="c-18" decimals="-5" id="f-990" unitRef="usd">55900000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-19" decimals="-5" id="f-991" unitRef="usd">21100000</us-gaap:InventoryNoncurrent>
    <biib:InventoryNetCurrentAndNoncurrent contextRef="c-18" decimals="-5" id="f-992" unitRef="usd">3038300000</biib:InventoryNetCurrentAndNoncurrent>
    <biib:InventoryNetCurrentAndNoncurrent contextRef="c-19" decimals="-5" id="f-993" unitRef="usd">1365500000</biib:InventoryNetCurrentAndNoncurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-116" decimals="-8" id="f-994" unitRef="usd">1700000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:InventoryWriteDown contextRef="c-442" decimals="-5" id="f-995" unitRef="usd">275000000</us-gaap:InventoryWriteDown>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-443" decimals="-5" id="f-996" unitRef="usd">136000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai contextRef="c-1" decimals="INF" id="f-997" unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-998">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.257%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.383%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.972%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.972%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.669%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,053.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,793.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,260.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,415.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,629.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,786.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,920.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,920.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Priority review voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,137.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,793.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,344.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,479.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,629.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,850.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortization and Impairments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2023, amortization and impairment of acquired intangible assets totale&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d $60.9 million and $164.0 million, re&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;spectively, compared to $56.5 million and $190.9 million, respectively, in the prior year comparative periods. For the three and nine months ended September 30, 2023 and 2022, we had no impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Completed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Completed technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations. In connection with our acquisition of Reata in September 2023 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;we acquired SKYCLARYS, a commercially-approved product in the U.S., with an estimated fair value of approximately &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.6&#160;billion&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life and amortize these amounts based upon an economic consumption method. IPR&amp;amp;D balances also include adjustments related to foreign currency exchange rate fluctuations. The carrying value associated with our IPR&amp;amp;D assets as of September 30, 2023, relates to the IPR&amp;amp;D programs we acquired in connection with our acquisition of Reata in September 2023 with an estimated fair value of approximately $1.9&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Priority Review Voucher&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata in September 2023 we acquired a rare pediatric disease priority review voucher that may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party. We recorded the priority review voucher based on its estimated fair value of $100.0&#160;million as an intangible asset. The estimated fair value was based on recent external purchase and sale transactions of similar vouchers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;325.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;440.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,749.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from Reata acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,057.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,807.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2023, we had&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; no ac&lt;/span&gt;cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock contextRef="c-1" id="f-999">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.257%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.383%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.972%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.972%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.669%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,053.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,793.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,260.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,415.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,629.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,786.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,920.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,920.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Priority review voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,137.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,793.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,344.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,479.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,629.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,850.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-444" decimals="-5" id="f-1000" unitRef="usd">11053800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-444" decimals="-5" id="f-1001" unitRef="usd">5793200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-444" decimals="-5" id="f-1002" unitRef="usd">5260600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-445" decimals="-5" id="f-1003" unitRef="usd">7415300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-445" decimals="-5" id="f-1004" unitRef="usd">5629200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-445" decimals="-5" id="f-1005" unitRef="usd">1786100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-446" decimals="-5" id="f-1006" unitRef="usd">1920000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-446" decimals="-5" id="f-1007" unitRef="usd">1920000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-447" decimals="-5" id="f-1008" unitRef="usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-448" decimals="-5" id="f-1009" unitRef="usd">100000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-448" decimals="-5" id="f-1010" unitRef="usd">100000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-449" decimals="-5" id="f-1011" unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-449" decimals="-5" id="f-1012" unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-450" decimals="-5" id="f-1013" unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-450" decimals="-5" id="f-1014" unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-18" decimals="-5" id="f-1015" unitRef="usd">13137800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-18" decimals="-5" id="f-1016" unitRef="usd">5793200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-18" decimals="-5" id="f-1017" unitRef="usd">7344600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-19" decimals="-5" id="f-1018" unitRef="usd">7479300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-19" decimals="-5" id="f-1019" unitRef="usd">5629200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-19" decimals="-5" id="f-1020" unitRef="usd">1850100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-15" decimals="-5" id="f-1021" unitRef="usd">60900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-1" decimals="-5" id="f-1022" unitRef="usd">164000000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-16" decimals="-5" id="f-1023" unitRef="usd">56500000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-17" decimals="-5" id="f-1024" unitRef="usd">190900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-121" decimals="-8" id="f-1025" unitRef="usd">3600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-122" decimals="-8" id="f-1026" unitRef="usd">1900000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-123" decimals="-5" id="f-1027" unitRef="usd">100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-1028">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;325.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;440.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-18" decimals="-5" id="f-1029" unitRef="usd">75000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-18" decimals="-5" id="f-1030" unitRef="usd">325000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-18" decimals="-5" id="f-1031" unitRef="usd">430000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-18" decimals="-5" id="f-1032" unitRef="usd">440000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-18" decimals="-5" id="f-1033" unitRef="usd">435000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-18" decimals="-5" id="f-1034" unitRef="usd">445000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-1035">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,749.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from Reata acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,057.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,807.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-19" decimals="-5" id="f-1036" unitRef="usd">5749000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-1" decimals="-5" id="f-1037" unitRef="usd">1057300000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillOtherIncreaseDecrease contextRef="c-1" decimals="-5" id="f-1038" unitRef="usd">1200000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill contextRef="c-18" decimals="-5" id="f-1039" unitRef="usd">6807500000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-18" decimals="INF" id="f-1040" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-1043">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,920.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,920.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;422.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;422.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,826.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,990.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;422.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of the current payment due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;During the third quarter of 2023 we sold all of our marketable debt securities and used the proceeds to partially fund our acquisition of Reata. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,847.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,847.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,231.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,231.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;810.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;810.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;798.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;798.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,117.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,122.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,204.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-1044">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,920.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,920.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;422.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;422.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,826.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,990.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;422.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of the current payment due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;During the third quarter of 2023 we sold all of our marketable debt securities and used the proceeds to partially fund our acquisition of Reata. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,847.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,847.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,231.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,231.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;810.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;810.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;798.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;798.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,117.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,122.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,204.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities represent investments in publicly traded equity securities. Our ability to liquidate our investments in Denali, Sage and Sangamo may be limited by the size of our interest, the volume of market related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Denali, Sangamo and Sage common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2022 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material impairments of our assets measured and carried at fair value as of September 30, 2023 and December 31, 2022. In addition, there have been no changes to our valuation techniques as of September 30, 2023 and December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2022 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Level 3 Assets and Liabilities Held at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers of assets or liabilities into or out of Level 3 as of September 30, 2023 and December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Convergence, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair value of our contingent consideration obligations, which were classified as Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of our contingent consideration obligations are recorded in (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2022 we discontinued further development efforts related to vixotrigine for the potential treatment of TGN and DPN, resulting in a reduction of our contingent consideration obligations of approximately $195.4&#160;million, reducing the fair value of vixotrigine to zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2022, the changes in fair value of our contingent consideration obligations were primarily due to increases in the discount rates used to revalue these obligations and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Financial Instruments Not Carried at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our senior notes debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,689.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,746.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,699.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,744.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,196.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,493.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,219.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;972.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,033.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;909.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,474.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;989.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;471.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;469.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;469.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,198.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,286.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,410.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,281.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The changes in the fair values of our Senior Notes as of September 30, 2023, compared to December 31, 2022, are primarily related to increases in U.S. treasury yields partially offset by a decrease in credit spreads used to value our Senior Notes since December 31, 2022. For additional information related to our Senior Notes, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2022 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata we drew&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.0 billion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; on term loans under our term loan credit agreement. As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2023, t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;he fair value of our term loans outstanding approximate book value based on the current borrowing rates available. For additional information on our term loan credit agreement, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Note 13, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-453" decimals="-5" id="f-1045" unitRef="usd">1920400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-454" decimals="-5" id="f-1046" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-455" decimals="-5" id="f-1047" unitRef="usd">1920400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-456" decimals="-5" id="f-1048" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-453" decimals="-5" id="f-1049" unitRef="usd">413600000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-454" decimals="-5" id="f-1050" unitRef="usd">413600000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-455" decimals="-5" id="f-1051" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-456" decimals="-5" id="f-1052" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-137" decimals="-5" id="f-1053" unitRef="usd">422300000</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-457" decimals="-5" id="f-1054" unitRef="usd">0</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-458" decimals="-5" id="f-1055" unitRef="usd">0</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-459" decimals="-5" id="f-1056" unitRef="usd">422300000</biib:OtherAssetsCurrentFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-453" decimals="-5" id="f-1057" unitRef="usd">27800000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-454" decimals="-5" id="f-1058" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-455" decimals="-5" id="f-1059" unitRef="usd">27800000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-456" decimals="-5" id="f-1060" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-453" decimals="-5" id="f-1061" unitRef="usd">39000000.0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-454" decimals="-5" id="f-1062" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-455" decimals="-5" id="f-1063" unitRef="usd">39000000.0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-456" decimals="-5" id="f-1064" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:DerivativeAssets contextRef="c-18" decimals="-5" id="f-1065" unitRef="usd">3400000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-454" decimals="-5" id="f-1066" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-455" decimals="-5" id="f-1067" unitRef="usd">3400000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-456" decimals="-5" id="f-1068" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-453" decimals="-5" id="f-1069" unitRef="usd">2826500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-454" decimals="-5" id="f-1070" unitRef="usd">413600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-455" decimals="-5" id="f-1071" unitRef="usd">1990600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-456" decimals="-5" id="f-1072" unitRef="usd">422300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-453" decimals="-5" id="f-1073" unitRef="usd">37500000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-454" decimals="-5" id="f-1074" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-455" decimals="-5" id="f-1075" unitRef="usd">37500000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-456" decimals="-5" id="f-1076" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-453" decimals="-5" id="f-1077" unitRef="usd">37500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-454" decimals="-5" id="f-1078" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-455" decimals="-5" id="f-1079" unitRef="usd">37500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-456" decimals="-5" id="f-1080" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c-460"
      decimals="3"
      id="f-1081"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-461" decimals="-5" id="f-1082" unitRef="usd">2847600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-462" decimals="-5" id="f-1083" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-463" decimals="-5" id="f-1084" unitRef="usd">2847600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-464" decimals="-5" id="f-1085" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-465" decimals="-5" id="f-1086" unitRef="usd">1231600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-466" decimals="-5" id="f-1087" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-467" decimals="-5" id="f-1088" unitRef="usd">1231600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-468" decimals="-5" id="f-1089" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-469" decimals="-5" id="f-1090" unitRef="usd">810300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-470" decimals="-5" id="f-1091" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-471" decimals="-5" id="f-1092" unitRef="usd">810300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-472" decimals="-5" id="f-1093" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-473" decimals="-5" id="f-1094" unitRef="usd">137300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-474" decimals="-5" id="f-1095" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-475" decimals="-5" id="f-1096" unitRef="usd">137300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-476" decimals="-5" id="f-1097" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-461" decimals="-5" id="f-1098" unitRef="usd">791100000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-462" decimals="-5" id="f-1099" unitRef="usd">791100000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-463" decimals="-5" id="f-1100" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-464" decimals="-5" id="f-1101" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-477" decimals="-5" id="f-1102" unitRef="usd">798800000</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-478" decimals="-5" id="f-1103" unitRef="usd">0</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-479" decimals="-5" id="f-1104" unitRef="usd">0</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure contextRef="c-480" decimals="-5" id="f-1105" unitRef="usd">798800000</biib:OtherAssetsCurrentFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-461" decimals="-5" id="f-1106" unitRef="usd">63000000.0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-462" decimals="-5" id="f-1107" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-463" decimals="-5" id="f-1108" unitRef="usd">63000000.0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-464" decimals="-5" id="f-1109" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-461" decimals="-5" id="f-1110" unitRef="usd">32800000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-462" decimals="-5" id="f-1111" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-463" decimals="-5" id="f-1112" unitRef="usd">32800000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-464" decimals="-5" id="f-1113" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure contextRef="c-477" decimals="-5" id="f-1114" unitRef="usd">405400000</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure contextRef="c-478" decimals="-5" id="f-1115" unitRef="usd">0</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure contextRef="c-479" decimals="-5" id="f-1116" unitRef="usd">0</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure contextRef="c-480" decimals="-5" id="f-1117" unitRef="usd">405400000</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-461" decimals="-5" id="f-1118" unitRef="usd">7117900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-462" decimals="-5" id="f-1119" unitRef="usd">791100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-463" decimals="-5" id="f-1120" unitRef="usd">5122600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-464" decimals="-5" id="f-1121" unitRef="usd">1204200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-461" decimals="-5" id="f-1122" unitRef="usd">26000000.0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-462" decimals="-5" id="f-1123" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-463" decimals="-5" id="f-1124" unitRef="usd">26000000.0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-464" decimals="-5" id="f-1125" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-461" decimals="-5" id="f-1126" unitRef="usd">26000000.0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-462" decimals="-5" id="f-1127" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-463" decimals="-5" id="f-1128" unitRef="usd">26000000.0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-464" decimals="-5" id="f-1129" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c-460"
      decimals="3"
      id="f-1130"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:AssetImpairmentCharges contextRef="c-15" decimals="INF" id="f-1131" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="INF" id="f-1132" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-1133">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Convergence, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair value of our contingent consideration obligations, which were classified as Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-481" decimals="-5" id="f-1134" unitRef="usd">197500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-482" decimals="-5" id="f-1135" unitRef="usd">209100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-16" decimals="-5" id="f-1136" unitRef="usd">2100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-17" decimals="-5" id="f-1137" unitRef="usd">13700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-483" decimals="-5" id="f-1138" unitRef="usd">195400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-483" decimals="-5" id="f-1139" unitRef="usd">195400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="c-484" decimals="-5" id="f-1140" unitRef="usd">195400000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="c-1" id="f-1141">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our senior notes debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,689.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,746.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,699.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,744.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,196.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,493.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,219.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;972.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,033.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;909.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,474.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;989.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;471.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;469.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;469.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,198.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,286.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,410.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,281.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-485" decimals="-5" id="f-1142" unitRef="usd">1689600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-485" decimals="-5" id="f-1143" unitRef="usd">1746200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-486" decimals="-5" id="f-1144" unitRef="usd">1699900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-486" decimals="-5" id="f-1145" unitRef="usd">1744700000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-487" decimals="-5" id="f-1146" unitRef="usd">1196200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-487" decimals="-5" id="f-1147" unitRef="usd">1493600000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-488" decimals="-5" id="f-1148" unitRef="usd">1219000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-488" decimals="-5" id="f-1149" unitRef="usd">1492900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-489" decimals="-5" id="f-1150" unitRef="usd">972700000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-489" decimals="-5" id="f-1151" unitRef="usd">1100500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-490" decimals="-5" id="f-1152" unitRef="usd">1033200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-490" decimals="-5" id="f-1153" unitRef="usd">1100300000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-491" decimals="-5" id="f-1154" unitRef="usd">909200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-491" decimals="-5" id="f-1155" unitRef="usd">1474200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-492" decimals="-5" id="f-1156" unitRef="usd">989000000.0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-492" decimals="-5" id="f-1157" unitRef="usd">1473800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-493" decimals="-5" id="f-1158" unitRef="usd">430800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-493" decimals="-5" id="f-1159" unitRef="usd">471900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-494" decimals="-5" id="f-1160" unitRef="usd">469100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-494" decimals="-5" id="f-1161" unitRef="usd">469300000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue contextRef="c-18" decimals="-5" id="f-1162" unitRef="usd">5198500000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable contextRef="c-18" decimals="-5" id="f-1163" unitRef="usd">6286400000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue contextRef="c-19" decimals="-5" id="f-1164" unitRef="usd">5410200000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable contextRef="c-19" decimals="-5" id="f-1165" unitRef="usd">6281000000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-120" decimals="-8" id="f-1166" unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-1167">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,920.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,581.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,920.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,847.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;We partially funded our Reata acquisition through available cash, cash equivalents and marketable securities. As of September 30, 2023, we have sold all of our marketable debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;993.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(579.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;993.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(579.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;936.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;931.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;305.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;547.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;542.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,199.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,179.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(342.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(342.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Summary of Contractual Maturities: Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,483.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;694.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;703.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,179.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,199.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average maturity of our marketable debt securities classified as available-for-sale as of December 31, 2022, was approximately 8 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Proceeds from Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.905%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.918%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,698.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,643.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,380.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,104.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized losses for the three and nine months ended&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2023, primarily relate to sales of U.S. treasuries and corporate bonds. Realized losses for the three and nine months ended September 30, 2022, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;During the third quarter of 2023 we sold all of our marketable debt securities and used the proceeds to partially fund our acquisition of Reata. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8, Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements, as well as venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2023 and December 31, 2022, our strategic investment portfolio was comprised of investments totaling $465.5 million and $846.0 million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decrease in our strategic investment portfolio as of September 30, 2023, was primarily due to the decrease in the fair value of our investments in Denali, Sangamo and Sage common stock. Additionally, we sold a portion of our Sangamo common stock during the third quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our strategic investments in Denali, Sangamo and Sage common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2022 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-1168">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,920.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,581.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,920.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,847.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-495" decimals="-5" id="f-1169" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-496" decimals="-5" id="f-1170" unitRef="usd">177200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-497" decimals="-5" id="f-1171" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-498" decimals="-5" id="f-1172" unitRef="usd">59000000.0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-499" decimals="-5" id="f-1173" unitRef="usd">1920400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-500" decimals="-5" id="f-1174" unitRef="usd">2581500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-501" decimals="-5" id="f-1175" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-502" decimals="-5" id="f-1176" unitRef="usd">29900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-18" decimals="-5" id="f-1177" unitRef="usd">1920400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-19" decimals="-5" id="f-1178" unitRef="usd">2847600000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-1179">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;993.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(579.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;993.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(579.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;936.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;931.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;305.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;547.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;542.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,199.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,179.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(342.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(342.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-503" decimals="-5" id="f-1180" unitRef="usd">993300000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-503" decimals="-5" id="f-1181" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-503" decimals="-5" id="f-1182" unitRef="usd">579700000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-503" decimals="-5" id="f-1183" unitRef="usd">413600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-18" decimals="-5" id="f-1184" unitRef="usd">993300000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-18" decimals="-5" id="f-1185" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-18" decimals="-5" id="f-1186" unitRef="usd">579700000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-18" decimals="-5" id="f-1187" unitRef="usd">413600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-504" decimals="-5" id="f-1188" unitRef="usd">936200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-504" decimals="-5" id="f-1189" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-504" decimals="-5" id="f-1190" unitRef="usd">4900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-504" decimals="-5" id="f-1191" unitRef="usd">931300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-505" decimals="-5" id="f-1192" unitRef="usd">305300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-505" decimals="-5" id="f-1193" unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-505" decimals="-5" id="f-1194" unitRef="usd">5100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-505" decimals="-5" id="f-1195" unitRef="usd">300300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-506" decimals="-5" id="f-1196" unitRef="usd">547100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-506" decimals="-5" id="f-1197" unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-506" decimals="-5" id="f-1198" unitRef="usd">5000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-506" decimals="-5" id="f-1199" unitRef="usd">542200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-507" decimals="-5" id="f-1200" unitRef="usd">271400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-507" decimals="-5" id="f-1201" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-507" decimals="-5" id="f-1202" unitRef="usd">3300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-507" decimals="-5" id="f-1203" unitRef="usd">268100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-508" decimals="-5" id="f-1204" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-508" decimals="-5" id="f-1205" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-508" decimals="-5" id="f-1206" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-508" decimals="-5" id="f-1207" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-509" decimals="-5" id="f-1208" unitRef="usd">139100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-509" decimals="-5" id="f-1209" unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-509" decimals="-5" id="f-1210" unitRef="usd">1900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-509" decimals="-5" id="f-1211" unitRef="usd">137300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-19" decimals="-5" id="f-1212" unitRef="usd">2199100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-19" decimals="-5" id="f-1213" unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-19" decimals="-5" id="f-1214" unitRef="usd">20200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-19" decimals="-5" id="f-1215" unitRef="usd">2179200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-510" decimals="-5" id="f-1216" unitRef="usd">1133800000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-510" decimals="-5" id="f-1217" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-510" decimals="-5" id="f-1218" unitRef="usd">342700000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-510" decimals="-5" id="f-1219" unitRef="usd">791100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-19" decimals="-5" id="f-1220" unitRef="usd">1133800000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-19" decimals="-5" id="f-1221" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-19" decimals="-5" id="f-1222" unitRef="usd">342700000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-19" decimals="-5" id="f-1223" unitRef="usd">791100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-1224">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,483.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;694.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;703.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,179.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,199.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-19" decimals="-5" id="f-1225" unitRef="usd">1473500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-19" decimals="-5" id="f-1226" unitRef="usd">1483300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-19" decimals="-5" id="f-1227" unitRef="usd">694400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c-19" decimals="-5" id="f-1228" unitRef="usd">703700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="c-19" decimals="-5" id="f-1229" unitRef="usd">11300000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="c-19" decimals="-5" id="f-1230" unitRef="usd">12100000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-19" decimals="-5" id="f-1231" unitRef="usd">2179200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-19" decimals="-5" id="f-1232" unitRef="usd">2199100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <biib:AverageMaturityOfMarketableSecurities contextRef="c-1" id="f-1233">P8M</biib:AverageMaturityOfMarketableSecurities>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock contextRef="c-1" id="f-1234">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.905%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.918%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,698.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,643.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,380.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,104.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-15" decimals="-5" id="f-1235" unitRef="usd">5698600000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-16" decimals="-5" id="f-1236" unitRef="usd">1643200000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-5" id="f-1237" unitRef="usd">7380800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-17" decimals="-5" id="f-1238" unitRef="usd">3104700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-15" decimals="-5" id="f-1239" unitRef="usd">1000000.0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-16" decimals="-5" id="f-1240" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-1" decimals="-5" id="f-1241" unitRef="usd">1400000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-17" decimals="-5" id="f-1242" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-15" decimals="-5" id="f-1243" unitRef="usd">-16300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-16" decimals="-5" id="f-1244" unitRef="usd">-7900000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-1" decimals="-5" id="f-1245" unitRef="usd">-18400000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-17" decimals="-5" id="f-1246" unitRef="usd">-9300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <biib:StrategicInvestmentPortfolio contextRef="c-511" decimals="-5" id="f-1247" unitRef="usd">465500000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio contextRef="c-512" decimals="-5" id="f-1248" unitRef="usd">846000000</biib:StrategicInvestmentPortfolio>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c-1" id="f-1249">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency forward contracts and foreign currency options in effect as of September 30, 2023 and December 31, 2022, had durations of 1 to 15 months and 1 to 12 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains and losses on the portion of these foreign currency forward contracts and foreign currency options that are included in the effectiveness test are reported in AOCI. Realized gains and losses of such contracts and options are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from AOCI and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,006.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,495.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,144.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,715.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect the net unrealized gains of approximately $11.5&#160;million to be settled over the next 15 months, of which approximately $7.9 million of these net unrealized gains are expected to be settled over the next 12 months, with any amounts in AOCI to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2023 and December 31, 2022, credit risk did not materially change the fair value of our foreign currency forward contracts and forward currency options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.154%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Net Investment Hedges - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. Our investment in the equity of Samsung Bioepis related to this transaction was exposed to the currency fluctuations in the South Korean won.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we entered into foreign currency forward contracts. These contracts were designated as net investment hedges. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and closed these foreign currency forward contracts. Upon completing this sale, the cumulative gains on our net investment hedges of $57.0&#160;million were reclassified from AOCI and reflected within the total pre-tax gain recognized from the sale, which was recorded in other (income) expense, net in our condensed consolidated statements of income. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our net investment hedges in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.931%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses) Recognized in Net Income (Amounts Excluded from Effectiveness Testing)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Other Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate notional amount of these outstanding foreign currency forward contracts was $1,340.8 million and $1,238.8 million as of September 30, 2023 and December 31, 2022, respectively. Net losses of $22.6 million and $28.0 million related to these contracts were recorded as a component of other (income) expense, net for the three &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and nine months ended September 30, 2023, respectively, compared to net losses of $36.5 million and $85.8 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Summary of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-513" id="f-1250">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-514" id="f-1251">P15M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-515" id="f-1252">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-516" id="f-1253">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="c-1" id="f-1254">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,006.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,495.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,144.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,715.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount contextRef="c-517" decimals="-5" id="f-1255" unitRef="usd">1006500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-518" decimals="-5" id="f-1256" unitRef="usd">1495500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-519" decimals="-5" id="f-1257" unitRef="usd">43500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-520" decimals="-5" id="f-1258" unitRef="usd">162800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-521" decimals="-5" id="f-1259" unitRef="usd">78700000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-522" decimals="-5" id="f-1260" unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-523" decimals="-5" id="f-1261" unitRef="usd">15400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-524" decimals="-5" id="f-1262" unitRef="usd">57200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-525" decimals="-5" id="f-1263" unitRef="usd">1144100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-526" decimals="-5" id="f-1264" unitRef="usd">1715500000</us-gaap:DerivativeNotionalAmount>
    <biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock contextRef="c-1" id="f-1265">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock>
    <biib:UnrealizedGainOnDerivatives contextRef="c-527" decimals="-5" id="f-1266" unitRef="usd">19000000.0</biib:UnrealizedGainOnDerivatives>
    <biib:UnrealizedGainOnDerivatives contextRef="c-528" decimals="-5" id="f-1267" unitRef="usd">29900000</biib:UnrealizedGainOnDerivatives>
    <biib:UnrealizedLossOnDerivatives contextRef="c-527" decimals="-5" id="f-1268" unitRef="usd">7500000</biib:UnrealizedLossOnDerivatives>
    <biib:UnrealizedLossOnDerivatives contextRef="c-528" decimals="-5" id="f-1269" unitRef="usd">21300000</biib:UnrealizedLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-527" decimals="-5" id="f-1270" unitRef="usd">11500000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-528" decimals="-5" id="f-1271" unitRef="usd">8600000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-527" decimals="-5" id="f-1272" unitRef="usd">11500000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-529" id="f-1273">P15M</us-gaap:DerivativeRemainingMaturity1>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax contextRef="c-530" decimals="-5" id="f-1274" unitRef="usd">7900000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-530" id="f-1275">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="c-1" id="f-1276">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.154%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-531" decimals="-5" id="f-1277" unitRef="usd">-1700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-532" decimals="-5" id="f-1278" unitRef="usd">77700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-533" decimals="-5" id="f-1279" unitRef="usd">-2100000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-534" decimals="-5" id="f-1280" unitRef="usd">6600000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-535" decimals="-5" id="f-1281" unitRef="usd">1200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-536" decimals="-5" id="f-1282" unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-537" decimals="-5" id="f-1283" unitRef="usd">900000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-538" decimals="-5" id="f-1284" unitRef="usd">-100000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-539" decimals="-5" id="f-1285" unitRef="usd">18300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-540" decimals="-5" id="f-1286" unitRef="usd">143200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-541" decimals="-5" id="f-1287" unitRef="usd">-1500000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-542" decimals="-5" id="f-1288" unitRef="usd">-800000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-543" decimals="-5" id="f-1289" unitRef="usd">2100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-544" decimals="-5" id="f-1290" unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-545" decimals="-5" id="f-1291" unitRef="usd">-2000000.0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-546" decimals="-5" id="f-1292" unitRef="usd">-400000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="c-547"
      decimals="3"
      id="f-1293"
      unitRef="number">0.050</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c-460"
      decimals="3"
      id="f-1294"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c-127"
      decimals="3"
      id="f-1295"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-134" decimals="-5" id="f-1296" unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-1297">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our net investment hedges in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.931%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses) Recognized in Net Income (Amounts Excluded from Effectiveness Testing)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease contextRef="c-548" decimals="-5" id="f-1298" unitRef="usd">20400000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease contextRef="c-548" decimals="-5" id="f-1299" unitRef="usd">-3200000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="c-549" decimals="-5" id="f-1300" unitRef="usd">-4600000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c-460"
      decimals="3"
      id="f-1301"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DerivativeNotionalAmount contextRef="c-550" decimals="-5" id="f-1302" unitRef="usd">1340800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-551" decimals="-5" id="f-1303" unitRef="usd">1238800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-15" decimals="-5" id="f-1304" unitRef="usd">-22600000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-1" decimals="-5" id="f-1305" unitRef="usd">-28000000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-16" decimals="-5" id="f-1306" unitRef="usd">-36500000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-17" decimals="-5" id="f-1307" unitRef="usd">-85800000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="c-1" id="f-1308">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-552" decimals="-5" id="f-1309" unitRef="usd">20800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-553" decimals="-5" id="f-1310" unitRef="usd">37900000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-554" decimals="-5" id="f-1311" unitRef="usd">3400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-555" decimals="-5" id="f-1312" unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-556" decimals="-5" id="f-1313" unitRef="usd">5400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-557" decimals="-5" id="f-1314" unitRef="usd">18400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-558" decimals="-5" id="f-1315" unitRef="usd">7000000.0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-559" decimals="-5" id="f-1316" unitRef="usd">25100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-560" decimals="-5" id="f-1317" unitRef="usd">32100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-561" decimals="-5" id="f-1318" unitRef="usd">7600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-1319">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $2,342.7 million and $2,165.7 million as of September 30, 2023 and December 31, 2022, respectively. For the three and nine months ended September 30, 2023, depreciation expense totaled $64.1 million and $190.7 million, respectively, compared to $64.2 million and $207.7 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to support our future growth and drug development pipeline, we are nearing completion of a large-scale biologics manufacturing facility in Solothurn, Switzerland. This facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of September 30, 2023 and December 31, 2022, we had approximately $742.0 million and $711.1 million, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021 a portion of the facility (the first manufacturing suite) received a GMP multi-product license from the SWISSMEDIC and was placed into service. Solothurn has been approved for the manufacture of ADUHELM and LEQEMBI by the FDA. We estimate the second manufacturing suite will be operational by the end of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;125 Broadway Building Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022 we completed the sale of our building and land parcel located at 125 Broadway for an aggregate sales price of approximately $603.0&#160;million, which is inclusive of a $10.8&#160;million tenant allowance. This sale resulted in a pre-tax gain on sale of approximately $503.7&#160;million, net of transaction costs, which is reflected within gain on sale of building in our condensed consolidated statements of income for the three and nine months ended September 30, 2022. This transaction included approximately $79.2&#160;million of property, plant and equipment, net, which comprised of approximately $72.6&#160;million for buildings, approximately $1.6&#160;million for land and approximately $5.0&#160;million for machinery and equipment.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-18" decimals="-5" id="f-1320" unitRef="usd">2342700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-19" decimals="-5" id="f-1321" unitRef="usd">2165700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation contextRef="c-15" decimals="-5" id="f-1322" unitRef="usd">64100000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-1323" unitRef="usd">190700000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-16" decimals="-5" id="f-1324" unitRef="usd">64200000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-17" decimals="-5" id="f-1325" unitRef="usd">207700000</us-gaap:Depreciation>
    <biib:NumberOfSquareFeet
      contextRef="c-562"
      decimals="INF"
      id="f-1326"
      unitRef="sqft">393000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="c-563"
      decimals="INF"
      id="f-1327"
      unitRef="sqft">290000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="c-564"
      decimals="INF"
      id="f-1328"
      unitRef="sqft">51000</biib:NumberOfSquareFeet>
    <us-gaap:ConstructionInProgressGross contextRef="c-565" decimals="-5" id="f-1329" unitRef="usd">742000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-566" decimals="-5" id="f-1330" unitRef="usd">711100000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-567" decimals="-5" id="f-1331" unitRef="usd">603000000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <biib:GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance contextRef="c-568" decimals="-5" id="f-1332" unitRef="usd">10800000</biib:GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-569" decimals="-5" id="f-1333" unitRef="usd">503700000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-568" decimals="-5" id="f-1334" unitRef="usd">503700000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-570" decimals="-5" id="f-1335" unitRef="usd">79200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-571" decimals="-5" id="f-1336" unitRef="usd">72600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-572" decimals="-5" id="f-1337" unitRef="usd">1600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-573" decimals="-5" id="f-1338" unitRef="usd">5000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-1339">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;6100 Legacy Drive Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata we assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We recorded a lease liability of approximately $151.8&#160;million, which represents the net present value of rental expense over the remaining lease term of approximately 15 years, with a corresponding right-of-use asset of approximately $122.4&#160;million, which represents our estimate of the fair value for a market participant of the current rental market in the Dallas, Texas area. Included in our estimate of the market rental rate is the value of any leasehold improvements or tenant allowances related to the building. We do not intend to occupy this building and are evaluating opportunities to sublease the property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;125 Broadway Building Sale and Leaseback Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the sale of our 125 Broadway building during the third quarter of 2022, we simultaneously leased back the building for a term of approximately 5.5 years, which resulted in the recognition of approximately $168.2&#160;million in a new lease liability and right-of-use asset recorded within our condensed consolidated balance sheets as of December 31, 2022. The sale and immediate leaseback of this building qualified for sale and leaseback treatment and is classified as an operating lease. For additional information on the sale of our 125 Broadway building, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11, Property, Plant and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;300 Binney Street Lease Modification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022 we entered into an agreement to partially terminate a portion of our lease located at 300 Binney Street, as well as to reduce the lease term for the majority of the remaining space. The agreement was driven by our 2022 efforts to reduce costs by consolidating real estate locations. The transaction was treated as a lease modification as of the effective date and resulted in the derecognition of a right-of-use asset of approximately $47.4&#160;million and lease liability of approximately $52.7&#160;million, which resulted in a gain of approximately $5.3&#160;million, which was recorded within restructuring charges in our condensed consolidated statements of income for the three and nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <biib:OperatingLeaseArea contextRef="c-116" decimals="0" id="f-1340" unitRef="sqft">327400</biib:OperatingLeaseArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-116" id="f-1341">P16Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities contextRef="c-116" decimals="-5" id="f-1342" unitRef="usd">151800000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-116" id="f-1343">P15Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets contextRef="c-116" decimals="-5" id="f-1344" unitRef="usd">122400000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-574" id="f-1345">P5Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-575" decimals="-5" id="f-1346" unitRef="usd">168200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c-575" decimals="-5" id="f-1347" unitRef="usd">168200000</us-gaap:OperatingLeaseLiability>
    <biib:OperatingLeaseRightOfUseAssetDerecognized contextRef="c-576" decimals="-5" id="f-1348" unitRef="usd">47400000</biib:OperatingLeaseRightOfUseAssetDerecognized>
    <biib:OperatingLeaseLiabilityDerecognized contextRef="c-576" decimals="-5" id="f-1349" unitRef="usd">52700000</biib:OperatingLeaseLiabilityDerecognized>
    <biib:GainLossOnRestructuringCharges contextRef="c-576" decimals="-5" id="f-1350" unitRef="usd">5300000</biib:GainLossOnRestructuringCharges>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-1351">Credit Agreement&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata in September 2023 we entered into a $1.5&#160;billion term loan credit agreement. On the closing date of the Reata acquisition we drew $1.0 billion from the term loan, comprised of a $500.0&#160;million floating rate 364-day tranche and a $500.0&#160;million floating rate three-year tranche. The remaining unused commitment of $500.0&#160;million was terminated. As of September 30, 2023, we had $1.0&#160;billion outstanding under the term loan credit agreement, of which $500.0&#160;million was outstanding under the 364-day tranche and $500.0&#160;million outstanding under the three-year tranche.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2015, we issued $1.0&#160;billion aggregate principal amount of our 3.625% Senior Notes due September 15, 2022, at 99.920% of par. Our 3.625% Senior Notes were senior unsecured obligations. In July 2022 we redeemed our 3.625% Senior Notes prior to their maturity and recognized a net pre-tax charge of approximately $2.4&#160;million upon the extinguishment of these Senior Notes, which primarily reflects the payment of an early call premium as well as the write-off of remaining unamortized original debt issuance costs and discount balances. These charges were recognized as interest expense in other (income) expense, net in our condensed consolidated statements of income for the three and nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-577" decimals="-3" id="f-1352" unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-120" decimals="-8" id="f-1353" unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-578" decimals="-3" id="f-1354" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-579" decimals="-3" id="f-1355" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-580" decimals="-3" id="f-1356" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-581" decimals="-3" id="f-1357" unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-582" decimals="-3" id="f-1358" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-583" decimals="-3" id="f-1359" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-584" decimals="-8" id="f-1360" unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-18"
      decimals="INF"
      id="f-1361"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-18"
      decimals="INF"
      id="f-1362"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:DebtInstrumentRedemptionRate
      contextRef="c-585"
      decimals="INF"
      id="f-1363"
      unitRef="number">0.99920</biib:DebtInstrumentRedemptionRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-18"
      decimals="INF"
      id="f-1364"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-18"
      decimals="INF"
      id="f-1365"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-18"
      decimals="INF"
      id="f-1366"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-18"
      decimals="INF"
      id="f-1367"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount contextRef="c-586" decimals="-5" id="f-1368" unitRef="usd">2400000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1369">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 1.2 million and 3.6 million shares of our common stock at a cost of approximately $250.0 million and $750.0 million during the three and nine months ended September 30, 2022, respectively. There were no share repurchases of our common stock during the three and nine months ended September 30, 2023. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in AOCI, net of tax by component:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.626%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(163.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(164.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(159.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedges, Net of Tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(106.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(154.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(125.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(97.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(234.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(163.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from AOCI:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-587" decimals="INF" id="f-1370" unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-16"
      decimals="-3"
      id="f-1371"
      unitRef="shares">1200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-17"
      decimals="-3"
      id="f-1372"
      unitRef="shares">3600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-16" decimals="-5" id="f-1373" unitRef="usd">250000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-17" decimals="-5" id="f-1374" unitRef="usd">750000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-588" decimals="-8" id="f-1375" unitRef="usd">2100000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-1376">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in AOCI, net of tax by component:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.626%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(163.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(164.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(159.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedges, Net of Tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(106.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(154.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(125.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(97.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(234.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(163.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-589" decimals="-5" id="f-1377" unitRef="usd">-15700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-590" decimals="-5" id="f-1378" unitRef="usd">15100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-591" decimals="-5" id="f-1379" unitRef="usd">-1100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-592" decimals="-5" id="f-1380" unitRef="usd">-163200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-19" decimals="-5" id="f-1381" unitRef="usd">-164900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-593" decimals="-5" id="f-1382" unitRef="usd">2300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-594" decimals="-5" id="f-1383" unitRef="usd">18900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-595" decimals="-5" id="f-1384" unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-596" decimals="-5" id="f-1385" unitRef="usd">-11800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-1" decimals="-5" id="f-1386" unitRef="usd">10000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-593" decimals="-5" id="f-1387" unitRef="usd">13400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-594" decimals="-5" id="f-1388" unitRef="usd">-17800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-595" decimals="-5" id="f-1389" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-596" decimals="-5" id="f-1390" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-1" decimals="-5" id="f-1391" unitRef="usd">-4400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-593" decimals="-5" id="f-1392" unitRef="usd">15700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-594" decimals="-5" id="f-1393" unitRef="usd">1100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-595" decimals="-5" id="f-1394" unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-596" decimals="-5" id="f-1395" unitRef="usd">-11800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-1396" unitRef="usd">5600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-597" decimals="-5" id="f-1397" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-598" decimals="-5" id="f-1398" unitRef="usd">16200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-599" decimals="-5" id="f-1399" unitRef="usd">-500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-600" decimals="-5" id="f-1400" unitRef="usd">-175000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-18" decimals="-5" id="f-1401" unitRef="usd">-159300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-601" decimals="-5" id="f-1402" unitRef="usd">-2200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-602" decimals="-5" id="f-1403" unitRef="usd">53800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-603" decimals="-5" id="f-1404" unitRef="usd">25500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-604" decimals="-5" id="f-1405" unitRef="usd">-44800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-605" decimals="-5" id="f-1406" unitRef="usd">-139000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-28" decimals="-5" id="f-1407" unitRef="usd">-106700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-606" decimals="-5" id="f-1408" unitRef="usd">-26400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-607" decimals="-5" id="f-1409" unitRef="usd">204500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-608" decimals="-5" id="f-1410" unitRef="usd">12600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-609" decimals="-5" id="f-1411" unitRef="usd">4200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-610" decimals="-5" id="f-1412" unitRef="usd">-154500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-17" decimals="-5" id="f-1413" unitRef="usd">40400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-606" decimals="-5" id="f-1414" unitRef="usd">7400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-607" decimals="-5" id="f-1415" unitRef="usd">-125500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-608" decimals="-5" id="f-1416" unitRef="usd">-38100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-609" decimals="-5" id="f-1417" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-610" decimals="-5" id="f-1418" unitRef="usd">58900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-17" decimals="-5" id="f-1419" unitRef="usd">-97300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-606" decimals="-5" id="f-1420" unitRef="usd">-19000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-607" decimals="-5" id="f-1421" unitRef="usd">79000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-608" decimals="-5" id="f-1422" unitRef="usd">-25500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-609" decimals="-5" id="f-1423" unitRef="usd">4200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-610" decimals="-5" id="f-1424" unitRef="usd">-95600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-17" decimals="-5" id="f-1425" unitRef="usd">-56900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-611" decimals="-5" id="f-1426" unitRef="usd">-21200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-612" decimals="-5" id="f-1427" unitRef="usd">132800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-613" decimals="-5" id="f-1428" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-614" decimals="-5" id="f-1429" unitRef="usd">-40600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-615" decimals="-5" id="f-1430" unitRef="usd">-234600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-29" decimals="-5" id="f-1431" unitRef="usd">-163600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c-460"
      decimals="3"
      id="f-1432"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock contextRef="c-1" id="f-1433">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from AOCI:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-616" decimals="-5" id="f-1434" unitRef="usd">-15200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-617" decimals="-5" id="f-1435" unitRef="usd">-8000000.0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-618" decimals="-5" id="f-1436" unitRef="usd">-17000000.0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-619" decimals="-5" id="f-1437" unitRef="usd">-9400000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-616" decimals="-5" id="f-1438" unitRef="usd">3200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-617" decimals="-5" id="f-1439" unitRef="usd">1700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-618" decimals="-5" id="f-1440" unitRef="usd">3600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-619" decimals="-5" id="f-1441" unitRef="usd">2000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:Revenues contextRef="c-620" decimals="-5" id="f-1442" unitRef="usd">-1700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-621" decimals="-5" id="f-1443" unitRef="usd">77700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-622" decimals="-5" id="f-1444" unitRef="usd">18300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-623" decimals="-5" id="f-1445" unitRef="usd">143200000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses contextRef="c-620" decimals="-5" id="f-1446" unitRef="usd">-1200000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-621" decimals="-5" id="f-1447" unitRef="usd">800000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-622" decimals="-5" id="f-1448" unitRef="usd">-2100000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-623" decimals="-5" id="f-1449" unitRef="usd">3500000</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-620" decimals="-5" id="f-1450" unitRef="usd">-100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-621" decimals="-5" id="f-1451" unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-622" decimals="-5" id="f-1452" unitRef="usd">-300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-623" decimals="-5" id="f-1453" unitRef="usd">-200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-620" decimals="-5" id="f-1454" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-621" decimals="-5" id="f-1455" unitRef="usd">-7800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-622" decimals="-5" id="f-1456" unitRef="usd">-2300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-623" decimals="-5" id="f-1457" unitRef="usd">-14000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-624" decimals="-5" id="f-1458" unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-625" decimals="-5" id="f-1459" unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-626" decimals="-5" id="f-1460" unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-627" decimals="-5" id="f-1461" unitRef="usd">38100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-628" decimals="-5" id="f-1462" unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-629" decimals="-5" id="f-1463" unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-630" decimals="-5" id="f-1464" unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-631" decimals="-5" id="f-1465" unitRef="usd">-58900000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:NetIncomeLoss contextRef="c-632" decimals="-5" id="f-1466" unitRef="usd">-12600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-633" decimals="-5" id="f-1467" unitRef="usd">62800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-634" decimals="-5" id="f-1468" unitRef="usd">4400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-635" decimals="-5" id="f-1469" unitRef="usd">97300000</us-gaap:NetIncomeLoss>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c-460"
      decimals="3"
      id="f-1470"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1471">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(68.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,134.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;911.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,496.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts excluded from the calculation of net income (loss) per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1472">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(68.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,134.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;911.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,496.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-5" id="f-1473" unitRef="usd">-68100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-5" id="f-1474" unitRef="usd">1134700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-1475" unitRef="usd">911400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-5" id="f-1476" unitRef="usd">2496500000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-15"
      decimals="-3"
      id="f-1477"
      unitRef="shares">144800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-16"
      decimals="-3"
      id="f-1478"
      unitRef="shares">144400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-1479" unitRef="shares">144700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-17"
      decimals="-3"
      id="f-1480"
      unitRef="shares">145800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-636"
      decimals="-5"
      id="f-1481"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-637"
      decimals="-5"
      id="f-1482"
      unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-638"
      decimals="-5"
      id="f-1483"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-639"
      decimals="-5"
      id="f-1484"
      unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-640"
      decimals="-5"
      id="f-1485"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-641"
      decimals="-5"
      id="f-1486"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-642"
      decimals="-5"
      id="f-1487"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-643"
      decimals="-5"
      id="f-1488"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c-15"
      decimals="-5"
      id="f-1489"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c-16"
      decimals="-5"
      id="f-1490"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="-5" id="f-1491" unitRef="shares">800000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c-17"
      decimals="-5"
      id="f-1492"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-15"
      decimals="-3"
      id="f-1493"
      unitRef="shares">144800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-16"
      decimals="-3"
      id="f-1494"
      unitRef="shares">144800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-1495" unitRef="shares">145500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-17"
      decimals="-3"
      id="f-1496"
      unitRef="shares">146200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-1497">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;609.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;449.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;601.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(98.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(126.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income (loss) attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata in September 2023 we&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; recognized Reata equity-based compensation expense, inclusive of employer taxes, of approximately $393.4&#160;million attributable to the post-acquisition service period, of which $196.4&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $197.0&#160;million as a charge to research and development expense within our condensed consolidated statements of income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the three and nine months ended September 30, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;hese amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reata equity awards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;609.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;449.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;601.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; During the fourth quarter of 2022 we granted stock options. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Share-Based Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2022 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Relates to the Reata equity-based compensation expense attributable to the post-acquisition service period, associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest. For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-1498">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;609.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;449.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;601.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(98.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(126.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income (loss) attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata in September 2023 we&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; recognized Reata equity-based compensation expense, inclusive of employer taxes, of approximately $393.4&#160;million attributable to the post-acquisition service period, of which $196.4&#160;million was recognized as a charge to selling, general and administrative expense with the remaining $197.0&#160;million as a charge to research and development expense within our condensed consolidated statements of income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the three and nine months ended September 30, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;hese amounts were associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-644" decimals="-5" id="f-1499" unitRef="usd">217100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-645" decimals="-5" id="f-1500" unitRef="usd">24500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-646" decimals="-5" id="f-1501" unitRef="usd">276300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-647" decimals="-5" id="f-1502" unitRef="usd">72600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-648" decimals="-5" id="f-1503" unitRef="usd">234900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-649" decimals="-5" id="f-1504" unitRef="usd">46500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-650" decimals="-5" id="f-1505" unitRef="usd">333400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-651" decimals="-5" id="f-1506" unitRef="usd">129300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-15" decimals="-5" id="f-1507" unitRef="usd">452000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-16" decimals="-5" id="f-1508" unitRef="usd">71000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-1" decimals="-5" id="f-1509" unitRef="usd">609700000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-17" decimals="-5" id="f-1510" unitRef="usd">201900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-15" decimals="-5" id="f-1511" unitRef="usd">2600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-16" decimals="-5" id="f-1512" unitRef="usd">2000000.0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-1" decimals="-5" id="f-1513" unitRef="usd">8500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-17" decimals="-5" id="f-1514" unitRef="usd">7100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-15" decimals="-5" id="f-1515" unitRef="usd">449400000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-16" decimals="-5" id="f-1516" unitRef="usd">69000000.0</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-1" decimals="-5" id="f-1517" unitRef="usd">601200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-17" decimals="-5" id="f-1518" unitRef="usd">194800000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-15" decimals="-5" id="f-1519" unitRef="usd">98500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-16" decimals="-5" id="f-1520" unitRef="usd">13000000.0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-5" id="f-1521" unitRef="usd">126500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-17" decimals="-5" id="f-1522" unitRef="usd">36000000.0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-652" decimals="-5" id="f-1523" unitRef="usd">350900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-653" decimals="-5" id="f-1524" unitRef="usd">56000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-654" decimals="-5" id="f-1525" unitRef="usd">474700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-655" decimals="-5" id="f-1526" unitRef="usd">158800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:OperatingExpenses contextRef="c-117" decimals="-5" id="f-1527" unitRef="usd">393400000</us-gaap:OperatingExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-117" decimals="-5" id="f-1528" unitRef="usd">196400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-117" decimals="-5" id="f-1529" unitRef="usd">197000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-1530">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reata equity awards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;609.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;449.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;601.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; During the fourth quarter of 2022 we granted stock options. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Share-Based Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2022 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Relates to the Reata equity-based compensation expense attributable to the post-acquisition service period, associated with the accelerated vesting of stock options and RSUs previously granted to Reata employees and required no future services to vest. For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-656" decimals="-5" id="f-1531" unitRef="usd">700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-657" decimals="-5" id="f-1532" unitRef="usd">4000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-658" decimals="-5" id="f-1533" unitRef="usd">4200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-659" decimals="-5" id="f-1534" unitRef="usd">11400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-660" decimals="-5" id="f-1535" unitRef="usd">53400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-661" decimals="-5" id="f-1536" unitRef="usd">48700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-662" decimals="-5" id="f-1537" unitRef="usd">175000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-663" decimals="-5" id="f-1538" unitRef="usd">150400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-664" decimals="-5" id="f-1539" unitRef="usd">7800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-665" decimals="-5" id="f-1540" unitRef="usd">10500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-666" decimals="-5" id="f-1541" unitRef="usd">27100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-667" decimals="-5" id="f-1542" unitRef="usd">22100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-668" decimals="-5" id="f-1543" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-669" decimals="-5" id="f-1544" unitRef="usd">5400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-670" decimals="-5" id="f-1545" unitRef="usd">4800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-671" decimals="-5" id="f-1546" unitRef="usd">7900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-672" decimals="-5" id="f-1547" unitRef="usd">2000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-673" decimals="-5" id="f-1548" unitRef="usd">2400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-674" decimals="-5" id="f-1549" unitRef="usd">8800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-675" decimals="-5" id="f-1550" unitRef="usd">10100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-676" decimals="-5" id="f-1551" unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-677" decimals="-5" id="f-1552" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-678" decimals="-5" id="f-1553" unitRef="usd">2800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-679" decimals="-5" id="f-1554" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-680" decimals="-5" id="f-1555" unitRef="usd">387000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-681" decimals="-5" id="f-1556" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-682" decimals="-5" id="f-1557" unitRef="usd">387000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-683" decimals="-5" id="f-1558" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-15" decimals="-5" id="f-1559" unitRef="usd">452000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-16" decimals="-5" id="f-1560" unitRef="usd">71000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-1" decimals="-5" id="f-1561" unitRef="usd">609700000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-17" decimals="-5" id="f-1562" unitRef="usd">201900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-15" decimals="-5" id="f-1563" unitRef="usd">2600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-16" decimals="-5" id="f-1564" unitRef="usd">2000000.0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-1" decimals="-5" id="f-1565" unitRef="usd">8500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-17" decimals="-5" id="f-1566" unitRef="usd">7100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-15" decimals="-5" id="f-1567" unitRef="usd">449400000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-16" decimals="-5" id="f-1568" unitRef="usd">69000000.0</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-1" decimals="-5" id="f-1569" unitRef="usd">601200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-17" decimals="-5" id="f-1570" unitRef="usd">194800000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1571">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Inflation Reduction Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2022 the IRA was signed into law in the U.S. The IRA introduced new tax provisions, including a 15.0% corporate alternative minimum tax and a 1.0% excise tax on stock repurchases. The provisions of the IRA are effective for periods after December 31, 2022. The IRA did not result in any material adjustments to our income tax provision or other income tax balances as of September 30, 2023 and December 31, 2022. Preliminary guidance has been issued by the IRS and we expect additional guidance and regulations to be issued in future periods. We will continue to assess its potential impact on our business and results of operations as further information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sale of Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation settlement agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Neurimmune tax impacts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International reorganization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, including permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate for the three months ended September 30, 2023, reflects a tax benefit of $72.9 million recognized as a result of a pretax loss from operations of $141.2 million recorded during the third quarter of 2023, which was driven, in part, by the impact of the non-cash changes in the value of our equity investments and Reata acquisition-related expenses. For all other periods presented, the effective tax rates reflect tax expense on pretax income from operations in the respective periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended September 30, 2023, compared to the same period in 2022, the change in our effective tax rate was driven by the impact of the non-cash changes in the value of our equity investments and Reata acquisition-related expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the nine months ended September 30, 2023, compared to the same period in 2022, our effective tax rate, in addition to the items noted above, was also impacted by the combined net unfavorable tax rate impacts in 2022 related to a litigation settlement agreement, the sale of our equity interest in Samsung Bioepis, the impact of a Neurimmune valuation allowance and an international reorganization to align with global tax developments. The change also benefits from the resolution of an uncertain tax matter during the first quarter of 2023 related to tax credits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;federal tax examination for years before 2019 or state, local or non-U.S. income tax examinations for years before 2013.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters, withholding taxes and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;decrease by up to approximately $460.0&#160;million, including approximately $450.0&#160;million related to the unrecognized&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tax benefits related to Neurimmune's tax basis in ADUHELM, as discussed above, in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations. Any changes to our gross unrecognized tax benefits related to Neurimmune's tax basis in ADUHELM would result in a zero net impact to net income attributable to Biogen, Inc., as we have recorded a full valuation allowance against the relevant deferred tax assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1572">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sale of Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation settlement agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Neurimmune tax impacts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International reorganization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, including permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate for the three months ended September 30, 2023, reflects a tax benefit of $72.9 million recognized as a result of a pretax loss from operations of $141.2 million recorded during the third quarter of 2023, which was driven, in part, by the impact of the non-cash changes in the value of our equity investments and Reata acquisition-related expenses. For all other periods presented, the effective tax rates reflect tax expense on pretax income from operations in the respective periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-15"
      decimals="INF"
      id="f-1573"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-16"
      decimals="INF"
      id="f-1574"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-1"
      decimals="INF"
      id="f-1575"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-17"
      decimals="INF"
      id="f-1576"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-15" decimals="3" id="f-1577" unitRef="number">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-16" decimals="3" id="f-1578" unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1579" unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-17" decimals="3" id="f-1580" unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-15" decimals="3" id="f-1581" unitRef="number">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-16" decimals="3" id="f-1582" unitRef="number">-0.034</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="3" id="f-1583" unitRef="number">-0.061</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-17" decimals="3" id="f-1584" unitRef="number">-0.044</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-15" decimals="3" id="f-1585" unitRef="number">-0.246</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-16" decimals="3" id="f-1586" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-1" decimals="3" id="f-1587" unitRef="number">0.077</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-17" decimals="3" id="f-1588" unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="c-15" decimals="3" id="f-1589" unitRef="number">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="c-16" decimals="3" id="f-1590" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="c-1" decimals="3" id="f-1591" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="c-17" decimals="3" id="f-1592" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-15" decimals="3" id="f-1593" unitRef="number">0.148</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-16" decimals="3" id="f-1594" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-1" decimals="3" id="f-1595" unitRef="number">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-17" decimals="3" id="f-1596" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis contextRef="c-15" decimals="3" id="f-1597" unitRef="number">0</biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis>
    <biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis contextRef="c-16" decimals="3" id="f-1598" unitRef="number">0.008</biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis>
    <biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis contextRef="c-1" decimals="3" id="f-1599" unitRef="number">0</biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis>
    <biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis contextRef="c-17" decimals="3" id="f-1600" unitRef="number">0.019</biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis>
    <biib:EffectiveTaxRateReconciliationLitigationAgreement contextRef="c-15" decimals="3" id="f-1601" unitRef="number">0</biib:EffectiveTaxRateReconciliationLitigationAgreement>
    <biib:EffectiveTaxRateReconciliationLitigationAgreement contextRef="c-16" decimals="3" id="f-1602" unitRef="number">-0.012</biib:EffectiveTaxRateReconciliationLitigationAgreement>
    <biib:EffectiveTaxRateReconciliationLitigationAgreement contextRef="c-1" decimals="3" id="f-1603" unitRef="number">0</biib:EffectiveTaxRateReconciliationLitigationAgreement>
    <biib:EffectiveTaxRateReconciliationLitigationAgreement contextRef="c-17" decimals="3" id="f-1604" unitRef="number">0.031</biib:EffectiveTaxRateReconciliationLitigationAgreement>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts contextRef="c-15" decimals="3" id="f-1605" unitRef="number">-0.001</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts contextRef="c-16" decimals="3" id="f-1606" unitRef="number">0</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts contextRef="c-1" decimals="3" id="f-1607" unitRef="number">0</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts contextRef="c-17" decimals="3" id="f-1608" unitRef="number">0.028</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationInternationalReorganization contextRef="c-15" decimals="3" id="f-1609" unitRef="number">0</biib:EffectiveTaxRateReconciliationInternationalReorganization>
    <biib:EffectiveTaxRateReconciliationInternationalReorganization contextRef="c-16" decimals="3" id="f-1610" unitRef="number">0</biib:EffectiveTaxRateReconciliationInternationalReorganization>
    <biib:EffectiveTaxRateReconciliationInternationalReorganization contextRef="c-1" decimals="3" id="f-1611" unitRef="number">0</biib:EffectiveTaxRateReconciliationInternationalReorganization>
    <biib:EffectiveTaxRateReconciliationInternationalReorganization contextRef="c-17" decimals="3" id="f-1612" unitRef="number">-0.017</biib:EffectiveTaxRateReconciliationInternationalReorganization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-15" decimals="3" id="f-1613" unitRef="number">-0.077</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-16" decimals="3" id="f-1614" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-1615" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-17" decimals="3" id="f-1616" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-15" decimals="3" id="f-1617" unitRef="number">0.516</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-16" decimals="3" id="f-1618" unitRef="number">0.172</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1619" unitRef="number">0.092</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-17" decimals="3" id="f-1620" unitRef="number">0.194</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-5" id="f-1621" unitRef="usd">-72900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-15" decimals="-5" id="f-1622" unitRef="usd">-141200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible contextRef="c-18" decimals="-5" id="f-1623" unitRef="usd">460000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible contextRef="c-684" decimals="-5" id="f-1624" unitRef="usd">450000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="c-1" id="f-1625">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other (Income) Expense, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other (income) expense, net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain on sale of equity interest in Samsung Bioepis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,505.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation settlement agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;900.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(252.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gains) losses on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;317.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(101.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;289.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange (gains) losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(221.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;49.9%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The (gains) losses on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus settlement fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015. This charge is included within other (income) expense, net in our condensed consolidated statements of income for the nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net (gains) losses realized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the three months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali and Sangamo common stock of approximately $295.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized gains recognized during the three months ended September 30, 2022, primarily reflect an increase in the aggregate fair value of our investments in Sage, Ionis, Sangamo and Denali common stock of approximately $112.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the nine months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali, Sangamo and Ionis common stock of approximately $265.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the nine months ended September 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $198.0&#160;million, partially offset by an increase in the fair value of Ionis and Sage common stock of approximately $52.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accrued Expense and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reata acquisition-related accrued expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,407.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;940.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;891.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;395.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;712.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;746.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,838.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,521.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reata Acquisition-Related Accrued Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata we accrued approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$983.9&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to Reata's outstanding equity awards, inclusive of employer taxes, of which approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$980.0&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was subsequently paid in October 2023. As of September 30, 2023, this amount was included within accrued expense and other within our condensed consolidated balance sheets. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Additionally, we assumed a payable to Blackstone of approximately $300.0&#160;million related to a one-time contract termination fee to eliminate potential future royalty obligations related to SKYCLARYS, which was triggered as part of the change in control provision under Reata's funding agreement with Blackstone. Payment to Blackstone is expected to be made in November 2023. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities were $747.9 million and $944.2 million as of September 30, 2023 and December 31, 2022, respectively, and included accrued income taxes totaling $393.8 million and $541.7 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="c-1" id="f-1626">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other (income) expense, net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain on sale of equity interest in Samsung Bioepis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,505.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation settlement agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;900.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(252.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gains) losses on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;317.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(101.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;289.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange (gains) losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(221.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;49.9%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c-15" decimals="-5" id="f-1627" unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c-16" decimals="-5" id="f-1628" unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c-1" decimals="-5" id="f-1629" unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c-17" decimals="-5" id="f-1630" unitRef="usd">1505400000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:LitigationSettlementExpense contextRef="c-15" decimals="-5" id="f-1631" unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense contextRef="c-16" decimals="-5" id="f-1632" unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense contextRef="c-1" decimals="-5" id="f-1633" unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense contextRef="c-17" decimals="-5" id="f-1634" unitRef="usd">900000000.0</us-gaap:LitigationSettlementExpense>
    <us-gaap:InvestmentIncomeInterest contextRef="c-15" decimals="-5" id="f-1635" unitRef="usd">95900000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-16" decimals="-5" id="f-1636" unitRef="usd">23900000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-5" id="f-1637" unitRef="usd">252700000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-17" decimals="-5" id="f-1638" unitRef="usd">39400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense contextRef="c-15" decimals="-5" id="f-1639" unitRef="usd">63800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-16" decimals="-5" id="f-1640" unitRef="usd">59900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-5" id="f-1641" unitRef="usd">175400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-17" decimals="-5" id="f-1642" unitRef="usd">191800000</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-15" decimals="-5" id="f-1643" unitRef="usd">-317300000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-16" decimals="-5" id="f-1644" unitRef="usd">101800000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-1" decimals="-5" id="f-1645" unitRef="usd">-289600000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-17" decimals="-5" id="f-1646" unitRef="usd">-167500000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-15" decimals="-5" id="f-1647" unitRef="usd">-11400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-16" decimals="-5" id="f-1648" unitRef="usd">-11500000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-5" id="f-1649" unitRef="usd">-30800000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-17" decimals="-5" id="f-1650" unitRef="usd">-39000000.0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-15" decimals="-5" id="f-1651" unitRef="usd">-3400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-16" decimals="-5" id="f-1652" unitRef="usd">1700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-1653" unitRef="usd">-5100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-17" decimals="-5" id="f-1654" unitRef="usd">-25200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-15" decimals="-5" id="f-1655" unitRef="usd">-300000000.0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-16" decimals="-5" id="f-1656" unitRef="usd">56000000.0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-5" id="f-1657" unitRef="usd">-248200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-17" decimals="-5" id="f-1658" unitRef="usd">221300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c-127"
      decimals="3"
      id="f-1659"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:LitigationSettlementExpense contextRef="c-685" decimals="-5" id="f-1660" unitRef="usd">900000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:GainLossOnInvestmentsTextBlock contextRef="c-1" id="f-1661">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net (gains) losses realized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the three months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali and Sangamo common stock of approximately $295.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized gains recognized during the three months ended September 30, 2022, primarily reflect an increase in the aggregate fair value of our investments in Sage, Ionis, Sangamo and Denali common stock of approximately $112.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the nine months ended September 30, 2023, primarily reflect a decrease in the aggregate fair value of our investments in Sage, Denali, Sangamo and Ionis common stock of approximately $265.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the nine months ended September 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $198.0&#160;million, partially offset by an increase in the fair value of Ionis and Sage common stock of approximately $52.2&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-15" decimals="-5" id="f-1662" unitRef="usd">302000000.0</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-16" decimals="-5" id="f-1663" unitRef="usd">-109800000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-1" decimals="-5" id="f-1664" unitRef="usd">273600000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-17" decimals="-5" id="f-1665" unitRef="usd">158100000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-15" decimals="-5" id="f-1666" unitRef="usd">4400000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-16" decimals="-5" id="f-1667" unitRef="usd">-500000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-1" decimals="-5" id="f-1668" unitRef="usd">5300000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-17" decimals="-5" id="f-1669" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-15" decimals="-5" id="f-1670" unitRef="usd">297600000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-16" decimals="-5" id="f-1671" unitRef="usd">-109300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-5" id="f-1672" unitRef="usd">268300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-17" decimals="-5" id="f-1673" unitRef="usd">158100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-686" decimals="-5" id="f-1674" unitRef="usd">295600000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-687" decimals="-5" id="f-1675" unitRef="usd">112500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-688" decimals="-5" id="f-1676" unitRef="usd">265000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-689" decimals="-5" id="f-1677" unitRef="usd">198000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain contextRef="c-689" decimals="-5" id="f-1678" unitRef="usd">52200000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-1679">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reata acquisition-related accrued expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,407.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;940.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;891.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;395.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;277.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;712.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;746.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,838.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,521.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:SettlementLiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-1680" unitRef="usd">1407000000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-1681" unitRef="usd">0</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-422" decimals="-5" id="f-1682" unitRef="usd">940900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-423" decimals="-5" id="f-1683" unitRef="usd">891600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-1684" unitRef="usd">276700000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-1685" unitRef="usd">395600000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <biib:Collaborationexpensesaccrual contextRef="c-18" decimals="-5" id="f-1686" unitRef="usd">298300000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual contextRef="c-19" decimals="-5" id="f-1687" unitRef="usd">277900000</biib:Collaborationexpensesaccrual>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-18" decimals="-5" id="f-1688" unitRef="usd">202800000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-19" decimals="-5" id="f-1689" unitRef="usd">209400000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-1690" unitRef="usd">712700000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-1691" unitRef="usd">746900000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-18" decimals="-5" id="f-1692" unitRef="usd">3838400000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-19" decimals="-5" id="f-1693" unitRef="usd">2521400000</us-gaap:OtherLiabilitiesCurrent>
    <biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards contextRef="c-118" decimals="-5" id="f-1694" unitRef="usd">983900000</biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-119" decimals="-5" id="f-1695" unitRef="usd">980000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:LossOnContractTermination contextRef="c-117" decimals="-5" id="f-1696" unitRef="usd">300000000</us-gaap:LossOnContractTermination>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-18" decimals="-5" id="f-1697" unitRef="usd">747900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-19" decimals="-5" id="f-1698" unitRef="usd">944200000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-18" decimals="-5" id="f-1699" unitRef="usd">393800000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-19" decimals="-5" id="f-1700" unitRef="usd">541700000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-1701">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 19:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Genentech, Inc. (Roche Group)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO (mosunetuzumab), for the treatment of relapsed or refractory follicular lymphoma, which was granted accelerated approval in the U.S. during the fourth quarter of 2022; COLUMVI (glofitamab), a bispecific antibody for the treatment of non-Hodgkin's lymphoma, which was granted accelerated approval by the FDA during the second quarter of 2023; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RITUXAN&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt"&gt;U.S.:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt"&gt;Canada:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GAZYVA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. The level of gross sales of GAZYVA in the U.S. has impacted our percentage of the co-promotion profits for RITUXAN and LUNSUMIO, as summarized in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCREVUS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24.0% if annual net sales exceed $900.0&#160;million. There will be a 50.0% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we receive a gross 3.0% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;OCREVUS royalty revenue is based on our estimates from third-party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;LUNSUMIO (mosunetuzumab)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022 we exercised our option with Genentech to participate in the joint development and commercialization of LUNSUMIO. Under our collaboration with Genentech, we were responsible for 30.0% of development costs for LUNSUMIO prior to FDA approval and will be entitled to a tiered share of co-promotion operating profits and losses in the U.S., as summarized in the table below. In addition, we receive low single-digit royalties on sales of LUNSUMIO outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022 LUNSUMIO was granted accelerated approval by the FDA for the treatment of relapsed or refractory follicular lymphoma. Prior to regulatory approval, we record our share of the expense incurred by the collaboration for the development of anti-CD20 products in research and development expense and pre-commercialization costs within selling, general and administrative expense in our condensed consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development and sales and marketing expense related to that product as a reduction of our share of pre-tax profits in revenue from anti-CD20 therapeutic programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;COLUMVI (glofitamab)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022 we entered into an agreement with Genentech related to the commercialization and sharing of economics for COLUMVI, a bispecific antibody for the treatment of B-cell non-Hodgkin's lymphoma, which was subsequently granted accelerated approval by the FDA in June 2023. Under the terms of this agreement, we will have no payment obligations. Genentech will have sole decision-making rights on the commercialization of COLUMVI within the U.S. and we will receive tiered royalties in the mid-single digit range on net sales of COLUMVI in the U.S. The commercialization of COLUMVI does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit-sharing Formulas&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RITUXAN and LUNSUMIO Profit Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our current pretax co-promotion profit-sharing formula for RITUXAN and LUNSUMIO in the U.S. provides for a 30.0% share on the first $50.0&#160;million of combined co-promotion operating profits earned each calendar year. As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After LUNSUMIO Approval until the First Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After First Threshold Date until the Second Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;First Threshold Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; means the earlier of (i)&#160;the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0&#160;million or (ii)&#160;the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $150.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Second Threshold Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; means the later of (i) the first date the gross sales in any calendar year in which U.S. gross sales of LUNSUMIO reach $350.0&#160;million or (ii) January 1 of the calendar year following the calendar year in which the First Threshold Date occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023 the First Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for RITUXAN and LUNSUMIO was 35.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GAZYVA Profit Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our current pretax profit-sharing formula for GAZYVA provides for a 35.0% share on the first $50.0&#160;million of operating profits earned each calendar year. Our share of annual co-promotion profits in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Until Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Second GAZYVA Threshold Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; means the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0&#160;million. The second GAZYVA threshold date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023 the Second GAZYVA Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for GAZYVA was 35.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Eisai Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2023 we accrued a $31.0&#160;million payable to Eisai related to the termination of an agreement whereby Eisai co-promoted or distributed our MS products in certain Asia-Pacific markets and settings. This termination fee is included in selling, general and administrative expense in our condensed consolidated statements of income for the nine months ended September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;LEQEMBI (lecanemab) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Eisai to jointly develop and commercialize LEQEMBI (lecanemab), an anti-amyloid antibody for the treatment of Alzheimer's disease (the LEQEMBI Collaboration).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. We and Eisai co-promote LEQEMBI and share profits and losses equally. We currently manufacture LEQEMBI drug substance and drug product and in March 2022 we extended our supply agreement with Eisai related to LEQEMBI from five years to ten years for the manufacture of LEQEMBI drug substance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023 the FDA granted traditional approval of LEQEMBI. Prior to receiving traditional approval, LEQEMBI had been granted accelerated approval by the FDA in January 2023, at which time it became commercially available in the U.S. Additionally, in September 2023 the Japanese Ministry of Health, Labor and Welfare approved LEQEMBI in Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon commercialization of LEQEMBI, we began recognizing our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, within other revenue in our condensed consolidated income statements, as we are not the principal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2023 we recorded a reclassification of $38.7&#160;million in LEQEMBI collaboration costs from other revenue to selling, general and administrative expense within our condensed consolidated statements of income. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that this reclassification does not materially impact the current or previously issued condensed consolidated financial statements. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our share of LEQEMBI development expense will continue to be recorded within research and development expense in our condensed consolidated income statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of LEQEMBI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;282.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;264.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the LEQEMBI Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The LEQEMBI Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (the ADUHELM Collaboration Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our initial ADUHELM Collaboration Agreement, we would lead the ongoing development of ADUHELM, and we and Eisai would co-promote ADUHELM with a region-based profit split. Beginning in 2019, Eisai was reimbursing us for&#160;45.0%&#160;of development and sales and marketing expense incurred by the collaboration for the advancement of ADUHELM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. As of the amendment date, we have sole decision making and commercialization rights worldwide on ADUHELM, and beginning January 1, 2023, Eisai receives only a tiered royalty based on net sales of ADUHELM, and no longer participates in sharing ADUHELM's global profits and losses. Eisai's share of development, commercialization and manufacturing expense was limited to $335.0&#160;million for the period from January 1, 2022 to December 31, 2022, which was achieved as of December 31, 2022. Once this limit was achieved, we became responsible for all ADUHELM related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense and sales and marketing expense related to our initial ADUHELM Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.321%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM Collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM Collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#6dad46;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ADUHELM C&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#6dad46;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;o-promotion Profits and Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our initial ADUHELM Collaboration Agreement, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;we recognized revenue on sales of ADUHELM in the U.S. to third parties as a component of product revenue in our condensed consolidated statements of income. We also recorded the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs were incurred. Payments made to and received from Eisai for its 45.0% share of the co-promotion profits or losses in the U.S. were recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the three and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended September 30, 2022,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;we recognized net reductions to our operating expense of approximately $3.4&#160;million and $214.0&#160;million, respectively, to reflect Eisai's 45.0% share of net collaboration losses in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2022, as a result of the final NCD, we recorded approximately $275.0&#160;million of charges associated with the write-off of inventory and purchase commitments in excess of forecasted demand related to ADUHELM. Additionally, for the nine months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2022,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; we recorded approximately $76.0&#160;million of aggregate gross idle capacity charges related to ADUHELM. These charges were recorded in cost of sales within our consolidated statements of income for the nine months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized approximately $177.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit sharing/(loss reimbursement) within our condensed consolidated statements of income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts receivable from Eisai related to the agreements discussed ab&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ove were approximately $34.3&#160;million and $88.0&#160;million as of September 30, 2023 and December 31, 2022, respectively. Amounts payable to Eisai related to the agreements discussed above were $122.6&#160;million and $81.2&#160;million as&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of September 30, 2023 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2022, respectively&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2022 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;UCB&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with UCB, effective November 2003, to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of SLE and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, both companies will co-promote dapirolizumab pegol and share profits and losses equally.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense related to the UCB collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total UCB collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Sage Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize ZURZUVAE (zuranolone) for the potential treatment of MDD and PPD and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023 the FDA approved ZURZUVAE for adults with PPD, pending DEA scheduling, which was completed in October 2023. Upon approval, ZURZUVAE became the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms by day 15 for women with PPD. We expect ZURZUVAE for PPD to be commercially available beginning in the fourth quarter of 2023. Additionally, the FDA issued a CRL for the NDA for zuranolone in the treatment of adults with MDD. The CRL stated that the application did not provide substantial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;evidence of effectiveness to support the approval of zuranolone for the treatment of MDD and that an additional study or studies would be needed. We and Sage are reviewing the feedback and evaluating next steps. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties. We will pay Sage a milestone payment of $75.0&#160;million upon the first commercial sale of ZURZUVAE for PPD in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2023, we recorded $5.9&#160;million to reflect Sage's 50.0% share of net collaboration expense in the U.S. related to commercialization activities to support ZURZUVAE for PPD, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development and sales and marketing expense related to the Sage collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Sage collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of LRRK2 for Parkinson's disease and also entered into a separate agreement to obtain an exclusive option to license two preclinical programs from Denali's Transport Vehicle platform, including its ATV-enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023 we exercised our option with Denali to license the ATV-enabled anti-amyloid beta program. In connection with this exercise, we assumed responsibility for all development and commercial activities and associated expenses related to this program. In addition, we made a one-time option exercise payment to Denali and, should certain milestones be achieved, may pay Denali additional development and commercial milestone payments and royalties based on future net sales. Our agreement with Denali was amended in August 2023, whereby certain milestone criteria were changed, while the total amount of development, regulatory and commercial milestones remains the same. In addition, we agree to waive our option right to the second option program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the LRRK2 collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to the Denali collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other Research and Discovery Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2023, we recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;zero&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.8&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$14.0&#160;million and $51.5&#160;million, respectively,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Samsung Bioepis Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Development and Commercialization Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately 45.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with this transaction, we may also pay Samsung Bioepis up to approximately $180.0 million in additional development, regulatory and sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired an option to extend the term of our 2013 c&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2013 Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the three and nine months ended September 30, 2023, we recognized net profit-sharing expense of $56.4&#160;million and $170.4 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of $48.7 million and $171.4 million, respectively, in the prior year comparative periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement with Samsung Bioepis. Under this license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on biosimilar products developed and commercialized by Samsung Bioepis. Royalty revenue under the license agreement is recognized as a component of contract manufacturing, royalty and other revenue in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts receivable from Samsung Bioepis related to the agreements di&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;scussed above were $13.0&#160;million and $2.0&#160;million as of September 30, 2023 and December 31, 2022, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were $81.6&#160;million and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$40.5&#160;million as of September 30, 2023 and December 31, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt; to our consolidated financial statements included in our 2022 Form 10-K.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="c-690"
      decimals="INF"
      id="f-1702"
      unitRef="number">0.135</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="c-691"
      decimals="INF"
      id="f-1703"
      unitRef="number">0.240</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage contextRef="c-692" decimals="-5" id="f-1704" unitRef="usd">900000000</biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage>
    <biib:Reductioninroyaltyrate
      contextRef="c-692"
      decimals="INF"
      id="f-1705"
      unitRef="number">0.500</biib:Reductioninroyaltyrate>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="c-693"
      decimals="INF"
      id="f-1706"
      unitRef="number">0.030</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:PeriodOfCollaborationAgreement contextRef="c-692" id="f-1707">P11Y</biib:PeriodOfCollaborationAgreement>
    <biib:PercentageOfFutureDevelopmentCosts
      contextRef="c-694"
      decimals="INF"
      id="f-1708"
      unitRef="number">0.300</biib:PercentageOfFutureDevelopmentCosts>
    <biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion
      contextRef="c-695"
      decimals="INF"
      id="f-1709"
      unitRef="number">0.300</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-696" decimals="-5" id="f-1710" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-696" decimals="-5" id="f-1711" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionProfitSharingFormulaTableTextBlock contextRef="c-1" id="f-1712">As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After LUNSUMIO Approval until the First Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After First Threshold Date until the Second Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</biib:CoPromotionProfitSharingFormulaTableTextBlock>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-696" decimals="-5" id="f-1713" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-696" decimals="-5" id="f-1714" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="c-695"
      decimals="INF"
      id="f-1715"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-695"
      decimals="INF"
      id="f-1716"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour
      contextRef="c-695"
      decimals="INF"
      id="f-1717"
      unitRef="number">0.300</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour>
    <biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne contextRef="c-697" decimals="-5" id="f-1718" unitRef="usd">500000000</biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne>
    <biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne contextRef="c-697" decimals="-5" id="f-1719" unitRef="usd">150000000</biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne>
    <biib:SalesTriggerGrossSalesThreshold contextRef="c-697" decimals="-5" id="f-1720" unitRef="usd">350000000</biib:SalesTriggerGrossSalesThreshold>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-696"
      decimals="INF"
      id="f-1721"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-696"
      decimals="INF"
      id="f-1722"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-696" decimals="-5" id="f-1723" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-696" decimals="-5" id="f-1724" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PretaxProfitSharingFormulaTableTextBlock contextRef="c-1" id="f-1725">Our share of annual co-promotion profits in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Until Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</biib:PretaxProfitSharingFormulaTableTextBlock>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-696" decimals="-5" id="f-1726" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-696" decimals="-5" id="f-1727" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="c-696"
      decimals="INF"
      id="f-1728"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-696"
      decimals="INF"
      id="f-1729"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne contextRef="c-697" decimals="-5" id="f-1730" unitRef="usd">500000000</biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-696"
      decimals="INF"
      id="f-1731"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:AccruedPaymentToTerminationAgreement contextRef="c-440" decimals="-5" id="f-1732" unitRef="usd">31000000</biib:AccruedPaymentToTerminationAgreement>
    <biib:ShareOfNonControlingInterestRecognized
      contextRef="c-440"
      decimals="2"
      id="f-1733"
      unitRef="number">0.500</biib:ShareOfNonControlingInterestRecognized>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-441" decimals="-5" id="f-1734" unitRef="usd">38700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock contextRef="c-1" id="f-1735">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of LEQEMBI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;282.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;264.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the LEQEMBI Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock>
    <biib:ExpenseIncurredByCollaboration contextRef="c-698" decimals="-5" id="f-1736" unitRef="usd">88500000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration contextRef="c-699" decimals="-5" id="f-1737" unitRef="usd">109300000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration contextRef="c-700" decimals="-5" id="f-1738" unitRef="usd">282600000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration contextRef="c-701" decimals="-5" id="f-1739" unitRef="usd">264900000</biib:ExpenseIncurredByCollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-698" decimals="-5" id="f-1740" unitRef="usd">44300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-699" decimals="-5" id="f-1741" unitRef="usd">54700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-700" decimals="-5" id="f-1742" unitRef="usd">141300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-701" decimals="-5" id="f-1743" unitRef="usd">132500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration contextRef="c-702" decimals="-5" id="f-1744" unitRef="usd">163400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-703" decimals="-5" id="f-1745" unitRef="usd">29000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-704" decimals="-5" id="f-1746" unitRef="usd">191000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-705" decimals="-5" id="f-1747" unitRef="usd">68300000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-702" decimals="-5" id="f-1748" unitRef="usd">81700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-703" decimals="-5" id="f-1749" unitRef="usd">14500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-704" decimals="-5" id="f-1750" unitRef="usd">95500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-705" decimals="-5" id="f-1751" unitRef="usd">34200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="c-1"
      decimals="INF"
      id="f-1752"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-706" decimals="-5" id="f-1753" unitRef="usd">335000000</us-gaap:ResearchAndDevelopmentExpense>
    <biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock contextRef="c-1" id="f-1754">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense and sales and marketing expense related to our initial ADUHELM Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.321%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM Collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM Collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration contextRef="c-707" decimals="-5" id="f-1755" unitRef="usd">34600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-708" decimals="-5" id="f-1756" unitRef="usd">116000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-707" decimals="-5" id="f-1757" unitRef="usd">19000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-708" decimals="-5" id="f-1758" unitRef="usd">63800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration contextRef="c-709" decimals="-5" id="f-1759" unitRef="usd">-8000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-710" decimals="-5" id="f-1760" unitRef="usd">127800000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-709" decimals="-5" id="f-1761" unitRef="usd">-3900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-710" decimals="-5" id="f-1762" unitRef="usd">68100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="c-1"
      decimals="INF"
      id="f-1763"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:CollaborativeArrangementProfitLossSharing contextRef="c-711" decimals="-5" id="f-1764" unitRef="usd">3400000</biib:CollaborativeArrangementProfitLossSharing>
    <biib:CollaborativeArrangementProfitLossSharing contextRef="c-712" decimals="-5" id="f-1765" unitRef="usd">214000000</biib:CollaborativeArrangementProfitLossSharing>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="c-713"
      decimals="INF"
      id="f-1766"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:InventoryWriteDown contextRef="c-714" decimals="-5" id="f-1767" unitRef="usd">275000000</us-gaap:InventoryWriteDown>
    <biib:AggregateGrossIdleCapacityCharges contextRef="c-715" decimals="-5" id="f-1768" unitRef="usd">76000000</biib:AggregateGrossIdleCapacityCharges>
    <biib:CollaborativeArrangementProfitLossSharing contextRef="c-716" decimals="-5" id="f-1769" unitRef="usd">177000000</biib:CollaborativeArrangementProfitLossSharing>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="c-1"
      decimals="INF"
      id="f-1770"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AccountsReceivableFromCollaborator contextRef="c-717" decimals="-5" id="f-1771" unitRef="usd">34300000</biib:AccountsReceivableFromCollaborator>
    <biib:AccountsReceivableFromCollaborator contextRef="c-718" decimals="-5" id="f-1772" unitRef="usd">88000000</biib:AccountsReceivableFromCollaborator>
    <biib:AccountsPayableToCollaborator contextRef="c-717" decimals="-5" id="f-1773" unitRef="usd">122600000</biib:AccountsPayableToCollaborator>
    <biib:AccountsPayableToCollaborator contextRef="c-718" decimals="-5" id="f-1774" unitRef="usd">81200000</biib:AccountsPayableToCollaborator>
    <biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock contextRef="c-1" id="f-1775">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense related to the UCB collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total UCB collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration contextRef="c-719" decimals="-5" id="f-1776" unitRef="usd">13600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-720" decimals="-5" id="f-1777" unitRef="usd">18300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-721" decimals="-5" id="f-1778" unitRef="usd">46200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-722" decimals="-5" id="f-1779" unitRef="usd">51500000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-719" decimals="-5" id="f-1780" unitRef="usd">6800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-720" decimals="-5" id="f-1781" unitRef="usd">9100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-721" decimals="-5" id="f-1782" unitRef="usd">23100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-722" decimals="-5" id="f-1783" unitRef="usd">25700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="c-723" decimals="-5" id="f-1784" unitRef="usd">75000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:Collaborationprofitlosssharing contextRef="c-724" decimals="-5" id="f-1785" unitRef="usd">5900000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-725" decimals="-5" id="f-1786" unitRef="usd">5900000</biib:Collaborationprofitlosssharing>
    <biib:ShareOfNetProfitFromSageTherapeuticsPercent contextRef="c-18" decimals="2" id="f-1787" unitRef="number">0.500</biib:ShareOfNetProfitFromSageTherapeuticsPercent>
    <biib:SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock contextRef="c-1" id="f-1788">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development and sales and marketing expense related to the Sage collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Sage collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock>
    <biib:Expenseincurredbythecollaboration contextRef="c-726" decimals="-5" id="f-1789" unitRef="usd">72000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-727" decimals="-5" id="f-1790" unitRef="usd">40900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-728" decimals="-5" id="f-1791" unitRef="usd">158900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-729" decimals="-5" id="f-1792" unitRef="usd">130400000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-726" decimals="-5" id="f-1793" unitRef="usd">36000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-727" decimals="-5" id="f-1794" unitRef="usd">20500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-728" decimals="-5" id="f-1795" unitRef="usd">79500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-729" decimals="-5" id="f-1796" unitRef="usd">65200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration contextRef="c-730" decimals="-5" id="f-1797" unitRef="usd">54000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-731" decimals="-5" id="f-1798" unitRef="usd">28500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-732" decimals="-5" id="f-1799" unitRef="usd">152300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-733" decimals="-5" id="f-1800" unitRef="usd">69900000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-730" decimals="-5" id="f-1801" unitRef="usd">27000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-731" decimals="-5" id="f-1802" unitRef="usd">14200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-732" decimals="-5" id="f-1803" unitRef="usd">76100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-733" decimals="-5" id="f-1804" unitRef="usd">34900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock contextRef="c-1" id="f-1805">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to the Denali collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration contextRef="c-734" decimals="-5" id="f-1806" unitRef="usd">12600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-735" decimals="-5" id="f-1807" unitRef="usd">19900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-736" decimals="-5" id="f-1808" unitRef="usd">51300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-737" decimals="-5" id="f-1809" unitRef="usd">58000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-734" decimals="-5" id="f-1810" unitRef="usd">7600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-735" decimals="-5" id="f-1811" unitRef="usd">11400000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-736" decimals="-5" id="f-1812" unitRef="usd">30800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-737" decimals="-5" id="f-1813" unitRef="usd">33500000</biib:Expensereflectedwithinstatementsofincome>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-738" decimals="-5" id="f-1814" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-739" decimals="-5" id="f-1815" unitRef="usd">2800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-740" decimals="-5" id="f-1816" unitRef="usd">14000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-741" decimals="-5" id="f-1817" unitRef="usd">51500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:ContingentCommercializedRightsNumberOfProducts
      contextRef="c-742"
      decimals="INF"
      id="f-1818"
      unitRef="product">2</biib:ContingentCommercializedRightsNumberOfProducts>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="c-742"
      decimals="INF"
      id="f-1819"
      unitRef="number">0.450</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-134" decimals="-5" id="f-1820" unitRef="usd">180000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:CollaborationAgreementTerm contextRef="c-134" id="f-1821">P5Y</biib:CollaborationAgreementTerm>
    <biib:ContractOptionExerciseFee contextRef="c-134" decimals="-5" id="f-1822" unitRef="usd">60000000</biib:ContractOptionExerciseFee>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="c-134"
      decimals="INF"
      id="f-1823"
      unitRef="number">0.500</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:Collaborationprofitlosssharing contextRef="c-743" decimals="-5" id="f-1824" unitRef="usd">56400000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-744" decimals="-5" id="f-1825" unitRef="usd">170400000</biib:Collaborationprofitlosssharing>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="c-134"
      decimals="INF"
      id="f-1826"
      unitRef="number">0.500</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:Collaborationprofitlosssharing contextRef="c-745" decimals="-5" id="f-1827" unitRef="usd">48700000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-746" decimals="-5" id="f-1828" unitRef="usd">171400000</biib:Collaborationprofitlosssharing>
    <us-gaap:AccountsReceivableNet contextRef="c-747" decimals="-5" id="f-1829" unitRef="usd">13000000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-748" decimals="-5" id="f-1830" unitRef="usd">2000000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c-747" decimals="-5" id="f-1831" unitRef="usd">81600000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c-748" decimals="-5" id="f-1832" unitRef="usd">40500000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="c-1" id="f-1833">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Neurimmune SubOne AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#x2019;s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on commercial sales of ADUHELM, range from the high single digits to sub-teens.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an increase in a valuation allowance of approximately $85.0&#160;million to reduce the net value of a previously recorded deferred tax asset to zero. This adjustment to our net deferred tax asset is recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2023 and December 31, 2022, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $24.4 million and $27.8 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Neurimmune and other variable interest entities, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 20, Investments in Variable Interest Entities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2022 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <biib:CollaborationAgreementTerm contextRef="c-749" id="f-1834">P12Y</biib:CollaborationAgreementTerm>
    <biib:ResearchAndDevelopmentCostsPercentage
      contextRef="c-749"
      decimals="INF"
      id="f-1835"
      unitRef="number">1.000</biib:ResearchAndDevelopmentCostsPercentage>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-18" decimals="-5" id="f-1836" unitRef="usd">85000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="c-18" decimals="-5" id="f-1837" unitRef="usd">24400000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="c-19" decimals="-5" id="f-1838" unitRef="usd">27800000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="c-1" id="f-1839">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2022 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions. If an estimate of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;possible loss or range of loss can be made at this time, it is included in the potential loss contingency description below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Loss Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ADUHELM Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and certain current and former officers are defendants in two actions related to ADUHELM filed in the United States District Court for the District of Massachusetts (the District Court). Both actions allege violations of federal securities laws under 15 U.S.C. &#xa7;78j(b) and &#xa7;78t(a) and 17 C.F.R. &#xa7;240.10b-5 and seek declarations of the actions as class actions and monetary relief. In October 2023 the United States Court of Appeals for the First Circuit reversed in part and affirmed in part the dismissal of the shareholder action related to ADUHELM that was filed in November 2020. In March 2023 the District Court dismissed the shareholder action that had been filed in February 2022. In May 2023 the plaintiff filed a motion to alter the judgment and amend the complaint, which is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and members of the Board of Directors are named as defendants in derivative actions filed by shareholders in February and July 2022, in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C. &#xa7;78n(a) and 17 C.F.R. &#xa7;240 14.a-9, and breaches of fiduciary duties and waste of corporate assets, and seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys&#x2019; fees and costs payable to the plaintiffs. The District Court has stayed both cases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) filed a claim for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen commercializes in Europe, infringes the French counterpart of European Patent 3 145 488 (the EP &#x2018;488 Patent), which expires in May 2035. In August 2022 Fresenius Kabi filed a claim for damages and injunctive relief against Biogen GmbH in the D&#xfc;sseldorf Regional Court, alleging infringement of the German counterpart of the EP '488 Patent. A hearing in the D&#xfc;sseldorf Regional Court has been set for December 2023. No hearing has been set in the French action. The EP '488 Patent is the subject of opposition proceedings in the EPO and a hearing before the EPO's Technical Boards of Appeal is set for June 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation with Former Convergence Shareholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015 Biogen acquired Convergence, a U.K. company. In 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, asserted claims of $200.0 million for alleged breaches of the contract pursuant to which we acquired Convergence. In June 2023 Shareholder Representative Services LLC and 24 former shareholders filed suit against us in the High Court of Justice of England and Wales on one of the previously asserted claims, seeking payment of $49.9&#160;million, interest and costs. No trial date has been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ERISA Class Action Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020 participants in the Biogen 401(k) Savings Plan filed actions against us in the U.S. District Court for the District of Massachusetts alleging breach of fiduciary duty under ERISA and seeking a declaration of the actions as class actions and monetary and other relief. In August 2023 the court preliminarily approved a settlement under which we agree to pay $9.75&#160;million without any admission of liability. The court has set a hearing for January 2024 to determine whether to grant final approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Humana Patient Assistance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023 the District Court for the District of Massachusetts dismissed the previously disclosed action filed against us by Humana in September 2020. Humana had alleged damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients and had &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;alleged violations of the federal RICO Act and state laws. In April 2023 Humana filed a motion to alter the judgment and amend the complaint, which is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Distributor Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022 we terminated our distribution agreement with the distributor of products for Biogen in various countries in the Middle East and northern Africa. The former distributor has asserted breach of contract. No suit has been filed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Genentech Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023 Genentech, Inc. filed suit against us in the U.S. District Court for the Northern District of California, alleging that it is owed royalties on sales of TYSABRI that occurred after the expiration of a patent licensed by Genentech to Biogen, together with interest and costs. The Company estimates that the royalties claimed total approximately $88.3&#160;million. No trial date has been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bardoxolone Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021 and 2022 putative stockholders of Reata (later acquired by Biogen) filed litigation in the United States District Court for the Eastern District of Texas alleging violations of the federal securities laws by Reata, certain former officers and directors and certain underwriters under 15 U.S.C. &#xa7;78j(b) and &#xa7;78t(a), 17 C.F.R. &#xa7;240.10b-5, and 15 U.S.C. &#xa7;&#xa7;77k, 77l(a)(2) and 77o in connection with Reata's asset bardoxolone. Plaintiffs seek declaration of the actions as a class actions and monetary relief. In October 2023 the parties reached a settlement, subject to approval by the court, providing for payment by Reata of $45.0&#160;million without any admission of liability. We expect a portion of the payment to be reimbursed under Reata's insurance coverage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lender Dispute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;One of Reata's lenders claims that approximately $23.3&#160;million is owing under its loan agreement with Reata.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has received subpoenas from the Securities and Exchange Commission seeking information relating to ADUHELM, including healthcare sites and ADUHELM&#x2019;s approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;TYSABRI Biosimilar Patent Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022 we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc., other Sandoz entities and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. &#xa7;262, seeking a declaratory judgment of patent infringement. The trial has been set for May 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Annulment Proceedings in the General Court of the European Union relating to TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020 Mylan Ireland filed an action in the General Court of the European Union (the General Court) to annul the EMA's decision not to validate its applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. No hearing has been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,669,281, 9,090,558 and 10,080,733) pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC. No trial date has been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-750" decimals="-5" id="f-1840" unitRef="usd">200000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-18" decimals="-5" id="f-1841" unitRef="usd">49900000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-751" decimals="-4" id="f-1842" unitRef="usd">9750000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-752" decimals="-5" id="f-1843" unitRef="usd">88300000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-753" decimals="-5" id="f-1844" unitRef="usd">45000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-754" decimals="-5" id="f-1845" unitRef="usd">23300000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c-116"
      decimals="1"
      id="f-1846"
      unitRef="usdPerShare">172.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-117" decimals="-8" id="f-1847" unitRef="usd">6600000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards contextRef="c-118" decimals="-5" id="f-1848" unitRef="usd">983900000</biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards>
    <biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices contextRef="c-117" decimals="-5" id="f-1849" unitRef="usd">590500000</biib:BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices>
    <biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards contextRef="c-118" decimals="-5" id="f-1850" unitRef="usd">983900000</biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards>
    <us-gaap:OperatingExpenses contextRef="c-117" decimals="-5" id="f-1851" unitRef="usd">393400000</us-gaap:OperatingExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-117" decimals="-5" id="f-1852" unitRef="usd">196400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-117" decimals="-5" id="f-1853" unitRef="usd">197000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-119" decimals="-5" id="f-1854" unitRef="usd">980000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards contextRef="c-118" decimals="-5" id="f-1855" unitRef="usd">983900000</biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards>
    <us-gaap:Revenues contextRef="c-354" decimals="-5" id="f-1856" unitRef="usd">443300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-351" decimals="-5" id="f-1857" unitRef="usd">453000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-355" decimals="-5" id="f-1858" unitRef="usd">891400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-352" decimals="-5" id="f-1859" unitRef="usd">875600000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-117" decimals="-5" id="f-1860" unitRef="usd">197000000</us-gaap:ResearchAndDevelopmentExpense>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>122
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M@'1C -_?2*EW-^9MA/W;)_/_ %!+ P04    " !IA&A7IFRS[Y8(  #)*
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MC=;07IL-I6MZ$S>]S1CZ\T4N,2D>+A;&3MAB%D6C^PNB64\.L;Z;A3J"0#T
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M2+6F\!^M!DA:0G$]Z4>"F%M2I0Q_:W,];)'!0=(,Y08GWQ'5BHBR)5B=F-;
M3*8"2 @-J."([X1 H?A0[R6A#FKC\H_H=+NEN<F??3#)_+/.$9-TE14+D\FN
M.!X.6;HA(*8FX0/B7C7B/EP?]X<[:F6[5!8(P:_$^^CC]=6.M?7. &GTSBJ5
MMA'P2IP=C_M7EY-=41M->.F8JGEX>3JY' W.MM]K52H+QE-+_9'HA;&K[9L>
MGPTO1U>#+O40S3"*1H^-2CTUR>K[_/J7P /9S E"-YF"<]RWFQ"_ L0!ZE(Y
MX>/9\<GA_KK#(E4KZRIB+EA$B+]1^>@^T'2N?!?CY'JO<GQ1\8)<LD3_2E?/
MS#*' 9G*IEXS4F5LD/?B/?H"6.)9+L 62W_#X<MN*).E:M4!+9+QETH[71?J
M&$Z5/1%1UT12@]I[Z> @@(G<23]++,-""RF37Z^/A]'X&FC<ZMR4S'FZ\NUL
M6SEOC>,[4"$T;00-88Q*>:LE5:M$-9>^_F1B4N5B]@Y0)Q$'+\4*C<__:M)$
MV9[ O$+AJ$%-YWYX8QMS]ODVLQ&9E#!2T' G3A%$<8@NM[[3B2XS%V:'E!N8
MS52RR>G6^.!*7. P,J2T<5$1CW,ZTRDICOT]QR ':>().JY;+^7B4?^T?QX-
MJ2)RH4J90PQ"VY+A.:?R+*5_>C3N#[MB,!I'PQ._2B;8-JLR.=VUZ@.*E]H[
M=[+AX(_HR*^$[U)]JQ]8.>Z/!L?H?%V*5(V93,F)U]+%/G$CM!Z4X1+C)WT>
M79^=70T^4D8CK?14?WU(N>'E<?_T8C#Q]"QU9EU_ZA9N<L1A QXC0)NNOC@C
MZG)ZW*?-2A/K].'-HN.+_HA<L0:/;?G; HJM+2D$G083-'QH%3@9KU@C1$N)
MP+K$Y.C@!](5WPM#"281@NDW@GX][$>/2?S=8+,E_0]^0FM:+R!>C_0X8Y ;
M ]*Y*!:Z<*VZJ'*)M"U]73RV0L23[[CYZ9^S\QZH_DFS&4[6)G_#T,"HF830
M2J3*(9F3B8/]9[]B"B16R.V5"'U>>OT'>6@V&&,\8F4RE]Z@;K#W\<ZN6;VD
M6DP^5:X,"4!+M>-1FILJ?$J#15Q9SG7T3ENA_&C<P:3LI/7M6(J9U':] RTF
MG;9N3@MX:-$92!NFRH0Q@J9XFQ (^OA<]E#M[Z/HO"<N%FHCPFT7<F<*E8=N
M8Y6?H_+&I;\)MS!5BM(-$69PRC]5>>ADM-GWA9"2P;?.,'N3;_QAP;>B>\:M
MY]YY!8^<"=J:19TW_/2T/G\X;JOTKE%ITH[HENU8T:K@90R^3=2ZC>N\P[R/
MJ8T^4_G.PIW*E./C#TMQC2"*DY0\9:P_B@@5 Y)#X.48/]&4-<'GS)ILP]G;
M_-L%X89X@[5PZD:RTEB<&E=A5V@>^ <P^4ZR>.+"582^4T]4#>%86.4K.J<Y
M/O-'=(J.Z%J4J3YEZW)L2)':>QIYID'08V]H(%]A(P2UWKW>;U9!<_(MD5\N
MEWP5B"(= ,$,*IG-DN#FX44JBIS)VSLX-?>%__UG/LU1S?]T^E,?>/#!$WN0
M+B1J#C -<6\.A5K-GMA_X)O8AP^N"'=D3,V+CD#6"4XE>?:=<(8^2&?<.R&'
M>"E2L4:E#0;=/H+S9TJ!P-S@DIRFR@=&@=)2PR[IMN6")OFE/RCB;H[ $19.
MX0;,*I"V\BUJ0_?[ZZ$"Y02)4;>^U:/:4QHURP6XU\'^?F__[W6&T31B,E!#
M9O% 9> E L 58C(EGJ RW%,A2_ N5! K#W$8C8B%6!JU^-#/F\,@[LF]O*WQ
M8X?76[[&_6$[Y"V\[-L^92U1<CX&V-26#"176VJ8:V=:15[V6.<JT*S&.X%B
MA8F:4NJ.!8"8DK-F0,+JX\\ 3@&=UZ.*QU840(;,",-_W$XWDH,*@:C,GQ$B
M/%R<#P>86?NN+%EQB, : 162VE.JRT DB$E*V(L E\VV/BGJ79G;3H$0XLG!
MTT 7E_Y(.0'BT3%#R\' Q=6=\W#LY'U9QX)U8L\\.?02S335<]F,KE-G[%10
M O&JK@C8Q9R:[L"VBO3W'B!T Y1WV]+9H)A;;<-N4W+9AG*<+[)V4YLC U_(
M6Z2!^[_$@) G7A#MXR:J;@.SL6T&QYA<E15MTDZ:3*[J^1<)4[4/[ID=6<3N
MSB6":(MV8AND67-08WDG2ETJA9ZX]'C4ATI@-=#P@DU4OG]ZBO>]M"YT1$?J
MPN!,?D9PZ@VZXE.5S-<$!HZNLL(;RQ$AB^5L5J>7)P8T?&3$5OR4BN 0<*3P
M-Z:HDD\S:%-*>(N>0Y../V4N2&E_VAW ?]V[290/^IPZGY?*][8$\PF&)#H_
M-^3>*?-BY(.ZD6E%;9'<\QCS.,GHP>7F"FJ:8$ (#7<S4AE-@/B-/[O@O**F
MYUOU/7\MJ1A2K6Y\BH);.LPBR,-NC5\U!_%S)/%7_L5;0IT6$2+36II/3>7=
M'V-B85Y)UJI=WO?.Y@"L62G'RQ^ZW8M(3T1Q6?FG!:P>13W1,WIBQ>3,SW"-
MDWK?>BA*>6MKR%(J!U@+6FDI-UO51Z[_QD.[.D,\1OM!K"L>_WQ6_!736'WT
M>VRR*340CG]S-6Y?]5E 71GRZ([YO0.V#*AF$@YFH_]#E#7@=W/45C<[VNJN
MZMLE3-4<1,_CTSUUR#'=NERX!NN-[A2CSWZZ'FQ$(+YZWKE-)C@(7=>VW<5Y
M1/39C"R$$>J6^'0  Y"PH+/'820DZ4&,EK<@KK)9$XUS'JOZICO;ZO(<U!A%
MA\7&@"2G*6+3.O3T:.9*6Z&&F$W'QI4M>FO6CPKN948H0!:/T%5DG@_]VC'K
M*O^V.>VS-N;;5,G4;*OII_ D O6O^=T1 K\F6%0':<,\FF;3TB*<;,DPB[#;
M=.:'(&ZDL:)SU\-Z=*J!XYYC0:UFA),-S=D:L,2PY(R&2OK=/ZRM]9*-3[OA
MN+AU"HT0D<VAF,(42N=UN=]E0R.DUX*SB7[=&JF>.%7+#6BQX%@5>H)'BW=L
M*+F": P^B4,O-[!L<P'7*0+6.CF,)D=,B?W\5R*\$C0>NO+ZJ4DHR'6#D8DI
MRE;FAJ<A-$QPI^:!BQU]F?/8P&*7&,$83"M'<9_2BT=,2(.GZ[;%NW!$DO 4
M@YL&$7D:<;W>M8K.8_Q"\C,<2K;PG+]!>PULBLOU^=OCB0NQJ?5DC]&)<O&*
M<W&$MHJ+_CX0]5\J9!&C=./-H&@TN433Z/&/S_8QMV^7(IY<8#".Q8^'^T]_
MWG4/,3/?52=T^.4K;[*NK&,:1Z3OI!,)ZCDF6-"!.U)9 U*:X,8IF,2LB:MD
M\E,OM^N5=84ZDDBIG]>]W7DM*"@<P1HPZ5&]M&6='A7*IM5<&OI_1PC4XEK"
MW RRVMTB5%.K(G=03JZ1X:YA4T63H&LE(]5?Q=3J%YE7U+</^!CE!9,P?A7-
M Z62=%SG\[O<$$I 2W74- [/E[YQW'Z($BCX90V?RJT9F4&4WL&H$S4P).J;
M7(5/_$3[M,;H;IBJOW<DYC.V]F,S9).YJ;6NRV,6Z"&],.A[R#H9./*VG4L-
MMK;P.=O,U+H-N(6T_GD+/8[O;7OA:J_UGERF[)S?!G3^88U_9:ZYVKQP&/GW
M[-:W^[<51]*"63B1JAF6[O?^]4/'3XOUE](4_-8=!MG29/SG0DGD%]V WV<&
M#"]\H0V:US#?_A=02P,$%     @ :81H5PE0%'.;#P  '"L  !@   !X;"]W
M;W)K<VAE971S+W-H965T."YX;6R]6FUSW+81_BL854VE&>IT+Y8L*;9G9#MN
M/4UB5;*;23O]@"-Q=XA)@@9(29=?WV<7 %_N14[2F7ZQQ2.YV%WL/OOL@B\>
MC/WL5DK5XK'(2_?R8%77U=7IJ4M7JI!N9"I5XL["V$+6N+3+4U=9)3-^J<A/
MI^/Q^6DA=7GPZ@7_=F-?O3!-G>M2W5CAFJ*0=OU:Y>;AY<'D(/YPJY>KFGXX
M??6BDDMUI^I/U8W%U6DK)=.%*ITVI;!J\?+@>G+U^AD]SP_\4ZL'U_M;D"5S
M8S[3Q?OLY<&8%%*Y2FN2(/'?O7JC\IP$08TO0>9!NR2]V/\[2G_'ML.6N73J
MC<E_TEF]>GEP<2 RM9!-7M^:A[^I8,\9R4M-[OA?\>"?G<T.1-JXVA3A96A0
MZ-+_+Q^#'WHO7(SWO# -+TQ9;[\0:_E6UO+5"VL>A*6G(8W^8%/Y;2BG2]J4
MN]KBKL9[]:OK]$NCG28/N1>G-232[Z=I>/NU?WNZY^U+\8,IZY43WY69RH;O
MGT*35IUI5.?U]$F!=ZH:B=DX$=/Q=/:$O%EKWHSES?;(>]TX_.*<>&.*N2XE
MVRG^?3UWM45 _&>7R5[BL]T2*4FN7"53]?( 6>"4O5<'K[[YT^1\_.T3^CYK
M]7WVE/2O;L?3;]\JA("X64F$:ZJ:6J<R=XEX7Z8C\:$4<&ZMBKFR8GKN/9R(
M!R524U2YJE4FZI5"FK0:"+,0,L_I/[JCG6OPD"PS@>QV-?[0Y5(X+*<</<3+
M)T**N3;50 E>0Y9KL3"(:0B!\$S= Q(J$@'I5E;\K,.%K)'NRR:7-91#ON(O
M*PI5R[G)M2M8 UTN<@D<83UU*; 1VC1.E*JQ)C=+G8I,.X5\=2-Q[: 4E$2F
M>F,TEK&R=-)#PT,PVT*SN[___.;[Z]N?[Q(V>J&MJ[W-9;X6F6V60E:5-?=X
M=K[F9]Z]O89AEO^N@8PU0(L7>F>URJS2Z>HO3ES7\E%+TE5F4,2Q4)F97+D4
MS^-Z"9&3<[%6TOJ[)L^4A4,=-,0^X']#KA(I-I[=2@\A"MOK2E>*@@(_FJ65
M!6S_N+VG/DS@ _58 1QIXTV( J]Y8\4R-W,2:&R]@-<-O<>^+1J7\H;0VA9;
M'_T<=E&KN&B6M2NV3J5598E]UI4,"Y,O=0:538W%-19%Q;'86(JM=:GL$B*!
MBO5*W-V\__'V^E_7O/8_KK^_^_#VYY'X!.P)SE>V<.T.]ZSF.*^DSH+M'+,K
M=J\3AY/GT]'9F'8FE6[%6ZEDNMH7\#T1D+O"[L*,6N;T*$7&HT98*@3+X?GH
M'+F0PWWE"%G8NH35D4NK@@?D>O/-RXO9Z!)XS^\.-./5$4Y]C10,K2'C0=H,
M^:[+- ?NW2MRA<*VFC4Y2#XJW,1/7N>-%<\NQZ.S=L4'Q)JL:ZOG#=(N5WZC
MU$D_D@C[=*I\J%)&8?\55%14K',?6"2&0\N4(2?85:)J;+JBH*DL1/#6 *(\
MSFP8S]N&Y:/A?6-%V$-V*/+ +$O]Z_8^S"YGHV>M0.A$&H%8>/38M)-TJ(RK
M=QDK*L*9K.?&P\GE>4\X.:ZO"-N/4%FR:+ 1I.<R$4N%P X)+#/4=4T%B0@*
M)V4)SW#$DRY6$;FB?<9:ST?COB%]X52-I*6=A=" KIS/?8D()4KOU"!I2D)B
M_.60X!FG(R*J9@S@+$(<F4)UT+9"P++PDB"F\)5?4>7OE998O 6C %:5A6E(
MX .B RH[DVI>J[5/I@!YRGC\>*\<)SY6!_5)/P,+?,FF96_O/CF*PGM">NPK
M$*X,(.)S,L1Z"$FK J271BR:NL'R;<CB%5H*I6$S[\8]!YL] ;EFMX90V16/
M' :%!*K!WQ_2VG#1A5=&XB<XM&&?;8(4.=@T2^S?O=0Y1R-E?>)SGY:Y!\B4
MH7* 0G]6/F:=2AL+$93>KJD"C'?UB7!,EBG#@400P<* 2HR8(C>R% VC*,5&
M]UL*[^G:(Q6)' DPX1;%$+ZHPDR-V5GE5]Y.!#2CG*?F0?P(N!>3&;&33,VA
M+=.T)'C5J7TAN@"+*U,J$UVPLE<11A1H] @'[(9S.5GFD0ZF'1T4]-MRB_N
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M<\7S3YOCQTU*1@XETDA]TK]F&/HVW:J4_"9F/&6C)@F0-J0C$O?B.(*+%H(
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M@7<L\@I$=6W7UH>Z(];. 3D&QS(V9=!;$3FAL;!O3_:>;]RN-9TTATXCR$[
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M:$VU^[V)NRA587_CL5!EJ3+[E5[2"DT+\#Q14$E]00S:'_U<_P=02P,$%
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MZW%Y_X-J] F(7UKF%8_BWJSUHP.1KJNZ7#;$D&"9%>8J/S=VV"*([2<(W(;
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MA+!T <^7!BZI-R2@^7YU]1]02P,$%     @ :81H5U]8SDA\"P  ]"(  !D
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M%*1GS<!E>]*/WN2?O?8EY[V0&T[.D)W2>8JCN-Y X!P6/]?P^\7AK+"3/'+
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MA#?"SY28YF8L<U%(3XHT$V%**X G5E)$NHY8&,OOJF=6W:H"Y\DJ<1^HJSM
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M<VAE970Q-RYX;6R=5^]OVS80_5<(+Q@VP+5EV4F:+C$0-\D:H :R>ET_#/M
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M'T0<G3_OJXK O[0*D:Q)V@9-LH% AI5)74_,C#8^JRS\9ROE?Y#5C#V51;6
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ML@&^7QCC-P^\0?OK:?PO4$L#!!0    ( &F$:%<)#\-3U04  %$.   9
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MG65>;;8^U<D8[TSZPR(+>9^N=Y*>^FT\$$(+E\RODJ^\U:J,\2X4,E%P'_B
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M!30U/J%0NY*9%-N;FA.O]L@5&\30V/*,+TA-*#6?+V@;JH<E#@9@\FC-="@
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M+:*^Q>.Y%7K*4)"'AJTVXQF69E.,877"VUV8W_A7ZC8<6AJ=D<_52<8WO,Q
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M%WDJX?.]@J&XA,<%X3/=<C0/JYXO GMG9M1>1^Q3'?]LYP7+EZ)/*--)LNC
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M[5:R/E:B:O)2UC-;Q;!?^1.OKC0;0[$=41MKOQ5&VQ ^/$%_(O9*-W47^1O
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MXR<&]KA?BG3%?W0"V+=(E_SC MM0&0W ]_2Z<O<++>#_"LFK_P-02P,$%
M  @ :81H5PX$R1_Y!@  ]Q(  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&ULI5C;<MLV$/T5C)JVZ8PJR;+3N*GM&3M.FDR;--,D[4.G#Q"Y$M&   .
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M%/P32(%40@/P?FJ (N$/VJ#]=/'-_P!02P,$%     @ :81H5]!<$Z,[#@
M R<  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&ULM5IK<]I(%OTK7=[:
MW:2*X$<>DXD35\D8)\R [0'C&6=K/S12 YU(:J5;,F9^_9Y[6Q(B!F+O['ZQ
M>73?OL]SSVWQ?F'L5S=7*A?W29RZ#WOS/,_>[>^[<*X2Z=HF4RF^F1J;R!QO
M[6S?95;)B#<E\?[1P<&;_43J=._D/7]V94_>FR*/=:JNK'!%DDB[/%6Q67S8
M.]RK/ACJV3RG#_9/WF=RID8J'V=7%N_V:RF13E3JM$F%5=,/>\'AN].WM)X7
MW&BU<(W7@BR9&/.5WO2B#WL'I)"*59B3!(E_=ZJCXI@$08UOI<R]^DC:V'Q=
M23]GVV'+1#K5,?'O.LKG'_;>[HE(3641YT.S^*1*>UZ3O-#$CO^*1;GV8$^$
MA<M-4FZ&!HE._7]Y7_KA,1N.R@U'K+<_B+4\D[D\>6_-0EA:#6GT@DWEW5!.
MIQ2446[QK<:^_&3D@R',5(ST+-53'<HT%T$8FB+-=3H35R;6H59./&'IL^K5
M\_?[.;2DL_;#4J-3K]'1%HU^%@.3YG,GNFFDHO7]^["N-O&H,O'T:*? D<K:
MXN5!2QP='+W<(>]E[;*7+._E%GF;#/Y7,'&Y18K]>Y/!7MZKS?*H[-ZY3(;J
MPQ[JRBE[I_9._O&WPS<'QSNT?55K^VJ7])/+.PA$+F_2:_?.4VUF*A7:"2EF
ML9G(6$RTR>82Q1"J(D?X8Q&:))/I4DP-DE5% H46:1<:G H'M5 @=RC\C)PE
MTPAO8^V_$CI-S9VDFA3Y7%F9D1^!,B)3)HN5P$):MM#Y7, IVA2.1=")L;JG
M8Q3*T5'9QQ&J1K7%[TK,)01*,;%&1B(S-I\B1H:2-E$1@I5B1VY$#@3+Q6#4
M\AMTFEL3%2$L@#)BJJW+A<PR"T,BOQA(E+-^HT%0*O*BM(Z6+,QJ&9\@HPC1
M).<!)'1*MF0RGYO8S+B&@OC/N0*^V7^ZRA8V0%K5]*:,[F0:TFY3P#<Z4Q0G
M*"Q255B6UO(O,[<,YUKF%A^X3(5:QOI/"-%)4J3^6%+;T@&5\_A$5V3D*#X@
MLL6LCN"RC!D;R?:K*3Q ]LVM*69S\INR*?* $E?:</Y@!UPXLS+QL5/WY7+
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ML/6=K7[QI@SWI(7Q=.L*CVO* EH^0/M+0^EH7MA!>W&>_@-02P,$%     @
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MZ]#$*6H01\"SP;M;:'*9:0+/)3Z'-MLE6<*K"GQ=4"?KT7W.%-@'GXDU"E(
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MD1_M-7G#7Y@#& =XA@GU#[U10OM2"$E(FUTJ1[ V]J/@/;!&8Y9,(PP*@T&
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M!OX4NJ[K.\RZ8-7:W1O.E;6J<*\KY#6AJ0&^+Q3XW!1H@.XB^?QW4$L#!!0
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M$C":G ;"$5XRY #*(_))< "Y_'VDB2![D?G!@M;-'LEY?H69 "R0K2#P+.\
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M#>2.X?J6-\:O7OB#SNL:EWJE2[TZZ6/$)Z)/(EZTYC*\!R3KAND(0MP*LMB
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M5"U[;"F4,+STZCQ'$4NB&'4CE@S3:,;2,;2'PV&4LCB9P<)U,W?:024=)=&
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MKI@M^H#S(3+K+N+P)Q%WQ-V*VXX#$40L46,A/;ODEVE*(51+I;JNEIE2K_-
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M*25VTE0R8K.2#>5W*QM/QTXUIVSBE!U-D/]:60H!N2OC:]Y;?K/..:4''5I
M)W QJ[2@*"H>:=*DFL(X#G>9=KDF?*;R!=;Q!47-G O-[GBQ:C)W+]9O<*#%
MM 3,>>'&AQLLG[Q4F(=E2<W!JNP3T?*JTNH!95M V2]BK/BC=0P$;<8Z/'_
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M4!J%T@(HC:%HNM1KK\TV>VUOWPQ!OI.?')1C3GGJ(',HS872/"C-A](HE!9
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M>OTI3>7KDSS!=J7JJ_\#4$L#!!0    ( &F$:%>#J& 1Y@(  /D&   9
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;'V5;6_:,!#'OXJ555,G41("A+:#
M2(5N6J5U0J7=7DQ[89*#6'7BU':@E?;A=[8A3;O &Q*?[^%W?^S+>"ODH\H
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MX^+EDM& B;R!>O^6<_FXD7>P^26&^?]02P,$%     @ :81H5RGLG[(?!0
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M(/>O+#\/D]^(=)\=^+A+A4CC[')'O8 R54"^OT]3\7BC",I32:L?4$L#!!0
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M3_*W2T9#)K( _?F"<_5VD U0;;N9_@=02P,$%     @ :81H5]UF;B;$!0
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M:9Q_7)-@26@6(+Y_3%/^>I U4&U0G?\'4$L#!!0    ( &F$:%=U'),B2!,
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MK/_^ZWR^VGVS>8#O\\5O3\,Y_7]02P,$%     @ :81H5QR+WI^A!   :18
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M;:+LY/R!'FA>4 $>J*#\H"[43(/;1*Q9D4L!2!Z#ZU3-'<G7ZN7[6RI)D@H
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M@NY06R<N [7'[-%59*0"V:7B=;I#;1F8A%'O,C<J@.PJ4%>C,Z35\MSN-Q*
MPC>F-V35H',3-$J#[$KS8_36_GA N+=;C78@^\?#8.S6\8TQZA-A;)@?VYG_
M3&[#;2V 4=^7,C92@.U2, RUU4&"%\3; \V( +:+P!"LAKL4 ?=.XLFQDET1
M7B>UVL'X)#)&K9VM=W+ZEU&^+<\X!2C[O3H(;)XVYZC7U>FA&5X=PMX3KGI.
M@)1NE*GOAFHV>'6N6=U(MB_/$A^9E"PK+W>4Q)3K >K]AC'Y?*,#-*?+\_\
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M;W)K<VAE971S+W-H965T-3DN>&ULO9E=;Z,X%(;_BL6.5AUI-WPE]&.32&V
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MKF]0UQ>,R=<3':#=I)[^!U!+ P04    " !IA&A7Z+AZB4((  !O3P  &0
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MS&/UH%#R>Y2,E2 TDX(HV"V\Y>AZ-;/Z3N$G@T8?K8F-9"OEDQ7NLH476$+
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M:W-H965T<R]S:&5E=#8R+GAM;,6=_W/;MAF'_Q6>U]NU=YDMDA(E98GO6A'
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M6]]7>1.T>AU\G>9U5BS7WP1_"W[^D 9??_5-\%50K()WQ7+99&C]YJQNNM]
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M^QDZ/6>>K]#"AB_9MK%G242*QJ*6'=A5(+EJ5_;4W<,>P/$, Y(.D/PM(.T
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MH/')>]>OIIT9K8&Z#FVWU.B:.&PK-V;!^ !WOM(:=X9/T _N_#=02P,$%
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M \$QH3) ?+\KA/KZ1@[0_-BR^A=02P,$%     @ :81H5\'.RYM# P  O@T
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M <XM$_KQO2;UFCTM\'S\R/[9!8_!W%$-&\G_8ZG)UM["(RGL:,G-5WG\&^J
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M8=$5<M$6$A\H9 'U@"71.Q9'<;('/GT9/H."X$,/CY_#0[*D]R7N?8D]7WJ
M[RN68)C2JFB,(?6,6PODP1]&61QA+0KR9@,6O3?[]+ZX@;N=9[;F!4P"NGX6
MS :"_.V;X3CZM$_]*Y$]\R+IO4@\>W+ BXO&4L1:=EX\-,(*?_]^?J$8FR-4
M]M<^]<EKJG\ELF?JTUY]^N*7\.^\17_>K-8&5YH^]7W26[ZQYW-==).GX]%@
ME(6;74UMUL>=K--TW.>TI88[%]LUU2MNUD)9)F%%J&CP810PTS:J=H*Z]G?]
M3B-U#C\LJ;>#<0FTOM(:GR:N??1_B_PO4$L#!!0    ( &F$:%<[?2/C/0\
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M70_0G]_F>?7PHDYPGQ>?=].Y^1]02P,$%     @ :81H5[@EGR65!P  -$H
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ME '>7S(FMP/EH/U[(_@?4$L#!!0    ( &F$:%>'3D;;>@@  -M(   9
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M_85GQ^I5,8\9YUE2?3RP<,?RTD#\OL\R_OU+Z>#\/J/[_P-02P,$%     @
M:81H5^A!T?;F!@  LC,  !D   !X;"]W;W)K<VAE971S+W-H965T-S@N>&UL
MS5M=;]LV%/TKA%<,"=#((F7+5I882"QI*]"L0;-N#\,>&)FVM>K#E6@G!?;C
M1WW$LD26L9T;('E(9/G>0_+P\O+R*+IX2+.O^9(QCA[C*,DO>TO.5^?]?AXL
M64QS(UVQ1'PS3[.8<O$Q6_3S5<;HK'2*HSXQ3;L?TS#I32[*>[?9Y")=\RA,
MV&V&\G4<T^S[-8O2A\L>[CW=^!PNEKRXT9]<K.B"W3'^976;B4_]+<HLC%F2
MAVF",C:_[%WA<Y\XA4-I\6?('O*=:U0,Y3Y-OQ8?/LPN>V;1(Q:Q@!<05/S9
ML"F+H@))].-;#=K;MEDX[EX_H?OEX,5@[FG.IFGT5SCCR\O>N(=F;$[7$?^<
M/OS&Z@$-"[P@C?+R-WJH;<T>"M8Y3^/:6?0@#I/J+WVLB=AQ$#AJ!U([D*[#
MX <.5NU@[=O"H'88[-O"L'88[NM@UPYVR7U%5LFT2SF=7&3I \H*:X%67)33
M57H+@L.DB*P[GHEO0^'')Y]9$-$\#^=A0,NI%M&'TCFZ"H)UO(XH9S/TB2]9
MAJ9I+&)W6035AJ$/29#&#)U\3//\%)VXC-,P$E=GZ,N=BT[>G:)W*$S031A%
M C6_Z'/1V:+)?E!W[+KJ&/E!QRQTDR9\F2,OF;&9PM_5^SL:_[X@:<L4>6+J
MFF@![]C*0);Y'A&36(K^3/=W)ZKAO*QU[V6M^WKW&YH)=ZQR;W%I;:/.*O&L
M?:/N:O:OB'61L?B! 2A\79:%&UHDJ!S]_5&TA#YP%N?_J&*NZM9 W:TBBY_G
M*QJPRYYH*6?9AO4F/_^$;?,7U81#@KF08!XDF \$U@J4P390!CKT237S)V$Y
MV:>(/8H=-6>JF:UPG!*GV$XWDS/+-"_ZF]T9DXV&=MO$K4SL71PR&!ND;>;)
M9H1@PVI;^=K!'4G=<$O=4$M=O4#^H(_(JVA#)]<L8?.0GZH(K-!&NP,?$<,Q
M=WYPAT[9A5AVERI7MG*(,71V?SKDRA[#T=@8=LC5#O](<NTMN;:6W-LLG:T#
M+FJK#4O63+F_V3([0\OLQLA4969*HW5EL]%@X'31/(6931QCT.%..[HCN1MM
MN1MIN?M=U,MA73Y$9?E .<_"^S6G]Q%#/$778;I@29'B#16Q(WF)VF/#U$34
M="31@K$U,$8=DF5D!^,N>9X,1@:.+<6GEH4C.1YO.1YK.;ZC<;Y.%@63;!4J
MPU,+<.A6" GF0H)YD& ^$%AK2IWME#IOLV9R( ,%$LR%!/,@P7P@L%:@8+,Y
MTYG:U>]]6X?\^WN4/B0LRY?A2N1;SD1+7'D.J\ PWDEHIC&0<JB^T4/G;L]6
M/=!6_>=;;5.^<XS&6LI?=HY63HNVP4/7'2B:"XKF@:+Y4&CM0"!-()"WF:;K
M?D'%"R2:"XKF@:+Y4&CM>&F4$*P]/[^\&J[Q6^4P)H;=S=Z65+7:Q!AW"F %
MV$"J?Q50SD@Z^^K'?2ROC7" ]<K!KS1,\HI2)D@5BREGP3H+>2C6$MW0,"KY
MG:<9RJFX^ ^]0@H'.O_7,PB)YH*B>:!H/A1:.W0:X00/WV@*!Y(TZGB!1'-!
MT3Q0-!\*K1TOC1:$]6+0_B(EEN69,SSL*F;3VFRX:R9E:H4-'G4SM:(]60S2
M#^]8^AHY".OUH$.%2BSK+Y9,H4+QD>0>)9+=Y7 D$4VZ!+Z&U(,;K0?KQ1YY
MJPMHOD3S2  MV6PA,L^K[&Z@"A(HF@N*YH&B^5!H[6AI9"3\1G4D#"HD@:*Y
MH&@>*)H/A=9^ZMV(240O)NV_N]5 K=W&-+H/C6JKW7S:>4SGJH&ZCSK45MW<
MK!_=L>PUNA#1ZT*';FXUG(:=:6W2?E(GG>145D3F4&[N#'?K _T0CZ6P452(
M]@2^U[.V&J)=6'7W^ZG":C22J@*%%1[+S"FL!E(=XNO'=BQWC;I ].K"IQ7+
M1'I.%D_1IV9//M!CJ:)2&(GE)H6=;$6Z*<!305G2\S/]T(ZEKA$0R*$"0E)*
M-6*KJS;+LK1ZE<I*W[-#=TI0-!<4S0-%\Z'0VA'3Z ;DC>H&!%0W $5S0=$\
M4#0?"JT=+XUN0*!T R(?]J6JX%D3]WD3C\B"@37NYF]?/ZYC>6L$ Z(7#*;K
M+&-)\!WQC"9Y5*TUNEUKKW/:U??IX#4&B>:"HGF@:#X46CM6&FV$C-]H3@95
M1T#17% T#Q3-AT)KQTNCCA#M:?J0G%P!.;J<_*R)^[R)5YNT'O -QX;33<J@
M,D%_YY6"F&6+\N6/' 7I.N'5_WEO[VY?,+DJ7ZOHW+_&YU.LN._B<Z]Z?:2!
MK]YFN:'9HBB](S8739G&2&Q86?6"2/6!IZORA8;[E/,T+B^7C,Y85AB([^=I
MRI\^% UL7].9_ ]02P,$%     @ :81H5P41IZQF!   >18  !D   !X;"]W
M;W)K<VAE971S+W-H965T-SDN>&ULK5C;CMLV$/T50@V*!,A:%\NWK6T@NU+0
M/&RPB)/FF9;&-A&)=$G*3O^^I"3+EL75.BWW82U29\YP+AJ2,S\R_D/L "3Z
MF6=4+)R=E/M[UQ7)#G(L!FP/5+W9,)YCJ89\ZXH]!YR60GGF!IXW=G-,J+.<
MEW//?#EGA<P(A6>.1)'GF/_S !D[+AS?.4U\(=N=U!/N<K['6UB!_+9_YFKD
M-BPIR8$*PBCBL%DX'_S[V!]I@1+Q%X&CN'A&VI0U8S_TX%.Z<#R](L@@D9H"
MJY\#/$*6:2:UCK]K4J?1J04OGT_L'TOCE3%K+."19=])*G<+9^J@%#:XR.07
M=OP3:H/*!28L$^5_=*RPD]!!22$DRVMAM8*<T.H7_ZP=<2&@>,P"02T07 N\
MI&%8"PQOU1#6 N&M&D:U0&FZ6]E>.B["$B_GG!T1UVC%IA]*[Y?2RE^$ZD19
M2:[>$B4GES'FE-"M0'O@:+7#'-#;""0FF7B'[M"W583>OGF'A'XC$*'HZXX5
M M-4O$=O]/B)9)F*N)B[4BU'D[I)K?JA4AV\H'J(GAB5.X%BFD)JD(_ZY6<]
M\JYR0^.+X.2+AZ"7< 7[ 1IZ[U'@!4/#>AYO%P],YOP_[?%_UMYRQK!)C&')
M-WR![W.1 \>2\7M39"O9T"RKB]N]V.,$%HZJ7@+X 9SE[[_Y8^\/DUMMDD4V
MR6)+9*T A$T PC[VY6>U2Q":L%Q]D1D3ZG/$4G*R+B1>9X D0P^$;8&B3S09
MF&)4T8]+>KU?')9WX^G FUW^S=W#922Z(KX_# >3-BSJPF:^/PC;J+B+"L+9
M>#!J8"VWC!JWC'KS\GM9^B&]PP>5GULXE:9"0*KK48*SI,BP5$7-F+DCFYEK
MDRRR219;(FN%:-R$:-R;N:<0H5.(:)&OU?;"-DBE<ZZ.!W7,U,%%2+67J%B9
M0E5I&5UF8QA./>\J:8VP\!H6&6&3:UAL@HTNE;9<,FE<,NG-VGBS42<C[8&4
M9(4^&R$!2<&))"",>3JQF:<VR2*;9+$ELE90IDU0IKUY&IU"L6<2J"0X:^>G
M*2S33GI<IV,7T<W%+J:3UG$_3\O@66/PK-?@U8NELDI+-0V7Y\'2#28OS&[[
M,F^#12;8:-1QB DV#E[RB>^=3\!>KU>^JHO/W0&$-E^Y1^VQB7Y41^_D!RHH
MD>:S;2_IKWZ@5MDBJVRQ+;9V>"XN*+[ETED3V@J-3;;(*EMLBZT=FN <FJ"_
MGKSRB02O%DL#9-BI#P90=]]^A:EMX?D2Y/<>\9?/P,MF#$W@LB"H#)0RJZIH
M.6TTW^HER2I;9)4MML76#M+YHN2'MBM$[]7KET-CDRVRRA;;8FN'YGQ9\WLO
M&J]6B-'K%:(+\;L5X@90_ JHLM"]:*7EP+=E#U.H<V%!9=4\:6:;/NF'LCMX
M-?_@WS_ZAOE(]U7+UMV9OFK*/F&^)52@##9*E3>8J)7RJL]9#23;EXV\-9.2
MY>7C#G *7 /4^PU3Y]AZH!4TW>;EOU!+ P04    " !IA&A7W%Y!??$%  #9
M*   &0   'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6S%FEMSHS84Q[^*QMWI
M[,XDF#LF=3R3&&CW(=-,TFV?%9!M9KEX04ZR_?25@'"5U3@Y,\E##/B<G]#_
M'(1TK.537GPO=X10])PF67DYVU&ZOYC/RW!'4EPJ^9YD[)M-7J28LM-B.R_W
M!<%1Y90F<UU5[7F*XVRV6E;7;HO5,C_0),[(;8'*0YKBXN<U2?*GRYDV>[EP
M%V]WE%^8KY9[O"7WA'[;WQ;L;-Y2HC@E61GG&2K(YG)VI5T$NL$=*HN_8_)4
M]HX1[\I#GG_G)U^CRYG*[X@D)*0<@=G'(UF3).$D=A\_&NBL;9,[]H]?Z$'5
M>=:9!UR2=9[\$T=T=SE;S%!$-OB0T+O\Z0_2=,CBO#!/RNH_>JIM'7>&PD-)
M\[1Q9G>0QEG]B9\;(7H.FGG$06\<]+&#=<3!:!R,U[9@-@[F:UNP&@?KM2W8
MC8-=:5^+52GM88I7RR)_0@6W9C1^4(6K\F8"QQG/K'M:L&]CYD=7]SM<D/-K
M%IL(W>*?+&=HB3Y[A.(X*;^@<_3MWD.?/WU!GU"<H9LX25@^E,LY96USPCQL
MVEG7[>A'VC'039[178G\+"*1P-^7^[L2_SGK<]MQ_:7CU[H4>$_V"M+M,Z2K
MNB'JSRO<#?6HN_=Z=UVDQOM:#][<^D!+HTTBH^(9TB1ZJ))HG:=LU"MQ-6[X
MS_R8L-0)DP.+&\^AD.5/GL01INR\I.RC3KI\P\WRE CZ<UVW;XK;YZ/O1;G'
M(;F<L>&U),4CF:U^_46SU=]$D86$>9 P'Q(6 ,$&&6&V&6'*Z(.,"/L90>J,
M$,582CPUQC7,KF#\[?JX.K=-9;&</_:#)[*R%&=HY0NL=,T9PP*!F>::BM::
M#92T6B4MN9*'!YI3G(@4DWJ>JE@-LWJW;UKZ2*^IC:.-Q*I-G)Z)K;IC28.I
ME:YJBBN6RFZELJ52K?$^9DK%__*!Y5@"AGE)1>^O:RG[5#'M2?_.=<4>J6E/
MU#P?">X+. O%&HDI,'*.I9W3:NF\ZP$>#.E5@M;*(IQ%+S9"F:7-GBJS,^FY
M:;J*.=+9F>ALNR.=IR";Y>,H&L'4BC_@"['2BU;IA53IK]5+#U'\C,AFPR;<
M(M6DB%-56TSSQ9UDE;>89J=FC&03D#3=GB2H &788M7<5C57GI]L+1)GVS/T
M.\E(P;*/Y]U5Q&;(<4D+S)<K+[,/D9Y2^*EZNA,5G,5BG#S>U,JR#66LZ-2*
MI=@T$P5FCJ,>2T5-[58#JE36.\(6$>B6/?PIZ_Z!QB%.RC/$<E2DHAQVJHR@
M- ^4YH/2 BC:,,B])9_VP=/UY@:@$@.2YH'2?%!: $4;)H;>)88N??K_W!,^
M=&9;Z1N\@?0GNH9KC-^Z:WE;)T<-DN:#T@(HVC!JW>);DZ[DWOLJ;.C#5XX]
M#2?HJAF4YH/2 BC:,)S=REF3+YWO&!,7X:X*8T0>29+O^9#;SKQQ61**</CC
M$!?"4MIUTX(["*DS#BCD>ML#I?F@M "*-@QHMX#7Y"OX8P$51@YT20]*\T!I
M/B@M@*(-0]P5'C3[HV=4H.4)4)H'2O-!:0$4;9@8715%>U\911AJT!*)-BU:
M\.+EJ&SGB<S,\4+>%UDY]G@1&PC,'%VQW/[?D95J5S71Y&63=M:S[<UZ\&#6
M(Q07M)("2O- :3XH+8"B#:/=57LT]Z,'6-"2$"C- Z7YH+0 BC;\$;<K6.GR
M@M5;!E@Y\M10-[3!F&B8RJC"[ G,S$FEU!=8&<9D;1T(S#3=[8W#0S6[RI N
M+3"L_JH*^4=_.VDT/4,96X"PIXGB9Z&^H-4?4)H'2O-!:0$4;1C\KOJCZQ\\
MQNJ099<U*,T#I?F@M "*-DR,KL"D_T^!Z2UC+.B.C88V*#E:ZG2,-29U#\L>
MC[!3E.F8DQ^H!6::M9C\P#+O[;Q*2;&M]LB53*5#1NO],^W5=A_>5;7[;'1]
MK5UXFN"ZKUT$]2Z[#E]O^KO!Q3;.2I20#6M*51RV!"[J?73U"<WWU;ZOAYS2
M/*T.=P1'I. &[/M-GM.7$]Y NYMQ]1]02P,$%     @ :81H5WT'K+7T!0
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M")32B8_LTD=VJX_R$1_CR?I*$1$C1O$#96<-T@J[U""0,->N5<5D-.D[%8M
MAO0@87ZG_ /(D&$.LX^[SM&H;Y4A3PPU*0TU:374NR@2.]T(Z;Z-QP0I_-3L
MI%;*I4Z"A+F36DT,G6%_6G$29$@/$N9WRC^ #!E.:DX:C\S^I-E)T]))TU8G
M?23Z%1;=;["(=2([12/,Y%L4)E&3GUI9E_H)$N9"PA:0, \2YD/" DA8" 0[
M,;%3FMAI?^O3@S.4S01*@D6T03C1 S2R)XQOLQ? B"=*X$A)E/:_-,DF70Y4
M;=""2DR;K.[47GF&U5>>N]:L+G4P)&P!"?,@83XD+("$A4"P$P>;QLNDH-'J
MX4]<88:T2Q.)\TGI[#VUR9H%Z;@GL&W#JHYC[MHC7NI/4-H"E.:!TGQ06@!*
M"Z%HIRX]FKHV_^-P ?V#EKL'J=^ TP9WL3\SV];.OW0( 4IS06D+4)H'2O-!
M:0$H+82BG3K<>G&X!=8.MY(N]K)5GV2=5D8<+FC(!2C- Z7YH+0 E!9"T4XM
M^K+&8;8O<H0\H;K17>)DC6/^%KDDP8QF@]XE7C=;%725 Y3F@M(6H#0/E.:#
MT@)06@A%._7TRP*.^;^MX+1'OMC[H&LX!>UX*&\YX]HB3D,QT[1JT^Z@N?D%
M[;A#LNQ*R* H=#SS;CJ5:; 0*J]3;[VLXIA=EW'JWEJ1G_,6Z&(.*,T%I2U
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M];ZMHM1*7UA2PD.O"SL[SO0W5J!WT'V9DEJ#)MPYL\:%_EIC?,<YHUN:V$C
MJ(QI8AT;1E!4<\8&YPR%+J\\+]KQ]UL\>\JUAX86=G>TUZ(GXOFUN"L @R/<
MX<F0/#2XL+O#+1&HQEK!L@P1',#K0PJV@AE^9<3>5V#\H\FUH"IS\[G&]-P(
M4PVQS=OF'V!63;Z'[=4/Q#U1&1,:.$U1-#@?H1E4-9-7"R-+-P>OI<&IVCWF
M^!]#E=V WU,IS7YA#VC^C*;_ %!+ P04    " !IA&A7<>IHMSL"   2!0
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MEZS6< T3IBF#RS$:RKB^@@M@ J:,<Q>3!,92<8!!OB\[:LI&)\HNL.Y!''Z
M*(QB>%Z,X?+BZF^8P"IIY42MG,CC#D[@?IO\F$Q'C]"1)<4Q>F=AW$T8ZIKF
MF!([ZAK5%DGV_EW_-OQ\AF3<DHP]>OQO/5>*B@+MH!OM#T!(<9V?"@%C34W]
M2!_M>_P?A U:88.SW9_1-[KD".,-PI.$)U1V8OT1P'VAT LXQKE!_>11W2NR
MS>)^$FR[3(+.B+O78DI5P80&CFN;%/;N;@BHY@8VCI&UG_JE-/8.>;.TCQ8J
M%V#WUU*:@^,N4OL,9G\ 4$L#!!0    ( &F$:%=UZ;NT@00  , 6   9
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M%)G/!']"PK36-'.0U3>+UA5AB9'BO1+Z4Z;CU%R7,"*/7!"C"$22)?I+;:A
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M1W"\>_3]<]=EK\9Z;K?&]KL\SF6_QO:EH.=T._+A@)B_F"[LQ@=V*^[/:/K
M8]<'CK=]?GP>6_1>7)QYU\>+_B\5;G?N"0:DYO[47C0_77_W569N=T41C;O@
M7!=;C<T'&>;;8IN(?DO>4UG^_%M?K;>B?"HV8'2NW\"K6SAP/8!78;G1Y(@O
M][U\1GQ+J  IWBA3]G2N,IN76TG*$\GR8NO# Y.29<7A#J,$<RV@OM\P];Y?
MG6@#]8:>U7]02P,$%     @ :81H5_-ZY+H9 P  <PD  !D   !X;"]W;W)K
M<VAE971S+W-H965T.30N>&ULK59;3]LP%/XK5H8F)HU<6VYK(P'MM#V@(0K;
MLYN<-A:.G=EN"_]^QT[(>@E5M?'2^O)]YYYS/%A)]:0+ $.>2R[TT"N,J2Z#
M0&<%E%3[L@*!-S.I2FIPJ^:!KA30W)%*'L1A>!J4E DO';BS.Y4.Y,)P)N!.
M$;TH2ZI>KH'+U="+O->#>S8OC#T(TD%%YS !\UC=*=P%K92<E2 TDX(HF V]
MJ^ARW+=X!_C)8*77UL1Z,I7RR6Z^YT,OM 8!A\Q8"13_EG #G%M!:,;O1J;7
MJK3$]?6K]*_.=_1E2C7<2/Z+Y:88>N<>R6%&%]S<R]4W:/QQ!F:2:_=+5@TV
M]$BVT$:6#1DM*)FH_^ES$X<U LKI)L0-(=XF]-X@) TA.51#KR'T#M70;PC.
M]:#VW05N1 U-!TJNB+)HE&87+OJ.C?%BPM;)Q"B\9<@S*0:8TZE4U.:+4)&3
M'Z8 1>Z!4YM)7;!*DQ,RJ>N(R!FYLKEEYJ7&0$X>)!F!H)R1!Z32"A:&99H<
MC\!0QO4GI-^#!JJRPFG(88GU66&U&;SJHIZ0Q\F('!]](D>$"7++.+>V# *#
M+EO#@ZQQ[[IV+W[#O83<2F$*3<8BA[R#/]K/O]C##S#4;;SCUWA?QWL%3J#R
M21)^)G$8)QWVW!Q.C[O<^3_MXW_6OA&,I"V^Q,E+#BL^I:B8@RT+[>I$2'&2
MO04A!I>:NG;361BUZEZW:MM^+W5%,QAZV%\UJ"5XZ<</T6GXI2LK[REL])["
MQN\D;"-_O39_O7W2T_$SCBL-^(EF"Z6P$TQ?"'8/LI8T*;IR4XL]=6+M)%NF
M4>R?#H+E>LP[0!?^Q29HM OJ1WZR"1K7H(MUT'D+V?"\WWK>/\ASG&IVY*'K
M*V8*;%7:8$NL2QA;)09&EM 5@?Z.W6<[ =C%1)'?VPK +B@)_?.M '2 $K^_
M%8)@;8J4H.9N?&M,YD*8^IMN3]L7PI4;C%OGU]'E3=1Q/L(71?T ^"N^?H[<
M4C5G0A,.,U05^F=HL*I'?+TQLG(S;"H-3D2W+/!5!,H"\'XFI7G=6 7M.RO]
M U!+ P04    " !IA&A7VA_MCA #  !6#   &0   'AL+W=O<FMS:&5E=',O
M<VAE970Y-2YX;6S%5UMOVC 4_BM65DV=M)(KH3"(5!JF[:%:!>KV;)(#B9K8
MF6V@_?>SG9 12!';(NV%^'*^[UQS<ACO*'OF"8! +WE&^,1(A"A&ILFC!'+,
M>[0 (F]6E.58R"U;F[Q@@&,-RC/3L2S?S'%*C&"LSQY9,*8;D:4$'AGBFSS'
M['4*&=U-#-O8'\S3=2+4@1F,"[R&!8BGXI')G5FSQ&D.A*>4( :KB7%GCV8#
M):\%OJ>PXP=KI#Q94OJL-E_CB6$I@R"#2"@&+!];N(<L4T32C)\5IU&K5,##
M]9[]L_9=^K+$'.YI]B.-13(Q;@T4PPIO,C&GNR]0^=-7?!'-N/Y%NTK6,E"T
MX8+F%5A:D*>D?.*7*@X' ,G3#G J@',,\-X N!7 O52#5P&\2S7T*X!VW2Q]
MUX$+L<#!F-$=8DI:LJF%CKY&RWBE1-7)0C!YFTJ<"&2 ,[RD#*M\(4QB]$TD
MP- <,JPRR9.TX.BF.KUC#),UR#H1'%V'('":\0_R^FD1HNNK#^@*I00]I%FF
MH&-32 N5'C.JK)F6UCAO6..B!TI$PM&,Q!"WX,/S^.$9O"DC4X?'V8=GZIPE
M7$#10Z[U$3F6X[;8<W\YW&ESY]^TS_Y:>R,8;ETKKN9S+ZN5PUI0A4,HN8G>
M$D%"+CG6W:&U,$K57KMJU2U'O, 13 S9#CFP+1C!^W>V;WUJRTJ79&&79+..
MR!KY\^K\>>?8@[EDQ"Q*=+9BV,J/1*%RTY:.DLG73.I;LPT&KM^31;@]C/.I
M5-\;]IRF5'@J9=\.[9[=%)NUB/G.L->OQ1I.]VNG^V>=+AL7:[B>\HAN@;VV
M.7Z6[4_KL$NRL$NR64=DC93X=4K\_]='_"[SUR59V"79K".R1OX&=?X&G?61
MDFEX\%);1SWD5,+VCAK(X*0S.+W;H^YQ*M.W3WJ'>3 HY<#6>D+E**(;(LKO
M8'U:#\%W>O8[.I_:HWN[Y3R40W,YX_ZF+R?N!\S6*>$H@Y549?4&\@UDY11;
M;@0M])BVI$(.?7J9R,$?F!*0]RM*Q7ZC%-1_)8)?4$L#!!0    ( &F$:%?P
M9<G5?P4  -$G   9    >&PO=V]R:W-H965T<R]S:&5E=#DV+GAM;,6:;7.C
M-A#'OXK&O>G<S5QLP,^IXYE+>&A?I)>YS+6O95C;F@-$)3D/G7[X2D P$,+9
MT^U<7L2 M3^MM'^TL-;JD8MO<@^@R%,2I_)JL%<JNQR-9+B'A,HASR#5WVRY
M2*C2IV(WDID &N5&23QR+&LV2BA+!^M5?NU.K%?\H&*6PIT@\I D5#Q?0\P?
MKP;VX.7"%[;;*W-AM%YE= ?WH+YF=T*?C2I*Q!)()>,I$;"]&GRR+P-[80SR
M%G\P>)2U8V*&LN'\FSGY+;H:6,8CB"%4!D'UQP/<0!P;DO;CKQ(ZJ/HTAO7C
M%[J?#UX/9D,EW/#X3Q:I_=5@,2 1;.DA5E_XXZ]0#FAJ>"&/9?Z?/)9MK0$)
M#U+QI#36'B0L+3[I4SD1-0/'></ *0V<4PW&I<'X5(-):3 YU6!:&DQ/-9B5
M!K-3#>:EP3P/5C&[>6A<JNAZ)?@C$::UIIF#/+ZYM8X(2XT4[Y70WS)MI]8Z
MA#'=<$&-(@A-(_)9[4&0+Q!3HQ6Y9YDD%^2>)O*0[L@UXY Q2=Z[H"B+Y0?R
MCK"4W+(X-JU7(Z6=,NA16#IP73C@O.& 36YYJO:2>&D$48?]3;_]^'OV7K_]
MLL=^I">SFE'G94:OG5Z@"^&0C.V/Q+'L)<D$CPZAZAI7/^8>,HVQ#,89DZ_W
M+GG_[D,'QCT=X_1@/!QO?!QO@I.G^"U,(W3CZF88Y]SQ:3>#$#3=@5YWE<SO
MC)2G%^%;38C2AY+F"VSG;5!T/>GNVF2<2YG1$*X&.J5($ \P6/_\DSVS?NG2
M#B;,Q81YF# ?$Q8@P1K*FE3*FO31Z\K2^5<O"ENFB-Q3P=+=Z'W,I=1YG26;
M@Y"YFKINBNO>+LY54 &;Y3#SO/*PGEK#Z6KT4%?&ZT:3Z7#<;.2];F3/)FV4
M_[K5Q<09SIJM J0A-F(TK6(T[8U1*\5U1: 7<&X$,&$N)LS#A/F8L  )UM#'
MK-+'[,=EAQFFLC!A+B;,PX3YF+  "=90UKQ2UOS_SPZ]79RKH (VKV>'V7#2
MR@[SU]EA,9RWLL/K1O;<:J/\KE9VNU6 -,1&C!95C!;_-3OT LZ- ";,Q81Y
MF# ?$Q8@P1KZ6%;Z6/ZX[+#$5!8FS,6$>9@P'Q,6(,$:RK*M8XW&^DY^2)5.
M!48I-SQ)0(2,QNQOB$A>.I0?R>^'9 ."?-Z2NZ+@(,D_/;6'Z[+#:6W!=9J+
M[4V_3^?J!)7FH=)\5%J 16MJI5;/LWNUXCUE$"HMC=IC!)!,:T;+A^Z@4PUE
MC="JR4'GZ&E;$;T]GZT(3)K7/83V2RAJGP$6K1EIYQAIIS_24K&$FE#3*&(F
M=]"89/2Y2#J'+"_T[QD\%#F&;TFDCV.>Y:<F*8758D(2%H-4/(7N$FZO)^<F
M(%2:BTKS2MJR_B2ZL-HRPNPRP*(U972L>=J]A:_6RP?="2B?24 DG5I +62B
MTEQ4FO>=B9N29Z"BZW[Q4?T(L&A-@1Q+EW9_[?)SEBL#GLQ2(8%LH3N)H)8G
M46DN*LTK:?4U8O9JB<#L,<"B-15P+(S:9U5&]:-E_O.@SCQW5*CG3C6@EDI1
M:2XJS4.E^:BT (O6U,VQ8&K_P(JIC5HR1:6YJ#0/E>:CT@(L6E-AQ\*IW5\Y
M_12&_&#T)" $]D W<7=N0BV.EK3ZR[/=^E',1>W1.Z%''[7'H*35<]RQ0- ,
MUK&":O>74*M@Z9>4-R.%6D0M:?6Z\L(>3I?UOW;@4&NEYSO@HSH0=#@PJ;\7
M%Z$<U380Z3?"7;XW3)(\7,7VB>IJM?_L4[[KJG7]QKYT[8[KGGWI%[O+COAB
ML]LM%3N62A+#5G=E#>=:Y*+8/U:<*)[EVY<V7"F>Y(=[H!$(TT!_O^5<O9R8
M#JI=?.M_ 5!+ P04    " !IA&A7%IGIU5T$  "&%P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Y-RYX;6RU6-MNXS84_!5"710)D%H77V*GMH%-I&T#-$60
M8+</11]HZ=@B5B*U)&4G_?J2DB);CL*-4>Z+K0MG#CDC\O!POF/\JT@!)'K*
M,RH63BIE<>6Z(DXAQV+ "J#JS9KQ'$MURS>N*#C@I +EF1MXWL3-,:'.<EX]
MN^?+.2ME1BC<<R3*/,?\^1HRMELXOO/RX(%L4JD?N,MY@3?P"/)S<<_5G=NR
M)"0'*@BCB,-ZX7STKR)_I %5BR\$=N+@&NFAK!C[JF]NDX7CZ1Y!!K'4%%C]
M;>$&LDPSJ7Y\:TB=-J8&'EZ_L'^J!J\&L\(";ECV%TEDNG"F#DI@C<M,/K#=
M[] ,:*SY8I:)ZA?MFK:>@^)22)8W8-6#G-#Z'S\U0AP %$\_(&@ P7L!PP8P
M/ :,W@",&L#HO8!Q ZB&[M9CKX0+L<3+.6<[Q'5KQ:8O*O4KM-*+4/VA/$JN
MWA*%D\M;N@4AE?-2($+1%\P)7F6 ;JD$KMZ@B$HB"0AT%H+$)!/GZ!?T^3%$
M9Q_.T0>-N2-9ICP7<U>J#FE:-VZ"7]?!@S>"#]$=HS(5*D@"20_^QHR?&?"N
M$J)5(WA1XSHP$CY",4!#[P(%7A#T]>?]\&$///Q_T2,S/(18P?T^>$>,8?MI
M#"N^X1M\;WP+S^CO/U1+="LA%__TF5[3COII]<IW)0H<P\)12YL O@5G^?-/
M_L3[M4]QFV2A3;+($EG'FU'KS<C$OCS[3>6 <Y0Q(9!:;N%;J8W)0:8L47.R
MG=-]]AB93[6G)IM59#HI;9?>W-T>:EZWF!RT" :3;IO(4I<Z4HY;*<=&*>^!
MQTHJE1416Z-U*4L.*M5L50XMM(8H9D(MCAPR+"%!DJ&("$SZE#4&.E79FLSW
M#J4=C,9'ZMH,&5DBZ]@P:6V8&&T(80V<:X'Q$\)"@!07J*0<8K:AY-_FQ0HH
MK(GL$]](?ZKXDU>?]?18>9OQ(DMD'>4O6^4OC<KOMP ZFZ\(DQ"GE&5L\ZR^
M_;S 5*=_F6*)<#4U5#90.Y%Z+JQ F12K[,\RDE039/N2-LA+VH!F"]'GFK%K
MI[IV^7JI&0U&1[[9C!CU1+P<3-N('3^FK1]3HQ]_0LE)GI<4^@0S8D\5S"99
M:),LLD36,6#6&C#[,1N?F4UO;)*%-LDB2V0=;WQO7[!XQNFA2L(,KQC'=:&Y
MX0#5VJ57I=X2Q$AWJBO?Z9P?H&? O&^I"ZUV)++%UG7AH&STC0-]4)R8QRG"
M-'F]6[I 1;NKZO7$2'ZR)_[KK9)_M.I;C1C98NN*'^S%#XSBO[D!->-.UM4F
M6VB5+;+%UG5@7QK[/Z@V]JT6QU;90JMLD2VVKD/[ MDW5\@6R[HFTG=*L1MS
MATXVPR9;9(NM-L,].&_,@6^J@UZA%"VIK _;VJ?M8?+'Z@CUZ/F-?Q761\)[
MFOJ$^@[S#:$"9;!6E-[@4M6FO#[TK6\D*ZI3S163DN7590HX :X;J/=KINJ8
MYD8':(_>E_\!4$L#!!0    ( &F$:%<B:EN5K00  .$C   9    >&PO=V]R
M:W-H965T<R]S:&5E=#DX+GAM;*V::V_B.!2&_XJ5':UFI$YS@P!=0*+D,I5F
M-%69V?VPV@]N<@!KDIB-36GWUZ]S:2 4K"*=+Y"+W\<.YY6/<_!XQXM?8@T@
MR7.6YF)BK*7<W)BFB->047'--Y"K.TM>9%2JTV)EBDT!-*E$66HZEN69&66Y
M,1U7U^Z+Z9AO9<IRN"^(V&89+5YN(>6[B6$;KQ<>V&HMRPOF=+RA*UB _+FY
M+]29V5(2ED$N&,]) <N),;-O(MLK!56+/QGLQ,$Q*1_ED?-?Y<E=,C&L<D20
M0BQ+!%5?3S"'-"U):AS_-E"C[;,4'AZ_TL/JX=7#/%(!<Y[^Q1*YGAA#@R2P
MI-M4/O#=%V@>J%_R8IZ*ZI/LZK9]SR#Q5DB>-6(U@HSE]3=];GZ( X'=.R-P
M&H%S+.B?$;B-P'UO#[U&T'NOH-\(^N\5>(W >Z]@T @&5;#J7[<*C4\EG8X+
MOB-%V5K1RH,JOI5:183EI147LE!WF=+)Z5<FV8I6KOCH@Z0L%9_(9_)SX9./
M'SZ1#X3EY,>:;P7-$S$VI>JR%)IQ@Y_7>.<,WB;?>"[7@@1Y DE7;ZJAMN-U
M7L=[ZVB!"]A<$\>[(H[EN*?&HY=_C^4U<>VS<E\OGVU76GF@EX?PJ 8_/"L/
MW_'LKG56'NGE/L2O@[='FE"XK77<BN>>LPX7@LQ5>%F^@CQF(,C?7U4;<B<A
M$_^<&.!M#>R=!I:S[HW8T!@FAII6!11/8$Q__\WVK#].11H3YF/" DQ8B F+
MD& =O_1:O_1T]&._O%R10$BFL@D0OB3WZBY[3(&4S4YY1PN_U#N8,!\3%F#"
MPAHVJF#EHN1IVAN-+&ML/AV:XFTKM9"Q#IIUPMUOP]W7ACMXN%O,R#RE*NJS
M>MU1)QLF>7XJP%K<I0'&A/F8L  3%F+"(B18QRU>ZQ8/.YEXF'[!A/F8L  3
M%F+"(B18QR^#UB\#?3+9KUO5ZY),0;T>R2LRR_@VEV2VHX5:;Q+)R7>YAH+<
MTT*^G#*1MI=+380)\P=O9N71H'\T=0>8/8:8L @)UC''L#7'4&N."'+E!HC7
MIR*NE5X:<4R8CPD+,&$A)BQ"@G6<,6J=,<).,R-,OV#"?$Q8@ D+,6$1$JSC
M%]O:UT<L[5QR6]#_6$HD?29J)0M"U(F&Y7&Z392+U)$$U;$D-$_(!G*:2F6K
M4T[2]W2IE5!I/BHM:&B'R6LX=(]?/$+43B,L6M<H!X4T6[\B@3Q1*PV?B<U6
MPLGX:P$7QQ^3YJ/2 E1:B$J+L&A=FSA[FSC8&:@A8OD&D^:CT@)46HA*B[!H
M7=_LBZVVMC:'FH?<MP4?]\WL/-</Z&*CH%9846DA*BW"HG6-LJ^RVOHRZZUZ
M]>7//.5J3EE O"W861^@EE11:3XJ+4"EA:BT"(O6M<N^2FOWT?,1:J46E>:C
MT@)46HA*B[!H7=_LZ[6VMKR'5H#3=W.QF;RW_WCTK>/4YJ-V&J#20E1:A$6K
M76(>;#3(H%A5>T@$B<N8U__AMU?;?2JS:G?&T?6Y?1/4NTWVF'KSRS=:K%@N
M2 I+A;2N!\KF1;V?I#Z1?%-M9WCD4O*L.EP#5:]>90-U?\FY?#TI.VAW]4S_
M!U!+ P04    " !IA&A7G78SU6$#  #L%0  #0   'AL+W-T>6QE<RYX;6S=
M6%%OVC 0_BM1NDZM-#6$C$!60-J0*DW:IDKMP]XJ0QRPY#B98SKHX_[-_M9^
MR7QQ2 +UM;0/:UD0C7U?[KOOSI?$95BH-:=7"TJ5LTJY*$;N0JG\@^<5LP5-
M27&6Y51H),ED2I2>RKE7Y)*2N "GE'O=3B?T4L*$.QZ*97J1JL*994NA1FY4
MFQQS^AR/7#]\[SJ&;I+%=.3>G+S]L<S4^1O'G(_>'1UUSCHWI^>[R$D%G;J>
ME;BW3=P0/>88[J7H(4DH=7\/:I07(QU8$CVN\SS&W")K?5J>,$&<^QV[<[N\
M:!7ZOKT*?W[]1A>]P1Y9O7X74;:55Y685[7H>)ADHNG4P#4&S4]2ZMP2/G(G
MA+.I9."5D)3QM3%WP3#+>"8=I6\1'= '2W%G8-_,X.ZI>%(F,EG&-A',WVEU
M^0ZPF8% QGDML.L:PWB8$Z6H%!=Z4EY<&N]!3C6^7N=:X5R2M=_MN8U#>=)!
MIIF,J:S#^.[&-!YRFH <R>8+.*LL]P!4*DOU(&9DG@E2:MAX5 --.Z.<7\&C
MY7NRQ;U*6BM7=I2HAUI0-30T9@+\;3;#W:;M/8O7R=EMICXM=3JBG$.KT4M)
M$[8JYZND%H"Q^S@[R7.^_LC97*34)+]WP/&0;/R<12;9G8X&K3+3!BI=YY9*
MQ69MRT])\FNZ4IMV6B6XYNX!:OZW=9Y3027A;=&Z]U]SE9^M..B_E.3RJ;(K
MV*JQVB^\=I&]0Q 9'H+(@^C)P2&(C Y 9/_%GII/$>D?@LCNJQ3I5?NUUJ9P
M:TM86QW8>H_<;["5YTU09[ID7#%1S18LCJFXMS/4](I,];^R6_SZ^I@F9,G5
M=0V.W&;\E<9LF4;U59=0B.JJ9OP%TO/#>M^O8S$1TQ6-)]54SJ?ET-$#';4Z
MP&$7N2@/.X+Y&,R. (;%P11@/L8+B_,_Y3- \S$8IFU@10:HSP#U,5XV9%)^
ML#AVGT@?]DRC* C"$*OH9&)5,,'J%H;PM;-AVL #BP.1GE9K?+7Q#GFX#[ U
M?:A#L$SQ3L0RQ6L-B+UNX!%%]M7&XH 'M@I8[T!\>QSH*;M/$,"J8MJP.QA'
MH@A#H!?M/1J&2'5"^-C7![M+@B"*[ A@=@5!@"%P-^((I@ T8$@0E._!G?>1
MMWE/><WON^._4$L#!!0    ( &F$:%>7BKL<P    !,"   +    7W)E;',O
M+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +
M&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P
M6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,
M-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4
M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ :81H5TKMXD^?!@   D    \
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M>D<!O2/UC@)Z1^H=!?2.U#L*Z!VI=Q30.TX.FPCH':EW%- [4N\HH'>DWE%
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M3?M_'+\\TZ'NQI?\;/FCWNU/4$L! A0#%     @ :81H5P=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" !IA&A7,O?_D>\    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " !IA&A7F5R<(Q &  "<)P  $P
M    @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &F$:%=W
M02=0P04  +D>   8              " @0X(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " !IA&A77]V+U9((  "R+   &
M    @($%#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M:81H5RA?0,;$!   E!,  !@              ("!S18  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( &F$:%?4>N6^:P<  (DB   8
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M965T,3 N>&UL4$L! A0#%     @ :81H5[UC_>27"P  ]1\  !D
M     ("!27,  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &F$:%<KG>,P,PL  #HC   9              "
M@1F?  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ :81H
M5R8R#@1W!0  20T  !D              ("!@ZH  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    " !IA&A7"0_#4]4%  !1#@  &0
M        @($QL   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( &F$:%>[M*)(4 0   (*   9              " @3VV  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ :81H5S1S%E;!!@  A1,
M !D              ("!Q+H  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    " !IA&A7BEH7SG8#  #$!P  &0              @(&\P0
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &F$:%=GF*P_
M/P8  * 1   9              " @6G%  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ :81H5ZG*N/8E"0  MA8  !D
M ("!W\L  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !I
MA&A7-? ZEK$(   U&   &0              @($[U0  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( &F$:%>L7G*,:!L  )%D   9
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M970R.2YX;6Q02P$"% ,4    " !IA&A7MHIHZ]@$  #V#0  &0
M    @(%)) $ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M &F$:%<.'3#E70D  %D9   9              " @5@I 0!X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ :81H5U_DCRK- @  (P8  !D
M             ("![#(! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    " !IA&A73!#(15\$   &"P  &0              @('P-0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( &F$:%?*V=0C<@<
M %06   9              " @88Z 0!X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ :81H5P?6DH"0!0  %A   !D              ("!
M+T(! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !IA&A7
MB%SZ&4<&  #'$P  &0              @('V1P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( &F$:%<-\BMHW04  #L1   9
M      " @71. 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ :81H5V<U($5' P  :P<  !D              ("!B%0! 'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !IA&A7(<P-RM0%  !3$0
M&0              @($&6 $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( &F$:%?[F77)9@0  ,0)   9              " @1%> 0!X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ :81H5]F/J*%2
M!@  [!$  !D              ("!KF(! 'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    " !IA&A7 P'P2Q(&  !(&   &0
M@($W:0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( &F$
M:%<-4#NY5P(  $X%   9              " @8!O 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ :81H5T'A.X3B"@  M7H  !D
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M=#0X+GAM;%!+ 0(4 Q0    ( &F$:%?F/>N+# 0  *85   9
M  " @663 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M:81H5\8'7DWT!   @B,  !D              ("!J)<! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    " !IA&A7W69N)L0%  "L*@  &0
M            @('3G $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( &F$:%=U'),B2!,  ";H   9              " @<ZB 0!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ :81H5QR+WI^A!
M:18  !D              ("!3;8! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    " !IA&A75+;16) "  !8!P  &0              @($E
MNP$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( &F$:%>P
MM1=I3 0   @6   9              " @>R] 0!X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ :81H5X3TZ;C! P  /A0  !D
M     ("!;\(! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &F$:%<.VR[\M@(  .H&   9              "
M@</; 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ :81H
M5^=L<E].#P  8-D  !D              ("!L-X! 'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6Q02P$"% ,4    " !IA&A78FL[V4\"  #$!0  &0
M        @($U[@$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0
M   ( &F$:%=KTOR=T 0  '@9   9              " @;OP 0!X;"]W;W)K
M<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ :81H5\'.RYM# P  O@T
M !D              ("!PO4! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q0
M2P$"% ,4    " !IA&A7Q3F^0GL#  #S$   &0              @($\^0$
M>&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( &F$:%?#]#G9
MK@8  #XT   9              " @>[\ 0!X;"]W;W)K<VAE971S+W-H965T
M-C<N>&UL4$L! A0#%     @ :81H5Z]QC./= @  3 @  !D
M ("!TP," 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " !I
MA&A76XEKI X#  "Y"0  &0              @('G!@( >&PO=V]R:W-H965T
M<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( &F$:%<14R]*.P(  . $   9
M          " @2P* @!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#
M%     @ :81H5_#GQ>-N @  .08  !D              ("!G@P" 'AL+W=O
M<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " !IA&A7.WTCXST/  !$
MS@  &0              @(%##P( >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM
M;%!+ 0(4 Q0    ( &F$:%>X)9\EE0<  #1*   9              " @;<>
M @!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ :81H5R0G
M<YJJ!   (!X  !D              ("!@R8" 'AL+W=O<FMS:&5E=',O<VAE
M970W-"YX;6Q02P$"% ,4    " !IA&A7[_0/.D4%   C*@  &0
M    @(%D*P( >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    (
M &F$:%>NGRI4E ,  .H0   9              " @> P @!X;"]W;W)K<VAE
M971S+W-H965T-S8N>&UL4$L! A0#%     @ :81H5X=.1MMZ"   VT@  !D
M             ("!JS0" 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"
M% ,4    " !IA&A7Z$'1]N8&  "R,P  &0              @(%</0( >&PO
M=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( &F$:%<%$:>L9@0
M 'D6   9              " @7E$ @!X;"]W;W)K<VAE971S+W-H965T-SDN
M>&UL4$L! A0#%     @ :81H5]Q>07WQ!0  V2@  !D              ("!
M%DD" 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4    " !IA&A7
M?0>LM?0%  #A*0  &0              @($^3P( >&PO=V]R:W-H965T<R]S
M:&5E=#@Q+GAM;%!+ 0(4 Q0    ( &F$:%?I#IRY<0(  ,<&   9
M      " @6E5 @!X;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%
M  @ :81H5ZE(2L>'!   3A,  !D              ("!$5@" 'AL+W=O<FMS
M:&5E=',O<VAE970X,RYX;6Q02P$"% ,4    " !IA&A7L[>B=N0(  #+1@
M&0              @('/7 ( >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+
M 0(4 Q0    ( &F$:%>PC-)IR 4  $$H   9              " @>IE @!X
M;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ :81H5]^D-" .
M!   YA0  !D              ("!Z6L" 'AL+W=O<FMS:&5E=',O<VAE970X
M-BYX;6Q02P$"% ,4    " !IA&A7G7JKUNP#   E#0  &0
M@($N< ( >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( &F$
M:%=QZFBW.P(  !(%   9              " @5%T @!X;"]W;W)K<VAE971S
M+W-H965T.#@N>&UL4$L! A0#%     @ :81H5W7IN[2!!   P!8  !D
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M=#DS+GAM;%!+ 0(4 Q0    ( &F$:%?S>N2Z&0,  ',)   9
M  " @=^/ @!X;"]W;W)K<VAE971S+W-H965T.30N>&UL4$L! A0#%     @
M:81H5]H?[8X0 P  5@P  !D              ("!+Y," 'AL+W=O<FMS:&5E
M=',O<VAE970Y-2YX;6Q02P$"% ,4    " !IA&A7\&7)U7\%  #1)P  &0
M            @(%VE@( >&PO=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4
M Q0    ( &F$:%<6F>G5700  (87   9              " @2R< @!X;"]W
M;W)K<VAE971S+W-H965T.3<N>&UL4$L! A0#%     @ :81H5R)J6Y6M!
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M2P$"% ,4    " !IA&A7H[0U,<D"  ">.0  &@              @ 'EL (
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !IA&A78=MX
MD5$"  "P-P  $P              @ 'FLP( 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     :@!J !T=  !HM@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>754</ContextCount>
  <ElementCount>430</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>168</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statement of Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement</Role>
      <ShortName>Condensed Consolidated Statement of Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Dispositions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Dispositions</Role>
      <ShortName>Dispositions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Indebtedness</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Indebtedness</Role>
      <ShortName>Indebtedness</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SharebasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Acquisitions</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Revenues</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Acquisitions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsDetailsTextual</Role>
      <ShortName>Acquisitions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AcquisitionsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Acquisitions - Purchase Price Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails</Role>
      <ShortName>Acquisitions - Purchase Price Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Acquisitions Preliminaty Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails</Role>
      <ShortName>Acquisitions Preliminaty Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Dispositions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DispositionsDetailsTextual</Role>
      <ShortName>Dispositions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Dispositions</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Revenues - Revenues by product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails</Role>
      <ShortName>Revenues - Revenues by product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1</Role>
      <ShortName>Revenues Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2</Role>
      <ShortName>Revenues- Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Revenues - Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails</Role>
      <ShortName>Revenues - Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Revenues - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Inventory - Components of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails</Role>
      <ShortName>Inventory - Components of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Inventory - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryNarrativeDetails</Role>
      <ShortName>Inventory - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesDetailsTextual</Role>
      <ShortName>Leases (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Leases</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails</Role>
      <ShortName>Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Indebtedness</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareRepurchasesDetails</Role>
      <ShortName>Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShareTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - Collaborative and Other Relationships - OCREVUS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails</Role>
      <ShortName>Collaborative and Other Relationships - OCREVUS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - Collaborative and Other Relationships - Profit Sharing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails</Role>
      <ShortName>Collaborative and Other Relationships - Profit Sharing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - Collaborative and Other Relationships - Eisai (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails</Role>
      <ShortName>Collaborative and Other Relationships - Eisai (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954534 - Disclosure - Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails</Role>
      <ShortName>Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954535 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954536 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9954537 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9954538 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9954540 - Disclosure - Collaborative and Other Relationships - Other Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Other Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9954541 - Disclosure - Collaborative and Other Relationships - Samsung Bioepis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails</Role>
      <ShortName>Collaborative and Other Relationships - Samsung Bioepis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9954542 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="biib-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9954543 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>98</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="biib-20230930.htm">biib-20230930.htm</File>
    <File>biib-20230930.xsd</File>
    <File>biib-20230930_cal.xml</File>
    <File>biib-20230930_def.xml</File>
    <File>biib-20230930_lab.xml</File>
    <File>biib-20230930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>biib-20230930_g1.jpg</File>
    <File>biib-20230930_g10.jpg</File>
    <File>biib-20230930_g11.jpg</File>
    <File>biib-20230930_g12.jpg</File>
    <File>biib-20230930_g13.jpg</File>
    <File>biib-20230930_g2.jpg</File>
    <File>biib-20230930_g3.jpg</File>
    <File>biib-20230930_g4.jpg</File>
    <File>biib-20230930_g5.jpg</File>
    <File>biib-20230930_g6.jpg</File>
    <File>biib-20230930_g7.jpg</File>
    <File>biib-20230930_g8.jpg</File>
    <File>biib-20230930_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1532">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>128
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "biib-20230930.htm": {
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20230930",
   "dts": {
    "inline": {
     "local": [
      "biib-20230930.htm"
     ]
    },
    "schema": {
     "local": [
      "biib-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "biib-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20230930_pre.xml"
     ]
    }
   },
   "keyStandard": 331,
   "keyCustom": 99,
   "axisStandard": 41,
   "axisCustom": 6,
   "memberStandard": 69,
   "memberCustom": 93,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/dei/2023": 6,
    "http://fasb.org/us-gaap/2023": 2
   },
   "contextCount": 754,
   "entityCount": 1,
   "segmentCount": 168,
   "elementCount": 810,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1532,
    "http://xbrl.sec.gov/dei/2023": 30
   },
   "report": {
    "R1": {
     "role": "http://www.biogenidec.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
     "longName": "0000002 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "longName": "0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "longName": "0000004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
     "longName": "0000006 - Statement - Condensed Consolidated Statement of Equity Statement",
     "shortName": "Condensed Consolidated Statement of Equity Statement",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-96",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-96",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000007 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.biogenidec.com/role/Acquisitions",
     "longName": "0000008 - Disclosure - Acquisitions",
     "shortName": "Acquisitions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.biogenidec.com/role/Dispositions",
     "longName": "0000009 - Disclosure - Dispositions",
     "shortName": "Dispositions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives",
     "longName": "0000010 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.biogenidec.com/role/Revenues",
     "longName": "0000011 - Disclosure - Revenues",
     "shortName": "Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.biogenidec.com/role/Inventory",
     "longName": "0000012 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill",
     "longName": "0000013 - Disclosure - Intangible Assets and Goodwill",
     "shortName": "Intangible Assets and Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R14": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "longName": "0000014 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "longName": "0000015 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "longName": "0000016 - Disclosure - Derivative Instruments",
     "shortName": "Derivative Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipment",
     "longName": "0000017 - Disclosure - Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.biogenidec.com/role/Leases",
     "longName": "0000018 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.biogenidec.com/role/Indebtedness",
     "longName": "0000019 - Disclosure - Indebtedness",
     "shortName": "Indebtedness",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.biogenidec.com/role/Equity",
     "longName": "0000020 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.biogenidec.com/role/EarningsperShare",
     "longName": "0000021 - Disclosure - Earnings per Share",
     "shortName": "Earnings per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.biogenidec.com/role/SharebasedPayments",
     "longName": "0000022 - Disclosure - Share-based Payments",
     "shortName": "Share-based Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "longName": "0000023 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "longName": "0000024 - Disclosure - Other Consolidated Financial Statement Detail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationships",
     "longName": "0000025 - Disclosure - Collaborative and Other Relationships",
     "shortName": "Collaborative and Other Relationships",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities",
     "longName": "0000026 - Disclosure - Investments in Variable Interest Entities",
     "shortName": "Investments in Variable Interest Entities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.biogenidec.com/role/Litigation",
     "longName": "0000027 - Disclosure - Litigation",
     "shortName": "Litigation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.biogenidec.com/role/AcquisitionsTables",
     "longName": "9954472 - Disclosure - Acquisitions (Tables)",
     "shortName": "Acquisitions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables",
     "longName": "9954473 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "longName": "9954474 - Disclosure - Revenues (Tables)",
     "shortName": "Revenues (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "longName": "9954475 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables",
     "longName": "9954476 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "longName": "9954477 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "longName": "9954478 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "longName": "9954479 - Disclosure - Derivative Instruments (Tables)",
     "shortName": "Derivative Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "longName": "9954480 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.biogenidec.com/role/EarningsperShareTables",
     "longName": "9954481 - Disclosure - Earnings per Share (Tables)",
     "shortName": "Earnings per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "longName": "9954482 - Disclosure - Share-Based Payments (Tables)",
     "shortName": "Share-Based Payments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "longName": "9954483 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "longName": "9954484 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables",
     "longName": "9954485 - Disclosure - Collaborative and Other Relationships (Tables)",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:CoPromotionProfitSharingFormulaTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:CoPromotionProfitSharingFormulaTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
     "longName": "9954487 - Disclosure - Acquisitions (Details Textual)",
     "shortName": "Acquisitions (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-118",
      "name": "biib:PaymentsToAcquireBusinessesGrossOutstandingEquityAwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
     "longName": "9954488 - Disclosure - Acquisitions - Purchase Price Consideration (Details)",
     "shortName": "Acquisitions - Purchase Price Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-117",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "biib:BusinessAcquisitionNumberOfCommonStockSharesAcquired",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
     "longName": "9954489 - Disclosure - Acquisitions Preliminaty Purchase Price Allocation (Details)",
     "shortName": "Acquisitions Preliminaty Purchase Price Allocation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.biogenidec.com/role/DispositionsDetailsTextual",
     "longName": "9954490 - Disclosure - Dispositions (Details Textual)",
     "shortName": "Dispositions (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-460",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-128",
      "name": "us-gaap:EquityMethodInvestmentSoldCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
     "longName": "9954491 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-149",
      "name": "us-gaap:OtherRestructuringCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
     "longName": "9954492 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-151",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-151",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails",
     "longName": "9954493 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-153",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
     "longName": "9954494 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-187",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
     "longName": "9954495 - Disclosure - Revenues - Revenues by product (Details)",
     "shortName": "Revenues - Revenues by product (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-241",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1",
     "longName": "9954496 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)",
     "shortName": "Revenues Reserves for Discounts and Allowances (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2",
     "longName": "9954497 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)",
     "shortName": "Revenues- Reserves for Discounts and Allowances (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-420",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails",
     "longName": "9954498 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "shortName": "Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-428",
      "name": "biib:ShareOfCoPromotionProfits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
     "longName": "9954499 - Disclosure - Revenues - Other Revenues (Details)",
     "shortName": "Revenues - Other Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-432",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "biib:OtherrevenuesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
     "longName": "9954500 - Disclosure - Revenues - Narrative (Details)",
     "shortName": "Revenues - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "biib:NumberOfWholesalers",
      "unitRef": "wholesaler",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "biib:NumberOfWholesalers",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "biib:NumberOfWholesalers",
      "unitRef": "wholesaler",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "biib:NumberOfWholesalers",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
     "longName": "9954501 - Disclosure - Inventory - Components of Inventory (Details)",
     "shortName": "Inventory - Components of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.biogenidec.com/role/InventoryNarrativeDetails",
     "longName": "9954502 - Disclosure - Inventory - Narrative (Details)",
     "shortName": "Inventory - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-443",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
     "longName": "9954503 - Disclosure - Intangible Assets and Goodwill (Details)",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1",
     "longName": "9954504 - Disclosure - Intangible Assets and Goodwill (Details 1)",
     "shortName": "Intangible Assets and Goodwill (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
     "longName": "9954505 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
     "longName": "9954506 - Disclosure - Fair Value Measurements (Details Textual)",
     "shortName": "Fair Value Measurements (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
     "longName": "9954508 - Disclosure - Fair Value Measurements (Details 1)",
     "shortName": "Fair Value Measurements (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:NotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:NotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
     "longName": "9954509 - Disclosure - Fair Value Measurements (Details 2)",
     "shortName": "Fair Value Measurements (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R66": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails",
     "longName": "9954510 - Disclosure - Financial Instruments (Details)",
     "shortName": "Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
     "longName": "9954511 - Disclosure - Financial Instruments (Details 1)",
     "shortName": "Financial Instruments (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails2",
     "longName": "9954512 - Disclosure - Financial Instruments (Details 2)",
     "shortName": "Financial Instruments (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails3",
     "longName": "9954513 - Disclosure - Financial Instruments (Details 3)",
     "shortName": "Financial Instruments (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual",
     "longName": "9954514 - Disclosure - Financial Instruments (Details Textual)",
     "shortName": "Financial Instruments (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
     "longName": "9954515 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)",
     "shortName": "Financial Instruments Financial Instruments (Details Textual 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-511",
      "name": "biib:StrategicInvestmentPortfolio",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-511",
      "name": "biib:StrategicInvestmentPortfolio",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
     "longName": "9954516 - Disclosure - Derivative Instruments (Details)",
     "shortName": "Derivative Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails",
     "longName": "9954517 - Disclosure - Property, Plant and Equipment (Details)",
     "shortName": "Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.biogenidec.com/role/LeasesDetailsTextual",
     "longName": "9954518 - Disclosure - Leases (Details Textual)",
     "shortName": "Leases (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-576",
      "name": "biib:OperatingLeaseRightOfUseAssetDerecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.biogenidec.com/role/IndebtednessDetails",
     "longName": "9954519 - Disclosure - Indebtedness (Details)",
     "shortName": "Indebtedness (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-584",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-584",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.biogenidec.com/role/ShareRepurchasesDetails",
     "longName": "9954520 - Disclosure - Share Repurchases (Details)",
     "shortName": "Share Repurchases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-16",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-587",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "longName": "9954521 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
     "longName": "9954522 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "shortName": "Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:OtherOperatingIncomeExpenseNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-632",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.biogenidec.com/role/EarningsperShareDetails",
     "longName": "9954523 - Disclosure - Earnings per Share (Details)",
     "shortName": "Earnings per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
     "longName": "9954524 - Disclosure - Share-Based Payments (Details)",
     "shortName": "Share-Based Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
     "longName": "9954525 - Disclosure - Share-Based Payments (Details 1)",
     "shortName": "Share-Based Payments (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-656",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
     "longName": "9954526 - Disclosure - Income Taxes (Details Textual)",
     "shortName": "Income Taxes (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails",
     "longName": "9954527 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
     "longName": "9954528 - Disclosure - Other Consolidated Financial Statement Detail (Details)",
     "shortName": "Other Consolidated Financial Statement Detail (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
     "longName": "9954529 - Disclosure - Other Consolidated Financial Statement (Details Textual)",
     "shortName": "Other Consolidated Financial Statement (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:LitigationSettlementExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
     "longName": "9954530 - Disclosure - Collaborative and Other Relationships - OCREVUS (Details)",
     "shortName": "Collaborative and Other Relationships - OCREVUS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-692",
      "name": "biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-692",
      "name": "biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
     "longName": "9954531 - Disclosure - Collaborative and Other Relationships - Profit Sharing (Details)",
     "shortName": "Collaborative and Other Relationships - Profit Sharing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-695",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-695",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
     "longName": "9954532 - Disclosure - Collaborative and Other Relationships - Eisai (Details)",
     "shortName": "Collaborative and Other Relationships - Eisai (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-440",
      "name": "biib:AccruedPaymentToTerminationAgreement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-440",
      "name": "biib:AccruedPaymentToTerminationAgreement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
     "longName": "9954533 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-698",
      "name": "biib:ExpenseIncurredByCollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-698",
      "name": "biib:ExpenseIncurredByCollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
     "longName": "9954534 - Disclosure - Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details)",
     "shortName": "Collaborative and Other Relationships - ADUHELM Collaboration Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:PercentageoffuturedevelopmentcostsrelatedtoEisai",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-706",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
     "longName": "9954535 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to ADUHELM Collaboration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-715",
      "name": "biib:AggregateGrossIdleCapacityCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
     "longName": "9954536 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-719",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-719",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
     "longName": "9954537 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "biib:ShareOfNetProfitFromSageTherapeuticsPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-724",
      "name": "biib:Collaborationprofitlosssharing",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
     "longName": "9954538 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-734",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-734",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
     "longName": "9954540 - Disclosure - Collaborative and Other Relationships - Other Arrangements (Details)",
     "shortName": "Collaborative and Other Relationships - Other Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-738",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
     "longName": "9954541 - Disclosure - Collaborative and Other Relationships - Samsung Bioepis (Details)",
     "shortName": "Collaborative and Other Relationships - Samsung Bioepis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "biib:Collaborationprofitlosssharing",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-743",
      "name": "biib:Collaborationprofitlosssharing",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
     "longName": "9954542 - Disclosure - Investments in Variable Interest Entities (Details)",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.biogenidec.com/role/LitigationDetails",
     "longName": "9954543 - Disclosure - Litigation (Details)",
     "shortName": "Litigation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20230930.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due in one year or less, amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ParentMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parent",
        "verboseLabel": "Total share-based compensation expense, net of tax",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due after one year through five years, amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r443",
      "r471",
      "r626",
      "r865",
      "r866"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r921",
      "r941"
     ]
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, plant and equipment, net",
        "terseLabel": "Property, Plant and Equipment, Net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r691",
      "r703",
      "r898"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r83",
      "r84"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cumulative translation loss",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r156"
     ]
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r27",
      "r255",
      "r258",
      "r264",
      "r608",
      "r609",
      "r614",
      "r682",
      "r708",
      "r934",
      "r935"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Acquisitions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r564"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r146",
      "r188"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r628"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net income to net cash flow from operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax (benefit) expense",
        "terseLabel": "Income Tax Expense (Benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r222",
      "r302",
      "r303",
      "r329",
      "r547",
      "r556",
      "r719"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments related to issuance of stock for share-based compensation arrangements, net",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type Categorization [Domain]",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r745",
      "r747",
      "r748",
      "r751",
      "r754",
      "r812",
      "r814",
      "r816",
      "r819",
      "r820",
      "r831",
      "r832",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r903"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r83",
      "r145",
      "r146",
      "r188"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due in one year or less, estimated fair value",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r689"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due after one year through five years, estimated fair value",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r690"
     ]
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnTerminationOfLease",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (Loss) on Termination of Lease",
        "label": "Gain (Loss) on Termination of Lease",
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expense included in condensed consolidated statements of income",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_OtherRestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherRestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated Depreciation and Other Costs",
        "label": "Other Restructuring Costs",
        "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency [Axis]",
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange (gains) losses, net",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r605",
      "r606",
      "r803"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r391"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r115"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81",
      "r186",
      "r187",
      "r188",
      "r237",
      "r238",
      "r239",
      "r321",
      "r469",
      "r470",
      "r471",
      "r473",
      "r476",
      "r481",
      "r483",
      "r734",
      "r735",
      "r736",
      "r737",
      "r880",
      "r918",
      "r946"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r346",
      "r391"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of roll forward of the changes in goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991"
     ]
    },
    "us-gaap_RestructuringChargesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringChargesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "label": "Restructuring Charges [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r321",
      "r469",
      "r470",
      "r471",
      "r473",
      "r476",
      "r481",
      "r483",
      "r734",
      "r735",
      "r736",
      "r737",
      "r880",
      "r918",
      "r946"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New accounting pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable debt securities",
        "label": "Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable debt securities",
        "verboseLabel": "Fair value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r391",
      "r680",
      "r959"
     ]
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesFairValueLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives [Line Items]",
        "label": "Derivatives, Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product, net",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value $0.0005 per share",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r697",
      "r898"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring, Business Transformation and Other Cost Saving Initiatives",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r413",
      "r416",
      "r422"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "verboseLabel": "Expense",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r417",
      "r419",
      "r994"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ]
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasuryAndGovernmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Government securities",
        "label": "US Treasury and Government [Member]",
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r888",
      "r1042"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r146",
      "r765",
      "r784",
      "r1047",
      "r1048"
     ]
    },
    "us-gaap_ForeignExchangeContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignExchangeContractMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign exchange contract",
        "label": "Foreign Exchange Contract [Member]",
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r888",
      "r897"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r942"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r269",
      "r345"
     ]
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RealizedInvestmentGainsLosses",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Gains) losses on investments, net",
        "label": "Realized Investment Gains (Losses)",
        "documentation": "Amount of realized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r443",
      "r471",
      "r626",
      "r864",
      "r866"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized gains (losses) on securities available for sale, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r251"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Restructuring reserve, beginning",
        "periodEndLabel": "Restructuring reserve, ending",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r418"
     ]
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of fair and carrying value of debt instruments",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r156"
     ]
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExtinguishmentOfDebtAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extinguishment of debt, amount",
        "label": "Extinguishment of Debt, Amount",
        "documentation": "Gross amount of debt extinguished."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unfunded status of postretirement benefit plans",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r18",
      "r46",
      "r934",
      "r935",
      "r936"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r91",
      "r563"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedTranslationAdjustmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation adjustments",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r18",
      "r46",
      "r260",
      "r261",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r934"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r225",
      "r259",
      "r260",
      "r261",
      "r291",
      "r292",
      "r293",
      "r295",
      "r301",
      "r303",
      "r320",
      "r384",
      "r385",
      "r484",
      "r539",
      "r540",
      "r541",
      "r553",
      "r554",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r608",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r622",
      "r727",
      "r728",
      "r729",
      "r742",
      "r806"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Credits and net operating loss utilization",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative contracts",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of assets and liabilities recorded at fair value",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r593"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Components of inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r152",
      "r153",
      "r154"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r842",
      "r904",
      "r1038"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r623",
      "r624",
      "r625",
      "r626",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r783",
      "r785",
      "r811"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r950",
      "r951"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Biogen Idec Inc. shareholders' equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r342",
      "r883",
      "r1008",
      "r1040",
      "r1041"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r278",
      "r468",
      "r470",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r484",
      "r587",
      "r809",
      "r810",
      "r840"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Currencies [Domain]",
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Capitalized share-based compensation costs",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Compensation related to share-based payments",
        "verboseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r542"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r235",
      "r279",
      "r322",
      "r333",
      "r337",
      "r383",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r570",
      "r575",
      "r602",
      "r693",
      "r778",
      "r898",
      "r911",
      "r1003",
      "r1004",
      "r1026"
     ]
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation adjustments",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r18",
      "r46",
      "r259",
      "r935",
      "r936"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax effect",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Litigation",
        "label": "Legal Matters and Contingencies [Text Block]",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OCREVUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "OCREVUSMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OCREVUS",
        "label": "OCREVUS [Member]",
        "documentation": "OCREVUS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of equity interest in Samsung Bioepis",
        "label": "Proceeds from Sale of Equity Method Investments",
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost (in shares)",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r145",
      "r146",
      "r188"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "biib_FLIXABIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "FLIXABIMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FLIXABI",
        "label": "FLIXABI [Member]",
        "documentation": "FLIXABI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": []
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due after five years, amortized cost",
        "label": "Available For Sale Securities Debt Maturities After Five Years Amortized Cost",
        "documentation": "This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cost and expense",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r540",
      "r541",
      "r742",
      "r952",
      "r953",
      "r954",
      "r1017",
      "r1047"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r593",
      "r598"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost (in shares)",
        "terseLabel": "Repurchase of common stock, at cost (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r146",
      "r188"
     ]
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInJointVenture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromDivestitureOfInterestInJointVenture",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from divestiture of interest in joint venture",
        "label": "Proceeds from Divestiture of Interest in Joint Venture",
        "documentation": "The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from marketable debt securities",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of co promotion operating profits first fifty million",
        "label": "Percentage Of Co Promotion Operating Profits First Fifty Million",
        "documentation": "Percentage of co promotion operating profits first fifty million."
       }
      }
     },
     "auth_ref": []
    },
    "biib_DistributorTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "DistributorTwoMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributor Two",
        "label": "Distributor Two [Member]",
        "documentation": "Distributor two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of assets and liabilities recorded at fair value",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost and expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r415",
      "r419",
      "r420",
      "r421"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r419",
      "r420"
     ]
    },
    "biib_BardoxoloneSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "BardoxoloneSecuritiesMember",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bardoxolone Securities",
        "label": "Bardoxolone Securities [Member]",
        "documentation": "Bardoxolone Securities"
       }
      }
     },
     "auth_ref": []
    },
    "biib_RoyaltyAttributedToOCREVUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "RoyaltyAttributedToOCREVUSMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Attributed To OCREVUS",
        "label": "Royalty Attributed To OCREVUS [Member]",
        "documentation": "Royalty Attributed To OCREVUS"
       }
      }
     },
     "auth_ref": []
    },
    "biib_InventoryNetCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "InventoryNetCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventory",
        "terseLabel": "Inventory",
        "label": "Inventory, Net Current and Noncurrent",
        "documentation": "Inventory, Net Current and Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfOtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of strategic investments",
        "label": "Proceeds from Sale of Other Investments",
        "documentation": "Amount of cash inflow from the sale of investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "biib_UnrealizedGainOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "UnrealizedGainOnDerivatives",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gain on Derivatives",
        "label": "Unrealized Gain on Derivatives",
        "documentation": "Unrealized Gain on Derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales price",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Realized losses",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "biib_AdministrativeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "AdministrativeSpaceMember",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Administrative Space",
        "label": "Administrative Space [Member]",
        "documentation": "Administrative Space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax liability",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546",
      "r694"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "biib_BYOOVIZMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "BYOOVIZMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BYOOVIZ",
        "label": "BYOOVIZ [Member]",
        "documentation": "BYOOVIZ"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CentersForMedicareAndMedicaidServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "CentersForMedicareAndMedicaidServiceMember",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Centers for Medicare and Medicaid Service",
        "label": "Centers for Medicare and Medicaid Service [Member]",
        "documentation": "Centers for Medicare and Medicaid Service"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock award plan",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r43",
      "r188"
     ]
    },
    "biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Limit of gross sale of GAZYVA to be achieved in any 12 months under option one",
        "label": "Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One",
        "documentation": "Threshold of gross sales to be achieved in any twelve consecutive months under option one."
       }
      }
     },
     "auth_ref": []
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "documentation": "Revenues from anti-cd20 therapeutic programs"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r570",
      "r571",
      "r575",
      "r576",
      "r627",
      "r853",
      "r1002",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "parentTag": "biib_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r861"
     ]
    },
    "biib_ADUHELMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ADUHELMMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADUHELM",
        "label": "ADUHELM [Member]",
        "documentation": "ADUHELM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "parentTag": "biib_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Work in process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r862"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r570",
      "r571",
      "r575",
      "r576",
      "r627",
      "r853",
      "r1002",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r419",
      "r420"
     ]
    },
    "biib_InterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "InterestInSubsidiary",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest in subsidiary (less than given percentage)",
        "label": "Interest In Subsidiary",
        "documentation": "Interest in subsidiary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance Costs",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "parentTag": "biib_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r863"
     ]
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignExchangeForwardMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Exchange Forward",
        "label": "Foreign Exchange Forward [Member]",
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r776",
      "r781",
      "r795",
      "r801",
      "r825",
      "r826",
      "r827",
      "r903"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r65",
      "r665"
     ]
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Related Costs",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r71",
      "r72"
     ]
    },
    "biib_EquitySecuritiesCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "EquitySecuritiesCurrentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities, Current",
        "label": "Equity Securities, Current [Member]",
        "documentation": "Equity Securities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive income:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r339",
      "r664",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r856",
      "r881",
      "r899",
      "r923",
      "r1000",
      "r1001",
      "r1008",
      "r1040"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive income (loss), net of tax",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r17",
      "r196",
      "r255",
      "r258"
     ]
    },
    "biib_ContractManufacturingAndOtherRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ContractManufacturingAndOtherRevenueMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract manufacturing revenue",
        "label": "Contract manufacturing and other revenue [Member]",
        "documentation": "Other corporate revenues [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "biib_EquitySecuritiesNonCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "EquitySecuritiesNonCurrentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities, Non-Current",
        "label": "Equity Securities, Non-Current [Member]",
        "documentation": "Equity Securities, Non-Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty and other revenue",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "biib_ShareOfNetProfitFromSageTherapeuticsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ShareOfNetProfitFromSageTherapeuticsPercent",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of net profit from sage therapeutics, Percent",
        "label": "Share Of Net Profit From Sage Therapeutics, Percent",
        "documentation": "Share Of Net Profit From Sage Therapeutics, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TrademarksAndTradeNamesMember",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trademarks and Trade Names",
        "label": "Trademarks and Trade Names [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r43",
      "r225",
      "r259",
      "r260",
      "r261",
      "r291",
      "r292",
      "r293",
      "r295",
      "r301",
      "r303",
      "r320",
      "r384",
      "r385",
      "r484",
      "r539",
      "r540",
      "r541",
      "r553",
      "r554",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r608",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r622",
      "r727",
      "r728",
      "r729",
      "r742",
      "r806"
     ]
    },
    "biib_A2023And2022CostSavingInitiativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "A2023And2022CostSavingInitiativesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 and 2022 Cost Saving Initiatives",
        "label": "2023 and 2022 Cost Saving Initiatives [Member]",
        "documentation": "2023 and 2022 Cost Saving Initiatives"
       }
      }
     },
     "auth_ref": []
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "documentation": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r339",
      "r664",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r856",
      "r881",
      "r899",
      "r923",
      "r1000",
      "r1001",
      "r1008",
      "r1040"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Revenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r494"
     ]
    },
    "biib_GainLossOnRestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "GainLossOnRestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain due to lease termination",
        "label": "Gain (Loss) On Restructuring Charges",
        "documentation": "Gain (Loss) On Restructuring Charges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r291",
      "r292",
      "r293",
      "r295",
      "r301",
      "r303",
      "r384",
      "r385",
      "r539",
      "r540",
      "r541",
      "r553",
      "r554",
      "r580",
      "r582",
      "r583",
      "r585",
      "r588",
      "r727",
      "r729",
      "r742",
      "r1047"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r18",
      "r46",
      "r581",
      "r584",
      "r622",
      "r727",
      "r728",
      "r934",
      "r935",
      "r936",
      "r952",
      "r953",
      "r954"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Component of accrued expenses and other",
        "label": "Other Current Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains (losses) on securities available for sale",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r252",
      "r260",
      "r261",
      "r934"
     ]
    },
    "biib_CorporateDebtSecuritiesCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "CorporateDebtSecuritiesCurrentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Corporate debt securities Current",
        "label": "Corporate Debt Securities Current [Member]",
        "documentation": "Corporate debt securities Current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent assets",
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r91"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under award plan, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r145",
      "r146",
      "r188",
      "r516"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r207",
      "r262",
      "r326",
      "r616",
      "r790",
      "r909",
      "r1046"
     ]
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r415",
      "r419",
      "r420",
      "r421"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r74"
     ]
    },
    "biib_ExpenseIncurredByCollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ExpenseIncurredByCollaboration",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total development expense incurred by the collaboration related to the advancement of LEQEMBI",
        "label": "Expense Incurred By Collaboration",
        "documentation": "Total expense incurred by collaboration."
       }
      }
     },
     "auth_ref": []
    },
    "biib_A2.25SeniorNotesdueMay12030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "A2.25SeniorNotesdueMay12030Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.250% Senior Notes due May 1, 2030",
        "label": "2.25% Senior Notes due May 1, 2030 [Member]",
        "documentation": "2.25% Senior Notes due May 1, 2030 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total transaction value",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r565"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r192",
      "r221",
      "r557",
      "r558",
      "r949"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341",
      "r746",
      "r750",
      "r752",
      "r814",
      "r816",
      "r820",
      "r834",
      "r841",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r857",
      "r882",
      "r903",
      "r1008",
      "r1040"
     ]
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of revenues from major distributors",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "documentation": "Entity wide percentage of revenue from major distributors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable equity securities",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After Second GAZYVA Threshold Date",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three",
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option two sub option three."
       }
      }
     },
     "auth_ref": []
    },
    "biib_RoyaltiesClaimed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "RoyaltiesClaimed",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties Claimed",
        "label": "Royalties Claimed",
        "documentation": "Royalties Claimed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets acquired and liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in Variable Interest Entities [Abstract]",
        "label": "Investments in Variable Interest Entities [Abstract]",
        "documentation": "Investments In Variable Interest Entities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable debt and equity securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r974"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Royalties and licensing fees",
        "label": "Accrued Royalties, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r860"
     ]
    },
    "biib_CollaborativeArrangementProfitLossSharingComponentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "CollaborativeArrangementProfitLossSharingComponentsDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Profit (Loss) Sharing Components [Domain]",
        "label": "Collaborative Arrangement, Profit (Loss) Sharing Components [Domain]",
        "documentation": "Collaborative Arrangement, Profit (Loss) Sharing Components"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r943"
     ]
    },
    "biib_ContingentCommercializedRightsNumberOfProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ContingentCommercializedRightsNumberOfProducts",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Commercialized Rights, Number Of Products",
        "label": "Contingent Commercialized Rights, Number Of Products",
        "documentation": "Contingent Commercialized Rights, Number Of Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected number of positions eliminated",
        "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated",
        "documentation": "The expected number of positions to be eliminated as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "biib_BiosimilarsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "BiosimilarsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biosimilars",
        "label": "Biosimilars [Member]",
        "documentation": "Biosimilars"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted earnings (loss) per share attributable to Biogen Inc.",
        "totalLabel": "Shares used in calculating diluted earnings per share",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r315"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Dilutive potential common shares",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r593",
      "r598"
     ]
    },
    "currency_JPY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "JPY",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Japan, Yen",
        "label": "Japan, Yen"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OutLicensedPatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "OutLicensedPatentsMember",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Completed technology",
        "label": "Out Licensed Patents [Member]",
        "documentation": "Out-licensed patents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AverageMaturityOfMarketableSecurities": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "AverageMaturityOfMarketableSecurities",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Average maturity of marketable securities, months",
        "label": "Average Maturity Of Marketable Securities",
        "documentation": "Average remaining time to maturity of marketable debt securities, available-for-sale securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic earnings (loss) per share attributable to Biogen Inc.",
        "terseLabel": "Weighted average number of common shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r315"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r229",
      "r279",
      "r383",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r571",
      "r575",
      "r576",
      "r602",
      "r898",
      "r1003",
      "r1026",
      "r1027"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341",
      "r746",
      "r750",
      "r752",
      "r814",
      "r816",
      "r820",
      "r834",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r857",
      "r882",
      "r903",
      "r1008",
      "r1040"
     ]
    },
    "biib_BENEPALIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "BENEPALIMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BENEPALI",
        "label": "BENEPALI [Member]",
        "documentation": "BENEPALI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Tenant Allowance",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Tenant Allowance",
        "documentation": "Gain (Loss) on Disposition of Property Plant Equipment, Tenant Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageoffuturedevelopmentcostsrelatedtoEisai": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PercentageoffuturedevelopmentcostsrelatedtoEisai",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of future development costs related to Eisai",
        "label": "Percentage of future development costs related to Eisai",
        "documentation": "Percentage of future development costs related to Eisai"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r320",
      "r664",
      "r733",
      "r743",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r765",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r774",
      "r775",
      "r776",
      "r777",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r785",
      "r787",
      "r788",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r806",
      "r904"
     ]
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.200% Senior Notes due 2045",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AccruedPaymentToTerminationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "AccruedPaymentToTerminationAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payable Due To Termination Agreement",
        "label": "Accrued Payment To Termination Agreement",
        "documentation": "Accrued Payment To Termination Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SPINRAZAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "SPINRAZAMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SPINRAZA",
        "label": "SPINRAZA [Member]",
        "documentation": "SPINRAZA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income (expense), net",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "biib_OtherrevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "OtherrevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues [Abstract]",
        "label": "Other revenues [Abstract]",
        "documentation": "Other revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r496",
      "r501",
      "r593",
      "r633",
      "r876",
      "r877",
      "r888",
      "r889",
      "r890"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated future amortization for acquired intangible assets",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r496",
      "r501",
      "r593",
      "r632",
      "r888",
      "r889",
      "r890"
     ]
    },
    "biib_InventoryIdleCapacityChargesAndContractualCommitmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "InventoryIdleCapacityChargesAndContractualCommitmentsMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Idle Capacity Charges And Contractual Commitments",
        "label": "Inventory, Idle Capacity Charges And Contractual Commitments [Member]",
        "documentation": "Inventory, Idle Capacity Charges And Contractual Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total reserves included in consolidated balance sheets",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets."
       }
      }
     },
     "auth_ref": []
    },
    "biib_Collaborationprofitlosssharing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "Collaborationprofitlosssharing",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration profit sharing/(loss reimbursement)",
        "label": "Collaboration profit (loss) sharing",
        "documentation": "Collaboration profit (loss) sharing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gains",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Unobservable Inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r593",
      "r634",
      "r876",
      "r877",
      "r888",
      "r889",
      "r890"
     ]
    },
    "biib_TheCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "TheCreditFacilityMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Credit Facility",
        "label": "The Credit Facility [Member]",
        "documentation": "The Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic and diluted earnings per share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "biib_Reductioninroyaltyrate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "Reductioninroyaltyrate",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in royalty rate",
        "label": "Reduction in royalty rate",
        "documentation": "Reduction in royalty rate"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of stake in entity",
        "label": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "documentation": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesReturnsAndAllowancesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Returns",
        "label": "Sales Returns and Allowances [Member]",
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HedgingDesignationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingDesignationDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Domain]",
        "label": "Hedging Designation [Domain]",
        "documentation": "Designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "MortgageAndOtherAssetBackedSecuritiesCurrentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Mortgage and other asset backed securities Current",
        "label": "Mortgage And Other Asset Backed Securities Current [Member]",
        "documentation": "Mortgage and other asset backed securities Current."
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "BusinessOverviewPolicyTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Overview",
        "label": "Business Overview [Policy Text Block]",
        "documentation": "Describes an overview of the company and its operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense asset acquired",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r543",
      "r1034"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "biib_FacilityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "FacilityTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Type [Domain]",
        "label": "Facility Type [Domain]",
        "documentation": "Facility Type"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment, Amount Sold",
        "label": "Equity Method Investment, Amount Sold",
        "documentation": "Amount of the entity's equity method investment which has been sold."
       }
      }
     },
     "auth_ref": []
    },
    "biib_OtherAssetsCurrentFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "OtherAssetsCurrentFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets, receivable",
        "label": "Other Assets, Current, Fair Value Disclosure,",
        "documentation": "Other Assets, Current, Fair Value Disclosure,"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations [Abstract]",
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Related to Denali Therapeutics Collaboration",
        "label": "Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]",
        "documentation": "Summary of Activity Related to Denali Therapeutics Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excess and obsolescence charges related to inventory",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "biib_A125BroadwayBuildingSaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "A125BroadwayBuildingSaleMember",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "125 Broadway Building Sale",
        "label": "125 Broadway Building Sale [Member]",
        "documentation": "125 Broadway Building Sale"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "SamsungBiosimilarAgreementMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Samsung Bioepis",
        "label": "Samsung Biosimilar Agreement [Member]",
        "documentation": "Samsung bio-similar agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "biib_SKYCLARYSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "SKYCLARYSMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Completed technology for SKYCLARYS (U.S.)",
        "label": "SKYCLARYS [Member]",
        "documentation": "SKYCLARYS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, unrecognized tax benefit",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PriorityReviewVoucherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PriorityReviewVoucherMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Priority review voucher",
        "label": "Priority Review Voucher [Member]",
        "documentation": "Priority Review Voucher"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OperatingLeaseRightOfUseAssetDerecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "OperatingLeaseRightOfUseAssetDerecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets derecognized",
        "label": "Operating Lease, Right-Of-Use Asset, Derecognized",
        "documentation": "Operating Lease, Right-Of-Use Asset, Derecognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PeriodOfCollaborationAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PeriodOfCollaborationAgreement",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement term",
        "label": "Period Of Collaboration Agreement",
        "documentation": "Period Of Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring",
        "verboseLabel": "Fair Value, Measurements Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r599"
     ]
    },
    "biib_ERISAClassActionLitigaitonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ERISAClassActionLitigaitonMember",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ERISA Class Action Litigaiton",
        "label": "ERISA Class Action Litigaiton [Member]",
        "documentation": "ERISA Class Action Litigaiton"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PayablesToDivestitureOfInterestInJointVenture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PayablesToDivestitureOfInterestInJointVenture",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables to divestiture of interest in joint venture",
        "label": "Payables To Divestiture Of Interest In Joint Venture",
        "documentation": "Payables To Divestiture Of Interest In Joint Venture"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TysabriProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "TysabriProductMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TYSABRI",
        "label": "TYSABRI product [Member]",
        "documentation": "TYSABRI product [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains (losses) on net investment hedges, net of tax",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity."
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "biib_VUMERITYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "VUMERITYMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VUMERITY",
        "label": "VUMERITY [Member]",
        "documentation": "VUMERITY"
       }
      }
     },
     "auth_ref": []
    },
    "biib_MarketStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "MarketStockUnitsMember",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Market stock units",
        "label": "Market Stock Units [Member]",
        "documentation": "Market stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r593",
      "r632",
      "r633",
      "r634",
      "r876",
      "r877",
      "r888",
      "r889",
      "r890"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value of contingent consideration obligations",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r123"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r320",
      "r664",
      "r733",
      "r743",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r765",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r774",
      "r775",
      "r776",
      "r777",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r785",
      "r787",
      "r788",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r806",
      "r904"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "biib_FacilityLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "FacilityLocationAxis",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Location [Axis]",
        "label": "Facility Location [Axis]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
        "negatedTerseLabel": "Contingent consideration",
        "terseLabel": "Contingent consideration impairment",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated impairment losses related to goodwill",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r401",
      "r874"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expense and other",
        "terseLabel": "Total accrued expense and other",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r898"
     ]
    },
    "biib_OperatingLeaseLiabilityDerecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "OperatingLeaseLiabilityDerecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities derecognized",
        "label": "Operating Lease, Liability, Derecognized",
        "documentation": "Operating Lease, Liability, Derecognized"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessAcquisitionNumberOfCommonStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "BusinessAcquisitionNumberOfCommonStockSharesAcquired",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common stock shares acquired",
        "label": "Business Acquisition, Number of Common Stock Shares Acquired",
        "documentation": "Business Acquisition, Number of Common Stock Shares Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r593",
      "r595",
      "r596",
      "r599"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "biib_ReserveforCashDiscountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ReserveforCashDiscountsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discounts",
        "label": "Reserve for Cash Discounts [Member]",
        "documentation": "Reserve for Cash Discounts [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r902",
      "r905",
      "r906",
      "r907",
      "r908",
      "r1043",
      "r1047"
     ]
    },
    "biib_MSProductRevenuesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "MSProductRevenuesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MS Product Revenues",
        "label": "MS Product Revenues [Member]",
        "documentation": "MS Product Revenues [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four",
        "documentation": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four"
       }
      }
     },
     "auth_ref": []
    },
    "biib_NoncontrollingInterestCapitalContribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "NoncontrollingInterestCapitalContribution",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital contribution from noncontrolling interest",
        "label": "Noncontrolling Interest, Capital Contribution",
        "documentation": "Noncontrolling Interest, Capital Contribution"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains (losses) on cash flow hedges, net of tax",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r251"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "biib_UnrealizedLossOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "UnrealizedLossOnDerivatives",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Loss on Derivatives",
        "label": "Unrealized Loss on Derivatives",
        "documentation": "Unrealized Loss on Derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Fair Value Disclosure",
        "label": "Debt Instrument, Fair Value Disclosure",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r601",
      "r876",
      "r877"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains (losses) on cash flow hedges",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r260",
      "r261",
      "r574",
      "r867",
      "r934"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r127",
      "r440",
      "r617",
      "r876",
      "r877"
     ]
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Mortgage and other asset backed securities",
        "label": "Asset-Backed Securities [Member]",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r967",
      "r972",
      "r973"
     ]
    },
    "biib_LEQEMBICollaborationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "LEQEMBICollaborationMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEQEMBI Collaboration",
        "label": "LEQEMBI Collaboration [Member]",
        "documentation": "LEQEMBI Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillOtherIncreaseDecrease",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Goodwill, Other Increase (Decrease)",
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party, Type [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r623",
      "r624",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r783",
      "r785",
      "r811"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "biib_DebtInstrumentRedemptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "DebtInstrumentRedemptionRate",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption rate",
        "label": "Debt Instrument, Redemption Rate",
        "documentation": "Debt Instrument, Redemption Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangements and non-collaborative arrangement transactions",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "biib_A2023CostSavingInitiativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "A2023CostSavingInitiativesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Cost Saving Initiatives",
        "label": "2023 Cost Saving Initiatives [Member]",
        "documentation": "2023 Cost Saving Initiatives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r251",
      "r253"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), before reclassifications, net of tax",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r46",
      "r260",
      "r608",
      "r611",
      "r614",
      "r934"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "biib_Collaborationexpensesaccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "Collaborationexpensesaccrual",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration expense",
        "label": "Collaboration expenses accrual",
        "documentation": "Collaboration expenses accrual"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts reclassified from accumulated other comprehensive income, net of tax",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r46",
      "r260",
      "r608",
      "r613",
      "r614",
      "r934"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": []
    },
    "biib_AVONEXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "AVONEXMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AVONEX",
        "label": "AVONEX [Member]",
        "documentation": "AVONEX"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset impairment charges",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r66"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative contracts",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r601",
      "r744",
      "r745",
      "r746",
      "r748",
      "r749",
      "r751",
      "r752",
      "r753",
      "r755",
      "r756",
      "r771",
      "r772",
      "r821",
      "r823",
      "r827",
      "r828",
      "r829",
      "r830",
      "r866",
      "r903",
      "r1044"
     ]
    },
    "biib_A3250SeniorNotesDueFebruary152051Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "A3250SeniorNotesDueFebruary152051Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.250% Senior Notes, Due February 15, 2051",
        "label": "3.250% Senior Notes, Due February 15, 2051 [Member]",
        "documentation": "3.250% Senior Notes, Due February 15, 2051"
       }
      }
     },
     "auth_ref": []
    },
    "biib_NumberOfWholesalers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "NumberOfWholesalers",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of wholesalers",
        "label": "Number of Wholesalers",
        "documentation": "Number of Wholesalers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "125 Broadway Building",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CoPromotionProfitSharingFormulaTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "CoPromotionProfitSharingFormulaTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Co-promotion profit sharing formula",
        "label": "Co Promotion Profit Sharing Formula [Table Text Block]",
        "documentation": "Co-promotion profit sharing formula."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected future amortization expense, 2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "biib_ShareOfNonControlingInterestRecognized": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ShareOfNonControlingInterestRecognized",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of non-controling interest recognized",
        "label": "Share Of Non-Controling Interest Recognized",
        "documentation": "Share Of Non-Controling Interest Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected future amortization expense, 2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due after five years, estimated fair value",
        "label": "Available For Sale Securities Debt Maturities After Five Years Fair Value",
        "documentation": "This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected future amortization expense, 2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Equity in (income) loss of investee, net of tax",
        "label": "Income (Loss) from Equity Method Investments, Net of Tax",
        "documentation": "Income (Loss) from Equity Method Investments, Net of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected future amortization expense, 2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill resulting from Reata acquisition",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r874"
     ]
    },
    "biib_OperatingLeaseArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "OperatingLeaseArea",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Area",
        "label": "Operating Lease Area",
        "documentation": "Operating Lease Area"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected future amortization expense, 2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected future amortization expense, 2023 (remaining three months)",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "biib_DerivativeMaturityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "DerivativeMaturityDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Maturity [Domain]",
        "label": "Derivative Maturity [Domain]",
        "documentation": "[Domain] for Derivative Maturity [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on derivative used in net investment hedge",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r464",
      "r481",
      "r586",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r709",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r974",
      "r975",
      "r976",
      "r977"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of treasury stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior notes interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r441"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AdditionalMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "AdditionalMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional milestone payment",
        "label": "Additional Milestone Payment",
        "documentation": "Additional milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative Instruments",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r579",
      "r586"
     ]
    },
    "biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "DerivativeInstrumentsUnrealizedGainLossTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments, Unrealized Gain (Loss)",
        "label": "Derivative Instruments, Unrealized Gain (Loss) [Table Text Block]",
        "documentation": "Derivative Instruments, Unrealized Gain (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "biib_A2020ShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "A2020ShareRepurchaseProgramMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Share Repurchase Program",
        "label": "2020 Share Repurchase Program [Member]",
        "documentation": "2020 Share Repurchase Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_MosunetuzumabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "MosunetuzumabMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mosunetuzumab",
        "label": "Mosunetuzumab [Member]",
        "documentation": "Mosunetuzumab"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Gain) loss on equity method investments",
        "terseLabel": "(Gain) loss on equity method investments",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r157",
      "r205",
      "r328",
      "r379",
      "r704"
     ]
    },
    "biib_DivestituresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "DivestituresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Divestitures [Abstract]",
        "label": "Divestitures [Abstract]",
        "documentation": "Divestitures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CollaborativeArrangementProfitLossSharingComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "CollaborativeArrangementProfitLossSharingComponentsAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Profit (Loss) Sharing Components [Axis]",
        "label": "Collaborative Arrangement, Profit (Loss) Sharing Components [Axis]",
        "documentation": "Collaborative Arrangement, Profit (Loss) Sharing Components"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r91",
      "r563",
      "r891",
      "r892"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r285",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r617",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r947"
     ]
    },
    "biib_FUMADERMAndADUHELMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "FUMADERMAndADUHELMMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FUMADERM And ADUHELM",
        "label": "FUMADERM And ADUHELM [Member]",
        "documentation": "FUMADERM And ADUHELM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r891",
      "r892"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Biogen Inc. shareholders\u2019 equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r149",
      "r150",
      "r171",
      "r767",
      "r784",
      "r807",
      "r808",
      "r898",
      "r911",
      "r948",
      "r980",
      "r1019",
      "r1047"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (gains) losses recognized on equity securities",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r978"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r167"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rates",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable equity securities",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Remaining Lease Term",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_InterestIncomeExpenseNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNetAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Income (Expense), Net",
        "label": "Interest Income (Expense), Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and Equipment",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DilutiveSecuritiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Effect of dilutive securities:",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r600",
      "r859"
     ]
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract manufacturing, royalty and other revenue",
        "label": "Product and Service, Other [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r167",
      "r275"
     ]
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeRemainingMaturity1",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Range of durations of foreign currency forward contracts",
        "label": "Derivative, Remaining Maturity",
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration expected to be received for sale of Denmark Manufacturing Operations",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes payable, fair value",
        "label": "Notes Payable, Fair Value Disclosure",
        "documentation": "Fair value portion of notes payable."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiCost",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Equity Securities, FV-NI, Cost",
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationships"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaborative and Other Relationships",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r212",
      "r224"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net unrealized (gains) losses recognized on equity securities",
        "terseLabel": "Net gains recognized on the increase in fair value of equity securities",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r716",
      "r978"
     ]
    },
    "us-gaap_InventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, noncurrent",
        "label": "Inventory, Noncurrent",
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains (losses) on net investment hedge",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r252",
      "r259",
      "r935",
      "r936"
     ]
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative contracts",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Less: Net (gains) losses realized on equity securities",
        "terseLabel": "Net gains (losses) realized during the period on equity securities",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r978"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Gain) loss on strategic investments",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r272"
     ]
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net gains recognized on the decrease in fair value of equity securities",
        "label": "Equity Securities, FV-NI, Unrealized Gain",
        "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r404",
      "r405",
      "r407",
      "r665",
      "r666"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r65"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiGainLossAlternativeAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]",
        "label": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r902",
      "r903",
      "r905",
      "r906",
      "r907",
      "r908",
      "r952",
      "r953",
      "r1017",
      "r1043",
      "r1047"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r1037"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, net",
        "totalLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r64"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intangible assets, gross",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r214",
      "r219",
      "r220"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from borrowings, net",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r734"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets",
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r665"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Goodwill",
        "terseLabel": "Goodwill",
        "periodStartLabel": "Goodwill, beginning of period",
        "periodEndLabel": "Goodwill, end of period",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r397",
      "r679",
      "r874",
      "r898",
      "r982",
      "r989"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r666"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sales and maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r632",
      "r633",
      "r634",
      "r876",
      "r877",
      "r888",
      "r889",
      "r890"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents",
        "label": "Cash Equivalents, at Carrying Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost and Net",
        "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r426",
      "r427",
      "r495",
      "r503",
      "r530",
      "r531",
      "r532",
      "r635",
      "r662",
      "r726",
      "r755",
      "r756",
      "r813",
      "r815",
      "r817",
      "r818",
      "r833",
      "r854",
      "r855",
      "r872",
      "r880",
      "r893",
      "r900",
      "r903",
      "r993",
      "r1007",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based Compensation Expense included in consolidated statements of income",
        "label": "Share-Based Payment Arrangement, Recognized Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromPaymentsToMinorityShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromPaymentsToMinorityShareholders",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (distribution) contribution to noncontrolling interest",
        "label": "Proceeds from (Payments to) Noncontrolling Interests",
        "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r290"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r426",
      "r427",
      "r503",
      "r662",
      "r726",
      "r755",
      "r756",
      "r813",
      "r815",
      "r817",
      "r818",
      "r833",
      "r854",
      "r855",
      "r872",
      "r880",
      "r893",
      "r900",
      "r1007",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r290"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r426",
      "r427",
      "r495",
      "r503",
      "r530",
      "r531",
      "r532",
      "r635",
      "r662",
      "r726",
      "r755",
      "r756",
      "r813",
      "r815",
      "r817",
      "r818",
      "r833",
      "r854",
      "r855",
      "r872",
      "r880",
      "r893",
      "r900",
      "r903",
      "r993",
      "r1007",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss) attributable to Biogen Inc.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r256",
      "r258",
      "r267",
      "r685",
      "r712"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r426",
      "r427",
      "r503",
      "r662",
      "r726",
      "r755",
      "r756",
      "r813",
      "r815",
      "r817",
      "r818",
      "r833",
      "r854",
      "r855",
      "r872",
      "r880",
      "r893",
      "r900",
      "r1007",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Line Items]",
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r756",
      "r770",
      "r771",
      "r772",
      "r774",
      "r775",
      "r776",
      "r777",
      "r779",
      "r780",
      "r781",
      "r782",
      "r793",
      "r794",
      "r795",
      "r796",
      "r799",
      "r800",
      "r801",
      "r802",
      "r821",
      "r822",
      "r827",
      "r829",
      "r901",
      "r903"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration expense",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Brazil tax assessment, including interest and penalties",
        "label": "Loss Contingency, Damages Sought, Value",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r997",
      "r998",
      "r999"
     ]
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other",
        "label": "Accrued Liabilities [Member]",
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationGiltiPercent",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GILTI",
        "label": "Effective Income Tax Rate Reconciliation, GILTI, Percent",
        "documentation": "Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)."
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DesignatedAsHedgingInstrumentMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Designated as hedging instrument",
        "label": "Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r414",
      "r789"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r789"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r188",
      "r699",
      "r730",
      "r732",
      "r738",
      "r766",
      "r898"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r628"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues by product",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r112",
      "r120"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r1035"
     ]
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r82",
      "r146"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of fair value and presentation of derivatives",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r898"
     ]
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Abstract]",
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_ConstructionInProgressGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressGross",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress, Gross",
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandMember",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) attributable to Biogen Inc.",
        "terseLabel": "Net income (loss) attributable to Biogen Inc.",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r169",
      "r206",
      "r227",
      "r254",
      "r257",
      "r261",
      "r279",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r302",
      "r303",
      "r312",
      "r322",
      "r332",
      "r336",
      "r338",
      "r383",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r590",
      "r602",
      "r707",
      "r786",
      "r804",
      "r805",
      "r871",
      "r909",
      "r1003"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued Expenses and Other",
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r544",
      "r549",
      "r550",
      "r552",
      "r555",
      "r560",
      "r561",
      "r562",
      "r739"
     ]
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expense",
        "label": "Operating Expense [Member]",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887"
     ]
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepurchaseAgreementsMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Overnight reverse repurchase agreements",
        "label": "Repurchase Agreements [Member]",
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term certificates of deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r905",
      "r906",
      "r907",
      "r908"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r504",
      "r955"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r197",
      "r254",
      "r257",
      "r302",
      "r303",
      "r706",
      "r936"
     ]
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r304",
      "r504",
      "r919",
      "r920",
      "r955"
     ]
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity [Line Items]",
        "label": "Variable Interest Entity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r571",
      "r575",
      "r576",
      "r643",
      "r644",
      "r645"
     ]
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued income taxes",
        "label": "Accrued Income Taxes, Noncurrent",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r201"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r898"
     ]
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Variable Interest Entities [Table]",
        "label": "Schedule of Variable Interest Entities [Table]",
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r570",
      "r571",
      "r575",
      "r576",
      "r643",
      "r644",
      "r645"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r868"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average shares used in calculating:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r304",
      "r504",
      "r919",
      "r955"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities and sales",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r960"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_SalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Sales [Member]",
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r196",
      "r256",
      "r258",
      "r265",
      "r683",
      "r710"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r892"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_NondesignatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NondesignatedMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not designated as hedging instrument",
        "label": "Not Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r98",
      "r107",
      "r256",
      "r258",
      "r266",
      "r684",
      "r711"
     ]
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetInvestmentHedgingMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Investment Hedging",
        "label": "Net Investment Hedging [Member]",
        "documentation": "Hedges of a net investment in a foreign operation."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted earnings (loss) per share attributable to Biogen Inc.",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r308",
      "r313",
      "r314",
      "r315",
      "r319",
      "r589",
      "r590",
      "r686",
      "r713",
      "r869"
     ]
    },
    "biib_TheCreditFacilityTerminatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "TheCreditFacilityTerminatedMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Credit Facility, Terminated",
        "label": "The Credit Facility, Terminated [Member]",
        "documentation": "The Credit Facility, Terminated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r325"
     ]
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenseAndOther",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accrued expense and other",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued expense And Other",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued expense And Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r892"
     ]
    },
    "biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "EffectiveTaxRateReconciliationSaleOfSamsungBioepis",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Sale of Samsung Bioepis",
        "label": "Effective Tax Rate Reconciliation, Sale Of Samsung Bioepis",
        "documentation": "Effective Tax Rate Reconciliation, Sale Of Samsung Bioepis"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EffectiveTaxRateReconciliationInternationalReorganization": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "EffectiveTaxRateReconciliationInternationalReorganization",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International reorganization",
        "label": "Effective Tax Rate Reconciliation, International Reorganization",
        "documentation": "Effective Tax Rate Reconciliation, International Reorganization"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OtherAssetsMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "OtherAssetsMeasurementInput",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-adjusted discount rates",
        "label": "Other Assets, Measurement Input",
        "documentation": "Other Assets, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of activity related to the UCB collaboration",
        "label": "Summary of Activity Related to the UCB Collaboration [Table Text Block]",
        "documentation": "Summary of Activity Related to the UCB Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Dispositions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dispositions",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r177"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "biib_A3.15SeniorNotesdueMay12050Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "A3.15SeniorNotesdueMay12050Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.150% Senior Notes due May 1, 2050",
        "label": "3.15% Senior Notes due May 1, 2050 [Member]",
        "documentation": "3.15% Senior Notes due May 1, 2050 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r24",
      "r29",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r179"
     ]
    },
    "biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "FairValueIndefiniteLivedIntangibleAssetsDiscountRate",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Indefinite Lived Intangible Assets Discount Rate",
        "label": "Fair Value Indefinite Lived Intangible Assets Discount Rate",
        "documentation": "Fair Value Indefinite Lived Intangible Assets Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected operating expense reduction",
        "label": "Restructuring And Related Activities, Expected Operating Expense Reduction",
        "documentation": "Restructuring And Related Activities, Expected Operating Expense Reduction"
       }
      }
     },
     "auth_ref": []
    },
    "biib_IonisSangamoDenaliAndSageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "IonisSangamoDenaliAndSageMember",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ionis, Sangamo, Denali and Sage",
        "label": "Ionis, Sangamo, Denali and Sage [Member]",
        "documentation": "Ionis, Sangamo, Denali and Sage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HedgingRelationshipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingRelationshipDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Domain]",
        "label": "Hedging Relationship [Domain]",
        "documentation": "Nature or intent of a hedge."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r628"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Noncontrolling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r203",
      "r279",
      "r383",
      "r430",
      "r432",
      "r433",
      "r434",
      "r437",
      "r438",
      "r602",
      "r700",
      "r767"
     ]
    },
    "biib_IMRALDIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "IMRALDIMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IMRALDI",
        "label": "IMRALDI [Member]",
        "documentation": "IMRALDI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r484",
      "r952",
      "r953",
      "r954",
      "r1047"
     ]
    },
    "biib_WarehouseUtilitiesAndSupportSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "WarehouseUtilitiesAndSupportSpaceMember",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warehouse, Utilities and Support Space",
        "label": "Warehouse, Utilities and Support Space [Member]",
        "documentation": "Warehouse, Utilities and Support Space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r105",
      "r225",
      "r226",
      "r260",
      "r291",
      "r292",
      "r293",
      "r295",
      "r301",
      "r384",
      "r385",
      "r484",
      "r539",
      "r540",
      "r541",
      "r553",
      "r554",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r608",
      "r610",
      "r614",
      "r622",
      "r728",
      "r729",
      "r740",
      "r767",
      "r784",
      "r807",
      "r808",
      "r839",
      "r910",
      "r948",
      "r980",
      "r1019",
      "r1047"
     ]
    },
    "biib_BIIB054Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "BIIB054Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BIIB054",
        "label": "BIIB054 [Member]",
        "documentation": "BIIB054"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CorporateDebtSecuritiesNonCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "CorporateDebtSecuritiesNonCurrentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Corporate debt securities Non-current",
        "label": "Corporate Debt Securities Non Current [Member]",
        "documentation": "Corporate Debt Securities Non Current."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ShareOfNetProfitFromSageTherapeuticsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ShareOfNetProfitFromSageTherapeuticsAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of net profit from sage therapeutics",
        "label": "Share Of Net Profit From Sage Therapeutics, Amount",
        "documentation": "Share Of Net Profit From Sage Therapeutics, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "AmortizationAndImpairmentOfAcquiredIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization and impairment of acquired intangible assets",
        "label": "Amortization and Impairment of Acquired Intangible Assets",
        "documentation": "Amortization and Impairment of Acquired Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "biib_EisaiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "EisaiMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eisai",
        "label": "Eisai [Member]",
        "documentation": "Eisai [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on sale of equity interest in Samsung Bioepis",
        "label": "Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee",
        "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r681",
      "r939",
      "r940",
      "r945",
      "r1039"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "biib_DistributorOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "DistributorOneMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributor One",
        "label": "Distributor One [Member]",
        "documentation": "Distributor one."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserveTranslationAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserveTranslationAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign currency and other adjustments",
        "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r995",
      "r996"
     ]
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for (Proceeds from) Tenant Allowance",
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r165"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "biib_CashflowsrevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "CashflowsrevenueMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows, revenue",
        "label": "Cash flows, revenue [Member]",
        "documentation": "Cash flows, revenue [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PaymentDueAtFirstAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PaymentDueAtFirstAnniversaryMember",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Due At First Anniversary",
        "label": "Payment Due At First Anniversary [Member]",
        "documentation": "Payment Due At First Anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryAmortizationPeriod",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r211",
      "r213",
      "r215",
      "r216"
     ]
    },
    "biib_ShorttermderivativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ShorttermderivativeMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term derivative",
        "label": "Short-term derivative [Member]",
        "documentation": "Short-term derivative [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other (income) expense, net",
        "terseLabel": "Other (income) expense",
        "negatedTerseLabel": "Other (income) expense",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in operating assets and liabilities, net:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "biib_RocheGroupGenentechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "RocheGroupGenentechMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genentech",
        "label": "Roche Group Genentech Member",
        "documentation": "Roche group Genentech."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance Costs",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "biib_FutureContingentMilestoneTypesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "FutureContingentMilestoneTypesAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Axis]",
        "documentation": "Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expense and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock units",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r315",
      "r506"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Contractual Maturities: Available-for-Sale Securities",
        "label": "Available-for-Sale Securities, Debt Maturities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Analysis of change In reserves",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "documentation": "Analysis of amount of and change in product revenue reserves."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on sale",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "biib_TheCreditFacilityFloatingRateThreeYearTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "TheCreditFacilityFloatingRateThreeYearTrancheMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Credit Facility Floating Rate Three-Year Tranche",
        "label": "The Credit Facility Floating Rate Three-Year Tranche [Member]",
        "documentation": "The Credit Facility Floating Rate Three-Year Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r176"
     ]
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on sale of equity interest in Samsung Bioepis(1)",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment."
       }
      }
     },
     "auth_ref": [
      "r939",
      "r940",
      "r945"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r406"
     ]
    },
    "biib_E2609andBAN2401Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "E2609andBAN2401Member",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "E2609 and BAN2401",
        "label": "E2609 and BAN2401 [Member]",
        "documentation": "E2609 and BAN2401 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based Payments",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r507",
      "r536",
      "r537",
      "r538",
      "r894"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense included in total costs and expenses",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "documentation": "Share based compensation expense included in costs and expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "negatedTerseLabel": "Operating lease liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Provisions Relating To Sales In Current Year",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "documentation": "Current provisions to product revenue reserves relating to sales in current year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r905",
      "r906",
      "r907",
      "r908"
     ]
    },
    "biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gain/Loss on fair value of foreign currency forward contracts",
        "label": "Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax",
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r1020",
      "r1021"
     ]
    },
    "biib_ResearchanddevelopmentassetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ResearchanddevelopmentassetAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development asset [Axis]",
        "label": "Research and development asset [Axis]",
        "documentation": "Research and development asset [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement agreement",
        "label": "Litigation Settlement, Expense",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": []
    },
    "biib_DerivativeMaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "DerivativeMaturityAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Axis]",
        "documentation": "Derivative Maturity [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FumarateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "FumarateMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fumarate",
        "label": "Fumarate [Member]",
        "documentation": "Fumarate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Adjustments Relating To Prior Years",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred tax liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "biib_Expenseincurredbythecollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "Expenseincurredbythecollaboration",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expense incurred by the collaboration",
        "terseLabel": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "documentation": "Expense incurred by the collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Subtotal",
        "verboseLabel": "Subtotal",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "biib_FAMPYRAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "FAMPYRAMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAMPYRA",
        "label": "FAMPYRA [Member]",
        "documentation": "FAMPYRA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "biib_PLEGRIDYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PLEGRIDYMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PLEGRIDY",
        "label": "PLEGRIDY [Member]",
        "documentation": "PLEGRIDY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax assets and liabilities",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "biib_BiologicsManufacturingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "BiologicsManufacturingMember",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biologics Manufacturing",
        "label": "Biologics Manufacturing [Member]",
        "documentation": "Biologics Manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "biib_SageTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "SageTherapeuticsIncMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sage Therapeutics",
        "label": "Sage Therapeutics Inc. [Member]",
        "documentation": "Sage Therapeutics Inc."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ResearchAndDevelopmentCostsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ResearchAndDevelopmentCostsPercentage",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development costs, percentage",
        "label": "Research and Development Costs, Percentage",
        "documentation": "Research and Development Costs, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossOnContractTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossOnContractTermination",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on research and development contracts terminated with Eisai",
        "label": "Loss on Contract Termination",
        "documentation": "The loss recognized on termination of a contract."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "biib_UCBPharmaS.A.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "UCBPharmaS.A.Member",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UCB Pharma S.A.",
        "label": "UCB Pharma S.A. [Member]",
        "documentation": "UCB Pharma S.A. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_WorkforceReductionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "WorkforceReductionMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Workforce Reduction",
        "label": "Workforce Reduction [Member]",
        "documentation": "Workforce Reduction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of significant accounting policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r276"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on sale of equity interest in Samsung Bioepis",
        "label": "Gain (Loss) on Sale of Investments",
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "biib_ShareOfCoPromotionProfits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ShareOfCoPromotionProfits",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA",
        "label": "Share Of Co Promotion Profits",
        "documentation": "Share of co promotion profits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic earnings (loss) per share attributable to Biogen Inc.",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r306",
      "r308",
      "r313",
      "r314",
      "r315",
      "r319",
      "r589",
      "r590",
      "r686",
      "r713",
      "r869"
     ]
    },
    "biib_GAZYVAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "GAZYVAMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GAZYVA",
        "label": "GAZYVA [Member]",
        "documentation": "GAZYVA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "documentation": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r327"
     ]
    },
    "biib_OtherresearchanddiscoveryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "OtherresearchanddiscoveryMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other research and discovery",
        "label": "Other research and discovery [Member]",
        "documentation": "Other research and discovery [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "documentation": "The amount of inventory recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93"
     ]
    },
    "biib_OtherrevenuesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "OtherrevenuesTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues",
        "label": "Other revenues [Table Text Block]",
        "documentation": "Other revenues [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "EffectiveTaxRateReconciliationNuerImmuneTaxImpacts",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Neurimmune tax impacts",
        "label": "Effective Tax Rate Reconciliation, NuerImmune Tax Impacts",
        "documentation": "Effective Tax Rate Reconciliation, NuerImmune Tax Impacts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets:",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Contingent payable to Blackstone(1)",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability",
        "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total identifiable net assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93"
     ]
    },
    "biib_LenderDisputeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "LenderDisputeMember",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender Dispute",
        "label": "Lender Dispute [Member]",
        "documentation": "Lender Dispute"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Line Items]",
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "biib_TheCreditFacilityFloatingRate364DayTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "TheCreditFacilityFloatingRate364DayTrancheMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility Floating Rate 364-Day Tranche",
        "label": "The Credit Facility Floating Rate 364-Day Tranche [Member]",
        "documentation": "Credit Facility Floating Rate 364-Day Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Table]",
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r87",
      "r190",
      "r191"
     ]
    },
    "biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty percentage to be received",
        "label": "Future Royalties Percentage To Be Received On Sale Of Product",
        "documentation": "Future royalties percentage to be received on sale of product."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "biib_PaymentsToAcquireBusinessesGrossOutstandingEquityAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PaymentsToAcquireBusinessesGrossOutstandingEquityAwards",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to Acquire Businesses, Gross, Outstanding Equity Awards",
        "label": "Payments to Acquire Businesses, Gross, Outstanding Equity Awards",
        "documentation": "Payments to Acquire Businesses, Gross, Outstanding Equity Awards"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CollaborationAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "CollaborationAgreementTerm",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement term",
        "label": "Collaboration Agreement Term",
        "documentation": "Collaboration Agreement Term"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BasicAndDilutedEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic and diluted earnings per share",
        "label": "Basic And Diluted Earnings Per Share [Abstract]",
        "documentation": "Basic and diluted earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments/Returns Relating To Sales in Prior Year",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed",
        "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed",
        "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "MortgageAndOtherAssetBackedSecuritiesNonCurrentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Mortgage and other asset backed securities Non-current",
        "label": "Mortgage And Other Asset Backed Securities Non Current [Member]",
        "documentation": "Mortgage And Other Asset Backed Securities Non Current."
       }
      }
     },
     "auth_ref": []
    },
    "biib_DenaliTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "DenaliTherapeuticsIncMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denali Therapeutics",
        "label": "Denali Therapeutics Inc [Member]",
        "documentation": "Denali Therapeutics Inc"
       }
      }
     },
     "auth_ref": []
    },
    "biib_GenentechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "GenentechMember",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genentech",
        "label": "Genentech [Member]",
        "documentation": "Genentech"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance stock units settled in cash",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "documentation": "Performance Stock Units Settled in Cash [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Time-vested restricted stock units",
        "label": "Time Vested Restricted Stock Units [Member]",
        "documentation": "Time vested restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "biib_EquityAwardsOfAcquiredCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "EquityAwardsOfAcquiredCompanyMember",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Of Acquired Company",
        "label": "Equity Awards Of Acquired Company [Member]",
        "documentation": "Equity Awards Of Acquired Company"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Plan assets for deferred compensation",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r114",
      "r116",
      "r119",
      "r753",
      "r756",
      "r770",
      "r771",
      "r772",
      "r774",
      "r775",
      "r776",
      "r777",
      "r779",
      "r780",
      "r781",
      "r782",
      "r793",
      "r794",
      "r795",
      "r796",
      "r799",
      "r800",
      "r801",
      "r802",
      "r821",
      "r822",
      "r827",
      "r829",
      "r866",
      "r901",
      "r903"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of contractual maturities: available-for-sale securities",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction of accounts receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of term loan",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_StockholdersEquityOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityOther",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Stockholders' Equity, Other",
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost",
        "terseLabel": "Treasury stock, value, acquired, cost method",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r83",
      "r188"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basis of presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Repurchase Program, Authorized Amount",
        "label": "Stock Repurchase Program, Authorized Amount",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount remaining under 2019 Share Repurchase Program",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "documentation": "Amount remaining of a stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other changes in operating assets and liabilities, net",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r890",
      "r1042"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Payable",
        "label": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r202",
      "r1036"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Samsung Bioepis",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r379",
      "r932",
      "r979"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value $0.001 per share",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r696",
      "r898"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Earnings per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r316",
      "r317",
      "r318"
     ]
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnInvestmentsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on investments in equity securities",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income",
        "terseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r254",
      "r257",
      "r273",
      "r279",
      "r294",
      "r302",
      "r303",
      "r322",
      "r332",
      "r336",
      "r338",
      "r383",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r569",
      "r572",
      "r573",
      "r590",
      "r602",
      "r687",
      "r705",
      "r741",
      "r786",
      "r804",
      "r805",
      "r871",
      "r895",
      "r896",
      "r910",
      "r936",
      "r1003"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r664"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, ownership interest",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected cost",
        "label": "Restructuring and Related Cost, Expected Cost",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r415",
      "r419",
      "r421"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in contingent consideration",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset",
        "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r944"
     ]
    },
    "us-gaap_OtherAssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets, receivable",
        "label": "Other Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r898",
      "r1045"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments and other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "biib_SalesTriggerGrossSalesThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "SalesTriggerGrossSalesThreshold",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales trigger gross sales threshold",
        "label": "Sales Trigger Gross Sales Threshold",
        "documentation": "Sales trigger gross sales threshold."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Until Second GAZYVA Threshold Date",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two",
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option two sub option two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments, contingencies and guarantees",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r129",
      "r695",
      "r764"
     ]
    },
    "biib_InterferonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "InterferonMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interferon",
        "label": "Interferon [Member]",
        "documentation": "Interferon"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r67"
     ]
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of roll forward of the changes in goodwill",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SpinalMuscularAtrophyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "SpinalMuscularAtrophyMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Spinal Muscular Atrophy",
        "label": "Spinal Muscular Atrophy [Member]",
        "documentation": "Spinal Muscular Atrophy"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ContractOptionExerciseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ContractOptionExerciseFee",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option exercise fee",
        "label": "Contract Option Exercise Fee",
        "documentation": "Contract Option Exercise Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of share based compensation expense associated with different programs [Abstract]",
        "label": "Summary of share based compensation expense associated with different programs [Abstract]",
        "documentation": "Summary of share-based compensation expense associated with different programs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r405"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration obligations",
        "periodStartLabel": "Fair value, beginning of period",
        "periodEndLabel": "Fair value, end of period",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r95",
      "r566"
     ]
    },
    "us-gaap_HedgingDesignationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingDesignationAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Axis]",
        "label": "Hedging Designation [Axis]",
        "documentation": "Information by designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r578"
     ]
    },
    "currency_CAD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "CAD",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Canadian dollar",
        "label": "Canada, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r243",
      "r279",
      "r383",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r570",
      "r575",
      "r602",
      "r898",
      "r1003",
      "r1004",
      "r1026"
     ]
    },
    "currency_CHF": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "CHF",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Swiss franc",
        "label": "Switzerland, Francs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r464",
      "r617",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r947"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "negatedTerseLabel": "Operating Expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r142",
      "r143",
      "r200",
      "r202",
      "r285",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r617",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r947"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive income (loss)",
        "periodStartLabel": "Accumulated other comprehensive income (loss), net of tax beginning balance",
        "terseLabel": "Balance, January 1, 2018",
        "periodEndLabel": "Accumulated other comprehensive income (loss), net of tax ending balance",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r156",
      "r240",
      "r698",
      "r731",
      "r732"
     ]
    },
    "biib_SolothurnSwitzerlandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "SolothurnSwitzerlandMember",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Solothurn, Switzerland",
        "label": "Solothurn, Switzerland [Member]",
        "documentation": "Solothurn, Switzerland [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r78",
      "r81",
      "r124",
      "r125",
      "r127",
      "r130",
      "r186",
      "r187",
      "r285",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r464",
      "r617",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r947"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial Instruments",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnDerivatives",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gain (Loss) on Derivatives",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r799",
      "r800",
      "r801",
      "r802",
      "r824"
     ]
    },
    "biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of activity related to Aducanumab collaboration",
        "label": "Summary of Activity Related to Aducanumab Collaboration [Table Text Block]",
        "documentation": "[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party, Type [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r623",
      "r624",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r783",
      "r785",
      "r811",
      "r1025"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r231",
      "r702"
     ]
    },
    "biib_GovernmentSecuritiesNonCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "GovernmentSecuritiesNonCurrentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Government securities Non-current",
        "label": "Government Securities Non-current [Member]",
        "documentation": "Government Securities Non Current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "biib_StrategicInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "StrategicInvestmentsMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Strategic Investments",
        "label": "Strategic Investments [Member]",
        "documentation": "Strategic investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FacilityTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "FacilityTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Type [Axis]",
        "label": "Facility Type [Axis]",
        "documentation": "Facility Type"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flow provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated additional payments upon achievement of development and commercial milestones",
        "label": "Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones",
        "documentation": "Estimated additional payments upon achievement of development and commercial milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r73"
     ]
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Consolidated Financial Statement Detail",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flow provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of post-combination equity compensation",
        "label": "Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized",
        "documentation": "The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "currency_EUR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "EUR",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Euro",
        "label": "Euro Member Countries, Euro"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of Reata, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flow provided by (used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169"
     ]
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employee stock purchase plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leased Assets [Line Items]",
        "label": "Operating Leased Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r279",
      "r383",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r571",
      "r575",
      "r576",
      "r602",
      "r763",
      "r870",
      "r911",
      "r1003",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total revenue",
        "terseLabel": "Product revenues",
        "totalLabel": "Total revenues from anti-CD20 therapeutic programs",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r279",
      "r323",
      "r324",
      "r331",
      "r334",
      "r335",
      "r339",
      "r340",
      "r342",
      "r383",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r602",
      "r687",
      "r1003"
     ]
    },
    "biib_NumberOfSquareFeet": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "NumberOfSquareFeet",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of square feet",
        "label": "Number of Square Feet",
        "documentation": "Number of Square Feet"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PretaxProfitSharingFormulaTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PretaxProfitSharingFormulaTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pretax profit sharing formula",
        "label": "Pretax Profit Sharing Formula [Table Text Block]",
        "documentation": "Pretax Profit Sharing Formula [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Authority",
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income tax (benefit) expense and equity in loss of investee, net of tax",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r332",
      "r336",
      "r338",
      "r718",
      "r871"
     ]
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments in Variable Interest Entities",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Asset Class",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Leased Assets [Table]",
        "label": "Schedule of Operating Leased Assets [Table]",
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term debt securities",
        "label": "Debt Securities [Member]",
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r903",
      "r1050"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one",
        "label": "Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One",
        "documentation": "Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one."
       }
      }
     },
     "auth_ref": []
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities."
       }
      }
     },
     "auth_ref": []
    },
    "biib_StrategicInvestmentPortfolio": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "StrategicInvestmentPortfolio",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Strategic investment portfolio",
        "label": "Strategic Investment Portfolio",
        "documentation": "Strategic investment portfolio."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfFutureDevelopmentCosts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PercentageOfFutureDevelopmentCosts",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of future development costs",
        "label": "Percentage Of Future Development Costs",
        "documentation": "Percentage Of Future Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income per share:",
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "label": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "documentation": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AccountsPayableToCollaborator": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "AccountsPayableToCollaborator",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts payable",
        "label": "Accounts Payable, To Collaborator",
        "documentation": "Accounts Payable, To Collaborator"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r204",
      "r701",
      "r898",
      "r948",
      "r980",
      "r1019"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative asset, fair value",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r113",
      "r155",
      "r244",
      "r866"
     ]
    },
    "biib_ContractualAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ContractualAdjustmentsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual adjustments",
        "label": "Contractual Adjustments [Member]",
        "documentation": "Contractual adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Indebtedness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indebtedness",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r277",
      "r439",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r455",
      "r462",
      "r463",
      "r465"
     ]
    },
    "biib_GovernmentSecuritiesCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "GovernmentSecuritiesCurrentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Government securities Current",
        "label": "Government Securities Current [Member]",
        "documentation": "Government securities Current."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r342",
      "r883",
      "r1008",
      "r1040",
      "r1041"
     ]
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Estimate of Possible Loss",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r428",
      "r429"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Selling, general and administrative",
        "terseLabel": "Selling, General and Administrative Expense",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "biib_EffectiveTaxRateReconciliationLitigationAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "EffectiveTaxRateReconciliationLitigationAgreement",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement agreement",
        "label": "Effective Tax Rate Reconciliation, Litigation Agreement",
        "documentation": "Effective Tax Rate Reconciliation, Litigation Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "Expensereflectedwithinstatementsofincome",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSangamoTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "documentation": "Expense reflected within statements of income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.050% Senior Notes due 2025",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EquityMethodInvestmentsExpectedProfitShare": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "EquityMethodInvestmentsExpectedProfitShare",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected profit share percentage",
        "label": "Equity Method Investments, Expected Profit Share",
        "documentation": "Equity Method Investments, Expected Profit Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential future milestone payments commitment to third party",
        "label": "Potential Future Milestone Payments Commitment To Third Party Approximately",
        "documentation": "Potential future milestone payments commitment to third party approximately."
       }
      }
     },
     "auth_ref": []
    },
    "biib_AccountsReceivableFromCollaborator": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "AccountsReceivableFromCollaborator",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts receivable",
        "label": "Accounts Receivable, From Collaborator",
        "documentation": "Accounts Receivable, From Collaborator"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type [Axis]",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r745",
      "r747",
      "r748",
      "r751",
      "r754",
      "r812",
      "r814",
      "r816",
      "r819",
      "r820",
      "r831",
      "r832",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r903"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability, fair value",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r113",
      "r155",
      "r244",
      "r866"
     ]
    },
    "biib_AcceleratedDepreciationAndOtherCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "AcceleratedDepreciationAndOtherCostsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated Depreciation and Other Costs",
        "label": "Accelerated Depreciation And Other Costs [Member]",
        "documentation": "Accelerated Depreciation And Other Costs"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments/Returns Relating To Sales in Current Year",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year."
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "BusinessCombinationConsiderationTransferredEquityCompensationPreAcquisitionServices",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services",
        "label": "Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services",
        "documentation": "Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services"
       }
      }
     },
     "auth_ref": []
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "documentation": "Intangible assets excluding goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "biib_EffectiveTaxRateReconciliationGILTItax": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "EffectiveTaxRateReconciliationGILTItax",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "auth_ref": []
    },
    "biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Related to BAN2401 and Elenbecestat Collaboration",
        "label": "Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]",
        "documentation": "[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_NeurimmuneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "NeurimmuneMember",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Neurimmune",
        "label": "Neurimmune [Member]",
        "documentation": "Neurimmune."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "biib_FutureContingentMilestoneTypesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "FutureContingentMilestoneTypesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Contingent Milestone Types [Domain]",
        "label": "Future Contingent Milestone Types [Domain]",
        "documentation": "[Domain] for Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Related to Sage Therapeutics",
        "label": "Summary of Activity Related to Sage Therapeutics [Table Text Block]",
        "documentation": "Summary of Activity Related to Sage Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Information about Litigation Matters [Abstract]",
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsOtherAssetsAndLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets and liabilities, net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and (Liabilities) Assumed, Assets,Other Assets And Liabilities, Net",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and (Liabilities) Assumed, Assets,Other Assets And Liabilities, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, gross",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r202",
      "r466"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r548",
      "r559"
     ]
    },
    "biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains (losses) on net investment hedge, excluded component",
        "label": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "documentation": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SettlementLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SettlementLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reata acquisition-related accrued expense",
        "label": "Settlement Liabilities, Current",
        "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Taxes on foreign earnings",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1013"
     ]
    },
    "biib_CashflowsoperatingexpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "CashflowsoperatingexpensesMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows, operating expenses",
        "label": "Cash flows, operating expenses [Member]",
        "documentation": "Cash flows, operating expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Co-promotion operating profit threshold for Rituxan in US and Canada to determine share of co promotion operating profit prior to amendment",
        "label": "Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment",
        "documentation": "Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment."
       }
      }
     },
     "auth_ref": []
    },
    "biib_CollaborativeArrangementProfitLossSharing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "CollaborativeArrangementProfitLossSharing",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized net reductions to operating expense",
        "label": "Collaborative Arrangement, Profit (Loss) Sharing",
        "documentation": "Collaborative Arrangement, Profit (Loss) Sharing"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A2022CostSavingInitiativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "A2022CostSavingInitiativesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Cost Saving Initiative",
        "label": "2022 Cost Saving Initiatives [Member]",
        "documentation": "2022 Cost Saving Initiatives"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance stock units settled in stock",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "documentation": "Performance Stock Units Settled in Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of borrowings and premiums paid",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r737"
     ]
    },
    "biib_ResearchAndDevelopmentAssetDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ResearchAndDevelopmentAssetDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development asset [Domain]",
        "label": "Research and development asset [Domain]",
        "documentation": "Research and development asset [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_RituxanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "RituxanMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RITUXAN",
        "label": "RITUXAN [Member]",
        "documentation": "RITUXAN."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Purchased intangible assets",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1013"
     ]
    },
    "biib_OtherClinicalProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "OtherClinicalProgramsMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other clinical programs",
        "label": "Other Clinical Programs [Member]",
        "documentation": "Other Clinical Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "terseLabel": "Total Reserves",
        "verboseLabel": "Revenue-related reserves for discounts and allowances",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r290"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r116",
      "r578"
     ]
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Settlement, Amount Awarded to Other Party",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Axis]",
        "label": "Hedging Relationship [Axis]",
        "documentation": "Information by type of hedging relationship."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r111",
      "r116"
     ]
    },
    "biib_TECFIDERAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "TECFIDERAMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TECFIDERA",
        "label": "TECFIDERA [Member]",
        "documentation": "TECFIDERA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r290"
     ]
    },
    "biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty operating profit threshold for highest royalty rate percentage",
        "label": "Royalty operating profit threshold for highest royalty rate percentage",
        "documentation": "Royalty operating profit threshold for highest royalty rate percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r290"
     ]
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, Notional Amount",
        "label": "Derivative, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1015"
     ]
    },
    "biib_ReataPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "ReataPharmaceuticalsIncMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reata Pharmaceuticals, Inc",
        "label": "Reata Pharmaceuticals, Inc [Member]",
        "documentation": "Reata Pharmaceuticals, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) recognized in net income, excluded component",
        "label": "Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net",
        "documentation": "The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r121"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1013"
     ]
    },
    "biib_FacilityLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "FacilityLocationDomain",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Location [Domain]",
        "label": "Facility Location [Domain]",
        "documentation": "-- None. No documentation exists for this element. --"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PaymentDueAtSecondAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "PaymentDueAtSecondAnniversaryMember",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Due At Second Anniversary",
        "label": "Payment Due At Second Anniversary [Member]",
        "documentation": "Payment Due At Second Anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State taxes",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1013"
     ]
    },
    "biib_CollaborationProfitSharingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "CollaborationProfitSharingMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsADUHELMCollaborationAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration profit sharing",
        "label": "Collaboration Profit Sharing [Member]",
        "documentation": "Collaboration Profit Sharing"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AggregateGrossIdleCapacityCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20230930",
     "localname": "AggregateGrossIdleCapacityCharges",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross idle capacity charges",
        "label": "Aggregate Gross Idle Capacity Charges",
        "documentation": "Aggregate Gross Idle Capacity Charges"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, treasury stock, shares",
        "periodEndLabel": "Ending balance, treasury stock, shares",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gain on interest rate swap",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r608",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Current [Table]",
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes payable and term loan",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r202",
      "r452",
      "r467",
      "r876",
      "r877",
      "r1036"
     ]
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Line Items]",
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale of building",
        "negatedTerseLabel": "Gain on sale of building",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r15"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoADUHELMCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r945",
      "r992"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r464",
      "r481",
      "r586",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r709",
      "r873",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r974",
      "r975",
      "r976",
      "r977"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r425",
      "r429",
      "r998",
      "r999"
     ]
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentAssetsMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other current assets."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r120"
     ]
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of the share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r425",
      "r429",
      "r998",
      "r999"
     ]
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Step acquisition, equity interest in acquiree, fair value",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value",
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination",
        "label": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination",
        "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r22"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsDetailsTextual",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share",
        "label": "Business Acquisition, Share Price",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt",
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rest of World",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1051",
      "r1052",
      "r1053"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "terseLabel": "Inventory, current",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r858",
      "r898"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r391",
      "r692"
     ]
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on foreign currency derivative instruments not designated as hedging instruments",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r118"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, All Other Investments [Abstract]",
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r608",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a),(b),(c)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i),(j),(k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i-k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-9"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a),(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1),(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "c",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//815/tableOfContent"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479567/321-10-45-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "30",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-19"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479092/842-20-40-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "275",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482094/912-275-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(g))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>129
<FILENAME>0000875045-23-000038-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-23-000038-xbrl.zip
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M"][=<_WM6\!V6>_@24",$?+P4WCXT,)I10UV4OOZN]()%K@5^?%4I2+V]OB
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MVZV0LW[.>028M.-%B*<!2R$KO(#T+^ XTUWQ,E=E<X3(,/UA2(A; <N5*IA
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M%:5ZV>BFE%LB2 I(K.]M?']\:/TCI;$6),=TJ#)D\KNB%"\;U91J*P1)_F3
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M62W@R*<EM2Q'D7!N W5L_B@@3O?5\O^-"0TY\@RI5<"1/>#$G6C,!LNOK$Q
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M>SJ4P?(7C5=$S-YT@A>HW'M$?F(_[7-KRF 9"@ Z$15=P'(0 '0B*JR Y18
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M-;U0_>II$T*[:$V0K>$W; 1LJR!Z)W7EV-NJ(CS9J,/Z_LWG,T6=PX16MI.
M> &K=WU7HW?PH%30?^G_RH3 !BD:AG^Y3>\*!3$T>KE2V*>\+98O2I7B7H7H
MQ]?*Q>UH]%T:6ZA<Y&O[5<VG;VS]HE*H)_[4HGY1K^XT=2>QU')LF::-!9EN
MR)Q;OLWY*8R,D6:PB;P[Y-!+$X[2(Q.">%CJ3L=]U_[%VZ5<VBB1BLP2>8A(
M3 X2_,96Q0_I%X[V2I\_6G#Z1RW%3RF'0UF-*"1."WJ?F]@LPRN'(S%4=EW?
M-7Z>:?^9OZ M+VL31+079 >'T%ZRV^.A4H\L-S3<F<CY^$+[^AARE<2JDT)S
M*S+]</1FE=%ECF&9S&6G;_9HIO> /!/]J7VSW3[-<;LTP3=\[1Z1G^^+[P,I
M"\MA+,BESN8RB$V*VX[)J!BL]:>:,<+&3XVV]R?UF)B3=BP!7A@3^J40%9$C
MY&D#RZ;Y,[)M>@<;\&=I]9^!Q9)JFDOW<70#?7"45\^&MET2#6U'*?9"9A[K
MCJ7=[#(;VM;,@!TBRV^=$&Q@'O<*>O@\/K?'TWZA#Z6JUKR NGIOY+)QJGA:
MD3]"_FI77M%R>UECPQ]'O?DUK/-^T1>ZW*>HH3?U_\6007_$[Z>_9.V)'L:F
M0GB\);RYR/.U>CY\@HFFWF7XY_O_[LI_- -"Z*O"N1;,F_C(#[P9I&NYJQ_8
MVP3;+>'6L\94)0_X5>NX8^0<AK2ESN[6CK_3_C&=>X>UX U*]P\01?(>X,&%
M(A8QJ'"WI"[D]MS,>U''-;9\G_H['MJ(Z[! ;T\US+:-TMHL_K,5TB]8NT$^
M"B?@K/CT^3,6B9-.8.-0AR6:(U*WW<'#P$9SI]\][VF_L#^K7W5:R49W44GP
M.043-J?@)%X^;/[,;V/OU\0<\H+XF/0B_SQSR'7ED)5#5@Y9.>3(,U'/AS2;
M=@AKR#"H0R9LFP3NE C+/-=^JU'7<;[V@C>FGIR^A<3Y('588RJ)Z1G+MNGC
M:&+*A#?4AL1]]4?QY0N:?&/>-A,/+(?/W_68;V:LOTZ[N:&%_'+A:WS;IS=L
M;E]\(TNV<QM:F6,3T%B0H?&@?Z['=<-BL; 51R]HIGLU7]V'HM<+%W4]^;EB
M]*G5Y/GI4N&B7#G"=+GJ1;Z\W<2V'650VV[,8']Z\,034+8D2?>924V:U+"'
M+IFN85/X3=SDC>BF.;&BYW-7=^L="+Q9<X='K_Q23G-T(I2PM\(#6..]J@]1
M;2*]W'9MS.HZCDV3N*+U*HF,(L!T$P_+B4:8#R:@SE.N=-I?FQDTVVZ8H(6*
MGF5IX<<H"TN=(>\:"[F,K@.//LCSEI>9#JPW;-)FVMYL$$TO;+>T;4O7L0/J
MCG.K/%ANK:\B,H_?6"[?N%B:<6WU&8[U'7 LZS#8X(,:F4WM6UO:6X-U-"LG
M5VGRX[B<&PV\L+ZF'0Z7M_NSA;(Q<\D83?8N>\I>_FK15]/7:@Y^9<4[P2^6
MQY,I!SD&PP\-S&S-"KN9[>%G(F*RV7GNBV5NFM%6_ 7]NJYLOM 4R7-DDL<;
M8=N.L:3]0A'"J99P5=V<.=_(;/QZL8FJ_(&] ^BZ+6G#3UW17I/?NTPH6WN@
MXJ<>2#15"H0[#IOQX!X3$+NT1/"X@F3.A4U""6>3,S_@C1#!7NP1+,\+6'H>
MS<5>.SLKE/ELBM:9Y@8^#Q L4B#^J ?WA6]T$MY:#3<[.>/C9)$)WY)PEV2-
MG<K!#3AL2&[%J/4<]6.&15-B[_=<^^%VS10%WD;>Q"Y_Q..\.<LV3SM];KK^
M>?1 FH[1%(L^*S_S *7<5:%4.JO5:V>%PFQ=1]S6JTA8%UM-U,Y+M=_)*?;L
MB[:".'S#OL4M%R=NF.5<$K:EMO6"WVW".&\%%V1^_A/4ITT)_/<_^6S?QETW
MCV1;YX>_&9%Y$3#$YWV"T<]S-/ QN43V*YIZ;*.#]3M,EG3N.C8T=HTK&0P.
M7]WQP0JBT*]18XI65EX&;.M0=A=M%P+5'FU$F#OYRU::ZG&3I5ZLR3R1XWN_
M?4%K4;#/FIMRO[J_%+;<QW!I XE#%PF=HL&WCYW[*#W-G_^-#^85]*_:;-<W
M+9Q_)DEGHDEY\]:'^X9I+5Z7K=L$;&/V4J[6"O7*L5N\U6JZPD[+Z:IYXY,\
MYAZ;5C ^;./17N/ZKL6V)FH^/O1:#[WW^Z4>(\VJ[Y&9 APNWC-1J%T4].17
M,U5I>RK)[[=6NZ@6CKV:Z<0C*ZOH6S^=/8D= .3NV/(^T86-:2>$K0^VZ_H3
M8LOF/Z/TZX=M6W?R=<1;]KW1Z86J;\=,2)@C?%+Z'Y!R;M.P4Z; ![9G^Q28
MK1&Z;3\T'IKMQAW-(EEVUNCQ7;S?Y<'[U8,G'&Q*UJ\?:R.A3U,*;@1MFCAJ
MA8ODO?K,]$]A1^OZ)M*.=FS/#G94IW8T&TWA^Y2$RW9^"1P4F):/S5\WF-3N
M )?:^@X;'E:(/A6BV1AMTV5$-ALI7#QX;1'>[D!CV]^-\7*DCNOB'GT=YO-P
M.?AEEL4#_8GTG=#N7;[H):0GI._.C%^1OB<S@H@;"SO+<:]HD4#ZSR>E;$Y\
ME"O=3\'5%"?4*J1+@L/REB&=S:(@>,0.D7O!48#7TAK;RRRV2]\%V9.3<KJ2
MDW*8G$C?B11D5V657:4^JM54=J6R*]$XK&W,KJZ1C1P#:]T1QKZW3)4T6,8E
MMX>E'==24HK75H/%#3869C<6"V<J?*3/;.LJ?*CP(1B'Q<*VQ3GR1MJM[;ZN
MI]RE]K],"-(3[:P3*:IE67?2$=VY8E0IF&X?6LBK8*Z"N6@@EK8,YJT_ \N?
MII5;9V*0/YR7TA7.2ZD)YR45SE/O1=GARBJ<JW N%HA5MGV5CSVV <:&N+YN
M]J?R1:F"0*&<8E\DSZQX7<V*E\1H"NS4GWODH"'WA[.M)FXLSP@\CVT)P=*V
MAH/LJ6?Q@FCN1IF?#?<T8O=TL!?88<WT.,%AFY1_31E4RFE.]N1QL$7E8"6Q
M&KU<SUW]C6W-9OE\0Q3N*^D7=OR9N5K;]0*V[T^C[P;Q\5-:Q_)^*O^9+B34
MTLQ]R^,_2\I_RF(UE7"5FT^H@KCO?"*N@4WF+I5S3)>::YNHX?7.L5!^YQW?
M;[?PN1]+_18-:H^&8^_1H%=H:?38^Z/541LT (OT:H,&>4) +7=UAX?(#D,\
M/PM0Q?B4*;A65&Y1O%N,MG=L*.<HB^U4"[DK1@AIM\CP7:+\8LITJ_PB!+^H
M1BXELII2[NK9"0_>P.RHYRZR\>*4S2XV F+Y%@YYHV>/;R,=Y9;*@:8,"O4T
MKS"6QX&6E0.5QFJJN:M'?H)1VPD/YJ"/4FXQ70I6;A&$6ZPHMRB+U=3RN:O6
MV\CJ6VIZ<-KT6C]T'X'*<5W<^\<K7R 4,Y7<59?*%_EJOD'Z-$N?]I$[>'?@
MV>9SR-Z?AA8?#W:4 ]%..^%@RX,,]22.9BOD<_&/U-ELJ3R;;>40JTV(/<V1
M50^/O58X%M9I?6MT;MH/W[3;Q\[?Z9_G=X^/?V6?N[U&KW6_]CRK-7T2?IJH
MY6F$G\_&C^Y$EN.Q4S=?$3'/;?KXZ/SH>(&[/T*^A@C6^IA=&2,3+YTES9:Z
M\T.FV5*0V;FD3\1Z8><A+S"L=_2?(0>3UL&,36"G&+/["_5Z6?N%_8H=:QP>
M=,W/-N6(8??3F]P^:REK ;O4QPX>6/[L=6SFDI[_VD4#K/V!2-_E1Z+JA:]K
MFL:/M^Z-L(<_ZO883>E;^)G:[#1B"YOL;&<O,$;:J\L.UD9>_%9DC<_BU\5?
MT78;UH0^;?5*']L6?GGWM>$&MKGZ)?9\:[SF&?AM@@U_]5O:&6P@;_Y];N@B
M^RP77^?B?/<.VL_5KR8V<MY]YW)=T.>]N^!Y%K7QU>]?+?O=O:^LD_%WC'!W
M.;<4R9-^IIY[S/7D613^B&ACC)C.+QAB,,%L_SW+"S%(;6*"6((4L!LI$#]0
M)L%#>H7E6ML> 1SE9N<L$;O4]8MRG)]%QP*?L[-,19HQ%V-%]-'2RW)BQQ?F
MKIB-S?%O:FC,3J4_TRB6^8'#5,\+)]5391-J#TZ OW)W1+_#[&[:7@I_U\%G
M&G&GR/:G"XB9H&FH6!Z5--LRV#;7SO",I=DVZD=!ZXR^Z,_ "G,ES24:U3>S
M*9:J:VA(< B/KYJ/WK0XIPJ1.&N*05W75_Y8:G*H;]ELW(@WVL#4Q5'D>\S)
MX',T8:X&V128M#N^2Z;L9Q[W<![BM]$" 2-"/0A[@TE[;;L3U@)^'W_+>$([
M@F8+YL+>>MBV>>=H<S"A;^ B-*DT^8'R?(D(<PF.1V5(I4V-XM\H]IO4ZI$S
M9!9*/9:'V6N8HZ )H48],S.I*?UQ=*P\L;R?7[78[9C: %G1H='L4>'O^=MM
M*Q0%%P[[PJ).TB*\,^PVSPLENXVY596Y'6)N83 (UU*>:<QWARJB:/38%>;]
M6%W!(J?+OC4#&G9CM-*?<'#27Q)JL1QEQ'WU1]3LL#7NTT"/0ZTRK:/ H>AE
MT3B@OIFO06(&SMYF33!K;?P"I?H3>=I98.8F&"94EF/04HCM;A"KFWL6/_2#
MM$WLAZ'Z//;QE3:0IC4XNHVZ7/H$.^#GP\^?M?B, 7''FH-?J5.UJ#*1'^YY
M1-#$8ECBCLHR.*I<DP3#$))]RXT".P_R^(WZ+_:.&#,Q;J,/'*+TQ:&31WU:
MW[U8W"_1>$ZC/O.Q-!3X(U;J+;8Y>CWS^/-7:B^8S/) AM_9B^AM4=\6VJ+P
M>WS\LOR %1$LZSO3%CY1:/@LHH<N+?S>'0QHF*<1?1ZD0]?'/- +HBJ.@C,'
M$3_!V0L#]0PK-,[9@6>]T+N4>H^O7FYDLWC$TB+/#],V^EY^D:8J ]>V7%9,
MO=(LA_U+W9C-0\XLA6&W&BZ9L*R.G;C,_ADJ#9XHP)BTDJ>>DV6-/#7@23O5
M2)]:DD,3O47'NZKQN'ZGB0?UL&/+9RDPO<G RUF):7D&=?5D>K8Y1Z:.>4C0
M.(HDT<N7[G G#%"!$TWHFD-J.4[.N /V(#+;DN(LK$!7BA<6&&P<(9&6%Y@P
M&F+]^RDP:?)N+!81GG].,(LG[ &TF.5KN%<E=DOEPJ3[C2=><4<5OD^#[^7\
M>0EQ,R0O(H+61CS375(C+^!" (55+G5;<\09]'XVD$,18O&4>R$F#2Q6VT6O
MF2?E*SD*;1C-HC2#WL6WJO+>)=W<-I:;M% )>S&K9A'SG-,FK/T;321,Y7!
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MJRBJ+ N*,9TFR]H%'*6]P $" UGW'$?'1CD,ITD=E@L"-!EQ'/ME6KN H\+
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MI3U=C#5DL.5-R)FRF0&.ZV./S1CP1]C#- U"-%WQ,<NE'9-F-.%?//(C]O7
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MID"B)5$NSZ]_S\F40(  "01(^,S&=F'0)?/<\URO+5L\3]ST<<+<%Q!B@2)
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M,1579&!?FH&]3@Z)3V+M*OEMJ=UN[FV^SXX;)?L(P:^D\*\3> T5?_+N)"0
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MN7TVVDTK $Y$NG\[!PVDP'T.F3K.S$W2S&M)Y_5L8SQ#@#PZ+CZ^Z\O160Q
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M['8A ,RN;4HA8M[.7 #0(RS3,3>.[6A7Z;!#9M!EP#>E&;1C;L&2&12PU,(
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MD-DNDA6#3<.!$_<R9?X(,/@B9%]W_"\ -Y#5?WCA7L0&F,NCT&3F#SRKPMW
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MF*)Q2%"C""U<@9<)#E#!&B,,T@CW&O\9>&7=:'!#V'(S?X8OB=+UA+V%B2%
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M9T_(C&^,H6SI#8&'K!,N.][Z%.:XQ^<)]:^8],L\SS$L >PY44;;P_[@\UY
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MM9X""C:IQW%CKN7)N0/I)/Y*+?>1)7[*RM&(S&\!7VQL5A'(_$5S<R=2_@_
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M=:O@*PN2B9=S@92)F/^;)*%$@A0@D9]'S!2>U0D"S$4Y)'-UA$-@XVOW4]Q
MRV TA/A"LS-PA\;M&A> KF-8U14\L*+<SG@(H<5J@P>(;?V'%^8_21Y96-01
MZH;W2KMJB<X-8<*%^4D; ?G)<L 8$@^7@!3B7AY[(R(_41@?K;;=0=-ZL[33
MS@E+7Z^P><"U.I\H8J'"\:^O\)O2J6N>11*Q#*2G+7JN52N-=O;5R2V]HB8L
M>M[1/F,]-R<P*K?4*(O?LVZ-&*0$[2VA5JN(U\R\ZKQ45;M>(>HM0QJ/!X6X
M&NOZL2S]9-"!@UR82Q/7*C*F5GQKG&'UD"D?S\:_ [U-O5Z8[2ERD8,@]\-<
M1BT.E<_PR$]PNOB^.!YJI45<O.L'W^$+.1PEIQC.=V<\?0!<;>C:@&5PGMIZ
MU.@SF3CR7PX82\H?(-?0:7D'*@,40 ]S#T#IHPW19Q-O!G(<1#6?6MY^1\6<
M)-_92G?J6F/4G:KR&K78A#D<@ 2U=-IT>%6/NC:T5:*3</W*_9$C:OMD">3#
MJPTV[<B:/G(7\SW %(Y+@V_52YUZ7(OX?U>XQ)>U&5^BCFGQU1?GQ3+$>9G_
MA+.Q_1+X#$0Y]+(7_$!?L=K:[NR)!TG?&9LWS'7?@"6[$TSN2^U+QGE+&WM'
M!;[DBO)-)"H*DPO,Y^ 8@^!:.)?*2")8'X"U"X?!HKW=;_Z(U<'<]#Z#P7]K
M(2PL9,>'8<B(/5OP:<"FJ4$BBITW5;8L$I%EXCA&'^0A.0R6'K!SK1J_<Q$&
M?91])KQGYQB;QG#X+CJ8;UH6 <\]_#+J\^I@*PR9H1.<N%S/7UP5_"A2)L[M
MN$F)E@W3=X^%EHA3M57JM&IQK;>7G*CYS> 6\<2Y5+ B*D6;5R5Y&/PS8PDE
M)9XVS&0] 9[:H'0T?1>>T,=CPCF2^=&-,]N&%;D>^@[""&O4[[8L9Y> N)JR
M7:QR*C$O-3Q4HSTARUR,0*-)O\O9945HY%ASM1MO.,B(UF:*_>Z^KE/LCK+<
M>+6?.DFE72UU&JW:QNJ:2:CG\RM(;F690H1M N\,HB>T4*.I!NB2N\+8\PMZ
M1 \TS[3ZJF)>Z5X]C^G#R[XXGO=@XY$!Q4M*I"U4<CMMP%!KG&&16'0:(_:2
MMPV(L2-E %HJ#ID4@!@4L>0/TO/\RZ)*T)993WO&_LXO71)X+M4\,Z;H7;/$
M:_/0$Z!OS#Q/!$T"QRWZZ+L/-SW$O,2<P$:V[+G>7#ZD?-'M[ :S&O@(* 74
M;D\L +GAL^/"OFR9(6B\1>+F75M&T<=B%]UY4YY/'*B(/[.?J>6QAO)X8V'>
M)&)NSR8S65,E>40N00'S0'B615Z@"$@YPR%&+P9O&0,R.?SNN;\0)/_)S1<>
MRIFG%3K8'VYPMF_$E;BOP0T)T0L\Z4M99"OQ*10;D@[GRGV$2R^J7553@27_
MP14^#MHUK80R944A6MY!186\)#RX">L46',6L.JZ+P1,U\7S*DI7R-2X6,NN
M?@.+K.A-]G_8Q0'KNJ_F[1O6@QN1M&6J4*RUJ4(Q5^NA"D6J4,S%]@ZN4!3A
MFJ+IPH-;]VC-V%B%K%U;#!?ZNBA0[&'58UQHHMTH=9HQE2+_+@X[!]EM^A;/
M5V250?G+O.70(F*7VA1KECIU-2YTH,R]"?)H$&CS>6N$T!8,,G_FU9Z1$L^P
M4T+0$2%Z  S+7L+.3SLS/P=LC,4HBC?B(DEK@\%2:(/O<Y /DRP+9M51DHF#
M9$?\:N%RB 2L'X:2*FNIB0^C%=K&AK3A.0 ,V8""I%]11O!@LQ%K=*5$:4/,
M8FX6KW@G8MS:H/WFZ3[CM_+>N4K+6)+GF4.1U#XIDEJECKZQ3"6:_IUN%_7J
M27>!]7W-74=UT>(*NPT!/2#28RG/VTYZFXY!<]H3435O\311HG$\%UE1)6*0
M[BY\(QL#U9C&"?3CP$'9DJFO F6"H9795'1RM*.)>P>%L)?U\4(^?+7&7(P+
M>)2X3DF<S2KZ]7=W89Q-@U[8S!A97%9L(F06;8'FO=0FX8J";F=3(!%#]@I8
M'GDP)Q8!7IN)A!B90#$76\NNA2!K?2KZ,B__)/-\<58"ICL/QCQ2O1:4?P0U
M9AZ ,7P$/%!>M?0L42W*7'LM#[)8!+Q]!(5DY7'0PD#(4==%J1!TY,!$A)4(
MU>Z)%"?;^%ZS*MIE.!3/=_Q#JE(YO>*)2[<H)@?%-F/,!TK+85+S[@J,U>H-
M$> "DI@HM>K5?V>9X-NF!%]*\,U!@F^=$GSCH?,$^MB=!>,CCI#AN_3\KFT^
M2:NTB[:L*%_:DM7;K-;6LGKANZ)D]8HLI,^6+\R;WUWG%;3F$CB41]EZ^O]G
M[\V;$T>R/="OHF!F[JN.P)16)+GZ$4'95 _OVKBN<77?OO],")0838-$:[';
M\^G?.2FQ2R ) 1)D=4>5#5HR3_[.DB?/4H$\GJX=!E6]DZA,$<VL6AH0M"*O
M9[S1KB:AIX4Z0^96,FJ9#5+,ZVY3D\X,L&?*HDAOE,<-]A<6]**%0,+:'(LJ
MOEAHR<*#U# 9!G00W1UAQG(8'ICPMHUF(Z'Y!P+BD(VOG% "EYKC>QF@$PUG
M42XF2I%^#FLJ.';&H(DF+Z:,, 4E@%4W-DLC1^OHX6DO++I2!P$8'J)'SHDH
MQ<XEX;%F:$>\&6 U!]X<'A@$MV\AEI5*ER=YL";SK"_<5X[!FHP<K'-R9*@6
M1J:SB?-!R/:*K87R=7O?4HJM>08[KE>/.G2?1M_G^1&=,$7/3YO<SB]73*)M
M=N,*C,VGL)GMETD(]X=CH![&XNR8EQ<C?^48^2NGEK]GEEEA6['A& 9$G2,4
M;BME1ZA 6Q5<*]"E^SPOF&)5BO^$KN21@Y6'O-LM:5TAVQ0K*&CY;-/=WTF:
M7+C%"X8T+^0=T,D'"U]*J1\;8W;.T0%<37)=>6X"5&JU*C58H2&)S6N'5J;.
MN\?JC;MZJ: D=9S_LG4P?\96\_';OOF1W@L]-GH,3XLZ":=%![2:ORQJ]?!H
M+0NQ]L#Q8,9D5Y[ERI12)JN'Z%SP_@2[^^@PQ_NI"&;?<J9%[<)7FIKO<J.5
M5 KT"8P(@SU^'KB?6W3+E()8^REP961L#X=D0ITN)G>/U3J'EK$(&Y[W"T]'
MVV/P.UNOC?6BVV@F%?9*A=2H90C;E@AA'@J3")58KVV)L._$,<_DSVPJ;?D4
M(V[?6S;T %&9>$!K#O"_+^GHR'-%4%-LFD-R9&K^?9-6!1%@=>*TFT#I9I[M
M?&E/&O="!5$IN1&#.++^(N;-?XCKQ$5X*;76?_U-$P7Q2\)QT7%6"+_*N%*,
MG1@[G8:=J,6Q=E!&^2J.?9JUEI(8O%L%UCF&O<38D;%C@>RXSHGA:6X<+ZI5
MY\4J\,UA,6E5YIM3S#P;W^PIIG" 5:@QJY"Q$V.GO%8AYG2IB2W;JL [UVH6
M,GZL##^F- L%OD+,6-ESY?CUAB4BAHLM0FCBZ1N9.#-,0"KB,$G<D<X2K=5>
M\7 )FZ<]7<KR&X&"4+01>'I3CZ$E&UK2VSB"6&OQ#;'TR#BE(</0E@UM:36X
M5 VHE106Y3/L]C2>/$!ER4QE71M:,J@L!>5(4E&?\B#CBE16Y="65F4URP:U
MR]M9KJ111RE^;%M9'!\D%/Q+U-';+*#66I):*AY@D#@F)#(H8HVZY)*Z 94'
M&E>DB2L'M[2:6*^U%"6Q&$)YL%927)3/0MM3"72_9A+Y6JLI)C:K89"X-$BD
MUTRB $:+U-!*#XTKTDR5@UM*S22*M98>5ZZ[*IM$^@JU IO%M3HPQ\_.B$JY
M2$ ATPFP, P]'V9A#$60Y])DR9Z2V2FL&:G0?781BU2J,#[&C8P;B^+&#(:D
M7&N)4M%11R7BRA(&"#).9YQ>%*>GM>&QXXZ0V(2B^FS.6)*QY*E8,J&[>@93
MN%FH8X]Q(^-&QHV'F\*8ERD4G9A9(JYDIC#C]'+1I5!.3VL*XZ&^(#>4"^!S
M5K6377EA5Y8$TB49!IL:NY)=R2#-KKRV*QFDV947=B6#-+ORPJYDD&977MB5
M,7U4/Z_U\,O11.^P_K!Y^V6O%&1?],*+'=XI>OS-FT5Z'&T9RAF>YPS#[J2T
M2[GEDZG'>0$6H:'?$I\S!H9M.C9M4X^5:=Y=N.K&&8V\.C<RAM;$\C^XJ"<M
M%W4BG;G$-_[B7@W+]NA-\+4';W6)%TQH\TS:5A";!/G$I6T@HU:50^+Z<!='
MNZ/#D^8-'3E8>ICUO'E U'NSCN[9Q2,)"5_F4)+3H:3J.G_FQK?/Q/ -KFO[
MY#5L'U^!!K??:'='I#JN(:X^_@SKA[^&$S*&?P96V.NS3AOAPDK2ANK8'Q(;
MJB[FRP'[VQR@TGJUPYZF+@'N^L]JBUOOPR8P>5AA?^PZP>N86VE%&2Z[\>98
M)J*CP?U&HK:U48/4P$7H;>? ;C='S=;*5N$SG ;$]T7%GX5T'5!7C@_T6DOB
M$_.TILNFM=ACBS:6]0AG3+$U;-BL<^9:V*P39NR&8T)*+?F+TM,E:\U_!W"7
M89G8YQ97F2"GC? %<H.;M_SR:8,TO-O&YE]3AS;_(@G-OR@N7#)T7NVP;>@A
M2R$<4"=C/\4E/N-!D9(U0"/C>(1:2XQK6[P'$K!BV"@8!/0-2NA8KJBOH /E
MJ^7Y$7<OI/$2*941LP XD>IAKA_VK^TN^]=60.)V;>Z>#$/^@:D(E,D>#=IS
M6D0^,FP;V'L(;(3=>E&D>E3ZS<4N9W#XZE#HX:K=+'M$+WJ0FR$0\)ESJ;$0
ML2 .!@2_-89C"];?7(AB@[-I=V=\\DI7X'ID;N ]BW?10>$(WQWW#\#\$)0X
M2@XO&'B^8<.]$XY$K:$CP.+50V<*=M\0OVW?__AGY^$1'CYRC3E\X2DF =@Z
M8)U8_]DR)]R$VGKS_MI>. A$.QZ.QMR/PX(!^@1LF:$1SH0:&]M-UI'&QC#L
M%@Y#]_8W0:$?)8YQ!,M*7]C@HA/E5:$=]6865Q7B6F_F=^*ND1>X>M'=>66]
M0PO0)5.8+WXV,S[P[=ZF#I@:)EFL/-S8W&#^'79Z!&@9^S;/HC[@MW0J,-!E
MNV8\DU^Y*SK4YI>W& -8I<!/OF6K*= Y.5?D-PBT\O?8G0]I9KR2FP'@[(\;
M8P0COC4F[\:'5_N\+H] &$4/;ZH-I.,F"1(G.AH5%D<1)V##H %06$YHU-T&
MH/1=O K&991J/!P8*:"D_V9IDJ@,S!%L' 9#63?5@2ZKBB@+QD@82D.1_$NM
MM5YHLW(0!7>HWVULJV6T$O5%:N IFII__EO B]=X7[M/OW1Z7+=WU^#:O7NN
M_^-KOWO?;3]W._UJS*#W]-+IAP;,RQ-W]]2[[_3ZG7O\J?_TT+UOO\ OW[J]
M=N^NVW[@^B_PP6.G]U*1Z7T*; /4(\A6NI$%+1(0\Z<X:0$R-;H@5$WSVMG"
MC5!+_E:FWY;2G%G+,EWJ(^H6V*O1#*K0IFBBTFV#!\8S[D>7'I;%NK=^IDZD
MI2ZAD5 PU8DQ\\CM_(<O<R>49=.QTIN^1.2*%!!*VXU *(JF\.M($.M:0])I
M@^W((1N]>'_;;E%KR$T]\>L#FJSKQ?<8UQNPP:G(6 6A(4I5&6R5"%NEL0IB
M0Q;S#N@<A-52/35E#8(4'3?W7[J\=CW:M/(-.N?.JQ?JO$IN6)^EAV>1E!>4
M)>4/KK1_Z'H4&I =OQ[H&CQN8^!5BEY0IUDTFO* M'QU+./G]ZEK<Y$CT_OI
M@-(DN<!4'1@L7,L_#]S/+=9G.W^?;3)!Y][A?;89;??VQ&8<',?!%4#83DUQ
M<I]L:M8.IL$D-6L7/TZE(:88:8R7'!?G1FQHV\Z(@>&1T-_Z2=AT(I41."7E
MO6W1M,>**IYKCC_UT]0)+V;3PEH87UBQ8D7*DT.;NJ^))+)^K(RGKHVG<O5_
M3,]3$N,IQE/7QE.Y.K*EYZG"^V^5D:=.643E!"9R(NN<I!K*"2:8C4.*:0 E
M*328-6LI,H9VAO8#)_@I&]RWNJQ@R@+\E!?W6((OIE?GUMD&0SQ#_%GD>S'-
M&R2UUA*4S/6=2]0\GG5O...6J,S%\:ZL_)V2JQ)T^BV1=@U;(L93C*=6>*J9
M)8DT!T_IC*<83UT;3^W)!CZ0IV3^&GB*;>TN>&O7+*:0L2PPUQU#>_E==\VM
MF(/#7'>RR%QW)0/$Q2,^&^!S!01LXUPJK>MN_K(YC10*\A,D0L5%_FV6W&<O
M9"\LYH4LQ:\ T3E/\>MA52J6X<<R_$J/8Y;AQS+\+B(_J*0D9-E]++N/<2_+
M[F/9?5?%>RR[CV7W7=31:^FR)IK'S9J0KR)K@O$4XZE5GBHFST+&/(NB.[XS
MOF%\4UJ^V4K8R,<WS4OG&W84?,E'P<5D<<B8Q2'P,4$/+-:'P;U$<,^5H[ -
M=PW@+C5TAO:2@8&A?17M:J[L@6VTZX!V46X(98([R]$K8M,3Q7!L!INPS(@B
MR'-A>1/J<?,FE&/E31RTB*5R43!N9=R:FEN+R>%0A".X-QA',HZ\0H[,5=IR
MFR/%Z^;(\C#>^?>S9^6OTNUVB\EJ4:1#7)F,D1@C59Z1<D5I;#.2?("3E/$1
MXZ/*\U$QD1F*<HC[]2R,1)VSGVFCS-;.QNFQ@:&8J7G:QIQZ0Q:4/(TY):G!
M"VKA3?XDH2'P2O&/%1N*FJEYX/R"B FD'6FTN[(",P85'WII//Q.$\P=U]+V
M\&#N,\@[VHJ7:T]AT^AC4_G1A Q]SN!>PY[W0USN19-XS)^$-[HF]V=@N,##
MV!6;]NF%?XW9S'7^ C'HD\D']_<#RZJNR]!?8#0/CN<]V2_$G5HV#>9_&CT0
MH.*Z\]D.IC>F0]M^X]/B!&VSUE(:4H*8C5+/.+J$8<=[G/4,IFL9$\Y?OI[.
MF9LY[OP7;%H\P1%Q$V=(;S9\3N)Y[JMEV^2#Z_LN(7YC(W)_HW/S7/?T@BDL
MY7"34)N$Z0_'Q PFY&FTIF;@%^*^D:\?+Q\S^ YS'5[@*5]A8'\L"0%$)T">
M&29ON &I)8IO\;R=HB.E29,WO!FQ412L+E#4+5JB%U XOCON'X"*(8'+S("N
M;WC[,S%\@^L"35_=*".DO)VDP1AI\*%!DE5C-9L-69:.T>Q6.T)G7KFAI!]L
MC'J8$QSXAI3FRC(0M7E11#UA.KZ>)G^ZI E.ORV$W_-"^*6(,:CL>I=O4WWZ
MS'96,H(E/!95,:)\@H!=65(1?*FIL6ZX?\+= &SL[LDPJ@\DL&19EJ!4L/LX
M2X)2M*^/\VIHM9:D9#Z&*5.&4OFD'PNV9\'VF^R:)9-JP:[IPV-SE^IG#'NY
MZ0*=OV;$]D@1>T9Q_YYQKYBZ!*U;3(98DZ^UU,Q'MFD(?^F<>C!\CX#2TBD;
MK9C,KB9&=ZL--1M,KPF-%ZHWOAL?4V+[3&\4UT5@G^*(2.Y]<]PU[HQC2Y$6
M5M^.\4[L(, 4Q_4JCFPPW:<YLL!4RM;GXIK >*%Z U !O]K<,'!=8@\_:.B$
M0\MF&N:_ \^GV&%JY8C;D32]:2+WP@L,W9O0:);V8G7B&%FNM?C"4HJNB<VO
M5><<;[.R&[JIW65-):>[[)K06]DPBNPG=8^&.QP?=DR7134=X.J_@$Q7+4NE
MB.23JR:6UM,:/#NY*I/&.BVT2Z?+LI15V %ME;;&5-A1#MM:L:.<8_%J,047
MFECL3VUH;'O$MD='@6DQ=0N:>JW5Y+/&^5P3&B]4<;"SG.*=Y'LT1P8GN<K3
M*@C;37+960Y3'(?"=(_FR )3C 308R(!V&'.Q2H.=IA3-KURR"&.*N(ASG;$
M&=,S3,\<6<\<!%L)8;OM"&-ZYZK.9_Z_P":<Q+/CF5,X'++4=TOV8:MRK26)
MB?52V/$,.YXY/;2SE%S; 6VEUE+$*G0S*A^"+W2SQ(YG"N?58AKPJ5BU2\N:
MP\!V/U>\^\D&TV(ZY*GAB7_&(,MK0N.%*@YV/%.\/V*/YLCB]\;J"$+,X3YS
MFS'%<2A,]VB.+##5$_;:S$UVL8J#'<^<?4-RA%P;C8\_IF&[%:9T3J%T#L*N
M4&L)3 E=^UE-G\S\J.S=(0<V*0\$RM!8A;78J\C)5I;B/<GN?TVLM12]Z).M
M$K4T*I_XS"<ZRB,ASE]NC[5>6A$$>HZ4XSA!(-5:\@6T BP?O\>TZ/F\UM^D
M%=, 9:4)200-&=ME;'?7673)0-RLW!4M";^\Q1C  @1^\BUQW:F*9X&4_4[$
M9?YR2+*5OW',"%M+DT1E8(Y&A R&LFZJ UU6%5$6C)$PE(8B^1=VD(UN&KM+
M4?M*;@8N,?ZX,48PS5MC\FY\>+7/Z[U?+'L^HJ;:0.)OTBV1.J-180)BJYHY
M]EBB"V5B7R**EEO0P\0-&RG];)1J/-S813'UM_TKI=9:+[2Q#%C==RCAJ,/'
M:&TUH,F,5D53\\]_"ZUQ!*BUOG:??NGTN&[OKL&U>_=<_\?7?O>^VW[N=OK5
MF$'OZ:73#V7]RQ-W]]2[[_3ZG7O\J?_TT+UOO\ OW[J]=N^NVW[@^B_PP6.G
M]U*1Z7T*;",P+9^8=2Z2M,3\*4[$Q+=_TE'XADKK!DVF6W'A5[4 [;9_>X.?
MP!0KTQY)X!N*7GSG/4UMB"D;^NTKK+^URXBV83OZ[]'O\WH@DF3ZB/[)#]'-
MQGGQ+2IZCD\X9:/CU@Y;XXA4B&$ 04[N?W;0WC@E=9[)&P&>C:%.C'V5J7U<
M].1OKC-%Q8-V[V^6/[X+/* '<;=[QF&,^$*&M/WH,WQPJDYR^K$(*:22A-]=
M!QLB<;$$S42X>\LS7E]=\AIU(HR>2-5X#-64&*HIJ:G6/&_[O6ANW."#FT4$
MM+RR]LS3]8:F2'ET@B0T%"7YZ_PM\Q1)+%S3Z U9SCN>TX]5S*EK&5T97<\S
MUD*,N*J=!L6[N_*<QDJI3#4^QAU6@7YJWQR7]@1^@0T^X1[A^K''=6SLD[QZ
M9E;/TG.MR-Z5@K(KT(/^279/%KXDHJ(:P\&1E^30UH"KLTY%UY.1[R2(SMHA
ML+R"[?2=-R\+"3]L]!/]/' _M_J^X9,T@6>'<=7%DA(/GSAG1&GYF^-.3$;*
MO*1\<7QCPOB6\2WCVTJ1<IMO\_:3W3/_4FZG'H.);\TFA.L/)\1U/&O%/5:,
M##O(NC_D!6R0&0=9M RXPE?FR?]HJ$H%!,5+Y^Y;][[SW#YBF&WAP7 %[^L+
M"I<M+MKM)//+%NVVM]X^/:>)2TO6PNSY\N>C['TEP_WUX7YO,?YDW*NUEJ )
M,759&? 9\$L/_+UU)).!K]5:HJ1G;CUQ>N#OP?=E!?%?=##^WO*1R6C5:RU=
MS I6ADF&R7V8W%L#,1&3.@\25&XR4#)0%@W*O=4+DT$IU%H2J/6,S=** .7E
MNE]^_?'8>>Z^_%[9&ALEM%SW%OU+ACAV19>U"C1BRKQE8RC90,G>(A;)*)$
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MKKG'LR3D[F>@@=9LJ6!59?7F,#B4& [Y/<"@ZEJ:U,Q9(HW!H91P.$Y!/4W
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M#W)A^]>2E<R=YMAQ?P51DC\["S9\+4U56#O;*T!)ZL/B;/LTV/_!WEX2M0J
MB)TRKT,B_RFS@AV.Y<Q-<=C2GFII\Q?C G72TO3,;A>VM*=:VB,=4BKTD%*2
M9!8[4F#L2/_Q5!NBZTYL5/*G("ERL5LEEC)[6<C*7YP+M'"AVRN&K,M"UI&.
M6Y5FT5LREFY98H.PF3\G2%%S;>,8',H,A_Q.8U!U>;9^# YEAD.NS* 42D;/
MN5T\23(V"\ZXP&=<TZ47YA#Y:CF>!<\V7(\%9)3^&==TZ>4&9'SM]#K?VP^G
M*@9Y#3OV9JY#U)UIUK![8^4[K@8_^4]<85O7DB2!!?1< 4KR'][";J\B*&&G
MNNMKGNM4=[=FD5@!CY(O>OY#RR;F=,J9$ZK8TIYJ:?.?&C:5LRWMY6Z&NH_/
M[8=[MA<J$.'%ES)LLE*&UX,?-?^Q)>C-EM!4*Q!QS%!R*$KRGV:""JX(2ICM
MM+[FQ1<S;+)BAF5?]/S%#%5,05'/TF.8+6V:I<WO]52%LRWMY>Z%OCUT_[?]
ME>V%"D1XKKJ%.S46*$&V%[H:_.3OIP-ZL]7,7EB)@:1Z(,GO+5;EBH"$64[K
M2YZKB-]NO:*PG5#)%SU_SW;0(ZVFF/7TEZWLB596R^_R5-5SK>R1(E%-ZVWC
M$3=X_6V3[J'.&3;W^]/3K]W_FU.T^&$H#3'%0+[,',_"%;YUR<3PK3?R!4/F
M;\0&3F.3JH9'\ &UUB?AIP46@,1L=U<$V^;W08,";XE"YOPJ9IU7#R3YJS"I
MF$I36.-<AI'R8B2_CQM,AY:8O?$EV\&=>\GS^[XU(8=88 M[JH4MWN6KY77Y
MLD4_U:+G]]-JTIFX^<(R"9>EE59R"EF)I5. /[__&;1@D=L@5@?GLH"5/U8:
MM'!+:?+';VS$D%5)9.5WI8.J;RF:T- JC"Q6)"4E3O3\CGE-S>.\86 H,1CR
MNWM!D[4456D(# Z7 X?\CEU0/P"'9KG*J[$*29?[C&NZ=(]?P[2\V<3X0*XC
MNY_.KKST*QE4V)4,*NQ*!A5V91FA<D ,W?DV44_^F+A5C9(3691<X?OD_,$M
M.E]KR9FK3K, J.IA)'\TC"[46LT*U#5C&#D4(_FKW^EBK27P%1 D+*QF?<GS
MA]6 U@'5D?'XERWLJ18V?\B(CBF+K*1#61<V?\@&R'<4TGK9(^'"E1,;8A5*
M.KQ@2!PW<QTS&/J<&U+_@*BXE-$,X;SQ\(@SG6 P(>$QU0$'AEFI>Q+[Y>\Y
M@ST.(\^EV75'ZG8&QD-+K(MZ]BY6QUR],V\J&/\R_BV6?^$)1^)?M=:2ZH)8
M7-%RQK^,?QG_;O!OKG2E%-R+$6]U69 O6/ON8]*R\.))=AJ)O'AVEBO=+EGF
M4T>29F0Z'4W>IJ#G[+W(>(OQ5N5YZSA]374P<\$<E9M2YKK1C+<8;UT$;^5J
M192"L_ $M\YK>=N-GX6SJ,_XLV_ Z^:Q(BN5JZ:&^VK9\W>O/GI(@*(NAM3C
MK1LS@86?&#./W,Y_^#(/&K)LNG3TIB_1TZ-Y*]L!+?1]X==?WBW3']_J>D,6
M%%SOR,\=O3C\%K;8_]B6 ^%WDM3@!37Q:[XA)'ZW\[%"0^"5XA\K-A152_78
M[/D.ZWA;!]4JKDX5Y)X2?D>1+BG"L,0BBI6=02Z*""\N*O?&#<@0I!PLS'1*
MW*%E3"8?G/%F6!/*O_!&?TRX'XU^@S,#%]:)_@YC<$WNS\!P@=DY9\2)O"AR
MAFWN>(Z%@L$VD%K&A(,E_(/X'GX!]TJ-];"T2UIK\?QK34,6@=3#26 2C_OV
MX[%]WWE^K'/M^Q__[#P\TI7[G_9#_^G^]SKW#B\=Y\.%1T"C;@)C<W%1!Z+B
MM>R HB%IN9M'6FZ!3T6UWPCGPG1>;;C'G!\M<B/7F7*)1L7[V)D0#_2_NVE;
MK.V(N[UO<^-B8%F#VUXP'1#W:?3;XO9U(P.F,$1#XQT$M$?LA8W!+VT,<8>I
MLV-4RI&')=5:_KNS9?9L?< MQ^AQQG#H!(B/5WQ;,K5M.K[M'9*T:U(=>+#_
M\9MEDN^ :[!6C%?R-(ILNV^PNH_&OQWWWO)\UQH$ON,NS_)OQ.7$L+!',^8P
M_Q^4ES(/63[!D,/X@^V0H7\@G[ZZCN=M'J13\H?RWB6$F\*@QQY';!,8HD]F
M/L')<!)?IVQ>SS?UG1 L:.IX5*K&9"?G7*WF"8:LUEIZ[(CW+I8-HFS?6J72
MMTP 9Y!T6CD%L'X. ;P6_28=@3L$OECQJQU]P,)QA:^84_CJ1Y^X2%=JNYI,
MOI42^*,/6*(KM7W 4(SD%3<D;_@28'20D<-MD;4RO39LFSX\RWL:M:?(G?"O
M;=Z-#?N5=.WOX8BBR3X3$+EOQ'M!6_T%'OAUX@S_6$X1K T",Y_!HWTW(+62
M*H"V#1@))XVT1PH/Z7QQ^^%&<Z3$-RV/2BR/@@KV*LZ[80_A2[C3"Z8P):I#
M#+P:O_1NT^B_L![[:1U9 L\W^-!SF=63)8.%H^1S.>W^3A&;A3NR!/2/Z6RP
M;+""(&?Q9Q:=2WI\IXP:>S#QJ6MS\.@)J!;OIP,BEK.1(G3/EXX8]W/Y?>V$
MN(,KT. (C,G/ _=SJVW^._#\*6&D:3T3/W#MJR<#S7A8(\(>P9AX3AAS5%@B
MJ9G0I,:8H&%7Y^[),+*KA="N/G[2QWX*7GYD:0H:7%;XJ"SLB67[U9B$QQCM
MQ:X#]F7S'5B$UYBH  '=L8IT_#JKU8SP9LQVE<RV)[@M-[,U:RU-40MK!,J8
MC3%;]9EM3^&:W,RFUEJB=/S2](S7S@TWQFLI>4W8DP.<DM6RQ9T*&EB8=5Y2
MBDXP/!XKYJA4H-*^J:7?N-X%KDML'X^.WBP/G7Y<&$:&D5,.AP>O-!AN&%WW
M00RW"%<'*ZX4ZKJ$ EST9"U:F^^+I7EQXL_3GJ,5>W'ZN%Y=.[KS=UBL. ;$
M,NB*G+DJ/BO>53U\):29%HFO;-)?Y%'ZZUKV?!X&O^K!+R%UY:CB3<28%IGU
M[[UX>"5X0,\HVS"HJ*XH0M9J6D<%W^4:KRNGD&M6Z\RU')>:JJ?J1'D%W!9C
MJWHP"?AI/1QLN2:I6>X[KA<R7$Q].EV4:BV>2?-*XNM3<<9J\;C"5(FX4J5;
M42\,4V7"U($&Z&ED%AZBZJ6R AC CB*T=MF@Q<.J&5^7_RP2ZW+-RN_&!UVT
MST.7F);//**GM0)VN43G2Q,%W;5GLXE%S/:K8=F>OX_%]K@-5&"NV&KUS""X
M)'CM,C*+@U=&QP$]$I.:8DPI%H:^2T+?+H?H,84;5JB+.6]EX+H<<.TR1<\E
MV"1ZVJ.J<DR(&[-:SV"U,M=HQ8S6Q88PCKOPI$M2F0_KPL%U-)-U)[C$6DL!
MP;V=",# =4G@.II%NA-<$HW%W3[58=BZ'&P=S2#=B2RYUE(EI2PZL;+9X7OR
M'+=+-YVKNQ6_J^;L]<6P%T&D\LNA;"IN3]?#O DE$I[R-8N+32AN!:N1<L+X
MF?%S+G[>T^PR-S]C-J::O8D'XV?&SXR?#^#G8K+0MOD9.]F)A;4?9^S,V)FQ
M\_Y=?S':.>,Y4YA3JL8=H%>5VV-Z37Q>*\O9VEVR/EI!&0^OMGL$+,HZXO*N
MW!5-F%_>8@Q@;H&??$M<FY7B'10IBW.N.")"DJW\/7:7GHA7<C-PB?''C3&"
M$=\:DW?CPZM]7J^Y:=GSAS?5!M)QDP2)$QV-CE=O"YL^4)H#/S@N7?A; #!Q
MP\X./QNE&@\W=E$P_,W2)%$9F*,1(8.AK)OJ0)=5190%8R0,I:%(_@7JFE:&
MQ:*J6' NK"YGM!)KHJ8&GJ*I^>>_!;PX M1:7[M/OW1Z7+=WU^#:O7NN_^-K
MOWO?;3]W._UJS*#W]-+IA]+RY8F[>^K==WK]SCW^U']ZZ-ZW7^"7;]U>NW?7
M;3]P_1?XX+'3>ZG(]#X%MA&8ED_,.A<)36+^%"<M-J1JI&2:FGRS;&>1IC1R
MGY;X_7@:Q3NTNV'C$[-K ]JI_C!@<)$&[(\)\9,J)4MZRDK)RGDK);]@F7 L
M#+@LBVP,G#<R;^9BN&3>_L7$Z 0G<)&@)K$]@K;NDBK<("0+YU&ZU.FM*4LH
MMZI3*[G9;&B:>(0BN9*6KIIMIB*Y<D/@\SWV+(-5Y'2%@BM[9G/RBKYIC\X.
MJU]:\!8GGDIM6LN]T&.M;-@I:5W7D"Z[RYI>4Z779X*:'*T"($O4D 1C[8;$
M>D.%P>J]LDI=QW"2BOQQG*0R1NA*0M%>TE,[0=/U5CX1ZYQ$$.UIH'QL#CG)
M'+-QR)$J(LNTGHR4F4/*592N]'B^<Z8SQ\:,RE"QPK;6Y,A?,]P+TO8Y#G8+
M94'KQ?'+D8H:RV*M!6JE MGO&9!2/"!**$"/5'A7EFHM31>R%GP[4[J/(%5
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MA;6 8JF"IUKR_ D[31U,8B7KDI=B9:^;R_-GCZA\K25IC,LKQ^6I,Q:VEUP
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MV(_8T%1I;*9WQ0TQ)J\=@U5NQ(:VG:2"?77#9.=/PF8&)]OP'5JN1U+C]>/
ML@:W5,2&H6IWH9Q-:[=CY7Y1+%5Q/&9@'<? *@! &8PLN8Q&%H/6<:"54$OL
M2-!2&+2N!UH)19@/5'O-\JF]'!M 0:_&#O >[GJCYB-=7J0U.PLXW5G M[
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M/!6H,_G@1F#"T,<80\!JN,#XY&=B^$;CB N]19'XE=[-;TD#/Q57+2>1AZU
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M=!\R!4U!'H.:O 'M.@6-XH/5L8K99;J-M9Q?Q*BPE!_S+"DT6D9128#=1LG
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MG,E^EUD:K$K57U]MRD@&D^0:4&>N%1*93\OR7! K<^9/-F'16"5YIE)]54T
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M5><.&K:G'C&!]YG##\RN;0.,D'>JVSZ[<'=ZS3*^:A$O&#/(( ;)6-]XP,*
MO3%PO?T8[FP[&V,[&P(231QO\A\$1N*"S3SN: 2.1^D\U,VPKJY!'8:C.+.8
MZV[-YP[HA-!+=- .^'R0D:6A3XRE@?<DX"OMA DXZ*+O*V_ +/FIW(0NK3?R
M9GD8Y(?W3]@LT(=V#1;.F!E@/]@,:I,YV2F&QFQO/I%\X+ABA75DCH, VO/\
M<Q!5^^;;T)]UP_Z_^M*+0>)2VKT42%R^5:X HU2'(5-@<\UAXN0'SIRMRQK4
M"YZ%\%TU \\$[!Z.J,2S/BHM/-KFN(F6LX_FN?#1DD.W1*&^2C@E[JG**:?$
MX)(J\FEH1DD82:EAPJYSL-@Y4COML24-MIOE^#WIU+MZV43QM3*?1F9@O3AI
MBIBOHG-&/"GN?)4Y9M'X#*5=>334KE_/[.&!<._%F*BBU6><+I%X=^D%:95(
M.V 4PDY"!%L)Q?5>N,U9X'(JD<Q#QLL82^979MO?6-*AUM+4:C#B4;8;.GO.
MF!'COU[YSG<L-YX?K;J^(UA@,]P/TN^V9BUMLYT\1QIU'CIYWOCN8<^?B6)L
MB*W/:ANC(;:ZM!B,T0#U+RVH6?5 -DY6BN%D"9L=:C&)J4<Y^8+M9(O)]JX+
MJV\SC7G(DZ<0G+WU;2Z]WHZ)V:0KH1G*R=(E8<5EUA+XZFP3,7Q2TT:)V=@A
MDJEU"CN$C^WFQD\ZN_F;VE8LF\@-8(F>+,F_558/U]"3^N*?#[T+;RK.SYQ.
M;8_.@C2T[?8B]I7\%$DD7R*3(MDP<*S28(T6Q=Y2OB1E8XE(&DF.+-%I#*1>
M5IZXP"92/5CL<J\4Y#J%7'LIS\=JB2]8*UQ$('Y7)U^JX%DPI)!?0:[RKQ3D
MRI-<%?3+,AY$'ZMPS?D<^L/N<#4.<X@#XPL=&(OHQIXKFX N>W+47&T,#G?^
M%I&-JD8V(OAF.;%#MS' CL:5BVK4>,\0H7$1&B]76W13@UJ<$ ?5&@-%SJHQ
MQ Y2.D^D!@HY@2=Z:%1$,2TNLXGL8@GNXW[% SS@R%.4TW<;@Z/UC'T$AN#S
MN$%M>RMK >,86)/EWM[@)QA*O6@U%/!'J\UY)&LYE-1NJ?W\T2U[6DM."9J9
ME!D?427MMM:>MG\[@G')OL\;LWK._IQ>(K@/3GF@-QX#3)/V*NR2\[V+($.,
M!$B=PQ64['4%D^>;;:UAP.]-\FVIHR,*Y@3"2:[1U(JA68S&R%3$&KR/O6UH
MSC;O>C <1,ST[+@*5:F?HD*U O6H6VJN-]2DP0Q92?06@L<E"\-Q+1MY!:CF
MN!QLQYHC0)FW\CB4SXRNX1:#J=X6&1[X!M$.UT??G1G92TIPH$-#>0B-!'Y>
MTBW.,XC"W^SS@^N>&4) ;H/+U50Z<DO+$T$AP4$L;[H23E?JJD>G>Q9NV.<=
M?*?T,!X['!CX(Z[EPA2R4C\QJ6W[INP4E!N#;B?&XLX1,BS/X2)07+]]9+F/
M :B<"9F2YSPZC.S1EAYYPISD.5Z$5VMK&>A^/=@D\#)WX=DPP_&;X?Y-[26N
MS5?=].9  \_& L//^I0Y,#7 *1G!AHA&' J$XZW7H)<9=L/<@[E0 M;OF[M@
M[#>S/81Q@/6T^#ZY-M8,H)QAD."&;<*ZXO1Q:;FJ9ULT6<)LZ0UC(S(Q8':O
MQM0AJQV2S7V2,5SK6!HC$HGA;"]\ T[SX2/H891PYZ^Y&W50=^J)1D^?=_KW
M/#%@\>?Y&+'-Z6>ZGP1\2$#:(0%!W**^TH0%C(J(PYY+YECW'8(AS$:G9M8I
M*T5/60.=T&\G3QE8X@U^65@>@B9Z;@#]@CP6<""(PY1OKQEGV2EZEKW&0)52
M35*?K0P3S%9?Q[$I@5F:T?QX0VQ>,('78+/^A%&YH$XSXK9V$RR&>XL%C-F3
M1FB.O8+N=GZW+2<[:)7<;PPTL#>/(&]F!Y[M)NR]>4Y  9-9DZ0C)E#$I-#7
M+ 7@;PY9,PT-!I79VA_.+N)H2)&UR.A(1P4)],*:MX/QH8JW&O 3^\VP'7=/
M23B>X=)?T(&B,$@8%OG]ZS<"-KEKW,!X9C ZLC2FS AE+>WQ0>-_C\;CKX\/
MHWNV1.@%@7<TA=L9FC7L+S\,Y."-=@;&=,B$4I-S)[XH@#_=#H?A0PX?_OCO
MQR]?V7._//Z_CU_O1F3RSJ[\_#!D -38R&850%K[E(B9%-?Z$W@JV RZC^3L
M/XIB>)\133D7EKI+)V=$6])9$I*LDCO;TF=O^CNY\XPE0T$: T/6PVS8ZK"@
M\8>_[R./[S6OF 338WA?#%Q*MZ=T29:(>\)=_!UZ("/!U+:PW?@T!^W'*7OH
M6?HPP30&!3*E=.9@MR5<CN=Y?BZJ BYJMZT</!7?Z)@W6*<%84U#P,)Q< =A
MME3&J1Z(3+#M< MP&.K(L3?9S4Q?J(ES1_PPA*W)/G'$)#]<:AUL#BY[#=&#
M]_A&'^,ET**@P9@^0J5H8]#Z)WEE^'KFAMW.XHR$R,:68C%\<093*%D/6!("
M3D6-$]Q4%9@WZO8E<;,?K0MU#F!A/"?$YS:=^ZT'$.H0UG1_83<ZY#@4W;8U
M!M[$0;KW8+E3AFUDG_G"H_;]C?,,,BWAS/2@NGE*:[&&%PVS</HQL85=P0-:
M'8V*LC4,E@L5O6T@Z<\4."TA.I0O)< IT^+P\'<I@;P2\!HPZ%G32\"MR'=Z
MX(!)J6;'-F#V_SES2T RR'=NZ'8E;9IL;BM]"LJ#VN^[[)N^8],'!>+O' ;B
MSW"(W=\<8@OT?H'>+]#[!7I_$GJ_2'81R2XE)KO((MDEGCQ?L+6C4T!6RQ?J
M.)0^\_"=^<K?$Y/'HN20QW*),%X7Z$6^T%=]^DX>;(S3L"G5(X8':V52;NQO
M&@SH4S":N1&+UL%WJKLZ.^%S'%CA&8M^@\-M^(GG+%)''%C*)2A6%KYI<O\)
MYGB#0=NMYQ[Q%C.=[DB[9_#MG6#6+D,-P=S,?+;300PU66MV4ASN6/.YX9]0
M^:U%+7 Y^+%5$-.$M4+GQVH28&\=8QT&.TJ%+PSLD$!X^U38JE?XR.-BA'-/
M%J07>-;S/&BKN4,!X)+I[<RS\? ]-&<)G,;NOC_$3NAY8\AM$I8_W.6FY. \
MWU\ZE%'!EO/. XZ""=Y;JXEA,COW.XSDU<1CEA%: ,;<0!W$RDV<(?*L36?@
M9W[9=I,8<HY]LDR_=BSTW2[=0E]D]DT[&-E4I:309A [L:G?5X'W7,#(F/^!
MWWH!R(IC!?X(\H2L'Y2'KVRZT@W6A'N7=6*%ZBQ&^AZ\:<-6:9@)TW'4>&8*
MN!^&8W,-PC0"2[R^L>8WGN/W!*D-6_%V0"Z_<D_]L,^R<Q+BOLCR0>"7PYS$
M&H0')VB;8\)--P^NHV'G^1.Y#3O'3(VUOFE^NBFM]/G.O]#/V7G0P8AV?"6&
M>1XZGECZ85 _%KO_;O\)_O-L_,;@_+[A<=U\YUR\L);PG!4[0?3CMG;D'&#O
M^)1N]A2FI/P&.-@;W6176-.IMW[GYZP[9T^HPRF.@2T6L5BZ ?(39B"P%)B)
M+UHL6XF'L.K0Y#:YO7?<OEZ/'MYRDPRW@W<N,<RC@VJ6T*F[[#-I?G:/O()^
M(GG9GHG40#AB+-W]$^J=F6]4QHRG'O"C(\/>3\[@^3F.@9D5NDDMSUGZ2@U;
M(@&9PIK*U\(G[-FJUBG&^%,QJGYXP_9WF>VI*[=!V'ZYR>X[YP@A(3%ISR3!
M!7V>_^'$ 7.FV5V[&4]9LPTO5+66=6!X<-/MQ1S1)9QWL'-PD[Y%+'.4U1C+
M:F/+^R>LZ1MZZ?%=1GAS."=0#\8*S"(#-_OE1E$P@R"\"X,$+<'(\I.%-O=N
M[W!A+W)Y$0@^TR%3,#\<?@L:(&:0^Q.8P3PK__#FETK4Z[$32D#X5&5(8F_,
M?6]4VFUR9\ N\D[&P*/8M(DQS%=K!LRYU[ZITGMA-'.+'1@$F7XL[PHFR&00
M?F<. VOHB'L7NDUT-RD1A<I70=MTK@BYFBB];W2YQ'_AL? ^;\H-[9 WN\T@
M_(]E^U&&7=?73Z1E;2DWP\1LQ1E&WTS,!L0!L:G1.3S/#;^.I9W@-5N>9'XH
M17^;,22?!!J:_"7A] ]\#=-/06-X/O)5B 5\7<D2$N=SGB9*9HQFYBRRF\[H
M_GZ:OTNL:L=<XJ.;[$,P/'"/L^]KO<:@HR5YLUOMGUMH*<N$-]OV>5/M@R45
M5V5WP'$/)[*]^@UB"YOP-AOL.^6IR<RJO5]@N4'V*(7:1JM123=5%)A]L\,.
MCX),^3 NF-65G J2+MNAIXJ2?7&*68533$6<8L:39P1B-@']@3'?=&>9E30]
MT;,G7RQX>[:SU@>8_%&P %5J;/,SAF[P(3YI]^SU'LPGPR7#P."*8I^$B;N'
M@Q)Z'3RYNG9QZM-08\^&5J(V=-8-?+<F08G$>V"\SW.^"D%UZ5<=K 5O=6?9
M-FOJ?:^#99PZ -$/<0&>8&WC0'L[^F23F@],N$0FG')FV%C?+?+,K5ED-!8V
M"QT%<(J%R8@=ZVWZEO%<1]Y-FN[%\?H64/5>M^UW&,J0-:[/3A$\R8HK8@N(
ML:F:VE"EN9<5G94!>I=F@+!)QQ+[V\D)MC!1[B[A BO=SLU,?V<.TG3!#;#,
MT^Z7.6WUE&DS:_.&U;#[,^=^XM9#]4R/&["KE<$C6< 0V>C2:Y=)EVXZNC!O
M. @)S [7MFZJ6#/20"I3)VKQ&F!7)UJ>"YX)/\IF:;B[.B&B*9NL^IEY1AEI
M(9?)#[WT_!!/D3A5D9$ 2ID$Z*<CP %VB"J,.H0[6UU9_2=(LXF0'>AG.&3F
MT9!X2^I>K_'J!CV?S<BX\>\W3$MPO*P0/&JOD\46 7:D)]HAW78:+;2MD@7[
MP\34CB71V0N#Z.S!V9D,$N$XH%4(1B%^@B-F^3KN=QC"& ,ULV_4QB1T_95N
M9G4CAZ8E'3F**VE(LL_RR8=PJ82BB3'PC'-4>^HQ^(K=&7ZG,[I:LPPFF%[\
MG,"*[?=;?3G*0/]D!7^Z#:9[!=FC4SWV4$]ECS=X$7'X)Y[IT*F'3J(U61JO
MP2D#N)[_VUN^;TYCX (T%V:5%-UCI^@E#4D[=6TX'!4_L#2P=A!CTL'Y^>8T
M@!VRNYN"<QZP/C=BWTO -'G\B1X'^,P+I G"XT[<+)M(R'KI@OF6F%1(O+5_
M5$YWWNR[\0[=H5P0W@<"PB8/FW90OLV3_-;Z>W O;/A@^, %,*PETG!E>*N=
MDT"X_@VH3F^L^9PGOV[]*)WC!*(HV ;8$K"Q84"/[=HL/X$?YS%X*L.9LBW/
M3UW@IW=X#.T?,#!!#*^JPQ(&D=4VF;9X",&:37SB1PR_!-_P$O8RSRBBP,(?
MNV!5S:-@M=<3!:NB8%44K(J"55&P*HYZZW#4VQ%'O?'DP13(?<357 I6QZXU
M_1.+5*CM\)?@2AP]5D4<J<BQ:K<?/5;-'BT[CY0I,6X76";SG:X]&XSG2!EP
M)2-\X$,_3UW+/Y!M,SO]SM)M=ACW8(#=[UHV> J>NP!7XF_?N6:7[D^7, 1)
M?14"I](YC*.^XIF$FRN]=68@:=C-$MQAQG#;X?BC&6Y&SMU *7,P46O'@^AL
M#C7]8"&>6R'N%@Z#QX>.DHG,+/"NL/YJH?^@S.'[N3:XJ<=.@L'D 5?/67!,
M_PU3^1'RQ&780#[:U,5BO!;Y(]V-31Y+"3Z>^6X]>TCJ.F1\MI, !AXYC'@!
MYP%4PSM;23:\32EA9N]=PPK=)&CPK.-/R#;(=?P\L'IX_'R(<<R'(52=N?CG
M%H4F!%MVYLOZ$073O8>7?Z4@>2=,7,%^=W&'1L6ANA<SD4YCH!V?R$Z=5)9
MQWY_A9<%1FE8J,:T8G1&')><^G(%%-,Y$;S>\4.@>#6^*:S>ZO/M-2=K=L3C
MCX,L#C0[CZFAVONA&TOF@:35OH?Z99Q[AGD)0R;< X8WD;W''!VZH*;#&S"S
M&-TGS([^)9+"EL%$G"[HS$.DS= ;V0MWWL=?AR]CH8P8PQ'SN.O0O ?S7>86
M%F<SR</9.,3Q5A@,_IO7=  7F7Y>]_#Y?K3% -5_\O*+U=HRT3$.Z%X;QUB1
M6MU.[R3'^/AWJG+XI:>ZVQ(,5NI?Y6"+Z%5?*P*(P68;K-S-(^R49[-[6<O6
M178O3,/CIMF:A9ZU[R:&^YE&C1H+.WTYL[5CKE"7X?C9?AJ9@1T<,B)R:;CL
M[X(LO!8.WQV-W9W"%!<@TQ\FUEBRR L6I#G<ZJ+.+UBB/<:T" [",MQ8J'AT
MBM 33?+$38<7_6<*^B8335!^2_E[W5F0SV#(D?^FLU<\V<]$[+,W7+& 9R[@
M-_0MX-\[:M*YX9+G36:1D)OSR,X!OJ;O'.QFR0.:P]E_/(<E]3N"IMEI^H(M
M+[-8 P<GGS#_DDV%^"[J=SPUJ1E%4CG#;DBR'U-3,+8=?58ZRJJF3R<%T_&_
M#O1YSX$&Z;O"ES7Y3]FBE)&6-@[, GXZTK7W6.0*MI3G.6PHL8%BK)F):[X;
M,8MS6R_\-N.Z"1$3(I8P^4P2UD_HYI.'8/688$4#_#PAJR;2582O("162&SV
M3;$?:3M5X*;8Q_/[J.B*/5%(V!5+6*3S67$2UL,BR:X2DR-3%QE+C/T+X1/"
MESY)Z((N7X_UC^BT^C60O6SG3EPPY):LUB"PQ)-;ICO)+7X!VJ<E)K>0"9U;
MO/[-1]/U,2[S.+"2LQUBQNJ<:LI=MCTOH2/F,1F[8\OS?7]UCHJ>C$E?AW 8
MLTK?Y0U(P3Y[[-.Y+/L@Q%4O1G%7C7\N&380/+G'DTD0^#GS9*<Q:!]L85P=
MEOS [)/1#8PDWA\P1?-F)!646UQ+KLQ6:86<O@_ 79G<G,NJIBYPU&$$L#+8
MZHK]&5X(X83<%6P<@9B;F$LN?):+^2S[,O(9UB!%V,#OC?<-)F#-CHH5'ADK
M!\%IJJ.M/S!#9=SR(V[,@2V_<-;"0U.MVC: \&VJZ]ODRY_ABKZY\9/.;OZF
MMA7+M_T&:+^>+,F_":UX+;R64(!<%J_UV_7A->$OG7LN5)&-N2\U!IT8DZ^4
M??D$)TIK:77PH3#Y/VCLO&:+XF,;'CDFNI!G==[Q=#5%\6)'14=%2SZ0@5NK
M1$'!8B4?)QUE,24^GZU6'%95OTMP[1D'3D>Y-M>3):$7*\5A)9Q)'>6UW Z?
MZI*.^-$9\$+'5@'3?>.MEX>N:QL3CT'@O%C?=+3T8_D1VSG51_?5%AXBH>8S
M 16CD.Q['Q%)@:6861Z"*@23%AG"N1+ING24VD_ &<R<.9PA)*GE'9+,;YDK
M55DC9%O(]DFRW2N\7K6/1Z_=F(*<ZQ+@"A:T"J4@E,)I7O$%BX;@78-V3+_I
M4_WCRBD&(<1"B$L0XFX[ D51F!##<#&]*JZ?P-6(<5%EN4*^A7R?E, 1L=P+
M%&\L[%7[,?6%-13OF!9 !V'5HR!Z\)3+8I/W^ZV>JIP*3=Y/AW*<%9)9SAV2
MN=^23^PO5L98V^W3GBKHFM!DKM,5#)O_6'N@0M)ALU\0[EQ)=8Q34>C2:/,:
M@6HN4,T%JGD5*7\FJGEYQ$[;>/,RO;C3K424_$CLD?F#<J#L(VN0_Y#55IIV
MH3&-TG&=;N16+VJ@3W2'LF[5@T_2?DO@*O)0'056H-@+%/OZT%2@V,>BV$LY
M)#1=- !Z$7(=#(!>)HQYD3EF/*:X'/QNI\U0TC) @U;SQ%"(11W%(IM41"!S
M\Q<&I3%0E9C,].-Y.4(DA$B4(Q()99)YB$0'NW3')*,(D:@"NWP$D<AH/*7%
MU\E#.-3&H-/)4LDDY$+(14ER$:D<+5 N$ Q0Z6?)?1*"(02C%,&0+YDTA&A^
M[6Z6#G#5JB:L%4AF54#_\R_:K9X4==OE(!EWVCWP3[H9T)(J 3]04Y;(QA$)
M-9)Y,T(?&*'=R>JI"G:X%#LDE-7ES X2IM_+6:OZ!3=<BALBY53%<@.#U,M8
M;RF8X5+&@Y2V+B=OMF!P<'%[AK >2D:!N:SQ("F@']I98=:%_U69)@4?0"1B
M7*R+XM)VI$YCH)4A(Q^5.S)ZX!&560Y^<4="?+?8,T.QJY;.)&FCG84S2;<Q
M4'H9^GX+'JF(:U82%G]'.A7X2G#.A3@GZL9=6*?T&@,U<\M.P1Z7*L^OC('2
M;PSZ6H;2?=%(H>*-%"Z+F5L]T<KG^.V8S,@83Z]Q1L<'X9J+G= =Y16I,=#B
M>*5..:,?A&$*<A]/9AWY0+JQ4#-5XIJ+G?4=Y17EA$,]P2_5US*Y' <>Y9P.
M. !QD/]"R]26:U)[E_EWD.C(:F.@=F,"#S5)ZZR\BWFX281\AB>YNQA509V\
M"$$3TL!+!Y>LGG[I2A>LRI:[8 9+V<NR*P<1*T1/B-[YYPK%5W[+6)FAR">6
M?@NQ$V)WA6*7=W5Y^K->N7=JDR,AD$(@:R20&4W0"]:VRWV6$ILY1B)$3XC>
M-8K>!<OGE39X?TI'R)Z0/2%[TQOY<JVW.@JV]>@JM1*]^G7OZ$CJ2=T[E%9;
MTG)O!:!(+:E]6M^"HX^56ZK6R])B(+C %Q6%J<RC@*D^W0_S52Y="8Y?&L]^
ME\&NCF@7.0_LZA*THHQ\1.XH"),)%";P5-!@Q*&@"F?D+T^W0501Y1F//,@;
M):9%EI;Y"A\NZ')&3.K"/1M$\05#%">Z@T]YA^MM2J9+RZ$S\F:X"_YLT'WX
M1,NSR4%U;'IXV+*OD3O=G1-:95\1/_[E&>[[5^HNK-D6Y_SYS:2VLS#6WZB-
MND=_I1L5?".'=+ ,GD<_YC3MGX2R!\-,@1KP5"336%\Y'E#LSK#HVG#PH^':
M-I:,4BWRV;()<BT^0%_"MSP(@9.TS @=DI_?).LE!:8A-M5GY (<PYYZ:[C
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M4G=AS4:;43V_F=1V%L;Z&[51]^BO=*/';^2M(M?:8"+U8V*I_R24/1AF"M2
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MP2=I6VC,X52$0C];?@L[55"QBX8P^6JGT',Z5 A#U\V-GW1V\S>UK5A&D1O
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M!6(_N,"7 (6W6LK:%F>'D?) Y4^X-)[?2H*PE?. L"U!V;$N*@3T&/87=1A
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M<SUBP"&I<ZHI"KFX[%6>83J@)^OV9N(XA2A\)5'8LZS>+XFS5S,3**26$Y3
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M4&EL6G:MK. ;\Q1\K-%OAJSLS^/MG*&8RU;G36Q;R-3GL%G]1$A4TL(CJID
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M<X>/5J^Y/AZ8@\;Q:[;/Y51A*\=VG8F,VUJT:F'"V[C5&BLNJ;%B#UIKUF@
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M6,/I/_772'DN*#C9S/+K%2PN6+AZXHQ9.YP+PU5*IUZEG]:2BK1L*#I55<]
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MG9,%T0=@UZ'-T=XG=1J6.@TA3P,)D%/C<OZ-3 ;1 ):>< 0XN!;\O8RCZ^1
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M9#D#/95L"JP/@=MEA"AW.(0/D;J3XSCA6R"Z^":Y7)@*<:GD\KUA!H%G]<)
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MHZ-A\;D^K7I (K85"7@EG[-_JUJ^HF*(UX#W,6G2_#357K;0B%E(49IIH[R
M13;./JB.Q15>*96@6ZI1^73^N>U'[58-%.;2*:4=*//:7.E1NI0Q#3B];&E-
MZZ!(F1<I\QU(F5>+E'GV\5R"\!J19'^%G/BE&)GVE1F J/0)R$2B'_71XLS(
MA[=FBYWAA_C<EZ;)WPI"!,P+6:2.3JSSY-I/+&:5/]VW36LL@SUX.FA[](5
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M!8WJS^#;[4.R_Q)/-Q&VV,MZ:U4$W$7L:TY<Y,5]=E((?I40-VI$'D=8F"_
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MY^S3Q7GGKKT?Q)]HOC"NIEA;<8'[H0:W3#98YD3>S7SP/5GQ>-+\^:LV3D<
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MI)?FEL0-][78B;.@5Q1=0,;$0P6BY'%N%*4D']X/D3ALFL[,,R "D?;JU!Y
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MGT9W1F+<8!L;Z@?1Z)IDO:8Z) Z-\=V B6#C",C1XXP6 W?0MJB&'Q<3%]3
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M!]^8_<<\7M(VI^;AY;A=\[8\N]43?:N'S?1>;^5\K7NWS5SP,1KL\]ES??_
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M4SJ@ X85O+>#$2I>MH!F41@<!(DSP"X<O/ 7UC-E.1-P]T\?GDDGGJJ(?AS
MII4_=']OMMDAP!%SG-,1C)];7>7S0UOYTG[X5_?W?$C$*%S.;+O0HB-LUOMG
MDT\#_L)[G 9IIX'(,[U 2O!@6U@\N)@+I*G%69$+K/T)#VC#PD%,?POR(3SR
M@XW!Z['5E N*A^D.LV2:,%KK4M/&LW(N9'\0GA9L8GL'9O,%$Y]7+!R6W)^Z
M+G CK P/]\=AJ# X06-%CB-*!JQ;,"^6GR5+S^U+*P!^HC/^0X_:TB'0/QJW
MG8>;;\JE[PQQAK&=%[4]<4UKA=8.]Y1\1G/;B:5D/X^<</KZ>.K/DLOQ+GB$
MQDAX-EI]$&H)S%4.7\9+LI+/<4B0^1X1#?8 MH@W)CQO?0AJDBW,PMUALA F
M /4P#823<ZS#-(VR4H(-JLQ<Q*'*L9?R3<^O%V=5,QV-5S_A^Z9H??Q Z(?7
M &AF6>5\^+K/&URQ8R/B.RX:&J '+[U?\D':UP^WCW=_MI3+)PL [9,C'+FF
M)H%#[WJ)ML--)=(V(^J(9ABM?+K"B@HP:NRKWYW!TW<3S[\LL/I&SI@<@[0]
M("5,Z6""GK5*=PE(=XP,PI)FWP=<]96ESVKO=&[>')6$>6(=#J:=[$;2^:#G
M6<_[?!!Q[%@6$7_]C^8CR]\*DE)8/SI$$9]E6XA.!6P>/6I>!S1CND@:E-O3
M1&F"W(1_P6*#S-)K="EF(^>Y)3TB&$2RIY85Q*+@R7_'D\#AU(-;0+T'!C%*
M_G"$ !!3&*R*Y@N@/S;UZ-R'[$FL7@E):("I?5$=/9HP0,@^91(_<#MP\QX8
M$@3SYMF"YE8/#_SO=/#$^)B/ O8P<A:L/5C?W[%"AC_S@3,3<*$9E<]$'?YF
ML(C!<H!GUN,@@7\NSLH %FT8C3A@,M\*JO?G?!(L56*#&-A68_MD3&OZ.+1X
M '87@C/B7I8;WJ.627_0#:^+P34)G*$88?,;P![#L0Z@/2D!1SDZP"@$!B/+
M.69IE?0[\XH [9BIUJ<<8G$T-5;V,@C-3GSOTMP)CYL/Z#.^ $"&4_1_Z4^6
M(Q._D2TX/%C&=;$O0\H+6C)Z009TN$NP!VR;6G'W&RX(7<O9"ECC#;P^P JS
MC'WRG<8Q!Y8MY1XC *1O.1Z:K&,'S&0GJ&4'@'BF/XUDZ;/C+H(-T] L^@3/
M<YG% E\MD<)RG0];4#\0](N/:WY5=*52-I1:U4#=19F5/3NQGT$\C*L ($R7
MM2U&_-2$E]W,A>T^X";NKYO*)<@@"OX&FP/1N.XV[]J-G)@E"X?P<][A+)HR
M9ZW,MHU5HK[3![/@KRD&_GNFXYFP5()G.4OP*"2;-QZ(#RR4(RSR$M1"@AL7
MA++<$9VB5L<T+=<?81N3PR,<Z9 'P*AQVXKG.#[<YX,FE@Z";BA(F_A)$/@[
M-@N1A?J'Q@Q!0[EM??F]^_O#8Z<9!+P0]9]:K4\:CITG"OA*(#S&CD7[4PO-
MR)'90YG%4K+:[7_J* B^$I14GF/'<JV8XD6IY !,9@3%7ZOW%#"C&\MOG/.Y
MHK2N*Y;6%;T&S^:TZH?9RWCAV9C7.L!6;>=Y%C\ M?=DLKZ[<\\EP>I1BON
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M%S<<>DKH'B#!<2R<A.ZI:%??D($D!'#/30MJU0TD+;86/#=TE/;-PCL&-F0
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M+B7)\U:/O0_VV.V'2M\[/E5*!64N?Z^0QD+7DW0PW*WOV ,<SSR(C:?#V65
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M8F"CO*DMDJR W_L0_'D^Z'?ZD_!@HDA"?$D>E1\52.+;$T:A9&AJ[:#CA2-
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M'U;9C47W1*6>DFPZ32MDRJQ'X[2Y2=,BT"O$JQAI/%IR<(,25Q9,.9&,PN*
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M/^-H_$;UV'?PP+#?F++FT<.B^XV*-G.IKHRX V>3UF_'!)D5]S 4/5^RY [
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M&L% ZCLX)I1MQC+%\KG'Z21#QZH%>?9;AB!:E!-V23+,7A/!0 4?X5.TG3R
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M.5/+5KHR:GD25D>V;Q)RBX'QXM-,5 FS>M;]@>D_58T_F($HD)<?2#"5G2&
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MGSHIW3[:D*]2LS:D=#NVH7)1ULT%%:7\'.S:C&R%&S<CH31J1O6.H8E%2B!
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MF)**7[X/"\+V1$F/7"E);BN2(^P"K5ZI"-*A02YU"5?UYRVP^/ISQI0Y:H>
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M0.;5VRP\U%-:!X6<BZB+BNA;9^\/)'%,UQ<&0MD-=GXP(;9T!,^)?+Y<KNL
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MEN9#3.Y"YYB,W8!8&UR$0QO 3?^_,'T^6ZX6ZXO&A-_) '[M^QH9P+U);F0
M;YJ\_FR^7$U<I-!4,81<>";/%RFBY#$""=3+DI(73#?>BK?1<JPJNG&ZO"7%
MIWAPP"53M#%DAJAJOW=E"+E)*%5.L;XQF:TF6+BJ1(YF?IL;15?)N#HBYT(
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MK7"QN?47IJ^1V!UFNZOJUJM@342PAC%03-0.2)4OQM4S3IE5V/-FPEU).'!
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M1T*E?2GL)M?XKES[ "/\T:??8 Q3/\(%G*135$(1RGSX%99K& @7DXT, <:
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ME;QU*MG:F:27GW^LQOU]1=S@B+\18;PD@1)F3$X(4YKT>0,*X9F2;.0824:
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MPRA-_,1/K] MQO7,!]EP[B,'DH7"?3&GTC%$*;2B7(B!9\:J%R#707[PY'H
M!3:P6S].N^DJW[O5+-^7[E49*!,\"XD1:\H JL #\8(I$E%6,5F6;?4&"AO!
M'#Q9ZHBY1<KYQ4C/Y%-@,I8^ZM$0:1&.+Q6$D8K,:-(Q5V\F]9"S4RMK^)Z"
M;'!=VB7&E/3@*7PN;OM7N&A_U56M?_3?!CIQEW37'Z_TZO31$L1L"!J"V=+
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M8V52);6L(=+.L=R34?<[D-8W?EC-%71&2$85)UJ+4N(O!0F*2>)=L'@VXQI
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MWZWFWKX8#4^'X_)K Y QH-]G"'1SDZ36Q'4]Q25P6]H\.^]:OG);(SXB!CZ
M"EO;Y>O1E[^S00Q,Y(SVBN:N9"ZF1(*D@EBK&(_1>JJ:&NJW8/LQ2;6]6EID
M5%S+]S(I()L!2/0T$FD\)9:A*>J2 *N"DCR;RBPYC*2Z7<BPBY K=H.Y3V +
MRN2^E!T)-.62\)-)2+[DXE-J@J%2Q]H'U*%FT>S$D$8J>2Q9-.O#)"(X+9AG
MQ"J.[T%(Z.B:8-'1A60LER&8I@['(468M])ZKPCS-M+?8T"Q#ZP?-\*\E=)Z
M1A;O(_$]$D*;[)C-GL0@RIV;]R1$=/B,<TX) Q!U[18!CS_"W(('VPBZ1829
MWQ84M4QRFY4F3*HR83@XXHS7)./>9U,P2,]^[<CN>M+CB3!OI8_K$>9JPJS=
M@>K.\#=P0(-)&9)"Z6!.62#!&$&H$,PH"S2I?NVG#N<N82=-5Q-F@SU]%0\_
MB?]]-ES$3A8UO51ZEE,@1KIR7U[27R(M7Z:8T1/.CM?.G-X Y=AMOQH::!!W
M6 >K_'4*Y[V+>@!L9 ?>">YA+,(JJNQ!C]WUL*>=Y"I0I76&:!))1N-;8B@:
M1RD!H9QE*:,TJ7KHZH&(<H?%^# \V4;\M:W']^#G_MUG/SWU$<[FP^A'I:'-
MJIT1=TEJ6B(QR> 9B&:R,XP3)ZR5 "ER;GL9%+<^9O_61&6=3)H(M,&=VVT5
M I%ZK2P""CEI(AERW%)A"22(7%EMM:_M+!YX2=8NQD4M330(<M^>Q]L'W%-)
MUM9JW*KDYCXZV'M)EJ59R! S83&6/'TOB(_*(5+*LM')>%/;J#BLDJQV_-A&
M]/LMD; >(CKFFF1/51FTYHJ[[DFIHA8V,Q#BQRV1V$IM_4LDMI'YH21%?IS,
M_6BYS%A.Y.X7AH^A^U)?:(\BA?)><MQK9F5T/LKL20JEBXX!28*)AF1'94Q!
M2Z%JA[OVT9%I;8L0*Y7EPE.B%2L#DP3Z',P*PO @4"(&EG33E+;'W9%E&R;T
MZLBRC;@;^&*_H61>3V:SM^./,.U2XE#&;_-K\#,8,'S+D[**X)8-1/I4>@4Q
M1A2'#!X7SVAM*MR&YP@I44W\+6K:MW!"$Y.!"<L(#8$3:5E %B=1KJ8HQR,^
M>*A=E'RP:48[T*652AYEFM%5 7;.BH]0AA=3(D*IRV(B$Q<D;I: YB5$P]"8
MW-\Y?"@1HJV8<.N9M9M&&NQ1I:?^-1&L*KU[ &L4(=H(ZA$D(NVJPDE+^>^5
M()PJ$R+@V\;+./2L./'9:A)X5"I#-RO]L(FQ36+2WGBQC=@;\.$%.M^3[P#G
M*=VKQB]694.9(Y%1W!EY"F5J8 E/<*4@"SR5:[-A Y3]6[F5E#6I+^GJN4LQ
MPJA4HD%Z#E^F$(>+0.BEX,0J7J4%=3)93AQ00]!)D\0F7B;)16F",(S*:Q;M
MIBRFWL\\=,VW%''M&^=_3*;_S)-IO*A$7((2W##E<+F*F659N..IS&\*QJ+W
M%8Q0O?2^Z0E'H>4JXMM;)QRM <J]-M$N9B)#1D>ZM'BQ,4BFE7(N-&B9=9AU
M"M6<A7M)?X^=</K ^G'K%+926M_\]'M(?(]U"D%3G9+A)(?211G0U W)1?Q2
M4,]M-SGKD(EPKSJ%%CS81M![KU-PZ-U('CF)-#D$%R+Q)>LZX9D8<LY>4M[/
M[CN8.H6M]+%5G<(VPMQSHAG5:.)05KKUE0(<ES/QHO1^2^!$,#)Q7MLF./!$
MLUTL@UJ:V'NB61]P3XEF6ZMQJT2B^^A@[XEFH'.RT@O"4T9GU@,EUIA,\(0T
M7-MH+:L]KN*P$LW:\6,;T>\WT8PFS8-SC@!"(9(+2X*PG(1L98XFTRCVD4OQ
M.!/-ME);_T2S;61^*(EF5_[],D;_?C(:O9Q,__33](!Y9CV1/8HTL_M(<9]9
M9A8X#\I1PEA*:"TS2SQNBL2" Z6M!0^^Z6ZQARRSY8</K(@,URN(R+R< 4JA
M7\DIB1"3 9:HL$V[62UQ/-*4HFV8<.O6>!]QM^ZRM\I\\SPI1A%)J5TC4B:*
M>S1BHMP(&43V(C>-RC[N1,-J%+B/N!M82>_\]VX6+VZV5^ -LK0Y"%QC5"Z5
M^B5.7*!0*M(@1"HYU;5S>C9A.4(J5!%[ZZC\<L7=43Y:> SIO\YF\X)\P)"U
MU@@@R0FTYX+%A7LT&&WD*1FK5?*UA^7T!G>$A&FCF 9QF[7GG$O62(;GG >%
MF$ @)A<X,292E1)09YHF"*XU*]JFWBJ0(:)%3X2)&O=U[DEPWA >J2XLL%!]
MR8>:>KO+>]%*)8>2>DL=IQ2LPC5I7)-0CG@:&.':94$C9Q#WZ)P<2LQ\*R9L
MF7J[C4;VFEG9!]A3ZNW6*NR=8GD?^>^5((8[A5NN)MIW\> 82UN++DX7)(LY
MQNK)EH>5>MN&%]N(?8^IMVA'<N8]D,! (BQKRH!Z2;C) 62Y- ZU6WX<0.KM
M5LKJF7J[C:1;1X'.,TQ ( ZO@6CD-1Z1L82FT"7EC//,P.ODF@^@^N',B7M)
M?X_)>7U@_;C)>5LIK6=2UGTDOL?D/'3G533:$<=+\DDH8Q:T"43RF&(PF7/>
M]";U42;G->'!%H+>>W*>9()SPQ-QBGHB4XEA:R^)M8+:1+DSUV_(#CXY;RM]
M;)6<MXTP]]]$F,D,>*H1ZR2"LZ77H4E E-'1,:XHL'X]_PZGB?!.FJXFS":C
M)]&8N8N-0EHN0 @2I$+3QD$D+G-#F(P\@\F6@>BO\+L?>"QZKRS:C39>]8R8
MKS ^*SD9B_\/W[],)Z64:*=<ECL^LU(6RC;(*^6//!_._*=/4_BT;!"R?/A%
M:!N<$<PII$YQ$B5H3IP4C@3.%9<J!@>U6YK=A6EW4W AX(%+I<]I",3S@/P-
M-)(RL8UDFY/02F5EZP^06#Q[_[M$54W?-/KN(=(&D8 -BUSFF7N37<;C*08.
M:-5Z3KR 5-H2)JZSE2[4;K9U&YY]W6 U57PU@3_T==5L.A^\6^RW;Z<?8/IU
M&!<A4_"*:Q$2,4#1%XI)DT"E(DG8*#AC4O1+GL,'7&(,?G7!EDW/?JC(43VE
M3BH*MZ(!>0G/#.V<):+9RF[J 6J;&%$_S=\$LM_(4!T=W51X)0'O3?O)@/&2
M41*=*"<8"&*C1KI'YG-"BS:P7K/G'I?6-X2!]JCT;>1:VU=\\V&):V6GK%+Z
M>5">"D.XZEK2<DYLJ4D->/PQX;F,+O?R#3<\8']67D793RH+KG:(Y^79J2]M
M0)90C+;9!DO1ZV2EV8>2)"BMB'=9.:^S#HGUTN'5S]V?ZNH)>E)'2K7?OH\O
M?GWYZOF+]R>KCLW*.6:#("S'5#HV,UR.9VAT:LAEKG'TJ9?&KGWPGE6VBX0G
ME<136U5__^/-B_>O/O[G$DIFG)>2:J+QJ03W?(-^':X.$H)@,>MH^LW6N_JY
M!ZJH'813\8:S@_(*?9]IANEY>QQGDI?HIQ&>K<#SF@%Q&1RQ0EJP@5)K72]-
M7?_D0]\'=Y)4;;6=_/WM[R_^8]6E2AJN V2""RC#<DH_?!L<$>"TI4DS"3T'
M5U[ZU#VK:S?I3FJ(IO86^.[UB]_>OWJ^>LO10DHVRT2X9HI(=''Q+<^6 .AN
M'+NCJM^+=?5S#U9/.XBG]MOT\?O,A^EPN6&LN@!*ZY04%)>C4TEOTL1:)LL=
MB"Z7(3Z8?C>YZS[]X.WYG456^VU[>?+FW7^>FSXILVA29,3*D!%)\NAU0IE,
MJBT/WBC<%/K9\I<_]N"U=G\AU7[E/KQ[]?O[D_^S@J(!A&2(PL2 I[*DBC@+
ME/!HE>7>9Q[[Z>OJYQZ\PG804\6"I@[*L^%D-CP=COQT94KYY!4';@CNV/BZ
M6XFF%'>.:&O1N&+6XR_T4MJ-CSYXO>TFK)NJD[NI[L7O+]Z=O'ZUVJ8]>AP:
M/.$^,"+!!X2"-A+G!I*S3@O5KW'LU<_=LR6RHX@G=>13^QA[]>;]R>OG*R0V
M!P!O%;&,!5R18L7#C 1M(DA:V^ABO[#BE8\]7$7=7SJUSZ^7KU_]Q\FS%1+E
MRLP,/#^UX6@$HS./3F40B,0!KM1$+OKMA%<^]G#U='_I5#^U_O/MV[^_^C\K
M9T6)+&,LNWA495Z-(3YX2JPN8TV44T[V"QA>^=C#U=/]I5/QB#IO!'#%EY 1
MDG#!$F,,);+T?'8![9V4#;[H'#E3O=?IT7AHNTOTIGK5;MOE'V].GK]X_P;7
M=_+\CW]_\?K-*O//Y)@4RT1EB3Z(\)8$"8SP ":KY*.E_6R134\X9#W6$]U-
M?>K=W+<OP[$?O3F;Q3/<AT[FT\F7S]]7;B7G-*H,!&QIUAI+YI9!)T5:GD*9
MW)J#[*726QYR\%JM)<";BC6[9#.<=\+[#2:?IO[+YS*7?=D<T:?L'".TR^WB
M)4.;HK&EC#11*Q.3@S[[\1W9#!L!'%4*4QTQ5[1I.U"+O+?+D,[;F]X-JF(>
MTT8@^\]CJJ2H22LI5TYFV@Q.0@R&!X\>ED5?2QA53,Q$%.Y.T0KEDU.'I_I;
MDIGVJ?EMA%M1XW%R-IY/OP_^^##0B4MELR6>:C3]C4?;4)2NZ,XD[F*"$&\K
M7IQ!_,NGR==?EI^XT/#RBPL%7SQOO\=W)<%/=I):@QSUWR?C/U8N( _.JY09
MGC_%Q[;H_=D$DF0>?6!9.K0(*[M+EQY_R/K<59H;7\AF]4A=%X[2419MDXZ-
M,X^^P6@T^;-T4I@MJWRN96%M6Z#4]R&5*Y;NM;8=2Y@*I_[N1V>K,6#_^\R/
MAOE[:7$0%Q@*F-%D=C:]5.Q@J$N))XK'0,FNPDV?.)": &1MN5*!^QHGXM;
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M7H^SR4:0]XT(2&L&)<D;)R=<@S4HD,Z^HG+K^,03GA"TC^X/$FD/@V&W-@9
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MR>VUU@'Z0EXU"X&'%NW$?YA+HYV4^MBET2["'>S:H NHG^C2:"<==;H_V$?
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MD3Q\C]9'RXM,W?JM;GW,\(&2QCJ9]"+0H3JJO@JCZ7^&\TNRGL+L<GK5JOZ
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M%KRJM;6\U'L-;4)L;;]N1W1J/&DH_X9WLE<9'?-/.+U:_?5@JW4(&7/<%&=
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MY#A';>O -A,=8R%Y;#Z_\_C<>JSERE.CUBY:ZI-2K\>?+^>SA03XLGRS"/*
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M0DRFYJC:H&F*888O\>KO,V.PF-I[TJALR>P,%KPT":03/H=2E%LM5VYSH]8
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M&!DC-WZP?,^&"QDK[?.8U/7P&G$L2:!75;K7AO"'C=5<,V18EHYS0UM_J07
M43-Z;4T"EBSC1N3H0NL!GH_ .7P2YL%TY<'!K_MS-H!=N 7:.BS?!=Q B92/
M CM,%F4S&KNIQQX<C*XHM0!$*;(\L]+DW6C!P>7B(25=O..QF-(ZW'$ !7DB
M^?$P^M%'](,T97W$D%RGWB1M2G1F50;G01GMP"6O@%L=%&?:ZM)ZBE0'6.,[
M  V)[&/.[\#" #'Z;C[L)G</!2L\HP-C&+TT1AHR&[D"*Y)(MMZDR-:U@;T
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MK$.)%G_FF"??Z]79;R2[&VG-YJ<E9I<MD@^["I#K0DY-H(.4:U\2)PEXW6U
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MO+/ JRTEB3N5J%JAT[!;[^%3>C7IRGQMJ*#CKD5 /(TYW1D!E6E\W$49.)K
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MH16G='LB6$NE-,_F>;.8;&U"_?:\/#.=XH"?L)XU$5?I0.CA=+VC-IR\T\D
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MK(Y',2)I::,TS!EC9C>(;-6J=K- [5EJU=5@GB]/L&J7M/E.(%=\;%6TD,G
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MP_+4[H'-=R$KR3 ]Q%.IGONCVL@5)<V=$76^V2[2[0&$JPE%=$)U7!_!HV'
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M\\!:;D;D1XOXP!SXA'7@T-V-^"^>>,_[>+!DV59LA6!&'UB9&SI W;=]!'G
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M(>+0\M ;#EU_P2D7M"YXP@777/!C^"QX!#\;_@C\NR)6](NO+GX=.1%I($]
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MEIM?]NUWOOKA#_W(Z><^>_"L&^JK7]SPW?<8SWC]8_\?ZMT[J,GNW?N-!5%
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M4%M>$WL5OMI7^9[=J\T-41 2S/PAS@!E>O1\- JGQH5#/F< WD_ ^C2;+!D
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M@.$UTQ@%67DGTT-+^ ZA06!C'X2+Q8A4YN26-\RY($[=78JUP'G2.3/8*DO
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MCJYS^]G) )2#9H 8(=8Q\$M6F7+[FE>C8#<7I9EM+4# Y0TU!Q?BN3K7KFF
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M$74R7VQ:$*Z>V/ES/[MT:TO./%AKZPB\^*[%[8*N[J5K[Q?>2^WL 9CDW<P
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M>1KRID7T1;H%);H.%$;MH8^I4V8B[5(#U(N&ZO;J2X>U*F_Y2GUCPX+>54/
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M[-"<1N4;T2&(V7WI4PJK<LG(+,:Z2R[F-<++T> M_36PCY6)GR4<FGQ.8DW
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M,ALV?Q]QE2H/JKM!F<#.JM@S= M$@"N:$[-_4)1;J"V$)0*L*2%N_S5 -L)
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MD[NSG_=_L^9-_'GRFKKA2]76>UWUD( ,0R'D[-/$IU23&"]@',I4Y.<6MKC
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M!(XB-$2D' -=W1-/+=8/-?;C?'B&QTS;:6O0[[\ZSQ^2CWMQ ^X/W(VA0QS
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M"8S#:Z\)T=SIB"]><O64K5=6;^UEND)>KU7K:$M-TD?;KOKDX>58KZ'GB3@
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MRXX.H*2NXO?L5(;<6OW/70_^:HK,LJ0#AB75/\I+\ZH*(I_YD<9NG?A1_CG
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MN.^\E7V5CQYP&#$+&5R-R1;NES/STF9#Y[8$1F6GNF2 #3N>KLZ09MY+,HI
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M*KYH>9UY()_ -S>>]Z)1H\")EY8_0-TY]*Z$N/EOQ95FD"(5HO=0!\(1XU^
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M3XX]?_B25M@%P[>UNP]=-.C2J/@RLK,"Z0<E/K7R&\"@4)-GDCAE-+7I*V7
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M(?CG[S]V,0!,#/_G^+^UBX]N%^,_/F#[QRX&QJA_)O QLYPXS<IO:L=V(U1
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M@(ZX[H/&$4OM>ZVU37Y!M^6R-'T?W73QX7QNN0<L?LF;^U:LWA&XNK#"BWE
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M_J8@-T%UL,..CABOB;[]/+R@!2GLJ%B+7'*V=Q;CU454[)>*N2\M=?F;;/N
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M#2W@CQ;M.HE(V[OM.OV6$DAD/'1LSA2Q^,FOFN+M8G*.*?M\P_',P *B)D4
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M6124=/6JNL)M(VB-?Y=V6TOG)27'#WD1ALNX;HEUQ;##DTVQ0K$?/:5!V[5
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M7R8=D&?G&;Q2M/W+Z2N=.?U>F1.@9LQ27;%U-$"6GAT\'D?QT!^=J.\U;VC
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MJ^D>;50[J6&]]:QKG4<J/J.A&D+A0!7],A/ZB?D?9Z+^>V? MIQ'_QQJMM*
M7"A6E.</^3^PUF*J'OUS#QY& V3^5Q%5>[AJL9M(-HB=-"A]44;A ]..6L(J
MSN7#AXYRHX.^R]5?T_^0QG0KL?M35:F(P&6CB42;+V=PF3W3Q9DJ9BWC6O.;
MX79FU\.3_KU].5*,CJUT/,GS_^<EQ;X6]%\%U7T#\"R5JYT&R$_B:,!12@CT
ME[73B\>HC[T0Z*=2QRAZVK259ORT6'\L: >_$WM'T,X,$+3SS"=#Z>DI3@](
MPXQ)PD+/;,.\L\OBB,GKF3R)$!TEZ6O-_"QR7QZ^-H,[N:^&V>GW/HLNW\FH
MO%SA\KK'HZ%HTD0%7+ $?:LH<O7315JV;@[-F(Z63Y\*F(L$V(R4!;IPBTF*
M>^G]$[\]'"Y,W9C1LK7&?]W#FBIT3K_](IFK]V-XV-3>V,P/D8C;SS%27F,#
M[^'AK $%!EON\L?*EIP_%IH$>MUD_[AH<RNH^\_[T\_2]SN<R+RQ4U1.0N=*
MIM$%0OJ>H;'!(JS*(N1^4&B8M_#9KGM^%?XOKN@KC)\34Q2M"GMQ#.N^DO.G
MH JO$B3\!UF*_A8J;0#6$"WP#][!B)KXRQB\8I-]\VCMML#2$],MP>$OC?=5
M"JK7("*!Q2?1N)J0 8/'ZR7E:HG6DWMUY7E<,M]$^,S[W]Y+9=YEDN>>P?36
M):#IE'MKUD"W#\)A4V7C';*Q<LDWFUU=]JONB-;GW/YR M>[3YL6 R$)&$$3
M]FV=OR(#/.Q?*KY$!VNHE9\9TA*Q$\@BV@IHW:U%#)\&)NU?5GPLQH2 C*%U
M2@99AB9M"_L<L7J4 '1/&6Z*!H@:V5,A?.S)#Z@RK3JQSE0>N=@O77,#=Z=U
MT)4K6[,$?]=KF;.Z3F?5'&=FB")Y+J)QK]_H^\C' =_R/5_@1^=22)4$6-(>
MY09>\X%3Z/SF#/[^9<-[VX$93Y7J2WXN#*C:<L9_TD@'/ND-'+_J;ZCSF.HD
MGA0SO*GO-CUW4*STLO'TOVH[:114U*24[O?5D8^CCP04$"7W?"D"A518%&[V
M* 5&3<M[-X!JAXU3+2YS'1V@P<+UG 5KI9<8$ZC#_R->4.@HE=!/ S[M;:V0
M&"<QOVQC.V>_*5*$%>FW=:1#AC ]]5X&SG_$K,#+CGC0>/@?D3JBYB>TNIV9
MT.^-GG\E4 2<]29X(6+M0S@-R-9UK:F-CPC2X@\P,$@I&/3)3*WEOA7[AX_4
M8,[N ZQN) [/UB#<2">.*I#>A,CMM<OQA#I7-"P9OQ2D+F#S9!%N*FN]OL[,
M520+4V/LJRO^\/'KV6J#.SF=JO + 5I;7Z,>1-?4U* Z_JHZ$&%]\/DR7$KB
M[_91[)G1?M>K*^P10;)]O0;J)?N%^,A6S%2!_BNK,DM<LLX384UR-^'4-3F6
MCC 8NA?3>+@SN;J??(P(Z5N6).;T93S=ON>'O%9M<2.PVC_*/FTZ;]W=_'W?
MR>\'<[7?KIO*W^P07]^XVG&@IK&GH4 ^\R3H>>Y\QXL/S0-L>UF?AYA:C;\$
M4LQ!-R(;3KB5)YE.6QRWS:<4WR4?&*IV,R>(.=T]JR1?)0>Z<1OP'@N[P"5Z
MOR[F$ 8S01NC<-FM:[YV2.GO;V>Z/"*:ZQU__39V6*M,I8C@X(FE[$=Y'1)K
MG6==[VNZM,T@/>HV\\6T:, N5TFN_)7A<_SEIYX?D_GC\F37R.DI,@",>$E1
M O-?(WCZ: #?+Y0PUD7MI#KJW!,K_[ N^8</KE^.+%"*)@\'/@?]R3+4<;0(
M\K1(EA$'8<;E5WM1L:KJPI(Y]I.FU&6QZ^1+]44?]45SHF2R.YRX\&A.L+";
M*MM!R,D,5^T\>W5RX]3R'/S<^ A7]IOAQ1SXG3#7<5)HH9IO9%W$J]W];S<\
MIAY%?^=2##0.NM7L<01S/6I#NN#4 _'9B:O[*<NR]=-:$#90P&(\?*%39],G
MX7S!B%K_&7ZNZ(F/$L_VV(S2B:X+8#1A;0@J;.04M(I*,1%MF_[MUCDH87CQ
M$[9,;><RHY)DP4W!XU9"K40O4B@X2C ?''4"<U>;&]Y-R?OM-!G:D.\M6-WR
M=#UMW)AGT7'<.GBI9RW]3>S7]"R-()2P+3S0T[YF>'?SY4%K/SV8Z[_^4Y^%
M#BLIO!E4:W@_#YG!A0;\V*A+V-Z'@2=$*(\PJ1 28P,-&!_UC*433=D_%(Q6
M3)$B)4OY+^83NN*1G1E2_^\Y.S-!X-\C3CUH@L?*GY-H'AJP8QA-SS+[KI]U
MB=#5=LR!K0F$!LQ%_J0!%RMBQ)PHF2=^4HJ^^Z(.5*M^8+1B_>GJ'K)M,)@)
M7F& >\4.=>F#%XAAW:62H&TMY5P7H1:S.LJ*Z)T/VM,Z1%^:>MY9WQ'5Z9O5
M<D%-62YXL:93]DJEGA#QRWU5LAIU' 4$/6\D' [Q)-O-K_C%<L^&+_ (^QDD
M.'^Z%V2<-7%4L"['5=YP^O%:=JSHV5>$54GBV@OEL7&=V1#SMKVH[]-R,/[6
M8JN%>POA?X.:R%'Z^VD&&[L\9'6*#R&D_]B](5>+]#VM&@9(=ZQ"^HW7SNZ;
M8+'>YTL]SG]N'P"U3.:K,<HU=7/F$'X$%_X2#6B.ZB^YN3740Q5S&YS^;3-_
MF0;P>MIRI[>%&V+6UET\^O2^J21\M1#ZNH)$@2>($OBZA!VJ(E)SNI'>1W1Q
M37H.]_6V2;]4[,P[,W'IB_R!Z&%'"T_;^?9311P)9V+VLR 2-,"+)]N@LVDT
MC6)*C!R]-'GB0 MRW-_@9#XKNKR'!A@]?P!+DCHSI-'O_:1X." 8W7!GR:6Q
M+?!5"8HE]M6O)6T'K#F*J\/A_NVFV<K@6NS<$/%J61^4<#F(I4,O80GI2S2@
MWD=VAW8&R60%[<X=FOV4/E>9-60<:COV/83.(GIT?I-1O,/>(2Q(Z_?Y?1/#
M=\<JOG=DA 8_^&7N-V-?EM6G_86>P_.$KRNXX/K_PMY[1S71KNO#XVM!!$2I
M"D)40%0$1"DB)3::B$@1E!85!!%#1"E!(5&1+D2ZHACIG8CT&ND"(M(%I"0T
MZ0DE!)),OL%SUCKOV:_Z[7V^<_;O_+ZU_YBU,D\R\[3KON[KOI]G)@PUYIVV
MY6;"5IMIIZSOI6]\1^/.ZA!-%78+J5ZU?2D9O)4:C2C=M4-+BXH=,:PIP? [
M8O-:/WA+7"VB5*2\6_N<G4X/.%?45_FV;55W?L^11FX7G:ASW$.>+U['$AS4
M%OIMG(::05%(V#RRG^H8FQCOB(@>0$%*<QZQ?*+U*4* :40Q)!]X13U;I>_(
MRDPJ:[S14UA]JZU/V8!A*/KHABGMVM91\P),]5$Z#M) M9:X?C6R6;:;[? \
M3S*IJT#FQP0.&FQ:GT V ,V@V+_/X);B9L1.3/U.KSN4^CR51\Q;X.;\-N@6
M3U//JQQ]U3QPVNP,:.E9?&5W^5OM,60\U<?'F@W4XT+80*Y_@^R-OODZ\7WT
M,L>4R>>K(KS^KMG\>CZ&[4B&%FHK?NO)FZ%7 YH5%*>+C.XMP#UOSW84$49W
MV:5K.BBN6K=7QG0@#"J02-Y8.:FK.>)VOK;;QYXZM9W6X"@XAG>A8?/AO?HO
MBO!'/FZ9+1DY,7(BQ=QE_(>;^UMO6WZQ(@_D;&8#TF64:; F%;+6QBLWB .I
MW]F 1.IF<-60J;^H,YL,J3\\+/V74A-S!EMU SNZXH9B;' <6CM M)E>X >Y
M^-?OFXG]R@6-8)O2S"ABGM &^K=2Y9G!/?28T=;HM(2@M<7AZJ"#;S>'U-X[
MXKL1><V]Z.R,T[SLV<L4X5DC2*C6884P/. 7GZK!_=U>#TF9Q7?4KTGFX<YU
M[LTCAHJ>D-\_Z*=RX.S.OL?G+*_\45W)US&?TB$_W)D=KAP^>#-:*58PC.O0
MIBUFFZ^X?-SK\R5H+:6&]I85[L8&?-Y(4F'!E8!&(1$[(@LSZ5272$2_FND6
M2>X\BMAX7V37[MG9FO->'R_CCJ5T7]J.=GGWNL3*!.E>Y%:*P;=K'*E,VM>R
M.S]B'M-JVD,8^;:P"R/-M&3%52JARTRIAOZ*O>I><G/(N0(-^WJU0->R1>5)
MY]F&M5SEL\@(;N!><^,F-R+%2(8Q:TY.]5DV,*99OGJ%]]44BR:3/;G*WRN]
M/3+3$"T9KJ<>[O2LF!Y"Z1EQJ,/Q,TU8*6YPOGZKZ:)LSUT4#!YY\*IUX$$S
MLFF_2$Z7E9#Z_6EKXJP*U8.F0Q\03 WPTH#7.ED[:5.\0X.3+0<GS?[HMG7<
M&J02%4V*.VLKF[_'7>!J?;GD2';63/XDG>-8M$B2P%)%.\IZD-!JFT2?I_C7
M$PML<,.(0-@&):2H*64P9MA 1;>T/9DJF/R*?IL\N#>B0=V#+Z7686!O)/?1
M.Q$=J@B*D8&$5A'*5X2%#TKH<1-M]5..[JLLVG"C-+(PSP!%>_YIHV[VNXR/
MGJXAHA4N@[ >-G##<"?=Y"S$?S@2KQ@=:]D^T]UOAN H*.C*R3>-H#UQ'C,O
MB*K:4!C(_RQ#?B!-_3ZUAS1?C\"5R@=K'D ?H#5_.*F4G!-A2PK9/JI4]R;,
MV=?VL>2]LE')& ?)FW&XW7\DQ)T,2Q<32\3@_=9 \0<Q9LF'VJ,S8[TJ7#NR
ML[*B^X::SR;3.<NJAW*%ZPGBWR_:=A'DEC2VZ:>%2CZI]AP-=]UT3\A$1&([
MR>4B*T(2)81IA>\!=SN]CVF_1C&UV5<0:A)5U"DKE[#SXTM&Z+3$/HEH&]X_
M2HB^6#',GO5G]T/+>;Q)8L90#(@+]>D;F-P_QG^IH"ATN-GV7JC'OA(?'[\F
M92M^GS"'VJ'=&"XO.%TMA[F7]?J(EZ$:O?HAEGY>78?\479V0ODY_*78ZQW]
MC?L3=A^=&UOH_V/VCXQ+K^Z9T5];>&>CFCZ],$W=56W5U/8LPKI_O+]Q &NF
M?COH8,[BIQ]:F=$!;M5B U+R9 [6HRPVL'2_I\KMKWH!K@3%OEX@(E;C0@2H
M'<E"C+:V-QU,J-S#VOOW+C3+#+?2Y>:9$8;^;( F5@X1P"&$9T\]D0+%UCO4
M!=G ]6 "2R"J,?0S_-W1]Y]455EORHL*YF8KXHIF6F74.F0RUV6":9M-B9;7
M!%.;N/:(#30169^8_2\63LKT'$P$)1"L4]@Q!#B^IR%L_6<P*A203FUD X?9
MP,K1<?70H.6F@VP@ (+7)=BJ.1LH\5<8=37/,=+YT^U4<1()%?>"X&2HQYT<
MX&4V,'?]DZ>8X'2D$:0^">!;^ *!#=S?;OOQ.\$J 4</P2YO8 -16,:+^^(Z
M-KUL8-,8&X@8H$.$<KT#$D!V66O+^*^6X,6A#T3:+C;09VCQA>HSO9SHMQ92
MD6A$+*@HB2.@[ E.LZZNP\E@[P]^G;:&^-48D_%OT?5?#\'50U#H[DDIK,@
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M-X[K+CV80$SF[:K^U7V)"O!A:)H6W-=B6(]GL$N7,7$]X]),01ADI! AO]/
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M7=YVM^:1]L6)P'UTEU2Z,5:HCL$Q38M53*MNKC6A^Y@PY+:?T15+_%ISXL2
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M?380/<3Z!B=+L(%.>="0#?3![A@A^-MTF.?-61>Q"_ULH,R?>0Z[YLL&&MD
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M.'Y0QE3K;WJ*E81]]?OO&40SOU>IIY,M@O4]PB(55*.:Q;U;KOR_)!.976S
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M: HY8D656C?9]*'-+3MOYK8KO7K**3A*S;&VW31W357T0_]S[7M;=X'"%&(
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M>XO<"0XW4P*6L1NG$+G.@=2\J_CZ6 [<,M$_53=*<>OC@J(NK<E0N.P$Y\&
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MJKJ2<_?*EFN<H\Z:*6\);ZI&E8ZB@XI]K9N2\HW#@]_G>[S''5\QRY[L,#\
MXD1K!:C%MT\XG%%(Y;&Z,9HSKY$SUE0QD6"QC#R83)-G"JB0E'VH')>^:!Y
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M-'?ZU43F!;H:0\=K1S<HYR1TR#5V(KC<^Z8@X<E*VN'"PG#GQ?D8]9:C7/S
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M@R^2:U[U[_42O=-=' F.LH'J Y8RK<VMZA[CY?,T8XH.DT^%;%@#\[<1HO*
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MK<W@A0]#+ :/R.%9$G72H,8*K*]@=4ZOF,[#@&988=PT62N<M@_HZ824YWR
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M2^6!*"Y/AO2\,:;/LM:D<,(U]F9K*T7N"T_WV29V2>.3'W\$ER!<#VO\U>G
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MME+\D./0^G/1%'7$)8OCZWJ2[=/JDD:V#:-4=?S\^=+FR3WM[!G6#^X8&Z5
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MD4RTSW7@(HZFTAX'%ILK.M76-&?>BW*[:')ZLU3<1M_PVK!J;KLY$ (]AKQ
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M-BG8.FCY3,N,QM\\B*%BA<Q+_W=+NR:.)_#_%%EG!MXZPLB0&?-@,,.3Q^E
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M<M PL .C4>5/MQJT'=S5/N8K,_-L6UIN:5N3A-_I U?+.QL.N#:[0/[MBR&
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M>8[Z"E1#-=_P,+/8L/Z6YB*<>$K9_6 D684-Z^ $C=FP^1M?//=!9T(>O9L
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M.><HZ8=F7WRJ^87$YD^Q'%^B0W@O;#A5^6:#ECGK!9.//,3%A.')+57F^X[
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M(,+-F(;RZB3'TOM__!;C,&#X WYQ/T8&K!)"KQV6F<VD=X/;]T"4D-.7.*L
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ML*NTCG'T<5W%Q#&\S//]Z7(FY/D719Z7O08R',/-:>VLU_GPWKJ1\0RJKKE
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MG7]5'$P5 B]\0?],[BZD0F8,'6D*3/$B+=;!?0'YX1\_/D94 89'":L2Z!W
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MP4C1HV ED;?7*BJ:9-X+USH,OGG)$XZ08QYC$8EW>9[$$#^B:O%/DP4H,3A
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M$9.7>'I+[:=96YM.\%: KE*Z9T[9,\:[6BFZPUXJ$F> Y@,:Z@ +\M^#Q<%
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M"F"/]J171A5 ,JSY31]^&PTJE$#=Y']\)4Y2IIS[UQ-P:>!%^5W_P6U_M'!
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MZXL>*XVT1BH@F'VIW3BLJS%[R_>!5O;VM6B*23[%W>OVV6#R^?-5[%8-LC'
M%C(#FG\[#>& '?D%20[G9S.A)(V[7#EQC&%B*7SY>&0F];6*B6SF1=ES%XYZ
M<(&"H (L528&$&'<\,8T]E.4:."QOC\AJ5J/9Q=!P(RA\&D]2NW&A&=;?5L4
M9.ZMG/LI\TC-*/!+9BM+@+9#L6'X @-][$9-@?9MD?37/ (,9*T2_@C,%\:<
MUG99/#SO_ RK\X]41YE]-RQ=^X)T5(-JJQ@DE6E'JIL)9($UJ:57 ;-:Y_5<
M9+> L3.1B:CV":PF$C,69I(L](UU^>"ZJ3ERJ;I3[Q1JE=DO4#]<$8#0453\
M4XPG)AFG,6:@LXSD0)'M6DT?SJY1K"K*7>?>3[PMYC>_D*7C=$3XK&VE0')R
MA.TDWA<_TPB=WB+#(@>)&9 ^6&2ZBQO<[?L?WY;L>*U7%T.D/W6=V#KYJCGE
MH>=-<]-2GZ,SAAAR'>6&%REU*G>+_A+P$/^Q[DSMK6;Q1S[7;<6/<P9,]=GN
MD5=AXE]_"13$=NR#Z)J6FN1ABCYMEEXQXM>[&F5P0RV35,B_:(!Y1Y0;HZRD
M_"1I]M1KC8J:'+7GG3*\0(-->\%H)["T@>Y%JN7[<.(/2_TEB1[+.SUMT3O@
M@,"RKD97#C64Q]WQD(V-M_%AO* _^MW[('$C'4?6G+/)!GZY3FIVP4EI@]Y&
M?QT@DP/.^=TR3FY^7&]W$6S;\#-6I"!S=;'%L)]2P=!F:L%%"(P0BSI4DL,X
M6^2D2"[P&&=G6(UO1G[];/%"<)U#2!=O?']&Q",_+]NQ9C;]S"*<>S?LB5F8
MQKV>'0?-5MM$K<F1G*D"$$@85E2K20\$&%1U>B:P$\9 H&\#DR1I%?,1W%@I
M6IJ*:UIV<51J:)J[N6Z?>U110+IWQ/4-[Z%GE<<VN2.,ZH'+Y4S3$9S$FIY7
M'U3$!6%T*LXB'O7$IK'%4:Y@R]]3HR3B(+>B(/<%'H[SM2FO48$]N&.TV"3D
M,IP/%35@.U8[WE);7.%:1KU^0/9YT'%'3Z&N'P*N_^ZGFG^Q!$.6=R(P) 3Z
M!,VD>XN"K,=TFY%FYU4H"R9Y=&3S!>INGH[:7OLV]L&01AH1)[0/BN/#3!#W
M05_9VCL_?L/5$>VO!,XM5X%_#*]<[KT[97#_>=4U2FC+KA:42E+_T[;(;, P
MVM[GT=F0%<6F#\(1IM-X.#O NS?^>LA36-)YY@P(4P%SY^?.,%(G!T\YNRIS
M[1P%^EB7S%G2\CJ'7&7SX.5F8?H^2$%2U\CUTIO7O$XU+9AO87:6N4?\W1\_
MCL\R7;E9F_+N$(3S\*-$Y5J.L9. 5S?K*-4MQH^$Y$$%]YN-J99.>U7X9"5P
M'E8SFTDK I<JO@3I3:HOLU&PE!X /%E6294 =N@8JA6VRG6#X?;ZOYG<+[ZR
M?27][&"TW8V,3FL]=GDY$'(9D*8Z$"2#"\M0"!)/3/.ZI=)-O=A,Q!T2P_M.
M4X=*\]R5R@B3DVXZM5+'[KWMT"?!^%&71A$0/A0"-KK4VI[U8UE:;U#6S"LM
MR4R%$Z3YGP]"2HJYRD6'9M6C"\'-B^+&J<U;L6XRV$G/UO1E2U\!<<YV'\^+
M4A_N\74TR8)==$^=0=5 1%'&W6[G1_OBR##^[S.]SPIT8PI>WY7NN>0X==;H
MXP&IS(C; <\NR+.1.8NFL_&>H0F,N;VCP9(Q7LB#/V;R-_*VM*5AW>=LAO5O
M"PPK]#BE@(XJ_JI-G"1M1=SOD%8GM*MSK%&!<(33Z5=?2L;D773EGAVF:<D%
MB]XV/76-5\G0NR1"*^B]^O41K8$PB:MC14U-39&RS<TM,7<2>=,NO9&O/& +
M H%N'XBT&?F_YD,.O7! 896INI@HH_BW(@L(T=4!TX>,08L-.#4A%.^UO1J*
M9A,]PI410@[F#G@I^/R&W=%/D$M*O(./^WB8NA*L6N0^2!7/HK +=PR<:C(,
MV,-%#71H"BQ)!0J>FHJ@/\J>PI.$?^)&5JS2=Q^SB+,Z]_LVCGF=-U0NJ9NU
MW;Q4;&:8VN)=DOAABM1APSC#&G33G=Q$.Y#ATZN=,WVO45UUVJ=MNNU#)$3J
MK8LZTJ\YQ8,$81>X'KH=I5;$,,5*KY*&N0%_@NE8S?:*HT^6#_)0J*[^#= -
M *Q<Q#V%,NE^!(^O8\)?H>Y8O9UH<219VMA&?=)J[7",%%)M/-!V(3+>NH?"
M23Y:V8%84C_(-/]RG%K8@^3ZKL?*U.3.LR3^6JNEK"@4>W^UMTD-8,<=- (G
MA=8#'(HA_,PS5,$DTOLSIIZ2P4_*+WN! B<Z6C,=E#A>!K^!"N&XT2( X7@S
M7IP%0;GTJM\M;,#&,XW]T+>'E=QSI)"DOUF?9#'Z:U#$ZHG)2-":*N6TAV--
MC9^[(SE&U-W.[@*XZ %HR<X"RHTROD[3WGD:M CV>?MGJ.+0#5_G9G&-\HFY
M@.1KZ9^X=\5,P$>>Z7LD*A\TO-SIQC71,MUA\P:E;O9N?%,K>W1UW%]KK2!4
MU0G;4F7J$!"-_7Q'R<> K,WF'X)4^ ?C7[Z% GAJ[-@^"!@4M>8)("'Y )?.
M&2YLC($8J<;89'1CO*8@KWRZ_'T'V+&![]CM4U%F!H)EN5_^Y4[!_O1_ 5!+
M P04    " !IA&A7IMTU M,H 0!&F $ %0   &)I:6(M,C R,S Y,S!?9S$R
M+FIP9^R[!U13W;HNO.C=@/0:I"L@"@@J2%1$1/2+E2I$08%0502"Q(0B'8RB
MPB<*01%I8J17"1T1$>D0E)!@HP16+&%IVA_WW^[^SAGWGKO'V??<<<=>C)F1
M,->:F>]\G_=YGW=F+?XT?QZ0/WS0Y2 @)"P$G!7\ ?Q58,.^\Q%^%X +@. 0
MXL\"CH"PT._C]ZOP[T-4Y/>KF*BHB*BXF+CXWYJ$E*2@28B+2\I(2DG_/@3O
M9&6D97]_^#W(_WVIL)B(B)BTA+B$]/_TP>\ %"3%.,)7183T &$%(1$%(7X/
M !?,4>QOTQ,"_I]#2%A$5$Q<0C -&<$)]?*"Z8N(""8M)IBQH/>:H!\051#;
MN&G[/G'%X^<D]"XI62;<>BBIO[^Z4_G$"&A@Y7<Y44I:155-7</0R-AD\Q;K
M'3:V.W?M=CS@=-#YD,OADZ=.N[E[>'KYG[\0$!B$#HZ\$A4=@XF]FG0].24U
M+3TCY_:=N[EY?][+?U3\N.1):5EY14UM77U#8U-S2U=W3V]?_\N!5Z-CXQ.3
M4],S%!I]X</'3Y^_+"XQOW[[_H.U#OW\]=LN(4!$Z/\]_EV[% 1V"?_V@<1O
MNX2$8WZ?H" JMFF[^,9]QR7.75+4LTR05-I_ZV%UIY2^U0E0V>_RB+2*@37-
MD/G;M+]9]A\S+/$?LNS_,^S_MXL"R(H("9PGH@ @ "[G488)\']*(]TD!Q&@
MS18,D7G$;"Z;I<R]ASBWF;=EF>+>'6>A'IR?#MWU?^@D5M+[@94@_'Y_Y[2]
M+CBSZ9=L0/L+TNOA3,0&/H#&IU'!B\-9W]=F;K-NC_+4EZ+Y0$UALE%Q^5*[
M$*%'*D:"]>.+_%-D5+B>75H8^_Z3[6^"1!B$&>\%&,.5Z=?MW<PMY0/^G6!&
MB-19C0,2=.4;9.[C+*V7["J% W;21=V!T3R'1=+)L1UAIMZU&BG9Y;/O9VOE
M:RFO:S;ISF>_.C3/1#T@-O8G.3A@"/28E0(^(/J#2R('&3"'K_.V84]-G8?N
M5P7Y:CEH)IVI'K-.MWA:MXN6^.GD!^1.8:>-(B99LH"D[>P\OHL(&1,X*IGS
M%MW(Z=J.7!TID-"/%X+ZJ/2(>(Z5ZLSW!*/L,'3DN4H9:^ZXK=BGN,@M%7EN
MG0,&;R6^7*'<($;$;BBXA)<^<R;%!K0OLG]XT#NXT!O(6G@2,H0/M: LT) K
M3J E'V E0B_S[[1L)9:C&RR]@][VFX_G^"ZIL!247 RR/=V\RP8+NH/%[6\*
M07B>W"PWDR<[S#:#_%F?F84W?O&!'N^"N%X**B7JQ1\QD;0J/;A\<&XJLH80
MDR=[^5"CXLO.F-;W#I]T=7U;>1O^@*1 ;SJ1HYAT',IDPFG1J57+[8I,?/(\
M.$DJ7UPT[[NGS ?2OX?$C2=/!VRWUW76A<<>A"D)?9_J0\WJ.T+.[%/8#=P_
M%\"XI6%FS;<>-]951L/C2I7<*P7;2=,UH1%VKZ7]U2Y08G<M^G:7!N<'5(>Q
MAHR/)RYIKQ2&U;U:;OY#[8*+NJB\LY_IMT">M!!;F3<,XF;)S_$K<>!:!VM.
M!KI,$=ATH1GL3TH8*XJS>>N[NO0Z5O.PT^6^4W]N%AN-/7AP93*\E$:4PG=:
MD><?XW7LM[,W<G:,<8QIS8AS;)( ?R3LGJ!-H\_L79\LN4>SUH]3C%<7;M%.
MI;/$J/%_(*V%?H5&%>@&%^_?7=4X>\0AJ/;;U-#7;]ELJX+FA9V]GJ2>B 1J
M-:)WF  'C_B(+*"NX\^:2Z\M(+.QL(@%'UM6U82#E:<C_5";XZ5P"[T)7T81
MVZE-X=6KJL!/DI,&VQ4Z=[#-P:O+=+GU+J2,+\<KY15"^2AM4)5I?37TD>N%
M<;D6S01%"SFU/-SH3GWQ>(=-W"+$_#-\8^,*@^G=R0>D[0,%H,6,4Y;IMIF?
MP;7NGPO0VD.%IS[.2K=EDP^RMP7Y!7(7CSFL1O9>G4KF _-%5/7O$1E\0)@G
MSAOE ]79G[N)RM@PID6Z]> U\[8X_\IL/6W30[=/>.?ECLA&2O6$J>U]]1+G
M7WCW,QETP__<8S&-XKU1^<P'CN3=S>8#8A<ANR(.G@\DIN*Z^8 $Q[,\6(5R
ML'$!KM7_]-F]JZQ1GYG2Y,\Y<8X&YW?W7MIHOS%L4U;D3E'%FT+K<P45Z/P7
MS:VC46I;'VVT5#?_Y'[LU<7!NP;G=209AW_=(&K_0I] =36>Z!MU#AU-T']T
M4SWQLX'P061H!@>"-$%3FL6*P'PQ$C-FA0^PS3&J2- BOBV0;6R143\LA@D7
M"BL9J/(*H9Z[\=/\MD+OYH8[?;W .\#8V("#!O5IV8V_+Q<?]N$#G7_P%&4J
M2806<I>KCPP22KT4M:D%9&5&/O5>3 _QLPVM39F;N?ZA2*S4O2#=OT-B]=JS
MVL>^U#/H7*^JNBF;ZS*5F%(WS&5+V[)=9V[<*SXU>25[@UC+9+UWR,Y"IVR#
ME@)_M\B1?7Y"QL])KV#R^$Z'=FN.(=C?C5?#]2' HPAQ+!Q*GH]0^;)^"^O%
M!Y('SQFNIYG+O78M\UH:>RRUM:+QN77%H%7#^5OJ%_<^<:&A-'FS?  \!:=$
M'(=FV$*8.%;2*$XEA.*>Q('1\-J8-V^F_@!+;B]6OQN\)$Z,D:UN6\\Y?,'V
M0DQR]G$UL5X 5S_U$@6>1D*FJ&3\?*X[6?8)L[33W+VWQ9T0%3<=E>U\>'Q2
M!>0FE\[D?_KY:/NN)H^%)DNE$Z4*.GL_"!8L<1_'D%O,$^%(,0E=<,+N'<_R
MBK]0%7<@H=,460=KGZMA(MV7TTH:1P-:1"(U/7WI!K!O9OL-OSQJLH"V(#K7
MQ'AOR8W#*^4@G+XGE7(%IOZ%JG3%QT]6MKY^.)ESS^9SL=CE?2M[]Y2)+,,H
MCJQT4&)ED&V+Z6<1F?7T(=J:!,9MS:?99FRS[25'F</5/>]28@^=.A(8N3OA
MP=0#?.=V/A"A+X"&)C?/CUL<".W SVO>HOL@#[2#[:45YA]8>2KNXE(BAZK[
MK)J1FI@^RY!YY$RJ(&X1(<-)B%H^P%'HIY?P@5G["'"67L\CL/?MRYD+3&V3
MLU?TMJ_ ^<MQO@9)&MB[M"^(/3_TC9SJ8,F\1N)L;.VD"GU'*B]YJ20P*WG2
MFZZ!?*#_5P/A*JMQ>Y#JG"XYKJRXT%)#!#&ST+A5\F?@!9Z9/&RVRLYC-"KY
M[O>"$Y0O^[9G^(?M)N?I+F77/=BV"K->9B"/CHDZGQ@_VZCXNGI_X+V3KV^U
MZ'WXVO]<*Y\SSWV,N, 'XO'@$<%D*UE(*($MCC4=Y>F<P3I!MRWB[:_1D))=
M8:%MKH]<G[Q#LC);K]@%Y+[QV'BA2?_U8,%*![T9!ADW<A3=62[<VONL.F8J
M(Q!\1>U_1JW/Z[D&[VZXNO(,Q$3/LAVQ.=-%NMX^+F99PU?^O)-&\^GT.[X7
M7D2LZV?$@GFLXVW0M7/,O4LPBQY2&B4F\;OHF%_Z:_?U<KM>,][Y])IW,K&V
M.]_MHP@_8-XJP\UH:*<REA_CNOT[UPQ:&CO9:W"+C)3'[0<NS@9'3QK-OIH9
M\+]L\,UV7E0?_<;YHU$QF$=#,@@"LAL1@"^,<Y5;RM,(*MS%S$OC64..G86;
MF+;I5[ZWOAC_;J@Q6I_<,RH\VO5)*<;-."Y[*,>%5,+;S>LE PY;!+$>WJ[(
M&]K].:'J+(2FD6=D3KV?EQ']:EVUOV^V9S?6[5=4CU2"X2,[1XN;N(,A0=WB
M1U_M1;BL6*Q$N>[\H6W)TKP?>]/:JE/W2M2>[@V2OTZY7?V4688Z@X[6Z'VZ
M;G->IA43KOPXOC!A7.O9M>5O[BP,)%$&B2RX<Y00+'$NH0TMT46&.=*0<KZ<
M'8UUS7'7K#HI?8TT-BTR*E3Q_B$*73) 3]=&_K!0O&EONSPD05-=@=&IB2TD
M1KG _$0FO$,[ILMWR^B5$NYCAPV8KNZ38_4O]OLUE-0W,V8B-/I8@3WIT3DV
MBTKA/#TAMAU*@J,E6+(JG( PZE[C3)GPE6'!.(^)O3AUL)^P@R#-!\+?82-&
MKRQ$19;Z[&E[IML4OUOXE,*#'TN7\ME=9&/R_$VX*#XB0@>K!57183.?62"X
MWKVVP9:Q::%I 5PM 0.T+Y^Z%Q5K.\@J'=<UV-ZG&CAXXTD\XDB["#1(;^R!
M)6L@,]MM.>H"9KM&S^Q$L$JO(VAZ26Z\X5G[=/@OGR:%P?8=-U!WL.T!8Z_R
MEZP%D)]@M,\\7MKFX_@B;ZCQGD_,YD[U$P?WB2I,9W!^"LRIX"C40C_8>%PW
M7)AGB,G_==3.:PI[22*C=-0H3G4B[!$XDD^?_O,^]MB[M'QUA3.*2J-&JY%G
MLC]?;U,06/]:,,1M[ 4P<,45'.WN<E GLO3&<9N&YLW%%77RHNA[K$[ESE$8
MYOMFM*ID)(EG?>:%.PH/2;Q'-< 8^VAK,\:L "B;?6#NRR+)!5SKS&O?U I^
M;'AT$QFEW&9N--1CFT<.%[FK/SWE/X]*NXK*<E#Y0E1:NW[5YTGU0Z^E\#QW
MTX89HV0#RIN+.ZE9S ?N'XQ[UB#CX97L*GQG$V6845X)7=9<R_+=PB5Z]SL8
M0 .&RP3YX/R^AZ55$Q_;UA^V#81]B#U?%^)FI*\^4WM1] I*Z39=E>$HH#P8
MY,XVA[I9GL^A$0'[T*96B$50JROD34>J=#Y!VU*J/O;/H-R;$^F[],9%%;H:
MF/UZ-3VCK5E6QR26ZU_TOG@G%16RVU6I3&>7_ME72X(UO[A/>[E7 !+$++(;
M41W1$4?*'L.<Q92N^)J_K=.LTNL_?<@@Y2CR1$.U>S2%'7VMR*7NF<=62ZM;
M/V>9T8A9=YY4*5L91T$H\)0XFT9Y"I .4FSQ:EX7'P"@F/Z+2T/S!;X?AW)+
M(@-N/LI4,_#T;STT+CGJX7,3.%3Y.\GQ <C(>&4'VU@0N_9M"DP104C%EG[Q
MU1OEZ4,;YA;Z-$YW.U];4/LT]=1^K/RUYNZ\/S\SS@ZU/;UE^N2M9!%L<LGD
M4;ST/Z619+@5^/EB5,W4"GYA#YR&ZEE3"*$T9K?M.[O^2Z!%9&C:CCT:[R?R
MMSNWL VO6PYH"259W-<]8.@A?/@FL&>TC>3"O8E3_4)MB*YF7Z$$>XTP;S2#
M7\<Z\W(),>IC4\C&MAR&MO_7]?2LG.=FY[>XBP39C^-K8AC-;!O>K([F1-L^
MM@/TU6<_?L.2<'>OAGC5XW>+^0VIT>X7$[_VK>[\W.@G1/$1;I_<XB$<,FDB
M\@H1:C$]-O^9T0R^&J8U]O9-AAJ.U,^&17:UFX#M%9,:Y-2HD,MS3MSL5XGG
M[HGL%$TYH9UD*I+QD1R @(Q1W?"90?IJ*=L)DTI?ZT%F$!5^F,M=<6)2>X]>
ME5E>EC-Q^<1-&3$/8S 8#]%[;_5<K#S4H1K0>TW(L]V224C&Z6 <3T,)"R3Y
MF44-G>0GPV4ANQL>[NZ-N("6#3,8>\7HTM.KM=(!3@2))',%7'\!D4*MMEWA
M/L8-D25_:/NN[1V)^.$ZZ/)CMNQ3"]KBAV;!_K/#6I?*A4/*A6D'Y4T,;GK,
M<"O) ;!D?$/$RCH]8H:X<+KJ>[LF\^C32[[M>9BPU:H/&4&KNDV)QS8,^!6:
ME!S4C1]YMD]=H@XD9=C;+1!DT>T[0%Q]1#EZ=^]UVQ;?XD 33'A5R3Z#$\4;
MU#W5/13&%=R_B'PF2N [[>P-'V/W0TAF!-V=H<UTIAMG.,@MY3/6DJ.HFL'Y
M(<,(UK,'UC]IS6S#Y)8!C0,RSO7'NZL#T589C&>(\\3D1F(]A]I0];&OW#;C
MF8,J'^@2LR&:,6T>_')G)9#-_+:O6:E[E/NQ#U^JM9\J$V1:94$,BF[EW@NK
MTR0FL1#P=IM9K$;K>.$J/MZ-AS@%WLO^]*UPR%^%#X2YVMS,M:F,UMNE'RZE
MS(J^_V3QET.!^*W''HXAZ!#I[I"P"/E#M.R]IYV.QU< @%"'<!-5&#="EG0P
MX(0P/Z_\F%]3?#&5B5-_<F?.:LRK*VBR)]AM[5)@NH_HY;4,VXCWM6%]FJ()
M/KU +(HAPM;E6' ?MQMAS:#*!8:K5]()R'%!@FF<O#"ZNG!#_1EETM6O49K9
MC&$=[@^^LZOS_8TM_;VD&22ML0\E<+(T @U37MK=YK7>.>3LT08^5;$]7O)T
M--CK2CZ6_E'#!@VDN)DHW(8ENL)R7UAF %_9?&#&F)9;S/:%SYZXYNJI8XZ0
M*0$5ZKW+>-W<>T9%C9^0%H/4SS\K@&OL:&:M_22BDS!M+.",'6QY-!5$GGOX
M'B+2J@C)I>#W7_B,4I=/Y.H_7YYW*31(4W'P/W?KV W)3F#J*53:ZZ !(E*B
M8!J8X1X5KS\(CV=<8RN"\^^^ZHP(C-BHFH,^?UE9X;2KU48 N(W:@HGAR0@*
M(M%O3/$7CSIM;V#//<9$]% >7(U)<="'"+0;C4\@;[>66PW]6AKU0X^\Y?LW
MG0_TF%67W:<.$&A3' 7B?,SU*+*D<0^<@ER(Z2%)8?=,A/VP$,':0-D+9:0Z
M<YVEZ4]O]BE%5Q^-887;WXJQ7M:9Z*"WD"@B/*ETD+Q@VU\Y3,'3IOK)&62)
MMMBJ(!"-,V-*="$WSDX3%2@=TK-5WU6C&[<= 2LM^[=E!SC9.<Z;Z"2Q3_%F
MR+7K*VA:E>"[M;"G8^6&T^HM5M9D,#'[1\+K?5 ^;13O%9:;S:6!/=W)ZF%I
MI\5EE$4U2MB;<>\1M:6,NWQ 2OP>&-.SNTY'%TP>=^-9@(&9]K:QCY;SM7+*
M,<D3R=^/']5X673G-MJ9TNEQ]RRP@WS!8L9NGKH2"!;@Y#G*8Q8Y;\).?#X]
M61\6<B*'?6+RAUT>-;+,]_UAUW=G7DV;K5P5.RU=46$ W6=OP]I#)*8@L>4Q
M-M&]N6Y[XFCV^8-0L(S=GY.3_N4SF:Z$.OV#KZ&L"S8UYYKM4I6_3'3S1O!U
M>1W4&5.:42ESC)4)$<[14-*+0F*?RO$O:E8[_3-V+KCEH'W23F7L"+Q\L>(H
M<(D/R"#.1LR,S:\Q;C--60S0/77UD>!K>WV,CXRU(2/-7H:-FIIT;4X0%M$\
MO%%QLUGG4-MY,;O&RQH(SL88UN%J[DW[DVR%Y08-7N/\L JF\1ASQS@E]ZGB
ML>J)K6O9ZQ3S</.%M [PW3GZ6=NM;]6:#-3)@41HR]I*%-N9XU,#B14MX\Q
M4G94W.8(["X:*=T!F+"WC7Q&Z6LM#%$H\^YIW'=*Q51]JY+*%J6--@@T =HL
ML3+ -N,<K(6V+\@053!Y?>M7728(B3PMC.H)IE%YR),4DXAGNF/S=ZN*WDG"
MMK[O]0YG5,7+(N)1X!%D"E["P08-KT/UX"DB]/X^A#J$<FD:PZI687V83NU%
M6-N(BP^W'GW@UM P8C:F5^%R\<NW%KDG1S;"BGE#J!I\-W(&]0=S[AZX<'QR
MJSZ4RC3U8O8U1<65?=R^Y/7XD??UU//H!OF.4+=W'5$!Y3QIWA2J-I A \KA
M@V'7R:K?LYT[,M&1EV+IZA]M;J&7(UH9IM&-0CHC-,J<WY&R$89=/$D:)'!4
M37E2$W0^L/$+)1A[D/G'W2),WLFC=@(Q(<]Q!A<\Q[ 63]^WAAVJ^A%R_U1]
MV&M)]\!3H=BGERV%Z@1:PL5BYAEBVK\#\=SM]@),:[$%UL7P'70');*L&>&2
M;?L>+47G;3SC375"S'!N;ZD;)0V);'+6+5_V(711IYT[\1MX#E"(H :%]2%T
M,%/]#AH0^MI\U!36YYK?6AEZW>N!5^;@Q=S<FYL*SJ?LG"CV>'NPR<3[4Y4%
MI9&US,TG^ZO5F2*RY[:U:U SGADD=>'DP<F$V*<A5S]4EZ'%JI+OG!@VV>L>
MR9B^GQ<IU[T#<9X*F<!7^ME!P;A-8&GGL-+2Y)P)F'F@W0QTSN18Q3U<OHK(
METHOK6G/V+Q_I]:ABI=7PX>5A+R]!/(VAC?DNY6YU@_7Y.Q]2VIS@C%DBK[\
M0O0<%7%O<:O.&3M:5S@IUN@Q8I"<<<;.ZF=6YX2ZM#+)\BUY/ALOE4U-J<-G
MHNH;^X?3<3)@2FU@11!<KET7\W5NS2F#/C3I:K4MXXUI94_RB+I^<^'I5UOG
MITG/38J$V[7?(N:3^< &CD0%E+%,D^ HF;)*01LB/4(YV&%3NT"1)K6;>,V@
MF2C?=];?ZB[)B-2I^H_?CK=$>K$S,H"?:YUX\ ]\*DZ3*5AN':A[(:^'#VAA
M4N<#'M)EAF4PJ?TZABF_UH]=\YWT=DTFYZTL!7C0_GRZS_[%?47#CDZ&Q>_<
MVI+*P/,!N:JXR I7>C'8CA1R(!K\3JW>2S*XUR-JZ_>R*E2CN:U2FE9#H5A7
M;C%.'KL)NC\/3^(AF'8SF"1Z=%7,$VCK0*C1'=2962^76$O5;&G'!LF"VDW'
M+L6[Z+J'ORXK>1\/G,^Y>DRB1V.=(^_*<A-0[5 <ZV(KQ&16(*YKM-DNEV(U
M4_OE"1N^6)[YF650FT6YQQ0=U4S;5(@NNG'!^6NZ4W\Y)T[@J_-816@!$6_O
M6<PY!"6 Z_UPV>^;'F'<Z<ANDKS3N2JC/X^KN&ZF>!@VMB2\#OJTZV'4!AG=
M_4.%5IZ"BY<%LMCVNX\?\S%40 \A2:-;:M%7\WJU;6EO:B-IFJZ=QKE^UP),
MW>HZ+BN]U.J1^M@QH,-D[^5-(6I)*V30#T$164#TL,WMNAI/S#J6H&8>YY$J
MD9%\0.>MIV-HC6NL6?/K2UW/7EON[3  +@HR'&(^GUB+ZJ2FXA7LI>C63(F>
M$'+FVS\=MF!(=-]J;DDEI@)>6U^S+W++XZ";_3)ME[JEG;3.W?<K-R#JMPLF
MK,![4V@,&A% $CV"L8M)[7-0 >_R[L<(L-'=;L)\_Z*W]/I<WZIFFD-?9<"3
M_?JI*P]7LWO2(\RJ^[Z<J8]#KI %98X2-Q\18J&]1)7$2N'I>!CT^<#8R1/C
M;1),6.=50FK4X^<QTWGEZ#)'Q:%P;YE/_<VG:E*V>.[[A'/ =YY!^ DTQ#=Z
M'PET])IJ0]&)BE" Y&=F[GUP@?:IBHZ #CZ\%?,X_WK^M;;RD+L_&ZQB[\?.
M)DH!OP(ROL&E<11X3:D@U0=80*%KLMA8D#'<-3%J./Z16=VN,.,8H6"ZZ6:3
MG&:QJ?[!CD//I)7EOD[=PNH)#!_F=9+5</I0)*TD-9/C0QLD:+XW;XS?(:BL
M;2>O:%OUGGC^ROE<[+4P):O6K-"CG8_?"8L;*PG]\%$ZOE?L/[MA-[-/\P1U
M,'@L(I[<R"()UE25&X\5FT>D#RS 4QMTU)C4;J3&\O!C%.SYL%G#M\4\MH9)
M=_KAMLOQK7=LWWC$XJ.F!HC:?,!O;5:FDP_4;VAEHP18W,,'T#!9*,Z-V5#@
MCV;*T*B]YN++I\#5:O,' :8AD,8DYIG95C?%CXVY1R['9RTWNYR%:4#^@N]W
M@O;02"J\MWCE=L$@G8@?U$1\76DW.>$;U-H[ISKUS'R5VNNK,[8Q.M'UZ.&I
M=??G)=UJ]D/%Z+M[S102L0O%O%E$O1(?J-EZEWT>,F7E<BNPI]G[J4$LG!%\
M@RZW +L7*U16UVJ,AW4*?VGW:/BJUI&W?/E\H/"E[7(9[,!Y*D=1DQ[1@\HB
MR^.#X=!F1"]1#L/NP\L[*+W#6J,V8!2[OZ&OBB?1XM(UO%L/B?6,G3GC:I_=
M7'HW2>AK0J/:IW8=7@<9/(T$."HCB',,59ZTT#S7EF:;JEL_6D=*NVJ;%$Z#
MXO/EJH_+)0ZQ;OLKT96\\0UIF:&:G*KO0@7,QGYR?03#6; 6!\&8E8?@%(O
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M@97);>!98[IT>5N;N!51%C+OSKQ&8*V/ZA]]GNF::7Q+[08ZXP9QUYZA<-P
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M;'"C9XM>F4&U+B"U8QXA3IZ_BY+F:7-"!0*$(<:,865 W<SBGCDY%S)-_+Y
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M7(]+ '_/'*L=4(M8%4>R*B&Q=,+FJR(>A!!,*A(J_#'4)N/C$H7_$XC5[T-
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M!K,Q%7YA@P$!@;>ZFL6!FZCTB\FT='!8>,:.].Q9I6J:/BJ;<:,Z^%WNS>;
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M;#.I=EW4UU)Q^C04,$)7[S8V)GY]&[/B<N@#PK%C<+0)X-+ "V.N@MWC8GL
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M%9D69X<V9IX!!'.EOY(?GSGC>O'%:^;7X97"_I$[%#9,X!+F*C,"TEC!=Y*
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M</O>D8-WK5E>1TP<XKB(XJA3KI4=)58;''B?.$83NL%P>LU Q@?D^N9^;#B
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MIM&ZSEQ^=S,F>BA3:NM0TOG.D[M&W%A%-]7WG<:D&KB^J" QB?ET;%"^+49
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MD(&93&<9X[> #$9(=;P-)GA!W8%ZZFV[Y\,KQ6]VO&V\_D0IUC#&ER0V3#
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M?2DRV'/J&<,IISDDO=5;4&T*^8X_D7^S8;3$M;R;)5M">8WV,O26T;2M!?U
MMR+S)D-WLF0 $.OVBZ]/T2MYQT4$A6>.:]_WXFRDM&+UU+7XC21$$JZV'2<K
M3,U6.0@@GZJ=>)VK4+#M4]K3U*9I8_BG4Y:Q,N.&=;?]GD#/N<_CI]+/;KIW
MQJEQIFY/:VS?_4)JC7M6F<E$ \Q);H8D_L10_DK4Q*PH9/HAW)*! )FU"0<#
M:V .?@;&^@8=.$A:<P""OT:'"T"["8TKR4]+ 9-_:[[B_SNV.,CJY'X:L"0+
MB0/?-,_"WC2N8#GFKYR=A4&2A[*?CZ,Y"D;UC%%V] ('AN3T6O;*33'+!Z&
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MMPUD!%&4V_4/W<P<,3GRN5&N(G\7S3C7<8O"8?X&>2&DSXO*@Z [K!DZ8-4
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M20W<ZYA7**SW(>=MG_'&VL/N:DP;N,]0L)[F.Z7R"JH#"D(FRS+QLB )-P"
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MXFNL +JYAVD_@>B$HV7NR)W2E^+D7!U/J\L\;CUEWKG[G?63Y$?-12_%*R-
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M,8T[<]EB YB0RGUTLZ);4[M[$O3)?#4T6_4MWL97WM7V*,B4W6\Y%73_R[!
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M.GP7^<)U/1FLLD=].$47T"NE%T4?+>9P!"J?^EKJ=GW.W]M0:ZAZ#;UK"ML
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MAJF-T5=K:(1M8 _=(06G%%QZ#("F"Q11(17?O?VROY8%G= +KDQB?*P]+5C
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M?MA,.P<C(IOAA3!PM]N]3G4,Y<QMMU,@$G!P (^VY2>'A]4M/-Q;V^Q%/5'
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MXQHIN+&WW+H],EWMZ[?K@7MC]\Z?=67<8RD:*=G6M:NY_O'C/R9%.LHNY6#
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M<:MX,.9)K4W;>_#N[(DW,(E/8Y(PB&J(@B0LUD#, E*],<61!PP+P5630B\
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M+X'219;2M$TA+K/UR>7&<[17,$/;P)KRE']/C"@5MQCDV,T3\!).E#:'"?
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MNI%> TA'B(@("HA254I %$3$*"H@$:(@74!4)$A(!*2#"'S")PA145$ID:Z
MA!**(B*]2@J*4@():MR2-MMS[YV[SO_,NG?FK'-FYLPZF_6&DKP[S_.^S_,K
MF[TBF!10 ?FC3BY.@- F(> \] 4(5@$YAXN1?@%    =0H(9P!'8)/3G^/.X
MZ<\A(OSG451$1%A$3%1,[)^&N*0$-,3%Q"2D)22E_AS03S+24C)_?OESDO]K
MZB9186%1*7$Q<:G_X4/0#BA(B+5ONB$LM W8I" DK" D( -P*$;1?PI/"/B_
M#Z%-PB*B8N)0&-+0"QKDH?"%A:&@1:&(H6?CH><!$05119V]#F*;3UX0WQ:E
M9)J0^U!"]V!-A[+[$'.[F=^51$DI%54U=0V]'?H&.W>96UA:[=M_P/'082?G
M(RY'3YT^X^'I==;;_V) 8%!P2.C5:]'78S"Q-Y)N):>DIJ5GY.7_=;>@\.][
M18_*'C]Y6O[L^8O:NOJ&QJ97KYL[N\C=/;U];]\-CXR.C4],3DW3Z/.?ORQ\
M_;:XQ%K__N,G^Q?X>^-/7D* L-#_<_PW\U* \MKT9P_$_^0EM"GFSPL41$1U
M]HHI.IP4OQ"U>9MI@H32P=R'-1V2NF;N3&6_*T-2*MO-:7JL/ZG]4V;_?8DE
M_JLR^Z^)_;]Y30,RPD+0Y@DK  B QWV480#\GS(J!8!JV"(-*16*VYDW^J$Y
M@F Q<A ><L=9TV[V>]:\>I745[L] N"M+@O)RRRD;!S_(<1"KTP) -'3 B Q
M!3=.$+:QX#ACY:'?; >>8Y#=S?B9:];+.3G-%G4#<FRWGIWG/1WOVNP1:YO[
MV'KJ,G9GV1(?\;*1N5K^W!M5_&;;_*G;Z-I/S6)Q9_ZZ$!C@U_\:$_Y:6(QD
MCJ F"X!-".I#[PGN9D.J2297&GI38>9",O6US7XE]IS,*U!7]#-S6OIYS(SF
M_+,RLSTR-A0#Y4^_CN^?Y>7B Q!3%+X4GN/"'T>KDB*)MS;09!]4AP#0:D"G
MM,E^Q'IE1X73"'*+[.N!XC7)MXWU7L>EZ\>E=?8-)&XY_U%\,< QX-GB1E[?
M1C372EJI2NFII..MW./J<@?VV#J?1*=Y+U2P3M$% '=S,2UF9>89]P)+-9]*
M '<JP:5ME%D2%/7H4P]02U8%UYNB9NU<!V3,S*/>74V**!DGG1< @9%3_E3Q
ME:O,%S/4PI4QYG!_9ZEZPZNX6R.7'N?^^@!^WY'G<K;T+#S8:+7[[ZP\-R!@
M$=T([V#XL]^,(_PR78BIF3^0PF<Q+U9IPSH7QPL]\Z>=I5P6(D/(!:MG+0&E
MY[,N[7V\/ $0#I?ECZ:S#CHS7S&'N1;@2"77^GK;F*+#\UFO6/CBSO6G@U8?
MU#(7="/G]A-SN-(<:7ZOH@#H()?:C'_AW6M5B307  E\..M3\MN/.A3Q]$"6
M]N/UI6_76=<'-#;O^9WN,*@\"+W>%D^]#Z^-9)30B3/"9$)#:B<'H=TC !K*
M;]?'2[M-?+=H3-H<G_OT=6W6?=3<T6'9"9?TZQU2*4)[[!'N)7>56EY*B;GH
MW]PE:^(QW-"B-UKO<WQN_=-;2=O*_FV6<G+J+N)%7!OFUQ[2M"[[+B^)1+V/
MKJ5DFKLAZ<?361?!$K[.-]52$_Y;N]VI78WKQ5J[UW]W122W*[IL_CJH$G?<
M92 ^B:/#[X=KVPGA.P[5FZ3!Q06 'T4,!P4OW>I,#7=%@OE4I RX\8[>[_'F
M5M>.DN<S(8TON[?$*,!-)0,/]SM?;JFU-Q=BBS-R.$YG<7WH6@+99#K'G5G9
MS"#=M-&-KQXH<[B^-6ZL,?WQ7DFIEP=GHEX][[FAL8"@EA*:3!(1U >4NFQB
M+U(:=/_5=>!)8T5,&::WXT9]QQK6JF+Z;6V<>I]T ? X8U*SK,"R_8.X'E3O
M+P3 7T?X0Q2V<P.%IYO7:M;MS]=ZPO'D'N"],J?\0"8) /BU</$.RI9'Z +*
M099:TY%K" 6KX.%SO$2Z8X/3<HS?@+VV .!8\3\)  5\*&$JC(IGN#*3V&=&
MH[6LZ!\>1@H 2>4,\,6X)1-71+^\<:MJ5_F,LO9V]"X].>Q'^\ZB#9.38^8#
MVJ.4T.DLE9>&P,BY]\]NYM\T)<LAE4$*QQ;_;B^)>I?"OJP!YQ=';_Q<F\IA
MR_**2)<BP9WZC(H7_#&\',,F_M$WBE)]6+ATI^\VL?#=[^B1LE[QCT#45__9
M9J.]E>^ER36YZDA3MW9XN07*=?Q:=H18\U T*JPOSR/[<T/)Q3-18R[NEYVC
MT&E%Q&[T;1,!(-(.:G(T,$[A,3[,KQGX2_%7:=?+ _E[\I&OQVQ,RI>:RU"8
MV :K'4<4,8Q'C922'K4LQY3N^,-,:[8]2($>V: K"\6.Y-W$2G.L,8>K?MIJ
MTC^DTR+3"F3#Z -[*_N]]X\P'J0'MC0T'_FL"JA?=]E5IQP*<#CS^F0OG#Q6
MAX7NKBC922QCDE+6&F*-W$]JGC-N:'GO+^,PC0HT2\KZ*M8*YTNZ0ONXEYG#
M5=9E7VL%*8^X>]J8=A6/EU/=QKFZ+T(-HVV?<H)W,\H5=^T RQM?IYP.?Z#U
M7NQZOB^!$X9_6XQ%"8#: ")^L?D&MYE7P-\'FO E+>B1"5!S69%1I)=8$]Y#
MO!\2-D@_*RQZAA69C+42?2^N_\7S]? 4-1OWH[;]0<0^)2%V=3H42"0S"/I&
MK?2$,UUS9+E:HQ%%O<[-1;_HVY;ZC"9.-M8TOGDU,BRDOIO5%1?RIK6CX>FT
MYZZP9=<2?Y>ZMB37UC'C1Z^;/[%1L?IG\B[)E+PXCA*N/N#Y.6<EF8GJ(8B3
MJ(\I-6UUK.L3_6 "2Y6&)!.UN<Y&C_>-_[RW0BQ/3EC\;%3CG?!1[T7"<"/4
M&(B7I)4F*"P(9!*O@X5L.J\1JQ!&Q/J !"*F^M=9UFK590$PW2899^RQ,?QN
MQNW^RWA+ZWU5%ZX=R9#Y_/)\E#V\XJ<'Q6=H]X_Y2N\PR]KI30[-MVG>>QPZ
M-!-ZQ7.J<'NQ-JVL0JY2F0OT%N<&.6>6I]^0^1;,0K(2:_3.W-O(JW1-E-MN
MY2F;FKOQA9EA"H00[4M7CZ9^N3,Q!(<HQS]G*HR&Y"H/TI$KFZG(A%+MEZ Q
M2Y5]?M@&12<E/_?3/-@\OI6EW%WTJ:HXT*#DX6V]\(R'[X^\EY;Y*-X,%O*E
MNIE^2'"':AJ)^@POC56N6"[5^/C#FG<4+AOJ*3])F35^PFT\?OO$^YJ(/-4
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MH#/HR;(F>[.KYB/EO6SYF5233:#S"9984W1@ULG5MK<79&J=@?/]"WT*DAY
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M]'FJ&8'J4L2PQE_QN%#<%"3W6/A6B[Q'I-^F6(O+K0]W(O0#P8S^J2@"W81
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M_:4(YKQ4!/M>_WH*_*7^!2/?6Q]Y*1K_'MK_AT.KL&?NXZ3KJ[%/@$4*8=B
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ME^?<^;(H4[V<#&SH*_MG5)\5ZX]>YANRJ4*NKMP)]1+H:""&((4-'L1$]<F
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M=\L%^OM- LP2/--Q#3:7PLB:7S518KT%ZW!73F^\S?-QDF7^3=M/+IFE#7U
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MYB'AY??>_DYRM#*?> ?HSP"F9>E)G$#80YO_@_@6]L?%MU\RJ#_'M=Z[Y@:
M*\'Z7WKL\I?(U/J</0QFP$/5K@68<DNE^;^+>JI^13UKD9&4M?I(]GGZM@QZ
M$Y5P<W*NF=<FY%V'1M/8O-'VH5VZEU^\X%%>+F5[:/GJ594 "".8%:_!#72
MVO>:@:H5>.Y_5R'Z3*>N@!/1GW"\,MQ@=W>O_8N8#;7O[YS*KF8I7/P0MW#T
MA6X>/O/9B^UG7LX]-[P2Y7G!U[R>2I_-,'M(OE5BS$4X%$U_7.BE8M@BP!L
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M)8&[T<,!]1S=-E8?#Y'2S4/$]27"L+X=(#>A/*8650D+'J,D3J2CL %R#"T
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MZLRXW@9[LH+E\C57CUV/CBGAR[H+FC(,:?A:TFW_N&!7./XP9%"C"B<OE;I
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M1C/P:4B]$LVYL6!N@,OB(<@1%U&?>EX1YGD(V.X.EJ)H=7N1,Y/]9FP> G8
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M%N=4FD.^VM"<=S&HKCVX5'F?U8!J/AW9AY=CA;(KN#W6=D:U#V-8Q\YGG5Y
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MQC":T9!DK[-D/)JGVI_8>H/Q=&8H5/,;R=ER*>A(Q-6L\ R%5'%''W/[#70
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M6I!'[X*5C<,?@OP>0**:9C1G9.OMY=+VYO>@WU#5Q<K;@XW-_%<[9>A(4,V
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MOZK.M=3F+2"A'&LV8@E>BU^^P*?9D0.J1H!I4BC=G9K73)/<.UCRTU,I\EN
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M%?1$@ >3Z$@FJ@=[E/M\$^(M.7VPARI/)$!0;GE%L)0P6(INV9*J/N]S-I6
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M>]F.CM8>OW"+\:'OAH9"+B]VQCRMOP:)0EI'-"^7,2NIR %<? K?+_'U36U
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M5[SS[JE7D!!2S*4O(M_7E_V8[JRT+<_CO7_"X.P)<>7&61Y!,_HM12<YUL%
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M_9\<FT NLE\_;.?1/MN!TDX9EYWA>Y-]W]1</7?&2?M!6:-'NA;_]Z,ZW:1
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M*->L+P$%45NNCV&&D,HK^<_JYYE7!YVZ9<BO%B67O.UJ!)3?="Q<0WPXXQL
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MTXI:.54$G])^RX<C?B7:3H$'6$ROHI80"^)"; Z>*T#J6@]*6LOFJLZR)'A
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M[7?_OOOW^_E>U\W[S!L'Q$Z869H!?.OX@(O("^#- YM-+ON[>0 > ++X>"/
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M*2D5MN0!'X[!.ZA;D=" JV%;I-.E?E.#I?S;"&MJ>0B/QF4J#Y RA]1IMWG
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MYYWQQIZ,?PT867/.__OK]P-(-\(&%N_;:[<7D)"4 'Y"OP#D&[!HUPG2<1_
M!T"7!-(+6 &2$C_6CZ?DCR4M]>,I(RTM);U 9L&"OXBLO!PJL@L6R"G*R2O\
M6.AW"Q45%O[XX<<A_W.KI(R4E(R"[ )9A7]Z(6\ 93G@K:2;E(0.(*DL(:4L
M@=0 6%1'F;^H)P'\KR4A*24MLT 654,1?:%H,:J^E!2JM RJ,?II./HY(*TL
MH[)J_:X%2PYYR>J<5MUPZ?I#.=W=^95JAUMX>AN/GXF45U#76*JY3-_ T,AX
M]2:SS>9;MFZSVF.]U\;6;I^3\Q$75S?WH]XG?$[Z^OD'G#T7'!(:=OY"U.7H
M*S&Q<?')-V[>2DF]?2<M(_/1XZPG3[.?O2PH+'I5_+JDM*JZIK:N_FU#8VM;
M>T=G5S>KA\,=^O3YR_#7D5'^U/3,=\$L-#?_ Y<$("7QU_6[N)117)(_?"#[
M Y>$9.B/%Y2E95:M7Z"RZY"LU^DE.ALNR:GNOOXPOU)>=^-AGMKQ,RT*ZGJ;
M./K\']#^@NR/ 8O\/T+VOX']!ZX>8*&4!.H\*64 #XA%&?%&P+^OQ$^=-\GU
M# M*.WFDL>8^H?N@=*$+7J17RA0K:#!G6UL00'XM'0%V1T^*9PHE\JV]$:#*
M_CD"?'QX$0'"3;"\Y%$$F#'R1(!!^YW+5?]5>\EB82@"5+HP?:B0H6]TSG=Z
MCVEMR@5*=G8_J_XQ1! >9P5O?VM8'M]C_W2BO[IP<=PR=[TZR1JV3]XCJ9$T
M7#.\"&[%*B& GV-,)U[=4B:P)S318F/V\^5*H=5IA1HI!4%;?%3VU(;B)'-*
M&J_M A)=/*\+O<@:?-D)S#-*0X]&7!"=HO.5HD7UZ"0;!FY)_E+MF&Q]U>"N
M'T[SY+FJC;*K1WM#\O2D.HQR0,@N&)Q7-04G'],7BC- =C:8CP#CS_F2F,O,
M91;AIP.Y#>,N,V&$W2VF1;D'<"Y;W#\7M?V4[G?<\%'RZNS*2O9'V99SKK?(
M$N)\B@*EG:987P=&:!L7\O%7]DP3^@)2-/9EM(:!G=6_) ==/.^TLO#,L])(
M>4#9\Q!O#%:T0P#I&2B?;^\ [6#CDUYUI3%*GKVZPQ%F;VIJ"C=UKSCL.MYY
M]-Y'DUN?'M^,MC4X4Q\M?7TGUN60IY3P"&KC?0C@X]A-=>;!<<*#$-=1T3,L
M:WG).47W34W/2TQU7ZV+ZS;)V: FYWM9I5LXI#FL##<Q>4Z.+!O!1_Z"; Z)
M1:MSI1@P6WYN'7.Z=&Y[KZ..>GA\[XL'5PDF=1*&/1&6D1DE8D)]T -_UVW?
MRA[:^WC[G)H>\/3HLUEQ<$^\^Z?0XY+/GNKEKP3DS:;-JQ$ 6HL7+?'EQM1X
M;.2 47B_!,WO6F>=X \?34_-C/4ZF+J4]3GO\L]VE'3OMW4+.A+ON\962B\>
MF/\27X\ EU-=$>#A[EEX_BB>H]^! %\/5B  (R5B\Z_\E FK>!#A:,5!X8B?
MU/$_-^(T7* $]@[%^FWFU3M\:SO5&:OX2O<_=\9D.IQY?CI<YLD-P1T=JZ8<
MHE_4>6SH^_W?52?_)NC?)&"7DV7X71/9/*8M D321.%0/J]^B-X-K^H5V?$-
MX^!5H[ FM7K^QL#(T.YPA;-K7!9WR[F$Q.ZZG57GJT+Y%H%_,(_[,AB_S'7B
M"^@S*$->+;X#X_R*&1ONN8T,K(8JN>)E6_LW<?P-:<][NGOS(B\.7_=:7S-N
M,HW;Z./J'>8J6KR^G,"F10T68B/,[I^MM32]44TK:DZ:N=DE<LA.R-T]8O*D
M.-J3ZW1UZMK=VQ&J!2K BH.R7W>H#>.Q#$.R \_\#75Y6"_G236APKXF#7\Y
M&#>)&7EWJ;9CQN6EG33!^7.Q[=/7*^YU?2&-LX1J:-I8PI;HTZ20!!E1ZVDK
MPJ*.0*FY9#QJY<Q:!"B\!$6'+BKBB,,JO_2%I_M]4S.1N?_A)_L]UM19A:O+
M5<Y(S/.M*6N@:ECASA"I)Q.6[Q5JA6T47(6>Y$**!R"6N,RT'JOYU<G.]^GH
M-N(5Q9Y!M][PV^=;'+,]Q2F2>1*ZFCU&[9,L3YI0RX_&.T"/81;'5(NW"^RA
M(_P"@1?_<?]540QG\BK9-'MD&:DV?'U0\^TK)G8#6X>+MY^2RB8\KE9WT322
MF*=;DXV?@Y6&#"VXE;B4H4M&RVYD*A0RQ/T\D,_U1P#.L:^SRSHF7MQ@TY4R
M5KY"5]()V\D-VG8OZM]]LS(^<-85EG/@VW--8YF^8-S1A=JK^*97X65AQ*&8
MV'/X2&V3KN\&%25,7E%!S;6G9==2RJ\8PVT+SR:'ZGGMJI+8B;W0XJDO/-8L
M](/*. (:>[#[R_!N7GKQ\S&[(#I47R-8,%=H8E1MG#+:^'%QJOFE&MRR_57*
M%7=F97H&-Z(.D#S!)T919$3!/ -Z#O2D]F48**#S!VZFS<8%XXL&^_4KVM?C
M^O:=9AQ><G8QL*8F8F,\();)0 OTWV8 ]3^B^8%2/ [[-ZGSJ[0!NO\5.P.M
M',K3Y]L=3WOI%ZCK-MY,%(<]4%0]9 W\(U&;TT< F3N0FO (Y3W# JH6$B!9
M=E8T'_>&IA%,C\X?-;\>V,(*BZER/6H>>ZXVOFY@Z\?'_8_'F^04DO=ZIW,>
MG2[: !("IPM@!51;:;'X-=G^ 33(Q8R["JT' M)(5)$/N]^^ABE']GK8E$,@
M#+H%'B6LS7S<IWC[47Z<2J?Q"Y,\?L,*E?&I[FQ NT"H#"& X(0XUQ)#_IG7
M-=[$&T.3 R@/S0F+%#1S/T2%9J+=/*':4K>T;>AJ,-[PW"LXL/I3LU+-Q<S;
M#\ZF#.!JF">:643VY#A*"V2@=HJR2*/E!;< ['[1=K#3S.,H;-]O?ZP]BW]U
MD/:4Z+%O?ZKKX5N'ITH^J#G+6!_!6L/O:?FI]436V2JB.KP!D[ -4\.D,M6#
MEYH%A=905K9^:MEDO-;$1*7-,2]IH+O//LA7VCAOL\^MIHWY>A$6!AB6*ZQH
M+RM251B#%20W$5EA8QIXV970A0&LY7H^EI728^(29.M!@M_U?]&XG3585BC5
M&8'?\WR*Z"1^@/?'L+"P0K_0)NPN+#\A7-<@=!H9L*3:ET.965_3+K5\*Y>E
M^_=<Z*W/8N2>7>+>'Z=3G;#G9+I*;8CDZ]3QYJN,S>+R-6  AA7UA@%T6>C[
M/AJ[-A:*+UQ ]?$Q:5UJDF/B[ONR)&5Q2Z76>/K.-=XI5N<ENG>_]>98& I7
M@I4[$> X+1X!5,T<N_'.T';NI"39!8I["DTA0#5-[;N6DUW[)@?2P:GW7Z\(
MJGHF3N7>'YI6TXO6WE%KG@=\E'T#JN#][A-JB3Q;9N]%P15:;3)D-613,QFK
MK94'O>=5:2T:VY?*R:V8F3\5;^(3_VG-#8M.R9,7/SY+Q>BJ235Y$3,&>2[-
MK#*. EBI25E'UFD1F?H^]@,QE$6# 13%R!9I8O?L-I,$CY')4TWO'%>DY --
M48E)PQ:3D7AV<EIS'54);K$T1 M2%-16W3.9"/J'2QWX*#KDPQ-4!0;AJM-"
M[I/T7.1/=%EGO7Z=9&?Y\92!U+FXI<K/LI8KUN/S#45JH. FI!@HE$%9E9:E
M,BTZ=5VOO^=6Z Y']QD]H=P]8V<#HX_EL+@P[W59TOH5T[DUHQEV"C;3 +#U
MEB-DC*W'7L6^[)J($FX7:?->/0%S*0UMN[B8I>1=[0-:V.J>5SGS6C.MCD$_
M4SJ"5]G;6$?BUVRT3[FEOID>(+Z/_YG:4U^) *_.$?/P$PC ;I8PC2/;L\?H
MJF1S_G"U3$6475=0D$$2KLDX9_)$2J#]:W+W(ZZ[=]C@JIM7GSP0/V+Z,GMC
MJO%J%L9\&BP_QZ=5I;@<U8C&<Y9WP M%=N;7(>+!(G>IRO,DLV2+3O-\B<\D
MY7U4]8[596>Z:074<5_A(8@FJ''L'1,(^5V1:\D>#Z!M0U4(@+%0Y'W87K*)
MM(C5]WY%5RHI^$)^\_G0K?%&3></Z>R]K5#[\H'VB-")\GX0 P8B &NV%E]@
M4YN0>]14*:S>0;B@\-P.N]RUGGVE!7M?/M4_4C7N%:FI>3-R:5<]ED>PGXQF
M*H,^6T#V-7Q!5T3A?9!+KQ&:X _PL)<VW75>#-GL+RZY_*HB]'.B?Z?+]1IR
MB9S,)\457HP@1L-9-@G"W:4T837*MY+XF1Q9D4D_H<[<EUW'Z GN;BWTD+0S
M25%C["*5VG=G" F2NLD;5\6$S/3AAIN[QP1&:*S44&I[%CPE*[*;68Y$/AA_
M*GJ8:JD'%==9&E=TB0Z%+; 8:\H\+G]D9(61^M+4R]8-;V6_%D<7)C QD.^!
MCZ3O<47RXSFKBM/A(;%/4X;,AF+A_EW>WP+$1SY^*#Q'V,C=4^2QIZ=>\#W_
MY#IYP57NAC?K'5B5*U=XFP5$*!AE_"%9U:[+2*D**RQ[^J#$SXWP?I/!GJ3]
M6CEO->V!7_9=.9:T85O7)],)'-];\)5/FKC$P[/I$X_1>IQ?#.4.A6_D--=X
MZ.!,I-Q;:%4,2T+4PV>CZ^\*(^;)<JNL+$*5YZXOOSQ54S('_K0Z]T-TAF>
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M\K+(7@>Y=+5K5F<U[73[)'H:*6,+V4EU61GQ@-&?\M\J".M_ %!+ P04
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ML!3V)NP6>&3KU9OTW0@;5S[0I*\_$E=B%3,3B<@&HH#$9U$\V'>?F!_Q1'@
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M$Y&=G/&<NE"2;[:S$P16^:J\WOK-V\N3X^.3Y7HU]>K=S(//HHX>D<7R6*W
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MUBQ,I3?.R57*J_/H7:(BXNJ"A:'<O]NE1K5JS6_7]ULVOD]?O7 4<&XM% H
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M%'TNBY^WU#*L5;=P&N ^1A#S%#A(.[A,*F@B(621PGWT";X=N!!RS=+-YL6
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M#>-P-64H(7+,Z?(/5]4'JEF;?RV?U_8)!OSU2Z,6Q6SB5O6H<3U$1;3H[P*
M:MFSZ]1)F"_1R)?M<3TW4$28,3_X"?JLK'LP_GE8JT^"HPG5,FT&9<$AD^_M
MR,_1BMBI.'(#?27GYP_4F<S^%?VZNX:[12NB04%PPE3+M%(93\)N&29P+:%
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ME[I&T9,OR5P0#GNZ250?H _5+!S_(/<%:THZ 2@ZK0K^\X.'J2DB9I8'2\G
M42?-P2S2/5IP1NMI<OZI!_GG9[_W%!H+FXO8MYY;W) I$7YZU1ZB:IB[LLRX
M@ SEC)IZZ$.T* H"_IUC \G*O+3VW+)S[[KG6C0M_#/%;AM^^TO]DIM;3_M(
MNYBJ>NO@5YDQ0PNS*C9 P:\$TZ3(8=54[!QD)4;L:12.J4;MI Z P3U.Z8&0
M)'W'9/&>(!FW3_DNL%[/%IN3FAV=*RS(#&N:*,'2<D-NSQDEUB(26"*C^E.O
M[;B7FEM/#?ZL#C\,-#:UB!_ME+[N+2FY[UG^?!4O@"2N8%^AOR'J9/LP204:
M8 RGO+K/4S.[H9F1"YF)FU#(;[Q/H,LJ+N=R<"3#^H$ >?V&VXWHZ>*!>S+T
MJ-ZVMH76G-P[JM7GXP^EG!.I>G,]%K)'@M"*H'. _1PQYCW*(;._GEZ-E47Y
MT_B3:S$??B0;.7O ;(5-39<?)6H0VH)[\PY-)J,TWR+#!CQ:1TKP[_-FE:[8
M75>K"3]3Z#O S?/Z0,+I?3S[O_&G,<-HVZN:#/B2/XDXI4!7'&F]\NK[KRZ;
M?0$P-^\WG3XG(XS.Y!R2;BX3 BW<%SZG2>2!Q-Y<4\%A-D#*.(5-,(6"/UDL
MC 3J<NP Y69NI)??Z%)D_-=2D=SZX""7],8+ELHS/;KUH1ND*&/2FA0;Z+0S
M%47:3Y,O5E-5NA#25?>^GZM,[+$#G:%3V(!DM///MKH\_L=?I^/4<E;VU<1]
MG4.0^YE2.8%7Z'9@+M6'_I 67\P&4DRUP93M'@^-<?T3<JY+A"=#BH]VGR)$
MAKM5+S?.Q/:(WQ'HX&]GNE#5XF&V5/,>C&B=K=;4/3>B\,S2.B'B^MF<U:#A
M59Y77)%>);P14*9D>*_K=AJ&E$\4OI\I::/RH_^US:WT(R>/3[O;!4,\9J]>
MGIN6&?"?0%"OX)11:EBZYV2[ JAWL04_*I99CO).[.WS?5-[<[VX)=5VW?'&
M/9KDF5P!U9,?%<4>T[,S*;@5!$,6Q'3BJS.RBJ[=+H VC^@K*0_TJ-^4]3N6
M&O#JJ*YL@;6'[D6S 6-%P K8,6RR0HLRM4;:M8CH;ZGDCT4T]]GHO',_&S3'
M'N[&GA0I%W<,S"I#51]]53!/\BK?US$SJ3CYD0TT)'81IW/GL#TOX  ([9#W
MJ*%&*OC.3VP:!RNR 4\/9,I=W6_7OA[,FAB[(W(Y7I?[[JYAM&7A<@ZV?H@I
MK=V)W]<N?HZ>": @[R<"@UK])2E$CW$<R2V\I@[S-UA:P*@V]>D/JWTBQ;5P
MTM,/1DFU^'2BI$$QL<H?KKP%UIV\AEX_L<I\1FI0J_K^[5'1>R_WT@YM2?0$
M82_N-<J0!EEQ)^%YP,-?]S;X9T*89VRR2L]45Z=[UMF<Z.8F.W$E&.U=E(.-
M#W5!"#[TRR!Q#I$,_;#=[:[0/RL.9KT3]7&C!FXGRUHUC]S/CE%KCO5302ZD
MW'GW-3U!A&^63X!/*[/PNS.F\WIK.$G8[<P]C#)Z:*(9F[(_UN*TP=BIF.KT
M9Z_W&$U-/1$/OSXOX=$PAX&BOR*H=HBIG]UV2*ES'-8(O*?B$X^Y++:.J:D^
M6]7,>O8I1*\E7'4AU9@KIPI!@G1@,DQE:&H]=H1^RD)&8BC-IB_2T\UW5F%T
M+7]S=^_G"4/#O#N-WHZ/6M_ 1N*%G)FON(:2F4?!<YRV)T9E [TOL 3H7.E*
M.1F:5&#JDZ4?A;@,%N9,H*%U7KWM^;>.S;O=R) _,Z2Q;L/\(L!?Q>I U(B5
MD^VFPAV_87S7$O/<9IAG:!E%E$&?SKRG;\(=FWT("]8':WQGSDO)]RM(9#[]
MI.1DT(/I/&NJS9H,9>ZG#74;[F:_&6V'WA:_MD18['D!%9^^O3'UZXN0;62S
M?83]XX6] 1'8EGU>^77+'NK4[=4(&H,>-J[?LJ1I*H8RBW.R9L)-DRG057\_
M>ZC665FQ VE_[1N>*_1)/WIE-)B?F$1;2X&32C'2+.7?"-Y)^@TJ)&%+U,<V
M]R*>ML$T-W)%"1Z5FR]0.!"@IEGWK-!87&QF.N$<\"!S91+:78Z96NR8@ J@
MK.YG"KLB;>SJJ?2R+S;N+KU!63VKCP0\WQEQ<XD^,E.1F2<V(%)J,T7 Q"X\
MM0X>8(Q+,.4MT(AO&VG54,WR9^UO^RQ0%&OEE7T_GNL0\^D/FS*UIRH<Y'<+
M%[,#7YFBRG;AN6LU[=V6,2)+$E.[S3<)D[HBM=FKGZ:;IIYI7?QF]JG/GU-
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M1,B?$C!JSL3B(]&/4%(V4?.V[L3#RORQNP$Z?[P:E3I>$Q0&\*27D79=36S
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M/'NGTV?VF9ELD%+],ZE>7:*4NXOVIK*C7U]Y?YV#3Q5MZ!4P:A FK$'<(3;
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M S?78:_W?44]-_+Y0N\S_MFJPH(:L %'(AO(360#(9-Q&114IE;/ "2I?,#
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MXK[PC'!1O*G6I%#? YZ&HN3:-,+8)5/Q,@*.Z]NMBGU[)+V?<L@>N'8V55O
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M6*#]AK& GM;&487Z 4C+:1)$__VU/E0]3Q:J\]L*DZT,=,?J*D!20^;!:VL
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M<;!U8P--%QI8\)J@RK5$%ZDHI8^-0GON"SR[B6JLY3';TL65Z)@S31$\C"
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MQS1W@F9!UG] %[%<D.G0^NT^H&/Q.VWL9>S_EU;QZG^)7$A 3M2U8U85$!+
M %^4L4 92XNK3W'YU2> 8%'D7H0P3DEN"3=!ME3\7!)8H/4?.]%?"S'X[5Z+
M)!;H*1"8[1=J@7@<,MYD@2P&;1A[[-;6?BV(9ED@$<ATYEL@ Y*9R>K;7G6P
M+1G 0H-S@&E/ UVG1S-^NVOA;R,3 UJ<0K5?H'OL9($DT.# QJK!(S\6B*UY
MISUJ+V!3$V9JX>)T$/,K7G5+F@396, PX] $'S5@E-BC@*1ZCYK_V\Z2/7._
MS>G>":H6EFD\$86C'.Q&K;O-(+&#,^QT,8"#2/HV3=#8;^.V3Z[B[!;_BO(
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M%[.UWHWFC(MZ>7O/^HU*U0/4S1;1P28</Y7K*M4B..=VD'+9ZQ1(E$QMS.2
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MG0J/1.4@6RVJF^8NUR5NNWR.BONA[[+'H@6)O!L._IB.5Q'RK6%(W_/K= 3
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M:QKHWOXE1:^)W?%9^[Y0)::"&,^YDS\J?YHV+K0^5KPL4#([/-1&.]-[>6+
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M=1RJ7&+M\JOGLXP,-3LA6C=?GCQQ_84^]?A"CB/"-C]9^/\??/^_'O #TK\
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M_%J*71_#AZ9/IMCG6JF*.0ATR$JP;?Q&D^PP"1E4)40\I7L2J5-U*8 8D-A
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M57HV5O"*B/A^H_N_C7*[ZE+.ATLERI0ATB:^:5R4/O:Z5,DJ4&=^EO*4M)[
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MH5?7P<2[C:#8]1/OH:?.SEUV"3AQ/OR@8D>+8"KP&S)? TNZP00:)F*K3$7
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M+!L;1:%Y#RX8[>6XM7.CS%SNH[IOUOK4TU\QY!&K*P[I6!]LHM+)IC8P@7A
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MB_EC'O*6%;A2T=X@_X?IR<04>_'3L@<]"9[/'8[^3^R]=U@3[;HO/%94FHB
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MJ6!B&'(JJPD[L(#;-E>'<>?Y'?I51I8Z"UT/E"?3&JIX>U8A7KHNY4X%N7E
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MSPNXOW5.!5%U[@_-A! ZQ8;%U$_ZBHZ[\YS.M=<#9UCPX")T8)+B00I(WUM
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MO\ =S7$F_2F6HK!_M-$=@R [HNGA!#[LDM ')C#7VL) XZ<1W(2IHOKM*TQ
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M_Z\;8U&A+^=5\L;KGD)VX?[&D;-W]B27U3]-R;!_>M[DTS^W85H12B0L6V>
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M3/A:2W2DB<XLSL0;NRWB\/7]A1?!2I3U3"!UC2!6J_?1[/5UK&JD\$+?\\@
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M?A'\3<*1HN=#@P9.#7@\$C_D;N!^C=-N$F7U$JE-M3VHP'@'I[@?DFE*)2]
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MPAF1UJY$@LG[7@41 W2IB<9BG9\LH16WFVR_G3W.I:AWE[5ZM++2&$+>(C&
M7GE)NC N:8%CK/U,!0]_?._YB<,-"9%K<X?MKS\5#,$WJ16D&IN5(<_W-M,U
M*/(_FR9^MQT+VOKE+'W_RD#B//G9PT2[.RS&=U196KD2:;HD([\JFB9I3L!
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MCV;-R?L'\:?XWP@Y!.94HNK4GI5\)WJ^D>Z:GY&;^<  FI-["',%2]B^(A@
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M/[='_^ORM33V! ,@'6&6[I]7F%NM,S\;M K'_!73QFR55Z?]3^J9TPY_75J
MX5X .*VTVM&-]>Z1^\XT74K% &*V:!#!BY9?]Z]8+U$D]\]G/0G;?F2KD?-
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MD+J7T%_(W*MI,,Z-(R6!?)8%O?B_?ND5"T[7#Y*F_C?VWCNJJ6YK%]^H"!9
M.D@)2E,1>"V 2(F*B( 8 0&E106D"1&0)B%14.D@(*(@1 5$I42Z% F]*DB7
M&A*:](02-J3=[;GCCG&^MYQ[SN]WR_?=<?[8@^R]R5QSS37G,Y^YUMXKV6;S
ML*WS-M'O;Z$^W^6P>\TK6 <O3@NK13Q*N1!&$46POE$?CS:L!A0UBE8X"G0
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M!X0(]Y-9H1[(75:C!,IUQ"9'P'96];HJ<^=0M0"^]O,PR\B:2%MFQ0NNQLI
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M7_E*N:\.L_8KC1.9O/!-Q&<V,.&[OLR0_, &#F;7J=*YYY%;*AV$0TK+*W
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M[1?B<@>WW>626]N>:+\VL_NN=VJA35FA[OU]:8;OS]I]$; N=>BRKZ=?PS3
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M+6__9*U?A=VK;8&+;Y[Y"'XKM[J_ L@^O?B:[UU.O>Y15C^!_QYBB(=PF_@
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M/V0S$=>@*CS*0%#[G@U]P46?7!:V'RH+2S?P\1".YC<JT)<\(CAYQ%]J< (
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MH$K(1MWR !FVH4M9)E8,EN"6!^#\[><C*7I,H ]GTYB?=FM"XW>Z/%GCD<N
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MC'508SML)W94C8\+8(]2+Z#@NQ&Q)6*UFB&09"QONS;)*%4X]=CO#:XERL9
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M<ER.U+[>VC2-LG5_X52>*W!W+3@<FBOZ+OO"@1,+[SD>&1Y;/2NG1H;&2/3
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M0%@640HNOY]VVO/>IT@U]A4F -[H/$1/P"(@<<7L]"=>;1/&NI2+<OZ3_9U
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M=R-T#LT$J W@L8H F)"Q9KG;'_U!TXD?"22U"3/'']LUUPRDCMHOS5[?CK$
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MOH1R:U3BY._2B@3Y]$\A_I X_%1+-O-C+I/NGO$*76ZK[1%[P"[7LT?2'S$
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MOS]V6*L. QR*BBJ3*WQ>/)6Y=.;A_C#UK6]?7P-X@74DG+[@.GK#[#Z6%&:
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MA!.7WBK7[H#C_';DUSZV4-Y>528QVX#NR>SYBJ59731E"VA3[7AI$UQ@#56
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MMI?A-G>]9MX6<?N4EVN(1^@]S!8*N?\2&LM2!+N('Y,;'K*]*<Q9%9U+E.D
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MLQBG.6.8("YM=L0N]#<WAN_%!;V\H!7XBGODEQ WVQSSB./(;'X=A-9;9X;
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M(4DCB(,LA"@4 N8Q93 .HR2-4YP%U&I/]$P_<YN0AU5BM9R. 5?G<#7;*O6
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M4&?QQD&NF"?/68Y(;EB.Y4HYYD8_O1JMR?'0:E!TE7UU*D/+#%&NPV-&4A.
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MYHP01K/HL.+RR(2T)RC8E]3;D<VYX;CZ&.<:B.=QM&.-O<_SG@OPC7\&=$Z
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MDC URI/A4ZBY+4"-K& G;'/\;6BV>QTL@^.S%QB"::XCG#?G]>60FX/5X.2
M;:O$#]6"'V_L+ [87F ,)SIKFW0L[<[=/(,^> 3GJZ_I3N,\HW-P,.>[;<<S
MNDVMUN6ZOMVEZ[W]4=0+EH0L#7 "61Y(Y;4Q"2D-8D@B@D2$DT!OA5MX;6?Z
MF=N:UXL)]N0$OVE)+5VE<[@:'KQ=C];8)VT.0-F?J@W#X.L8[4POTYZ;#:MZ
M=%!VX7$'T_K+YN&!5$_-U0"^8>O/XIM8;<1G48M*F>_*HE]NN.#O5J_+55TN
M"ZZ9Z159ZHL"7^Z%.(I%"C.2QBD1D,9Z?YQ)96/'&8*<9@)%6/),(F,;V[=T
M<R.>MG1BU:D#BDX??=67[6D$:*L2J!N=+ PZ[\-K8)6_Y*"-S'^=:N!C<U=*
M*P<Z[4"O'NCU4S^ ?0U!IR)H=;0)6IM@7"TL]I<<WXE,]WZ<2PF:"JK@L1OM
MJAMMVRG[DR?#?2SL!RUX[YU.9\J/A=>!33]:)ZY)UP@7^O!55T=M?M%Y,?H,
MICE!,FLNVLD$ZWC& -(09S B3*8)$H@(:9>W:Z"WV:VW6V&;>G[-KTU>%\MS
MZ6&(S:Q];\"-O.:=QVR$9+%&H'A+P#74U\29MPS4/DZY9?*2@T^@PV-6:IR>
M/HAU6T1]K7K0=V_:7Q8RQH2C3-GXN5 V?A@@F!.,84B"*$])G&;8J,*Y46]6
M'#)!N?.MO!;FVD5$<X1(PIMK1))!1$6B_"<<0ISD3!>\90G"QEZ35T0G8.51
M$#5P5'SB-#();T6] 4I8T$G;$/).7I_P6?@#/F&<R+Z_#DX[D]T4GD$3_&(C
MTYG4IOH<F,C&+[GD.3_>%?NPT6M@$Q/_4*Z:G)1-&'S=)Z5<9#3D:92&D+!
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MHB<.Z90!51>HOB[!^EX I1!@^QI9;&!<,V0&>T$3#<386[R[,>CU )^/Q^!
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MIH$/YWL<WSZ5RU7QGUJ!]S]UF63Q64T^]S_$_+OX5"Y6C]4LC<*8(!9!3*-
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M"RGM%-WN;&[#;ER*[@WX6EB>F;SJ8 \\ZXPZSNX'-(,-@>]S'?^*OLYQT&"
MGSU%&DZB:Z8S6PI2B8\+W5V'E0\+W5_GGOQ\(Q9"%JOJ8_5-_;Y<*%DO7?'G
M64R)Q)P*&,=8>?F9^HD@FL"4Q&E.48;3#-DE0SMH,;7)I#-"I_&O=\S038<
M;0T!1066&U/ <VN+;5:URZ"9S0>##\7 5+\["KL6Z)(ZX,W.*&RMV!2B]YG!
M?06*WI*\7708.0_\"IB.4\6O>9C_.FH?RJ505-W4QV,O]TNRJ'1ATW)QN^#U
MG^8UC6^;%&V+:B&*PBA# <0)BI5+GV00<RX5RV*$,,VRG(8.-? '4M?H\Q^_
MAO[;]=-ZWGAPJZW^8&[=PF.H439CY-<<M,G446L-!9VE8,?4IC7<S@AOK1V_
MH)J'$1FANMHU6DZFU)H'J&WJKOD0Y[#=7JNT%-_%8MW6+]]&(C',@A1GNE4*
MPA!%/(=Y+B6,0AS1/$$D%T:)()<$3<W5;@BCT]5BU[@/3(--=D\0C4*GG9KM
M?@4P"=>R \QBE]T3<"-MLKL#:+?/;H!*[S9[W_WC[;(;6+&WR6YRO4LEE:?G
M>?DB1-VGYJMZ%1[56D ?@;8Q/0D.1<1%"".1AQ!11F >(UVV.&29C&F<2,-.
MRR;B;-[J<4I8=@J#2FL,GEN5P;.ZRJ:<R 68#5C4(W0#,^D&LUI5T.E:A\8Z
MU6*Y )Y-519_((Y5GZ7G!?15;\H0E?YB+1>>,6+9%C-K]@NX&-[CMM]1!_Q4
M;<G_69 )Y6<&"(J$"$6I4D""DQ0R1D,:!U2&,K')6=Q[NI7/.5K6(FN4 Z16
MU6X;81\\L\6_,R0#,V.CUP#='TX:[&E%O/_L4=>Q)\TZ7'V>OL@U.E1([6;Q
MF@C:^44PRG N.8PQSR#"801QH%:. 0M3&HDLI6:Q]WU"IK96W.C8S#NVP9XG
M4#3[<J_%9N /> M+X]OXJY5F H"WJ,T3(D8.TSQOY'%<9L^U#BN>VP69OU1%
M]47>/I7KQ4K]=\'?/JI1%A]UO#E?L]6W9IWU351B^?UH!9]*D2><4QBGL80H
MRBC$)*'J)\I2F2:A"(RZ:OI19VK,T1FD&T*RV@Y=R7[9ZF[A]E\_4 :KJE'A
M']J[Z)#_(D%C3?W3@H.WFW%H30*M3: SZKK]KNN'RF(--^J0C;3*V_UH2#-T
M^B<U=.TG5-1Y;_70M9M FT_*URK0&ZZ]Z\3KI8RWDO2&R-Y:T]]3'6:_;^4+
MF:]>=*H#T5T0FV3*E1JR2G>IEN7RL7AX%-5JV5RHKA+;]BRS/,WB"&$):9(A
MB$B>01PA KD:9DSC*&*14=LR#[I,;=YKK0$;<[I$U8U!0%D$6I- :Q/01NTT
MP+$@W2N'TF!R'&^ !IX9_VQC8S$;CC=&(TV% X^5W9SH!]W>"?%*$>/-AGZP
MV)L*/3WRBEW9CT_/I%CJUUK-P,L'4<TD%Y*@,(%!2JEN621A'JO5':4BYCF1
M @789K?GM)BIS5Y-3FJQ45/[G5I/A[W:8T@M-FVO FJ,W5NPU1"\O8"1VS;N
M60A\[N<>"QE_8_>LH2=W>,]?[?;YOUE7Q4)4U=ORB19-:H!.'5 LI$64BZK@
MHDEIZ^KDO<Q$&B<)8PG,6"0A"JG4=:0HE(D,B<SK7]IP@X,.4R..K;Z [2H,
M2CHO'NH?+4G$96!2FLL@3',889JK@<$,YB'3&7UAG 9YFI,LF*F9HRCYW8HL
M5Y,8GD-]AAND.I/KN\ZDT:&=#\5BH?VJ4H)&A>'')PL(RJD,8,(B-3Y2K2#S
MC# 8BU3*)$V99&$[/N\7?$*CTVDSSMB(!1]S5,SFY8%Q'GC2[K0'.^K?@!W6
MVK/@!FQL\#>K7P&@IRG?18-1_8$K(#IT%JYYE$L G92"Z6R)>_+SFUJ>?!/:
M9/785L2JG01O'Y:B+H,YXU$:H"C#BOS"%*)8,DB2'$$2AT&$8Y2BR*)-F:WX
MJ?D/6Q6!<O)6\Z:R*^G4M0D3LQX)@RVP0?$=F/HVNM=9?%I[L*^^9KL-^K>C
M0&X3JS<D]&-%[WD> LNX/E<$^R/]K)\Z8NR?J\7[T8#.3W&80'92990M34NE
M3V+U6/*/B^^B28FI/HO5%ZF3WUBH9@<I(HA%DD"$$54_Z506AK*8!G$@:6"1
MXFBO@=%'-G[68MMS3+<7*VIS?JTS%K4W7=1&".5>+T1]K+KJR6J[=GP,IA3_
M<(\SG>SE%@+]X8$6]49[L*/^#?C<8-V707@MUA9SR6"8CS2/>,?>;B)Q@J]W
M$K%[XG@3B).E>Y.'VQ-< MD8T^$#U5?R4H<'E-LZ7.5R%D<DBCC*81Z&!**<
M<4AR-5$0(H,@I"G-B7F/]EY14UM1-%$5%7ANE+4)8^I%U(#:O>$T]$E&JR=H
M%;T!]R78U=4;:#9Q7;[ &RMFRQE$R[@L$USZ8ZYZGS!B/)6))?NQ4D9WN!T
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M;"T%K:E VPIJ8T%M+6C-!8V-0!D,E,6;/VJ;IS'L%E4\IS'\(Y7^W'D-E#/
M2IV_W;X&VYSMY_8U>&A?@Y5^#63]&LCZ-7AJ7X.R&?>5>@TJ]1IT?]2VG^]'
M8U<W=/C1Z2TV.J#X\2J4#H_A7EG3$<0YUHS95LW6H3G:G6D3LC_,RQ]_%?Q!
M?"7+;7FY3,@P(C2&/"4((HH"F&-$8)*2% <HRV60VYPF6,J?VI2O=:[ +W.E
MMJA^!>I+WY:!>-3*V]:3L1P.LT7B@" //$7OEO[7JF_6?)]U&:VZ#(0V =0V
MW(#&BB&JTK@AZ*M2C:7T<:O7N$%S5-'&\3%NM/<WLBQT=&)W4/M^L2I6+Z?:
M3^9IQ'*:1S!E>0I1F <09YF$4O)$AD$0$!+9;;(9RY[>OMG'Q7?1K& K'8K1
M6;*-SZAML2YL8SX:9GPW",(#,]T9+%^&[P!JC98G5C.7.RJ?6<-QR&3V#_ 6
M$_EM$]'PD:N/M)"U(FW=P;;&BB[YK/ZZF#=QVE6EUEA\YWAXYY>S.,^5NZ=X
MCV)=KCF.,20AP3!.L@BE"199P!UR-8?7W.C#'C_?<R\09=ZJ^W)U%*/O83=C
MV8F,XFO&,&[M!;L&=\V;.Y.;"OQ;NT!KM2[_L!-&LW/%H"&, XW2<!&,OA5^
M[0#&@0; ('YQ*,D.YQ>W>N25+/6?Z&U9K>[(]SIG6#V8Z-8%71G5/%#^-N4!
M#'&20)0'$22)3CG$.!%)D/#8XC#"4.C4MAFTUC6):+V!5APTFH,=U2UVF4VQ
M-S@I& #1@:G<"$R77MFFJ%ILQ ^ [DB[ZM>]LG8;XI8H]>YNFSYKO*UJ2^OV
M]IUM[W7@\;OUTQ-9OI2R+=3Y\DW4NSBK\I:O&5FLGPA]6\[5]64;-K]?9A&1
M#/,@03!A00X133.8\SB$A$6,TEBB)(R-^?U*9:;&^ZTY^ERJ+1K\ I:-13KG
M96L38+M&67#6M:-G,$.,."8#SQP[P]'9 KZ='(X]>VR*8/H?(8O99L21&FD6
M.D:^KC=[W4!ZV'OS"7?O=':MC/&F.4]H[$U_OI[IMD'W=:GC!U8O7]4KN5*3
ML,X->]8O_9N7>_7$VY]%-9,1Y3)1JQNUC@D@0A)#&B4,2I)G,4J2(&96W=D-
M9$YMDON]7#RTQ87O]TH+@W]J=0VYT@9TL_TMSU ./#<YHVB]HV2!BZ<M(1.)
MH^[I6$!PN"EC<ZL=[7!1S)JSAO=/8OF@_/S?EN6/U:..6B6+EUG*!1)1G, L
MR#!$F:YBG.EV:3E+DX!)3*11(N@%.5.CE_88K=,5-,J"5ELS<KD$;3^A> 1L
M8!)QQ,J80@R1.$$;E6!_>2B__Y=Z0L,8ZH<M45QZ[BCD8&A<1PBFE[OY'H?5
MU#^+U?N?;8[Z;V7)?Q3S^0Q%-*8XS=726T00)9)#@F*BUM\!#5D:22J%76R#
MB=@IAC4<=)UP*"ML!'A">!K$F$#..='%A1$D6&K <1!$42 P"VPZ)OF&>XQ>
M2:.!;>;E^89P8(8^T7Y#9S']LM$9=$K_ZL_CL\'(D\MG)')4G\\&A$.GS^K>
M*W),/RM3ZBRD52.G/7"@41Q$6/E[(6,A1$2$$%/.(<VS*$D2ED2A4;*]@:RI
M>7]-^N!BHZM36Z$^;,U8QA-B Y-+ ]96S2Z.P7\\K0$>/E,=ST@:/U^QW^23
M28<7;G$YL2GGY>IQO5S<_2A6_Q%+]0[P]FTF(HYT!P2(PXQ#%(0QQ%F,8<8#
M) A)&$9&-? NR)D:2VPTO0$[NMILTI^'U.2$Q M00Q]^G,3(Y9R\!RR;PPHO
MH(UT#N$*GN6!PD5(^L\*SM\^XC' 11OV=_@O7_[ZT;5ORX5.\E+W=+][F64\
MUPMN"<-0\2LB+(>4!1@&-$$*,Y2Q\+5#:T^H;?1IC1]7N]44/).7^LAO58(W
M<\+^5:W*A?@E/+\:>I71-_,:IS"8?^KPVIWW8F/U-$-K>X9G@G&UI[3]TP;5
M]D _9$1MGUBW*4OGS&V>REX^+F2Y?&HJC]!RK<2LBH?ZCY_(2GO5FU8Y@4 8
M11&!&56N/T)Q!O. (LA9HN8D20.&K0ZA7169VK) VP%V#-&5B3>F *)M 5MC
M0&N-2;\=O^-G-IN,,2J#'W(/-2#6Y'\MFIY8W5F-4>GZ6K .>?CJYSGLFGP@
MK";I;>A.GF0R#@,8L%BQ9H1RB"/.("8B$'F>!WG$C/=*#I\^-2KL] -:0:O
MG-/@&>R*7 /)P#SD&PV+;8]K4!EILV,/'4];&^?,[MW0.+IIO&V,<_KN;5Z<
MO<@EG8HQ,=?59'2NUK9=L7(]V])UU>;(@F$4QED<0()(KH@K8C#/L@QB+(3
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M>N<,!HR1/(A9FB;4KN+@*3%3HZRVB%ZKZ@UHE 5*6Z#5M:TX>!+9?O[QA]?
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MPY3%]%CC\D]2L++-$?[E]P;4SPVHHQ6>?(4JDM,K"7E-?4=/Q1HWR<A?I'9
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M]:4P5E,"R3C+96S4--*;1E.;& YMTL7P]+>TFRQU,=_=.HO7WP ;S"MC#]O
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M+%;"'B$<:2EL\!;Z2J@W!*=W.7SI&>.MAPVMV5L0F]YS;>O8$W&<VP#E5*"
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M*/93(*WWP$Z:#8'LP-+L.E#=4R(<$0J5'F&[[+BI$HY@'*5-N-Y_K<;UN2H
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MU'32/?%&6NB-_@]IZH?,:-S-BT.(+^CN6011WVI/!A;G-5N@Y@OL&;L!.]9
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M(M[3OV8288XYS6$:2PX15QQBIF*8R"+%*2,TS^AL(1_,@_S<<UYT61U 4A_
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M)']<+.?+AZKB#.SH!K_\\=O=;Y8MQT_B::%+7H'2T ;V#@</_>_HS;)7[JY
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M[N^KY<.*/MT 6I=X.DXFMMDU.TTHV":,U,^NU1X;R=10?%/WR*R)UI9@17;
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M35*3S0<:9HHSPC!4 0H@TDL_)$+/>!P+ED92_QC%3B6!]IJ?VBI?2]<[]ND
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M\Z\FX7:QV/T&'XK/&D!MLFLPM52/]PM-,;)<;;)HF]1,E,!$20%1$A!(5!S
M2,8D8@FGC#O5A9J4=E,C7KOB4H-DTQSI<_)&[M/\2(9>0%SR@-[LU%P&6X
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M%B0D0,RQXLJ9KEP^^'%2U'ZNG+LJ2^M%?_]5?H1_<[2TSN%*(T:"-)$PY)&
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MJ$65%"IO!.\1:>0 OITM. RD8]R&;J6^ :W<5?C035W$3X"M[/ZL0'>\/)F
M#AV/:O^Y W)H_/5HP8VY>'4%PE]G'_[\IO>OB<H$IC C2IKH'@E)A#.(.$I8
M3),LRI3=)>=NL].[RORP7A9VW+('3S=K]%5Y8#XPNH+:\P?<F5W#LCKAZH3
M>N:?TKDC9T/[>#VGV]^V\WFON5%FZBD%VCEX\M^NS).T4Q?S:U'FU8%]6[DC
M)@G),%7FK#R!*.88,DXBJ+BII2)1(I13$16;3B=G"VS2".U5GFW%[ET]Q6H
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MM\]W-*X/]T6%CURY+[_1CR-:SV-MA["\OH/Z)GGQN##5H^^%L5U43C>1=DT
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MGLLOZL/SR[QXE;+9,IRN '<[KX9#__1%;4.=OLIE7E3I5,MMJ0/$E20DU%N
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M,S[[50-\-]YO.W"_T'UQ69:F$_WVDU[@W^MNY\6+$:_-(Z<4C4*,H,AB4V?
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M&(8,*1%0DBD2N!T GNAE:O;Y1LB;S5U*K\#$TY#:GNM="=3@YWC.&/4XM>O
MP-LIW:D^1CZ5ZU#S^!2NZ^&>WMHF(==]6:ZE>%]=]M=)_RJ?P?)!,U*Y7KY6
M#WV3>?783-OG0FAR@%@(!%%L\I\HPHP!SU'(,B[=ZDJYBS YTM!243W>QFS0
M"_:S-@S;A/MZ))J?BY?*"=L<>-=_>-'=/YGD"2^Z,6TMEI7"CO[6[L-GQT'#
M#LK !%67DJBE![7XH);_!M0:W(!6AZ;N1*N%1Z_IW@CZ\HQV%V!<[^?> !UY
M./=OJ1]KOEN7VL8NR[OBF>6+:E/S?25?;OE_K?,R-[_6R0W;G.CWB^J?EE)N
M"J.&LT!Q%84QAI1G#*),,LCB*(4XP#Q+1<*8<K*O? @U-68U"NA=TD:#FR85
MJMX9U4K4NZA:C9N='9P;C7H93SMB'7N4!J;:5AVPHX\F63-LM[O#5BNU*1)@
MANUV,VS;,L[^Z-<GSIX(V8M(HU*T3Q /2=MKV]<62;BCI;G3-O\QO6H*,8<U
M]::-X"0B,5>0()E )!B!F,<9%*$*8J802IE5L+A3KY,CXIV$-$;>)FN]_F%'
M\GY;9;M1L#1;?6,[M*7J!=8KTO];P.0]E7]7GV^4EM\"AO,I]FU>]A"X<Z?-
MV4=9SA(1,I6@$')BSN42H2#-(@8C'I.4L$00%O8.TFDZF1K][,>4\%K(*P)S
M-E@&*1<R1!!C;7DC(2.(42(AP9KLXY#&H>)NT>77HCG.%6,3"NX!05L7A.M0
M&=P)8??SNKOP>5T7FG2@_1!A2&T7;Q=R=*!D9WC1X;/>MN3;/ (HB(5""84\
MPJDI7)5!QA,$LYB0@*0RQK$3979U-C7J/+5#*VWR!+C#W'L'/,7D"[UQ\[%5
M'2I;0F=7;[VUO)C)P.J=*^Y!OLGV3/[KLGA<TN=O\IGF"Q,"N5X]%4MS.;M]
MIG8V"&>"IHR'80A#GIA$T%CO#T5,H%0)3XDBJ2#N]R&]1)D:]33N&,M6].8^
M) I"4I_#@ZT*H-&SQ_U'OV%SN <9?#!&N0\YQMHDD&F'9JO)[H.U+IXO1:Z"
MT^?E2#]!QK\DN0JPDY<EU[78NW@UEU*4)M^8"3;66^8_J#$!5Z]?U!]T^2]9
ME9;=UO.8B021+)8,\E 0B*)00:)P#$/!>:""D,6(.M=K=I-A>ENW5@5@/A90
M5E';YM3HN=;#%#\KE/ZMU064&V6<2QL[CI<=I0XZ!@,SZ3[X1OH*^U9^@_Q6
M@YU:1%Z+(O=#SU_M9,?^QRZQW ^>$Y68>S;4PY?>'!T:1\ZR:,L1-/6 VZS+
MD609SKC>P&8I@X@B"7&293 .4L0)3T,IK +AK'J;FAEYU_JYEC=@(W);,=G%
MX?TBS-T$YAV\@<FJ&[<^V<$O NC@>NX3R)'<RZ\%U,W3VA:@3F_JBXV,YS%M
MJ\^>5[3U2W[*AV[I?+^TW"P)8QK@+(0R"!1$@=[I$QPB* 0)@@PASKA5:0;7
MCJ?&Q3O6C3#52/H:E]; *YZ1@"8*!IC%$.$TA%0Q"F4LL$SB* Y1[+8'& +Z
M<4S_CSW=FZS!MC/@AP!PX*70HC3H<*5 +^$S4 G0L]V^:>G/2V!<*OEY\?U!
MZDAOX[1^7Q9EN1^KLXV\HTS0**#4E.W1JX0,$&11DD+$XTC3E\HBNZ2V7J6:
MVA)2R7H8G'?E\M%ON/K1W>"#\/9<J/^V$YE8#]A!&*Q58*OO*LIN6(]36ME2
MIBG56W:#T;$(LV/CUWIN?I:K;5WB?S=QL*7Q%-T(416&O=N-JKVO@FI-@&7E
MHO4@_UJ]T^#]:Y8F$2,4<<BS3$*DT@2R%"$8QH3R-$UDG#G9^$,(.34R_[Y^
M?J;+ZN"S"E&NPHW-;^?CHTUH=KY!XU20M(FLUQ*>*4[1NS;%$-^,Y2WB&W\)
M0]\O[GBQ:@7!5D-0JUB[^V]7E+I&]IZ:H-:SSJ[P:^/R"HRVH%)W$.]7_Z/A
MW5G6HXAOY%OK'^3SKK@#]-5O@:IC%[;+XL<?G_,VKG\69SR-"(\A23&"*)$4
M,AEBB!BF 8E(% 5BMBI6=&ZWT'1UYK1@;+H<CBL,/_Q26?R_@GF5Y,"4H6NK
MV&CB;P*\^AXL=0)OQ]:^X!R8=9N0JEU+_N/?X>?[FYTT-;_Z8TT;5#RQ7V=7
MH[*8C=*';&3U3H]+PLY2Y>_E=A;-!":<)T$&<1HPS2\TA2PB,<QH&&2(XBP,
ME/5MH76W4S--*U%AH>"ZE-KNU-(:2W0KK\.]ESWT%C>(@P Z,-=L9 :5T#>@
M!O>+@G\:+S$C^0UX/S2X#K>+@X \TC6C/[#=+AR=,>N\>;1O;;PK2&<-]^XB
MW=_NFXY)2)4O\I7\I U4<:\_N,5CKHW3JJ/RW>L?])_%LJK95A4'BS.:X) A
M2%F<:B/2)&1)PA@&##&::NL29=@M49-3_U/C_:WX<&[D!UL%ZLE3.M5BZSLJ
M=K;F@%@/O"3LP/RI'\P]DD+U LM;NBBWWD=.)-4+FN,44_V:Z4=TU6Z\;GD3
MT_\^+[G>%ZZ7T@1GBBBFD6$S#I'D 60T"*&42"0!"3%+G"I0='<W-1JKS\AJ
MN_7&N52[)<1V).4/N*'-U JSVP:S;5H1L)76'QO9H>*)?"YT-BK7V"E^2"V6
M;_6\OA?_7->'?N5#83*L+G@^E]5IX.9XKS"^9%^7Q8]<2/'N51MNFM\V-MVM
MR9):WV"UX8RQ2#3#L!"&,DWT-CH)(<W2&!**6$0%XC1U# X?0LSIN2GM:&FR
MT"Y;/9N;GS:EK?EMF\*V<JC?.E72C9[_YN@9,,278.DH\,:C.S"Y'@SK1L'F
MRF?W]D;_<^4KVRH*V"OXQ>BJA_]7L-W?;O4=)+!VR 'QY5PPA(CC^AH,"/*1
MZ\&0??5;>?ZHL@M6%]/WBY?UZD$W4^W_F)(R)3R!,I#:>DVC#&+%8TA%E@29
MX@DBD8OU>JZCJ=FM.W*"2E!@).VUY3Z+K1T?^T!L8$[M!Y8S$5Y"PA.9G>UF
M5$*ZI.PAJ5Q\OA\Q?"Y6LOQ*7\V>K4G8/$-IRG# $D@"S"#B&=4_Q1S*%!.9
MT"P6R.FD[D0?4Z.#-D/X2[&L\A\;1R&Y? ;S@EK6,^L"U(X(KH1I8 ZHI .-
M>)N4ZOXF?X?VGN;]J1Y&G?(=*A[.]JY'>US*WNHM%7V4%P*C,QJB(" (,A%3
MB.)00HJ9@%FD[0*>\(2@T*'<D56G$]P7UF*WD>JO9^/4;\!SL5@]N81VVHV#
MQ>VL=VR'WI4UH&Y"T+^XAJ#W!=/A-M8[J&/5$VK W6:P6>7UX<69;_@@)NX&
MT#W?>I.M8>>??=7D<8*W\]+6KJ7Q+FR=--N[K'5[LP?S'[KY-(M)$PB-!.$A
M2CE4Q#CVD81!2B0QSGY,TB3*@CBV=L'I[&IJ!M\)M[1+)HTKN!8T[@VR@>G[
M/%I]XO.[87,@;&_PC434/3XZ-XJU J236KM;&(]2K339HU*[-WI0Z#NZ%,5?
MQ;Q8['!R\[%F0B4X3BB409I"E&$*68@$%/KW)%1"< <?QHZ.ID:?.Z+V,]ZZ
M0+4@3D]0#4R;IU'J0YE=<#D0IB?81J)+QX_,C2HMH.@DRJ[WQZ-)"RWV2-+F
M^7X'B2?"53[+U1?U0/^Z7:V6.5M75NU#\5FK9<H %W/=VF-;-V-&:) E&$4P
M$DD,D8PB2)A",)(!32.,>>86UGBE/%,CW+M3%5>;4K%T1Y_JRGI/HTT1(FUM
MF,ML<[1I6^77U^#:'8"..&0#$W]'S&!5;]D,@M;J!MP>#-V^9IM"1/Z.63UA
M[.E(]EII1CV^]03=X5&OKV;[NB2)JHH1G7^EN;A?W-&7?$7GLS3-%$NER1%"
M(HB(4)!(E<&(LR1B%+- )*Y>12=[FN !\$90\*(EA?D"\%I65Q^?T]#:D:$'
MN(8^T]WB9$0TT=-W%W#JX1O3B8(W]Y;3O8SLH=*IZK&32??C/3:Z39:$0C7N
M)Z_?ZAKTJ^)#E :$+L2[V\\1"L([34&4%<O*_C](-1!3*1*F*$0TS"#B86B*
M6##(5<+2A(<LEE;U(KU)-#5+;B<71:L5:-0R%D"C4)6P]\-<+ICDTB25 'LJ
M.FP=O8RJQ99\[+$:F-TN#%.E4S5([8#MJ>62&6*@(7,X%AA[Z$8Z/S@> Z"*
M)? RLK[2I_J$OO.\PDM'XQUL^,1E[P3$:\-]%EE34>2+TL;\76W,[]CRW[9!
MQ %5$B,:02+"&"(4"L@"(JJB B$)$Q9E5N5:'/J<W$)9U5[1LW11+"#?"+XM
MJMPKCML2?YL%SSNJ0R]I%:!?E#EE@%N9M^6.OPT(J,MRY!W8D18<'P [+A].
M4'4O$'9-C;@$..FV3_)NK_:L%$-?*Q__C\5RMPS#@US0Q>IV/B]^4JWD#%-,
MN%"F,'.*#)-C2)3,8,HYC7"B-TO<J:J?7;=3(_-6ZLH"^V6O0,FOH)8=;(1W
MK !C-PYVQR[^T1V8U/T ZU[@Q0DG7U5=[#H=MY2+$Q!']5O<WO90G_FK_GJJ
MZ)0D"25+-"71-#5)W4()<:Q_DB+$.))Z><!6K@N=O4R-AO9+Z!HI>X7\G$;4
MCF&NQFE@0G&'Z+I*PX<0#%%J>-/'V]4:/E2SL]CPT<-]?/XW!\1_Y'/=>+&0
M#=O,N,ST!$\#*+@*(4H"#%F"*4Q42(-8Z.]"6J6LN-#/U";_SH7%<RLJ>*EE
M=?$[/P^LQ:[1#USC7>ULI 1??2+EXI;O!;&Q?/$[OC%OCO07 >GVGC__^H@N
M\Q=UV/>3O_SXM2G:/SR_S(M7*;_+Y8^<RVH+^8Z64I@+>KDHJP_'F&2\^NF+
MVFXDO\IE7NCGRE6=GG<F4(I)'*:0<Q9 1 )S>A=F,,Q8EF1$15F(^N5H]RCE
MU.BYT@4RHTS+->!VN=2/5%&O-^!#75-+5(?SS7VG4>RF*0!\\6A^Q"_ SA9\
M\W$=X\01OAMP2*](JSX Y-[SJON4\8T2JP\ \_G,ZD-TUF]A^7@^/YW^M)>K
M_+\K"9H)\)^2+A_TUZ.7#LQ%&&BSG+"80Q2$ 63&+58&QGDBI6'(K2Y^KI1C
M:HN#D8^;&UJUUELD">B.[&UMRQN@9U+JQOY]A\F.WT< ?V &_]B5.[/F[VI8
M=M6Y 4834*GBC[BOQ-(3-?>58E3RO1*J0WJ]MKD^,5?K,E_(LM2TS?)%U?Q=
ML2AS(9O[>&U#E$HNEU+4<5^[_/YU*6^Y_FM9;1F:I:"<:>Y$+*89Y,K$:IE$
M!X1B#$4:89DQEL2I?77J 02<&N6V*H(='6_ GI9@1TU-!G5XXZZF0*L*Z597
MT"KK$OLTP+=@<5#SQB,\,*__KSRX+@%Q;SO(8P72O<E@.\;C#3<2W7%\ _0[
M8OS?<*CMQPT.V$_?2\W*;>\K7:Y>J]Y-+E8MTKO7W7^I[N5PP CA@D"EH@0B
M1!'$*N4P)8(K3 0+L%.&;ONNI[:DMVZNE8 W_5,>.H!O>RDZ!*2#WY0ZH]GC
MJM05&&_WI]8=CWRIZ@K(\4VK<PMN%"5D/ONP6%6^Q8^YR=^Z6'W6W]$,292R
M- DA)@&%2*]#D&8DAH1S&N P4QQG-D1TKH.IT4TM(]@*"8R4=E1S%L1N0O$!
MS<"TX8B*-65<4OT$,922__98_/B;?K7F!/W#E@K.-CC*A+^D3CNM+S[7LS1F
M52-X$Y+[0/_ZIKFAS>:<5X;-QV(I\\?%WA/O<_VB23R3T_D,(85EC%.8T#2"
M2,89)%E*H" "*QR&,8L=HVA]B.4R%\8)N=5"RJJ>LJI%!Y(N32([UZJ:/L;,
MSF 9>QR&YJ16G399@187&'G!ODHWH%'JZ+E=Q6[ 5ZD%\YD>UB?>ONI_^A!I
MW#JA'D$\JB?JL^W1KMQ^%C.6(:62",$H3(VO!B*0T!A#%2<Q%4F,1(#<.+J7
M'-,C9>LKMV3P*S<]3(-=N+E!/^'KMI_%FUZV;7%\NZLV+</4+]JV,'FX9MMI
MK*>5N_&7,(EHM<Y-3CG-B$&<\A@JDNF=:D@PI(AED"?&:@WU_T=661PN]#.U
M#>M&/%#Y@3A:GV>PM#0HKT=H:!NQD1!L4;J8R=#=SNN&P9?I=J:7<:VQ;E6/
M#*P+C_<L#)0O"I-Y>I.J+0BS1-(X@)(28LRA&-(0I3"C..%)&H>"$C=SZ+"+
MZ5DZG\\DS'.L W0(I=W$OP:>H6=\=97S!EGJSF'BJP+08?/C5OXYH]Q1Q9]S
MS_7,],;Y^GE='7"_ER]+R>L]F?YY+BNOR(78-3.^+DV9P]6K"45:Z7\SW\)+
M';JAPD2J%$&9,@01BP3$0H0P"Y.(8,PDHT[7:;X$FYHQL:,7$#N*.6:1\S5L
M=FST%H,Q,(OMCL.N3C=@HU7E?KZ_IVHUNZE"(/7>JTK(U:KG,<.=9\!]I<3S
M)=:X.?0\@WF4=,]W^_VHO#Y ^[[2<IC6WM&YL0>_/TEI>MG&2FT+%Y?O7O4O
M+T5)Y[\OB_5+J9N8KX5>O<TS>BW/%VLIFOJ3Q:(JFS[C2:"80!D,T\"D9$8!
MI%&208P8UU9@C%#H1/3CB#VU9:!5 %0:5'=]O7PN1AITNV5B>D,Y\"+28Q2=
MEX)Q0?6T4(PD]*C+R+@#<;C(C-S[M7&S'VF^_#N=K]NCRH7XE%.6SYO2 E75
M4O%E\<V4&S"Y#=[1,B\/<E5&L3E9B!AD<:*W%#RM$A)$4,01#BE"'*G([=#!
MJWS3.['8R6%)*[4J\W2^5:Q*CK<T1<WI"B@- ?AA,.@;&NMCD.U6EC<;N($7
MD%8O,V1&,U"I=E/?[-3#MZ,>:/4S3A$;#4&EHDMNV2O"8SW"[STLUH=L;Q0.
MZQ'6\V&P/COIF1QO)YO5^_R'+%>YN43^HMK3K/O%_U7DB]7?]0JG_SX+DU (
MA*1> 4R] 2HP)&E((2<957&LE$R<PEX=^Y_:IF$OCQL06P4,?6P2H.8+\$^C
M!/A1:^&8-\]QB.SX>T#@!V;H?<S?[V-^OX-Y)3_X^P7,W5/J]4/.5VX]Q]['
M3;+7#YJC;'L]F^D;H=+D_2F_J$_%XO%!+I_?2[::)3)"G$0QU&.@N4YE <1A
MDD*4Q%&$L(A%D+C%HYSN:&JDMI'33"A6+)?%3^/C6=D^+TOYG*^?RZKDBFLP
MRAF<[0C+!WH#,]-61(.<$1(:*8$1TV>H23<0W@)+SG0S<AA)M[+'02,7GN\;
M(G*GVUS2^?U"R+_^;_DZXRS(,$<,QA'-( KB##(5"$@IC1*42"*9E2%TMH>I
ML4(3#M%("2HQ@9;3-4SD$,CNV>\%GJ&OWUV1Z1$J<D;[*V)%#EL<.5CDC$+'
MT2+G'NRWV._LKS:;K^T!W2TS<2E\-<LRO<!CQ2#- @R14!CB" <0\9BG,6(R
MT-L<IX,NNXZG=X*U(_>_N:WWEE#;K?[^X1N8%'8$OMDY2 );H<$_6K$]G@NY
MX>3)5+#L=%3#P0V(0S/"\>V>GCYU?C,I3J<_:QR(9P'*4L)#"J-0*(A"FD*J
M4@$#CI,@R=(XS=1L(1]-2P\.[CQ6O5O-*%+/J",9AIM=>QDOEMNB4.5.;LK6
M$'3TX[$;E(PD4<STMI#1F.F]81I!$F %&</:'N0LI%GJ6'?3WWB,>\6Q SG?
M'98F]&00^.T6#?^0#GWY8)F'TZ-;DQ-$OIR6[#H=UR7)"8@CAR.WM[W'S?V^
M+,IR1G"6(1QE4 :1A @%'))0(!@*$6*2LBQ.N+<0N:K+Z=&1"0CQ%N=6PVI'
M-CZA&IAF.J/7M+E:R3M*D-H>,L/'H]7=327T;$]YARBS_??ZNB::NZAB^6KZ
M*9^D^+TH1%D5-/\F2[G\(<L9EBB)D500<V8,3\0@C@6%.! <IVE*1>CH[6'1
MZ_08I945/!IA79T!+\-L1R^>H1N883;2ZKUO"U\E\ W0(IO3\59HGVYYU@AY
M\ZF[W./(#G'6$!Q[L]F_VJ><JMXPK^1CSDT_Y<I8LU^+Y4H5\[R8819AK@C6
M)DNJ-U."(XA1J#=3BA&E$J2M%VI'-!?[FAZ];*0%^49<\-+*ZU+@LPOB;I+Q
M"MO0>Z0-7ELYP5??>+F40?6$VUC%3SN_-U^U;VQ Z2YSVM7 B,5-+?38+VEJ
M\T(_F^U$<L]M681[87*SJ)QNDQ&87)Y+*?:]RO2_Z:],W*V7)IE+_:1N1>8_
MS)OE+&,RXU&"H,R(-OI2E4 B20*I"FG*<(00=2J#.H;04[LJO>7<%$6IG'L;
M&=W,QE%&VL[NG-KX#;RZG$[!O-48[*K<.@6W2A]Y!S=ZWX!&\\T.>T=Y?P;P
MF$/ER8(>1>113? Q!^'0AA^U[^L2V30I7'?Z;3J<D2S6]GZ"81!'J5Z (@P9
M"?6O/"4BDFDBA)/7W<4>I[9ZW!5S+7^QO.(6Y3+*=N3O%;N!F;N5%;;7@7LW
M\(V\_A/@7(3&<RJ<\_V]25*<B^J?2X]S^<5^!/-E]227YNYE*9_TQ-DD.OQ4
ME/5IQ@/]RQCD)@I\)UW*0_&5UO0C513&F;9_61!"1#'2]B_"4,DHDDC$),9H
MMBI6=&Y'/U?*XT1.&ZF&FV4/I@]0&*6JV]Z-5GHW624:_66N%?OU!BSJ8[X5
M_<N-NJX=/R4P"Z@04,2!J<N688C#*($LHR'/8AICCEV6CS'';X3%Y<MT1\YN
M21IQ/ 9>L.JAV%.ES=;[RZ=Z*)JS<JW2#6B4.DKR5.OE;V'S!+"G9>]::49=
M%#U!=[AD^FJVWX+Z/B_IX^/2^';E=27.'W*QE@=!PS1.0R($@YQ' B)3I9Z@
M*(99%"4J1/J//':A7:M>IT:NC9 E8*_@95F(-7=T1;##VHXHO2,X,!WNRUM?
M$582#QI'[822)TZSZW-4YG*"X9"?W%[N<7FXN9N\%W-Y1_4'9.("GNCR49J8
MZ3N3XY#RU9K.-4L^Y]6A>]ED=162\C35]GPDTPRB&(>01IF )$91&B@:QH&5
M/7BM(%/CJIT;>J,,:+4!C3K@UE3ZWBH$=C1RN&2[9N@L[BQ'&I#QO"6<Q^)R
M;E_/\\G^8G2DP1GIWG20">-VJ>H!T,X[UVO:'^]*U@,*>S>V/MKK&U7ZOGBF
M^6*6IE1FDE$8(%/;0IBR\@&A,([CB(F,*.):<*QN>&J+3A,I^8]:.DO*.D*K
M>UVX!H.ACZ@MU>\1'[JOZQ5AH4U#(T>#[HM_' 1Z\.\];,B/U)2W6;U^,F":
MG;))HABEF<@DCF#*8@21\75E,L4P"(00"I-,),K:.#S5P]0F8"LC:(5T2G%Y
M'D@+4^U:> :>FT,AXV O78O02(80A":QO/Q-_R_8ZQ)(+;"V2%6Q!*NGO 1R
M7H4M_08@]&0!=4'4:=J<?'$\FZ5+[CUCI//!'K3W[O[^79"@QGA/(VGB%@7D
M49!H.R.AD$A->H%($Q9&:4A2*^>NXZ:G1G2-<"X5[O>0LB"TWOH/S&2-7'TV
MAOL8.%!7;RQ&XJQ+GX,;"YW4MKMZ_=X;(]:=/R7I?L7XDT_TNRJXH^63V3'I
M_Y@4ZC_HW&R5/N4+>;^2S^6,!1+Q+$XA8Q&&*,LXI $G,,A,%'O$PB!T<NVY
MT-_4.,G(6;D(5C_L2 S^860&E=".V<8O06YW5^ 1R(')[4H,G>\'+)'Q=#-P
MJ;=1[P0L53^\#;!]K6?^GF+QN&IR>CWH)NH""*8&EI0"DD@EQN=#0JP4A7'
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M_=GULES5#?,HZ\R6E)-@ZBT -B":F*Z[O<?N]<M??@=?/UT-HV5,J>>@L$2
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M>)NTZ+*F]PA/#RI\CVGAU+JP.X"?Y?]^_J'_C?R'DHK__,/_ 5!+ P04
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MK!6!@;*U+\WM):0=$!VCW;LEJ">+N@&\?+C/ ?=4.N42B;9<&;#E0A?UG)A
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M* $M4PD85:;<ZL!K]V#:3\FX!PT#(:>"T)L 3Y<JWI?11'&IN!<HD3+C2S)
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M2,C-;[ NU2;?W^7?8/FWU+4FNZE F7B37 *>,5()R*)6"EDLBUTJ%*C6D.0
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M>0GSU88R-N&1 C.F5%'@/U)3Y$TCJ]YG+3%;@"QK-Y,]A+YQ#U4&QUMU%34
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M JL#A=$!O%Z%V>)OX?0<?_MQ;7.O%OBO<SQ+/RX.HI61^*0AYIKAS(R&(+"
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MW/^/I8(P3ZLBW3O2&MJ.U)YNH,A!&%\D2X)C"L?S5YY65M9.4-@Q*VL7N70
ML_L?=:WP&CT:(/NX1J-2JETCUIY^5#R5E)JGTSS1K*R=1#XX*VL7_G< I/OR
M@[CF@H> $#G9W,H[6_O/*Q"V1%3UQ22V;JWQQ+*R=A+TP*RL7;C> 7CN?M9%
M270'@V#H#)&:3N1D!9]!<"$*QV"R'WULUM/*GVAVL>TE@QZ!M V$:ZN3-1Z\
MJ,')6,OMC(V@1,HIVB*$&#7NUG?^Q$Y"'I@_L0O'N\^?4%P*844&KUD@'R4S
MVDQ0X)QD+C/A+0Z?P/;T\B=VDN5.^1.[,+8'E#S<WY.K@J1IP?DZJ,+5KGPV
M(VAKDN=",^3#NLT]S<:I!Z&D&6.[0 E=SH\A7RHG)$H)46FZJCTF\$58X"J)
M@K8XCG(X6!Y?L*/"^V:8:<SFWNR7^]XR'(IJS#'@G/BE"/P0A*#305Z$-LYA
MN'D;]?-4W47*UDCQG_TDU!OJ-ILY<3)QVH<$641-/]+5*!0,$J9LD6<FW:C>
MUX:.CBRB)M)^"$[[L'YO^'S#Q6R>/Z["8C5>OD,067-&]->NQ'32JGU7:"=,
M6*FB+$&644L@=LEWF/:!NAF(]F']WB#ZCHLX;Z2%WH<?-85M^6K^\_3*DT(6
M7Y3$E:3)*55:"/"151N08TQ,"69:O[/=1TM'5M080&HB@MW!Y"_ =(:?ZT7]
M:=1[;?T8?WHALOQ_SI>KNN$:+V7.2H3LI24[U!&_0K'@DLC9.J-SB$>X[.XD
M[@ET.FI] QXNI+Y!>.*SLXK3#1_( R*&R>K;D@=D;6(Z9V2^>>K WL:5_J6@
MM1/K#S2N7I[E<9.VON/9>4T:NO@]_OBVF-<ZVH/2K1[YS&:)4KO0WBC%Z<5L
M&3Y_7M03OL[@VRQ^-=:0V6)=T>!8J*-_F )?K(%DDPU9,9>:YU0\0M*ARN>>
MC]]D; =;?,D(*0HD"S$("!)S[;F>A2E.^=@ZY?TA>J;U]%IBXZ8>:B:%"6,%
MR\7JY/W%$7VW^$B:=)8NLA\P:&%DS&"1$6-2-A"9TI"E2U)PKN2P:!0M< U!
M]-45>NY;NTO$["'5>4,6]P&1)5WEFQTL-Z'>;-$&Q1DD3U>NBBC)<#/$H,1#
MR1QEY(.:S _#R6T"I@%+&YG>!LB!#)[ZE>3MQ\T^MO?_MK*,;+W R+H7>CVT
M@?Q,5PO[HY*>RR!4\F70J\@]"TP.@D/E-F_,Q*F!\.K\:Z@=@C:D6^.*BXZL
M?<5K'R"M(&JC(?BB?3#%Q,P'R?_GSYU&[.V$-&_#L:F%_>GE\U>O7[S\\&P[
M2T5[SUV4P$O*=98*I^V3=>65P5);8*>0!TG[Q@=/*.Y#I#-OQ*JIQ?RW/]^^
M_/#ZTS\VI!<N1.V' 8:H!+K7+'GPQ W,1#1/Q20[;.KPSY\[34R_J9 /8-34
M,GY]1A]$RUYV[/(V!^51@"A.DCW#D?PC]."D<N@B8\[Y05*^^<D3RKFY[CZ(
M:U.+_-G?WOWQ\G]M&_8I*TS$ K3A.ORQ3M=RT8-$;QS+ABL<.$K\VJ=.J+</
MD\R\!9NFEN_[-R]___#ZQ58;D?6975$9A.$:%'FMI(V* T2SGC;@F1YVH'_^
MW F/<SL9'\"JJ:7\Z<<RQ,5LH]BV35R5\UI)1MLWN98@&'".JYJ596IZ5HAV
M6'[K79\^C<1'\KD.9M_4\G_U[.W[?UR:E;GP9'/BX%0L1'D.$!G6N?3&B1BL
M)N4US-^Z_K'3O)*/)/']&3:UJ#^^?_W'AV?_>TNZ092*$]4V1;):%-/@'3(0
MR6DG0B@B#9/USY\[S?/T2,(^@&532_NWV7PY^SH[#8NMF1IRT *%!;J52"TY
M16:J\!Z,<V2X<A?H!P8)_-9'3_-N/)+,#V/<Y&)_^<?+]\_>O-Y>18&\2(,!
M1(@<%(9(I)/]*83%[)TW4@_K6_[SYTYHF1\HGGD;7DTMYM=O/SQ[\V)+N2L1
M,3@-CO-('-"\1AP2D+V)V1B7?!H6)O_I8R<TS1L*>7].32WC5V]>_Z]GOVTI
MU[[V+"+[PEA!SDF.-<@0)5'ND3ACDY##M/=/'SN-:=9:QOMS:FH9__:/=^_^
M]OI_;QU0+8M*J=Y42=?F419"K*/]3&U)I;WV:E@ _*>/G<8B:ZZL]^94!Q45
M/_N'*F&6/CJPUC)0=32"CV1+YF+7XSZ%;-Z]?7</W/1OKAW.W:F/_ZL_WSY[
M\?+#6^+'LQ=__M?+-V^W=6JVI*QY 5T4^94R.(@*.8B(MN@<DF/#[+;[5AB$
M =L_!MJQ<6HL?/PV.PNG;\^7Z9STY;/58O[MRX]MF$$(EG3!.IF:',_$$D1+
MCJ=R(D?'))DU:A <'EAD$"+<$T%$*V9.G#YUV<CY=YQ_7H1O7V8IG&[Z@H=<
MO.? :F\8)6H--"-#5EMED]$V93^HZ=XCZ5/W$C!M"=4HN79MF#TU8O#SS2UL
MSI+"%*V(@1P>1ZZ/M+I:7ADT'8#DI [9ZQ:(N8^ Z7*M&@EVWIK+$T(ES<_/
M5HL?)W]^/#%9*.V*@\",KJ/$R5Z2=82)MUGXE#&FAWKA+#']C\_S[__/YA,O
MH+'YX@H95^M-"(,V0IL?Q,$.G)$_YF=_;MTQ$7W0N7#2D-57=N2)N8P*BD@A
M\J(\64F-79%KRT_W%-@6"X=RM@-0W'.COKDLO$)O)??DL\>UJD0CP"OI(0JA
M"?XI>FP]>_TQFJ:MOFUN@XPBB@Z@M<V6.O'9DA,>(P01JS5?#6_Z%8HK61JM
MBW:M>S]NU^ZR-&1/B=ZJ:MR#O3VWGM]6 J[K,VNC=&+?^K9=!O+O3T_G?]7.
MELM-9>"-+>U:UCATD>9UCGOM[L#"QWKS_2V<GF_G[O[/\W Z*S]J7YQT0<-5
M?5M(BM"305I/B#2<=!?6>0G,*2>9X%&W*,\91LTA#M'#*U3FG\Z7YXN-WBY)
M>>]DAJ*B!96BIC-4)ZK[P(4QB>4XJ#'D0=N^0=1T%O,(6+GN18TGF@YNO:O-
M79[IJWKV96W_>S&K5&?M6*XA*&*@"MR#1]J:L\)PZWD*I?7PA&&4]8JZ@V Q
M'UU&W2-OVV6:Q\1B';.0JIN3+)D-DF5@2IF$02KK6YOS0^B:UDX; P\[06X/
MX4S];+$AG0R9YV'YY=*8V=:P&"7(#RK BZAM'$6= E\$<4XBDB><Y,!,X@>7
MZ1DU^XAT/@I_IT;*\_G9VEX@E7[5Q>>R\V\Q3B,O@*AB]8 RG:DLP=M"^IWS
M'/FPD=0/K3+MH\6X.&G&W0YNL(_AM+I(J_/%6671%;^VL34>3$[(@60?0'%#
M3/*,@<B<I12%O066PR<M/4S2M*&HT9 UAD F?B ;:EU>!6<L\SF+S("N?+KN
MLT<Z/,K06:)3);2.(K1X.-N9L.FBY^-;Z.-+J@,U]_"Q_2V<UF^=6(V^I-H.
MVTM?K4T#+LK:&%L:;U'0/=^Z9^H@POIW$/<$QDX6^SY2FKQ'[X7!<+ZHC'Z_
MF'^?+6E[RT_SG\N;MUM<-\PF!G^:KZ^!UV>;?_D/#(N3R)3(GFS/R$G]*\W6
MV782,*%7FI=H!U;S-R&G?Y5X&"8G$MS4GL,U@W;P7M_345G4G59.*S)N,MF\
ML6:$!DF<UI8N(&ZXH;_@U@W+GCN,CNG*((\(SB.*ZM">K@U*Y#?]D;>6\;=O
MIS/,SSZ3N;U</;;YZX?1)D?7AW5 ]X8"96LW0>L\64P\:>]**D.+ZQM1-%T5
MYQ&Q.HGXGCAJ+\_JB1/"&J1K0QG%ZU$ELSZF!)I;H73AR95AH;TV]$Q7@_I4
M$+N?Z";%ZXXVN!=DTS & <G\5D'1,0PV063">2R)%W/<-XU=/*51ZFVZ])1V
MD-)3:;@]+)GCQK;&25414Z6JW-C=\5)5BD2M,G=@2ZA# ^D*CDXKT)%I$PLC
MWV906MFDJ2J7D=9MKOI%[,PKFUDL$8I6KEH6#AQ3M>.?C%Y8[YEKG1[P,P6]
M1GGVDOZML/;^S.X@?+A1J!^_(*[>U)^NO%KW$DZ*H98>K##KD0:D:VM[.HLF
M<"<#CZXT!LU]M$S[,GN(?.<C,+M3T&P>B)A%1Q=S I^9H)-4.Q@ZU'6R2F%%
M1^EE:UUS/S73 J>-M = : _6=P"BK1+^@ EGW^O9VM;;"E5"81(BKYF K&1P
M1G-(R2CO?%;<RL80NH^6_@"TCZSG(S"^ P"]6WW!Q2:"\F86XNQTMII=OB:;
M7#RG'0)Y"8H.F:OA0(%TR#3MAN[U@K8QBAXD:-JTD9&@U$X$'>#I\J*_<F29
M"")8&4"[J&NO-D:7O0V0<L;(?'#%#GJUW\=R?C/M$_T(YL^!#.X (L."$S$D
MB4(C)!YK/ETN$)3Q4&QPF*,)SK<>_-?Q8WLKZ>\5)]I%%$^AG.GB]\K<9V>K
MV?,7@GTB#1R^X?EJEMXO:B'JUV7#46T#5QII@-L^^VPTUFU#PBNB8)L4^??9
MZLOS\^5J_A47U\I6(A/61(C:(]E,AD&L.6R)!VY1Y6QRZWEG TD;=<P;BA*X
M\ RR+I[.%1W:* 69#S+R8BW=#:EUR7>_8][&P,I.X]YVD48?L[Q^GEL5(Z:$
MPH!.LL[CC(E81#>"%BF[FEHJ68L^-$]LW-M.4GULW-LN+.X#(G=T<G+"N6@*
M!UUX %5,H-L\"#"EH#-!B(&1@5]DW-M.,ATT[FT7!D^=SW7=2 AD)*0LV.K*
M2/BV,1*VXU5JCG LKL;<..E>XI5/6H.)44GA"AF"P]*W=EIV<L <*N/Y41@^
M.93F/\+IZL>SU6HQB^=U4O?\W?,/+__VY\=MIU T*15=  5+H'+)X(TQ4#(S
MKCH1FK%AZ'EDI1[G6NP/F)9LG?A2>AO^SWRQM>B6:_7K),NFYA6&7(CZDCDX
M2PYFCLGK7*(5HD5W@]LK=]PV;U^;Y4#V3@R./\)7?%=^VL/F[)C$HY8:(7B'
M=<)S+9>32/>TM8Z3$M3#BLP>P<B]!$QW 1TJT7EK]DY_R:0O^/MB?O[M=SPC
MYF'Z<MEK/+' F*7SHDC!)I6J@JVS>U&BYMGIF_D9]]XN]RPQ'0P:R6[>G)$=
M1),?[>B4A?268:K-F.C D J%F&P":8W(4>LB;G;L_4]NE[;/W3.***;6-!^_
M$#/?E>>U=.+KO&Z(_E!FJ^5)<,8@67/@991DE"L+SI<"*7G#DV2,\3A(T]R[
M1)?QE#W%.&_.TZF1L7ZO7=SPXVIT_0X_[D1Y%S3=S."Q]LWV9/+312W!U*80
MVGJ?C!T$EEU6[=*V;8"?T3C?P3UVV3PP&^&80@0D'I'>90Z\L!JL08$6=2$7
M;YS'D#[OI<-P<Q![]X?%?!5.C_&8N3X1VR\:/%G>^7F-'R8?I_G Y\?;NN+R
M]<BDG!P/=2)X**!,-A",*R#(8#:8)*:0=E?'1WDM=!8]KU/'@Y;UBDRU,RDJ
M8$E'IQ,K'%O/JNGOM;"1:'=Z&-R%\7V\^OS\PB$M<J-E)),^DTGOHH,@/0>)
MQH:L(Z:;DP?_$QX&=Y+J8P^#N["X#XC<$:(6F:G":V0IEOH2QB0X1HY_X5'(
M2.K8#LO"^$4>!G>2Z:"'P5T8/+63L\W!>!O.SDMM9K:H)3]G^?KE?3F+U^7L
M8X08Z@0XE:JA79MGAZA=82X;RP?=J</7G!PJATKWKGYQC5G=@T]S\7:UG>HJ
M4U&6+/?"9)WJ6INL%YX!R0C7UA'7Y*".SKLX-M<)Z/%9<!_0',[=#J"Q8<D5
M1]9HW^P%R34W,D7@3I#K3E8=^&(->%8L-\E(Y5N7'3Q$SW3M8L8!3C/>=X"C
M1X,&00:97% 0U/KAG92G0T6;8IK3<3',L]:YI4W"_],\/>]C%8\BB@Z@=1DR
MLE)C5G363(ED"<:<:GN9&J'FWB3'>+DY\/D_95K*3A*]+R*W"WOWAL5W7,3Y
M<0H,_@B+!7W<=VP0C[OU68UC<0_3>N0R (%"*NGJX#:%%_."HS4*O*]=<@+3
M D>*?$]:!L B9N%5!JXRKQ.J KC,ZA#$;%R4:$UJ7:K;7V!O3*SL%.W;11I]
MA')^#EMD76>N6P2&D:A62*:;M0[0%[(,60@\M)B;\\2B?3M)];%HWRXL[@,B
M=S@0VDE.UIR'D(T 90(Y$$77JS=(P5EPF0]2MK](M&\GF0Z*]NW"X ZLW0>=
M0A6$];PH*#J3MM6\=I6/]6U%QBA52"&W[N=VL$-^Y/#?3N+>Q2'?A?=31XW?
MO/R?+]_^]OKY_)3^9KY8BV2S#>=%CL%K("?2T@'C=,"XJ/-Z:J)/5.1YRL>L
MXD?6Z#' MP\L6K*ROXQ_HP5I6B' DP57(]>B4D^6FW A!+0^B4'>]*^4\;^O
M>7(@>[O-^)>>99^] ,X\ P)T &_JA"_&H^(!2V(MC-BGD?&_DT0'9?SOPMZI
MKQ0Z-Q>53_/%N[/M.U@I7N+ZX<N0&E3%DGYERD H:+D-)D8[;$;579_>8Y[_
M3A*;MV1?1_+_]-=\^]@548;H% 1GUP.6R?LO/H PW+ 8Z?]J6"'J79\^G1DQ
MKOSW8U\'KLFC86@AD*PI$2"5X G/RI&&- 52YKP49S6[69?<QQO/-"4>^Q@;
MHXAB:M7R\FPU6_WX^RSC>URD*I_/>+FE&H%<G\1K)ZAV"U"6!9-!,T::4TJR
MY)/FX&..SC#IM-&#%,_N:W<97=M3\//C26%JD/UQ7E7NN_+W+_2ARW!*GWJ2
M38I%,%*X(=83F 6X@ YD1BEDS647PVH5[_CP+KV<!C YE(\=W&.7+YX%A2V,
MK"[G?:ISRA""M 6(WN),L8;SUH/DGDB)QS[P.(B]4ZN'34G<'_.S]7/7G'[H
M\^LS^G!<KCY@FG\^F_TWYAH$C#8Y [IDLO]DJ7-MF "I)'?>:5*!PT:\#%MO
MFJ%#XRN1$;C=@5[YB*=U([60>Q%.ZU38_'5V5B_,]=/^RW]_P[,EG@CIE4&R
M^E.VM5%(IEV9VC%;VR!-5MDV'U\YC+)I!@8=12>-()J>4V!>GQ'O"*P_GL^_
M?IO7O@++>;G\Y@'Y,,,^N%%RS!Z[:)0I<[7(Y4"@RXP'K3&(4FR=#46.O] .
MHN6UA%%%[Q"S2JT;XCY SJ$ZZ_*C/X2_W@;2A;-PNOP#5_7\772?K9VO%1;)
MH%A+UEV4M=S3"2AH.+*"/&%KK_YQJJ;UPEKAXZ:::BR-ABJJ <+^/E_\LXZV
MG"=<WM@4&8E!)MH*5\E?O*U&2\J7N*>D#4*%YHGF \B:UH4;'6.-Y-$7R%[5
M6_T+YM_G\WQC4T'Q["3Q*VLN:L?:"*'X""88Q\B!S;IY__L!9$WK"(X.LD;R
MF!1D:Y?E<D>TB<V0"#(CR8-)%U^<&"M4J3,CN8XU/P09>*T]).F4D$DXAL."
M28^M-*U3V!HQ[9G;K%M$ W5$^SG)J@C/Y7H(3:%?,%^DZ=M4@<Z9*#?K,MOI
M'5I_6J]N= 6S*X<[B!-<T7X%<"$BN;82@79-6XA*D#)D=0JM-#;;@EFT[D%_
M!QG3S&4]'E;VXW>_LS2N=M:@UN7^#VOMSQ^EVN4A-+%,-BWC!4*69'JLZS>9
M,) 1-0]1,].\A\LQ?/C-U7GQO&R"<M:*FE*2:F4&Y^ 5\R"0NQ*SS\ZT+KB\
MDY!^/?5=4'"O3MF;YWU4)/R<?<^LS89) TS7+%D,$9PA+9N,"YX3\:A:# [N
MKVBE@3@?JU;9A;=]8...-&KF.3."^! RCW1D,H(KB0,F%9UV$DUN")#NJU5V
MDNF@:I5=&#SUF^FS%W_^U\LW;S?);($G:63Q8&NW+V6# :<]@Q0$BJ"=-]D\
M9H+<_MC)!7ZHC.9-&-:!U_*)?NY=>4:6V]GG]>B[]0D00>AD-6U>BD36> X0
M$A=@LJ=;%$M.JG7D]DY".HG5'GQ]M.-V!Y"Y1O[R(IX3KK[SB?ZT)#.,1+2\
M+*BQ+#EN:H"G-E,R# )7!GSF6KFL@RNM&SSL2.*T5DH#4-P<GSRBA*:^GE[.
MEF&VH9M[FWFM]RI<!B)>D:D?I(;BI7).%^\'MG^^]J'38F%4R<T;L'%B&_9Y
M'0N."V+FZD?-Y[_H)<@EVIH]DHO6Q 3B1 S9 I-)>.)#%IXU,%_O6KN3=YXF
M_LW!O)T8&Q_PV_DB?0E+?/9Y@>L3<W-+&U.O=I=D*AF(RM*I24R!EZ: ]:XX
MI30+H<7(F\$$36<.'R[S^=@"F/K">8YU!\M7\\5;S+-$+"7%?/''V=:'V X+
MTT(7IA#01$:,HS_%.N$E1V]8UL0^.:S_]? UIX/.2-*>C\_Z#FSH2\W]YC(1
MTHJ<1)8.F*K-X;@J$$Q]$>4Y%!>Y+J&UF7R;BDY>H9LY7 ?RN2>D_'TQ6]&)
M^NOL1 :RTWAT8$QM1EJ#5*Z(0%S1(0:5<@ZM4XUO4]%)9'=/N=Z;/;47D[N
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MZ1(S@38O%9 "U,XRI:)H47+PTZ(3"WT?D<U;\&]JP8=_7R?<D?%"WCZ@975
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M]ZL]7F4^D)MMK5<:?*A1'VL"!"1OW,I2>!$6HVW=GV0G J=O"3SF8\9XLNH
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MN'I -^(,*F#@/D#.J9#33Y)T%&T"=]ES98I2I;77>BBMO509G3J6.HLN.W
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MK9R>\7;'\:^99<G: )FE.DVS!'!1!*#OG$!10N9GP]O0-VPG@\*N4#M0+QU
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MR6\M3[.CY=L'/NJ5YIJ#^7K[2&N4\%9 8I+"#H<5WR8!QJ@3.FNR%>U \IB
MX>S*\3I]#) C!3ST<?/F_6__^L//OZSMGW+%6E];&R1!YV]1$:*B'<-L#AJ+
M)\.[V^O=O8\=7.''ZFC:1& =/)H]929O'UV$%MPF"@LEDXPXXA9BB@S(4B;C
M1%()3W;7_11!PY9-MSU2VFN@ SB]7R]+[+R9SW$Q_[=P>7WSU/='K?$>A1"M
M<([3]JH[1/L KAC:(9Q[98V5!EOWHMV!K/YNC0\$P?2T&ND 9$^'D?.1S3ZE
M9!@D@20F5 5<8)R,L"E!Q%3ST%KG7CU-2G\7.6W U$+R'0#H/:89AIK[\MMD
M=OO\?]-^?O[3_!/]?CHAX_[]XW0^'U<CGU(0F4)),(D1DS*%&@HB&*<QI<QH
MQ[3N"7<0H?W%7:TLV:FU]IJ2-=ID:9PN/6. O(R2I&$%C/0)5$P<HI >R 31
M 189_;CU]CQA7L8/I6"J?=]OUO@4%KC:4]>TK=:#"Z:3^?I7-3]IDL:7X]5.
MWTBE4/0:12H@@BZ@<LU5<MI13**,TC)H%9J?B6U([\0A.Q)ICT[0 ?3:1\+]
MDXP_X&[Q(^8Z_:"^CE_3YWV_]\<C%67*ECOPT99:NRO RZ! QNQYS%QY?1XP
M[T7VP 5\0P!N)]"?3O>O!O#++)!EBFD*EW?.T)'7B8OL)?AE1,:Y)A,3(V0G
M9#::89"MDX^/H7?@5.-7 O$FVGXUV*YI)N.+R;V_N"EN&(?+4139Y. I%O"&
MN*[;.@8*'V,2)D4I-$8< .,OT3WPQ*)7@O6FVG\UF*]A+]%&L>B(SB9)^ O
M3$WE$SZ#0^- E*B"CEZ1"SD NF\I''C6T2O!\8$:[6+XX"[\_3JM8?DU_5F\
MW,P8>X]$<UH+>E)+%F>+\?\LOQUYC%9%Y6I7GEKH:P)XC@F"-28[RXM'-P"L
M]V1CV*ZHKP7[I\3&JS'I_QA?+L8?<99(L2/!)$_16 )IG:AFE %O@X;$$@K/
M%)<XA,MRE\9ANZV^%F@?K-6ALS-NF'LZP@@US?(VJ0V_C><CBIH9FMK;4U'0
MK%BLUU6.@\L&BW>J3LW=*85C_[6'[<HZ)!C/H:Q.&@,\S^7/X\7X8B7/36KE
MR.;LB#T'7NL RCD%OGA69TAF6Z*W5NW6:&OOI7<"I/N; O)85?5M&W^]QME/
M5U?7D_KKGZZ^D2#G(ZXP&64=:(T65"&?/DH3:QODPHOSP@;; (E/K;T3%/W?
M%(I'*ZMO+/XTH656C0C"Y2<D"L)DXT5;.@%\;9!K948*,V,$[[R%(HEA(V5T
MN%OWUX-)V.W!@OU-H=E*=QWDP>SB*7]8?,79F_R?UYM<GZPHIK->0#"9=F&@
M ,]CH"C/I)QDD$KEUNE[A]"Y&XC_]L]N1ZFWXR#^*4F/DI0N"11T8I ?HZ1-
MX&3)M%M5XDPGKW/SYL<[4[<;8/^&CVA'J_)P2SM=A,M3IG4M=Q_Q-Y]>CG,-
MR7X<3P()=?4*OO3 5^E41R1][;U&HY2PXWAKE##VX<[I?$O+ZN[RXQWF/I3'
MU-UV7E.(M>BT%H3$>K&I-<2D)7 7D\A<\<A:O\8W(?SHT<J;3UQ5.=#&B#HP
MB@!]O=^5T4/ 6I K'*>?<U2L]=W_?0J&S:0Y/Y8>C4$^7!\=>)MOP^5RQM]7
MQ,7/Z[9ORWJ[K#PSR!.0T2*70[D,GN5Z!<:TX44E[UL_E6ZC9>")QT?H]V'+
MNQ;"[A0TZX(]'T44)5K@QOIE4TKPEBL0CMQ7S$:HYHW8ME,S\#25)MK> 4('
MB+X#$*U<D>M9%>7/XQ#):5V,<3-16>62]-*+#$: LKJ.\,ZULTXTW*)-P;=^
MU'N6H/Z@=(C6IZ=2P8!XRC@>_8P7X?('BD@6WU<MNV()+%" [**PM677\F[<
MTC\A16LH1'DV(6).+O/%]/=_H8]> 8>^N,7+$PL./&?N^!/J6"$.K/\5U9L=
M88VQ-B(9U>K,^<J_5[:.[3116EDL>^XN[&7EWUUM&+MPM+JF#60W]&W^3]/)
M>/XY3"["U?0]3L+EN/8/"!>XME_6(?-U%'6(+))E9 8\';:@352F9(4^/^@M
MMN7._H6%AH/ X:J;GDB.K[D779&8;2$_S$5.)RE7=-Y9FX%;"@JE1(8/\=)G
M+[K3C5D[_IPYJY(Z;T"78PI")."^NE<^.?"%6= L"UL=+65V\G#_C@WH]D+!
M'@WH]E#)T*??BTW2G-'(5%; HZ?MR4@\D;8DV6[4.I60?/BK-Z#;1YU[-:#;
M1[8=A-HWAOOGFYK_:*022-Y"BJ&VTU++%R$$FZ(0S+L4'F9[M;LV_KF/SD$-
M+_:.%' '$%DF4- &6CWRW4X2N[DB=R9;&V@S24E<J$P[*B1B2AJ%!/@28MRI
M'=U>E?S/T]3)O?"!.G_4<:JA OK( 7CR7/^$JYE;_R +78>X?)B\'\^_3>?A
M<B0]R[(.:\#(:Z A.&T^8CA)BR)9%43S.[]]:1RZ_T%+C.S41JB1NH;/BMZP
M>9M/^QD7B\OE#MY,^31H;!:!@72!'(9<^Z\[$2$I9[AQWKG0&H#/D#-TOZH3
M8JV5$KHX.#=;926IC=Q&WOD@N/3U;:<.:F-8TVT8V*!5EM'8J%KG)VRC9>CF
M4R=$4A/Q]V.=-N1O-H/'X)(P$KQ6J3X51O Y1]#&V>)U,LZTSNM\0,+0W3U/
MBIW#A=V%A[4YG&\W03VFYZO9>"-4TJ%'#JS4\SD1^ /6YSRC8^"!NT==@H_&
MSK,$#5O?>U(DM5-$/Z9HW2QB]3R<OM^9P[CQ!=]BH;^IDZ9=+C9[AX!%AM7;
M4Q2FOAS7#D QF*Q;WR;L0=ZPU;<G!=ZIE-1%JX1E>L*OT\ETE6$\N;@GPI&5
MEK:1K;/]T-2)GP:"(KD9XM,(&UV4K5.-GJ=HV,+:D^*LH2KZL7!+ICX\R1')
M;90-,U+H IF'#,I[ \X:#I+V$$;ILFA>4_,\1</6R9X>7VU4T0^^GKY1^?#'
MA%;X.OZV[G00+G"D5! JNSHNSI+G&4IMTJ%D34+VRJJ<4)_GYNL)XH8MB1W@
MRNM8!75P*;%B[#.FZ]DRH^_'WW\=;QR"-Y?K4LG?;YNGZL0#JZF#3&M=[UPX
MN)K_;G*02B@,%$J?!'\[D]A)AEV;N_Y3JJ=S](V2$THQ6=_J)=9>&C7<1@$Q
MZD@AMRW,[)1ETPAJ _>!/240]@#=7EII5KG7%F$/7RI&R$E2-@NP0E"4P]'7
MY__:9-X682CP=LV?N'>A:^"VK ,C[B@M=7'I]A17=?;! [Z$3JEPX4"GFGQB
M7)W@JRA"BL(Y9U +W[RL>2?*!FZ5.C#^CM14%PA\D]+LFM:]K=A8UW#<2,U*
M83.7 HRH+ FG:CP>0!8A4M3*![G3@,D]P/<B49WDKK;QX-JJH M4W;[$/N9J
M%#PFS$J#3X)1 %YJ*PJ3@ =AB3]&45CK[)_GZ!G6:VNL_(>Y9*WTT$$D\'BL
M69WQ^(G4-:-H>UW5-F).,J&M V<L,55T!!<RDLB8ESD+Q9OWU=^)L&$]M=.B
MK+UFNC!B/UQ]NYQ^1_R$E\MGB,<[R 9IO2\&=*PMSC.YFCZ82#+4Z"7]SC2?
M2/0B4<,>C:<%6EN-=&#3UN+Z-/T>+N^RD;B. I4"ED4$I92!X'D&%J067)'H
M9.N+C2VD#)NR<5HXM9#^H)9J66#P;GI)/YJN^B;AZE)['BIKX7*D4#.//D*P
MLH8\=9)5YAJ*YQCK8ZT5N[4&?FZ589,Q3H.1MJ+MP-2L^L!MD]5(^\*"+1RR
M<Y*X$04\2QX*:IDT"TJGYAV0GJ5HV$2+TQJ>AKKHPE-:\O,$(S$5P8AHTKUQ
MH+@O$$U*@%P[&4Q@KGG6V!92ADVG. .:CI1^OX-1=^XR-_^"?R[J:72/I<8M
M]&X6.7</O:>YZZJ)'D_"T(&804I3&Y^%")%I#AAU+%Y8Y.'OT$2/L9*,)I]1
M8:WGC"6 X[633B39Q()%EM;OWW^])GK[8.F%)GK[Z*.SUD,I$XE991#>D8L9
M61T302YF$"%[%H3,]KE4GM.T'CI7<[R]]/9,ZZ%]A-A3ZZ',HD9.46BI0]15
M[5! AW8"SC%%3ILA\N.4_T.7K8?V4M>VUD/[R&[HY@LOM<Q)0<2<:E):JOL@
MTU=!D$",$"'JQ$KP[B7_YA6U'MI+=?NT'MI'CAW$ZV^OY^,)SN=OTG]?C^?C
MFX:/= "*HKP +"ROVNGY$ I(05$#5I6+UCUZMY#221K=X:=%2U%WBICZY0PW
M34R\B)R"/P%,T+92'#4X@[73H^$YL8A!MLXC>9&H@9MAME#]#G Z7 ]#'T^?
M,"S"QZ]A=A427B_&*5S.?YJDM5$M2:/P(8-6==M)Y2!:X4"XQ)C@F+E*.QU.
MSR[3'T:.T.?T),+MP/Y\OHYS_._K6G[_>[7+])\M]Y)P4800&"!'MXKE'".&
MI,R..(F"['/K@/AI4CI)&SK^Q&HAZCX1L]Y1,F! EA@P)6@?D>L&D7@"4824
MT=?AX:U/JJW$#!P5MU#UR_ Y0.[] 6AM-Z5 ;8JM@4.DP]O6E[G:@LLHVFXQ
M!'2Q];/#DX1T!YQ#E/P\= Z0> ^P>9S F;PPJ(("F6V=BD5?.451J!!*4^3H
MK VM1U1TWL/NJ//I. %W )'GN@JQ4DSM6@^<)UW],@_1Y02E9'++F"[1Q\98
M.;:UTSD[U^VEZ3V:.>TC]@X0M&/% )=>H$6*-(.*-7.\0,@8@*M01*%-%GSK
MPZIA;<<YJR2/P=4)E/$J(#8B*>6@!.T2FY V#6?$D23Q.>/**H&I]:/LRU1U
M$H>="UI[*:%36#VJM2M52@S)$)/AK3<=IEZG,XC<:%0&78FG:3/0H"+R]"[4
MZ:!UE"(Z ->J\6<=^5D?^K_@[&J\FK4\BBGZ8(L%CY$8R=& RYF!\RFB%(XI
M8UN[5=N(&3:EM;53U43D'6#G8:;;K]-)6B>[L:B-J!VW*=RLT4I]-F3,TD&>
MB161G&]>5+:=FF%S5QNCIY'0NTA472=BWDP?OL>-\*SD7 Q(PQ6=S:*./\J"
M#*F/@1LID*7&$'J.GF%35AN#J)G@.[!"'\/W9;+:E^GZ&6CS0(3S?\SJB1Q1
M)2[)O^-*..(G410A9  ?DG1,^EQLZ\OKEV@:MMU78S U54"_F<]WJD]^QS#)
M2T.\+'VK ]*_CK_-/[S[],.__?;YB-GA>Z_1*._Y.-ZZ2GL67*)T-;F>FP!*
M)4O!G;(0<XE)69ZQ>7^$/M*>;X8NW5/FF]DL3"[62TUR-?-;?GVGP>A\?>4L
MF$[,,= 6&>W;.I2)>P&!\^ ]5YJ$V_H2OCD7?X7TZWTP_>CN?UA<##RH[>-L
MFJ_3XL/L,\Y^'Z?56ZV)E8$20'I5^Q*1)+W3'JST7";O8E0[/1B\,)[MJ;4'
M?AT8& O3AHKI UA57FL.YIOG7*><BBY#J9'\LN=0C*(.UB2FM!4NY8;H>DS
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M]R]U0(UZ=@792/P8L2!W@@R[JQ#1W3-.]II!UVOE)\N0&TZ'667 A2J+4J)
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M409<+(YXYTKU3/&<?5>J03RZORO5$()-S>K?WOS7F]]?O;WQLG=]#"$C'SR
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M14-R*1J/T4N7>R%TG.3"YY'PM37^QN7'3-#U>/I:FPR62W20M=L4:SG@FR+
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M\-&"E;O7GTOMYOBJ:S2JSQ Y5XE;UK$P4+YUXV^C4$H0$$R4P(+78PS*4[]
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M9=V=N;4W(:O/<"]SW]\'_1]02P,$%     @ :81H5Q2K(17[!P  PR@  !8
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M/QRW+CIKSFQ=6TN.9I0Q2!Q5R1/;;IR5.!4I@YEL5_'-:WH?U$K+7\F$SDJ
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M,:,1(BM$69I=4[C(P?"N!/[/);"_UW7[J60(;%-$MG25_=6C4+?1OU\"AQ9
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M+3(P,C,P.3,P7V1E9BYX;6Q02P$"% ,4    " !IA&A7I#+#TJ.^  "B]
M%               @ $_1@0 8FEI8BTR,#(S,#DS,%]G,2YJ<&=02P$"% ,4
M    " !IA&A7A0V0EO24   EP   %0              @ $4!04 8FEI8BTR
M,#(S,#DS,%]G,3 N:G!G4$L! A0#%     @ :81H5Q%IXY-EF0  DKX  !4
M             ( !.YH% &)I:6(M,C R,S Y,S!?9S$Q+FIP9U!+ 0(4 Q0
M   ( &F$:%>FW34"TR@! $:8 0 5              "  =,S!@!B:6EB+3(P
M,C,P.3,P7V<Q,BYJ<&=02P$"% ,4    " !IA&A7O2K/PGL\ 0##N0$ %0
M            @ '97 < 8FEI8BTR,#(S,#DS,%]G,3,N:G!G4$L! A0#%
M  @ :81H5W6-*UCY(   430  !0              ( !AYD( &)I:6(M,C R
M,S Y,S!?9S(N:G!G4$L! A0#%     @ :81H5^UV=@.4'@  2BL  !0
M         ( !LKH( &)I:6(M,C R,S Y,S!?9S,N:G!G4$L! A0#%     @
M:81H5](^30W@(0   S,  !0              ( !>-D( &)I:6(M,C R,S Y
M,S!?9S0N:G!G4$L! A0#%     @ :81H5RC#(Q+2(@  /#<  !0
M     ( !BOL( &)I:6(M,C R,S Y,S!?9S4N:G!G4$L! A0#%     @ :81H
M5THUPX67CP  7;,  !0              ( !CAX) &)I:6(M,C R,S Y,S!?
M9S8N:G!G4$L! A0#%     @ :81H5[6:L-+SD@  W+,  !0
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8=&U02P4&     !8 %@"T!0  $ P.

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
